Alfa Aesar

Bio

Chemicals for Life

Including:
Amino Acids and Derivatives
Buffers
Click Chemistry Reagents
Electrophoresis Reagents
Signal Transduction Reagents
Western Blot and ELISA Reagents
...and much more

Introducing Alfa Aesar Bio

Alfa Aesar is pleased to introduce the latest addition to its complete range of over 46,000 products.

The new biochemical product range adds over 4,000 products to the existing offering, providing a more complete selection for all of your research needs.

With a wide and continuously growing variety of materials for biological research including electrophoresis reagents, enzymes, signal transduction reagents and much more, Alfa Aesar now truly offers one stop chemical shopping combined with unparalleled customer service.

Visit www.alfa.com for the latest news and product availability



Alfa Aesar

Table of Contents

Key to Chemical Listings

1	2	7		4
J62011	**A-7 hydrochloride** *[N-(10-Aminodecyl)-5-chloro-1-naphthalenesulfonamide hydrochloride]* [79127-24-5], $C_{20}H_{29}ClN_2O_2S$ HCl, F.W. 433.44, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a (12) Application(s): Calmodulin antagonist			**25mg**
J60039	**Abamectin, 97+%** *[Avermectin B1]* [71751-41-2], $C_{48}H_{72}O_{14}$, F.W. 873.10, Powder, m.p. 150-155°, Merck **14**,2, UN2811, (9) MDL MFCD01769550 H:H300-H400-H332, P:P261-P301+P310-P321-P304+P340-[illegible]P501a (8) Application(s): Interacts with GABA receptors to cause chloride chan[illegible]tivation (14)		5	**1g** **5g** **25g**
[illegible]70	**Abietic acid, tech. 75%** △ [514-10-3], $C_{20}H_{30}O_2$, F.W. 302.45, Merck **14**,7, EINECS 208-178-3, BRN 2221451, MDL MFCD03423567, t H:H315-H319-H335, P:P261-P305+P351+P338-P302+P35[illegible]-P405-P501a	3	6	**25g** **100g**

11 — 10 — 13



1	Stock number
2	Product name and grade
3	Sensitivity symbol (see abbreviations index)
4	Unit size
5	Alternative name(s)
6	Chemical Abstract Service (CAS) number
7	Molecular formula
8	Physical form
9	UN Dangerous Goods number
10	Denotes substance is listed in Toxic Substance Control Act (TSCA) inventory
11	Globally Harmonized System (GHS) Pictograms
12	Precautionary and Hazard Codes
13	Chemical structure
14	EINECS (European Inventory of Existing Chemical Substances) Number

F.W.	Formula weight	**Merck**	Merck Index Number
m.p.	Melting point	**BRN**	Beilstein Registry number
b.p.	Boiling point	**Fieser**	Fieser's Reagents reference
f.p.	Flash point	**RTECS**	Registry of Toxic Effects of Chemical Substances reference
d.	Density in g/ml		
n_D^{20}	Refractive index	**MDL**	MDL number
$[\alpha]_D^{20}$	Optical rotation		

How to Order

TELEPHONE

Please have the following information available when placing an order:

- Your customer number (if applicable).
- Billing and shipping addresses.
- Product stock number, size, and quantity for each item you wish to order.
- Your purchase order number or government/corporate credit card number and expiration date.

INTERNET

www.alfa.com
Our web catalogue features up-to-date prices and a user-friendly e-commerce system.

EMAIL

info@alfa.com
for catalogue product orders and general inquiries

tech@alfa.com
for technical inquiries

specialquotes@alfa.com
for bulk and specialty inquiries

We do not require a confirming purchase order. If you choose to send one, please mark it clearly, "CONFIRMING ORDER" to avoid possible duplication. There is no minimum order. We welcome all orders, regardless of size.

Alfa Aesar is ISO 9001 and ISO 14001 Certified

General Information

ORDERING

Customer Service Representatives are available weekdays to assist you. When you call to place an order, we will work with you to learn your specific needs. There is no minimum order. All orders are accepted, regardless of size.

PRICING

Most current pricing may be found at our website: www.alfa.com. In cases where the selling price has changed significantly, we will contact you prior to filling your web, email or faxed order.

SHIPPING

Whenever possible, we will ship products by the method specified on your order.

TECHNICAL SERVICE

At your request, we will furnish technical assistance and information with respect to our products. Our Technical Service Representatives are trained in specific product lines to answer your questions regarding applications, specifications, product properties and handling.

MATERIAL SAFETY DATA SHEETS

Each product ordered is automatically accompanied by a Material Safety Data Sheet (MSDS) if applicable. If one is not immediately available, a copy will be sent via mail as soon as possible. If an MSDS is needed prior to shipment of a product please visit our MSDS website at www.alfa. com.

RETURN SHIPMENTS

Some materials are not returnable. Returned shipments cannot be accepted unless prior arrangements have been made.

TERMS OF SALE

Full details of Terms and Conditions are listed on our website (www.alfa.com). For health and safety reasons, we shall not supply chemicals to private individuals or deliver to residential addresses. Orders will be accepted from legitimate business customers only.

NEW CUSTOMERS

We welcome new customers and setting up an account with Alfa Aesar is easy. Just call your local sales office and a customer service representative will assist you.

Product Information

HOW TO FIND A PRODUCT

BY PRODUCT CATEGORY

All chemicals are listed by category in the application index at the beginning of the catalogue.

ALPHABETICALLY

All chemicals are listed in alphabetical order in the main section.

ELECTRONIC FORMATS

Online at www.alfa.com you can search by description, stock number, CAS number, MDL number, and competitor matching stock number. There are also tools for substructure search, alphabetical index, pure element search and a labware search. MSDS and Certificate of Analysis searches are also offered.

SPECIFICATIONS

Alfa Aesar quality control chemists employ a variety of analytical methods consistent with the diversity of the product range. Products are tested according to our current specifications, available on request.

PRODUCT GRADES

The purity determined for an individual product can vary slightly from lot to lot. The percentage grade figures shown in the catalogue represent typical purity values, defined as shown. Similarly, catalogue figures for physical data, such as melting point, boiling point or refractive index, are typical values, and may not form part of the product specification.

Where possible, products are assigned one of the grades shown here, based on the assays of different lots determined by the method defined on the product specification.

For these grades, the following tolerances apply:

Grade	Assay Range
99+%	>99.0%
99%	>98.5%
98+%	>98.0%
98%	>97.5%
97+%	>97.0%
97%	>96.0%
96.0%	>95.0%
95.0%	>94.0%
94%	>92.5%
90+%	>90.0%
Tech. 90%	>88.0%
Tech. 85%	>83.0%

Other numerical grades may apply to specific products. While we make every effort to maintain the grades shown in the catalogue, we also reserve the right to amend product grades and specifications up or down as dictated by stock availability. If you require confirmation of any product grade, or wish to know the actual purity for material we hold in stock, contact our Technical Service department. For bulk orders we can also supply you with a certificate of analysis with full analytical results for the particular lot number you have purchased.

PRODUCT USE AND HAZARDOUS INFORMATION

Chemicals listed in this catalogue are only for use in research and development laboratories or chemical manufacturing facilities. All products listed in this catalogue should be handled only by properly trained personnel. Please refer to the terms and conditions of sale on our website for further use limitations and hazard information.

STORAGE CONDITIONS

Product listings include sensitivity symbols that indicate recommended storage and handling conditions.

△ **Air Sensitive**
The product can react with air, oxygen, or carbon dioxide. It should be stored in an inert atmosphere in a tightly sealed container.

◪ **Moisture Sensitive**
The product can react chemically with water. It should be protected from humidity by storing under an inert atmosphere in a tightly sealed container.

■ **Hygroscopic**
The product can absorb water from the atmosphere. It should be protected from humidity by storing under an inert atmosphere in a tightly sealed container.

▲ **Light Sensitive**
The product may deteriorate if exposed to strong light. It short be stored in the dark or in a light-proof container.

Packaged Under Argon
Products we package under argon are particularly sensitive to air and/or moisture, and especially if the product can react with nitrogen.

Product Safety - MSDS

MATERIAL SAFETY DATA SHEETS FROM ALFA AESAR

Please consult risk and safety codes and the Material Safety Data Sheet (MSDS) before ordering. You can obtain MSDS online at www.alfa.com or on request.

- Transportation data from DOT, IATA, IMDG and ADR/AID
- Canadian DSL and NDSL lists
- European country specific OELs

TO OBTAIN AN MSDS

Go to www.alfa.com

Call your regional sales office

Send an email to tech@alfa.com

PRECAUTIONARY AND HAZARD CODES

The catalogue displays Precautionary

and Hazard Codes for all products where applicable. A full listing of Precautionary and Hazard Phrases is listed in the back of this catalogue.

SPECIAL HANDLING

Items requiring special handling are listed in the catalogue with a notation to that effect.

ENVIRONMENTAL, HEALTH AND SAFETY CONTACT DETAILS

For product handling or safety inquiries, or in case of emergency, please contact your local sales office.

Bulk & Specialty Capabilities

The expert technical and commercial personnel in our Bulk and Specialty Sales group can aid in your search for the ideal bulk, special or custom manufactured product.

MANUFACTURING

Alfa Aesar's combined resources bring you a broader range of unique building blocks and other novel compounds. Over 100 production chemists employ a variety of techniques in the development of new products, many of which are otherwise unavailable commercially.

Alfa Aesar's production operations offer a single source for fine chemicals, from research to pilot scale.

CUSTOMER SERVICE

Our dedicated scientific and commercial teams offer full service from production to delivery. Most products are stocked in catalogue pack sizes and the majority are available from stock in semi-bulk and bulk quantities as well. All specialty and bulk products are shipped with a batch specific certificate of analysis and material safety data sheet. Because we understand that specific packaging is often important, we offer custom packaging and labeling to meet your requirements.

Additional Product Lines

Alfa Aesar brands represent the finest in novel and specialized organic and inorganic compounds, metals and standards.

ACTIVE DRY™

Active Dry™ anhydrous solvents feature the alkali metal silica gel system (Na-SG-I), an efficient drying agent and impurity remover for solvents and anionic polymerization processes. Each solvent includes an Active Dry™ pouch immersed in the solvent to ensure dryness, and is sealed using our exclusive ChemSeal™ septum caps.

CHEMSEAL™

A range of air, oxygen and moisture sensitive products is offered in ChemSeal packaging. The ChemSeal system employs a resealable septum through which a volumetric quantity of the reagent can be withdrawn without exposure to oxygen or moisture.

FIBRECAT™

FibreCat precious metal catalysts are anchored to a series of functionalized fibres, creating a combination of selectivity and ease of handling and separation.

PREMION®

PREMION
HIGH PURITY PRECIOUS METALS

Premion is Alfa Aesar's trademarked name for high purity precious metal compounds and pure elements. The minimum purity for Premion pure elements is 99.99% (metals basis). Premion pure elements include the following metals: Platinum (Pt), Palladium (Pd), Rhodium (Rh), Iridium (Ir), Ruthenium (Ru), Osmium (Os), Silver (Ag), and Gold (Au). The minimum purity for Premion compounds is 99.95% (metals basis). They include the compounds of the elements listed above. All Premion products automatically come with a batch-specific Certificate of Analysis.

PURATRONIC®

PURATRONIC®
HIGH PURITY RESEARCH CHEMICALS & MATERIALS

Puratronic high purity base metals and salts are the leading choice of pharmaceutical and electronic companies as the basic building blocks for many research and development processes. Alfa Aesar ensures the quality and purity of each Puratronic product during manufacturing. Each Puratronic compound has a minimum purity of 99.99% (many exceed 99.999%) and a lot specific Certificate of Analysis is shipped with each item.

REACTON®

Recognized as a benchmark for high purity rare earths, the REacton brand line encompasses the entire Lanthanide series (excluding promethium) along with scandium and yttrium. REacton rare earths feature extremely low impurity levels and exacting Certificates of Analysis are issued with each REacton product.

SPECPURE®

Specpure is the trade name for Alfa Aesar's analytical standard solutions. Specpure standards are produced using the highest quality raw materials and ASTM Type 1 deionized water for the greatest calibration accuracy possible. All Specpure standards are shipped with a batch-specific Certificate of Analysis. Specpure atomic absorption standard solution concentrations are accurate to ±1.0% and plasma solutions to ±0.3%.

SPECTROFLUX®

Spectroflux is Alfa Aesar's brand of lithium borate based fluxes prepared for daily use in a variety of analytical methods. A range of fluxes is available for use is methods such as X-ray emission spectrometers, atomic absorption spectrometers, spectrophotometers, polarographs, ion selective electrodes, ICP or classical analytical techniques. Regardless of the method chosen, Spectroflux analytical fluxes offer the benefits of speed and analytical precision.

ULTRA DRY ANHYDROUS MATERIALS

Alfa Aesar provides a comprehensive line of ultra dry materials, the first choice for air and moisture sensitive applications. Ultra dry compounds are manufactures under exacting conditions to ensure that oxygen and water impurities are in the parts per million range. Only high purity starting materials are used in the manufacturing process, which produces results in overall purities of 99.9% to 99.999%. All ultra dry salts are ampouled under argon, and most are available in -10 mesh beads and powder form.

VACPURE™

Evaporation processes and other exacting applications require ultra purity. The new Vacpure system is a specially engineered sealing/packaging process for a range of high purity metals. The Vacpure system ensures that oxygen, moisture and other impurities are extracted from the packaging before sealing, maintaining the purity of the enclosed material.


Alfa Aesar
Visit Our Website at
www.alfa.com
Periodic Table of Elements
ISO 9001:2008
ISO 14001:2004
BS OHSAS 18001:2007
Certified
Key
Element
Density
Boiling or Melting Point in °C
Electron Configuration
Symbol
Atomic Weight
Physical State
Solid
Liquid
Gas
Natural Radioactive
Artificial

Abbreviations and Codes

The following abbreviations are used throughout our listing of products.

Å	Angstrom
AAS	Atomic absorption spectrometry
ACS	Chemicals meeting the specifications outlined by the American Chemical Society
AES	Atomic emission spectrometry
APS	Average particle size
anhy	Anhydrous
approx.	Approximately
aq.	Aqueous
Atm	Atmospheres
b.p.	Boiling point in °C at 760mm pressure, unless otherwise specified
(c)	Contained weight of active material
°C	Celsius
ca	Circa
cc	Cubic centimeter
cm	Centimeter
cont.	Contained
cP	Centipoise
cS	Centistoke
d.	Density
dec.	Decomposes
dia.	Diameter
ea.	Each
ee	Enatiomeric excess
eV	Electron volt
°F	Fahrenheit
f.p.	Flash point
FSSS	Fisher sub-sieve sizer
F.W.	Formula weight
g	Gram
g/l	Grams per liter (gas density)
GC	Gas chromotography
GLC	Suitable for use in gas liquid chromotography
HPLC	High-performance liquid chromotography
ICP	Inductively Coupled Plasma
ID	Inner diameter
in	Inch
incl	Includes
IR	Infrared
J/mol·K	Joule(s) per mole Kelvin
kg	Kilogram
L or l	Liter
lb	Pound
µ	Micro
µg	Microgram
µm	Micrometer (micron)
m	Meter
M	Molarity of solution
max	Maximum
meq	Milliequivalent
Merck	The Merck Index
mg	Milligram
micron	Micrometer
min.	Minimum
ml	Milliliter
mm	Millimeter
mmol	Millimole
Mn	Number averaged molecular weight
mol	Mole
m.p.	Melting point
M.W.	Molecular weight
Mw	Weighted averaged molecular weight
Mw/Mn	Monodispersity value
(N)	Nematic phase of a liquid crystal
N	Normality of solution
n_D^{20}	Refractive index for the sodium D line at 20 °C (or temperature indicated)
nm	Nanometer
NEW!	New product
NMR	Nuclear magnetic resonance
OD	Outer diameter
oz	Ounce
optical gr.	Suitable for optical applications
pc(s)	Piece(s)
pH	Value taken to represent the acidity or alkalinity of an aqueous solution
POR	Price on request
ppb	Parts per billion
ppm	Parts per million
prec.	Precipitated
Primary Standard	Analytical reagent of exceptional purity, for standardizing volumetric solutions and preparing reference standards
P.T.	Passes test
PTFE	Poly(tetrafluoroethylene)
Purified	A grade of higher quality than technical, often used where there are no official standards
P.V.	Pore volume
Reagent	Reagent grade
REM	Rare earth metal
(REO)	Rare earth oxide base - content of specific rare earth element in comparison to total rare earths present
S.A.	Surface area
soln.	Solution
Sp.Gr.	Specific gravity
Sp.Rot.	Specific rotation
stab.	Stabilized
subl.	Sublimes
Tc	Critical temperature
tech.	Technical grade
TLC	Thin-layer chromotography
TSCA	Toxic Substance Control Act
UN	Hazardous material transportation identification number
λ	Wavelength in nanometers
wt	Weight
w/w	Weight/weight
w/v	Weight/volume
XRD	X-ray diffraction
△	Air sensitive
◪	Moisture sensitive
■	Hygroscopic
▲	Light sensitive
≈	Approximately
>	Greater than
≥	Greater than or equal to
<	Less than
≤	Less than or equal to
[ ]	Numbers in brackets after the chemical description indicate the Chemical Abstract Service Registry Number
- mesh #	90% particles pass through screen having a given mesh size
+ mesh #	90% particles are retained by a screen having a given mesh size
†	Denotes substance is listed in Toxic Substance Control Act (TSCA) inventory

ACS Reagents

ACS reagents are high purity reagents for laboratory use. These reagents meet the specifications of the American Chemical Society (ACS) Committee on Analytical Reagents. These specifications are listed in the Tenth Edition of Reagent Chemicals: Specifications and Procedures.

Description	Stock #	Page #
Sodium hydrogen carbonate, ACS, 99.7-100.3%	14707	346
Sodium hydrogen phosphate heptahydrate, ACS, 98.0-102.0%	11592	346
Sodium sulfate, ACS, 99.0% min	11560	349
Sodium tungsten oxide dihydrate, ACS, 99.0-101.0%	36489	349
Starch, soluble, ACS (for iodometry)	36703	352
5-Sulfosalicylic acid dihydrate, ACS, 99+%	43144	356
Thymol Blue sodium salt, ACS	42785	369
Trisodium citrate dihydrate, ACS, 99.0% min	36439	382
Zinc chloride, ACS, 97%	12307	396
Zinc sulfate heptahydrate, ACS, 99.0-103.0%	33399	396

Contact us for pricing on bulk sizes

Amino Acids and Derivatives

Amino acids are the building blocks of peptides and proteins. All amino acids contain a carboxylic acid group, an amine group, and a side-chain that varies for each amino acid. These side-chains differ in polarity and pH, and are important to both and protein structure and function.

Description	Stock #	Page #
N(α)-Boc-N(ε),N(ε)-dimethyl-L-lysine, 97%	H52437	130
N-Boc-O-ethyl-L-serine, 97%	H52781	130
N-Boc-3-fluoro-D-phenylalanine, 98%	H51963	130
N-Boc-3-fluoro-L-phenylalanine, 95%	H51988	130
N(ω)-Boc-N(β)-Fmoc-L-β-homolysine, 95%	H52189	130
N(ε)-Boc-N(α)-Fmoc-D-lysine, 98%	H28301	130
N-Boc-D-glutamic acid 1-benzyl ester, 99%	B21944	130
N-Boc-L-β-glutamic acid 5-benzyl ester, 95%	H52191	131
N-Boc-L-glutamic acid 5-tert-butyl ester, 99%	B22322	131
N(α)-Boc-D-glutamine, 98+%	L08536	131
N(α)-Boc-L-glutamine, 98+%	L08604	131
N-Boc-glycine, 98+%	A11579	131
N(α)-Boc-D-histidine, 98+%	L08810	131
N(α)-Boc-L-histidine, 98+%	B22042	131
N-Boc-4-iodo-L-phenylalanine, 98%	H51960	131
N-Boc-D-leucine hydrate, 98+%	L09124	131
N(ε)-Boc-L-lysine, 97%	B21738	131
N-Boc-L-tert-leucine, 98%	H51136	133
N-Boc-D-methionine, 98+%	L09207	131
N-Boc-L-methionine, 98+%	L08366	131
N-Boc-4-methoxy-D-phenylalanine, 95%	H52082	131
N-Boc-N-methyl-L-alanine, 98%	H31317	131
N-Boc-4-methyl-L-phenylalanine, 95%	H51983	132
N-Boc-2-methyl-D-serine, 97%	H52787	132
N-Boc-2-methyl-L-serine, 97%	H52570	132
N-Boc-3-nitro-L-phenylalanine, 95%	H52058	132
N-Boc-4-nitro-L-phenylalanine, 95%	H51986	132
N-Boc-L-norvaline, 98+%	L08615	132
N-Boc-D-phenylalanine, 98%	L08722	132
N-Boc-L-phenylalanine, 99%	A16017	132
N-Boc-D-phenylglycine, 99%	L18540	132
N-Boc-L-phenylglycine, 99%	L18541	132
N-Boc-D-proline, 98+%	L08826	132
N-Boc-L-proline, 99%	A13744	132
N-Boc-L-prolinol, 98+%	L09885	132
N-Boc-2-propargyl-L-glycine, 95%	H52128	132
N-Boc-D-serine, 98+%	L08904	132
N-Boc-L-serine, 98% (dry wt.), may cont. up to 10% water	A16224	132
N-Boc-L-threonine, 98+%	L09111	133
N-Boc-trans-4-hydroxy-L-proline, 97%	H27110	131
N(α)-Boc-D-tryptophan, 97%	L09214	133
N(α)-Boc-L-tryptophan, 98+%	A16023	133
N-Boc-L-tyrosine, 98+%	A10810	133
N-Boc-L-tyrosine methyl ester, 99%	B22164	133
N-Boc-D-valine, 98+%	L09193	133
N-Boc-L-valine, 98+%	A16007	133
4-Bromo-N-Fmoc-L-phenylalanine, 95%	H51978	137
O-tert-Butyl-N-Fmoc-L-β-homoserine, 95%	H52065	141
O-tert-Butyl-N-Fmoc-L-β-homotyrosine, 95%	H52192	141
L-Carnitine, 99+%	A17618	148
4-Chloro-D-phenylalanine, 95%	H51982	158
L-Citrulline, 98%	A13316	165
D-Cycloserine, 98+%	A18000	172
Cystamine dihydrochloride, 97+%	B22873	172
DL-Cysteine, 96%	H56126	172
L-Cysteine, 98+%	A10435	172
D-Cysteine hydrochloride monohydrate, 99%	H27107	173
L-Cysteine hydrochloride monohydrate, 99%	A10389	173
L-Cysteine hydrochloride, anhydrous, 98%	L06328	173
DL-Cystine	J63564	173
D-Cystine, 98%	L13772	173
L-Cystine, 99%	A13762	173
L-Cystine dihydrochloride, 99%	J62292	173
L-Cystine disodium salt monohydrate, 98+%	J63071	173
L-Cystine disodium salt, 98+%	J62310	173
N(α)-Ethoxycarbonyl-L-asparagine, 97%	L09327	214

Contact us for pricing on bulk sizes

Description	Stock #	Page #
L-Lysine monohydrochloride, 99+%	A16249	273
L-Lysine monohydrochloride, Cell Culture Reagent	J62099	273
L-Lysine methyl ester dihydrochloride, 99%	A18157	273
DL-Methionine, 99%	A11457	283
D-Methionine, 99%	B21213	284
L-Methionine, 98+%	A10318	284
L-Methionine, Cell Culture Reagent	J61904	284
DL-Methionine sulfone, 98%	B25094	284
L-Methionine sulfone, 99+%	A17027	284
DL-Methionine sulfoxide, 98+%	A18081	284
L-Methionine sulfoxide	J62873	284
N-Methyl-L-arginine	J62431	286
N-Methyl-D-aspartic acid, 98+%	J61361	286
(R)-(-)-α-Methylhistamine dihydrochloride	J61636	288
α-Methyl-DL-histidine dihydrochloride, 99%	J60865	288
D-(-)-Norleucine, 99%	L08257	304
L-(+)-Norleucine, 99%	L03913	305
DL-Norvaline, 98%	A15900	305
D-Norvaline, 99%	B23444	305
L-Norvaline, 99%	L08658	305
DL-Ornithine monohydrochloride, 99%	A18173	308
D-Ornithine hydrochloride, 98+%	L00793	308
L-Ornithine hydrochloride, 99%	A12111	309
DL-Phenylalanine, 99%	A10132	315
D-Phenylalanine, 99%	A10572	315
L-Phenylalanine, 99%	A13238	315
D-Phenylalaninol, 98%	L09697	316
L-Phenylalaninol, 98%	A11586	316
D-(-)-2-Phenylglycine, 99%	A15669	317
L-(+)-2-Phenylglycine, 98+%	A19360	317
N-Phenylglycine, 97%	A14182	317
Sarcosine, 98%	A14594	340
Sarcosine hydrochloride, 99%	B25536	340
DL-Serine, 99%	A15184	341
D-Serine, 99%	A11353	341
L-Serine, 99%	A11179	341
L-Serine, Cell Culture Reagent	J62187	341
Serotonin hydrochloride, 99%	B21263	342
Taurine, 99%	A12403	359
DL-Threonine, 99%	A10606	368
D-Threonine, 99%	B21177	368
L-Threonine, 98+%	A16851	368
N-Tritylglycine, 97%	L09095	383
DL-Tryptophan, 99%	L05936	384
D-Tryptophan, 99%	A18426	384
L-Tryptophan, 99%	A10230	384
Tryptophol, 97%	L02555	385
L-Tyrosine disodium salt dihydrate, 99%	J61770	386
DL-Valine, 99%	A16756	390
D-Valine, 98+%	A18894	390
L-Valine, 99%	A12720	390

Contact us for pricing on bulk sizes

Antibiotics

Antibiotics are molecules that either kill or prevent the growth of microorganisms. The term antibiotic is frequently used interchangeably with the word antibacterial, but antiviral, antifungal and antineoplastic compounds are also classified as antibiotics. Antibiotics work by a number of different actions including inhibition or regulation of cell wall synthesis, nucleic acid metabolism, and protein synthesis.

Description	Stock #	Page #
Paromomycin sulfate	J61274	312
Penicillin G potassium salt	J63901	313
Penicillin G sodium salt	J63032	313
Penicillin V potassium salt	J62442	313
Polymixin B sulfate	J63074	325
Puromycin, 98+%	J60175	331
Puromycin dihydrochloride, 99+%	J61278	331
Rapamycin, 99+%	J62473	335
Rifampin, Molecular Biology Grade	J60836	338
Rifamycin SV sodium, 98+%	J63095	338
Spectinomycin dihydrochloride pentahydrate, Cell Culture Grade	J61820	350
Streptomycin sulfate, Cell Culture Reagent	J61299	352
Streptozotocin, 97+%	J61601	352
Sulfacetamide, 98%	A19836	355
Sulfamerazine, 98+%	L04194	355
Tetracycline	J61714	361
Thiamphenicol	J63575	366
Thiostrepton, Streptomyces laurentii, 90+%	J62332	368
Tobramycin sulfate	J62995	370
Tunicamycin, 95%	J62217	385
Tylosin tartrate, 98+%	J62633	386
Valinomycin, 90+%	J62312	390
Vancomycin hydrochloride, Molecular Biology Grade	J62790	390

Contact us for pricing on bulk sizes

Antibodies

An antibody is a large Y-shaped protein that is used by the immune system to identify and neutralize foreign objects such as bacteria and viruses. Using a binding mechanism, an antibody can tag a microbe or an infected cell for attack by other parts of the immune system, or can neutralize its target directly. Alfa Aesar offers antibodies to the cytoskeletal proteins, growth & attachment factors, lipoproteins, hormones and keratinocyte differentiation markers are also offered. Most of the antibodies are provided lyophilized or in buffer containing 0.02% sodium azide.

Apoptosis Reagents

Apoptosis is a highly regulated programmed cell death. It is a critical part of normal cell development, immunity and wound repair. Abnormalities in apoptosis can lead to a variety of pathologies including cancer and neurodegenerative disease. At least three major pathways are known to initiate apoptosis and the choice of the correct apoptosis reagent depends on which of these pathways you desire to activate. This list contains reagents that are commonly used in apoptosis protocols.

Contact us for pricing on bulk sizes

Buffers

Buffers are aqueous solutions of weak acids and their conjugate bases or weak bases and their conjugate acids. Buffers show little change in pH when small amounts of strong acids and bases are added. Buffer solutions are used as a means of keeping pH at a nearly constant value. The pH plays an important role in many biochemical processes and can affect internal and external environments of living tissue. Living organisms have developed mechanisms to maintain a normal pH for each cell or organ system. Buffer solutions are often necessary to maintain the correct pH for enzymes and proteins, as many proteins require very precise conditions to function properly.

Description	Stock #	Page #
ACES, 99%	A11553	69
ACES, 0.5M buffer soln., pH 6.0	J61761	69
ACES, 0.5M buffer soln., pH 6.5	J60366	70
ACES, 0.5M buffer soln., pH 7.0	J60755	70
ACES, 0.5M buffer soln., pH 7.5	J61011	70
Acetate, 1M buffer soln., pH, 3.0	J63876	70
Acetate, 1M buffer soln., pH, 3.5	J60340	70
Acetate, 1M buffer soln., pH, 4.0	J60104	70
Acetate, 1M buffer soln., pH, 5.0	J60964	70
Acetate, 1M buffer soln., pH, 5.5	J61033	70
ADA, 98+%	A15267	78
ADA, 0.2M buffer soln., pH 6.0	J60054	78
ADA, 0.2M buffer soln., pH 6.5	J61259	78
ADA, 0.2M buffer soln., pH 7.0	J61176	78
ADA, 0.2M buffer soln., pH 7.5	J62424	78
Alkaline Phosphatase Buffer-1 (5X)	J62907	89
Alkaline running buffer soln.	J63170	89
2-Amino-2-ethyl-1,3-propanediol, 97%	B24509	94
2-Amino-2-methyl-1,3-propanediol, 99+%	J63144	97
AMP, 0.2M buffer soln., pH 9.0	J62043	102
AMP, 0.2M buffer soln., pH 9.5	J63988	102
AMP, 0.2M buffer soln., pH 10.0	J63290	102
AMP, 0.2M buffer soln., pH 10.5	J62474	102
AMPD, 0.2M buffer soln., pH 7.5	J60276	102
AMPD, 0.2M buffer soln., pH 8.9	J61377	102
AMPD, 0.2M buffer soln., pH 9.5	J60916	102
AMPSO, 98+%	J62378	103
AMPSO, 0.2M buffer soln., pH 8.0	J61467	103
AMPSO, 0.2M buffer soln., pH 8.5	J61238	103
AMPSO, 0.2M buffer soln., pH 9.0	J62328	103
AMPSO, 0.2M buffer soln., pH 9.5	J63354	103
BES, 99%	A16092	123
BES, 0.5M buffer soln., pH 6.0	J60058	123
BES, 0.5M buffer soln., pH 6.5	J60624	123
BES, 0.5M buffer soln., pH 7.0	J60061	123
BES, 0.5M buffer soln., pH 7.5	J63168	123
BES-buffered saline (2X)	J61955	123
Bicarbonate, 1M buffer soln., pH 8.0	J63491	124
Bicarbonate, 1M buffer soln., pH 8.5	J60092	124
Bicarbonate, 1M buffer soln., pH 9.0	J60116	124
BICINE, 99%	A14957	124
BICINE, 0.5M buffer soln., pH 7.5	J60494	124
BICINE, 0.5M buffer soln., pH 8.0	J63924	124
BICINE, 0.5M buffer soln., pH 8.5	J61632	124
BICINE, 0.5M buffer soln., pH 9.0	J62838	124
2,2-Bis(hydroxymethyl)-2,2',2''-nitrilotriethanol, 98+%	B22515	127
BIS-TRIS, 0.5M buffer soln., pH 6.0	J62928	127
BIS-TRIS, 0.5M buffer soln., pH 6.5	J63036	127
BIS-TRIS, 0.5M buffer soln., pH 7.0	J60656	127
BIS-TRIS, 0.5M buffer soln., pH 7.5	J62177	127
1,3-Bis[tris(hydroxymethyl)methylamino]propane, 98+%	43496	128
BIS-TRIS propane, 0.2M buffer soln., pH 7.0	J63555	128
BIS-TRIS propane, 0.2M buffer soln., pH 7.5	J61292	128

Contact us for pricing on bulk sizes

Contact us for pricing on bulk sizes

Description	Stock #	Page #
Phosphate, 0.2M buffer soln., pH 4.4	J60467	319
Phosphate, 0.2M buffer soln., pH 6.8	J60325	319
Phosphate, 0.2M buffer soln., pH 7.0	J60669	319
Phosphate, 0.2M buffer soln., pH 7.2	J62899	319
Phosphate, 0.2M buffer soln., pH 7.4	J60380	319
Phosphate, 0.2M buffer soln., pH 7.5	J61324	319
Phosphate, 0.2M buffer soln., pH 7.6	J61870	319
Phosphate, 0.2M buffer soln., pH 8.0	J60480	319
Phosphate, 0.2M buffer soln., pH 8.5	J61925	319
Phosphate, 0.2M buffer soln., pH 9.0	J63581	320
Phosphate, 0.2M buffer soln., pH 9.5	J60819	320
Phosphate, 0.5M buffer soln., pH 6.5	J60845	320
Phosphate, 0.5M buffer soln., pH 7.0	J62749	320
Phosphate, 0.5M buffer soln., pH 7.2	J63974	320
Phosphate, 0.5M buffer soln., pH 7.4	J60785	320
Phosphate, 0.5M buffer soln., pH 7.5	J63349	320
Phosphate, 0.5M buffer soln., pH 7.6	J60197	320
Phosphate, 0.5M buffer soln., pH 8.0	J61722	320
Phosphate, 0.5M buffer soln., pH 8.5	J61086	320
Phosphate, 0.5M buffer soln., pH 9.0	J62345	320
Phosphate, 0.5M buffer soln., pH 9.5	J62025	320
Phosphate buffered RIPA	J62694	320
Phosphate buffered RIPA (2X)	J60780	320
Phosphate buffered RIPA with glycerol (2X)	J62939	320
Phosphate-buffered saline (PBS, 10X), pH 7.4	J62036	320
Phosphate-buffered saline (PBS, 10X), pH 7.4, for Western blot	J60801	320
Phosphate-buffered saline (PBS, 10X), pH 7.6	J62692	320
Phosphate-buffered saline (PBS, 10X), RNAse free	J62851	320
Phosphate-buffered saline (DPBS, 10X), Dulbecco's formula	J61917	320
Phosphate-buffered saline (PBS, 1X), sterile	J61196	320
Phosphate-buffered saline (PBS, 5X), with EDTA	J60893	320
Phosphate-buffered saline (PBS, 10X), no potassium	J60465	321
Phosphate-Citrate Buffer (5X)	J62982	321
PIPES, 98%	A16090	322
PIPES monosodium salt hydrate, 99%	B21835	322
PIPES, 0.5M buffer soln., pH 5.5	J60891	322
PIPES, 0.5M buffer soln., pH 6.0	J62224	322
PIPES, 0.5M buffer soln., pH 6.5	J61224	322
PIPES, 0.5M buffer soln., pH 6.8	J61786	322
PIPES, 0.5M buffer soln., pH 7.0	J63234	322
PIPES, 0.5M buffer soln., pH 7.5	J63617	322
PIPES, 0.5M buffer soln., pH 8.0	J61406	322
PIPES, 1.0M buffer soln., pH 6.0	J60611	322
PIPES, 1.0M buffer soln., pH 6.5	J60659	322
PIPES, 1.0M buffer soln., pH 6.8	J60300	322
PIPES, 1.0M buffer soln., pH 7.0	J62195	322
PIPES, 1.0M buffer soln., pH 7.5	J62494	322
PIPES, 1.0M buffer soln., pH 8.0	J60618	322
PIPES-buffered saline (5X), pH 6.5	J63152	322
PIPES-buffered saline (5X), pH 6.8	J60947	322
PIPES-buffered saline (5X), pH 7.0	J63543	322
PIPES lysis buffer with NP-40	J62278	322
PIPES lysis buffer with NP-40 (2X)	J60568	322
PIPES lysis buffer with Triton® X-100	J62360	322
PIPES lysis buffer with Triton® X-100 (2X)	J62068	323
POPSO, 0.2M buffer soln., pH 7.0	J63333	326
POPSO, 0.2M buffer soln., pH 7.5	J60869	326
POPSO, 0.2M buffer soln., pH 8.0	J60085	326
POPSO, 0.2M buffer soln., pH 8.5	J60623	326
Potassium acetate, 1M aq. soln., pH 7.5	J62817	326
Potassium acetate, 1M aq. soln., pH 7.5, RNAse free	J60832	326
Potassium acetate, 8M aq. soln., RNAse free	J62856	326
Potassium phosphate, 0.2M buffer soln., pH 7.0	J61261	327
Potassium phosphate, 0.2M buffer soln., pH 7.2	J60664	327
Potassium phosphate, 0.2M buffer soln., pH 7.4	J62397	327
Potassium phosphate, 0.2M buffer soln., pH 7.5	J62239	327

Contact us for pricing on bulk sizes

Description	Stock #	Page #
Potassium phosphate, 0.2M buffer soln., pH 7.6	J63128	327
Potassium phosphate, 0.2M buffer soln., pH 8.0	J60851	327
Potassium phosphate, 0.5M buffer soln., pH 7.0	J60584	327
Potassium phosphate, 0.5M buffer soln., pH 7.2	J60326	327
Potassium phosphate, 0.5M buffer soln., pH 7.4	J61413	327
Potassium phosphate, 0.5M buffer soln., pH 7.5	J61553	327
Potassium phosphate, 0.5M buffer soln., pH 7.6	J63189	327
RBC lysis buffer for human	J62990	335
RBC lysis buffer for mouse	J62150	335
RIPA buffer	J63306	338
RIPA buffer (2X)	J63324	338
RIPA buffer (5X)	J62524	338
RIPA buffer with EDTA	J61529	338
RIPA buffer with EDTA + EGTA	J60645	338
RIPA buffer with EGTA	J61951	338
RIPA with glycerol (2X)	J61734	338
RIPA buffer with Triton® X-100 (1X)	J62725	338
RIPA buffer with Triton® X-100 (2X)	J60488	338
RIPA buffer with Triton® X-100 (5X)	J62885	338
RIPA buffer with Triton® X-100 + 10% glycerol (2X)	J60423	338
RIPA buffer-2	J62189	338
RIPA buffer-2 (2X)	J60629	338
SM buffer, pH 7.5	J61367	342
Sodium acetate, 1M aq. soln., pH 4.5, RNAse free	J63669	342
Sodium acetate, 3M aq. soln., pH 4.5, autoclaved	J61288	343
Sodium acetate, 3M aq. soln., pH 5.2, autoclaved	J63560	343
Sodium acetate, 3M aq. soln., pH 5.2, RNAse free	J61928	343
Sodium acetate, 3M aq. soln., pH 7.0, autoclaved	J60899	343
Sodium acetate, 3M aq. soln., pH 7.0, RNAse free	J61934	343
Sodium bicarbonate, 1M buffer soln., pH 8.0	J62495	343
Sodium bicarbonate, 1M buffer soln., pH 8.5	J60408	344
Sodium bicarbonate, 1M buffer soln., pH 9.0	J60066	344
Sodium bicarbonate, 1M buffer soln., pH 9.4	J62808	344
Sodium bicarbonate, 1M buffer soln., pH 10.0	J63025	344
Sodium borate, 0.5M buffer soln., pH 8.0	J60068	344
Sodium borate, 0.5M buffer soln., pH 8.5	J62902	344
Sodium borate, 0.5M buffer soln., pH 9.0	J63637	344
Sodium cacodylate, 0.1M buffer soln., pH 6.5	J60367	344
Sodium cacodylate, 0.1M buffer soln., pH 6.8	J62202	344
Sodium cacodylate, 0.1M buffer soln., pH 7.0	J60344	344
Sodium citrate, 0.5M buffer soln., pH 5.0	J62918	345
Sodium citrate, 0.5M buffer soln., pH 5.5	J63199	345
Sodium citrate, 0.5M buffer soln., pH 6.0	J61815	345
Sodium citrate, 0.5M buffer soln., pH 6.5	J63888	345
Sodium hydroxide and β-mercaptoethanol buffer	J60415	347
Sodium phosphate, 0.2M buffer soln., pH 7.0	J63482	347
Sodium phosphate, 0.2M buffer soln., pH 7.2	J63816	347
Sodium phosphate, 0.2M buffer soln., pH 7.4	J62152	347
Sodium phosphate, 0.2M buffer soln., pH 7.5	J62041	348
Sodium phosphate, 0.2M buffer soln., pH 7.6	J62815	348
Sodium phosphate, 0.2M buffer soln., pH 8.0	J62733	348
Sodium phosphate, 0.2M buffer soln., pH 8.5	J61372	348
Sodium phosphate, 0.2M buffer soln., pH 9.0	J60565	348
Sodium phosphate, 0.2M buffer soln., pH 9.5	J63159	348
Sodium phosphate, 0.5M buffer soln., pH 7.0	J63791	348
Sodium phosphate, 0.5M buffer soln., pH 7.5	J61561	348
Sodium phosphate, 0.5M buffer soln., pH 7.6	J60158	348
Sodium phosphate, 0.5M buffer soln., pH 8.0	J60825	348
Sodium phosphate, 0.5M buffer soln., pH 8.5	J61151	348
Sodium phosphate, 0.5M buffer soln., pH 9.0	J60651	348
Sodium phosphate, 0.5M buffer soln., pH 9.5	J61456	348
Sodium pyrophosphate, 200mM buffer soln.	J62052	348
SSC buffer (20X)	J60839	351
SSC (20X), RNAse free	J60561	351
SSPE (20X)	J61214	351
SSPE (20X), RNAse free	J60783	351

Contact us for pricing on bulk sizes

Description	Stock #	Page #
Veronal-buffered saline (VBS), 10mM buffer soln., pH 7.4	J63779	391
Veronal-buffered saline with MG + CA (VBS++), 5mM buffer soln., pH 7.2	J60003	391
Veronal-buffered saline with MG + CA (VBS++), 10mM buffer soln., pH 7.2	J63853	391
Veronal-buffered saline with EDTA (VBSE), 5mM buffer soln., pH 7.2	J62759	391
Veronal-buffered saline with EDTA (VBSE), 10mM buffer soln., pH 7.2	J63338	391
Veronal-buffered saline with MG + EGTA (VBSMG), 5mM buffer soln., pH 7.2	J60535	392
Veronal-buffered saline with MG + EGTA (VBSMG), 10mM buffer soln., pH 7.2	J63417	392
Wash buffer, pH 8.0	J61918	393
Wash buffer, 1.0% Triton® X-100, pH 8.0	J60428	393
Wash buffer, 0.5% Tween 20, pH 8.0	J60165	393
Yeast lysis solution for DNA isolation	J61459	395
Zymogram developing buffer (10X), pH 7.45	J61375	397
Zymogram renaturation buffer (10X)	J63137	397
Zymogram sample buffer, pH 6.6	J62774	397

Contact us for pricing on bulk sizes

Carbohydrates and Derivatives

Carbohydrates consist of only carbon, hydrogen and oxygen. This class of molecules includes all sugars and starches, and plays many important roles in living systems. Their major function is the storage and transport of energy. This list includes sugars, sugar alcohols and oligosaccharides.

Contact us for pricing on bulk sizes

Cell Culture Reagents

Cell culture reagents are high purity products suitable for use in cell culture applications. Cell culture reagents include cell culture media, laboratory preparations, biological extracts and sterile reagents.

Contact us for pricing on bulk sizes

Chiral Compounds

Chiral compounds lack an internal plane of symmetry and thus have non-superimposable mirror images. Many biologically active molecules are chiral, including amino acids, DNA, and sugars. Chiral molecules are often useful in drug design and synthesis. This list includes chiral reagents with biological activity. It also includes chiral building blocks useful for drug design.

Description	Stock #	Page #
(R)-(+)-2-Phenyl-1-propanol, 98+%	L13999	318
(S)-(-)-2-Phenyl-1-propanol, 98+%	L13988	318
(R)-2-Phenylpropionamide	J61693	318
(S)-2-Phenylpropionamide	J60150	318
(R)-(+)-1-Phenylpropylamine, ChiPros® 99+%, ee 98%	L16319	318
(S)-(-)-1-Phenylpropylamine, ChiPros® 99+%, ee 99%	L16320	318
(R)-(-)-Prolinol, 98+%	L11109	329
(S)-(+)-Prolinol, 98%	L09779	329
(R)-Tetrahydrofuran-2-carboxamide	J62007	363
(S)-Tetrahydrofuran-2-carboxamide	J60420	363
(R)-(-)-Tetrahydrofurfuryl alcohol, 98+%	L19044	363
(S)-(+)-Tetrahydrofurfuryl alcohol	J62573	363
D-(-)-Valinol, 98%	L14166	390
L-(+)-Valinol, 97%	L11300	390

Contact us for pricing on bulk sizes

Click Chemistry Reagents

Click chemistry is a newer approach to synthesis that makes use of simple, rapid and reliable reactions. It has several benefits over other synthesis approaches such as being orthogonal to conventional methods and occurring under relatively mild conditions. These reactions also proceed with high, almost quantitative, yields. These benefits have made click chemistry reactions a popular method of introducing labels and other tags to biomolecules. The most popular click chemistry reaction is the Huisgen 1,3-dipolar cycloaddition of alkynes to azides, which is generally carried out with catalysis by copper (I), or by introduction of an azide to a strain-promoted cyclooctyne.

Electrophoresis Reagents

Gel electrophoresis is a technique used to separate DNA, RNA and proteins. When an electric current is applied to these molecules in a gel matrix, they can be separated based on their sizes, shapes and net charges. Agarose gels, because of their larger pore size, are used for the separation of large macromolecules such as nucleic acids, large proteins and protein complexes. Polyacrylamide gels are used to separate most proteins and small oligonucleotides that require a small gel pore size for retardation. This list includes reagents that can be used for agarose and polyacrylamide gel electrophoresis

Description	Stock #	Page #
Acridine Orange, dye content 55-65%	L13159	76
Acrylamide, 30% soln, bisacrylamide free	J62100	76
Acrylamide, 40% soln, bisacrylamide free	J62480	77
Acrylamide, electrophoresis grade, 99+%	L15075	77
Acrylamide/Bisacrylamide 19:1, 30% soln	J60126	77
Acrylamide/Bisacrylamide 19:1, 40% soln	J60909	77
Acrylamide/Bisacrylamide 19:1, powder	J60486	77
Acrylamide/Bisacrylamide 29:1, 30% soln	J63279	77
Acrylamide/Bisacrylamide 29:1, 40% soln	J63079	77
Acrylamide/Bisacrylamide 29:1, powder	J60824	77
Acrylamide/Bisacrylamide 37.5:1, 30% soln	J61505	77
Acrylamide/Bisacrylamide 37.5:1, 40% soln	J60868	77
Acrylamide/Bisacrylamide 37.5:1, powder	J61220	77
Acrylamide/Bisacrylamide 39:1, 30% soln	J60412	77
Acrylamide/Bisacrylamide 39:1, 40% soln	J63323	77
Agarose, high EEO	J60299	81
Agarose, high melting temperature, high resolution	J62714	81
Agarose, high melting temperature, medium resolution	J61123	81
Agarose D1-LE, molecular biology grade	H26855	81
Agarose gel loading dye (6X), alkaline	J62157	81
Agarose gel loading dye (6X), Ficoll based	J62800	81
Agarose gel loading dye (6X), glycerol based	J63869	81
Agarose gel loading dye (6X), glycerol based, bromophenol free	J63429	81
Agarose gel loading dye (6X) glycerol based, Xylene Cyanol FF free	J60933	81
Agarose gel loading dye (6X), sucrose based	J60333	81
Alcian Blue 8GX	J60122	85
Alkaline running buffer soln.	J63170	89
Amido Black 10B	A11374	91
2-Amino-2-methyl-1-propanol, 95%, may cont. ca 5% water	A17814	97
Ammonium chloride, ACS, 99.5% min	40193	101
Ammonium chloride, 99.5% min	12361	101
Ammonium peroxydisulfate, 98%	A10533	101
Ammonium peroxydisulfate, Electrophoresis Grade	J61856	102
Ammonium sulfate, ACS, 99.0% min	11566	102
Ammonium sulfate, 99.95% (metals basis)	89363	102
Bathocuproin sulfonate disodium salt hydrate, 97%	B22550	118
N,N'-Bis(acryloyl)cystamine, 98%	44132	126
bis-Benzimide H-33342 trihydrochloride trihydrate, 98%	J62134	126
Boric acid, ACS, 99.5% min	33253	134
Brilliant Blue G, ultrapure	43318	135
Bromophenol Blue sodium salt	A16899	137
Cesium chloride, 99.9% (metals basis)	10018	152
CHAPS, 98+%	B21927	152
N,N'-Diallyl-L-tartardiamide, 99%	A12195	182
N,N'-(1,2-Dihydroxyethylene)bisacrylamide, 97%	L19211	192
Dimethylsuberimidate dihydrochloride	43244	197
Dimethyl sulfoxide, ACS, 99.9% min	36480	197
1,4-Dithioerythritol, 99%	A10138	200
1,4-Dithio-DL-threitol, 99%	A15797	200
DNA marker, broad range	J62291	200
DNA marker, high range, 1,000 Base Pair Ladder	J63178	200
DNA marker, low range, 250 Base Pair Ladder	J63973	200

Contact us for pricing on bulk sizes

Description	Stock #	Page #
Riboflavin-5'-phosphate sodium salt dihydrate	A14545	337
RNA sample loading buffer	J62832	339
RNA sample loading buffer (6X)	J62468	339
RNA sample loading buffer, no ethidium bromide	J61937	339
Separating or resolving buffer (4X)	J60181	341
Sodium n-dodecyl sulfate, 99% (dry wt.), water <1.5%	A11183	346
Stacking buffer (4X)	J63450	351
Stains-All, 95%	J62630	351
5-Sulfosalicylic acid dihydrate, ACS, 99+%	43144	356
TAE (10X), TRIS + acetate + EDTA	J63677	357
TAE (50X), TRIS + acetate + EDTA	J63931	357
TBE sample buffer (6X)	J60357	359
TBE running buffer (10X)	J62788	359
TBE urea sample buffer (2X)	J60186	359
N,N,N',N'-Tetramethylethylenediamine, 99%	A12536	364
N,N,N',N'-Tetramethylethylenediamine, Electrophoresis Grade	J63734	365
Transfer or electro blotting buffer (10X), pH 8.5	J63037	373
Tricine-SDS Sample Buffer (2X), non-reducing	J62677	375
Tricine-SDS Sample Buffer (2X), reducing	J61042	375
TRIS-CAPS buffer (10X)	J61339	381
TRIS-glycine-native running buffer (10X), pH 8.5	J62914	381
TRIS-glycine-SDS running buffer (10X), pH 8.3	J61006	381
TRIS-glycine native sample buffer (4X), pH 8.6	J61864	381
TRIS-HEPES-native running buffer (10X), pH 8.0	J62737	382
TRIS-HEPES-SDS running buffer (10X), pH 8.0	J61789	382
TRIS-Tricine-SDS kit (10X)	J63948	383
TRIS-Tricine-SDS running buffer (10X), anode buffer, pH 8.9	J63375	383
TRIS-Tricine-SDS running buffer (10X), cathode buffer, pH 8.3	J60992	383
Tris(hydroxymethyl)aminomethane, ACS, 99.8-100.1% (Assay, dried basis)	31801	382
Tris(hydroxymethyl)aminomethane, Electrophoresis Grade, 99.5%	J61016	382
Tris(hydroxymethyl)aminomethane, Electrophoresis Grade, 99.9%	J62569	382
Tris(hydroxymethyl)aminomethane hydrochloride, 99+%	A11379	382
Urea, 98+%	A12360	388
Urea, ACS, 99.0-100.5%	36428	388
Water, RNase, DNase-free	J60610	393
Xylenecyanol FF, dye content 70%	B21530	394
Zymogram developing buffer (10X), pH 7.45	J61375	397
Zymogram renaturation buffer (10X)	J63137	397
Zymogram sample buffer, pH 6.6	J62774	397

Contact us for pricing on bulk sizes

Electrophoresis Reagents - Buffers

The buffer system in electrophoresis controls the pH of the gel, acting to prevent damage to sample molecules and controlling the ionization state of the molecules. Electrophoresis buffers also provide ions that carry the electric current through the gel matrix. Common electrophoresis buffers include TAE buffer for agarose gel electrophoresis and Tris-glycine for PAGE.

Description	Stock #	Page #
Alkaline running buffer soln.	J63170	89
2-Amino-2-methyl-1-propanol, 95%, may cont. ca 5% water	A17814	97
Citric acid, 99+%	A10395	164
Ethylenediaminetetraacetic acid, 99%	A10713	215
Ethylenediaminetetraacetic acid, ACS, 99.4+%	11931	215
Ethylenediaminetetraacetic acid disodium salt dihydrate, ACS, 99.0-101.0%	33312	216
HEPES hemisodium salt	J61830	242
HEPES sodium salt, 99%	A16516	242
IEF Anode buffer (50X)	J63303	253
IEF Cathode buffer (10X) with lysine	J61903	253
IEF Cathode buffer (10X) with lysine and arginine	J62204	253
IEF Sample buffer (2X) pH 3-10 with lysine and arginine	J62241	253
IEF Sample buffer (4X) pH 3-7 with lysine	J63633	253
Laemmli SDS sample buffer, non-reducing (4X)	J63615	265
Laemmli SDS sample buffer, reducing (4X)	J60015	265
Laemmli SDS sample buffer with pyronin Y, non-reducing (4X)	J61716	265
Laemmli SDS sample buffer with pyronin Y, reducing (4X)	J62115	266
LDS-sample buffer (4X), non-reducing	J61894	267
LDS-sample buffer (4X), reducing	J61942	267
MES-SDS running buffer (20X)	J62138	283
MOPS-SDS running buffer (20X)	J62847	295
Separating or resolving buffer (4X)	J60181	341
Stacking buffer (4X)	J63450	351
TAE (10X), TRIS + acetate + EDTA	J63677	357
TAE (50X), TRIS + acetate + EDTA	J63931	357
TBE sample buffer (6X)	J60357	359
TBE running buffer (10X)	J62788	359
TBE urea sample buffer (2X)	J60186	359
Transfer or electro blotting buffer (10X), pH 8.5	J63037	373
Tricine-SDS Sample Buffer (2X), non-reducing	J62677	375
Tricine-SDS Sample Buffer (2X), reducing	J61042	375
TRIS-CAPS buffer (10X)	J61339	381
TRIS-glycine-native running buffer (10X), pH 8.5	J62914	381
TRIS-glycine-SDS running buffer (10X), pH 8.3	J61006	381
TRIS-glycine native sample buffer (4X), pH 8.6	J61864	381
TRIS-HEPES-native running buffer (10X), pH 8.0	J62737	382
TRIS-HEPES-SDS running buffer (10X), pH 8.0	J61789	382
TRIS-Tricine-SDS kit (10X)	J63948	383
TRIS-Tricine-SDS running buffer (10X), anode buffer, pH 8.9	J63375	383
TRIS-Tricine-SDS running buffer (10X), cathode buffer, pH 8.3	J60992	383
Tris(hydroxymethyl)aminomethane, ACS, 99.8-100.1% (Assay, dried basis)	31801	382
Tris(hydroxymethyl)aminomethane, Electrophoresis Grade, 99.5%	J61016	382
Tris(hydroxymethyl)aminomethane, Electrophoresis Grade, 99.9%	J62569	382
Tris(hydroxymethyl)aminomethane hydrochloride, 99+%	A11379	382
Zymogram developing buffer (10X), pH 7.45	J61375	397
Zymogram renaturation buffer (10X)	J63137	397
Zymogram sample buffer, pH 6.6	J62774	397

Electrophoresis Reagents - Co-monomers

Polyacrylamide gels are formed by the polymerization of acrylamide monomer in aqueous solution in the presence of small amounts of a bifunctional crosslinker. In most cases the cross linker is N, N'-methylenebisacrylamide, but others such as N, N'-bis(acryloyl)cystamine and N, N'-diallyl-L-tartardiamide are sometimes used. Crosslinking of these co-monomers produces a three-dimensional mesh-like gel matrix that enables the purification of macromolecules. This list includes acrylamide, bisacrylamide, and premixed mixtures for PAGE gel casting.

Description	Stock #	Page #
Acrylamide, 30% soln, bisacrylamide free	J62100	76
Acrylamide, 40% soln, bisacrylamide free	J62480	77
Acrylamide, electrophoresis grade, 99+%	L15075	77
Acrylamide/Bisacrylamide 19:1, 30% soln	J60126	77
Acrylamide/Bisacrylamide 19:1, 40% soln	J60909	77
Acrylamide/Bisacrylamide 19:1, powder	J60486	77
Acrylamide/Bisacrylamide 29:1, 30% soln	J63279	77
Acrylamide/Bisacrylamide 29:1, 40% soln	J63079	77
Acrylamide/Bisacrylamide 29:1, powder	J60824	77
Acrylamide/Bisacrylamide 37.5:1, 30% soln	J61505	77
Acrylamide/Bisacrylamide 37.5:1, 40% soln	J60868	77
Acrylamide/Bisacrylamide 37.5:1, powder	J61220	77
Acrylamide/Bisacrylamide 39:1, 30% soln	J60412	77
Acrylamide/Bisacrylamide 39:1, 40% soln	J63323	77
N,N'-Bis(acryloyl)cystamine, 98%	44132	126
N,N'-Diallyl-L-tartardiamide, 99%	A12195	182
1,4-Diacryloylpiperazine, 97%	L15694	182
N,N'-(1,2-Dihydroxyethylene)bisacrylamide, 97%	L19211	192
N,N'-Methylenebisacrylamide, 2% soln.	J63265	287
N,N'-Methylenebisacrylamide, 99+%	43701	287

Contact us for pricing on bulk sizes

Electrophoresis Reagents - Initiators of Polymerization

Crosslinking in polyacrylamide gels is achieved by the addition of a catalyst. The most common system of catalytic initiation involves the production of free oxygen radicals by ammonium persulfate in the presence of the tertiary aliphatic amine N,N,N',N'-tetramethylethylenediamine (TEMED). Initiation can also be achieved by a photochemical process where a very small amount of riboflavin is added in the presence of TEMED; however, gelation may take longer with this method.

Description	Stock #	Page #
Ammonium peroxydisulfate, 98%	A10533	101
Ammonium peroxydisulfate, Electrophoresis Grade	J61856	102
Potassium peroxydisulfate, ACS, 99.0% min	13145	327
Riboflavin, 98%	A11764	337
Riboflavin-5'-phosphate sodium salt dihydrate	A14545	337
N,N,N',N'-Tetramethylethylenediamine, 99%	A12536	364
N,N,N',N'-Tetramethylethylenediamine, Electrophoresis Grade	J63734	365

Electrophoresis Reagents - Protein Purification

These items can be used to isolate and purify proteins that have been separated by PAGE.

Description	Stock #	Page #
Ammonium chloride, 99.5% min	12361	101
Ammonium sulfate, 99.95% (metals basis)	89363	102
Boric acid, ACS, 99.5% min	33253	134
Cesium chloride, 99.9% (metals basis)	10018	152
Cesium chloride, 99.999+% (metals basis)	89188	152
Cesium hydroxide hydrate, 99.9% (metals basis)	13233	152
Cesium nitrate, 99.8% (metals basis)	12884	152
CHAPS, 98+%	B21927	152
Chloroform, HPLC Grade, 99.5+% min	22920	156
Chloroform, HPLC Grade, 99.5+% min, stab. with amylene	43685	156
Chloroform, Spectrophotometric Grade, 99.5+%	32442	156
Chloroform, ethanol-free, 99+%, stab. with ca 50 ppm amylene	L14759	156
Dimethylsuberimidate dihydrochloride	43244	197
Dimethyl sulfoxide, ACS, 99.9% min	36480	197
1,4-Dithioerythritol, 99%	A10138	200
1,4-Dithio-DL-threitol, 99%	A15797	200
Ethidium bromide soln., 10mg/ml	J62282	214
Ethidium bromide, 98% (dry wt.)	L07482	214
Ethidium bromide de-staining bags	J62931	214
Formamide, ACS, 99.5+%	14835	227
(1-Hexadecyl)trimethylammonium bromide, 98%	A15235	244
N-Lauroylsarcosine sodium salt, 95%	J60040	266
2-Mercaptoethanol, 98+%	A15890	281
n-Octyl-β-D-thioglucopyranoside, 98+%	J61028	306
Phenol:Chloroform:Isoamyl alcohol 25:24:1, Ready-to-use saturated aq. soln., pH 5.2, with alkaline buffer	J62336	314
Phenol:Chloroform:Isoamyl alcohol 25:24:1, Ready-to-use saturated aq. soln., pH 6.7, with alkaline buffer	J60331	314
Phenol:Chloroform 1:1, Ready-to-use soln., pH 6.7, with alkaline buffer	J63452	314
Polyethyleneimine, M.W. 60,000, 50% w/w aq. soln.	J61270	324
Polysorbate 20	L15029	325
Polysorbate 80	L13315	325
Proteinase K, Ready-to-use soln.	J63710	331
Sodium n-dodecyl sulfate, 99% (dry wt.), water <1.5%	A11183	346
5-Sulfosalicylic acid dihydrate, ACS, 99+%	43144	356
Urea, 98+%	A12360	388
Water, RNase, DNase-free	J60610	393

Contact us for pricing on bulk sizes

Electrophoresis Reagents - Stains

Stains bind non-specifically to peptides, proteins and oligonucleotides and are used to visualize their location within the gel matrices. The most common dye for DNA or RNA staining is ethidium bromide while Brilliant Blue is traditionally used for protein staining.

Description	Stock #	Page #
Acridine Orange, dye content 55-65%	L13159	76
Alcian Blue 8GX	J60122	85
Amido Black 10B	A11374	91
Bathocuproin sulfonate disodium salt hydrate, 97%	B22550	118
bis-Benzimide H-33342 trihydrochloride trihydrate, 98%	J62134	126
Brilliant Blue G soln., Ready-to-Use	J63797	135
Brilliant Blue R	J64297	135
Brilliant Blue R soln., Ready-to-Use	J61384	135
Bromophenol Blue sodium salt	A16899	137
Ethidium bromide soln., 0.625mg/ml	J62029	214
Fast Green FCF	A16520	219
India Ink	J61007	255
Methyl Green, zinc chloride	J61509	288
Orange G, Electrophoresis Grade	J62743	308
Ponceau S, Electrophoresis Grade	J60744	325
Pyronin Y	J61068	332
Rapid stain R-250	J61969	335
Stains-All, 95%	J62630	351
Xylenecyanol FF, dye content 70%	B21530	394

Enzymes

Enzymes are proteins that catalyze biochemical reactions on specific substrates. Enzymes serve a wide variety of functions inside living organisms and play important roles in cell cycle regulation and metabolism.

Description	Stock #	Page #
Alcohol dehydrogenase kit - 12 variants (A1 through A12)	J64628	85
Alcohol dehydrogenase kit - 35 variants (A1 through A35)	J64194	85
Alcohol dehydrogenase, yeast	J65869	85
R1-Alcohol Dehydrogenase	45391	87
R2-Alcohol Dehydrogenase	45393	87
S1-Alcohol Dehydrogenase	45392	87
S2-Alcohol Dehydrogenase	45394	87
S3-Alcohol Dehydrogenase	45395	87
S4-Alcohol Dehydrogenase	45397	87
S5-Alcohol Dehydrogenase	45399	87
S6-Alcohol Dehydrogenase	45401	87
Aldehyde Dehydrogenase Kit - 5 variants (AD1 through AD5)	J64713	87
Aldehyde Reductase Kit - 10 variants (AR1-AR10)	J65717	88
Alkaline Phosphatase, calf intestine, EIA Grade	J61037	89
Cathepsin G, 95%	J61280	150
Cellulase, chromatographically purified, T. reesei	J64019	151
Clostripain, Clostridium histolyticum	J61362	166
Cofactor Recycling Enzymes Kit - 8 variants	J64535	166
Collagenase, Type I, Clostridium histolyticum	J62406	167
Deoxyribonuclease I, bovine pancreas	J62229	179
Deoxyribonuclease II, porcine spleen	J63389	179
DNA Polymerase I Large (Klenow Fragment)	J65056	106
Elastase, porcine pancreas	J61874	205
Ene Reductase Kit - 8 variants (ENR1 through ENR8)	J64291	206
Esterase Kit - 50 variants (E1 through E50)	J65256	211
Esterase Kit - 30 variants (E1 through E30)	J64957	210
Ficin, fig tree latex	J60136	221
Formate Dehydrogenase	J65016	227
Glucose Dehydrogenase variant B	J65832	233
Glucose-6-phosphate dehydrogenase, Leuconostoc mesenteroides	J60117	234
Glucose-6-phosphate dehydrogenase, yeast	J61181	234
Glutamic oxalacetic transaminase, porcine heart	J60044	235
Glutamic pyruvic transaminase, porcine heart	J62109	235
Hexokinase, yeast	J63795	245
Isocitrate Dehydrogenase	J65073	260
Lactate dehydrogenase, rabbit muscle	J63220	265
Lipase, from porcine pancreas	J62903	270
Lipase Kit - 12 variants (L1 through L12)	J64732	270
Lysozyme, chicken egg white	J60701	274
Malic decarboxylase variant A	J65970	276
Malic decarboxylase variant B	J64878	276
Neuraminidase, Clostridium perfringens	J63259	300
Pancreatin, porcine pancreas	J62162	311
Papain, Carica Papaya Latex	J61875	311
Pectinase, Aspergillus niger	J63408	312
Pepsin, porcine stomach	J61679	313
Peroxidase, horseradish	J60026	314
Phenylalanine Dehydrogenase	J64524	316
Proteinase K, Tritirachium album limber	J62051	331
Proteinase K, Ready-to-use soln.	J63710	331
Pyruvate Kinase, rabbit muscle	J61373	333
Reverse Transcriptase, Avian Myeloblastosis Virus in phosphate buffer	J65829	336
Reverse Transcriptase, murine, Moloney Murine Leukemia Virus	J60167	336
Ribonuclease, bovine pancreas	J62952	337
Ribonuclease A, bovine pancreas, purified	J61996	337
Ribonuclease B, bovine pancreas	J62334	337
Ribonuclease T1, Aspergillus oryzae in 2.8M ammonium sulfate	J61644	337
SP6 RNA Polymerase in Tris buffer	J65792	350
SP6 RNA Polymerase in potassium phosphate buffer	J65573	350

Contact us for pricing on bulk sizes

Description	Stock #	Page #
Superoxide Dismutase, bovine erythrocytes	J63003	356
T4 DNA Ligase, 99+%, in 10mM Tris HCl and 50mM NaCl	J65133	357
T4 DNA Ligase, in 20mM Tris HCl and 50mM KCl	J65312	357
T4 Polynucleotide Kinase	J65162	372
T7 RNA Polymerase, in 20mM potassium phosphate and 10mM DTT	J65896	357
Taq DNA Polymerase	J64594	358
Transaminase Kit - 12 variants (TA1 through TA12)	J64941	372
Transaminase Kit - 20 variants (TA1 through TA20)	J64306	372
Trypsin, bovine pancreas	J63688	384
Trypsin 1:250, porcine pancreas	J63993	384
Trypsin, porcine pancreas	J60402	384
Urease, Jack Beans	J61455	388
Uricase, Candida utilis	J60875	389
Urokinase, human urine	J60553	389
Yeast Lytic Enzyme, Arthrobacter luteus	J63195	395

Growth Factors

Growth factors are naturally occurring substances which stimulate cellular growth, proliferation and cellular differentiation. Growth factors are important for regulating cellular processes and act as signaling molecules between cells. Our extensive product line includes receptor-grade, aseptically packaged GFs and AFs. These are highly purified proteins that have been membrane filtered, aseptically filled and lyophilized.

Contact us for pricing on bulk sizes

Natural Products

Natural products are chemical compounds that are synthesized in organisms. These compounds often play an important role in the development of medicinal compounds. Our list of natural products include steroids, terpenes, glycosides, and several alkaloids among other biochemicals.

Description	Stock #	Page #
Melatonin, 99+%	J62452	279
Mucin, bovine submaxillary gland	J63859	296
Myricetin, 98%	J60450	296
(+)-Nootkatone, crystalline, 98+%	A19166	304
D-Pinitol, 95%	H56648	321
Safflower oil, Carthamus tinctorius	J63982	339
Sodium cholate hydrate, 99%	A17074	345
Sodium DL-lactate, 60% w/w aq. soln.	41529	347
Sodium taurocholate hydrate, 97%	A18346	349
Soybean oil	J61399	350
α-Terpineol, 96%	16285	360
Thrombin, bovine plasma	J63383	368
Tragacanth powder	A18502	372
Transferrin (Apo), bovine plasma, 98+%	J61626	373
Transferrin (Holo), bovine plasma, 98+%	J61046	373
Ursodeoxycholic acid, 99%	B20490	389
Wheat Germ Oil	J63969	393
Yeast extract	J60287	395
2X YT Microbial medium	J63227	395

Nucleosides and Nucleotides

Nucleotides and nucleosides are the building blocks of RNA and DNA and are derived from nitrogenous bases. These nitrogenous bases are either purines (adenine and guanine) or pyrimidines (cytosine, uracil, and thymine). Nucleosides consist of a purine or pyrimidine base linked to a pentose sugar. Nucleotides consist of nucleosides with one or more phosphate groups.

Contact us for pricing on bulk sizes

Description	Stock #	Page #
4(3H)-Pyrimidone, 98+%	A10859	332
Ribonucleic acid from Baker's yeast	J61215	337
Theobromine, 99%	A11861	365
Theophylline	J60203	366
6-Thioguanine, 98%	B21280	367
Thionicotinamide, 98%	A11144	367
2-Thiouracil, 98%	A18119	368
4-Thiouridine, 98+%	J60679	368
Thymidine, 99%	A11493	369
Thymidine-5'-monophosphate disodium salt	J60747	369
Thymine, 97%	A15879	369
L-Thyroxine, 98%	J62606	370
3,3',5'-Triiodo-L-thyronine sodium salt	J63312	378
Uracil, 99+%	A15570	388
Uridine, 99%	A15227	389
Uridine-5'-diphosphate disodium salt, 98%	J64329	389
Uridine-5'-diphosphate sodium salt, 98+%	J60141	389
Uridine-5'-monophosphate disodium salt, 99%	A18601	389
Uridine-5'-triphosphate trisodium salt, 98+%	J63427	389
Xanthine, 99%	A11077	393

Contact us for pricing on bulk sizes

Peptides

Peptides are chains of less than 100 amino acids. They are key regulators of many biological functions including hormone release and various neurological processes. We offer a variety of peptides for biological research, including several opioid and neuropeptides.

Contact us for pricing on bulk sizes

Description	Stock #	Page #
α-Neo-Endorphin (1-7)	J65680	299
[Met5, Lys6] α-Neo-Endorphin (1-6)	J65819	299
[Met5, Lys6,7] α-Neo-Endorphin (1-7)	J64851	299
Neuromedin N	J63747	300
Neurotensin	J63359	300
Neurotensin (1-6)	J62461	300
Neurotensin (1-8)	J62253	300
Neurotensin (1-11)	J63799	300
Neurotensin (8-13)	J61112	300
Opiorphin	J62709	308
Orexin A, human	J65378	308
Orexin B, canine	J65811	308
Orexin B, human	J65110	308
Orexin B, mouse, rat	J65275	308
[Ala^{11}, D-Leu^{1}_{5}] Orexin B, human	J64476	308
Osteocalcin (1-49), human	J65012	309
Osteocalcin (7-19), human	J65386	309
Osteocalcin (45-49), human	J65959	309
Oxytocin, 96%	J63421	311
L-Phenylalanyl-L-phenylalanine	J60043	316
L-Phenylalanyl-L-proline	J60063	316
Physalaemin	J62647	321
Proctolin	J60532	328
Protein Kinase C Substrate	J61622	331
Protein Kinase Inhibitor	J61687	331
Ranatensin, 96%	J61334	335
Rigin, 96%	J63099	338
Substance P	J63489	353
Substance P free acid	J61828	353
Substance P (1-4)	J62756	353
Substance P (1-7), 96%	J60018	353
Substance P (4-11)	J61891	353
Substance P (6-11)	J63228	353
Syntide 2, 96%	J62843	357
Thymopentin, 99+%	J61431	369
Thyrotropin-Releasing Hormone	J62120	370
Tocinoic acid, 96%	J62846	370
Tuftsin, 96%	J63904	385
Uroguanylin, human	J65601	389
Vapreotide	J61096	391
Vasoactive Intestinal Peptide, human, porcine, rat	J63980	391
Vasopressin, 98+%	J61248	391
Xenopsin	J61481	394

Signal Transduction Reagents

Signal transduction involves the binding of extracellular signaling molecules and ligands to cell-surface receptors. This binding event leads to changes in the cell's biochemistry, cytoskeletal structure or gene transcription. This list includes some common ligands involved in cell signaling pathways.

Description	Stock #	Page #
Acebutolol hydrochloride	J63790	69
L-Adrenaline, 98+%	L04911	80
Alaproclate hydrochloride, 96%	J62741	82
9-Aminoacridine hydrochloride hydrate, 99%	B24356	91
Bexarotene, 99+%	J63701	124
Bromhexine hydrochloride, 98+%	J63451	135
Colcemid, 98+%	J63900	167
Colchicine, 98+%	J61072	167
Cytochalasin A	J60280	174
Dicyclomine hydrochloride	J61422	187
3,4-Dihydroxyphenylacetic acid, 98+%	A15893	193
3,4-Dihydroxy-DL-phenylalanine, 98%	41535	193
3,4-Dihydroxy-L-phenylalanine, 98+%	A11311	193
(-)-Epigallocatechin gallate	J61745	209
Forskolin, 98+%	J63292	228
1-n-Hexyltheobromine, 98+%	L13597	245
5-Hydroxyindole-3-acetic acid, 98%	J61435	249
6-Hydroxynicotinic acid, 98%	A15802	250
4-Hydroxy-TEMPO, free radical, 98+%	A12497	252
2-Mercaptoethane sulfonic acid sodium salt, 96%	J63989	281
2-Mercaptoethylamine hydrochloride, 98+%	A14377	281
2-Mercapto-1-methylimidazole, 98%	A13094	281
Nω-Methyl-L-arginine acetate, 99+%	J60890	286
N-Methyldeoxynojirimycin	J60509	287
1-(1-Naphthyl)piperazine hydrochloride	J62097	298
Nefazodone hydrochloride, 98+%	J62793	299
L-Noradrenaline, 98%	L08087	304
(±)-Octopamine hydrochloride, 99%	J61281	306
1H-[1,2,4]Oxadiazolo[4,3-a]-quinoxalin-1-one, 99+%	J62250	310
D-(-)-Penicillamine, 99%	A11446	313
Phenylbutazone, 98%	L03449	316
1-Pyrrolidinecarbodithioic acid ammonium salt, 98%	B23731	333
Rapamycin, 99+%	J62473	335
Serotonin hydrochloride, 99%	B21263	342
(-)-Shikimic acid, 98%	L04848	342
Sulindac	J61772	356
Tacrine hydrochloride hydrate, 98+%	J60070	357
Tamm Horsfall Glycoprotein, human, 99%	J64893	357
Thalidomide	J60271	365
(±)-Thalidomide, 99+%	J62266	365
DL-Thioctic acid, 98%	L04711	366
Tolmetin sodium salt dihydrate, 98+%	J62663	371
Triamcinolone acetonide, 98+%	J63548	374
Trimethoprim	J63053	378
Valethamate bromide, 99%	J62622	390
Vincamine, 98%	J60545	392

Signal Transduction Reagents - Agonists

Agonists bind to receptors and elicit a biological response. This list includes both natural ligands for receptors as well as synthetic agonists.

Description	Stock #	Page #
O-Acetyl-L-carnitine hydrochloride	J61536	71
S-Acetylthiocholine iodide, 98%	A16802	75
(±)-Anabasine, tech. 85%	L12089	103
Arvanil, 98%	J62812	110
(±)-Baclofen, 99+%	J62768	116
Bisacodyl, 98+%	J61997	126
Bryostatin 1	J63848	139
Bryostatin 2	J61551	139
Buspirone hydrochloride	J60476	140
Calcium-Like Peptide	J60926	143
Capsaicin	J62865	146
Carbachol, 99%	L06674	146
Carbamazepine, 98%	J62590	146
CGS 12066B dimaleate, 98+%	J63801	152
CGS 21680 hydrochloride, 99+%	J60793	152
2-Chloroadenosine	J63810	155
1-(3-Chlorophenyl)biguanide hydrochloride, 97%	B20355	158
1-(4-Chlorophenyl)piperazine, 97%	J60278	158
1-(3-Chlorophenyl)piperazine monohydrochloride, 97%	A14057	158
Cimaterol	J60650	163
Clonidine hydrochloride, 98+%	J63707	166
Cloprostenol sodium salt	J60577	166
Deltorphin I	J60952	176
Deltorphin II	J62286	176
Dermorphin	J62019	180
1,10-Diaminodecane, 98%	J63821	183
2,6-Diisopropylphenol, 97%	L06841	193
Dimaprit dihydrochloride	J61079	194
Dobutamine hydrochloride	J61333	201
Domoic acid	J61608	201
Dynorphin A (1-7), porcine	J63897	203
5'-N-Ethylcarboxamidoadenosine	J60405	215
Evodiamine	J62771	218
(±)-7-Hydroxy-2-di-n-propylaminotetralin hydrobromide	J61065	248
Ibotenic acid hydrate, 98+%	J60748	253
Imetit dihydrobromide, 98%	J62346	254
Ingenol 3-angelate, 99%	J60601	256
2-Iodomelatonin, 98+%	J61498	258
Isoguvacine hydrochloride, 99%	J63243	260
Isonipecotic acid, 98%	A11795	261
DL-Isoproterenol hydrochloride, 99%	J61788	261
Isosorbide mononitrate, 98+%	J63674	261
Lofexidine hydrochloride, 98+%	J63960	272
DL-Menthol, 98+%	A18098	280
D-Menthol, 99%	L06102	280
L-Menthol, 99%	A10474	280
N-Methyldopamine hydrochloride, 98+%	J60306	287
Mezerein, Daphne mezereum	J62440	291
Morphiceptin acetate	J61987	296
Muscimol, 99+%	J61720	296
2-(1-Naphthylmethyl)-2-imidazoline nitrate, 99%	L12617	298
Nicergoline	J63295	301
(S)-(-)-Nicotine, 99%	A12398	302
DL-Nornicotine, 98%	L10809	305
Phorbol 12-myristate 13-acetate, 99+%	J63916	319
Pyridine-2,3-dicarboxylic acid, 99%	A11414	332
Pyrilamine maleate	J63247	332
Quipazine dimaleate, 99+%	J61933	334
(+)-Quisqualic acid, 99+%	J61591	334

Contact us for pricing on bulk sizes

Description	Stock #	Page #
Salbutamol, 99%	J63741	339
Spermidine trihydrochloride, 99+%	J61595	351
Spermine, 97%	L19562	351
Spermine tetrahydrochloride, 99%	J63060	351
Tulobuterol	J63975	385
Xylazine	J61430	394
Zolmitriptan	J60616	397

Signal Transduction Reagents - Antagonists

Antagonists are receptor ligands that block or dampen agonist responses upon binding. Antagonists do not provoke any biological effects on their own but prevent actions from agonists.

Contact us for pricing on bulk sizes

Description	Stock #	Page #
Naftopidil, 98+%	J60311	297
Nalidixic acid sodium salt	J63550	297
Naloxone hydrochloride, 98%	J60013	297
Naltrexone hydrochloride	J60590	297
α-Naphthoflavone, 97%	A18542	297
β-Naphthoflavone, 98+%	A18543	297
Phenoxybenzamine hydrochloride	J61900	315
4α-Phorbol 12-myristate 13-acetate, 99%	J61099	319
Pirenzepine dihydrochloride, 99%	J62252	323
Prazosin hydrochloride	J61712	328
Ranitidine hydrochloride, 99%	B22260	335
Rauwolscine hydrochloride, 99%	J63198	335
Saclofen, 99+%	J63345	339
Sotalol hydrochloride, 98%	J63772	350
Tamsulosin hydrochloride, 98+%	J61999	357
Telmisartan, 99%	J61441	360
Terazosin hydrochloride, 99+%	J62055	360
Terfenadine	J61936	360
6,7,8,9-Tetrahydro-5H-benzocycloheptene-5-ol-4-ylidene acetic acid	J63941	362
Thioridazine hydrochloride	J60895	367
3-Tropanyl-3,5-dichlorobenzoate, 99+%	J62583	383
3-Tropanylindole-3-carboxylate hydrochloride	J62807	383
Tropicamide, 99+%	J61132	383
D-Tubocurarine chloride	J60222	385
Urapidil hydrochloride, 98+%	J63219	388
Yohimbine hydrochloride, 98+%	J60185	395

Signal Transduction Reagents - Ca, Na, K Channel Blockers

Calcium, sodium and potassium channels are pore-forming proteins that regulate the flow of ions across cell membranes. They play key roles in many biological processes, but are especially important in neurotransmission. They are also involved in biological activities that involve rapid changes in cells, such as muscle contraction and T-cell activation. Items in this list block or inhibit action by these channel proteins.

Contact us for pricing on bulk sizes

Signal Transduction Reagents - Inhibitors

Inhibitors bind to enzymes and decrease their activity. Many drugs are enzyme inhibitors as they can cause a range of biological actions including correcting metabolic imbalances or inducing cell death.

Contact us for pricing on bulk sizes

Contact us for pricing on bulk sizes

Signal Transduction Reagents - Protease Inhibitors

During protein expression proteases can begin degrading protein samples as soon as cells or tissues are lysed, decreasing the protein yield and quality. In order to preserve the activity and nature of proteins, solutions are usually treated with a mixture of protease inhibitors during cell lysis. We offer a number of protease inhibitors to prevent protein sample degradation by the most common proteases.

Solvents, Acids and Bases

Solvents are used to dissolve other chemicals. For biological applications, water is the most commonly used solvent; however, some procedures require the use of other solvents like DMSO, DMF or acetonitrile. Acids and bases can be used to adjust the pH of biological samples. Alfa Aesar offers a variety of solvents, acids and bases to meet your research needs.

Description	Stock #	Page #
Acetic acid, glacial, ACS, 99.7+%	36289	70
Acetone, ACS, 99.5+%	30698	71
Acetonitrile, ACS, 99.5+%	36423	71
Acetyl chloride, 99+%	43262	71
Ammonium dihydrogen phosphate, ACS, 98.0% min	11598	101
Ammonium hydrogen phosphate, ACS, 98.0% min	11597	101
Ammonium hydroxide, ACS, 28.0-30.0% NH_3	33285	101
Chloroacetic acid, 99%	A11482	154
Chlorosulfonic acid, typically 99%	87977	159
Decahydronaphthalene, cis + trans, 98%	A13883	175
1,2-Dichloroethane, ACS, 99+%	39121	185
Dichloromethane, 99+%, stab. with ca. 50ppm 2-methyl-2-butene	L13089	186
2,6-Dichlorophenol, 99%	A14411	186
Diethylene glycol, 99%	A14728	189
Diethylene glycol diethyl ether, 99%	A17478	189
Diethylene glycol diethyl ether, HPLC Grade, 99+%	43464	189
Diethylene glycol dimethyl ether, 99%, stab. with 100ppm BHT	A13397	189
Diethylene glycol monoethyl ether acetate, 99%	L13446	189
Diethylene glycol monoethyl ether, 98%	A14670	189
2,3-Dihydrofuran, 98+%	B20575	190
N,N-Dimethylformamide, ACS, 99.8+%	39117	197
Dimethyl sulfoxide, ACS, 99.9% min	36480	197
Formic acid, ACS, 96+%	36617	228
Formic acid, 97%	A13285	228
Glycerol, ultrapure, HPLC Grade	38988	236
Glyoxylic acid, 50% w/w aq. soln.	B25149	238
Hydrochloric acid, ACS, HCl 36.5-38.0%	33257	247
Hydrochloric acid, 1.0N Standardized Solution	35640	247
1-Methyl-2-pyrrolidinone, Biograde, 99.5%	44063	290
Methanol, Biograde, 99.8+%	44571	283
Nitric acid, 1.0N Standardized Solution	35624	303
Orthophosphoric acid, 85% w/w aq. soln., ACS	33266	309
Potassium chloride, ACS, 99.0-100.5%	11595	326
Potassium dihydrogen phosphate, ACS, 99.0% min	11594	326
Potassium hydrogen phosphate, ACS, 98.0% min	11593	326
Potassium hydroxide, ACS, 85% min, K_2CO_3 2.0% max	13451	327
Potassium sulfate, ACS, 99.0% min	14311	328
Sodium chloride, ACS, 99.0% min	12314	345
Sodium hydrogen phosphate, anhydrous, ACS, 99.0% min	13437	346
Sodium hydroxide, 10N aq. soln.	J63736	346
Sodium hydroxide (low chloride), ACS, 97.0% min	13455	346
Tetraethylene glycol, 99%	B23880	362
Tetrahydrofuran, Biograde, 99.8%, unstab.	44505	363
Tetrahydrofuran, Spectrophotometric Grade, 99.7+%, unstab.	32468	363
2,2,2-Trifluoroethanol, 99+%	A10788	376

Contact us for pricing on bulk sizes

Stains, Dyes and Indicators

Dyes, stains and indicators are all integral tools in the laboratory. Stains can be used in microbiological assays as well as in histology. Indicators are useful for measuring or setting pH of solutions. Fluorescent dyes are used extensively to label macromolecules in fluorescent microscopy and purification techniques.

Description	Stock #	Page #
2,9-Dimethyl-1,10-phenanthroline, 98%	J63698	197
Direct Red 80	B21693	199
Eosin B	A17377	208
Eosin Yellowish	B24535	208
Eriochrome® Blue Black B	J63396	210
Erioglaucine sodium salt	J61780	210
Erythrosin B	A14180	210
Erythrosin B, spirit soluble	J62619	210
7-Ethoxyresorufin	J62987	214
Ethyl Orange sodium salt	J62863	217
Ethyl Red	J63446	217
Ethyl Violet	J63951	217
Evans Blue	A16774	218
Fast Blue BB base	J62456	218
Fast Blue BB salt	L09704	218
Fast Garnet GBC base	J60574	218
Field's Stain A	A18577	221
Field's Stain B	A18578	221
Fluo 3-AM	J63388	222
Fluorescamine	43749	222
Fluorescein, 90+%	L13251	222
Fluorescein amine isomer I, 96%	J62175	222
Fluorescein amine isomer II, 95%	J60609	223
Fluorescein diacetate, 97%	B24466	223
Fluorescein disodium salt	J61549	223
Fluorescein isothiocyanate, isomer 1, 95%	L09319	223
FURA 2 pentasodium salt	J63686	229
FURA 2-AM	J62728	229
Giemsa Stain	B21172	232
Hematoxylin hydrate, 96% (dry wt.), water ca 6%	A12431	242
India Ink	J61007	255
Indigo carmine	A16052	255
Iodonitrotetrazolium violet, 95%	B22301	258
Janus Green B	A17391	262
Jenner's Stain	J61077	262
Kiton Red S	A14769	264
Leishman Stain	A11644	268
Light Green SF Yellowish	B23330	270
Malachite Green oxalate	A16186	275
Metanil Yellow	A17527	283
7-Methoxycoumarin-4-acetic acid, 99%	J62475	284
Methyl Orange, 0.1% w/v aq. soln.	38695	289
Methyl Orange	A17604	289
Methyl Red, 0.1% w/v solution in ethanol	38698	290
Methyl Red, ACS	36682	290
Methyl Red hydrochloride, ACS	36668	290
Methyl Red sodium salt, ACS	36667	290
Naphthol Green B	A18268	298
Naphthol Yellow S	B20872	298
Neutral Red, 1% aq. solution, Ready-to-use	J61379	300
Neutral Red, ACS	J62643	300
Nigrosin water soluble	A18147	302
Nigrosin, alcohol soluble	J61186	302
Nile Blue A	A17174	302
Ninhydrin, ACS reagent	43846	303
Nitrazine Yellow	J60281	303
Nitro Blue Tetrazolium chloride, 99%	J60230	303
Oil Red O	A12989	307
Orcein, for analysis	B20294	308
Phenolphthalein, 98%	A17135	314
Phenolphthalein, ACS	38705	314
Phenolphthalein, 1% w/v in alcohol	38704	315
Phenol Red, ACS	16294	315
Phenol Red sodium salt, 0.02% w/v aq. soln.	38702	315
Ponceau S, 0.2% v/v soln. in 5% acetic acid	J63139	325
Pyronin Y, 0.2% w/v aq. soln.	J60505	332

Contact us for pricing on bulk sizes

Vitamins

Vitamins are organic compounds required as nutrients by organisms. Organisms do not synthesize sufficient amounts of vitamins and must obtain them through their diet. Vitamins have diverse biochemical functions. Some vitamins, like vitamin D, have hormone-like functions as regulators of mineral metabolism while others, like vitamin E, function as antioxidants. Others still, like members of the B family of vitamins, function as precursors for enzyme cofactors that help enzymes work as catalysts in metabolism.

Description	Stock #	Page #
L-(+)-Ascorbic acid, ACS, 99+%	36237	110
L-Ascorbic acid sodium salt, 99%	A17759	110
L-Ascorbic acid 6-palmitate, 99%	32791	110
D-(+)-Biotin, 98+%	A14207	125
(+)-Biotin N-hydroxysuccinimide ester, 98%	44771	125
Calciferol	J61610	142
Calciferol, 98%	J62163	142
Citric acid, anhydrous, ACS, 99.5+%	36664	164
Flavin adenine dinucleotide disodium salt hydrate, 94% (dry wt.), water <10%	A14495	221
Folic acid, crystalline	J60833	227
Methylcobalamin hydrate, 99%	A11176	286
2-Methyl-1,4-naphthoquinone, 98%	A13593	289
Nicotinamide, 99%	A15970	301
Nicotinic acid, 99%	A12683	302
D-Panthenol, 98+%	A18499	311
D-Pantothenic acid calcium salt hydrate, 98%	A16609	311
Pyridoxal-5-phosphate monohydrate, 98%	A12323	332
Pyridoxamine dihydrochloride, Cell Culture Reagent	J62679	332
9-cis-Retinoic acid	J62219	336
13-cis-Retinoic acid	J61666	336
Retinoic acid, 98%	44540	336
Retinol, 98%, synthetic	J62079	336
Riboflavin, 98%	A11764	337
Thiamine hydrochloride, 99% (dry wt.), may cont. up to 5% water	A19560	366
Thiamine nitrate	J60014	366
Thiamine pyrophosphate chloride, 98%	J61483	366
DL-α-Tocopherol, 97+%	A17039	370
Vitamin A acetate in gelatin, powder, 500,000 I.U./g	A16237	392
Vitamin A palmitate, 98+%	J63022	392
Vitamin B12, 98+% (dry wt basis)	A14894	392
Vitamin D3, 99%	B22524	392
Vitamin E acetate, 97%	A14505	393
Vitamin K_1	L10575	393

Contact us for pricing on bulk sizes

Western Blot and ELISA Reagents

ELISA and Western blotting are common techniques for protein detection and quantification. ELISA is a plate-based assay while Western blots are performed on a membrane surface after transfer from a gel. In both techniques enzyme-linked antibodies are usually used to detect immobilized proteins. This list includes blocking, transfer and wash buffers that are frequently used in ELISA or Western blots. It also includes stains for Western blots and substrates for ELISA.

Description	Stock #	Page #
Alkaline Phosphatase, calf intestine, EIA Grade	J61037	89
3-Amino-9-ethylcarbazole, 95%	B22529	94
Anti-Osteocalcin antibody, RIA Grade	J64638	107
BLOTTO	J61417	128
BLOTTO in PBS	J60296	128
BLOTTO in PBS, with 0.02% sodium azide	J60166	128
BLOTTO antifoam in PBS	J63851	128
BLOTTO antifoam in PBS, with 0.02% sodium azide	J61888	128
BLOTTO in TBS	J63238	128
BLOTTO in TBS, with 0.02% sodium azide	J62235	128
BLOTTO antifoam in TBS	J62031	128
BLOTTO antifoam in TBS, with 0.02% sodium azide	J63891	129
BLOTTO and Tween 20 in PBS	J61880	129
BLOTTO and Tween 20 in PBS, with 0.02% sodium azide	J62304	129
BLOTTO and Tween 20 in TBS	J62341	129
BLOTTO and Tween 20 in TBS, with 0.02% sodium azide	J63026	129
BSA blocking buffer, 3% in PBS	J61655	139
BSA blocking buffer, 3% in PBS, with 0.02% sodium azide	J60473	139
BSA blocking buffer, 3% in PBS, with 0.05% Tween-20	J61116	139
BSA blocking buffer, 3% in TBS	J61119	139
BSA blocking buffer, 3% in TBS, with 0.05% Tween-20	J62554	139
BSA blocking buffer, 5% in PBS	J61089	139
BSA blocking buffer, 5% in PBS, with 0.05% Tween-20	J63711	139
BSA blocking buffer, 5% in TBS	J62637	139
BSA blocking buffer, 5% in TBS, with 0.02% sodium azide	J62305	139
BSA blocking buffer, 5% in TBS, with 0.05% Tween-20	J60098	139
Casein blocking buffer, 3% in PBS	J60289	149
Casein blocking buffer, 3% in PBS, with 0.02% sodium azide	J63453	149
Casein blocking buffer, 3% in TBS	J61298	149
Casein blocking buffer, 3% in TBS, with 0.02% sodium azide	J62935	149
Cyclic AMP Enzyme Immunoassay Kit	J65001	171
Cyclic GMP Enzyme Immunoassay Kit	J65422	171
3,3'-Diaminobenzidine, tablets	J60972	182
3,3'-Diaminobenzidine tetrahydrochloride hydrate	J62216	182
Human Epidermal Growth Factor Enzyme Immunoassay Kit	J65512	247
FCS blocking buffer in PBS	J63160	219
FCS blocking buffer in TBS	J61327	219
Fibronectin, human, Enzyme Immunoassay Kit	J64057	221
Gelatin blocking buffer, 1% in PBS	J62755	230
Gelatin blocking buffer, 1% in PBS, with 0.02% sodium azide	J63104	230
Gelatin blocking buffer, 1% in TBS	J62966	230
Gelatin blocking buffer, 1% in TBS, with 0.02% sodium azide	J60805	230
Gelatin and Tween 20 in PBS	J60939	230
Gelatin and Tween 20 in PBS, with 0.02% sodium azide	J62479	230
Gelatin and Tween 20 in TBS	J62272	230
Gelatin and Tween 20 in TBS, with 0.02% sodium azide	J61671	230
Horse serum	J61851	246
Involucrin, human, Enzyme Immunoassay Kit	J64994	257
Lysozyme, human, Enzyme Immunoassay Kit	J64986	266
Osteocalcin, rat, 99.9%	J64231	309
Osteocalcin, human, intact, Enzyme Immunoassay Kit	J64816	309
Osteocalcin, human, mid-tact, Enzyme Immunoassay Kit	J64764	309
Osteocalcin, rat, Enzyme Immunoassay Kit	J65214	309
Osteocalcin, mouse, Enzyme Immunoassay Kit	J64239	309
Peroxidase, horseradish	J60026	314
Phosphate-buffered saline (PBS, 10X), pH 7.4, for Western blot	J60801	320

Description	Stock #	Page #
Semi dry blot transfer buffer (10X)	J63664	341
Stripping buffer (4X)	J60925	352
Stripping buffer-2 (4X)	J62023	353
Stripping buffer-3 (4X)	J60810	353
3,3',5,5'-Tetramethylbenzidine, 98%	A13868	364
3,3',5,5'-Tetramethylbenzidine dihydrochloride hydrate, 99+%	J60332	364
3,3',5,5'-Tetramethylbenzidine aq. soln.	J60808	364
3,3',5,5'-Tetramethylbenzidine soln., Ready-to-Use, high sensitivity	J61325	364
3,3',5,5'-Tetramethylbenzidine soln., Ready-to-Use, precipitating, standard sensitivity	J60461	364
TRIS-buffered saline (TBS, 10X), with 0.5% Tween 20	J60448	381
TRIS-buffered saline (TBS, 20X), with 0.5% Tween 20	J63682	381
TRIS-buffered saline (TBS, 10X), with 1% Tween 20	J62955	381
TRIS-buffered saline (TBS, 20X), with 1% Tween 20	J60497	381
Tween 20 blocking buffer, 1% in PBS (10X)	J61544	385
Tween 20 blocking buffer, 0.5% in PBS (10X)	J60304	385
Tween 20 washing buffer, 1% in PBS (10X)	J63314	385
Tween 20 washing buffer, 0.5% in PBS (10X)	J63596	385
Tween 20 washing buffer, 1% in PBS (20X)	J61419	385
Tween 20 washing buffer, 0.5% in PBS (20X)	J62844	385

Contact us for pricing on bulk sizes

Stock #	Description	Size
J65650	**10058-F4** *[5-[(4-Ethylphenyl)methylene]-2-thioxo-4-thiazolidinone, c-Myc Inhibitor]* [403811-55-2], $C_{12}H_{11}NOS_2$, F.W. 249.35, Solid, MDL MFCD00758517 H:H319-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501	**10mg**
J62760	**A-3 hydrochloride** *[N-(2-Aminoethyl)-5-chloronaphthalene-1-sulfonamide hydrochloride]* [78957-85-4], $C_{12}H_{13}ClN_2O_2S{\cdot}HCl$, F.W. 321.22, Solid, MDL MFCD00077311 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A protein kinase inhibitor	**25mg**
J62011	**A-7 hydrochloride** *[N-(10-Aminodecyl)-5-chloro-1-naphthalenesulfonamide hydrochloride]* [79127-24-5], $C_{20}H_{29}ClN_2O_2S{\cdot}HCl$, F.W. 433.44, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Calmodulin antagonist	**25mg**
J60039	**Abamectin, 97+%** *[Avermectin B1]* [71751-41-2], $C_{48}H_{72}O_{14}$, F.W. 873.10, Powder, m.p. 150-155°, Merck **14**,2, UN2811, RTECS CL1203000, MDL MFCD01769550 H:H300-H400-H332, P:P261-P301+P310-P321-P304+P340-P405-P501a Application(s): Interacts with GABA receptors to cause chloride channel activation	**1g** **5g**
L13770	**Abietic acid, tech. 75%** △ [514-10-3], $C_{20}H_{30}O_2$, F.W. 302.45, Merck **14**,7, EINECS 208-178-3, RTECS TP8580000, BRN 2221451, MDL MFCD03423567, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Useful precursor for synthesis of various natural products including diterpenes and steroids. Review: *Sci. Pharm.*, **53**, 173 (1985). 	**25g** **100g**
	ABT, see 1-Aminobenzotriazole, 98%, J63610, p. 92 **9-AC**, see Anthracene-9-carboxylic acid, A14049, p. 105 **7-ACA**, see 7-Aminocephalosporanic acid, A10530, p. 92	
36499	**Acacia, Total ash <4%** *[Gum Arabic]* [9000-01-5], -100 Mesh Powder, d. 1.35-1.49, Merck **14**,14, EINECS 232-519-5, MDL MFCD00081264, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Mixture of polysaccharides and glycoproteins used in the food industry as a stabilizer	**500g** **2kg**
J61737	**Acarbose, 95%** *[Bay-g 5421]* [56180-94-0], $C_{25}H_{43}NO_{18}$, F.W. 645.61, Powder, Merck **14**,18, EINECS 260-030-7, MDL MFCD00869592 Application(s): A reversible α-glucosidase inhibitor	**1g** **2g** **5g**
	ACBC, see 1-Aminocyclobutane carboxylic acid hydrochloride, J63873, p. 92	
J63790	**Acebutolol hydrochloride** [34381-68-5], $C_{18}H_{28}N_2O_4{\cdot}HCl$, F.W. 372.89, White to off-white powder, m.p. 141-143°, Merck **14**,19, EINECS 251-980-3, RTECS ES5235000, MDL MFCD00078860 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501 Application(s): Cardioselective β-adrenergic blocker	**1g** **5g** **10g**
J60355	**Aceclofenac, 99%** [89796-99-6], $C_{16}H_{12}Cl_2NO_4$, F.W. 354.18, Powder, m.p. 149-153°, Merck **14**,22, UN2811, RTECS CY1577900, MDL MFCD00864296 H:H301-H400-H410-H319, P:P280-P301+P310-P305+P351+P338-P321-P405-P501a Application(s): A non-steroidal, anti-inflammatory drug (NSAID) with potent inhibitory activity in several models of inflammation	**5g** **25g** **100g**
J63583	**Acemetacin** [53164-05-9], $C_{21}H_{18}ClNO_6$, F.W. 415.83, Powder, m.p. 149-153°, Merck **14**,27, UN2811, EINECS 258-403-4, RTECS NL3521400, MDL MFCD00151473 H:H300-H310-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): A potent inhibitor of COX-2 found to have anti-tumor activity in the colon	**2g** **10g**
A11553	**ACES, 99%** *[N-(2-Acetamido)-2-aminoethanesulfonic acid, N-(Carbamoylmethyl)taurine]* [7365-82-4], $H_2NCOCH_2NHCH_2CH_2SO_3H$, F.W. 182.20, m.p. ca 275° dec., Merck **14**,36, EINECS 230-908-4, BRN 2253770, MDL MFCD00008030, † Biological buffer, pK_a = 6.9 at 20 ° : *Biochemistry*, **5**, 467 (1966). Application(s): Good's buffers	**25g** **100g** **500g**
J61761	**ACES, 0.5M buffer soln., pH 6.0** [7365-82-4], Liquid, †	**100ml** **250ml**

Stock #	Description	Size
J60366	**ACES, 0.5M buffer soln., pH 6.5** [7365-82-4], Liquid, †	**100ml** **250ml**
J60755	**ACES, 0.5M buffer soln., pH 7.0** [7365-82-4], Liquid, †	**100ml** **250ml**
J61011	**ACES, 0.5M buffer soln., pH 7.5** [7365-82-4], Liquid, †	**100ml** **250ml**
A12589	**Acetamide, 99%** ■ [60-35-5], CH_3CONH_2, F.W. 59.07, m.p. 76-81°, b.p. 220-222°, d. 1.159, Merck **14**,43, Fieser **1**,3, EINECS 200-473-5, RTECS AB4025000, BRN 1071207, MDL MFCD00008023, † H:H351, P:P280h Useful additive for brominations of acid-sensitive compounds in non-polar solvents since it forms a stable, insoluble 1:1 complex with HBr: *Chem. Ber.*, **82**, 275 (1949). For amidocarbonylation in the presence of carbon monoxide and hydrogen in a route to phenylalanine, see **Benzyl chloride**, **A12481**.	**250g** **1kg** **5kg**
	Acetamidoacetic acid, see N-Acetylglycine, B21887, p. 73 **N-(2-Acetamido)-2-aminoethanesulfonic acid**, see ACES, A11553, p. 69 **2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose**, see β-D-Glucosamine pentaacetate, L09020, p. 233 **5-Acetamido-3,5-dideoxy-D-glycero-D-galactononulosonic acid**, see N-(-)-Acetylneuraminic acid, L13950, p. 74 **N-(2-Acetamido)iminodiacetic acid**, see ADA, A15267, p. 78	
A11240	**4-Acetamidophenol, 98%** *[Acetaminophen, 4'-Hydroxyacetanilide]* [103-90-2], $C_8H_9NO_2$, F.W. 151.17, m.p. 168-172°, d. 1.293, Merck **14**,47, EINECS 203-157-5, RTECS AE4200000, BRN 2208089, MDL MFCD00002328, † H:H302-H412, P:P273-P264-P270-P301+P312-P330-P501a Application(s): Cyclooxygenase inhibitor and widely used analgesic	**250g** **500g** **1kg** **5kg**
	5-Acetamido-1,3,4-thiadiazole-2-sulfonamide, see Acetazolamide, L07562, p. 70 **Acetaminophen**, see 4-Acetamidophenol, A11240, p. 70	
J63876	**Acetate, 1M buffer soln., pH, 3.0** [127-09-3], Liquid, †	**250ml** **500ml**
J60340	**Acetate, 1M buffer soln., pH, 3.5** [127-09-3], Liquid, †	**250ml** **500ml**
J60104	**Acetate, 1M buffer soln., pH, 4.0** [127-09-3], Liquid, †	**250ml** **500ml**
J60964	**Acetate, 1M buffer soln., pH, 5.0** [127-09-3], Liquid, †	**250ml** **500ml**
J61033	**Acetate, 1M buffer soln., pH, 5.5** [127-09-3], Liquid, †	**250ml** **500ml**
L07562	**Acetazolamide, 99%** *[5-Acetamido-1,3,4-thiadiazole-2-sulfonamide]* [59-66-5], $C_4H_6N_4O_3S_2$, F.W. 222.25, m.p. ca 255° dec., Merck **14**,53, EINECS 200-440-5, RTECS AC8225000, BRN 212994, MDL MFCD00003105, † H:H360, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Carbonic anhydrase inhibitor; increases cerebral blood flow	**5g** **25g**
36289	**Acetic acid, glacial, ACS, 99.7+%** [64-19-7], CH_3CO_2H, F.W. 60.05, Liquid, m.p. 16.6°, b.p. 118.1°, f.p. 40°(104°F), d. 1.049, n_D^{20} 1.3721, Merck **14**,55, Fieser **2**,5 **5**,3 **7**,1 **8**,1 **19**,1 **21**,1, UN2789, EINECS 200-580-7, MDL MFCD00036152, † Maximum level of impurities: Color (APHA) 10, Dilution Test P.T., Evaporation Residue 0.001%, $(CH_3CO)_2O$ 0.01%, Cl 1ppm, SO_4 1ppm, Heavy Metals (as Pb) 0.5ppm, Fe 0.2ppm, Substances reducing dichromate P.T., Substances reducing permanganate P.T., Titratabl H:H314-H226, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	**100ml** **500ml** **2L** **4x500ml**
	Acetic acid cholesteryl ester, see Cholesteryl acetate, A15052, p. 161 **Acetic chloride**, see Acetyl chloride, 43262, p. 71 **Acetic phenylhydrazide**, see N-Acetyl-N'-phenylhydrazine, A14446, p. 74	
L01569	**Acetohydroxamic acid, 98%** ■ [546-88-3], $C_2H_5NO_2$, F.W. 75.07, m.p. 86-90°, Merck **14**,63, Fieser **13**,2, EINECS 208-913-8, RTECS AK8157000, BRN 1739019, MDL MFCD00009994 H:H360, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Urease inhibitor	**1g** **5g** **25g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
30698	**Acetone, ACS, 99.5+%** [67-64-1], CH_3COCH_3, F.W. 58.08, Liquid, m.p. -94°, b.p. 56°, f.p. -17°(1°F), d. 0.791, n_D^{20} 1.3590, Merck **14**,66, Fieser **2**,13 **3**,4 **6**,9, UN1090, EINECS 200-662-2, RTECS AL3150000, BRN 635680, MDL MFCD00008765, † Maximum level of impurities: Color (APHA) 10, Evaporation residue 0.001%, Solubility in water P.T., Titratable acid 0.0003meq/g, Titratable base 0.0006meq/g, Aldehyde as (HCHO) 0.002%, Isopropyl alcohol 0.05%, Methanol 0.05%, Substances reducing permangan H:H225-H319-EUH066-H336, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	**10ml** **500ml** **1L** **4L** **4x1L**
36423	**Acetonitrile, ACS, 99.5+%** *[Methyl cyanide]* [75-05-8], CH_3CN, F.W. 41.05, Liquid, m.p. -48° to -45°, b.p. 80-82°, f.p. 5°(41°F), d. 0.786, n_D^{20} 1.3440, Merck **14**,70, Fieser **2**,13 **15**,1 **18**,2 **19**,1, UN1648, EINECS 200-835-2, RTECS AL7700000, BRN 741857, MDL MFCD00001878, † Maximum level of impurities: Color (APHA) 10, Evaporation residue 0.005%, Titratable acid 8µeq/g, Titratable base 0.6µeq/g, H_2O 0.3% H:H225-H302-H312-H332-H319, P:P210-P241-P303+P361+P353-P305+P351+P338-P302+P352-P501a	**500ml** **1L** **4L** **4x1L** **4x4L**
	2-Acetoxybenzoic acid, see O-Acetylsalicylic acid, A12488, p. 74 **3-Acetoxyindole**, see 3-Indoxyl acetate, L04932, p. 256 **(R)-3-Acetoxy-4-(trimethylammonio)butyrate hydrochloride**, see O-Acetyl-L-carnitine chloride, J61536, p. 71 **Aceturic acid**, see N-Acetylglycine, B21887, p. 73	
J64039	**Acetyl-Adrenocorticotropic Hormone (1-14)** *[Acetyl-ACTH (1-14), Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly]* $C_{79}H_{111}N_{21}O_{21}S$, F.W. 1722.92, Solid	**5mg**
L10329	**N-Acetyl-DL-alanine, 97+%** *[Ac-DL-Ala-OH]* [1115-69-1], $C_5H_9NO_3$, F.W. 131.13, m.p. 135-139°, EINECS 214-229-0, BRN 774333, MDL MFCD00037238 	**5g** **25g**
L11811	**N-Acetyl-L-alanine, 96%** *[Ac-Ala-OH]* [97-69-8], $C_5H_9NO_3$, F.W. 131.13, m.p. 122-128°, $[\alpha]_D^{20}$ -64° (c=2 in water), EINECS 202-602-0, BRN 1722932, MDL MFCD00063132 	**1g** **5g**
J64106	**N-Acetyl-Arg-Glu-Lys-Arg-7-amido-4-trifluoromethylcoumarin** *[Ac-REK-R-AFC, Ac-Arg-Glu-Lys-Arg-AFC]* $C_{35}H_{51}F_3N_{12}O_9$, F.W. 840.80, Solid	**10mg**
J65204	**N-Acetyl-Asp-Glu-Val-Asp-al** ◪ *[Ac-Asp-Glu-Val-Asp-CHO, Ac-DEVD-CHO]* [169332-60-9], $C_{20}H_{30}N_4O_{11}$, F.W. 502.47, Powder, RTECS EK7643000, MDL MFCD00671412	**1mg** **5mg**
J64134	**N-Acetyl-Asp-Glu-Val-Asp-7-amido-4-trifluoromethylcoumarin** *[Ac-DEVD-AFC]* [201608-14-2], $C_{30}H_{34}F_3N_5O_{13}$, F.W. 729.61, Powder, MDL MFCD01310970	**10mg**
J65878	**N-Acetyl-Asp-Glu-Val-Asp p-nitroanilide** *[Ac-DEVD-pNA]* [189950-66-1], $C_{26}H_{34}N_6O_{13}$, F.W. 638.58, Powder, MDL MFCD00792707	**25mg**
	Acetylbenzoylaconine, see Aconitine, 98%, J60023, p. 207 **N-Acetyl-2-benzyltryptamine**, see Luzindole, 97%, J61915, p. 273	
J61536	**O-Acetyl-L-carnitine hydrochloride** *[(R)-3-Acetoxy-4-(trimethylammonio)butyrate hydrochloride, L-Carnitine acetyl ester hydrochloride]* [5080-50-2], $C_9H_{17}NO_4 \cdot HCl$, F.W. 239.70, White powder, Merck **14**,84, BRN 4340103, MDL MFCD00082230 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Weak cholinergic agonist	**5g** **25g**
	Acetyl ceramide, see N-Acetyl-D-sphingosine, 98%, J60534, p. 74	
43262	**Acetyl chloride, 99+%** ◪ *[Ethanoyl chloride, Acetic chloride]* [75-36-5], CH_3COCl, F.W. 78.50, Liquid, m.p. -112°, b.p. 50-52°, f.p. 4°(39°F), d. 1.104, n_D^{20} 1.3890, Merck **14**,85, UN1717, EINECS 200-865-6, RTECS AO6390000, BRN 605303, MDL MFCD00000719, † H:H225-H314-EUH014, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	**50ml** **250ml** **1L**
L02168	**Acetylcholine chloride, 98+%** ■ *[2-Acetoxy-N,N,N-trimethylethanium chloride, 2-Acetyloxy-N,N,N-trimethylethanium chloride]* [60-31-1], $CH_3CO_2CH_2CH_2N(CH_3)_3Cl$, F.W. 181.66, m.p. 149-152°, Merck **14**,87, EINECS 200-468-8, RTECS FZ9800000, BRN 3571875, MDL MFCD00011698, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Endogenous neurotransmitter at cholinergic synapses	**25g** **100g**
	(Acetylcyclopentadienyl)cyclopentadienyliron, see 1-Acetylferrocene, A13078, p. 72	

Stock #	Description	Size
A15409	**N-Acetyl-L-cysteine, 98+%** [616-91-1], $C_5H_9NO_3S$, F.W. 163.20, m.p. 108-111°, $[\alpha]_D^{20}$ +5.3° (c=2 in water), Merck **14**,88, Fieser **21**,2, EINECS 210-498-3, RTECS HA1660000, BRN 1724426, MDL MFCD00004880, † Catalyzes the addition of ammonia to nitriles to form amidines in high yield: *Tetrahedron Lett.*, **40**, 7067 (1999).  Application(s): A mucolytic agent for isolation of mycobacteria from sputum	**25g** **100g** **500g**
J65262	**N4-Acetyl-5'-O-(4,4'-dimethoxytrityl)-2'-fluoro-2'-deoxycytidine, 98%** *[N4-Acetyl-2'-deoxy-5'-O-DMT-2'fluorocytidine, 2'-Fluoro-5'-O-DMT-N4-acetylcytidine]* $C_{32}H_{32}FN_3O_7$, F.W. 589.61, Powder	**1g** **5g**
J65064	**N4-Acetyl-5'-O-(4,4'-dimethoxytrityl)-2'-fluoro-2'-deoxycytidine-3'-CE-phosphoramidite, 98%** $C_{41}H_{49}FN_5O_8P$, F.W. 789.83, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J65490	**N4-Acetyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methylcytidine, 98%** $C_{33}H_{35}N_3O_8$, F.W. 601.64, Powder	**1g**
J65996	**N4-Acetyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methylcytidine-3'-CE-phosphoramidite** $C_{42}H_{52}N_5O_9P$, F.W. 801.86, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J64680	**Acetyl α-Endorphin** *[Ac-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr]* $C_{79}H_{122}N_{18}O_{27}S$, F.W. 1787.98, Solid	**1mg**
J65577	**Acetylene-PEG4-biotin conjugate** *[15-[(R)-(+)-Biotinylamino]-4,7,10,13-tetraoxapentadec-1-yne]* $C_{21}H_{35}N_3O_6S$, F.W. 457.59, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
J65593	**Acetylene-PEG4-carboxyrhodamine 6G conjugate** *[Acetylene-Fluor 525]* $C_{38}H_{46}N_3O_8$, F.W. 672.79, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
J64892	**Acetylene-PEG4-carboxyrhodamine 110 conjugate** *[Acetylene-Fluor 488]* $C_{32}H_{34}N_3O_8$, F.W. 588.63, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg** **25mg**
J64523	**Acetylene-PEG4-carboxytetramethylrhodamine 110 conjugate** *[Acetylene-Fluor 545]* $C_{36}H_{42}N_3O_8$, F.W. 644.73, Amorphous solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg** **25mg**
J64859	**Acetylene-PEG4-maleimide** *[3-(N-maleimidyl)-N-(3,6,9,12-tetraoxapentadec-14-yn-1-yl)propionamide]* $C_{20}H_{30}N_2O_8$, F.W. 426.46, Viscous liquid or solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg** **500mg**
J65924	**Acetylene-PEG4-sulforhodamine 101 conjugate** *[Acetylene-Fluor 585]* $C_{42}H_{50}N_3O_{10}S_2$, F.W. 820.99, Amorphous solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
J64948	**Acetylene-PEG4-sulforhodamine B conjugate** *[Acetylene-Fluor 568]* $C_{38}H_{50}N_3O_{11}S_2$, F.W. 772.98, Amorphous solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
A13078	**1-Acetylferrocene, 97%** *[(Acetylcyclopentadienyl)cyclopentadienyliron, Ferrocenyl methyl ketone]* [1271-55-2], $C_{12}H_{12}FeO$, F.W. 228.07, m.p. 79-86°, b.p. 160-163°/4mm, UN3467, EINECS 215-043-2, RTECS OB3700000, MDL MFCD00001432, †  H:H300-H311, P:P301+P310-P361-P302+P352-P321-P405-P501a A procedure for the conversion of methyl ketones to terminal acetylenes is exemplified by reaction with $POCl_3$ - DMF to give (2-formyl-1-chlorovinyl)ferrocene which, by elimination with NaOH, affords ethynylferrocene: *J. Organomet. Chem.*, **6**, 173 (1966); *Org. Synth. Coll.*, **9**, 411 (1998).	**5g** **25g** **100g** **250g**
J65915	**N4-Acetyl-2'-fluoro-2'-deoxycytidine, 98%** $C_{11}H_{14}FN_3O_5$, F.W. 287.24, Powder	**1g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A13047	**N-Acetyl-D-glucosamine, 98+%** ■ [7512-17-6], $C_8H_{15}NO_6$, F.W. 221.21, m.p. 213° dec., $[\alpha]_D^{20}$ +42° (c=2 in water), Merck **14**,4458, EINECS 231-368-2, BRN 1727589, MDL MFCD00136044, † 	**10g** **50g** **100g**
B23621	**N-Acetyl-L-glutamic acid, 99%** *[Ac-Glu-OH]* [1188-37-0], $C_7H_{11}NO_5$, F.W. 189.17, m.p. 194-199°, $[\alpha]_D^{20}$ -16.5° (c=1 in water), EINECS 214-708-4, RTECS LZ9725000, BRN 1727473, MDL MFCD00002802, † 	**25g** **100g**
L06780	**N-α-Acetyl-L-glutamine, 99%** *[Ac-Gln-OH]* [2490-97-3], $C_7H_{12}N_2O_4$, F.W. 188.18, m.p. ca 206° dec., $[\alpha]_D^{20}$ -12° (c=3 in water), Merck **14**,25, EINECS 219-647-7, BRN 1727471, MDL MFCD00038159, † 	**50g** **250g**
B21887	**N-Acetylglycine, 99%** *[Acetamidoacetic acid, Aceturic acid]* [543-24-8], $CH_3CONHCH_2CO_2H$, F.W. 117.10, m.p. ca 210° dec., Merck **14**,80, EINECS 208-839-6, BRN 774114, MDL MFCD00004275, †	**100g** **500g** **2.5kg**
J65657	**N-Acetyl-L-histidine monohydrate** *[Ac-His-OH]* [39145-52-3], $C_8H^{11}N_3O_3.H_2O$, F.W. 215.21 (197.09anhy), Powder, m.p. 163°, MDL MFCD00149320	**1g** **5g** **25g**
B22741	**DL-N-Acetylhomocysteine thiolactone, 99%** [1195-16-0], $C_6H_9NO_2S$, F.W. 159.21, m.p. 109-111°, EINECS 214-793-8, RTECS AC8680000, MDL MFCD00005480, † 	**5g** **25g** **100g**
	3-Acetyl-4-hydroxy-6-methyl-2-pyrone sodium salt, see Sodium dehydroacetate, B21060, p. 345	
J65828	**N-Acetyl-Ile-Glu-Pro-Asp-7-amino-4-trifluoromethylcoumarin** *[Ac-IEPD-AFC]* $C_{32}H_{38}N_5O_{11}F_3$, F.W. 725.66, Powder, MDL MFCD03452821	**10mg**
J65683	**N-Acetyl-Ile-Glu-Thr-Asp-7-amido-4-trifluoromethylcoumarin** *[Ac-IGTD-AFC, Ac-Ile-Glu-Thr-Asp-AFC]* $C_{31}H_{38}F_3N_5O_{12}$, F.W. 729.60, Solid	**10mg**
J64258	**N-Acetyl-Ile-Glu-Thr-Asp-7-amino-4-trifluoromethyl coumarin** *[Ac-IETD-AFC]* $C_{31}H_{38}F_3N_5O_{12}$, F.W. 729.65, Lyophilized powder	**5mg**
L00137	**1-Acetylimidazole, 98%** ◢ [2466-76-4], $C_5H_6N_2O$, F.W. 110.12, m.p. 98-104°, EINECS 219-577-7, RTECS NI3400000, BRN 108425, MDL MFCD00005287, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Mild acylating agent. Reactivity can be enhanced by quaternization with, e.g. benzyl bromide: *Chem. Pharm. Bull.*, **30**, 4242 (1982). Acylation of nitromethane salts leads to acylnitro compounds: *Synthesis,* 478 (1978). Application(s): Acetylates hydroxyl group of tyrosyl residues	**5g** **25g** **100g**
	N-Acetyl-2-iodo-5-methoxytryptamine, see 2-Iodomelatonin, 98+%, J61498, p. 258	
L13926	**N-Acetyl-L-leucine, 99%** *[Ac-Leu-OH]* [1188-21-2], $C_8H_{15}NO_3$, F.W. 173.21, m.p. 177-179°, $[\alpha]_D^{20}$ -23° (c=5 in ethanol), EINECS 214-706-3, BRN 1724849, MDL MFCD00065131, † 	**5g** **25g**
J65269	**N-Acetyl-Leu-Glu-Glu-Asp-7-amido-4-trifluoromethylcoumarin** *[Ac-LEED-AFC]* $C_{32}H_{38}F_3N_5O_{13}$, F.W. 757.66, Powder, MDL MFCD03452816	**5mg**
J64911	**N-Acetyl-Leu-Gly-His-Asp-7-amino-4-trifluoromethylcoumarin** *[Ac-LEHD-AFC]* $C_{33}H_{38}F_3N_7O_{11}$, F.W. 765.69, Solid, MDL MFCD01862610	**5mg**
J65083	**N(α)-Acetyl-L-lysine, 99%** *[Ac-L-Lys-OH]* [1946-82-3], $C_8H_{16}N_2O_3$, F.W. 188.20, Powder, m.p. 256-258° dec., EINECS 217-747-5, MDL MFCD00008233	**1g** **5g**
J64139	**N(ε)-Acetyl-L-lysine, 99%** *[L-Lys(Ac)-OH]* [692-04-6], $C_8H_{16}N_2O_3$, F.W. 188.20, Powder, m.p. 250° dec., EINECS 211-725-9, MDL MFCD00002639	**1g** **5g**
J65515	**Acetyl-[Lys0,Nle3]-γ2-Melanocyte Stimulating Hormone, amide** *[Ac-Lys-Tyr-Val-Nle-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-NH2, Acetyl-(Lys0,Nle3)-g2-MSH, amide]* [237761-41-0], $C_{83}H_{116}N_{24}O_{17}$, F.W. 1721.96, Solid	**0.5mg** **1mg**

Stock #	Description	Size
J64841	**N-Acetyl-Lys-Pro-Arg-7-amino-4-trifluoromethylcoumarin** *[Ac-KPR-AFC]* $C_{29}H_{39}F_3N_8O_6$, F.W. 652.66, Solid, MDL MFCD03452898	10mg 25mg
L11167	**N-Acetyl-D-mannosamine monohydrate, 99%** [7772-94-3], $C_8H_{15}NO_6 \cdot H_2O$, F.W. 239.24 (221.22anhy), m.p. ca 130° dec., $[\alpha]_D^{20}$ +10.5° (c=1 in water), BRN 1346524, MDL MFCD00149493, † 	250mg 1g 5g
B21866	**N-Acetyl-DL-methionine, 99%** *[Ac-DL-Met-OH]* [1115-47-5], $C_7H_{13}NO_3S$, F.W. 191.25, m.p. 113-117°, Merck **14**,96, EINECS 214-224-3, RTECS PD0500000, BRN 1725554, MDL MFCD00008681, † 	50g 250g 1kg
	N-Acetyl-5-methoxytryptamine, see Melatonin, 99+%, J62452, p. 279	
J65560	**N4-Acetyl-2'-O-methylcytidine, 98%** $C_{12}H_{17}N_3O_6$, F.W. 299.28, Powder	1g
	N-Acetylmuramly-L-alanyl-D-isoglutamine, see Adjuvant Peptide, J62385, p. 80	
L13950	**N-(-)-Acetylneuraminic acid, 97%** △ *[5-Acetamido-3,5-dideoxy-D-glycero-D-galactononulosonic acid, NANA]* [131-48-6], $C_{11}H_{19}NO_9$, F.W. 309.28, m.p. ca 185° dec., $[\alpha]_D^{20}$ -32° (c=1 in water), Merck **14**,8484, EINECS 205-023-1, BRN 1716283, MDL MFCD00006620, † 	25mg 100mg
	2-Acetyloxy-N,N,N-trimethylethanium chloride, see Acetylcholine chloride, L02168, p. 71	
B23812	**N-Acetyl-L-phenylalanine, 99%** *[Ac-Phe-OH]* [2018-61-3], $C_{11}H_{13}NO_3$, F.W. 207.23, m.p. 166-170°, $[\alpha]_D^{20}$ +40° (c=1 in methanol), EINECS 217-959-8, MDL MFCD00063158, † 	1g 5g 25g
A14446	**N-Acetyl-N'-phenylhydrazine, 98%** *[Acetic phenylhydrazide, 2-Phenylacetohydrazide]* [114-83-0], $C_6H_5NHNHCOCH_3$, F.W. 150.18, m.p. 128-131°, UN2811, EINECS 204-055-3, RTECS AJ2900000, BRN 742880, MDL MFCD00008672, † H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a	25g 100g 500g
L14300	**N-Acetyl-L-proline, 99%** *[Ac-Pro-OH]* [68-95-1], $C_7H_{11}NO_3$, F.W. 157.18, m.p. 117-118°, $[\alpha]_D^{20}$ -116° (c=1 in water), EINECS 200-698-9, BRN 83200, MDL MFCD00020837 	1g 5g
A12688	**2-Acetylpyridine, 98%** *[Methyl 2-pyridyl ketone]* [1122-62-9], C_7H_7NO, F.W. 121.14, m.p. 8-10°, b.p. 189-190°, f.p. 76°(169°F), d. 1.082, n_D^{20} 1.5235, EINECS 214-355-6, RTECS OB5310000, BRN 107759, MDL MFCD00006303, † H:H315-H319, P:P280g-P305+P351+P338 	25g 100g 500g
A14246	**3-Acetylpyridine, 98%** *[Methyl 3-pyridyl ketone]* [350-03-8], C_7H_7NO, F.W. 121.14, m.p. 12-13°, b.p. 218-220°, f.p. 104°(219°F), d. 1.106, n_D^{20} 1.5350, Merck **14**,6116, UN2810, EINECS 206-496-7, RTECS OB5425000, BRN 107751, MDL MFCD00006396, † H:H301-H315-H319, P:P280h-P305+P351+P338-P309-P310 	25g 100g 500g
A12488	**O-Acetylsalicylic acid, 99%** *[2-Acetoxybenzoic acid]* [50-78-2], $C_9H_8O_4$, F.W. 180.15, m.p. 136-140°, f.p. 250°(482°F), d. 1.400, Merck **14**,851, EINECS 200-064-1, RTECS VO0700000, BRN 779271, MDL MFCD00002430, † H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a 	100g 500g 2.5kg
J64933	**O-Acetyl-L-serine hydrochloride** *[L-Ser(Ac)-OH]* [66638-22-0], $C_5H_9NO_4$.HCl, F.W. 183.59, Powder, MDL MFCD00060169 Application(s): Substrate for cysteine synthase and β-substituted alanine synthase in higher plants	1g 5g
J60534	**N-Acetyl-D-sphingosine, 98%** *[Acetyl ceramide, C2-Ceramide]* [3102-57-6], $C_{20}H_{39}NO_3$, F.W. 341.53, Powder, m.p. 77-78°, MDL MFCD00153903 Application(s): Inhibits cell proliferation and induces monocytic differentiation of HL-60 cells. Activates protein phosphatases	1mg 5mg 10mg

Contact us for pricing on bulk sizes

Stock #	Description	Size
A16802	**S-Acetylthiocholine iodide, 98% ▲■** [1866-15-5], $CH_3COSCH_2CH_2N(CH_3)_3I$, F.W. 289.18, m.p. 205-209°, UN2811, EINECS 217-474-1, RTECS FZ9865000, BRN 3916578, MDL MFCD00011819, † H:H301-H312-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
J64597	**(R)-2-Acetylthio-3-phenylpropionic acid** *[D-2-Thioacetyl-3-phenylpropionic Acid]* [57359-76-9], $C_{11}H_{12}O_3S$, F.W. 224.28, Oil H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**250mg** **500mg**
J65409	**(S)-2-Acetylthio-3-phenylpropionic acid** *[(S)-α-(Acetylthio)benzenepropanoic acid]* [76932-17-7], $C_{11}H_{12}O_3S$, F.W. 224.28, Powder H:H302-H318-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501	**1g** **5g**
J64780	**N-Acetyl-Trp-Glu-His-Asp-7-amido-4-trifluomethylcoumarin** *[Ac-WEHD-AFC]* $C_{38}H_{37}F_3N_8O_{11}$, F.W. 838.74, Powder, MDL MFCD01862607	**1mg** **5mg**
J65062	**N-Acetyl-Trp-Val-Ala-Asp-7-amido-4-methylcoumarin ▲◪** *[Ac-WVAD-AMC]* $C_{35}H_{40}N_6O_9$, F.W. 688.73, Lyophilized powder	**5mg**
J64096	**N-Acetyl-L-tryptophan, 99%** *[Ac-L-Trp-OH]* [1218-34-4], $C_{13}H_{14}N_2O_3$, F.W. 246.30, Powder, m.p. 186°, EINECS 214-935-9, RTECS YN6160000, MDL MFCD00065976, †	**5g** **25g** **100g**
J65646	**N-Acetyl-Tyr-Glu-Val-Asp-7-amido-4-methylcoumarin ▲** *[Ac-YEVD-AMC, Caspase 1 (ICE) Substrate 1M fluorogenic]* $C_{35}H_{41}N_5O_{12}$, F.W. 723.72, Powder	**5mg**
A17307	**N-Acetyl-L-tyrosine, 99%** *[Ac-Tyr-OH]* [537-55-3], $C_{11}H_{13}NO_4$, F.W. 223.23, m.p. 150-151°, $[\alpha]_D^{20}$ +58° (c=5 in ethanol), EINECS 208-671-3, BRN 2697172, MDL MFCD00037190, † 	**10g** **50g** **250g**
J65213	**N-Acetyl-Tyr-Val-Ala-Asp-7-amido-4-trifluoromethylcoumarin** *[Ac-YVAD-AFC]* $C_{33}H_{36}N_5O_{10}F_3$, F.W. 719.66, Powder	**10mg**
J64931	**N-Acetyl-Tyr-Val-Ala-Asp-p-nitroanilide** *[Ac-YVAD-pNA]* $C_{29}H_{36}N_6O_{10}$, F.W. 628.63, Powder	**25mg**
J65806	**N-Acetyl-Val-Asp-Val-Ala-Asp-7-amido-4-trifluoromethylcoumarin** *[Ac-VDVAD-AFC]* $C_{33}H_{41}N_6O_{12}F_3$, F.W. 770.71, Powder, MDL MFCD04037014	**5mg**
J65299	**N-Acetyl-Val-Asp-Val-Ala-Asp-p-nitroanilide** *[Ac-VDVAD-pNA, Caspase-2 substrate (chromogenic)]* $C_{29}H_{41}N_7O_{12}$, F.W. 679.67, Lyophilized powder	**25mg**
J65277	**N-Acetyl-Val-Glu-Ile-Asp-al** *[Ac-VEID-CHO, Ac-Val-Glu-Ile-Asp-CHO]* $C_{22}H_{36}N_4O_9$, F.W. 500.54, Lyophilized powder, MDL MFCD01318861	**5mg**
J65287	**N-Acetyl-Val-Glu-Ile-Asp-7-amido-4-trifluoromethylcoumarin** *[Ac-VEID-AFC]* $C_{32}H_{40}N_5O_{11}F_3$, F.W. 727.68, Powder, MDL MFCD01318833	**10mg**
J64992	**N-Acetyl-Val-Glu-Ile-Asp-p-nitroanilide** *[Ac-VEID-pNA]* [189684-54-6], $C_{28}H_{40}N_6O_{11}$, F.W. 636.65, Lyophilized solid	**25mg**
	ACIA, see Acivicin, 98+%, J63105, p. 76 **Acid Black 1**, see Amido Black 10B, A11374, p. 91 **Acid Black 2**, see Nigrosin water soluble, A18147, p. 302 **Acid Blue 9**, see Erioglaucine sodium salt, J61780, p. 210 **Acid Blue 147**, see Xylenecyanol FF, B21530, p. 394	

Stock #	Description	Size
B22222	**Acid Fuchsin sodium salt** *[Acid Violet 19, C.I. 42685]* [3244-88-0], $C_{20}H_{17}N_3Na_2O_9S_3$, F.W. 585.53, Merck **14**,107, EINECS 221-816-5, RTECS DD4737000, BRN 4111656, MDL MFCD00013286, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g** **500g**
	Acid Green 1, see Naphthol Green B, A18268, p. 298 **Acid Green 5**, see Light Green SF Yellowish, B23330, p. 270 **Acid Orange 10**, see Orange G, Electrophoresis Grade, J62743, p. 308 **Acid Red 51** , see Erythrosin B, certified , A14180, p. 210 **Acid Red 87**, see Eosin Yellowish, B24535, p. 208 **Acid Violet 19**, see Acid Fuchsin sodium salt, B22222, p. 76 **Acid Yellow 1**, see Naphthol Yellow S, B20872, p. 298 **Acid Yellow 23**, see Tartrazine, A17682, p. 358 **Acid Yellow 73**, see Fluorescein disodium salt, J61549, p. 223	
J63105	**Acivicin, 98+%** *[ACIA]* [42228-92-2], $C_5H_7ClN_2O_3$, F.W. 178.57, Solid, m.p. 209-211°, UN2811, RTECS NY2103000, MDL MFCD00058450 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Inhibits glutamine amidotransferases in purine and pyrimidine synthetic pathways. Tumor growth inhibitor	**10mg** **25mg**
A16010	**cis-Aconitic acid, tech. 90%** ■ *[(1Z)-Propene-1,2,3-tricarboxylic acid]* [585-84-2], $C_6H_6O_6$, F.W. 174.11, m.p. 115-120°, EINECS 209-561-1, MDL MFCD00063184, † H:H315-H319-H335, P:P280g-P305+P351+P338	**1g** **5g** **25g**
B20087	**trans-Aconitic acid, 98%** *[1,2,3-Propenetricarboxylic acid]* [4023-65-8], $C_6H_6O_6$, F.W. 174.11, m.p. ca 190° dec., Merck **14**,117, EINECS 223-688-6, RTECS UD2380000, MDL MFCD00002721, † H:H315-H319-H335, P:P280g-P305+P351+P338	**25g** **100g** **500g**
J62056	**Aconitine, 98%** *[Acetylbenzoylaconine]* [302-27-2], $C_{34}H_{47}NO_{11}$, F.W. 645.75, Crystalline powder, m.p. 194-202°, Merck **14**,118, UN1544, EINECS 206-121-7, RTECS AR5960000, BRN 74608, MDL MFCD00082375 H:H300-H330, P:P301+P310-P304+P340-P320-P330-P405-P501a Application(s): Opens tetrodotoxin-sensitive sodium channels. Useful for creating models of cardiac arrhythmia	**50mg** **250mg**
L01657	**Acridine, 98+%** [260-94-6], $C_{13}H_9N$, F.W. 179.22, m.p. 107-111°, b.p. 346°, d. 1.005, Merck **14**,122, UN2713, EINECS 205-971-6, RTECS AR7175000, BRN 120200, MDL MFCD00005025, † H:H318-H302-H312-H332-H335-H315-H411, P:P280-P273-P305+P351+P338-P337+P313	**5g** **25g**
J62634	**Acridine hydrochloride** [17784-47-3], $C_{13}H_{10}ClN$, F.W. 215.68, Powder, EINECS 241-762-6, RTECS AR9322000, BRN 3697519, MDL MFCD00035149 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Acid fast bacillus stain	**1g**
L13159	**Acridine Orange, dye content 55-65%** ■ *[3,6-Bis(dimethylamino)acridine hydrochloride zinc chloride double salt, C.I. 46005]* [10127-02-3], $C_{17}H_{20}Cl_3N_3Zn$, F.W. 438.10, EINECS 233-353-6, RTECS AR7600000, BRN 3734978, MDL MFCD00081043 H:H341, P:P281-P201-P202-P308+P313-P405-P501a Biological stain. Application(s): Fluorescent stain for proteins. An RNA polymerase inhibitor	**5g** **25g**
J60048	**Acriflavine hydrochloride** *[3,6-Diamino-10-methylacridinium chloride hydrochloride, Euflavine]* [8063-24-9], Powder, Merck **14**,123, UN3077, BRN 6265525, MDL MFCD00069039 H:H318-H302-H411, P:P280-P273-P305+P351+P338-P310-P301+P312-P501a Application(s): An intercalating dye	**10g** **25g**
J62100	**Acrylamide, 30% soln, bisacrylamide free** [79-06-1], Liquid, Merck **14**,129, UN3426, EINECS 201-173-7, BRN 605349, MDL MFCD00008032, † H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a	**500ml** **1L**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62480	**Acrylamide, 40% soln, bisacrylamide free** [79-06-1], Liquid, Merck **14**,129, UN3426, EINECS 201-173-7, BRN 605349, MDL MFCD00008032, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a	**500ml** **1L**
L15075	**Acrylamide, electrophoresis grade, 99+% ▲■** *[Propenamide]* [79-06-1], CH_2=$CHCONH_2$, F.W. 71.08, m.p. 82-85°, b.p. 125°/25mm, f.p. 138°(280°F), d. 1.322, Merck **14**,129, UN2074, EINECS 201-173-7, RTECS AS3325000, BRN 605349, MDL MFCD00008032, †  H:H301-H340-H350-H372-H361f-H312-H332-H315-H319-H317, P:P260-P301+P310-P305+P351+P338-P302+P352-P405-P501a	**25g** **100g** **500g**
J60126	**Acrylamide/Bisacrylamide 19:1, 30% soln** Liquid, UN3426, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Premixed solution for preparing protein PAGE gels	**500ml** **1L**
J60909	**Acrylamide/Bisacrylamide 19:1, 40% soln** Liquid, UN3426, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a	**500ml** **1L**
J60486	**Acrylamide/Bisacrylamide 19:1, powder** Powder, UN2074, †  H:H301-H340-H350-H372-H361f-H312-H332-H315-H319-H317, P:P260-P301+P310-P305+P351+P338-P302+P352-P405-P501a Application(s): Premixed powder for preparing protein PAGE gels	**100g** **500g**
J63279	**Acrylamide/Bisacrylamide 29:1, 30% soln** Liquid, UN3426, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a	**500ml** **1L**
J63079	**Acrylamide/Bisacrylamide 29:1, 40% soln** Liquid, UN3426, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a	**500ml** **1L**
J60824	**Acrylamide/Bisacrylamide 29:1, powder** Powder, UN2074, †  H:H301-H340-H350-H372-H361f-H312-H332-H315-H319-H317, P:P260-P301+P310-P305+P351+P338-P302+P352-P405-P501a Application(s): Premixed powder for preparing protein DNA gels	**100g** **500g**
J61505	**Acrylamide/Bisacrylamide 37.5:1, 30% soln** Liquid, UN3426, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a	**500ml** **1L**
J60868	**Acrylamide/Bisacrylamide 37.5:1, 40% soln** Liquid, UN3426, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Premixed solution for preparing nucleic acid PAGE gels	**500ml** **1L**
J61220	**Acrylamide/Bisacrylamide 37.5:1, powder** Powder, UN2074  H:H301-H340-H350-H372-H361f-H312-H332-H315-H319-H317, P:P260-P301+P310-P305+P351+P338-P302+P352-P405-P501a Application(s): Premixed powder for preparing nucleic acid PAGE gels	**100g** **500g**
J60412	**Acrylamide/Bisacrylamide 39:1, 30% soln** Liquid, UN3426, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a	**500ml** **1L**
J63323	**Acrylamide/Bisacrylamide 39:1, 40% soln** Liquid, UN3426, †  H:H340-H350-H372-H361f-H302-H312-H315-H319-H317, P:P260-P305+P351+P338-P302+P352-P321-P405-P501a	**500ml** **1L**
	ACTH [1-10], see Adrenocorticotropic Hormone 1-10 (ACTH 1-10), J63084, p. 80 **ACTH [1-13]**, see Adrenocorticotropic Hormone 1-13 (ACTH 1-13), J61247, p. 80 **ACTH [1-14]**, see Adrenocorticotropic Hormone 1-14 (ACTH 1-14), J60060, p. 80 **ACTH [1-4] Peptide**, see Adrenocorticotropic Hormone 1-4 (ACTH 1-4), J61985, p. 80	
J61490	**Actin, from rabbit muscle** [51005-14-2], Solution, MDL MFCD00130338 Application(s): Used in cell transport studies, and inhibits deoxyribonuclease I	**1mg**
	Actinomycin C1, see Actinomycin D, J60148, p. 78	

Stock #	Description	Size
J60148	**Actinomycin D** *[Dactinomycin, Actinomycin C1]* [50-76-0], $C_{62}H_{86}N_{12}O_{16}$, F.W. 1255.40, Powder, m.p. 251-253°, Merck **14**,2800, UN3462, EINECS 200-063-6, RTECS AU1575000, BRN 605235, MDL MFCD00005033 H:H300-H360-H351, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Inhibits nulceic acid synthesis and potently induces apoptosis	**5mg**
J64144	**Acycloguanosine, 98%** *[9-(2-Hydroxyethoxymethyl)guanine, Acyclovir]* [59277-89-3], $C_8H_{11}N_5O_3$, F.W. 225.20, Powder, m.p. 256-260°, Merck **14**,146, EINECS 261-685-1, RTECS UP0791400, MDL MFCD00057880 Application(s): Inhibits cytomegalovirus replication; induces apoptosis	**1g** **5g** **25g**
	Acyl-neuraminyl hydrolase, see Neuraminidase, Clostridium perfringens, J63259, p. 300	
A15267	**ADA, 98+%** *[N-(2-Acetamido)iminodiacetic acid]* [26239-55-4], $H_2NCOCH_2N(CH_2CO_2H)_2$, F.W. 190.16, m.p. ca 218° dec., Merck **14**,147, EINECS 247-530-0, BRN 1787181, MDL MFCD00008031, † Biological buffer, pK_a = 6.9 at 20°: *Biochemistry*, **5**, 467 (1966).	**25g** **100g** **500g**
J60054	**ADA, 0.2M buffer soln., pH 6.0** [7415-22-7], Liquid	**100ml** **250ml**
J61259	**ADA, 0.2M buffer soln., pH 6.5** [7415-22-7], Liquid	**100ml** **250ml**
J61176	**ADA, 0.2M buffer soln., pH 7.0** [7415-22-7], Liquid	**100ml** **250ml**
J62424	**ADA, 0.2M buffer soln., pH 7.5** [7415-22-7], Liquid	**100ml** **250ml**
A12699	**1-Adamantanamine hydrochloride, 99%** *[Amantadine hydrochloride, 1-Aminoadamantane hydrochloride]* [665-66-7], $C_{10}H_{17}N{\cdot}HCl$, F.W. 187.71, m.p. 360°, Merck **14**,374, EINECS 211-560-2, RTECS AU4375000, BRN 4198854, MDL MFCD00074723, † H:H361-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): Antiviral drug that inhibits ion channels of influenza and disrupts T-cell development	**25g** **100g** **500g**
	7-ADCA, see 7-Aminodesacetoxycephalosporanic acid, L03417, p. 93	
A14906	**Adenine, 99%** *[6-Aminopurine]* [73-24-5], $C_5H_5N_5$, F.W. 135.13, m.p. >360° dec., Merck **14**,152, UN2811, EINECS 200-796-1, RTECS AU6125000, BRN 5777, MDL MFCD00041790, † H:H302, P:P264-P270-P301+P312-P330-P501a	**25g** **50g** **250g** **500g**
	Adenine deoxyriboside, see 2'-Deoxyadenosine, 99%, J63886, p. 177 **Adenine hemisulfate**, see Adenine sulfate, A16964, p. 78	
A17622	**Adenine hydrochloride, 98+%, cont. up to ca 5% water** *[6-Aminopurine hydrochloride]* [2922-28-3], $C_5H_5N_5{\cdot}HCl$, F.W. 171.59, m.p. ca 290° dec., EINECS 220-867-0, BRN 4009585, MDL MFCD00150864, † H:H302, P:P264-P270-P301+P312-P330-P501a	**5g** **25g** **100g**
A16964	**Adenine sulfate, 98+%** ■ *[Adenine hemisulfate, 6-Aminopurine sulfate]* [321-30-2], $C_{10}H_{10}N_{10}{\cdot}H_2SO_4$, F.W. 368.34, m.p. ca 210° dec., Merck **14**,152, EINECS 206-286-5, RTECS AU7140000, BRN 3820263, MDL MFCD00213655, † H:H302, P:P280h	**10g** **50g**
A10781	**Adenosine, 99%** [58-61-7], $C_{10}H_{13}N_5O_4$, F.W. 267.25, m.p. 234-237°, $[\alpha]_D^{20}$ -70° (c=2 in 5% NaOH), Merck **14**,153, EINECS 200-389-9, RTECS AU7175000, BRN 93029, MDL MFCD00005752, †	**10g** **50g** **250g**
J60558	**Adenosine-2',3'-cyclic monophosphate sodium salt, 98%** [37063-35-7], $C_{10}H_{11}N_5NaO_6P$, F.W. 351.19, Powder, m.p. 241-243°, EINECS 253-328-3, MDL MFCD00005757	**100mg** **250mg** **500mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62174	**Adenosine-3',5'-cyclic monophosphate sodium salt, 99%** *[3',5'-Cyclic AMP.Na]* [37839-81-9], $C_{10}H_{11}N_5NaO_6P$, F.W. 351.19, Crystalline powder, BRN 54612, MDL MFCD00069736	250mg 1g 5g
	Adenosine 3',5'-cyclophosphate, see Adenosine-3',5'-monophosphoric acid free acid, 98%, J60936, p. 79	
J60672	**Adenosine-5'-diphosphate monopotassium salt dihydrate, 99%** *[5'-ADP-K]* [72696-48-1], $C_{10}H_{14}KN_5O_{10}P_2 \cdot 2H_2O$, F.W. 501.33 (465.29anhy), Crystalline powder, MDL MFCD00066472	1g 5g
L14029	**Adenosine-5'-diphosphate disodium salt, 97% (dry wt.), water 7% max.** ■ *[5'-ADP-Na2]* [16178-48-6], $C_{10}H_{13}N_5Na_2O_{10}P_2$, F.W. 471.17, $[\alpha]_D^{20}$ -30° (c=0.5 in 0.5M Na_2HPO_4), EINECS 240-314-7, BRN 3645656, MDL MFCD00066635, † 	250mg 1g
J64497	**Adenosine-5'- diphosphate trilithium salt, 98%** *[5'-ADP]* [31008-64-7], $C_{10}H_{12}N_5O_{10}P_2Li_3$, F.W. 445.00, Powder, MDL MFCD00065469	1g 5g 25g
J61643	**Adenosine-5'-monophosphate disodium salt** *[5'AMP.Na]* [4578-31-8], $C_{10}H_{12}N_5NaO_7P$, F.W. 391.20, Powder, Merck **14**,158, EINECS 224-961-2, RTECS AU7481600, BRN 3586732, MDL MFCD00065023	5g 25g 100g
J60936	**Adenosine-3',5'-monophosphoric acid, 98%** *[3',5'-Cyclic AMP, Adenosine 3',5'-cyclophosphate]* [60-92-4], $C_{10}H_{12}N_5O_6P$, F.W. 329.21, Crystalline powder, m.p. 260° dec., Merck **14**,2708, EINECS 200-492-9, RTECS AU7357600, BRN 52645, MDL MFCD00005845, †	1g 5g
L14051	**Adenosine-5'-monophosphoric acid, 99% (dry wt.), water <6%** *[Adenylic acid, 5'-AMP]* [61-19-8], $C_{10}H_{14}N_5O_7P$, F.W. 347.22, m.p. ca 190° dec., $[\alpha]_D^{20}$ -47° (c=2 in 2% NaOH), Merck **14**,158, EINECS 200-500-0, RTECS AU7480500, BRN 5205540, MDL MFCD00149360, † 	1g 5g
J61125	**Adenosine-5'-triphosphate disodium salt hydrate, 98% ▲■** *[ATP disodium salt hydrate]* [34369-07-8], $C_{10}H_{14}N_5Na_2O_{13}P_3$, F.W. 551.15, Powder, Merck **14**,155, EINECS 213-579-1, † H:H303, P:P312	5g 10g 25g
J60336	**Adenosine-5'-triphosphate disodium salt hydrate, ultrapure, 98% ▲■** *[ATP disodium salt hydrate]* [34369-07-8], $C_{10}H_{14}O_{13}N_5Na_2P_3 \cdot xH_2O$, F.W. 605.19 (551.15anhy), Powder, Merck **14**,155, EINECS 213-579-1, † H:H303, P:P312	25g 100g
L14522	**Adenosine-5'-triphosphate disodium salt hydrate, 99+%, water <10% ▲■** *[5'-ATP-Na2]* [34369-07-8], $C_{10}H_{14}N_5Na_2O_{13}P_3 \cdot xH_2O$, F.W. 551.15(anhy), $[\alpha]_D^{20}$ -19° (c=3 in water), Merck **14**,155, EINECS 213-579-1, RTECS AU7417000, BRN 3585462, MDL MFCD00150755, † H:H303, P:P312 	1g 5g
	Adenylic acid, see Adenosine-5'-monophosphoric acid, L14051, p. 79	
J64042	**Adenylyl Cyclase Type V Inhibitor, NKY80 ▲** *[NKY80, 2-Amino-7-(furan-2-yl)-7,8-dihydroquinazolin-5(6H)-one]* [299442-43-6], $C_{12}H_{11}N_3O_2$, F.W. 229.23, Powder, MDL MFCD02026323 ! H:H302, P:P264-P270-P301+P312-P330-P501	5mg
A13705	**Adipic acid, 99%** *[Butane-1,4-dicarboxylic acid, Hexanedioic acid]* [124-04-9], $HOOC(CH_2)_4COOH$, F.W. 146.14, m.p. 151-155°, b.p. ca 205°/3mm, f.p. 196°(384°F), d. 1.360, Merck **14**,162, Fieser **1**,15, EINECS 204-673-3, RTECS AU8400000, BRN 1209788, MDL MFCD00004420, † ! H:H319	1kg 5kg 25kg
	Adipic acid dimethyl ester, see Dimethyl adipate, B21174, p. 196	

Stock #	Description	Size
A13168	**Adipoyl chloride, 98%** ◪ *[1,4-Butanedicarbonyl chloride, Hexanedioyl dichloride]* [111-50-2], $ClCO(CH_2)_4COCl$, F.W. 183.03, b.p. 105-107°/2mm, f.p. >110°(230°F), d. 1.255, n_D^{20} 1.4705, UN3265, EINECS 203-876-4, BRN 507709, MDL MFCD00000759, † H:H314-EUH014, P:P280-P303+P361+P353-P305+P351+P338-P310	**25g** **100g** **500g**
J62385	**Adjuvant Peptide** *[N-Acetylmuramly-L-alanyl-D-isoglutamine, Muramyl dipeptide]* [53678-77-6], $C_{19}H_{32}N_4O_{11}\cdot xH_2O$, F.W. 492.48(anhy), Powder, Merck **14**,6305, EINECS 258-696-9, RTECS MA2275260, BRN 4220745, MDL MFCD00077638 Application(s): Used in immunization to replace more complex proteins. Inhibits the HIV replication in CD4+ H9 lymphocytes	**1mg** **5mg**
L03253	**Adonitol, 99%** ■ *[Ribitol]* [488-81-3], $C_5H_{12}O_5$, F.W. 152.15, m.p. 102-104°, Merck **14**,168, EINECS 207-685-7, RTECS VJ0800000, BRN 1720524, MDL MFCD00064291, † 	**5g** **25g**
	5'-ADP-K, see Adenosine-5'-diphosphate monopotassium salt, 99%, J60672, p. 79 **5'-ADP-Na2**, see Adenosine-5'-diphosphate disodium salt, L14029, p. 79	
L04911	**L-Adrenaline, 98+%** ▲△ *[L-Epinephrine]* [51-43-4], $C_9H_{13}NO_3$, F.W. 183.20, m.p. 216-219°, $[\alpha]_D^{20}$ -52° (c=1 in 0.6N HCl), Merck **14**,3619, UN2811, EINECS 200-098-7, RTECS DO2625000, BRN 2368277, MDL MFCD00002204, † H:H301-H310-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a 	**5g** **25g**
J63005	**DL-Adrenaline** ▲ *[DL-Epinephrine, 3,4-Dihydroxy-a-(methylaminomethyl)benzyl alcohol]* [329-65-7], $(HO)_2C_6H_3CH(CH_2NHCH_3)OH$, F.W. 183.20, Powder, m.p. 197° dec., Merck **14**,3619, UN2811, EINECS 206-347-6, RTECS DO2975000, MDL MFCD00063027 H:H311-H315-H319-H335, P:P305+P351+P338-P361-P302+P352-P321-P405-P501a Application(s): A hormone and neurotransmitter	**1g** **5g** **25g**
J64615	**β-Adrenergic Receptor Kinase1 Inhibitor** ▲ *[β-ARK1 Inhibitor, GRK2 Inhibitor]* [24269-96-3], $C_{12}H_9NO_6$, F.W. 263.20, Powder	**5mg**
J61985	**Adrenocorticotropic Hormone (1-4)** *[ACTH [1-4] Peptide, H-Ser-Tyr-Ser-Met-OH]* [19405-50-6], $C_{20}H_{30}N_4O_8S$, F.W. 486.55, Powder	**1mg** **2mg** **5mg**
J63084	**Adrenocorticotropic Hormone (1-10)** *[ACTH [1-10], Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly]* [2791-05-1], $C_{59}H_{78}N_{16}O_{16}S_1$, F.W. 1299.40, Powder	**1mg** **5mg**
J61247	**Adrenocorticotropic Hormone (1-13)** *[ACTH [1-13], H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-OH]* [22006-64-0], $C_{75}H_{106}N_{20}O_{19}S$, F.W. 1623.85, Powder	**0.5mg** **1mg** **5mg**
J60060	**Adrenocorticotropic Hormone (1-14)** *[ACTH [1-14], H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-OH]* [25696-21-3], $C_{77}H_{109}N_{21}O_{20}S$, F.W. 1680.90, Powder	**1mg** **2mg** **5mg**
J65775	**Adrenocorticotropic Hormone (1-39), guinea pig** *[ACTH (1-39), guinea pig]* [111524-36-8], $C_{206}H_{308}N_{56}O_{58}S$, F.W. 4529.04, Solid	**1mg**
J64495	**Adrenocorticotropic Hormone (12-39), rat** *[ACTH (12-39), rat,* *Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Val-Ala-Glu-Asn-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe]* $C_{145}H_{227}N_{39}O_{41}$, F.W. 3172.58, Solid	**1mg**
J64410	**Adrenocorticotropic Hormone (34-39)** *[ACTH (34-39), Ala-Phe-Pro-Leu-Glu-Phe]* $C_{37}H_{50}N_6O_9$, F.W. 722.83, Solid	**10mg** **25mg**
J65314	**Tyr-Adrenocorticotropic Hormone (4-9)** *[Tyr-ACTH (4-9), Tyr-Met-Glu-His-Phe-Arg-Trp]* [129813-57-6], $C_{51}H_{65}N_{13}O_{11}S$, F.W. 1068.2, Solid, MDL MFCD00133037	**1mg** **5mg**
J64183	**Tyr-Adrenocorticotropic Hormone (4-10)** *[Tyr-ACTH (4-10), Tyr-Met-Glu-His-Phe-Arg-Trp-Gly]* [131374-17-9], $C_{53}H_{68}N_{14}O_{12}S$, F.W. 1125.26, Solid	**1mg** **5mg**
	AEBSF, see 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride, H26473, p. 94	

Stock #	Description	Size
	Aerosporin , see Polymixin B sulfate, J63074, p. 325 **AET**, see S-(2-Aminoethyl)isothiourea dihydrobromide, L14232, p. 94	
J62625	**AG-879, 99%** *[Tyrphostin AG 879, α-Cyano-(3,5-di-t-butyl-4-hydroxy)thiocinnamide]* [148741-30-4], $C_{18}H_{24}N_2OS$, F.W. 316.50, Solid, MDL MFCD00236450 Application(s): Inhibits the tyrosine kinase activity of the nerve growth factor receptor (TrkA; pp140trk) and heregulin receptor erbB-2 (HER-2)	**5mg** **25mg**
	AG-1749, see Lansoprazole, 98+%, J62008, p. 266	
A10752	**Agar powder** [9002-18-0], $(C_{12}H_{18}O_9)_X$, Merck **14**,184, EINECS 232-658-1, RTECS AW7950000, MDL MFCD00081288, † For gel preparation.	**100g** **500g** **2.5kg**
H26724	**Agar, plant cell culture tested** ◪ ■ [9002-18-0], Merck **14**,184, EINECS 232-658-1, RTECS AW7950000, MDL MFCD00081288, †	**100g** **500g** **2.5kg**
J60299	**Agarose, high EEO** [9012-36-6], Powder, EINECS 232-731-8, MDL MFCD00081294, † Application(s): For electrophoresis of serum proteins, immuno electrophoresis and counter immuno electrophoresis	**50g** **100g** **250g**
J62714	**Agarose, high melting temperature, high resolution** [9012-36-6], Powder, EINECS 232-731-8, MDL MFCD00081294, † Application(s): For resolution of small fragments	**25g** **100g**
J61123	**Agarose, high melting temperature, medium resolution** [9012-36-6], Powder, EINECS 232-731-8, MDL MFCD00081294, † Application(s): For standard DNA applications	**25g** **100g** **500g**
H32601	**Agarose beads 4% B** [9012-36-6], b.p. 100°, f.p. 38°(100°F), d. 1.040, UN1170, MDL MFCD00081294, † H:H226, P:P210-P241-P280-P240-P303+P361+P353-P501a	**1L**
H32305	**Agarose beads 4% B-CL (Cross-linked)** [61970-08-9], b.p. 100°, f.p. 38°(100°F), d. 1.040, UN1170, MDL MFCD00081294 H:H226, P:P210-P241-P280-P240-P303+P361+P353-P501a	**1L**
H32491	**Agarose beads 6% B** [9012-36-6], b.p. 100°, f.p. 38°(100°F), d. 1.040, UN1170, MDL MFCD00081294, † H:H226, P:P210-P241-P280-P240-P303+P361+P353-P501a	**1L**
H32568	**Agarose beads 6% B-CL (Cross-linked)** [62610-50-8], b.p. 100°, f.p. 38°(100°F), d. 1.040, UN1170, MDL MFCD00081294 H:H226, P:P210-P241-P280-P240-P303+P361+P353-P501a	**1L**
H26855	**Agarose D1-LE, molecular biology grade** ■ [9012-36-6], EINECS 232-731-8, MDL MFCD00081294, † A general-purpose agarose for molecular biology applications. It has a low electroendosmosis(EEO) and high electrophoresis mobility. Suitable for analytical and preparative nucleic acid electrophoresis, blotting and protein electrophoresis.	**25g** **100g** **500g**
J62157	**Agarose gel loading dye (6X), alkaline** Liquid, Note: 300mM sodium hydroxide, 6mM EDTA, 0.25% bromocresol green, 0.25% xylene cyanol FF and 18% Ficoll	**10ml** **25ml**
J62800	**Agarose gel loading dye (6X), Ficoll based** Viscous liquid, Note: 0.25% bromophenol blue, 0.25% xylene cyanol FF and 15% Ficoll in water, †	**10ml** **25ml**
J63869	**Agarose gel loading dye (6X), glycerol based** Liquid, Note: 0.25% bromophenol blue, 0.25% xylene cyanol FF and 40% glycerol, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**25ml** **50ml**
J60933	**Agarose gel loading dye (6X) glycerol based, Xylene Cyanol FF free** Liquid, Note: No Xylene cyanol FF. Contains 0.25% bromophenol blue, 30% glycerol., † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**25ml** **50ml**
J63429	**Agarose gel loading dye (6X), glycerol based, bromophenol free** Liquid, Note: No Bromophenol blue. Contains 0.25% xylene cyanol FF and 30% glycerol.	**25ml** **50ml**
J60333	**Agarose gel loading dye (6X), sucrose based** Liquid, Note: 0.25% Bromophenol blue, 0.25% xylene cyanol FF, 40% sSucrose (w/v)., †	**25ml** **50ml**

Stock #	Description	Size
H26417	**Agarose LM, low melt, for recovery of samples after separation** ◪ ■ [9012-36-6], EINECS 232-731-8, MDL MFCD00081294, † Low melting temperature agarose which has a high resolving capacity for DNA fragments smaller than 1000 bp, especially PCR products ranging from 200-800 bp. Ideal for preparative electrophoresis.	5g 25g 100g
A16693	**Agarose ME, for electrophoresis of macromolecules** [9012-36-6], EINECS 232-731-8, MDL MFCD00081294, Note: Gel point 36°, †	5g 25g
H26738	**Agarose MS8, molecular sieve grade, for small DNA fragments** ◪ ■ [9012-36-6], EINECS 232-731-8, MDL MFCD00081294, † For molecular screening that improves resolution of small DNA fragments and polymerase chain reaction (PCR) products. Enhanced visibility and high gel strength.	25g 100g
J65119	**Akt Inhibitor X** ▲ ■ *[10-(4'-(N-Diethylamino)butyl)-2-chlorophenoxazine hydrochloride, 4-(2-Chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride]* [925681-41-0], $C_{20}H_{25}ClN_2O$.HCl, F.W. 381.34, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	5mg
	H-β-Ala-OH, see β-Alanine, Cell Culture Reagent, J63435, p. 82 **H-Ala-OH**, see L-Alanine, Cell Culture Reagent, J60279, p. 82	
J63829	**Alamethicin** *[U-22324]* [59588-86-2], $C_{92}H_{150}N_{22}O_{25}$, F.W. 1964.40, Powder, m.p. 267-270°, UN3462, RTECS AY1900000 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A channel-forming ionophore that activates membrane enzymes	1mg 5mg
A16665	**β-Alanine, 98%** *[H-β-Ala-OH, 3-Aminopropionic acid]* [107-95-9], $H_2NCH_2CH_2CO_2H$, F.W. 89.09, m.p. ca 205° dec., d. 1.437, Merck **14**,205, Fieser **1**,16 **5**,6 **6**,10 **17**,3, EINECS 203-536-5, RTECS UA2369200, BRN 906793, MDL MFCD00008200, † Effective catalyst for the Knoevenagel condensation, for example of ethyl cyanoacetate with 2-butanone: *Org. Synth. Coll.*, **4**, 93 (1963), and of malononitrile with various substrates, where stronger bases would cause self-condensation of the nitrile: *J. Org. Chem.*, **38**, 1512 (1973); *Synthesis*, 669 (1974).	250g 1kg 5kg
J63435	**β-Alanine, Cell Culture Reagent** *[H-β-Ala-OH, 3-Aminopropionic acid]* [107-95-9], $H_2NCH_2CH_2CO_2H$, F.W. 89.09, Powder, m.p. ca 205° dec., d. 1.437, Merck **14**,205, EINECS 203-536-5, RTECS UA2369200, BRN 906793, MDL MFCD00008200, †	250g 500g 1kg
A12230	**DL-Alanine, 99%** *[H-DL-Ala-OH, DL-2-Aminopropionic acid]* [302-72-7], $C_3H_7NO_2$, F.W. 89.09, m.p. ca 292° dec., d. 1.42, Merck **14**,204, EINECS 206-126-4, RTECS AY2980000, BRN 635807, MDL MFCD00064408, †	250g 1kg 5kg
A10231	**D-Alanine, 99%** *[H-D-Ala-OH, D-2-Aminopropionic acid]* [338-69-2], $C_3H_7NO_2$, F.W. 89.09, m.p. ca 295° dec., $[\alpha]_D^{20}$ -14° (c=5 in 5N HCl), Merck **14**,204, EINECS 206-418-1, BRN 1720249, MDL MFCD00008077, †	5g 25g 100g
A15804	**L-Alanine, 99%** *[H-Ala-OH, L-2-Aminopropionic acid]* [56-41-7], $C_3H_7NO_2$, F.W. 89.09, m.p. ca 295° dec., d. 1.432, $[\alpha]_D^{20}$ +14° (c=5 in 5N HCl), Merck **14**,204, Fieser **17**,2, EINECS 200-273-8, RTECS AY2990000, BRN 1720248, MDL MFCD00064410, † α-Amino acids can be converted to the corresponding α-chloro acids with a high degree of retention of configuration, by diazotization in the presence of HCl: *J. Am. Chem. Soc.*, **76**, 6054 (1954). The intermediate is thought to be a rigid oxiranone which prevents racemization. For an improved technique and list of examples, see: *Org. Synth. Coll.*, **8**, 119 (1993):  	25g 100g 500g
J60279	**L-Alanine, Cell Culture Reagent** *[H-Ala-OH, L-2-Aminopropionic acid]* [56-41-7], $C_3H_7NO_2$, F.W. 89.09, Powder, m.p. ca 295° dec., Merck **14**,204, EINECS 200-273-8, RTECS AY2990000, BRN 1720248, MDL MFCD00064410, †	50g 100g 500g
	DL-Alanine 2-(4-chlorophenyl)-1,1-dimethylethyl ester hydrochloride, see Alaproclate hydrochloride, 96%, J62741, p. 82 **L-Alanine: 2-oxoglutarate aminotransferase**, see Glutamic pyruvic transaminase, porcine heart, J62109, p. 235 **D-Alaninol**, see (R)-(-)-2-Amino-1-propanol, L11030, p. 99 **L-Alaninol**, see (S)-(+)-2-Amino-1-propanol, B24916, p. 99	
J62741	**Alaproclate hydrochloride, 96%** *[DL-Alanine 2-(4-chlorophenyl)-1,1-dimethylethyl ester hydrochloride]* [60719-83-7], $C_{13}H_{18}ClNO_2$·HCl, F.W. 292.21, Crystalline powder, RTECS AY4397300, MDL MFCD00153761 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501 Application(s): Powerful, selective serotonin uptake inhibitor	25mg

Stock #	Description	Size
H25925	**Albendazole, 98+%** *[Methyl 5-n-propylthio-2-benzimidazolecarbamate]* [54965-21-8], $C_{12}H_{15}N_3O_2S$, F.W. 265.34, m.p. 208-210°, Merck **14**,210, EINECS 259-414-7, MDL MFCD00083232  H:H360-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a	**10g** **50g** **100g**
J65097	**Albumin, Bovine, Cohn Fraction V, 98%, Cell Culture Grade, Low Endotoxin** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**10g** **50g** **100g** **250g** **1kg**
J64682	**Albumin, Bovine, Cohn Fraction V, 98%, Fatty Acid Free, pH 5.2** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**50g** **100g** **250g** **500g** **1kg**
J64944	**Albumin, Bovine, Cohn Fraction V, 98%, Fatty Acid Free, pH 7.0** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**50g** **100g** **250g** **500g** **1kg**
J65973	**Albumin, Bovine, Cohn Fraction V, 98%, Immunoassay Grade, protease and enzyme-free, pH 5.2** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**50g** **100g** **250g** **500g** **1kg**
J65731	**Albumin, Bovine, Cohn Fraction V, 98%, Immunoassay Grade, protease and enzyme-free, pH 7.0** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**50g** **100g** **250g** **500g** **1kg**
J65525	**Albumin, Bovine, Cohn Fraction V, 98%, Low Fatty Acid, pH 5.2** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**50g** **100g** **250g** **500g** **1kg**
J65969	**Albumin, Bovine, Cohn Fraction V, 98%, Low Fatty Acid, pH 7.0** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**50g** **100g** **250g** **500g** **1kg**
J65399	**Albumin, Bovine, Cohn Fraction V, Reagent Grade, pH 5.2** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**50g** **100g** **250g** **500g** **1kg**
J65966	**Albumin, Bovine, Cohn Fraction V, Reagent Grade, pH 7.0** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**50g** **100g** **250g** **500g** **1kg**
J64100	**Albumin, Bovine, Fraction V, 98%, Reagent Grade, pH 7.0** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**10g** **50g** **100g** **250g** **500g** **1kg**

Stock #	Description	Size
J65855	**Albumin, Bovine, Fraction V, 96%, Standard Grade, pH 5.2** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**10g** **50g** **100g** **250g** **1kg**
J64655	**Albumin, Bovine, Fraction V, 97%, Standard Grade, pH 7.0** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**10g** **50g** **100g** **250g** **1kg**
J65788	**Albumin, Bovine, Fraction V, 96%, Standard Grade, New Zealand origin, pH 7.0** *[Bovine serum albumin, BSA]* [9048-46-8], Lyophilized powder, EINECS 232-936-2, MDL MFCD00130384, †	**10g** **50g** **100g** **250g** **1kg**
J65833	**Albumin, Bovine, Fraction V, 30% soln., Standard Grade, no preservative** *[Bovine serum albumin solution, BSA solution]* [9048-46-8], Liquid, EINECS 232-936-2, MDL MFCD00130384, †	**100ml** **500ml** **1L**
J65569	**Albumin, Bovine, Fraction V, 30% soln., Standard Grade, with azide as preservative** *[Bovine serum albumin solution, BSA solution]* [9048-46-8], Liquid, EINECS 232-936-2, MDL MFCD00130384, † H:H302, P:P264-P270-P301+P312-P330-P501	**100ml** **500ml** **1L**
J65042	**Albumin, Bovine, Fraction V, 35% soln., Reagent Grade, Fatty Acid Free, no preservative** *[Bovine serum albumin solution, BSA solution]* [9048-46-8], Liquid, EINECS 232-936-2, MDL MFCD00130384, †	**100ml** **500ml** **1L**
J64728	**Albumin, Bovine, Fraction V, 35% soln., Reagent Grade, Fatty Acid Free, with azide as preservative** *[Bovine serum albumin solution, BSA solution]* [9048-46-8], Liquid, EINECS 232-936-2, MDL MFCD00130384, † H:H302, P:P264-P270-P301+P312-P330-P501	**100ml** **500ml** **1L**
J64248	**Albumin, Bovine, Fraction V, 35% soln., Cell Culture Grade, no preservative** *[Bovine serum albumin solution, BSA solution]* [9048-46-8], Liquid, EINECS 232-936-2, MDL MFCD00130384, †	**50ml** **100ml**
J64101	**Albumin, Bovine, Fraction V, 35% soln., Cell Culture Grade, with azide as preservative** *[Bovine serum albumin solution, BSA solution]* [9048-46-8], Liquid, EINECS 232-936-2, MDL MFCD00130384, † H:H302, P:P264-P270-P301+P312-P330-P501	**50ml** **100ml**
J65030	**Albumin, Bovine, Low Endotoxin, Cell Culture Grade, Chromatographically purified** *[Bovine Serum Albumin, BSA]* [9048-46-8], F.W. 66kDa, Powder, EINECS 232-936-2, MDL MFCD00130384, †	**10g** **25g** **50g** **100g**
J65400	**Albumin, Bovine, Low Fatty Acid, Chromatographically purified** *[Bovine Serum Albumin, BSA]* [9048-46-8], F.W. 66kDa, Powder, EINECS 232-936-2, MDL MFCD00130384, † Application(s): Suitable for immunoassays. Reduced fatty acid content minimizes non-specific binding of antibodies	**10g** **25g** **50g** **100g**
J65470	**Albumin, Bovine, Low IgG, Chromatographically purified** *[Bovine Serum Albumin, BSA]* [9048-46-8], F.W. 66kDa, Powder, EINECS 232-936-2, MDL MFCD00130384, † Application(s): For immunoassays that require low IgG so as not to interfere with antibody-antigen binding	**10g** **25g** **50g** **100g** **500g**
J64912	**Albumin, Bovine, Protease-free, Chromatographically purified** *[Bovine Serum Albumin, BSA]* [9048-46-8], F.W. 66kDa, Powder, EINECS 232-936-2, MDL MFCD00130384, † Application(s): Suitable for immunoassay applications where protease activity would be undesirable	**25g** **100g** **500g**
J65189	**Albumin, Bovine, RIA Grade, Chromatographically purified** *[Bovine Serum Albumin, BSA]* [9048-46-8], F.W. 66kDa, Powder, EINECS 232-936-2, MDL MFCD00130384, † Application(s): For standard use in radioimmunoassays	**10g** **50g** **100g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64777	**Albumin, Bovine, Standard Grade, Chromatographically purified** *[Bovine Serum Albumin, BSA]* [9048-46-8], F.W. 66kDa, Powder, EINECS 232-936-2, MDL MFCD00130384, †	**10g** **50g** **100g**
	Application(s): Suitable for standard protein research applications	**500g**
J64752	**Albumin, Bovine plasma, crystalline, 98%** *[Bovine Serum Albumin, BSA]* [9048-46-8], Powder, EINECS 232-936-2, MDL MFCD00130384, †	**5g** **10g**
	Application(s): For lipid solubilization; also a blocking agent in Western blots	
A16951	**Albumin, ex egg, 80%** [9006-59-1], EINECS 232-692-7, MDL MFCD00804580, †	**50g** **250g**
	Albuterol, see Salbutamol, 99%, J63741, p. 339 **Albuterol sulfate**, see Salbutamol sulfate, A18544, p. 339 **AICA**, see 5-Amino-4-imidazolecarboxamide hydrochloride, B24012, p. 95	
J60122	**Alcian Blue 8GX** *[Ingrain blue 1, C.I. 74240]* [33864-99-2], $C_{56}H_{68}Cl_4CuN_{16}S_4$, F.W. 1298.88, Powder, m.p. 148°, EINECS 251-705-7, MDL MFCD00010720, Note: Certified by the Biological Stain Commission, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**10g** **25g** **100g**
J65869	**Alcohol dehydrogenase, yeast** *[ADH, Alcohol: NAD+ oxidoreductase]* [9031-72-5], Lyophilized powder, EINECS 232-870-4, RTECS SZ5999500, MDL MFCD00081305, Note: from Baker's yeast, † Application(s): Catalyzes the oxidation of alcohol and the reduction of aldehydes	**30kilounits** **150kilounits**
J64628	**Alcohol dehydrogenase kit - 12 variants (A1 through A12)** *[EC 1.1.1.1]* Lyophilized powder, Note: Contains 100mg of each variant Application(s): Catalyzes stereoselective reduction of ketones to produce enatiomerically pure alcohols	**1each**
J64194	**Alcohol dehydrogenase kit - 35 variants (A1 through A35)** *[EC 1.1.1.1]* Lyophilized powder, Note: Contains 100mg of each variant ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): Catalyzes stereoselective reduction of ketones to produce enatiomerically pure alcohols	**1each**
J65760	**Alcohol Dehydrogenase A1** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65907	**Alcohol Dehydrogenase A2** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65344	**Alcohol Dehydrogenase A3** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64009	**Alcohol Dehydrogenase A4** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65129	**Alcohol Dehydrogenase A5** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64820	**Alcohol Dehydrogenase A6** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64660	**Alcohol Dehydrogenase A7** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64842	**Alcohol Dehydrogenase A8** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64213	**Alcohol Dehydrogenase A9** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**

Stock #	Description	Size
J65285	**Alcohol Dehydrogenase A10** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65660	**Alcohol Dehydrogenase A11** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64939	**Alcohol Dehydrogenase A12** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65084	**Alcohol Dehydrogenase A13** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64220	**Alcohol Dehydrogenase A14** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65514	**Alcohol Dehydrogenase A15** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64185	**Alcohol Dehydrogenase A16** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J66000	**Alcohol Dehydrogenase A17** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65821	**Alcohol Dehydrogenase A18** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64662	**Alcohol Dehydrogenase A19** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64564	**Alcohol Dehydrogenase A20** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64491	**Alcohol Dehydrogenase A21** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64145	**Alcohol Dehydrogenase A22** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65454	**Alcohol Dehydrogenase A23** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65139	**Alcohol Dehydrogenase A24** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65992	**Alcohol Dehydrogenase A25** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65124	**Alcohol Dehydrogenase A26** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65951	**Alcohol Dehydrogenase A27** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64317	**Alcohol Dehydrogenase A28** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64321	**Alcohol Dehydrogenase A29** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65989	**Alcohol Dehydrogenase A30** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65743	**Alcohol Dehydrogenase A31** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65451	**Alcohol Dehydrogenase A32** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65860	**Alcohol Dehydrogenase A33** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J65190	**Alcohol Dehydrogenase A34** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64886	**Alcohol Dehydrogenase A35** *[EC 1.1.1.1]* [9031-72-5], Lyophilized powder, EINECS 232-870-4	**250mg** **500mg** **1g**
J64450	**Alcohol Dehydrogenase A36** Lyophilized powder, Note: Component in the Cofactor Recycling Enzymes Kit, item J64535	**250mg** **500mg** **1g**
45391	**R1-Alcohol Dehydrogenase** MDL MFCD00081305 Application(s): Synthesis of enantiometically pure alcohols with (R)-configuration. Very broad substrate specificity: aliphatic, cyclic and aromatic ketones, diketones and keto acid esters	**1kilounit** **5kilounits**
45393	**R2-Alcohol Dehydrogenase** [9028-12-0], Powder, MDL MFCD00081305 Application(s): Synthesis of enantiomerically pure alcohols with (R)-configuration. Very broad substrate specificity: aliphatic, cyclic and aromatic ketones and diketones	**1kilounit** **5kilounits**
45392	**S1-Alcohol Dehydrogenase** [9031-72-5], Powder, EINECS 232-870-4, MDL MFCD00081305 Application(s): Synthesis of enantiomerically pure alcohols with (S)-configuration. High activity to α-diketones, shortchain aliphatic ketones and aliphatic keto acid esters	**1kilounit** **5kilounits**
45394	**S2-Alcohol Dehydrogenase** [9031-72-5], Powder, EINECS 232-870-4, MDL MFCD00081305 Application(s): Synthesis of enantiomerically pure alcohols with (S)-configuration. High activity to ketones with bulky side chains, such as acetophenones, ring-halogenated acetophenones or pinacoline	**1kilounit** **5kilounits**
45395	**S3-Alcohol Dehydrogenase** [9031-72-5], Powder, EINECS 232-870-4, MDL MFCD00081305 Application(s): Synthesis of enantiomerically pure aromatic alcohols with (S)-configuration. High activity to ketones with bulk side chains such as ecetophenones, ring-halogenated acetophenones or pinacoline	**1kilounit** **5kilounits**
45397	**S4-Alcohol Dehydrogenase** [9031-72-5], Powder, EINECS 232-870-4, MDL MFCD00081305 Application(s): Synthesis of enantiomerically pure alcohols with (S)-configuration. Broad substrate specificity that includes linear and cyclic ketones and acetaldehyde	**1kilounit** **5kilounits**
45399	**S5-Alcohol Dehydrogenase** MDL MFCD00081305 Application(s): Enzymic catalysis in organic solvents	**1kilounit** **5kilounits**
45401	**S6-Alcohol Dehydrogenase** [9031-72-5], Powder, EINECS 232-870-4, MDL MFCD00081305, † Application(s): Synthesis of enantiomerically pure alcohols with (S)-configuration. High activity to ketones with bulk side chains such as ecetophenones, ring-halogenated acetophenones or pinacoline	**1kilounit** **5kilounits**
J64713	**Aldehyde Dehydrogenase Kit - 5 variants (AD1 through AD5)** *[EC 1.2.1.3]* Lyophilized powder, Note: Contains 100mg of each variant Application(s): Catalyzes the oxidation of aldehydes to the corresponding carboxylic acids with NAD+/NADP+ as cofactor	**1each**

Stock #	Description	Size
J65968	**Aldehyde Dehydrogenase AD1** *[EC 1.2.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J65229	**Aldehyde Dehydrogenase AD2** *[EC 1.2.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J64511	**Aldehyde Dehydrogenase AD3** *[EC 1.2.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J65123	**Aldehyde Dehydrogenase AD4** *[EC 1.2.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J64097	**Aldehyde Dehydrogenase AD5** *[EC 1.2.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J65717	**Aldehyde Reductase Kit - 10 variants (AR1-AR10)** Lyophilized powder, Note: Contains 100mg of each variant Application(s): Catalyzes the reduction of aldehydes to the corresponding primary alcohols with NADH/NADPH as cofactor	**1each**
J64832	**Aldehyde Reductase AR1** Lyophilized powder	**250mg** **500mg** **1g**
J64744	**Aldehyde Reductase AR2** Lyophilized powder	**250mg** **500mg** **1g**
J64714	**Aldehyde Reductase AR3** Lyophilized powder	**250mg** **500mg** **1g**
J64367	**Aldehyde Reductase AR4** Lyophilized powder	**250mg** **500mg** **1g**
J65435	**Aldehyde Reductase AR5** Lyophilized powder	**250mg** **500mg** **1g**
J65614	**Aldehyde Reductase AR6** Lyophilized powder	**250mg** **500mg** **1g**
J65548	**Aldehyde Reductase AR7** Lyophilized powder	**250mg** **500mg** **1g**
J65082	**Aldehyde Reductase AR8** Lyophilized powder	**250mg** **500mg** **1g**
J65242	**Aldehyde Reductase AR9** Lyophilized powder	**250mg** **500mg** **1g**
J65021	**Aldehyde Reductase AR10** Lyophilized powder	**250mg** **500mg** **1g**
J61397	**Alendronate sodium trihydrate, 97%** *[MK-217]* [121268-17-5], $C_4H_{12}NaNO_7P_2 \cdot 3H_2O$, F.W. 325.12 (271.08anhy), Solid, Merck **14**,229, RTECS SZ6523500, MDL MFCD01748233 ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Inhibits CD45 protein tyrosine phosphatase and farnesyl diphosphate synthase; induces apoptosis	**5g**
	Algin, see Alginic acid sodium salt, high viscosity, J61887, p. 89	

Contact us for pricing on bulk sizes

Stock #	Description	Size
A17582	**Alginic acid** ■ *[Polymannuronic acid]* [9005-32-7], m.p. >300°, Merck **14**,242, EINECS 232-680-1, RTECS AZ5775000, MDL MFCD00081309, Note: Insoluble in water, †  Application(s): A straight chain, hydrophilic, colloidal polyuronic acid	**100g** **500g** **2.5kg**
B25266	**Alginic acid sodium salt, low viscosity** ■ *[Algin, Polymannuronic acid sodium salt]* [9005-38-3], Merck **14**,241, RTECS AZ5820000, MDL MFCD00081310, † Application(s): A gelling polysaccharide extracted from giant brown seaweed, useful in viscosity studies	**50g** **100g** **250g** **500g**
J61887	**Alginic acid sodium salt, high viscosity** *[Algin, Sodium alginate]* [9005-38-3], Powder, Merck **14**,241, MDL MFCD00081310, † Application(s): A gelling polysaccharide extracted from giant brown seaweed, useful in viscosity studies	**100g** **250g** **1kg**
A18565	**Alginic acid sodium salt, very low viscosity** ■ *[Algin, Polymannuronic acid sodium salt]* [9005-38-3], Merck **14**,241, MDL MFCD00081310, †	**100g** **500g** **2.5kg**
	Aliquat® 100, see Tetra-n-butylammonium bromide, A10249, p. 361	
A14404	**Alizarin, 94%** *[1,2-Dihydroxyanthraquinone]* [72-48-0], $C_{14}H_8O_4$, F.W. 240.21, m.p. 286-290°, b.p. ca 430° subl., Merck **14**,251, EINECS 200-782-5, RTECS CB6580000, BRN 1914037, MDL MFCD00001201, †  ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Acid-base indicator: pH 5.8 - 7.2, 11.0 - 13.0.	**100g** **500g** **2.5kg**
42040	**Alizarin Red S sodium salt** *[3,4-Dihydroxy-9,10-dioxo-2-anthracenesulfonic acid sodium salt, C.I. 58005]* [130-22-3], $C_{14}H_7O_7SNa$, F.W. 342.27, Powder, Merck **14**,8573, EINECS 204-981-8, RTECS CB1095300, BRN 4117090, MDL MFCD00013049, Note: Transition interval: pH 4.6 (yellow) to pH 6.0 (red), † 	**5g** **25g**
38707	**Alizarin Yellow R sodium salt** *[Mordant Yellow 3R, 5-(4-Nitrophenylazo)salicylic acid sodium salt]* [1718-34-9], $C_{13}H_8N_3NaO_5$, F.W. 309.22, Powder, Merck **14**,255, EINECS 217-002-4, RTECS DH2528600, BRN 962365, MDL MFCD00067121, Note: Transition interval: pH 10.1 (yellow) to pH 12.1 (orange), †  ! H:H302, P:P280f	**10g** **25g**
J61037	**Alkaline Phosphatase, calf intestine, EIA Grade** *[EC 3.1.3.1, CIAP]* [9001-78-9], Liquid, 140 kDa, EINECS 232-631-4, MDL MFCD00131849, Note: Minimum 3,000 units per mg protein. One unit hydrolyzes 1 micromole of p-nitrophenol phosphate per minute at 37 degrees and pH 9.8, † Application(s): Used to dephosphorylate proteins; also used to dephosphorylate the 5' termini of DNA or RNA to prevent self ligation	**1mg** **5mg**
J62907	**Alkaline Phosphatase Buffer-1 (5X)** Liquid, Note: Contains 200mM Tris, 200mM NaCl, and 40mM magnesium chloride at pH 9.5, †	**100ml** **250ml**
J63170	**Alkaline running buffer soln.** Liquid, Note: Contains 0.5M NaOH and 50mM EDTA, †	**250ml** **500ml**
	Alkylbenzyldimethylammonium chloride, see Benzalkonium chloride, 41339, p. 119	
A15571	**Allantoin, 98%** *[5-Ureidohydantoin]* [97-59-6], $C_4H_6N_4O_3$, F.W. 158.12, m.p. ca 230° dec., Merck **14**,258, EINECS 202-592-8, RTECS YT1600000, BRN 102364, MDL MFCD00005260, † 	**250g** **1kg** **5kg**
	Allantoxanic acid potassium salt, see Oxonic acid potassium salt, J60400, p. 310 **ALLM**, see Calpain Inhibitor II, 95+%, J62491, p. 144 **ALLN**, see Calpain Inhibitor I, 95+%, J61766, p. 144 **Allopurinol**, see 4-Hydroxypyrazolo[3,4-d]pyrimidine, A16974, p. 251	
A15324	**Alloxan monohydrate, 98%** △ *[Mesoxalylurea monohydrate, 2,4,5,6(1H,3H)-Pyrimidinetetrone]* [2244-11-3], $C_4H_2N_2O_4{\cdot}H_2O$, F.W. 160.09 (142.07anhy), m.p. ca 260° dec., Merck **14**,282, EINECS 200-062-0, RTECS UW0492000, BRN 5309394, MDL MFCD00149399, †  Application(s): Cytotoxic compound that causes oxidative base damage to nuclear DNA	**25g** **50g** **100g** **250g** **1kg**
H52177	**2-Allyl-N-Fmoc-L-glycine, 95%** *[Fmoc-allyl-Gly-OH]* [146549-21-5], $C_{20}H_{19}NO_4$, F.W. 337.37, BRN 5884047, MDL MFCD01311749 	**250mg** **1g** **5g**

Stock #	Description	Size
	4-Allylguaiacol, see Eugenol, A14332, p. 217 **4-Allyl-2-methoxyphenol**, see Eugenol, A14332, p. 217	
J62153	**Aloin** *[Barbaloin, 1,8-Dihydroxy-10-(β-D-glucopyranosyl)-3-(hydroxymethyl)-9(10H)-anthracenone]* [1415-73-2], $C_{21}H_{22}O_9$, F.W. 418.40, Powder, EINECS 215-808-0, RTECS LZ6520000, BRN 6077558, MDL MFCD00151160 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Aloe exudant, used as a stimulant-laxative	**10g** **25g** **50g**
J61582	**Aluminum chloride, 0.5M aq. soln.** [7784-13-6], $AlCl_3$, F.W. 133.34, Liquid, UN2581, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**50ml** **100ml**
46200	**Aluminum oxide, for Bio-Mass Cleanup** [1344-28-1], Al_2O_3, F.W. 101.96, 50-150 Micron APS Powder, m.p. 2045°, b.p. 2980°, n_D^{20} 1.765, Merck **14**,356, EINECS 215-691-6, MDL MFCD00003424, †	**250g** **1kg**
J65155	**AM 580** *[4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid]* [102121-60-8], $C_{22}H_{25}NO_3$, F.W. 351.44, Crystalline solid, RTECS DH6834890, MDL MFCD00673916	**10mg**
	Amantadine hydrochloride, see 1-Adamantanamine hydrochloride, A12699, p. 78	
J62932	**Amastatin hydrochloride, 98+%** *[[(2S,3R)-3-Amino-2-hydroxy-5-methylhexanoyl]-Val-Val-Asp-OH]* [100938-10-1], $C_{21}H_{38}N_4O_8 \cdot HCl$, F.W. 511.01, Powder, BRN 8888370, MDL MFCD00150636 Application(s): Inhibitor for aminopeptidase A and leucine aminopeptidase	**1mg** **5mg**
L14285	**Amberlite® IR-120(H), ion exchange resin** [78922-04-0], d. 1.2800, Merck **14**,382, Fieser **1**,511 **4**,266 **5**,355 **6**,302 **9**,256, MDL MFCD00132707 H:H318, P:P280i-P305+P351+P338-P310 Strongly acidic gel-type cation-exchange resin, 8% crosslinked, H^+ form. Catalyst for preparation of enol ethers or ketals from ketones: *Synthesis*, 348 (1974), and for selective ketalization of diketo steroids: *J. Chem. Soc. Perkin 1*, 2376 (1974). See also **Amberlyst® 15(H)**, **89079**, p. 90.	**250g** **500g** **1kg**
42253	**Amberlite® IRA-67, ion exchange resin** [80747-90-6], Merck **14**,382, MDL MFCD00145567, Note: Acrylic-DVB; Weakly basic gel type resin	**250g** **1kg** **5kg**
17246	**Amberlite® IRA-400(Cl), ion exchange resin** [9002-24-8], Styrene-DVB; Strongly basic gel type resin, Merck **14**,382, MDL MFCD00132708, † Strongly-basic gel-type anion-exchange resin, Cl^- form. In the hydroxide form, is a catalyst for preparation of esters from carboxylic acids and alkyl iodides: *Synthesis*, 723 (1975), and has also been used as a low-cost, recyclable alternative to silver oxide for the preparation of quaternary ammonium hydroxides: *Org. Synth. Coll.*, **6**, 550 (1988).	**100g** **500g** **2kg**
L19567	**Amberlite® IRA-900(Cl), ion exchange resin** [9050-97-9], Merck **14**,382, MDL MFCD00132712 Macroreticular strongly basic ionic exchange resin, Cl^- form.	**250g** **1kg**
44079	**Amberlyst® 15(H), wet, ion exchange resin** ■ [39389-20-3], Styrene-DVB; Strongly acidic macroreticular resin, Beads, Fieser **5**,355 **6**,302 **9**,256 **11**,276 **13**,152 **15**,178 **18**,194, MDL MFCD00145841, †	**250g** **1kg** **5kg**
89079	**Amberlyst® 15(H), ion exchange resin** [39389-20-3], Styrene-DVB; Strongly acidic macroreticular resin, Pale brown beads, Fieser **5**,355 **6**,302 **9**,256 **11**,276 **13**,152 **15**,178 **18**,194, MDL MFCD00145841, † Amberlyst is a registered trademark of Rohm and Haas Co. Macroreticular strongly acidic cation-exchange resin, H^+ form, suitable for non-aqueous applications. Useful catalyst for a variety of reactions, for example: Formation of THP ethers: *Synthesis*, 618 (1979). Protection of alcohols as *tert*-butyl ethers: *Tetrahedron Lett.*, **29**, 2951 (1988). Protection of aldehydes as dithioacetals: *Synth. Commun.*, **19**, 2383 (1989). Esterification of acids with methanol: *Synth. Commun.*, **18**, 847 (1988). Cleavage of acetals: *Synthesis*, 1021 (1984); *J. Am. Chem. Soc.*, **117**, 10143 (1995). Regeneration of carbonyl compounds from hydrazones: *J. Chem. Soc., Perkin 1*, 2563 (1988). For use in the Fischer indole synthesis, see: *Heterocycles*, **22**, 1211 (1984); *J. Chem. Soc., Perkin 1*, 1319 (1990).	**50g** **250g** **1kg**
A17956	**Amberlyst® A-21, ion exchange resin** [9049-93-8], Fieser **18**,194 **21**,237, MDL MFCD00145842 Macroreticular weakly basic anion-exchange resin, free base, suitable for non-aqueous applications. Effective catalyst for the Michael addition of nitroalkanes to methyl acrylate: *Synthesis*, 711 (1987), and also for the cleavage of 2-nitrocycloalkanones: *Synthesis*, 355 (1992). Promotes the Henry (nitro-aldol) reaction of aldehydes with nitroalkanes giving superior results to conventional conditions: *Liebigs Ann. Chem.*, 1235 (1994); *J. Org, Chem.*, **59**, 5466 (1994); *Tetrahedron*, **52**, 1677 (1996). Useful heterogeneous catalyst for conversion of carbonyl compounds to oximes with hydroxylamine hydrochloride: *Chem. Lett.*, 475 (1997).	**250g** **1kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63712	**Ambroxol hydrochloride, 99%** [18683-91-5], $C_{13}H_{18}Br_2N_2O \cdot HCl$, F.W. 414.57, Powder, Merck **14**,386, EINECS 242-500-3, RTECS GV8423000, MDL MFCD00078932 Application(s): Sodium channel blocker. Metabolite of bromhexine	**5g**
	N-Amidino-3,5-diamino-6-chloropyrazine-2-carboxamide hydrochloride, see Amiloride hydrochloride, J62168, p. 91 **N-Amidinosarcosine monohydrate**, see Creatine monohydrate, B25009, p. 168	
J61978	**Amido Black 10B, 0.2% v/v soln. in 5% acetic acid** *[Acid black 1, C.I. 20470]* [1064-48-8], $C_{22}H_{14}N_6Na_2O_9S_2$, F.W. 616.49, Liquid, BRN 5374263, MDL MFCD00004017, † H:EUH210	**500ml** **1L**
A11374	**Amido Black 10B** ■ *[C.I. 20470, Naphthalene Black 10B]* [1064-48-8], $C_{22}H_{14}N_6Na_2O_9S_2$, F.W. 616.49, EINECS 213-903-1, RTECS QJ6196000, BRN 5374263, MDL MFCD00004017, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g**
33233	**Amidosulfonic acid, ACS, 99.3-100.3% (Assay dried basis)** *[Sulfamic acid]* [5329-14-6], H_2NSO_3H, F.W. 97.09, Crystalline, m.p. ca 205° dec., d. 2.12, Merck **14**,8921, Fieser **1**,1117 **20**,353, UN2967, EINECS 226-218-8, RTECS W05950000, MDL MFCD00011603, † Maximum level of impurities: Insoluble matter 0.01%, Residue after ignition 0.01%, Cl 0.001%, SO_4 0.05%, Heavy Metals (as Pb) 0.001%, Fe 5ppm H:H315-H319-H412, P:P280-P305+P351+P338-P302+P352-P321-P362-P501a	**100g** **500g**
	Amidotrizoic acid, see Diatrizoic acid, J63444, p. 184	
J60849	**Amikacin** *[N1-[(S)-(-)-4-Amino-2-hydroxybutyryl]kanamycin A]* [37517-28-5], $C_{22}H_{43}N_5O_{13}$, F.W. 585.61, Crystalline powder, m.p. 203°, Merck **14**,405, EINECS 253-538-5, RTECS WK1955000, BRN 1445422, MDL MFCD00883675 Application(s): An aminoglycoside antibiotic derived from Kanamycin A	**1g** **5g** **25g**
J63862	**Amikacin disulfate** [39831-55-5], $C_{22}H_{43}N_5O_{13} \cdot 2H_2SO_4$, F.W. 781.77, Powder, m.p. 220-230°, Merck **14**,405, EINECS 254-648-6, RTECS WK1961200, BRN 6172633, MDL MFCD00167475, Note: Potency: 674-786 micrograms per mg Application(s): An aminoglycoside antibiotic derived from Kanamycin A	**25g** **100g**
J62168	**Amiloride hydrochloride dihydrate** *[N-Amidino-3,5-diamino-6-chloropyrazine-2-carboxamide hydrochloride]* [2016-88-8], $C_6H_8ClN_7O.HCl.2H_2O$, F.W. 266.09, Powder, m.p. >240°, Merck **14**,406, UN2811, EINECS 217-958-2, RTECS UQ2275500, MDL MFCD00058197 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Sodium channel blocker	**1g** **5g**
	Aminoacetic acid, see Glycine, 99.5+%, Cell Culture Reagent, J62407, p. 237	
B24356	**9-Aminoacridine hydrochloride hydrate, 99%** *[9-Acridinamine hydrochloride hydrate]* [52417-22-8], $C_{13}H_{10}N_2 \cdot HCl \cdot xH_2O$, F.W. 230.69(anhy), m.p. >300°, UN2811, EINECS 205-145-5, RTECS AR7350000, MDL MFCD00150071, † H:H301-H341, P:P280h-P309-P310 Application(s): A mutagen and DNA modifier	**5g** **25g**
	1-Aminoadamantane hydrochloride, see 1-Adamantanamine hydrochloride, A12699, p. 78 **L-2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid**, see L-Kynurenine, J60199, p. 264	
A13846	**4-Aminoantipyrine, 97%** *[4-Amino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one, 4-Aminophenazone]* [83-07-8], $C_{11}H_{13}N_3O$, F.W. 203.25, m.p. 106-110°, Merck **14**,591, EINECS 201-452-3, RTECS CD2480000, BRN 181635, MDL MFCD00003145, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2.5kg**
J64308	**1-Amino-11-azido-3,6,9-trioxaundecane** *[Azido-PEG3-amine]* [134179-38-7], $C_8H_{18}N_4O_3$, F.W. 218.26, Viscous liquid, UN2735, MDL MFCD00269874 H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501	**25mg** **100mg**
A10793	**3-Aminobenzamide, 98%** [3544-24-9], $C_7H_8N_2O$, F.W. 136.15, m.p. 111-115°, EINECS 222-586-9, RTECS CU8992000, BRN 2802373, MDL MFCD00007989 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Endogenous poly-ADP-ribosyltransferase inhibitor	**5g** **25g**
	5-Aminobenzene-1,3-dicarboxylic acid, see 5-Aminoisophthalic acid, A15074, p. 96 **4-Aminobenzenesulfonamide**, see Sulfanilamide, A13001, p. 355 **N-(4-Aminobenzenesulfonyl)acetamide**, see Sulfacetamide, A19836, p. 355	

Stock #	Description	Size
A12673	**4-Aminobenzoic acid, 99%** ▲ △ *[H-4-Abz-OH, PABA]* [150-13-0], $C_7H_7NO_2$, F.W. 137.14, m.p. ca 187° dec., d. 1.374, Merck **14**,423, Fieser **2**,24, EINECS 205-753-0, RTECS DG1400000, BRN 471605, MDL MFCD00007894, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g** **1kg**
	4-Aminobenzoic acid ethyl ester, see Ethyl 4-aminobenzoate, A12754, p. 214	
J63428	**4-Aminobenzoic acid sodium salt, 99%** *[PABA, Sodium 4-aminobenzoate]* [555-06-6], $C_7H_6NNaO_2$, F.W. 159.12, Powder, m.p. >300°, EINECS 209-080-3, RTECS DG2975000, MDL MFCD00064395, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Pharmaceutical intermediate	**25g** **100g** **250g**
J63610	**1-Aminobenzotriazole, 98%** *[1-Benzotriazolamine, ABT]* [1614-12-6], $C_6H_6N_4$, F.W. 134.14, Powder, m.p. 81-84°, BRN 607843, MDL MFCD00132902 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Suicide inhibitor of cytochrome P450 and chloroperoxidase	**250mg** **1g** **5g**
	N-(4-Aminobenzoyl)glycine, see 4-Aminohippuric acid, A13786, p. 95 **5-Amino-(3,4'-bipyridin)-6(1H)-one**, see Amrinone, 98%, J62655, p. 103	
H51980	**4-Amino-N-Boc-L-phenylalanine, 95%** *[Boc-Phe(4-NH2)-OH]* [55533-24-9], $C_{14}H_{20}N_2O_4$, F.W. 280.32, m.p. 124-126°, MDL MFCD00038139	**250mg** **1g** **5g**
	2-Amino-8-bromo-6-hydroxypurine riboside, see 8-Bromoguanosine, J63940, p. 137	
L03889	**(R)-(-)-2-Aminobutane, 99%** △ *[(R)-(-)-2-Butylamine, (R)-(-)-1-Methylpropylamine]* [13250-12-9], $C_4H_{11}N$, F.W. 73.14, b.p. 63°, f.p. -19°(-2°F), d. 0.722, n_D^{20} 1.3930, $[\alpha]_D^{20}$ -7.5° (neat), Merck **14**,1544, UN2733, EINECS 236-232-6, BRN 1718760, MDL MFCD00064416 H:H225-H314-H400-H302-H332, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	**250mg** **1g** **5g**
L10069	**(S)-(+)-2-Aminobutane, 98%** △ *[(S)-(+)-2-Butylamine, (S)-(+)-1-Methylpropylamine]* [513-49-5], $C_4H_{11}N$, F.W. 73.14, b.p. 63°, f.p. -19°(-2°F), d. 0.722, n_D^{20} 1.3930, $[\alpha]_D^{20}$ +7.5° (neat), Merck **14**,1544, UN2733, EINECS 208-164-7, RTECS EO3327000, BRN 1718760, MDL MFCD00064417, † H:H225-H314-H400-H302-H332, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	**250mg** **1g** **5g**
J62670	**(2S)-2-Aminobutyramide** [143164-46-9], $C_4H_{10}N_2O$, F.W. 102.14, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**Call**
J61307	**4-Aminobutyric acid, 99+%** *[γ-Aminobutyric acid, GABA]* [56-12-2], $H_2N(CH_2)_3CO_2H$, F.W. 103.12, Powder, m.p. ca 195° dec., Merck **14**,430, EINECS 200-258-6, RTECS ES6300000, BRN 906818, MDL MFCD00008226, †	**10g**
	γ-Aminobutyric acid, see 4-Aminobutyric acid, 99+%, J61307, p. 92 **ε-Aminocaproic acid**, see 6-Aminocaproic acid, A14719, p. 95 **6-Aminocaproic acid**, see 6-Aminohexanoic acid, A14719, p. 95	
A10530	**7-Aminocephalosporanic acid, 98% (dry wt.), may cont. up to 2% water** *[7-ACA]* [957-68-6], $C_{10}H_{12}N_2O_5S$, F.W. 272.28, m.p. >300°, Merck **14**,434, EINECS 213-485-0, BRN 622638, MDL MFCD00005177 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a	**1g** **5g** **25g**
	(R)-2-Amino-3-(4-chlorophenyl)propionic acid, see 4-Chloro-D-phenylalanine, H51982, p. 158	
A18195	**2-Amino-6-chloropurine, 99%** *[6-Chloroguanine]* [10310-21-1], $C_5H_4ClN_5$, F.W. 169.57, m.p. >300°, EINECS 233-686-7, RTECS UO7502000, BRN 9626, MDL MFCD00075252	**1g** **5g** **25g**
J64468	**2-Amino-6-chloropurine riboside, 95%** *[6-Chloroguanine riboside]* [2004-07-1], $C_{10}H_{12}ClN_5O_4$, F.W. 301.69, Powder, m.p. 165-167°, EINECS 217-905-3, MDL MFCD00005735	**1g** **5g**
	6-Amino-2-chloropurine riboside, see 2-Chloroadenosine, J63810, p. 155	
J63873	**1-Aminocyclobutanecarboxylic acid hydrochloride** *[ACBC hydrochloride]* [98071-16-0], $C_5H_9NO_2 \cdot HCl$, F.W. 151.63, Powder, RTECS GU1336000, MDL MFCD00661068 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): NMDA receptor antagonist acting at the glycine site	**1g** **5g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
	Aminocyclohexane, see Cyclohexylamine, A15851, p. 171	
J65118	**1-Amino-1-cyclopropanecarboxylic acid, 99%** *[ACPC]* [22059-21-8], $C_4H_7NO_2$, F.W. 101.11, Crystalline powder, m.p. 229-231°, RTECS GZ1110000, BRN 2076413, MDL MFCD00009944 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A NMDA glutamate receptor agonist at glycine site	**250mg** **1g**
	N-(10-Aminodecyl)-5-chloro-1-naphthalenesulfonamide hydrochloride, see A-7 hydrochloride, J62011, p. 69	
J64266	**2-Amino-2'-deoxyadenosine, 99%** *[2,6-Diaminopurine 2'-deoxyriboside, 9-(2-Deoxy-β-D-ribofuranosyl)-2,6-diaminopurine]* [4546-70-7], $C_{10}H_{14}N_6O_3$, F.W. 266.26, Powder, RTECS UO7523300	**1g** **5g** **25g**
J65532	**2'-Amino-2'-deoxyadenosine, 98%** [10414-81-0], $C_{10}H_{14}N_6O_3$, F.W. 266.26, Powder	**1g**
J64650	**2'-Amino-2'-deoxyguanosine, 98%** *[9-(2-Amino-2-deoxy-β-D-ribofuranosyl)guanine]* [60966-26-9], $C_{10}H_{14}N_6O_4$, F.W. 282.26, Powder, RTECS MF8752000 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J65374	**2'-Amino-2'-deoxyinosine, 98%** *[9-(2-Amino-2-deoxy-β-D-ribofuranosyl)hypoxanthine]* [75763-51-8], $C_{10}H_{13}N_5O_4$, F.W. 267.24, Powder	**1g**
J65923	**2'-Amino-2'-deoxyuridine, 98%** [26889-39-4], $C_9H_{13}N_3O_5$, F.W. 243.22, Powder	**1g**
L03417	**7-Aminodesacetoxycephalosporanic acid, 98%** *[7-ADCA]* [22252-43-3], $C_8H_{10}N_2O_3S$, F.W. 214.24, m.p. ca 234° dec., EINECS 247-654-5, BRN 5273616, MDL MFCD00151456 	**250mg** **1g** **5g**
J65090	**3'-Amino-2',3'-dideoxyadenosine, 99%** *[9-(3-Amino-2,3-dideoxy-β-D-erythro-pentafuranosyl)adenine, 9-(3-Amino-2,3-dideoxy-β-D-ribofuranosyl)-hypoxanthine]* [7403-25-0], $C_{10}H_{14}N_6O_2$, F.W. 250.26, Powder	**1g**
J65326	**3'-Amino-2',3'-dideoxyguanosine, 99%** *[9-(3-Amino-2,3-dideoxy-β-D-ribofuranosyl)guanine]* [66323-49-7], $C_{10}H_{14}N_6O_3$, F.W. 266.26, Powder ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J64758	**3'-Amino-2',3'-dideoxyinosine, 99%** $C_{10}H_{13}N_5O_3$, F.W. 251.24, Powder, MDL MFCD10566669	**1g**
J64342	**3'-Amino-2',3'-dideoxythymidine, 99%** [52450-18-7], $C_{10}H_{15}N_3O_4$, F.W. 241.24, Powder, MDL MFCD00038057	**1g**
	4'-Amino-2',5'-diethoxybenzanilide, see Fast Blue BB base, J62456, p. 218 **4-Amino-2,6-dihydroxypyrimidine**, see 6-Aminouracil, L03332, p. 100 **5-Amino-2,4-dihydroxypyrimidine**, see 5-Aminouracil, L04452, p. 100 **4-Amino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one**, see 4-Aminoantipyrine, A13846, p. 91	
H27607	**(1R,2S)-(-)-2-Amino-1,2-diphenylethanol, 99%** [23190-16-1], $C_{14}H_{15}NO$, F.W. 213.28, m.p. 141-143°, MDL MFCD00074960 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g**
H27834	**(1S,2R)-(+)-2-Amino-1,2-diphenylethanol, 99%** [23364-44-5], $C_{14}H_{15}NO$, F.W. 213.28, m.p. 141-143°, MDL MFCD00074959 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g**
	Aminodiphenylmethane, see Benzhydrylamine, B24303, p. 119	
B25121	**12-Aminododecanoic acid, 96%** *[12-Aminolauric acid]* [693-57-2], $H_2N(CH_2)_{11}CO_2H$, F.W. 215.34, m.p. 185-187°, EINECS 211-754-7, MDL MFCD00008153, †	**1g** **5g** **25g**
	2-Aminoethanesulfonic acid, see Taurine, A12403, p. 359 **Aminoethanethiol hydrochloride**, see 2-Mercaptoethylamine hydrochloride, A14377, p. 281	

Stock #	Description	Size
H26473	**4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride, 97%** ◢ *[AEBSF]* [30827-99-7], $C_8H_{10}FNO_2S \cdot HCl$, F.W. 239.69, m.p. ca 184° dec., UN3261, BRN 7604627, MDL MFCD00132962  H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Irreverersible serine protease inhibitor: *Thromb. Res.*, **2**, 343 (1973); *Acta Biol. Med. Ger.*, **39**, 355 (1980). Application(s): A covalent binding serine protease inhibitor	**250mg** **1g**
B22529	**3-Amino-9-ethylcarbazole, 95%** [132-32-1], $C_{14}H_{14}N_2$, F.W. 210.28, m.p. 98-100°, EINECS 205-055-7, RTECS FE3590000, MDL MFCD00004964, †  H:H350, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Peroxidase substrate for immunoblotting and immunohistochemical staining procedures	**25g** **100g**
	N-(2-Aminoethyl)-5-chloronaphthalene-1-sulfonamide hydrochloride, see A-3 hydrochloride, J62760, p. 69 **3-(2-Aminoethyl)-5-hydroxyindole hydrochloride**, see Serotonin hydrochloride, B21263, p. 342 **N-(2-Aminoethyl)-5-isoquinolinesulfonamide hydrochloride**, see H-9 dihydrochloride, J63638, p. 240	
L14232	**S-(2-Aminoethyl)isothiourea dihydrobromide, 98%** *[AET, S-(2-Aminoethyl)isothiouronium bromide dihydrobromide]* [56-10-0], $C_3H_9N_3S \cdot 2HBr$, F.W. 281.02, m.p. 190-192°, Merck **14**,178, EINECS 200-257-0, RTECS UM0175000, BRN 3911163, MDL MFCD00037011, †  H:H302, P:P280f Radioprotective agent.	**5g** **25g**
	S-(2-Aminoethyl)isothiouronium bromide dihydrobromide, see S-(2-Aminoethyl)isothiourea dihydrobromide, L14232, p. 94 **4-(2-Aminoethyl)phenol**, see Tyramine, 98+%, J60990, p. 386	
B24509	**2-Amino-2-ethyl-1,3-propanediol, 97%** ■ *[1,1-Bis(hydroxymethyl)propylamine]* [115-70-8], $C_5H_{13}NO_2$, F.W. 119.16, b.p. 152-153°/10mm, f.p. >110°(230°F), d. 1.099, n_D^{20} 1.490, Merck **14**,439, EINECS 204-101-2, MDL MFCD00004680, †  H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100g** **500g**
B22769	**2-Aminofluorene, 98%** *[2-Fluorenamine, 2-Fluorenylamine]* [153-78-6], $C_{13}H_{11}N$, F.W. 181.24, m.p. 126-130°, EINECS 205-817-8, RTECS LL5075000, BRN 1945861, MDL MFCD00001125  H:H341-H351, P:P281-P201-P202-P308+P313-P405-P501a	**1g** **5g** **25g**
	5-Aminofluorescein, see Fluorescein amine isomer I, 96%, J62175, p. 222 **6-Aminofluorescein**, see Fluorescein amine isomer II, 95%, J60609, p. 223	
J65741	**2-Amino-2'-fluoro-2'-deoxyadenosine, 99%** *[9-(2-Deoxy-2-fluoro-β-D-ribofuranosyl)-2,6-diaminopurine, 2,6-Diaminopurine 2'-fluoro-2'-deoxyriboside]* [134444-47-6], $C_{10}H_{13}FN_6O_3$, F.W. 284.25, Powder	**1g**
	D-2-Aminoglutaramic acid, see D-Glutamine, 99+%, J60784, p. 235 **DL-2-Aminoglutaric acid monohydrate**, see DL-Glutamic acid monohydrate, A17719, p. 234 **D-2-Aminoglutaric acid**, see D-Glutamic acid, A14191, p. 234 **L-2-Aminoglutaric acid**, see L-Glutamic acid, A15031, p. 234 **L-2-Aminoglutaric acid hydrochloride**, see L-Glutamic acid hydrochloride, A12505, p. 234	
J62182	**DL-Aminoglutethimide, 99%** *[(±)-3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione]* [125-84-8], $C_{13}H_{16}N_2O_2$, F.W. 232.28, Powder, m.p. 152-154°, Merck **14**,440, EINECS 204-756-4, RTECS MA4026950, MDL MFCD00010122 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Adrenocortical suppressant which also inhibits conversion of androgens to estrogens by the aromatase enzyme system	**1g** **5g** **25g**
B24696	**Aminoguanidine hydrogen carbonate, 98+%** [2582-30-1], $CH_6N_4 \cdot H_2CO_3$, F.W. 136.11, m.p. ca 170° dec., d. 1.600, UN3077, EINECS 219-956-7, RTECS FG1772000, BRN 3569869, MDL MFCD00012949, †  H:H317-H411, P:P261-P280-P302+P352-P321-P363-P501a	**100g** **500g** **2.5kg**
H55363	**1-Amino-4-guanidinobutane sulfate salt, 97%** [2482-00-0], $H_2N(CH_2)_4NHC(=NH)NH_2 \cdot H_2SO_4$, F.W. 228.27, Merck **14**,188, EINECS 219-617-3, RTECS ME8413000, BRN 3918807, MDL MFCD00013109	**250mg** **1g** **5g**
	D-2-Amino-5-guanidinopentanoic acid, see D-Arginine, A16137, p. 109 **L-2-Amino-5-guanidinopentanoic acid**, see L-Arginine, A15738, p. 109 **DL-2-Amino-5-guanidinopentanoic acid monohydrochloride monohydrate**, see DL-Arginine monohydrochloride monohydrate, A10758, p. 109 **L-2-Amino-5-guanidinopentanoic acid hydrochloride**, see L-Arginine monohydrochloride, A14730, p. 109 **(R)-(-)-2-Aminohexanoic acid**, see D-(-)-Norleucine, L08257, p. 304 **(S)-(+)-2-Aminohexanoic acid**, see L-(+)-Norleucine, L03913, p. 305	

Contact us for pricing on bulk sizes

Stock #	Description	Size
A14719	**6-Aminohexanoic acid, 99%** *[ε-Aminocaproic acid, EACA]* [60-32-2], $H_2N(CH_2)_5CO_2H$, F.W. 131.18, m.p. 210-212°, Merck **14**,432, EINECS 200-469-3, RTECS MO6300000, BRN 906872, MDL MFCD00008238, † Has been recommended as a reagent for the extraction of aldehydes from reaction mixtures, giving better recovery than bisulfite: *Chem. Pharm. Bull.*, **28**, 1917 (1980).	**100g** **500g** **2.5kg**
J63012	**N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride** *[W-7 hydrochloride]* [61714-27-0], $C_{16}H_{21}ClO_2N_2S \cdot HCl$, F.W. 377.33, Powder, m.p. 217-220°, BRN 6030174 Application(s): Calmodulin antagonist	**100mg**
A13786	**4-Aminohippuric acid, 97%** *[N-(4-Aminobenzoyl)glycine]* [61-78-9], $C_9H_{10}N_2O_3$, F.W. 194.19, m.p. ca 200° dec., Merck **14**,442, EINECS 200-518-9, BRN 1213676, MDL MFCD00007890, † Application(s): Useful in kidney function testing	**25g** **100g**
	(2S,3R)-2-Amino-3-hydroxybutyric acid, see L-Threonine, Cell Culture Reagent, J63709, p. 368	
L08256	**2-Amino-5-hydroxybenzoic acid, 98%** *[5-Hydroxyanthranilic acid]* [394-31-0], $C_7H_7NO_3$, F.W. 153.14, m.p. ca 248° dec., BRN 2803663, MDL MFCD00007870 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g**
	4-Amino-2-hydroxybenzoic acid, see 4-Aminosalicylic acid, B23289, p. 99 **(+/-)-2-Amino-3-hydroxybutyric acid**, see DL-Threonine, A10606, p. 368 **(2R,3S)-2-Amino-3-hydroxybutyric acid**, see D-Threonine, B21177, p. 368 **(2S,3R)-2-Amino-3-hydroxybutyric acid**, see L-Threonine, A16851, p. 368	
J65145	**4-Amino-3-hydroxybutyric acid** *[DL-γ-Amino-β-hydroxybutyric acid]* [924-49-2], $C_4H_9NO_3$, F.W. 119.12, Powder, m.p. 223° dec., Merck **14**,444, EINECS 213-106-9, RTECS ES7015000, BRN 1721708, MDL MFCD00008141, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Reduces uptake of iodine by the thyroid glands in animals. Antispasmodic	**5g** **25g** **100g**
	N1-[(S)-(-)-4-Amino-2-hydroxybutyryl]kanamycin A, see Amikacin, J60849, p. 91 **DL-2-Amino-3-[3-(5-hydroxyindole)]propionic acid**, see DL-5-Hydroxytryptophan, A12237, p. 252 **L-2-Amino-3-[3-(5-hydroxyindole)]propionic acid**, see L-5-Hydroxytryptophan hydrate, A13954, p. 252 **α-Amino-3-hydroxy-5-isoxazoleacetic acid**, see Ibotenic acid, 98+%, J60748, p. 253 **2-Amino-2-hydroxymethyl-1,3-propanediol hydrochloride**, see Tris(hydroxymethyl)aminomethane hydrochloride, A11379, p. 382 **2-Amino-5-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]benzonitrile**, see Cimaterol, J60650, p. 163 **[(2S,3R)-3-Amino-2-hydroxy-5-methylhexanoyl]-Val-Val-Asp-OH**, see Amastatin hydrochloride, 98+%, J62932, p. 90	
J65847	**(S)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid** ■ *[(S)-2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid]* [83643-88-3], $C_7H_{10}N_2O_4$, F.W. 186.16, Powder, MDL MFCD00672630	**5mg**
J64884	**Amino-3-hydroxy-5-methylisoxazole-4-propionic acid** *[(±)-α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid, (RS)-AMPA]* [74341-63-2], $C_7H_{10}N_2O_4$, F.W. 186.17, Powder, MDL MFCD00213388 Application(s): Selective quisqualate agonist	**10mg**
	N-[(2S,3R)-3-Amino-2-hydroxy-1-oxo-4-phenylbutanoyl]-L-leucine, see Bestatin, J61106, p. 124 **(R)-(-)-α-Amino-(4-hydroxyphenyl)acetic acid**, see D-(-)-4-Hydroxyphenylglycine, L07190, p. 251 **(+/-)-2-Amino-3-hydroxypropionic acid**, see DL-Serine, A15184, p. 341 **(R)-2-Amino-3-hydroxypropionic acid**, see D-Serine, A11353, p. 341 **(S)-2-Amino-3-hydroxypropionic acid**, see L-Serine, A11179, p. 341 **2-Amino-6-hydroxypurine**, see Guanine, A12024, p. 240 **2-Amino-4-hydroxypyrimidine**, see Isocytosine, H54228, p. 260 **4-Amino-2-hydroxypyrimidine**, see Cytosine, A14731, p. 174	
B24012	**4-Aminoimidazole-5-carboxamide hydrochloride, 98%** ■ *[AICA]* [72-40-2], $C_4H_8N_4O \cdot HCl$, F.W. 162.58, m.p. ca 270° dec., EINECS 200-778-3, RTECS NI3911000, BRN 3701645, MDL MFCD00012704, † Starting material for synthesis of the antitumour agent temozolomide. A synthetic pathway employing **Ethyl isocyanatoacetate**, **L10609**, avoids the use of the highly toxic methyl isocyanate: *J. Chem. Soc., Perkin 1*, 2783 (1995).	**1g** **5g** **25g**
J64720	**5-Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside, 98%** *[Acadesine, AICAR]* [2627-69-2], $C_9H_{14}N_4O_5$, F.W. 258.23, Powder, m.p. 214-215°, EINECS 220-097-5, MDL MFCD00869751, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Activator of AMP-activated protein kinase (AMPK)	**50mg** **200mg**
	L-2-Amino-3-(4-imidazolyl)propionic acid, see L-Histidine, Cell Culture Reagent, J63065, p. 246 **L-2-Amino-3-(4-imidazolyl)propionic acid monohydrochloride monohydrate**, see L-Histidine monohydrochloride monohydrate, Cell Culture Reagent, J61465, p. 246 **(+/-)-2-Amino-3-(3-indolyl)propionic acid**, see DL-Tryptophan, L05936, p. 384 **(R)-2-Amino-3-(3-indolyl)propionic acid**, see D-Tryptophan, A18426, p. 384	

Stock #	Description	Size
	(S)-2-Amino-3-(3-indolyl)propionic acid, see L-Tryptophan, A10230, p. 384 **2-Amino-4-(5-indolyl)-1,1,3-tricyanobuta-1,3-diene**, see Tyrphostin B7, 95%, cis + trans, J63126, p. 387	
A19838	**2-Amino-5-iodobenzoic acid, 98%** ▲ *[5-Iodoanthranilic acid]* [5326-47-6], $C_7H_6INO_2$, F.W. 263.03, m.p. ca 220° dec., EINECS 226-205-7, RTECS DG2802000, BRN 639029, MDL MFCD00007849, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g**
A13021	**2-Aminoisobutyric acid, 99%** *[H-Aib-OH, 2-Methylalanine]* [62-57-7], $C_4H_9NO_2$, F.W. 103.12, m.p. >300°, Merck **14**,445, EINECS 200-544-0, RTECS AY7000000, BRN 506496, MDL MFCD00008049, †	**25g** **100g** **250g**
A15074	**5-Aminoisophthalic acid, 95%** *[5-Aminobenzene-1,3-dicarboxylic acid]* [99-31-0], $C_8H_7NO_4$, F.W. 181.15, m.p. >300°, EINECS 202-748-5, BRN 2805628, MDL MFCD00002522, † ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g**
	DL-2-Aminoisovaleric acid, see DL-Valine, A16756, p. 390 **D-2-Aminoisovaleric acid**, see D-Valine, A18894, p. 390 **L-2-Aminoisovaleric acid**, see L-Valine, A12720, p. 390 **(R)-(+)-4-Amino-3-isoxazolidinone**, see D-Cycloserine, A18000, p. 172 **5-Amino-4-ketovaleric acid hydrochloride**, see 5-Aminolevulinic acid hydrochloride, A16942, p. 96 **12-Aminolauric acid**, see 12-Aminododecanoic acid, B25121, p. 93	
A16942	**5-Aminolevulinic acid hydrochloride, 99%** ■ *[5-Amino-4-ketovaleric acid hydrochloride]* [5451-09-2], $C_5H_9NO_3 \cdot HCl$, F.W. 167.59, m.p. ca 156 dec., Merck **14**,446, EINECS 226-679-5, RTECS OI1640000, BRN 3690651, MDL MFCD00012869	**100mg** **500mg** **2g**
	2-Amino-3-mercapto-3-methylbutanoic acid, see DL-Penicillamine, B24710, p. 313 **DL-2-Amino-3-mercaptopropionic acid**, see DL-Cysteine, H56126, p. 172 **L-2-Amino-3-mercaptopropionic acid**, see L-Cysteine, Cell Culture Reagent, J63745, p. 173 **D-2-Amino-3-mercaptopropionic acid hydrochloride monohydrate**, see D-Cysteine hydrochloride monohydrate, H27107, p. 173 **2-Amino-6-mercaptopurine**, see 6-Thioguanine, B21280, p. 367	
J64244	**2-Amino-3-methoxybenzoic acid** *[3-Methoxyanthranilic acid]* [3177-80-8], $C_8H_9NO_3$, F.W. 167.16, Powder, m.p. 169-170°, MDL MFCD00075178 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5g** **10g** **25g**
J64485	**2'-Amino-3'-methoxyflavone, 99%** *[PD 98059, 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one]* [167869-21-8], $C_{16}H_{13}NO_3$, F.W. 267.28, Powder, MDL MFCD00671789 ! H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A MAP kinase inhibitor	**5mg** **10mg** **25mg**
J60524	**(R)-(+)-1-Amino-2-(methoxymethyl)pyrrolidine** *[RAMP]* [72748-99-3], $C_6H_{14}N_2O$, F.W. 130.19, Liquid, b.p. 186-187°, f.p. 71°(160°F), d. 0.978, n_D^{20} 1.464, BRN 4229866, MDL MFCD00010622 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**Call**
J61723	**(S)-(-)-1-Amino-2-(methoxymethyl)pyrrolidine** *[SAMP]* [59983-39-0], $C_6H_{14}N_2O$, F.W. 130.19, Liquid, b.p. 42°, f.p. 71°(160°F), d. 0.97, n_D^{20} 1.465, BRN 1523794, MDL MFCD00064485 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**Call**
J65334	**2-Amino-2'-O-methyladenosine, 99%** *[2,6-Diamino-9-(2'-O-methyl-β-D-ribofuranosyl)purine, 2,6-Diaminopurine 2'-O-methylriboside]* [80791-87-3], $C_{11}H_{16}N_6O_4$, F.W. 296.28, Powder	**1g**
B24230	**2-Amino-3-methylbenzoic acid, 98%** *[2-Amino-m-toluic acid, 3-Methylanthranilic acid]* [4389-45-1], $C_8H_9NO_2$, F.W. 151.16, m.p. 174-177°, EINECS 224-505-2, BRN 2359694, MDL MFCD00007745 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g**
	(R)-(-)-2-Amino-3-methyl-1-butanol, see D-(-)-Valinol, L14166, p. 390 **(S)-(+)-2-Amino-3-methyl-1-butanol**, see L-(+)-Valinol, L11300, p. 390 **(+/-)-2-Amino-3-methylbutyric acid**, see DL-Valine, A16756, p. 390 **(R)-(-)-2-Amino-3-methylbutyric acid**, see D-Valine, A18894, p. 390 **(S)-(+)-2-Amino-3-methylbutyric acid**, see L-Valine, A12720, p. 390 **β-(Aminomethyl)-4-chlorobenzeneethanesulfonic acid**, see Saclofen, 99+%, J63345, p. 339	

Contact us for pricing on bulk sizes

Stock #	Description	Size
A15017	**7-Amino-4-methylcoumarin, 98%** *[Coumarin 120]* [26093-31-2], $C_{10}H_9NO_2$, F.W. 175.19, m.p. 225-228°, EINECS 247-454-8, BRN 142231, MDL MFCD00006868, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250mg** **1g** **5g**
B21742	**trans-4-(Aminomethyl)cyclohexanecarboxylic acid, 97%** [1197-18-8], $C_8H_{15}NO_2$, F.W. 157.21, m.p. >300°, Merck **14**,9569, EINECS 214-818-2, RTECS GU8400000, BRN 2207452, MDL MFCD00001466  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibits plasmin-induced fibrinolysis	**10g** **50g** **250g**
	α-(Aminomethyl)-4-hydroxybenzyl alcohol hydrochloride, see (+/-)-Octopamine hydrochloride, 99%, J61281, p. 306 **4-(Aminomethyl)-5-hydroxy-6-methyl-3-pyridinemethanol dihydrochloride**, see Pyridoxamine dihydrochloride, Cell Culture Reagent, J62679, p. 332 **2-Amino-1-methyl-2-imidazolin-4-one**, see Creatinine hydrochloride, 99+%, J61755, p. 169 **(+/-)-2-Amino-3-methylpentanoic acid**, see DL-Isoleucine, A17521, p. 260 **(2R,3R)-2-Amino-3-methylpentanoic acid**, see D-Isoleucine, H27488, p. 260 **(2S,3S)-2-Amino-3-methylpentanoic acid**, see L-Isoleucine, Cell Culture Reagent, J63045, p. 260 **(±)-2-Amino-4-methylpentanoic acid**, see DL-Leucine, A10590, p. 268 **(R)-2-Amino-4-methylpentanoic acid**, see D-Leucine, A14842, p. 268 **(S)-2-Amino-4-methylpentanoic acid**, see L-Leucine, A12311, p. 268 **(S)-2-Amino-4-methylpentanol**, see L-Leucinol, B23745, p. 268	
J63144	**2-Amino-2-methyl-1,3-propanediol, 99+%** *[Ammediol, AMPD]* [115-69-5], $(HOCH_2)_2C(NH_2)CH_3$, F.W. 105.14, Powder, m.p. 100-110°, b.p. 151°/10mm, Merck **14**,448, EINECS 204-100-7, RTECS TY2975000, BRN 635708, MDL MFCD00004678, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A useful biological buffer	**25g** **100g** **250g**
A17814	**2-Amino-2-methyl-1-propanol, 95%, may cont. ca 5% water** *[AMP, Isobutanolamine]* [124-68-5], $C_4H_{11}NO$, F.W. 89.14, m.p. 24-28°, b.p. 164-166°, f.p. 67°(152°F), d. 0.934, n_D^{20} 1.4455, Merck **14**,449, Fieser **1**,37 **3**,14 **6**,20, EINECS 204-709-8, RTECS UA5950000, BRN 505979, MDL MFCD00008051, †  H:H315-H319-H412, P:P280g-P273-P305+P351+P338-P337+P313 Buffer and phosphate acceptor in assay of phosphatases: *Methods of Enzymatic Analysis*, 3rd ed., H. U. Bergmeyer, Ed., Verlag Chemie, Weinheim (1984), vol. 4, p76. Precursor of 2-substituted-4,4-dimethyl-2-oxazoline derivatives of carboxylic acids: *J. Org. Chem.*, **39**, 2787 (1974), developed by Meyers. The oxazoline, which is readily formed with the acid chloride and thionyl chloride, is stable to base, organometallic reagents, etc., but readily cleaved by dilute acid. For further information on the reactivity of these derivatives, see **2,4,4-Trimethyl-2-oxazoline**, **L00181**. 2-Aryl-4,4-dimethyl-2-oxazolines are activated towards ortho-lithiation: *J. Org. Chem.*, **40**, 3058 (1975). Methoxy- or fluoro-substituents in the ortho-position are readily substitutied by organolithiums or Grignards, providing a versatile route to biaryls: *J. Am. Chem. Soc.*, **97**, 7383 (1975). For examples, see: *Org. Synth. Coll.*, **9**, 258 (1998). The oxazoline can also be converted to an aldehyde by methylation and borohydride reduction.  For reviews of the use of oxazolines in synthesis, see: *Angew. Chem. Int. Ed.*, **15**, 270 (1976); *Tetrahedron*, **41**, 837 (1985); **50**, 2297 (1994).	**100ml** **500ml** **2.5L**
J60492	**(S)-(+)-2-(Aminomethyl)pyrrolidine** △ [69500-64-7], $C_5H_{12}N_2$, F.W. 96.14, Liquid, b.p. 65°/10mm, f.p. 47°(117°F), d. 0.933, n_D^{20} 1.482, UN2734, MDL MFCD00191745 H:H314-H226, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Application(s): For synthesis of optically active products	**Call**
	(±)-2-Amino-4-(methylthio)butyric acid, see DL-Methionine, A11457, p. 283 **(R)-2-Amino-4-(methylthio)butyric acid**, see D-Methionine, B21213, p. 284 **(S)-2-Amino-4-(methylthio)butyric acid**, see L-Methionine, Cell Culture Reagent, J61904, p. 284	
L03099	**5-Aminonaphthalene-2-sulfonic acid, 97%** *[1,6-Cleve's Acid, 1-Naphthylamine-6-sulfonic acid]* [119-79-9], $C_{10}H_9NO_3S$, F.W. 223.25, m.p. >300°, Merck **14**,2350, EINECS 204-351-2, RTECS QK1285000, BRN 1819887, MDL MFCD00004030, † 	**5g** **25g**
J65304	**8-Aminonaphthalene-2-sulfonic acid, 95%** *[1-Naphthylamine-7-sulfonic acid, Cleves acid-1,7]* [119-28-8], $C_{10}H_9NO_3S$, F.W. 223.25, Powder, m.p. >300°, Merck **142**,351, UN2585, EINECS 204-311-4, BRN 2115629, MDL MFCD00004032, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**25g** **100g**

Stock #	Description	Size
J64358	**4-Amino-1,8-naphthalimide, 97%** *[6-Aminobenzo[de]isoquinoline-1,3-dione]* [1742-95-6], $C_{12}H_8N_2O$, F.W. 212.2, Solid, m.p. >360°, d. 1.105, EINECS 217-110-1, RTECS DE4081000, MDL MFCD00006921, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg** **1g**
L06692	**6-Aminonicotinamide, 99%** *[6-Aminopyridine-3-carboxamide]* [329-89-5], $C_6H_7N_3O$, F.W. 137.14, m.p. 246-248°, EINECS 206-349-7, RTECS US4550000, BRN 116042, MDL MFCD00006327 H:H360, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Induces apoptosis in tumor cells	**1g** **5g**
	(2R*,3S*)-(+/-)-2-Aminooctadecane-1,3-diol, see DL-erythro-Dihydrosphingosine, J62103, p. 191 **trans-D-erythro-2-Amino-4-octadecene-1,3-diol**, see D-erythro-Sphingosine, 99+%, J63584, p. 351 **trans-D-erythro-2-Amino-4-octadecene-1,3-diol hydrochloride**, see D-erythro-Sphingosine hydrochloride, H52427, p. 351 **(S)-2-Aminopentanedioic acid**, see L-Glutamic acid monosodium salt, J63424, p. 234 **(±)-2-Aminopentanoic acid**, see DL-Norvaline, A15900, p. 305 **(R)-2-Aminopentanoic acid**, see D-Norvaline, B23444, p. 305 **(S)-2-Aminopentanoic acid**, see L-Norvaline, L08658, p. 305 **4-Aminophenazone**, see 4-Aminoantipyrine, A13846, p. 91 **D-(-)-α-Aminophenylacetic acid**, see D-(-)-2-Phenylglycine, A15669, p. 317 **(S)-(+)-α-Aminophenylacetic acid**, see L-(+)-2-Phenylglycine, A19360, p. 317	
J65331	**4-Amino-DL-phenyalanine** *[DL-Phe(4-NH2)-OH]* [2922-41-0], $C_9H_{12}N_2O_2$, F.W. 180.2, Powder, EINECS 220-869-1, MDL MFCD00007917	**1g** **5g**
	(R)-(-)-2-Amino-2-phenylethanol, see (R)-(-)-2-Phenylglycinol, A19030, p. 317 **(S)-(+)-2-Amino-2-phenylethanol**, see (S)-(+)-2-Phenylglycinol, L13265, p. 317 **(+/-)-3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione**, see DL-Aminoglutethimide, 99%, J62182, p. 94	
J65814	**4-Aminophenyl phosphate monosodium salt hydrate, 97%** *[Monosodium 4-aminophenyl phosphate hydrate]* [52331-30-3], $C_6H_7NNaO_4P.xH_2O$, F.W. 211.09(anhy), Crystalline solid Application(s): Substrate for the electrochemical measurement of alkaline phosphatase	**10mg** **50mg** **100mg**
	(R)-(+)-1-Amino-1-phenylpropane, see (R)-(+)-1-Phenylpropylamine, L16319, p. 318 **(S)-(-)-1-Amino-1-phenylpropane**, see (S)-(-)-1-Phenylpropylamine, L16320, p. 318 **(R)-(+)-2-Amino-3-phenyl-1-propanol**, see D-Phenylalaninol, L09697, p. 316 **(S)-(-)-2-Amino-3-phenyl-1-propanol**, see L-Phenylalaninol, A11586, p. 316 **(+/-)-2-Amino-3-phenylpropionic acid**, see DL-Phenylalanine, A10132, p. 315 **(R)-2-Amino-3-phenylpropionic acid**, see D-Phenylalanine, A10572, p. 315 **(S)-2-Amino-3-phenylpropionic acid**, see L-Phenylalanine, A13238, p. 315 **N-(4-Aminophenylsulfonyl)acetamide**, see Sulfacetamide, A19836, p. 355	
J64075	**(S)-(+)-2-Amino-4-phosphonobutyric acid, 99% ▲** *[L-AP-4]* [23052-81-5], $C_4H_{10}NO_5P$, F.W. 183.1, Powder, MDL MFCD00083244 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A NMDA agonist	**1mg** **10mg**
J64210	**(±)-2-Amino-5-phosphonopentanoic acid, 99% ▲** *[DL-AP5, DL-2-Amino-5-phosphonovaleric acid]* [76326-31-3], $C_5H_{12}NO_5P$, F.W. 197.13, Powder, BRN 2446389, MDL MFCD00010515 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A potent NMDA antagonist	**10mg** **50mg**
J64887	**(R)-(-)-2-Amino-5-phosphonopentanoic acid, 99% ▲** *[D-AP5, D-2-Amino-5-phosphonovaleric acid]* [79055-68-8], $C_5H_{12}NO_5P$, F.W. 197.13, Powder, RTECS RD2513000, MDL MFCD00078839 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A competitive NMDA antagonist	**1mg** **10mg**
J64921	**4-Aminophthalhydrazide, 98% △** *[6-Amino-2,3-dihydro-1,4-phthalazinedione, Isoluminol]* [3682-14-2], $C_8H_7N_3O_2$, F.W. 177.16, Powder, m.p. 300°, BRN 164804, MDL MFCD00010560 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A chemiluminescent molecule	**1g** **5g**
J60705	**Aminophylline, anhydrous, 98%** *[3,7-Dihydro-1,3-dimethylpurine-2,6-dione, complex with 1,2-ethanediamine (2:1), Theophylline hemi(ethylenediamine) complex]* [317-34-0], $C_7H_8N_4O_2 \cdot 0.5C_2H_8N_2$, F.W. 210.21, Powder, m.p. 269-274°, Merck **14**,465, UN2811, EINECS 206-264-5, RTECS XH5600000, MDL MFCD00013221, † H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A non-selective phosphodiesterase inhibitor	**25g** **100g** **500g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
L14101	**(R)-(-)-1-Amino-2-propanol, 98%** △ ■ *[(R)-(-)-Isopropanolamine]* [2799-16-8], C_3H_9NO, F.W. 75.11, m.p. 24-26°, b.p. 160°, f.p. 71°(159°F), d. 0.960, n_D^{20} 1.4482, $[\alpha]_D^{20}$ -18° (c=1.8 in water), UN3259, EINECS 220-532-9, RTECS UA5775000, BRN 1718869, MDL MFCD00064428 H:H314-H312, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a For an extensive review of the use of 1,2-amino alcohols as chiral auxiliaries in asymmetric synthesis, see: *Chem. Rev.*, **96**, 835 (1996).	**250mg** **1g** **5g**
L14102	**(S)-(+)-1-Amino-2-propanol, 98%** △ ■ *[(S)-(+)-Isopropanolamine]* [2799-17-9], C_3H_9NO, F.W. 75.11, m.p. 24-26°, b.p. 160°, f.p. 71°(159°F), d. 0.960, n_D^{20} 1.4490, $[\alpha]_D^{20}$ +18.5° (c=1.8 in water), UN3259, EINECS 220-533-4, RTECS UA5775000, BRN 1718868, MDL MFCD00064429 H:H314-H312, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**250mg** **1g**
L11030	**(R)-(-)-2-Amino-1-propanol, 98%** △ ■ *[H-D-Ala-ol, D-Alaninol]* [35320-23-1], C_3H_9NO, F.W. 75.11, b.p. 174-176°, f.p. 83°(181°F), d. 0.965, n_D^{20} 1.4493, $[\alpha]_D^{20}$ -22° (c=2 in ethanol), UN2735, BRN 1718866, MDL MFCD00064413 H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**1g** **5g** **25g**
B24916	**(S)-(+)-2-Amino-1-propanol, 98%** △ ■ *[H-Ala-ol, L-Alaninol]* [2749-11-3], C_3H_9NO, F.W. 75.11, b.p. 174-176°, f.p. 83°(181°F), d. 0.965, n_D^{20} 1.4498, $[\alpha]_D^{20}$ +22° (c=2 in ethanol), UN2735, EINECS 220-388-7, BRN 1718865, MDL MFCD00064412 H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**1g** **5g** **25g**
	3-Aminopropionic acid, see β-Alanine, Cell Culture Reagent, J63435, p. 82 **DL-2-Aminopropionic acid**, see DL-Alanine, A12230, p. 82 **D-2-Aminopropionic acid**, see D-Alanine, A10231, p. 82 **L-2-Aminopropionic acid**, see L-Alanine, Cell Culture Reagent, J60279, p. 82 **N-(3-Aminopropyl)-1,4-butanediamine trihydrochloride**, see Spermidine trihydrochloride, 99+%, J61595, p. 351 **N-(3-Aminopropyl)-1,4-diaminobutane**, see Spermidine, A19096, p. 350	
J64782	**1-(4-Amino-2-n-propyl-5-pyrimidinylmethyl)-2-methylpyridinium chloride** *[Amprolium hydrochloride]* [137-88-2], $C_1H_{19}N_4Cl.HCl$, F.W. 315.24, Powder, EINECS 205-307-5, RTECS TJ565000, BRN 4118699, MDL MFCD00078831 Application(s): A thiamine analogue; blocks thiamine uptake and prevents carbohydrate synthesis	**25g** **100g**
J64919	**2-Aminopurine, 98%** [452-06-2], $C_5H_5N_5$, F.W. 135.13, Powder, m.p. 280-282°, EINECS 207-197-4, RTECS UO7475000, MDL MFCD00005566 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A protein kinase R inhibitor	**250mg** **500mg** **1g**
	6-Aminopurine, see Adenine, A14906, p. 78 **6-Aminopurine hydrochloride**, see Adenine hydrochloride, A17622, p. 78 **6-Aminopurine sulfate**, see Adenine sulfate, A16964, p. 78 **2-Amino-6-purinethiol**, see 6-Thioguanine, B21280, p. 367	
B23707	**3-Aminopyrazine-2-carboxylic acid, 98+%** [5424-01-1], $C_5H_5N_3O_2$, F.W. 139.11, m.p. 204-206° dec., EINECS 226-558-7, BRN 124835, MDL MFCD00006141 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
J61470	**4-Aminopyridine, 99+%** *[Fampridine, 4-Pyridinamine]* [504-24-5], $C_5H_6N_2$, F.W. 94.12, Crystalline powder, m.p. 157-161°, b.p. 273-274°, f.p. 164°(327°F), d. 1.26, Merck **14**,3933, UN2671, EINECS 207-987-9, RTECS US1750000, BRN 105782, MDL MFCD00006439, † H:H300-H311-H315-H319-H335-H411, P:P280h-P273-P270-P301+P310-P305+P351+P338-P302+P352 Application(s): A potassium channel blocker	**25g** **100g**
	6-Aminopyridine-3-carboxamide, see 6-Aminonicotinamide, L06692, p. 98	
B24594	**2-Aminopyrimidine, 98%** *[2-Pyrimidinamine]* [109-12-6], $C_4H_5N_3$, F.W. 95.11, m.p. 123-127°, b.p. 159°/186mm, EINECS 203-648-4, RTECS UV6326000, BRN 107014, MDL MFCD00006089, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g**
B23289	**4-Aminosalicylic acid, 98+%** *[4-Amino-2-hydroxybenzoic acid]* [65-49-6], $C_7H_7NO_3$, F.W. 153.14, m.p. ca 135-145° dec., Merck **14**,477, EINECS 200-613-5, RTECS VO1225000, BRN 473071, MDL MFCD00007789, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g**
	DL-2-Aminosuccinamic acid monohydrate, see DL-Asparagine monohydrate, B20273, p. 110 **L-2-Aminosuccinamic acid monohydrate**, see L-(+)-Asparagine monohydrate, A15012, p. 111	

Stock #	Description	Size
	DL-Aminosuccinic acid, see DL-Aspartic acid, A13646, p. 111 **D-Aminosuccinic acid**, see D-Aspartic acid, B21184, p. 111 **L-Aminosuccinic acid**, see L-Aspartic acid, A13520, p. 111 **(S)-2-Aminosuccinic acid 4-amide**, see L-Asparagine monohydrate, Cell Culture Reagent, J62869, p. 111 **3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid**, see Bumetanide, 98+%, J62302, p. 139 **9-Amino-1,2,3,4-tetrahydroacridine hydrochloride** , see Tacrine hydrochloride hydrate, 98+%, J60070, p. 357 **9-Amino-1,2,3,4-tetrahydro-1-acridinol (2Z)-2-butenedioate**, see Hydroxytacrine maleate salt, J60680, p. 252	
J64527	**1-Amino-3,6,9,12-tetraoxapentadec-14-yne** *[Acetylene-PEG4-amine]* $C_{11}H_{21}NO_4$, F.W. 231.29, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg** **500mg**
	2-Amino-m-toluic acid, see 2-Amino-3-methylbenzoic acid, B24230, p. 96 **4-Amino-1,3,5-triazin-2(1H)-one**, see 5-Azacytosine, A13410, p. 112 **4-Aminouracil**, see 6-Aminouracil, L03332, p. 100	
L04452	**5-Aminouracil, 97%** *[5-Amino-2,4-dihydroxypyrimidine]* [932-52-5], $C_4H_5N_3O_2$, F.W. 127.10, m.p. >300°, EINECS 213-252-3, RTECS YQ8740000, BRN 127250, MDL MFCD00006025, † H:H302, P:P264-P270-P301+P312-P330-P501a Condensation with crotonaldehyde gives 2,4-dioxo-6-methylpyrido[3,2-d]pyrimidine: *J. Chem. Soc. (C)*, 1745 (1967). An improved procedure has been used in synthesis of inhibitors of human thymidylate synthase: *J. Med. Chem.*, **27**, 1710 (1984), and of dihydrofolate reductases: *J. Med. Chem.*, **39**, 1836 (1996):  Review of the use of uracils as starting materials in heterocyclic synthesis: *Adv. Heterocycl. Chem.*, **55**, 130 (1992).	**5g** **25g**
L03332	**6-Aminouracil, 98%** *[4-Amino-2,6-dihydroxypyrimidine, 4-Aminouracil]* [873-83-6], $C_4H_5N_3O_2$, F.W. 127.10, m.p. 360°, EINECS 212-854-3, RTECS YQ8750000, BRN 120491, MDL MFCD00006071, † H:H302, P:P280f Silylation method regioselective alkylation at the 3-nitrogen: *Tetrahedron Lett.*, **32**, 6539 (1991). The products are intermediates in a versatile synthesis of xanthines: *Synthesis*, 1295 (1995):  	**100g** **500g**
	L-(+)-2-Amino-5-ureidovaleric acid, see L-Citrulline, A13316, p. 165 **DL-2-Aminovaleric acid**, see DL-Norvaline, A15900, p. 305 **D-2-Aminovaleric acid**, see D-Norvaline, B23444, p. 305 **L-2-Aminovaleric acid**, see L-Norvaline, L08658, p. 305	
J60456	**Amiodarone hydrochloride** *[2-n-Butyl-3-benzofuranyl [4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl] ketone hydrochloride]* [19774-82-4], $C_{25}H_{29}I_2NO_3$·HCl, F.W. 681.77, Powder, m.p. 156°, Merck **14**,482, EINECS 243-293-2, RTECS OB1361000, MDL MFCD00069204 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501 Application(s): A non-selective ion channel blocker; also an antiarrhythmic agent	**1g** **5g** **25g**
J62242	**Amlodipine, 97+%** *[UK-48340]* [88150-42-9], $C_{20}H_{25}ClN_2O_5$, F.W. 408.88, Crystalline powder, m.p. 134-136°, Merck **14**,491, UN2811 H:H301-H318-H373-H400-H410, P:P260-P301+P310-P305+P351+P338-P321-P405-P501a Application(s): A calcium channel antagonist with potent antioxidant activity	**1g** **5g** **10g**
J62164	**Amlodipine besylate, 98+%** [111470-99-6], $C_{20}H_{25}ClN_2O_5.C_6H_5SO_3H$, F.W. 567.05, Solid, m.p. 195-204°, Merck **14**,491, RTECS US7967700, MDL MFCD00887594 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An L-type calcium channel antagonist with potent antioxidant activity	**1g** **5g** **25g**
	Ammediol, see 2-Amino-2-methyl-1,3-propanediol, 99+%, J63144, p. 97	
J60688	**Ammonium acetate, 5M aq. soln.** [631-61-8], CH_3COONH_4, F.W. 77.08, Liquid, †	**250ml** **500ml**
J62046	**Ammonium chloride, 0.5M aq. soln.** [12125-02-9], NH_4Cl, F.W. 53.49, Liquid, † H:H302-H319, P:P280-P264-P305+P351+P338-P301+P312-P337+P313-P501	**50ml** **100ml**

Stock #	Description	Size
12361	**Ammonium chloride, 99.5% min** ■ [12125-02-9], NH_4Cl, F.W. 53.49, Granular, m.p. 340° subl., d. ≈1.53, n_D^{20} 1.642, Merck **14**,509, Solubility: Soluble in water, methanol, ethanol. Insoluble in acetone, ether, ethyl acetate., EINECS 235-186-4, RTECS BP4550000, MDL MFCD00011420, † H:H302-H319, P:P280-P264-P305+P351+P338-P301+P312-P337+P313-P501a Application(s): As a flux in galvanizing steel sheet, in batteries, to clean soldering irons, analytical lab reagent, in washing powders, electroplating, lustering cotton	**500g** **2kg**
40193	**Ammonium chloride, ACS, 99.5% min** ■ [12125-02-9], NH_4Cl, F.W. 53.49, Crystalline, m.p. 340° subl., d. ≈1.53, n_D^{20} 1.642, Merck **14**,509, EINECS 235-186-4, RTECS BP4550000, MDL MFCD00011420, † Maximum level of impurities: Insoluble matter 0.005%, Residue after ignition 0.01%, PO_4 2ppm, SO_4 0.002%, Ca 0.001%, Mg 5ppm, Heavy Metals (as Pb) 5ppm, Fe 2ppm, pH of a 5% solution 4.5-5.5 at 25° H:H302-H319, P:P280-P264-P305+P351+P338-P301+P312-P337+P313-P501a	**1kg** **5kg**
87777	**Ammonium diamminetetrathiocyanatochromate(III) monohydrate, ACS, 93.0% min** *[Reinecke salt, Ammonium reineckate]* [13573-16-5], $NH_4[Cr(NH_3)_2(SCN)_4]\cdot H_2O$, F.W. 354.44 (336.42anhy), Powder, Merck **14**,8128, Solubility: Insoluble in dilute hydrochloric acid. Moderately soluble in water. Soluble in alcohol, UN3077, EINECS 237-003-3, MDL MFCD00066638, † Maximum level of impurities: Insoluble in dilute hydrochloric acid ≤ 0.05%, Sensitivity P.T. H:H400-H410-H302-EUH032-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501a Application(s): Used to precipitate primary and secondary amines as their ammonium salts	**25g** **100g**
11598	**Ammonium dihydrogen phosphate, ACS, 98.0% min** *[mono-Ammonium phosphate, Ammonium phosphate, monobasic]* [7722-76-1], $NH_4H_2PO_4$, F.W. 115.03, Crystalline, m.p. 190°, d. 1.803, Merck **14**,543, Solubility: Freely soluble in water. Slightly soluble in alcohol. Insoluble in acetone, EINECS 231-764-5, MDL MFCD00003396, † Maximum level of impurities: Insoluble matter 0.005%, pH of a 5% solution 3.8-4.4 at 25°, Cl 5ppm, NO_3 0.001%, SO_4 0.01%, Heavy metals (as Pb) 5ppm, Fe 0.001%, Ca 0.001%, Mg 0.0005%, K 0.005%, Na 0.005%. H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Preparation of baking powder with sodium bicarbonate, in fermentation	**500g** **2kg**
	Ammonium ferric sulfate, see Ammonium iron(III) sulfate dodecahydrate, 39391, p. 101	
11597	**Ammonium hydrogen phosphate, ACS, 98.0% min** *[Diammonium hydrogen phosphate, Phosphoric acid diammonium salt]* [7783-28-0], $(NH_4)_2HPO_4$, F.W. 132.06, Crystalline, m.p. 155° dec., d. 1.619, Merck **14**,542, EINECS 231-987-8, MDL MFCD00010891, † Maximum level of impurities: Insoluble matter 0.005%, pH of a 5% solution 7.7-8.1 at 25°, Cl 0.001%, NO_3 0.003, SO_4 0.01%, Heavy metals (as Pb) 0.001%, Fe 0.001%, Ca 0.001%, Mg 0.0005%, K 0.005%, Na 0.005% H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **1kg**
33285	**Ammonium hydroxide, ACS, 28.0-30.0% NH_3** [1336-21-6], NH_4OH, F.W. 35.05, Liquid, d. 0.90, Merck **14**,494, UN2672, EINECS 215-647-6, MDL MFCD00066650, † Maximum level of impurities: Residue after ignition 0.002%, CO_2 0.002%, Cl 0.5ppm, PO_4 2ppm, NO_3 2ppm, Sulfate (SO_4) 2ppm, Fe 0.2ppm, Substances reducing permanganate P.T., Heavy Metals (as Pb) 0.5ppm H:H314-H400, P:P280-P273-P305+P351+P338-P309-P310	**250g** **1kg** **5x1kg**
39391	**Ammonium iron(III) sulfate dodecahydrate, ACS, 98.5-102.0%** *[Ammonium ferric sulfate, Ferric ammonium sulfate]* [7783-83-7], $NH_4Fe(SO_4)_2\cdot 12H_2O$, F.W. 482.19 (266.07anhy), Broken Crystals, m.p. 39-41°, d. 1.71, Merck **14**,521, Solubility: Freely soluble in water. Insoluble in alcohol, MDL MFCD00150004, † Maximum level of impurities: Insoluble matter 0.01%, Cl 0.001%, NO_3 0.01%, Ca 0.01%, Mg 0.005%, K 0.005%, Na 0.02%, Cu 0.003%, Ferrous iron (Fe^{+2}) P.T. (limit about 0.001%), Zn 0.003% Application(s): In dyeing and printing textiles, as analytical lab reagent	**500g** **2.5kg**
13448	**Ammonium iron(II) sulfate hexahydrate, ACS, 98.5-101.5%** ▲ △ *[Iron(II) ammonium sulfate, Ferrous ammonium sulfate]* [7783-85-9], $(NH_4)_2Fe(SO_4)_2\cdot 6H_2O$, F.W. 392.13 (284.04anhy), Crystalline, m.p. ca 100° dec., d. 1.864, Merck **14**,521, Solubility: Soluble in water. Insoluble in alcohol, EINECS 233-382-4, RTECS BR6500000, MDL MFCD00150530, † Maximum level of impurities: Insoluble matter 0.01%, PO_4 0.003%, Ca 0.005%, Cu 0.003%, Mg 0.002%, Ferric ion (Fe^{+3}) 0.01%, Mn 0.01%, K 0.002%, Na 0.02%, Zn 0.003% H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Polymerization catalyst, photography	**500g** **2kg**
A10533	**Ammonium peroxydisulfate, 98%** ◢ *[Ammonium persulfate]* [7727-54-0], $(NH_4)_2S_2O_8$, F.W. 228.19, m.p. 120° dec., f.p. None, d. 1.982, n_D^{20} 1.50, Merck **14**,541, Fieser **1**,952 **3**,238 **5**,5 **6**,20 **12**,33 **18**,24, UN1444, EINECS 231-786-5, RTECS SE0350000, MDL MFCD00003390, Note: Aqueous solution decomposes slowly at room temperature, † H:H334-H272-H302-H335-H315-H319-H317, P:P221-P210-P285-P305+P351+P338-P405-P501a In combination with $AgNO_3$ and $Cu(OAc)_2$, promotes a carbamoyl radical process for the conversion of oxalic acid monoamides to isocyanates: *J. Org. Chem.*, **60**, 5430 (1995).	**500g** **1kg** **5kg**

Stock #	Description	Size
J61856	**Ammonium peroxydisulfate, Electrophoresis Grade** ◪ *[Ammonium persulfate]* [7727-54-0], $(NH_4)_2S_2O_8$, F.W. 228.20, Powder, m.p. 120° dec., f.p. None, d. 1.982, n_D^{20} 1.5, Merck **14**,541, UN1444, EINECS 231-786-5, RTECS SE0350000, MDL MFCD00003390, † H:H272-H334-H302-H335-H315-H319-H317, P:P221-P210-P285-P305+P351+P338-P405-P501a	**25g** **100g**
	Ammonium persulfate, see Ammonium peroxydisulfate, Electrophoresis Grade, J61856, p. 102 **Ammonium purpurate**, see Murexide, A17540, p. 296 **Ammonium pyrrolidinedithiocarbamate**, see 1-Pyrrolidinecarbodithioic acid ammonium salt, B23731, p. 333 **Ammonium reineckate**, see Ammonium diamminetetrathiocyanatochromate(III) monohydrate, 87777, p. 101	
J60368	**Ammonium sulfate, 0.5M aq. soln.** [7783-20-2], $(NH_4)_2SO_4$, F.W. 132.14, Liquid, † H:H303, P:P312	**50ml** **100ml**
J61620	**Ammonium sulfate, saturated soln.** [7783-20-2], $(NH_4)_2SO_4$, F.W. 132.14, Liquid, EINECS 231-984-1, †	**50ml**
11566	**Ammonium sulfate, ACS, 99.0% min** [7783-20-2], $(NH_4)_2SO_4$, F.W. 132.14, Granular, m.p. ca 280° dec., d. 1.769, Merck **14**,555, Solubility: Soluble in water. Insoluble in alcohol and acetone, EINECS 231-984-1, RTECS BS4500000, MDL MFCD00003391, † Maximum level of impurities: Insoluble matter 0.005%, Residue after ignition 0.005%, pH of a 5% solution 5.0-6.0 at 25°, Cl 5ppm, NO_3 0.001%, PO_4 5ppm, Heavy Metals (as Pb) 5ppm, Fe 5ppm H:H303, P:P312 Application(s): In galvanizing steel, manufacturing of ammonia alum and sulfuric acid	**100g** **500g** **2kg** **10kg**
89363	**Ammonium sulfate, 99.95% (metals basis)** [7783-20-2], $(NH_4)_2SO_4$, F.W. 132.14, Crystalline, m.p. ca 280° dec., d. 1.769, Merck **14**,555, EINECS 231-984-1, RTECS BS4500000, MDL MFCD00003391, † H:H303, P:P312	**100g** **500g** **2kg**
J64419	**Ammonium sulfate, ultrapure, 99+%** [7783-20-2], $(NH_4)_2SO_4$, F.W. 132.14, Crystalline, m.p. ca 280° dec., d. 1.769, Merck **14**,555, EINECS 231-984-1, RTECS BS4500000, MDL MFCD00003391, †	**100g** **500g** **2kg**
17658	**Ammonium L-(+)-tartrate, 98%** ■ *[L-(+)-Tartaric acid diammonium salt, Ammonium tartrate, dibasic]* [3164-29-2], $C_4H_{12}N_2O_6$, F.W. 184.15, Crystalline, d. 1.6, Solubility: Soluble in water, alcohol, EINECS 221-618-9, RTECS WW8050000, BRN 6120352, MDL MFCD00013073, † H:H412, P:P273-P501a 	**50g** **250g** **1kg**
	Ammonium tartrate, dibasic, see Ammonium L-(+)-tartrate, 17658, p. 102 **Ammonium tetrathiocyanatodiammine chromate(III)**, see Ammonium diamminetetrathiocyanatochromate(III) monohydrate, 87777, p. 101 **AMN107**, see Nilotinib, 99+%, J62578, p. 303 **Amosyt**, see Dimenhydrinate, J63718, p. 194	
J61290	**Amoxicillin trihydrate** [61336-70-7], $C_{16}H_{19}N_3O_5S \cdot 3H_2O$, F.W. 419.45 (365.40anhy), Powder, Merck **14**,577, EINECS 243-003-8, RTECS XH8310000, BRN 7507120, MDL MFCD00072029 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): A semi-synthetic antibiotic similar to penicillin	**10g** **25g**
	AMP, see 2-Amino-2-methyl-1-propanol, A17814, p. 97 **5'-AMP**, see Adenosine-5'-monophosphoric acid monohydrate, L14051, p. 79	
J62043	**AMP, 0.2M buffer soln., pH 9.0** [4958-39-8], Liquid	**100ml** **250ml**
J63988	**AMP, 0.2M buffer soln., pH 9.5** [4958-39-8], Liquid	**100ml** **250ml**
J63290	**AMP, 0.2M buffer soln., pH 10.0** [4958-39-8], Liquid	**100ml** **250ml**
J62474	**AMP, 0.2M buffer soln., pH 10.5** [4958-39-8], Liquid	**100ml** **250ml**
	5'-AMP.2Na, see Adenosine-5'-monophosphate disodium salt, J61643, p. 79 **AMPD**, see 2-Amino-2-methyl-1,3-propanediol, 99+%, J63144, p. 97	
J60276	**AMPD, 0.2M buffer soln., pH 7.5** [115-69-5], Liquid, †	**100ml** **250ml**
J61377	**AMPD, 0.2M buffer soln., pH 8.9** [115-69-5], Liquid, †	**100ml** **250ml**
J60916	**AMPD, 0.2M buffer soln., pH 9.5** [115-69-5], Liquid, †	**100ml** **250ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J61491	**Amphotericin B, Streptomyces nodosus** [1397-89-3], $C_{47}H_{73}NO_{17}$, F.W. 924.10, Powder, Merck **14**,585, EINECS 215-742-2, RTECS BU2625000, BRN 78342, MDL MFCD00877763 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	100mg 1g 5g
J60977	**Ampicillin** [69-53-4], $C_{16}H_{19}N_3O_4S$, F.W. 349.40, Powder, m.p. 208° dec., Merck **14**,586, EINECS 200-709-7, RTECS XH8350000, BRN 1090925, MDL MFCD00005175 H:H334-H335-H315-H319-H317, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a	5g 25g
J63807	**Ampicillin sodium salt** [69-52-3], $C_{16}H_{18}N_3NaO_4S$, F.W. 371.39, Powder, m.p. 215°, Merck **14**,586, EINECS 200-708-1, RTECS XH8400000, BRN 4119211, MDL MFCD00064313 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a	1g 5g 10g
J62378	**AMPSO, 98+%** *[N-(1,1-Dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid]* [68399-79-1], $C_7H_{17}NO_5S$, F.W. 227.28, Crystals, m.p. 215-225°, EINECS 269-991-7, BRN 5929916, MDL MFCD00041777, † Application(s): Useful as a buffer	25g 100g
J61467	**AMPSO, 0.2M buffer soln., pH 8.0** [102029-60-7], Liquid	100ml 250ml
J61238	**AMPSO, 0.2M buffer soln., pH 8.5** [102029-60-7], Liquid	100ml 250ml
J62328	**AMPSO, 0.2M buffer soln., pH 9.0** [102029-60-7], Liquid	100ml 250ml
J63354	**AMPSO, 0.2M buffer soln., pH 9.5** [102029-60-7], Liquid	100ml 250ml
J62655	**Amrinone, 98%** *[5-Amino-(3,4'-bipyridin)-6(1H)-one]* [60719-84-8], $C_{10}H_9N_3O$, F.W. 187.20, Crystals, m.p. 294-297° dec, Merck **14**,592, UN2811, EINECS 262-390-0, RTECS DW2500000, MDL MFCD00083228 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Phosphodiesterase III inhibitor and inhibits platelet aggregation	250mg 1g
J61472	**D-Amygdalin, 98%** *[D-Mandelonitrile-β-D-glucosido-6-β-D-glucoside]* [29883-15-6], $C_{20}H_{27}NO_{11}$, F.W. 457.44, Powder, m.p. 210-215°, Merck **14**,597, EINECS 249-925-3, RTECS OO8450000, BRN 66856, MDL MFCD00006598 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A benzylic glycoside that has been used as an antineoplastic agent	1g 5g 25g
L12731	**D-Amygdalin hydrate, 96%** *[D-Mandelonitrile-β-D-glucosido-6-β-D-glucoside]* [29883-15-6], $C_{20}H_{27}NO_{11}\cdot xH_2O$, F.W. 457.44(anhy), m.p. 215-220°, $[\alpha]_D^{20}$ -38° (c=1.2 in water), Merck **14**,597, EINECS 249-925-3, RTECS OO8450000, BRN 66856, MDL MFCD00006598 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A benzylic glycoside that has been used as an antineoplastic agent	2g 10g
	Amylodextrin, see Starch, 36703, p. 352	
L12089	**(±)-Anabasine, tech. 85%** *[Neonicotine, 2-(3-Pyridyl)piperidine]* [13078-04-1], $C_{10}H_{14}N_2$, F.W. 162.24, m.p. ca 9°, b.p. 270-272°, f.p. 93°(199°F), d. 1.046, n_D^{20} 1.5440, Merck **14**,619, UN3140, RTECS BV4375000, BRN 82639, MDL MFCD00006370 H:H300-H310-H411, P:P301+P310-P361-P302+P350-P321-P405-P501a	25mg 100mg
	Anafranil hydrochloride, see Clomipramine hydrochloride, J62485, p. 165 **Ancitabine hydrochloride**, see Cyclocytidine hydrochloride, 98+%, J63845, p. 171	
A13482	**trans-Anethole, 98+% ▲** *[(E)-1-Methoxy-4-propenylbenzene, trans-4-Propenylanisole]* [4180-23-8], $C_{10}H_{12}O$, F.W. 148.21, m.p. 20-23°, b.p. 232-235°, f.p. 96°(205°F), d. 0.991, n_D^{20} 1.5610, Merck **14**,643, EINECS 224-052-0, RTECS BZ9275000, BRN 774229, MDL MFCD00009284, † H:H227, P:P210-P280-P370+P378a-P403+P235-P501a Application(s): Inhibits lung and forestomach carcinogenesis	25g 100g 500g
	Aneurine hydrochloride, see Thiamine hydrochloride, A19560, p. 366 **Aneurinepyrophosphoric acid**, see Thiamine pyrophosphate chloride, 98%, J61483, p. 366	

Stock #	Description	Size
J61129	**Angiotensin, (rat or canine)** *[H-Asp-Arg-Val-Tyr-Ile-His-Pro-OH]* $C_{41}H_{82}N_{12}O_{11}$, F.W. 899.03, Powder	**5mg**
J62102	**Angiotensin I (human)** *[Hypertensin I, H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH]* [484-42-4], $C_{62}H_{89}N_{17}O_{14}$, F.W. 1296.50, Powder, MDL MFCD00133091	**5mg** **10mg** **25mg**
J60866	**Angiotensin II (human)** *[H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH acetate salt]* [4474-91-3], $C_{50}H_{71}N_{13}O_{12}$, F.W. 1046.19, Powder, RTECS BW2165000	**5mg** **10mg** **25mg**
J61756	**Angiotensin III (human)** *[H-Arg-Val-Tyr-Ile-His-Pro-Phe-OH]* [12687-51-3], $C_{46}H_{66}N_{12}O_9$, F.W. 931.10, Powder, BRN 8385695, MDL MFCD00133094	**5mg** **25mg**
J63143	**Angiotensin Converting Enzyme Inhibitor** *[H-pGlu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro-OH]* [35115-60-7], $C_{53}H_{76}N_{14}O_{12}$, F.W. 1101.30, Powder, MDL MFCD00076208	**5mg**
J61332	**Angiotensin Converting Enzyme Substrate** *[Bz-Phe-Ala-Pro-OH]* [69677-91-4], $C_{24}H_{27}N_3O_5$, F.W. 437.50, Powder	**5mg**
A13024	**Aniline hydrochloride, 99%** ■ [142-04-1], $C_6H_7N{\cdot}HCl$, F.W. 129.59, m.p. 196-200°, b.p. 245°, f.p. 193°(379°F), d. 1.221, Merck **14**,659, UN1548, EINECS 205-519-8, RTECS CY0875000, BRN 3593823, MDL MFCD00012958, † H:H301-H311-H331-H372-H341-H351-H318-H400-H317, P:P280-P273-P305+P351+P338-P361-P304+P340-P309+P311 A convenient method has been described for generating aryl isocyanates from aniline hydrochlorides and oxalyl chloride, via thermolysis of the intermediate oxamic chloride: *Tetrahedron Lett.*, **45**, 4769 (2004).	**100g** **500g** **2.5kg**
J65332	**8-Anilinonaphthalene-1-sulfonic acid, 95%** *[N-Phenyl peri acid, ANS]* [82-76-8], $C_{16}H_{13}NO_3S$, F.W. 299.34, Powder, m.p. 215-217°, Merck **14**,661, EINECS 201-438-7, BRN 1843887, MDL MFCD00003998, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Fluorescent probe for proteins on polyacrylamide gels	**5g** **25g** **100g**
J65538	**8-Anilinonaphthalene-1-sulfonic acid ammonium salt, 98%** ▲△■ *[1,8-ANS NH4, Ammonium 8-anilino-1-naphthalenesulfonate]* [28836-03-5], $C_{16}H_{13}NO_3S.NH_3$, F.W. 316.37, Crystalline powder, m.p. 242-244°, EINECS 249-265-6, BRN 3581235, MDL MFCD00012560, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Fluorescent probe for proteins on polyacrylamide gels	**5g** **25g** **100g**
J61661	**Aniracetam** *[1-(4-Methoxybenzoyl)-2-pyrrolidinone]* [72432-10-1], $C_{12}H_{13}NO_3$, F.W. 219.24, Powder, Merck **14**,662, RTECS UY5781900, MDL MFCD00153767 Application(s): AMPA receptor potentiator. Slows the rate of ion-channel closing	**1g**
J62964	**Anisomycin, 97+%** *[(2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate, Flagecidin]* [22862-76-6], $C_{14}H_{19}NO_4$, F.W. 265.31, Powder, m.p. 140-141°, Merck **14**,670, UN3462, EINECS 245-269-7, RTECS BZ9800000, BRN 20705, MDL MFCD00077650 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A protein synthesis inhibitor. Causes apoptosis of PC12 Cells	**10mg** **50mg**
J63107	**Anorexigenic Peptide** *[pGlu-His-Gly-OH]* [69275-10-1], $C_{13}H_{17}N_5O_5$, F.W. 323.40, Powder, MDL MFCD00079240 Application(s): An appetite-suppressing peptide	**1mg** **2mg**
	Ansimar, see Doxofylline, J60575, p. 201	
J62511	**Antazoline hydrochloride, 98%** *[2-(N-Benzylanilinomethyl)-2-imidazoline hydrochloride]* [2508-72-7], $C_{17}H_{19}N_3{\cdot}HCl$, F.W. 301.82, Powder, m.p. 237-241°, Merck **14**,680, EINECS 219-719-8, RTECS NJ2150000, MDL MFCD00058145 H:H302-H312-H332-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Imidazoline binding site ligand and an antihistamine	**25g**

Stock #	Description	Size
A14049	**Anthracene-9-carboxylic acid, 98+%** *[9-Anthroic acid]* [723-62-6], $C_{15}H_{10}O_2$, F.W. 222.24, m.p. ca 218° dec., EINECS 211-964-9, RTECS CB8764000, BRN 1875336, MDL MFCD00001257, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a  Application(s): Chloride ion transport inhibitor	**10g** **50g** **250g**
	β-**Anthraniloyl-L-alanine**, see L-Kynurenine, J60199, p. 264 **9-Anthroic acid**, see 9-Anthracenecarboxylic acid, A14049, p. 105	
30739	**Anthrone, ACS ▲** [90-44-8], $C_{14}H_{10}O$, F.W. 194.23, Crystalline, m.p. 155-158°, Merck **14**,691, EINECS 201-994-0, RTECS CB8925500, BRN 1910173, MDL MFCD00001187, † Maximum level of impurities: Melting point no more than a 5° range including 156°, Sensitivity to carbohydrates P.T., Absorbance of reagent solution P.T., Solubility in ethyl acetate P.T. ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a  Application(s): Used for determination of carbohydrates	**25g** **100g**
J64642	**Anti-Apo[a] antibody, from goat**	**1ml**
J65053	**Anti-Fibroblast Growth Factor, basic, from rabbit** Note: Source: Rabbit IgG Application(s): Suitable for immunohistochemical applications, inhibition and Western blotting.	**0.5mg**
J63020	**Antibiotic A23187, 99+%** *[Calcimycin, Calcium ionophore A23187]* [52665-69-7], $C_{29}H_{37}N_3O_6$, F.W. 523.62, Powder, Merck **14**,1639, EINECS 258-084-1, RTECS DM4676000, BRN 1096801, MDL MFCD00151202 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An antibiotic and calcium ionophore	**10mg** **50mg**
	Antibiotic AM-2282, see Staurosporine, 99+%, J62837, p. 352 **Antibiotic K178 sodium salt**, see Nigericin sodium salt, 98+%, J61349, p. 302 **Antibiotic S 7481F1**, see Cyclosporin A, 99+%, J63191, p. 172	
J60749	**Antibody & Antigen purification buffers** Liquid, Note: Contains 1L of 1M Tris-HCl (pH 8.0) and 500 ml of 100mM Glycine (pH 2.5), † Application(s): Buffers for immunoaffinity purification of antibodies.	**1kit**
J63014	**Antibody purification on protein A column** Liquid, Note: This kit contains: 1L of 1M Tris-HCl (pH 8.0) and 500ml of 100mM Glycine (pH 3.0)., † Application(s): Buffers to be used when performing antibody purification using immobilized Protein A.	**1kit**
J64001	**Anti-cyclic AMP anitbody** Note: Source: Rabbit Application(s): Unconjugated antibody. Suitable for radioimmunoassays.	**100tubes** **1000tubes**
J64263	**Anti-cyclic AMP antibody, preconjugated** Note: Source: Rabbit Application(s): Preconjugated antibody. Suitable for radioimmunoassays.	**100tubes**
J64025	**Anti-cyclic GMP antibody** Note: Source: Rabbit Application(s): Unconjugated antibody. Suitable for radioimmunoassays.	**100tubes** **1000tubes**
J64514	**Anti-cyclic GMP antibody, preconjugated** Note: Source: Rabbit Application(s): Preconjugated antibody. Suitable for radioimmunoassays.	**100tubes**
J65649	**Anti-Cytokeratin antibody, from rabbit, whole serum** Note: Source: Rabbit; Species reactivity: Vertebrates Application(s): Suitable for immunohistochemical applications and Western blotting. A whole serum preparation	**1ml**
J65390	**Anti-EGF antibody, from rabbit** Note: Source: Rabbit; Species reactivity: rat Application(s): Suitable for radioimmunoassays. A component in Rat EGF Assay kit.	**500tubes**
J65464	**Anti-EGF antibody, from rabbit** Note: Source: Rabbit; Species reactivity: mouse Application(s): Suitable for radioimmunoassays, double immunodiffusion and inhibition. A whole serum preparation	**100microliters**
J64008	**Anti-EGF antibody, from rabbit, whole serum** Note: Source: Rabbit; Species reactivity: human Application(s): Affinity purified. Suitable for immunohistochemical applications. A whole serum preparation.	**0.5ml**
J65866	**Anti-EGF antibody, from rabbit, whole serum** Note: Source: Rabbit; Species reactivity: rat Application(s): Suitable for immunohistochemical applications, inhibition, and western blotting. A whole serum preparation	**1each**

Stock #	Description	Size
J65056	**DNA Polymerase I Large (Klenow Fragment)** [9012-90-2], F.W. 68kDa, Liquid, EINECS 232-741-2, †	**500units**
	Application(s): Has 5' to 3' polymerase activity as well as 3' to 5' exonuclease activity. For generating complementary strands of cDNA	
J64158	**Anti-Fibronectin, antibody, from rabbit** Note: Source: Rabbit; Species reactivity: human	**100micrograms**
	Application(s): Affinity purified.	
J65644	**Anti-Fibronectin antibody, from rabbit** Note: Source: Rabbit IgG; Species reactivity: mouse	**0.5ml**
	Application(s): Affinity purified. Suitable for immunohistochemical applications and Western blotting	
J64763	**Anti-Fibronectin antibody, from rabbit, whole serum** Note: Source: Rabbit; Species reactivity: human	**1ml**
	Application(s): Suitable for immunohistochemical applications and double immunodifusion studies. A whole serum preparation.	
J64334	**Anti-GFAP antibody, from rabbit** Note: Source: Rabbit	**0.5ml**
	Application(s): Suitable for immunohistochemical applications and Western blotting	
J64177	**Anti-Goat IgG, from donkey** Note: Source: Donkey	**5ml**
	Application(s): Precipitating Antibody	
J65602	**Anti-Involucrin antibody kit** Note: Source: Rabbit; Species reactivity: human	**1kit**
	Application(s): Suitable for immunohistochemical applications.	
J65295	**Anti-Laminin antibody, from rabbit** Note: Source: Rabbit IgG	**0.5ml**
	Application(s): Suitable for immunohistochemical applications, ELISA and Western blotting. Adsorbed	
J64398	**Anti-LDL antibody, from rabbit** Note: Affinity purified	**1ml**
J65202	**Anti-Lysozyme antibody, from mouse** Note: Source: Mouse IgG1; Species reactivity: human	**1each**
	Application(s): Monoclonal antibody. Suitable for immunohistochemical applications, Western blotting, ELISA, and inhibition studies.	
J64787	**Anti-Mouse IgG-Peroxidase, from goat** Note: Source: Goat	**1mg**
	Application(s): Adsorbed. Suitable for enzyme immunoassays, immunohistochemistry and Western blotting.	
J63522	**Antimycin A ▲** [1397-94-0], $C_{28}H_{40}N_2O_9$, F.W. 548.63, Powder, m.p. 149-150°, Merck **14**,714, UN3462, RTECS CD0350000, MDL MFCD01779723, Note: Isolated from Streptomyces sp. H:H300, P:P264-P270-P301+P310-P321-P405-P501a	**5mg** **10mg**
J64817	**Anti-Myosin (Smooth Muscle) antibody, from rabbit** Note: Source: Rabbit IgG. Species reactivity: vertebrates.	**0.5ml**
	Application(s): Suitable for immunohistochemical applications, Western blotting and immunoprecipitation studies.	
J64913	**Anti-Myosin antibody, from rabbit** Note: Source: Rabbit IgG. Species reactivity: vertebrates. Reacts with smooth and non-muscle myosin.	**0.5ml**
	Application(s): Suitable for immunohistochemical applications, Western blotting and immunoprecipitation studies.	
J65418	**Anti-Myosin IIA (non muscle) antibody, from rabbit** Note: Source: Rabbit. Species reactivity: vertebrates.	**0.5ml**
	Application(s): Suitable for immunohistochemical applications, Western blots, and immunorecipitations.	
J64696	**Anti-Nerve Growth Factor antibody, from rabbit** Note: Source: Rabbit	**0.5ml**
	Application(s): Adsorbed. Suitable for immunohistochemical applications, Western blotting and inhibition studies.	
J65216	**Anti-Osteocalcin antibody, from goat, whole serum** Note: Source: Goat; Species reactivity: mouse	**0.25ml**
	Application(s): Suitable for immunohistochemical applications. Lyophilized from whole serum	
J64663	**Anti-Osteocalcin antibody, from goat, whole serum, RIA Grade** Note: Source: Goat; Species reactivity: mouse	**500each**
	Application(s): Suitable for radioimmunoassays. A whole serum preparation	

Stock #	Description	Size
J64503	**Anti-Osteocalcin antibody, from rabbit, whole serum** Note: Source: Rabbit; Species reactivity: bovine Application(s): Suitable for immunohistochemical applications. Lyophilized from whole serum.	0.5ml
J65982	**Anti-Osteocalcin antibody, from rabbit, whole serum** Note: Source: Rabbit; Species reactivity: human Application(s): Suitable for immunohistochemical applications. Lyophilized from whole serum	0.5ml
J64638	**Anti-Osteocalcin antibody, RIA Grade** Note: Species reactivity: rat	500each
J60011	**Antipain** *[[(S)-1-Carboxy-2-phenyl-ethyl]-carbamoyl-Arg-Val-Arg-aldehyde]* [37691-11-5], $C_{27}H_{44}N_{10}O_6$, F.W. 604.70, Powder, EINECS 253-631-0, RTECS YV9350700, BRN 6837629, MDL MFCD00135959 ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A natural protease inhibitor for trypsin, papain and cathepsins A and B	50mg
J63680	**Antipain dihydrochloride, 99+%** [37682-72-7], $C_{27}H_{44}N_{10}O_6 \cdot 2HCl$, F.W. 677.60, Powder, RTECS YV9350800, MDL MFCD00135957 Application(s): A natural protease inhibitor for trypsin, papain and cathepsins A and B	5mg
J64286	**Anti-Platelet Derived Growth Factor-BB antibody, from sheep** Note: Source: Sheep IgG Application(s): Neutralizing Antibody. Suitable for use in ELISA.	0.5mg
J64160	**Anti-Rabbit IgG, from goat** Note: Source: Goat Application(s): Precipitating Antibody	5ml
J64967	**Anti-Rabbit IgG-FITC from goat** Note: Source: Goat Application(s): A monospecific IgG suitable for immunohistochemical applications.	1ml
J64155	**Anti-Rabbit IgG-Peroxidase, from goat** Note: Source: Goat Application(s): Affinity purified. Suitable for immunohistochemical applications and Western blotting	1ml
J65031	**Anti-Rabbit IgG-TRITC, from goat** Note: Source: Goat Application(s): Adsorbed. Suitable for immunohistochemical applications.	1ml
J64717	**Antireproductive tripeptide** *[Bovine Pineal Antireproductive Tripeptide, H-Thr-Ser-Lys-OH acetate salt]* [71730-64-8], $C_{13}H_{26}N_4O_6$, F.W. 334.37, Powder	10mg 25mg
J65931	**Anti-Sheep IgG, from donkey** Note: Source: Donkey Application(s): Precipitating Antibody	5ml
J65429	**Anti-Tamm Horsfall Glycoprotein antibody, from rabbit** *[Anti-UMOD, Anti-Uromodulin antibody]*	0.5ml
J65575	**Anti-Transglutaminase Type I antibody** Note: Source: Mouse IgG2a; Species reactivity: human Application(s): Monoclonal antibody. Suitable for immunohistochemical applications, ELISA and immunoprecipitation.	0.5ml
J60961	**Apamin** *[H-Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg- Arg-Cys-Gln-Gln-His-NH2(Cys1-Cys11, Cys3-Cys15)]* [24345-16-2], $C_{79}H_{131}N_{31}O_{24}S_4$, F.W. 2027.37, Powder, Merck **14**,725, EINECS 246-182-7, RTECS CD6899900, MDL MFCD00167944 Application(s): Neurotoxic peptide isolated from honeybee venom. Blocks calcium-activated potassium channels	0.5mg
	APC, see Aphidicolin, J60236, p. 107 **APDC**, see 1-Pyrrolidinecarbodithioic acid ammonium salt, B23731, p. 333	
J60236	**Aphidicolin** *[APC]* [38966-21-1], $C_{20}H_{34}O_4$, F.W. 338.48, Cyrstalline powder, m.p. 224°, Merck **14**,727, RTECS PB9185000, BRN 4689958, MDL MFCD00083214 Application(s): A DNA polymerase inhibitor. Blocks the cell cycle at the early S-phase	1mg 5mg 10mg
	Apigenin, see 4',5,7-Trihydroxyflavone, L15041, p. 377	
J60630	**Apoferritin, from horse spleen** [9013-31-4], Freeze-dried powder, MDL MFCD00081365 Application(s): Gel filtration molecular weight marker	100mg

Stock #	Description	Size
J64506	**Apolipoprotein A-I, human plasma 95%** *[Apo A-I]*	**1mg**
J64658	**Apolipoprotein A-II, human plasma, 95%** *[Apo A-II]*	**1mg**
J65320	**Apoptosis Activator 2 ▲** *[1-[(3,4-Dichlorophenyl)methyl]-1H-indole-2,3-dione]* [79183-19-0], $C_{15}H_9Cl_2NO_2$, F.W. 306.14, Powder	**5mg** **25mg**
J65987	**Apoptosis Inhibitor II, Ns3694** *[4-Chloro-2-[3-(3-trifluoromethyl-phenyl)-ureido]benzoic acid]* [426834-38-0], $C_{15}H_{10}ClF_3N_2O_3$, F.W. 358.70, Powder, MDL MFCD00249000	**10mg** **50mg**
J65477	**APP Gamma Secretase Inhibitor ▲** *[3-5 Difluorophenacetyl-Ala-S-phenylglycine-methylester]* $C_{20}H_{20}F_2N_2O_4$, F.W. 390.38, Lyophilized powder	**5mg**
J63874	**Apramycin, 98+%** *[D-Streptamine]* [37321-09-8], $C_{21}H_{41}N_5O_{11}$, F.W. 539.60, Powder, b.p. 823°, f.p. 451.6°(845°F), d. 1.56, Merck **14**,752, EINECS 253-460-1 Application(s): Potent inhibitor of protein synthesis in bacteria	**1g** **5g**
J63039	**Aprotinin, from bovine lung** [9087-70-1], $C_{284}H_{432}N_{84}O_{79}S_7$, F.W. 6511.52, Powder, Merck **14**,757, EINECS 232-994-9, RTECS YN5080000, MDL MFCD00130541 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A potent protease inhibitor	**10mg** **25mg** **100mg**
J65076	**9-β-D-Arabinofuranosyladenine, 99%** *[Vidarabine, Ara-A]* [5536-17-4], $C_{10}H_{13}N_5O_4$, F.W. 267.24, Powder, Merck **14**,9976, EINECS 226-893-9, RTECS AU6200000, BRN 624881, MDL MFCD00065471, †  H:H361, P:P281-P201-P202-P308+P313-P405-P501	**1g** **5g** **25g**
J65653	**9-β-D-Arabinofuranosyladenine-5'-monophosphate, 99%** *[Vidarabine monophosphate]* [29984-33-6], $C_{10}H_{14}N_5O_7P$, F.W. 347.22, Powder, EINECS 249-990-8, RTECS AU6204000, MDL MFCD00069723 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g**
J65154	**9-β-D-Arabinofuranosyl-2-fluoroadenine-5'-monophosphate, 99%** *[Fludarabine monophosophate, 2-F-ara-AMP]* [75607-67-9], $C_{10}H_{13}FN_5O_7P$, F.W. 365.21, Powder, RTECS UO7440900, MDL MFCD00866418 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J64147	**1-β-D-Arabinofuranosyluracil, 99%** *[Ara-U, Arauridine]* [3083-77-0], $C_9H_{12}N_2O_6$, F.W. 244.20, Powder, EINECS 221-386-9, RTECS YQ8818000, BRN 28749, MDL MFCD00065998	**1g** **5g** **25g**
L09895	**DL-Arabinose, 98+%** [147-81-9], $C_5H_{10}O_5$, F.W. 150.13, m.p. 158-160°, Merck **14**,761, EINECS 205-699-8, BRN 1723086, MDL MFCD00135867, †	**10g** **50g**
A10357	**D-(-)-Arabinose, 99%** [10323-20-3], $C_5H_{10}O_5$, F.W. 150.13, m.p. 154-158°, $[\alpha]_D^{20}$ -104° (c=10 in water, 24h), EINECS 233-708-5, BRN 1723079, MDL MFCD00135608, † Chiral building block. For use in the synthesis of a chiral quinuclidine-3,5-diol, see: *J. Chem. Soc., Perkin 1*, 1065 (1989). 	**10g** **50g** **250g**
A11921	**L-(+)-Arabinose, 99%** [87-72-9], $C_5H_{10}O_5$, F.W. 150.13, m.p. 155-160°, $[\alpha]_D^{20}$ +104° (c=10 in water, 24h), Merck **14**,761, EINECS 201-767-6, BRN 1723085, MDL MFCD00067709, † 	**50g** **250g**
A17801	**D-(+)-Arabitol, 99%** [488-82-4], $C_5H_{12}O_5$, F.W. 152.15, m.p. 100-104°, $[\alpha]_D^{20}$ +11° (c=5 in 8% borax solution), Merck **14**,762, EINECS 207-686-2, BRN 1720520, MDL MFCD00004709, † 	**5g** **25g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A13103	**L-(-)-Arabitol, 98%** ■ [7643-75-6], $C_5H_{12}O_5$, F.W. 152.15, m.p. 98-103°, $[\alpha]_D^{20}$ -11° (c=5 in 8% borax soln), Merck **14**,762, EINECS 231-582-6, BRN 1720521, MDL MFCD00064290, † 	5g 25g 100g
	D-Araboascorbic acid, see D-(-)-Isoascorbic acid, 36366, p. 260	
L14945	**Arbutin, 98+%** △ ■ *[Hydroquinone-glucose, 4-Hydroxyphenyl-β-D-glucopyranoside]* [497-76-7], $C_{12}H_{16}O_7$, F.W. 272.26, m.p. 196-200°, $[\alpha]_D^{20}$ -65° (c=2 in water), Merck **14**,773, EINECS 207-850-3, RTECS CE8863000, BRN 89673, MDL MFCD00016915 	1g 5g
J63277	**Arcaine sulfate salt** *[1,4-Diguanidinobutane sulfate salt]* [14923-17-2], $C_6H_{16}N_6 \cdot H_2SO_4$, F.W. 270.30, White powder, RTECS MF6550000, MDL MFCD00050545 Application(s): An NMDA antagonist and a nitric oxide synthase inhibitor	1g 2.5g 5g
J65468	**Arg-Gly-Asp** *[Arginyl-glycyl-aspartic acid, RGD]* [99896-85-2], $C_{12}H_{22}N_6O_6$, F.W. 346.34, Powder, MDL MFCD00057952 Application(s): Fragment from cell-attachment domain of fibronectin; a cell-attachment peptide	1mg 5mg
J64877	**Arg-Gly-Asp-Ser** *[RGDS, Arginyl-glycyl-aspartyl-serine]* [91037-65-9], $C_{15}H_{27}N_7O_8$, F.W. 433.42, Powder, MDL MFCD00076452 Application(s): Supports fibroblast attachment	5mg
A17520	**DL-Arginine, 98%** △ [7200-25-1], $C_6H_{14}N_4O_2$, F.W. 174.20, m.p. ca 230° dec., EINECS 230-571-3, BRN 1725411, MDL MFCD00063117, † 	5g 25g
A16137	**D-Arginine, 98%** △ *[D-2-Amino-5-guanidinopentanoic acid, H-D-Arg-OH]* [157-06-2], $C_6H_{14}N_4O_2$, F.W. 174.20, m.p. ca 235°, EINECS 205-866-5, RTECS CF1934220, BRN 1725412, MDL MFCD00063116, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 	1g 5g
A15738	**L-Arginine, 98+%** △ *[L-2-Amino-5-guanidinopentanoic acid, H-Arg-OH]* [74-79-3], $C_6H_{14}N_4O_2$, F.W. 174.20, m.p. 226° dec., $[\alpha]_D^{20}$ +26° (c=1.6 in 6N HCl), Merck **14**,780, EINECS 200-811-1, RTECS CF1934200, BRN 1725413, MDL MFCD00002635, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 	25g 100g 500g 2.5kg
A10758	**DL-Arginine monohydrochloride monohydrate, 98+%** *[DL-2-Amino-5-guanidinopentanoic acid monohydrochloride monohydrate, H-DL-Arg-OH.HCl]* [332360-01-7], $C_6H_{14}N_4O_2 \cdot HCl \cdot H_2O$, F.W. 228.69 (210.67anhy), EINECS 250-903-0, BRN 4158960, MDL MFCD00151031, † 	5g 25g
J61420	**DL-Arginine hydrochloride** [32042-43-6], $C_6H_{14}N_4O_2 \cdot HCl$, F.W. 210.67, Powder, EINECS 250-903-0, MDL MFCD00064549 Application(s): Substrate for nitric oxide synthase; induces insulin release by a nitric oxide-dependent mechanism	5g 25g
A16222	**D-Arginine monohydrochloride, 99%** ■ [627-75-8], $C_6H_{14}N_4O_2 \cdot HCl$, F.W. 210.67, m.p. 216-218°, EINECS 211-010-1, RTECS CF1995000, BRN 5773432, MDL MFCD00012620, † 	1g 5g 25g
A14730	**L-Arginine monohydrochloride, 98+%** ■ *[L-2-Amino-5-guanidinopentanoic acid hydrochloride, H-Arg-OH.HCl]* [1119-34-2], $C_6H_{14}N_4O_2 \cdot HCl$, F.W. 210.67, m.p. 216° dec., d. 1.42, $[\alpha]_D^{20}$ +22° (c=5 in 5N HCl), Merck **14**,780, EINECS 214-275-1, RTECS CF1995500, BRN 3631658, MDL MFCD00064550, † 	100g 500g 2.5kg
	Arlacel® 83, see Sorbitan sesquioleate, J62648, p. 350	
J64151	**ARP 100** *[N-Hydroxy-2-(N-isopropoxy-[1,1'-biphenyl]-4-ylsulfonamido)acetamide]* [704888-90-4], $C_{17}H_{20}N_2O_5S$, F.W. 364.42, Solid ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	5mg
	Arpamyl, see (+/-)-Verapamil hydrochloride, 99+%, J61535, p. 391	

Stock #	Description	Size
A11838	**Arsenazo III disodium salt** *[3,6-Bis(2,2'-arsonophenylazo)-4,5-dihydroxy-2,7-naphthalenedisulfonic acid disodium salt]* [62337-00-2], $C_{22}H_{16}As_2N_4Na_2O_{14}S_2$, F.W. 820.34, m.p. >320°, UN3465, EINECS 263-516-7, MDL MFCD00003936 H:H301-H331-H400-H410, P:P261-P301+P310-P321-P304+P340-P405-P501a 	**1g** **5g** **25g**
J63031	**Arsenazo III free acid** [1668-00-4], $(HO)_2C_{10}H_2(SO_3H)_2(N{=}NC_6H_4AsO_3H_2)_2$, F.W. 776.37, Powder, UN3465, EINECS 216-788-6, BRN 5717957, MDL MFCD00036695 H:H301-H331-H400-H410, P:P261-P301+P310-P321-P304+P340-P405-P501a Application(s): Suitable for determination of micromolar amounts of calcium	**5g** **25g**
J65406	**Artemisinin, 99%** *[Arteannuin, Qinghaosu]* [63968-64-9], $C_{15}H_{22}O_5$, F.W. 282.33, Powder to crystals, m.p. 156-157°, Merck **14**,817, RTECS KD4170000, MDL MFCD00081057 Application(s): Natural anti-malarial compound	**1g** **5g**
	L-Arterenol, see L-Noradrenaline, L08087, p. 304	
J62812	**Arvanil, 98%** [128007-31-8], $C_{28}H_{41}NO_3$, F.W. 439.64, Liquid, RTECS JX3845000, MDL MFCD01752675, Note: Supplied as a 50mg/ml solution in ethanol Application(s): Cannabinoid and vanilloid receptor agonist. Induces apoptosis through a caspase-8 pathway	**5mg** **10mg** **50mg**
J64218	**AS 19** *[(2S)-N,N-Dimethyl-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydronaphthalen-2-amine]* $C_{18}H_{25}N_3$, F.W. 283.41, Oil	**10mg**
J65125	**α-Asarone ▲** *[trans-1,2,4-Trimethoxy-5-(1-propenyl)benzene, Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH2]* [2883-98-9], $(CH_3O)_3C_6H_2CH{=}CHCH_3$, F.W. 208.25, Powder, m.p. 57-61°, b.p. 296°, EINECS 220-743-6, RTECS DC2975000, BRN 1910606, MDL MFCD00064457	**1g** **5g**
J65782	**Ascorbate oxidase, from Cucurbita sp.** *[EC 1.10.3.3]* [9029-44-1], Lyophilized powder, EINECS 232-852-6, MDL MFCD00130560	**1kilounit**
11188	**L-(+)-Ascorbic acid, 98+%** *[Vitamin C]* [50-81-7], $C_6H_8O_6$, F.W. 176.12, Powder, m.p. ca 191° dec., d. 1.65, Merck **14**,830, EINECS 200-066-2, RTECS CI7650000, BRN 84272, MDL MFCD00064328, † 	**100g** **500g** **2kg**
36237	**L-(+)-Ascorbic acid, ACS, 99+%** *[Vitamin C]* [50-81-7], $C_6H_8O_6$, F.W. 176.12, Powder, m.p. ca 191° dec., d. 1.65, Merck **14**,830, EINECS 200-066-2, RTECS CI7650000, BRN 84272, MDL MFCD00064328, † Maximum level of impurities: Specific rotation $[\alpha]_D^{25}$ +21.0 ±0.5°, Residue after ignition 0.1%, Heavy Metals (as Pb) 0.002%, Fe 0.001%	**25g** **100g** **500g**
A17759	**L-Ascorbic acid sodium salt, 99%** *[Vitamin C sodium salt]* [134-03-2], $C_6H_7NaO_6$, F.W. 198.11, m.p. ca 220°, Merck **14**,830, EINECS 205-126-1, RTECS CI7671000, BRN 3767246, MDL MFCD00082340, † 	**100g** **500g**
32791	**L-Ascorbic acid 6-palmitate, 99%** [137-66-6], $C_{22}H_{38}O_7$, F.W. 414.52, Crystalline, m.p. 113-114°, EINECS 205-305-4, MDL MFCD00005377, † 	**25g** **100g** **500g**
	Asparaginase, see Aspartame, 98%, J61523, p. 111	
B21473	**L-(+)-Asparagine, 99% ■** [70-47-3], $C_4H_8N_2O_3$, F.W. 132.12, m.p. 234-236° dec., Merck **14**,837, EINECS 200-735-9, BRN 1723527, MDL MFCD00064401, † 	**100g** **500g** **2.5kg**
B20273	**DL-Asparagine monohydrate, 98%** *[DL-2-Aminosuccinamic acid monohydrate, H-DL-Asn.H_2O]* [3130-87-8], $C_4H_8N_2O_3{\cdot}H_2O$, F.W. 150.14 (132.12anhy), m.p. ca 220° dec., EINECS 221-521-1, BRN 6234992, MDL MFCD00151039, † 	**100g** **500g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
B24556	**D-(-)-Asparagine monohydrate, 99%** [5794-24-1], $C_4H_8N_2O_3 \cdot H_2O$, F.W. 150.14 (132.12anhy), m.p. 274-276° dec., Merck **14**,837, MDL MFCD00149558 	**25g** **100g**
A15012	**L-(+)-Asparagine monohydrate, 98+%** *[L-2-Aminosuccinamic acid monohydrate, H-Asn-OH.H2O]* [5794-13-8], $C_4H_8N_2O_3 \cdot H_2O$, F.W. 150.14 (132.12anhy), m.p. ca 245° dec., d. 1.543, $[\alpha]_D^{20}$ +31° (c=5 in 5N HCl), Merck **14**,837, EINECS 200-735-9, BRN 5767869, MDL MFCD00151038, † Starting material for synthesis of β -amino acids: *Arch. Pharm.*, **324**, 551 (1991) 	**100g** **500g** **2.5kg**
J62869	**L-Asparagine monohydrate, Cell Culture Reagent** *[(S)-2-Aminosuccinic acid 4-amide, L-Aspartic acid 4-amide]* [5794-13-8], $C_4H_8N_2O_3 \cdot H_2O$, F.W. 150.14 (132.12anhy), White to off-white, m.p. 215-217°, EINECS 200-735-9, BRN 1723527, MDL MFCD00151038, †	**100g** **500g** **1kg**
	Aspartate aminotransferase, see Glutamic oxalacetic transaminase, porcine heart, J60044, p. 235 **L-Aspartate: 2-oxoglutarate aminotransferase**, see Glutamic oxalacetic transaminase, porcine heart, J60044, p. 235	
A13646	**DL-Aspartic acid, 98+%** *[DL-Aminosuccinic acid, H-DL-Asp-OH]* [617-45-8], $C_4H_7NO_4$, F.W. 133.10, m.p. >300° dec., EINECS 210-513-3, RTECS CI9097800, BRN 774618, MDL MFCD00063083, † 	**100g** **500g** **2.5kg**
B21184	**D-Aspartic acid, 99%** *[D-Aminosuccinic acid, H-D-Asp-OH]* [1783-96-6], $C_4H_7NO_4$, F.W. 133.10, m.p. >300° dec., d. 1.66, $[\alpha]_D^{20}$ -25° (c=1 in 1N HCl), Merck **14**,840, EINECS 217-234-6, RTECS CI9097500, BRN 1723529, MDL MFCD00063081 	**5g** **25g** **100g**
A13520	**L-Aspartic acid, 98+%** *[L-Aminosuccinic acid, H-Asp-OH]* [56-84-8], $C_4H_7NO_4$, F.W. 133.10, m.p. >300° dec., d. 1.66, $[\alpha]_D^{20}$ +25° (c=2 in 5N HCl), Merck **14**,840, EINECS 200-291-6, RTECS CI9098500, BRN 1723530, MDL MFCD00002616, † Readily forms β-lactam derivatives which are valuable intermediates for the synthesis of a variety of products, including thienamycin: *J. Am. Chem. Soc.*, **102**, 6163 (1980); *Tetrahedron Lett.*, **23**, 2293 (1982). 	**100g** **250g** **500g** **1kg** **5kg**
	L-Aspartic acid 4-amide, see L-Asparagine monohydrate, Cell Culture Reagent, J62869, p. 111	
L08956	**L-Aspartic acid 4-benzyl ester, 98%** *[H-Asp(OBzl)-OH, β-Benzyl L-aspartate]* [2177-63-1], $C_{11}H_{13}NO_4$, F.W. 223.23, m.p. ca 220° dec., $[\alpha]_D^{20}$ +27.5° (c=1 in 1N HCl), EINECS 218-541-8, BRN 1983183, MDL MFCD00037208 	**1g** **5g** **25g**
J65983	**L-Aspartic acid dimethyl ester hydrochloride, 99%** *[L-Asp(OMe)-Ome.HCl, Dimethyl L-aspartate hydrochloride]* [32213-95-9], $C_6H^{11}NO_4.HCl$, F.W. 197.62, Powder, m.p. 115-117°, EINECS 250-957-4, MDL MFCD00038878	**5g** **25g**
B22321	**L-Aspartic acid monosodium salt monohydrate, 99%** *[Sodium L-aspartate monohydrate]* [323194-76-9], $C_4H_6NNaO_4 \cdot H_2O$, F.W. 173.11 (155.10anhy), EINECS 223-264-0, MDL MFCD00152960 	**100g** **500g**
J61523	**Aspartame, 98%** *[Asp-Phe methyl ester, Asp-Phe-OMe, Asparaginase]* [22839-47-0], $HOOCCH_2CH(NH_2)CONHCH(CH_2C_6H_5)COOCH_3$, F.W. 294.30, Powder, m.p. 243-245°, Merck **14**,839, EINECS 245-261-3, RTECS WM3407000, BRN 2223850, MDL MFCD00002724, † Application(s): A non-nutritive sweetener and dipeptide ester about 160 times sweeter than sucrose	**5g** **25g** **100g**
J60339	**Astemizole, 99+%** *[1-(4-Fluorobenzyl)-2-(1-[4-methoxyphenethyl]piperidin-4-yl)aminobenzimidazole, Hismanal]* [68844-77-9], $C_{28}H_{31}FN_4O$, F.W. 458.57, Powder, m.p. 149-150°, Merck **14**,856, EINECS 272-441-9, RTECS DD8968000, MDL MFCD00153919 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Selective histamine H1 receptor antagonist	**50mg**
J61199	**(R,S)-Atenolol** [29122-68-7], $C_{14}H_{22}N_2O_3$, F.W. 266.34, Powder, m.p. 163°, Merck **14**,859, EINECS 249-451-7, RTECS AC3600000, MDL MFCD00057645 Application(s): Cardioselective β-adrenergic blocker. An antihypertensive	**1g**
	ATP disodium salt, see Adenosine-5'-triphosphate disodium salt, 98%, J61125, p. 79 **ATP disodium salt trihydrate**, see Adenosine-5'-triphosphate disodium salt trihydrate, 98%, J60336, p. 79 **5'-ATP-Na2**, see Adenosine-5'-triphosphate disodium salt hydrate, L14522, p. 79	
J64988	**Atrial Natriuretic Peptide (1-28), rat** [88898-17-3], $C_{128}H_{205}N_{45}O_{39}S_2$, F.W. 3062.41, Powder	**0.5mg** **1mg**
J65178	**Atrial Natriuretic Peptide (4-24), frog** [118691-44-4], $C_{93}H_{150}N_{34}O_{27}S_3$, F.W. 2272.59, Powder, MDL MFCD00076224	**0.5mg** **1mg**

Stock #	Description	Size
A10236	**Atropine sulfate monohydrate, 98+% ▲** [5908-99-6], $C_{34}H_{46}N_2O_6 \cdot H_2SO_4 \cdot H_2O$, F.W. 694.84 (676.82anhy), m.p. 187-192°, Merck **14**,875, UN1544, EINECS 200-104-8, RTECS CK2455000, BRN 6109275, MDL MFCD00074815, † H:H300-H330, P:P301+P310-P304+P340-P320-P330-P405-P501a Application(s): Antagonist at muscarinic receptors; also a bronchodilator	**10g** **50g**
J60343	**Auramine O, 80% dye content** *[C.I. 41000]* [2465-27-2], $C_{17}H_{21}N_3 \cdot HCl$, F.W. 303.84, Powder, m.p. 250° dec., UN2811, EINECS 219-567-2, RTECS BY3675000, BRN 4030061, MDL MFCD00012484, † H:H311-H351-H302, P:P280-P281-P361-P302+P352-P405-P501a Application(s): Fluorescent stain for acid-resistant bacteria in sputum	**25g** **50g**
	Aureomycin, see Chlortetracycline hydrochloride, J60095, p. 160	
J65997	**Aurora Kinase/Cdk Inhibitor ▲** *[4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide]* [443797-96-4], $C_{15}H_{12}F_2N_6O_3S.CH_3CN$, F.W. 435.41, Powder H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
A15905	**Aurintricarboxylic acid** [4431-00-9], $C_{22}H_{14}O_9$, F.W. 422.35, m.p. >300°, EINECS 224-628-1, RTECS GU4790000, BRN 2228904, MDL MFCD00011663, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibits protein-nucleic acid interactions	**5g** **25g** **100g**
J65067	**Autocamtide 2** *[Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Thr-Val-Asp-Ala-Leu]* $C_{65}H_{118}N_{22}O_{20}$, F.W. 1527.76, Solid	**0.5mg** **1mg**
J64813	**Autophagy Inhibitor, 3-MA** *[3-Methyladenine, 6-Amino-3-methylpurine]* [5142-23-4], $C_6H_7N_5$, F.W. 149.15, Solid, EINECS 225-908-6, RTECS AU6520000, BRN 14,6087, MDL MFCD00010531	**25mg** **50mg**
	Auxit, see Bromhexine hydrochloride, 98+%, J63451, p. 135 **Avermectin B1**, see Abamectin, 97+%, J60039, p. 69	
J64972	**Avidin, from egg** [1405-69-2], Lyophilized powder, EINECS 215-783-6, RTECS CL1590000, MDL MFCD00130572 Application(s): Has extremely strong affinity for biotin	**10mg**
	AVP peptide, see Vasopressin, 98+%, J61248, p. 391 **AY-22989**, see Rapamycin, 99+%, J62473, p. 335	
J65079	**AY 9944 dihydrochloride ■** *[1,4-Bis(2-chlorobenzylaminomethyl)cyclohexane dihydrochloride, trans-N,N-Bis[2-chlorophenylmethyl-]-1,4-cyclohexanedime thanamine dihydrochloride]* [366-93-8], $C_{22}H_{28}Cl_2N_2 \cdot 2HCl$, F.W. 464.30, Solid, UN2811, RTECS GU7025000 H:H301-H360, P:P281-P301+P310-P321-P308+P313-P405-P501	**10mg** **50mg**
H26082	**O-(7-Aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 99% ◢** *[HATU, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 1-oxide hexafluorophosphate]* [148893-10-1], $C_{10}H_{15}F_6N_6OP$, F.W. 380.23, m.p. ca 185° dec., MDL MFCD00274639 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
	1-Azabicyclo[2.2.2]octan-3-ol, see 3-Quinuclidinol, B21503, p. 334 **1-Azabicyclo[2.2.2]octan-3-one hydrochloride**, see 3-Quinuclidinone hydrochloride, A13320, p. 334	
J64159	**5-Azacytidine, 98%** *[4-Amino-1-(β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one, Ladakamycin]* [320-67-2], $C_8H_{12}N_4O_5$, F.W. 244.2, Powder, m.p. 226-232° dec., Merck **14**,890, EINECS 206-280-2, RTECS XZ3017500, BRN 620461, MDL MFCD00006539 H:H302-H340-H350, P:P281-P264-P301+P312-P308+P313-P405-P501 Application(s): Causes DNA demethylation or hemi-demethylation; a powerful mutagen	**1g** **5g**
A13410	**5-Azacytosine, 98% (dry wt.), may cont. up to ca 7% water** *[4-Amino-1,3,5-triazin-2(1H)-one]* [931-86-2], $C_3H_4N_4O$, F.W. 112.09, m.p. >300°, EINECS 213-242-9, RTECS XZ2854300, BRN 116378, MDL MFCD00149402 H:H302, P:P264-P270-P301+P312-P330-P501a	**5g** **25g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J65513	**5-Aza-2'-deoxycytidine, 98%** *[2'-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one]* [2353-33-5], $C_8H_{12}N_4O_4$, F.W. 228.21, Powder, Merck **14**,2853, EINECS 219-089-4, RTECS XZ3012000, BRN 617982, MDL MFCD00043011 H:H302-H315-H319-H341-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg** **250mg**
J64549	**Azadibenzocyclooctyne acid** *[ADIBO-acid]* $C_{21}H_{19}NO_3$, F.W. 333.38, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Simplest amine reactive reagent for introducing a dibenzylcyclooctyne to available amine functionality	**25mg** **100mg**
J65637	**Azadibenzocyclooctyne-amine** *[ADIBO-amine]* [1255942-06-3], $C_{18}H_{16}N_2O$, F.W. 276.33, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A carbonyl reactive reagent used to incorporate DBCO into organic compounds, surfaces or particles	**25mg** **100mg**
J65472	**Azadibenzocyclooctyne-Biotin conjugate** *[ADIBO-Biotin conjugate]* $C_{28}H_{30}N_4O_3S$, F.W. 502.63, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **25mg**
J65377	**Azadibenzocyclooctyne-maleimide** *[ADIBO-maleimide]* $C_{25}H_{21}N_3O_4$, F.W. 427.45, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
J65981	**Azadibenzocyclooctyne-NHS ester** ◢ *[ADIBO-NHS ester]* $C_{25}H_{22}N_2O_5$, F.W. 430.45, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Unique and simple NHS ester allows DBCO incorporation into amine-containing molecules	**25mg** **100mg**
J64977	**Azadibenzocyclooctyne-PEG, MW 5,000** *[ADIBO-PEG, MW 5,000]* F.W. 5kDa, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg**
J65322	**Azadibenzocyclooctyne-PEG, MW 10,000** *[ADIBO-PEG, MW 10,000]* F.W. 10kDa, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg**
J65953	**Azadibenzocyclooctyne-PEG, MW 20,000** *[ADIBO-PEG 20,000]* F.W. 20 kDa, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg**
J65338	**Azadibenzocyclooctyne-PEG4-acid** *[ADIBO-PEG4-acid]* $C_{32}H_{40}NO_8$, F.W. 566.66, Viscous liquid or solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Amine reactive reagent for introducing a dibenzylcyclooctyne to available amine functionality. PEG4 spacer enhances water solubility and reduces or eliminates aggregation and precipitation when labeling biological materials	**10mg** **25mg**
J64617	**Azadibenzocyclooctyne-PEG4-alcohol** *[ADIBO-PEG4-alcohol]* $C_{29}H_{36}N_2O_7$, F.W. 524.61, Viscous liquid or solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): DBCO-containing reagent with PEG4 spacer and alcohol terminus	**25mg** **100mg**
J65301	**Azadibenzocyclooctyne-PEG4 amine** *[ADIBO-PEG4-amine]* [1255942-08-5], $C_{29}H_{37}N_3O_6$, F.W. 523.62, Viscous liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A carbonyl reactive reagent with a PEG4 spacer. PEG4 spaces increases water solubility and accessibility of the DBCO moiety	**10mg** **25mg** **100mg**
J65737	**Azadibenzocyclooctyne-PEG4 biotin conjugate** *[ADIBO-PEG4-biotin conjugate]* $C_{39}H_{51}N_5O_8S$, F.W. 749.92, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **25mg** **100mg**

Stock #	Description	Size
J65673	**Azadibenzocyclooctyne-PEG4-maleimide** *[ADIBO-PEG4-maleimide]* $C_{36}H_{42}N_4O_9$, F.W. 674.74, Viscous liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	10mg 25mg 100mg
J65223	**Azadibenzocyclooctyne-PEG4-NHS ester** ◢ *[ADIBO-PEG4-NHS ester]* $C_{36}H_{43}N_3O_{11}$, F.W. 693.74, Viscous liquid or solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	10mg 25mg 100mg
J65570	**Azadibenzocyclooctyne-PEG4-phorphoramidite** *[ADIBO-PEG4-phosphoramidite]* $C_{38}H_{53}N_4O_7P$, F.W. 708.82, Viscous liquid or solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	25mg
J65780	**Azadibenzocyclooctyne-PEG12 biotin conjugate** *[ADIBO-PEG12-biotin conjugate]* $C_{55}H_{83}N_5O_{16}S$, F.W. 1102.34, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	10mg 25mg
J64040	**Azadibenzocyclooctyne-SETA 650** *[ADIBO-SETA 650]* F.W. 1173.36, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	0.5mg
J65628	**Azadibenzocyclooctyne-S-S-NHS ester** *[ADIBO-S-S-NHS ester]* $C_{28}H_{27}N_3O_6S_2$, F.W. 565.65, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	25mg 100mg
J64256	**Azadibenzocyclooctyne-S-S-PEG3-biotin conjugate** *[ADIBO-S-S-PEG3-biotin conjugate]* $C_{42}H_{56}N_6O_6S_3$, F.W. 869.12, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	10mg 25mg
J64671	**Azadibenzocyclooctyne-sulfo-biotin conjugate** *[ADIBO-sulfo-biotin conjugate]* $C_{37}H_{50}N_6O_2S_2$, F.W. 652.76, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	10mg 25mg
L07983	**7-Azaindole, 98%** *[1H-Pyrrolo[2,3-b]pyridine]* [271-63-6], $C_7H_6N_2$, F.W. 118.14, m.p. 103-107°, b.p. 270°, EINECS 205-981-0, RTECS UY8710000, BRN 109667, MDL MFCD00005606 Glycosylation at the pyrrole nitrogen has been carried out under phase-transfer conditions to give nucleoside analogues: *Heterocycles*, **29**, 795 (1989). For a review of the chemistry of azaindoles, see: *Russ. Chem. Rev.*, **49**, 428 (1980).	1g 5g 25g
J62314	**Azathioprine** [446-86-6], $C_9H_7N_7O_2S$, F.W. 277.26, Crystalline powder, Merck **14**,902, EINECS 207-175-4, RTECS UO8925000, MDL MFCD00069203 H:H302-H315-H319-H350-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An immunosuppressant. A purine synthesis inhibitor which inhibits the proliferation of cells	1g 5g 10g
L06762	**6-Azathymine, 98%** *[6-Methyl-1,2,4-triazine-3,5(2H,4H)-dione]* [932-53-6], $C_4H_5N_3O_2$, F.W. 127.10, m.p. 211-215°, Merck **14**,903, EINECS 213-253-9, RTECS XY8050000, BRN 126863, MDL MFCD00006457	5g 25g
A14389	**6-Azauracil, 98%** *[1,2,4-Triazine-3,5(2H,4H)-dione]* [461-89-2], $C_3H_3N_3O_2$, F.W. 113.08, m.p. 274-282°, EINECS 207-318-0, RTECS XY7700000, BRN 116472, MDL MFCD00006456, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	5g 25g
	6-Azauracil riboside, see 6-Azauridine, J61309, p. 114	
J61309	**6-Azauridine** *[6-Azauracil riboside, 2-β-D-Ribofuranosyl-1,2,4-triazine-3,5(2H,4H)-dione]* [54-25-1], $C_8H_{11}N_3O_6$, F.W. 245.19, Powder, m.p. 160-161°, Merck **14**,904, EINECS 200-199-6, RTECS XY8575000, MDL MFCD00006472 H:H302-H312-H332-H351, P:P261-P280-P281-P302+P352-P405-P501	1g 5g

Contact us for pricing on bulk sizes

Stock #	Description	Size
36308	**Azelaic acid, 98%** *[Nonanedionic acid]* [123-99-9], $HOOC(CH_2)_7COOH$, F.W. 188.22, Crystalline, m.p. ca 102°, b.p. 286°/100mm, f.p. 215°(419°F), d. 1.225, Merck **14**,905, EINECS 204-669-1, RTECS CM1980000, BRN 1101094, MDL MFCD00004432, †	**25g** **100g** **5x100g**
J65127	**3'-Azido-3'-deoxythymidine, 98% ▲■** *[AZT, Zidovudine]* [30516-87-1], $C_{10}H_{13}N_5O_4$, F.W. 267.24, Powder, m.p. 113-115°, Merck **14**,10123, RTECS XP207200, BRN 3595791, MDL MFCD00006536 H:H351, P:P281-P201-P202-P308+P313-P405-P501 Application(s): Anti-viral agent	**1g** **5g** **25g**
J64387	**2'-Azido-2'-deoxyuridine, 98%** *[N3-dU]* [26929-65-7], $C_9H_{11}N_5O_5$, F.W. 269.21, Powder, m.p. 149-153°, EINECS 248-113-6, BRN 4204828, MDL MFCD00043045	**500mg**
J64574	**Azido-PEG(3+3)-S-S-biotin conjugate** $C_{32}H_{58}N_8O_{11}S_3$, F.W. 811.05, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **25mg**
J65147	**Azido-PEG12-biotin conjugate** *[35-[(R)-(+)-Biotinylamino]-1-azido-3,6,9,12,15,18,21,24,27,30,33-undecaoxapentatriacontane]* $C_{34}H_{64}N_8O_{13}S$, F.W. 796.96, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
J64996	**Azido-PEG3-biotin conjugate** *[11-[(R)-(+)-Biotinylamino]-1-azido-3,6,9-trioxaundecane]* $C_{18}H_{32}N_8O_5S$, F.W. 444.55, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25mg** **100mg**
J65107	**Azido-PEG3-carboxyrhodamine 110 conjugate** *[Azide-Fluor 488]* $C_{29}H_{31}N_6O_7$, F.W. 575.59, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg** **25mg**
J64906	**Azido-PEG3-carboxyrhodamine 6G conjugate** *[Azide-Fluor 525]* $C_{35}H_{43}N_6O_7$, F.W. 659.75, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
J64510	**Azido-PEG3-carboxytetramethylrhodamine 110 conjugate** *[Azide-Fluor 545]* $C_{33}H_{39}N_6O_7$, F.W. 631.70, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg** **25mg**
J65984	**Azido-PEG3-maleimide kit** *[N-(11-Azido-3,6,9-trioxaundecyl)-3-(N-maleimidyl)pro pionamide]* $C_{15}H_{23}N_5O_6$, F.W. 369.37, Solid, Note: Kit contains two components: a) 1.1 eq. of solution of azido-PEG4-amine in DMSO; b) 1.0 eq. of maleimide-NHS ester as a solid. H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
J64895	**Azido-PEG3-S-S-NHS ester** $C_{18}H_{29}N_5O_8S_2$, F.W. 507.58, Viscous liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **25mg** **100mg**
J65598	**Azido-PEG3-sulfo-biotin conjugate** $C_{21}H_{36}N_7O_9S_2$, F.W. 594.67, Amorphous solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
J65476	**Azido-PEG3-sulforhodamine 101 conjugate** *[Azide-Fluor 585]* $C_{39}H_{47}N_6O_9S_2$, F.W. 807.96, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg** **25mg**
J65529	**Azido-PEG3-sulforhodamine B conjugate** *[Azide-Fluor 568]* $C_{35}H_{47}N_6O_9S_2$, F.W. 759.91, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
J65668	**3-Azido-1-propylamine** *[1-Azido-3-aminopropane]* [88192-19-2], $C_3H_8N_4$, F.W. 100.12, Liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100mg** **1g**

Stock #	Description	Size
J64030	**15-Azido-4,7,10,13-tetraoxapentadecanoic acid** *[Azido-PEG4-acid]* $C_{11}H_{21}N_3O_6$, F.W. 291.30, Liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	25mg 100mg
J65535	**2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diam monium salt, 98% ▲** *[ABTS diammonium salt]* [30931-67-0], $C_{18}H_{24}N_6O_6S_4$, F.W. 548.68, Powder, EINECS 250-396-6, RTECS DL7002000, BRN 7329461, MDL MFCD00010404 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Chromogenic substrate for peroxidase assays	1g 5g
J64865	**1,1'-Azobis(N,N-dimethylformamide), 95%** *[Diamide, TMAD]* [10465-78-8], $(CH_3)_2NCON=NCON(CH_3)_2$, F.W. 172.19, Powder, m.p. 112°, EINECS 233-951-7, RTECS LQ1041000, BRN 1910409, MDL MFCD00008318	1g 5g
	Azo Black, see Chlorazol Black E, A13259, p. 154	
A12507	**Azocarmine G** *[C.I. 50085]* [25641-18-3], $C_{28}H_{18}N_3NaO_6S_2$, F.W. 579.58, EINECS 247-157-3, MDL MFCD00042002, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	5g 25g
J62887	**Aztreonam** [78110-38-0], $C_{13}H_{17}N_5O_8S_2$, F.W. 435.43, Powder, m.p. 227° dec., Merck **14**,925, EINECS 278-839-9, RTECS UA2451400, MDL MFCD00072145 Application(s): Synthetic monocyclic β-lactam antibiotic. Inhibits cell wall synthesis in gram-negative bacteria	1g 5g
A17508	**Azure I** *[C.I. 52010, Methylene Azure]* [531-55-5], $C_{15}H_{16}ClN_3S$, F.W. 305.83, m.p. ca 205° dec., Merck **14**,6058, EINECS 208-511-2, RTECS SO5550000, BRN 3922630, MDL MFCD00011935 H:H341, P:P281-P201-P202-P308+P313-P405-P501a  Application(s): For differentiating cellular RNA and DNA in plant tissues	5g 25g 100g
A11777	**Azure II** [37247-10-2], MDL MFCD00080716, Note: Mixture containing equal amounts of Azure I and Methylene Blue H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	10g 50g
J61346	**Azure A** *[C.I. 52005]* [531-53-3], $C_{14}H_{14}ClN_3S$, F.W. 291.80, Powder, m.p. 290° dec., Merck **14**,927, EINECS 208-510-7, RTECS SP5660000, BRN 3922287, MDL MFCD00012112, † Application(s): For staining cell granules and tissues	25g 100g
J64515	**Azure C** *[C.I. 52002, 3-Amino-7-methylaminophenothiazin-5-ium chloride]* [531-57-7], $C_{13}H_{12}ClN_3S$, F.W. 277.78, Powder, EINECS 208-512-8, BRN 4060661, MDL MFCD00067677	1g 5g
	BAC, see N,N'-Bis(acryloyl)cystamine, 44132, p. 126 **Baccidal**, see Norfloxacin, J62652, p. 304	
J62432	**Bacitracin** [1405-87-4], $C_{66}H_{103}N_{17}O_{16}S$, F.W. 1421.60, Powder, m.p. 222°, Merck **14**,934, EINECS 215-786-2, RTECS CP0175000, MDL MFCD00062640, † H:H303, P:P312 Application(s): Inhibits cell wall synthesis in Gram-positive bacteria	5g 25g
J62768	**(±)-Baclofen, 99+%** *[(R,S)-Baclofen]* [1134-47-0], $C_{10}H_{12}ClNO_2$, F.W. 213.66, Powder, Merck **14**,937, UN2811, EINECS 214-486-9, RTECS MW5084200, MDL MFCD00055143 H:H301-H334-H360-H315-H319-H317-H335, P:P285-P301+P310-P305+P351+P338-P302+P352-P405-P501a Application(s): Selective GABA-b receptor agonist	1g
	(R,S)-Baclofen, see (+/-)-Baclofen, 99+%, J62768, p. 116 **Bactidan**, see Enoxacin, J61912, p. 207	
J61835	**Bafilomycin A1** [88899-55-2], $C_{35}H_{58}O_9$, F.W. 622.83, Oil, RTECS RN9781000, BRN 4730700, MDL MFCD06795130 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Specific, potent inhibitor of vacuolar ATPases	1mg 5mg 10mg
	BAL, see 2,3-Dimercaptopropanol, L03953, p. 194 **Balsam Canada**, see Canada balsam, A16289, p. 145	

Stock #	Description	Size
J60424	**Bambuterol hydrochloride, 98+%** *[KWD-2183]* [81732-46-9], $C_{18}H_{29}N_3O_5 \cdot HCl$, F.W. 403.91, Powder, Merck **14**,953, MDL MFCD03427293 Application(s): β-adrenoceptor agonist. Inhibits plasma cholinesterase during metabolism	**500mg** **1g**
J65901	**Bandrowski's Base** [20048-27-5], $C_{18}H_{18}N_6$, F.W. 318.40, Powder, RTECS GU4805000, BRN 2395527, MDL MFCD00210781 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g**
A13190	**BAPTA, 97%** *[1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid]* [85233-19-8], $C_{22}H_{24}N_2O_{10}$, F.W. 476.44, m.p. ca 174° dec., Merck **14**,957, RTECS MC0423000, MDL MFCD00036255 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Acts as a calcium chelator	**1g** **5g** **25g**
	Barbaloin, see Aloin, J62153, p. 90	
12310	**Barium chloride dihydrate, ACS** [10326-27-9], $BaCl_2 \cdot 2H_2O$, F.W. 244.28 (208.25anhy), Crystalline, m.p. 113° -$2H_2O$, d. 3.097, Merck **14**,971, Solubility: Very soluble in water. Soluble in methanol. Insoluble in ethanol, acetone, ethyl acetate, UN1564, EINECS 233-788-1, RTECS CQ8751000, MDL MFCD00149154, † Maximum level of impurities: Insoluble matter 0.005%, Oxidizing substances (as NO_3) 0.005%, K 0.0025%, Na 0.005%, Ca 0.05%, Heavy Metals (as Pb) 5ppm, Fe 2ppm, Sr 0.1%, Loss on drying at 150° 14.0-16.0%, pH of a 5% solution 5.2-8.2 at 25% H:H301-H332, P:P261-P301+P310-P321-P304+P340-P405-P501a	**500g** **2kg**
14499	**Barium hydroxide octahydrate, ACS, 98+%** △ ■ [12230-71-6], $Ba(OH)_2 \cdot 8H_2O$, F.W. 315.48 (171.36anhy), Crystalline, m.p. 78°, d. 2.18, Merck **14**,977, Fieser **12**,38 **18**,28 **19**,18, Solubility: Soluble in water, methanol. Slightly soluble in ethanol. Practically insoluble in acetone, UN3262, EINECS 241-234-5, RTECS CQ9200000, MDL MFCD00149152, † Maximum level of impurities: Carbonate (as $BaCO_3$) 2.0%, Insoluble in dilute hydrochloric acid 0.01%, Cl 0.001%, S P.T. (limit about 0.001%), K 0.01%, Na 0.01%, Ca 0.05%, Heavy Metals (as Pb) 5ppm, Fe 0.001%, Sr 0.8% H:H314-H302-H332, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Used in manufacture of alkali, glass; in synthetic rubber vulcanization, alkalizing agent in water softening, boiler scale remedy, softening water	**250g** **1kg**
12194	**Barium nitrate, ACS, 99+%** ■ [10022-31-8], $Ba(NO_3)_2$, F.W. 261.35, Crystalline, m.p. 592° dec., d. 3.24, Merck **14**,983, Solubility: Freely soluble in water. Slightly soluble in alcohol and acetone, UN1446, EINECS 233-020-5, MDL MFCD00003442, † Maximum level of impurities: Insoluble matter 0.01%, pH as a 5% solution 5.0-8.0 at 25°, Cl 5ppm, K 0.005%, Na 0.005%, Ca 0.05%, Heavy Metals (as Pb) 5ppm, Fe 2ppm, Sr 0.1% H:H302-H332, P:P261-P264-P304+P340-P301+P312-P312-P501a	**50g** **500g** **2kg**
13989	**Barium sulfate, 97%** [7727-43-7], $BaSO_4$, F.W. 233.40, 1-4 Micron Powder, m.p. 1580° dec., d. 4.5, Merck **14**,994, Solubility: Insoluble in water, dilute acids, alcohol. Soluble in hot, concentrated H_2SO_4, EINECS 231-784-4, MDL MFCD00003455, †	**100g** **1kg** **5kg**
	Basic Blue 9, see Methylene Blue **Basic Blue 12**, see Nile Blue A, A17174, p. 302	
A12952	**Basic Fuchsin** *[C.I. 42510, Fuchsin basic]* [632-99-5], $C_{20}H_{20}ClN_3$, F.W. 337.86, m.p. 268-270° dec., Merck **14**,5652, Solubility: Soluble in water, EINECS 211-189-6, RTECS CX9850000, BRN 4166684, MDL MFCD00012569, † H:H351-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): Biological stain for distinguishing coli and aerogene bacteria	**5g** **25g** **100g**
	Basic Green 1, see Brilliant Green, A12801, p. 135 **Basic Red 1**, see Rhodamine 6G, J62315, p. 337 **Basic Red 5**, see Neutral Red, ACS, J62643, p. 300 **Basic Red 5**, see Neutral Red, J63054, p. 300 **Basic Red 5**, see Neutral Red, 1% aq. solution, Ready-to-use, J61379, p. 300 **Basic Violet 3**, see Crystal Violet, B21932, p. 170 **Basic Violet 4**, see Ethyl Violet, J63951, p. 217 **Basic Violet 10**, see Rhodamine B, A13572, p. 337 **Basic Violet 14**, see Basic Fuchsin, A12952, p. 117 **Basic Yellow 1**, see Thioflavine T, tech. 75%, J61043, p. 367	
B22841	**Bathocuproin, 98%** *[2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline]* [4733-39-5], $C_{26}H_{20}N_2$, F.W. 360.46, m.p. 279-285°, EINECS 225-240-5, BRN 306714, MDL MFCD00004972, † Reagent for the determination of copper: *Anal. Chem.*, **25**, 510 (1953).	**1g** **5g**
	Bathocuproin sulfonate, see Bathocuproin sulfonate disodium salt hydrate, B22550, p. 118	

Stock #	Description	Size
B22550	**Bathocuproin sulfonate disodium salt hydrate, 97%** *[Bathocuproin sulfonate, 2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline disulfonic acid disodium salt]* [52698-84-7], $C_{26}H_{18}N_2Na_2O_6S_2 \cdot xH_2O$, F.W. 564.55(anhy), m.p. >300°, EINECS 258-111-7, BRN 9033637, MDL MFCD03012947, † Reagent for copper: *Clin. Chim. Acta*, **3**, 328 (1958).  Application(s): Used as a stain for proteins in polyacrylamide gels; for determination of iron and copper; and uric acid by automated procedures	**250mg** **1g** **5g**
A14258	**Bathophenanthroline, 98+%** *[4,7-Diphenyl-1,10-phenanthroline]* [1662-01-7], $C_{24}H_{16}N_2$, F.W. 332.41, m.p. 218-222°, EINECS 216-767-1, RTECS SF8427000, BRN 261048, MDL MFCD00004976, † Reagent for iron.  Application(s): For colorimetric iron determinations	**1g** **5g** **25g**
J64257	**Bax Channel Blocker ■** *[1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(piperazin-1-yl)propan-2-ol bis(trifluoracetate) salt]* [335165-69-0], $C_{19}H_{21}Br_2N_3O.2CF_3CO_2H$, F.W. 695.24, Powder H:H341, P:P281-P201-P202-P308+P313-P405-P501	**10mg**
	BAY 43-9006, see Sorafenib, 99+%, J62984, p. 349 **Bay-g 5421**, see Acarbose, 95%, J61737, p. 69	
J61480	**(±)-Bay K 8644** [71145-03-4], $C_{16}H_{15}F_3N_2O_4$, F.W. 356.30, Powder, MDL MFCD00036697 Application(s): An active L-type, voltage-gated calcium channel agonist	**1mg** **5mg**
	BCA, see Bicinchoninic acid disodium salt, 44247, p. 124	
J63283	**BCA protein assay kit** Liquid, Note: Solution A: Bicinchonic acid and tartrate in an alkaline carbonate buffer Solution B: 4% copper sulfate Application(s): Contains two separate solutions for 500 estimations of proteins	**1kit**
J64464	**Bcl-2 Inhibitor ▲** *[2,9-Dimethoxy-11,12-dihydrodibenzo[c,g]1,2]-diazocine 5,6-dioxide, 5,5'-Dimethoxy-2,2'-dinitrosobenzyl]* [383860-03-5], $C_{16}H_{16}N_2O_4$, F.W. 300.30, Solid	**5mg**
J65675	**Bcl-2 Inhibitor II, YC137 ▲** *[2-Methoxycarbonylamino-4-methylsulfanyl-butyric acid, YC137]* [810659-53-1], $C_{24}H_{21}N_3O_6S_2$, F.W. 511.57, Solid	**5mg**
A12850	**Behenic acid, tech. 85%** *[Docosanoic acid]* [112-85-6], $CH_3(CH_2)_{20}CO_2H$, F.W. 340.60, m.p. 74-78°, b.p. 306°/60mm, Merck **14**,1023, EINECS 204-010-8, BRN 1792887, MDL MFCD00002807, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g** **1kg** **5kg**
	Bemesetron, see 3-Tropanyl-3,5-dichlorobenzoate, 99+%, J62583, p. 383	
J61093	**Benazepril hydrochloride, 98%** [86541-74-4], $C_{24}H_{28}N_2O_5 \cdot HCl$, F.W. 460.95, Crystalline powder, m.p. 148-149°, Merck **14**,1031, RTECS CX7065000, MDL MFCD00895734 Application(s): An angiotensin converting enzyme (ACE) inhibitor that reduces blood pressure	**25mg** **100mg**
J64581	**Benserazide hydrochloride ▲** *[DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide hydrochloride]* [14919-77-8], $C_{10}H_{15}N_3O_5.HCl$, F.W. 293.70, Powder, m.p. 146-148°, Merck **14**,1050, EINECS 238-991-9, RTECS VT9632300, MDL MFCD00078571 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g**
A15795	**Bentonite, sodium form** *[Sodium bentonite]* [1302-78-9], Merck **14**,1055, EINECS 215-108-5, MDL MFCD00130611, Note: Forms a colloidal suspension in water, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Suspending agent, gel binder, filler in ceramics, catalyst support	**500g** **2.5kg**
B20760	**Benzalkonium chloride, 50% w/w aq. soln.** [63449-41-2], f.p. None, d. 0.99, Merck **14**,1059, UN1760, EINECS 264-151-6, RTECS BO3151000, BRN 4062599, MDL MFCD00145757, †  H:H301-H314-H400-H312, P:P260-P301+P310-P303+P361+P353-P305+P351+P338-P405-P501a Application(s): Cationic surface active agent	**500ml** **2.5L**

Contact us for pricing on bulk sizes

Stock #	Description	Size
41339	**Benzalkonium chloride** *[Alkylbenzyldimethylammonium chloride]* [63449-41-2], $C_6H_5CH_2N(CH_3)_2RCl$, Semi-solid/solid, R=C_8H_{17} to $C_{18}H_{37}$, Merck **14**,1059, Solubility: Soluble in water, UN2923, EINECS 264-151-6, MDL MFCD00145757, † H:H314-H400-H302-H312, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Cationic surface active agent	**25g** **100g** **500g**
A16002	**Benzamidine hydrochloride hydrate, 98%, water ca 10-14%** ■ [206752-36-5], $C_7H_8N_2 \cdot HCl \cdot xH_2O$, F.W. 156.62(anhy), m.p. 82-85°, Fieser **6**,27, EINECS 216-795-4, RTECS CV6260000, BRN 3594959, MDL MFCD00066285, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A proteolytic inhibitor and apoptosis reagent	**5g** **25g** **100g**
J62823	**Benzamidine hydrochloride, 99%** [1670-14-0], $C_7H_8N_2 \cdot HCl$, F.W. 156.62, Powder or beads, m.p. 80-85°, EINECS 216-795-4, RTECS CV6260000, BRN 3594959, MDL MFCD00013025, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Reversible inhibitor of trypsin, trypsin-like proteins and serine proteases	**5g** **10g**
	4-Benzamido-2,5-diethoxybenzene diazonium chloride hemi zinc salt, see Fast Blue BB salt, L09704, p. 218 **Benzene-1,2-dicarboxylic acid di-n-butylester**, see Di-n-butyl phthalate, A13257, p. 185 **1,2-Benzenediol**, see Catechol, A10164, p. 150 **1,3-Benzenediol**, see Resorcinol, 36248, p. 336 **1,4-Benzenediol**, see Hydroquinone, A11411, p. 248 **Benzene hexabromide**, see 1,2,3,4,5,6-Hexabromocyclohexane, J60853, p. 244	
A16148	**Benzenesulfonic acid, 94%** ■ [98-11-3], $C_6H_6O_3S$, F.W. 158.18, m.p. ca 45-50°, f.p. >110°(230°F), d. 1.32, Merck **14**,1070, UN2585, EINECS 202-638-7, RTECS DB4200000, BRN 742513, MDL MFCD00011689, † H:H314-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Acid catalyst for direct esterification of amino acids and peptides	**100g** **500g** **2.5kg**
A17491	**1,2,3-Benzenetricarboxylic acid dihydrate, 99%** *[Hemimellitic acid dihydrate]* [36362-97-7], $C_9H_6O_6 \cdot 2H_2O$, F.W. 246.19 (210.14anhy), m.p. ca 191° dec., EINECS 209-317-0, BRN 2214816, MDL MFCD00149097 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **10g** **25g**
	1,3,5-Benzenetriol, anhydrous, see Phloroglucinol, B25502, p. 318	
B24303	**Benzhydrylamine, 97%** △ *[Aminodiphenylmethane]* [91-00-9], $(C_6H_5)_2CHNH_2$, F.W. 183.25, m.p. 11-13°, b.p. 294-296°, f.p. >110°(230°F), d. 1.064, n_D^{20} 1.5950, Merck **14**,1076, Solubility: Slightly soluble in water, UN2735, EINECS 202-032-2, RTECS DA4407300, BRN 776434, MDL MFCD00008059 H:H314-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**5g** **25g** **100g**
A12763	**Benzimidazole, 99%** [51-17-2], $C_7H_6N_2$, F.W. 118.14, m.p. 170-174°, b.p. 360°, Merck **14**,1081, EINECS 200-081-4, RTECS DD5425000, BRN 109682, MDL MFCD00005585, † H:H303, P:P312	**50g** **250g** **1kg**
	1,2-Benzisothiazol-3(2H)-one 1,1-dioxide sodium salt hydrate, see o-Benzoic sulfimide sodium salt hydrate, A15530, p. 119 **Benzocaine**, see Ethyl 4-aminobenzoate, A12754, p. 214 **5,6-Benzoflavone**, see β-Naphthoflavone, A18543, p. 297 **7,8-Benzoflavone**, see α-Naphthoflavone, A18542, p. 297	
36230	**Benzoic acid, ACS, 99.5% min** [65-85-0], $C_7H_6O_2$, F.W. 122.12, Crystalline, m.p. 121-124°, b.p. 249°, f.p. 121°(250°F), d. 1.32, Merck **14**,1091, Fieser **1**,49, EINECS 200-618-2, RTECS DG0875000, BRN 636131, MDL MFCD00002398, † Maximum level of impurities: Freezing point 122°-123°, Residue after ignition 0.005%, Insoluble in methanol 0.005%, Chlorine compounds (as Cl) 0.005%, Sulfur compounds (as S) 0.002%, Heavy Metals (as Pb) 5ppm, Substances reducing permanganate P.T. H:H302-H319-H335, P:P280f-P305+P351+P338	**25g** **100g** **500g**
	Benzoic acid benzyl ester, see Benzyl benzoate, L03258, p. 122	
B23938	**o-Benzoic sulfimide, 98+%** *[Saccharin, 1,2-Benzothiazol-3(2H)-one 1,1-dioxide]* [81-07-2], $C_7H_5NO_3S$, F.W. 183.18, m.p. 227-230°, d. 0.828, Merck **14**,8311, EINECS 201-321-0, RTECS DE4200000, BRN 6888, MDL MFCD00005866, † Application(s): An artificial sweetener which is an inhibitor for phosphotransferase activity	**100g** **500g** **2.5kg**
A15530	**o-Benzoic sulfimide sodium salt hydrate, 99%** *[1,2-Benzisothiazol-3(2H)-one 1,1-dioxide sodium salt hydrate, Saccharin sodium hydrate]* [82385-42-0], $C_7H_4NNaO_3S \cdot xH_2O$, F.W. 241.21 (205.18anhy), m.p. >300°, Merck **14**,8312, EINECS 204-886-1, RTECS DE4550000, BRN 3599229, MDL MFCD00151213, † Effective catalyst for the silylation of a wide range of functional groups by **Hexamethyldisilazane**, **A15139**: *J. Org. Chem.*, **47**, 3966 (1982).	**250g** **1kg** **5kg**

Stock #	Description	Size
A10188	**Benzoin, 99%** *[2-Hydroxy-2-phenylacetophenone]* [119-53-9], $C_{14}H_{12}O_2$, F.W. 212.25, m.p. 131-136°, b.p. 334-344°, f.p. 181°(357°F), d. 1.310, Merck **14**,1093, Fieser **6**,34, EINECS 204-331-3, RTECS DI1590000, BRN 391839, MDL MFCD00004496, † Exclusive C-alkylation occurs with an alkyl bromide and NaOH in DMSO: *Liebigs Ann. Chem*., **735**, 56 (1970). Borohydride reduction and periodate cleavage of the product lead to a useful synthesis of aryl ketones, with benzoin functioning as a benzoyl anion equivalent: *Synthesis*, 268 (1975):  This has been extended to include alkylation with other electrophiles including primary and secondary alkyl iodides and Michael acceptors, and the route shortened by direct cleavage of the alkylated benzoin with hydrogen peroxide: *Synthesis*, 36 (1980).	**250g** **1kg** **5kg**
A10739	**Benzophenone, 99%** *[Diphenyl ketone]* [119-61-9], $C_{13}H_{10}O$, F.W. 182.22, m.p. 47-50°, b.p. 305°, f.p. 138°(280°F), d. 1.111, Merck **14**,1098, UN3077, EINECS 204-337-6, RTECS DI9950000, BRN 1238185, MDL MFCD00003076, † H:H400-H410, P:P273-P391-P501a For a review of the use of benzophenone as a triplet-sensitizer in photochemistry, see: *Synthesis*, 249 (1981).	**250g** **1kg** **5kg**
J64901	**Benzopurpurin 4B** *[C.I. 23500, Direct Red 2]* [992-59-6], $C_{34}H_{26}N_6Na_2O_6S_2$, F.W. 724.73, Powder, Merck **14**,1011, EINECS 213-594-3, RTECS QK1765000, MDL MFCD00012410, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25g** **100g**
	1-Benzopyran-2-one, see Coumarin, A15336, p. 168 **Benzothiazole-2-thiol**, see 2-Mercaptobenzothiazole, A14086, p. 280 **1,2-Benzothiazol-3(2H)-one 1,1-dioxide**, see o-Benzoic sulfimide, B23938, p. 119 **1-Benzotriazolamine**, see 1-Aminobenzotriazole, 98%, J63610, p. 92	
A15423	**1H-Benzotriazole, 99%** [95-14-7], $C_6H_5N_3$, F.W. 119.13, m.p. 96-99°, b.p. 204°/15mm, f.p. 212°(413°F), d. 1.360, Merck **14**,1108, Fieser **13**,262 **19**,20 **20**,21 **21**,24, EINECS 202-394-1, RTECS DM1225000, BRN 112133, MDL MFCD00005699, † H:H302-H332-H319-H412, P:P280h-P273-P305+P351+P338 The combination with thionyl chloride (1:1), dissolved in DCM, is a useful and convenient reagent for conversion of alcohols and carboxylic acids to the alkyl or acyl chlorides: *Synlett*, 1763 (1999). For reviews of Katritzky's extensive work on benzotriazoles as versatile synthetic intermediates, see: *Tetrahedron*, **47**, 2683 (1991); *Chem. Soc. Rev*., 363 (1994) *Synthesis*, 445 (1994); 1315 (1995). For use in the synthesis of indolo[2,3-b]quinolines, see **2-Chloroquinoline**, **B23443**.	**50g** **250g** **1kg**
B23597	**O-(1H-Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 98%** *[HBTU]* [94790-37-1], $C_{11}H_{16}F_6N_5OP$, F.W. 379.25, m.p. ca 200° dec., EINECS 423-020-5, BRN 7328329, MDL MFCD00075445 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Peptide coupling reagent giving high yields with minimal racemization: *Synthesis*, 572 (1984).	**5g** **25g** **100g**
L13470	**O-(1H-Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, 99%** *[TBTU]* [125700-67-6], $C_{11}H_{16}BF_4N_5O$, F.W. 321.08, m.p. 195-198° dec., EINECS 423-040-4, BRN 7066325, MDL MFCD00077413 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Peptide coupling reagent, suited to solid-phase peptide synthesis: *Tetrahedron Lett* ., **30**, 1927 (1989). Of several coupling methods tried in the synthesis of the marine sponge cycloheptapeptide stylopeptide 1, the combination of TBTU and N-ethyldiisopropylamine in DCM gave the best results: *J. Org. Chem*., **61**, 2322 (1996). Reagent for cleavage of THP, silyl, and 4,4-dimethoxytrityl (Dmt) ethers. Selective cleavage of THP ethers in the presence of TBDMS can also be achieved: *Synlett*, 709 (1999).	**1g** **5g** **25g**
J61954	**Benzotropine mesylate** *[Benztropine methanesulfonate, Benztropine hydrobromidum]* [132-17-2], $C_{21}H_{25}NO.CH_3SO_3H$, F.W. 403.54, Solid, UN2811, EINECS 205-048-8, RTECS YM3150000, MDL MFCD00074784 H:H301-H311-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Muscarinic receptor antagonist	**100mg** **1g** **5g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A14537	**Benzoylacetone, 98+%** *[1-Phenyl-1,3-butanedione]* [93-91-4], $C_{10}H_{10}O_2$, F.W. 162.19, m.p. 55-60°, b.p. 260-262°, d. 1.090, EINECS 202-286-4, RTECS EK3540200, BRN 742413, MDL MFCD00008786, †  Dimetallated derivatives react with electrophiles preferentially at the terminal position; e.g. arylation by 2-chloroquinoline: *J. Org. Chem.*, **37**, 3199 (1972); *J. Am. Chem. Soc.*, **97**, 374 (1975). Reaction with aromatic esters gives 1,3-diaryl-1,3,5-pentanetriones, which can be cyclized with acid to γ-pyrones: *Org. Synth. Coll.*, **5**, 718, 721 (1973): 	**50g** **250g** **1kg**
J64915	**N-α-Benzoyl-L-arginine p-nitroanilide hydrochloride** *[Bz-L-Arg-pNA.HCl]* [21653-40-7], $C_{19}H_{22}N_6O_4$.HCl, F.W. 434.90, Powder, m.p. 223°, EINECS 244-505-6, BRN 4081878, MDL MFCD00063682	**100mg** **250mg** **500mg**
L08292	**N-Benzoylaminopurine, 99%** *[N-Benzoyladenine]* [4005-49-6], $C_{12}H_9N_5O$, F.W. 239.23, m.p. 241-244°, BRN 20585, MDL MFCD00037927 	**1g** **5g** **25g**
A15179	**Benzoylcholine chloride, 99%** ■ *[(2-Benzoyloxyethyl)trimethylammonium chloride]* [2964-09-2], $C_6H_5CO_2CH_2CH_2N(CH_3)_3Cl$, F.W. 243.73, m.p. 205-208°, EINECS 221-000-9, RTECS GA0830000, BRN 3919727, MDL MFCD00011786	**10g** **50g** **250g**
J65790	**N_4-Benzoylcytidine, 99%** [13089-48-0], $C_{16}H_{17}N_3O_6$, F.W. 347.32, Crystalline powder, m.p. 230-234° dec., MDL MFCD00010572	**5g** **10g** **25g**
J64175	**N_6-Benzoyl-2'-deoxyadenosine, 98%** $C_{17}H_{17}N_5O_4$, F.W. 355.35, Powder	**5g**
J65402	**N_6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-fluoro-2'-deoxyadenosine, 98%** $C_{38}H_{34}FN_5O_6$, F.W. 675.70, Powder	**1g**
J64064	**N_6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-fluoro-2'-deoxyadenosine-3'-CE-phosphoramidite, 98%** $C_{47}H_{51}FN_7O_7P$, F.W. 875.92, Powder ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J64614	**N_4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-fluoro-2'-deoxycytidine, 98%** $C_{37}H_{34}FN_3O_7$, F.W. 651.68, Powder	**100mg** **1g**
J64259	**N_4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-fluoro-2'-deoxycytidine-3'-CE-phosphoramidite, 98%** $C_{46}H_{51}FN_5O_8P$, F.W. 851.90, Powder ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J65098	**N_6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methyladenosine, 98%** $C_{39}H_{37}N_5O_7$, F.W. 687.74, Powder	**1g**
J65669	**N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methyladenosine-3'-CE-phosphoramidite, 98%** $C_{48}H_{54}N_7O_8P$, F.W. 887.96, Powder ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J65169	**N_4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methylcytidine, 98%** $C_{38}H_{37}N_3O_8$, F.W. 663.71, Powder	**1g**
J65701	**N_4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methylcytidine-3'-CE-phosphoramidite, 98%** $C_{17}H_{19}N_3O_6$, F.W. 361.35, Powder ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J64345	**N_6-Benzoyl-2'-fluoro-2'-deoxyadenosine, 98%** [305808-19-9], $C_{17}H_{16}FN_5O_4$, F.W. 373.34, Powder, MDL MFCD00149575	**1g**
J65736	**N_4-Benzoyl-2'-fluoro-2'-deoxycytidine, 98%** $C_{16}H_{16}FN_3O_5$, F.W. 349.31, Powder	**1g**
	N-Benzoyladenine, see N-Benzoylaminopurine, L08292, p. 121 **N-Benzoylglycine**, see Hippuric acid, A12690, p. 245	

Stock #	Description	Size
J65492	**N_2-Benzoylguanosine** [3676-72-0], $C_{17}H_{17}N_5O_6$, F.W. 387.35, Powder, m.p. 250-252°, MDL MFCD00057045	500mg 1g 2g
J65475	**N_6-Benzoyl-2'-O-methyladenosine, 98%** $C_{18}H_{19}N_5O_5$, F.W. 385.37, Powder	1g
J64474	**N_4-Benzoyl-2'-O-methylcytidine, 98%** $C_{17}H_{19}N_3O_6$, F.W. 361.35, Powder	1g
	(2-[3-Benzoylphenyl]propionic acid), see Ketoprofen, J62702, p. 263 **4'-N-Benzoylstaurosporine**, see Midostaurin, J62917, p. 291	
J64910	**N-Benzyl-p-toluenesulphonamide ▲** *[BTS, 4-Methyl-N-(phenylmethyl)benzenesulfonamide]* [1576-37-0], $C_{14}H_{15}NO_2S$, F.W. 261.34, Crystalline powder, m.p. 115°, RTECS XT5490000 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	5mg 10mg
	Benztropine hydrobromidum, see Benzotropine mesylate, J61954, p. 120 **Benztropine methanesulfonate**, see Benzotropine mesylate, J61954, p. 120	
J61180	**Benzydamine hydrochloride** [132-69-4], $C_{19}H_{23}N_3O{\cdot}HCl$, F.W. 345.87, Crystalline powder, m.p. 156-161°, Merck **14**,1122, EINECS 205-076-0, RTECS NK7875000, MDL MFCD00078957 H:H302-H312-H332-H319, P:P261-P280-P305+P315+P338-P302+P352-P304+P340-P501 Application(s): Nonsteroidal analgesic and anti-inflammatory compound. A prostaglandin synthase inhibitor	5g 25g
A14678	**6-Benzyladenine, 99%** *[6-Benzylaminopurine]* [1214-39-7], $C_{12}H_{11}N_5$, F.W. 225.26, m.p. 229-233°, EINECS 214-927-5, RTECS AU6252200, BRN 19406, MDL MFCD00005572, † H:H302, P:P280f-P330 Application(s): Inhibitor of respiratory kinase in plants. Increases post-harvest life of green vegetables	1g 5g 25g
	6-Benzylaminopurine, see 6-Benzyladenine, A14678, p. 122 **2-(N-Benzylanilinomethyl)-2-imidazoline hydrochloride**, see Antazoline hydrochloride, 98%, J62511, p. 104 **β-Benzyl L-aspartate**, see L-Aspartic acid 4-benzyl ester, L08956, p. 111	
L03258	**Benzyl benzoate, 99+%** *[Benzoic acid benzyl ester]* [120-51-4], $C_6H_5CO_2CH_2C_6H_5$, F.W. 212.25, m.p. 18-20°, b.p. 323-324°, f.p. 147°(296°F), d. 1.112, n_D^{20} 1.5680, Merck **14**,1127, UN3082, EINECS 204-402-9, RTECS DG4200000, BRN 2049280, MDL MFCD00003075, † H:H302-H411, P:P273-P264-P270-P301+P312-P330-P501a	250g 1kg 2.5kg
	N-Benzyl-2-(3,4-dihydroxybenzylidene)cyanoacetamide, see Tyrphostin B42, 99+%, J61715, p. 387	
J63465	**Benzyldimethyl-n-tetradecylammonium chloride hydrate, 98%** *[n-Tetradecylbenzyldimethylammonium chloride hydrate, Myristyltrimethylammonium chloride hydrate]* [139-08-2], $C_{23}H_{42}ClN{\cdot}xH_2O$, F.W. 368.05(anhy), White powder, Merck **14**,1059, UN3261, EINECS 205-352-0, RTECS BO7150000, BRN 4062599, MDL MFCD00011771, † H:H314-H400-H302-H312, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Phase transfer catalyst	25g
L19497	**(S)-(-)-1-Benzyl-3-hydroxypyrrolidine, 99%, ee 99%** *[(S)-(-)-1-Benzyl-3-pyrrolidinol]* [101385-90-4], $C_{11}H_{15}NO$, F.W. 177.25, b.p. 116°/0.9mm, f.p. 148°(298°F), d. 1.070, n_D^{20} 1.5480, $[\alpha]_D^{20}$ -3.7° (c=5 in methanol), EINECS 212-273-5, BRN 4982831, MDL MFCD00075485 H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 Product of Toray Industries, Inc. Application(s): For synthesis of optically active products	1g 5g
	2-(Benzylidene)acetophenone, see trans-Chalcone, A14734, p. 152	
B21764	**2-Benzyl-2-imidazoline hydrochloride, 99%** *[Tolazoline hydrochloride]* [59-97-2], $C_{10}H_{12}N_2{\cdot}HCl$, F.W. 196.68, m.p. 174-176°, Merck **14**,9506, EINECS 200-447-3, MDL MFCD00012693, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An α adrenergic blocking agent	25g 100g
A16856	**4-Benzyloxyaniline hydrochloride, 98%** [51388-20-6], $C_{13}H_{13}NO{\cdot}HCl$, F.W. 235.72, m.p. ca 225° dec., EINECS 257-170-6, RTECS BW7615000, BRN 3633307, MDL MFCD00012995	25g 100g
	4-Benzyloxybenzyl alcohol, polymer supported, see Wang resin, L17028, p. 393	
B22372	**N-Benzyloxycarbonyl-D-alaninol, 98%** *[(2R)-N-Benzyloxycarbonylamino-1-propanol, N-Cbz-D-Alaninol]* [61425-27-2], $C_{11}H_{15}NO_3$, F.W. 209.25, m.p. 82-84°, MDL MFCD00672531	1g 5g 25g

Contact us for pricing on bulk sizes

Stock #	Description	Size
H27066	**N-Benzyloxycarbonyl-L-alaninol** *[(S)-(2-Hydroxy-1-methylethyl)carbamic acid benzyl ester, Z-Ala-ol]* [66674-16-6], $C_{11}H_{15}NO_3$, F.W. 209.25, MDL MFCD00672530 	1g 5g
	(2R)-N-Benzyloxycarbonylamino-1-propanol, see N-Benzyloxycarbonyl-D-alaninol, B22372, p. 122 **N-Benzyloxycarbonyl-L-leucyl-norleucinal**, see Calpeptin, 98+%, J60481, p. 144 **(2-Benzoyloxyethyl)trimethylammonium chloride**, see Benzoylcholine chloride, A15179, p. 121	
J65150	**5-Benzyloxygramine, 99%** *[5-Benzyloxy-3-(dimethylaminomethyl)indole]* [1453-97-0], $C_{18}H_{20}N_2O$, F.W. 280.37, Powder, m.p. 139°, EINECS 215-927-8, MDL MFCD00005631 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g
	Benzylpenicillin potassium salt, see Penicillin G potassium salt, J63901, p. 313 **Benzylpenicillin sodium salt**, see Penicillin G sodium salt, J63032, p. 313	
A13850	**Benzylphosphonic acid, 97%** *[Phenylmethanephosphonic acid, α-Toluenephosphonic acid]* [6881-57-8], $C_6H_5CH_2PO_3H_2$, F.W. 172.11, m.p. 166-172°, UN3261, BRN 2519318, MDL MFCD00039519, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Structural mimic of phosphotyrosine	1g 5g 25g
J61031	**(R)-1-Benzyl-3-pyrrolidinol** [101930-07-8], $C_{11}H_{15}NO$, F.W. 177.24, Liquid, b.p. 116°/0.9mm, f.p. 113°(235°F), d. 1.07, n_D^{20} 1.548, MDL MFCD00075484 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	Call
41717	**Benzyltrimethylammonium hydroxide, 20% w/w aq. soln.** [100-85-6], $C_6H_5CH_2N(CH_3)_3OH$, F.W. 167.25, Liquid, UN3267, EINECS 202-895-5, MDL MFCD00008281, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	50ml 250ml 1L
A14927	**Benzyltrimethylammonium hydroxide, 40% w/w in methanol** △ *[Triton B]* [100-85-6], $C_6H_5CH_2N(CH_3)_3OH$, F.W. 167.25, b.p. 65°, f.p. 15°(59°F), d. 0.920, n_D^{20} 1.4250, Fieser **1**,1252 **5**,29 **8**,36, UN2924, EINECS 202-895-5, RTECS BO8575000, BRN 3917256, MDL MFCD00008281, † H:H224-H301-H311-H330-H370-H314, P:P301+P310-P303+P361+P353-P304+P340-P305+P351+P338-P320-P330-P361-P405-P501a Triton® is a registered trademark of Rohm and Haas Co. Useful base catalyst or reagent for many reactions. For use in the Michael addition of nitro-compounds to α,β-unsaturated esters, see: *Org. Synth. Coll.*, **4**, 652 (1963). For C-methylation of **2-Methylcyclohexane-1,3-dione**, **A11218**, see: *Org. Synth. Coll.*, **8**, 312 (1993).	100ml 500ml 2.5L
J62311	**Berberine chloride** *[C.I. 75160, Natural Yellow 18]* [633-65-8], $C_{20}H_{18}ClNO_4$, F.W. 371.82, Powder, EINECS 211-195-9, BRN 3836585, MDL MFCD00011939, † Application(s): Apoptosis inhibitor. Increases P-glycoprotein expression in hepatoma cells. Stain for heparin in mast cells	5g
L03807	**Berberine chloride hydrate, 97%, water <17%** ▲ [141433-60-5], $C_{20}H_{18}ClNO_4 \cdot xH_2O$, F.W. 371.82(anhy), m.p. ca 200° dec., Merck **14**,1154, EINECS 211-195-9, RTECS DR9866400, BRN 3836585, MDL MFCD00149998, † Application(s): Antiprotozoal and antidiarrheal agent. Apoptosis inhibitor 	5g 25g
A16092	**BES, 99%** *[N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid]* [10191-18-1], $C_6H_{15}NO_5S$, F.W. 213.25, m.p. 153-157°, Solubility: Soluble in water, EINECS 233-465-5, RTECS KI7363500, BRN 1781572, MDL MFCD00007533, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Biological buffer, pK_a 7.15 at 20øC: *Biochemistry*, **5**, 467 (1966). 	25g 100g 500g
J60058	**BES, 0.5M buffer soln., pH 6.0** [66992-27-6], Liquid	100ml 250ml
J60624	**BES, 0.5M buffer soln., pH 6.5** [66992-27-6], Liquid	100ml 250ml
J60061	**BES, 0.5M buffer soln., pH 7.0** [66992-27-6], Liquid	100ml 250ml
J63168	**BES, 0.5M buffer soln., pH 7.5** [66992-27-6], Liquid	100ml 250ml
J61955	**BES-buffered saline (2X)** [66992-27-6], Liquid, Note: Contains 10.7 g/L BES, 16 g/L NaCl, 0.27g/L sodium phosphate, pH 6.96	250ml 500ml

Stock #	Description	Size
J64052	**BES sodium salt** *[N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid sodium salt]* [66992-27-6], $C_6H_{14}NNaO_5S$, F.W. 235.23, Powder, MDL MFCD00067425	**25g** **100g**
J61106	**Bestatin** *[Ubenimex, N-[(2S,3R)-3-Amino-2-hydroxy-1-oxo-4-phenylbutanoyl]-L-leucine]* [58970-76-6], $C_{16}H_{24}N_2O_4$, F.W. 308.37, Powder, m.p. 233-236°, Merck **14**,9842, EINECS 261-529-2, RTECS OH2915000, MDL MFCD00083262 Application(s): Aminopeptidase B inhibitor. Also inhibits leucine aminopeptidase	**25mg** **50mg** **250mg**
J60384	**Bestatin hydrochloride, 99+%** [65391-42-6], $C_{16}H_{24}N_2O_4 \cdot HCl$, F.W. 344.87, Powder, m.p. 216-218°, BRN 4628066, MDL MFCD00058004 Application(s): Aminopeptidase B inhibitor. Also inhibits leucine aminopeptidase	**5mg** **25mg**
A16122	**Betaine hydrochloride, 99%** *[(Carboxymethyl)trimethylammonium chloride]* [590-46-5], $(CH_3)_3NCH_2CO_2 \cdot HCl$, F.W. 153.61, m.p. ca 240° dec., Merck **14**,1179, EINECS 209-683-1, RTECS BP3136000, BRN 3916181, MDL MFCD00011903, † H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): An organic osmolyte	**250g** **1kg** **5kg**
J65919	**Bethanechol chloride, 98%** *[Carbamyl-β-methylcholine chloride]* [590-63-6], $C_7H_{17}ClN_2O_2$, F.W. 196.68, Crystalline powder, m.p. 187-190°, EINECS 209-686-8, RTECS BR5425000, MDL MFCD00055224, †	**1g** **5g**
J63701	**Bexarotene, 99+%** *[LGD-1069, Targretin]* [153559-49-0], $C_{24}H_{28}O_2$, F.W. 348.48, Powder, m.p. 220-225°, Merck **14**,1194, Solubility: Soluble in DMSO and ethanol, RTECS DH6834830 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Synthetic retinoid analog with specific affinity for the retinoid X receptor	**100mg** **300mg**
J61412	**Bezafibrate, 98+%** [41859-67-0], $C_{19}H_{20}ClNO_4$, F.W. 361.82, Powder, m.p. 183-186°, Merck **14**,1195, EINECS 255-567-9, RTECS UE8755000, MDL MFCD00078970 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A peroxisome proliferator-activated receptor agonist and hypolipidemic agent	**500mg** **1g** **5g**
	BHA, see 2(3)-tert-Butyl-4-methoxyphenol, B23530, p. 141 **BHT**, see 2,6-Di-tert-butyl-4-methylphenol, A16863, p. 185 **BIBF 1120**, see Vargatef, 99+%, J63082, p. 391 **BIBR 277**, see Telmisartan, 99%, J61441, p. 360	
J63491	**Bicarbonate, 1M buffer soln., pH 8.0** [144-55-8], Liquid, †	**250ml** **500ml**
J60092	**Bicarbonate, 1M buffer soln., pH 8.5** [144-55-8], Liquid, †	**250ml** **500ml**
J60116	**Bicarbonate, 1M buffer soln., pH 9.0** [144-55-8], Liquid, †	**250ml** **500ml**
44247	**Bicinchoninic acid disodium salt** *[BCA, 2,2'-Biquinoline-4,4'-dicarboxylic acid disodium salt]* [979-88-4], $C_{20}H_{10}N_2O_4Na_2$, F.W. 388.29, Powder/chunks, MDL MFCD00037500, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): For determination of Cu and protein assays	**2g** **10g**
A14957	**BICINE, 99%** *[N,N-Bis(2-hydroxyethyl)glycine]* [150-25-4], $C_6H_{13}NO_4$, F.W. 163.17, m.p. ca 191° dec., Merck **14**,1201, Solubility: Soluble in water, EINECS 205-755-1, RTECS MB9700000, BRN 1769362, MDL MFCD00004295, † Biological buffer, pK_a = 8.35 at 20 ° : *Biochemistry*, **5**, 467 (1966). Application(s): Good's buffers	**50g** **250g** **1kg**
J60494	**BICINE, 0.5M buffer soln., pH 7.5** [150-25-4], Liquid, †	**100ml** **250ml**
J63924	**BICINE, 0.5M buffer soln., pH 8.0** [150-25-4], Liquid, †	**100ml** **250ml**
J61632	**BICINE, 0.5M buffer soln., pH 8.5** [150-25-4], Liquid, †	**100ml** **250ml**
J62838	**BICINE, 0.5M buffer soln., pH 9.0** [150-25-4], Liquid, †	**100ml** **250ml**

Stock #	Description	Size
J65603	**Biebrich Scarlet sodium salt** *[C.I. 26905, Acid Red 66]* [4196-99-0], $C_{22}H_{14}N_4Na_2O_7S_2$, F.W. 556.49, Powder, m.p. 181-188°, f.p. 300°(572°F), EINECS 224-084-5, BRN 3883900, MDL MFCD00003891, †	25g 100g
J63253	**Bifonazole, 99%** *[Mycosporan, 1-(α,4-Diphenylbenzyl)imidazole]* [60628-96-8], $C_{22}H_{18}N_2$, F.W. 310.39, Powder, m.p. 142°, Merck **14**,1213, EINECS 262-336-6, RTECS NI3517000, MDL MFCD00865567 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Inhibits synthesis of ergosterol in dermatophytes. Calmodulin antagonist	1g 5g 25g
J64631	**BigCHAP** ■ *[N,N-Bis(3-D-gluconamidopropyl)cholamide]* [86303-22-2], $C_{42}H_{75}N_3O_{16}$, F.W. 878.07, Powder, m.p. 136-145°, MDL MFCD00082541 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	250mg 1g 5g
A17522	**Bilirubin, 97%** ▲ [635-65-4], $C_{33}H_{36}N_4O_6$, F.W. 584.68, Merck **14**,1218, EINECS 211-239-7, RTECS DU3038000, BRN 74376, MDL MFCD00005499, †	1g 5g 25g
J65226	**Biliverdin hydrochloride** ▲ [55482-27-4], $C_{33}H_{35}ClN_4O_6$, F.W. 619.12, Powder, RTECS DU3033000, MDL MFCD08669554	100mg 250mg
A14207	**D-(+)-Biotin, 98+%** ▲ *[Vitamin H]* [58-85-5], $C_{10}H_{16}N_2O_3S$, F.W. 244.32, m.p. 224-226°, $[\alpha]_D^{20}$ +91° (c=1 in 0.1N NaOH), Merck **14**,1231, EINECS 200-399-3, RTECS XJ9088200, BRN 86838, MDL MFCD00005541, † Application(s): Essential vitamin that is important for amino acid and energy metabolism	1g 5g 10g 25g
44771	**(+)-Biotin N-hydroxysuccinimide ester, 98%** *[Biotin-NHS, N-Hydroxysuccimidobiotin]* [35013-72-0], $C_{14}H_{19}N_3O_5S$, F.W. 341.40, Powder, MDL MFCD00078531 Application(s): In coupling reactions to amino acids, peptides and proteins through primary amines	50mg 250mg 1g
	Biotin-NHS, see (+)-Biotin N-hydroxysuccinimide ester, 44771, p. 125	
J64477	**Biotin-Phe-Ala-fluoromethyl ketone** *[Biotin-FA-FMK, Biotin-Phe-Ala-FMK]* $C_{27}H_{36}FN_5O_7S$, F.W. 593.67, Powder	5mg
J65533	**Biotin-Val-Ala-Asp(OMe)-fluoromethyl ketone** *[Biotin-VAD-FMK, Biotin-VAD(OMe)-FMK]* $C_{30}H_{49}FN_6O_8S$, F.W. 672.81, Powder	1mg
J64265	**Biotinyl-Ala-Ser-Thr-DL-Asp-fluoromethyl ketone** *[Biotinyl-ASTD-FMK]* $C_{25}H_{39}FN_6O_{10}S$, F.W. 634.67, Powder	1mg
A10265	**Biphenyl, 99%** *[Diphenyl, Phenylbenzene]* [92-52-4], $C_{12}H_{10}$, F.W. 154.21, m.p. 69-72°, b.p. 254-255°, f.p. 113°(235°F), d. 0.990, Merck **14**,3314, Solubility: Soluble in alcohol and ether, UN3077, EINECS 202-163-5, RTECS DU8050000, BRN 1634058, MDL MFCD00003054, † H:H400-H410-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a For use in combination with Li metal for the generation of activated Ca metal, see: *Org. Synth. Coll.*, **9**, 9 (1998).	250g 1kg 5kg
A13956	**Biphenyl-4-carbonyl chloride, 98%** ◪ *[4-Phenylbenzoyl chloride]* [14002-51-8], $C_{13}H_9ClO$, F.W. 216.67, m.p. 110-115°, b.p. 160°/2mm, Fieser **4**,376 **7**,282, UN3261, EINECS 237-804-8, BRN 472842, MDL MFCD00000692, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Protection of the OH group of a non-crystalline prostaglandin intermediate, in the presence of pyridine, enabled isolation as the crystalline 4-phenylbenzoate ester: *J. Am. Chem. Soc.*, **93**, 1491 (1971). For protection of 3-azido-2,3-dideoxypentoses in a short AZT synthesis, see: *Synthesis*, 451 (1991). Again, the solid nature of these intermediates facilitates isolation. Protection of amines as their crystalline 4-phenylbenzamides has also been recommended. These amides can be cleaved with sodium amalgam: *Tetrahedron Lett.*, 3853 (1976).	10g 50g 250g

Stock #	Description	Size
	Biphenyl-2-ol, see 2-Phenylphenol, A10592, p. 317	
A15782	**2,2'-Bipyridine, 99+%** *[2,2'-Bipyridyl, 2,2'-Dipyridyl]* [366-18-7], $C_{10}H_8N_2$, F.W. 156.19, m.p. 70°, b.p. 272-273°, f.p. 121°(249°F), Merck **14**,3347, UN2811, EINECS 206-674-4, RTECS DW1750000, BRN 113089, MDL MFCD00006212, † H:H301-H311, P:P301+P310-P361-P302+P352-P321-P405-P501a Reagent for iron. Chelating ligand. For use as an alternative to phosphines in Heck type reactions, see: *Synlett*, 871 (1992). Complex with **Chromium(VI) oxide**, **12522**, has been used in a mild selective oxidation of alcohols to aldehydes and ketones: *Acta Chem. Scand.*, **25**, 1125 (1971). Application(s): Reagent for iron determinations	**25g** **100g** **500g**
	2,2'-Bipyridyl, see 2,2'-Bipyridine, A15782, p. 126	
A10907	**2,2'-Biquinoline, 98+%** *[Cuproin, 2,2'-Diquinolyl]* [119-91-5], $C_{18}H_{12}N_2$, F.W. 256.31, m.p. 193-196°, EINECS 204-357-5, BRN 187259, MDL MFCD00006740, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reagent for spectrophotometric determination of Cu: *Analyst*, **83**, 299 (1958). Indicator for titration of organolithium reagents, giving yellow-green charge-transfer complexes.	**1g** **5g** **25g**
	2,2'-Biquinoline-4,4'-dicarboxylic acid disodium salt, see Bicinchoninic acid disodium salt, 44247, p. 124	
B21457	**α-Bisabolol, 96%** △ [515-69-5], $C_{15}H_{26}O$, F.W. 222.37, f.p. 135°(275°F), d. 0.93, n_D^{20} 1.4950, Merck **14**,1241, EINECS 208-205-9, RTECS MJ9685000, BRN 5733954, MDL MFCD03846910, †	**10g** **50g**
J61997	**Bisacodyl, 98+%** [603-50-9], $C_{22}H_{19}NO_4$, F.W. 361.40, Crystalline powder, Merck **14**,1242, EINECS 210-044-4, RTECS SM8750000, MDL MFCD00038039, † Application(s): A diphenolic laxative that stimulates adenyl cyclase activity	**10g** **25g**
	Bis-acrylamide, see N,N'-Methylenebisacrylamide, 43701, p. 287 **1,2-Bis(acrylamido)ethylene glycol**, see N,N'-(1,2-Dihydroxyethylene)bisacrylamide, L19211, p. 192	
44132	**N,N'-Bis(acryloyl)cystamine, 98%** *[BAC]* [60984-57-8], $(CH_2{=}CHC(O)NHCH_2CH_2S)_2$, F.W. 260.37, Powder, Packaged under argon, m.p. 123-124°, EINECS 262-546-8, MDL MFCD00036225 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used as a reversible cross-linker for polyacrylamide gels	**1g** **5g** **25g**
	1,4-Bis(acryloyl)piperazine, see 1,4-Diacryloylpiperazine, L15694, p. 182 **Bis(2-aminoethyl) disulfide dihydrochloride**, see Cystamine dihydrochloride, B22873, p. 172 **1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid**, see BAPTA, A13190, p. 117 **N,N'-Bis(3-aminopropyl)-1,4-butanediamine tetrahydrochloride**, see Spermine tetrahydrochloride, 99%, J63060, p. 351 **3,6-Bis(2,2'-arsonophenylazo)-4,5-dihydroxy-2,7-naphthalenedisulfonic acid disodium salt**, see Arsenazo III disodium salt, A11838, p. 110	
J62134	**bis-Benzimide H-33342 trihydrochloride trihydrate, 98%** *[Hoechst 33342®]* [23491-52-3], $C_{27}H_{28}N_6O{\cdot}3HCl.3H_2O$, F.W. 615.99 (561.94anhy), Powder, EINECS 245-691-1, RTECS SM1140500, BRN 4088183, MDL MFCD00012679 H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501 Application(s): Stain for identifying specific chromosome banding patterns	**50mg** **100mg**
	Bis[N,N-bis(carboxymethyl)aminomethyl]fluorescein sodium salt, see Calcein sodium salt, L10255, p. 142	
J64065	**1,3-Bis(4-bromophenyl)-5-phenyl-2,4-imidazolidinedione** *[1,3-Bis(4-bromophenyl)-5-phenylimidazolidine-2,4-dione]* [878533-35-8], $C_{21}H_{14}Br_2N_2O_2$, F.W. 486.16, Solid	**50mg**
	N,N-Bis(carboxymethyl)glycine, see Nitrilotriacetic acid, 36515, p. 303 **Bis(3-carboxy-4-nitrophenyl) disulfide**, see 5,5'-Dithiobis(2-nitrobenzoic acid), A14331, p. 200	
A13118	**Bis(2-chloroethyl)amine hydrochloride, 98%** [821-48-7], $C_4H_9Cl_2N{\cdot}HCl$, F.W. 178.49, m.p. 211-215°, UN2923, EINECS 212-479-5, RTECS IA1225000, BRN 3550356, MDL MFCD00012515, † H:H331-H314-H341-H302-H317, P:P280-P262-P305+P351+P338-P309-P310	**50g** **250g** **1kg**
	4-(4-[Bis(2-chloroethyl)amino]phenyl)butyric acid, see Chlorambucil, 98%, J61964, p. 154 **Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester**, see Cyclophosphamide monohydrate, L11508, p. 172 **Bis(cyclopentadienyl)iron**, see Ferrocene, 87202, p. 219 **1,4-Bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane**, see Nordihydroguaiaretic acid, L03149, p. 304 **3,6-Bis(dimethylamino)acridine hydrochloride zinc chloride double salt**, see Acridine Orange, L13159, p. 76 **1,2-Bis(dimethylamino)ethane**, see N,N,N',N'-Tetramethylethylenediamine, A12536, p. 364	

Contact us for pricing on bulk sizes

Stock #	Description	Size
	1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 1-oxide hexafluorophosphate, see O-(7-Aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, H26082, p. 112 **Bis(2-ethoxyethyl) ether**, see Diethylene glycol diethyl ether, A17478, p. 189 **1-(2-[Bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride**, see GBR 12909 dihydrochloride, J60684, p. 230 **1-[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride**, see Flunarizine dihydrochloride, 99+%, J62969, p. 222 **2,2'-Bis(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene)**, see Gossypol, 98+%, J63767, p. 238 **N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid**, see BES, A16092, p. 123 **Bis(2-hydroxyethyl)aminotris(hydroxymethyl)methane**, see 2,2-Bis(hydroxymethyl)-2,2',2''-nitrilotriethanol, B22515, p. 127 **Bis(2-hydroxyethyl) ether**, see Diethylene glycol, A14728, p. 189 **N,N-Bis(2-hydroxyethyl)glycine**, see BICINE, A14957, p. 124 **Bis(2-hydroxyethyl) sulfide**, see 2,2'-Thiodiethanol, A17002, p. 367 **1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione**, see Curcumin, B21573, p. 170	
B22515	**2,2-Bis(hydroxymethyl)-2,2',2''-nitrilotriethanol, 98+%** *[Bis(2-hydroxyethyl)aminotris(hydroxymethyl)methane, Bis-TRIS]* [6976-37-0], $(HOCH_2)_3CN(CH_2CH_2OH)_2$, F.W. 209.24, m.p. 102-105°, EINECS 230-237-7, BRN 2205275, MDL MFCD00002853, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Buffer: pH range 5.5 - 8.0. Application(s): Good's buffers	**25g** **100g** **500g**
	1,1-Bis(hydroxymethyl)propylamine, see 2-Amino-2-ethyl-1,3-propanediol, B24509, p. 94 **meso-3,4-Bis(4-hydroxyphenyl)hexane**, see Hexestrol, 98+%, J60889, p. 245	
J63401	**Bisindolylmaleimide 1** *[GF 109203X]* [133052-90-1], $C_{25}H_{24}N_4O_2$, F.W. 412.48, Crystalline powder, MDL MFCD00236428 Application(s): Very potent and selective inhibitor of protein kinase C	**5mg** **25mg**
J64757	**Bismarck Brown R** *[C.I. 21010, Basic Brown 4]* [5421-66-9], $C_{21}H_{24}N_8$, F.W. 461.40, Powder, m.p. 222°dec., EINECS 226-541-4, BRN 1829673, MDL MFCD00036386, †	**25g** **100g**
A16674	**Bismarck Brown Y** *[C.I. 21000]* [10114-58-6], $C_{18}H_{18}N_8 \cdot 2HCl$, F.W. 419.32, Merck **14**,1253, Solubility: Soluble in water, EINECS 233-314-3, MDL MFCD00012977, † Application(s): Plasma stain for mucins, cartilage and goblet cells	**25g** **100g**
	Bis(2-methoxyethyl) ether, see Diethylene glycol dimethyl ether, A13397, p. 189 **2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt**, see XTT sodium salt, J61726, p. 394	
L00183	**N,O-Bis(trimethylsilyl)acetamide, 95%** *[BSA]* [10416-59-8], $C_8H_{21}NOSi_2$, F.W. 203.43, m.p. -24°, b.p. 71-73°/35mm, f.p. 42°(107°F), d. 0.829, n_D^{20} 1.4170, Fieser **1**,61 **2**,30 **3**,23 **18**,57 **20**,50 **21**,62, UN2920, EINECS 233-892-7, RTECS AK3000000, BRN 1306669, MDL MFCD00008270, † H:H314-H226-H302-EUH014, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Powerful silylation reagent for a wide range of functional groups under mild conditions. Reviews: *J. Prakt. Chem./ Chem. Ztg.*, **337**, 332 (1995); *Synthesis*, 357 (1998). Unlike halosilanes, silylated amides often need no added base catalysts. For an example of use without added solvent or catalyst for the silylation of a tertiary α-hydroxy ketone, see: *Org. Synth. Coll.*, **7**, 381 (1990). Silylating power can be increased in polar solvents such as DMF or acetonitrile, or by addition of acidic catalysts, often TMS chloride, or an acid such as TFA or HCl. O-Silylation in the presence of TBAF (0.02 equiv.) occurs under very mild conditions: *Tetrahedron Lett.*, **35**, 8409 (1994). BSA catalyzes the acylation of acylphosphoranes with activated derivatives of carboxylic acids. Subsequent ozonolysis, or oxidation with singlet oxygen or dimethyldioxirane, provides a route to 1,2,3-triketones: *J. Org. Chem.*, **54**, 2785 (1989); **60**, 8231 (1995): 	**5g** **25g** **100g**
	Bis-tris, see 2,2-Bis(hydroxymethyl)-2,2',2''-nitrilotriethanol, B22515, p. 127	
J62928	**BIS-TRIS, 0.5M buffer soln., pH 6.0** [6976-37-0], Liquid, †	**100ml** **250ml**
J63036	**BIS-TRIS, 0.5M buffer soln., pH 6.5** [6976-37-0], Liquid, †	**100ml** **250ml**
J60656	**BIS-TRIS, 0.5M buffer soln., pH 7.0** [6976-37-0], Liquid, †	**100ml** **250ml**
J62177	**BIS-TRIS, 0.5M buffer soln., pH 7.5** [6976-37-0], Liquid, †	**100ml** **250ml**

Stock #	Description	Size
43496	**1,3-Bis[tris(hydroxymethyl)methylamino]propane, 98+%** *[Bis-Tris Propane]* [64431-96-5], $CH_2[CH_2NHC(CH_2OH)_3]_2$, F.W. 282.34, Powder, m.p. 168-170°, EINECS 264-899-3, MDL MFCD00004689, Note: pKa_1=6.8, useful pH range 6.3-9.5	**25g** **100g** **500g**
	Bis-tris propane, see 1,3-Bis[tris(hydroxymethyl)methylamino]propane, 43496, p. 128	
J63555	**BIS-TRIS propane, 0.2M buffer soln., pH 7.0** [64431-96-5], Liquid	**100ml** **250ml**
J61292	**BIS-TRIS propane, 0.2M buffer soln., pH 7.5** [64431-96-5], Liquid	**100ml** **250ml**
J62831	**BIS-TRIS propane, 0.2M buffer soln., pH 8.0** [64431-96-5], Liquid	**100ml** **250ml**
J62012	**BIS-TRIS propane, 0.2M buffer soln., pH 8.5** [64431-96-5], Liquid	**100ml** **250ml**
J63943	**BIS-TRIS propane, 0.2M buffer soln., pH 9.0** [64431-96-5], Liquid	**100ml** **250ml**
J62354	**BIS-TRIS propane, 0.5M buffer soln., pH 6.5** [64431-96-5], Liquid	**100ml** **250ml**
	Bitrex® Macfarlan Smith, A Johnson Matthey Co., see Denatonium benzoate, J61048, p. 176	
L00812	**Biuret, 97%** *[Carbamylurea]* [108-19-0], $H_2NCONHCONH_2$, F.W. 103.08, m.p. ca 189° dec., d. 1.46, Merck **14**,1309, EINECS 203-559-0, BRN 1703510, MDL MFCD00007946, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g**
J61883	**Blasticidin S hydrochloride, 98+%, 10mg/ml in 1M HEPES buffer soln.** [3513-03-9], $C_{17}H_{26}N_8O_5 \cdot HCl$, F.W. 458.90, Liquid, Merck **14**,1316, UN2810, MDL MFCD02091640 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Inhibits protein synthesis and induces apoptosis	**20mg** **100mg**
J60727	**Bleomycin sulfate** [9041-93-4], Powder, Merck **14**,1318, EINECS 232-925-2, RTECS EC5991990, MDL MFCD00070310 H:H340-H351, P:P281-P201-P202-P308+P313-P405-P501a Application(s): A glycopeptide antibiotic. Inhibits DNA synthesis and causes breaks in DNA strands	**25mg** **100mg**
J61417	**BLOTTO** Liquid, Note: 5% non-fat dried milk, 0.02% sodium azide. Application(s): Blocking reagent for immunohistochemistry experiments.	**500ml** **1L**
J60296	**BLOTTO in PBS** Liquid, Note: Contains 5% nonfat dry milk in PBS. Application(s): Blocking reagent for immunohistochemistry experiments	**250ml** **500ml**
J60166	**BLOTTO in PBS, with 0.02% sodium azide** Liquid, Note: 5% nonfat dry milk, 0.02% Sodium azide in PBS Application(s): Blocks non-specific binding site for antibodies on the membrane	**250ml** **500ml**
J63851	**BLOTTO antifoam in PBS** Liquid, Note: Contains 5% nonfat dry milk and 0.01% Antifoam A in PBS Application(s): Blocking buffer for immunohistochemistry experiments	**250ml** **500ml**
J61888	**BLOTTO antifoam in PBS, with 0.02% sodium azide** Liquid, Note: 5% nonfat dry milk, 0.01% Antifoam A , and 0.02% azide in PBS. Application(s): Blocking reagent for immunohistochemistry experiments	**250ml** **500ml**
J63238	**BLOTTO in TBS** Liquid, Note: 5% nonfat dry milk in TBS Application(s): Blocks non-specific binding site for antibodies on the membrane	**250ml** **500ml**
J62235	**BLOTTO in TBS, with 0.02% sodium azide** Liquid, Note: 5% nonfat dry milk and 0.02% sodium azide in TBS Application(s): Blocking reagent in immunohistochemistry experiments	**250ml** **500ml**
J62031	**BLOTTO antifoam in TBS** Liquid, Note: Contains 5% nonfat dry milk and 0.01% Antifoam A in TBS Application(s): Blocks non-specific binding site for antibodies on the membrane	**250ml** **500ml**

Stock #	Description	Size
J63891	**BLOTTO antifoam in TBS, with 0.02% sodium azide** Liquid, Note: Contains 5% nonfat dry milk, 0.01% Antifoam A and 0.02% azide in TBS. Application(s): Blocking reagent for immunological procedures.	**250ml** **500ml**
J61880	**BLOTTO and Tween 20 in PBS** Liquid, Note: Contains 5% nonfat dry milk and 0.05% Tween-20 in PBS Application(s): Blocking reagent in immunohistochemistry experiments	**250ml** **500ml**
J62304	**BLOTTO and Tween 20 in PBS, with 0.02% sodium azide** Liquid, Note: This buffer contains 5% nonfat dry milk, 0.05% Tween-20 and 0.02% sodium azide in PBS Application(s): Blocking reagent for immunohistochemistry experiments	**250ml** **500ml**
J62341	**BLOTTO and Tween 20 in TBS** Liquid, Note: 5% nonfat dry milk and 0.05% Tween-20 in TBS Application(s): Blocks non-specific binding site for antibodies on the membrane	**500ml** **1L**
J63026	**BLOTTO and Tween 20 in TBS, with 0.02% sodium azide** Liquid, Note: This product contains 5% nonfat dry milk, 0.05% Tween-20 and 0.02% sodium azide in TBS Application(s): Blocking reagent for immunohistochemistry experiments	**500ml** **1L**
A12502	**Blue Tetrazolium chloride** *[BTC, Tetrazolium Blue chloride]* [1871-22-3], $C_{40}H_{32}Cl_2N_8O_2$, F.W. 727.66, m.p. ca 255° dec., Merck **14**,9244, Fieser **1**,61 **15**,43, EINECS 217-488-8, BRN 3894077, MDL MFCD00040933, † Reagent for identification of reducing sugars. For use in the oxidation of steroids, see: *J. Chem. Soc., Chem. Commun.*, 2687 (1988).	**1g** **5g** **25g**
	BK, see Bradykinin, J63131, p. 134 **BMY-13754**, see Nefazodone hydrochloride, 98+%, J62793, p. 299 **BMS-354825**, see Dasatinib, J60621, p. 175 **BN-52021**, see Ginkgolide B, J60646, p. 232	
B22522	**N-Boc-β-alanine, 99%** *[Boc-β-Ala-OH, N-tert-Butoxycarbonyl-β-alanine]* [3303-84-2], $(CH_3)_3CO_2CNHCH_2CH_2CO_2H$, F.W. 189.21, m.p. 73-76°, EINECS 221-979-2, MDL MFCD00037291	**2.5g** **10g**
B22706	**N-Boc-D-alanine, 98+%** *[Boc-D-Ala-OH, N-(tert-Butoxycarbonyl)-D-alanine]* [7764-95-6], $C_8H_{15}NO_4$, F.W. 189.21, m.p. 81-84°, $[\alpha]_D^{20}$ +26° (c=2 in acetic acid), BRN 2048396, MDL MFCD00063123	**5g** **25g**
A16018	**N-Boc-L-alanine, 98+%** *[Boc-Ala-OH, N-(tert-Butoxycarbonyl)-L-alanine]* [15761-38-3], $C_8H_{15}NO_4$, F.W. 189.21, m.p. 80-84°, $[\alpha]_D^{20}$ -26° (c=2 in acetic acid), EINECS 239-847-8, BRN 1726365, MDL MFCD00037225, †	**5g** **25g**
B22407	**N-Boc-γ-aminobutyric acid, 98+%** *[N-tert-Butoxycarbonyl-γ-aminobutyric acid]* [57294-38-9], $(CH_3)_3COCONH(CH_2)_3CO_2H$, F.W. 203.2, m.p. 57-60°, MDL MFCD00037313	**1g** **5g**
	(S)-2-(Boc-amino)-6-(dimethylamino)hexanoic acid, see N(a)-Boc-N(e),N(e)-dimethyl-L-lysine, H52437, p. 130 **(S)-2-(Boc-amino)-3,3-dimethylbutyric acid**, see N-Boc-L-tert-leucine, H51136, p. 133 **(S)-2-(Boc-amino)-3-ethoxypropionic acid**, see N-Boc-O-ethyl-L-serine, H52781, p. 130	
H51990	**(S)-4-(Boc-amino)-2-(Fmoc-amino)butyric acid, 95%** *[Fmoc-Dab(Boc)-OH, Nγ-Boc-Nα-Fmoc-L-2,4-diaminobutyric acid]* [125238-99-5], $C_{24}H_{28}N_2O_6$, F.W. 440.50, BRN 6250328, MDL MFCD00151941	**250mg** **1g** **5g**
	(S)-7-(Boc-amino)-3-(Fmoc-amino)heptanoic acid, see Nχ-Boc-Nβ-Fmoc-L-β-homolysine, H52189, p. 130 **(R)-3-(Boc-amino)-3-(4-methoxyphenyl)propionic acid**, see N-Boc-4-methoxy-D-phenylalanine, H52082, p. 131	
H52173	**(S)-3-(Boc-amino)-5-methylhexanoic acid, 95%** *[N-Boc-L-β-homoleucine, Boc-β-Homoleu-OH]* [132549-43-0], $C_{12}H_{23}NO_4$, F.W. 245.32, m.p. 53-55°, BRN 4251252, MDL MFCD02101665	**250mg** **1g**
H52174	**(S)-3-(Boc-amino)-4-phenylbutyric acid, 95%** *[N-Boc-L-β-homophenylalanine, Boc-β-Homophe-OH]* [51871-62-6], $C_{15}H_{21}NO_4$, F.W. 279.34, m.p. 101-107°, BRN 3060457, MDL MFCD01076271	**250mg** **1g**
	Boc anhydride, see Di-tert-butyl dicarbonate, A14708, p. 184	
A16019	**N(α)-Boc-L-asparagine, 98+%** *[Boc-Asn-OH, N(α)-tert-Butoxycarbonyl-L-asparagine]* [7536-55-2], $C_9H_{16}N_2O_5$, F.W. 232.24, m.p. ca 170° dec., $[\alpha]_D^{20}$ -7.3° (c=2 in DMF), EINECS 231-405-2, BRN 1977963, MDL MFCD00038152, †	**5g** **25g**

Stock #	Description		Size
L08498	**N-Boc-L-aspartic acid, 98+%** *[Boc-Asp-OH, N-(tert-Butoxycarbonyl)-L-aspartic acid]* [13726-67-5], $C_9H_{15}NO_6$, F.W. 233.23, m.p. 115°, $[\alpha]_D^{20}$ -5.5° (c=1 in methanol), EINECS 237-294-7, BRN 1913973, MDL MFCD00037279		**1g** **5g**
B22314	**N-Boc-L-aspartic acid 1-benzyl ester, 99%** *[Boc-Asp-OBzl, N-tert-Butoxycarbonyl-L-aspartic acid 1-benzyl ester]* [30925-18-9], $C_{16}H_{21}NO_6$, F.W. 323.35, m.p. 95-97°, MDL MFCD00065563		**1g** **5g**
B21758	**N-Boc-L-aspartic acid 4-benzyl ester, 98%** *[Boc-Asp(OBzl)-OH, N-tert-Butoxycarbonyl-L-aspartic acid 4-benzyl ester]* [7536-58-5], $C_{16}H_{21}NO_6$, F.W. 323.35, m.p. 110-112°, EINECS 231-406-8, MDL MFCD00065564, †		**1g** **5g**
J65812	**N-Boc-L-aspartic acid 4-methyl esther fluoromethyl ketone** *[Boc-D-FMK, Boc-Asp(OMe)-FMK]* [187389-53-3], $C_{11}H_{18}FNO_5$, F.W. 263.26, Powder, MDL MFCD03453073		**5mg**
B22666	**N-Boc-O-benzyl-D-serine, 99%** *[Boc-D-Ser(Bzl)-OH, N-tert-Butoxycarbonyl-O-benzyl-D-serine]* [47173-80-8], $C_{15}H_{21}NO_5$, F.W. 295.31, m.p. 60-63°, MDL MFCD00038248		**1g** **5g**
B21677	**N-Boc-O-benzyl-L-threonine, 99%** *[Boc-Thr(Bzl)-OH, N-tert-Butoxycarbonyl-O-benzyl-L-threonine]* [15260-10-3], $C_{16}H_{23}NO_5$, F.W. 309.36, m.p. 115-116°, EINECS 239-304-5, MDL MFCD00066062, †		**1g** **5g**
B23455	**N-Boc-O-benzyl-L-tyrosine, 98%** *[Boc-Tyr(Bzl)-OH, N-tert-Butoxycarbonyl-O-benzyl-L-tyrosine]* [2130-96-3], $C_{21}H_{25}NO_5$, F.W. 371.43, m.p. 108-110°, EINECS 218-349-4, MDL MFCD00065597		**1g** **5g** **25g**
H51969	**N-Boc-4-bromo-L-phenylalanine, 98%** *[Boc-Phe(4-Br)-OH]* [62129-39-9], $C_{14}H_{18}BrNO_4$, F.W. 344.20, m.p. 118-120°, MDL MFCD00237571		**1g** **5g**
H52015	**N-Boc-3-chloro-L-phenylalanine, 95%** *[Boc-Phe(3-Cl)-OH]* [114873-03-9], $C_{14}H_{18}ClNO_4$, F.W. 299.75, MDL MFCD00672515		**250mg** **1g** **5g**
H52181	**N-Boc-4-chloro-D-phenylalanine, 95%** *[Boc-D-Phe(4-Cl)-OH]* [57292-44-1], $C_{14}H_{18}ClNO_4$, F.W. 299.75, m.p. 110°, BRN 5381988, MDL MFCD00076978		**250mg** **1g** **5g**
H52437	**N(α)-Boc-N(ε),N(ε)-dimethyl-L-lysine, 97%** *[(S)-2-(Boc-amino)-6-(dimethylamino)hexanoic acid, N(α)-tert-Butoxycarbonyl-N(ε),N(ε)-dimethyl-L-lysine]* [65671-53-6], $C_{13}H_{26}N_2O_4$, F.W. 274.36		**250mg** **1g**
H52781	**N-Boc-O-ethyl-L-serine, 97%** *[(S)-2-(Boc-amino)-3-ethoxypropionic acid, N-tert-Butoxycarbonyl-O-ethyl-L-serine]* [104839-00-1], $C_{10}H_{19}NO_5$, F.W. 233.26		**250mg** **1g**
H51963	**N-Boc-3-fluoro-D-phenylalanine, 98%** *[Boc-D-Phe(3-F)-OH]* [114873-11-9], $C_{14}H_{18}FNO_4$, F.W. 283.30, m.p. 75-79°, MDL MFCD00672523		**1g** **5g**
H51988	**N-Boc-3-fluoro-L-phenylalanine, 95%** *[Boc-Phe(3-F)-OH]* [114873-01-7], $C_{14}H_{18}FNO_4$, F.W. 283.30, m.p. 75-80°, BRN 5347375, MDL MFCD00672522		**250mg** **1g** **5g**
H52189	**N(ω)-Boc-N(β)-Fmoc-L-β-homolysine, 95%** *[(S)-7-(Boc-amino)-3-(Fmoc-amino)heptanoic acid, Fmoc-β-Homolys(Boc)-OH]* [203854-47-1], $C_{27}H_{34}N_2O_6$, F.W. 482.58, BRN 8022293, MDL MFCD01863054		**250mg** **1g**
H28301	**N(ε)-Boc-N(α)-Fmoc-D-lysine, 98%** *[N(ε)-(tert-Butoxycarbonyl)-N(α)-9-fluorenylmethoxycarbonyl-D-lysine, Fmoc-D-Lys(Boc)-OH]* [92122-45-7], $C_{26}H_{32}N_2O_6$, F.W. 468.54, m.p. 135-139°, $[\alpha]_D^{20}$ +11° (c=1 in DMF), MDL MFCD00065660		**1g** **5g**
B21944	**N-Boc-D-glutamic acid 1-benzyl ester, 99%** *[Boc-D-Glu-OBzl, N-tert-Butoxycarbonyl-D-glutamic acid 1-benzyl ester]* [34404-30-3], $C_{17}H_{23}NO_6$, F.W. 337.37, MDL MFCD00038266		**1g** **5g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
H52191	**N-Boc-L-β-glutamic acid 5-benzyl ester, 95%** *[N-Boc-L-β-homoaspartic acid 5-benzyl ester, Boc-β-Glu(OBzl)-OH]* [254101-10-5], $C_{17}H_{23}NO_6$, F.W. 337.37, BRN 8430789, MDL MFCD01862861	250mg 1g
B22322	**N-Boc-L-glutamic acid 5-tert-butyl ester, 99%** *[Boc-Glu(OtBu)-OH, N-tert-Butoxycarbonyl-L-glutamic acid 4-tert-butyl ester]* [13726-84-6], $C_{14}H_{25}NO_6$, F.W. 303.36, m.p. 110-112°, MDL MFCD00038257	1g 5g
L08536	**N(α)-Boc-D-glutamine, 98+%** *[Boc-D-Gln-OH, N(α)-tert-Butoxycarbonyl-D-glutamine]* [61348-28-5], $C_{10}H_{18}N_2O_5$, F.W. 246.26, m.p. 117-119°, $[\alpha]_D^{20}$ +3.5° (c=2 in ethanol), BRN 1981311, MDL MFCD00038158	250mg 1g
L08604	**N(α)-Boc-L-glutamine, 98+%** *[Boc-Gln-OH, N(α)-tert-Butoxycarbonyl-L-glutamine]* [13726-85-7], $C_{10}H_{18}N_2O_5$, F.W. 246.26, m.p. 118-120°, $[\alpha]_D^{20}$ -3.5° (c=2 in ethanol), EINECS 237-296-8, BRN 2127805, MDL MFCD00065571, †	5g 25g
A11579	**N-Boc-glycine, 98+%** *[Boc-Gly-OH, N-(tert-Butoxycarbonyl)glycine]* [4530-20-5], $(CH_3)_3COCONHCH_2CO_2H$, F.W. 175.18, m.p. 87-90°, EINECS 224-864-5, BRN 1101514, MDL MFCD00002690, † H:H318, P:P280-P305+P351+P338-P310	5g 25g 100g
L08810	**N(α)-Boc-D-histidine, 98+%** *[Boc-D-His-OH, N(α)-tert-Butoxycarbonyl-D-histidine]* [50654-94-9], $C_{11}H_{17}N_3O_4$, F.W. 255.27, m.p. ca 197° dec., $[\alpha]_D^{20}$ -26° (c=1 in methanol), BRN 4196575, MDL MFCD00037851	250mg 1g
B22042	**N(α)-Boc-L-histidine, 98+%** *[Boc-His-OH, N(α)-tert-Butoxycarbonyl-L-histidine]* [17791-52-5], $C_{11}H_{17}N_3O_4$, F.W. 255.27, m.p. ca 198° dec., $[\alpha]_D^{20}$ +26° (c=1 in methanol), EINECS 241-768-9, BRN 755289, MDL MFCD00065576	1g 5g
	N-Boc-L-β-homoaspartic acid 5-benzyl ester, see N-Boc-L-▲-glutamic acid 5-benzyl ester, H52191, p. 131 **N-Boc-L-β-homoleucine**, see (S)-3-(Boc-amino)-5-methylhexanoic acid, H52173, p. 129	
H27110	**N-Boc-trans-4-hydroxy-L-proline, 97%** *[Boc-Hyp-OH, 1-tert-Butoxycarbonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid]* [13726-69-7], $C_{10}H_{17}NO_5$, F.W. 231.25, m.p. 123-127°, MDL MFCD00053370	1g 5g 25g
H51960	**N-Boc-4-iodo-L-phenylalanine, 98% ▲** *[Boc-Phe(4-I)-OH]* [62129-44-6], $C_{14}H_{18}INO_4$, F.W. 391.21, m.p. 150° dec., BRN 4503851, MDL MFCD00037119	5g 25g
L09124	**N-Boc-D-leucine hydrate, 98+%** *[Boc-D-Leu-OH.H2O, N-(tert-Butoxcarbonyl)-D-leucine]* [16937-99-8], $C_{11}H_{21}NO_4 \cdot xH_2O$, F.W. 231.30(anhy), m.p. 80-84°, $[\alpha]_D^{20}$ +25° (c=2 in acetic acid), BRN 2331060, MDL MFCD00065583	1g 5g
B21738	**N(ε)-Boc-L-lysine, 97%** *[N(epsilon)-tert-Butoxycarbonyl-L-lysine, H-Lys(Boc)-OH]* [2418-95-3], $C_{11}H_{22}N_2O_4$, F.W. 246.31, m.p. ca 250° dec., BRN 4252546, MDL MFCD00037221	1g 5g
L09207	**N-Boc-D-methionine, 98+%** *[Boc-D-Met-OH, N-(tert-Butoxycarbonyl)-D-methionine]* [5241-66-7], $C_{10}H_{19}NO_4S$, F.W. 249.32, m.p. 47-50°, $[\alpha]_D^{20}$ +29° (c=1 in methanol), EINECS 226-043-7, BRN 4294122, MDL MFCD00038256	1g 5g
L08366	**N-Boc-L-methionine, 98+%** *[Boc-Met-OH, N-(tert-Butoxycarbonyl)-L-methionine]* [2488-15-5], $C_{10}H_{19}NO_4S$, F.W. 249.32, m.p. 48-51°, $[\alpha]_D^{20}$ -22° (c=1 in methanol), EINECS 219-639-3, BRN 1727869, MDL MFCD00065586	1g 5g
H52082	**N-Boc-4-methoxy-D-phenylalanine, 95%** *[(R)-3-(Boc-amino)-3-(4-methoxyphenyl)propionic acid, Boc-D-Tyr(Me)-OH]* [68856-96-2], $C_{15}H_{21}NO_5$, F.W. 295.33	250mg 1g 5g
H31317	**N-Boc-N-methyl-L-alanine, 98%** *[Boc-N-Me-Ala-OH, N-tert-Butoxycarbonyl-N-methyl-L-alanine]* [16948-16-6], $C_9H_{17}NO_4$, F.W. 203.24, m.p. 88-92°, $[\alpha]_D^{20}$ -31° (c=1 in ethanol), MDL MFCD00037242	1g 5g

Stock #	Description		Size
H51983	**N-Boc-4-methyl-L-phenylalanine, 95%** *[Boc-Phe(4-Me)-OH]* [80102-26-7], $C_{15}H_{21}NO_4$, F.W. 279.34, m.p. 84-88°, BRN 5381557, MDL MFCD01317027		**250mg** **1g** **5g**
H52787	**N-Boc-2-methyl-D-serine, 97%** [84311-18-2], $C_9H_{17}NO_5$, F.W. 219.24		**250mg** **1g**
H52570	**N-Boc-2-methyl-L-serine, 97%** [84311-19-3], $C_9H_{17}NO_5$, F.W. 219.24		**250mg** **1g**
H52058	**N-Boc-3-nitro-L-phenylalanine, 95%** *[Boc-Phe(3-NO2)-OH]* [131980-29-5], $C_{14}H_{18}N_2O_6$, F.W. 310.31, MDL MFCD01317033		**250mg** **1g** **5g**
H51986	**N-Boc-4-nitro-L-phenylalanine, 95%** *[Boc-Phe(4-NO2)-OH]* [33305-77-0], $C_{14}H_{18}N_2O_6$, F.W. 310.31, EINECS 251-450-1, BRN 2820671, MDL MFCD00038128		**250mg** **1g** **5g**
L08615	**N-Boc-L-norvaline, 98+%** *[Boc-Nva-OH, N-(tert-Butoxycarbonyl)-L-norvaline]* [53308-95-5], $C_{10}H_{19}NO_4$, F.W. 217.28, m.p. 43-47°, $[\alpha]_D^{20}$ -15° (c=2 in methanol), BRN 3607582, MDL MFCD00037268		**250mg** **1g**
L08722	**N-Boc-D-phenylalanine, 98%** *[Boc-D-Phe-OH, N-(tert-Butoxycarbonyl)-D-phenylalanine]* [18942-49-9], $C_{14}H_{19}NO_4$, F.W. 265.31, m.p. 85-88°, $[\alpha]_D^{20}$ -24° (c=1 in ethanol), BRN 3593396, MDL MFCD00063149		**1g** **5g**
A16017	**N-Boc-L-phenylalanine, 99%** *[Boc-Phe-OH, N-(tert-Butoxycarbonyl)-L-phenylalanine]* [13734-34-4], $C_{14}H_{19}NO_4$, F.W. 265.31, m.p. 84-88°, $[\alpha]_D^{20}$ +25° (c=1 in ethanol), EINECS 237-305-5, BRN 2219729, MDL MFCD00002663, †		**5g** **25g**
L18540	**N-Boc-D-phenylglycine, 99%** *[Boc-D-Phg-OH, N-(tert-Butoxycarbonyl)-D-phenylglycine]* [33125-05-2], $C_{13}H_{17}NO_4$, F.W. 251.28, m.p. 90-92°, $[\alpha]_D^{20}$ -144° (c=1 in ethanol), BRN 3033982, MDL MFCD00062043 Reagent of choice for assignment of absolute configuation of chiral primary amines by ^{1}H NMR, giving better results than Mosher's acid (**(R)-(+)-α-Methoxy-α-(trifluoromethyl)phenylacetic acid**, **B22968**): *J. Org. Chem.*, **64**, 4669 (1999).		**1g** **5g**
L18541	**N-Boc-L-phenylglycine, 99%** *[Boc-Phg-OH, N-(tert-Butoxycarbonyl)-L-phenylglycine]* [2900-27-8], $C_{13}H_{17}NO_4$, F.W. 251.28, m.p. 88-90°, $[\alpha]_D^{20}$ +144° (c=1 in ethanol), BRN 3592362, MDL MFCD00065588		**1g** **5g**
L08826	**N-Boc-D-proline, 98+%** *[Boc-D-Pro-OH, N-(tert-Butoxycarbonyl)-D-proline]* [37784-17-1], $C_{10}H_{17}NO_4$, F.W. 215.25, m.p. 133-135°, $[\alpha]_D^{20}$ +61° (c=1 in acetic acid), BRN 479316, MDL MFCD00063226		**1g** **5g**
A13744	**N-Boc-L-proline, 99%** *[Boc-Pro-OH, N-(tert-Butoxycarbonyl)-L-proline]* [15761-39-4], $C_{10}H_{17}NO_4$, F.W. 215.25, m.p. 132-136°, $[\alpha]_D^{20}$ -61° (c=1 in acetic acid), EINECS 239-848-3, BRN 15828, MDL MFCD00037324, †		**5g** **25g**
L09885	**N-Boc-L-prolinol, 98+%** *[Boc-Pro-ol, N-(tert-Butoxycarbonyl)-L-prolinol]* [69610-40-8], $C_{10}H_{19}NO_3$, F.W. 201.27, m.p. 59-62°, $[\alpha]_D^{20}$ -54° (c=5 in methanol), BRN 3542667, MDL MFCD00066232		**250mg** **1g** **5g** **25g**
H52128	**N-Boc-2-propargyl-L-glycine, 95%** [63039-48-5], $C_{10}H_{15}NO_4$, F.W. 213.23, MDL MFCD01320855		**250mg** **1g**
L08904	**N-Boc-D-serine, 98+%** *[Boc-D-Ser-OH, N-(tert-Butoxycarbonyl)-D-serine]* [6368-20-3], $C_8H_{15}NO_5$, F.W. 205.21, m.p. 88-91°, $[\alpha]_D^{20}$ +3.5° (c=2 in acetic acid), BRN 1874714, MDL MFCD00063142		**1g** **5g**
A16224	**N-Boc-L-serine, 98% (dry wt.), may cont. up to 10% water** *[Boc-Ser-OH, N-(tert-Butoxycarbonyl)-L-serine]* [3262-72-4], $C_8H_{15}NO_5$, F.W. 205.21, m.p. 90-91° dec., $[\alpha]_D^{20}$ -3.5° (c=2 in acetic acid), EINECS 221-867-3, BRN 2212252, MDL MFCD00037243		**1g** **5g** **25g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
H51136	**N-Boc-L-tert-leucine, 98%** *[N-tert-Butoxycarbonyl-L-leucine, Boc-Tle-OH]* [62965-35-9], $C_{11}H_{21}NO_4$, F.W. 231.29, m.p. 118-121°, MDL MFCD00065574 	1g 5g 25g
L09111	**N-Boc-L-threonine, 98+%** *[Boc-Thr-OH, N-(tert-Butoxycarbonyl)-L-threonine]* [2592-18-9], $C_9H_{17}NO_5$, F.W. 219.24, m.p. 77-81°, $[\alpha]_D^{20}$ -8.5° (c=1 in acetic acid), EINECS 219-987-6, BRN 2331474, MDL MFCD00065946 	1g 5g
H51965	**(R)-N-Boc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 98%** *[N-Boc-D-Tic]* [115962-35-1], $C_{15}H_{19}NO_4$, F.W. 277.32, MDL MFCD00143818 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	1g 5g
L09214	**N(α)-Boc-D-tryptophan, 97%** *[Boc-D-Trp-OH, N(α)-tert-Butoxycarbonyl-D-tryptophan]* [5241-64-5], $C_{16}H_{20}N_2O_4$, F.W. 304.35, m.p. ca 138° dec., $[\alpha]_D^{20}$ +21° (c=1 in acetic acid), EINECS 226-042-1, BRN 4237334, MDL MFCD00037944 	1g 5g
A16023	**N(α)-Boc-L-tryptophan, 98+%** *[Boc-Trp-OH, N(α)-tert-Butoxycarbonyl-L-tryptophan]* [13139-14-5], $C_{16}H_{20}N_2O_4$, F.W. 304.35, m.p. ca 138° dec., $[\alpha]_D^{20}$ -19.5° (c=1 in DMF), EINECS 236-072-7, BRN 39677, MDL MFCD00065595, † 	5g 25g
A10810	**N-Boc-L-tyrosine, 98+%** *[Boc-Tyr-OH, N-(tert-Butoxycarbonyl)-L-tyrosine]* [3978-80-1], $C_{14}H_{19}NO_5$, F.W. 281.31, m.p. 141° dec., $[\alpha]_D^{20}$ +37° (c=1 in dioxan), EINECS 223-613-7, BRN 2816406, MDL MFCD00037179 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	1g 5g 25g
B22164	**N-Boc-L-tyrosine methyl ester, 99%** *[N-tert-Butoxycarbonyl-L-tyrosine methyl ester, Boc-Tyr-OMe]* [4326-36-7], $C_{15}H_{21}NO_5$, F.W. 295.34, m.p. 105-108°, MDL MFCD00191181 	5g 25g 100g
J64264	**Boc-Val-Ile[(S)-4-amino-2;2-difluoro-3-oxo-pentanoyl]-Val-Ile-OMe** *[N-Boc-V-Ile[(S)-4-Amino-2;2-Difluoro-3-Oxo-Pentanoyl]-V-I-OMe]* $C_{33}H_{57}F_2N_5O_9$, F.W. 705.83, Powder	1mg
L09193	**N-Boc-D-valine, 98+%** *[Boc-D-Val-OH, N-(tert-Butoxycarbonyl)-D-valine]* [22838-58-0], $C_{10}H_{19}NO_4$, F.W. 217.27, m.p. 76-80°, $[\alpha]_D^{20}$ +6.3° (c=1 in acetic acid), BRN 2050408, MDL MFCD00038282 	1g 5g
A16007	**N-Boc-L-valine, 98+%** *[Boc-L-Val-OH, N-(tert-Butoxycarbonyl)-L-valine]* [13734-41-3], $C_{10}H_{19}NO_4$, F.W. 217.27, m.p. 77-80°, $[\alpha]_D^{20}$ -7.5° (c=1 in acetic acid), EINECS 237-307-6, BRN 1711290, MDL MFCD00065605, † 	5g 25g
J64508	**Bolton-Hunter Reagent** *[N-Succinimidyl-3-(4-hydroxyphenyl)propionate, Rudinger reagent]* [34071-95-9], $C_{13}H_{13}NO_5$, F.W. 263.25, Powder, m.p. 132-133°, EINECS 251-818-1, BRN 1545011, MDL MFCD00005515 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g 5g
J63514	**Bombesin** *[Glp-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2]* [31362-50-2], $C_{71}H_{110}N_{24}O_{18}S$, F.W. 1619.90, Powder, Merck **14**,1329, RTECS BD3480000, MDL MFCD00167514 H:H341, P:P281-P201-P202-P308+P313-P405-P501 Application(s): Gut tetradecapeptide with the ability to stimulate release of various hormones	1mg 5mg
	3-BOPH·HCl, see 1-(3-tert-Butoxyphenyl)homopiperazine monohydrochloride, H51752, p. 140 **4-BOPH·HCl**, see 1-(4-tert-Butoxyphenyl)homopiperazine monohydrochloride, H51687, p. 141 **Boracic acid**, see Boric acid, 33253, p. 134	
J63742	**Borate, 0.5M buffer soln., pH 8.0** [1330-43-4], Liquid, † H:H360FD, P:P281-P201-P202-P308+P313-P405-P501a	250ml 500ml
J60803	**Borate, 0.5M buffer soln., pH 8.5** [1330-43-4], Liquid, † H:H360FD, P:P281-P201-P202-P308+P313-P405-P501a	250ml 500ml

Stock #	Description	Size
J62125	**Borate, 0.5M buffer soln., pH 9.0** [1330-43-4], Liquid, †  H:H360FD, P:P281-P201-P202-P308+P313-P405-P501a	**250ml** **500ml**
J62154	**Borate, 0.5M buffer soln., pH 9.5** [1330-43-4], Liquid, †  H:H360, P:P281-P201-P202-P308+P313-P405-P501	**500ml** **1L**
J60979	**Borate-buffered saline (5X)** [1330-43-4], Liquid, Note: 125mM sodium borate, 750mM sodium chloride, pH 7.0, †  H:H360, P:P281-P201-P202-P308+P313-P405-P501	**250ml** **500ml**
	Borax, see Sodium tetraborate decahydrate, 40114, p. 349	
33253	**Boric acid, ACS, 99.5% min** *[Boracic acid, Orthoboric acid]* [10043-35-3], H_3BO_3, F.W. 61.83, Granular, m.p. ca 185° dec., f.p. None, d. 1.435, Merck **14**,1336, Fieser **1**,63 **2**,32 **3**,29 **4**,41 **5**,48 **9**,59 **11**,70, Solubility: Soluble in water (1 gram in 18ml cold or 4ml boiling water). Solubility in water is increased by addition of HCl, citric or tartaric acid, EINECS 233-139-2, RTECS ED4550000, BRN 1697939, MDL MFCD00011337, † Maximum level of impurities: Insoluble in methanol 0.005%, Nonvolatile with methanol 0.5%, Cl 0.001%, PO_4 0.001%, SO_4 0.01%, Ca 0.005%, Heavy Metals (as Pb) 0.001%, Fe 0.001%  H:H360FD, P:P201-P308+P313 Application(s): In hardening steel, preservatives, manufacturing of cements, porcelain, enamels, glass, borates, artificial gems, in nickeling baths, painting, photography	**500g** **2kg**
A16624	**Boric acid, 98%** *[Boracic acid, Orthoboric acid]* [10043-35-3], H_3BO_3, F.W. 61.83, m.p. ca 185° dec., f.p. None, d. 1.435, Merck **14**,1336, Fieser **1**,63 **2**,32 **3**,29 **4**,41 **5**,48 **9**,59 **11**,70, EINECS 233-139-2, RTECS ED4550000, BRN 1697939, MDL MFCD00011337, †  H:H360FD, P:P201-P308+P313	**1kg** **5kg**
	DL-2-Bornanone, see (±)-Camphor, A10936, p. 144 **L-2-Bornanone**, see (1S)-(-)-Camphor, B23469, p. 144	
J60378	**Bortezomib, 99%** *[MG-341]* [179324-69-7], $C_{19}H_{25}BN_4O_4$, F.W. 384.24, Powder, m.p. 139-143°, Merck **14**,1351, UN3249, RTECS ED7771666  H:H301-H311-H330-H372, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): A potent, highly selective and reversible inhibitor of the 20S proteasome	**5mg** **10mg** **25mg**
J62631	**Bovine Gamma Globulin, 1mg/ml** [9007-83-4], Liquid	**25ml** **50ml**
J64417	**Bovine Pituitary Extract** *[BPE]* Note: Receptor Grade. Suitable for cell culture. Supplied partially purified as an aseptically lyophilized powder.	**50mg** **10x50mg**
J60205	**Bovine Serum Albumin, 1mg/ml** [9048-46-8], Liquid, EINECS 232-936-2, †	**25ml** **50ml**
	4-BPHP·2HCl, see 1-(4-tert-Butylphenyl)homopiperazine dihydrochloride, H51702, p. 141	
J61522	**Bradford Dye Reagent, ready to use** Liquid, UN1760  H:H314-H318-H371, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**500ml** **1L**
J63131	**Bradykinin** *[Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH, BK]* [58-82-2], $C_{50}H_{73}N_{15}O_{11}$, F.W. 1060.23, Powder, Merck **14**,1359, EINECS 200-398-8, RTECS EE1530000 Application(s): An endogenous vasodilator peptide	**10mg**
J61719	**Bradykinin (1-3)** *[H-Arg-Pro-Pro-OH]* $C_{16}H_{28}N_6O_4$, F.W. 368.40, Powder Application(s): Biologically active fragment of bradykinin	**5mg**
J63233	**Bradykinin (1-5)** *[H-Arg-Pro-Pro-Gly-Phe-OH]* $C_{27}H_{40}N_8O_6$, F.W. 572.67, Powder, MDL MFCD00076260 Application(s): Biologically active fragment of bradykinin	**5mg** **25mg**
J60345	**Bradykinin acetate salt** *[Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH]* [6846-03-3], $C_{50}H_{73}N_{15}O_{11}.C_2H_4O_2$, F.W. 1120.21, Powder, MDL MFCD06763566	**25mg** **100mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J61171	**Lys-Bradykinin acetate salt** *[Kallidin, Lys-Arg-Pro-Pro-Gly- Phe-Ser-Pro-Phe-Arg]* [342-10-9], $C_{56}H_{85}N_{17}O_{12}$, F.W. 1188.40, Powder, Merck **14**,5278, EINECS 206-438-0 Application(s): Endogenous bradykinin receptor agonist	**5mg** **25mg**
J61532	**Met-Lys-Bradykinin** *[Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg]* [550-19-6], $C_{61}H_{94}N_{18}O_{13}S_1$, F.W. 1319.60, Powder	**5mg** **25mg**
J65458	**Brain Derived Acidic Fibroblast Growth Factor (102-111)** *[His-Ala-Glu-Lys-His-Trp-Phe-Val-Gly-Leu]* $C_{59}H_{82}N_{16}O_{13}$, F.W. 1223.38, Solid	**1mg**
J64990	**Brassinin** *[Methyl ((1H-indol-3-yl)methyl)carbamodithioate]* [105748-59-2], $C_{11}H_{12}N_2S_2$, F.W. 236.36, Powder, m.p. 142-144°	**100mg**
J62340	**Brefeldin A, 99%** [20350-15-6], $C_{16}H_{24}O_4$, F.W. 280.36, Crystalline powder, m.p. 201-205°, Merck **14**,1369, RTECS GY8410000, BRN 25191, MDL MFCD00083258 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Inhibits protein transport from the endoplasmic reticulum to Golgi apparatus. Brefeldin A mediated apoptosis has been observed in human tumor cells	**10mg** **25mg** **50mg**
	Brij® 35, see Brij® L23, A15809, p. 135	
A15809	**Brij® L23** *[Brij® 35, Tricosaethylene glycol mono-n-dodecyl ether]* [9002-92-0], $CH_3(CH_2)_{10}CH_2(OCH_2CH_2)_{23}OH$, F.W. 1199.57, m.p. ca 35-40°, EINECS 500-002-6, RTECS JR5990000, MDL MFCD00080891, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Non-ionic surfactant. Detergent for ion chromatography. Solubilizing agent for membrane proteins. Application(s): For use in Stein-Moore chromatography	**250g** **1kg** **5kg**
43318	**Brilliant Blue G, ultrapure** *[Coomassie Brilliant Blue G 250, C.I. 42655]* [6104-58-1], $C_{47}H_{48}N_3NaO_7S_2$, F.W. 854.04, Powder, EINECS 228-058-4, MDL MFCD00078482, Note: E(m) (595nm, H_2O) >36,300, † Application(s): Protein staining following gel electrophoresis	**2g** **10g** **50g**
J63797	**Brilliant Blue G soln., Ready-to-Use** *[Coomassie Brilliant Blue G, C.I. 42655]* [6104-58-1], $C_{47}H_{48}N_3NaO_7S_2$, F.W. 854.04, Liquid, UN1992, EINECS 228-058-4, BRN 5230822, Note: This solution contains 30% methanol, 5% acetic acid, 0.2% Brilliant Blue G., † H:H311-H331-H370-H226, P:P210-P241-P303+P361+P353-P361-P405-P501a	**500ml** **1L**
J64297	**Brilliant Blue R** *[Coomassie Brilliant Blue R, C.I. 42660]* [6104-59-2], $C_{45}H_{44}N_3NaO_7S_2$, F.W. 825.97, Crystalline powder, EINECS 228-060-5, BRN 5718025, MDL MFCD00041762, †	**50g**
J61384	**Brilliant Blue R soln., Ready-to-Use** *[Coomassie Brilliant Blue R, C.I. 42660]* [6104-59-2], $C_{45}H_{44}N_3NaO_7S_2$, F.W. 825.97, Liquid, UN1992, EINECS 228-060-5, BRN 5718025, † H:H311-H331-H370-H226, P:P210-P241-P303+P361+P353-P361-P405-P501a	**500ml** **1L**
A12801	**Brilliant Green** *[Basic Green 1, C.I. 42040]* [633-03-4], $C_{27}H_{34}N_2O_4S$, F.W. 482.65, m.p. 210° dec., Merck **14**,1374, EINECS 211-190-1, RTECS BP6825000, BRN 3901207, MDL MFCD00011880, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a  	**25g** **100g**
J63451	**Bromhexine hydrochloride, 98+%** *[Auxit]* [611-75-6], $C_{14}H_{20}Br_2N_2 \cdot HCl$, F.W. 412.60, Powder, m.p. 240-244°, Merck **14**,1391, EINECS 210-280-8, RTECS XS9950000, BRN 4848376, MDL MFCD00056626 Application(s): A mucolytic agent	**100g** **500g**
J65582	**8-Bromoadenine** *[6-Amino-8-bromopurine]* [6974-78-3], $C_5H_4BrN_5$, F.W. 214.03, Powder, m.p. >250°, EINECS 230-225-1, RTECS UO7410000, MDL MFCD00082518	**100mg** **500mg** **1g**

Stock #	Description	Size
L03544	**8-Bromoadenosine, 98%** △ [2946-39-6], $C_{10}H_{12}BrN_5O_4$, F.W. 346.15, m.p. ca 211° dec., $[\alpha]_D^{20}$ -33° (c=1 in 1N HCl), EINECS 220-959-0, BRN 627737, MDL MFCD00005733 Adenosine binding inhibitor. 	**250mg** **1g**
J64469	**8-Bromoadenosine-3',5'-cyclic monophosphate** ■ *[8-Br-cAMP]* [23583-48-4], $C_{10}H_{11}BrN_5O_6P$, F.W. 408.11, Powder, m.p. 254°, EINECS 245-760-6, MDL MFCD00075580	**50mg** **100mg** **250mg**
B25681	**3-Bromobenzenesulfonamide, 97%** [89599-01-9], $C_6H_6BrNO_2S$, F.W. 236.09, m.p. 154-158°, MDL MFCD00084903 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g**
J60151	**5-Bromo-4-chloro-3-indolyl-α-D-galactoside** *[X-α-Gal]* [107021-38-5], $C_{14}H_{15}BrClNO_6$, F.W. 408.63, Powder, MDL MFCD00063780 ! H:H302-H332, P:P261-P264-P304+P340-P301+P312-P312-P501a Application(s): Substrate for β-galactosidase	**250mg** **1g**
B21034	**5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside, 98+%** ▲◪ *[X-gal]* [7240-90-6], $C_{14}H_{15}BrClNO_6$, F.W. 408.64, m.p. ca 236° dec., $[\alpha]_D^{20}$ -60° (c=1 in 50% DMF), EINECS 230-640-8, BRN 1402009, MDL MFCD00005666 Application(s): Substrate for β-galactosidase 	**10mg** **50mg** **250mg**
J65677	**5-Bromo-4-chloro-3-indolyl β-D-glucoside, 99%** *[5-Bromo-4-chloro-3-indolyl β-D-glucopyranoside, X-Glucoside]* [15548-60-4], $C_{14}H_{15}BrClNO_6$, F.W. 408.63, Powder, EINECS 239-603-0, BRN 1552603, MDL MFCD00063690	**500mg** **1g** **5g**
J64360	**5-Bromo-4-chloro-3-indolyl β-D-glucuronide sodium salt, 99%** ▲ *[BC-Indicator, X-Glucuronide]* [129541-41-9], $C_{14}H_{12}BrClNNaO_7$, F.W. 444.59, Powder, MDL MFCD00135782	**250mg** **1g**
J64451	**5-Bromo-4-chloro-3-indolyl phosphate disodium salt, 98%** ▲◪ *[X-Phosphate disodium salt]* [102185-33-1], $C_8H_4BrClNNa_2O_4P$, F.W. 370.43, Powder, MDL MFCD00036757	**250mg** **1g**
J65225	**Bromocresol Green, ACS** [76-60-8], $C_{21}H_{14}Br_4O_5S$, F.W. 698.04, Powder, m.p. 225° dec., Merck **14**,1386, EINECS 200-972-8, BRN 372527, MDL MFCD00005874, †	**5g** **25g**
38696	**Bromocresol Green sodium salt, 0.04% w/v aq. soln.** *[Bromocresol Green, water soluble]* [62625-32-5], $C_{21}H_{13}Br_4NaO_5S$, F.W. 720.01, Liquid, MDL MFCD00148898, Note: Transition interval: pH 3.8 (yellow) to pH 5.4 (blue), †	**100ml** **500ml**
J64284	**Bromocresol Green sodium salt, ACS** *[Bromocresol Green, water soluble]* [62625-32-5], $C_{21}H_{13}Br_4NaO_5S$, F.W. 720.02, Crystalline powder, m.p. 230° dec., Merck **14**,1386, EINECS 263-657-4, MDL MFCD00148898, †	**5g** **25g**
38700	**Bromocresol Purple sodium salt, 0.04% w/v aq. soln.** *[Bromocresol Purple, water soluble]* [62625-30-3], $C_{21}H_{15}Br_2NaO_5S$, F.W. 562.22, Liquid, MDL MFCD00148896, Note: Transition interval: pH 5.2 (yellow-green) to pH 6.8 (purple), †	**100ml** **500ml** **6x100ml**
J65357	**8-Bromo-2'-deoxyadenosine, 99%** *[8-Bromo-2'-deoxy-D-adenosine]* [14985-44-5], $C_{10}H_{13}FN_6O_3$, F.W. 284.25, Powder, MDL MFCD01630970 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J65456	**5-Bromo-2'-deoxycytidine, 99%** [1022-79-3], $C_9H_{11}BrN_2O_5$, F.W. 307.10, Powder, EINECS 213-824-2, RTECS HA3705000, MDL MFCD00047496	**1g**
J64723	**8-Bromo-2'-deoxyguanosine, 99%** [13389-03-2], $C_{10}H_{12}BrN_5O_4$, F.W. 346.14, Powder ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64704	**2'-Bromo-2'-deoxyuridine, 98%** [72218-68-9], $C_9H_{11}BrN_2O_5$, F.W. 307.10, Powder	**500mg**
J64219	**5-Bromo-2'-deoxyuridine-5'-monophosphate sodium salt, 98%** *[5-BrdUMP]* [51432-32-7], $C_9H_{12}BrNNa_2O_8P$, F.W. 419.05, Powder, MDL MFCD00057406 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
	Bromoenol lactone, see Haloenol Lactone Suicide Substrate, 98+%, J63728, p. 240 **Bromofluorescein**, see Eosin Yellowish, B24535, p. 208	
H54587	**4-Bromo-7-fluoroindole, 95%** [883500-66-1], C_8H_5BrFN, F.W. 214.04 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250mg** **1g** **5g**
H51978	**4-Bromo-N-Fmoc-L-phenylalanine, 95%** *[Fmoc-Phe(4-Br)-OH]* [198561-04-5], $C_{24}H_{20}BrNO_4$, F.W. 466.33, m.p. 165-168°, MDL MFCD00273460	**250mg** **1g** **5g**
J63940	**8-Bromoguanosine** *[2-Amino-8-bromo-6-hydroxypurine riboside]* [4016-63-1], $C_{10}H_{12}BrN_5O_5$, F.W. 362.14, Powder, EINECS 223-677-6, MDL MFCD00037985	**5g**
L02992	**8-Bromoguanosine hydrate, 97%** [332359-99-6], $C_{10}H_{12}BrN_5O_5 \cdot xH_2O$, F.W. 362.14(anhy), m.p. >300°, $[\alpha]_D^{20}$ -30° (c=2 in DMSO/water, 1:1), EINECS 223-677-6, BRN 578725, MDL MFCD00150531	**1g** **5g** **25g**
	(R)-4-Bromo-3-hydroxybutyric acid ethyl ester, see Ethyl (R)-4-bromo-3-hydroxybutyrate, J60862, p. 214 **(S)-4-Bromo-3-hydroxybutyric acid ethyl ester**, see Ethyl (S)-4-bromo-3-hydroxybutyrate, J62782, p. 214	
J65978	**5-Bromo-3-indolyl β-d-galactopyranoside, 98+%** *[Bluo-Gal]* [97753-82-7], $C_{14}H_{16}BrNO_6$, F.W. 374.18, Powder, MDL MFCD00063691 Application(s): α-Galactosidase substrate for Lac-gene detection systems	**100mg** **1g**
	3-Bromo-3-methyl-2-(2-nitrophenylthio)-3H-indole, see BNPS-Skatole, J61050, p. 196	
J64131	**6-Bromo-2-naphthyl β-D-glucopyranoside** *[Br-Nap-β-D-Glc]* [15548-61-5], $C_{16}H_{17}BrO_6$, F.W. 385.12, Powder, EINECS 239-604-6, MDL MFCD00063007 Application(s): Chromogenic substrate for β-glucosidase	**1g** **5g**
	5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester, see Nicergoline, J63295, p. 301	
J65443	**5-Bromo-5-nitro-1,3-dioxane, 98%** [30007-47-7], $C_4H_6BrNO_4$, F.W. 212.00, Powder, m.p. 58-61°, EINECS 250-001-7, RTECS JG9650000, MDL MFCD00101855, † ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Reactive against both gram-positive and gram-negative bacteria. Less toxic than sodium azide	**5g** **25g**
J63480	**Bromo-7-nitroindazole, 98+%** [74209-34-0], $C_7H_4BrN_3O_2$, F.W. 242.00, Powder, MDL MFCD00159910 Application(s): Inhibitor of nitric oxide synthase (NOS)	**5mg** **25mg** **50mg**
32641	**Bromophenol Blue, ACS** [115-39-9], $C_{19}H_{10}Br_4O_5S$, F.W. 669.98, Crystalline, m.p. 270° dec., Merck **14**,1444, Solubility: Freely soluble in NaOH, EINECS 204-086-2, RTECS SJ7453000, BRN 61698, MDL MFCD00005875, † Specifications: Clarity of solution P.T., Visual transition interval pH 3.0 (yellow) to pH 4.6 (blue)	**1g** **5g** **25g**
A16899	**Bromophenol Blue sodium salt** *[Bromphenol Blue, water soluble]* [34725-61-6], $C_{19}H_9Br_4NaO_5S$, F.W. 691.96, m.p. >300°, Merck **14**,1444, EINECS 252-170-2, MDL MFCD00013793, † Acid-base indicator: pH 3.0 - 4.6. Application(s): Tracking dye for alkaline and neutral buffer systems, for nucleic acid staining	**10g** **50g**
38693	**Bromophenol Blue sodium salt, 0.04% w/v aq. soln.** [34725-61-6], $C_{19}H_9Br_4NaO_5S$, F.W. 691.96, Liquid, Merck **14**,1444, MDL MFCD00013793, Note: Transition interval: pH 3.0 (yellow) to pH 4.6 (blue), †	**100ml** **500ml** **6x100ml**
	Bromphenol Blue, water soluble, see Bromophenol Blue sodium salt, A16899, p. 137	

Stock #	Description	Size
A15922	**N-Bromosuccinimide, 99% ▲** *[NBS]* [128-08-5], $C_4H_4BrNO_2$, F.W. 177.99, m.p. 175-180° dec., d. 2.098, Merck **14**,1438, Fieser **1**,78 **12**,79 **13**,49 **14**,57 **15**,50 **16**,49 **18**,65 **19**,50 **20**,58 **21**,72, UN3261, EINECS 204-877-2, BRN 113916, MDL MFCD00005510, †	**250g** **1kg** **5kg**



H:H314-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a

Source of free-radical or positive bromine. For examples of radical benzylic bromination (Wohl-Ziegler), see: *Org. Synth. Coll.*, **4**, 921 (1963); **5**, 145, 329, 825 (1973). The use of the ozone depleting solvent CCl_4 has been avoided by the use of the ionic liquid **1-n-Butyl-3-methylimidazolium hexafluorophosphate**, **L19086**: *Synlett*, 702 (2003).
Cleavage of carbohydrate benzyl ethers: *J. Org. Chem.*, **55**, 378 (1990), and of benzyl esters: *Synlett*, 219 (1994), occur under mild conditions; the benzyl group is converted to benzaldehyde. For allylic bromination, see e.g.: *Org. Synth. Coll.*, **4**, 108 (1963);.**9**, 112, 191 (1998) review: *Chem. Rev.*, **43**, 271 (1948).
For free-radical α-bromination of a Boc glycine ester, see: *Org. Synth. Coll.*, **9**, 526 (1998).
Both aliphatic and aromatic aldehydes are converted to acyl bromides under free-radical conditions: *Tetrahedron Lett.*, 3809 (1979); *Synlett*, 347 (1990); *Tetrahedron Lett.*, **31**, 7237 (1990).
In acetonitrile, NBS is a mild and regiospecific nuclear brominating agent for activated aromatics such as methoxybenzenes and naphthalenes: *J. Org. Chem.*, **60**, 5328 (1995). Deactivated aromatics, e.g. nitroarenes and benzotrifluorides, can be *m*-brominated under mild conditions in good yield with NBS in TFA, in the presence of H_2SO_4: *Synlett*, 1245 (1999).
In the presence of a phosphine or phosphite, converts alcohols to alkyl bromides with inversion: *Tetrahedron Lett.*, 3937 (1973). For a review of this and related reactions, see: *Org. React.*, **29**, 1 (1983).
Alkenes undergo *trans*-addition reactions with NBS in combination with a nucleophile. For examples, see: *Org. Synth. Coll.*, **6**, 184, 560 (1988). With alcohols, bromohydrin ethers are formed. For use in the synthesis of cyclopropenone, see: *Org. Synth. Coll.*, **6**, 361 (1988):



In the presence of DBU in MeOH, amides rearrange to amines in good yields, providing a mild and efficient alternative to the classical Hofmann halogen/ caustic alkali conditions: *J. Org. Chem.*, **62**, 7495 (1997).
Examples of the use of NBS as a mild, selective oxidizing agent:
Sulfides to sulfoxides: *J. Org. Chem.*, **37**, 3976 (1968). Oximes to nitrile oxides: *J. Org. Chem.*, **37**, 436 (1968). Secondary alcohol in the presence of primary: *Tetrahedron Lett.*, 2745 (1979). (In DMSO): Alkynes to α-diketones: *Can. J. Chem.*, **49**, 1099 (1979).
(Free radical): Aldehydes to acyl bromides or amides: *Tetrahedron Lett.*, **31**, 7237 (1990). Benzyl silyl ethers to aldehydes: *Synlett*, 345 (1990). Aldehydes to esters: *Synlett*, 347 (1990).
For use as a mild catalyst in acetalization reactions, see **Triethyl orthoformate**, **A13587**.
For a brief feature on uses in synthesis, see: *Synlett*, 498 (2006). See also **1,3-Dibromo-5,5-dimethylhydantoin**, **A15510**.

Application(s): Allylic bromination reagent. Cleaves peptides at tryptophyl residues

38701	**Bromothymol Blue sodium salt, 0.04% w/v aq. soln.** [34722-90-2], $C_{27}H_{27}Br_2NaO_5S$, F.W. 646.38, Liquid, MDL MFCD00077263, Note: Transition interval: pH 6.0 (yellow) to pH 7.6 (blue), †	**100ml** **500ml** **6x100ml**
A14799	**5-Bromouracil, 98+%** [51-20-7], $C_4H_3BrN_2O_2$, F.W. 190.99, m.p. ca 310° dec., Merck **14**,1440, EINECS 200-084-0, RTECS YQ9060000, BRN 127176, MDL MFCD00006017, † H:H341, P:P281-P201-P202-P308+P313-P405-P501a	**5g** **25g** **100g**



A18507	**5-Bromouridine, 98%** [957-75-5], $C_9H_{11}BrN_2O_6$, F.W. 323.10, m.p. 191-193°, EINECS 213-486-6, MDL MFCD00006528	**250mg**



J63922	**Brompheniramine** [86-22-6], $C_{16}H_{19}BrN_2$, F.W. 319.24, Powder, Merck **14**,1443, EINECS 201-657-8, † Application(s): An antihistamine and also an inhibitor of serotonin reuptake	**10mg** **25mg** **100mg**
J61178	**Brucine** *[10,11-Dimethoxystrychnine]* [357-57-3], $C_{23}H_{26}N_2O_4$, F.W. 394.47, Powder, m.p. 175-178° dec., Merck **14**,1455, UN1570, EINECS 206-614-7, RTECS EH8925000, BRN 63046, MDL MFCD00005942, † H:H300-H330-H412, P:P301+P310-P304+P340-P320-P330-P405-P501a	**5g** **25g** **100g**
A16251	**Brucine dihydrate, 98%** [5892-11-5], $C_{23}H_{26}N_2O_4 \cdot 2H_2O$, F.W. 430.50 (394.47anhy), m.p. 176-178°, UN1570, MDL MFCD00149384, † H:H300-H330-H412, P:P301+P310-P304+P340-P320-P330-P405-P501a Resolving agent for chiral acids. Application(s): Resolving agent	**10g** **50g**



Contact us for pricing on bulk sizes

Stock #	Description	Size
36249	**Brucine sulfate heptahydrate, ACS** [60583-39-3], $(C_{23}H_{26}N_2O_4)_2 \cdot H_2SO_4 \cdot 7H_2O$, F.W. 1013.15 (887.03anhy), Powder, m.p. 180° dec., Merck **14**,1455, UN2811, EINECS 225-432-9, MDL MFCD00150159, † Maximum level of impurities: Clarity of solution P.T., Loss on drying at 105° 13.0%, Residue after ignition 0.1%, Sensitivity to nitrate P.T. H:H300-H330-H412, P:P301+P310-P304+P340-P320-P330-P405-P501a  Application(s): Resolving agent	25g
	Bryamycin, see Thiostrepton, Streptomyces laurentii, 98%, J62332, p. 368	
J63848	**Bryostatin 1** [83314-01-6], $C_{47}H_{68}O_{17}$, F.W. 905.03, Solid, m.p. 230-235°, Merck **14**,1457, RTECS EH9455000, MDL MFCD00893832 Application(s): Binds to and activates protein kinase C	10micrograms 25micrograms
J61551	**Bryostatin 2** *[NSC 339554]* [87745-28-6], $C_{45}H_{66}O_{16}$, F.W. 863.00, Solid Application(s): A macrocyclic lactone with anti-tumor properties. Binds to and activates protein kinase C	10micrograms 25micrograms
	Butylated hydroxytoluene, see 2,6-Di-tert-butyl-4-methylphenol, A16863, p. 185 **BSA**, see N,O-Bis(trimethylsilyl)acetamide, L00183, p. 127	
J61655	**BSA blocking buffer, 3% in PBS** Liquid, Note: 3% Bovine serum albumin in PBS, pH 7.4, †	250ml 500ml
J60473	**BSA blocking buffer, 3% in PBS, with 0.02% sodium azide** Liquid, Note: 3% Bovine serum albumin in PBS with 0.02% sodium azide, †	250ml 500ml
J61116	**BSA blocking buffer, 3% in PBS, with 0.05% Tween-20** Liquid, Note: 3% Bovine serum albumin in PBS, with 0.05% Tween 20, pH 7.4, †	250ml 500ml
J61119	**BSA blocking buffer, 3% in TBS** Liquid, Note: 3% Bovine serum albumin in Tris-buffered saline, pH 7.4, † H:H360, P:P281-P201-P202-P308+P313-P405-P501	250ml 500ml
J62554	**BSA blocking buffer, 3% in TBS, with 0.05% Tween-20** Liquid, Note: 3% Bovine serum albumin in TBS, wih 0.05% Tween 20, pH 7.4, †	250ml 500ml
J61089	**BSA blocking buffer, 5% in PBS** Liquid, Note: 5% Bovine serum albumin in Phosphate-buffered saline, pH 7.4, †	250ml 500ml
J63711	**BSA blocking buffer, 5% in PBS, with 0.05% Tween-20** Liquid, Note: 5% Bovine serum albumin in phosphate-buffered saline, 0.05% Tween-20, pH 7.4, †	250ml 500ml
J62637	**BSA blocking buffer, 5% in TBS** Liquid, Note: 5% Bovine serum albumin in Tris-buffered saline, pH 7.4, †	250ml 500ml
J62305	**BSA blocking buffer, 5% in TBS, with 0.02% sodium azide** Liquid, Note: 5% Bovine serum albumin in TBS, with 0.02% azide, pH 7.4, † H:H360, P:P281-P201-P202-P308+P313-P405-P501	250ml 500ml
J60098	**BSA blocking buffer, 5% in TBS, with 0.05% Tween-20** Liquid, Note: 5% Bovine serum albumin in Tris-buffered saline, 0.05% Tween-20, pH 7.4, †	250ml 500ml
	BTC, see Blue Tetrazolium chloride, A12502, p. 129	
J60655	**Buccalin** *[Buccalin A, Gly-Met-Asp-Ser-Leu-Ala-Phe-Ser-Gly-Gly-Leu-NH2]* [116844-51-0], $C_{45}H_{72}N_{12}O_{15}S_1$, F.W. 1053.50, Powder Application(s): A modulatory neuropeptide involved in regulation of acetylcholine release	1mg 5mg
	Buccalin A, see Buccalin, J60655, p. 139	
J62302	**Bumetanide, 98+%** *[3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid]* [28395-03-1], $C_{17}H_{20}N_2O_5S$, F.W. 364.40, Solid, m.p. 230-231°, Merck **14**,1484, EINECS 249-004-6, RTECS DG4910000, MDL MFCD00078949 Application(s): Inhibitor of the sodium-potassium-chloride cotransporter	1g 5g
J62742	**Bupivacaine** [38396-39-3], $C_{18}H_{28}N_2O$, F.W. 288.43, Cyrstalline powder, m.p. 106-110°, UN2811, EINECS 253-911-2, † H:H300-H310-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Sodium channel blocker	1g 5g 25g

Stock #	Description	Size
J62835	**Bupivacaine hydrochloride, 98+%** *[Marcaine, Carbostesin]* [18010-40-7], $C_{18}H_{28}N_2O{\cdot}HCl$, F.W. 324.89, White powder, m.p. 255-259°, Merck **14**,1495, UN2811, EINECS 241-971-8, RTECS TK6125000, MDL MFCD00078956 H:H300-H310-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Inhibits TREK-1 channels and depolarizes the cell membrane	**1g** **5g** **25g**
J61105	**Bupropion hydrochloride, 99%** *[1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride]* [31677-93-7], $C_{13}H_{18}ClNO{\cdot}HCl$, F.W. 276.20, Powder, m.p. 233-234°, Merck **14**,1499, EINECS 250-759-9, RTECS UG8858000, MDL MFCD00055209 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A selective inhibitor of dopamine uptake	**1g** **5g**
J60476	**Buspirone hydrochloride** [33386-08-2], $C_{21}H_{31}N_5O_2{\cdot}HCl$, F.W. 421.96, White to off-white powder, Merck **14**,1504, UN2811, EINECS 251-489-4, RTECS CL9915000, MDL MFCD00078569 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A 5-HT-1A serotonin receptor agonist. Affects dopaminergic, serotonergic and noradrenergic pathways	**1g** **5g** **25g**
J61348	**Busulfan, 98%** *[1,4-Butanediol dimethanesulfonate]* [55-98-1], $CH_3SO_2O(CH_2)_4OSO_2CH_3$, F.W. 246.29, Crystalline powder, Merck **14**,1505, UN2811, EINECS 200-250-2, RTECS EK1750000, BRN 1791786, MDL MFCD00007562 H:H300-H310-H330-H350, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): A cell cycle non-specific alkylating antineoplastic agent	**5g** **25g** **100g**
	1,4-Butanediamine, see 1,4-Diaminobutane, B21316, p. 182 **1,4-Butanediamine dihydrochloride**, see 1,4-Diaminobutane dihydrochloride, A18312, p. 182 **1,4-Butanedicarbonyl chloride**, see Adipoyl chloride, A13168, p. 80 **Butane-1,4-dicarboxylic acid**, see Adipic acid, A13705, p. 79 **Butanedioic acid**, see Succinic acid, 33272, p. 353 **Butanedioic anhydride**, see Succinic anhydride, A12245, p. 354 **1,4-Butanediol dimethanesulfonate**, see Busulfan, 98%, J61348, p. 140	
A14339	**2,3-Butanedione monoxime, 99%** ■ *[Diacetyl monoxime]* [57-71-6], $C_4H_7NO_2$, F.W. 101.11, m.p. 74-77°, b.p. 185-186°, EINECS 200-348-5, RTECS EK3150000, BRN 605582, MDL MFCD00002116, † Reagent for colorimetric determination of urea: *Anal. Biochem.*, **97**, 421 (1979). Reagent for Co, Ni, Pd and Re: *Talanta*, **26**, 425 (1979). Formation of the silyl enol ether (1-aza-3-siloxy-1,3-butadiene), followed by hetero Diels-Alder reaction with **Dimethyl acetylenedicarboxylate**, **A11437**, affords a highly-functionalized pyridine: *Tetrahedron*, **62**, 5454 (2006). Application(s): For determination of urea	**100g** **500g** **2.5kg**
	Butanimide, see Succinimide, A13503, p. 354	
L13983	**(R)-(-)-2-Butanol, 98+%** *[(R)-(-)-sec-Butyl alcohol]* [14898-79-4], $C_4H_{10}O$, F.W. 74.12, b.p. 99-100°, f.p. 26°(79°F), d. 0.806, n_D^{20} 1.3980, $[\alpha]_D^{20}$ -15° (c=10 in methanol), Merck **14**,1541, UN1120, EINECS 238-967-8, BRN 1718764, MDL MFCD00064280, † H:H226-H319-H335+H336, P:P262-P233-P301+P310-P305+P351+P338-P315-P403 Application(s): For synthesis of optically active products	**1g** **5g**
L14164	**(S)-(+)-2-Butanol, 98+%** *[(S)-(+)-sec-Butyl alcohol]* [4221-99-2], $C_4H_{10}O$, F.W. 74.12, b.p. 99-100°, f.p. 26°(79°F), d. 0.806, n_D^{20} 1.3980, $[\alpha]_D^{20}$ +13.5° (c=10 in methanol), Merck **14**,1541, UN1120, EINECS 224-168-1, BRN 1718763, MDL MFCD00064281 H:H226-H319-H335+H336, P:P262-P233-P301+P310-P305+P351+P338-P315-P403 Application(s): For synthesis of optically active products	**1g** **5g**
	cis-2-Butenedioic acid, see Maleic acid, A14596, p. 275 **trans-2-Butenedioic acid**, see Fumaric acid, A10976, p. 228 **cis-Butenedioic anhydride**, see Maleic anhydride, A12178, p. 275 **N-tert-Butoxycarbonyl products**, see Boc, B22706, p. 129 **1-tert-Butoxycarbonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid**, see N-Boc-trans-4-hydroxy-L-proline, H27110, p. 131 **N-tert-Butoxycarbonyl-L-leucine**, see N-Boc-L-tert-leucine, H51136, p. 133 **2-Butoxy-N-(2-diethylaminoethyl)-4-quinolinecarboxamide hydrochloride**, see Dibucaine hydrochloride, J62804, p. 184	
H51752	**1-(3-tert-Butoxyphenyl)homopiperazine monohydrochloride, 98%** *[3-BOPH·HCl]* [934992-04-8], $C_{15}H_{24}N_2O{\cdot}HCl$, F.W. 284.83, m.p. 143-147°, MDL MFCD16172200, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd.	**500mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
H51687	**1-(4-tert-Butoxyphenyl)homopiperazine monohydrochloride, 98%** *[4-BOPH·HCl]* [934991-96-5], $C_{15}H_{24}N_2O$·HCl, F.W. 284.83, m.p. 197-201°, MDL MFCD16251545, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd. 	500mg
	1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone, see Dyclonine hydrochloride, J61330, p. 202 **(R)-(-)-sec-Butyl alcohol**, see (R)-(-)-2-Butanol, L13983, p. 140 **(S)-(+)-sec-Butyl alcohol**, see (S)-(+)-2-Butanol, L14164, p. 140 **(R)-(-)-2-Butylamine**, see (R)-(-)-2-Aminobutane, L03889, p. 92 **(S)-(+)-2-Butylamine**, see (S)-(+)-2-Aminobutane, L10069, p. 92 **α-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol sulfate**, see Salbutamol sulfate, A18544, p. 339 **Butylated hydroxyanisole**, see 2(3)-tert-Butyl-4-methoxyphenol, B23530, p. 141 **2-n-Butyl-3-benzofuranyl [4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl] ketone hydrochloride**, see Amiodarone hydrochloride, J60456, p. 100 **4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione**, see Phenylbutazone, L03449, p. 316	
H52065	**O-tert-Butyl-N-Fmoc-L-β-homoserine, 95%** *[Fmoc-β-Homoser(tBu)-OH]* [203854-51-7], $C_{23}H_{27}NO_5$, F.W. 397.47, m.p. 96-98°, BRN 8014825, MDL MFCD01862865 	250mg 1g
H52192	**O-tert-Butyl-N-Fmoc-L-β-homotyrosine, 95%** *[Fmoc-β-Homotyr(tBu)-OH]* [219967-69-8], $C_{29}H_{31}NO_5$, F.W. 473.57, BRN 8236890, MDL MFCD01862862 	250mg 1g
B23530	**2(3)-tert-Butyl-4-methoxyphenol, 96% ▲** *[BHA, Butylated hydroxyanisole]* [25013-16-5], $C_{11}H_{16}O_2$, F.W. 180.25, m.p. 55-65°, Merck **14**,1547, EINECS 246-563-8, MDL MFCD01779059, †  H:H351-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): Antioxidant	50g 250g 1kg
H51702	**1-(4-tert-Butylphenyl)homopiperazine dihydrochloride, 98%** *[4-BPHP·2HCl]* [934992-03-7], $C_{15}H_{24}N_2$·2HCl, F.W. 305.30, m.p. 240-244°, MDL MFCD08436124, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd.  H:H315-H319-H335, P:P280g-P305+P351+P338 Application(s): Useful intermediate for synthesis	500mg
	n-Butyl phenyl ketone, see Valerophenone, A10525, p. 390 **1-n-Butyl-3-(p-tolylsulfonyl)urea**, see Tolbutamide, B21698, p. 371	
L13189	**Butyric acid, 99+%** [107-92-6], $CH_3CH_2CH_2COOH$, F.W. 88.11, m.p. -8°, b.p. 162-164°, f.p. 69°(156°F), d. 0.964, n_D^{20} 1.3980, Merck **14**,1593, UN2820, EINECS 203-532-3, RTECS ES5425000, BRN 906770, MDL MFCD00002814, † H:H311-H314, P:P260-P303+P361+P353-P305+P351+P338-P361-P405-P501a	100ml 500ml 2.5L
J64844	**(4S)-3-Butyryl-4-benzyl-2-oxazolidinone** *[UIC-1017, Cell Sheet Migration Inhibitor, Negative Control]* [112459-79-7], $C_{14}H_{17}NO_3$, F.W. 247.29, Powder	5mg
J64391	**Butyrylcholine chloride, 98+% ■** *[(2-Hydroxyethyl)trimethylammoniumchloride butyrate]* [2963-78-2], $C_9H_{20}ClNO_2$, F.W. 209.71, Powder, EINECS 220-999-9, MDL MFCD00011844	50g 100g
A12622	**S-Butyrylthiocholine iodide, 98% ▲■** [1866-16-6], $CH_3CH_2CH_2COSCH_2CH_2N(CH_3)_3I$, F.W. 317.23, m.p. 172-176°, EINECS 217-475-7, BRN 3729509, MDL MFCD00011845, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	5g 25g
	C2-Ceramide, see N-Acetyl-D-sphingosine, 98%, J60534, p. 74	
J61832	**CABS, 0.2M buffer soln., pH 10.5** [161308-34-5], Liquid	100ml 250ml
A18139	**Cacodylic acid sodium salt trihydrate** *[Sodium cacodylate trihydrate, Dimethylarsinic acid sodium salt trihydrate]* [6131-99-3], $(CH_3)_2AsO_2Na·3H_2O$, F.W. 214.03 (159.98anhy), Merck **14**,8595, UN1688, EINECS 204-708-2, RTECS CH7700000, BRN 3702348, MDL MFCD00149079, † H:H301-H331-H400-H410, P:P261-P301+P310-P321-P304+P340-P405-P501a Application(s): An integral component of terminal deoxynucleotidyl transferase buffer.	25g 100g 500g
	Cadavarine, see 1,5-Diaminopentane, B23039, p. 183 **2-CADO**, see 2-Chloroadenosine, J63810, p. 155	

Stock #	Description	Size
J64396	**Caerulein, non-sulfated** *[Pyr-Gln-Asp-Tyr-Thr-Gly-Trp-Met-Asp-Phe-NH]* [20994-83-6], $C_{58}H_{73}N_{13}O_{18}S$, F.W. 1272.36, Powder Application(s): Stimulates smooth muscle and increases digestive secretions	**1mg**
J64320	**Caerulein, sulfated** *[Glp-Gln-Asp-Tyr(SO3H)-Thr-Gly-Trp-Met-Asp-Phe-NH2, Ceruletide]* [17650-98-5], $C_{58}H_{73}N_{13}O_{21}S_2$, F.W. 1352.40, Powder, BRN 5422487, MDL MFCD00076478 Application(s): Stimulates smooth muscle and increases digestive secretions	**0.5mg** **1mg**
J65355	**Cafestol** [469-83-0], $C_{20}H_{28}O_3$, F.W. 316.44, Powder, m.p. 156-158°, d. 1.23, Merck **14**,1634, RTECS PB9185090 Application(s): Natural extract from coffee beans which induces glutathione S-transferase	**50mg** **100mg**
	Caffeic acid, see 3,4-Dihydroxycinnamic acid, A15950, p. 192 **Caffeic acid methyl ester**, see Methyl caffeate, J63786, p. 286	
A10431	**Caffeine, 99%** *[3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione, 1,3,7-Trimethylxanthine]* [58-08-2], $C_8H_{10}N_4O_2$, F.W. 194.19, m.p. 234-236°, d. 1.230, Merck **14**,1636, Solubility: Soluble in pyrrole, THF-H_2O mixture, ethyl acetate, UN1544, EINECS 200-362-1, RTECS EV6475000, BRN 17705, MDL MFCD00005758, † ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Has inhibitory action against lung and colon tumorigenses, and virus induction	**100g** **250g** **1kg**
L10255	**Calcein sodium salt, ca 2-3 Na** *[Bis[N,N-bis(carboxymethyl)aminomethyl]fluorescein sodium salt, Fluorexon]* [108750-13-6], $C_{30}H_{24}N_2Na_2O_{13}$, F.W. 666.51, MDL MFCD00005049 Reagent for complexometric determination of Ca and Mg: *Analyst*, **82**, 284 (1957); **83**, 188 (1958). Application(s): Indicator for the determination of calcium in biological systems	**5g** **25g**
J61610	**Calciferol** *[Ergocalciferol, Vitamin D_2]* [50-14-6], $C_{28}H_{44}O$, F.W. 396.65, Powder, m.p. 114-118°, Merck **14**,10018, UN2811, EINECS 200-014-9, RTECS KE1050000, BRN 1916682, MDL MFCD00166988, † H:H300-H311-H372, P:P260-P301+P310-P361-P302+P352-P405-P501a	**1g** **5g** **10g**
J62163	**Calciferol, 98%** *[Ergocalciferol, Vitamin D_2]* [50-14-6], $C_{28}H_{44}O$, F.W. 396.66, Powder, m.p. 118-119°, Merck **14**,10018, UN2811, EINECS 200-014-9, RTECS KE1050000, BRN 1916682, MDL MFCD00166988, † H:H301-H311-H330-H372, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a	**1g** **5g** **25g**
	Calcimycin, see Antibiotic A23187, 99+%, J63020, p. 105	
J64047	**Calcineurin Autoinhibitory Fragment** *[Ile-Thr-Ser-Phe-Glu-Glu-Ala-Lys-Gly-Leu-Asp-Arg-Ile-Asn-Glu-Arg-Met-Pro-Pro-Arg-Arg-Asp-Ala-Met-Pro]* $C_{124}H_{205}N_{39}O_{39}S_2$, F.W. 2930.31, Solid	**0.5mg** **1mg**
J61049	**Calcitonin, chicken** $C_{145}H_{240}N_{42}O_{46}S_2$, F.W. 3371.89, Powder, Merck **14**,1643 Application(s): A peptide hormone produced by thyroid cells, shown to inhibit osteoclasts activity	**0.5mg**
J63006	**Calcitonin, eel** [57014-02-5], $C_{146}H_{241}N_{43}O_{47}S_2$, F.W. 3414.94, Powder, Merck **14**,1643, MDL MFCD00133858 Application(s): A peptide hormone	**1mg**
J63192	**Calcitonin, human, 97+%** *[Calcitonin M, Human C carcinoma]* [21215-62-3], $C_{151}H_{226}N_{40}O_{45}S_3$, F.W. 3417.90, Powder, Merck **14**,1643, EINECS 244-276-2, RTECS XP3560000, MDL MFCD00167520 Application(s): Decreases blood calcium and phosphate due to inhibition of resorption by osteoblasts and osteocytes. A carrier peptide that can be used to internalize fusion proteins	**0.5mg** **1mg**
J64341	**Calcitonin, porcine** $C_{159}H_{232}N_{46}O_{45}S_3$, F.W. 3604.01, Solid, EINECS 235-585-3, RTECS XP3561000	**0.5mg** **1mg**
J61231	**Calcitonin, rat** [11118-25-5], $C_{148}H_{228}N_{40}O_{46}S_3$, F.W. 3399.90, Powder, Merck **14**,1643, MDL MFCD00133857 Application(s): A peptide hormone	**0.5mg**
J63531	**Calcitonin, salmon** [47931-85-1], $C_{145}H_{240}N_{44}O_{48}S_2$, F.W. 3417.90, Powder, Merck **14**,1643, EINECS 256-342-8, RTECS EV8000000, MDL MFCD00133859 Application(s): A peptide hormone	**0.5mg**

Stock #	Description	Size
J64415	**Calcitonin (8-32), salmon** *[Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2]* [155069-90-2], $C_{119}H_{198}N_{36}O_{37}$, F.W. 2725.06, Solid	0.5mg 1mg
J65667	**Calcitonin Gene Related Peptide, human** *[CGRP, human]* [90954-53-3], $C_{163}H_{267}N_{51}O_{49}S_2$, F.W. 3789.3, Solid, MDL MFCD00285485	0.5mg 1mg
J65912	**Calcitonin Gene Related Peptide (8-37), human** *[α-CGRP (8-37), human]* [119911-68-1], $C_{139}H_{230}N_{44}O_{38}$, F.W. 3125.58, Powder, MDL MFCD00133153	0.5mg 1mg
J64037	**Calcitonin Gene Related Peptide II, human** [98824-26-1], $C_{162}H_{267}N_{51}O_{48}S_3$, F.W. 3793.35, Solid	0.5mg
J65250	**[Tyr0] Calcitonin Gene Related Peptide II, human** $C_{171}H_{276}N_{52}O_{50}S_3$, F.W. 3956.52, Solid	0.5mg 1mg
	Calcitonin M, see Calcitonin, human, 97+%, J63192, p. 142	
12365	**Calcium carbonate, 98%** [471-34-1], $CaCO_3$, F.W. 100.09, Powder, m.p. 800° dec., d. 2.930, n_D^{20} 1.6583, Merck **14**,1657, Solubility: Practically insoluble in water. Soluble in diluted acids, EINECS 207-439-9, RTECS FF9335000, MDL MFCD00010906, † Application(s): Manufacture of paint, rubber, plastics, etc. In food, cosmetics, and pharmaceuticals. As soil conditioner, neutralizer of surface waters, and as an industrial acid neutralizer	500g 2kg
33295	**Calcium carbonate, ACS, 99.0% min** [471-34-1], $CaCO_3$, F.W. 100.09, Powder, m.p. 800° dec., d. 2.930, n_D^{20} 1.6583, Merck **14**,1657, EINECS 207-439-9, RTECS FF9335000, MDL MFCD00010906, † Maximum level of impurities: Insoluble in dilute hydrochloric acid 0.01%, Cl 0.001%, F 0.0015%, SO_4 0.01%, NH_4 0.003%, Heavy Metals (as Pb) 0.001%, Fe 0.003%, Ba 0.01%, Mg 0.02%, K 0.01%, Na 0.1%, Sr 0.1%	100g 500g
J62905	**Calcium chloride, 100mM aq. soln., sterile** [10043-52-4], $CaCl_2$, F.W. 110.99, Liquid, † ! H:H302, P:P264-P270-P301+P312-P330-P501a	500ml 1L
J63122	**Calcium chloride, 1M aq. soln.** [10043-52-4], $CaCl_2$, F.W. 110.99, Liquid, MDL MFCD00010903, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	50ml 100ml
33296	**Calcium chloride dihydrate, ACS, 99.0-105.0%** ■ [10035-04-8], $CaCl_2{\cdot}2H_2O$, F.W. 147.02 (110.99anhy), Powder, d. 0.835, Merck **14**,1659, EINECS 233-140-8, MDL MFCD00149613, † Maximum level of impurities: Insoluble matter 0.01%, pH of a 5% solution 4.5-8.5 at 25°, Oxidizing substances (as NO_3) 0.003%, SO_4 0.01%, NH_4 0.005%, Ba 0.005%, Heavy Metals (as Pb) 5ppm, Fe 0.001%, Mg 0.005%, K 0.01%, Na 0.02%, Sr 0.1% ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	500g 2kg
89866	**Calcium chloride, anhydrous, ACS, 96.0% min** ■ [10043-52-4], $CaCl_2$, F.W. 110.99, Powder, Packaged under argon, m.p. 782°, b.p. >1600°, Merck **14**,1659, EINECS 233-140-8, RTECS EV9800000, MDL MFCD00010903, Note: d_4^{25}2.15, † Maximum level of impurities: Titratable base 0.006meq/g ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): Typical ionic halide, often used as a dessicant	50g 250g
	Calcium ionophore A23187 , see Antibiotic A23187, 99+%, J63020, p. 105	
J60926	**Calcium-Like Peptide** *[Val-Ala-Ile-Thr-Val-Leu-Val-Lys, CALP1]* [145224-99-3], $C_{40}H_{75}N_9O_{10}$, F.W. 827.09, Powder Application(s): Cell-permeable calmodulin agonist	1mg 5mg
	Calcium D-pantothenate hydrate, see D-Pantothenic acid calcium salt hydrate, A16609, p. 311 **Calcium phosphate hydroxide**, see Hydroxylapatite, high resolution, J61818, p. 250 **Calcium phosphate hydroxide**, see Hydroxylapatite, fast flow, J60076, p. 249	
89836	**Calcium phosphate (pyro), 96% min** *[Calcium pyrophosphate]* [7790-76-3], $Ca_2P_2O_7$, F.W. 254.10, Powder, m.p. 1230°, d. 3.09, EINECS 232-221-5, MDL MFCD00015983, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	250g 1kg 5kg
	Calcium pyrophosphate, see Calcium phosphate (pyro), 89836, p. 143	
J63270	**Calmidazolium chloride** [57265-65-3], $C_{31}H_{23}Cl_7N_2O$, F.W. 687.71, Solid, MDL MFCD00077679 Application(s): Inhibits the calcium-calmodulin dependent phosphodiesterase	10mg

Stock #	Description	Size
J60231	**Calmodulin, bovine testes** [77107-46-1], Lyophilized powder, 16.680 kDa, Merck **14**,1719, MDL MFCD00131869 Application(s): Activates cyclic phosphodiesterase	**1mg** **2.5mg**
	CALP1, see Calcium-Like Peptide, J60926, p. 143	
J61766	**Calpain Inhibitor I, 95+%** *[Ac-LLnL-CHO, ALLN]* [110044-82-1], $C_{20}H_{37}N_3O_4$, F.W. 383.53, Powder, BRN 7656053, MDL MFCD00065505 Application(s): An inhibitor of both Calpain I and II	**5mg** **25mg**
J62491	**Calpain Inhibitor II, 95+%** *[N-Ac-Leu-Leu-Methioninal, ALLM]* [136632-32-1], $C_{19}H_{35}N_3O_4S$, F.W. 401.60, Powder, BRN 7693643, MDL MFCD00065506 Application(s): An inhibitor of calpains I and II	**5mg** **25mg**
J62919	**Calpain Inhibitor III, 95+%** *[MDL, Z-Val-Phe-CHO]* [88191-84-8], $C_{19}H_{35}N_3O_4S$, F.W. 401.60, Powder, MDL MFCD00798796 Application(s): Inhibits calpain proteolysis	**25mg**
J65052	**Calpain Inhibitor IV** ◢ *[Z-Leu-Leu-Tyr-fluoromethyl ketone, Z-LLY-FMK]* $C_{30}H_{40}FN_3O_6$, F.W. 557.65, Powder	**1mg**
J65826	**Calpain Inhibitor X** ▲ *[Z-Leu-α-aminobutyric acid-CONHC2H5, Z-Leu-Abu-CONHC2H5]* $C_{21}H_{31}N_3O_5$, F.W. 405.50, Solid	**1mg** **5mg**
J65991	**Calpain Inhibitor XI** *[Z-Leu-α-aminobutyric acid-CONH(CH2)3-morpholine, Z-L-Abu-CONH(CH2)3-morpholine]* $C_{26}H_{40}N_4O_6$, F.W. 504.60, Solid	**1mg** **5mg**
J64751	**Calpain Inhibitor XII** *[Z-L-Nva-CONH-CH2-2-Py]* $C_{26}H_{34}N_4O_5$, F.W. 482.60, Solid	**1mg** **5mg**
J63222	**Calpain Substrate I** *[Suc-Leu-Tyr-AMC]* [94367-20-1], $C_{29}H_{33}N_3O_8$, F.W. 551.59, Powder, MDL MFCD00057900 Application(s): Flourogenic substrate for both calpains I and II	**50mg** **100mg** **250mg**
J60481	**Calpeptin, 98+%** *[N-Benzyloxycarbonyl-L-leucyl-norleucinal, Z-Leu-norleucinal]* [117591-20-5], $C_{20}H_{30}N_2O_4$, F.W. 362.50, Powder, MDL MFCD00155623 Application(s): Inhibitor of the calcium-dependent protease calpain and cathepsin L	**10mg** **50mg**
J60647	**Calphostin C, 99+%** *[UCN-1028c]* [121263-19-2], $C_{44}H_{38}O_{14}$, F.W. 790.76, Powder, MDL MFCD00133155 Application(s): Potent inhibitor of protein kinase C	**100micrograms**
J61952	**Calyculin A, 98+%** [101932-71-2], $C_{50}H_{81}N_4O_{15}P$, F.W. 1009.17, Solid, Merck **14**,1724, UN3462, BRN 4903216, MDL MFCD06795864 H:H301-H311-H330-H315, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Very potent inhibitor (Ki = ca. 0.1 nM) with high specificity for the PP-1 and PP-2 classes of protein serine/threonine phosphatase	**100micrograms**
J62362	**Camostat mesylate, 98%** [59721-29-8], $C_{20}H_{22}N_4O_5.CH_3SO_3H$, F.W. 494.52, Powder, m.p. 150-155°, Merck **14**,1728, MDL MFCD00941410 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An orally active synthetic serine protease inhibitor	**25mg** **100mg** **500mg**
A10936	**(±)-Camphor, 96%** *[DL-2-Bornanone]* [76-22-2], $C_{10}H_{16}O$, F.W. 152.24, m.p. 172-176°, b.p. 204°, f.p. 64°(147°F), d. 0.992, Merck **14**,1732, Solubility: Soluble in alcohols, ether, chloroform, benzene, UN2717, EINECS 200-945-0, RTECS EX1225000, BRN 1907611, MDL MFCD00074738, †  H:H228-H315-H319, P:P210-P280g-P305+P351+P338	**100g** **500g** **2.5kg** **10kg**
B23469	**(1S)-(-)-Camphor, 98%** *[L-2-Bornanone]* [464-48-2], $C_{10}H_{16}O$, F.W. 152.24, m.p. 175-180°, b.p. 204°, f.p. 65°(149°F), d. 0.990, $[\alpha]_D^{20}$ -43° (c=10 in ethanol), Merck **14**,1732, UN2717, EINECS 207-354-7, RTECS EX1250000, BRN 4291747, MDL MFCD00064148, †  H:H228-H315-H319, P:P210-P280g-P305+P351+P338	**5g** **25g** **100g**

Stock #	Description	Size
J62523	**Camptothecin** *[(S)-(+)-Camptothecin]* [7689-03-4], $C_{20}H_{16}N_2O_4$, F.W. 348.35, Powder, m.p. 260° dec., Merck **14**,1735, UN1544, RTECS UQ492000, BRN 631069, MDL MFCD00081076 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Cytotoxic antitumor agent that inhibits topoisomerase I	**250mg** **1g** **5g**
	(S)-(+)-Camptothecin, see Camptothecin, J62523, p. 145	
A16289	**Canada balsam, natural filtered** *[Balsam Canada]* [8007-47-4], f.p. 43°(109°F), d. 0.99, n_D^{20} 1.5230, Merck **14**,946, UN1993, EINECS 232-362-2, RTECS CP2352500, MDL MFCD00132800, †	**25g** **100g** **500g**
	H:H226, P:P210-P241-P280-P240-P303+P361+P353-P501a For microscopy. Application(s): Mounting medium for microscopy	
J62818	**Candesartan, 98%** *[Celexetil]* [139481-59-7], $C_{24}H_{20}N_6O_3$, F.W. 440.45, Powder, m.p. 183-185°, Merck **14**,1739, MDL MFCD00081076 H:H302-H312-H332-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Angiotensin II receptor antagonist	**100mg** **1g**
J63403	**Canertinib, 99+%** *[CI-1033]* [267243-28-7], $C_{24}H_{25}ClFN_5O_3$, F.W. 485.94, Solid, Merck **14**,1744 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An irreversible pan-HER tyrosine kinase inhibitor	**25mg** **100mg**
J63750	**Canertinib dihydrochloride salt, 99+%** *[CI-1033, PD-183805]* [289499-45-2], $C_{24}H_{25}ClFN_5O_3 \cdot 2HCl$, F.W. 558.86, Powder, Merck **14**,1744, RTECS UC6316110, MDL MFCD09954112 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An irreversible pan-HER tyrosine kinase inhibitor	**25mg** **50mg** **100mg**
	Cannabiscetin, see Myricetin, 98%, J60450, p. 296	
J61394	**Canrenoic acid potassium salt, 98+%** [2181-04-6], $C_{22}H_{30}KO_4$, F.W. 396.58, Powder, Merck **14**,1750, EINECS 218-554-9, RTECS TU3500000, MDL MFCD05662375 H:H302, P:P264-P270-P301+P312-P330-P501a	**1g** **5g** **25g**
J60238	**Canrenone, 98%** [976-71-6], $C_{22}H_{28}O_3$, F.W. 340.46, Solid, m.p. 149-151°, Merck **14**,1752, EINECS 213-554-5 Application(s): Inhibits aldosterone biosynthesis and blocks ouabain effects	**1g** **5g** **25g**
J61801	**Cantharidin, 98%** [56-25-7], $C_{10}H_{12}O_4$, F.W. 196.20, Powder, m.p. 215-217°, Merck **14**,1752, UN2811, EINECS 200-263-3, RTECS RN8575000, MDL MFCD00134968, † H:H300-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibitor of protein phosphatase 2A	**100mg**
	Capric aldehyde, see Decanal, A11656, p. 176 **Caproamide**, see Hexanoamide, H25929, p. 244 **Caprylic acid methyl ester**, see Methyl caprylate, A10991, p. 289	
A17037	**CAPS, 99%** *[3-Cyclohexylamino-1-propanesulfonic acid]* [1135-40-6], $C_9H_{19}NO_3S$, F.W. 221.32, m.p. 324°, Merck **14**,1767, EINECS 214-492-1, RTECS TZ6395000, BRN 2835588, MDL MFCD00003837, †  H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Buffer, pKa = 10.40 at 20°: *Biochemistry*, **5**, 467 (1966).	**25g** **100g** **500g**
J63749	**CAPS, 0.5M buffer soln., pH 9.0** [1135-40-6], Liquid, † H:H302, P:P264-P270-P301+P312-P330-P501a	**250ml** **500ml**
J60022	**CAPS, 0.5M buffer soln., pH 9.0** [1135-40-6], Liquid, † H:H302, P:P264-P270-P301+P312-P330-P501a	**250ml** **500ml**
J60776	**CAPS, 0.5M buffer soln., pH 9.5** [1135-40-6], Liquid, † H:H302, P:P264-P270-P301+P312-P330-P501a	**100ml** **250ml**

Stock #	Description	Size
J60569	**CAPS, 0.5M buffer soln., pH 10.0** [1135-40-6], Liquid, †	250ml 500ml
J62446	**CAPS, 0.5M buffer soln., pH 10.5** [1135-40-6], Liquid, † H:H302, P:P264-P270-P301+P312-P330-P501a	250ml 500ml
J63138	**CAPS, 0.5M buffer soln., pH 11.0** [1135-40-6], Liquid, † H:H302, P:P264-P270-P301+P312-P330-P501a	250ml 500ml
J62865	**Capsaicin** *[8-Methyl-N-vanillyl-trans-6-nonenamide, (E)-Capsaicin]* [404-86-4], $C_{18}H_{27}NO_3$, F.W. 305.41, Solid, m.p. 56-58°, b.p. 210-220°, f.p. 113°(235°F), Merck **14**,1768, UN2811, EINECS 206-969-8, RTECS RA8530000, BRN 2816484, MDL MFCD00017259, † H:H300-H311, P:P301+P310-P361-P302+P352-P321-P405-P501a Application(s): Prototypic vanilloid receptor agonist. Reversibly inhibits aggregation of platelets	1g 5g
	(E)-Capsaicin, see Capsaicin, J62865, p. 146	
J63055	**Capsazepine, 99+%** [138977-28-3], $C_{19}H_{21}ClN_2O_2S$, F.W. 376.90, Powder, m.p. 159-161°, MDL MFCD00153778 Application(s): A competitive antagonist for capsaicin and resiniferatoxin	10mg 50mg
B21305	**CAPSO, 98% ■** *[3-Cyclohexylamino-2-hydroxy-1-propanesulfonic acid]* [73463-39-5], $C_9H_{19}NO_4S$, F.W. 237.32, m.p. 270-274°, MDL MFCD00041778 	25g 100g 500g
J60973	**CAPSO, 0.2M buffer soln., pH 8.5** [102601-34-3], Liquid	100ml 250ml
J61126	**CAPSO, 0.2M buffer soln., pH 9.0** [102601-34-3], Liquid	100ml 250ml
J63242	**CAPSO, 0.2M buffer soln., pH 9.5** [102601-34-3], Liquid	100ml 250ml
B25202	**CAPSO sodium salt, 98% ■** *[3-Cyclohexylamino-2-hydroxy-1-propanesulfonic acid sodium salt]* [102601-34-3], $C_9H_{18}NNaO_4S$, F.W. 259.30, MDL MFCD00070063 	25g 100g 500g
J63593	**Captopril** *[N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline]* [62571-86-2], $C_9H_{15}NO_3S$, F.W. 217.29, Powder, m.p. 104-108°, Merck **14**,1774, EINECS 263-607-1, RTECS UY0550000, BRN 477887, MDL MFCD00168073 H:H361-H317, P:P261-P280-P302+P352-P321-P405-P501a Application(s): Orally active inhibitor of angiotensin-converting enzyme	1g 5g 25g
L06674	**Carbachol, 99% ■** *[Carbamoylcholine chloride]* [51-83-2], $H_2NCO_2CH_2CH_2N(CH_3)_3Cl$, F.W. 182.65, m.p. ca 210° dec., Merck **14**,1779, UN2811, EINECS 200-127-3, RTECS GA0875000, BRN 3917459, MDL MFCD00012011, † H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Cholinergic agonist	5g 25g
J60284	**Carbadox, 98+%** [6804-07-5], $C_{11}H_{10}N_4O_4$, F.W. 262.22, Solid, m.p. 239-240°, f.p. 18°(64°F), Merck **14**,1780, UN1325, RTECS FE2779000, MDL MFCD00057293 H:H228-H350-H302, P:P210-P241-P280-P281-P405-P501a Application(s): Quinoxaline derivative. A broad spectrum antibiotic agent	25g 100g
J62590	**Carbamazepine, 98%** *[5H-Dibenz[b,f]azepine-5-carboxamide]* [298-46-4], $C_{15}H_{12}N_2O$, F.W. 236.27, Powder, m.p. 189-192°, Merck **14**,1781, EINECS 206-062-7, RTECS HN8225000, MDL MFCD00005073 H:H334-H302-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): Cytochrome P450 3A4 inducing anti-epileptic drug; ligand for the GABA-A receptor benzodiazepine modulatory site	25g 100g
	Carbamide, see Urea, 36428, p. 388 **Carbamothioic acid**, see Tolnaftate, J61834, p. 371 **Carbamoylcholine chloride**, see Carbachol, L06674, p. 146 **N-(Carbamoylmethyl)taurine**, see ACES, A11553, p. 69 **Carbamylurea**, see Biuret, L00812, p. 128	

Contact us for pricing on bulk sizes

Stock #	Description	Size
A11448	**Carbazole, 95%** [86-74-8], $C_{12}H_9N$, F.W. 167.21, m.p. 240-246°, b.p. 354-356°, f.p. 220°(428°F), d. 1.150, Merck **14**,1790, UN3077, EINECS 201-696-0, RTECS FE3150000, BRN 3956, MDL MFCD00004960, †  H:H351-H400-H410, P:P281-P273-P308+P313-P391-P405-P501a	**50g** **100g** **500g**
J61949	**Carbenicillin disodium salt** [4800-94-6], $C_{17}H_{16}N_2Na_2O_6S$, F.W. 422.36, Powder, Merck **14**,1792, EINECS 225-360-8, RTECS ON9105000, BRN 5722128, MDL MFCD00077683 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): Water-soluble antibiotic effective against gram-negative bacteria	**1g** **5g** **25g**
J63714	**Carbenoxolone disodium salt, 97+%** [7421-40-1], $C_{34}H_{48}Na_2O_7$, F.W. 614.70, Solid, Merck **14**,1793, EINECS 231-044-0, RTECS RK0250000, MDL MFCD00079043 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A triterpenoid chemopreventive agent	**1g** **5g**
J64446	**Carbetapentane citrate** *[Pentoxyverine citrate, 2-[2-(Diethylamino)ethyloxy]ethyl 1-phenylcyclopentane-1-carboxylate citrate]* [23142-01-0], $C_{29}H_{31}NO_3.C_6H_8O_7$, F.W. 633.70, Powder, EINECS 245-449-5, RTECS GY3500000, MDL MFCD00055697 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**50mg** **1g**
	N(α)-Carbethoxy-L-asparagine, see N(α)-Ethoxycarbonyl-L-asparagine, L09327, p. 214 **Carbimazole**, see Ethyl 3-methyl-2-thionoimidazoline-1-carboxylate, L08218, p. 217	
L16334	**Carbon, activated, Norit ROW 0.8mm pellets, steam activated** [7440-44-0], EINECS 231-153-3, MDL MFCD00133992, † Extruded carbon with large pore volume and pore size distribution, suitable for decolorization, deodorisation and purification applications. Application(s): Decolorizing carbon	**100g** **500g** **2kg**
L11860	**Carbon powder, activated, Norit GSX, steam activated, acid washed** [7440-44-0], UN1362, EINECS 231-153-3, RTECS FF5250100, MDL MFCD00133992, † H:H228-H252, P:P210-P241-P280-P235+P410-P240-P420 High purity grade with high internal surface area, suitable for decolorization, purification and catalyst carrier applications. Application(s): Decolorizing carbon	**100g** **500g** **2kg**
J63899	**Carbonate, 0.5M buffer soln., pH 9.0** [497-19-8], Liquid, † H:H303, P:P312	**250ml** **500ml**
J61064	**Carbonate, 0.5M buffer soln., pH 9.4** [497-19-8], Liquid, † H:H303, P:P312	**250ml** **500ml**
J63658	**Carbonate, 0.5M buffer soln., pH 9.5** [497-19-8], Liquid, † H:H303, P:P312	**250ml** **500ml**
J62610	**Carbonate, 0.5M buffer soln., pH 9.6** [497-19-8], Liquid, † H:H303, P:P312	**250ml** **500ml**
J61229	**Carbonate, 0.5M buffer soln., pH 10.0** [497-19-8], Liquid, † H:H303, P:P312	**250ml** **500ml**
J61396	**Carbonate-buffered saline (5X), pH 9.0** [497-19-8], Liquid, Note: 125mM sodium carbonate, 750mM sodium chloride, pH 9.0, † H:H303, P:P312	**250ml** **500ml**
J63928	**Carbonate-buffered saline (5X), pH 9.5** [497-19-8], Liquid, Note: 125mM sodium carbonate, 750mM sodium chloride, pH 9.5, † H:H303, P:P312	**250ml** **500ml**
	N-(Nα-Carbonyl-Cpd-X-Phe-al)-Phe, see Chymostatin, J63275, p. 162	
A14688	**1,1'-Carbonyldiimidazole, 97%** ◢ *[CDI]* [530-62-1], $C_7H_6N_4O$, F.W. 162.15, m.p. 116-120°, Merck **14**,1819, Fieser **1**,114 **5**,97 **6**,97 **8**,77 **9**,96 **12**,106 **13**,66 **16**,64 **18**,85 **21**,90, UN3263, EINECS 208-488-9, BRN 6826, MDL MFCD00005286, †  H:H314-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**10g** **50g** **250g**

Stock #	Description	Size
	Reagent for peptide coupling via the acylimidazolide: *Liebigs Ann. Chem.*, **609**, 75 (1957); *J. Am. Chem. Soc.*, **80**, 4423 (1958); **82**, 4596 (1960): *J. Org. Chem.*, **27**, 2094 (1962). One-pot esterification of a carboxylic acid with t-BuOH occurs in the presence of DBU: *Synthesis*, 833 (1982). The reactivity of acyl imidazolides can be increased by N-alkylation: *Chem. Pharm. Bull.*, **32**, 5044 (1984). Acylimidazolides can also be reduced to aldehydes by DIBAL-H. This reaction has been applied to N-protected amino acids: *J. Chem. Soc., Chem. Commun.*, 79 (1979). Dehydrates aldoximes, including chiral oximes, to nitriles in high yield: *J. Chem. Soc., Chem. Commun.*, 628 (1973); *Synth. Commun.*, **12**, 25 (1982). Ketoximes can be converted to amides by the spontaneous Beckmann rearrangement of imidazolium salts: *Chem. Pharm. Bull.*, **32**, 2560 (1984):  β-Hydroxy amino acids are dehydrated to dehydroamino acids: *Synthesis*, 968 (1982). α,β-Dihydroxyketones are converted to α-diketones: *Synth. Commun.*, **23**, 2219 (1993). Application(s): Peptide coupling reagent	
J60433	**Carboplatin** *[1,1-Cyclobutanedicarboxylatodiammineplatinum(II), cis-Diammine(1,1-cyclobutanedicarboxylato) platinum]* [41575-94-4], $[C_4H_6(CO_2)_2]Pt(NH_3)_2$, F.W. 371.25, Powder, Merck **14**,1822, EINECS 255-446-0, RTECS TP2300000, MDL MFCD00070464 H:H334-H340-H360-H302-H312-H332-H317, P:P285-P261-P302+P352-P321-P405-P501a Application(s): An antitumor agent	**1g** **5g**
	Carbostesin, see Bupivacaine hydrochloride, 98+%, J62835, p. 140 **Carbowax®**, see Polyethylene glycol 12,000, 42635, p. 324 **4(5)-Carboxyfluorescein**, see 5(6)-Carboxyfluorescein, L13439, p. 148	
L13439	**5(6)-Carboxyfluorescein, mixture of isomers, 97%** *[4(5)-Carboxyfluorescein]* [72088-94-9], $C_{21}H_{12}O_7$, F.W. 376.32, m.p. ca 300°, EINECS 276-331-1, MDL MFCD00151081, † Used as a probe of intracellular pH: *Anal. Biochem* ., **156**, 202 (1986)  	**250mg** **1g**
	(Carboxymethyl)trimethylammonium chloride, see Betaine hydrochloride, A16122, p. 124 **3-Carboxy-4-nitrophenyl disulfide**, see 5,5'-Dithiobis(2-nitrobenzoic acid), A14331, p. 200	
J65311	**Carboxypeptidase Y from yeast** *[Serine carboxypeptidase, E.C. 3.4.16.1]* [9046-67-7], Lyophilized powder, EINECS 232-934-1, MDL MFCD00130723 H:H315-H319-H334-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For C-terminal sequencing of proteins. Also for C-terminal modification of proteins and peptides	**1mg** **5mg** **10mg**
J61316	**Carboxy-PTIO potassium salt, 98+%** [148819-94-7], $C_{14}H_{16}KN_2O_4$, F.W. 315.38, Solid, MDL MFCD00216153 Application(s): Stable, water-soluble free radical that reacts with nitric oxide to inhibit NO synthase	**10mg** **50mg**
A17618	**L-Carnitine, 99+%** ■ *[(R)-(-)-3-Hydroxy-4-(trimethylammonio)butyrate, Vitamin BT]* [541-15-1], $C_7H_{15}NO_3$, F.W. 161.20, m.p. ca 190° dec., Merck **14**,1849, EINECS 208-768-0, RTECS BP2980000, BRN 4292315, MDL MFCD00038747  	**10g** **50g** **250g**
	L-Carnitine acetyl ester hydrochloride, see O-Acetyl-L-carnitine chloride, 98%, J61536, p. 71 **Carrageen**, see Carrageenan, iota type, J60603, p. 148	
J60603	**Carrageenan, iota type** *[Carrageenan gum, Carrageen]* [9062-07-1], Powder, EINECS 232-949-3, MDL MFCD00151512 Application(s): Forms soft gels in the presence of calcium ions	**100g** **250g**
	Carrageenan gum, see Carrageenan, iota type, J60603, p. 148	
A13707	**Casein, tech.** ■ [9000-71-9], m.p. ca 280° dec., Merck **14**,1883, EINECS 232-555-1, RTECS FI3519500, MDL MFCD00081481, † Application(s): Natural protein source, typically isolated from bovine milk	**500g** **2.5kg** **10kg**
J64482	**Casein, high nitrogen, 95%** ■ [9000-71-9], Powder, m.p. ca 280° dec., EINECS 232-555-1, RTECS FI3519420, †	**500g** **1kg**
J64214	**Casein, Hammarsten Grade** ■ *[Casein, Hammerstein Grade]* [9000-71-9], Powder, EINECS 232-555-1, RTECS FI3519420, †	**100g**
J65590	**Casein sodium salt** *[Sodium caseinate]* [9005-46-3], Powder, RTECS FI3540000, MDL MFCD00130736, †	**500g** **1kg** **5kg**

Stock #	Description	Size
J60289	**Casein blocking buffer, 3% in PBS** Liquid, Note: 3% Casein in phophate-buffered saline, pH 7.4 Application(s): For Western Blots and ELISA	250ml 500ml
J63453	**Casein blocking buffer, 3% in PBS, with 0.02% sodium azide** Liquid, Note: 3% Casein in PBS with 0.02% sodium azide Application(s): For Western Blots and ELISA	250ml 500ml
J61298	**Casein blocking buffer, 3% in TBS** Liquid, Note: 3% Casein in Tris-buffered saline, pH 7.4	250ml 500ml
J62935	**Casein blocking buffer, 3% in TBS, with 0.02% sodium azide** Liquid, Note: 3% Casein in TBS with 0.02% sodium azide Application(s): For Western Blots and ELISA	250ml 500ml
J64565	**Casein hydrolysate enzymatic** *[Casamino acids]* [65072-00-6], Powder, EINECS 265-363-1, RTECS FI3519450, †	100g 500g
J64362	**Casein Kinase II Inhibitor III** *[CKII Inhibitor, TBCA]* [934358-00-6], $C_9H_4Br_4O_2$, F.W. 463.74, Powder ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	5mg
H26557	**Casein Peptone** ■ *[Peptones, casein]* [91079-40-2], EINECS 293-428-4, MDL MFCD00131829 Application(s): Peptone is used in nutrient media for growing bacteria and fungi	100g 500g
J62791	**β-Casomorphin, bovine** [72122-62-4], $C_{41}H_{55}N_7O_9$, F.W. 789.93, Powder Application(s): A synthetic peptide with opioid activity which has first been isolated from an enzymatic casein digest	5mg 25mg
J62271	**β-Casomorphin, human, 95+%** *[H-Tyr-Pro-Phe-Val-Glu-Pro-Ile-OH]* [102029-74-3], $C_{44}H_{61}N_7O_{11}$, F.W. 864.01, Powder, MDL MFCD00076324 Application(s): An opioid peptide	5mg 25mg
	▲**-Casomorphin (1-4) amide (bovine)**, see Morphiceptin acetate, J61987, p. 296	
J64407	**Caspase-1 Inhibitor I** ◪ *[Ac-YVAD-CHO, Ac-Tyr-Val-Ala-Asp-CHO]* [143313-51-3], $C_{23}H_{32}N_4O_8$, F.W. 492.52, Powder	1mg 5mg
J64226	**Caspase-1 Inhibitor II** *[Ac-YVAD-CMK, IL-1β Converting Enzyme (ICE) Inhibitor II]* [178603-78-6], $C_{24}H_{33}ClN_4O_8$, F.W. 540.99, Powder, RTECS AY3079566	5mg
J64583	**Caspase-1 Inhibitor IV** *[ICE Inhibitor IV, Ac-YVAD-AOM]* [154674-81-4], $C_{33}H_{42}N_4O_{10}$, F.W. 654.71, Powder	1mg
J64442	**Caspase-3 Inhibitor III** *[Ac-DEVD-CMK, Ac-Asp-Glu-Val-Asp-CMK]* $C_{21}H_{31}ClN_4O_{11}$, F.W. 550.94, Powder	1mg 5mg
J64801	**Caspase-3/7 Inhibitor** ▲ *[5-[(S)-(+)-2-(Methoxymethyl)pyrrolidino]sulfonylisatin]* $C_{14}H_{16}N_2O_5S$, F.W. 324.35, Powder	1mg
J64729	**Caspase-9 Inhibitor I** ◪ *[Z-Leu-Glu(OMe)-His-Asp(OMe)-fluoromethyl ketone, Z-LE(OMe)HD(OMe)-FMK]* $C_{32}H_{43}FN_6O_{10}$, F.W. 690.71, Powder	1mg
J65501	**Caspase-9 Inhibitor III** *[Ac-LEHD-CMK]* [403848-57-7], $C_{24}H_{35}ClN_6O_9$, F.W. 587.02, Powder	1mg 5mg
J65218	**Caspase-1 Substrate III, Fluorogenic** ◪ *[N-Acetyl-Tyr-Val-Ala-Asp-7-amido-4-methylcoumarin, Ac-YVAD-AMC]* [149231-65-2], $C_{33}H_{39}N_5O_{10}$, F.W. 665.69, Powder, MDL MFCD00171369	5mg
J65867	**Caspase-3 Substrate II, Fluorogenic** ◪ *[N-Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin, Ac-DEVD-AMC]* [169332-61-0], $C_{30}H_{37}N_5O_{13}$, F.W. 675.64, Powder, MDL MFCD00671411	5mg

Stock #	Description	Size
J61071	**Castanospermine, 99%** *[(1S,6S,7R,8R,8aR)-1,6,7,8-Tetrahydroxyoctahydroindolizidine]* [79831-76-8], $C_8H_{15}NO_4$, F.W. 189.21, Solid, m.p. 213-217°, Merck **14**,1896, BRN 3588654, MDL MFCD00017555 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501a Application(s): Potent α and β-glucosidase inhibitor.	**100mg** **500mg**
J64793	**(+)-Catechin, 98% ▲** *[3,3',4',5,7-Pentahydroxyflavan]* [154-23-4], $C_{15}H_{14}O_6$, F.W. 290.27, Powder, EINECS 205-825-1, RTECS DJ3450000, MDL MFCD00075649 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **25mg**
A10164	**Catechol, 99%** *[1,2-Dihydroxybenzene, Pyrocatechol]* [120-80-9], $C_6H_6O_2$, F.W. 110.11, m.p. 104-107°, b.p. 245-246°, f.p. 127°(260°F), d. 1.370, Merck **14**,7999, UN2811, EINECS 204-427-5, RTECS UX1050000, BRN 471401, MDL MFCD00002188, †  H:H301-H311-H315-H319, P:P301+P310-P305+P351+P338-P361-P302+P352-P405-P501a Ring-opening with O_2 in the presence of CuCl, pyridine and methanol gives the monoester of cis,cis-muconic acid: *Org. Synth. Coll.*, **8**, 490 (1993). In the presence of catechol, carboxylic acids are reduced to alcohols by $NaBH_4$: *Tetrahedron*, **48**, 371 (1992). For an example of the use of catechol in the synthesis of crown ethers, see: *Org. Synth. Coll.*, **6**, 395 (1988).	**250g** **1kg** **5kg**
	Catechol monomethyl ether, see 2-Methoxyphenol, A16319, p. 285	
J65308	**Cathepsin B_1, Human Liver, 95%** *[EC 3.4.22.1]* [9047-22-7], F.W. 27.5kDa, Liquid, RTECS FI5725000, MDL MFCD00130748	**25micrograms**
J61280	**Cathepsin G, 95%** *[EC 3.4.21.20]* [107200-92-0], Powder, Merck **14**,1905, MDL MFCD00130750, Note: Minimum 2 units per mg protein. One unit is defined as the amount of enzyme that will hydrolyze 1.0 micromole of Suc-AAPF-pNA per minute at 25 degrees and pH 7.5 Application(s): Enzyme that degrades collagen and proteoglycans	**100milliunits**
J65347	**Cathepsin B Inhibitor III** *[CA-074, [L-3-trans-(Propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline]* [134448-10-5], $C_{18}H_{29}N_3O_6$, F.W. 383.44, Powder, MDL MFCD00797531	**1mg** **10mg**
J64737	**Cathepsin B Inhibitor IV** *[CA-074 ME, (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester]* [147859-80-1], $C_{19}H_{31}N_3O_6$, F.W. 397.46, Powder, MDL MFCD03452890	**1mg** **10mg**
J65957	**Cathepsin G Inhibitor I ▲** [429676-93-7], $C_{36}H_{33}N_2O_6P$, F.W. 620.60, Solid	**1mg** **10mg**
J63798	**Cathepsin G Substrate, 98+%** *[N-Methoxysuccinyl-Ala-Ala-Pro-Met p-nitroanilide, MeOSuc-Ala-Ala-Pro-Met-pNa]* [70967-91-8], $C_{27}H_{38}N_6O_9S$, F.W. 622.69, Powder Application(s): Suc-Ala-Ala-Pro-Phe-pNA. Colorimetric substrate for chymotrypsin, human leukocyte cathepsin G, and peptidyl prolyl isomerase	**25mg**
J64082	**Cathepsin K Substrate (fluorogenic)** *[Z-Leu-Arg-7-amido-4-methylcoumarin, Z-LR-AMC]* $C_{30}H_{38}N_6O_6$, F.W. 578.65, Solid	**10mg** **25mg**
J64690	**Cdc2-Like Kinase Inhibitor, TG003 ▲** *[Clk Inhibitor, TG003]* [300801-52-9], $C_{13}H_{15}NO_2S$, F.W. 249.33, Solid, MDL MFCD00624584 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg** **50mg**
	CDI, see N,N'-Carbonyldiimidazole, A14688, p. 147	
J64252	**Cefaclor** *[Panoral, (R)-3-Chloro-7-((S)-2-amino-2-phenylacetamido)-3-cephem-4-carboxylic acid]* [53994-73-3], $C_{15}H_{14}ClN_3O_4S$, F.W. 367.81, Powder, Merck **14**,1912, EINECS 258-909-5, RTECS XI0363000, BRN 8176092, MDL MFCD00151471 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a	**1g** **10g**
J65274	**Cefazolin sodium salt ▲** *[Cefamedin]* [27164-46-1], $C_{14}H_{14}N_8NaO_4S_3$, F.W. 476.49, Powder, m.p. 170-172°, Merck **14**,1917, EINECS 248-278-4, RTECS XI0390000, BRN 3585038, MDL MFCD00056883 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501	**1g** **5g**

Stock #	Description	Size
J65185	**Cefoperazone sodium salt** *[Cefobid sodium salt, Cefazone sodium salt]* [62893-20-3], $C_{25}H_{26}N_9NaO_8S_2$, F.W. 667.65, Powder, Merck **14**,1930, EINECS 263-751-5, RTECS XI0374000, BRN 4902135, MDL MFCD07793331 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501	**1g** **5g** **25g**
J62690	**Cefotaxime sodium salt** [64485-93-4], $C_{16}H_{16}N_5NaO_7S_2$, F.W. 477.40, Powder, Merck **14**,1933, EINECS 264-915-9, RTECS XI0250000, BRN 5711411, MDL MFCD00079073 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a	**1g** **5g** **25g**
	Celexetil, see Candesartan, 99%, J62818, p. 145	
J65943	**Celiprolol hydrochloride** *[NSC 324509, Corliprol]* [57470-78-7], $C_{20}H_{34}ClN_3O_4$, F.W. 415.95, Crystalline solid, EINECS 260-752-2, RTECS YR6560000	**10mg**
	Celite®, see Filter aid, L14552, p. 221	
A14553	**D-(+)-Cellobiose, 98+%** *[4-O-β-Glucopyranosyl-D-glucose]* [528-50-7], $C_{12}H_{22}O_{11}$, F.W. 342.30, m.p. 234° dec., $[\alpha]_D^{20}$ +34° (c=10 in water, 15h), Merck **14**,1961, EINECS 208-436-5, BRN 93795, MDL MFCD00136034, † 	**5g** **25g** **100g**
L08780	**D-Cellobiose octaacetate** *[4-O-β-Glucopyranosyl-D-glucose octaacetate]* [5346-90-7], $C_{28}H_{38}O_{19}$, F.W. 678.59, m.p. 224-231°, $[\alpha]_D^{20}$ +40° (c=1 in chloroform), Merck **14**,1961, EINECS 226-304-5, BRN 79280, MDL MFCD00009600 	**5g** **25g**
	Cellosolve®, see 2-Ethoxyethanol, A16100, p. 214	
J64019	**Cellulase, chromatographically purified, T. reesei** *[EC 3.2.1.4, 1,4-(1,3;1,4)-β-D-Glucan-4-glucanohydrolase]* [9012-54-8], Lyophilized powder, EINECS 232-734-4, RTECS FJ5375000, † Application(s): Converts crystalline, amorphous, and chemically-derived celluloses quantitatively to glucose	**250mg** **1g**
A17730	**Cellulose, microcrystalline** [9004-34-6], Merck **14**,1965, EINECS 232-674-9, MDL MFCD00081512, † H:H335, P:P261-P304+P340-P312-P405-P403+P233-P501a	**500g** **2.5kg** **10kg**
J64196	**Centrophenoxine hydrochloride, 98%** *[Meclofenoxate hydrochloride, 2-[2-(Dimethylamino)ethyl] 2-(4-chlorophenoxy)acetate hydrochloride]* [3685-84-5], $C_{12}H_{16}ClNO_3 \cdot HCl$, F.W. 294.17, Powder, m.p. 135-145°, EINECS 222-975-3, RTECS AG0440000, MDL MFCD00012533 Application(s): Ester of dimethylethanolamine and 4-chlorophenoxyacetic acid; activates acetylcholinesterase activity in hippocampus of aged rats	**5g** **25g** **100g**
J63172	**Cephalexin hydrate, 97+%** [15686-71-2], $C_{16}H_{17}N_3O_4S \cdot xH_2O$, F.W. 347.39(anhy), Powder, Merck **14**,1974, EINECS 239-773-6, RTECS XI0350000, BRN 965503, MDL MFCD00167148 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): Colorimetric substrate for chymotrypsin, human leukocyte cathepsin G, and peptidyl prolyl isomerase	**5g** **25g**
J65607	**Cephalothin sodium salt** *[7-(2-Thienylacetamido)cephalosporanic acid sodium salt, Cephalotin sodium salt]* [58-71-9], $C_{16}H_{15}N_2NaO_6S_2$, F.W. 418.42, Powder, Merck **14**,1982, EINECS 200-394-6, RTECS XI038830, BRN 4120706, MDL MFCD00072025 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501	**1g** **5g**
33254	**Cerium(IV) ammonium nitrate, ACS, 98.5% min** [16774-21-3], $(NH_4)_2Ce(NO_3)_6$, F.W. 548.23, Granular, Merck **14**,1992, Fieser **1**,120 **13**,67 **14**,74 **15**,70 **16**,66 **17**,68 **18**,85 **19**,67 **20**,73 **21**,90, Solubility: Soluble in water and alcohol, UN1477, EINECS 240-827-6, MDL MFCD00151121, † Maximum level of impurities: Insoluble in dilute sulfuric acid 0.05%, Cl 0.01%, PO_4 0.02%, Fe 0.005% H:H272-H315-H319-H335, P:P221-P210-P305+P351+P338-P302+P352-P405-P501a Application(s): Analytical chemistry, as an oxidant for organic compounds, as a polymerization catalyst for olefins, and as a scavenger in the manufacture of azides	**100g** **500g** **2kg**

Stock #	Description	Size
J64538	**Cerulenin, 98%** *[(2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide]* [17397-89-6], $C_{12}H_{17}NO_3$, F.W. 223.27, Powder, Merck **14**,2004, EINECS 241-424-8, RTECS JR1670000, BRN 4140423, MDL MFCD00077686 H:H302, P:P264-P270-P301+P312-P330-P501	**5mg** **10mg**
10018	**Cesium chloride, 99.9% (metals basis)** ■ [7647-17-8], CsCl, F.W. 168.36, Crystalline, m.p. 646°, b.p. 1303°, d. 3.99, n_D^{20} 1.6418, Merck **14**,2011, EINECS 231-600-2, RTECS FK9625000, MDL MFCD00010955, †	**25g** **100g**
	Application(s): For density gradient work to separate and purify proteins	
J65950	**Cesium chloride, ultrapure, 99.9% (metals basis)** ■ [7647-17-8], CsCl, F.W. 168.36, Crystalline, m.p. 646°, b.p. 1303°, d. 3.99, n_D^{20} 1.6418, Merck **14**,2011, EINECS 231-600-2, RTECS FK9625000, MDL MFCD00010955, †	**25g** **100g**
89188	**Cesium chloride, 99.999+% (metals basis)** ■ [7647-17-8], CsCl, F.W. 168.36, Powder, m.p. 646°, b.p. 1303°, d. 3.99, n_D^{20} 1.6418, Merck **14**,2011, EINECS 231-600-2, RTECS FK9625000, MDL MFCD00010955, †	**10g** **50g**
13233	**Cesium hydroxide hydrate, 99.9% (metals basis)** △ ■ [12260-45-6], $CsOH{\cdot}xH_2O$ (15-20% H_2O), F.W. 149.91(anhy), Crystalline, Merck **14**,2013, Fieser **21**,96, UN2682, EINECS 244-344-1, MDL MFCD00010964, † H:H314-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**5g** **25g** **100g**
12884	**Cesium nitrate, 99.8% (metals basis)** ■ [7789-18-6], $CsNO_3$, F.W. 194.91, Crystalline, m.p. 414°, b.p. dec., d. 3.68, n_D^{20} 1.55, Merck **14**,2015, Solubility: Soluble in 5 parts cold and 0.5 parts boiling water. Soluble in acetone. Slightly soluble in alcohol, UN1451, EINECS 232-146-8, MDL MFCD00010963, † H:H272, P:P221-P210-P220-P280-P370+P378a-P501a	**50g** **250g**
	Application(s): Preparation of Cs compounds	
J63549	**Cetirizine dihydrochloride, 99+%** [83881-52-1], $C_{21}H_{25}ClN_2O_3{\cdot}2HCl$, F.W. 461.82, Solid, Merck **14**,2022, RTECS AG0980000, MDL MFCD00941428 H:H302, P:P264-P270-P301+P312-P330-P501	**5g** **10g** **25g**
	Application(s): Histamine H-1 receptor antagonist. Inhibits activation of eosinophils and neutrophils	
	Cetrimonium bromide, see (1-Hexadecyl)trimethylammonium bromide, A15235, p. 244 **Cetyl alcohol**, see 1-Hexadecanol, A11180, p. 244 **Cetylpyridinium chloride monohydrate**, see (1-Hexadecyl)pyridinium chloride monohydrate, A13499, p. 244 **Cetyltrimethylammonium bromide**, see (1-Hexadecyl)trimethylammonium bromide, A15235, p. 244	
J63801	**CGS 12066B dimaleate, 98+%** [109028-10-6], $C_{17}H_{17}F_3N_4.2(C_4H_4O_4)$, F.W. 566.49, Solid, m.p. 126-127°	**10mg** **50mg**
	Application(s): 5-HT-1B full agonist	
J61313	**CGS 15943, 99+%** *[9-Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine]* [104615-18-1], $C_{13}H_8ClN_5O$, F.W. 285.69, Solid, MDL MFCD01529897	**10mg** **50mg**
	Application(s): Potent adenosine receptor antagonist	
J60793	**CGS 21680 hydrochloride, 99+%** [124182-57-6], $C_{23}H_{29}N_7O_6{\cdot}HCl$, F.W. 535.98, Solid, MDL MFCD11045878	**5mg** **10mg**
	Application(s): A-2A Adenosine receptor agonist	**50mg**
A14734	**trans-Chalcone, 97%** *[2-(Benzylidene)acetophenone, 1,3-Diphenyl-2-propen-1-one]* [614-47-1], $C_{15}H_{12}O$, F.W. 208.26, m.p. 55-57°, b.p. 208°/25mm, Merck **14**,2037, EINECS 210-383-8, RTECS UD5576750, BRN 509985, MDL MFCD00003082, †  H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g**
	Application(s): Inhibits lung and forestomach carcinogenesis	
B21927	**CHAPS, 98+%** ■ *[3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate]* [75621-03-3], $C_{32}H_{58}N_2O_7S$, F.W. 614.88, m.p. 156-158° dec., MDL MFCD00012116  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
	Application(s): Buffer; zwitterionic nondenaturing detergent for solubilizing membrane proteins	
J60580	**CHAPS lysis buffer** Liquid, Note: Contains 50mM Tris-HCl (pH 7.4), 110mM NaCl, 5mM EDTA and 1% CHAPS	**50ml** **100ml**
	Application(s): For cell lysis and protein extraction	
J60812	**CHAPS lysis buffer (2X)** Liquid, Note: Contains 100mM Tris-HCl (pH 7.4), 220mM NaCl, 10mM EDTA and 2% CHAPS	**25ml** **50ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62906	**Chelerythrine chloride, 99+%** *[Toddaline]* [3895-92-9], $C_{21}H_{18}ClNO_4$, F.W. 383.82, Solid, Merck **14**,2051, EINECS 223-444-9, RTECS FL9200000, MDL MFCD00060717 H:H302-H312-H332-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A natural benzophenanthridine alkaloid. Inhibits protein kinase C. Induces apoptosis in leukemia cells	**5mg** **10mg** **25mg**
L00782	**Chelidamic acid hydrate, 95%** *[1,4-Dihydro-4-oxo-2,6-pyridinedicarboxylic acid hydrate, 4-Hydroxypyridine-2,6-dicarboxylic acid hydrate]* [138-60-3], $C_7H_5NO_5 \cdot xH_2O$, F.W. 183.12(anhy), m.p. ca 260° dec., EINECS 205-335-8, MDL MFCD00066478 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g**
J65184	**Chemotactic Peptide** *[N-Formyl-Met-Leu-Phe, fMLP]* [59880-97-6], $C_{21}H_{31}N_3O_5S$, F.W. 437.55, Lyophilized powder, RTECS SQ7342000, BRN 2315783, MDL MFCD00036780	**25mg**
J60364	**Chenodeoxycholic acid** [474-25-9], $C_{24}H_{40}O_4$, F.W. 392.57, Needle crystals, m.p. 164-168°, Merck **14**,2054, EINECS 207-481-8, RTECS FZ1980000, BRN 3219887, MDL MFCD00064142 H:H361, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Bile acid that induces apoptosis through protein kinase C signaling pathways	**5g** **25g**
A18047	**CHES, 99%** ■ *[2-(Cyclohexylamino)ethanesulfonic acid]* [103-47-9], $C_8H_{17}NO_3S$, F.W. 207.29, m.p. >300°, Merck **14**,2055, EINECS 203-115-6, BRN 2967601, MDL MFCD00003835, † H:H319, P:P280-P264-P305+P351+P338-P337+P313 Biological buffer, pKa = 9.3 at 20°: *Biochemistry*, **5**, 467 (1966). Application(s): Zwitterionic buffer useful in pH range 8.6 to 10.0	**25g** **100g** **500g**
J61492	**CHES, 0.5M buffer soln, pH 8.5** [103-47-9], Liquid, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100ml** **250ml**
J63670	**CHES, 0.5M buffer soln, pH 9.0** [103-47-9], Liquid, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100ml** **250ml**
J62333	**CHES, 0.5M buffer soln, pH 9.5** [103-47-9], Liquid, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100ml** **250ml**
J63419	**CHES, 0.5M buffer soln, pH 10.0** [103-47-9], Liquid, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100ml** **250ml**
A14242	**Chicago Sky Blue 6B** *[C.I. 24410, Direct Blue 1]* [2610-05-1], $C_{34}H_{24}N_6Na_4O_{16}S_4$, F.W. 992.79, EINECS 220-026-8, RTECS QJ6430000, MDL MFCD00004020, † H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): Inhibits L-glutamate uptake	**25g** **100g** **500g**
	CHIR-258, see Dovitinib, J61776, p. 201	
J61206	**Chitin** [1398-61-4], $C_{10}H_{19}NO_5$, F.W. 233.26, Powder, Merck **14**,2065, EINECS 215-744-3, MDL MFCD00466914, † Application(s): A long-chain polymer of a N-acetylglucosamine	**100g** **500g**
J64143	**Chitosan, 85% deacetylated** *[Poly(D-glucosamine), Deacetylated chitin]* [9012-76-4], Powder, RTECS FM6300000, MDL MFCD00161512, †	**50g** **250g** **500g**
A11492	**α-Chloralose, 98+%, β anomer ca 15%** *[1,2-O-(2,2,2-Trichloroethylidene)-α-D-glucofuranose]* [15879-93-3], $C_8H_{11}Cl_3O_6$, F.W. 309.53, m.p. 180-184°, $[\alpha]_D^{20}$ +19° (c=2 in ethanol), Merck **14**,2072, EINECS 240-016-7, RTECS FM9450000, BRN 85418, MDL MFCD00005542, † H:H302-H332, P:P261-P264-P304+P340-P301+P312-P312-P501a Application(s): Used as sedative and anesthetic in lab animals	**25g** **100g**

Stock #	Description	Size
J61964	**Chlorambucil, 98%** *[4-(4-[Bis(2-chloroethyl)amino]phenyl)butyric acid]* [305-03-3], $C_{14}H_{19}Cl_2NO_2$, F.W. 304.21, Powder, m.p. 66-67°, Merck **14**,2073, UN2811, EINECS 206-162-0, RTECS ES7525000, BRN 999011, MDL MFCD00021783 H:H301-H350-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Alkylates DNA; induces apoptosis in chronic lymphocytic leukemia cells	**5g** **25g**
42374	**Chloramine-T trihydrate, ACS, 98.0-103.0%** ◢ [7080-50-4], $CH_3C_6H_4SO_2N(Cl)Na\cdot 3H_2O$, F.W. 281.69 (227.67anhy), Crystalline, m.p. 167-170°, f.p. 192°(377°F), Merck **14**,2075, Fieser **4**,75 **7**,58 **8**,83 **9**,101 **10**,85 **11**,118 **13**,70 **15**,79 **20**,103 **21**,125, UN3263, EINECS 204-854-7, RTECS XT5616800, BRN 3924168, MDL MFCD00149066, † Maximum level of impurities: pH of a 5% solution 8.0-10.0 @25°, Suitable for determination of bromide P.T., Clarity of aqueous solution, P.T., Insoluble in alcohol 1.5% H:H334-H314-H302, P:P260-P280-P303+P361+P353-P305+P351+P338-P310-P420g Application(s): Reagent for selective oxidation of methionine	**100g** **500g**
B20841	**Chloramphenicol, 99+%** *[Chloromycetin]* [56-75-7], $C_{11}H_{12}Cl_2N_2O_5$, F.W. 323.14, m.p. 149-152°, $[\alpha]_D^{20}$ +19° (c=6 in ethanol), Merck **14**,2077, EINECS 200-287-4, RTECS AB6825000, BRN 2225532, MDL MFCD00078759, †  H:H350-H361, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Inhibitor of translation on the 50S subunit at the peptidyltransferase step	**25g** **100g**
A10493	**Chloranilic acid, 98+%** *[2,5-Dichloro-3,6-dihydroxy-1,4-benzoquinone]* [87-88-7], $C_6H_2Cl_2O_4$, F.W. 208.99, m.p. >300° dec., Merck **14**,2079, EINECS 201-780-7, RTECS DK4005000, BRN 1875040, MDL MFCD00001596, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reagent for determination of Ca, Sr, Zr and Mo.	**25g** **100g** **500g**
A13259	**Chlorazol Black E** *[Azo Black, C.I. 30235]* [1937-37-7], $C_{34}H_{25}N_9Na_2O_7S_2$, F.W. 781.73, EINECS 217-710-3, RTECS QJ6160000, MDL MFCD00066363, †  H:H350-H361d, P:P281-P201-P202-P308+P313-P405-P501a	**10g** **50g**
41385	**Chlorhexidine digluconate, 20% w/v aq. soln., non-sterile** ▲ [18472-51-0], $C_{22}H_{30}Cl_2N_{10}\cdot 2C_6H_{12}O_7$, F.W. 897.76, Liquid, d. 1.06, EINECS 242-354-0, MDL MFCD00083599, †  Application(s): Antiseptic and disinfectant agent	**25ml** **100ml** **500ml** **4x500ml**
J62934	**Chlormezanone, 98+%** [80-77-3], $C_{11}H_{12}ClNO_3S$, F.W. 273.74, Powder, m.p. 114°, Merck **14**,2106, EINECS 201-307-4, RTECS XJ1050000, MDL MFCD00143951 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Skeletal muscle relaxant	**5g** **25g**
A11482	**Chloroacetic acid, 99%** ■ *[Monochloroacetic acid]* [79-11-8], $ClCH_2CO_2H$, F.W. 94.50, m.p. 60-63°, b.p. 189°, f.p. 126°(258°F), d. 1.404, Merck **14**,2112, Solubility: Soluble in water, alcohols, benzene, chloroform, ether, UN1751, EINECS 201-178-4, RTECS AF8575000, BRN 605438, MDL MFCD00002683, † H:H301-H311-H331-H314-H400, P:P301+P310-P303+P361+P353-P305+P351+P338-P361-P405-P501a A convenient one-pot alternative to the Knoevenagel or Horner-Wadsworth-Emmons reactions for the synthesis of α-unsubstituted cinnamic acids involves the reaction of chloroacetic acid with dimethyl phosphite in the presence of sodium methoxide, and treatment of the resulting phosphonoacetate salt with a benzaldehyde: *J. Org. Chem.*, **46**, 2514 (1981):  For a more general version of this reaction, applicable to the synthesis of a variety of substituted acrylic acids, see **2-Bromopropionic acid**, **A17569**.	**250g** **1kg**
41724	**Chloroacetic acid, ACS, 99+%** [79-11-8], $ClCH_2CO_2H$, F.W. 94.50, Crystalline, m.p. 60-63°, b.p. 189°, f.p. 126°(258°F), d. 1.404, Merck **14**,2112, UN1751, EINECS 201-178-4, RTECS AF8575000, BRN 605438, MDL MFCD00002683, † Maximum level of impurities: Insoluble matter 0.01%, Residue after ignition 0.02%, Carbonyl compounds (as acetone) 0.02%, Other carbonyl compounds 0.01%, Cl 0.01%, SO_4 0.02%, Heavy Metals (as Pb) 0.001%, Fe 0.002%, Substances darkened by sulfuric acid P.T H:H301-H311-H331-H314-H400, P:P301+P310-P303+P361+P353-P305+P351+P338-P361-P405-P501a	**100g** **500g** **4x500g**

Stock #	Description	Size
A15846	**Chloroacetyl chloride, 98%** ◪ [79-04-9], $ClCH_2COCl$, F.W. 112.94, m.p. -22°, b.p. 105-106°, d. 1.417, n_D^{20} 1.4530, Merck **14**,2067, Fieser **1**,130 **3**,46, UN1752, EINECS 201-171-6, RTECS AO6475000, BRN 605439, MDL MFCD00000725, † H:H301-EUH029-H311-H331-H372-H314-H400-EUH014, P:P301+P310-P303+P361+P353-P305+P351+P338-P361-P405-P501a Reagent for the protection of amines as their chloroacetamides. The protecting group can be removed by reaction with thiourea derivatives, forming 2-thiazolidin-4-ones as by-products: *J. Am. Chem. Soc.*, **90**, 4508 (1968); *Gazz. Chim. Ital.*, **98**, 1261 (1968). Side reactions can be minimized by using **Piperidine-1-thiocarboxamide**, **L12445**, as the thiourea: *Angew. Chem. Int. Ed.*, **10**, 75 (1971). Also used for the protection of alcohols as their chloroacetates: *Tetrahedron Lett.*, 251 (1979). They are hydrolyzed very readily in the presence of many other ester functions: *J. Am. Chem. Soc.*, **86**, 118 (194); *J. Chem. Soc., Perkin 1*, 934 (1975); or can be cleaved with thiourea: *Tetrahedron Lett.*, 251 (1979), ethylenediamine, or mercaptoethylamine: *J. Org. Chem.*, **35**, 1940 (1970).	**25ml** **250ml** **500ml** **2.5L**
J63810	**2-Chloroadenosine** *[2-CADO, 6-Amino-2-chloropurine riboside]* [146-77-0], $C_{10}H_{12}ClN_5O_4$, F.W. 301.69, Powder, EINECS 205-678-3, BRN 43957, MDL MFCD00005734 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A selective A1-adenosine receptor agonist. Induces apoptosis	**250mg** **1g**
J60927	**2-Chloro-2'-arabino-fluoro-2'-deoxyadenosine, 99+%** *[Clofarabine]* [123318-82-1], $C_{10}H_{11}ClFN_5O_3$, F.W. 303.68, Powder, Merck **14**,2372, UN2811, RTECS UD7473000, MDL MFCD00871077 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A purine nucleoside anti-metabolite. Toxic to nondividing lymphocytes and monocytes	**50mg** **100mg** **250mg**
A10832	**2-Chlorobenzoic acid, 98+%** [118-91-2], $C_7H_5ClO_2$, F.W. 156.57, m.p. 138-142°, b.p. 284-286°, f.p. 173°(343°F), d. 1.544, Merck **14**,2124, EINECS 204-285-4, RTECS DG4976000, BRN 907340, MDL MFCD00002412, † H:H319-H335, P:P305+P351+P338 The Ullmann-Goldberg reaction with anilines to give diarylamines can be carried out with Cu powder in water: *Synth. Commun.*, **23**, 1447 (1993). The reaction in DMF has been shown to be greatly accelerated by ultrasonic irradiation: *Synth. Commun.*, **19**, 2077 (1989). Ullmann-Goldberg reaction with phenols to give diaryl ethers gives improved results with pyridine as a co-catalyst: *Synth. Commun.*, **25**, 1077 (1995).	**250g** **1kg** **5kg**
A15135	**4-Chlorobenzoic acid, 98+%** [74-11-3], $C_7H_5ClO_2$, F.W. 156.57, m.p. 239-243°, b.p. 275°, f.p. 238°(460°F), d. 1.54, Merck **14**,2125, EINECS 200-805-9, RTECS DG4976010, BRN 907196, MDL MFCD00002531, † H:H302-H315-H319-H335, P:P280h-P305+P351+P338	**250g** **1kg**
	5-Chloro-2-benzoxazolinone, see 5-Chloro-2(3H)-benzoxazolone, B24507, p. 155	
B24507	**5-Chloro-2(3H)-benzoxazolone, 99%** *[5-Chloro-2-benzoxazolinone, Chlorzoxazone]* [95-25-0], $C_7H_4ClNO_2$, F.W. 169.57, m.p. 189-192°, Merck **14**,2194, EINECS 202-403-9, MDL MFCD00005717, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g** **1kg**
	1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid, see Indomethacin, 99+%, J63255, p. 256 **N-4-Chlorobenzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine**, see Chloropyramine hydrochloride, J60350, p. 159 **5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride**, see Ticlopidine hydrochloride, J63971, p. 370 **3-Chloro-10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride**, see Clomipramine hydrochloride, J62485, p. 165 **5-Chloro-2,4-dihydroxypyrimidine**, see 5-Chlorouracil, A11084, p. 160 **6-Chloro-2,4-dihydroxypyrimidine**, see 6-Chlorouracil, L01875, p. 160	
B21964	**4-Chloro-3,5-dimethylphenol, 98+%** *[4-Chloro-3,5-xylenol, PCMX]* [88-04-0], C_8H_9ClO, F.W. 156.61, m.p. 112-116°, b.p. ca 246°, f.p. 138°(280°F), Merck **14**,2176, EINECS 201-793-8, RTECS ZE6850000, BRN 1862539, MDL MFCD00002324, † H:H315-H319-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a	**100g** **500g**
	8-Chloro-1,3-dimethyl-2,6-purinedione, see 8-Chlorotheophylline, A12408, p. 160	
A13774	**1-Chloro-2,4-dinitrobenzene, 98%** *[2,4-Dinitrochlorobenzene]* [97-00-7], $C_6H_3ClN_2O_4$, F.W. 202.55, m.p. 48-52°, b.p. 314-316°, f.p. 186°(366°F), d. 1.700, Merck **14**,2136, UN3441, EINECS 202-551-4, RTECS CZ0525000, BRN 613161, MDL MFCD00007075, † H:H301-H311-H331-H373-H400-H410, P:P260-P301+P310-P361-P302+P352-P405-P501a The doubly-activated chloro-substituent is readily displaced by nucleophiles, e.g.: Ammonia/ammonium acetate to give 2,4-dinitroaniline: *Org. Synth. Coll.*, **2**, 221 (1943); or with ammonia gas in toluene in the presence of TBAB which improves the solubility of ammonia in the organic medium and accelerates the reaction: *J. Chem. Soc., Chem. Commun.*, 1267 (1987). Benzyl mercaptan to give the thioether: *Org. Synth. Coll.*, **5**, 474 (1973). Iodide ion to give 2,4-dinitro-1-iodobenzene: *Org. Synth. Coll.*, **5**, 478 (1973). Nitrite in toluene (phase-transfer) to give 1,2,4-trinitrobenzene (caution!): *J. Org. Chem.*, **56**, 4967 (1991).	**100g** **500g** **2.5kg**

Stock #	Description	Size
	2-(4-[(1Z)-4-Chloro-1,2-diphenyl-1-butenyl]phenoxy)-N,N-dimethylethanamine, see Toremifene, 98+%, J63803, p. 371	
	(±)-1-Chloro-2,3-epoxypropane, see (±)-Epichlorohydrin, A15823, p. 208	
J65111	**7-(2-Chloroethyl)theophylline, 97%** *[1,3-Dimethyl-7-(β-chloroethyl)xanthine]* [5878-61-5], $C_9H_{11}ClN_4O_2$, F.W. 242.66, Powder, m.p. 122-127°, EINECS 227-553-2, RTECS XH5090000, MDL MFCD00005760	**1g** **5g**
B21209	**1-Chloro-2-fluorobenzene, 98+%** *[2-Chlorofluorobenzene]* [348-51-6], C_6H_4ClF, F.W. 130.55, m.p. -43°, b.p. 137-138°, f.p. 31°(87°F), d. 1.242, n_D^{20} 1.5010, UN1993, EINECS 206-476-8, BRN 1855301, MDL MFCD00000533, † H:H226-H332-H315-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Benzyne precursor, compare **1-Bromo-2-fluorobenzene**, **A10635**. Lithiation at low temperatures with n-BuLi occurs ortho to F; subsequent reaction with electrophiles provides access to mixed dihalo derivatives such as 3-chloro-2-fluorobenzoic acid: *Tetrahedron Lett.*, **36**, 881 (1995). Improved yields are obtained by the use of the superbasic combination of n-BuLi and KO-t-Bu: *Tetrahedron Lett.*, **37**, 6551 (1996).	**25g** **100g** **500g**
32614	**Chloroform, ACS, 99.8+%** *[Trichloromethane]* [67-66-3], $CHCl_3$, F.W. 119.38, Liquid, m.p. -63°, b.p. 60.5-61.5°, d. 1.492, n_D^{20} 1.4460, Merck **14**,2141, Fieser **1**,29 **3**,140 **4**,22 **5**,28 **8**,92 **12**,517 **15**,84, UN1888, EINECS 200-663-8, RTECS FS9100000, BRN 1731042, MDL MFCD00000826, † Maximum level of impurities: Color (APHA) 10, Residue after evaporation 0.001%, Acetone and aldehyde P.T. (limit about 0.005% as $(CH_3)_2CO$), Acid and chlorine P.T., Free chlorine (Cl) P.T., Pb 0.05ppm, Substances darkened by sulfuric acid P.T. H:H351-H373-H302-H315, P:P260-P280-P302+P352-P321-P405-P501a	**1L** **4L** **4x4L**
22920	**Chloroform, HPLC Grade, 99.5+% min** [67-66-3], $CHCl_3$, F.W. 119.38, Liquid, m.p. -63°, b.p. 60.5-61.5°, d. 1.492, n_D^{20} 1.4460, Merck **14**,2141, Fieser **1**,29 **3**,140 **4**,22 **5**,28 **8**,92 **12**,517 **15**,84, UN1888, EINECS 200-663-8, RTECS FS9100000, BRN 1731042, MDL MFCD00000826, Note: Filtered through 0.2µ filters., † Maximum level of impurities: Evaporation residue 3ppm, Chlorinated pesticides 5ppt, H_2O 0.03% H:H351-H373-H302-H315, P:P260-P280-P302+P352-P321-P405-P501a **UV absorption - 1cm cell vs H_2O** λ(nm) 290 270 260 255 245 A 0.01 0.02 0.05 0.15 1.00	**1L** **4L** **4x1L**
43685	**Chloroform, HPLC Grade, 99.5+% min, stab. with amylene** [67-66-3], $CHCl_3$, F.W. 119.38, Liquid, m.p. -63°, b.p. 60.5-61.5°, d. 1.492, n_D^{20} 1.4460, Merck **14**,2141, Fieser **1**,29 **3**,140 **4**,22 **5**,28 **8**,92 **12**,517 **15**,84, UN1888, EINECS 200-663-8, RTECS FS9100000, BRN 1731042, MDL MFCD00000826, † H:H351-H373-H302-H315, P:P260-P280-P302+P352-P321-P405-P501a **UV absorption - 1cm cell vs H_2O** λ(nm) 290 270 260 255 245 A 0.01 0.02 0.05 0.15 1.00	**1L** **4L** **4x1L** **4x4L**
32442	**Chloroform, Spectrophotometric Grade, 99.5+%** [67-66-3], $CHCl_3$, F.W. 119.38, Liquid, m.p. -63°, b.p. 60.5-61.5°, d. 1.492, n_D^{20} 1.4460, Merck **14**,2141, Fieser **1**,29 **3**,140 **4**,22 **5**,28 **8**,92 **12**,517 **15**,84, UN1888, EINECS 200-663-8, RTECS FS9100000, BRN 1731042, MDL MFCD00000826, Note: Meets ACS Spectrophotometric Requirements. Filtered through 0.2µ filters., † Maximum level of impurities: Evaporation residue 3ppm, Chlorinated pesticides 5ppt, H_2O 0.04% H:H351-H373-H302-H315, P:P260-P280-P302+P352-P321-P405-P501a **UV absorption - 1cm cell vs H_2O** λ(nm) 290 270 260 255 245 A 0.01 0.02 0.05 0.15 1.00	**1L** **4L** **4x1L**
L14759	**Chloroform, ethanol-free, 99+%, stab. with ca 50 ppm amylene** *[Trichloromethane]* [67-66-3], $CHCl_3$, F.W. 119.38, m.p. -63°, b.p. 60.5-61.5°, d. 1.492, n_D^{20} 1.4460, Merck **14**,2141, Fieser **1**,29 **3**,140 **4**,22 **5**,28 **8**,92 **12**,517 **15**,84, UN1888, EINECS 200-663-8, RTECS FS9100000, BRN 1731042, MDL MFCD00000826, † H:H351-H373-H302-H315, P:P260-P280-P302+P352-P321-P405-P501a	**500ml** **1L** **2.5L**
	Chloroformic acid 9-fluorenylmethyl ester, see 9-Fluorenylmethyl chloroformate, A11683, p. 222 **9-Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine**, see CGS 15943, 99+%, J61313, p. 152 **4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid**, see Furosemide, 97+%, J61457, p. 229	

Stock #	Description	Size
B21962	**Chlorogenic acid hemihydrate, 97%** [6001-76-9], $C_{16}H_{18}O_9 \cdot 0.5H_2O$, F.W. 363.32 (354.31anhy), m.p. ca 208° dec., Merck **14**,2142, EINECS 206-325-6, MDL MFCD00003862  Application(s): An analog of caffeic acid	**1g** **5g**
J60457	**Chlorogenic acid** *[3-(3,4-Dihydroxycinnamoyl)quinic acid, 1,3,4,5-Tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate)]* [327-97-9], $C_{16}H_{18}O_9$, F.W. 354.31, Powder, m.p. 210° dec., Merck **14**,2142, EINECS 206-325-6, RTECS GU8480000, MDL MFCD00003862 Application(s): An analog of caffeic acid	**250mg** **1g** **5g**
	6-Chloroguanine, see 2-Amino-6-chloropurine, A18195, p. 92 **1-(3-Chloro-2-hydroxypropyl)-2-methyl-5-nitroimidazole**, see Ornidazole, 99%, J63100, p. 308 **7-Chloro-4-hydroxyquinoline-2-carboxylic acid**, see 7-Chlorokynurenic acid, 99+%, J61359, p. 157	
A18626	**5-Chloroindole-2-carboxylic acid, 98%** [10517-21-2], $C_9H_6ClNO_2$, F.W. 195.60, m.p. 287° dec., EINECS 234-050-1, RTECS NL5998400, BRN 153229, MDL MFCD00005613  H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Potent antagonist at the glycine site of the NMDA receptor	**1g** **5g** **25g**
J61359	**7-Chlorokynurenic acid, 99+%** *[7-Chloro-4-hydroxyquinoline-2-carboxylic acid]* [18000-24-3], $C_{10}H_6ClNO_3$, F.W. 223.62, Powder, EINECS 241-913-6, MDL MFCD00069227 Application(s): NMDA receptor antagonist at the glycine site	**10mg** **50mg**
J61283	**7-Chlorokynurenic acid sodium salt, 99+%** $C_{10}H_5ClNNaO_3$, F.W. 245.60, Powder, MDL MFCD12195840 Application(s): NMDA receptor antagonist at the glycine site	**10mg** **50mg**
	2 (3-Chloro-2-methylanilino)benzoic acid, see Tolfenamic acid, 99+%, J61256, p. 371 **Chloromethylated styrene-divinylbenzene copolymer**, see Merrifield Resin, L17027, p. 282 **8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine**, see Clozapine, 98+%, J61583, p. 166	
A11967	**Chloromethyl pivalate, 97%** *[Chloromethyl trimethylacetate, Pivaloyloxymethyl chloride]* [18997-19-8], $(CH_3)_3CCO_2CH_2Cl$, F.W. 150.60, b.p. 146-148°, f.p. 40°(104°F), d. 1.045, n_D^{20} 1.4170, UN2924, EINECS 242-735-1, BRN 1560838, MDL MFCD00000884, † H:H314-H226, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Reagent for the N-protection of amines, e.g. adenine in the presence of K_2CO_3 in DMF, as pivaloyloxymethyl (Pom) derivatives, which have been found useful in the synthesis of sensitive nucleosides. The Pom group is cleaved in mild base, e.g. methanolic ammonia: *J. Am. Chem. Soc.*, **89**, 5439 (1967).	**25g** **100g**
	Chloromethyl trimethylacetate, see Chloromethyl pivalate, A11967, p. 157 **Chloromycetin**, see Chloramphenicol, B20841, p. 154	
A14165	**4-Chloro-7-nitrobenzofurazan, 99%** *[4-Chloro-7-nitrobenzo-2,1,3-oxadiazole, NBD chloride]* [10199-89-0], $C_6H_2ClN_3O_3$, F.W. 199.56, m.p. 96-100°, EINECS 233-496-4, RTECS DF8002400, BRN 614212, MDL MFCD00005808, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Fluorogenic reagent for amines and thiols: *Anal. Biochem.*, **53**, 290 (1973). Reagent for pre-column derivatization of amines: *Anal. Chim. Acta*, **130**, 377 (1981), **170**, 81 (1985); and of imino acids: *Anal. Biochem.*, **138**, 390 (1984), allowing detection after HPLC.	**5g** **25g**
	4-Chloro-7-nitrobenzo-2,1,3-oxadiazole, see 4-Chloro-7-nitrobenzofurazan, A14165, p. 157	
B21561	**2-Chloro-4-nitrophenol, 97%** [619-08-9], $C_6H_4ClNO_3$, F.W. 173.56, m.p. 108-112°, EINECS 210-578-8, RTECS SK5075000, BRN 2046372, MDL MFCD00043910, †  H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**10g** **50g** **250g**
J64455	**2-Chloro-5-nitro-N-4-pyridinylbenzamide ▲** *[T0070907]* [313516-66-4], $C_{12}H_8ClN_3O_3$, F.W. 277.66, Solid, MDL MFCD00121849 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
B21623	**Chlorophenol Red** *[3',3''-Dichlorophenolsulfonaphthalein]* [4430-20-0], $C_{19}H_{12}Cl_2O_5S$, F.W. 432.28, EINECS 224-619-2, BRN 354053, MDL MFCD00005877, Note: Transition interval: pH 4.8 (yellow) to 6.4 (red), †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g**

Stock #	Description	Size
L10364	**Chlorophenol Red sodium salt** *[Chlorophenol Red, water soluble]* [123333-64-2], $C_{19}H_{11}Cl_2NaO_5S$, F.W. 445.26, m.p. ca 267° dec., EINECS 224-619-2, MDL MFCD00151199, Note: Transition interval: pH 4.8 (yellow) to 6.4 (red) 	**5g**
38699	**Chlorophenol Red sodium salt, 0.04% w/v aq. soln.** $C_{19}H_{11}Cl_2NaO_5S$, F.W. 445.26, Liquid, d. 0.990, MDL MFCD00151199, Note: Transition interval: pH 4.8 (yellow) to 6.4 (red), †	**100ml** **500ml** **6x100ml**
	Chlorophenol Red, water soluble, see Chlorophenol Red sodium salt, L10364, p. 158	
A17624	**2-(4-Chlorophenoxy)isobutyric acid, 98%** *[2-(4-Chlorophenoxy)-2-methylpropionic acid, Clofibric acid]* [882-09-7], $C_{10}H_{11}ClO_3$, F.W. 214.65, m.p. 119-120°, Merck **14**,2378, EINECS 212-925-9, RTECS UE9455000, BRN 1874067, MDL MFCD00004192 ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A drug used to reduce cholesterol levels in the blood 	**25g** **100g**
	2-(4-Chlorophenoxy)-2-methylpropionic acid, see 2-(4-Chlorophenoxy)isobutyric acid, A17624, p. 158 **2-(4-Chlorophenoxy)-2-methylpropionic acid ethyl ester**, see Clofibrate, 95+%, J60342, p. 165	
H51982	**4-Chloro-D-phenylalanine, 95%** *[(R)-2-Amino-3-(4-chlorophenyl)propionic acid, H-D-Phe(4-Cl)-OH]* [14091-08-8], $C_9H_{10}ClNO_2$, F.W. 199.64, m.p. 260°, UN2811, BRN 2416151, MDL MFCD00079675 H:H301-H317, P:P261-P301+P310-P302+P352-P321-P405-P501a 	**250mg** **1g** **5g**
B20355	**1-(3-Chlorophenyl)biguanide hydrochloride, 97%** ■ [2113-05-5], $C_8H_{10}ClN_5 \cdot HCl$, F.W. 248.12, m.p. 191-194°, MDL MFCD00053019 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Specific agonist for 5-HT receptor 	**1g** **5g**
	1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride, see Bupropion hydrochloride, 99%, J61105, p. 140 **1-[(2-Chlorophenyl)diphenylmethyl]-1H-imidazole**, see Clotrimazole, J63895, p. 166 **1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole**, see TRAM 34, J60019, p. 372 **4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutyramide hydrochloride**, see Loperamide hydrochloride, 98+%, J60168, p. 272 **1-[2-(4-Chlorophenylmethoxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole nitrate**, see Econazole nitrate, J63173, p. 204 **[(4-Chlorophenyl)methyl]-3-(1H-imidazol-4-yl)propyl ester carbamimidothioic acid dihydrobromide**, see Clobenpropit dihydrobromide, 99+%, J60807, p. 165	
J60278	**1-(4-Chlorophenyl)piperazine, 97%** [38212-33-8], $C_{10}H_{13}ClN_2$, F.W. 196.70, Crystalline powder, m.p. 76-79°, b.p. 113°, MDL MFCD00044823 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A 5-HT-1 serotonin receptor agonist	**1g** **5g** **25g**
A14057	**1-(3-Chlorophenyl)piperazine monohydrochloride, 97%** [13078-15-4], $C_{10}H_{13}ClN_2 \cdot HCl$, F.W. 233.14, m.p. ca 214° dec., UN2811, EINECS 235-976-9, RTECS TL2833500, BRN 4768691, MDL MFCD00012764 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): 5-HT2C/2B receptor agonist/partial agonist 	**10g** **50g**
B25283	**1-(4-Chlorophenyl)piperazine dihydrochloride, 95%** ■ [38869-46-4], $C_{10}H_{13}ClN_2 \cdot 2HCl$, F.W. 269.60, m.p. 275-278° dec., EINECS 254-165-0, MDL MFCD00012766 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): 5-HT2C/2B receptor agonist/partial agonist 	**5g** **25g** **100g**
A16155	**Chlorophyllin, coppered trisodium salt** ▲ [11006-34-1], $C_{34}H_{31}CuN_4Na_3O_6$, F.W. 724.15, EINECS 234-242-5, RTECS GS2168866, MDL MFCD00012149, † 	**5g** **25g** **100g**
J64066	**2-Chloro-11-(1-piperazinyl)dibenzo[b,f]-1,4-oxazepine, 98%** *[Amoxapine]* [14028-44-5], $C_{17}H_{16}ClN_3O$, F.W. 313.78, Powder, EINECS 237-867-1, RTECS HQ4025500, MDL MFCD00069210 ! H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A tricyclic norepinephrine uptake inhibitor	**250mg** **1g** **5g**

Stock #	Description	Size
A11202	**6-Chloropurine, 99%** [87-42-3], $C_5H_3ClN_4$, F.W. 154.56, m.p. >300° dec., Merck **14**,2161, EINECS 201-745-6, RTECS UO7520000, BRN 5774, MDL MFCD00075825 ! H:H302, P:P264-P270-P301+P312-P330-P501a 	**1g** **5g** **25g**
J64871	**6-Chloropurine 2'-deoxyriboside, 97%** *[6-Chloro-9-(2-deoxy-β-D-ribofuranosyl)purine]* [4594-45-0], $C_{10}H_{11}ClN_4O_3$, F.W. 270.67, Powder, MDL MFCD00083282 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J64612	**6-Chloropurine riboside, 98%** [2004-06-0], $C_{10}H_{11}ClN_4O_4$, F.W. 286.67, Powder, m.p. 158-162°, EINECS 217-904-8, RTECS UO7520800, BRN 40573, MDL MFCD00005738 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**50g** **100g** **250g**
J60350	**Chloropyramine hydrochloride** *[N-4-Chlorobenzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine]* [6170-42-9], $C_{16}H_{20}ClN_3 \cdot HCl$, F.W. 326.26, Crystalline powder, Merck **14**,2162, EINECS 228-216-2, MDL MFCD00079009 Application(s): Competitive reversible H-1 receptor antagonist	**1g**
A15394	**2-Chloropyrimidine, 98%** ■ [1722-12-9], $C_4H_3ClN_2$, F.W. 114.54, m.p. 64-67°, b.p. 75-76°/10mm, f.p. 98°(208°F), UN2811, EINECS 217-020-2, BRN 107171, MDL MFCD00006060  H:H301-H319-H317-H335, P:P280h-P262-P305+P351+P338-P309-P310 Alkoxylation with 3-butyn-1-ol, followed by intramolecular Diels-Alder reaction, leads to a fused pyridine system, by a sequence analogous to that shown for **2-Chloropyrazine**, **A10108**: *Tetrahedron*, **45**, 803 (1989). For a similar sequence using the anion of an alkynylmalononitrile, see: *Tetrahedron*, **45**, 5151 (1989). For synthesis of a benzofuropyridine by the cyclization of a 2-(alkynylphenoxy)pyrimidine, see: *Tetrahedron*, **45**, 6511 (1989). Organolithium reagents add to the 1,6-imine bond, giving, after aromatization with DDQ, 6-substituted 2-chloropyrimidines: *J. Org. Chem.*, **53**, 4137 (1988).	**10g** **25g** **100g**
J64459	**Chloroquine diphosphate salt, 98%** *[N4-(7-Chloro-4-quinolinyl)-N1,N1-dimethyl-1,4-pentanediamine diphosphate salt]* [50-63-5], $C_{18}H_{26}ClN_3.2H_3PO_4$, F.W. 515.87, Powder, m.p. 213-216°, Merck **14**,2163, EINECS 200-055-2, RTECS VB2450000, BRN 4223142, MDL MFCD00069852 ! H:H302, P:P264-P270-P301+P312-P330-P501	**25g** **100g**
J64326	**4-(7-Chloro-4-quinolinylamino)-2-(diethylaminomethyl)phenol dihydrochloride dihydrate, 98%** *[Amodiaquine dihydrochloride dihydrate]* [6398-98-7], $C_{20}H_{22}ClN_3O \cdot 2HCl.2H_2O$, F.W. 464.82 (392.33anhy), Yellow powder, Merck **14**,572, EINECS 200-706-0, RTECS GO7300100, MDL MFCD00078857 Application(s): An anti-malarial quinoline derivative that acts as an histamine N-methyltransferase inhibitor	**5g** **25g** **100g**
A10310	**N-Chlorosuccinimide, 98%** ◢ *[NCS]* [128-09-6], $C_4H_4ClNO_2$, F.W. 133.53, m.p. 146-150°, d. 1.65, Merck **14**,2164, Fieser **1**,139 **13**,79 **14**,87 **15**,86 **16**,84 **18**,101 **19**,95 **20**,108 **21**,131, UN3261, EINECS 204-878-8, RTECS UY1013500, BRN 113915, MDL MFCD00005511, † ! H:H314-H302, P:P280-P305+P351+P338-P309-P310  Source of positive chlorine in chlorination and oxidation reactions. Methyl ketones may be monochlorinated via their Li enolates: *J. Org. Chem.*, **49**, 1286 (1984). For the α-chlorination of acid chlorides formed *in situ*, see: *Tetrahedron Lett.*, 3235 (1974). For chlorination of deactivated anilines, see: *Synthesis*, 669 (1985). In the presence of triphenylphosphine or triphenyl phosphite, converts alcohols to alkyl chlorides stereospecifically with inversion: *Tetrahedron Lett.*, 3937 (1973). For a review, see: *Org. React.*, **29**, 1 (1983). Amides have been prepared by treatment of a carboxylic acid with NCS/PPh_3 followed by an amine: *Synth. Commun.*, **25**, 959 (1995). With dimethyl sulfide, forms the Corey-Kim reagent, a mild, selective oxidant for alcohols. For a review, see: *Synthesis*, 857 (1990); for tabulated examples, see: *Org. Synth. Coll.*, **6**, 220 (1988). Primary alcohols are oxidized cleanly to aldehydes using NCS and a catalytic amount of **TEMPO**, **A12733**, under phase-transfer conditions: *J. Org. Chem.*, **61**, 7452 (1996). NCS in ether is a convenient alternative to hypochlorite for the conversion of amines to N-chloroamines, for use, e.g. in the Hofmann-Loeffler reaction, see: *Chem. Ber.*, **88**, 883 (1955). Application(s): Regioselective chlorination and oxidizing reagent	**50g** **250g** **1kg**
	6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, see Hydrochlorothiazide, B22093, p. 247	
87977	**Chlorosulfonic acid, typically 99%** ◢ [7790-94-5], HSO_3Cl, F.W. 116.52, Liquid, b.p. 158°, d. 1.753, n_D^{20} 1.433, Merck **14**,2165, UN1754, EINECS 232-234-6, RTECS FX5730000, MDL MFCD00011523, † ! H:H314-H335-EUH014, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**250g** **1kg** **3x1kg**
	7-Chlorotetracycline hydrochloride, see Chlortetracycline hydrochloride, J60095, p. 160	

Stock #	Description	Size
A12408	**8-Chlorotheophylline, 99%** *[8-Chloro-1,3-dimethyl-2,6-purinedione]* [85-18-7], $C_7H_7ClN_4O_2$, F.W. 214.61, m.p. ca 290° dec., EINECS 201-590-4, RTECS XH5063000, BRN 203068, MDL MFCD00005581 H:H302, P:P264-P270-P301+P312-P330-P501a 	**50g** **250g** **1kg**
	2-Chloro-N-[([4-(trifluoromethoxy)phenyl]amino)carbonyl]benzamide, see Triflumuron, 98+%, J63112, p. 376	
44407	**2-Chlorotrityl chloride on polystyrene, 1% cross-linked, 100-200 mesh, 1.0-1.4 mmol/g** [42074-68-0], Powder, MDL MFCD00040399	**2g** **10g** **50g**
	1-(o-Chlorotrityl)imidazole, see Clotrimazole, J63895, p. 166 **4-Chlorouracil**, see 6-Chlorouracil, L01875, p. 160	
A11084	**5-Chlorouracil, 98%** *[5-Chloro-2,4-dihydroxypyrimidine]* [1820-81-1], $C_4H_3ClN_2O_2$, F.W. 146.53, m.p. >300°, EINECS 217-339-7, RTECS YQ9410000, BRN 127173, MDL MFCD00006019 	**5g** **25g** **100g**
L01875	**6-Chlorouracil, 98+%** *[6-Chloro-2,4-dihydroxypyrimidine, 4-Chlorouracil]* [4270-27-3], $C_4H_3ClN_2O_2$, F.W. 146.53, m.p. ca 295° dec., EINECS 224-258-0, BRN 120492, MDL MFCD00014595 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g**
	4-Chloro-3,5-xylenol, see 4-Chloro-3,5-dimethylphenol, B21964, p. 155	
B25238	**Chlorpheniramine maleate, 99%** [113-92-8], $C_{20}H_{23}ClN_2O_4$, F.W. 390.86, m.p. 130-135°, EINECS 204-037-5, RTECS US6503000, MDL MFCD00069225, † H:H302, P:P264-P270-P301+P312-P330-P501a  Application(s): An antihistaminic agent	**5g** **25g**
J63659	**Chlorpromazine hydrochloride, 98+%** *[Hebanil, Klorpromex]* [69-09-0], $C_{17}H_{19}ClN_2S{\cdot}HCl$, F.W. 355.30, Crystalline solid, m.p. 196°, Merck **14**,2185, UN2811, EINECS 200-701-3, RTECS SO1750000, BRN 3779989, MDL MFCD00012654, † H:H301-H330, P:P301+P310-P304+P340-P320-P330-P405-P501a Application(s): Reported to be useful as a substitute for benzidine, o-dianisidine and o-tolidine in the determination of microquantities of hemoglobin and peroxidase.	**10g** **25g** **100g**
J64110	**Chlorpropamide** *[1-(4-Chlorobenzenesulfonyl)-3-n-propylurea]* [94-20-2], $C_{10}H_{13}ClN_2O_3S$, F.W. 276.74, Powder, Merck **14**,2186, EINECS 202-314-5, RTECS YS6650000, MDL MFCD00079004 H:H302-H312-H332-H351, P:P261-P280-P281-P302+P352-P405-P501	**25g** **100g**
J60095	**Chlortetracycline hydrochloride ▲** *[7-Chlorotetracycline hydrochloride, Aureomycin]* [64-72-2], $C_{22}H_{23}ClN_2O_8{\cdot}HCl$, F.W. 515.34, Powder, m.p. 210-215° dec., Merck **14**,2192, EINECS 200-591-7, RTECS QI7800000, BRN 3858364, MDL MFCD00082440 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Bacteriostatic antibiotic active against gram positive and gram negative bacteria	**25g** **100g**
	Chlorzoxazone, see 5-Chloro-2(3H)-benzoxazolone, B24507, p. 155 **3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate**, see CHAPS, B21927, p. 152 **Cholecalciferol**, see Vitamin D3, B22524, p. 392	
L08624	**5α-Cholestan-3β-ol, 98%** *[Dihydrocholesterol]* [80-97-7], $C_{27}H_{48}O$, F.W. 388.68, m.p. 140-144°, $[\alpha]_D^{20}$ +24° (c=1 in chloroform), Merck **14**,2200, EINECS 201-315-8, RTECS FZ6350000, BRN 2418594, MDL MFCD00066413, † 	**5g** **25g**
L08726	**5α-Cholestan-3-one, 97%** [566-88-1], $C_{27}H_{46}O$, F.W. 386.66, m.p. 128-132°, $[\alpha]_D^{20}$ +43° (c=1 in chloroform), BRN 2625580, MDL MFCD00065901 	**1g** **5g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A11470	**Cholesterol, 95%** *[5-Cholesten-3β-ol]* [57-88-5], $C_{27}H_{46}O$, F.W. 386.66, m.p. 147-150°, b.p. 360°, d. 1.067, $[\alpha]_D^{20}$ -36° (c=2 in dioxane), Merck **14**,2201, Fieser **1**,141, EINECS 200-353-2, RTECS FZ8400000, BRN 1915888, MDL MFCD00003646, †  Application(s): Component of all biological membranes. Appears to inhibit basal channel activity in the brain	50g 250g 1kg
J64282	**Cholesterol Esterase, from porcine pancreas** *[EC 3.1.1.13, Sterol-ester acylhydrolase]* [9026-00-0], F.W. 440kDa, Lyophilized powder, EINECS 232-808-6, MDL MFCD00071052, †	100units 500units
A15052	**Cholesteryl acetate, 97+%** *[Acetic acid cholesteryl ester]* [604-35-3], $C_{29}H_{48}O_2$, F.W. 428.70, m.p. 112-114°, $[\alpha]_D^{20}$ -43° (c=5 in chloroform), Merck **14**,2201, EINECS 210-066-4, BRN 2064235, MDL MFCD00003636, † 	25g 100g 500g
L02857	**Cholesteryl nonanoate** *[Cholesteryl pelargonate, Nonanoic acid cholesteryl ester]* [1182-66-7], $C_{36}H_{62}O_2$, F.W. 526.89, m.p. 75-79°, $[\alpha]_D^{20}$ -30° (c=5 in chloroform), EINECS 214-658-3, BRN 3179820, MDL MFCD00003643, † 	25g 100g
	Cholesteryl octadecanoate, see Cholesteryl stearate, A14771, p. 161	
A11378	**Cholesteryl oleate** *[Oleic acid cholesteryl ester]* [303-43-5], $C_{45}H_{78}O_2$, F.W. 651.12, m.p. 44-47°, $[\alpha]_D^{20}$ -24° (c=1 in chloroform), EINECS 206-142-1, BRN 2343071, MDL MFCD00003645, † 	5g 25g 100g
	Cholesteryl pelargonate, see Cholesteryl nonanoate, L02857, p. 161	
A14771	**Cholesteryl stearate, 96%** *[Cholesteryl octadecanoate, Octadecanoic acid cholesteryl ester]* [35602-69-8], $C_{45}H_{80}O_2$, F.W. 653.13, m.p. 76-79°, $[\alpha]_D^{20}$ -23° (c=5 in chloroform), EINECS 252-637-0, BRN 2068492, MDL MFCD00003639 	5g 25g 250g
J62050	**Cholic acid sodium salt** [206986-87-0], $C_{24}H_{39}NaO_5$, F.W. 430.60, Powder, BRN 3582354, MDL MFCD00150749, † H:H303, P:P312 Application(s): Biochemical solubilizing agent	25g 100g 250g
J64657	**Choline bitartrate, 98+%** ■ *[2-(Hydroxyethyl)trimethylammonium bitartrate]* [87-67-2], $C_9H_{19}NO_7$, F.W. 253.25, Powder, m.p. 151-153°, EINECS 201-763-4, MDL MFCD00036332, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	250g 1kg 2.5kg
A15828	**Choline chloride, 98+%** ■ *[(2-Hydroxyethyl)trimethylammonium chloride]* [67-48-1], $HOCH_2CH_2N(CH_3)_3Cl$, F.W. 139.63, m.p. ca 305° dec., Merck **14**,2206, EINECS 200-655-4, RTECS KH2975000, BRN 3563126, MDL MFCD00011721, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An acyl group acceptor	100g 500g 2.5kg
J60341	**Chondroitin sulfate, 90+%** [9007-28-7], $C_{13}H_{21}NO_{15}S$, F.W. 463.37, Powder, Merck **14**,2214, EINECS 232-696-9, † Application(s): A mucopolysaccharide with N-acetylchondrosine as a repeating unit and with one sulfate group per disaccharide unit; acts as the flexible connecting matrix between the tough protein filaments in cartilage to form a polymeric system.A naturocetic agent	1g 5g 25g
J62927	**Chromomycin A3, 98%** [7059-24-7], $C_{57}H_{82}O_{26}$, F.W. 1183.30, Powder, m.p. 185° dec., Merck **14**,2238, UN3462, EINECS 230-348-0, RTECS GB7875000, MDL MFCD00043151 H:H300-H360, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): An inhibitor of DNA and RNA polymerases. Serves as a fluorescent DNA stain	10mg
	Chrysin, see 5,7-Dihydroxyflavone, L14178, p. 192	

Stock #	Description	Size
J64999	**Chrysophenine sodium salt** *[C.I. 24895, Direct Yellow 12]* [2870-32-8], $C_{30}H_{26}N_4O_8Na_2S_2$, F.W. 680.66, Powder, EINECS 220-698-2, MDL MFCD00007488, †	**50g**
J63275	**Chymostatin** *[N-(Nα-Carbonyl-Cpd-X-Phe-al)-Phe]* [9076-44-2], $C_{31}H_{41}N_7O_6$, F.W. 604.90, Powder, m.p. 276-278°, RTECS GC3047700, MDL MFCD00071059 Application(s): A highly specific chymotrypsin inhibitor produced by actinomycetes	**5mg**
J65266	**α-Chymotrypsin, from bovine pancreas** *[EC 3.4.21.1]* [9004-07-3], F.W. 25kDa, Lyophilized powder, EINECS 232-671-2, RTECS GC3050000, MDL MFCD00130481, † ! H:H315-H319-H334-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501	**100micrograms**
J64741	**Chymotrypsinogen A, from bovine pancreas** [9035-75-0], F.W. 25.6kDa, Powder, EINECS 232-905-3, MDL MFCD00130483	**1g** **5g**
J65561	**CI 994** △ *[N-Acetyldinaline, 4-Acetylamino-N-(2'-aminophenyl)benzamide]* [112522-64-2], $C_{15}H_{15}N_3O_2$, F.W. 269.30, Powder, RTECS CU8702023, MDL MFCD00866266 ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	**25mg** **100mg**

CI-1033, see Canertinib, 99+%, J63403, p. 145
CI-1033, see Canertinib dihydrochloride salt, 99+%, J63750, p. 145
C.I. 10020, see Naphthol Green B, A18268, p. 298
C.I. 10316, see Naphthol Yellow S, B20872, p. 298
C.I. 11050, see Janus Green B, A17391, p. 262
C.I. 12140, see Sudan II, A17613, p. 355
C.I. 13020, see Methyl Red, A16690, p. 290
C.I. 13025, see Methyl Orange, A17604, p. 289
C.I. 13065, see Mentanil Yellow, A17527, p. 283
C.I. 14030, see Alizarin Yellow R sodium salt, 38707, p. 89
C.I. 14640, see Eriochrome® Blue Black B, J63396, p. 210
C.I. 19140, see Tartrazine, A17682, p. 358
C.I. 20470, see Amido Black 10B, A11374, p. 91
C.I. 21000, see Bismarck Brown Y, A16674, p. 127
C.I. 22120, see Congo Red, B24310, p. 168
C.I. 23850, see Trypan Blue, A18600, p. 384
C.I. 23860, see Evans Blue, A16774, p. 218
C.I. 24410, see Chicago Sky Blue 6B, A14242, p. 153
C.I. 26105, see Sudan IV, A12181, p. 355
C.I. 26125, see Oil Red O, A12989, p. 307
C.I. 30235, see Chlorazol Black E, A13259, p. 154
C.I. 35780, see Direct Red 80, B21693, p. 199
C.I. 37175, see Fast Blue BB salt, L09704, p. 218
C.I. 42000, see Malachite Green oxalate, A16186, p. 275
C.I. 42040, see Brilliant Green, A12801, p. 135
C.I. 42053, see Fast Green FCF, A16520, p. 219
C.I. 42095, see Light Green SF Yellowish, B23330, p. 270
C.I. 42135, see Xylenecyanol FF, B21530, p. 394
C.I. 42510, see Basic Fuchsin, A12952, p. 117
C.I. 42555, see Crystal Violet, B21932, p. 170
C.I. 42655, see Brilliant Blue G, 43318, p. 135
C.I. 42685, see Acid Fuchsin sodium salt, B22222, p. 76
C.I. 45100, see Kiton Red S, A14769, p. 264
C.I. 45170, see Rhodamine B, A13572, p. 337
C.I. 45350, see Fluorescein disodium salt hydrate, A11659, p. 223
C.I. 45350.1, see Fluorescein, L13251, p. 222
C.I. 45370, see 4',5'-Dibromofluorescein, A18226, p. 184
C.I. 45380, see Eosin Yellowish, B24535, p. 208
C.I. 45400, see Eosin B, A17377, p. 208
C.I. 45430, see Erythrosin B, A14180, p. 210
C.I. 46005, see Acridine Orange, L13159, p. 76
C.I. 50040, see Neutral Red, J62643, p. 300
C.I. 50085, see Azocarmine G, A12507, p. 116
C.I. 50240, see Safranine O, B21674, p. 339
C.I. 50420, see Nigrosin water soluble, A18147, p. 302
C.I. 51180, see Nile Blue A, A17174, p. 302
C.I. 52010, see Azure I, A17508, p. 116
C.I. 52015, see Methylene Blue, A18174, p. 287
C.I. 58005, see Alizarin Red S sodium salt, 42040, p. 89
C.I. 58050, see 1, 4-Dihydroxyanthraquinone, A11010, p. 191
C.I. 59040, see Pyranine, L11252, p. 332
C.I. 73051, see Indigocarmine, A16052, p. 255
C.I. 74180, see Solvent Blue 38, A15395, p. 349
C.I. 75290, see Hematoxylin hydrate, A12431, p. 242
C.I. 75300, see Curcumin, B21573, p. 170
CIAP, see Alkaline Phosphatase, calf intestine, EIA Grade, J61037, p. 89
Cichorigenin, see 6,7-Dihydroxycoumarin, A15393, p. 192

J64094	**CIL-102** *[1-[4-(Furo[2,3-b]quinolin-4-ylamino)phenyl]ethanone]* [479077-76-4], $C_{19}H_{14}N_2O_2$, F.W. 302.33, Powder, MDL MFCD08277043	**10mg**

Stock #	Description	Size
J65319	**Cilostamide** *[N-Cyclohexyl-N-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide, OPC 3689]* [68550-75-4], $C_{20}H_{26}N_2O_3$, F.W. 342.43, Powder, MDL MFCD00673958	**10mg**
J65933	**Cilostamide, 98%** *[6-[3-(N-Cyclohexyl-N-methylcarbamoyl)propoxy]quinolin-2[1H]-one, OPC 3689]* [68550-75-4], $C_{20}H_{26}N_2O_3$, F.W. 342.44, Powder, MDL MFCD00673958	**5mg**
J62301	**Cilostazol, 98%** *[OPC-13013]* [73963-72-1], $C_{20}H_{27}N_5O_2$, F.W. 369.46, Solid, Merck **14**,2277, RTECS VC8277500, MDL MFCD00866780 H:H361, P:P281-P201-P202-P308+P313-P405-P501 Application(s): An inhibitor of phosphodiesterase III	**10mg** **50mg**
J60650	**Cimaterol** *[2-Amino-5-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]benzonitrile]* [54239-37-1], $C_{12}H_{17}N_3O$, F.W. 219.29, Solid, m.p. 159-161°, Merck **14**,2278, BRN 2418129, MDL MFCD00209815 Application(s): A β-adrenergic agonist	**10mg** **50mg**
J62825	**Cimetidine, 98+%** *[N-Cyano-N'-methyl-N''-(2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl)guanidine, SKF-92334]* [51481-61-9], $C_{10}H_{16}N_6S$, F.W. 252.34, Powder, m.p. 141-143°, Merck **14**,2279, EINECS 257-232-2, RTECS MF0035500, MDL MFCD00133296 H:H360, P:P281-P201-P202-P308+P313-P405-P501a Application(s): H2 histamine receptor antagonist	**5g** **10g** **25g**
J63370	**Cinanserin hydrochloride, 99+%** [1166-34-3], $C_{20}H_{24}N_2OS \cdot HCl$, F.W. 376.94, Solid H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A 5-HT antagonist	**10mg** **50mg**
	Cinchomeronic acid, see Pyridine-3,4-dicarboxylic acid, A14580, p. 332	
A18796	**(-)-Cinchonidine, 99% (total base), may cont. up to 5% quinine ▲** [485-71-2], $C_{19}H_{22}N_2O$, F.W. 294.39, m.p. 201-206°, Merck **14**,2286, EINECS 207-622-3, RTECS GD3500000, BRN 89690, MDL MFCD00006783, † 	**25g** **100g**
A17523	**(+)-Cinchonine, 98+%, cont. up to 3% quinidine/dihydroquinidine and 3% quinine/dihydroquinine ▲** [118-10-5], $C_{19}H_{22}N_2O$, F.W. 294.39, m.p. 253-258°, $[\alpha]_D^{20}$ +225° (c=0.5 in ethanol), Merck **14**,2287, Fieser **6**,501, EINECS 204-234-6, RTECS GD3500000, BRN 89689, MDL MFCD00064372, †  H:H302, P:P264-P270-P301+P312-P330-P501a Resolving agent for chiral acids. For practical details for use in the resolution of 1,1'-bi(2-naphthol) via the cyclic phosphate ester, see: *Org. Synth. Coll.*, **8**, 50 (1993).	**25g** **100g**
A12269	**1,8-Cineole, 99%** *[Eucalyptol, 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane]* [470-82-6], $C_{10}H_{18}O$, F.W. 154.24, m.p. 1.0°, b.p. 176-177°, f.p. 49°(120°F), d. 0.923, n_D^{20} 1.4555, Merck **14**,3895, UN3271, EINECS 207-431-5, RTECS OS9275000, BRN 105109, MDL MFCD00167977, †  H:H226, P:P210-P241-P280-P240-P303+P361+P353-P501a	**100ml** **500ml**
J64568	**Cinnarizine** *[1-trans-Cinnamyl-4-diphenylmethylpiperazine, 1-Benzhydryl-4-trans-cinnamylpiperazine]* [298-57-7], $C_{26}H_{28}N_2$, F.W. 368.52, Powder, m.p. 117-121°, Merck **14**,2305, EINECS 206-064-8, RTECS TL3430000, MDL MFCD00056037	**25g** **100g**
J61317	**Ciprofloxacin, 98%** [85721-33-1], $C_{17}H_{18}FN_3O_3$, F.W. 331.30, Powder, m.p. 253-257°, Merck **14**,2314, RTECS VB1993800, BRN 3568352, MDL MFCD00185755 Application(s): An anti-bacterial agent effective against anaerobic bacteria	**5g** **25g**
J61970	**Ciprofloxacin hydrochloride** [86393-32-0], $C_{17}H_{18}FN_3O_3 \cdot HCl$, F.W. 367.80, Lyophilized powder, Merck **14**,2314, RTECS VB1993800, MDL MFCD00242856 Application(s): An anti-bacterial agent effective against anaerobic bacteria	**5g** **25g**
	Cisplatin, see cis-Diamminedichloroplatinum(II), 10471, p. 184	

Stock #	Description	Size
L05238	**Citraconic anhydride, 98%** ◪ *[3-Methyl-2,5-furandione, Methylmaleic anhydride]* [616-02-4], $C_5H_4O_3$, F.W. 112.08, m.p. 7-8°, b.p. 213-214°, f.p. 101°(213°F), d. 1.243, n_D^{20} 1.4710, UN2810, EINECS 210-459-0, RTECS GE6825000, BRN 1835, MDL MFCD00005522, † H:H311-H315-H319, P:P305+P351+P338-P361-P302+P352-P321-P405-P501a Reagent for the protection of amino groups: *Biochem. J.*, **109**, 312 (1968).	**25g** **100g** **500g**
J63008	**Citrate, 0.5M buffer soln., pH 2.5** [6132-04-3], Liquid	**250ml** **500ml**
J61391	**Citrate, 0.5M buffer soln., pH 3.0** [6132-04-3], Liquid, †	**250ml** **500ml**
J61690	**Citrate, 0.5M buffer soln., pH 3.5** [6132-04-3], Liquid, †	**250ml** **500ml**
J61249	**Citrate, 0.5M buffer soln., pH 4.0** [6132-04-3], Liquid	**250ml** **500ml**
J60024	**Citrate, 0.5M buffer soln., pH 4.5** [6132-04-3], Liquid	**250ml** **500ml**
J60125	**Citrate, 0.5M buffer soln., pH 5.0** [6132-04-3], Liquid	**250ml** **500ml**
J60754	**Citrate, 0.5M buffer soln., pH 5.5** [6132-04-3], Liquid	**250ml** **500ml**
J63950	**Citrate, 0.5M buffer soln., pH 6.0** [6132-04-3], Liquid	**250ml** **500ml**
J60919	**Citrate, 0.5M buffer soln., pH 8.0** [6132-04-3], Liquid	**250ml** **500ml**
J63666	**Citrate-buffered saline (20X)** *[SSC buffer, 20X, Saline-sodium citrate buffer, 20X]* [6132-04-3], Liquid, Note: 300mM sodium citrate, 3M sodium chloride, pH 7.0	**1L** **2L**
A15461	**Citrazinic acid, 97%** *[2,6-Dihydroxyisonicotinic acid, 2,6-Dihydroxypyridine-4-carboxylic acid]* [99-11-6], $C_6H_5NO_4$, F.W. 155.11, m.p. >300° dec., Merck **14**,2325, EINECS 202-731-2, RTECS NS1400000, BRN 383736, MDL MFCD00006274, † H:H315-H319-H335, P:P280g-P305+P351+P338	**50g** **250g**
36665	**Citric acid monohydrate, ACS, 99.0-102.0%** ■ [5949-29-1], $C_6H_8O_7{\cdot}H_2O$, F.W. 210.14 (192.13anhy), Solid, d. 1.542, Merck **14**,2326, EINECS 201-069-1, RTECS GE7810000, MDL MFCD00149972, † Maximum level of impurities: Insoluble matter 0.005%, Residue after ignition 0.02%, Cl 0.001%, C_2O_4 P.T. (limit about 0.05%), PO_4 0.001%, SO_4 0.002%, Fe 3ppm, Pb 2ppm, Substances carbonizable by hot sulfuric acid (tartrates, etc.) P.T. H:H318-H302-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2kg**
A10395	**Citric acid, 99+%** [77-92-9], $C_6H_8O_7$, F.W. 192.13, m.p. 153-154°, d. 1.665, Merck **14**,2326, EINECS 201-069-1, RTECS GE7350000, BRN 782061, MDL MFCD00011669, † H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **1kg** **5kg**
36664	**Citric acid, anhydrous, ACS, 99.5+%** ■ [77-92-9], $HOCOCH_2C(OH)(COOH)CH_2COOH$, F.W. 192.13, Crystalline, m.p. 153-154°, d. 1.665, Merck **14**,2326, EINECS 201-069-1, RTECS GE7350000, BRN 782061, MDL MFCD00011669, † Maximum level of impurities: Insoluble matter 0.005%, Residue after ignition 0.02%, Cl 0.001%, C_2O_4 P.T. (limit about 0.05%), PO_4 0.001%, SO_4 0.002%, Fe 3ppm, Pb 2ppm, Substances carbonizable by hot sulfuric acid (tartrates, etc.) P.T. H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Vitamin C	**100g** **500g** **2kg**
J64322	**Citric acid, Electrophoresis Grade, 99.5+%** ■ [77-92-9], $C_6H_8O_7$, F.W. 192.13, Powder, m.p. 153-154°, d. 1.665, Merck **14**,2326, EINECS 201-069-1, RTECS GE7350000, BRN 782061, MDL MFCD00011669, † H:H315-H318-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100g** **500g** **2kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64007	**Citrinin, 98%** *[8-Hydroxy-3,4,5-trimethyl-6-oxo-4,6-dihydro-3H-isochromene-7-carboxylic acid]* [518-75-2], $C_{13}H_{14}O_5$, F.W. 250.25, Powder, Merck **14**,2327, UN3462, EINECS 208-257-2, RTECS DJ2275000, BRN 5282243, MDL MFCD00006912 H:H301-H311-H330-H351, P:P301+P310-P304+P340-P320-P330-P361-P405-P501	5mg 10mg
L15753	**(±)-Citronellal, 96%** △ *[(+/-)-3,7-Dimethyl-6-octenal]* [106-23-0], $C_{10}H_{18}O$, F.W. 154.25, b.p. 206-208°, f.p. 75°(167°F), d. 0.860, n_D^{20} 1.4490, Merck **14**,2329, EINECS 203-376-6, RTECS RH2140000, BRN 1720789, MDL MFCD00038090, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	100ml 500ml
A13316	**L-Citrulline, 98%** *[L-(+)-2-Amino-5-ureidovaleric acid]* [372-75-8], $C_6H_{13}N_3O_3$, F.W. 175.19, m.p. 212-214° dec., $[\alpha]_D^{20}$ +22° (c=2 in 1N HCl), Merck **14**,2331, EINECS 206-759-6, BRN 6055157, MDL MFCD00064397, †	10g 50g
J65211	**CL 316243 disodium salt** [151126-84-0], $C_{20}H_{18}ClNNa_2O_7$, F.W. 465.80, Powder	10mg
	Cleland's Reagent DTE, see 1,4-Dithioerythritol, A10138, p. 200 **Cleland's Reagent DTT racemic**, see 1,4-Dithio-DL-threitol, A15797, p. 200	
J62260	**Clenbuterol hydrochloride** [21898-19-1], $C_{12}H_{18}Cl_2N_2O{\cdot}HCl$, F.W. 313.65, Powder, Merck **14**,2347, UN2811, EINECS 244-643-7, RTECS DN3180000, MDL MFCD00083280 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A β- 2 adrenoceptor agonist	100mg
	1,6-Cleve's Acid, see 5-Aminonaphthalene-2-sulfonic acid, L03099, p. 97	
J61409	**Clindamycin hydrochloride monohydrate** [58207-19-5], $C_{18}H_{33}ClN_2O_5S{\cdot}HCl{\cdot}H_2O$, F.W. 479.46 (461.44anhy), Powder, Merck **14**,2356, EINECS 244-398-6, RTECS GF2275000, BRN 4070786, MDL MFCD07793327 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Antibiotic U-28508E, effective against gram-positive bacteria	1g 5g
J63387	**Clindamycin phosphate** [24729-96-2], $C_{18}H_{34}ClN_2O_8PS$, F.W. 504.96, Solid, m.p. 114°, Merck **14**,2356, EINECS 246-433-0, RTECS GF2625000, MDL MFCD07793328 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Antibiotic U-28508E, effective against gram-positive bacteria	20mg 100mg
J60807	**Clobenpropit dihydrobromide, 99+%** *[VUF 9153, [(4-Chlorophenyl)methyl]-3-(1H-imidazol-4-yl)propyl ester carbamimidothioic acid dihydrobromide]* [145231-45-4], $C_{14}H_{17}ClN_4S{\cdot}2HBr$, F.W. 470.66, Powder, m.p. 215-216°, MDL MFCD00467655 Application(s): A specific H-3 histamine receptor	10mg 50mg
	Clofarabine, see 2-Chloro-2'-arabino-fluoro-2'-deoxyadenosine, 99+%, J60927, p. 155	
J60342	**Clofibrate, 95+%** *[Ethyl 2-(4-chlorophenoxy)isobutyrate, 2-(4-Chlorophenoxy)-2-methylpropionic acid ethyl ester]* [637-07-0], $C_{12}H_{15}ClO_3$, F.W. 242.70, Liquid, b.p. 154-156°, f.p. 113°(235°F), d. 1.14, n_D^{20} 1.5, Merck **14**,2377, UN3082, EINECS 211-277-4, RTECS UE9480000, BRN 1913459, MDL MFCD00000615 H:H318-H302-H335-H315-H411, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Peroxisome proliferator-activated receptor-a agonist. Induces apoptosis in hepatoma cells	1g 5g 25g 100g
	Clofibric acid, see 2-(4-Chlorophenoxy)isobutyric acid, A17624, p. 158	
J63552	**Clofilium tosylate, 97+%** [92953-10-1], $C_{21}H_{37}ClN.C_7H_7O_3S$, F.W. 510.17, Powder, m.p. 98-99°, RTECS CY9040870, MDL MFCD00069233 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A potassium channel blocker	25mg 100mg 250mg
	Clomifene citrate, see Clomiphene citrate, J63663, p. 165	
J63663	**Clomiphene citrate** *[Clomifene citrate]* [50-41-9], $C_{26}H_{28}ClNO.C_6H_8O_7$, F.W. 598.08, Crystalline powder, Merck **14**,2386, EINECS 200-035-3, RTECS YE0875000, MDL MFCD00058322 H:H360, P:P281-P201-P202-P308+P313-P405-P501 Application(s): A selective estrogen receptor modulator	2g 10g
J62485	**Clomipramine hydrochloride** *[Anafranil hydrochloride, 3-Chloro-10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride]* [17321-77-6], $C_{19}H_{23}ClN_2{\cdot}HCl$, F.W. 351.32, Powder, m.p. 189-190°, Merck **14**,2387, EINECS 241-344-3, RTECS HN9055000, MDL MFCD00069234 H:H302-H312-332-H360, P:P261-P280-P281-P302+P352-P405-P501 Application(s): Potent, selective 5-HT uptake blocker	1g 5g

Stock #	Description	Size
J63707	**Clonidine hydrochloride, 98+%** *[2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride]* [4205-91-8], $C_9H_9Cl_2N_3 \cdot HCl$, F.W. 266.55, Powder, Merck **14**,2390, UN2811, EINECS 224-121-5, RTECS NJ2490000, BRN 4163525, MDL MFCD00036705 H:H300-H330, P:P301+P310-P304+P340-P320-P330-P405-P501a Application(s): α-2 adrenergic agonist	**1g** **5g**
H56409	**(±)-Clopidogrel hydrogen sulfate, 98+%** [135046-48-9], $C_{16}H_{16}ClNO_2S \cdot H_2SO_4$, F.W. 419.90, Merck **14**,2396, MDL MFCD05865229 	**25mg**
J60577	**Cloprostenol sodium salt** [55028-72-3], $C_{22}H_{28}ClNaO_6$, F.W. 446.90, Powder, m.p. 68-70°, Merck **14**,2399, EINECS 259-439-3 H:H302-H315-H319-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A potent prostaglandin F receptor agonist	**1mg** **5mg** **10mg**
	Clortetrin, see Demeclocycline hydrochloride, J63102, p. 176 **Clostridiopeptidase b**, see Clostripain, Clostridium histolyticum, J61362, p. 166	
J61362	**Clostripain, Clostridium histolyticum** *[Endoproteinase-Arg-C, Clostridiopeptidase b]* [9028-00-6], Powder, EINECS 232-822-2, Note: Minimum 50 units per mg dry weight. One unit hydrolyzes one micromole of N-benzoyl-L-arginine ethyl ester per minute at 25 degrees and pH 7.6 in the presence of dithiothreitol Application(s): A protease that cleaves proteins on the carboxyl bond of arginine	**1mg** **10mg**
	Clotam, see Tolfenamic acid, 99+%, J61256, p. 371	
J63895	**Clotrimazole** *[1-[(2-Chlorophenyl)diphenylmethyl]-1H-imidazole, 1-(o-Chlorotrityl)imidazole]* [23593-75-1], $C_{22}H_{17}ClN_2$, F.W. 344.84, Powder, m.p. 147-149°, Merck **14**,2417, EINECS 245-764-8, RTECS NI4377000, MDL MFCD00057220 H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501 Application(s): Specific inhibitor of calcium-activated potassium channels	**5g** **25g**
J64314	**Cloxacillin sodium salt** [642-78-4], $C_{19}H_{17}ClN_3NaO_5S$, F.W. 457.86, Powder, m.p. 170°, Merck **14**,2419, EINECS 211-390-9, RTECS XH8750000, BRN 4103180, MDL MFCD00063568	**1g** **5g** **25g**
J61583	**Clozapine, 98+%** *[8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine]* [5786-21-0], $C_{18}H_{19}Cl_4$, F.W. 326.83, Solid, m.p. 182-184°, Merck **14**,2423, UN2811, EINECS 227-313-7, RTECS HP1750000, MDL MFCD00153785 H:H301-H361-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Potent, selective muscarinic antagonist	**25mg** **100mg**
	5'-CMP.2Na, see Cytidine-5'-monophosphate disodium salt, 99+%, J63376, p. 174 **CNQX**, see 6-Cyano-7-Nitroquinoxaline-2,3-dione, 99+%, J63472, p. 170	
J63246	**Cobalt(II) chloride, 0.5M aq. soln.** [7791-13-1], $CoCl_2$, F.W. 129.84, Liquid, UN3077, † H:H334-H350-H360-H341-H317-H411, P:P285-P261-P302+P352-P321-P405-P501a	**50ml** **100ml**
36554	**Cobalt(II) chloride hexahydrate, ACS, 98.0-102.0%** ■ [7791-13-1], $CoCl_2 \cdot 6H_2O$, F.W. 237.93 (129.84anhy), Crystallin, m.p. 87°, d. 1.924, Merck **14**,2437, Fieser **1**,155 **6**,127 **10**,101 **14**,99 **15**,97 **18**,107 **19**,104 **20**,115 **21**,142, Solubility: Soluble in water, alcohol, acetone, ether, glycerol, UN3077, EINECS 231-589-4, RTECS GG0200000, MDL MFCD00149652, Note: m.p. 52-56° -4H_2O, 100° -5H_2O, 120-140° -6H_2O, † Maximum level of impurities: Insoluble matter 0.01%, NO_3 0.01%, SO_4 0.01%, Ca 0.005%, Cu 0.002%, Fe 0.005%, Mg 0.005%, Ni 0.1%, K 0.01%, Na 0.05%, Zn 0.03% H:H334-H350i-H360F-H341-H400-H410-H302-H317, P:P273-P201-P308+P313-P501a	**100g** **500g**
B22031	**Cobalt(II) chloride, anhydrous, 97%** ■ [7646-79-9], $CoCl_2$, F.W. 129.84, m.p. 735°, b.p. 1049°, d. 3.367, Merck **14**,2437, UN3077, EINECS 231-589-4, RTECS GF9800000, MDL MFCD00010938, Note: d_4^{25} 3.367. Decomposes at 400° on long heating in air., † H:H334-H350i-H360F-H341-H400-H410-H302-H317, P:P273-P201-P308+P313-P501a	**25g** **100g** **500g**
	Coban® 3M, see Monensin sodium salt, 90-95.5%, J61669, p. 294 **Cobinamide**, see Methylcobalamin hydrate, A11176, p. 286 **Cocarboxylase**, see Thiamine pyrophosphate chloride, 98%, J61483, p. 366 **Coenzyme M sodium salt**, see 2-Mercaptoethane sulfonic acid sodium salt, 96%, J63989, p. 281	
J64535	**Cofactor Recycling Enzymes Kit - 8 variants** Lyophilized powder, Note: Contains 100mg each of: Alcohol Dehydrogenase A36, Formate Dehydrogenase, Glucose Dehydrogenase A, Glucose Dehydrogenase B, Isocitrate Dehydrogenase, Malic Decarboxylase A, Malic Decarboxylase B, and Phenylalanine Dehydrogenase Application(s): Reduction of NAP+ or NADP+ is coupled to co-factor dependent enzymatic reductions	**1each**

Stock #	Description	Size
J63900	**Colcemid, 98+% ▲ △** *[Demecolcine, N-Methyl-N-desacetylcolchicine]* [477-30-5], $C_{21}H_{25}NO_5$, F.W. 371.43, Powder, m.p. 186°, Merck **14**,2887, UN2811, EINECS 207-514-6, RTECS GH0800000, BRN 2822892, MDL MFCD00075459 H:H301-H361, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Microtubule modulator that depolymerizes microtubules and inactivates spindle fiber formation	**50mg** **100mg**
J61072	**Colchicine, 98+% ▲** [64-86-8], $C_{22}H_{25}NO_6$, F.W. 399.44, Powder, m.p. ca 150° dec., Merck **14**,2471, UN1544, EINECS 200-598-5, RTECS GH0700000, BRN 2228813, MDL MFCD00078484, † H:H300-H340, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Microtubule disrupting agent, and induces apoptosis in human lymphoma cells	**1g**
J60915	**Colistin sulfate** *[Polymyxin E]* [1264-72-8], Powder, Merck **14**,2479, UN2811, EINECS 215-034-3, RTECS TR1500000, MDL MFCD00146495 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A cationic polypeptide antibiotic from the polymyxin family. Binds to lipids on the cell cytoplasmic membrane of Gram-negative bacteria and disrupts the cell wall integrity	**1g**
J60218	**Collagen, bovine achilles tendon** [9007-34-5], Powder, EINECS 232-697-4, MDL MFCD00130825, † Application(s): An attachment factor for primary cultures of epithelioid cells	**1g** **5g** **10g**
J62406	**Collagenase, Type I, Clostridium histolyticum** [9001-12-1], Powder, Merck **14**,2481, EINECS 232-582-9, MDL MFCD00130830, Note: Minimum 125 units per mg protein. One unit releases one micromole of L-leucine equivalents from collagen in 5 hours at 37 degrees and pH 7.5 H:H334-H335-H315-H319-H317, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Isolated from Clostridium histolyticum. Degrades native helical collagen fibrils	**100mg** **1g**
A11058	**2,4,6-Collidine, 99%** *[2,4,6-Trimethylpyridine]* [108-75-8], $C_8H_{11}N$, F.W. 121.18, m.p. -43°, b.p. 171-172°, f.p. 54°(129°F), d. 0.916, n_D^{20} 1.4980, Merck **14**,9718, Fieser **1**,155, UN1992, EINECS 203-613-3, RTECS UU0970000, BRN 107283, MDL MFCD00006338, †  H:H226-H302-H312-H315-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Hindered base. For use in the dehydrochlorination of α-chloroketones to enones, see: *Org. Synth. Coll.*, **4**, 162 (1963). For use in combination with **Trifluoromethanesulfonic anhydride**, **A11767**, for the generation of ketenimines from olefins, see **N,N-Dimethylacetamide**, **A10924**, p. 195. Superior base for peptide coupling reactions, causing less racemization than the more commonly used N-ethyldiisopropylamine or N-methylmorpholine: *J. Org. Chem.*, **59**, 695 (1994). For comparison with other hindered bases, see: *J. Org. Chem.*, **61**, 2460 (1996). Solvent for various O-alkyl cleavage reaction by LiI, including hindered esters: *J. Org. Chem.*, **28**, 2184 (1963), and methyl ethers of phenols: *Chem. Commun.*, 616 (1969).	**25ml** **100ml** **500ml**
J65434	**Coenzyme A trilithium salt, 95% ■** [18439-24-2], $C_{21}H_{33}Li_3N_7O_{16}P_3S$, F.W. 785.33, Powder, EINECS 242-317-9, MDL MFCD00075848	**25mg** **100mg**
J65137	**Coenzyme Q-10, 98+% ▲** *[Ubiquinone-10, Q-10]* [303-98-0], $C_{59}H_{90}O_4$, F.W. 863.36, Powder, m.p. 48-52°, Merck **14**,9843, EINECS 206-147-9, RTECS DK3900000, BRN 1900141, MDL MFCD00042919, †	**1g** **5g** **25g**
J65131	**Compound E ▲** *[γ-Secretase Inhibitor XXI, Compound E]* [209986-17-4], $C_{27}H_{24}F_2N_4O_3$, F.W. 490.50, Solid	**0.5mg**
	ConA, see Concanavalin A, J61221, p. 167	
J61221	**Concanavalin A** *[ConA]* [11028-71-0], Lyophilized powder, Merck **14**,2495, EINECS 234-258-2, RTECS GK6890000, MDL MFCD00071069 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): A plant lectin that is a T-cell mitogen, and induces apoptosis in human fibroblasts	**100mg** **250mg**
J62617	**Conessine, 97%** *[Neriine, Roquessine]* [546-06-5], $C_{24}H_{40}N_2$, F.W. 356.59, Powder, m.p. 125-127°, Merck **14**,2497, EINECS 208-897-2, MDL MFCD00016752 Application(s): Selective histamine H-3 receptor antagonist	**100mg** **250mg**

Stock #	Description	Size
B24310	**Congo Red, indicator grade** *[C.I. 22120]* [573-58-0], $C_{32}H_{22}N_6Na_2O_6S_2$, F.W. 696.67, m.p. >360°, Merck **14**,2498, EINECS 209-358-4, RTECS QK1400000, BRN 3894858, MDL MFCD00004028, † H:H350-H361d, P:P281-P201-P202-P308+P313-P405-P501a	**25g** **100g** **500g**
	Contraceptive Tetrapeptide, see Kentsin, J61809, p. 263 **Coomassie Brilliant Blue G 250**, see Brilliant Blue G, 43318, p. 135	
A16064	**Copper(II) chloride dihydrate, 99%** *[Cupric chloride dihydrate]* [10125-13-0], $CuCl_2{\cdot}2H_2O$, F.W. 170.48 (134.45anhy), m.p. 100° dec., d. 2.510, Merck **14**,2633, UN2802, EINECS 231-210-2, RTECS GL7030000, MDL MFCD00149674, † H:H314-H400-H410-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**250g** **1kg**
A11262	**Copper(II) sulfate pentahydrate, 99%** *[Cupric sulfate]* [7758-99-8], $CuSO_4{\cdot}5H_2O$, F.W. 249.68 (159.60anhy), d. 2.270, Merck **14**,2653, Fieser **1**,164 **2**,89 **5**,162 **6**,141 **10**,107 **19**,111, UN3077, EINECS 231-847-6, RTECS GL8900000, MDL MFCD00149681, † H:H400-H410-H302-H315-H319, P:P260-P273-P501a	**1kg** **5kg** **25kg**
14178	**Copper(II) sulfate pentahydrate, ACS, 98.0-102.0%** [7758-99-8], $CuSO_4{\cdot}5H_2O$, F.W. 249.68 (159.60anhy), Crystalline, d. 2.270, Merck **14**,2653, Fieser **1**,164 **2**,89 **5**,162 **6**,141 **10**,107 **19**,111, Solubility: Soluble in water, methanol, glycerol., UN3077, EINECS 231-847-6, RTECS GL8900000, MDL MFCD00149681, Note: m.p. 30° -$2H_2O$, 110° -$4H_2O$, 250° anhydrous; $d_2^{15.6}$ 2.286, † Maximum level of impurities: Insoluble matter 0.005%, Cl 0.001%, Nitrogen compounds (as N) 0.002%, Ca 0.005%, Ni 0.005%, K 0.01%, Na 0.02%, Fe 0.003% H:H400-H410-H302-H315-H319, P:P260-P273-P501a	**500g** **2kg**
	Corotrope, see Milrinone, 98+%, J62659, p. 292	
J64182	**Cortisone** *[17α,21-Dihydroxy-4-pregnene-3,11,20-trione, 17α-Hydroxy-11-dehydrocorticosterone]* [53-06-5], $C_{21}H_{28}O_5$, F.W. 360.44, Powder, m.p. 223-228° dec., Merck **14**,2539, EINECS 200-162-4, RTECS GM9020000, BRN 1356062, MDL MFCD00003610	**1g** **5g** **10g**
A15336	**Coumarin, 98%** *[1-Benzopyran-2-one]* [91-64-5], $C_9H_6O_2$, F.W. 146.15, m.p. 68-71°, b.p. 297-299°, f.p. 162°(323°F), d. 0.935, Merck **14**,2562, UN2811, EINECS 202-086-7, RTECS GN4200000, BRN 383644, MDL MFCD00006850, † H:H301-H351, P:P281-P301+P310-P321-P308+P313-P405-P501a	**250g** **1kg** **5kg**
	Coumarin 120, see 7-Amino-4-methylcoumarin, A15017, p. 97	
L07133	**Coumarin-3-carboxylic acid, 98%** *[2-Oxo-2H-1-benzopyran-3-carboxylic acid]* [531-81-7], $C_{10}H_6O_4$, F.W. 190.15, m.p. 190-193°, Merck **14**,2563, UN2811, EINECS 208-518-0, RTECS DJ2490000, BRN 154276, MDL MFCD00006852 H:H301, P:P264-P270-P301+P310-P321-P405-P501a	**25g** **100g**
	CPT11, see Irinotecan hydrochloride trihydrate, J62370, p. 259	
J63028	**C-Reactive Protein** *[CRP]* [9007-41-4], Solid, Merck **14**,2603, MDL MFCD00130690 Application(s): For immunological applications in the preparation of antisera	**1mg**
B25009	**Creatine monohydrate, 99%** *[N-Amidinosarcosine monohydrate]* [6020-87-7], $C_4H_9N_3O_2{\cdot}H_2O$, F.W. 149.15 (131.13anhy), m.p. ca 292° dec., Merck **14**,2568, EINECS 200-306-6, BRN 907175, MDL MFCD00071582, †	**100g** **500g** **2.5kg**
A15362	**Creatine phosphate disodium salt tetrahydrate, 98+%** *[Sodium creatine phosphate dibasic tetrahydrate]* [71519-72-7], $C_4H_8N_3Na_2O_5P{\cdot}4H_2O$, F.W. 327.14 (255.07anhy), EINECS 213-074-6, MDL MFCD00150192 Application(s): Substrate for creatine kinase determinations	**1g** **5g** **25g**
B23097	**Creatinine, 98%** *[2-Imino-1-methylimidazolidin-4-one]* [60-27-5], $C_4H_7N_3O$, F.W. 113.12, m.p. ca 255° dec., Merck **14**,2569, EINECS 200-466-7, BRN 112061, MDL MFCD00059730, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reacts with aromatic aldehydes in a route to derivatives of N-methylphenylalanine: *Org. Synth. Coll.*, **3**, 586 (1955):	**10g** **50g** **250g**

Contact us for pricing on bulk sizes



J61755 **Creatinine hydrochloride, 99+%** — **100g** **250g**
[2-Amino-1-methyl-2-imidazolin-4-one]
[19230-81-0], $C_4H_7N_3O \cdot HCl$, F.W. 149.60, Crystalline, EINECS 242-898-9, MDL MFCD00134958, †

Application(s): Break-down product of creatine phosphate in muscle

A12899 **o-Cresolphthalein** — **10g** **50g**
[596-27-0], $C_{22}H_{18}O_4$, F.W. 346.39, m.p. 223-225°, Merck **14**,2576, EINECS 209-881-8, RTECS SM8390000, BRN 310554, MDL MFCD00005912, Note: Transition interval pH 8.2 (colorless) to pH 9.8 (red), †



L03859 **o-Cresolphthalein complexone, indicator grade** — **1g** **5g** **25g**
[o-Cresolphthalexon, Phthalein complexone]
[2411-89-4], $C_{32}H_{32}N_2O_{12}$, F.W. 636.62, m.p. ca 198° dec., EINECS 219-318-8, BRN 381994, MDL MFCD00005911, †
Indicator for complexometric titration of Mg, Ca, Sr and Ba:
Helv. Chim. Acta, **72**, 113 (1954).



o-Cresolphthalexon, see o-Cresolphthalein complexone, L03859, p. 169

B24338 **m-Cresol Purple** — **5g** **25g**
[m-Cresolsulfonephthalein]
[2303-01-7], $C_{21}H_{18}O_5S$, F.W. 382.44, Merck **14**,2577, EINECS 218-960-6, BRN 350314, MDL MFCD00005871, Note: Transition interval (acid): pH 1.2 (red) to pH 2.8 (yellow); (alkaline) pH 7.4 (yellow) to pH 9.0 (purple), †



38691 **m-Cresol Purple sodium salt, 0.04% w/v aq. soln.** — **100ml** **500ml** **6x100ml**
[62625-31-4], $C_{21}H_{17}NaO_5S$, F.W. 404.42, Liquid, EINECS 263-656-9, MDL MFCD00005871, Note: Transition interval (acid): pH 1.2 (red) to pH 2.8 (yellow); (alkaline) pH 7.4 (yellow) to pH 9.0 (purple), †

A18025 **m-Cresol Purple sodium salt** — **5g** **25g**
[m-Cresol Purple, water soluble, m-Cresolsulfonephthalein sodium salt]
[62625-31-4], $C_{21}H_{17}NaO_5S$, F.W. 404.42, EINECS 263-656-9, MDL MFCD00010177, †



B21361 **Cresol Red sodium salt** — **5g** **25g** **100g**
[o-Cresolsulfonephthalein sodium salt]
[62625-29-0], $C_{21}H_{17}NaO_5S$, F.W. 404.42, m.p. ca 250° dec., EINECS 263-654-8, MDL MFCD00001618, Note: Transition interval (acid): pH 0.2 (red) to pH 1.8 (yellow); (alkaline) pH 7.2 (yellow) to pH 8.8 (red), †



m-Cresolsulfonephthalein, see m-Cresol Purple, B24338, p. 169
o-Cresolsulfonephthalein sodium salt, see Cresol Red sodium salt, B21361, p. 169
m-Cresolsulfonephthalein sodium salt, see m-Cresol Purple sodium salt, A18025, p. 169

J64318 **Cresyl Violet acetate** — **10g**
[9-Amino-5-imino-5H-benzo[a]phenoxazine acetate salt, Cresyl echt violet]
[10510-54-0], $C_{18}H_{15}N_3O_3$, F.W. 321.33, Powder, m.p. 140-143°, EINECS 234-043-3, MDL MFCD00013151

J65122 **Cromolyn sodium salt, 98%** — **1g** **5g** **25g**
[Cromoglycate, Cromoglycic acid]
[15826-37-6], $C_{23}H_{14}Na_2O_{11}$, F.W. 512.33, Powder, Merck **14**,2590, EINECS 239-926-7, RTECS DJ2380000, MDL MFCD00057744

J62367 **Croton oil** — **10g** **25g** **100g**
[Croton resin, Oleum tiglii]
[8001-28-3], Oil, f.p. 74°(165°F), RTECS GQ6300000, MDL MFCD00130880, †
H:H350-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P405-P501a

Application(s): A natural source of phorbol, phorbol esters and glycerides of saturated fatty acids

Croton resin, see Croton oil, J62367, p. 169
CRP, see C-Reactive Protein, J63028, p. 168
Crustecdysone, see Ecdysterone, J63091, p. 204

Stock #	Description	Size
B21932	**Crystal Violet** *[Basic Violet 3, C.I. 42555]* [548-62-9], $C_{25}H_{30}ClN_3$, F.W. 407.99, m.p. ca 215° dec., Merck **14**,4395, UN3077, EINECS 208-953-6, RTECS BO9000000, BRN 4077708, MDL MFCD00011750, † H:H318-H351-H400-H410-H302, P:P280-P281-P305+P351+P338-P310-P405-P501a 	**25g** **100g** **500g**
22866	**Crystal Violet, ACS, 90+%** *[Basic Violet 3, C.I. 42555]* [548-62-9], $C_{25}H_{30}ClN_3$, F.W. 407.99, Powder, m.p. ca 215° dec., Merck **14**,4395, UN3077, EINECS 208-953-6, RTECS BO9000000, BRN 4077708, MDL MFCD00011750, † Specifications: Sensitivity as indicator P.T., Loss on drying ≤7.5%, Absorbance characteristics P.T. H:H318-H351-H400-H410-H302, P:P280-P281-P305+P351+P338-P310-P405-P501a	**25g** **100g**
	CT53518, see Tandutinib, 99%, J62004, p. 358 **CTP**, see Cytidine-5'-triphosphate disodium salt, 98+%, J62238, p. 174	
A16551	**Cupferron, 97+%** *[N-Nitrosophenylhydroxylamine ammonium salt]* [135-20-6], $C_6H_8N_3O_2$, F.W. 155.16, m.p. 154° dec., Merck **14**,2622, UN2811, EINECS 205-183-2, RTECS NC4725000, MDL MFCD00078422, † H:H301-H351-H315-H319-H317, P:P280h-P305+P351+P338-P309-P310  Application(s): Reagent for determination of Ce, Cu, Fe, Sn, and Ti	**25g**
	Cupral, see Sodium diethyldithiocarbamate trihydrate, A15898, p. 345 **Cuproin**, see 2,2'-Biquinoline, A10907, p. 126	
B21573	**Curcumin, 95% (total curcuminoid content), from Turmeric rhizome**  *[1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, C.I. 75300]* [458-37-7], $C_{21}H_{20}O_6$, F.W. 368.39, m.p. 170-175°, Merck **14**,2673, EINECS 207-280-5, RTECS MI5230000, BRN 2306965, MDL MFCD00008365, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Natural Yellow 3. Inhibits lipoxygenase and cyclooxygenase	**10g** **50g** **250g**
	Cyanocobalamine, see Vitamin B12, A14894, p. 392 **α-Cyano-(3,5-di-t-butyl-4-hydroxy)thiocinnamide**, see AG-879, 99%, J62625, p. 81 **(E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)-2-propenamide**, see Tyrphostin B46, 99+%, J61704, p. 387 **(E)-2-Cyano-3-(3,4-dihydroxyphenyl)-2-propenamide**, see Tyrphostin A46, 99%, J60482, p. 386 **N-Cyanoguanidine**, see Dicyandiamide, A10451, p. 187 **N-Cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)me thyl]thio]ethyl]guanidine**, see Cimetidine, 98+% , J62825, p. 163	
J63472	**6-Cyano-7-nitroquinoxaline-2,3-dione, 99+%** *[CNQX]* [115066-14-3], $C_9H_4N_4O_4$, F.W. 232.16, Solid, m.p. >300°, MDL MFCD00069232 Application(s): Potent, selective kainate/quisqualate (non-NMDA) receptor antagonist	**10mg** **25mg** **50mg**
L03442	**Cyanuric chloride, 98%** ◢ *[TCT, 2,4,6-Trichloro-1,3,5-triazine]* [108-77-0], $C_3Cl_3N_3$, F.W. 184.41, m.p. 145-149°, b.p. 192-194°, f.p. >190°(374°F), d. 1.920, Fieser **3**,72 **4**,522 **5**,687 **6**,149 **10**,114 **15**,105 **20**,124, UN2670, EINECS 203-614-9, RTECS XZ1400000, BRN 124246, MDL MFCD00006046, †  H:H330-H314-H302-H317-EUH014, P:P303+P361+P353-P304+P340-P305+P351+P338-P320-P330-P405-P501a In the presence of triethylamine, carboxylic acids are converted to their acid chlorides, allowing *in situ* formation of esters, amides and peptides: *Tetrahedron Lett.*, **20**, 3037 (1979). Similarly, sulfonic acids are converted to sulfonyl chlorides: *Tetrahedron Lett.*, **44**, 1499 (2003). ω-Hydroxy acids are converted to their lactones: *Tetrahedron Lett.*, **21**, 1893 (1980). Mild reagent in β-lactam synthesis: *Synthesis*, 209 (1981). Carboxylic acids, including N-Boc, -Fmoc and -Cbz amino acids have been converted to alcohols in good yield by activation with cyanuric chloride and N-methylmorpholine (NMM), followed by reduction with aqueous $NaBH_4$: *Tetrahedron Lett.*, **40**, 4395 (1999). Hydroxamic acids can also be prepared in a simple one-flask method using hydroxylamine hydrochloride in the presennce of NMM and DMAP: *Org. Lett.*, **5**, 2715 (2003). Effects deoxygenation of diaryl sulfoxides. Alkyl sulfoxides undergo α-chlorination, which can be avoided by using cyanuric fluoride: *Synthesis*, 221 (1980). For use, in combination with DMSO, in a mild and efficient alternative to the Swern oxidation of alcohols to aldehydes or ketones, see: *J. Org. Chem.*, **66**, 7907 (2001). Reagent for dehydration of aldoximes: *J. Chem. Soc., Chem. Commun.*, 1226 (1972), and primary carboxamides: *Synthesis*, 657 (1980) to nitriles. The Vilsmeier-type complex with DMF also converts aldoximes cleanly to nitriles; ketoximes undergo the Beckmann rearrangement at room temperature in high yield: *J. Org. Chem.*, **67**, 6272 (2002). The complex converts primary and secondary alcohols to alkyl chlorides in high yield; addition of NaBr affords mainly the alkyl bromide: *Org. Lett.*, **4**, 553 (2002); whereas with 4 eq. of LiF, primary alcohols are selectively formylated, providing a mild and convenient method for their protection: *J. Org. Chem.*, **67**, 5152 (2002). For a brief feature on uses of the reagent in synthesis, see: *Synlett*, 2156 (2006). Application(s): Reagent for detection of glycine in presence of other amino acids	**50g** **250g** **1kg**
	3',5'-Cyclic AMP, see Adenosine-3',5'-monophosphoric acid free acid, 98%, J60936, p. 79	

Stock #	Description	Size
J65001	**Cyclic AMP Enzyme Immunoassay Kit** Note: Contains reagents reagents and two coated 96-well strip ELISA plates to perform the ELISA either acetylated or unacetylated Application(s): For detection of cGMP. Detection range is 0.05pmol/ml	**1kit**
	3',5'-Cyclic AMP·Na, see Adenosine-3',5'-cyclic monophosphate sodium salt, 99%, J62174, p. 79	
J65422	**Cyclic GMP Enzyme Immunoassay Kit** Note: Contains reagents reagents and two coated 96-well strip ELISA plates to perform the ELISA either acetylated or unacetylated Application(s): For detection of cAMP. Detection range is 0.05pmol/ml	**1kit**
	1,1-Cyclobutanedicarboxylatodiammineplatinum(II), see Carboplatin, J60433, p. 148	
J63845	**Cyclocytidine hydrochloride, 98+%** *[Ancitabine hydrochloride, O-2,2'-Cyclocytidine hydrochloride]* [10212-25-6], $C_9H_{11}N_3O_4 \cdot HCl$, F.W. 261.66, Powder, m.p. 248-250°, Merck **14**,629, EINECS 233-515-6, RTECS LV2615000, MDL MFCD00012636 Application(s): Anti-tumor agent	**1g** **5g**
	O-2,2'-Cyclocytidine hydrochloride, see Cyclocytidine hydrochloride, 98+%, J63845, p. 171	
J60687	**α-Cyclodextrin, 97+%** *[Schardinger α-dextrin, Cyclohexaamylose]* [10016-20-3], $C_{36}H_{60}O_{30}$, F.W. 972.84, Powder, EINECS 233-007-4, MDL MFCD00078207, † Application(s): Useful for selective precipitation of enantiomeric, positional or structural isomers	**5g** **25g** **100g**
J63161	**β-Cyclodextrin** [7585-39-9], $C_{42}H_{70}O_{35}$, F.W. 1134.98, Powder, m.p. 290° dec., EINECS 231-493-2, RTECS GU2293000, BRN 78623, MDL MFCD00078139, † Application(s): Use to solubilize non-polar compounds such a fatty acids, lipids and cholesterol. Reported useful for the selective precipitation of enantiomeric, positional or structural isomers	**25g** **100g**
A14529	**β-Cyclodextrin hydrate** *[Schardinger β-dextrin, Cycloheptaamylose]* [68168-23-0], $C_{42}H_{70}O_{35} \cdot xH_2O$, F.W. 1134.98(anhy), m.p. 288° dec., $[\alpha]_D^{20}$ +142° (c=1.5 in water), Merck **14**,2718, Fieser **6**,151 **8**,133 **9**,129 **12**,150 **15**,107 **18**,117 **21**,151, EINECS 231-493-2, RTECS GU2293000, BRN 5915513, MDL MFCD00150811, †  Has been used to influence regioselectivity in Diels-Alder reactions: *J. Chem. Soc., Chem. Commun.*, 971 (1995); for reaction scheme, see **2,6-Dimethyl-p-benzoquinone**, **A11342**. Encapsulation of aniline and N-substituted anilines allows regioselective bromination: *Tetrahedron*, **52**, 3487 (1996). Catalyzes the Boc protection of amines with **Di-tert-butyl dicarbonate**, **A14708**, p. 184 under neutral, aqueous conditions: *Synlett*, 1110 (2006). For a brief of uses as a supramolecular catayst in organic synthesis, see: *Synlett*, 175 (2007).	**5g** **25g** **100g**
L11271	**γ-Cyclodextrin hydrate** *[Schardinger γ-dextrin]* [91464-90-3], $C_{48}H_{80}O_{40} \cdot xH_2O$, F.W. 1297.15(anhy), m.p. ca 267° dec., $[\alpha]_D^{20}$ +177° (c=1 in water) on dry basis, Merck **14**,2718, Fieser **9**,129, EINECS 241-482-4, BRN 5725162, MDL MFCD00149574, †  For general reviews on cyclodextrins see α-cyclodextrin.	**100mg** **500mg**
	Cycloheptaamylose, see β-Cyclodextrin hydrate, A14529, p. 171 **Cyclohexaamylose**, see α-Cyclodextrin, 97+%, J60687, p. 171 **(1S)-trans-1,2-Cyclohexanediamine**, see (1S,2S)-(+)-1,2-Diaminocyclohexane, L14072, p. 182 **Cyclohexanone-4-carboxylic acid**, see 4-Oxocyclohexanecarboxylic acid, H27294, p. 310	
A15851	**Cyclohexylamine, 98+%** △ *[Aminocyclohexane]* [108-91-8], $C_6H_{13}N$, F.W. 99.18, m.p. -18°, b.p. 133-134°, f.p. 27°(81°F), d. 0.868, n_D^{20} 1.4585, Merck **14**,2729, UN2357, EINECS 203-629-0, RTECS GX0700000, BRN 471175, MDL MFCD00001486, †  H:H314-H226-H361f-H302-H312, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a For protection of an aldehyde as its cyclohexyl imine, see, e.g.: *Org. Synth. Coll.*, **8**, 586 (1993). Cyclohexyl imines of aldehydes have found use in the directed aldol synthesis: reaction with a less reactive ketone takes place in preference to self-condensation of the aldehyde. See, e.g.: *Org. Synth. Coll.*, **6**, 901 (1988): 	**100ml** **500ml** **2.5L**
	2-(Cyclohexylamino)ethanesulfonic acid, see CHES, A18047, p. 153 **3-Cyclohexylamino-2-hydroxy-1-propanesulfonic acid**, see CAPSO, B21305, p. 146 **3-Cyclohexylamino-2-hydroxy-1-propanesulfonic acid sodium salt**, see CAPSO sodium salt, B25202, p. 146 **3-Cyclohexylamino-1-propanesulfonic acid**, see CAPS, A17037, p. 145	
B23056	**N-Cyclohexylmaleimide, 97%** [1631-25-0], $C_{10}H_{13}NO_2$, F.W. 179.22, m.p. 89-91°, EINECS 216-630-6, MDL MFCD00043904, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
	1-Cyclohexyl-3-4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonylurea, see Glipizide, J63398, p. 232	

Stock #	Description	Size
J61528	**Cyclopamine, 99+%** [4449-51-8], $C_{27}H_{41}NO_2$, F.W. 411.62, Powder, m.p. 234-237°, RTECS GY0750000 H:H341-H361, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Inhibits hedgehog/smoothened signaling. A steroidal alkaloid	25mg 50mg
J61565	**8-Cyclopentyl-1,3-dimethylxanthine** *[NSC 101806]* [35873-49-5], $C_{12}H_{16}N_4O_2$, F.W. 248.28, Powder, m.p. 250-252°, RTECS XH5093600, MDL MFCD00055116 Application(s): A selective A1 adenosine receptor antagonist	100mg
L11508	**Cyclophosphamide monohydrate, 97+%** *[Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester, Cyclophosphane]* [6055-19-2], $C_7H_{15}Cl_2N_2O_2P{\cdot}H_2O$, F.W. 279.10 (261.09anhy), m.p. 51-53°, Merck **14**,2747, UN3464, EINECS 200-015-4, RTECS RP6157750, BRN 8167897, MDL MFCD00149395, Note: Special handling precautions required. View MSDS prior to purchase. MSDS are available online at www.alfa.com H:H301-H340-H350-H360, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Cancer research tool that induces apoptosis in tumor cells	 1g 5g
	Cyclophosphane, see Cyclophosphamide monohydrate, L11508, p. 172	
J61594	**Cyclopiazonic acid, 99+%** [18172-33-3], $C_{20}H_{20}N_2O_3$, F.W. 336.39, Powder, UN2811, RTECS UY8587000, MDL MFCD00167445 H:H300-H361, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Inhibitor of the sarco/endoplasmic reticulum calcium pump, calcium-ATPase	10mg 50mg
	1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid, see Enrofloxacin, J60023, p. 207	
A18000	**D-Cycloserine, 98+%** *[(R)-(+)-4-Amino-3-isoxazolidinone]* [68-41-7], $C_3H_6N_2O_2$, F.W. 102.09, m.p. 137° dec., $[\alpha]_D^{20}$ +115° (c=2 in water), Merck **14**,2751, Solubility: Soluble in water. Slightly soluble in methanol, propylene glycol., EINECS 200-688-4, RTECS NY2975000, BRN 80798, MDL MFCD00005353 Application(s): Inhibits bacterial cell wall biosynthesis. Prevents conversion of D-Alanine to L-Alanine	 1g 5g
J63191	**Cyclosporin A, 99+%** *[Cyclosporine A, Antibiotic S 7481F1]* [59865-13-3], $C_{62}H_{111}N_{11}O_{12}$, F.W. 1202.61, Crystalline solid, m.p. 146-151°, Merck **14**,2752, RTECS GZ4120000, BRN 3647785, MDL MFCD00274558 H:H361-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): Immunosuppressant. Induces apoptosis and inhibits angiogenesis induced by VEGF	1g 5g
	Cyclosporine A, see Cyclosporin A, 99+%, J63191, p. 172	
J65998	**Cypermethrin, 95%** *[α-Cyano-(3-phenoxyphenyl)methyl 3-(2,2-dichlorovinyl) -2,2-dimethylcyclopropanecarboxylate]* [52315-07-8], $C_{22}H_{19}Cl_2NO_3$, F.W. 416.30, Oil or liquid, f.p. 100°(212°F), Merck **14**,2767, UN2810, EINECS 257-842-9, RTECS GZ1250000, MDL MFCD00055328 H:H301-H335-H373-H410, P:P260-P261-P301+P310-P321-P405-P501	100mg 1g 5g 25g
J63142	**Cyproconazole** [94361-06-5], $C_{15}H_{18}ClN_3O$, F.W. 291.78, Crystalline, m.p. 108°, b.p. >250°, f.p. >100°(212°F), Merck **14**,2771, UN3077, RTECS XZ4803250, BRN 8396421, MDL MFCD01678672 H:H361d-H400-H410-H302, P:P281-P273-P301+P312-P308+P313-P405-P501a Application(s): Causes hepatocellular adenomas and carcinomas	5g 10g
	H-DL-(Cys)2-OH, see DL-Cystine, J63564, p. 173	
B22873	**Cystamine dihydrochloride, 97+%** ■ *[Bis(2-aminoethyl) disulfide dihydrochloride]* [56-17-7], $(H_2NCH_2CH_2S)_2{\cdot}2HCl$, F.W. 225.20, m.p. 217-220°, Merck **14**,2776, EINECS 200-260-7, RTECS KR7260000, BRN 3616850, MDL MFCD00012905, † H:H302, P:P280f	25g 100g
J62240	**Cystatin, 95%** [81989-95-9], Powder, MDL MFCD00130887	1mg
	Cysteamine hydrochloride, see 2-Mercaptoethylamine hydrochloride, A14377, p. 281	
H56126	**DL-Cysteine, 96%** *[DL-2-Amino-3-mercaptopropionic acid, H-DL-Cys-OH]* [3374-22-9], $C_3H_7NO_2S$, F.W. 121.16, m.p. 225° dec., EINECS 222-160-2, RTECS HA1595000, BRN 1721406, MDL MFCD00004881	 5g 25g 100g
A10435	**L-Cysteine, 98+%** △ *[L-2-Amino-3-mercaptopropionic acid, H-Cys-OH]* [52-90-4], $C_3H_7NO_2S$, F.W. 121.16, m.p. ca 220° dec., $[\alpha]_D^{20}$ +7.6° (c=5 in 5N HCl), Merck **14**,2781, EINECS 200-158-2, RTECS HA1600000, BRN 1721408, MDL MFCD00064306, † H:H302, P:P264-P270-P301+P312-P330-P501a	 50g 250g 1kg

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63745	**L-Cysteine, Cell Culture Reagent** △ *[L-2-Amino-3-mercaptopropionic acid]* [52-90-4], $C_3H_7NO_2S$, F.W. 121.16, Powder, m.p. ca 220° dec., Merck **14**,2781, EINECS 200-158-2, RTECS HA1600000, BRN 1721408, MDL MFCD00064306, † ! H:H302, P:P264-P270-P301+P312-P330-P501a	**25g** **100g**
H27107	**D-Cysteine hydrochloride monohydrate, 99%** *[D-2-Amino-3-mercaptopropionic acid hydrochloride monohydrate, H-D-Cys-OH.HCl.H_2O]* [207121-46-8], $C_3H_7NO_2S \cdot HCl \cdot H_2O$, F.W. 175.64 (157.62anhy), m.p. 184-186°, EINECS 251-043-9, MDL MFCD00150051 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g**
A10389	**L-Cysteine hydrochloride monohydrate, 99%** △ *[H-Cys-OH.HCl.H_2O]* [7048-04-6], $C_3H_7NO_2S \cdot HCl \cdot H_2O$, F.W. 175.64 (157.62anhy), m.p. ca 175° dec., $[\alpha]_D^{20}$ +5.5° (c=5 in 5N HCl), Merck **14**,2781, EINECS 200-157-7, RTECS HA2285000, BRN 5158059, MDL MFCD00065606, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g** **500g**
L06328	**L-Cysteine hydrochloride, anhydrous, 98%** △ ■ *[H-Cys-OH.HCl]* [52-89-1], $C_3H_7NO_2S \cdot HCl$, F.W. 157.62, m.p. ca 180° dec., $[\alpha]_D^{20}$ +6.4° (c=5 in 5N HCl), Merck **14**,2781, EINECS 200-157-7, RTECS HA2275000, BRN 3560277, MDL MFCD00064553, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g**
J64436	**L-Cysteine methyl ester hydrochloride** *[L-Cys-OMe HCl]* [18598-63-5], $C_4H_9NO_2S \cdot HCl$, F.W. 171.65, Crystalline powder, m.p. 142° dec., Merck **14**,5785, EINECS 242-435-0, RTECS HA2460000, BRN 3685824, MDL MFCD00038998	**25g** **100g** **250g**
J63564	**DL-Cystine** *[H-DL-(Cys)2-OH, (±)-3,3'-Dithiobis(2-aminopropionic acid)]* [923-32-0], $C_6H_{14}N_2O_4S_2$, F.W. 240.30, Powder, m.p. 227° dec., Merck **14**,2782, EINECS 213-094-5, BRN 1728095, MDL MFCD00084652	**5g** **25g** **100g**
L13772	**D-Cystine, 98%** *[H-D-$(Cys)_2$-OH, (+)-3,3'-Dithiobis(2-aminopropionic acid)]* [349-46-2], $C_6H_{12}N_2O_4S_2$, F.W. 240.30, m.p. ca 250° dec., $[\alpha]_D^{20}$ +219° (c=1 in 1N HCl), Merck **14**,2782, EINECS 206-486-2, BRN 1728093, MDL MFCD00002610	**1g** **5g**
A13762	**L-Cystine, 99%** *[H-(Cys)2-OH, (-)-3,3'-Dithiobis(2-aminopropionic acid)]* [56-89-3], $C_6H_{12}N_2O_4S_2$, F.W. 240.30, m.p. >240° dec., d. 1.68, $[\alpha]_D^{20}$ -219° (c=1 in 1N HCl), Merck **14**,2782, EINECS 200-296-3, RTECS HA2690000, BRN 1728094, MDL MFCD00064228, †	**50g** **250g** **1kg**
J61651	**L-Cystine, Cell Culture Reagent** *[H-$(Cys)_2$-OH, (-)-3,3'-Dithiobis(2-aminopropionic acid)]* [56-89-3], $C_6H_{12}N_2O_4S_2$, F.W. 240.30, Powder, m.p. >240° dec., d. 1.68, Merck **14**,2782, EINECS 200-296-3, RTECS HA2690000, BRN 1728094, MDL MFCD00064228, †	**10g** **100g** **500g** **1kg**
J62292	**L-Cystine dihydrochloride, 99%** [30925-07-6], $C_6H_{12}N_2O_4S_2 \cdot 2HCl$, F.W. 313.22, Powder, m.p. 228-232°, EINECS 250-391-9, MDL MFCD00070399, †	**25g** **100g** **250g**
J63717	**L-Cystine dihydrochloride, Cell Culture Reagent** [30925-07-6], $C_6H_{12}N_2O_4S_2 \cdot 2HCl$, F.W. 313.22, Powder, m.p. 228-232°, EINECS 250-391-9, MDL MFCD00070399, †	**250g** **1kg**
J63071	**L-Cystine disodium salt monohydrate, 98+%** [199329-53-8], $C_6H_{10}N_2Na_2O_4S_2 \cdot H_2O$, F.W. 302.27 (284.26anhy), Powder, EINECS 265-025-3, †	**50g** **250g**
J62310	**L-Cystine disodium salt, 98+%** [64704-23-0], $C_6H_{10}N_2Na_2O_4S_2$, F.W. 284.30, Powder, EINECS 265-025-3, †	**250g** **1kg**
A10261	**Cytidine, 99%** ■ [65-46-3], $C_9H_{13}N_3O_5$, F.W. 243.22, m.p. ca 215° dec., $[\alpha]_D^{20}$ +29° (c=9 in water), Merck **14**,2786, EINECS 200-610-9, RTECS UW7370000, BRN 89173, MDL MFCD00006545, †	**10g** **50g** **250g**

Stock #	Description	Size
J64234	**Cytidine-5'-diphosphate disodium salt, 98%** *[CDP disodium salt]* [54394-90-0], $C_9H_{13}N_3Na_2O_{11}P_2$, F.W. 447.10, Powder, MDL MFCD00084682	**1g**
J64350	**Cytidine-5'-diphosphate trisodium salt** *[CDP trisodium salt]* [34393-59-4], $C_9H_{12}N_3Na_3O_{11}P_2$, F.W. 469.12, Crystalline powder, EINECS 251-990-8, MDL MFCD00065201	**25mg** **1g**
J64161	**Cytidine-5'-diphosphocholine** *[Citicoline]* [987-78-0], $C_{14}H_{26}N_4O_{11}P_2$, F.W. 488.32, Powder	**10g** **25g** **50g**
J63376	**Cytidine-5'-monophosphate disodium salt, 99+%** *[5'-CMP.2Na]* [6757-06-8], $C_9H_{12}N_3Na_2O_8P$, F.W. 367.16, Crystalline powder, MDL MFCD00064355	**1g** **5g** **25g**
J62238	**Cytidine-5'-triphosphate disodium salt, 98+%** *[CTP]* [36051-68-0], $C_9H_{14}N_3Na_2O_{14}P_3$, F.W. 527.12, Powder, f.p. 113°(235°F), EINECS 252-849-3, MDL MFCD00078193	**500mg** **1g** **2g**
J60280	**Cytochalasin A ▲** [14110-64-6], $C_{29}H_{35}NO_5$, F.W. 477.60, Powder, Merck **14**,2790, UN1544, EINECS 237-964-9, BRN 949521, MDL MFCD00005935 H:H361-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An anti-cytoskeletal compound. Inhibits glucose transport, actin polymerization and blocks the formation of microtubules. Inhibits cell divisiion. Inhibits HIV-1 protease	**1mg** **5mg**
J65342	**Cytochalasin B** *[Phomin]* [14930-96-2], $C_{29}H_{37}NO_5$, F.W. 479.61, Powder, m.p. 218-221°, Merck **14**,2790, UN1544, EINECS 239-000-2, RTECS RO0205000, BRN 1096207, MDL MFCD00077704 H:H300-H310-H330-H361, P:P301+P310-P304+P340-P320-P330-P361-P405-P501	**5mg** **10mg**
J62122	**Cytochrome C, equine heart, 90+%** [9007-43-6], Powder, Merck **14**,2791, EINECS 232-700-9, RTECS HA5365000, MDL MFCD00130890, † Application(s): A component of the electron transport chain in mitochondria	**1g**
A14731	**Cytosine, 98+%** *[4-Amino-2-hydroxypyrimidine]* [71-30-7], $C_4H_5N_3O$, F.W. 111.10, m.p. >300°, Merck **14**,2795, EINECS 200-749-5, RTECS UW7350150, BRN 2637, MDL MFCD00006034, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g** **100g**
J65671	**Cytosine-β-D-arabinofuranose hydrochloride** *[1-(β-D-Arabinofuranosyl)cytosine HCl, Cytarabine HCl]* [69-74-9], $C_9H_{13}N_3O_5 \cdot HCl$, F.W. 279.68, Powder, m.p. 197-198°, EINECS 200-713-9, RTECS HA5500000, MDL MFCD00012839 H:H319-H317-H361, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g** **10g**
	Cytosine deoxyriboside hydrochloride, see 2'-Deoxycytidine hydrochloride, L14153, p. 178 **2,4-D**, see 2,4-Dichlorophenoxyacetic acid, A12467, p. 186 **D609 potassium salt**, see Tricyclodecan-9-yl xanthogenate potassium salt, 98+%, J63015, p. 376	
J65995	**D-64131** *[(5-Methoxy-1H-indol-2-yl)phenylmethanone]* [74588-78-6], $C_{16}H_{13}NO_2$, F.W. 251.28, Crystalline solid	**10mg**
	DAB tetrahydrochloride hydrate, see 3,3'-Diaminobenzidine tetrahydrochloride hydrate, J62216, p. 182	
J61023	**Dacarbazine** *[Dacatic, Deticene]* [4342-03-4], $C_6H_{10}N_6O$, F.W. 182.18, Powder, m.p. 210-212°, Merck **14**,2798, EINECS 224-396-1, RTECS NI3950000, MDL MFCD00057167 H:H302-H312-H332-H315-H319-H340-H350-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Used in treatment of malignant melanoma and sarcomas. Generates methyl adducts to purine bases in DNA	**500mg** **1g**
	Dacatic , see Dacarbazine, J61023, p. 174 **DACH**, see (1S,2S)-(+)-1,2-Diaminocyclohexane, L14072, p. 182 **Dactinomycin**, see Actinomycin D, J60148, p. 78	
J60431	**DAGO** *[Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol, DAMGO]* [100929-53-1], $C_{26}H_{35}N_5O_6$, F.W. 513.59, Powder, MDL MFCD00133215 Application(s): Mu-opioid receptor-specific enkephalin analog	**5mg**
	Daidzein, see 4',7-Dihydroxyisoflavone, 98+%, J63763, p. 192 **DAMGO**, see DAGO, J60431, p. 174	

Stock #	Description	Size
	4-DAMP methiodide, see 4-Diphenylacetoxy-N-methylpiperidine methiodide, J62298, p. 198	
J62200	**Danazol** [17230-88-5], $C_{22}H_{27}NO_2$, F.W. 337.46, Powder, Merck **14**,2812, EINECS 241-270-1, RTECS TU4157070, MDL MFCD00056838 H:H302-H312-H332-H361, P:P261-P280-P281-P302+P352-P405-P501 Application(s): Danazol is a weak androgen. Also an anterior pituitary suppressant	**100mg** **500mg**
J62904	**Danofloxacin** [112398-08-0], $C_{19}H_{20}FN_3O_3$, F.W. 357.38, Powder, m.p. 268-272°, Merck **14**,2813, MDL MFCD00864910 Application(s): Synthetic fluoroquinone with broad spectrum anti-bacterial activity	**500mg** **1g**
A11449	**Dansyl amide, 98%** *[5-Dimethylamino-1-naphthalenesulfonamide, DNSA]* [1431-39-6], $C_{12}H_{14}N_2O_2S$, F.W. 250.32, m.p. 218-221°, EINECS 215-854-1, BRN 2217203, MDL MFCD00004000 Active site probe for enzymes. Application(s): Active site probe for carbonic anhydrase	**1g** **5g** **25g**
A13828	**Dansyl chloride, 97+%** ◪ *[5-Dimethylaminonaphthalene-1-sulfonyl chloride, DNSCl]* [605-65-2], $C_{12}H_{12}ClNO_2S$, F.W. 269.75, m.p. 69-75°, Merck **14**,2814, UN3261, EINECS 210-092-6, RTECS QK3688000, BRN 2217205, MDL MFCD00003985, † H:H314, P:P280-P303+P361+P353-P305+P351+P338-P310 Reagent for the preparation of fluorescent derivatives of amino acids and proteins: *Biochemistry*, **9**, 3878 (1970); *Anal. Biochem.*, **53**, 132 (1973); **66**, 104 (1975). Application(s): Used for N terminal amino acid and peptide labeling	**1g** **5g** **25g**
J60887	**Dantrolene sodium salt** [14663-23-1], $C_{14}H_9N_4NaO_5$, F.W. 336.23, Crystalline powder, Merck **14**,2816, EINECS 238-706-8, RTECS MU3875000, MDL MFCD00079130 H:H360, P:P281-P201-P202-P308+P313-P405-P501 Application(s): Inhibits intracellular calcium release from the sarcoplasmic reticulum	**100mg**
J65864	**DAPT** ▲ *[LY-374973, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine tert-butyl ester]* [208255-80-5], $C_{23}H_{26}F_2N_2O_4$, F.W. 432.50, Lyophilized, MDL MFCD04974585	**10mg**
J60621	**Dasatinib** *[BMS-354825]* [302962-49-8], $C_{22}H_{26}ClN_7O_2S$, F.W. 488.01, Powder or granular, Merck **14**,2829, RTECS XJ3466000 H:H360-H373-H302, P:P260-P281-P301+P312-P308+P313-P405-P501a Application(s): Inhibitor of tyrosine kinases	**250mg** **500mg** **1g**
J62972	**Dasatinib monohydrate** [863127-77-9], $C_{22}H_{26}ClN_7O_2S \cdot H_2O$, F.W. 506.02 (488.01anhy), Crystalline powder H:H360-H373-H302, P:P260-P281-P301+P312-P308+P313-P405-P501a Application(s): Tyrosine kinase inhibitor	**100mg** **500mg** **1g**
	Daunomycin, see Daunorubicin hydrochloride, J60224, p. 175	
J60224	**Daunorubicin hydrochloride** ■ *[Daunomycin, Leukaemomycin C]* [23541-50-6], $C_{27}H_{29}NO_{10} \cdot HCl$, F.W. 563.98, Red powder, Merck **14**,2832, UN2811, EINECS 245-723-4, RTECS HB7878000, BRN 4229221, MDL MFCD04974507 H:H301-H334-H351-H317, P:P285-P301+P310-P302+P352-P321-P405-P501a	**10mg**
	DCC, see N,N'-Dicyclohexylcarbodiimide, A10973, p. 187 **DCM**, see Dichloromethane, L13089, p. 186 **DEAE-Dextran**, see Diethylaminoethyl dextran , J63781, p. 188	
J62821	**Deblock trichloroacetic acid soln., 3% w/w in dichloromethane** *[DEBLK soln.]* Liquid, d. 1.325, UN2810, † H:H318-H351-H335+H336-H315-H411, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Solvent specially purified and analyzed for biotechnology applications, including peptide and oligonucleotide synthesis	**200ml** **450ml** **2.5L**
A13883	**Decahydronaphthalene, cis + trans, 98%** [91-17-8], $C_{10}H_{18}$, F.W. 138.25, m.p. <-45°, b.p. 189-191°, f.p. 57°(134°F), d. 0.88, n_D^{20} 1.4740, Merck **14**,2846, UN1147, EINECS 202-046-9, RTECS QJ3150000, BRN 878165, MDL MFCD00004130, † H:H331-H226-H315-H319-H335-H411, P:P260-P280h-P273-P305+P351+P338-P309-P310	**100ml** **500ml** **2.5L** **10L**
	Decamethylenediamine, see 1,10-Diaminodecane, 98%, J63821, p. 183	

Stock #	Description	Size
A11656	**Decanal, 96%** △ *[Capric aldehyde, Decyl aldehyde]* [112-31-2], $CH_3(CH_2)_8CHO$, F.W. 156.27, m.p. -5°, b.p. 207-209°, f.p. 85°(185°F), d. 0.828, n_D^{20} 1.4280, EINECS 203-957-4, RTECS HD6000000, BRN 1362530, MDL MFCD00007031, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100ml** **500ml**
	1,10-Decanediamine, see 1,10-Diaminodecane, 98%, J63821, p. 183 **1-Decanesulfonic acid sodium salt**, see Sodium 1-decanesulfonate, A14638, p. 345	
J60173	**N-Decanoyl-N-methylglucamine** *[MEGA-10, N-(D-Glucityl)-N-methyldecanamide]* [85261-20-7], $C_{17}H_{35}NO_6$, F.W. 349.46, Powder, m.p. 91-93°, BRN 6974359, MDL MFCD00036801 Application(s): Non-ionic detergent for solubilizing membrane proteins	**1g** **5g**
	Decyl aldehyde, see Decanal, A11656, p. 176	
J65900	**(2S,5S)-8-Decylbenzolactam V** *[(2S,5S)-8-decyl-5-(hydroxymethyl)-2-isopropyl-1-methyl-1,2,5,6-tetrahydrobenzo[e][1,4]diazocin-3(4H)-one]* $C_{25}H_{42}N_2O_2$, F.W. 402.61, Oil	**0.5mg**
	n-Decyl methyl ketone, see 2-Dodecanone, A18862, p. 201	
J63123	**(+)-Dehydroabietylamine hydrochloride** *[Leelamine hydrochloride]* [1446-61-3], $C_{20}H_{31}N{\cdot}HCl$, F.W. 321.90, White solid, EINECS 215-899-7, RTECS TP8701000, BRN 3084620, MDL MFCD00213430, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Resolving agent for carboxylic acids	**10mg** **50mg**
	Dehydroacetic acid sodium salt, see Sodium dehydroacetate, B21060, p. 345	
A19666	**Dehydrocholic acid, 99%** *[3,7,12-Trioxo-5β-cholan-24-oic acid, 3,7,12-Triketocholanic acid]* [81-23-2], $C_{24}H_{34}O_5$, F.W. 402.54, m.p. 235-238°, $[\alpha]_D^{20}$ +26° (c=1 in ethanol), Merck **14**,2868, EINECS 201-335-7, RTECS FZ2300000, BRN 3226734, MDL MFCD00066410, † H:H303, P:P312 Application(s): A bile acid generated from oxidation of cholic acid	**50g** **250g**
J63678	**Delicious Peptide, bovine** *[H-Lys-Gly-Asp-Glu-Glu-Ser-Leu-Ala-OH]* [73984-05-1], $C_{34}H_{57}N_9O_{16}$, F.W. 847.88, Powder Application(s): A peptide with delicious beefy taste; originally extracted from beef meat	**5mg**
	Delphidenolon 1575, see Myricetin, 98%, J60450, p. 296	
J63334	**Delta Sleep-Inducing Peptide** *[DSIP, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu]* [62568-57-4], $C_{35}H_{48}N_{10}O_{15}$, F.W. 848.81, Powder, Merck **14**,3458, MDL MFCD00076883	**1mg** **5mg**
	Delta Yellow, see Nitrazine Yellow, J60281, p. 303 **Deltorphin B**, see Deltorphin II, J62286, p. 176 **Deltorphin C**, see Deltorphin I, J60952, p. 176	
J60952	**Deltorphin I** *[Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2, Deltorphin C]* [122752-15-2], $C_{37}H_{52}N_8O_{10}$, F.W. 768.87, Powder Application(s): Selective delta-opioid receptor agonist	**1mg** **5mg**
J62286	**Deltorphin II** *[Tyr-D-Ala-Phe-Glu-Val-Val-Gly amide, Deltorphin B]* [122752-16-3], $C_{38}H_{54}N_8O_{10}$, F.W. 782.88, Powder, MDL MFCD00080072 Application(s): Selective delta-2 opioid receptor agonist	**1mg** **5mg**
J63102	**Demeclocycline hydrochloride** *[Clortetrin, Mexocine]* [64-73-3], $C_{21}H_{21}ClN_2O_8{\cdot}HCl$, F.W. 501.32, Powder, m.p. >245° dec., Merck **14**,2886, EINECS 200-592-2, RTECS QI7700000, BRN 3849198, MDL MFCD00082371 ! H:H317, P:P261-P280-P302+P352-P321-P363-P501	**1g**
	Demecolcine, see Colcemid, 98+%, J63900, p. 167	
J61048	**Denatonium benzoate** *[Bitrex® MacFarlan Smith, A Johnson Matthey Co.]* [3734-33-6], $C_{21}H_{29}N_2O.C_7H_5O_2$, F.W. 446.59, Powder, m.p. 164-169°, Merck **14**,2891, EINECS 223-095-2, RTECS BO6650000, BRN 8179408, MDL MFCD00031578, † ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): The bitterest compound known	**1g** **5g** **25g**
J62977	**Denatured calf thymus DNA, phenol extracted** Liquid	**10mg** **20mg**
J61458	**Denatured salmon testes DNA, phenol extracted** Liquid	**10mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J60132	**Denaturing lysis buffer** Liquid, Note: 50mM Tris-HCl with 2% SDS, pH 7.4, †	**250ml** **500ml**
J60370	**Denaturing solution** Liquid, UN3266, Note: 1.5M NaCl with 0.5M NaOH H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**500ml** **1L**
J63135	**Denhardt's solution (50X)** Liquid, Note: 1% Ficolll (Type 400, Pharmacia), 1% polyvinylpyrrolidone, and 1% bovine serum albumin, †	**50ml** **100ml**
J62416	**Denhardt's solution (100X)** Liquid, Note: 2% Ficoll (Type 400, Pharmacia), 2% polyvinylpyrrolidone and 2% bovine serum albumin, †	**50ml** **100ml**
A11166	**2'-Deoxyadenosine monohydrate, 99%** *[Adenine deoxyriboside, 9-(2-Deoxy-β-D-ribofuranosyl)adenine]* [16373-93-6], $C_{10}H_{13}N_5O_3 \cdot H_2O$, F.W. 269.26 (251.24anhy), m.p. 186-189°, $[\alpha]_D^{20}$ -25° (c=0.5 in water), EINECS 213-488-7, RTECS AU7358600, BRN 5191174, MDL MFCD00149364, † 	**1g** **5g** **25g**
J63886	**2'-Deoxyadenosine, 99%** *[Adenine deoxyriboside, 9-(2-Deoxy-β-D-ribofuranosyl)adenine]* [958-09-8], $C_{10}H_{13}N_5O_3$, F.W. 251.24, Powder, EINECS 213-488-7, RTECS AU7358650, MDL MFCD00056003, †	**50g** **100g**
J65366	**3'-Deoxyadenosine, 98%** *[Cordycepin]* [73-03-0], $C_{10}H_{13}N_5O_3$, F.W. 251.24, Powder, UN2811, EINECS 200-791-4, RTECS AU7358610, BRN 35194, MDL MFCD00037998 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **25mg** **100mg**
J65307	**2'-Deoxyadenosine-5'-diphosphate trisodium salt, 98%** *[dADP]* [72003-83-9], $C_{10}H_{12}N_5Na_3O_9P_2$, F.W. 477.15, Powder, EINECS 276-280-5, MDL MFCD00083610 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
J64402	**2'-Deoxyadenosine-5'-monophosphate, 99%** *[2'-dAMP, 2'-Deoxyadenylic acid]* [653-63-4], $C_{10}H_{14}N_5O_6P$, F.W. 331.22, Crystalline powder, EINECS 211-503-1, MDL MFCD00005753	**1g** **5g** **25g**
J65542	**2'-Deoxyadenosine-5'-triphosphate disodium salt, 97%** *[dATP, 2'-Deoxyadenosine 5'-triphosphoric acid disodium salt]* [1927-31-7], $C_{10}H_{14}N_5Na_2O_{12}P_3$, F.W. 535.14, Powder, EINECS 217-662-3, RTECS AU7358800, MDL MFCD00080335	**500mg**
J64045	**2'-Deoxyadenosine-5'-triphosphate disodium salt, 98%** *[dATP-Na2]* [74299-50-6], $C_{10}H_{14}N_5Na_2O_{12}P_3$, F.W. 535.14, Powder, EINECS 277-809-2, MDL MFCD00080335	**10mg** **25mg** **100mg**
J64578	**Deoxy-bigCHAP** *[N,N-Bis[3-(D-gluconamido)propyl]deoxycholamide]* [86303-23-3], $C_{42}H_{75}N_3O_{15}$, F.W. 862.05, Powder, Merck **14**,1214, MDL MFCD00161482 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**250mg** **1g**
B20061	**Deoxycholic acid, 99%** [83-44-3], $C_{24}H_{40}O_4$, F.W. 392.58, m.p. 172-176°, $[\alpha]_D^{20}$ +54° (c=2 in ethanol), Merck **14**,2899, EINECS 201-478-5, RTECS FZ2100000, BRN 3219882, MDL MFCD00003673, † H:H302, P:P264-P270-P301+P312-P330-P501a 	**25g** **100g** **500g**
J62288	**Deoxycholic acid sodium salt** *[7-Deoxycholic acid sodium salt]* [302-95-4], $C_{24}H_{39}NaO_4$, F.W. 414.60, Powder, EINECS 206-132-7, RTECS FZ2250000, BRN 3581950, MDL MFCD00064139, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25g** **100g** **250g**
	7-Deoxycholic acid sodium salt, see Deoxycholic acid sodium salt, J62288, p. 177	
J63062	**2'-Deoxycytidine** [951-77-9], $C_9H_{13}N_3O_4$, F.W. 227.22, Crystalline powder, m.p. 209-211°, EINECS 213-454-1, RTECS HA3800000, BRN 87567, MDL MFCD00006547, †	**1g** **5g** **25g**

Stock #	Description	Size
L14153	**2'-Deoxycytidine hydrochloride, 99%** ■ *[Cytosine deoxyriboside hydrochloride, 1-(2-Deoxy-β-D-ribofuranosyl)cytosine hydrochloride]* [3992-42-5], $C_9H_{13}N_3O_4{\cdot}HCl$, F.W. 263.68, m.p. ca 170° dec., $[\alpha]_D^{20}$ +57° (c=1 in water), EINECS 223-639-9, BRN 3576124, MDL MFCD00012840, † 	**250mg** **1g**
J65408	**2'-Deoxycytidine-5'-diphosphate trisodium salt, 98%** *[dCDP]* [151151-32-5], $C_9H_{12}N_3Na_3O_{10}P_2$, F.W. 453.12, Powder, MDL MFCD00056068 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
J65244	**2'-Deoxycytidine-5'-monophosphate, 99%** *[Deoxycytidylic acid, dCMP]* [1032-65-1], $C_9H_{14}N_3O_7P$, F.W. 307.20, Crystalline powder, EINECS 213-849-9, BRN 41062, MDL MFCD00006546	**1g** **5g**
J65724	**2'-Deoxycytidine-5'-monophosphate disodium salt** *[Deoxycytidylic acid disodium salt, dCMP disodium salt]* [13085-50-2], $C_9H_{12}N_3Na_2O_7P$, F.W. 351.16, Powder, EINECS 235-995-2, MDL MFCD00069774	**25mg** **1g**
J65686	**2'-Deoxycytidine-5'-triphosphate disodium salt** *[5'-dCTP Na2, 2'-Deoxy-5'-triphosphocytidine disodium salt]* [102783-51-7], $C_9H_{13}N_3Na_2O_{13}P_3$, F.W. 511.12, Powder	**25mg** **250mg**
	Deoxyepinephrine hydrochloride, see N-Methyldopamine hydrochloride, 98+%, J60306, p. 287 **2'-Deoxy-5-fluorouridine**, see 5-Fluoro-2'-deoxyuridine, L16497, p. 224	
J65482	**2-Deoxy-D-galactose, 99%** *[2-Deoxy-D-lyxohexose, 2-Deoxy-D-galactopyranose]* [1949-89-9], $C_6H_{12}O_5$, F.W. 164.16, Powder, m.p. 107-110°, EINECS 217-765-3, BRN 1723333, MDL MFCD00014649	**2g** **5g** **10g**
	6-Deoxy-D-galactose, see D-(+)-Fucose, A18234, p. 228 **6-Deoxy-L-galactose**, see L-(-)-Fucose, A16789, p. 228	
L07338	**2-Deoxy-D-glucose, 98%** [154-17-6], $C_6H_{12}O_5$, F.W. 164.16, m.p. 147-152°, $[\alpha]_D^{20}$ +47° (c=0.5 in water, 45h), Merck **14**,2904, EINECS 205-823-0, RTECS MQ3325000, BRN 1723331, MDL MFCD00151328, †  Application(s): A useful culture media component for molecular genetics	**1g** **5g** **25g**
L14519	**2'-Deoxyguanosine hydrate, 99%** *[9-(2-Deoxy-β-D-ribofuranosyl)guanine hydrate, Guanine-2'-deoxyriboside hydrate]* [961-07-9], $C_{10}H_{13}N_5O_4{\cdot}xH_2O$, F.W. 267.25(anhy), $[\alpha]_D^{20}$ -32° (c=0.5 in water), EINECS 213-505-8, RTECS MF8760000, BRN 39814, MDL MFCD00150760, † 	**100mg** **500mg**
J60741	**2'-Deoxyguanosine** [961-07-9], $C_{10}H_{13}N_5O_4$, F.W. 267.25, Crystalline powder, EINECS 213-505-8, †	**1g** **5g** **10g**
J64490	**2'-Deoxyguanosine-5'-diphosphate sodium salt** *[dGDP]* [102783-74-4], $C_{10}H_{15}N_5Na_xO_{10}P_2$ (x=1-3), F.W. 427.20 (free acid), Powder, MDL MFCD00057075 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg**
J65186	**2'-Deoxyguanosine-5'-monophosphate disodium salt hydrate, 99%** *[2'-Deoxy-5'-guanylic acid disodium salt, 5'-dGMP disodium salt]* [33430-61-4], $C^1{}_0H^1{}_2N_5Na_2O_7P.xH_2O$, F.W. 391.18 (anhy), Crystalline powder, m.p. 245° dec., MDL MFCD00080331	**1g** **5g** **25g**
J65179	**2'-Deoxyguanosine-5'-triphosphate trisodium salt, 97%** *[5'-dGTP]* [93919-41-6], $C_{10}H_{13}N_5Na_3O_{13}P_3$, F.W. 573.13, Powder, MDL MFCD00080337	**25mg**
J61411	**2'-Deoxyinosine** *[9-(2-Deoxy-β-D-ribofuranosyl)hypoxanthine]* [890-38-0], $C_{10}H_{12}N_4O_4$, F.W. 252.23, Crystalline powder, m.p. >250°, EINECS 212-964-1, BRN 33517, MDL MFCD00005762	**1g** **10g** **25g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
H52292	**2'-Deoxyinosine, 98+%** *[9-(2-Deoxy-β-D-ribofuranosyl)hypoxanthine]* [890-38-0], $C_{10}H_{12}N_4O_4$, F.W. 252.23, EINECS 212-964-1, MDL MFCD00005762 	**250mg** **1g** **5g**
J64271	**2'-Deoxyinosine-5'-monophosphate disodium salt, 99%** *[2'-Deoxyinosine-5'-monophosphoric acid disodium salt]* [14999-52-1], $C_{10}H_{11}N_4Na_2O_7P$, F.W. 376.17, Powder, EINECS 239-090-3, MDL MFCD00134874 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g**
J64174	**2'-Deoxyinosine-5'-triphosphate trisodium salt, 98%** *[dITP]* [95648-77-4], $C_{10}H_{12}N_4Na_3O_{13}P_3$, F.W. 558.11, Powder, EINECS 306-018-8, MDL MFCD00167408	**100mg**
J61277	**(+)-1-Deoxymannojirimycin hydrochloride** *[DMJ, 1,5-Dideoxy-1,5-imino-D-mannitol hydrochloride]* [73465-43-7], $C_6H_{13}NO_4 \cdot HCl$, F.W. 199.60, Powder, MDL MFCD00083611 Application(s): Selective inhibitor of α-mannosidase	**5mg** **10mg** **25mg**
	6-Deoxy-L-mannose monohydrate, see L-(+)-Rhamnose monohydrate, A16166, p. 336 **D-1-Deoxy-1-(methylamino)glucitol**, see N-Methyl-D-glucamine, L14282, p. 288	
J62602	**(+)-1-Deoxynojirimycin** *[1,5-Dideoxy-1,5-imino-D-glucitol, (2R,3R,4R,5S)-2-(Hydroxymethyl)-3,4,5-piperidinetriol]* [19130-96-2], $C_6H_{13}NO_4$, F.W. 163.17, Powder, m.p. 195-196°, Merck **14**,2905, RTECS TN4350300 Application(s): An α-glucosidase inhibitor. Interferes with normal processing of N-linked glycoproteins.	**5mg** **50mg** **100mg**
	9-(2-Deoxy-β-D-ribofuranosyl)adenine, see 2'-Deoxyadenosine, 99%, J63886, p. 177 **1-(2-Deoxy-β-D-ribofuranosyl)cytosine hydrochloride**, see 2'-Deoxycytidine hydrochloride, L14153, p. 178 **9-(2-Deoxy-β-D-ribofuranosyl)guanine hydrate**, see 2'-Deoxyguanosine hydrate, L14519, p. 178 **9-(2-Deoxy-β-D-ribofuranosyl)hypoxanthine**, see 2'-Deoxyinosine, J61411, p. 178 **1-(2-Deoxy-β-D-ribofuranosyl)uracil**, see 2'-Deoxyuridine, A16026, p. 180	
J62229	**Deoxyribonuclease I, bovine pancreas** *[EC 3.1.21.1, DNase I]* [9003-98-9], Lyophilized powder, 31 kDa, Merck **14**,2906, EINECS 232-667-0, RTECS RF0750000, MDL MFCD00130918, Note: Minimum 2,000 units per mg dry weight. One unit causes an increase in absorbance at 260nm of 0.001 per minute per ml at 25 degrees when acting upon highly polymerized DNA at pH 5.0, †	**25mg** **100mg** **1g**
J60027	**Deoxyribonuclease I, bovine pancreas, Molecular Biology Grade** *[EC 3.1.21.1, DNase I]* [9003-98-9], Liquid, 31 kDa, Merck **14**,2906, EINECS 232-667-0, RTECS RF0750000, MDL MFCD00130918, Note: One unit causes an increase in absorbance at 260nm of 0.001 per minute per ml at 25 degrees when acting upon highly polymerized DNA at pH 5.0. Minimum 2,000 units per ml. Solution at 1 mg/ml containing 50% glycerol and 1 mM calcium chloride., † Application(s): Endonuclease that splits phosphodiester linkages, preferentially adjacent to a pyrimidine nucleotide	**100units** **500units**
J61061	**Deoxyribonuclease I, bovine pancreas, Purified** *[EC 3.1.21.1, DNase I]* [9003-98-9], Lyophilized powder, 31 kDa, Merck **14**,2906, EINECS 232-667-0, RTECS RF0750000, MDL MFCD00130918, Note: Minimum 2,000 units per mg protein. One unit causes an increase in absorbance at 260nm of 0.001 per minute per ml at 25 degrees when acting upon highly polymerized DNA at pH 5.0, † Application(s): Chromatographically purified	**5mg** **20mg** **100mg**
J63389	**Deoxyribonuclease II, porcine spleen** *[EC 3.1.22.1, DNase II]* [9025-64-3], Lyophilized powder, 38 kDa, EINECS 232-801-8, MDL MFCD00130919, Note: Minimum 800 units per mg dry weight. One unit causes an increase in absorbance at 260 nm of 0.001 per minute at 25°C, pH 4.6 using highly polymerized DNA as substrate. Supplied as a dialyzed, lyophilized powder. Store at 2-8°C., †	**80kilounits**
J61774	**Deoxyribonuclease II, porcine spleen, Purified** *[EC 3.1.22.1, DNase II]* [9025-64-3], Lyophilized powder, 38 kDa, EINECS 232-801-8, MDL MFCD00130919, Note: Minimum 12,000 units per mg protein. One unit will increase absorbance at 260nm by 0.001 per min per mL at pH 4.6 and 25°C. Chromatographically purified. Supplied as a dialyzed, lyophilized powder., † Application(s): Hydrolyzes deoxyribonucleotide linkages in native and denatured DNA yielding products with 3'-phosphates	**20kilounits**
J60840	**Deoxyribonucleic acid, salmon testes** *[Deoxyribonucleic acid, salmon sperm]* [9007-49-2], Lyophilized powder	**1g**
	Deoxyribonucleic acid, salmon sperm, see Deoxyribonucleic acid, salmon testes, J60840, p. 179	
J64400	**Deoxyribonucleic acid sodium salt, calf thymus** [91080-16-9], Lyophilized powder, EINECS 293-507-3, MDL MFCD00151698	**100mg** **1g**

Stock #	Description	Size
J65753	**Deoxyribonucleic acid sodium salt, salmon testes** *[SS-DNA]* [9007-49-2], Lyophilized powder, Merck **14**,2907, RTECS HG1933000	**1g** **5g**
A11990	**2-Deoxy-D-ribose, 99%** ■ *[Thyminose]* [533-67-5], $C_5H_{10}O_4$, F.W. 134.13, m.p. 76-85°, $[\alpha]_D^{20}$ -56° (c=1 in water, 24h), Merck **14**,2908, EINECS 208-573-0, RTECS SB7230000, BRN 1721978, MDL MFCD00135904, † Starting material for a free-radical coupling reaction (employing homolytic fission of a derivative with **2-Mercaptopyridine N-oxide**, **A14152**) which provides a facile preparative method for C-nucleosides: *Chem. Lett.*, 1673 (1992). 	**1g** **5g** **25g**
J65765	**3'-Deoxythymidine** *[2',3'-Dideoxythymidine, ddT]* [3416-05-5], $C_{10}H_{14}N_2O_4$, F.W. 226.23, Powder, m.p. 155-156°, BRN 21884, MDL MFCD00010570	**500mg** **1g**
J64938	**2'-Deoxythymidine-5'-diphosphate trisodium salt, 98%** [95648-78-5], $C_{10}H_{13}N_2Na_3O_{11}P_2$, F.W. 468.13, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
A16026	**2'-Deoxyuridine, 99%** △ *[1-(2-Deoxy-β-D-ribofuranosyl)uracil, Uracil deoxyriboside]* [951-78-0], $C_9H_{12}N_2O_5$, F.W. 228.21, m.p. 164-167°, $[\alpha]_D^{20}$ +52° (c=1.1 in 1N NaOH), Merck **14**,2910, EINECS 213-455-7, RTECS YU7490000, BRN 24433, MDL MFCD00006527, † 	**1g** **5g** **25g**
J65531	**3'-Deoxyuridine** *[3'-Deoxy-D-uridine]* [7057-27-4], $C_9H_{12}N_2O_5$, F.W. 228.21, Powder, MDL MFCD00079153	**10mg** **25mg**
J64627	**2'-Deoxyuridine-5'-monophosphate disodium salt, 99%** *[2'-dUMP, 2'-Deoxyuridine-5'-monophosphoric acid disodium salt]* [42155-08-8], $C_9H_{11}N_2Na_2O_8P$, F.W. 352.15, Powder, EINECS 255-687-1, MDL MFCD00065282 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**250mg** **1g**
J64716	**2'-Deoxyuridine-5'-triphosphate disodium salt, 95%** *[dUTP sodium salt]* [102814-08-4], $C_9H_{15}N_2Na_2O_{14}P_3$, F.W. 514.12, Powder, MDL MFCD00084701	**25mg** **50mg** **100mg**
	DEPC, see Diethyl cyanophosphonate, L14107, p. 188	
J61286	**(R)-(-)-Deprenyl hydrochloride** *[Selegiline]* [14611-52-0], $C_{13}H_{17}N{\cdot}HCl$, F.W. 223.74, Crystalline Powder, Merck **14**,8428, RTECS DA0292500, MDL MFCD00069299 H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 Application(s): Selective MAO-B inhibitor; anti-Parkinsonian agent	**1g**
J62019	**Dermorphin** *[Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2]* [77614-16-5], $C_{40}H_{50}N_8O_{10}$, F.W. 802.90, Powder Application(s): A mu-opioid receptor agonist	**5mg**
	[Des-Gly10, D-Leu6, Pro-NHEt9]LHRH, see Leuprolide, human, synthetic, J62967, p. 269 **Deticene**, see Dacarbazine, J61023, p. 174	
A17590	**Dexamethasone, 98%** ▲ [50-02-2], $C_{22}H_{29}FO_5$, F.W. 392.47, m.p. ca 260° dec., Merck **14**,2943, EINECS 200-003-9, RTECS TU3980000, BRN 2066651, MDL MFCD00064136, † H:H361d, P:P280h Application(s): Anti-inflammatory glucocorticoid 	**1g** **5g** **25g**
J63691	**Dexamethasone acetate** [1177-87-3], $C_{24}H_{31}FO_6$, F.W. 434.50, Powder, m.p. 240°, Merck **14**,2943, EINECS 214-646-8, RTECS TU4050000, BRN 2342608, MDL MFCD00027407, † H:H317, P:P261-P280-P302+P352-P321-P363-P501 Application(s): Glucocorticoid anti-inflamatory	**1g** **5g**
J64083	**Dexamethasone 21-phosphate disodium salt, 98%** [2392-39-4], $C_{22}H_{28}FNa_2O_8P$, F.W. 516.40, Powder, m.p. 233-240°, Merck **14**,2943, EINECS 219-243-0, RTECS TU4056000, BRN 6473066, MDL MFCD00079105, † H:H302-H351-H361, P:P281-P264-P301+P312-P308+P313-P405-P501	**1g** **5g**

Stock #	Description	Size
	Dexpanthenol, see D-Panthenol, A18499, p. 311	
J62775	**Dextran, MW ca 6,000** [9004-54-0], $(C_6H_{16}O_5)n$, Powder, Merck **14**,2948, EINECS 232-677-5, MDL MFCD00130935, Note: Biosynthesized by the non-pathogenic Leuconostoc mesenteroides, †	**10g** **50g** **100g** **500g**
J61216	**Dextran, MW ca 20,000** [9004-54-0], $(C_6H_{16}O_5)n$, Powder, Merck **14**,2948, EINECS 232-677-5, MDL MFCD00130935, Note: Biosynthesized by the non-pathogenic Leuconostoc mesenteroides., †	**10g** **50g** **100g** **500g**
J63690	**Dextran, MW ca 40,000** *[Dextran 40]* [9004-54-0], $(C_6H_{16}O_5)n$, Powder, Merck **14**,2948, EINECS 232-677-5, RTECS HH9246000, MDL MFCD00130935, Note: Biosynthesized by Leuconostoc mesenteroides., †	**10g** **50g** **100g** **500g**
J60989	**Dextran, MW ca 75,000** [9004-54-0], $(C_6H_{16}O_5)n$, Powder, Merck **14**,2948, EINECS 232-677-5, MDL MFCD00130935, Note: Biosynthesized by Leuconostoc mesenteroides., †	**10g** **50g** **100g** **500g**
J63789	**Dextran, MW ca 150,000** [9004-54-0], $(C_6H_{16}O_5)n$, Powder, Merck **14**,2948, EINECS 232-677-5, MDL MFCD00130935, Note: Biosynthesized by Leuconostoc mesenteroides., †	**10g** **50g** **100g** **500g** **1kg**
J60200	**Dextran, MW ca 250,000** [9004-54-0], $(C_6H_{16}O_5)n$, Powder, Merck **14**,2948, EINECS 232-677-5, MDL MFCD00130935, Note: Biosynthesized by Leuconostoc mesenteroides., †	**10g** **50g** **100g** **500g**
J63702	**Dextran, MW ca 500,000** [9004-54-0], $(C_6H_{16}O_5)n$, Powder, Merck **14**,2948, EINECS 232-677-5, MDL MFCD00130935, Note: Biosynthesized by the non-pathogenic Leuconostoc mesenteroides., †	**10g** **50g** **100g** **500g**
	Dextran 40, see Dextran, MW ca 40,000, J63690, p. 181 **Dextran sodium sulfate**, see Dextran sulfate sodium salt	
J60938	**Dextran sulfate sodium salt solution, 50% w/v aq. soln.** [9011-18-1], Powder, Merck **14**,2951, MDL MFCD00081551, †	**100ml**
J62101	**Dextran sulfate sodium salt, MW ca 8,000** *[Dextran sodium sulfate, Sodium dextran sulfate]* [9011-18-1], Powder, Merck **14**,2951, RTECS HH9290000, MDL MFCD00081551, Note: Biosynthesized by Leuconostoc mesenteroides., †	**25g** **100g** **1kg**
J63606	**Dextran sulfate sodium salt, MW ca 40,000** *[Dextran sodium sulfate, Sodium dextran sulfate]* [9011-18-1], Powder, Merck **14**,2951, RTECS HH9290000, MDL MFCD00081551, Note: Biosynthesized by Leuconostoc mesenteroides., †	**25g** **100g**
J62787	**Dextran sulfate sodium salt, MW ca >500,000** *[Dextran sodium sulfate, Sodium dextran sulfate]* [9011-18-1], Powder, Merck **14**,2951, RTECS HH9290000, MDL MFCD00081551, Note: Biosynthesized by Leuconostoc mesenteroides., †	**5g** **50g** **100g** **1kg**
A15717	**Dextrin, precipitated by alcohol** ■ [9004-53-9], Merck **14**,2953, EINECS 232-675-4, RTECS HH9450000, MDL MFCD00081554, †	**100g** **500g**
J61732	**Dextromethorphan hydrobromide** [125-69-9], $C_{18}H_{25}NO \cdot HBr$, F.W. 352.32, Solid, m.p. 125-127°, Merck **14**,8091, EINECS 204-750-1, BRN 6453793, MDL MFCD02173901 ! H:H302, P:P264-P270-P301+P312-P330-P501a	**5g** **10g** **50g**
	Dextrose, see D-(+)-Glucose, A16828, p. 233 **DHA**, see 1,3-Dihydroxyacetone, J60592, p. 191 **DHEBA**, see N,N'-(1,2-Dihydroxyethylene)bisacrylamide, L19211, p. 192	
J63775	**Diacerein** [13739-02-1], $C_{19}H_{12}O_8$, F.W. 368.29, Powder, m.p. 217-218°, Merck **14**,2960, EINECS 237-310-2, RTECS CB8781000, MDL MFCD00468030 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Interleukin-1 inhibitor	**1g** **5g**

Stock #	Description	Size
	1,6-Diacetamidohexane, see N,N'-Diacetyl-1,6-diaminohexane, B22771, p. 182	
B22771	**N,N'-Diacetyl-1,6-diaminohexane, 98+%** *[N,N'-Diacetyl-1,6-hexanediamine, N,N'-Hexamethylenebis(acetamide)]* [3073-59-4], $CH_3CONH(CH_2)_6NHCOCH_3$, F.W. 200.28, m.p. 126-129°, RTECS AC2976200, BRN 1775764, MDL MFCD00008684 Application(s): Induces apoptosis in various transformed cells	**10g** **50g** **250g**
	2,6-Diacetyl-7,9-dihydroxy-8,9b-dimethyldibenzofuran-1,3(2H,9bH)-dione, see (+)-Usnic acid, H56612, p. 389 **N,N'-Diacetyl-1,6-hexanediamine**, see N,N'-Diacetyl-1,6-diaminohexane, B22771, p. 182 **Diacetyl monoxime**, see 2,3-Butanedione monoxime, A14339, p. 140	
L15694	**1,4-Diacryloylpiperazine, 97%** *[1,4-Bis(acryloyl)piperazine, Diacroyl piperazine]* [6342-17-2], $C_{10}H_{14}N_2O_2$, F.W. 194.23, m.p. 91-95°, BRN 745431, MDL MFCD00077661  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Cross-linker in polyacrylamide gels.	**1g** **5g** **25g**
	5,3'-Diallyl-2,4'-dihydroxybiphenyl, see Honokiol, 98+%, J63434, p. 246	
A12195	**N,N'-Diallyl-L-tartardiamide, 99%** [58477-85-3], $C_{10}H_{16}N_2O_4$, F.W. 228.25, m.p. 184-186°, $[\alpha]_D^{20}$ +118° (c=3 in methanol), EINECS 261-277-3, BRN 1712934, MDL MFCD00008640, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Cross-linking co-monomer for the polymerization of soluble polyacrylamide gels	**50g** **250g**
J61029	**Dialysis tubing wash buffer (5X)** Liquid, Note: 10% (w/v) sodium bicarbonate solution, with 50mM EDTA, pH 8.0	**250ml** **500ml**
J64585	**Diamide, 96%** *[1,1'-Azobis(N,N-dimethylformamide), N,N,N',N'-Tetramethylazodicarboxamide]* [10465-78-8], $C_6H_{12}N_4O_2$, F.W. 172.18, Powder, EINECS 233-951-7, RTECS LQ1041000, BRN 1910409, MDL MFCD00008318	**1g** **5g**
	1,8-Diamino-4-azaoctane, see Spermidine, A19096, p. 350 **1,2-Diaminobenzene dihydrochloride**, see o-Phenylenediamine dihydrochloride, 98+%, J60354, p. 316	
J60972	**3,3'-Diaminobenzidine, tablets** [91-95-2], $C_{12}H_{14}N_4$, F.W. 214.27, Tablets, EINECS 202-110-6, RTECS DV8750000, BRN 1212988, MDL MFCD00007725, Note: Each tablet contains 5mg of DAB, each tablet weighs 240mg., † H:H315-H319-H334-H317-H350-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Widely used peroxidase substrate for immunoblotting and immunohistochemical staining techniques	**50each** **100each**
J62216	**3,3'-Diaminobenzidine tetrahydrochloride hydrate** *[DAB tetrahydrochloride hydrate]* [868272-85-9], $C_{12}H_{14}N_4 \cdot 4HCl \cdot xH_2O$, F.W. 360.11(anhy), Powder, MDL MFCD08273058 H:H315-H319-H351-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Widely used peroxidase substrate for immunoblotting and immunohistochemical staining techniques	**5g** **10g**
A14075	**3,5-Diaminobenzoic acid, 98%, may contain up to 3% moisture** [535-87-5], $C_7H_8N_2O_2$, F.W. 152.15, m.p. ca 235° dec., f.p. 210°(410°F), Merck **14**,2978, EINECS 208-621-0, RTECS DG6186000, BRN 2086484, MDL MFCD00007807, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **100g** **500g**
B21316	**1,4-Diaminobutane, 98+%** △ ■ *[1,4-Butanediamine, Putrescine]* [110-60-1], $H_2N(CH_2)_4NH_2$, F.W. 88.15, m.p. 25-28°, b.p. 158-160°, f.p. 63°(145°F), d. 0.877, n_D^{20} 1.4569, Merck **14**,7947, UN2928, EINECS 203-782-3, RTECS EJ6800000, BRN 605282, MDL MFCD00008235, † H:H331-H314-H302-H312, P:P280-P305+P351+P338-P309-P310	**25g** **100g** **500g**
A18312	**1,4-Diaminobutane dihydrochloride, 99%** ■ *[1,4-Butanediamine dihydrochloride, Putrescine dihydrochloride]* [333-93-7], $HCl \cdot H_2N(CH_2)_4NH_2 \cdot HCl$, F.W. 161.08, m.p. ca 280° dec., Merck **14**,7947, EINECS 206-375-9, RTECS EJ7280000, BRN 3906680, MDL MFCD00012526, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g**
	(S)-2,6-Diaminocaproic acid, see L-Lysine, 98%, J62225, p. 273	
L14072	**(1S,2S)-(+)-1,2-Diaminocyclohexane, 98%** △ *[(1S)-trans-1,2-Cyclohexanediamine, DACH]* [21436-03-3], $C_6H_{14}N_2$, F.W. 114.19, m.p. 43-45°, b.p. 104-110°/40mm, f.p. 70°(158°F), $[\alpha]_D^{20}$ +25.5° (c=5 in 1N HCl), Fieser **2**,223 **12**,396, UN3259, BRN 2801645, MDL MFCD00062986  H:H314-H317, P:P280-P262-P303+P361+P353-P305+P351+P338-P309-P310 Application(s): For synthesis of optically active products	**250mg** **1g** **5g**

Stock #	Description	Size
J63821	**1,10-Diaminodecane, 98%** *[1,10-Decanediamine, Decamethylenediamine]* [646-25-3], $NH_2(CH_2)_{10}NH_2$, F.W. 172.31, Powder, m.p. 59-61°, b.p. 140°/12mm, UN3259, EINECS 211-471-9, RTECS HD7175000, BRN 1738591, MDL MFCD00008151, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): NMDA receptor inverse agonist	**10g** **50g**
J65748	**2,2'-Diamino-2'-deoxyadenosine, 98%** *[9-(2-amino-2-deoxy-β-D-ribofuranosyl)-2,6-diaminopurine, 2,6-Diaminopurine 2'-amino-2'-deoxyriboside]* [215943-79-6], $C_{10}H_{15}N_7O_3$, F.W. 281.27, Powder	**1g**
	1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene, see U0126, 99+%, J61246, p. 387	
J65237	**2,3'-Diamino-2',3'-dideoxyadenosine, 99%** *[9-(3-Amino-2,3-dideoxy-β-D-ribofuranosyl)- 2,6-diaminopurine, 2,6-Diaminopurine 3'-amino-2',3'-dideoxyriboside]* [915399-37-0], $C_{10}H_{15}N_7O_2$, F.W. 265.27, Powder, MDL MFCD09750829	**1g**
	4,4'-Diamino-3,3'-dimethoxybiphenyl, see o-Dianisidine, A17150, p. 184 **4,4'-Diamino-3,3'-dimethoxybiphenyl dihydrochloride**, see o-Dianisidine dihydrochloride, A17175, p. 184 **3,7-Diamino-2,8-dimethyl-5-phenylphenazinium chloride**, see Safranine O, B21674, p. 339 **1,2-Diaminoethane**, see Ethylenediamine, A12132, p. 215 **3,8-Diamino-5-ethyl-6-phenylphenanthridinium bromide**, see Ethidium bromide soln., 10mg/ml, J62282, p. 214	
H55402	**2,7-Diaminofluorene, 97+%** *[2,7-Fluorenediamine]* [525-64-4], $C_{13}H_{12}N_2$, F.W. 196.25, m.p. 160-162°, Merck **14**,4156, EINECS 208-377-5, RTECS LL6980000, BRN 2099859, MDL MFCD00001128 	**250mg** **1g** **5g**
	(+/-)-2,6-Diaminohexanoic acid monohydrochloride, see DL-Lysine monohydrochloride, A11066, p. 273 **(R)-2,6-Diaminohexanoic acid monohydrochloride**, see D-Lysine monohydrochloride, L07710, p. 273 **(S)-2,6-Diaminohexanoic acid monohydrochloride**, see L-Lysine monohydrochloride, Cell Culture Reagent, J62099, p. 273 **(S)-2,6-Diaminohexanoic acid methyl ester dihydrochloride**, see L-Lysine methyl ester dihydrochloride, A18157, p. 273 **3,6-Diamino-10-methylacridinium chloride hydrochloride**, see Acriflavine hydrochloride, J60048, p. 76 **3,8-Diamino-5-methyl-6-phenylphenanthridinium bromide**, see Dimidium bromide, B24818, p. 197	
A12993	**2,3-Diaminonaphthalene, 97%** *[2,3-Naphthalenediamine]* [771-97-1], $C_{10}H_{10}N_2$, F.W. 158.20, m.p. 193-196°, d. 1.096, Solubility: Slightly soluble in water, EINECS 212-241-0, BRN 2206394, MDL MFCD00004116, †  H:H302-H312-H332-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
B23039	**1,5-Diaminopentane, 98%** △ ■ *[1,5-Pentanediamine, Cadavarine]* [462-94-2], $H_2N(CH_2)_5NH_2$, F.W. 102.18, m.p. 9°, b.p. 178-180°, d. 0.873, n_D^{20} 1.4563, Merck **14**,1609, UN2735, EINECS 207-329-0, MDL MFCD00008239 H:H314, P:P280-P305+P351+P338-P309-P310	**5g** **25g**
	(+/-)-2,5-Diaminopentanoic acid hydrochloride, see DL-Ornithine monohydrochloride, A18173, p. 308 **(R)-(-)-2,5-Diaminopentanoic acid hydrochloride**, see D-Ornithine hydrochloride, L00793, p. 308 **(S)-(+)-2,5-Diaminopentanoic acid hydrochloride**, see L-Ornithine hydrochloride, Cell Culture Reagent, J60241, p. 309	
A11932	**1,3-Diaminopropane, 98%** △ ■ *[1,3-Propanediamine, Trimethylenediamine]* [109-76-2], $H_2N(CH_2)_3NH_2$, F.W. 74.13, m.p. -12°, b.p. 134-136°, f.p. 48°(118°F), d. 0.888, n_D^{20} 1.4573, Fieser **13**,160, UN2734, EINECS 203-702-7, RTECS TX6825000, BRN 605277, MDL MFCD00008228, † H:H310-H314-H226-H302, P:P280-P305+P351+P338-P309-P310 The potassium derivative (KAPA) is a very strong base, valuable for its ability to cause the migration of acetylenic unsaturation to the terminal positions of alkynes (known as the "zip" reaction). In the presence of excess amine, reaction occurs within seconds; the driving force is the formation of a stable acetylide anion: *J. Am. Chem. Soc.*, **97**, 891 (1975). For example, with acetylenic carbinols: *J. Chem. Soc., Chem. Commun.*, 959 (1976); *Tetrahedron Lett.*, 2565 (1976); *Can. J. Chem.*, **62**, 1333 (1984). For a further example (2- to 9-decynol), using a combination of **Potassium tert-butoxide**, **A13947**, and Li 3-aminopropanamide, see: *Org. Synth. Coll.*, **8**, 146 (1993). This technique avoids the use of KH. For the use of KAPA for the isomerization of β-pinene to the thermodynamically-more stable α-pinene, see: *Org. Synth. Coll.*, **8**, 553 (1993). For procedures for the generation of Na or K 3-amino-propylamides from the metals by ultrasound irradiation or in the presence of $Fe(NO_3)_3$, see: *J. Org. Chem.*, **49**, 2494 (1984).	**100ml** **500ml** **2.5L**
	4,4'-Diamino-3,3',5,5'-tetramethylbiphenyl, see 3,3',5,5'-Tetramethylbenzidine, A13868, p. 364	
B22775	**3,5-Diamino-1,2,4-triazole, 98+%** *[Guanazole, 1H-1,2,4-Triazole-3,5-diamine]* [1455-77-2], $C_2H_5N_5$, F.W. 99.10, m.p. ca 205° dec., EINECS 215-937-2, RTECS XZ4535000, BRN 112467, MDL MFCD00005233, †  Application(s): Inhibitor of DNA synthesis	**5g** **25g** **100g**
	2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine, see Trimethoprim, J63053, p. 378 **cis-Diammine(1,1-cyclobutanedicarboxylato) platinum**, see Carboplatin, J60433, p. 148	

Stock #	Description	Size
10471	**cis-Diamminedichloroplatinum(II), Pt 64.5% min** *[Cisplatin]* [15663-27-1], $PtCl_2(NH_3)_2$, F.W. 300.06, Micro Crystals, m.p. 270° dec., Merck **14**,2317, Solubility: Soluble in DMF. Insoluble in most common solvents, UN3288, EINECS 239-733-8, RTECS TP2450000, MDL MFCD00011623, Note: Special handling precautions required. View MSDS prior to purchase. MSDS are available online at www.alfa.com, † H:H300-H334-H350-H315-H319-H317-H335, P:P201-P301+P310-P308+P313 Application(s): Potent anticancer agent that blocks DNA synthesis	250mg 1g 5g
A17150	**o-Dianisidine, 98+%** *[4,4'-Diamino-3,3'-dimethoxybiphenyl, 3,3'-Dimethoxybenzidine]* [119-90-4], $C_{14}H_{16}N_2O_2$, F.W. 244.30, m.p. 134-138°, f.p. 206°(402°F), Merck **14**,2991, EINECS 204-355-4, RTECS DD0875000, BRN 1879884, MDL MFCD00008372, † H:H350-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Redox indicator.	5g 25g 100g
A17175	**o-Dianisidine dihydrochloride, 99%** *[4,4'-Diamino-3,3'-dimethoxybiphenyl dihydrochloride, 3,3'-Dimethoxybenzidine dihydrochloride]* [20325-40-0], $C_{14}H_{16}N_2O_2 \cdot 2HCl$, F.W. 317.21, m.p. 268° dec., EINECS 243-737-5, RTECS DD1050000, BRN 3917996, MDL MFCD00012488, † H:H350-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a	1g 5g
J65207	**Diarylpropionitrile** *[DPN, 2,3-Bis(4-hydroxyphenyl)-propionitrile]* [1428-67-7], $C_{15}H_{13}NO_2$, F.W. 239.27, Powder, RTECS UG0900000	10mg
J63444	**Diatrizoic acid** *[Amidotrizoic acid]* [117-96-4], $C_{11}H_9I_3N_2O_4$, F.W. 613.90, Powder, EINECS 204-223-6, RTECS DG5950000, MDL MFCD00069960 Application(s): A high-osmolality radiocontrast agent	5g 25g 100g
J64863	**1,11-Diazido-3,6,9-trioxaundecane** *[Azido(bis)-PEG3]* [101187-39-7], $C_8H_{16}N_6O_3$, F.W. 244.25, Viscous liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	100mg
J64904	**Dibenzazepine** *[γ-Secretase Inhibitor XX, Deshydroxy LY 411575]* [209984-56-5], $C_{26}H_{23}F_2N_3O_3$, F.W. 463.48, Solid	10mg
	5H-Dibenz[b,f]azepine-5-carboxamide, see Carbamazepine, 98%, J62590, p. 146 **Dibenzoylmethane**, see 1,3-Diphenyl-1,3-propanedione, A13450, p. 199 **4,5-Dibromo-2,7-dinitrofluorescein disodium salt**, see Eosin B, A17377, p. 208	
A12766	**1,2-Dibromoethane, 99% ▲** *[Ethylene dibromide]* [106-93-4], $BrCH_2CH_2Br$, F.W. 187.87, m.p. 9-10°, b.p. 132°, f.p. None, d. 2.179, n_D^{20} 1.5385, Merck **14**,3796, UN1605, EINECS 203-444-5, RTECS KH9275000, MDL MFCD00000233, Note: Special handling precautions required. View MSDS prior to purchase. MSDS are available online at www.alfa.com, † H:H301-H311-H331-H350-H315-H319-H335-H411, P:P301+P310-P305+P351+P338-P361-P302+P352-P405-P501a	1kg 5kg
A18226	**4',5'-Dibromofluorescein, 98%** *[C.I. 45370]* [596-03-2], $C_{20}H_{10}Br_2O_5$, F.W. 490.12, m.p. 270-273°, Merck **14**,3022, EINECS 209-876-0, RTECS LM5200000, BRN 57189, MDL MFCD00005042, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	50g 250g
J62804	**Dibucaine hydrochloride** *[2-Butoxy-N-(2-diethylaminoethyl)-4-quinolinecarboxamide hydrochloride]* [61-12-1], $C_{20}H_{29}N_3O_2 \cdot HCl$, F.W. 379.92, Crystalline powder, Merck **14**,3031, EINECS 200-498-1, RTECS GD3325000, MDL MFCD00012735 H:H302-H318, P:P280-P264-P305+P351+P338-P310-P301+P312-P501 Application(s): Potent, long-acting local anesthetic	5g 25g
	2,6-Di-tert-butyl-p-cresol, see 2,6-Di-tert-butyl-4-methylphenol, A16863, p. 185	
A14708	**Di-tert-butyl dicarbonate, 97+% ◢** *[Boc anhydride, Di-tert-butyl pyrocarbonate]* [24424-99-5], $C_{10}H_{18}O_5$, F.W. 218.25, m.p. 21-24°, b.p. 56-57°/0.5mm, f.p. 37°(99°F), d. 0.950, n_D^{20} 1.4090, Fieser **4**,128 **7**,91 **8**,145 **10**,122 **13**,94 **15**,113 **19**,117 **20**,133 **21**,162, UN2930, EINECS 246-240-1, RTECS HT0230000, BRN 1911173, MDL MFCD00008805, † H:H330-H318-H228-H315-H317-H335, P:P280-P305+P351+P338-P302+P352-P304+P340-P310 Reagent for amino group protection as the *tert*-butyl carbamate (*tert*-butoxycarbonyl, Boc derivatives), in high yield under mild conditions, widely used in peptide chemistry. For practical details, literature references and	25g 100g 500g

tabulated results, see: *Org. Synth. Coll.*, **7**, 70 (1990). For further examples see: *Synthesis*, 223 (1987): *Org. Synth. Coll.*, **9**, 124, 300 (1998). Benzyl carbamates (Cbz, Z) may be transformed into Boc in a one pot procedure catalyzed by Pd/C: *Tetrahedron Lett.*, **33**, 3167 (1992).
Rapid and efficient formation of Boc derivatives of amines, catayzed by **Copper(II) tetrafluoroborate hexahydrate**, **26127**, has been described: *Tetrahdron Lett.*, **47**, 1087 (2006).
For Boc protection of phenols, alcohols, thiols etc. under phase-transfer conditions, see: *Can. J. Chem.*, **63**, 153 (1985).
Amides can be protected in the presence of a catalytic quantity of DMAP (**4-(Dimethylamino)pyridine**, **A13016**): *J. Org. Chem.*, **48**, 2424 (1983); *Acta Chem. Scand. B*, **40**, 745 (1986); the amide link of the product undergoes facile alkaline hydrolysis or methanolysis. The nitrogen function of indoles and pyrroles can also be protected under similar conditions: *J. Chem. Soc., Chem. Commun.*, 1699 (1984); *Org. Synth. Coll.*, **9**, 121 (1998). 1-Boc indoles may be synthesized from N-Boc 2-alkylanilines: *Synthesis*, 871 (1991).
The Boc group is readily cleaved with acid, most often **Trifluoroacetic acid**, **L06374**.
In the presence of 1 equivalent of DMAP in acetonitrile, arylamines are converted to isocyanates, generally in high yield; the dicarbonate here behaves as a convenient phosgene replacement: *Angew. Chem. Int. Ed.*, **34**, 2497 (1995). The same reagent system has also been applied to nitroalkanes for the ambient temperature generation of nitrile oxides which were trapped *in situ* with dipolarophiles: *Synthesis*, 309 (1997). Carboxylic acids can be esterified in the presence of a catalytic amount of DMAP: *Synlett*, 263 (2004).
Carboxylic acids have also been converted to Boc-protected amines, via a one-pot Curtius rearrangement, using the reagent in the presence of sodium azide, with catalytic amounts of TBAB and zinc triflate: *Org. Lett.*, **7**, 4107 (2005).
For a brief feature on uses of the reagent in synthesis, see: *Synlett*, 1995 (2001).

Application(s): Reagent for the introduction of the Boc protecting group

A14606 **2,5-Di-tert-butylhydroquinone, 98+%** — **250g**, **1kg**

[88-58-4], $C_{14}H_{22}O_2$, F.W. 222.33, m.p. 214-218°, b.p. 321°, f.p. >200°(392°F), d. 1.070, EINECS 201-841-8, RTECS MX5160000, BRN 2049542, MDL MFCD00008825, †
H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a

A16863 **2,6-Di-tert-butyl-4-methylphenol, 99%** — **250g**, **1kg**

[BHT, Butylated hydroxytoluene]
[128-37-0], $C_{15}H_{24}O$, F.W. 220.36, m.p. 69-72°, b.p. 264-265°, f.p. 127°(260°F), d. 1.048, Merck **14**,1548, Fieser **15**,113, UN3077, EINECS 204-881-4, RTECS GO7875000, BRN 1911640, MDL MFCD00011644, †
H:H302-H319-H411, P:P273-P305+P351+P338
Radical inhibitor and antioxidant, readily soluble in nonpolar media. Finds widespread use in the inhibition of peroxide formation in ether solvents and also as a preservative/ antioxidant for unsaturated oils and fats in the food, synthetic rubber and paint industries.
Source of t-butyl group in aromatic substitution reactions. For reviews of the use of t-butyl as a positional protecting group for aromatic substitution reactions, readily removable with, e.g. $AlCl_3$ in toluene, see: *Org. Prep. Proced. Int.*, **8**, 51 (1976); *Synthesis*, 921 (1979).

Application(s): Antioxidant

A13257 **Di-n-butyl phthalate, 99%** — **500g**, **2.5kg**, **10kg**

[Benzene-1,2-dicarboxylic acid di-n-butylester, Phthalic acid di-n-butyl ester]
[84-74-2], $C_{16}H_{22}O_4$, F.W. 278.35, m.p. -35°, b.p. 339-340°, f.p. 171°(340°F), d. 1.045, n_D^{20} 1.4920, Merck **14**,3035, UN3082, EINECS 201-557-4, RTECS TI0875000, BRN 1914064, MDL MFCD00009441, †
H:H360Df-H400, P:P281-P273-P308+P313-P391-P405-P501a

Di-tert-butyl pyrocarbonate, see Di-tert-butyl dicarbonate, A14708, p. 184
2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride, see Clonidine hydrochloride, 98+%, J63707, p. 166

J64870 **5,6-Dichlorobenzimidazole riboside, 98%** — **50mg**, **100mg**, **250mg**
[DBR, 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole]
[53-85-0], $C_{12}H_{12}Cl_2N_2O_4$, F.W. 319.14, Powder, RTECS DD7310000, BRN 39123, MDL MFCD00036785

J65324 **7,8-Dichloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid** — **5mg**
[CAY10577]
[300675-28-9], $C_{10}H_5Cl_2NO_3$, F.W. 258.06, Crystalline solid

2,5-Dichloro-3,6-dihydroxy-1,4-benzoquinone, see Chloranilic acid, A10493, p. 154

39121 **1,2-Dichloroethane, ACS, 99+%** — **500ml**, **1L**, **4L**, **4x1L**
[EDC, Ethylene chloride]
[107-06-2], $ClCH_2CH_2Cl$, F.W. 98.96, Liquid, m.p. -35°, b.p. 83°, f.p. 15°(59°F), d. 1.256, n_D^{20} 1.4448, Merck **14**,3797, UN1184, EINECS 203-458-1, RTECS KI0525000, BRN 605264, MDL MFCD00000963, †
Maximum level of impurities: Color (APHA) 10, Evaporation residue 0.002%, Titratable acid 0.0003meq/g, H_2O 0.03%
H:H225-H350-H302-H315-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a

5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid, see 5,7-Dichlorokynurenic acid , J61138, p. 186

A10107 **2,6-Dichloroindophenol sodium salt hydrate ▲** — **5g**, **25g**, **100g**

[2,6-Dichlorophenolindophenol sodium salt hydrate, Sodium 2,5-dichloroindophenoxide hydrate]
[620-45-1], $C_{12}H_6Cl_2NNaO_2 \cdot xH_2O$, F.W. 290.08(anhy), m.p. >300°, Merck **14**,3068, EINECS 210-640-4, RTECS GU5495000, BRN 3641229, MDL MFCD00150014, †
H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a
Redox indicator: *Anal. Biochem.*, **101**, 421 (1980).

Application(s): Suitable for ascorbic acid determination

Stock #	Description	Size
J65198	**3,4-Dichloroisocoumarin, 99%** *[3,4-Dichloro-2-benzopyran-1-one, 3,4-DCI]* [51050-59-0], $C_9H_4Cl_2O_2$, F.W. 215.03, Powder, UN2811, BRN 6802625, MDL MFCD00036960 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501	**10mg**
J61138	**5,7-Dichlorokynurenic acid** *[5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid]* [131123-76-7], $C_{10}H_5Cl_2NO_3$, F.W. 240.06, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg** **100mg**
J61567	**5,7-Dichlorokynurenic acid sodium salt** [131123-76-7], $C_{10}H_5Cl_2NNaO_3$, F.W. 258.10, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Potent NMDA receptor glycine site antagonist	**10mg** **50mg**
L13089	**Dichloromethane, 99+%, stab. with ca. 50ppm 2-methyl-2-butene** *[DCM, Methylene chloride]* [75-09-2], CH_2Cl_2, F.W. 84.93, m.p. -95°, b.p. 39-40°, d. 1.325, n_D^{20} 1.4244, Merck **14**,6063, Fieser **1**,676 **2**,273 **4**,337 **7**,239 **18**,131, UN1593, EINECS 200-838-9, RTECS PA8050000, BRN 1730800, MDL MFCD00000881, † H:H351-H302, P:P260-P280h-P262	**500ml** **1L** **2.5L**
	(2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid, see Ethacrynic acid, J63684, p. 213 **2-[(2,6-Dichloro-3-methylphenyl)-amino]benzoic acid**, see Meclofenamic acid sodium salt, 99+%, J60484, p. 279	
A14411	**2,6-Dichlorophenol, 99%** [87-65-0], $C_6H_4Cl_2O$, F.W. 163.00, m.p. 65-68°, b.p. 218-220°, Merck **14**,3073, UN2020, EINECS 201-761-3, RTECS SK8750000, BRN 1447806, MDL MFCD00002176, † H:H314-H312-H411, P:P280-P273-P303+P361+P353-P305+P351+P338-P310	**25g** **100g** **500g**
	2,6-Dichlorophenolindophenol sodium salt hydrate, see 2,6-Dichloroindophenol sodium salt hydrate, A10107, p. 185 **3',3"-Dichlorophenolsulfonaphthalein**, see Chlorophenol Red, B21623, p. 157	
A13231	**2,3-Dichlorophenoxyacetic acid, 97%** [2976-74-1], $C_8H_6Cl_2O_3$, F.W. 221.04, m.p. 173-175°, EINECS 221-022-9, BRN 1963475, MDL MFCD00004299 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g**
A12467	**2,4-Dichlorophenoxyacetic acid, 98%** *[2,4-D]* [94-75-7], $C_8H_6Cl_2O_3$, F.W. 221.04, m.p. 136-140°, b.p. 160°/0.4mm, d. 1.42, Merck **14**,2796, EINECS 202-361-1, RTECS AG6825000, BRN 1214242, MDL MFCD00004300, † H:H318-H302-H312-H317-H335-H412, P:P280-P262-P273-P301+P310-P305+P351+P338	**50g** **250g** **1kg**
J64981	**2-(3-(2,3-Dichlorophenoxy)propylamino)ethanol hydrochloride** *[2,3-DCPE hydrochloride]* [418788-90-6], $C_{11}H_{15}Cl_2NO_2 \cdot HCl$, F.W. 300.61, Powder	**5mg** **10mg**
	2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid sodium salt, see Diclofenac sodium salt, J62609, p. 186 **4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester**, see Felodipine, J61195, p. 219	
A15131	**2,4-Dichloropyrimidine, 98+%** ◢ [3934-20-1], $C_4H_2Cl_2N_2$, F.W. 148.98, m.p. 57-62°, b.p. 101°/23mm, EINECS 223-508-6, BRN 110911, MDL MFCD00006061, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **10g** **50g** **250g**
L13212	**4,6-Dichloropyrimidine, 98%** [1193-21-1], $C_4H_2Cl_2N_2$, F.W. 148.98, m.p. 64-68°, b.p. 176°, UN3261, EINECS 214-770-2, BRN 111195, MDL MFCD00006109 H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**5g** **25g**
J62609	**Diclofenac sodium salt** *[2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid sodium salt, Sodium 2-(2,6-dichloroanilino)phenylacetate]* [15307-79-6], $C_{14}H_{10}Cl_2NNaO_2$, F.W. 318.14, Powder, m.p. 283-285°, Merck **14**,3081, UN2811, EINECS 239-346-4, RTECS AG6330000, MDL MFCD00082251 H:H301-H361, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Standard NSAID and cyclooxygenase (COX) inhibitor	**5g** **25g** **100g**
J61581	**Dicloxacillin sodium salt** [13412-64-1], $C_{19}H_{16}Cl_2N_3NaO_5S$, F.W. 492.33, Powder, m.p. 222-225°, Merck **14**,3084, RTECS XH8925000, MDL MFCD00056865 H:H334-H335-H315-H319-H317, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An antibiotic used in the treatment of staphyloccoci bacteria that are resistant to penicillin G	**1g** **5g**
	Dicoumarol, see Dicumarol, J63634, p. 187	

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63634	**Dicumarol** *[Dicoumarol, 3,3'-Methylenebis(4-hydroxycoumarin)]* [66-76-2], $C_{19}H_{12}O_6$, F.W. 336.30, Powder, m.p. 286-289°, Merck **14**,3090, UN2811, EINECS 200-632-9, RTECS GN7875000, MDL MFCD00006857, † H:H372-H302-H411, P:P260-P273-P264-P270-P301+P312-P501a Application(s): Vitamin K reductase inhibitor possessing anticoagulant properties	**5g** **25g**
A10451	**Dicyandiamide, 99%** *[N-Cyanoguanidine]* [461-58-5], $C_2H_4N_4$, F.W. 84.08, m.p. 208-211°, d. 1.400, Merck **14**,3092, Fieser **1**,229, EINECS 207-312-8, RTECS ME9950000, BRN 605637, MDL MFCD00008066, † Reacts with aromatic nitriles in the presence of base to give 6-aryl-1,3,5-triazines (benzoguanamines); see, e.g.: *Org. Synth. Coll.*, **4**, 78 (1963).	**250g** **500g** **2.5kg**
	Dicyanomethane, see Malononitrile, A15046, p. 276	
A15671	**Dicyclohexylamine, 98%** △ [101-83-7], $C_{12}H_{23}N$, F.W. 181.32, m.p. -2°, b.p. 256°, f.p. 99°(210°F), d. 0.913, n_D^{20} 1.4842, Merck **14**,3095, Fieser **1**,231, UN2565, EINECS 202-980-7, RTECS HY4025000, BRN 605923, MDL MFCD00011658, † H:H314-H400-H410-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Forms highly crystalline salts with N-protected amino acids: *Liebigs Ann. Chem.*, **640**, 157 (1961). Reacts with n-BuLi to give a hindered strong base; cf LDA (see **Diisopropylamine**, **A10280**), which has been used to promote, e.g. the α -carboethoxylation of ketones; see **Diethyl dicarbonate**, **B22753**, p. 189.	**100ml** **500ml** **2.5L**
A10973	**N,N'-Dicyclohexylcarbodiimide, 99%** ◪ *[DCC]* [538-75-0], $C_{13}H_{22}N_2$, F.W. 206.33, m.p. 33-36°, b.p. 154-156°/11mm, f.p. 138°(280°F), Merck **14**,3096, Fieser **1**,231 **11**,173 **13**,107 **14**,131 **15**,131 **16**,128 **18**,133 **21**,169, UN2811, EINECS 208-704-1, RTECS FF2160000, BRN 610662, MDL MFCD00011659, † H:H311-H318-H302-H317, P:P305+P351+P338-P361-P302+P352-P321-P405-P501a Promotes a variety of acylation reactions between carboxylic acids and nucleophiles; the dicyclohexylurea by-product is almost insoluble in most solvents: CyN=C=NCy + RCOOH → CyNH(NCy)C(=O)OR → NuH → RC(=O)Nu + CyNHCONHCy In peptide coupling reactions, various auxiliary reagents have been used to suppress racemization. See, e.g., **N-Hydroxysuccinimide**, **A10312**, p. 251, **N-Hydroxyphthalimide**, **A13862**, and **endo-N-Hydroxy-5-norbornene-2,3-dicarboximide**, **A13205**. For use of $CuCl_2$, see: *Tetrahedron Lett.*, **25**, 771 (1984); *J. Chem. Soc., Chem. Commun.*, 419 (1988). For ester or thioester formation from an acid and an alcohol, the rate is greatly increased by addition of **4-(Dimethylamino)pyridine**, **A13016**: *Angew. Chem. Int. Ed.*, **17**, 522 (1978). For t-butyl esters, see: *Org. Prep. Proced. Int.*, **20**, 180 (1988); *Org. Synth. Coll.*, **7**, 93 (1990). The same combination has been found useful in macrolactonization reactions: *J. Org. Chem.*, **50**, 2394 (1985); and in formation of propynoic esters under mild conditions: *Tetrahedron Lett.*, **30**, 4575 (1989). DCC-coupling is frequently used to prepare active esters, e.g. of **4-Nitrophenol**, **A14376**, or **Pentafluorophenol**, **A15574**, for peptide coupling. DCC has also been used in dehydrations, e.g. carboxylic acids to anhydrides: *J. Am. Chem. Soc.*, **85**, 1997 (1963); *J. Org. Chem.*, **54**, 1922 (1989); primary amides: *J. Org. Chem.*, **26**, 3356 (1961), and aldoximes: *Synth. Commun.*, **3**, 101 (1973); **12**, 25 (1982) to nitriles; dialkylacetic acids to ketenes (where stable): *Synthesis*, 568 (1989). The combination with **Dimethyl sulfoxide**, **A13280**, is used in the Pfitzner-Moffatt oxidation of alcohols to carbonyl compounds under mild conditions: *J. Am. Chem. Soc.*, **85**, 3027 (1963); **87**, 5661, 5670 (1965); *Org. Synth. Coll.*, **5**, 242 (1973); review: *Synthesis*, 857 (1990). In the presence of H_2SO_4 or $AlCl_3$, Friedel-Crafts cyclohexylation of arenes has been reported: *Tetrahedron Lett.*, **35**, 903 (1994). For reviews of advances in the chemistry of carbodiimides, see: *Chem. Rev.*, **67**, 107 (1967), **81**, 589 (1981); *Tetrahedron*, **37**, 233 (1981). Application(s): Carboxy group activating reagent for peptide synthesis	**25g** **100g** **500g**
J61422	**Dicyclomine hydrochloride** [67-92-5], $C_{19}H_{35}NO_2 \cdot HCl$, F.W. 345.95, Solid, m.p. 164-166°, Merck **14**,3097, EINECS 200-671-1, RTECS DT7350000, MDL MFCD00079158, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An anticholinergic that blocks muscarinic receptors	**10g** **50g**
	Di(cyclopentadienyl)iron, see Ferrocene, 87202, p. 219	
J64573	**2',3'-Dideoxyadenosine, 98%** *[ddA]* [4097-22-7], $C_{10}H_{13}N_5O_2$, F.W. 235.24, Powder, m.p. 181-184°, Merck **14**,3101, EINECS 223-853-2, RTECS AU7358900, BRN 619924, MDL MFCD00010534	**25mg** **50mg** **100mg**
L10619	**2',3'-Dideoxycytidine, 98+%** *[Zalcitabine]* [7481-89-2], $C_9H_{13}N_3O_3$, F.W. 211.22, m.p. 216-220°, $[\alpha]_D^{20}$ +90° (c=0.5 in water), Merck **14**,10109, RTECS HA3870000, BRN 654956, MDL MFCD00012188 H:H351-H361, P:P281-P201-P202-P308+P313-P405-P501a	**50mg** **250mg**

Stock #	Description	Size
J65810	**2',3'-Dideoxyguanosine, 90+%** [85326-06-3], $C_{10}H_{13}N_5O_3$, F.W. 251.24, Powder, MDL MFCD00057074	**25mg** **50mg** **100mg**
	1,5-Dideoxy-1,5-imino-D-glucitol , see (+)-1-Deoxynojirimycin , J62602, p. 179 **1,5-Dideoxy-1,5-imino-D-mannitol, hydrochloride**, see (+)-1-Deoxymannojirimycin hydrochloride, J61277, p. 179	
J64833	**2',3'-Dideoxyinosine, 98%** *[ddI, ddIno]* [69655-05-6], $C_{10}H_{12}N_4O_3$, F.W. 236.23, Powder, Merck **14**,3098, RTECS NM7460700, BRN 3619529, MDL MFCD00077728	**250mg** **500mg** **1g**
	4-(Diethylamino)azobenzene-2'-carboxylic Acid, see Ethyl Red, J63446, p. 217	
A17485	**2-Diethylaminoethyl 4-aminobenzoate hydrochloride, 99%** ▲ *[Procaine hydrochloride]* [51-05-8], $C_{13}H_{20}N_2O_2{\cdot}HCl$, F.W. 272.78, m.p. 155-157°, b.p. 195-196°/17mm, Merck **14**,7757, UN2811, EINECS 200-077-2, MDL MFCD00013000, †	**50g** **250g**
	H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A sodium channel blocker	
J63781	**Diethylaminoethyl dextran** *[DEAE-Dextran]* [9015-73-0], Powder, Merck **14**,2936	**25g** **100g**
	N,N-Diethylaminoethyl 2,2-diphenylvalerate, see Proadifen hydrochloride, J63833, p. 328	
J62528	**8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride, 97%** *[3,4,5-Trimethoxybenzoic acid 8-(diethylamino)octyl ester hydrochloride, TMB-8 hydrochloride]* [53464-72-5], $C_{22}H_{37}NO_5{\cdot}HCl$, F.W. 432.00, Powder, m.p. 92-97°, EINECS 258-574-5, BRN 5466611, MDL MFCD00012502 Application(s): Inhibits intracellular calcium mobilization	**50mg** **250mg**
	4-(4-Diethylaminophenylazo)benzene-sulfonic acid sodium salt, see Ethyl Orange sodium salt, J62863, p. 217	
L09919	**Diethyl chlorophosphite, 97%** ◢ *[Diethyl phosphorochloridite]* [589-57-1], $C_4H_{10}ClO_2P$, F.W. 156.55, b.p. 153-155°, f.p. 25°(77°F), d. 1.082, n_D^{20} 1.4375, Merck **14**,3841, Fieser **1**,248 **20**,142, UN2920, EINECS 209-652-2, BRN 1098392, MDL MFCD00009074, †	**5g** **25g**
	H:H314-H226-EUH014, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Reacts readily with nucleophiles, e.g. amines, alcohols or organometallic species, with the introduction of a phosphorus substituent. The phosphorylation of OH groups has been brought about by treatment with the reagent followed by oxidation of the P(III) product to P(V) with, e.g. iodine: *Synth. Commun.*, **12**, 821 (1982); *Synthesis*, 572 (1986). The chlorophosphite has the advantage of greater reactivity over one-step phosphorylation reagents, e.g. **Diphenyl phosphorochloridate**, **A13546**. Reagent for peptide coupling: *J. Am. Chem. Soc.*, **74**, 5304, 5309 (1952). Also useful, in the presence of TMS-OTf, in glycosidic couplings: *Tetrahedron Lett.*, **33**, 6123 (1992). In the presence of N-ethyldiisopropylamine, reduces both aryl and alkyl nitro compounds to amines: *J. Org. Chem.*, **63**, 393 (1998). The reagent also effects dehydration of aldoximes to nitriles, deoxygenation of N-oxides and sulfoxides, and conversion of epoxides to chlorohydrins can also be effected: *J. Org. Chem.*, **67**, 711 (2002).	
L14107	**Diethyl cyanophosphonate, tech. 90%** ◢ *[DEPC, Diethyl phosphorocyanidate]* [2942-58-7], $C_5H_{10}NO_3P$, F.W. 163.11, b.p. 104-105°/19mm, f.p. 80°(176°F), d. 1.075, n_D^{20} 1.4010, Fieser **5**,217 **6**,192 **7**,107 **10**,145 **20**,143, UN2922, EINECS 220-936-5, RTECS TD2500000, BRN 1768938, MDL MFCD00010256	**5g** **25g**
	H:H300-H310-H330-H314, P:P280-P305+P351+P338-P302+P352-P304+P340-P309-P310 Strecker reaction with aldehydes or ketones in the presence of amines or ammonia gives good yields of α-amino nitriles: *Tetrahedron Lett.*, 4663 (1979). Pre-formed enamines give the same products: *Synthesis*, 716 (1979). Phosphorylating agent for phenols: *Synth. Commun.*, **27**, 3035 (1997). Activates carboxylic acids towards nucleophiles: Promotes the formation of amides and esters from amines or alcohols in the presence of, e.g. triethylamine : *Tetrahedron*, **32**, 2211 (1976). The reaction is applicable to peptide synthesis, since little racemization has been observed: *J. Am. Chem. Soc.*, **97**, 7174 (1975). The extent of racemization in comparison with other methods has been studied: *Chem. Pharm. Bull.*, **30**, 3147 (1982). With 2 equivalents of reagent in the absence of a nucleophile, an intermediate 1-(1,1-dicyano)phosphate is formed, leading, on treatment with acid, to the homologated α-hydroxy acid: *Tetrahedron Lett.*, **39**, 9209 (1998). Thiol esters can be formed under similar conditions: *J. Org. Chem.*, **39**, 3302 (1974). Can also be used to activate carboxylic acids for the C-acylation of active methylene compounds: *J. Org. Chem.*, **43**, 3631 (1978). In the presence of Lewis acids, active methylene compounds such as dimethyl malonate react with the cyanophosphonate itself. The product can be converted to a uracil derivative by reaction with phenyl isocyanate: *Chem. Pharm. Bull.*, **42**, 1919 (1994):	

Stock #	Description	Size
J65918	**1,3-Diethyl-5,6-diaminouracil** ■ *[5,6-Diamino-1,3-diethylpyrimidine-2,4(1H,3H)-dione]* [52998-22-8], $C_8H_{14}N_4O_2$, F.W. 198.22, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**250mg**
B22753	**Diethyl dicarbonate, 97%** ◪ *[Diethyl oxydiformate, Diethyl pyrocarbonate]* [1609-47-8], $C_6H_{10}O_5$, F.W. 162.14, b.p. 93-94°/18mm, f.p. 69°(156°F), d. 1.101, n_D^{20} 1.3980, Merck **14**,7998, Fieser **13**,110, EINECS 216-542-8, RTECS LQ9350000, BRN 637031, MDL MFCD00009106, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a In the presence of the hindered base lithium dicyclohexylamide (from **Dicyclohexylamine**, **A15671**, p. 187), α -ethoxycarbonylation of ketones occurs to give β -keto esters: *Synthesis*, 1014 (1984). Application(s): Ribonuclease inhibitor	**5g** **25g** **100g**
A14728	**Diethylene glycol, 99%** ■ *[Bis(2-hydroxyethyl) ether, Digol]* [111-46-6], $(HOCH_2CH_2)_2O$, F.W. 106.12, m.p. -10°, b.p. 245-246°, f.p. 143°(289°F), d. 1.118, n_D^{20} 1.4470, Merck **14**,3119, EINECS 203-872-2, RTECS ID5950000, BRN 969209, MDL MFCD00002882, † H:H302, P:P264-P270-P301+P312-P330-P501a High-boiling solvent which is widely used in the Huang Minlon modification of the Wolff-Kishner reaction for the reduction of carbonyl groups to methylenes; see **Hydrazine monohydrate**, **A14005**.	**250g** **500g** **2.5kg** **10kg**
A17478	**Diethylene glycol diethyl ether, 99%** *[2-Ethoxyethyl ether, Bis(2-ethoxyethyl) ether]* [112-36-7], $(CH_3CH_2OCH_2CH_2)_2O$, F.W. 162.23, m.p. -44°, b.p. 188-190°, f.p. 71°(160°F), d. 0.909, n_D^{20} 1.4120, Merck **14**,3118, EINECS 203-963-7, RTECS KN3160000, BRN 1699259, MDL MFCD00009254, † H:H319-EUH019, P:P280-P264-P305+P351+P338-P337+P313	**100ml** **500ml** **2.5L**
43464	**Diethylene glycol diethyl ether, HPLC Grade, 99+%** *[2-Ethoxyethyl ether]* [112-36-7], $(CH_3CH_2OCH_2CH_2)_2O$, F.W. 162.23, Liquid, m.p. -44°, b.p. 188-190°, f.p. 71°(160°F), d. 0.909, n_D^{20} 1.4120, Merck **14**,3118, EINECS 203-963-7, RTECS KN3160000, BRN 1699259, MDL MFCD00009254, Note: Filtered through 0.2µ filter, † H:H319-EUH019, P:P280-P264-P305+P351+P338-P337+P313 **UV absorption - 1cm cell vs H_2O** λ(nm) 400 350 320 300 260 A 0.01 0.01 0.04 0.10 1.00	**250ml**
A13397	**Diethylene glycol dimethyl ether, 99%, stab. with 100ppm BHT** ■ *[Bis(2-methoxyethyl) ether, Diglyme]* [111-96-6], $(CH_3OCH_2CH_2)_2O$, F.W. 134.18, m.p. -64°, b.p. 161-162°, f.p. 51°(124°F), d. 0.944, n_D^{20} 1.4080, Merck **14**,3165, Fieser **1**,255, UN3271, EINECS 203-924-4, RTECS KN3339000, BRN 1736101, MDL MFCD00008503, † H:H360FD-H226-EUH019, P:P210-P241-P280-P303+P361+P353-P405-P501a Aprotic solvent which has useful solvent power, e.g. for **Sodium borohydride**, **35788** and hence has been widely used for *in situ* generation of diborane and for many other hydride reactions. For use in the hydroboration of olefins with borane-triethylamine complex, see: *Org. Synth. Coll.*, **7**, 427 (1990).	**500ml** **2.5L**
A14670	**Diethylene glycol monoethyl ether, 98%** ■ *[2-(2-Ethoxyethoxy)ethanol, Ethyl digol]* [111-90-0], $HOCH_2CH_2OCH_2CH_2OCH_2CH_3$, F.W. 134.18, m.p. -80°, b.p. 201-202°, f.p. 96°(204°F), d. 0.989, n_D^{20} 1.4280, Merck **14**,1800, EINECS 203-919-7, RTECS KK8750000, BRN 1736441, MDL MFCD00002872, † H:H319, P:P305+P351+P338	**500g** **2.5kg** **10kg**
L13446	**Diethylene glycol monoethyl ether acetate, 99%** *[2-(2-Ethoxyethoxy)ethyl acetate]* [112-15-2], $CH_3CO_2(CH_2CH_2O)_2C_2H_5$, F.W. 176.21, m.p. -25°, b.p. 218-219°, f.p. 95°(203°F), d. 1.012, n_D^{20} 1.4210, Merck **14**,1800, EINECS 203-940-1, RTECS KK8925000, BRN 1764643, MDL MFCD00041928, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100ml** **500ml** **2.5L**
A10926	**Diethylenetriaminepentaacetic acid, 98+%** *[DTPA, Pentetic acid]* [67-43-6], $C_{14}H_{23}N_3O_{10}$, F.W. 393.35, m.p. ca 220° dec., d. 1.56, Merck **14**,7125, EINECS 200-652-8, RTECS MB8205000, BRN 1810219, MDL MFCD00004289, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Chelating agent.	**50g** **250g** **1kg** **5kg**
	4,4'-(1,2-Diethylethylene)diphenol, see Hexestrol, 98+%, J60889, p. 245	
L04503	**N,N-Diethylformamide, 99%** [617-84-5], $HCON(CH_2CH_3)_2$, F.W. 101.15, b.p. 178°, f.p. 65°(149°F), d. 0.910, n_D^{20} 1.4340, EINECS 210-533-2, RTECS LQ1925000, BRN 1209392, MDL MFCD00003287, † H:H319, P:P280-P264-P305+P351+P338-P337+P313 Dipolar aprotic solvent, compare **N,N-Dimethylformamide**, **A13547**.	**100g** **500g**

Stock #	Description	Size
	3,3'-Diethyl-9-methyl-4,5,4',5'-dibenzothiacarbocyanine, see Stains-All, H32127, p. 352 **N,N-Diethyl-N-methyl-2-([3-methyl-1-oxo-2-phenylpentyl]oxy)ethanammonium bromide**, see Valethamate bromide, 99%, J62622, p. 390 **Diethyl oxydiformate**, see Diethyl dicarbonate, B22753, p. 189 **Diethyl phosphorochloridite**, see Diethyl chlorophosphite, L09919, p. 188 **Diethyl phosphorocyanidate**, see Diethyl cyanophosphonate, L14107, p. 188 **Diethyl phosphoryl cyanide**, see Diethyl cyanophosphonate, L14107, p. 188 **Diethyl pyrocarbonate**, see Diethyl dicarbonate, B22753, p. 189	
J63754	**Difloxacin hydrochloride** [98106-17-3], $C_{21}H_{19}F_2N_3O_3 \cdot HCl$, F.W. 435.85, White powder, Merck **14**,3141, MDL MFCD03840489 Application(s): A quinolone antibacterial compound. Structurally related to norfloxacin	**5g** **25g**
	Digitalin, see Digitoxin, J61736, p. 190	
J61736	**Digitoxin** *[Digitalin]* [71-63-6], $C_{41}H_{64}O_{13}$, F.W. 764.94, Crystalline powder, m.p. 240°, Merck **14**,3163, UN2811, EINECS 200-760-5, RTECS IH2275000, BRN 76678, MDL MFCD00003686, †  H:H301-H331-H373, P:P260-P261-P301+P310-P321-P405-P501a Application(s): A cardiac glycoside	**100mg**
	Diglycine, see Glycylglycine, A10523, p. 237 **Diglyme**, see Diethylene glycol dimethyl ether, A13397, p. 189 **Digol**, see Diethylene glycol, A14728, p. 189	
B21902	**Digoxin, 96%** [20830-75-5], $C_{41}H_{64}O_{14}$, F.W. 780.95, m.p. ca 250° dec., Merck **14**,3167, UN2811, EINECS 244-068-1, MDL MFCD00003674, †  H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A cardiac glycoside and substrate for Pgp; upregulates Pgp expression 	**1g** **5g**
	1,4-Diguanidinobutane sulfate salt, see Arcaine sulfate salt, J63277, p. 109 **22,23-Dihydroavermectin B1**, see Ivermectin, J62777, p. 262 **Dihydrocholesterol**, see 5α-Cholestan-3β-ol, L08624, p. 160 **3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione**, see Theophylline, J60203, p. 366 **3,7-Dihydro-1,3-dimethylpurine-2,6-dione, complex with 1,2-ethanediamine (2:1)**, see Aminophylline, anhydrous, 98%, J60705, p. 98	
J60638	**Dihydroergocristine methanesulfonate** [24730-10-7], $C_{36}H_{45}N_5O_8S$, F.W. 707.80, Powder, Merck **14**,3653, EINECS 246-434-6, RTECS KE7600000, MDL MFCD00153792 Application(s): 5-HT receptor antagonist; partial agonist at adrenergic and dopaminergic receptors	**200mg** **1g**
J63840	**Dihydroergotamine methanesulfonate** [6190-39-2], $C_{33}H_{37}N_5O_5.CH_4O_3S$, F.W. 679.78, Powder, m.p. 230-235°, Merck **14**,3174, EINECS 228-235-6, RTECS KE7920000, MDL MFCD00058615  H:H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501a Application(s): Agonist at vascular serotonin receptors; partial agonist at α-adrenergic and dopamine D2 receptors	**100mg** **1g**
J65759	**Dihydrofluorescein diacetate, 97%** *[Diacetyldihydrofluorescein, DADF]* [35340-49-9], $C_{24}H_{18}O_7$, F.W. 418.39, Powder, m.p. 213-215°, BRN 364167, MDL MFCD00005056	**1g**
	1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid, see Nalidixic acid, B25096, p. 297	
B20575	**2,3-Dihydrofuran, 98+%** [1191-99-7], C_4H_6O, F.W. 70.09, b.p. 54-55°, f.p. -24°(-11°F), d. 0.927, n_D^{20} 1.4245, UN3271, EINECS 214-747-7, BRN 103168, MDL MFCD00003205, †   H:H225-EUH019-H302-H319, P:P210-P241-P280-P303+P361+P353-P305+P351+P338-P501a For lithiation at the 5-position, see: *Tetrahedron Lett.*, 4187 (1977); *Org. Synth. Coll.*, **9**, 530 (1998). For alkylation by active methylene compounds, catalyzed by **trans-Dichlorobis(triphenylphosphine)palladium(II)**, **10491**, see: *J. Org. Chem.*, **47**, 2812 (1982). For catalytic asymmetric arylation, see: *J. Am. Chem. Soc.*, **113**, 1417 (1991); *Pure Appl. Chem.*, **64**, 421 (1992). Forms tetrahydrofuranyl esters (acyl hemiacetals) with carboxylic acids. These react with Grignard reagents to give good yields of ketones with minimal enolization or double addition (tertiary alcohol formation). The utility of other acyl hemiacetals as ketone precursors has also been studied: *J. Org. Chem.*, **61**, 6071 (1996):  	**25g** **100g** **500g**
	Dihydro-2,5-furandione, see Succinic anhydride, A12245, p. 354 **Dihydroharmine**, see Harmaline, 98+%, J61699, p. 241	

Stock #	Description	Size
L01996	**5,6-Dihydro-5-methyluracil, 98+%** *[5-Methyl-5,6-dihydrouracil]* [696-04-8], $C_5H_8N_2O_2$, F.W. 128.13, m.p. 263-265°, EINECS 211-787-7, BRN 81983, MDL MFCD00023159 	**5g** **25g**
	1,4-Dihydro-4-oxo-2,6-pyridinedicarboxylic acid hydrate, see Chelidamic acid hydrate, L00782, p. 153 **1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo(4,5-d)pyrimidin-7-one**, see Zaprinast, 98+%, J63326, p. 395 **2,3-Dihydropyran**, see 3,4-Dihydro-2H-pyran, L02731, p. 191	
L02731	**3,4-Dihydro-2H-pyran, 99%** *[2,3-Dihydropyran]* [110-87-2], C_5H_8O, F.W. 84.12, m.p. -70°, b.p. 85-86°, f.p. -15°(5°F), d. 0.926, n_D^{20} 1.4420, Fieser **1**,256 **3**,99 **5**,220 **7**,109 **10**,147, UN2376, EINECS 203-810-4, BRN 103493, MDL MFCD00006558, †  H:H225-H315-H319-H335, P:P210-P261-P280g-P305+P351+P338-P403+P233 Protects OH groups as their tetrahydropyranyl, (THP) ethers, stable to bases, Grignard or organolithium reagents, metal hydrides, etc., but readily removed by mild acid. Introduction (acetal formation) generally employs an acid catalyst, often *p*-TsOH. For example of protection, reaction with Grignard, and deprotection, see: *Org. Synth. Coll.*, **7**, 334 (1990). For alternative catalysts for THP ether formations, see: **Pyridinium p-toluenesulfonate**, **A15708**, **Triphenylphosphine hydrobromide**, **L14290**, **Boron trifluoride diethyl etherate**, **A15275**, **Amberlyst® 15(H)**, **89079**, p. 90, **Montmorillonite K10**, **L15160**, **Acetonyltriphenylphosphonium bromide**, **B22434**, **Indium(III) trifluoromethanesulfonate**, **40131**. Sulfuric acid/silica gel: *Synth. Commun.*, **22**, 159 (1992), allows the catalyst to be removed by simple filtration. $POCl_3$, described for the protection of diethyl hydroxymethylphosphonate, permits use in the Horner-Wadsworth-Emmons reaction: *Org. Synth. Coll.*, **7**, 160 (1990). See also **Iodotrimethylsilane**, **A12902**, providing non-acidic conditions; cf also **Tetrahydropyran**, **A13392**. For selective monotetrahydropyranylation of symmetrical diols, catalyzed by acidic ion-exchange resin, **Dowex® 50WX2 50-100 (H)**, **L13943**, see: *J. Org. Chem.*, **63**, 8183 (1998). For selective deprotection of THP ethers under non-acidic conditions with LiCl in wet DMSO, see: *J. Org. Chem.*, **61**, 6038 (1996). The lithio-derivative, formed with *tert*-BuLi, reacts with, e.g. alkyl iodides or carbonyl compounds: *Tetrahedron Lett.*, 4187 (1977). Acetals and ortho esters, in the presence of Lewis acid catalysts, add readily to the vinyl ether system: *Chem. Lett.*, 1101 (1988). Application(s): Widely used hydroxyl-protecting reagent	**25ml** **100ml** **500ml**
	1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, see 4-Hydroxy-1H-pyrazolo[3,4-d]pyrimidine, A16974, p. 251	
J62103	**DL-erythro-Dihydrosphingosine** *[DL-Sphinganine, (2R*,3S*)-(±)-2-Aminooctadecane-1,3-diol]* [3102-56-5], $C_{18}H_{39}NO_2$, F.W. 301.51, Powder, BRN 1724234, MDL MFCD00079141 Application(s): Protein kinase C inhibitor. Precursor to sphingosine	**10mg** **50mg**
J60495	**Dihydrostreptomycin sesquisulfate** [5490-27-7], $C_{21}H_{41}N_7O_{12}{\cdot}1.5H_2SO_4$, F.W. 730.71, Powder, Merck **14**,3179, EINECS 226-823-7, RTECS WK2236000, BRN 3894221, MDL MFCD00070252, †	**100g**
	3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione, see Caffeine, A10431, p. 142	
L01918	**5,6-Dihydrouracil, 99%** [504-07-4], $C_4H_6N_2O_2$, F.W. 114.10, m.p. 278-280°, EINECS 207-982-1, BRN 112496, MDL MFCD00006029, † 	**1g** **5g**
J60592	**1,3-Dihydroxyacetone dimer** *[DHA, 1,2-Dihydroxy-2-propanone]* [96-26-4], $C_3H_6O_3$, F.W. 90.08, Powder, m.p. 75-80°, Merck **14**,3182, EINECS 202-494-5, RTECS UC1645000, †	**5g**
	1,2-Dihydroxyanthraquinone, see Alizarin, A14404, p. 89	
A11010	**1,4-Dihydroxyanthraquinone, 96%** *[C.I. 58050, Quinizarin]* [81-64-1], $C_{14}H_8O_4$, F.W. 240.21, m.p. 195-198°, b.p. ca 450°, f.p. 222°(431°F), Merck **14**,8064, EINECS 201-368-7, RTECS CB6600000, BRN 1914036, MDL MFCD00001209, † 	**250g** **1kg** **5kg**
	1,2-Dihydroxybenzene, see Catechol, A10164, p. 150 **1,3-Dihydroxybenzene**, see Resorcinol, 36248, p. 336 **1,4-Dihydroxybenzene**, see Hydroquinone, A11411, p. 248	
A11459	**2,5-Dihydroxybenzoic acid, 99%** *[Gentisic acid]* [490-79-9], $C_7H_6O_4$, F.W. 154.12, m.p. ca 206° dec., Merck **14**,4398, EINECS 207-718-5, RTECS LY3850000, BRN 2209119, MDL MFCD00002460, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Aspirin metabolite and antioxidant excipient 	**25g** **100g**
	2-(3,4-Dihydroxybenzylidene)malononitrile, see Tyrphostin A23, 99%, J60308, p. 386 **2,3-Dihydroxybutanedioic acid**, see L-(+)-Tartaric acid, 36405, p. 358 **(R-(R'R'))-2,3-Dihydroxybutanedionate Tylosin (salt)**, see Tylosin tartrate, 98+%, J62633, p. 386	

Stock #	Description	Size
A15950	**3,4-Dihydroxycinnamic acid, predominantly trans, 99%** *[Caffeic acid]* [331-39-5], $C_9H_8O_4$, F.W. 180.16, m.p. ca 202° dec., Merck **14**,1635, EINECS 206-361-2, RTECS GD8950000, BRN 2210883, MDL MFCD00004392 H:H351-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a  Application(s): Inhibitor of ornithine decarboxylase and protein tyrosine kinase	**10g** **50g**
	3,4-Dihydroxycinnamic acid phenylethyl ester, see Phenylethyl 3,4-dihydroxycinnamate, 99+%, J61386, p. 316 **3-(3,4-Dihydroxycinnamoyl)quinic acid**, see Chlorogenic acid, J60457, p. 157	
A15393	**6,7-Dihydroxycoumarin, 98+%** *[Cichorigenin, Esculetin]* [305-01-1], $C_9H_8O_4$, F.W. 178.15, m.p. ca 270° dec., Merck **14**,3697, EINECS 206-161-5, RTECS GN6382500, BRN 152788, MDL MFCD00006874 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Ultraviolet absorbent.  Application(s): A lipoxygenase inhibitor	**1g** **5g**
	6,7-Dihydroxycoumarin-6-glucoside, see Esculin sesquihydrate, J63114, p. 210 **3,4-Dihydroxy-9,10-dioxo-2-anthracenesulfonic acid sodium salt**, see Alizarin Red S sodium salt, 42040, p. 89 **1,2-Dihydroxyethane**, see Ethylene glycol, A11591, p. 216 **N,N'-(1,2-Dihydroxy-1,2-ethanediyl)bisacrylamide**, see N,N'-(1,2-Dihydroxyethylene)bisacrylamide, L19211, p. 192	
L19211	**N,N'-(1,2-Dihydroxyethylene)bisacrylamide, 97%** *[1,2-Bis(acrylamido)ethylene glycol, DHEBA]* [868-63-3], $C_8H_{12}N_2O_4$, F.W. 200.20, m.p. 141-143°, EINECS 212-780-1, BRN 1941875, MDL MFCD00008624, † H:H340-H350-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a  Application(s): A cross-linking reagent for the recovery of separated biomolecules	**5g** **25g** **100g**
L14178	**5,7-Dihydroxyflavone, 98%** *[Chrysin]* [480-40-0], $C_{15}H_{10}O_4$, F.W. 254.24, m.p. 284-289°, Merck **14**,2256, EINECS 207-549-7, RTECS LK8329050, BRN 233276, MDL MFCD00006834 	**5g** **25g**
	1,8-Dihydroxy-10-(β-D-glucopyranosyl)-3-(hydroxymethyl)-9(10H)-anthracenone, see Aloin, J62153, p. 90 **(±)-3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-▲-phenethylamine hydrochloride**, see Dobutamine hydrochloride, J61333, p. 201 **2,2-Dihydroxy-1,3-indanedione**, see Ninhydrin, 43846, p. 303	
B22877	**4',7-Dihydroxyisoflavone, 97%** *[Daidzein]* [486-66-8], $C_{15}H_{10}O_4$, F.W. 254.24, m.p. 328-332° dec., Merck **14**,2801, EINECS 207-635-4, RTECS DJ3100040, BRN 231523, MDL MFCD00016954 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g** **25g**
J63763	**4',7-Dihydroxyisoflavone, 98+%** *[Daidzein]* [486-66-8], $C_{15}H_{10}O_4$, F.W. 254.24, Powder, m.p. 328-332° dec., Merck **14**,2801, EINECS 207-635-4, RTECS DJ3100040, BRN 231523, MDL MFCD00016954 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Analog of genistein and an agonist at estrogen recpetors	**100mg** **500mg** **1g**
	2,6-Dihydroxyisonicotinic acid, see Citrazinic acid, A15461, p. 164	
A12681	**4,6-Dihydroxy-2-mercaptopyrimidine, 98%** *[2-Thiobarbituric acid, 2-Mercaptopyrimidine-4,6-dione]* [504-17-6], $C_4H_4N_2O_2S$, F.W. 144.15, m.p. >300°, EINECS 207-985-8, RTECS CQ7700000, BRN 120663, MDL MFCD00006674, † H:H315-H319-H335, P:P280g-P305+P351+P338  Application(s): Used in a neuraminidase activity and inhibition assay	**25g** **100g** **500g**
	3,4-Dihydroxy-α-(methylaminomethyl)benzyl alcohol, see DL-Adrenaline, J63005, p. 80 **2,4-Dihydroxy-5-methylpyrimidine**, see Thymine, A15879, p. 369 **2,4-Dihydroxy-6-methylpyrimidine**, see 6-Methyluracil, B24191, p. 291	
A17739	**1,3-Dihydroxynaphthalene, 98% ▲** *[1,3-Naphthalenediol, Naphthoresorcinol]* [132-86-5], $C_{10}H_8O_2$, F.W. 160.17, m.p. 123-126°, Merck **14**,6396, EINECS 205-079-7, RTECS QJ4725000, BRN 2044002, MDL MFCD00003965, † H:H341-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g**
A17297	**4,5-Dihydroxynaphthalene-2,7-disulfonic acid disodium salt dihydrate, 98%** *[Chromotropic acid disodium salt dihydrate]* [5808-22-0], $C_{10}H_6Na_2O_8S_2 \cdot 2H_2O$, F.W. 400.29 (364.26anhy), m.p. >300°, Merck **14**,2241, EINECS 204-972-9, BRN 3647189, MDL MFCD00150612, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**10g** **50g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A15893	**3,4-Dihydroxyphenylacetic acid, 98+%** *[Homoprotocatechuic acid]* [102-32-9], $C_8H_8O_4$, F.W. 168.15, m.p. 128-130°, EINECS 203-024-1, RTECS AH0590000, BRN 2211017, MDL MFCD00004338 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g** **25g**
41535	**3,4-Dihydroxy-DL-phenylalanine, 98%** *[DL-DOPA, 3-Hydroxy-DL-tyrosine]* [63-84-3], $C_9H_{11}NO_4$, F.W. 197.19, Crystalline, m.p. 290° dec., Merck **14**,3420, EINECS 200-566-0, RTECS AY5250000, MDL MFCD00063060 ! H:H302, P:P264-P270-P301+P312-P330-P501a 	**5g** **25g** **100g**
A11311	**3,4-Dihydroxy-L-phenylalanine, 98+% ▲** *[L-DOPA, 3-Hydroxy-L-tyrosine]* [59-92-7], $C_9H_{11}NO_4$, F.W. 197.19, m.p. ca 295° dec., Merck **14**,5464, EINECS 200-445-2, RTECS AY5600000, BRN 2215169, MDL MFCD00002598, † ! H:H302, P:P264-P270-P301+P312-P330-P501a 	**5g** **25g** **100g**
	(-)-cis-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate, see (-)-Epicatechin gallate, J60814, p. 208 **2-(3,4-Dihydroxyphenyl)ethylamine hydrochloride**, see Dopamine hydrochloride, A11136, p. 201 **1,2-Dihydroxypropane**, see 1,2-Propanediol, 30948, p. 329 **1,2-Dihydroxy-2-propanone**, see 1,3-Dihydroxyacetone, J60592, p. 191 **7-[2,3-Dihydroxypropyl]-theophylline**, see Dyphylline, J63167, p. 203 **2,6-Dihydroxypurine**, see Xanthine, A11077, p. 393 **2,6-Dihydroxypyridine-4-carboxylic acid**, see Citrazinic acid, A15461, p. 164	
L07160	**4,6-Dihydroxy-1H-pyrazolo[3,4-d]pyrimidine, 98+%** *[Oxypurinol, 1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione]* [2465-59-0], $C_5H_4N_4O_2$, F.W. 152.11, m.p. >300°, EINECS 219-570-9, BRN 139956, MDL MFCD00056934 Application(s): An inhibitor of xanthine oxidase 	**250mg** **1g** **5g**
	2,4-Dihydroxypyrimidine, see Uracil, A15570, p. 388	
A15688	**4,6-Dihydroxypyrimidine, 98%** *[4,6-Pyrimidinediol]* [1193-24-4], $C_4H_4N_2O_2$, F.W. 112.09, m.p. >300°, EINECS 214-772-3, RTECS UW7523000, BRN 606433, MDL MFCD00016733, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**25g** **100g** **500g**
L18567	**3,5-Dihydroxytoluene, 99%** △ *[5-Methylresorcinol, Orcinol]* [504-15-4], $C_7H_8O_2$, F.W. 124.14, m.p. 106-108°, b.p. 287-290°, Merck **14**,6864, EINECS 207-984-2, RTECS VH2100000, BRN 1071903, MDL MFCD00002291, † ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used in production of orcein 	**5g** **25g**
A16554	**Diiodofluorescein ▲** *[C.I. 45425]* [31395-16-1], $C_{20}H_{10}I_2O_5$, F.W. 584.11, m.p. 239-241° dec., MDL MFCD00036461 	**10g** **50g**
L06841	**2,6-Diisopropylphenol, 97%** *[Propofol]* [2078-54-8], $C_{12}H_{18}O$, F.W. 178.28, m.p. 17-18°, b.p. 254-256°, f.p. 113°(235°F), d. 0.962, n_D^{20} 1.5140, Merck **14**,7834, EINECS 218-206-6, RTECS SL0810000, BRN 1866484, MDL MFCD00008885, † ! H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501a Application(s): An anesthetic that exhibits direct activation of the GABA-A receptor 	**25g** **100g** **500g**
	2,5-Diketopiperazine, see Glycine anhydride, A18822, p. 237	
J62459	**Dilazep dihydrochloride** [35898-87-4], $C_{31}H_{44}N_2O_{10}\cdot 2HCl$, F.W. 677.62, Powder, Merck **14**,3200, RTECS DI0250000, MDL MFCD00133267 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inhibits adenosine uptake and platelet aggregation; coronary vasodilator	**50mg**
J65568	**Dil-Lipoprotein, very low density, human plasma** *[DiI-VLDL, 3,3'-Dioctadecylindocarbocyanine- very low density lipoprotein]*	**1each**
J65330	**Dil-Lipoprotein, low density, human plasma** *[3,3'-Dioctadecylindocarbocyanine-low density lipoprotein, DiI-LDL]*	**200micrograms**
J65597	**Dil-Lipoprotein, low density, acetylated, human plasma** *[3,3'-Dioctadecyloxacarbocyanine-acetylated low density lipoprotein, DiI-Ac-LDL]*	**200micrograms**

Stock #	Description	Size
J64164	**Dil-Lipoprotein, low density, oxidized, human plasma** *[3,3'-Dioctadecyloxacarbocyanine-oxidized low density lipoprotein, Dil-Oxidized LDL]*	**1each**
J65503	**Dil-Lipoprotein, high density, human plasma** *[3,3'-Dioctadecylindocarbocyanine-high density lipoprotein, Hil-HDL]*	**1each**
J63245	**(+)-cis-Diltiazem hydrochloride** [33286-22-5], $C_{22}H_{26}N_2O_4S \cdot HCl$, F.W. 450.98, Powder, m.p. 207-212°, Merck **14**,3202, EINECS 251-443-3, RTECS DL0310000, BRN 4228706, MDL MFCD00069252 H:H302-H312-H332-H361, P:P261-P280-P281-P302+P352-P405-P501 Application(s): An L-type calcium channel blocker	**5g** **10g** **25g**
J61079	**Dimaprit dihydrochloride** *[(S)-(3-Dimethylaminopropyl)isothiourea dihydrochloride]* [23256-33-9], $C_6H_{15}N_3S \cdot 2HCl$, F.W. 234.19, Powder, RTECS UM3850000, MDL MFCD00069260 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Selective histamine H2 agonist	**100mg**
A10140	**Dimedone, 98%** *[5,5-Dimethyl-1,3-cyclohexanedione]* [126-81-8], $C_8H_{12}O_2$, F.W. 140.18, m.p. 146-150°, Merck **14**,3242, Fieser **1**,266, EINECS 204-804-4, RTECS GV0345000, BRN 471489, MDL MFCD00001588, † Classical reagent for the identification and isolation of aldehydes: *J. Org. Chem.*, **11**, 95 (1946). For conditions leading to exclusive 2-monomethylation, see: *Synth. Commun.*, **3**, 347 (1973). For direct nitration at the 2-position, see review on α-nitroketones: *Synthesis*, 261 (1980). Undergoes an example of an oxidative addition of 1,3-dicarbonyl compounds, mediated by CAN (**Cerium(IV) ammonium nitrate**, **A12882**), to give an alkene, e.g. with 2-methyl-2-pentene, the product is a fused dihydrofuran derivative: *J. Chem. Soc., Perkin 1*, 187 (1995):  A comparative study has shown that CAN is superior to $Mn(OAc)_3$ for this type of reaction: *J. Chem. Soc., Perkin 1*, 1487 (1996). Application(s): Reagent used in synthesis of fused 3-methylfurans	**25g** **100g** **500g**
J63718	**Dimenhydrinate** *[Amosyt]* [523-87-5], $C_{17}H_{21}NO.C_7H_7ClN_4O_2$, F.W. 469.96, Powder, m.p. 102-107°, Merck **14**,3207, EINECS 208-350-8, RTECS XH5082000, MDL MFCD00054265, † H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A histamine H1 antagonist	**25g**
	Dimercaprol, see 2,3-Dimercaptopropanol, L03953, p. 194 **erythro-1,4-Dimercapto-2,3-butanediol**, see 1,4-Dithioerythritol, A10138, p. 200 **(±)-threo-1,4-Dimercapto-2,3-butanediol**, see 1,4-Dithio-DL-threitol, A15797, p. 200 **1,2 Dimercaptoethane**, see Ethambutol dihydrochloride, J60695, p. 213	
L03953	**2,3-Dimercaptopropanol, 97%** △ *[BAL, Dimercaprol]* [59-52-9], $C_3H_8OS_2$, F.W. 124.22, b.p. 120°/15mm, f.p. >110°(230°F), d. 1.244, n_D^{20} 1.5740, Merck **14**,3209, UN2810, EINECS 200-433-7, RTECS UB2625000, BRN 1732058, MDL MFCD00004864, † H:H302-H315-H319-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a Application(s): British Anti-Lewisite. A chelator that inhibits sugar nucleotide degradation.	**1g** **5g** **25g**
	3,3'-Dimethoxybenzidine, see o-Dianisidine, A17150, p. 184 **3,3'-Dimethoxybenzidine dihydrochloride**, see o-Dianisidine dihydrochloride, A17175, p. 184 **1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride**, see Papaverine hydrochloride, B25412, p. 312 **10,11-Dimethoxystrychnine**, see Brucine, J61178, p. 138	
J65540	**cis-5-(3,5-Dimethoxystyryl)-2-methoxyphenol** *[5-[(1Z)-2-(3,5-Dimethoxyphenyl)ethenyl]-2-methoxyphenol, cis-3,4',5-Trimethoxy-3'-hydroxystilbene]* [586410-08-4], $C_{17}H_{18}O_4$, F.W. 286.32, Oil	**10mg**
J65136	**5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyinosine, 98%** *[2'-Deoxy-5'-O-DMT-inosine, 5'-O-DMT-2'-deoxyinosine]* [93778-57-5], $C_{31}H_{30}N_4O_6$, F.W. 554.59, Powder, MDL MFCD00080301	**1g**
J64050	**5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyinosine-3'-CE-phosphoramidite, 98%** $C_{40}H_{47}N_6O_7P$, F.W. 754.81, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J65960	**5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyuridine, 98%** *[5'O-DMT-dU, 5'-O-DMT-2'-deoxyuridine]* [23669-79-6], $C_{30}H_{30}N_2O_7$, F.W. 530.57, Powder, EINECS 245-814-9, MDL MFCD00063410	**1g**

Stock #	Description	Size
J65478	**5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyuridine-3'-CE-phosphoramidite, 98%** $C_{39}H_{47}N_4O_8P$, F.W. 730.78, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g
J65936	**5'-O-(4,4'-Dimethoxytrityl)-N_2-dimethylformamidinyl-2'-fluoro-2'-deoxyguanosine, 98%** $C_{34}H_{35}FN_6O_6$, F.W. 642.68, Powder	1g
J65536	**5'-O-(4,4'-Dimethoxytrityl)-N_2-dimethyl-formamidinyl-2'-fluoro-2'-deoxyguanosine-3'-CE-phosphoramidite, 98%** $C_{43}H_{52}FN_8O_7P$, F.W. 842.89, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g
J65794	**5'-O-(4,4'-Dimethoxytrityl)-N_2-dimethylformamidinyl-2'-O-methylguanosine, 98%** $C_{35}H_{38}N_6O_7$, F.W. 654.71, Powder	1g
J65699	**5'-O-(4,4'-Dimethoxytrityl)-N_2-dimethylformamidinyl-2'-O-methylguanosine-3'-CE-phosphoramidite, 98%** $C_{44}H_{55}N_8O_8P$, F.W. 854.93, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g
J65008	**5'-O-(4,4'-Dimethoxytrityl)-2'-fluoro-2'-deoxyinosine, 98%** *[2'-Deoxy-5'-O-DMT-2'-fluoroinosine]* $C_{31}H_{29}FN_4O_6$, F.W. 572.58, Powder	1g
J64217	**5'-O-(4,4'-Dimethoxytrityl)-2'-fluoro-2'-deoxyuridine, 98%** *[2'-Deoxy-5'-O-DMT-2'-fluorouridine, 2'-Fluoro-5'-O-DMT-uridine]* [146954-74-7], $C_{30}H_{29}N_2O_7F$, F.W. 548.56, Powder	5g
J65350	**5'-O-(4,4'-Dimethoxytrityl)-2'-fluoro-2'-deoxyuridine-3'-CE-phosphoramidite, 98%** $C_{39}H_{46}FN_4O_8P$, F.W. 748.77, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g
J64232	**5'-O-(4,4'-Dimethoxytrityl)-2'-fluoro-N_2-isobutyryl-2'-deoxyguanosine, 98%** $C_{35}H_{36}FN_5O_7$, F.W. 657.69, Powder	1g
J65817	**5'-O-(4,4'-Dimethoxytrityl)-2'-fluoro-N_2-Isobutyryl-2'-deoxyguanosine-3'-CE-phosphoramidite, 98%** $C_{44}H_{53}FN_7O_8P$, F.W. 857.90, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g
J65583	**5'-O-(4,4'-Dimethoxytrityl)-N_2-isobutyryl-2'-O-methylguanosine, 98%** $C_{36}H_{39}N_5O_8$, F.W. 669.72, Powder	1g
J65100	**5'-O-(4,4'-Dimethoxytrityl)-N_2-isobutyryl-2'-O-methylguanosine-3'-CE-phosphoramidite, 98%** $C_{45}H_{56}N_7O_9P$, F.W. 869.94, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g
J65498	**5'-O-(4,4'-Dimethoxytrityl)-N_6-methyl-2'-deoxyadenosine, 98%** $C_{32}H_{33}N_5O_5$, F.W. 567.63, Powder	1g
J64825	**5'-O-(4,4'-Dimethoxytrityl)-2'-O-methylinosine, 98%** $C_{32}H_{32}N_4O_7$, F.W. 584.62, Powder	1g
J64880	**5'-O-(4,4'-Dimethoxytrityl)-2'-O-methyluridine, 98%** $C_{31}H_{32}N_2O_8$, F.W. 560.59, Powder	1g
J65508	**5'-O-(4,4'-Dimethoxytrityl)-2'-O-methyluridine-3'-CE-phosphoramidite, 98%** $C_{40}H_{49}N_4O_9P$, F.W. 760.81, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1g
A10924	**N,N-Dimethylacetamide, 99%** *[DMA]* [127-19-5], $CH_3CON(CH_3)_2$, F.W. 87.12, m.p. -20°, b.p. 165-166°, f.p. 70°(158°F), d. 0.940, n_D^{20} 1.4385, Merck **14**,3227, Fieser **1**,270 **2**,144 **4**,165, EINECS 204-826-4, RTECS AB7700000, BRN 1737614, MDL MFCD00008686, † H:H360D-H312-H332, P:P261-P280-P281-P302+P352-P405-P501a Dipolar aprotic solvent, cf **N,N-Dimethylformamide**, **A13547**, **Dimethyl sulfoxide**, **A13280**, **1-Methyl-2-pyrrolidinone**, **A12260**. See also **Sodium hydride**, **13431**, for warning. Useful solvent in halex fluorinations of chloroarenes; compare **Sulfolane**, **A13466**. Undergoes Vilsmeier-type reactions (compare DMF), with reactive substrates, introducing an acetyl group: *Chem. Ber.*, **97**, 616 (1964).	250ml 500ml 2.5L

Stock #	Description	Size
	Reacts with alkyl and aryl Grignard reagents to give methyl ketones in good yields: *Synthesis*, 228 (1984). In the presence of triflic anhydride and 2,4,6-collidine, forms a highly-reactive keteniminium triflate, which undergoes a [2+2] cycloaddition reaction with terminal alkenes to give, after hydrolysis a 3-alkylcyclobutanone: *J. Am. Chem. Soc.*, **107**, 2192 (1985); *Org. Synth. Coll.*, **8**, 306 (1993):  	
B21174	**Dimethyl adipate, 99%** *[Adipic acid dimethyl ester, Hexanedioic acid dimethyl ester]* [627-93-0], $CH_3O_2C(CH_2)_4CO_2CH_3$, F.W. 174.20, m.p. 8°, b.p. 109-110°/14mm, f.p. 107°(224°F), d. 1.063, n_D^{20} 1.4280, Merck **14**,162, EINECS 211-020-6, RTECS AV1645000, BRN 1707443, MDL MFCD00008469, †	**50g** **250g** **1kg**
	cis-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, see Tamoxifen, 98+%, J63509, p. 357 **cis-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene citrate**, see Tamoxifen citrate, J60955, p. 357 **2-(Dimethylamino)ethyl 4-(n-butylamino)benzoate hydrochloride**, see Tetracaine hydrochloride, J63272, p. 361 **(S)-4-(3-[2-(Dimethylamino)ethyl]-5-indolylmethyl)oxazolidin-2-one**, see Zolmitriptan, J60616, p. 397	
J65367	**4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide** $C_{15}H_{23}N_3O_3$, F.W. 293.36, Crystalline solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg**
	5-Dimethylamino-1-naphthalenesulfonamide, see Dansyl amide, A11449, p. 175 **5-Dimethylamino-1-naphthalenesulfonyl chloride**, see Dansyl chloride, A13828, p. 175 **2-[4-(Dimethylamino)phenyl]azobenzoic acid**, see Methyl Red hydrochloride, 36668, p. 290 **2-[4-(Dimethylamino)phenyl]azobenzoic acid sodium salt**, see Methyl Red sodium salt, 36667, p. 290	
A10807	**1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 98+%** *[EDAC, EDCI]* [25952-53-8], $CH_3CH_2N=C=N(CH_2)_3N(CH_3)_2 \cdot HCl$, F.W. 191.70, m.p. ca 113°, Fieser **1**,371 **2**,196 **12**,199, EINECS 247-361-2, RTECS FF2200000, BRN 5764110, MDL MFCD00012503, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 'Water-soluble carbodiimide', widely used for peptide coupling, with the major advantage that excess reagent and the urea by-product can be easily removed by washing with dilute acid or water: *J. Org. Chem.*, **26**, 2525 (1961); *J. Am. Chem. Soc.*, **87**, 2492 (1965). For discussion of the mechanism of peptide coupling with this reagent, see: *J. Am. Chem. Soc.*, **103**, 7090 (1981). Often used in conjunction with an additive such as HOBt (1-hydroxybenzotriazole hydrate) to suppress racemization; see, for example: *Bull. Chem. Soc. Jpn.*, **55**, 2165 (1982). A two-phase solvent system (dichloromethane-water or isopropyl acetate-water) has been found to give superior results in this type of peptide coupling: *J. Org. Chem.*, **60**, 3569 (1995). In a comparative study, submolar quantities HOBt in DMF-water gave good results: *Chem. Lett.*, 1 (1997). For use in the synthesis of cyclic derivatives of 3'-amino-3'-deoxyadenosine-5'-di- and triphosphates, see: *Angew. Chem. Int. Ed.*, **33**, 1394 (1994). Promotes various other N-acylation reactions such as the formation of N-acylsulfonamides from primary sulfonamides and N-protected amino acids in the presence of DMAP: *Synlett*, 1141 (1995). For use in the acylation of phosphoranes, see **(Cyanomethyl)triphenylphosphonium chloride**, **A13096**.	**1g** **5g** **25g**
J65596	**5-[3-(Dimethylamino)propylidene]dibenzosuberane hydrochloride, 98%** *[Amitriptyline hydrochloride, 5-(10,11-Dihydro-5H-dibenzo[a,d]cycloheptene)-N,N-dimethylpropan-1-amine hydrochloride]* [549-18-8], $C_{20}H_{23}N \cdot HCl$, F.W. 313.86, Powder, m.p. 196-197°, Merck **14**,487, UN2811, EINECS 208-964-6, RTECS HO9450000, MDL MFCD00012537, † H:H301-H311-H330-H315-H319-H334-H317-H361-H335, P:P301+P310-P304+P340-P305+P351+P338-P320-P330-P361-P405-P501 Application(s): A tricyclic serotnonin reuptake inhibitor	**25g** **100g**
	11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepine hydrochloride, see Doxepin hydrochloride, J62579, p. 201 **(S)-(3-Dimethylaminopropyl)isothiourea dihydrochloride**, see Dimaprit dihydrochloride, J61079, p. 194 **Dimethylarsinic acid sodium salt trihydrate**, see Cacodylic acid sodium salt trihydrate, A18139, p. 141	
J63361	**1,1-Dimethylbiguanide hydrochloride** *[Metformin hydrochloride]* [1115-70-4], $NH_2C(=NH)NHC(=NH)N(CH_3)_2 \cdot HCl$, F.W. 165.62, Powder, m.p. 218-226°, Merck **14**,5938, EINECS 214-230-6, RTECS DU1800000, MDL MFCD00012582 H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501a Application(s): An antidiabetic agent	**5g** **25g** **100g**
	Dimethyl butane-1,4-dicarboxylate, see Dimethyl adipate, B21174, p. 196 **5,5-Dimethyl-1,3-cyclohexanedione**, see Dimedone, A10140, p. 194	
J61050	**(S)-(+)-2,2-Dimethylcyclopropanecarboxamide** [75885-58-4], $C_6H_{11}NO$, F.W. 113.16, Crystalline powder, EINECS 278-334-3, MDL MFCD00216614 H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501 Application(s): For synthesis of optically active products	**1g**
	3,3-Dimethyl-DL-cysteine, see DL-Penicillamine, B24710, p. 313 **3,3-Dimethyl-D-cysteine**, see D-(-)-Penicillamine, A11446, p. 313 **(±)-2,2-Dimethyl-1,3-dioxolane-4-methanol**, see Solketal, L02814, p. 349 **2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline**, see Bathocuproin, B22841, p. 117 **2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline disulfonic acid disodium salt**, see Bathocuproin sulfonate disodium salt hydrate, B22550, p. 118	

Stock #	Description	Size
39117	**N,N-Dimethylformamide, ACS, 99.8+%** [68-12-2], $HCON(CH_3)_2$, F.W. 73.09, m.p. -61°, b.p. 153°, f.p. 57°(135°F), d. 0.944, n_D^{20} 1.4310, Merck **14**,3243, Fieser **1**,273 **9**,182 **11**,198 **12**,203 **14**,148 **16**,144 **18**,146 **19**,137 **21**,178, UN2265, EINECS 200-679-5, RTECS LQ2100000, BRN 605365, MDL MFCD00003284, † Maximum level of impurities: Appearance Clear, Color (APHA) 15, Evaporation residue 0.005%, Titratable base 0.003meq/g, Titratable acid 0.0005meq/g, H_2O 0.15% H:H360D-H226-H312-H332-H319, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Application(s): A solvent for chromogenic substrates	**500ml** **1L** **4L** **4x1L** **4x4L**
J64577	**N_2-Dimethylformamidinyl-2'-O-methylguanosine, 98%** $C_{14}H_{20}N_8O_5$, F.W. 352.35, Powder	**1g**
	N-(1,1-Dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid, see AMPSO, 98+%, J62378, p. 103 **3,7-Dimethyl-2,6-octadienyl bromide**, see Geranyl bromide, A14093, p. 231 **(+/-)-3,7-Dimethyl-6-octenal**, see (±)-Citronellal, L15753, p. 165	
A11398	**2,9-Dimethyl-1,10-phenanthroline hemihydrate, 98+%** *[Neocuproine]* [34302-69-7], $C_{14}H_{12}N_2 \cdot 0.5H_2O$, F.W. 217.27 (208.26anhy), m.p. 160-164°, Merck **14**,6449, EINECS 207-601-9, BRN 153179, MDL MFCD00149306, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reagent for copper: *Anal. Chem.*, **46**, 692 (1974). Complexing agent for Cu(I) in the formation of aryl-sulfur bonds by reaction of aryl iodides with aryl and alkyl thiols: *Org. Lett.*, **4**, 2803 (2002). Co-catalyst in the Pd-catalyzed oxidation of alcohols: *Adv. Synth. Catal.*, **345**, 1341 (2003). Application(s): Reagent for the colorimetric determination of copper	**5g** **25g** **100g**
J63698	**2,9-Dimethyl-1,10-phenanthroline, 98%** *[Neocuproine]* [484-11-7], $C_{14}H_{12}N_2$, F.W. 208.26, Powder, m.p. 159-164°, Merck **14**,6449, Solubility: Soluble in methanol, EINECS 207-601-9, RTECS SF8380000, MDL MFCD00004973, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Reagent for the colorimetric determination of copper	**5g** **25g**
	2-[(2,3-Dimethylphenyl)amino]benzoic acid, see Mefenamic acid, 98%, J62705, p. 279 **2-(2,6-Dimethylphenylamino)-5,6-dihydro-4H-thiazine hydrochloride**, see Xylazine, J61430, p. 394 **N-(2,6-Dimethylphenylcarbamoylmethyl)triethylammonium bromide**, see Lidocaine N-ethyl bromide, 99+%, J60678, p. 270 **4'-[(1,4'-Dimethyl-2'-n-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]biphenyl-2-carboxylic acid**, see Telmisartan, 99%, J61441, p. 360 **N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide**, see Sulfamethazine, A19276, p. 355	
43244	**Dimethylsuberimidate dihydrochloride** ◢ [34490-86-3], $C_{10}H_{20}N_2O_2 \cdot 2HCl$, F.W. 273.20, Crystalline, m.p. 213-214°, Solubility: Soluble in water, EINECS 252-060-4, MDL MFCD00012574, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Crosslinking of proteins and poly(allylamine)	**2g** **10g**
36480	**Dimethyl sulfoxide, ACS, 99.9% min** ■ *[Methyl sulfoxide]* [67-68-5], $(CH_3)_2SO$, F.W. 78.13, Clear, colorless Liquid, m.p. 18.4°, b.p. 189°, f.p. 87°(189°F), d. 1.101, n_D^{20} 1.4790, Merck **14**,3259, Fieser **1**,296 **14**,150 **15**,146 **16**,149 **17**,127 **18**,149 **20**,154 **21**,180, EINECS 200-664-3, RTECS PV6210000, BRN 506008, MDL MFCD00002089, † Maximum level of impurities: Evaporation residue 0.01%, Titratable acid 0.001meq/g, H_2O 0.1% H:H227, P:P210-P280-P370+P378a-P403+P235-P501a	**500ml** **1L** **4L** **4x1L** **4x4L**
	3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, see Thiazolyl Blue tetrazolium bromide, L11939, p. 366	
L19664	**1,3-Dimethyluracil, 99%** [874-14-6], $C_6H_8N_2O_2$, F.W. 140.14, m.p. 119-122°, EINECS 212-856-4, BRN 124074, MDL MFCD00038065, †	**1g** **5g**
	1,3-Dimethylxanthine, see Theophylline, J60203, p. 366 **3,7-Dimethylxanthine**, see Theobromine, A11861, p. 365	
B24818	**Dimidium bromide, 95%** *[3,8-Diamino-5-methyl-6-phenylphenanthridinium bromide]* [518-67-2], $C_{20}H_{18}BrN_3$, F.W. 380.31, m.p. 230° dec., EINECS 208-256-7, RTECS SF7960500, MDL MFCD00011757 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Fluorescent probe for nucleic acids; intercalating agent	**250mg** **1g**
B21430	**2,4-Dinitrobenzenesulfonic acid hydrate, 98%** [89-02-1], $C_6H_4N_2O_7S \cdot xH_2O$, F.W. 248.17(anhy), m.p. 107-109°, UN2585, EINECS 201-876-9, RTECS DB6500000, MDL MFCD00150961, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Used to prepare ether-soluble 2,4-dinitrophenyl derivatives of amino alcohols	**25g** **100g**
	2,4-Dinitrochlorobenzene, see 1-Chloro-2,4-dinitrobenzene, A13774, p. 155	

Stock #	Description	Size
	5,7-Dinitro-8-hydroxy-2-naphthalenesulfonic acid disodium salt, see Naphthol Yellow S, B20872, p. 298	
J60911	**6,7-Dinitroquinoxaline-2,3-dione** *[DNXQ]* [2379-57-9], $C_8H_4N_4O_6$, F.W. 252.14, Powder, m.p. >300°, MDL MFCD00069257 Application(s): Potent competitive non-NMDA glutamate receptor antagonist	**10mg** **50mg**
J64267	**DiO-Lipoprotein, low density, human plasma** *[3,3'-Dioctadecyloxacarbocyanine-low density lipoprotein, DiO-LDL]*	**1each**
J64029	**DiO-Lipoprotein, low density, acetylated, human plasma** *[3,3'-Dioctadecyloxacarbocyanine-acetylated low density lipoprotein, DiO-Ac-LDL]*	**200micrograms**
J60976	**Diosgenin** *[3-β-Hydroxy-5-spirostene, Nitogenin]* [512-04-9], $C_{27}H_{42}O_3$, F.W. 414.63, Powder, m.p. 200-206°, Merck **14**,3295, EINECS 208-134-3, RTECS WH1450000, BRN 94582, MDL MFCD00016887 Application(s): Useful for synthesis of steroid products. Can be converted to pregnenolone and progesterone	**5g** **25g** **100g**
J62073	**Diosmin** *[3',5,7-Trihydroxy-4'-methoxyflavone 7-rutinoside]* [520-27-4], $C_{28}H_{32}O_{15}$, F.W. 608.50, Powder, m.p. 274°, Merck **14**,3297, EINECS 208-289-7, MDL MFCD00009772 Application(s): Natural flavanoid with anti-inflammatory effects	**5g** **25g** **100g**
	2,5-Dioxo-3-pyrroline, see Maleimide, A13135, p. 275 **β-(3,5-Dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine**, see (+)-Quisqualic acid, 99+%, J61591, p. 334 **3-(3,5-Dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine**, see (+)-Quisqualic acid, 99+%, J61591, p. 334 **2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid**, see Orotic acid hydrate, A18594, p. 309	
A10136	**Diphenhydramine hydrochloride, 99%** ▲ [147-24-0], $(C_6H_5)_2CHOCH_2CH_2N(CH_3)_2{\cdot}HCl$, F.W. 291.82, m.p. 168-169°, UN2811, EINECS 205-687-2, MDL MFCD00012479 H:H351-H361-H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A histamine H1 receptor antagonist	**50g** **250g** **1kg**
	Diphenyl, see Biphenyl, A10265, p. 125	
L02404	**Diphenylacetonitrile, 99%** [86-29-3], $C_{14}H_{11}N$, F.W. 193.25, m.p. 72-76°, b.p. 181°/12mm, f.p. 120°(248°F), Merck **14**,3316, EINECS 201-662-5, RTECS AL9800000, BRN 1911160, MDL MFCD00001862, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a In the presence of a phase-transfer catalyst, undergoes an unusual addition reaction with acetylene and other alkynes: *Org. Synth. Coll.*, **6**, 940 (1988):  	**100g** **500g**
J62298	**4-Diphenylacetoxy-N-methylpiperidine methiodide** *[4-DAMP methiodide]* [1952-15-4], $C_{21}H_{26}INO_2$, F.W. 451.40, Powder, m.p. 211-213°, MDL MFCD00078564	**25mg** **100mg**
	Di-L-Phenylalanine, see L-Phenylalanyl-L-phenylalanine, J60043, p. 316 **1-(α,4-Diphenylbenzyl)imidazole**, see Bifonazole, 99%, J63253, p. 125	
J64838	**Diphenyleneiodonium chloride** *[DPI chloride, Dibenziodolium chloride]* [4673-26-1], $C_{12}H_8I.Cl$, F.W. 314.55, Powder, MDL MFCD00214165	**25mg** **50mg** **100mg**
	cis-1,2-Diphenylethylene, see cis-Stilbene, A11924, p. 352 **Diphenyl ketone**, see Benzophenone, A10739, p. 120 **1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride**, see GBR 12935 dihydrochloride, J62991, p. 230	
L19398	**α,α-Diphenyl-N-methyl-D-prolinol, 97%, ee 99+%** *[(R)-α,α-Diphenyl-1-methylpyrrolidine-2-methanol]* [144119-12-0], $C_{18}H_{21}NO$, F.W. 267.37, m.p. 68-71°, $[\alpha]_D^{20}$ -52° (c=1 in chloroform), BRN 1535407, MDL MFCD00145217 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250mg** **1g**
L19399	**α,α-Diphenyl-N-methyl-L-prolinol, 97%, ee 99+%** *[(S)-α,α-Diphenyl-1-methylpyrrolidine-2-methanol]* [110529-22-1], $C_{18}H_{21}NO$, F.W. 267.37, m.p. 66-69°, $[\alpha]_D^{20}$ +52° (c=1 in chloroform), Fieser **17**,131, BRN 4749387, MDL MFCD00145245 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250mg** **1g**
J61001	**(R)-(+)-2-(Diphenylmethyl)pyrrolidine** [22348-31-8], $C_{17}H_{19}N$, F.W. 237.34, Liquid, MDL MFCD01861800 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**Call**
	(R)-α,α-Diphenyl-1-methylpyrrolidine-2-methanol, see α,α-Diphenyl-N-methyl-D-prolinol, L19398, p. 198	

Stock #	Description	Size
	(S)-α,α-Diphenyl-1-methylpyrrolidine-2-methanol, see α,α-Diphenyl-N-methyl-L-prolinol, L19399, p. 198 **4,7-Diphenyl-1,10-phenanthroline**, see Bathophenanthroline, A14258, p. 118	
A13450	**1,3-Diphenyl-1,3-propanedione, 98+%** *[Dibenzoylmethane, Dppd-H]* [120-46-7], $C_{15}H_{12}O_2$, F.W. 224.26, m.p. 76-80°, b.p. 219-221°/18mm, Merck **14**,3009, EINECS 204-398-9, RTECS TZ1930000, BRN 514910, MDL MFCD00003085, † Chelating ligand, e.g. for metal extraction. Reagent for uranium: *Anal. Chim. Acta*, **108**, 437 (1979). 	**25g** **100g** **500g**
J63641	**(R)-1,1-Diphenyl-2-propanol** [52199-85-6], $C_{15}H_{16}O$, F.W. 176.26, Crystalline solid, MDL MFCD06762638 Application(s): For synthesis of optically active products	**5mg** **10mg**
J63320	**(S)-1,1-Diphenyl-2-propanol** [41997-47-1], $C_{15}H_{16}O$, F.W. 176.26, Crystalline solid, MDL MFCD06762637 Application(s): For synthesis of optically active products	**Call**
	1,3-Diphenyl-2-propen-1-one, see trans-Chalcone, A14734, p. 152 **N-[3,3-Diphenylpropyl]-α-methylbenzylamine**, see Fendiline hydrochloride, J63254, p. 219	
J64676	**2,3-Diphospho-D-glyceric acid pentasodium salt** ■ *[Sodium 3-hydroxy-3-phosphonato-2-(phosphonatooxy)propanoate, D-Glycerate 2,3-diphosphate pentasodium salt]* [102783-53-9], $C_3H_3O_{10}P_2Na_5$, F.W. 375.95, Powder, MDL MFCD00070074	**100mg**
	Dipotassium phosphate, see Potassium hydrogen phosphate, 11593, p. 326 **Diprophylline**, see Dyphylline, J63167, p. 203 **4-(Di-n-propylaminosulfonyl)benzoic acid**, see Probenecid, B20010, p. 328	
J63554	**1,3-Dipropyl-8-phenylxanthine** [85872-53-3], $C_{17}H_{20}N_4O_2$, F.W. 312.37, Powder, RTECS UO8430880 Application(s): Selective A1 adenosine antagonist	**10mg** **50mg**
	4-(Di-n-propylsulfamoyl)benzoic acid, see Probenecid, B20010, p. 328	
J60369	**Diprotin A** *[H-Ile-Pro-Ile-OH, L-Isoleucyl-L-prolyl-L-isoleucine]* [90614-48-5], $C_{17}H_{31}N_3O_4$, F.W. 341.25, Powder, RTECS NR4737000, MDL MFCD00038707 Application(s): An inhibitor of dipeptidyl aminopeptidase IV	**50mg** **250mg**
J63321	**Diprotin B** *[H-Val-Pro-Leu-OH]* [90614-49-6], $C_{16}H_{29}N_3O_4$, F.W. 327.40, Powder Application(s): An inhibitor of dipeptidyl aminopeptidase IV	**50mg** **250mg**
J62498	**DIPSO, 0.2M buffer soln., pH 7.0** [102783-62-0], Liquid	**100ml** **250ml**
J63097	**DIPSO, 0.2M buffer soln., pH 7.5** [102783-62-0], Liquid	**100ml** **250ml**
J61388	**DIPSO, 0.2M buffer soln., pH 8.0** [102783-62-0], Liquid	**100ml** **250ml**
J62629	**DIPSO, 0.2M buffer soln., pH 8.5** [102783-62-0], Liquid	**100ml** **250ml**
J63329	**Dipyridamole** [58-32-2], $C_{24}H_{40}N_8O_4$, F.W. 504.63, Powder, m.p. 165-167°, Merck **14**,3346, EINECS 200-374-7, RTECS KK7450000, MDL MFCD00010555 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An inhibitor of adenosine transport and phosphodiesterase	**5g** **25g**
	2,2'-Diquinolyl, see 2,2'-Biquinoline, A10907, p. 126 **Direct Blue 1**, see Chicago Sky Blue 6B, A14242, p. 153 **Direct Blue 14**, see Trypan Blue, A18600, p. 384	
B21693	**Direct Red 80** *[C.I. 35780, Sirius Red]* [2610-10-8], $C_{45}H_{26}N_{10}Na_6O_{21}S_6$, F.W. 1373.09, EINECS 220-027-3, MDL MFCD00054389, † 	**5g** **25g** **100g**
	Direct Blue 86, see Solvent Blue 38, A15395, p. 349 **Disodium 3-indoxyl phosphate**, see 3-Indoxyl phosphate disodium salt, J60552, p. 256 **Disodium malonate**, see Malonic acid disodium salt, 44841, p. 276 **Disodium 1-naphthyl phosphate hydrate**, see 1-Naphthyl phosphate disodium salt hydrate, B22866, p. 298 **Disodium 4-nitrophenyl phosphate**, see 4-Nitrophenyl phosphate disodium salt hexahydrate, 5mg tablets, J61401, p. 304 **Disodium phosphate**, see Sodium hydrogen phosphate heptahydrate, 11592, p. 346 **Disulfiram**, see Tetraethylthiuram disulfide, B20721, p. 362 **Disulfo copper phthalocyanine amine salt**, see Solvent Blue 38, A15395, p. 349 **(+/-)-3,3'-Dithiobis(2-aminopropionic acid)**, see DL-Cystine, J63564, p. 173	

Stock #	Description	Size
	(+)-3,3'-Dithiobis(2-aminopropionic acid), see D-Cystine, L13772, p. 173 **(-)-3,3'-Dithiobis(2-aminopropionic acid)**, see L-Cystine, A13762, p. 173	
A14331	**5,5'-Dithiobis(2-nitrobenzoic acid), 99%** *[Bis(3-carboxy-4-nitrophenyl) disulfide, 3-Carboxy-4-nitrophenyl disulfide]* [69-78-3], $C_{14}H_8N_2O_8S_2$, F.W. 396.36, m.p. ca 240° dec., Fieser **1**,351, EINECS 200-714-4, RTECS DG9650000, BRN 1896821, MDL MFCD00007140, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reacts with free thiol groups to form a highly colored (yellow) thiolate anion: *Arch. Biochem. Biophys.*, **82**, 70 (1959); used for quantitative determination of thiols. Also used in chromogenic assay of acetylcholinesterase: *Enzyme Assays*, R. Eisenthal and M. J. Danson, Eds., OUP, Oxford (1992), p81. Application(s): Reagent for determination of sufhydryl groups	**1g** **5g** **25g**
	Dithiocarb sodium, see Sodium diethyldithiocarbamate trihydrate, A15898, p. 345	
A10138	**1,4-Dithioerythritol, 99%** *[Cleland's Reagent DTE, erythro-1,4-Dimercapto-2,3-butanediol]* [6892-68-8], $C_4H_{10}O_2S_2$, F.W. 154.25, m.p. 82-84°, EINECS 229-998-8, RTECS KF2410000, BRN 1719756, MDL MFCD00063750, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Protective agent for preventing oxidation of thiol groups and reagent for reduction of disulfide groups in proteins: *Biochemistry*, **3**, 480 (1964); **11**, 2939 (1972); *J. Biol. Chem.*, **243**, 716 (1968); compare **1,4-Dithio-DL-threitol**, **A15797**, p. 200. Application(s): Reagent for maintaining thiols in reduced state.	**1g** **5g** **25g**
J64656	**1,4-Dithioerythritol, Electrophoresis Grade, 99%** *[Cleland's Reagent DTE, erythro-1,4-Dimercapto-2,3-butanediol]* [6892-68-8], $C_4H_{10}O_2S_2$, F.W. 154.25, Powder, m.p. 82-84°, EINECS 229-998-8, RTECS KF2410000, BRN 1719756, MDL MFCD00063750, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g** **25g**
	1,2-Dithiolane-3-valeric acid, see DL-Thioctic acid, L04711, p. 366 **DL-6,8-Dithiooctanoic acid**, see DL-Thioctic acid, L04711, p. 366	
J65818	**1,4-Dithio-DL-threitol, 100mM aq. soln.** *[DTT racemic, (±)-threo-1,4-Dimercapto-2,3-butanediol]* [3483-12-3], Liquid, Merck **14**,3376, EINECS 222-468-7, BRN 1719757, MDL MFCD00004877 Application(s): For use with T7 RNA Polymerase, product no. J65896	**250microliters**
A15797	**1,4-Dithio-DL-threitol, 99%** △ *[Cleland's Reagent DTT racemic, (+/-)-threo-1,4-Dimercapto-2,3-butanediol]* [3483-12-3], $C_4H_{10}O_2S_2$, F.W. 154.25, m.p. 40-43°, b.p. 125-130°/12mm, f.p. >110°(230°F), Merck **14**,3376, EINECS 222-468-7, RTECS EK1610000, BRN 1719757, MDL MFCD00004877 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Protective agent for preventing oxidation of thiol groups and reagent for reduction of disulfide groups in proteins: *Biochemistry*, **3**, 480 (1964); **11**, 2939 (1972); *J. Biol. Chem.*, **243**, 716 (1968); *Methods Enzymol.*, **25**, 185 (1967); **143**, 246 (1987). Application(s): Useful for stabilizing sulfhydryl-containing enzymes	**1g** **5g** **25g**
J64545	**1,4-Dithio-DL-threitol, Electrophoresis Grade, 99%** △ *[Cleland's Reagent DTT racemic, (±)-threo-1,4-Dimercapto-2,3-butanediol]* [3483-12-3], $C_4H_{10}O_2S_2$, F.W. 154.25, Powder, m.p. 40-43°, b.p. 125-130°/12mm, f.p. >110°(230°F), Merck **14**,3376, EINECS 222-468-7, RTECS EK1610000, BRN 1719757, MDL MFCD00004877 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g** **25g**
	Dithranol, see 1,8,9-Trihydroxyanthracene, B20303, p. 377	
J63917	**Dizocilpine maleate, 99+%** *[(+)-MK 801 maleate, (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cycl ohepten-5,10-imine maleate]* [77086-22-7], $C_{16}H_{15}N.C_4H_4O_4$, F.W. 337.37, Crystalline powder, Merck **14**,3386, EINECS 278-614-5, RTECS HP1093575, MDL MFCD00082465 Application(s): NMDA receptor antagonist that prevents calcium flux	**10mg** **50mg**
	DMA, see N,N-Dimethylacetamide, A10924, p. 195 **DMJ**, see (+)-1-Deoxymannojirimycin hydrochloride, J61277, p. 179	
J62291	**DNA marker, broad range** Liquid, Note: From 250-5,000 base pairs: 5 bands from 125-1,000bp; Four bands from 1,500-5,000bp	**1ml** **2ml**
J63178	**DNA marker, high range, 1,000 Base Pair Ladder** Liquid, Note: Contains 8 bands from 1,000-10,000 base pairs: 1000bp increments from 1,000-6,000bp, 8,000 and 10,000bp.	**1ml** **2ml**
J63973	**DNA marker, low range, 250 Base Pair Ladder** Liquid, Note: Contains seven bands from 200-3,000 base pairs: 250bp increments from 250 -1000bp, 1500, 2000 and 3000bp.	**1ml** **2ml**
J64630	**DNA Methyltransferase Inhibitor** ▲ *[RG108, N-Phthalyl-L-tryptophan]* [48208-26-0], $C_{19}H_{14}N_2O_4$, F.W. 334.32, Solid	**10mg**

Stock #	Description	Size
	DNase I, see Deoxyribonuclease I, bovine pancreas, J62229, p. 179 **DNase II**, see Deoxyribonuclease II, porcine spleen, J63389, p. 179	
J60637	**DNAzol® Reagent** Liquid, Note: DNAzol is a registered trademark of Molecular Research Center, Inc. H:H302+EUH032-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501 Application(s): Complete and ready to use reagent for the isolation of genomic DNA from solid and liquid samples of animal and plant origin	**50ml** **100ml** **200ml**
	DNSA, see Dansyl amide, A11449, p. 175 **DNSCl**, see Dansyl chloride, A13828, p. 175 **DNXQ**, see 6,7-Dinitroquinoxaline-2,3-dione, J60911, p. 198	
J61333	**Dobutamine hydrochloride** *[(±)-3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenethylamine hydrochloride]* [49745-95-1], $C_{18}H_{23}NO_3 \cdot HCl$, F.W. 337.85, Off-white solid, m.p. 184-186°, Merck **14**,3395, EINECS 256-464-1, MDL MFCD00153795 H:H361-H302-H312-H332, P:P261-P280-P281-P302+P352-P405-P501a Application(s): A β-1 adrenoceptor agonist with weak β-2 adrenoceptor activity and some action at the α-1 adrenoceptor	**1g**
J60174	**Docetaxel** [114977-28-5], $C_{43}H_{53}NO_{14}$, F.W. 807.88, Powder, m.p. 186-192°, Merck **14**,3397, RTECS DA4172750, MDL MFCD00800737 Application(s): A second-generation cytotoxic antimicrotubule agent	**100mg** **500mg** **1g**
	Docosanoic acid, see Behenic acid, A12850, p. 118	
A18862	**2-Dodecanone, 98+%** *[n-Decyl methyl ketone]* [6175-49-1], $C_{12}H_{24}O$, F.W. 184.32, m.p. 17-20°, b.p. 247°, f.p. 110°(230°F), d. 0.820, n_D^{20} 1.4330, EINECS 228-222-5, BRN 1703135, MDL MFCD00015064, †	**10g** **50g**
	N-Dodecanoyl-N-methylglycine sodium salt, see N-Lauroylsarcosine sodium salt, J60040, p. 266	
L06233	**n-Dodecyl gallate, 98% ▲** *[n-Dodecyl 3,4,5-trihydroxybenzoate, Gallic acid n-dodecyl ester]* [1166-52-5], $C_{19}H_{30}O_5$, F.W. 338.45, m.p. 95-98°, EINECS 214-620-6, RTECS DH9100000, BRN 2701981, MDL MFCD00002195, † H:H317, P:P261-P280-P302+P352-P321-P363-P501a	**50g** **250g**
	n-Dodecyl sulfate sodium salt, see Sodium n-dodecyl sulfate, A11183, p. 346 **n-Dodecyl 3,4,5-trihydroxybenzoate**, see n-Dodecyl gallate, L06233, p. 201	
J61608	**Domoic acid** [14277-97-5], $C_{15}H_{21}NO_6$, F.W. 311.30, Crystalline powder, m.p. 213-217°, Merck **14**,3417, RTECS UX9665100, BRN 4229251, MDL MFCD06795841 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501 Application(s): Reported to be a potent glutamate agonist	**5mg**
J63681	**Domperidone** [57808-66-9], $C_{22}H_{24}ClN_5O_2$, F.W. 425.91, Crystalline powder, m.p. 243°, Merck **14**,3418, EINECS 260-968-7, RTECS DE2275900, MDL MFCD00069256 H:H361, P:P281-P201-P202-P308+P313-P405-P501 Application(s): Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier	**25mg** **100mg** **500mg**
	DL-DOPA, see 3,4-Dihydroxy-DL-phenylalanine, 41535, p. 193 **L-Dopa**, see L-3-(3,4-Dihydroxyphenyl)alanine, A11311, p. 193	
A11136	**Dopamine hydrochloride, 99% ▲■** *[2-(3,4-Dihydroxyphenyl)ethylamine hydrochloride, 3-Hydroxytyramine hydrochloride]* [62-31-7], $C_8H_{11}NO_2 \cdot HCl$, F.W. 189.64, m.p. 243-250°, Merck **14**,3421, EINECS 200-527-8, RTECS UX1092000, BRN 3656720, MDL MFCD00012898, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A neurotransmitter and vasopressor that modulates cortical activation	**5g** **25g** **100g**
J61776	**Dovitinib** *[CHIR-258]* [405169-16-6], $C_{21}H_{21}FN_8O$, F.W. 392.43, Powder, m.p. 285-310°, BRN 5702728 Application(s): Multitargeted small-molecule tyrosine kinase receptor inhibitor	**10mg** **25mg** **50mg**
J62579	**Doxepin hydrochloride** *[11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepine hydrochloride]* [1229-29-4], $C_{19}H_{21}NO \cdot HCl$, F.W. 315.84, Powder, m.p. 187-189°, Merck **14**,3435, UN2811, EINECS 214-966-8, RTECS HQ4375000, MDL MFCD00079135 H:H301-H361, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Potent H1-histamine receptor antagonist and a 5-HT receptor antagonist	**5g** **25g**
J60575	**Doxofylline** *[Ansimar, Maxivent]* [69975-86-6], $C_{11}H_{14}N_4O_4$, F.W. 266.25, Crystalline powder, m.p. 144-146°, Merck **14**,3438, EINECS 274-239-6 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Xanthine bronchodilator that inhibits phosphodiesterase activity	**5g**

Stock #	Description	Size
J64000	**Doxorubicin hydrochloride** *[14-Hydroxydaunomycin]* [25316-40-9], $C_{27}H_{29}NO_{11}$·HCl, F.W. 579.99, Solid, m.p. 216° dec., Merck **14**,3439, EINECS 246-818-3, RTECS QI9295900, BRN 4229251, MDL MFCD00077757 H:H350-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): Antitumor antibiotic agent that inhibits DNA topoisomerase II	**10mg** **50mg**
J63805	**Doxycycline monohydrate** *[Doxycycline]* [17086-28-1], $C_{22}H_{24}N_2O_8$·H_2O, F.W. 462.46 (444.44anhy), Powder, m.p. 167-168°, Merck **14**,3440, MDL MFCD02682958 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Inhibits angiogenesis and reduces lung metastases by inhibiting matrix metalloproteinases	**5g** **25g**
	Doxycycline, see Doxycycline monohydrate, J63805, p. 202	
J60579	**Doxycycline hyclate** *[Hydramycin, Doxycycline hydrochloride hemiethanolate hemihydrate]* [24390-14-5], $C_{22}H_{24}N_2O_8$·HCl.0.5H_2O.0.5C_2H_6O, F.W. 512.94 (503.94anhy), Powder, Merck **14**,3440, RTECS QI8925000, MDL MFCD07357237 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibits matrix metalloproteinases at subantimicrobial doses	**25g** **100g**
J60422	**Doxycycline hydrochloride** [10592-13-9], $C_{22}H_{24}N_2O_8$·HCl, F.W. 480.90, Crystalline powder, m.p. 195-201°, EINECS 234-198-7, MDL MFCD03427564 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibits angiogenesis and reduces lung metastases by inhibiting matrix metalloproteinases	**5g** **25g**
	Doxycycline hydrochloride hemiethanolate hemihydrate, see Doxycycline hyclate, J60579, p. 202	
J64090	**Dp44mT ▲** *[2-(Di(pyridin-2-yl)methylene)-N,N-dimethylhydrazinecarbothioamide, Di-2-pyridyl-ketone-4,4,-dimethyl-3-thiosemicarbazone]* [152095-12-0], $C_{14}H_{15}N_5S$, F.W. 285.37, Powder, UN2811, MDL MFCD20527329 H:H301, P:P264-P270-P301+P310-P321-P405-P501	**25mg**
	Dppd-H, see Dibenzoylmethane, A13450, p. 199 **DSIP**, see Delta Sleep-Inducing Peptide, J63334, p. 176 **DTE**, see 1,4-Dithioerythritol, A10138, p. 200 **DTPA**, see Diethylenetriaminepentaacetic acid, A10926, p. 189 **DTT**, see 1,4-Dithio-DL-threitol, A15797, p. 200	
A18402	**Dulcitol, 97% ■** *[Galactitol]* [608-66-2], $C_6H_{14}O_6$, F.W. 182.17, m.p. 187-191°, b.p. 275-280°/1mm, d. 1.47, Merck **14**,4332, EINECS 210-165-2, BRN 1721903, MDL MFCD00064288, †	**25g** **100g** **500g**
J63206	**Dulcitol, 99% ■** *[Galactitol]* [608-66-2], $C_6H_{14}O_6$, F.W. 182.17, Powder, m.p. 187-191°, b.p. 275-280°/1mm, d. 1.47, Merck **14**,4332, EINECS 210-165-2, BRN 1721903, MDL MFCD00064288, † Application(s): Useful reagent in bacteriology	**250g** **500g**
	Durapatite, see Hydroxylapatite **Durapatite**, see Hydroxylapatite, fast flow, J60076, p. 249	
J65171	**DY 131** *[N-(4-(Diethylaminobenzylidenyl)-N'-(4-hydroxybenzoyl)-hydrazine]* [95167-41-2], $C_{18}H_{21}N_3O_2$, F.W. 311.38, Solid, MDL MFCD00715585 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg**
J61330	**Dyclonine hydrochloride** *[1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone]* [536-43-6], $C_{18}H_{27}NO_2$·HCl, F.W. 325.88, Crystalline powder, m.p. 173-178°, Merck **14**,3473, EINECS 208-633-6, RTECS UG8750000, MDL MFCD00035386 H:H301-H318-H315-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g**
	Dynorphin A (1-5), see Leu-Enkephalin, J61408, p. 207	
J62646	**Dynorphin A (1-6), porcine** *[H-Tyr-Gly-Gly-Phe-Leu-Arg-OH]* [75106-70-6], $C_{34}H_{49}N_9O_8$, F.W. 711.80, Lyophilzed powder Application(s): Biologically active fragment of dynorphin A. kappa opioid receptor agonist	**1mg** **5mg**

Stock #	Description	Size
J63897	**Dynorphin A (1-7), porcine** *[H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-OH]* [77101-32-7], $C_{40}H_{61}N_{13}O_9$, F.W. 868.00, Lyophilized powder Application(s): A biologically active fragment of dynorphin, and an opioid receptor agonist	**1mg** **5mg**
J64636	**Dynorphin A (1-8), porcine** *[Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile]* [75790-53-3], $C_{46}H_{72}N_{14}O_{10}$, F.W. 981.15, Solid, MDL MFCD00076357	**1mg**
J64418	**Dynorphin A (1-9), porcine** *[Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg]* $C_{52}H_{84}N_{18}O_{11}$, F.W. 1137.33, Solid	**1mg**
J64015	**Dynorphin A (1-13), porcine** *[Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys]* [72957-38-1], $C_{75}H_{126}N_{24}O_{15}$, F.W. 1603.95, Solid, RTECS JV7436666	**1mg** **5mg**
J65394	**Dynorphin A (1-17), porcine** *[Prodynorphin (209-225), porcine, Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln]* $C_{99}H_{155}N_{31}O_{23}$, F.W. 2147.48, Solid	**1mg**
J64002	**Dynorphin A (2-17), porcine** *[Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln]* $C_{90}H_{147}N_{31}O_{20}$, F.W. 1983.32, Solid	**1mg**
J65126	**Dynorphin A (3-17), porcine** *[Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln]* $C_{88}H_{143}N_{29}O_{20}$, F.W. 1927.25, Solid	**1mg**
J65986	**Dynorphin A (6-17), porcine** *[Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln]* $C_{71}H_{120}N_{26}O_{17}$, F.W. 1609.87, Solid	**1mg**
J64991	**Dynorphin A (13-17), porcine** *[Lys-Trp-Asp-Asn-Gln]* $C_{30}H_{43}N_9O_{10}$, F.W. 689.72, Solid	**10mg** **25mg**
J65474	**[Phe7] Dynorphin A (1-7), porcine** *[Tyr-Gly-Gly-Phe-Leu-Arg-Phe]* $C_{43}H_{58}N_{10}O_9$, F.W. 858.98, Solid	**10mg** **25mg**
J65622	**Dynorphin A amide, porcine** *[Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-NH2]* [80448-90-4], $C_{99}H_{156}N_{32}O_{22}$, F.W. 2146.49, Solid, MDL MFCD00076351	**1mg**
J64409	**Dynorphin A (1-13) amide, porcine** *[Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-NH2]* $C_{75}H_{127}N_{25}O_{14}$, F.W. 1602.96, Solid	**1mg** **5mg**
J65159	**Dynorphin A (2-17) amide, porcine** *[Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-NH2]* $C_{90}H_{147}N_{31}O_{20}$, F.W. 1983.32, Solid	**1mg**
J64089	**Dynorphin B, porcine** *[Prodynorphin (228-240), Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr]* [85006-82-2], $C_{74}H_{115}N_{21}O_{17}$, F.W. 1570.83, Solid, MDL MFCD00076372	**1mg**
J64774	**Dynorphin B (1-9), porcine** *[Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe]* $C_{54}H_{78}N_{16}O_{12}$, F.W. 1143.29, Solid	**1mg**
J64335	**Dynorphin B 29, porcine** *[Prodynorphin (228-256), porcine, Leumorphin, porcine]* $C_{161}H_{236}N_{42}O_{48}$, F.W. 3527.84, Solid	**0.5mg** **1mg**
J63167	**Dyphylline** *[7-[2,3-Dihydroxypropyl]-theophylline, Diprophylline]* [479-18-5], $C_{10}H_{14}N_4O_4$, F.W. 254.24, Powder, m.p. 161-162°, Merck **14**,3479, EINECS 207-526-1, RTECS XH5100000, BRN 284563, MDL MFCD00005759, † ! H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): An adenosine receptor antagonist, phosphodiesterase inhibitor and vasodilator	**100g** **500g** **1kg**
J62933	**E-64** *[trans-Epoxysuccinyl-leucylamido- [4-guanidino]butane]* [66701-25-5], $C_{15}H_{27}N_5O_5$, F.W. 357.40, Powder, RTECS RR0390000, BRN 1405664, MDL MFCD00080261 Application(s): Selective and irreversible cysteine protease inhibitor	**5mg** **25mg**

Stock #	Description	Size
	EACA, see 6-Aminocaproic acid, A14719, p. 95	
J63088	**Ebastine** [90729-43-4], $C_{32}H_{39}NO_2$, F.W. 469.66, Powder, m.p. 84-87°, Merck **14**,3484, RTECS EL8140000, MDL MFCD00865661 Application(s): A histamine H1 receptor antagonist	**1g** **5g**
J64858	**EBPC** *[Ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, CP-10668]* [57056-57-2], $C_{14}H_{15}NO_4$, F.W. 261.27, Solid, MDL MFCD00179167 H:H302-H318, P:P280-P264-P305+P351+P338-P310-P301+P312-P501	**10mg**
J63190	**Ebselen** [60940-34-3], $C_{13}H_9NOSe$, F.W. 274.20, Powder, m.p. 180-181°, Merck **14**,3486, UN3283, RTECS DE4140750, MDL MFCD00210937 H:H330-H373-H400-H410, P:P260-P284-P304+P340-P320-P405-P501a Application(s): Seleno-organic compound that inhibits nitric oxide-induced apoptosis. Potent antioxidant. Protects calcium influx blockage	**5mg** **25mg**
	Eburnamenine-14-carboxylic acid ethyl ester, see Vinpocetine, 98%, J61000, p. 392	
J63091	**Ecdysterone** *[20-Hydroxyecdysone, Crustecdysone]* [5289-74-7], $C_{27}H_{44}O_7$, F.W. 480.64, Powder, m.p. 242-244°, Merck **14**,3491, RTECS FZ8060000, BRN 1917578, MDL MFCD00036740 Application(s): An insect steroid hormone that induces apoptosis	**10mg** **50mg**
	ECG, see (-)-Epicatechin gallate, J60814, p. 208	
J63402	**E. coli lysis buffer** Liquid, Note: This buffer contains: 50mM Tris-HCl (pH 8.0), 1% Triton X-100, 1mM EDTA, and 10mM beta-mercaptoethanol.	**250ml** **500ml**
J62613	**E. coli lysis buffer-II** Liquid, Note: This buffer contains: 10mM sodium phosphate (pH 7.4) with 2.7mM KCl, 140mM NaCl, and 1% Triton X-100.	**250ml** **500ml**
J63289	**E. coli sample buffer** Liquid, Note: This buffer contains: 100mM magnesium chloride 64mM Tris HCL(pH 6.8), 2% SDS, 10% glycerol, 2% beta-mercaptoethanol, and 0.01% Bromophenol blue	**25ml** **50ml**
J63173	**Econazole nitrate** *[Ecostatin, 1-[2-(4-Chlorophenylmethoxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole nitrate]* [24169-02-6], $C_{18}H_{15}Cl_3N_2O \cdot HNO_3$, F.W. 444.70, Powder, m.p. 162°, Merck **14**,3502, EINECS 246-053-5, RTECS NI4450000, MDL MFCD00058160 H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501	**5g** **25g**
	Ecostatin, see Econazole nitrate, J63173, p. 204 **EDAC**, see 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, A10807, p. 196 **EDCI**, see 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, A10807, p. 196 **EDDA**, see Ethylenediamine-N,N'-diacetic acid, J63570, p. 215 **Edetic acid**, see Ethylenediaminetetraacetic acid, 11931, p. 215 **EDF**, see Extracellular Death Factor trifluoroacetate salt, J61052, p. 218 **EDTA**, see Ethylenediaminetetraacetic acid, Cell Culture Reagent, J62948, p. 215 **EDTA tetrasodium salt**, see Ethylenediaminetetraacetic acid tetrasodium salt hydrate, A17385, p. 216 **EGCG**, see (-)-Epigallocatechin gallate, J61745, p. 209 **EGFR Peptide (985-996)**, see Epidermal Growth Factor Receptor Peptide (985-996), J64705, p. 209 **EGTA**, see Ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid, A16086, p. 216	
J61624	**5,8,11,14-Eicosatetraynoic acid** *[ETYA, Octadehydroarachidonic acid]* [1191-85-1], $C_{20}H_{24}O_2$, F.W. 296.40, Solid, m.p. 81-82°, BRN 1798411, MDL MFCD00036967 Application(s): A cyclooxygenase, lipoxygenase and cytochrome P450 inhibitor	**20mg** **100mg**
J63870	**cis-5,8,11-Eicosatrienoic acid** *[cis,cis,cis-5,8,11-Eicosatrienoic acid, MEAD acid]* [20590-32-3], $C_{20}H_{34}O_2$, F.W. 306.50, Oil, MDL MFCD00065719, Note: Supplied as a 10mg/ml solution in ethanol Application(s): Omega-3- fatty acid, with immunomodulatory activity	**1mg** **5mg** **10mg**
	cis,cis,cis-5,8,11-Eicosatrienoic acid, see cis-5,8,11-Eicosatrienoic acid, J63870, p. 204	
J60414	**5,8,11,-Eicosatriynoic acid** *[ETI]* [13488-22-7], $C_{20}H_{28}O_2$, F.W. 300.40, Solid, m.p. 68-69°, MDL MFCD00077343 Application(s): Immunomodulatory and anti-inflammatory activity; a lipoxygenase inhibitor	**1mg**

Stock #	Description	Size
A14832	**Elaidic acid, 98%** *[trans-9-Octadecenoic acid, trans-Oleic acid]* [112-79-8], $C_{18}H_{34}O_2$, F.W. 282.47, m.p. 41-45°, b.p. 288°/100mm, f.p. >110°(230°F), Merck **14**,3533, EINECS 204-006-6, RTECS JX6125000, BRN 1726543, MDL MFCD00063954 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g** **25g**
J64441	**Elastase Inhibitor I** ▲◪ *[Boc-AAA-NHO-Bz, PPE Inhibitor]* $C_{21}H_{30}N_4O_7$, F.W. 450.50, Solid	**1mg**
J65641	**Elastase Inhibitor II** ◪ *[HNE Inhibitor, MeOSuc-AAPA-CMK]* $C_{20}H_{31}ClN_4O_7$, F.W. 474.90, Solid	**5mg** **10mg**
J65894	**Elastase Inhibitor III** ◪ *[HLE Inhibitor, MeOSuc-AAPV-CMK]* $C_{23}H_{36}ClN_3O_7$, F.W. 503.00, Solid	**5mg** **10mg**
J61753	**Elastase, porcine pancreas aqueous suspension** *[E.C. 3.4.21.36, Pancreatopeptidase E]* [39445-21-1], Suspension, MW 25000, Merck **14**,3535, EINECS 254-453-6, RTECS TS5052000, MDL MFCD00130998, Note: Minimum 3 units per mg protein. One unit cleaves one micromole of N-succinyl-L-alanyl-L-alanyl-L-alanine-p-nitroanilide per minute at 25 degrees and pH 8.0. 2X crystallized. Supplied as an aqueous suspension. This preparation must be diluted to dissolve t H:H315-H319-H334-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A serious protease that acts on elastin. Suitable for the isolation of Type II lung cells	**25mg** **100mg**
J61874	**Elastase, porcine pancreas** *[E.C. 3.4.21.36, Pancreatopeptidase E]* [39445-21-1], Lyophilized powder, MW 25000, Merck **14**,3535, EINECS 254-453-6, RTECS TS5052000, MDL MFCD00130998, Note: Minimum 3 units per mg protein. One unit cleaves one micromole of N-succinyl-L-alanyl-L-alanyl-L-alanine-p-nitroanilide per minute at 25 degrees and pH 8.0 H:H334-H335-H315-H319, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A serious protease that acts on elastin	**25mg** **100mg** **1g**
J60093	**Elastase Substrate V** *[MeOSuc-AAPV-AMC, Neutrophil elastase substrate, fluorogenic]* [72252-90-5], $C_{31}H_{41}N_5O_9$, F.W. 627.70, Powder, MDL MFCD00077135, † Application(s): Fluorogenic substrate for quantification of human leukocyte and porcine pancreatic elastase	**25mg**
J61120	**Elastatinal** [51798-45-9], $C_{21}H_{36}N_8O_7$, F.W. 512.60, Powder, EINECS 257-426-7, RTECS LZ9600000, BRN 873543 Application(s): Irreversible elastase inhibitor	**5mg** **25mg**
J60596	**Eledoisin** *[pGlu-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2]* [69-25-0], $C_{54}H_{85}N_{13}O_{15}S$, F.W. 1188.44, Powder, Merck **14**,3539 Application(s): A potent vasodilating peptide that increases vascular permeability	**1mg** **2mg** **5mg**
J62110	**Eledoisin Related Peptide** *[H-Lys-Phe-Ile-Gly-Leu-Met-NH0, KFIGLM]* [2990-43-4], $C_{34}H_{58}N_8O_8S$, F.W. 706.96, Powder Application(s): Tachykinin receptor ligand; analog of substance P	**5mg**
A15722	**Ellagic acid hydrate, 97%, may cont. up to 12% water** ▲△ *[4,4',5,5',6,6'-Hexahydroxydiphenic acid 2,6,2',6'-dilactone hydrate]* [476-66-4], $C_{14}H_6O_8 \cdot xH_2O$, F.W. 302.20(anhy), m.p. 450° dec., Merck **14**,3547, EINECS 207-508-3, RTECS DJ2620000, BRN 47549, MDL MFCD00149494 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Selective, ATP-competitive inhibitor of casein kinase 2. Exhibits antitumor and anticarcinogenic activity and inhibits glutathione S-transferase 	**5g** **25g** **100g**
J61558	**Elution buffer, pH 8.0** Liquid, Note: This buffer contains: 50mM sodium phosphate, 300mM NaCl, and 250mM imidazole at pH 8.0. Application(s): For elution of His-tag proteins from nickel resins and columns	**250ml**
J64074	**Embelin** ▲ *[Apoptosis Activator III, 2,5-Dihydroxy-3-undecyl-2,5-cyclohexadiene-1,4-dione]* [550-24-3], $C_{17}H_{26}O_4$, F.W. 294.40, Solid, Merck **14**,3555, EINECS 208-979-8, RTECS DK4230000, MDL MFCD00016369	**10mg** **50mg**
	Embonic acid, see Pamoic acid, A15207, p. 311	
J61600	**Emodin** [518-82-1], $C_{15}H_{10}O_5$, F.W. 270.24, Powder, Merck **14**,3561, EINECS 208-258-8, RTECS CB7920600, BRN 1888141, MDL MFCD00001207 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A protein tyrosine kinase inhibitor	**100mg** **250mg** **1g**

Stock #	Description	Size
J60750	**Enalapril** [75847-73-3], $C_{20}H_{28}N_2O_5$, F.W. 376.45, Powder, m.p. 142-147°, Merck **14**,3567, RTECS TW3665500 Application(s): Long-acting ACE inhibitor and antihypertensive	**1g** **5g**
J63392	**Enalaprilat** *[Enalaprilic acid]* [76420-72-9], $C_{18}H_{28}N_2O_7$, F.W. 384.42, Crystalline solid, m.p. 148-151°, Merck **14**,3568, EINECS 278-459-3 Application(s): The active metabolite of enalapril	**10mg** **50mg**
	Enalaprilic acid, see Enalaprilat, J63392, p. 206	
J63932	**Enalapril maleate salt** [76095-16-4], $C_{20}H_{28}N_2O_5.C_4H_4O_4$, F.W. 492.52, Powder, m.p. 143-145°, Merck **14**,3567, EINECS 278-375-7, RTECS TW3666000, MDL MFCD00133304 Application(s): Long-acting ACE inhibitor and antihypertensive	**5g**
	Endoproteinase-Arg-C, see Clostripain, Clostridium histolyticum, J61362, p. 166	
J63462	**α-Endorphin, human** *[H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-OH, β-Lipotropin (61-76)]* [59004-96-5], $C_{77}H_{120}N_{18}O_{26}S$, F.W. 1745.98, Powder, MDL MFCD00076381 Application(s): An opioid peptide and substrate for transglutaminase	**1mg**
J62140	**α-Endorphin, human** [59004-96-5], $C_{158}H_{251}N_{39}O_{46}S$, F.W. 3465.06, Powder	**1mg**
J61230	**β-Endorphin, camel** [59887-17-1], $C_{155}H_{250}N_{42}O_{44}S$, F.W. 3438.00, Powder, MDL MFCD00151072 Application(s): An endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous system	**1mg**
J62374	**β-Endorphin, human** [61214-51-5], $C_{158}H_{251}N_{39}O_{46}S$, F.W. 3465.06, Powder, MDL MFCD00076383 Application(s): An endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous systemy	**1mg**
J62875	**β-Endorphin, rat** [77367-63-6], $C_{157}H_{254}N_{42}O_{44}S$, F.W. 3466.09, Powder, MDL MFCD00133129 Application(s): An endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous system	**1mg**
J64685	**[Des-Tyr1]-β-Endorphin, human** *[Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu]* $C_{149}H_{242}N_{38}O_{44}S$, F.W. 3301.8, Solid	**1mg**
J60948	**Endothall** *[7-Oxabicyclo [2.2.1] heptane-2,3-dicarboxylic acid]* [145-73-3], $C_8H_{10}O_5$, F.W. 186.20, Powder, Merck **14**,3575, UN2811, EINECS 205-660-5, RTECS RN7875000 H:H301-H312-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A moderately potent inhibitor of protein phosphatase 2A	**20mg** **100mg**
J64516	**Endothelial Cell Growth Supplement, bovine hypothalamus** *[Endothelial Mitogen, ECGS]* Note: Suitable for cell culture. Supplied partially purified as an aseptically lyophilized powder. Optimum concentration for endothelial cell culture media is 25-200 micrograms/ml. This product does not contain streptomycin which may be toxic to cells.	**50mg** **10x50mg**
J63502	**Endotoxin Inhibitor** *[H-Lys-Thr-Lys-Cys-Lys-Phe-Leu-Lys-Lys-Cys-OH, Lys-Thr-Lys-Cys-Lys-Phe-Leu-Lys-Lys-Cys, Disulfide Bridge: Cys4-Cys10]* [147396-10-9], $C_{55}H_{97}N_{15}O_{12}S_2$, F.W. 1224.60, Powder Application(s): Useful in the prophylaxis and treatment of LPS-mediated diseases; binds to and neutralizes endotoxin from gram-negative bacteria	**1mg**
J62862	**Endotoxin Substrate** *[Boc-Leu-Gly-Arg-pNA]* [68223-96-1], $C_{25}H_{40}N_8O_7$, F.W. 564.64, Powder Application(s): Chromogenic substrate for horseshoe crab clotting enzyme, which is used in quantitative assays of endotoxin	**50mg**
J64291	**Ene Reductase Kit - 8 variants (ENR1 through ENR8)** *[EC 1.3.1.44]* Lyophilized powder, Note: Contains 100mg of each variant Application(s): These enzymes perform stereoselective reduction of activated alkenes	**1each**

Stock #	Description	Size
J64706	**Ene Reductase ENR1** *[EC 1.3.1.44]* Lyophilized powder	**250mg** **500mg** **1g**
J65356	**Ene Reductase ENR2** *[EC 1.3.1.44]* Lyophilized powder	**250mg** **500mg** **1g**
J64993	**Ene Reductase ENR3** *[EC 1.3.1.44]* Lyophilized powder	**250mg** **500mg** **1g**
J65028	**Ene Reductase ENR4** *[EC 1.3.1.44]* Lyophilized powder	**250mg** **500mg** **1g**
J64840	**Ene Reductase ENR5** *[EC 1.3.1.44]* Lyophilized powder	**250mg** **500mg** **1g**
J64848	**Ene Reductase ENR6** *[EC 1.3.1.44]* Lyophilized powder	**250mg** **500mg** **1g**
J65955	**Ene Reductase ENR7** *[EC 1.3.1.44]* Lyophilized powder	**250mg** **500mg** **1g**
J64249	**Ene Reductase ENR8** *[EC 1.3.1.44]* Lyophilized powder	**250mg** **500mg** **1g**
J61408	**Leu-Enkephalin** *[H-Tyr-Gly-Gly-Phe-Leu-OH, Dynorphin A (1-5)]* [81678-16-2], $C_{28}H_{37}N_5O_7$, F.W. 555.70, Lyophilized powder Application(s): Endogenous opioid neurotransmitter that is an agonist at mu- and delta-opioid receptors	**25mg**
J63207	**(Ala^2)-Leu-Enkephalin** *[Tyr-Ala-Gly-Phe-Leu]* [60284-47-1], $C_{29}H_{39}N_5O_7$, F.W. 569.66, Lyophilized powder Application(s): An opioid peptide	**25mg** **100mg**
J61859	**(D-Ala^2)-Leu-Enkephalin** *[Tyr-D-Ala-Gly-Phe-Leu]* [64963-01-5], $C_{29}H_{39}N_5O_7$, F.W. 569.66, Lyophilized powder, EINECS 265-291-0, MDL MFCD00076409 Application(s): An opioid peptide	**25mg** **100mg**
J60677	**(Des-Tyr^1)-Leu-Enkephalin** *[Gly-Gly-Phe-Leu]* [60254-83-3], $C_{19}H_{28}N_4O_5$, F.W. 392.46, Lyophilized powder Application(s): An enkephalinase inhibitor	**100mg** **500mg**
J61684	**(Des-Tyr^1)-Met-Enkephalin** *[H-Gly-Gly-Phe-Met-OH]* [61370-88-5], $C_{18}H_{26}N_4O_5S$, F.W. 410.49, Powder Application(s): An enkephalinase inhibitor	**5mg**
J61154	**Met-Enkephalin** *[H-Tyr-Gly-Gly-Phe-Met-OH]* [58569-55-4], $C_{27}H_{35}N_5O_7S$, F.W. 573.67, Powder, EINECS 261-335-8 Application(s): Endogenous opioid peptide that also functions as a growth factor on many cell types at a receptor that is distinct from the neuronal opioid receptors	**25mg** **50mg** **125mg**
J61912	**Enoxacin** *[Penetrex® The Clorox Company, Bactidan]* [74011-58-8], $C_{15}H_{17}FN_4O_3$, F.W. 320.32, Crystalline powder, m.p. 220-224°, Merck **14**,3587, RTECS QN2800000, MDL MFCD00133308 Application(s): A quinolone antibacteral agent which acts on DNA gyrase	**1g** **5g** **25g**
J60023	**Enrofloxacin** *[1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid]* [93106-60-6], $C_{19}H_{22}FN_3O_3$, F.W. 359.39, Powder, m.p. 221-226°, Merck **14**,3592, RTECS VB1993650, BRN 5307824, MDL MFCD00792463	**5g** **25g** **100g**
	Enzymatic Digest of Lactalbumin, see Lactalbumin hydrolysate, J63215, p. 264	

Stock #	Description	Size
J63115	**Enzyme storage buffer in PBS and glycerol, autoclaved** Liquid, Note: This buffer contains 50% Glycerol in PBS. H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): For frozen storage of enzymes.	**125ml** **250ml**
J63264	**Enzyme storage buffer in TBS and glycerol, autoclaved** Liquid, Note: This buffer contains 50% Glycerol in TBS. H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): For frozen storage of enzymes	**125ml** **250ml**
A17377	**Eosin B** *[C.I. 45400, 4,5-Dibromo-2,7-dinitrofluorescein disodium salt]* [548-24-3], $C_{20}H_6Br_2N_2Na_2O_9$, F.W. 624.08, EINECS 208-943-1, MDL MFCD00005041, † Application(s): A counterstain for collagen 	**25g** **100g**
	Eosin-Methylene Blue, see Jenner's Stain, J61077, p. 262	
J62018	**Eosinophilotactic Tetrapeptide (AGSE)** *[Ala-Gly-Ser-Glu]* [61756-28-3], $C_{13}H_{22}N_4O_8$, F.W. 362.40, Powder Application(s): A chemotactic for eosinophils	**5mg**
J61884	**Eosinophilotactic Tetrapeptide (VGDE)** *[H-Val-Gly-Asp-Glu-OH]* [99624-52-9], $C_{16}H_{26}N_4O_9$, F.W. 418.40, Powder Application(s): A chemotactic for eosinophils	**250mg**
J61494	**Eosinophilotactic Tetrapeptide (VGSE)** *[H-Val-Gly-Ser-Glu-OH]* [61756-22-7], $C_{15}H_{26}N_4O_8$, F.W. 390.40, Powder Application(s): A chemotactic for eosinophils	**5mg**
B24535	**Eosin Yellowish** *[Acid Red 87, C.I. 45380]* [17372-87-1], $C_{20}H_6Br_4Na_2O_5$, F.W. 691.86, Merck **14**,3603, Solubility: Soluble in water, fairly soluble in alcohol, insoluble in ether, EINECS 241-409-6, RTECS LM5850000, BRN 3586809, MDL MFCD00133309, † H:H319, P:P280-P264-P305+P351+P338-P337+P313 Adsorption and fluorescence indicator. Application(s): Fluorescent stain for cytoplasm and collagen 	**50g** **250g**
	Epiadriamycin, see Epirubicin hydrochloride, J60411, p. 209	
J61218	**(-)-Epicatechin** *[(-)-cis-3,3',4',5,7-Pentahydroxyflavane, Epicatechol]* [490-46-0], $C_{15}H_{14}O_6$, F.W. 290.27, Crystalline powder, m.p. 240°dec, EINECS 207-710-1, RTECS KB3745000, BRN 92760, MDL MFCD00075648 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An antioxidant and natural product from green tea	**20mg**
J60814	**(-)-Epicatechin gallate** *[(-)-cis-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate, ECG]* [1257-08-5], $C_{22}H_{18}O_{10}$, F.W. 442.37, Powder, RTECS DH9030000, MDL MFCD00075936 Application(s): A natural product from green tea that induces apoptosis	**10mg** **20mg**
	Epicatechol, see (-)-Epicatechin , J61218, p. 208	
A15823	**(±)-Epichlorohydrin, 99%** *[(±)-1-Chloro-2,3-epoxypropane]* [106-89-8], C_3H_5ClO, F.W. 92.53, m.p. -57°, b.p. 115-117°, f.p. 32°(90°F), d. 1.182, n_D^{20} 1.4380, Merck **14**,3611, Fieser **1**,355 **4**,222 **5**,290, UN2023, EINECS 203-439-8, RTECS TX4900000, BRN 79785, MDL MFCD00005132, †  H:H301-H311-H331-H350-H314-H226-H317, P:P301+P310-P303+P361+P353-P305+P351+P338-P361-P405-P501a For use as an acid scavenger in bromination reactions, see: *J. Am. Chem. Soc.*, **95**, 4419 (1973). The preparation of glycidyl ethers, often carried out in two steps, via the ring-opened chlorohydrin ether and subsequent ring-closure with base, can be achieved as a single step, under phase-transfer conditions: *Synthesis*, 117 (1983). For extension to diglycidyl ethers of diols, see: *Synthesis*, 649 (1985). Reaction with primary amines provides a one-step route to 3-azetidinols: *J. Org. Chem.*, **55**, 2920 (1990):  Application(s): A cyclodextrin cross-linking reagent	**100g** **500g** **2.5kg**
J64012	**Epidermal Growth Factor, human, 99%** *[EGF, human]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for cell culture and radioimmunoassays. Supplied as an aseptically lyophilized powder.	**50micrograms**

Stock #	Description	Size
J65329	**Epidermal Growth Factor, mouse submaxillary gland, 99%** *[EGF, mouse]* Note: Receptor Grade. Suitable for cell culture and radioimmunoassays. Supplied as an aseptically lyophilized powder.	**100micrograms** **10x100micrograms**
J64798	**Epidermal Growth Factor, rat, 99%** *[EGF, rat]* Note: Receptor Grade. Suitable for cell culture and radioimmunoassays. Supplied as an aseptically lyophilized powder.	**10micrograms**
J64705	**Epidermal Growth Factor Receptor Peptide (985-996)** *[EGFR Peptide (985-996), Asp-Val-Val-Asp-Ala-Asp-Glu-Tyr-Leu-Ile-Pro-Gln]* $C_{61}H_{93}N_{13}O_{23}$, F.W. 1376.46, Solid	**1mg**
	Epidosin, see Valethamate bromide, 99%, J62622, p. 390	
J61630	**(-)-Epigallocatechin** [970-74-1], $C_{15}H_{14}O_7$, F.W. 306.27, Powder, RTECS KB100000, MDL MFCD00075939 Application(s): A natural product from green tea that induces apoptosis	**10mg**
J61745	**(-)-Epigallocatechin gallate** *[EGCG, 3-O-gallate]* [989-51-5], $C_{22}H_{18}O_{11}$, F.W. 458.40, Powder, m.p. 216-218°, Merck **14**,3526, RTECS KB5200000, MDL MFCD00075940 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An antioxidant that acts as an anti-promoter of carcinogenesis, inhibits angiogenesis and induces apoptosis	**5mg** **10mg** **50mg**
	DL-Epinephrine, see DL-Adrenaline, J63005, p. 80 **L-Epinephrine**, see L-Adrenaline, L04911, p. 80 **Epinine hydrochloride**, see N-Methyldopamine hydrochloride, 98+%, J60306, p. 287	
J60411	**Epirubicin hydrochloride** *[Epiadriamycin]* [56390-09-1], $C_{27}H_{29}NO_{11}{\cdot}HCl$, F.W. 579.98, Solid, m.p. 185°, Merck **14**,3623, EINECS 260-145-2, RTECS QI9295750 H:H302-H361, P:P281-P264-P301+P312-P308+P313-P405-P501 Application(s): Cell-permeable anthracycline anti-tumor antibiotic	**10mg** **100mg**
	trans-Epoxysuccinyl-leucylamido- [4-guanidino]butane, see E-64, J62933, p. 203	
J61538	**EPPS, 0.2M buffer soln., pH 7.0** *[HEPPS]* [16052-06-5], Liquid, †	**100ml** **250ml**
J60511	**EPPS, 0.2M buffer soln., pH 7.5** *[HEPPS]* [16052-06-5], Liquid, †	**100ml** **250ml**
J61296	**EPPS, 0.2M buffer soln., pH 8.0** *[HEPPS]* [16052-06-5], Liquid, †	**100ml** **250ml**
J61476	**EPPS, 0.2M buffer soln., pH 8.5** *[HEPPS]* [16052-06-5], Liquid, †	**100ml** **250ml**
	Epsom salt, see Magnesium sulfate heptahydrate, Cell Culture Grade, J61839, p. 275	
J61383	**(R,S)-Equol** *[4',7-Isoflavandiol]* [94105-90-5], $C_{15}H_{14}O_3$, F.W. 242.27, Crystalline powder, m.p. 151-153°, Merck **14**,3644, BRN 87752, MDL MFCD00016662 Application(s): Urinary metabolite of daidzein, produced by humans and horses	**100mg** **500mg**
J61612	**Erbstatin analog** *[Methyl 2,5-dihydroxycinnamate]* [63177-57-1], $C_{10}H_{10}O_4$, F.W. 194.19, Powder, MDL MFCD00132932 H:H301-H311-H330-H315-H319-H335, P:P301+P310-P304+P340-P305+P351+P338-P320-P330-P361-P405-P501 Application(s): An inhibitor of the EGF receptor associated tyrosine kinase	**1mg** **5mg** **10mg**
	Ergocalciferol, see Calciferol, J61610, p. 142	
B23840	**Ergosterol hydrate, 96% (dry wt.), cont. up to ca 6% water** *[Provitamin D2]* [57-87-4], $C_{28}H_{44}O{\cdot}xH_2O$, F.W. 396.65(anhy), m.p. 154-160°, Merck **14**,3659, UN2811, EINECS 200-352-7, MDL MFCD00003623 H:H300, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A membrane lipid found almost exclusively in fungi. It is used as an indicator of living fungal biomass 	**5g** **25g**

Stock #	Description	Size
J63396	**Eriochrome® Blue Black B** *[C.I. 14640, Mordant Black 3]* [3564-14-5], $C_{20}H_{14}N_2O_5S$, F.W. 416.39, Powder, EINECS 222-639-6, RTECS QK2195000, MDL MFCD00003934, Note: Eriochrome is a registered trademark of Ciba Specialty Chemicals Corp., † H:H319, P:P280-P264-P305+P351+P338-P337+P313	100g 500g
J61780	**Erioglaucine sodium salt** *[C.I. 42090, Acid Blue 9]* [3844-45-9], $C_{37}H_{34}N_2Na_2O_9S_3$, F.W. 792.86, Powder, m.p. 283°, Merck **14**,1373, EINECS 223-339-8, RTECS BQ4725000, MDL MFCD00012141, Note: Dye content: approx 60%, †	5g 25g
J61633	**Erlotinib hydrochloride** [183319-69-9], $C_{22}H_{23}N_3O_4 \cdot HCl$, F.W. 429.90, Powder, Merck **14**,3672, MDL MFCD07781272 Application(s): A selective inhibitor for EGFR tyrosine kinases	1g 2g 5g
	Erythorbic acid, see D-(-)-Isoascorbic acid, 36366, p. 260	
J60146	**Erythrina Christagalli Agglutinin (ECA)** Powder, MDL MFCD00163567 Application(s): Naturally occuring lectin with affinity for D-galactose and D-galactosides	10mg
A15813	**meso-Erythritol, 99%** [149-32-6], $C_4H_{10}O_4$, F.W. 122.12, m.p. 119-124°, b.p. 329-331°, Merck **14**,3675, EINECS 205-737-3, RTECS KF2000000, BRN 1719753, MDL MFCD00004710, † 	25g 100g
J62279	**Erythromycin, Cell Culture Grade** [114-07-8], $C_{37}H_{67}NO_{13}$, F.W. 733.93, Crystalline powder, Merck **14**,3681, EINECS 204-040-1, RTECS KF4375000, BRN 75279, MDL MFCD00084654 Application(s): Macrolide antibiotic that inhibits bacterial protein synthesis	10g 25g
B21093	**D-Erythrose, syrup, ca 70% w/v, >75% dry wt. basis** ■ [583-50-6], $C_4H_8O_4$, F.W. 120.10, n_D^{20} 1.4980, $[\alpha]_D^{20}$ -33° (c=2 in water, 72H), Merck **14**,3690, EINECS 209-505-2, BRN 1721698, MDL MFCD00006970 	250mg 1g
A14180	**Erythrosin B** ▲■ *[C.I. 45430, Tetraiodofluorescein sodium salt]* [568-63-8], $C_{20}H_6I_4Na_2O_5$, F.W. 879.87, EINECS 240-046-0, RTECS LM5950000, MDL MFCD00144257, † H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Acid Red 51 	25g 100g 500g
J62619	**Erythrosin B, spirit soluble** *[C.I. 45430:2, Solvent Red 140]* [15905-32-5], $C_{20}H_8I_4O_5$, F.W. 835.89, Powder, EINECS 240-046-0, RTECS LM5950000, MDL MFCD00005044, †	5g 25g 100g
	Esculetin, see 6,7-Dihydroxycoumarin, A15393, p. 192	
J63114	**Esculin sesquihydrate** *[6,7-Dihydroxycoumarin-6-glucoside]* [66778-17-4], $C_{15}H_{16}O_9 \cdot 1.5H_2O$, F.W. 367.31 (340.29anhy), Powder, m.p. 202-210°, Merck **14**,3698, EINECS 208-517-5, RTECS DJ3085000, MDL MFCD00149492, † Application(s): A naturally occuring antioxidant	5g 25g 100g
A11624	**Esculin sesquihydrate, 97%** *[6,7-Dihydroxycoumarin 6-glucoside sesquihydrate]* [66778-17-4], $C_{15}H_{16}O_9 \cdot 1.5H_2O$, F.W. 367.31 (340.28anhy), m.p. 203-205°, $[\alpha]_D^{20}$ -41° (c=5 in pyridine), Merck **14**,3698, EINECS 208-517-5, BRN 95387, MDL MFCD00149492, † Ultraviolet absorbent. Reversible inhibitor of phenylalanine hydroxylase. Application(s): Inhibits chemically induced carcinogenesis in mouse skin and kidney 	5g 25g 100g
J61477	**Eserine** ▲△ *[Physostigmine]* [57-47-6], $C_{15}H_{21}N_3O_2$, F.W. 275.35, Powder, m.p. 102-104°, Merck **14**,7384, UN1544, EINECS 200-332-8, RTECS TJ2100000, BRN 91230, MDL MFCD00151090, † H:H300-H330, P:P301+P310-P304+P340-P320-P330-P405-P501a Application(s): Inhibitor of acetylcholinesterase that crosses the blood-brain barrier	100mg
J64957	**Esterase Kit - 30 variants (E1 through E30)** Lyophilized powder, Note: Contains 100mg of each variant Application(s): Enzymes perform enantioselective hydrolysis on esters of primary, secondary and tertiary alcohols. Useful in the resolution of racemic mixtures of alcohols or carboxylic acids	1each

Contact us for pricing on bulk sizes

Stock #	Description	Size
J65256	**Esterase Kit - 50 variants (E1 through E50)** Lyophilized powder, Note: Contains 100mg of each variant Application(s): Enzymes perform enantioselective hydrolysis on esters of primary, secondary and tertiary alcohols. Useful in the resolution of racemic mixtures of alcohols or carboxylic acids	**1each**
J64051	**Esterase E1** Lyophilized powder	**250mg** **500mg** **1g**
J64600	**Esterase E2** Lyophilized powder	**250mg** **500mg** **1g**
J64099	**Esterase E3** Lyophilized powder	**250mg** **500mg** **1g**
J64204	**Esterase E4** Lyophilized powder	**250mg** **500mg** **1g**
J64799	**Esterase E5** Lyophilized powder	**250mg** **500mg** **1g**
J65545	**Esterase E6** Lyophilized powder	**250mg** **500mg** **1g**
J64561	**Esterase E7** Lyophilized powder	**250mg** **500mg** **1g**
J65370	**Esterase E8** Lyophilized powder	**250mg** **500mg** **1g**
J65259	**Esterase E9** Lyophilized powder	**250mg** **500mg** **1g**
J64621	**Esterase E10** Lyophilized powder	**250mg** **500mg** **1g**
J64909	**Esterase E11** Lyophilized powder	**250mg** **500mg** **1g**
J65558	**Esterase E12** Lyophilized powder	**250mg** **500mg** **1g**
J64470	**Esterase E13** Lyophilized powder	**250mg** **500mg** **1g**
J65303	**Esterase E14** Lyophilized powder	**250mg** **500mg** **1g**
J64246	**Esterase E15** Lyophilized powder	**250mg** **500mg** **1g**
J65461	**Esterase E16** Lyophilized powder	**250mg** **500mg** **1g**
J64745	**Esterase E17** Lyophilized powder	**250mg** **500mg** **1g**
J65471	**Esterase E18** Lyophilized powder	**250mg** **500mg** **1g**

Stock #	Description	Size
J65011	**Esterase E19** Lyophilized powder	**250mg** **500mg** **1g**
J65827	**Esterase E20** Lyophilized powder	**250mg** **500mg** **1g**
J65920	**Esterase E21** Lyophilized powder	**250mg** **500mg** **1g**
J65381	**Esterase E22** Lyophilized powder	**250mg** **500mg** **1g**
J65877	**Esterase E23** Lyophilized powder	**250mg** **500mg** **1g**
J65574	**Esterase E24** Lyophilized powder	**250mg** **500mg** **1g**
J65095	**Esterase E25** Lyophilized powder	**250mg** **500mg** **1g**
J65305	**Esterase E26** Lyophilized powder	**250mg** **500mg** **1g**
J64649	**Esterase E27** Lyophilized powder	**250mg** **500mg** **1g**
J64423	**Esterase E28** Lyophilized powder	**250mg** **500mg** **1g**
J64114	**Esterase E29** Lyophilized powder	**250mg** **500mg** **1g**
J65629	**Esterase E30** Lyophilized powder	**250mg** **500mg** **1g**
J65947	**Esterase E31** Lyophilized powder	**250mg** **500mg** **1g**
J64648	**Esterase E32** Lyophilized powder	**250mg** **500mg** **1g**
J64873	**Esterase E33** Lyophilized powder	**250mg** **500mg** **1g**
J64918	**Esterase E34** Lyophilized powder	**250mg** **500mg** **1g**
J65872	**Esterase E35** Lyophilized powder	**250mg** **500mg** **1g**
J64294	**Esterase E36** Lyophilized powder	**250mg** **500mg** **1g**
J65979	**Esterase E37** Lyophilized powder	**250mg** **500mg** **1g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64625	**Esterase E38** Lyophilized powder	**250mg** **500mg** **1g**
J64309	**Esterase E39** Lyophilized powder	**250mg** **500mg** **1g**
J65606	**Esterase E40** Lyophilized powder	**250mg** **500mg** **1g**
J64195	**Esterase E41** Lyophilized powder	**250mg** **500mg** **1g**
J65327	**Esterase E42** Lyophilized powder	**250mg** **500mg** **1g**
J65708	**Esterase E43** Lyophilized powder	**250mg** **500mg** **1g**
J65401	**Esterase E44** Lyophilized powder	**250mg** **500mg** **1g**
J65797	**Esterase E45** Lyophilized powder	**250mg** **500mg** **1g**
J64480	**Esterase E46** Lyophilized powder	**250mg** **500mg** **1g**
J65296	**Esterase E47** Lyophilized powder	**250mg** **500mg** **1g**
J64021	**Esterase E48** Lyophilized powder	**250mg** **500mg** **1g**
J65278	**Esterase E49** Lyophilized powder	**250mg** **500mg** **1g**
J64298	**Esterase E50** Lyophilized powder	**250mg** **500mg** **1g**
J63684	**Ethacrynic acid** *[(2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid]* [58-54-8], $C_{13}H_{12}Cl_2O_4$, F.W. 303.14, Crystalline powder, Merck **14**,3717, EINECS 200-384-1, RTECS AG6600000, MDL MFCD00056693 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Diuretic that acts by inhibiting sodium-potassium-chloride cotransport	**1g**
J60695	**Ethambutol dihydrochloride** *[2,2'-(1,2-Ethanediyldiimino)bis-1-butanol dihydrochloride, 1,2 Dimercaptoethane]* [1070-11-7], $C_{10}H_{24}N_2O_2$, F.W. 204.31, Powder, Merck **14**,3720, EINECS 213-970-7, RTECS EL3854000, MDL MFCD00216025 H:H360, P:P281-P201-P202-P308+P313-P405-P501 Application(s): An antibacterial agent	**25g**
	1,2-Ethanediamine, see Ethylenediamine, A12132, p. 215 **1,2-Ethanediol**, see Ethylene glycol, A11591, p. 216	
A11697	**Ethanolamine, 98+%** △ ■ *[2-Aminoethanol, 2-Hydroxyethylamine]* [141-43-5], $HOCH_2CH_2NH_2$, F.W. 61.08, m.p. 10°, b.p. 169-170°, f.p. 93°(199°F), d. 1.012, n_D^{20} 1.4540, Merck **14**,3727, Fieser **1**,357 **2**,189 **4**,222 **16**,162, UN2491, EINECS 205-483-3, RTECS KJ5775000, BRN 505944, MDL MFCD00008183, † H:H314-H302-H312-H332, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Reagent for the demethylation of quaternary ammonium salts formed by the exhaustive methylation of aromatic amines, providing a route to N,N-dimethyl arylamines: *Org. Synth. Coll.*, **5**, 1018 (1973). Base for the cleavage of Fmoc protecting groups: *J. Am. Chem. Soc.*, **92**, 5748 (1970); *J. Org. Chem.*, **37**, 3404 (1972).	**250g** **500g** **2.5kg**

Stock #	Description	Size
	Ethanoyl chloride, see Acetyl chloride, 43262, p. 71	
J62029	**Ethidium bromide soln., 0.625mg/ml** [1239-45-8], $C_{21}H_{20}BrN_3$, F.W. 394.31, Dropper bottle, Merck **14**,4731, UN2810, EINECS 214-984-6, RTECS SF7950000, Note: 0.625 mg/ml ethidium bromide solution H:H341, P:P281-P201-P202-P308+P313-P405-P501a Application(s): For visualization of DNA in gel electrophoresis	**5ml**
J62282	**Ethidium bromide soln., 10mg/ml** [1239-45-8], $C_{21}H_{20}BrN_3$, F.W. 394.32, Dropper bottle, Merck **14**,4731, UN2810, EINECS 214-984-6, RTECS SF7950000, MDL MFCD00011724 H:H341, P:P281-P201-P202-P308+P313-P405-P501a Application(s): For visualization of DNA in gel electrophoresis	**10ml**
L07482	**Ethidium bromide, 98% (dry wt.)** *[3,8-Diamino-5-ethyl-6-phenylphenanthridinium bromide, Homidium bromide]* [1239-45-8], $C_{21}H_{20}BrN_3$, F.W. 394.32, m.p. ca 261° dec., Merck **14**,4731, UN2811, EINECS 214-984-6, RTECS SF7950000, BRN 3642536, MDL MFCD00011724, Note: Special handling precautions required. View MSDS prior to purchase. MSDS are available online at www.alfa.com  H:H330-H341-H302, P:P260-P304+P340-P320-P330-P405-P501a Intercalation agent for DNA. Reviews: J.-B. Le Pecq, *Methods of Biochemical Analysis*, vol. **20**, Wiley, N.Y. (1971), p41; M. Waring, *Antibiotics*, vol. **3**, Springer-Verlag (1975), p141. Application(s): For DNA isolation and visualization	**1g** **5g**
J62931	**Ethidium bromide de-staining bags**	**25each**
J63580	**Ethisterone, 98%** *[Lutocyclin, 17α-Ethynyltestosterone]* [434-03-7], $C_{21}H_{28}O_2$, F.W. 312.45, Powder, m.p. 263-269°, Merck **14**,3741, EINECS 207-096-5, RTECS TU5570250, BRN 1889895, MDL MFCD00003656 H:H351, P:P281-P201-P202-P308+P313-P405-P501 Application(s): A progestogen that counteracts the estrogenic proliferative effect on the endometrium	**5g** **25g**
L09327	**N(α)-Ethoxycarbonyl-L-asparagine, 97%** *[N(alpha)-Carbethoxy-L-asparagine, N(alpha)-Carboethoxy-L-asparagine]* [16639-91-1], $C_7H_{12}N_2O_5$, F.W. 204.18, m.p. ca 166° dec., BRN 1712104, MDL MFCD00082761 	**1g** **5g**
A16100	**2-Ethoxyethanol, 99%** *[Cellosolve, Ethylene glycol monoethyl ether]* [110-80-5], $CH_3CH_2OCH_2CH_2OH$, F.W. 90.12, m.p. -90°, b.p. 134-135°, f.p. 44°(111°F), d. 0.931, n_D^{20} 1.4085, Merck **14**,3750, UN1171, EINECS 203-804-1, RTECS KK8050000, BRN 1098271, MDL MFCD00002869, † H:H360FD-H226-H302-H312-H332, P:P210-P241-P303+P361+P353-P302+P352-P405-P501a Application(s): A widely used solvent for nitrocelluloses and dyes	**500ml** **2.5L**
	2-(2-Ethoxyethoxy)ethanol, see Diethylene glycol monoethyl ether, A14670, p. 189 **2-(2-Ethoxyethoxy)ethyl acetate**, see Diethylene glycol monoethyl ether acetate, L13446, p. 189 **2-Ethoxyethyl ether**, see Diethylene glycol diethyl ether, 43464, p. 189 **7-Ethoxy-3H-phenoxazin-3-one**, see 7-Ethoxyresorufin, J62987, p. 214	
J62987	**7-Ethoxyresorufin** *[Resorufin ethyl ether, 7-Ethoxy-3H-phenoxazin-3-one]* [5725-91-7], $C_{14}H_{11}NO_3$, F.W. 241.24, Powder, m.p. 237-240°, BRN 225973, MDL MFCD00037661 Application(s): Fluorimetric substrate for detection of cytochrome P450 linked enzymes	**5mg**
A12754	**Ethyl 4-aminobenzoate, 98%** *[H-4-Abz-OEt, 4-Aminobenzoic acid ethyl ester]* [94-09-7], $C_9H_{11}NO_2$, F.W. 165.19, m.p. 88-92°, b.p. 310°, f.p. >110°(230°F), Merck **14**,1086, EINECS 202-303-5, RTECS DG2450000, BRN 638434, MDL MFCD00007892, †  H:H319-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a	**250g** **1kg** **5kg**
	(R)-(+)-α-Ethylbenzyl alcohol, see (R)-(+)-1-Phenyl-1-propanol, L05681, p. 318 **(S)-(-)-α-Ethylbenzyl alcohol**, see (S)-(-)-1-Phenyl-1-propanol, L06608, p. 318 **(R)-(+)-α-Ethylbenzylamine**, see (R)-(+)-1-Phenylpropylamine, L16319, p. 318 **(S)-(-)-α-Ethylbenzylamine**, see (S)-(-)-1-Phenylpropylamine, L16320, p. 318	
J60862	**Ethyl (R)-4-bromo-3-hydroxybutyrate** *[(R)-4-Bromo-3-hydroxybutyric acid ethyl ester]* [95310-48-8], $C_6H_{11}BrO_3$, F.W. 211.06, Liquid Application(s): For synthesis of optically active products	**Call**
J62782	**Ethyl (S)-4-bromo-3-hydroxybutyrate** *[(S)-4-Bromo-3-hydroxybutyric acid ethyl ester]* [95537-36-3], $C_6H_{11}BrO_3$, F.W. 211.06, Liquid Application(s): For synthesis of optically active products	**1g**

Stock #	Description	Size
J60405	**5'-N-Ethylcarboxamidoadenosine** *[NECA]* [35920-39-9], $C_{12}H_{16}N_6O_4$, F.W. 308.29, Powder, m.p. 229-231°, UN2811, RTECS VJ2232000, MDL MFCD00069195 H:H300, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Potent adenosine receptor agonist with some affinity at A1 and A2 receptors	**10mg** **50mg**
H27621	**Ethyl cellulose** [9004-57-3], d. 1.14, n_D^{20} 1.47, RTECS FJ5950500, MDL MFCD00131037, †	**250mg**
	Ethyl 2-(4-chlorophenoxy)isobutyrate, see Clofibrate, 95+%, J60342, p. 165 **Ethyl digol**, see Diethylene glycol monoethyl ether, A14670, p. 189 **1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid**, see Nalidixic acid, B25096, p. 297 **N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride**, see 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, A10807, p. 196 **Ethylenebis(oxyethylenenitrilo)tetraacetic acid**, see Ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid, A16086, p. 216 **Ethylene chloride**, see 1,2-Dichloroethane, 39121, p. 185	
A12132	**Ethylenediamine, 99%** △ *[1,2-Diaminoethane, 1,2-Ethanediamine]* [107-15-3], $H_2NCH_2CH_2NH_2$, F.W. 60.10, m.p. 8-11°, b.p. 117-118°, f.p. 38°(100°F), d. 0.899, n_D^{20} 1.4565, Merck **14**,3795, Fieser **1**,372 **4**,231 **13**,157, Solubility: Soluble in water, alcohol. Slightly soluble in ether, UN1604, EINECS 203-468-6, RTECS KH8575000, BRN 605263, MDL MFCD00008204, † H:H334-H314-H226-H302-H312-H317, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a The Li derivative in excess amine is a strong base for the rearrangement of primary allylic alcohols to the isomeric aldehydes in high yield: *J. Chem. Soc., Chem. Commun.*, 812 (1985). At high temperatures, reduces nitroarenes to azo-compounds. Reaction does not occur for nitro-compounds with o-substituents or p-amino-substituents: *J. Org. Chem.*, **49**, 1215 (1984). The ethylenediamine complex of Cr^{2+} reduces aryl bromides to the hydrocarbons. For an example, see: *Org. Synth. Coll.*, **6**, 821 (1988). Application(s): Strongly basic amine useful as a building block in chemical synthesis	**100ml** **500ml** **2.5L** **10L**
J63570	**Ethylenediamine-N,N'-diacetic acid** *[N,N'-Ethylenediglycine, EDDA]* [5657-17-0], $HOOCCH_2NHCH_2CH_2NHCH_2COOH$, F.W. 176.17, Powder, m.p. 224°, EINECS 227-105-6, BRN 1778355, MDL MFCD00004281, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Acts as a chelating agent	**5g** **25g**
J62786	**Ethylenediaminetetraacetic acid, 0.5M aq. soln, pH 8.0** *[EDTA]* [60-00-4], $(HO_2CCH_2)_2NCH_2CH_2N(CH_2CO_2H)_2$, F.W. 292.24, Liquid, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**250ml** **500ml**
J60292	**Ethylenediaminetetraacetic acid, 0.5M aq. soln., pH 8.0, autoclaved** *[EDTA]* [60-00-4], $(HO_2CCH_2)_2NCH_2CH_2N(CH_2CO_2H)_2$, F.W. 292.24, Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**250ml** **500ml**
A10713	**Ethylenediaminetetraacetic acid, 99%** *[Edetic acid, EDTA]* [60-00-4], $(HO_2CCH_2)_2NCH_2CH_2N(CH_2CO_2H)_2$, F.W. 292.24, m.p. ca 245° dec., Merck **14**,3517, Fieser **1**,373, EINECS 200-449-4, RTECS AH4025000, BRN 1716295, MDL MFCD00003541, † H:H319, P:P305+P351+P338 Widely-used complexing agent for many cations.	**500g** **1kg** **5kg**
11931	**Ethylenediaminetetraacetic acid, ACS, 99.4+%** *[Edetic acid, EDTA]* [60-00-4], $(HO_2CCH_2)_2NCH_2CH_2N(CH_2CO_2H)_2$, F.W. 292.24, Powder, m.p. ca 245° dec., Merck **14**,3517, Fieser **1**,373, EINECS 200-449-4, RTECS AH4025000, BRN 1716295, MDL MFCD00003541, † Maximum level of impurities: Insoluble in dilute ammonium hydroxide 0.005%, Residue after ignition 0.2%, $[(HOCOCH_2)_3N]$ 0.1%, Ca 0.001%, Heavy Metals (as Pb) 0.001%, Fe 0.005%, Mg 5ppm H:H319, P:P305+P351+P338 Application(s): Chelating agent	**100g** **500g** **2.5kg**
J65585	**Ethylenediaminetetraacetic acid, Electrophoresis Grade, 99.4+%** *[Edetic acid, EDTA]* [60-00-4], $C_{10}H_{16}N_2O_8$, F.W. 292.24, Powder, m.p. ca 245° dec., Merck **14**,3517, EINECS 200-449-4, RTECS AH4025000, BRN 1716295, MDL MFCD00003541, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100g** **500g** **2.5kg**
J62948	**Ethylenediaminetetraacetic acid, Cell Culture Reagent** *[EDTA]* [60-00-4], $C_{10}H_{16}N_2O_8$, F.W. 292.24, Powder, Merck **14**,3517, EINECS 200-449-4, RTECS AH4025000, BRN 1716295, MDL MFCD00003541, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**500g** **1kg**

Stock #	Description	Size
33312	**Ethylenediaminetetraacetic acid disodium salt dihydrate, ACS, 99.0-101.0%** *[EDTA disodium salt dihydrate]* [6381-92-6], $(NaO_2CCH_2)_2NCH_2CH_2N(CH_2CO_2H)_2 \cdot 2H_2O$, F.W. 372.24 (336.22anhy), Powder, m.p. 248° dec., Fieser **1**,373, EINECS 205-358-3, RTECS AH4375000, BRN 3900609, MDL MFCD00150037, † Maximum level of impurities: Insoluble matter 0.005%, pH of a 5% solution 4.0-6.0 at 25°, $[(HOCOCH_2)_3N]$ 0.1%, Heavy Metals (as Pb) 0.005%, Fe 0.01%	100g 500g
A17385	**Ethylenediaminetetraacetic acid tetrasodium salt hydrate, 98%** *[EDTA tetrasodium salt hydrate]* [194491-31-1], $C_{10}H_{12}N_2Na_4O_8 \cdot xH_2O$, F.W. 380.17(anhy), m.p. >300°, EINECS 200-573-9, RTECS AH5075000, BRN 3828865, MDL MFCD00150025, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Complexing agent for many cations.	250g 1kg 5kg
H56165	**Ethylenediaminetetraacetic acid trisodium salt hydrate, 99%** *[EDTA trisodium salt hydrate]* [85715-60-2], $C_{10}H_{13}N_2Na_3O_8 \cdot xH_2O$, F.W. 358.19, m.p. >300°, EINECS 205-758-8, MDL MFCD00149675 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	250g 500g
	Ethylene dibromide, see 1,2-Dibromoethane, A12766, p. 184 **N,N'-Ethylenediglycine**, see Ethylenediamine-N,N'-diacetic acid, J63570, p. 215	
A11591	**Ethylene glycol, 99% ■** *[1,2-Dihydroxyethane, 1,2-Ethanediol]* [107-21-1], $HOCH_2CH_2OH$, F.W. 62.07, m.p. -13°, b.p. 196-198°, f.p. 119°(246°F), d. 1.113, n_D^{20} 1.4310, Merck **14**,3798, Fieser **1**,375 **5**,296 **9**,217 **15**,156 **18**,157, EINECS 203-473-3, RTECS KW2975000, BRN 505945, MDL MFCD00002885, † ! H:H302, P:P264-P270-P301+P312-P330-P501a For examples of use in acetal (1,3-dioxolane) formation, catalyzed by tosic acid with azeotropic water removal, see: *Org. Synth. Coll.*, **6**, 567 (1988); **7**, 241, 271 (1990). A mild dehydrating agent, e.g. triethyl orthoformate may be used as an alternative: *J. Org. Chem.*, **48**, 2122 (1983). PPTS (**Pyridinium p-toluenesulfonate**, **A15708**) has been recommended as a catalyst for the formation and cleavage of ethylene acetals, being less likely to cause acid-catalyzed rearrangements than tosic acid itself: *Synthesis*, 724 (1979). For acetalization of α,β-enals, tartaric acid in the presence of anhydrous $MgSO_4$ gives good results: *J. Org. Chem.*, **60**, 2931 (1995). Review of the preparation of acetals: *Synthesis*, 501 (1981). See also **2,2-Dimethyl-1,3-dioxolane**, **L00482**. In combination with TMS chloride, α,β-enones are converted to β-chloro acetals in one step: *Tetrahedron Lett.*, **25**, 3805 (1984).	250g 500g 2.5kg 10kg
J60767	**Ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid, 0.5M aq. soln., pH 8.0** *[EGTA]* [67-42-5], $C_{14}H_{24}N_2O_{10}$, F.W. 380.35, Liquid, †	50ml 100ml
J61721	**Ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid, 0.5M aq. soln., pH 8.0, autoclaved** *[EGTA]* [67-42-5], $C_{14}H_{24}N_2O_{10}$, F.W. 380.35, Liquid, †	50ml 100ml
A16086	**Ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid, 97%** *[EGTA, Ethylenebis(oxyethylenenitrilo)tetraacetic acid]* [67-42-5], $C_{14}H_{24}N_2O_{10}$, F.W. 380.35, m.p. ca 242° dec., Merck **14**,3529, EINECS 200-651-2, RTECS AH3760000, BRN 1717370, MDL MFCD00004291, † Reagent for complexometry.	10g 50g 250g
	Ethylene glycol ethyl ether, see 2-Ethoxyethanol, A16100, p. 214 **Ethylene glycol monoethyl ether**, see 2-Ethoxyethanol, A16100, p. 214 **1-Ethyl-2-[(E)-3-(1-ethylnaphtho[1,2-d]thiazolin-2-ylidene)-2-methylpropenyl]naphtho[1,2-d]thiazolium bromide**, see Stains-All, H32127, p. 352 **Ethyl glycol**, see 2-Ethoxyethanol, A16100, p. 214 **(±)-N-[4-(4-[Ethyl(n-heptyl)amino]-1-hydroxybutyl)phenyl]methanesulfonamide hemifumarate salt**, see Ibutilide hemifumarate salt, H56358, p. 253	
A13172	**Ethyl 4-hydroxybenzoate, 99%** *[Ethylparaben, 4-Hydroxybenzoic acid ethyl ester]* [120-47-8], $C_9H_{10}O_3$, F.W. 166.18, m.p. 116-118°, b.p. 297-298° dec., Merck **14**,3837, EINECS 204-399-4, RTECS DH2190000, BRN 1101972, MDL MFCD00002353, † H:H303, P:P312	250g 1kg 5kg
J63400	**Ethyl (R)-(-)-3-hydroxybutyrate** *[(R)-(-)-3-Hydroxybutyric acid ethyl ester]* [24915-95-5], $C_6H_{12}O_3$, F.W. 132.16, Liquid, MDL MFCD00075386 Application(s): For synthesis of optically active products	1g 5g
J63184	**Ethyl (S)-(-)-3-hydroxybutyrate** *[(S)-(-)-3-Hydroxybutyric acid ethyl ester]* [56816-01-4], $C_6H_{12}O_3$, F.W. 132.16, Liquid, EINECS 260-393-1 H:H227, P:P210-P280-P370+P378a-P403+P235-P501a Application(s): For synthesis of optically active products	1g 5g

Contact us for pricing on bulk sizes

Stock #	Description	Size
L00355	**N-Ethylmaleimide, 98+%** *[1-Ethyl-1H-pyrrole-2,5-dione, NEM]* [128-53-0], $C_6H_7NO_2$, F.W. 125.13, m.p. 43-46°, b.p. 209-211°, f.p. 73°(163°F), Merck **14**,3822, UN2928, EINECS 204-892-4, RTECS UX9625000, BRN 112448, MDL MFCD00005509, †  H:H300-H311-H314-H317, P:P280-P305+P351+P338-P302+P352-P309-P310 Reactive dienophile and dipolarophile. Reagent for modification of sulfhydryl groups of cysteine residues in proteins: *Methods Enzymol.*, **25**, 449 (1972); *Eur. J. Biochem.*, **145**, 245 (1984). Application(s): Cysteine alkylating agent	**10g** **50g**
	2-(Ethylmercuriomercapto)benzoic acid sodium salt, see Thimerosal, J61799, p. 366	
L08218	**Ethyl 3-methyl-2-thionoimidazoline-1-carboxylate, 97% ▲** *[Carbimazole, 3-Methyl-2-thionoimidazoline-1-carboxylic acid ethyl ester]* [22232-54-8], $C_7H_{10}N_2O_2S$, F.W. 186.24, m.p. 122-126°, Merck **14**,1798, EINECS 244-854-4, RTECS NJ2441000, BRN 144339, MDL MFCD00027421  H:H302-H319-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a Application(s): A thyroid inhibitor	**5g** **25g** **100g**
J62863	**Ethyl Orange sodium salt** *[4-(4-Diethylaminophenylazo)benzene-sulfonic acid sodium salt]* [62758-12-7], $(C_2H_5)_2NC_6H_4N{=}NC_6H_4SO_3Na$, F.W. 355.39, Powder, EINECS 263-716-4, BRN 3821641, MDL MFCD00007503, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Indicator: pH 3.0 (red) to pH 4.5 (yellow)	**100g** **500g**
	Ethylparaben, see Ethyl 4-hydroxybenzoate, A13172, p. 216	
A14156	**Ethyl phenoxyacetate, 99%** *[Phenoxyacetic acid ethyl ester]* [2555-49-9], $C_6H_5OCH_2CO_2CH_2CH_3$, F.W. 180.20, b.p. 251-253°, f.p. >110°(230°F), d. 1.108, n_D^{20} 1.5055, EINECS 219-867-3, BRN 1871712, MDL MFCD00026895, †	**10g** **50g** **250g**
J61826	**2-Ethyl-5-phenylisoxazolium-3'-sulfonate** *[Woodward's Reagent K, NEPIS]* [4156-16-5], $C_{11}H_{11}NO_4S$, F.W. 253.30, Powder, Merck **14**,10050, EINECS 223-988-7 Application(s): Used to modify carboxyl groups of enzymes	**250mg** **1g**
	N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide, see Tropicamide, 99+%, J61132, p. 383 **1-Ethyl-1H-pyrrole-2,5-dione**, see N-Ethylmaleimide, L00355, p. 217	
J63446	**Ethyl Red** *[4-(Diethylamino)azobenzene-2'-carboxylic Acid]* [76058-33-8], $C_{17}H_{19}N_3O_2$, F.W. 297.36, Powder, m.p. ca 135° dec, BRN 3366056, MDL MFCD00002427 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Indicator: pH 4.5 (red) to pH 6.5 (yellow)	**25g** **100g**
J63951	**Ethyl Violet** *[C.I. 42600, Basic Violet 4]* [2390-59-2], $C_{31}H_{42}ClN_3$, F.W. 492.15, Powder, EINECS 219-231-5, RTECS KH2682000, BRN 4117566, MDL MFCD00011765, Note: Dye content approx. 80%, †	**25g** **100g**
	17a-Ethynyltestosterone, see Ethisterone, 98%, J63580, p. 214 **ETI**, see 5,8,11,-Eicosatriynoic acid, J60414, p. 204	
J62381	**Etidronate disodium** *[Etidronic acid, disodium salt]* [7414-83-7], $C_2H_8Na_2O_7P_2$, F.W. 249.99, Crystalline solid, m.p. >300°, Merck **14**,3863, EINECS 231-025-7, MDL MFCD00152567, † H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A bisphosphonate bone resorption inhibitor	**1g**
	Etidronic acid, disodium salt, see Etidronate disodium, J62381, p. 217	
J63651	**Etoposide** [33419-42-0], $C_{29}H_{32}O_{13}$, F.W. 588.56, Powder, m.p. 236-251°, Merck **14**,3886, EINECS 251-509-1, RTECS KC0190000, MDL MFCD00869325 H:H302-H350, P:P281-P264-P301+P312-P308+P313-P405-P501 Application(s): Topoisomerase inhibitor and inducer of apoptosis	**25mg** **100mg**
	ETYA, see 5,8,11,14-Eicosatetraynoic acid, J61624, p. 204 **Eucalyptol**, see 1,8-Cineole, A12269, p. 163 **Euflavine**, see Acriflavine hydrochloride, J60048, p. 76	
A14332	**Eugenol, 99%** *[4-Allyl-2-methoxyphenol, 4-Allylguaiacol]* [97-53-0], $C_{10}H_{12}O_2$, F.W. 164.21, m.p. -10°, b.p. 252-253°, f.p. 127°(260°F), d. 1.068, n_D^{20} 1.5410, Merck **14**,3898, EINECS 202-589-1, RTECS SJ4375000, BRN 1366759, MDL MFCD00008654, †  H:H302-H315-H319-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a Application(s): Internal standard in GC assays for presence of thymol in biological samples	**100g** **500g**

Stock #	Description	Size
A16774	**Evans Blue** *[C.I. 23860]* [314-13-6], $C_{34}H_{24}N_6Na_4O_{14}S_4$, F.W. 960.82, Merck **14**,3905, EINECS 206-242-5, MDL MFCD00004021, Note: Dye content: approx. 85%., † H:H351, P:P281-P201-P202-P308+P313-P405-P501a  Application(s): Direct Blue 53. Inhibits L-glutamate uptake, and AMPA and kainate receptor currents	**10g** **50g**
J60139	**Everolimus** [159351-69-6], $C_{53}H_{83}NO_{14}$, F.W. 958.22, Powder, Merck **14**,3907, MDL MFCD07785165 H:H372, P:P260-P264-P270-P314-P501 Application(s): A rapamycin analog	**5mg** **10mg** **25mg**
J62771	**Evodiamine** [518-17-2], $C_{19}H_{17}N_3O$, F.W. 303.40, Solid, Merck **14**,3908 Application(s): A vanilloid receptor agonist that induces apoptosis in leukemia U937 cells	**10mg** **50mg**
J64753	**EX 527** *[6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide]* [49843-98-3], $C_{13}H_{13}ClN_2O$, F.W. 248.71, Powder, MDL MFCD03009471 H:H302-H319, P:P280-P264-P305+P351+P338-P301+P312-P337+P313-P501	**50mg**
J61478	**Experimental Allergic Encephalitogenic Peptide, human** *[Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-Arg]* [29705-92-8], $C_{46}H_{64}N_{14}O_{14}$, F.W. 1037.20, Lyophilized powder Application(s): Active fragment of the myelin basic protein. Induces experimental allergic encephalomyelitis	**1mg** **5mg**
J61052	**Extracellular Death Factor trifluoroacetate salt** *[EDF, H-Asn-Asn-Trp-Asn-Asn-OH]* [960129-66-2], $C_{27}H_{36}N_{10}O_{10}.C_2HF_3O_2$, F.W. 774.66, Lyophilized powder Application(s): Useful to study mediated bacterial cell death	**5mg**
	Factor I, see Fibrinogen, bovine, J63276, p. 220 **Factor IIa**, see Thrombin, bovine plasma, J63383, p. 368	
J63878	**Factor XA protease digestion buffer** Liquid, Note: 20mM Tris-HCl, 50mM NaCl and 1mM calcium chloride, pH 8.0 Application(s): For His-tag protein purification from mammalian cells	**250ml**
	FAD-Na2, see Flavin adenine dinucleotide disodium salt hydrate, A14495, p. 221	
J63165	**Famotidine, 98+%** [76824-35-6], $C_8H_{15}N_7O_2S_3$, F.W. 337.45, Powder, m.p. 166-168°, Merck **14**,3930, RTECS UA2300000, MDL MFCD00079297 Application(s): A competitive histamine H2 receptor antagonist	**1g** **5g** **25g**
	Fampridine, see 4-Aminopyridine, 99+%, J61470, p. 99	
A19316	**Farnesol, mixture of isomers, 96%** ▲ *[3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol]* [4602-84-0], $C_{15}H_{26}O$, F.W. 222.37, b.p. 159-160°/10mm, f.p. 146°(295°F), d. 0.887, n_D^{20} 1.4890, Merck **14**,3937, EINECS 225-004-1, RTECS JR4979000, BRN 1763926, MDL MFCD00002918, † H:H319, P:P305+P351+P338  Application(s): Induces apoptosis in cell cultures	**5g** **25g** **100g**
A19778	**Farnesyl acetate, mixture of isomers, 96%** [29548-30-9], $C_{17}H_{28}O_2$, F.W. 264.41, f.p. 95°(203°F), d. 0.91, n_D^{20} 1.477, EINECS 249-689-1, BRN 1784823, MDL MFCD00036516, † 	**25g** **100g**
J62456	**Fast Blue BB base** *[C.I. 37175, 4'-Amino-2',5'-diethoxybenzanilide]* [120-00-3], $C_{17}H_{20}N_2O_3$, F.W. 300.35, Powder, m.p. 98-100°, EINECS 204-363-8, BRN 3416889, MDL MFCD00009091, † H:H315-H318-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): C.I. 37175	**25g** **100g**
L09704	**Fast Blue BB salt** ▲ *[4-Benzamido-2,5-diethoxybenzene diazonium chloride hemi zinc salt, C.I. 37175]* [5486-84-0], $C_{34}H_{36}Cl_4N_6O_6Zn$, F.W. 831.89, m.p. ca 157° dec., EINECS 226-817-4, BRN 1845288, MDL MFCD00074765, † 	**1g** **5g** **25g**
J60574	**Fast Garnet GBC base** *[C.I. 11160, Solvent Yellow 3]* [97-56-3], $CH_3C_6H_4N{=}NC_6H_3(CH_3)NH_2$, F.W. 225.29, Powder, m.p. 101-102°, Merck **14**,420, EINECS 202-591-2, RTECS XU8800000, BRN 6506005, MDL MFCD00007733, † H:H317-H350, P:P261-P280-P302+P352-P321-P405-P501 Application(s): C.I. 11160	**100g** **500g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A16520	**Fast Green FCF** ■ *[C.I. 42053]* [2353-45-9], $C_{37}H_{34}N_2Na_2O_{10}S_3$, F.W. 808.86, m.p. ca 290° dec., Merck **14**,3941, EINECS 219-091-5, RTECS BQ4425000, BRN 5718212, MDL MFCD00013053, † H:H341, P:P281-P201-P202-P308+P313-P405-P501a  Application(s): Stain for showing collagen, muscle, cytoplasm and cells in mammalian tissues	**5g** **25g** **100g**
J63525	**Fasudil, 98+%** *[HA-1077]* [103745-39-7], $C_{14}H_{17}N_3O_2S$, F.W. 327.83, Crystalline powder, Merck **14**,3942 Application(s): A potent Rho-kinase inhibitor with antivasospastic properties; inhibits vascular smooth muscle contraction by acting as an intracellular calcium antagonist	**10mg** **50mg**
J60594	**Fasudil dihydrochloride, 99+%** *[HA-1077 dihydrochloride]* [203911-27-7], $C_{14}H_{17}N_3O_2S{\cdot}2HCl$, F.W. 364.29, Powder, Merck **14**,3942, RTECS HM4031166, MDL MFCD00153805 Application(s): A vasodilator agent which inhibits vascular smooth muscle contraction by acting as an intracellular calcium antagonist	**250mg** **500mg** **1g**
J60751	**Fasudil monohydrochloride, 99+%** *[HA-1077 hydrochloride]* [105628-07-7], $C_{14}H_{17}N_3O_2S{\cdot}HCl$, F.W. 327.83, Powder, Merck **14**,3942, RTECS HM4031166 H:H302, P:P264-P270-P301+P312-P330-P501	**250mg** **500mg** **1g**
J65298	**FBPase-1 Inhibitor** ▲ *[F16BPase Inhibitor]* [883973-99-7], $C_{13}H_7Cl_3N_2O_3S$, F.W. 377.60, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
J63160	**FCS blocking buffer in PBS** Liquid, Note: 10% Fetal calf serum in PBS Application(s): For blocking excess solid surface in ELISA assays	**250ml** **500ml**
J61327	**FCS blocking buffer in TBS** Liquid, Note: 10% Fetal calf serum in TBS Application(s): For blocking excess solid surface in ELISA	**250ml** **500ml**
J61195	**Felodipine** *[Plendil, 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester]* [72509-76-3], $C_{18}H_{19}NO_4Cl_2$, F.W. 384.25, Powder, Merck **14**,3953, RTECS US7968700, MDL MFCD00868316 H:H302-H361, P:P281-P264-P301+P312-P308+P313-P405-P501 Application(s): A dihydropyridine calcium channel blocker	**50mg** **100mg** **250mg**
J63254	**Fendiline hydrochloride** *[N-[3,3-Diphenylpropyl]-α-methylbenzylamine]* [13636-18-5], $C_{23}H_{25}N{\cdot}HCl$, F.W. 351.92, Powder, m.p. 204-205°, Merck **14**,3970, EINECS 237-121-5, RTECS DP4790000, MDL MFCD00079301 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A calcium channel blocker	**5g**
J63562	**Fenvalerate, 99%** [51630-58-1], $C_{25}H_{22}ClNO_3$, F.W. 419.91, Waxy solid, m.p. 54-59°, Merck **14**,4010, UN2811, EINECS 257-326-3, RTECS CY1576350, BRN 2025982, MDL MFCD00055324 H:H301-H400-H410-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Type II pyrethrin and a potent inhibitor of calcineurin (protein phosphatase 2B)	**25mg** **100mg**
	Ferric ammonium sulfate, see Ammonium iron(III) sulfate dodecahydrate, 39391, p. 101 **Ferric citrate**, see Iron(III) citrate hydrate, A10276, p. 259 **Ferriprotoporphyrin IX chloride**, see Hemin, A11165, p. 242	
87202	**Ferrocene, 99%** △ ◪ *[Bis(cyclopentadienyl)iron, Di(cyclopentadienyl)iron]* [102-54-5], $C_{10}H_{10}Fe$, F.W. 186.04, Powder, Packaged under argon, m.p. 173-174°, b.p. 249°, Merck **14**,4037, UN1325, EINECS 203-039-3, RTECS LK0700000, MDL MFCD00001427, † H:H228-H302-H411, P:P210-P241-P280-P240-P301+P312-P501a Readily undergoes electrophilic substitution reactions such as acylation, formylation, Mannich reaction, etc. For a review, see: *Org. React.*, **17**, 1 (1969). For Mannich reaction using tetramethylmethylenediamine as the source of the Mannich intermediate, see: *Org. Synth. Coll.*, **5**, 434 (1973). Reacts with chlorobenzenes to give ferrocenium salts, which can be used to arylate diethyl malonate: *Synth. Commun.*, **18**, 291 (1988); *J. Chem. Soc., Perkin 1*, 469 (1989). Promotes the Pschorr cyclization of stilbene derivatives in acetone to give phenanthrenes: *J. Org. Chem.*, **60**, 196 (1995). In combination with TFA anhydride, reduces sulfoxides to sulfides at room temperature: *Chem. Lett.*, 400 (2000).	**50g** **250g** **1kg**

Stock #	Description	Size
	Ferrocenyl methyl ketone, see 1-Acetylferrocene, A13078, p. 72 **Ferrous ammonium sulfate**, see Ammonium iron(II) sulfate hexahydrate, 13448, p. 101 **Ferulic acid**, see trans-4-Hydroxy-3-methoxycinnamic acid, A13890, p. 250	
J60437	**Fetuin I, fetal bovine serum** [9014-81-7], Powder, EINECS 232-762-7, MDL MFCD00131055 Application(s): A glycoprotein recovered from the globulin fraction of calf serum	**100mg** **250mg** **1g**
J63262	**Fexofenadine hydrochloride** *[MDL 16455 hydrochloride, Terfenidine carboxylate hydrochloride]* [153439-40-8], $C_{32}H_{39}NO_4 \cdot HCl$, F.W. 538.12, Crystalline powder, m.p. 148-150°, Merck **14**,4068, RTECS CY1633377, MDL MFCD00865710 Application(s): H-1 receptor antagonist	**25mg** **100mg** **500mg**
J63276	**Fibrinogen, bovine** *[Factor I]* [9001-32-5], Powder, Merck **14**,4071, EINECS 232-598-6, MDL MFCD00163624, Note: Greater than 75% clottable protein., † Application(s): A soluble plasma glycoprotein, produced by the liver, that is converted by thrombin into fibrin during the blood coagulation process	**1g** **5g** **10g** **25g**
	Fibrinogen γ-chain dodecapeptide, see Fibrinogen-Binding Inhibitor Peptide, J60863, p. 220	
J60863	**Fibrinogen-Binding Inhibitor Peptide** *[H-His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val-OH, Fibrinogen γ-chain dodecapeptide]* [89105-94-2], $C_{50}H_{80}N_{18}O_{16}$, F.W. 1189.30, Solid, MDL MFCD00167528 Application(s): Inhibits the binding of fibrinogen and fibronectin	**1mg** **5mg**
J61540	**Fibrinogen-Binding Peptide** *[H-Glu-His-Ile-Pro-Ala-OH]* [137235-80-4], $C_{25}H_{39}N_7O_8$, F.W. 565.63, Powder Application(s): Antithrombotic agent	**5mg** **25mg**
J60967	**Fibrinolysis Inhibiting Factor** *[H-Gly-Pro-Arg-Pro-OH]* $C_{18}H_{31}N_7O_5$, F.W. 425.48, Powder	**1mg** **5mg**
J65635	**Fibroblast Growth Factor, acidic, bovine, 90%** *[FGF1, human, aFGF, human]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for cell culture and radioimmunoassays. Supplied as an aseptically lyophilized powder.	**10micrograms** **50micrograms**
J64035	**Fibroblast Growth Factor, acidic, human, 95%** *[FGF1, bovine, aFGF, bovine]* Note: Recombinantly expressed in E. Coli. Suitable for cell culture. Supplied as an aseptically lyophilized powder.	**5micrograms** **25micrograms**
J65713	**Fibroblast Growth Factor, basic, bovine, 95%** *[FGF2, bovine, bFGF, bovine]* Note: Receptor Grade. Suitable for cell culture and radioimmunoassays. Supplied as an aseptically lyophilized powder.	**5micrograms** **25micrograms**
J64811	**Fibroblast Growth Factor, basic, human, 95%** *[FGF2, human, bFGF, human]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for cell culture and radioimmunoassays. Supplied as an aseptically lyophilized powder.	**10micrograms** **50micrograms**
J65662	**Fibroblast Growth Factor Basic Fragment (1-24), bovine** *[FGF2, Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr]* [62031-54-3], $C_{118}H_{173}N_{31}O_{33}$, F.W. 2553.82, Powder, Merck **14**,4072, RTECS LK3641300, MDL MFCD00133317	**0.5mg** **1mg**
J62380	**Fibronectin, bovine plasma** [86088-83-7], Powder, EINECS 289-149-2, MDL MFCD00131062 Application(s): High molecular weight extracellular glycoprotein	**5mg**
J64560	**Fibronectin, human, 95%** *[HFN]*	**1mg** **10x1mg**
J64390	**Fribronectin, rat, 95%**	**1mg**
J65696	**Fibronectin, stabilized soln., bovine**	**5mg**
J64738	**Fibronectin, stabilized soln., human**	**1mg** **10x1mg**
J65555	**Fibronectin, stabilized soln., rat**	**1mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64057	**Fibronectin, human, Enzyme Immunoassay Kit** Note: One kit contains sufficient reagents and precoated 96-well strips to perform an ELISA for fibronectin Application(s): For detection of fibronectin. Detection range is 25-200ng/ml	**1kit**
J60136	**Ficin, fig tree latex** *[EC 3.4.22.3]* [9001-33-6], Lyophillized powder, Merck **14**,4077, EINECS 232-599-1, RTECS LK3675000, MDL MFCD00081597, † H:H315-H319-H334-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Proteolytic enzyme from fig latex, that is a cysteine endopeptidase	**25g**
B22095	**Ficoll® 400** *[Polysucrose 400]* [26873-85-8], F.W. ca 400,000, EINECS 200-334-9, MDL MFCD00081599, † Application(s): Co-polymer of sucrose and epichlorohydrin used to make density gradients for lymphocyte separation	**10g** **50g**
A18577	**Field's Stain A** MDL MFCD00146924, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used to stain blood smears to identify malarial parasites	**10g** **50g**
A18578	**Field's Stain B** [17372-87-1], MDL MFCD00146926, Note: Contains Eosin Yellowish, with sodium hydrogen phosphate and potassium hydrogen phosphate for buffering., † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used to stain blood smears to identify malarial parasites	**10g** **50g**
L14552	**Filter Aid, Celite® AW Standard Supercel®** *[Celite® 521AW, filter aid]* [61790-53-2], Merck **14**,4973, EINECS 319-127-6, RTECS VV7311000, MDL MFCD00132803, † H:H350-H373-H319-H335, P:P260-P261-P280-P305+P351+P338-P405-P501a Celite is a registered trademark of Celite Corp. Acid-washed grade for general filtrations.	**500g**
B21983	**Filter aid, Celite® Standard Super-cel** [61790-53-2], Merck **14**,4973, EINECS 319-127-6, RTECS VV7311000, MDL MFCD00132803, † H:H350-H373-H319-H335, P:P260-P261-P280-P305+P351+P338-P405-P501a	**500g** **2.5kg**
J63454	**Finasteride** [98319-26-7], $C_{23}H_{36}N_2O_2$, F.W. 372.54, Powder, Merck **14**,4082, RTECS CL5245000, MDL MFCD00869737 H:H302-H360, P:P281-P264-P301+P312-P308+P313-P405-P501 Application(s): Inhibitor of steroid 5-a-reductase	**100mg** **500mg** **1g** **5g**
	FK-506, see Tacrolimus, 99+%, J63571, p. 357 **Flagecidin**, see Anisomycin, 98+%, J62964, p. 104 **Flavianic acid disodium salt**, see Naphthol Yellow S, B20872, p. 298	
A14495	**Flavin adenine dinucleotide disodium salt hydrate, 94% (dry wt.), water <10%** *[FAD-Na2, Riboflavin 5'-adenosine diphosphate disodium salt]* [84366-81-4], $C_{27}H_{31}N_9Na_2O_{15}P_2 \cdot xH_2O$, F.W. 829.52, EINECS 282-733-8, MDL MFCD00151217 	**100mg** **500mg**
J63527	**Flecainide acetate, 98%** *[N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate salt]* [54143-56-5], $C_{17}H_{28}F_6N_2O_3 \cdot C_2H_4O_2$, F.W. 474.40, Powder, m.p. 145-147°, Merck **14**,4098, EINECS 258-997-5, RTECS CV5792550, MDL MFCD00214290 H:H300-H361-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Sodium channel blocker	**100mg** **1g**
	Floxuridine, see 5-Fluoro-2'-deoxyuridine, L16497, p. 224	
J64484	**Flt-3 Inhibitor ▲** *[2-[(3,4-Dimethoxybenzoyl)amino]-4,5,6,7-benzo[b]thiophene-3-carboxamide]* [301305-73-7], $C_{18}H_{20}N_2O_4S$, F.W. 360.43, Powder, MDL MFCD00617269 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
J62015	**Fluconazole, 99%** [86386-73-4], $C_{13}H_{12}F_2N_6O$, F.W. 306.27, Crystalline powder, m.p. 138-140°, d. 1.05, Merck **14**,4122, RTECS XZ4810000, MDL MFCD00274549 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
	Flucytosine, see 5-Fluorocytosine, L16496, p. 223	

Stock #	Description	Size
B23583	**Flufenamic acid, 97% ▲** *[N-(3-Trifluoromethylphenyl)anthranilic acid]* [530-78-9], $C_{14}H_{10}F_3NO_2$, F.W. 281.23, m.p. 133-135°, Merck **14**,4132, UN2811, EINECS 208-494-1, RTECS CB4375000, BRN 1996069, MDL MFCD00002422 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a  Application(s): An NSAID found to be a reversible gap junction blocker	**10g** **50g** **250g**
J62537	**Flumazenil, 98%** *[Ro 15-1788]* [78755-81-4], $C_{15}H_{14}FN_3O_3$, F.W. 303.29, Powder, Merck **14**,4135, RTECS NI2922170, MDL MFCD00242764 Application(s): Benzodiazepine antagonist	**100mg** **500mg**
J62969	**Flunarizine dihydrochloride, 99+%** *[1-[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride]* [30484-77-6], $C_{26}H_{26}F_2N_2 \cdot 2HCl$, F.W. 477.40, Powder, Merck **14**,4144, EINECS 250-216-6, RTECS TK9187000, BRN 4284243, MDL MFCD00058198 ! H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A dual sodium/calcium channel blocker; a cerebral and peripheral vasodilator	**1g**
J63388	**Fluo 3-AM** [121714-22-5], $C_{51}H_{50}Cl_2N_2O_{23}$, F.W. 1129.86, Crystalline powder, MDL MFCD00083336 Application(s): Fluorescent indicator for intracellular calcium	**1mg**
J63996	**Fluocinolone acetonide** *[6-α-Fluorotriamcinolone acetonide]* [67-73-2], $C_{24}H_{30}F_2O_6$, F.W. 452.49, Crystalline powder, m.p. 267-269°, Merck **14**,4150, EINECS 200-668-5, RTECS TU3830000, MDL MFCD00010525 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A glucocorticoid with anti-inflammatory properties	**100mg** **1g**
	2-Fluorenamine, see 2-Aminofluorene, B22769, p. 94 **2-Fluorenylamine**, see 2-Aminofluorene, B22769, p. 94 **N-(9-Fluorenylmethoxycarbonyl) products**, see Fmoc, B21107, p. 225	
A11683	**9-Fluorenylmethyl chloroformate, 98% ◢** *[Chloroformic acid 9-fluorenylmethyl ester, Fmoc-Cl]* [28920-43-6], $C_{15}H_{11}ClO_2$, F.W. 258.70, m.p. 60-64°, Fieser **3**,145 **4**,237 **5**,308 **21**,188, UN2923, EINECS 249-313-6, RTECS LQ6250000, BRN 2279177, MDL MFCD00001138  ! H:H314-H302-H332, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Reagent for the protection of amino groups in peptide synthesis as their 9-fluorenylmethoxycarbonyl (Fmoc) derivatives: *J. Org. Chem.*, **37**, 3404 (1972); *J. Am. Chem. Soc.*, **96**, 4987 (1974); **99**, 7363 (1977). Review: *Acc. Chem. Res.*, **20**, 401 (1987). They are particularly applicable in solid-phase peptide synthesis. The stability of Fmoc-protected amino acids to acidic conditions permits their conversion in many cases to the acid chlorides as active intermediates for peptide coupling, resistant to racemization, in contrast to other protected amino acid chlorides. For a review of peptide synthesis via amino acid halides, see: *Acc. Chem. Res.*, **29**, 268 (1996). In the presence of triethylamine, reacts with **Pentafluorophenol**, **A15574**, to give the PFP carbonate, a useful active ester for the preparation of Fmoc-amino acids. Moreover, the active PFP ester of the protected amino acid can be obtained by *in situ* DCC coupling with the liberated PFP: *Synthesis*, 303 (1986). Cleavage of the Fmoc group occurs under mildly basic conditions: Ethanolamine: *J. Am. Chem. Soc.*, **92**, 5748 (1970); *J. Org. Chem.*, **37**, 3404 (1972). Piperidine: *J. Org. Chem.*, **52**, 1197 (1987); applicable to solid-phase peptide synthesis. TBAF in DMF; rapid reaction at room temperature: *Tetrahedron Lett.*, **28**, 6617 (1987). For both the deblocking of Fmoc-protected amino acids and for the removal of excess reagent during the protection step, **4-(Aminomethyl)piperidine**, **L11577**, has been recommended: *J. Org. Chem.*, **51**, 3732 (1986); **55**, 721 (1990), particularly in conjunction with Fmoc-protected acid chlorides as the active species. Even better results have been obtained with **Tris(2-aminoethyl)-amine**, **B21789**, in this type of chemistry: *J. Org. Chem.*, **55**, 1673 (1990). Limited use has also been made in the protection of alcohols as 9-fluorenylmethyl carbonates, rapidly cleaved by triethylamine: *J. Chem. Soc., Chem. Commun.*, 672 (1982). Application(s): Base sensitive amino protecting group for solid-phase peptide synthesis	**1g** **5g** **25g**
43749	**Fluorescamine** [38183-12-9], $C_{17}H_{10}O_4$, F.W. 278.27, Powder, m.p. 155-158°, Merck **14**,4158, EINECS 253-814-5, MDL MFCD00005928  Application(s): For fluorescent detection of amino acids, peptides and proteins	**25mg** **100mg** **500mg**
L13251	**Fluorescein, 90+%** *[C.I. 45350.1, Solvent Yellow 94]* [2321-07-5], $C_{20}H_{12}O_5$, F.W. 332.32, m.p. 320°, Merck **14**,4159, EINECS 219-031-8, RTECS LM5075000, BRN 94324, MDL MFCD00005050, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Fluorescent agent. Adsorption indicator for halides. 	**100g** **500g**
J62175	**Fluorescein amine isomer I, 96%** *[5-Aminofluorescein]* [3326-34-9], $C_{20}H_{13}NO_5$, F.W. 347.32, Powder, m.p. 223° dec., EINECS 222-043-6, BRN 48395, MDL MFCD00005052, † ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A fluorescent labeling reagent	**1g** **5g**

Stock #	Description	Size
J60609	**Fluorescein amine isomer II, 95%** *[6-Aminofluorescein]* [51649-83-3], $C_{20}H_{13}NO_5$, F.W. 347.32, Powder, m.p. 285° dec., EINECS 257-334-7, BRN 51708, MDL MFCD00005051 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Fluorescent labeling reagent	**1g**
B24466	**Fluorescein diacetate, 97%** [596-09-8], $C_{24}H_{16}O_7$, F.W. 416.39, m.p. 200-203°, EINECS 209-877-6, BRN 62575, MDL MFCD00005062, † Application(s): A substrate for esterases; used in studies on intracellular interactions and membrane permeability 	**5g** **25g** **100g**
J61549	**Fluorescein disodium salt** *[Acid Yellow 73, C.I. 45350]* [518-47-8], $C_{20}H_{10}Na_2O_5$, F.W. 376.28, Powder, Merck **14**,4159, EINECS 208-253-0, RTECS LM5425000, BRN 3833041, MDL MFCD00167039, † Application(s): A fluorophore comonly used in microscopy	**100g** **500g**
A11659	**Fluorescein disodium salt hydrate** *[Acid Yellow 73, C.I. 45350]* [518-47-8], $C_{20}H_{10}Na_2O_5 \cdot xH_2O$, F.W. 376.28, m.p. >250°, Merck **14**,4159, EINECS 208-253-0, RTECS LM5425000, BRN 3833041, MDL MFCD00167039, † Water-soluble form of fluorescein. 	**100g** **500g** **2.5kg**
L09319	**Fluorescein isothiocyanate, isomer 1, 95%** ◪ [3326-32-7], $C_{21}H_{11}NO_5S$, F.W. 389.39, m.p. >360°, EINECS 222-042-0, BRN 1407295, MDL MFCD00005063, † H:H334-H317, P:P260-P280g-P262-P309-P310 Reagent for fluorescent labelling of proteins: *Anal. Biochem.*, **20**, 178 (1968). 	**50mg** **250mg** **1g**
	Fluorexon, see Calcein sodium salt, L10255, p. 142	
J65562	**2-Fluoro-9-β-D-arabinofuranosyladenine, 98%** *[Fludarabine, 2-F-araA]* [21679-14-1], $C_{10}H_{12}FN_5O_4$, F.W. 285.23, Powder, Merck **14**,4126, EINECS 244-525-5, RTECS AU6207000, BRN 1225932, MDL MFCD00132942	**1g**
	1-(4-Fluorobenzyl)-2-(1-[4-methoxyphenethyl]piperidin-4-yl)aminobenzimidazole, see Astemizole, 99+%, J60339, p. 111	
J60908	**5-Fluorocytidine, 98%** [2341-22-2], $C_9H_{12}FN_3O_5$, F.W. 261.21, Crystalline powder, m.p. 170-179°, RTECS HA3890000, MDL MFCD00210953 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g**
L16496	**5-Fluorocytosine, 98+%** ▲ *[Flucytosine]* [2022-85-7], $C_4H_4FN_3O$, F.W. 129.09, m.p. ca 297° dec., Merck **14**,4125, EINECS 217-968-7, RTECS HA6040000, BRN 127285, MDL MFCD00006035 H:H341, P:P281-P201-P202-P308+P313-P405-P501a 	**250mg** **1g**
J65441	**2'-Fluoro-2'-deoxyadenosine, 99%** *[2'-Deoxy-2'-fluoroadenosine]* [64183-27-3], $C_{10}H_{12}FN_5O_3$, F.W. 269.23, Powder	**1g**
J65632	**2'-Fluoro-2'-deoxycytidine, 99%** *[2'-Deoxy-2'-fluorocytidine]* [10212-20-1], $C_9H_{12}FN_3O_4$, F.W. 245.21, Powder, MDL MFCD00057445	**1g**
J64055	**2'-Fluoro-2'-deoxyguanosine, 99%** *[2'-Deoxy-2'-fluoroguanosine]* [78842-13-4], $C_{10}H_{12}FN_5O_4$, F.W. 285.23, Powder H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J65208	**2'-Fluoro-2'-deoxyinosine, 99%** *[2'-Deoxy-2'-fluoroinosine]* [80049-87-2], $C_{10}H_{11}FN_4O_4$, F.W. 270.22, Powder	**1g**

Stock #	Description	Size
J65948	**2'-Fluoro-2'-deoxyuridine, 99%** *[1-(2-Fluoro-2-deoxy-β-D-ribofuranosyl)uracil]* [784-71-4], $C_9H_{11}FN_2O_5$, F.W. 246.19, Powder, MDL MFCD01317293	**1g** **5g** **25g**
L16497	**5-Fluoro-2'-deoxyuridine, 98+%** *[2'-Deoxy-5-fluorouridine, Floxuridine]* [50-91-9], $C_9H_{11}FN_2O_5$, F.W. 246.20, m.p. 148-151°, Merck **14**,4112, UN2811, EINECS 200-072-5, RTECS YU7535000, BRN 2645818, MDL MFCD00006530 H:H360-H341-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a	**100mg** **500mg**
H51972	**4-Fluoro-N-Fmoc-L-phenylalanine, 95%** *[Fmoc-Phe(4-F)-OH]* [169243-86-1], $C_{24}H_{20}FNO_4$, F.W. 405.42, BRN 8287377, MDL MFCD00191197	**250mg** **1g** **5g**
	9α-Fluoro-16α-hydroxyprednisolone-16α,17α-acetonide, see Triamcinolone acetonide, 98+%, J63548, p. 374	
J65608	**2'-Fluoro-N2-isobutyryl-2'-deoxyguanosine, 98%** $C_{14}H_{18}FN_5O_5$, F.W. 355.32, Powder	**1g**
B22603	**2-Fluoro-α-methyl-4-biphenylacetic acid, 99%** *[Flurbiprophen]* [5104-49-4], $C_{15}H_{13}FO_2$, F.W. 244.27, m.p. 112-114°, Merck **14**,4199, UN2811, EINECS 225-827-6, RTECS DU8341000, MDL MFCD00079303 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A cyclooxygenase inhibitor	**1g** **5g** **25g**
J64953	**(S)-(+)-α-Fluoromethylhistidine dihydrochloride** *[(S)-2-((Fluoromethyl)amino)-3-(1H-imidazol-4-yl)propanoic acid dihydrochloride]* $C_7H_{12}Cl_2FN_3O_2$, F.W. 260.09, Solid	**10mg**
	cis-5-Fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]indene-3-acetic acid, see Sulindac, J61772, p. 356	
J61336	**4-Fluoro-7-nitrobenzofurozan** *[NBD-F, 4-Fluoro-7-nitro-2,1,3-benzoxadiazole]* [29270-56-2], $C_6H_2FN_3O_3$, F.W. 183.10, Powder, m.p. 53-57°, f.p. 110°(230°F), BRN 1077571, MDL MFCD00010196 H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 Application(s): Useful for amino acid and amine fluorescent labeling in HPLC	**100mg**
	4-Fluoro-7-nitro-2,1,3-benzoxadiazole, see 4-Fluoro-7-nitrobenzofurozan, J61336, p. 224	
H51701	**1-(4-Fluorophenyl)homopiperazine dihydrochloride, 98%** *[4-FPHP·2HCl]* [263409-96-7], $C_{11}H_{15}FN_2 \cdot 2HCl$, F.W. 267.17, m.p. 219-223°, MDL MFCD08436121, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd. H:H315-H319-H335, P:P280g-P305+P351+P338	**500mg**
H51686	**1-(3-Fluorophenyl)homopiperazine monohydrochloride, 98%** *[3-FPHP·HCl]* [934991-99-8], $C_{11}H_{15}FN_2 \cdot HCl$, F.W. 230.71, m.p. 187-191°, MDL MFCD09953903, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd.	**500mg**
	4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole, see SB 202190, 99+%, J60950, p. 340 **4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)imidazole**, see SB 203580, 99%, J61482, p. 341 **5-Fluoro-2,4(1H,3H)-pyrimidinedione**, see 5-Fluorouracil, A13456, p. 224 **6-α-Fluorotriamcinolone acetonide**, see Fluocinolone acetonide, J63996, p. 222	
A13456	**5-Fluorouracil, 99% ▲** *[5-Fluoro-2,4(1H,3H)-pyrimidinedione, 5-FU]* [51-21-8], $C_4H_3FN_2O_2$, F.W. 130.08, m.p. ca 282° dec., Merck **14**,4181, UN2811, EINECS 200-085-6, RTECS YR0350000, BRN 127172, MDL MFCD00006018, † H:H360-H341-H373-H302, P:P260-P281-P301+P312-P308+P313-P405-P501a Antineoplastic agent. Not for drug use.	**5g** **25g** **100g**
J62083	**5-Fluorouridine, 97%** [316-46-1], $C_9H_{11}FN_2O_6$, F.W. 262.19, Powder, EINECS 206-260-3, RTECS YU8050000, BRN 33662, MDL MFCD00036832 H:H341, P:P281-P201-P202-P308+P313-P405-P501a	**1g** **5g**
J61197	**Fluoxetine hydrochloride, 99%** *[LY-110,140 hydrochloride]* [56296-78-7], $C_{17}H_{18}F_3NO \cdot HCl$, F.W. 345.79, Powder, m.p. 158-159°, Merck **14**,4185, EINECS 260-101-2, RTECS UI4050000, MDL MFCD00214288 H:H302-H315-H318, P:P280-P305+P351+P338-P302+P352-P321-P310-P501 Application(s): A selective serotonin reuptake inhibitor	**50mg** **250mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J61179	**Fluphenazine, 98+%** [69-23-8], $C_{22}H_{26}F_3N_3OS$, F.W. 437.52, Powder, m.p. 268-274°, Merck **14**,4189, UN2811, EINECS 200-702-9, RTECS TL9730000 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Dopamine D1 receptor antagonist	1g 5g 25g
B20848	**Fluphenazine dihydrochloride, 98%** ■ [146-56-5], $C_{22}H_{26}F_3N_3OS{\cdot}2HCl$, F.W. 510.44, UN2811, EINECS 205-674-1, MDL MFCD00055212 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A dopamine D1 receptor antagonist	 25g 100g 500g
	Flurbiprophen, see 2-Fluoro-α-methyl-4-biphenylacetic acid, B22603, p. 224 **FMN-Na**, see Riboflavin-5'-phosphate sodium salt dihydrate, A14545, p. 337	
B21107	**N-Fmoc-L-alanine monohydrate, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-L-alanine monohydrate, Fmoc-Ala-OH]* [207291-76-7], $C_{18}H_{17}NO_4{\cdot}H_2O$, F.W. 329.36 (311.34anhy), m.p. ca 130°, $[\alpha]_D^{20}$ -19° (c=1 in DMF), EINECS 252-660-6, BRN 2225975, MDL MFCD00037139	 5g 25g
	(S)-3-(Fmoc-amino)adipic acid 6-tert-butyl ester, see N-Fmoc-L-β-homoglutamic acid 6-tert-butyl ester, H52188, p. 225	
H52828	**4-(Fmoc-amino)benzoic acid, 97%** *[Fmoc-4-Abz-OH]* [185116-43-2], $C_{22}H_{17}NO_4$, F.W. 359.38, BRN 7722986, MDL MFCD00144888	 250mg 1g 5g
	(S)-3-(Fmoc-amino)-5-methylhexanoic acid, see N-Fmoc-L-β-homoleucine, H51976, p. 225 **(R)-3-(Fmoc-amino)-4-methylpentanoic acid**, see N-Fmoc-L-β-homovaline, H52182, p. 225 **(S)-2-(Fmoc-amino)-4-pentynoic acid**, see N-Fmoc-L-propargylglycine, H52171, p. 226	
H52195	**L-3-(Fmoc-amino)-N-trityladipic acid 6-amide, 95%** *[Fmoc-β-Homogln(Trt)-OH, Nε-Trityl-Nβ-Fmoc-L-homoglutamine]* [401915-55-7], $C_{46}H_{38}N_2O_5$, F.W. 624.73, m.p. 113-117°, BRN 9601212, MDL MFCD03427580	 250mg 1g
B21008	**N(α)-Fmoc-L-asparagine, 98%** *[N(α)-9-Fluorenylmethoxycarbonyl-L-asparagine, Fmoc-Asn-OH]* [71989-16-7], $C_{19}H_{18}N_2O_5$, F.W. 354.36, m.p. ca 188° dec., $[\alpha]_D^{20}$ -12+/-1° (c=1 in DMF), EINECS 276-252-2, BRN 4335103, MDL MFCD00037132	 5g 25g
	Nα-Fmoc-Nγ-Boc-L-2,4-diaminobutyric acid, see (S)-4-(Boc-amino)-2-(Fmoc-amino)butyric acid, H51990, p. 129 **Fmoc-Cl**, see 9-Fluorenylmethyl chloroformate, A11683, p. 222	
H52190	**N-Fmoc-L-β-glutamic acid 5-tert-butyl ester, 95%** *[Fmoc-β-Glu(OtBu)-OH, N-Fmoc-β-homoaspartic acid 5-tert-butyl ester]* [209252-17-5], $C_{24}H_{27}NO_6$, F.W. 425.48, BRN 7952342, MDL MFCD01862860	 250mg 1g
B21050	**N-Fmoc-glycine, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-glycine, Fmoc-Gly-OH]* [29022-11-5], $FmocNHCH_2CO_2H$, F.W. 297.32, m.p. 172-175°, EINECS 249-373-3, BRN 2163967, MDL MFCD00037140	1g 5g
H52178	**N-Fmoc-L-β-homoalanine, 95%** *[Fmoc-β-Homoala-OH]* [193954-26-6], $C_{19}H_{19}NO_4$, F.W. 325.36, BRN 7719789, MDL MFCD00270346	 250mg 1g
	N-Fmoc-β-homoaspartic acid 5-tert-butyl ester, see Fmoc-L-β-glutamic acid 5-tert-butyl ester, H52190, p. 225	
H52188	**N-Fmoc-L-β-homoglutamic acid 6-tert-butyl ester, 95%** *[(S)-3-(Fmoc-amino)adipic acid 6-tert-butyl ester, Fmoc-β-Homoglu(OtBu)-OH]* [203854-49-3], $C_{25}H_{29}NO_6$, F.W. 439.51, m.p. 115-120°, BRN 8019724, MDL MFCD01863053	 250mg 1g
H51976	**N-Fmoc-L-β-homoleucine, 95%** *[(S)-3-(Fmoc-amino)-5-methylhexanoic acid, Fmoc-β-Homoleu-OH]* [193887-44-4], $C_{22}H_{25}NO_4$, F.W. 367.44, BRN 7723942, MDL MFCD01863059	 250mg 1g
H52060	**N-Fmoc-L-β-homoproline, 95%** *[(S)-2-(1-Fmoc-2-pyrrolidinyl)acetic acid, Fmoc-β-Homopro-OH]* [193693-60-6], $C_{21}H_{21}NO_4$, F.W. 351.40, BRN 7798553, MDL MFCD01863058	 250mg 1g
H52182	**N-Fmoc-L-β-homovaline, 95%** *[(R)-3-(Fmoc-amino)-4-methylpentanoic acid, Fmoc-L-β-leucine]* [172695-33-9], $C_{21}H_{23}NO_4$, F.W. 353.42, BRN 7388393, MDL MFCD01862853	 250mg 1g

Stock #	Description		Size
H52740	**trans-N-Fmoc-4-hydroxy-L-proline, 97%** *[Fmoc-Hyp-OH]* [88050-17-3], $C_{20}H_{19}NO_5$, F.W. 353.37, m.p. 189-193°, MDL MFCD00151929		**1g** **5g**
B21154	**N-Fmoc-L-isoleucine, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-L-isoleucine, Fmoc-Ile-OH]* [71989-23-6], $C_{21}H_{23}NO_4$, F.W. 353.42, m.p. 146-148°, EINECS 276-255-9, BRN 4716717, MDL MFCD00037125		**1g** **5g** **25g**
H29041	**N-Fmoc-D-leucine, 98%** *[N-(9-Fluorenylmethoxy)carbonyl-D-leucine, Fmoc-D-Leu-OH]* [114360-54-2], $C_{21}H_{23}NO_4$, F.W. 353.42, m.p. 151-154°, MDL MFCD00062957		**1g** **5g** **25g**
B21040	**N-Fmoc-L-leucine, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-L-leucine, Fmoc-Leu-OH]* [35661-60-0], $C_{21}H_{23}NO_4$, F.W. 353.42, m.p. 152-155°, $[\alpha]_D^{20}$ -25° (c=1 in DMF), EINECS 252-662-7, BRN 2178254, MDL MFCD00037133		**5g** **25g**
B21220	**N-Fmoc-L-methionine, 98+%** *[N-(9-Fluorenylmethoxycarbonyl)-L-methionine, Fmoc-Met-OH]* [71989-28-1], $C_{20}H_{21}NO_4S$, F.W. 371.46, m.p. 132-135°, $[\alpha]_D^{20}$ -30° (c=1 in DMF), EINECS 276-258-5, BRN 4300266, MDL MFCD00037134		**5g** **25g**
H52117	**N-Fmoc-4-methoxy-L-phenylalanine, 95%** *[Fmoc-Tyr(Me)-OH, N-Fmoc-O-methyl-L-tyrosine]* [77128-72-4], $C_{25}H_{23}NO_5$, F.W. 417.45, MDL MFCD00153368		**250mg** **1g** **5g**
	N-Fmoc-O-methyl-L-tyrosine, see N-Fmoc-4-methoxy-L-phenylalanine, H52117, p. 226		
H51962	**N-Fmoc-4-nitro-L-phenylalanine, 98%** *[Fmoc-Phe(4-NO2)-OH]* [95753-55-2], $C_{24}H_{20}N_2O_6$, F.W. 432.43, m.p. 213-223°, BRN 5178656, MDL MFCD00057810		**1g** **5g**
B22475	**N-Fmoc-L-norleucine, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-L-norleucine, Fmoc-Nle-OH]* [77284-32-3], $C_{21}H_{23}NO_4$, F.W. 353.42, m.p. 140-142°, MDL MFCD00037537		**1g** **5g** **25g**
B21689	**N-Fmoc-D-phenylalanine, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-D-phenylalanine, Fmoc-D-Phe-OH]* [86123-10-6], $C_{24}H_{21}NO_4$, F.W. 387.44, m.p. 181-185°, MDL MFCD00062955		**1g** **5g** **25g**
B21210	**N-Fmoc-L-phenylalanine, 98+%** *[N-(9-Fluorenylmethoxycarbonyl)-L-phenylalanine, Fmoc-Phe-OH]* [35661-40-6], $C_{24}H_{21}NO_4$, F.W. 387.44, m.p. 180-185°, $[\alpha]_D^{20}$ -40° (c=1 in DMF), EINECS 252-661-1, BRN 3597808, MDL MFCD00037128		**5g** **25g**
H28500	**N-Fmoc-D-proline, 98+%, may cont. up to ca 5% water** *[N-(9-Fluorenylmethoxy)carbonyl-D-proline, Fmoc-D-Pro-OH]* [101555-62-8], $C_{20}H_{19}NO_4$, F.W. 337.38, m.p. 110-116°, MDL MFCD00077067		**1g** **5g** **25g**
B21081	**N-Fmoc-L-proline, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-L-proline, Fmoc-Pro-OH]* [71989-31-6], $C_{20}H_{19}NO_4$, F.W. 337.38, m.p. 113-117°, $[\alpha]_D^{20}$ -40° (c=1 in ethyl acetate), EINECS 276-259-0, BRN 3596735, MDL MFCD00037122		**5g** **25g**
H52171	**N-Fmoc-L-propargylglycine, 95%** *[(S)-2-(Fmoc-amino)-4-pentynoic acid, Fmoc-propargyl-Gly-OH]* [198561-07-8], $C_{20}H_{17}NO_4$, F.W. 335.36, BRN 9151699, MDL MFCD01075095		**250mg** **1g** **5g**
H52193	**N-Fmoc-3-(4-pyridyl)-D-alanine, 95%** *[Fmoc-β-(4-pyridyl)-D-Ala-OH]* [205528-30-9], $C_{23}H_{20}N_2O_4$, F.W. 388.42, MDL MFCD00672567		**250mg** **1g** **5g**
H52172	**N-Fmoc-3-(4-pyridyl)-L-alanine, 95%** *[Fmoc-β-(4-pyridyl)-Ala-OH]* [169555-95-7], $C_{23}H_{20}N_2O_4$, F.W. 388.42, BRN 7316905, MDL MFCD00672566		**250mg** **1g** **5g**
	(S)-2-(1-Fmoc-2-pyrrolidinyl)acetic acid, see N-Fmoc-L-β-homoproline, H52060, p. 225		
B21079	**N-Fmoc-L-serine, 97+%** *[N-(9-Fluorenylmethoxycarbonyl)-L-serine, Fmoc-Ser-OH]* [73724-45-5], $C_{18}H_{17}NO_5$, F.W. 327.34, m.p. 102-106°, $[\alpha]_D^{20}$ +13.6° (c=1 in ethyl acetate), BRN 4715791, MDL MFCD00051928		**1g** **5g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
H51975	**(S)-N-Fmoc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 95%** *[Fmoc-Tic-OH]* [136030-33-6], $C_{25}H_{21}NO_4$, F.W. 399.45, BRN 4827574, MDL MFCD00144368 	250mg 1g 5g
H27363	**N-Fmoc-S-trityl-L-cysteine, 95%** *[N-(9-Fluorenylmethoxycarbonyl)-S-trityl-L-cysteine, Fmoc-Cys(Trt)-OH]* [103213-32-7], $C_{37}H_{31}NO_4S$, F.W. 585.71, m.p. 171-173°, MDL MFCD00038538 	1g 5g 25g
B22022	**N(α)-Fmoc-D-tryptophan, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-D-tryptophan, Fmoc-D-Trp-OH]* [86123-11-7], $C_{26}H_{22}N_2O_4$, F.W. 426.48, m.p. 182-185°, MDL MFCD00062954 	1g 5g 25g
B21130	**N(α)-Fmoc-L-tryptophan, 98%** *[N(α)-9-Fluorenylmethoxycarbonyl-L-tryptophan, Fmoc-Trp-OH]* [35737-15-6], $C_{26}H_{22}N_2O_4$, F.W. 426.48, m.p. 182-185°, $[\alpha]_D^{20}$ -27° (c=1 in DMF), EINECS 252-706-5, BRN 4216624, MDL MFCD00037126 	1g 5g 25g
J65446	**N-Fmoc-Tyr-Ala-diazomethyl ketone** *[B-3530]* [205763-22-0], $C_{28}H_{26}N_4O_5$, F.W. 498.54, Powder	10mg
B21030	**N-Fmoc-L-valine, 98%** *[N-(9-Fluorenylmethoxycarbonyl)-L-valine, Fmoc-Val-OH]* [68858-20-8], $C_{20}H_{21}NO_4$, F.W. 339.40, m.p. 142-145°, $[\alpha]_D^{20}$ -17° (c=1 in DMF), EINECS 272-515-0, BRN 2177443, MDL MFCD00037124 	5g 25g
	FMRF amide, see Molluscan Cardioexcitatory Neuropeptide, J62389, p. 294	
A14300	**Folic acid dihydrate, 97%** *[Pteroylglutamic acid]* [75708-92-8], $C_{19}H_{19}N_7O_6 \cdot 2H_2O$, F.W. 477.44 (441.40anhy), m.p. ca 250° dec., $[\alpha]_D^{20}$ +18° (c=0.5 in 0.1N NaOH), Merck **14**,4221, EINECS 200-419-0, RTECS LP5425000, BRN 100781, MDL MFCD00079305, † Application(s): Vitamin B9. A B-complex vitamin necessary for the body to produce red blood cells 	25g 100g
J60833	**Folic acid, crystalline** *[Pteroyl-L-glutamic acid]* [59-30-3], $C_{19}H_{19}N_7O_6$, F.W. 441.41, Crystalline, Merck **14**,4221, EINECS 200-419-0, RTECS LP5425000, BRN 100781, MDL MFCD00079305, † Application(s): Vitamin B9. A B-complex vitamin necessary for the body to produce red blood cells	25g 100g
J62937	**Folic acid, Cell Culture Reagent** *[PteGlu, Pteroyl-L-glutamic acid]* [59-30-3], $C_{19}H_{19}N_7O_6$, F.W. 441.41, Powder, Merck **14**,4221, EINECS 200-419-0, RTECS LP5425000, BRN 100781, MDL MFCD00079305, † Application(s): Vitamin B9. A B-complex vitamin necessary for the body to produce red blood cells	5g 25g 100g
J60401	**Formaldehyde, 4% in PBS** [50-00-0], Liquid, † H:H351-H302-H332-H317, P:P261-P280-P302+P352-P321-P405-P501a	250ml 500ml
33314	**Formaldehyde, 37% in aq. soln., ACS, 36.5-38.0%, stab. with 10-15% methanol** *[Formalin, Formol]* [50-00-0], HCHO, F.W. 30.03, Liquid, m.p. -15°, b.p. 97°, f.p. 60°(140°F), d. 1.083, n_D^{20} 1.3765, Merck **14**,4235, Fieser **1**,397 **11**,240 **12**,232 **13**,136 **14**,168 **15**,161 **16**,171 **21**,193, UN1198, EINECS 200-001-8, RTECS LP8925000, BRN 1209228, MDL MFCD00003274, † Maximum level of impurities: Color (APHA) 10, Residue after ignition 0.005%, Titratable acid 0.006meq/g, Cl 5ppm, SO_4 0.002%, Heavy Metals (as Pb) 5ppm, Fe 5ppm H:H301-H311-H331-H370-H351-H314-H226-H317, P:P301+P310-P303+P361+P353-P305+P351+P338-P361-P405-P501a	500ml 1L 4L 4x1L 4x4L
14835	**Formamide, ACS, 99.5+%** ■ [75-12-7], $HCONH_2$, F.W. 45.04, Liquid, m.p. 2°, b.p. 210°, f.p. 154°(310°F), d. 1.134, n_D^{20} 1.4475, Merck **14**,4237, EINECS 200-842-0, MDL MFCD00007941, † Specifications: Color (APHA) 10, Freezing point 2.0-3.0° H:H360, P:P281-P201-P202-P308+P313-P405-P501a	250g 1kg 4x1kg
J65016	**Formate Dehydrogenase** *[EC 1.2.1.2]* Lyophilized powder, Note: Component in the Cofactor Recycling Enzymes Kit, item J64535	250mg 500mg 1g

Stock #	Description	Size
36617	**Formic acid, ACS, 96+%** [64-18-6], HCOOH, F.W. 46.03, Liquid, m.p. 7-9°, b.p. 100-101°, f.p. 50°(156°F), d. 1.220, n_D^{20} 1.3710, Merck **14**,4241, Fieser **1**,404 **8**,232 **9**,226 **11**,243 **13**,137 **18**,163 **19**,148 **20**,168 **21**,193, UN1779, EINECS 200-579-1, RTECS LQ4900000, BRN 1209246, MDL MFCD00003297, † Maximum level of impurities: Color (APHA) 15, Dilution test P.T., Evaporation residue 0.003%, CH_3COOH 0.4%, NH_4 0.005%, Cl 0.001%, SO_4 0.003%, SO_3 P.T., Heavy Metals (as Pb) 0.001%, Fe 0.001% H:H331-H314-H226-H302, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	**500g** **2kg** **4x500g**
A13285	**Formic acid, 97% ■** [64-18-6], HCOOH, F.W. 46.03, m.p. 7-9°, b.p. 100-101°, f.p. 50°(156°F), d. 1.220, n_D^{20} 1.3710, Merck **14**,4241, Fieser **1**,404 **8**,232 **9**,226 **11**,243 **13**,137 **18**,163 **19**,148 **20**,168 **21**,193, UN1779, EINECS 200-579-1, RTECS LQ4900000, BRN 1209246, MDL MFCD00003297, † H:H331-H314-H226-H302, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Cleaves trityl groups selectively in the presence of benzylidene acetals or TBDMS ethers: *Tetrahedron Lett.*, **27**, 579 (1986). Instead of the unstable formic anhydride, formylations may be carried out with formic acid and acetic anhydride to generate the mixed acetic formic anhydride *in situ*. For a review, see: *Tetrahedron*, **46**, 1081 (1990). This reagent has been used for the deoxygenation of tertiary amine oxides: *Chem. Lett.*, 1517 (1985). Dehydration with sulfuric acid can be used to generate CO *in situ*. Subsequent reaction with tertiary carbocations gives the corresponding carboxylic acid (the Koch-Haaf carboxylation). For examples, see: *Org. Synth. Coll.*, **5**, 20, 739 (1973); improved procedure: *Synth. Commun.*, **19**, 1945 (1989). 1,4-Diols in which one alcohol is tertiary give γ-lactones: *Chem. Lett.*, 1187 (1982). Used in combination with formaldehyde in the Eschweiler-Clarke reductive methylation of amines, the formic acid acting as a hydride donor. Review: *Org. React.*, **5**, 290 (1949). For an example, see: *Org. Synth. Coll.*, **3**, 723 (1955). In the presence of Raney nickel alloy, reduces aromatic nitriles to aldehydes in high yield: *J. Chem. Soc.*, 5775 (1965); for list of examples, see: *Org. Synth. Coll.*, **6**, 631 (1988). Hydrogen donor, in combination with Pd on carbon, in catalytic transfer hydrogenations; see, e.g.: Selective reduction of dinitroarenes to nitroanilines: *J. Org. Chem.*, **45**, 4992 (1980). Dehalogenation of aryl halides: *Synthesis*, 876 (1982). Hydrogenation of aromatic rings: *Tetrahedron Lett.*, **33**, 7477 (1992). See also **Palladium**, **A12012**, **Cyclohexene**, **A11359**, and **Ammonium formate**, **A10699**. For a comparative mechanistic study of formic acid and formate salts in hydrogenolysis of aryl chlorides, see: *J. Org. Chem.*, **60**, 1347 (1995). In combination with **Selenium(IV) oxide**, **12358**, improved results have been obtained in the allylic oxidation of sterically-hindered olefins: *Synth. Commun.*, **24**, 29213 (1994).	**500g** **2.5kg** **10kg**
J63292	**Forskolin, 98+%** [66575-29-9], $C_{22}H_{34}O_7$, F.W. 410.51, Solid, Merck **14**,2476, EINECS 266-410-9, RTECS QL6150000, BRN 1692716, MDL MFCD00082317 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An adenylcyclase activator	**10mg** **50mg** **100mg**
	3-FPHP·HCl, see 1-(3-Fluorophenyl)homopiperazine monohydrochloride, H51686, p. 224 **4-FPHP·2HCl**, see 1-(4-Fluorophenyl)homopiperazine dihydrochloride, H51701, p. 224 **Frozen storage buffer**, see FSB buffer, J60262, p. 228	
A17718	**D-Fructose, 99%** *[D-Levulose]* [57-48-7], $C_6H_{12}O_6$, F.W. 180.16, m.p. ca 105-110°, d. 1.59, $[\alpha]_D^{20}$ -89° (c=2 in water), Merck **14**,4273, EINECS 200-333-3, RTECS LS7120000, BRN 1239004, MDL MFCD00148910, † 	**250g** **1kg** **5kg**
J60262	**FSB buffer** *[Frozen storage buffer]* Liquid, Note: Contains 10mM potassium acetate, 10mM calcium chloride, 100mM potassium chloride, 54.5mM manganese chloride, 3mM hexamine cobalt chloride and 10% glycerol Application(s): For frozen storage of competent cells	**125ml** **250ml**
	Fuchsin acid sodium salt, see Acid Fuchsin sodium salt, B22222, p. 76 **Fuchsin basic**, see Basic Fuchsin, A12952, p. 117	
A18234	**D-(+)-Fucose, 99% ■** *[6-Deoxy-D-galactose, Rhodeose]* [3615-37-0], $C_6H_{12}O_5$, F.W. 164.16, m.p. 135-141°, $[\alpha]_D^{20}$ +76° (c=10 in water, 24h), Merck **14**,4278, EINECS 222-792-9, BRN 1723320, MDL MFCD00135603, † 	**1g** **5g**
A16789	**L-(-)-Fucose, 99% ■** *[6-Deoxy-L-galactose]* [2438-80-4], $C_6H_{12}O_5$, F.W. 164.16, m.p. 139-142°, $[\alpha]_D^{20}$ -75° (c=10 in water, 24h), Merck **14**,4279, EINECS 219-452-7, BRN 1422661, MDL MFCD00069812, † 	**1g** **5g**
	5-FUDR, see 5-Fluoro-2'-deoxyuridine, L16497, p. 224 **Fugimycin**, see Tacrolimus, 99+%, J63571, p. 357	
A10976	**Fumaric acid, 99%** *[trans-2-Butenedioic acid]* [110-17-8], $HO_2CCH{=}CHCO_2H$, F.W. 116.07, m.p. ca 299° subl., f.p. 273°(523°F), d. 1.625, Merck **14**,4287, Fieser **5**,319, EINECS 203-743-0, RTECS LS9625000, BRN 605763, MDL MFCD00002700, † H:H319, P:P305+P351+P338	**500g** **2.5kg** **10kg**
	Fumaric acid disodium salt, see Sodium fumarate, A11276, p. 346	

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63686	**FURA 2 pentasodium salt** [113694-64-7], $C_{29}H_{22}Na_8N_3O_{14}$, F.W. 751.45, Powder, MDL MFCD00083328 Application(s): A very sensitive fluorescent calcium chelator	1mg
J62728	**FURA 2-AM** *[Fura-2 pentakis(acetoxymethyl) ester]* [108964-32-5], $C_{44}H_{47}N_3O_{24}$, F.W. 1001.87, Powder, BRN 8183748, MDL MFCD00036976 Application(s): A calcium indicator; derivative of Fura-2 used to load the chelator into cells	1mg
	Furacin, see 5-Nitro-2-furfurylidene semicarbazone, A18593, p. 304 **2,5-Furandione**, see Maleic anhydride, A12178, p. 275 **Fura-2 pentakis(acetoxymethyl) ester**, see FURA 2-AM, J62728, p. 229	
B20834	**Furazolidone, 98% ▲** *[3-(5-Nitrofurfurylideneamino)-2-oxazolidinone]* [67-45-8], $C_8H_7N_3O_5$, F.W. 225.16, m.p. 254-256° dec., EINECS 200-653-3, RTECS RQ3675000, MDL MFCD00010550, † H:H341, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Monoamine oxidase inhibitor	25g 100g 500g
J61378	**Furegrelate sodium salt, 99+%** *[U-63557A, Sodium furegrelate]* [85666-17-7], $C_{15}H_{10}NNaO_3$, F.W. 275.20, Crystalline solid Application(s): Inhibitor of thromboxane synthetase	5mg 10mg 50mg
	N^6-Furfuryladenine, see Kinetin, A13720, p. 264 **6-Furfurylaminopurine**, see Kinetin, A13720, p. 264 **7H-Furo[3,2-g]benzopyran-7-one**, see Psoralen, 97%, J60042, p. 331 **Furo[3,2-g]coumarin**, see Psoralen, 97%, J60042, p. 331	
J61457	**Furosemide, 97+%** *[4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid]* [54-31-9], $C_{12}H_{11}ClN_2O_5S$, F.W. 330.74, Crystalline powder, m.p. 206-209°, Merck **14**,4309, EINECS 200-203-6, RTECS CB2625000, MDL MFCD00010549 H:H360, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Loop diuretic that inhibits the Na+/2Cl-/K+ (NKCC) cotransporter	5g 10g 25g
J63871	**G418 disulfate, 50mg/ml solution** *[Geneticin]* [108321-42-2], $C_{20}H_{40}N_4O_{10}\cdot 2H_2SO_4$, F.W. 692.71, Liquid, MDL MFCD00058314 Application(s): Aminoglycoside that is toxic to bacteria, yeast, protozoans and helminths	10ml 50ml
J62671	**G418 disulfate, Cell Culture Reagent** *[Geneticin disulfate]* [108321-42-2], $C_{20}H_{40}N_4O_{10}\cdot 2H_2SO_4$, F.W. 692.71, Powder, MDL MFCD00058314 Application(s): Aminoglycoside that is toxic to bacteria, yeast, protozoans and helminths	1g 5g 25g
J64528	**G3335 ▲** *[H-Trp-Glu-OH]* [36099-95-3], $C_{16}H_{19}N_3O_5$, F.W. 333.34, Solid	50mg 100mg
	G6PD, see Glucose-6-phosphate dehydrogenase, Leuconostoc mesenteroides, J60117, p. 234 **GABA**, see 4-Aminobutyric acid, 99+%, J61307, p. 92 **Galactitol**, see Dulcitol, 99%, J63206, p. 202 **4-O-β-D-Galactopyranosyl-D-fructose**, see Lactulose, 99%, J60160, p. 265 **6-O-α-D-Galactopyranosyl-D-glucose**, see α-D-(+)-Melibiose, J60439, p. 279	
L07462	**D-Galactosamine hydrochloride, 98% ■** [1772-03-8], $C_6H_{13}NO_5\cdot HCl$, F.W. 215.64, m.p. ca 183° dec., $[\alpha]_D^{20}$ +97° (c=1 in water), Merck **14**,4334, EINECS 217-198-1, RTECS LW5500000, BRN 3697825, MDL MFCD00135830, †	250mg 1g
A12813	**D-(+)-Galactose, 98%** [59-23-4], $C_6H_{12}O_6$, F.W. 180.16, m.p. 164-168°, d. 1.50, $[\alpha]_D^{20}$ +80° (c=5 in water, 24h), Merck **14**,4335, EINECS 200-416-4, RTECS LW5490000, BRN 1724619, MDL MFCD00151230, †	50g 250g 1kg
B21448	**L-(-)-Galactose, 98%** [15572-79-9], $C_6H_{12}O_6$, F.W. 180.16, m.p. 163-165°, EINECS 239-630-8, BRN 1724622, MDL MFCD00063833	100mg 500mg
	Galanin Message Associated Peptide Fragment (16-41) amide, see GMAP (16-14) amide, J64666, p. 238 **Galanin Message Associated Peptide Fragment (25-41) amide**, see GMAP (25-41) amide, J64644, p. 238	
J62482	**Galanthamine hydrobromide** [1953-04-4], $C_{17}H_{21}NO_3\cdot HBr$, F.W. 368.27, Powder, Merck **14**,4340, UN2811, EINECS 217-780-5, RTECS DF8075000, MDL MFCD00067672 H:H300, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Centrally active and long-acting acetylcholinesterase inhibitor	50mg 1g

Stock #	Description	Size
	3-O-Gallate, see (-)-Epigallocatechin gallate, J61745, p. 209 **Gallic acid**, see 3,4,5-Trihydroxybenzoic acid, B24887, p. 377 **Gallic acid n-dodecyl ester**, see n-Dodecyl gallate, L06233, p. 201	
J60731	**(-)-Gallocatechin** *[(2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol]* [3371-27-5], $C_{15}H_{14}O_7$, F.W. 306.27, Powder, MDL MFCD01632616 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Polyphenolic compound from green tea. Possesses free-radical scavenging ability	**10mg**
J62740	**(-)-Gallocatechin gallate** *[(2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate)]* [4233-96-9], $C_{22}H_{18}O_{11}$, F.W. 458.38, Powder, RTECS DH9000000, MDL MFCD00214298 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An antioxidant from green tea	**10mg**
J64547	**GAP 26** *[Val-Cys-Tyr-Asp-Lys-Ser-Phe-Pro-Ile-Ser-His-Val-Arg]* [197250-15-0], $C_{70}H_{107}N_{19}O_{19}S$, F.W. 1550.87, Solid	**0.5mg** **1mg**
J64109	**GAP 27** *[Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile]* [198284-64-9], $C_{60}H_{102}N_{15}O_{17}$, F.W. 1305.54, Solid, MDL MFCD03456920	**0.5mg** **1mg**
J63405	**GBR 12783 dihydrochloride** [67469-57-2], $C_{28}H_{32}N_2O \cdot 2HCl$, F.W. 485.50, Powder Application(s): A very potent and selective inhibitor of dopamine uptake	**10mg** **50mg**
	Gentisic acid, see 2,5-Dihydroxybenzoic acid, A11459, p. 191	
J60684	**GBR 12909 dihydrochloride** *[1-(2-[Bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride]* [67469-78-7], $C_{28}H_{32}F_2N_2O \cdot 2HCl$, F.W. 523.49, Powder, MDL MFCD00055193 Application(s): Dopamine uptake inhibitor	**10mg** **50mg**
J62991	**GBR 12935 dihydrochloride** *[1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride]* [67469-81-2], $C_{28}H_{34}N_2O \cdot 2HCl$, F.W. 487.51, Powder, MDL MFCD00083175 Application(s): A very potent and selective inhibitor of dopamine uptake	**10mg** **50mg**
	GDP, see Guanosine-5'-diphosphate disodium salt, J61646, p. 240	
J62699	**Gelatin, 10% soln.** [9000-70-8], Liquid, †	**125ml** **250ml**
J61548	**Gelatin, type A, 175 Bloom** [9000-70-8], Powder, Merck **14**,4382, EINECS 232-554-6, RTECS LX8580000, MDL MFCD00081638, †	**100g** **500g** **1kg**
J62755	**Gelatin blocking buffer, 1% in PBS** Liquid, Note: 1% Gelatin in PBS, †	**500ml** **1L**
J63104	**Gelatin blocking buffer, 1% in PBS, with 0.02% sodium azide** Liquid, Note: 1% Gelatin and 0.02% Sodium azide in PBS	**500ml** **1L**
J62966	**Gelatin blocking buffer, 1% in TBS** Liquid, Note: 1% Gelatin in TBS	**500ml** **1L**
J60805	**Gelatin blocking buffer, 1% in TBS, with 0.02% sodium azide** Liquid, Note: 1% Gelatin and 0.02% Sodium azide in TBS	**500ml** **1L**
J60939	**Gelatin and Tween 20 in PBS** Liquid, Note: Contains 1% Gelatin and 0.05% Tween-20 in PBS.	**500ml** **1L**
J62479	**Gelatin and Tween 20 in PBS, with 0.02% sodium azide** Liquid, Note: This buffer contains 1% Gelatin and 0.05% Tween-20 in PBS with 0.02% sodium azide.	**500ml** **1L**
J62272	**Gelatin and Tween 20 in TBS** Liquid, Note: This buffer contains 1% Gelatin and 0.05% Tween-20 in TBS.	**500ml** **1L**
J61671	**Gelatin and Tween 20 in TBS, with 0.02% sodium azide** Liquid, Note: This buffer contains 1% Gelatin and 0.05% Tween-20 in TBS with 0.02% sodium azide.	**500ml** **1L**
J63358	**Gelatin veronal buffer (GVB), 5mM barbital** Liquid, Note: This buffer contains: 5mM barbital, 145mM NaCl 145 mM, and 0.1% gelatin at pH 7.2.	**250ml** **500ml**

Stock #	Description	Size
J62828	**Gelatin veronal buffer (GVB), 10mM barbital** Liquid, Note: This buffer contains: 10mM barbital, 145mM NaCl 145 mM, and 0.1% gelatin at pH 7.2.	**250ml** **500ml**
J63725	**Gelatin veronal buffer with EDTA (GVBE), 5mM barbital** Liquid, Note: This buffer contains: 5mM barbital, 145mM NaCl, 0.1% gelatin, 10mM EDTA at pH 7.2.	**250ml** **500ml**
J61085	**Gelatin veronal buffer with EDTA (GVBE), 10mM barbital** Liquid, Note: This buffer contains: 10mM barbital, 145mM NaCl, 0.1% gelatin, 10mM EDTA at pH 7.2.	**250ml** **500ml**
J61909	**Gelatin veronal buffer with Mg and EDTA (GVBMG), 5mM barbital** Liquid, Note: This buffer contains: 5mM barbital,145mM sodium chloride, 0.1% gelatin, 0.5mM magnesium chloride and 10mM EDTA at pH 7.2.	**250ml** **500ml**
J60686	**Gelatin veronal buffer with Mg and EDTA (GVBMG), 10mM barbital** Liquid, Note: This buffer contains: 10mM barbital,145mM sodium chloride, 0.1% gelatin, 0.5mM magnesium chloride and 10mM EDTA at pH 7.2	**250ml** **500ml**
J61165	**Gelatin veronal buffer with Mg and Ca (GVB++), 5mM barbital** Viscous liquid, Note: This buffer contains barbital 5 mM, 145mM sodium chloride, 0.1% gelatin, 0.5mM magnesium chloride, and 0.15mM calcium chloride at pH 7.2	**250ml** **500ml**
J61744	**Gelatin veronal buffer with Mg and Ca (GVB++), 10mM barbital** Liquid, Note: This buffer contains 10mM barbital, 145mM sodium chloride, 0.1% gelatin, 0.5mM magnesium chloride, and 0.15mM calcium chloride at pH 7.2	**250ml** **500ml**
J63397	**Geldanamycin, 99+%** *[NSC 122750, U-29135]* [30562-34-6], $C_{29}H_{40}N_2O_9$, F.W. 560.64, Powder, RTECS LX8920000, MDL MFCD00274570 H:H303, P:P312 Application(s): Benzoquinoid antibiotic that inhibits pp60src tyrosine kinase	**25mg** **100mg** **250mg**
J63423	**Gellan Gum** *[Phytagel]* [71010-52-1], Powder, Merck **14**,4383, EINECS 275-117-5, MDL MFCD00131909, † Application(s): An agar substitute and gelling agent	**250g** **1kg**
	Geneticin, see G418 disulfate, 50mg/ml solution, J63871, p. 229 **Geneticin disulfate**, see G418 disulfate, Cell Culture Reagent, J62671, p. 229 **Genistein**, see 4',5,7-Trihydroxyisoflavone, 99+%, J63241, p. 377 **Genistein-7-β-O-Glucopyranoside**, see Genistin, 99+%, J63445, p. 231 **Genistein 7-O-glucoside**, see Genistin, 99+%, J63445, p. 231	
J63445	**Genistin, 99+%** *[Genistein 7-O-glucoside, Genistein-7-β-O-Glucopyranoside]* [529-59-9], $C_{21}H_{20}O_{10}$, F.W. 432.38, Powder, m.p. 258-259°, Merck **14**,4391, RTECS DJ3093000, BRN 64479, MDL MFCD00016883 Application(s): Glucoside of genistein that inhibits protein tyrosine kinase	**25mg** **100mg**
J62834	**Gentamycin sulfate, 600 I.U./mg** [1405-41-0], Powder, Merck **14**,4392, EINECS 215-778-9, RTECS LY2625000, MDL MFCD00270181, Note: Composed of Gentamycin C1, Gentamycin C1a and Gentamycin C2 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): Bacterial antibiotic that inhibits protein synthesis	**1g** **5g** **10g**
	Gentian Violet, see Crystal Violet, B21932, p. 170	
A19864	**Geranyl acetate, 98%** [105-87-3], $(CH_3)_2C{=}CHCH_2CH_2C(CH_3){=}CHCH_2O_2CCH_3$, F.W. 196.29, b.p. 137-139°/25mm, f.p. 104°(219°F), d. 0.91, n_D^{20} 1.461, EINECS 203-341-5, RTECS RG5920000, MDL MFCD00015037, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**25g** **100g**
A14093	**Geranyl bromide, 96% ▲** *[3,7-Dimethyl-2,6-octadienyl bromide]* [6138-90-5], $C_{10}H_{17}Br$, F.W. 217.16, b.p. 99-101°/10mm, f.p. 95°(203°F), d. 1.094, n_D^{20} 1.5040, EINECS 228-123-7, BRN 1422412, MDL MFCD00000243, † H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Terpene building block. The Horner reaction with **Methyldiphenylphosphine oxide**, **A11484**, provides a convenient access to the natural product (3Z,6E)-α-farnesene, greatly superior to earlier multistep approaches: *J. Org. Chem.*, **60**, 6211 (1995):  	**5g** **25g** **100g**
	Gerontine, see Spermine, L19562, p. 351 **GF 109203X**, see Bisindolylmaleimide 1, J63401, p. 127	

Stock #	Description	Size
J65403	**GGTI-2133** *[N-[[4-(Imidazol-4-yl)methylamino]-2-(1-naphthyl)benzoyl]leucine]* $C_{27}H_{30}N_4O_3$, F.W. 458.55, Solid, MDL MFCD07776925 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1mg**
J65022	**GGTI-2147** ■ *[(S)-Methyl 2-(4-(((1H-imidazol-4-yl)methyl)amino)-2-(naphthalen-1-yl)benzamido)-4-methylpentanoate]* [191102-87-1], $C_{28}H_{32}N_4O_3$, F.W. 472.58, Solid	**0.5mg**
J64943	**Ghrelin, human** [258279-04-8], $C_{149}H_{249}N_{47}O_{42}$, F.W. 3370.85, Solid	**1mg**
J64669	**Ghrelin, rat** [258338-12-4], $C_{147}H_{245}N_{45}O_{42}$, F.W. 3314.78, Lyophilized powder, RTECS LY8965000, MDL MFCD02687544	**1mg**
J64299	**Ghrelin, Ser(palmitoyl), rat** [258338-12-4], $C_{155}H_{261}N_{45}O_{42}$, F.W. 3427, Solid, RTECS LY8965000	**0.5mg** **1mg**
J65946	**(Des-octanoyl)-Ghrelin, human** *[Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg]* [313951-59-6], $C_{141}H_{235}N_{47}O_{41}$, F.W. 3244.66, Solid, RTECS LY8960000	**0.5mg** **1mg**
	GHRF, see Growth Hormone Releasing Factor **GHRF (1-29), human**, see Growth Hormone Releasing Factor (GRF) (1-29) amide, human, J61111, p. 238 **GHRF (1-40), human**, see Growth Hormone Releasing Factor (GRF) (1-40), human, J61784, p. 238 **GHRF (1-44), human**, see Growth Hormone Releasing Factor (GRF) (1-44), human, J62895, p. 238	
A17843	**Gibberellic acid, 90+%** [77-06-5], $C_{19}H_{22}O_6$, F.W. 346.37, m.p. 222° dec., $[\alpha]_D^{20}$ +78° (c=2 in methanol), Merck **14**,4419, EINECS 201-001-0, RTECS LY8990000, BRN 54346, MDL MFCD00079329, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Plant growth regulator. For an overview of the chemistry of gibberelins, see: *Chem. Rev.*, **92**, 573 (1992). Application(s): Plant growth hormone	**1g** **5g** **25g**
45569	**Gibberellic acid, 98%** [77-06-5], $C_{19}H_{22}O_6$, F.W. 346.37, Powder, m.p. 222° dec., Merck **14**,4419, EINECS 201-001-0, RTECS LY8990000, BRN 54346, MDL MFCD00079329, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): Plant growth hormone	**500mg** **2g** **10g**
B21172	**Giemsa Stain** [51811-82-6], m.p. ca 300°, EINECS 257-438-2, MDL MFCD00081642, † Application(s): Used in histopathology as a stain specific for phosphate groups in DNA	**10g** **50g**
	Gindarine, see L-Tetrahydropalmatine, J63911, p. 363	
J62384	**Ginkgolide A** [15291-75-5], $C_{20}H_{24}O_9$, F.W. 408.41, Powder, Merck **14**,4426, MDL MFCD00133365 Application(s): Platelet-Activating Factor (PAF) antagonist	**20mg**
J60646	**Ginkgolide B** *[BN-52021]* [15291-77-7], $C_{20}H_{24}O_{10}$, F.W. 424.40, Powder, Merck **14**,4426, MDL MFCD05662347 Application(s): Platelet-Activating Factor (PAF) antagonist	**10mg** **50mg**
J63101	**Ginseng Tetrapeptide** *[H-Val-γ-D-Glu-D-Arg-Gly-OH]* [178553-95-2], $C_{18}H_{33}N_7O_7$, F.W. 459.50, Solid Application(s): Appears to stimulate the growth of epidermal fibroblasts	**5mg**
	Glibenclamide, see Glybenzcyclamide, B21459, p. 235	
J62032	**Glimepiride** [93479-97-1], $C_{24}H_{34}N_4O_5S$, F.W. 490.62, Powder, m.p. 212-215°, Merck **14**,4440, RTECS UX9363950, MDL MFCD00878417 Application(s): A sulfonylurea hypoglecemic agent and potent potassium channel blocker	**100mg** **1g**
J63398	**Glipizide** *[1-Cyclohexyl-3-4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonylurea]* [29094-61-9], $C_{21}H_{27}N_5O_4S$, F.W. 445.54, Powder, Merck **14**,4442, EINECS 249-427-6, RTECS YS7640000, MDL MFCD00072159 Application(s): An ATP-dependent potassium channel blocker	**1g** **5g**
	H-L-Gln-OH, see L-Glutamine, 99+%, J61560, p. 235 **GLP-2 (1-33), human**, see Glucagon Like Peptide-2 (1-33), human, J65432, p. 233	

Stock #	Description	Size
J60827	**Glucagon (1-29), human** [16941-32-5], $C_{153}H_{225}N_{43}O_{49}S$, F.W. 3982.80, Powder Application(s): A peptide hormone that plays a role in maintaining glucose homeostasis	**0.5mg** **1mg**
J63443	**Glucagon (19-29), human** *[Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr]* [64790-15-4], $C_{61}H_{89}N_{15}O_{18}S$, F.W. 1352.50, Powder Application(s): This fragment inhibits calcium activated ATPase activity	**1mg** **5mg**
J65432	**Glucagon Like Peptide-2 (1-33), human** $C_{165}H_{254}N_{44}O_{55}S$, F.W. 3766.1, Solid	**1mg**
J64460	**[Ser8] Glucagon Like Peptide-1 (7-36) amide, human** *[[Ser8]-GLP-1 (7-36)]* [215777-46-1], $C_{149}H_{225}N_{40}O_{46}$, F.W. 3312.61, Solid	**0.5mg** **1mg**
	D-Glucitol, see D-Sorbitol, 36404, p. 350 **N-(D-Glucityl)-N-methyldecanamide**, see N-Decanoyl-N-methylglucamine, J60173, p. 176 **N-(D-Glucityl)-N-methyloctanamide**, see N-Octanoyl-N-methylglucamine, J63574, p. 306 **α-1,6-Glucobiose**, see Isomaltose, J60884, p. 261 **D-(+)-Gluconic acid δ-lactone**, see D-(+)-Glucono-1,5-lactone, A13105, p. 233 **δ-Gluconolactone**, see D-(+)-Glucono-1,5-lactone, A13105, p. 233	
A13105	**D-(+)-Glucono-1,5-lactone, 99%** *[D-(+)-Gluconic acid δ-lactone, δ-Gluconolactone]* [90-80-2], $C_6H_{10}O_6$, F.W. 178.14, m.p. 154-159° dec., $[\alpha]_D^{20}$ +65° (c=4 in water), Merck **14**,4457, EINECS 202-016-5, RTECS LZ5184000, BRN 83286, MDL MFCD00006647, † 	**250g** **500g** **2.5kg**
	3-O-α-D-Glucopyranosyl-D-fructose, see D-Turanose, B21224, p. 385 **6-O-α-D-Glucopyranosyl-D-fructose**, see Palatinose hydrate, 98+%, J60091, p. 311 **α-D-Glucopyranosyl-α-D-glucopyranoside**, see D-(+)-Trehalose dihydrate, A19434, p. 374 **4-O-α-Glucopyranosyl-D-glucose monohydrate**, see D-(+)-Maltose monohydrate, A16266, p. 277 **4-O-β-Glucopyranosyl-D-glucose**, see D-(+)-Cellobiose, A14553, p. 151 **6-O-α-D -Glucopyranosyl-D -glucose**, see Isomaltose, J60884, p. 261 **4-O-β-Glucopyranosyl-D-glucose octaacetate**, see D-Cellobiose octaacetate, L08780, p. 151	
A15532	**D-Glucosamine hydrochloride, 98+%** [66-84-2], $C_6H_{13}NO_5 \cdot HCl$, F.W. 215.64, m.p. ca 192° dec., $[\alpha]_D^{20}$ +73° (c=1 in water, 20h), Merck **14**,4458, EINECS 200-638-1, RTECS LZ6665000, BRN 4157370, MDL MFCD00067674, † 	**50g** **250g** **1kg**
L09020	**β-D-Glucosamine pentaacetate, 96%** *[2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose]* [7772-79-4], $C_{16}H_{23}NO_{10}$, F.W. 389.37, m.p. 184-189°, $[\alpha]_D^{20}$ +4° (c=10 in chloroform), EINECS 231-865-4, BRN 98835, MDL MFCD00006595 	**1g** **5g**
J60067	**D-(+)-Glucose, 1M aq. soln., sterile** [50-99-7], $C_6H_{12}O_6$, F.W. 180.16, Liquid, †	**125ml** **250ml**
A11090	**D-(+)-Glucose monohydrate, 99%** [14431-43-7], $C_6H_{12}O_6 \cdot H_2O$, F.W. 198.18 (180.16anhy), m.p. ca 83°, EINECS 200-075-1, MDL MFCD00149450, † 	**500g** **2.5kg**
A16828	**D-(+)-Glucose, anhydrous, 99%** *[Dextrose]* [50-99-7], $C_6H_{12}O_6$, F.W. 180.16, m.p. 147-153°, $[\alpha]_D^{20}$ +53° (c=10 in water, 3h), Merck **14**,4459, EINECS 200-075-1, RTECS LZ6600000, BRN 1281608, MDL MFCD00063774, † 	**500g** **2.5kg** **10kg**
J65272	**Glucose Dehydrogenase variant A** *[EC 1.1.1.118]* Lyophilized powder, Note: Component in the Cofactor Recycling Enzymes Kit, item J64535	**250mg** **500mg** **1g**
J65832	**Glucose Dehydrogenase variant B** *[EC 1.1.1.118]* Lyophilized powder, Note: Component in the Cofactor Recycling Enzymes Kit, item J64535	**250mg** **500mg** **1g**
J60385	**Glucose gelatin veronal buffer (GGVB)** Liquid, Note: This buffer contains: 5mM barbital, 140 mM glucose, 71mM sodium chloride, 0.1% gelatin, 0.5mM magnesium chloride, and 0.15mM calcium chloride at pH 7.2.	**250ml** **500ml**
J61846	**Glucose gelatin veronal buffer with EDTA (GGVB)** Liquid, Note: This buffer contains: 5mM barbital, 140mM glucose, 71mM NaCl, 0.1% gelatin, and 10mM EDTA 10 mM at pH 7.2	**250ml** **500ml**

Stock #	Description	Size
J60117	**Glucose-6-phosphate dehydrogenase, Leuconostoc mesenteroides** *[G6PD]* [9001-40-5], Lyophilized powder, EINECS 232-602-6, MDL MFCD00081656, Note: Minimum 200 NADP units per mg protein. One unit reduces one micromole of NAD per minute at 37 degrees and pH 7.8, using glucose-6-phosphate as substrate, † Application(s): Oxidizes glucose-6-phosphate in the presence of NADP+ to yield 6-phosphogluconate	**1kilounit** **10kilounits**
J61181	**Glucose-6-phosphate dehydrogenase, yeast** *[EC 1.1.1.49, RP-87086]* [9001-40-5], Lyophilized powder, EINECS 232-602-6, MDL MFCD00081656, Note: One unit reduces one micromole of NADP per minute at pH 7.6 and 25 degrees. Minimum 20 units per mg protein, † Application(s): Converts p-glucose-6-phosphate to p-glucono-d-lactone-6-phosphate in presence of NADP+ or NAD+	**1kilounit**
J63656	**Glucose veronal buffer (GVB)** Liquid, Note: This buffer contains: 5mM barbital, 140mM glucose, 71mM sodium chloride, 0.5m magnesium chloride, and 0.15mM calcium chloride at pH 7.2.	**250ml** **500ml**
J60787	**Glucose veronal buffer with EDTA (GVB)** Liquid, Note: 5mM barbital, 140mM glucose, 71mM NaCl 10mM EDTA, pH 7.2	**250ml** **500ml**
L14350	**D-Glucuronic acid, 98+%** [6556-12-3], $C_6H_{10}O_7$, F.W. 194.14, m.p. ca 158° dec., $[\alpha]_D^{20}$ +35° (c=6 in water), Merck **14**,4465, EINECS 229-486-4, RTECS LZ8836600, BRN 1727083, MDL MFCD00077778, † 	**5g** **25g**
A15861	**D-Glucurono-6,3-lactone, 99%** [32449-92-6], $C_6H_8O_6$, F.W. 176.12, m.p. 174° dec., $[\alpha]_D^{20}$ +19° (c=8 in water), Merck **14**,4467, EINECS 251-053-3, RTECS LZ8930000, BRN 83595, MDL MFCD00135622, † 	**25g** **100g** **500g**
A14191	**D-Glutamic acid, 99+%** *[D-2-Aminoglutaric acid, H-D-Glu-OH]* [6893-26-1], $C_5H_9NO_4$, F.W. 147.13, m.p. 199° dec., $[\alpha]_D^{20}$ -30° (c=10 in 2N HCl), Merck **14**,4469, EINECS 230-000-8, BRN 1723800, MDL MFCD00063112, † 	**5g** **25g** **100g**
A15031	**L-Glutamic acid, 99+%** *[L-2-Aminoglutaric acid, H-Glu-OH]* [56-86-0], $C_5H_9NO_4$, F.W. 147.13, m.p. 189-192° dec., d. 1.525, $[\alpha]_D^{20}$ +31° (c=5 in 5N HCl), Merck **14**,4469, EINECS 200-293-7, RTECS LZ9700000, BRN 1723801, MDL MFCD00002634, †  For use as a chiral building-block in the synthesis of the (S)-isomer of γ-butyrolactone-4-carboxylic acid, see: *Org. Synth. Coll.*, **7**, 99 (1990):  For the differential protection of the α-carboxyl group of N-protected glutamic acid by reaction with formaldehyde to form the cyclic 5-oxazolidinone, see: *Synthesis*, 542 (1989).	**250g** **500g** **1kg** **5kg**
A17719	**DL-Glutamic acid monohydrate, 99%** *[DL-2-Aminoglutaric acid monohydrate, H-DL-Glu-OH.H_2O]* [19285-83-7], $C_5H_9NO_4 \cdot H_2O$, F.W. 165.15 (147.13anhy), m.p. ca 200° dec., d. 1.460, Merck **14**,4469, EINECS 210-522-2, RTECS LZ9648000, BRN 4155097, MDL MFCD00150703, † 	**25g** **100g** **500g**
J63424	**L-Glutamic acid monosodium salt** *[Monosodium glutamate, (S)-2-Aminopentanedioic acid]* [142-47-2], $C_5H_8NNaO_4$, F.W. 169.11, Powder, Merck **14**,6254, EINECS 205-538-1, RTECS MA1578000, MDL MFCD00013074, †	**10g** **25g**
A12505	**L-Glutamic acid hydrochloride, 99%** ■ *[L-2-Aminoglutaric acid hydrochloride, H-Glu-OH.HCl]* [138-15-8], $C_5H_9NO_4 \cdot HCl$, F.W. 183.59, m.p. 203° dec., d. 1.525, $[\alpha]_D^{20}$ +23° (c=6 in water), Merck **14**,4469, EINECS 205-315-9, BRN 3565569, MDL MFCD00012619, †  H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **1kg**
	D-Glutamic acid 5-amide, see D-Glutamine, 99+%, J60784, p. 235	
J64847	**L-Glutamic acid α-(7-amido-4-methylcoumarin)** *[H-Glu-AMC, Glutamic acid-AMC]* [98516-76-8], $C_{15}H_{16}N_2O_5$, F.W. 304.30, Powder	**50mg**
J64272	**L-Glutamic acid γ-(7-amido-4-methylcoumarin)** *[H-Glu(AMC)-OH]* [72669-53-5], $C_{15}H_{16}N_2O_5$, F.W. 304.30, Powder, MDL MFCD00038085	**50mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
B24859	**L-Glutamic acid 5-methyl ester, 99%** *[H-Glu(OMe)-OH, γ-Methyl L-glutamate]* [1499-55-4], $C_6H_{11}NO_4$, F.W. 161.16, m.p. 182° dec., EINECS 216-110-9, MDL MFCD00002632 	**5g** **25g** **100g**
J60044	**Glutamic oxalacetic transaminase, porcine heart** *[L-Aspartate: 2-oxoglutarate aminotransferase, Aspartate aminotransferase]* [9000-97-9], Suspension, EINECS 232-571-9, MDL MFCD00131191, Note: Minimum 200 units per mg protein. One unit catalyzes the transamination of one micromole of L-aspartate per minute at 25°C and pH 7.5, † Application(s): Converts L-aspartate and α-ketoglutarate to oxaloacetate and L-glutamate	**1kilounit**
J62109	**Glutamic pyruvic transaminase, porcine heart** *[L-Alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2]* [9000-86-6], Lyophilized powder, EINECS 232-561-4, BRN 3562140, MDL MFCD00131192, Note: Minimum 100 units/mg. One unit converts one micromole of alpha-ketoglutarate to L-glutamate, in potassium phosphate buffer, at pH 7.5 and 25 degrees C, † Application(s): Converts L-alanine and α-ketoglutarate to pyruvic acid and L-glutamate	**1kilounit**
J60784	**D-Glutamine, 99+%** *[D-2-Aminoglutaramic acid, D-Glutamic acid 5-amide]* [5959-95-5], $C_5H_{10}N_2O_3$, F.W. 146.14, Powder, BRN 1723796, MDL MFCD00065607 Application(s): Kinase inhibitor; has antivasospastic properties	**1g** **5g** **25g**
J61560	**L-Glutamine, 99+%** *[L-Glutamic acid 5-amide, H-L-Gln-OH]* [56-85-9], $C_5H_{10}N_2O_3$, F.W. 146.14, Powder, m.p. ca 185° dec., Merck **14**,4471, EINECS 200-292-1, RTECS MA2275100, BRN 1723797, MDL MFCD00008044, †	**100g** **500g** **1kg**
J60573	**L-Glutamine, Cell Culture Reagent** [56-85-9], $C_5H_{10}N_2O_3$, F.W. 146.14, Crystalline powder, Merck **14**,4471, EINECS 200-292-1, RTECS MA2275100, BRN 1723797, MDL MFCD00008044, †	**25g** **100g** **1kg**
	γ-L-Glutamyl-L-cysteinylglycine, see L-Glutathione, reduced, 98+%, J62166, p. 235	
A14442	**γ-L-Glutamyl-4-nitroanilide, 98+%** [7300-59-6], $C_{11}H_{13}N_3O_5$, F.W. 267.24, m.p. 185-188°, EINECS 230-748-5, BRN 2818758, MDL MFCD00036218, †  Application(s): Substrate for γ-glutamyl transpeptidase	**1g** **5g** **25g**
	Glutathiol, see L-Glutathione, oxidized, J63715, p. 235	
J63715	**L-Glutathione, oxidized** *[Glutathiol, GSSG]* [27025-41-8], $C_{20}H_{32}N_6O_{12}S_2$, F.W. 612.64, Powder, Merck **14**,4475, EINECS 248-170-7, RTECS MC0556500, BRN 1718700, MDL MFCD00063106 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Acts as hydrogen acceptor in enzymatic determination of NADP and NADPH	**1g** **5g**
A18014	**L-Glutathione, reduced, 97%** *[γ-L-Glutamyl-L-cysteinylglycine, GSH]* [70-18-8], $C_{10}H_{17}N_3O_6S$, F.W. 307.33, m.p. ca 193° dec., $[\alpha]_D^{20}$ -17° (c=2 in water), Merck **14**,4475, EINECS 200-725-4, RTECS MC0556000, BRN 1729812, MDL MFCD00065939, † H:H303, P:P312 	**5g** **25g** **100g**
J62166	**L-Glutathione, reduced, 98+%** *[γ-L-Glutamyl-L-cysteinylglycine, GSH]* [70-18-8], $C_{10}H_{17}N_3O_6S$, F.W. 307.33, Crystalline powder, m.p. ca 193° dec., Merck **14**,4475, EINECS 200-725-4, RTECS MC0556000, BRN 1729812, MDL MFCD00065939, † Application(s): A tripeptide used for reductive cleavage of disulfide bonds	**5g** **25g** **100g**
	H-Gly-OH, see Glycine, 99.5+%, Cell Culture Reagent, J62407, p. 237	
B21459	**Glybenzcyclamide, 99%** *[Glibenclamide, Glyburide]* [10238-21-8], $C_{23}H_{28}ClN_3O_5S$, F.W. 494.01, m.p. 171-174°, EINECS 233-570-6, MDL MFCD00056625 H:H303, P:P312  Application(s): ATP-dependent potassium channel (KATP) and cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel blocker	**25g** **100g**
	Glyburide, see Glybenzcyclamide, B21459, p. 235 **Glycerin**, see Glycerol, Cell Culture Grade, J62399, p. 235	
J62399	**Glycerol, Cell Culture Grade** *[1,2,3-Propanetriol, Glycerin]* [56-81-5], $C_3H_8O_3$, F.W. 92.09, Viscous liquid, m.p. 18°, b.p. 182°/20mm, f.p. 160°(320°F), d. 1.26, n_D^{20} 1.4740, Merck **14**,4484, EINECS 200-289-5, RTECS MA8050000, BRN 635685, MDL MFCD00004722, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): Useful as a cryoprotectant	**100ml** **250ml** **500ml**

Stock #	Description	Size
J61059	**Glycerol, Molecular Biology Grade** ■ [56-81-5], $HOCH_2CH(OH)CH_2OH$, F.W. 92.09, Liquid, m.p. 18°, b.p. 182°/20mm, f.p. 160°(320°F), d. 1.26, n_D^{20} 1.474, Merck **14**,4484, EINECS 200-289-5, RTECS MA8050000, BRN 635685, MDL MFCD00004722, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): Useful as a cryoprotectant	**100ml** **500ml** **1L**
J64719	**Glycerol, ultrapure, 99.5+%** ■ [56-81-5], $C_3H_8O_3$, F.W. 92.09, Viscous liquid, m.p. 18°, b.p. 182°/20mm, f.p. 160°(320°F), d. 1.260, n_D^{20} 1.4740, Merck **14**,4484, EINECS 200-289-5, RTECS MA8050000, BRN 635685, MDL MFCD00004722, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100ml** **250ml** **500ml**
38988	**Glycerol, ultrapure, HPLC Grade** ■ [56-81-5], $HOCH_2CH(OH)CH_2OH$, F.W. 92.09, Viscous liquid, m.p. 18°, b.p. 182°/20mm, f.p. 160°(320°F), d. 1.26, n_D^{20} 1.474, Merck **14**,4484, EINECS 200-289-5, RTECS MA8050000, BRN 635685, MDL MFCD00004722, Note: Suitable for spectrophotometry, chromatography. Filtered through 0.2µ filters., † Maximum level of impurities: H_2O 0.05% ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 **UV absorption - 1cm cell vs H_2O** λ(nm) 400 320 280 225 210 205 A 0.01 0.02 0.05 0.10 0.30 1.00	**500ml** **1L** **4L** **4x1L**
32450	**Glycerol, ultrapure, Spectrophotometric Grade** ■ [56-81-5], $HOCH_2CH(OH)CH_2OH$, F.W. 92.09, Viscous liquid, m.p. 18°, b.p. 182°/20mm, f.p. 160°(320°F), d. 1.26, n_D^{20} 1.474, Merck **14**,4484, EINECS 200-289-5, RTECS MA8050000, BRN 635685, MDL MFCD00004722, † Maximum level of impurities: H_2O 0.1% ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 **UV absorption - 1cm cell vs H_2O** λ(nm) 400 320 280 225 210 205 A 0.01 0.02 0.05 0.10 0.30 1.00	**100ml** **1L** **4L** **4x1L**
A17132	**Glycerol triacetate, 99%** *[Triacetin]* [102-76-1], $C_9H_{14}O_6$, F.W. 218.21, m.p. 2-4°, b.p. 257-259°, f.p. 149°(300°F), d. 1.155, EINECS 203-051-9, MDL MFCD00008716, †	**500g** **2.5kg**
A11830	**Glycerol tributyrate, 98%** *[Tributyrin]* [60-01-5], $C_{15}H_{26}O_6$, F.W. 302.37, m.p. -75°, b.p. 307-308°, f.p. 174°(345°F), d. 1.032, n_D^{20} 1.4358, Merck **14**,9620, EINECS 200-451-5, RTECS ET7350000, BRN 1714746, MDL MFCD00009392, † Application(s): A triglyceride that may inhibit cell growth and induce cell differentiation	**50g** **250g** **1kg**
	Glycerol trioleate, see Triolein, J62419, p. 379	
A10922	**Glycerol tripalmitate, 98%** *[Tripalmitin]* [555-44-2], $C_{51}H_{98}O_6$, F.W. 807.34, m.p. 60-64°, EINECS 209-098-1, MDL MFCD00008995, †	**1g** **5g** **25g**
J62121	**β-Glycerophosphate, 200mM soln.** [819-83-0], $C_3H_7Na_2O_6P$, F.W. 216.04, Liquid, †	**50ml** **100ml**
	Glyceryl tridodecanoate, see Trilaurin, J62962, p. 378 **Glyceryl trimethyristate**, see Trimyristin, 95%, J62819, p. 378	
J61855	**Glycine, 0.2M buffer soln., pH 2.5** [56-40-6], Liquid, †	**250ml** **500ml**
J62527	**Glycine, 0.2M buffer soln., pH 3.0** [56-40-6], Liquid, †	**250ml** **500ml**
J60154	**Glycine, 0.2M buffer soln., pH 3.5** [56-40-6], Liquid, †	**250ml** **500ml**
43497	**Glycine, ACS, 98.5+%** *[Aminoacetic acid, H-Gly-OH]* [56-40-6], $NH_2CH_2CO_2H$, F.W. 75.07, Crystalline, m.p. ca 245° dec., d. 1.595, Merck **14**,4491, Fieser **1**,412, EINECS 200-272-2, RTECS MB7600000, BRN 635782, MDL MFCD00008131, † Maximum level of impurities: Residue after ignition 0.1%, Heavy metals (as Pb) 0.002%, Cl 0.005%, SO_4 0.005%, NH_4 0.005%, Substances darkened by sulfuric acid P.T., Hydrolyzable substances P.T. H:H373, P:P260-P314-P501a	**100g** **500g** **3kg**

Stock #	Description	Size
A13816	**Glycine, 99%** *[Aminoacetic acid, H-Gly-OH]* [56-40-6], $NH_2CH_2CO_2H$, F.W. 75.07, m.p. ca 245° dec., d. 1.595, Merck **14**,4491, Fieser **1**,412, EINECS 200-272-2, RTECS MB7600000, BRN 635782, MDL MFCD00008131, †	**100g** **250g** **500g** **2.5kg** **10kg**
36435	**Glycine, 99.5+%** *[Aminoacetic acid, H-Gly-OH]* [56-40-6], $H_2NCH_2CO_2H$, F.W. 75.07, Powder, m.p. ca 245° dec., d. 1.595, Merck **14**,4491, Fieser **1**,412, EINECS 200-272-2, RTECS MB7600000, BRN 635782, MDL MFCD00008131, †	**250g** **1kg**
J62407	**Glycine, 99.5+%, Cell Culture Reagent** *[Aminoacetic acid, H-Gly-OH]* [56-40-6], $H_2NCH_2CO_2H$, F.W. 75.07, Powder, m.p. ca 245° dec., d. 1.595, Merck **14**,4491, EINECS 200-272-2, RTECS MB7600000, BRN 635782, MDL MFCD00008131, †	**100g** **500g** **1kg**
J64365	**Glycine, Electrophoresis Grade, 99.5+%** *[Aminoacetic acid, H-Gly-OH]* [56-40-6], $H_2NCH_2CO_2H$, F.W. 75.07, Powder, m.p. ca 245° dec., d. 1.595, Merck **14**,4491, EINECS 200-272-2, RTECS MB7600000, BRN 635782, MDL MFCD00008131, †	**250g** **1kg**
J65592	**L-Glycine-7-amido-4-methylcoumarin** *[L-Gly-AMC, L-G-AMC]* $C_{12}H_{12}N_2O_3$, F.W. 232.23, Solid	**10mg** **25mg**
J64033	**L-Glycine-7-amido-4-trifluoromethylcoumarin** *[Gly-AFC, G-AFC]* $C_{12}H_9F_3N_2O_3$, F.W. 286.20, Solid	**10mg** **25mg**
A18822	**Glycine anhydride, 99%** *[2,5-Piperazinedione, 2,5-Diketopiperazine]* [106-57-0], $C_4H_6N_2O_2$, F.W. 114.10, m.p. ca 300° dec., Merck **14**,7466, EINECS 203-411-5, RTECS TL6325250, BRN 112112, MDL MFCD00006009, † 	**25g** **100g**
	Glycine Soja, see Soybean oil, J61399, p. 350	
A12511	**Glycolic acid, 98%** ■ *[Hydroxyacetic acid]* [79-14-1], $HOCH_2CO_2H$, F.W. 76.05, m.p. 74-80°, d. 1.49, Merck **14**,4498, UN3261, EINECS 201-180-5, RTECS MC5250000, BRN 1209322, MDL MFCD00004312, † H:H314-H302, P:P280-P305+P351+P338-P309-P310	**100g** **500g**
J64191	**Glyco-SNAP-2** ▲ *[N-(2-Deoxy-α,β-D-glucopyranose-2-)-N -acetyl-S-nitroso-D,L-penicillaminamide]* [188849-82-3], $C_{13}H_{23}N_3O_8S$, F.W. 381.40, Solid	**5mg** **10mg**
J60282	**Glycylglycine, 0.2M buffer soln., pH 7.5** [556-50-3], Liquid	**100ml** **250ml**
J62920	**Glycylglycine, 0.2M buffer soln., pH 8.0** [556-50-3], Liquid	**100ml** **250ml**
J60717	**Glycylglycine, 0.2M buffer soln., pH 8.5** [556-50-3], Liquid	**100ml** **250ml**
J62591	**Glycylglycine, 0.2M buffer soln., pH 9.0** [556-50-3], Liquid	**100ml** **250ml**
A10523	**Glycylglycine, 99%** *[Diglycine, Gly-Gly]* [556-50-3], $H_2NCH_2CONHCH_2CO_2H$, F.W. 132.12, m.p. ca 220° dec., Merck **14**,4503, EINECS 209-127-8, BRN 1765223, MDL MFCD00008130, † Application(s): Buffer with a useful pH range 7.5 to 8.9	**25g** **100g** **500g**
A13778	**Glycylglycylglycine, 99%** *[Gly-Gly-Gly, Triglycine]* [556-33-2], $H_2NCH_2(CONHCH_2)_2CO_2H$, F.W. 191.14, m.p. ca 240° dec., Merck **14**,6579, EINECS 209-122-0, BRN 1711130, MDL MFCD00036223	**1g** **5g** **25g**
	Gly-Gly, see Glycylglycine, A10523, p. 237 **Gly-Gly-Gly**, see Glycylglycylglycine, A13778, p. 237 **Glyoxal bisacrylamide**, see N,N'-(1,2-Dihydroxyethylene)bisacrylamide, L19211, p. 192 **Glyoxaline**, see Imidazole, A10221, p. 254	

Stock #	Description	Size
B25149	**Glyoxylic acid, 50% w/w aq. soln.** [298-12-4], $OHCCO_2H$, F.W. 74.04, m.p. -93°, b.p. 111°, d. 1.339, UN3265, EINECS 206-058-5, MDL MFCD00006958, † H:H314-H317, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a For use in aqueous hetero Diels-Alder reactions, see: *Tetrahedron,* **50**, 10265 (1994). Reagent for the facile deprotection of oximes in aqueous medium: *Tetrahedron Lett.*, **45**, 3161 (2004).	**250g** **1kg** **5kg**
J64718	**Gly-Phe β-naphthylamide** *[Glycylphenylalanine 2-naphthylamide, (S)-2-(2-Aminoacetamido)-N-(naphthalen-2-yl)-3-phenylpropanamide]* [21438-66-4], $C_{21}H_{21}N_3O_2$, F.W. 347.41, Crystalline, MDL MFCD00021597 H:H351, P:P281-P201-P202-P308+P313-P405-P501	**100mg**
J64034	**GM 1489** *[(R)-3-((S)-3-(1H-Indol-3-yl)-1-oxo-1-((S)-1-phenylethylamino)propan-2-ylcarbamoyl)-5-methylhexanoic acid, N-[(2R)-2-(Carboxymethyl)-4-methylpentanoyl]-L-tryptophan-(S)-methyl-benzylamide]* [170905-75-6], $C_{27}H_{33}N_3O_4$, F.W. 463.60, Solid	**1mg** **5mg**
J65687	**GM 6001** ◢ *[Galardin, N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide]* [142880-36-2], $C_{20}H_{28}N_4O_4$, F.W. 388.50, Solid, MDL MFCD03453614	**1mg** **5mg**
J64386	**GM 6001, Negative Control** ◢ *[(N-t-Butoxycarbonyl-L-leucyl-L-tryptophan methylamide)]* $C_{23}H_{34}N_4O_4$, F.W. 430.54, Solid	**1mg** **5mg**
J64666	**GMAP (16-41) amide** *[Galanin Message Associated Peptide Fragment (16-41) amide, Preprogalanin (80-105) amide]* [129541-35-1], $C_{134}H_{219}N_{35}O_{37}S$, F.W. 2944.44, Solid	**0.5mg** **1mg**
J64644	**GMAP (25-41) amide** *[Galanin Message Associated Peptide Fragment (25-41) amide, Thr-Ile-Met-Glu-Phe-Leu-Ala-Phe-Leu-His-Leu-Lys-Glu-Ala-Gly-Ala-Leu-NH2]* [132567-21-6], $C_{90}H_{143}N_{21}O_{22}S$, F.W. 1903.29, Solid	**0.5mg** **1mg**
	GMBS, see N-(γ-Maleimidobutyryloxy)succinimide, J61850, p. 276	
J64301	**Goat Serum**	**5ml**
L02639	**DL-Goitrin, 98+%**  *[5-Vinyloxazolidone-2-thione]* [13190-34-6], C_5H_7NOS, F.W. 129.18, m.p. 62-66°, Merck **14**,4513, EINECS 236-145-3, BRN 80669, MDL MFCD00015467 The antithyroid factor of turnip root: *J. Biol. Chem.*, **181**, 121 (1949).	**100mg** **500mg**
J63767	**Gossypol, 98+%** *[Thespesin, 2,2'-bis(8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene)]* [303-45-7], $C_{30}H_{30}O_8$, F.W. 518.56, Powder, Merck **14**,4528, RTECS DU3100000, MDL MFCD00017352 H:H341-H361-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): Lipophilic agent derived from cottonseed	**25mg** **100mg** **250mg**
B23521	**(+)-Griseofulvin, 97%**  [126-07-8], $C_{17}H_{17}ClO_6$, F.W. 352.77, m.p. 218-220°, Merck **14**,4549, EINECS 204-767-4, RTECS WG9800000, BRN 95226, MDL MFCD00082343 H:H360-H351-H317, P:P261-P280-P302+P352-P321-P405-P501a Application(s): Interferes with microtubule formation	**5g** **25g** **100g**
J65580	**Growth Hormone Pro-Releasing Factor, human** $C_{153}H_{248}N_{44}O_{50}S_2$, F.W. 3567.99, Solid	**1mg**
J61111	**Growth Hormone Releasing Factor (GRF) (1-29) amide, human** *[GHRF (1-29), human, Sermorelin]* [86168-78-7], $C_{149}H_{246}N_{44}O_{42}S$, F.W. 3357.90, Powder, Merck **14**,8461, MDL MFCD00076559 Application(s): A peptide hormone that stimulates release of the growth hormone	**0.5mg** **1mg**
J61784	**Growth Hormone Releasing Factor (GRF) (1-40), human** *[GHRF (1-40), human]* [84069-10-3], $C_{194}H_{317}N_{61}O_{63}S$, F.W. 4544.08, Powder, MDL MFCD00081669 Application(s): A peptide hormone that stimulates release of the growth hormone	**0.5mg** **1mg**
J62895	**Growth Hormone Releasing Factor (GRF) (1-44), human** *[GHRF (1-44), human]* [83930-13-6], $C_{215}H_{358}N_{72}O_{66}S$, F.W. 5039.71, Powder, Merck **14**,8714, MDL MFCD00081671 Application(s): A peptide hormone that stimulates release of the growth hormone	**0.5mg** **1mg**
	GSH, see L-Glutathione, reduced, 98+%, J62166, p. 235	

Contact us for pricing on bulk sizes

Stock #	Description	Size
J65166	**GSK 4716** *[4-Hydroxy-2-[(1E)-[4-(1-methylethyl)phenyl]methylene]hydrazide, GW4716]* [101574-65-6], $C_{17}H_{18}N_2O_2$, F.W. 282.34, Solid, UN3077, MDL MFCD00567155 H:H410, P:P273-P391-P501	**10mg** **50mg**
J64048	**GSK-3β Inhibitor I ▲** *[TDZD-8, 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione]* $C_{10}H_{10}N_2SO_2$, F.W. 222.26, Solid H:H317, P:P261-P280-P302+P352-P321-P363-P501	**5mg**
J64336	**GSK-3β Inhibitor VI** *[2-Chloro-1-(4,5-dibromothiophen-2-yl)ethanone]* [62673-69-2], $C_6H_3Br_2ClOS$, F.W. 318.41, Solid	**5mg**
J64554	**GSK-3β Inhibitor VIII ▲** *[AR-A014418]* [487021-52-3], $C_{12}H_{12}N_4O_4S$, F.W. 308.31, Solid, MDL MFCD08277040 H:H302-H315-H318-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg**
J64307	**GSK-3 Inhibitor IX, Control, MeBIO ▲** *[1-Methyl-BIO]* [710323-61-8], $C_{17}H_{12}BrN_3O_2$, F.W. 370.20, Solid	**1mg**
J64659	**GSK-3 Inhibitor X ▲** *[BIO-Acetoxime, (2'Z,3'E)-6-Bromoindirubin-3'-acetoxime]* [740841-15-0], $C_{18}H_{12}BrN_3O_3$, F.W. 398.21, Solid H:H340-H350, P:P281-P201-P202-P308+P313-P405-P501	**1mg** **5mg**
	GSSG, see L-Glutathione, oxidized, J63715, p. 235	
J62597	**GTE buffer** Liquid, Note: Contains 25mM Tris, 50mM glucose, and 10mM EDTA. Application(s): For miniprep and DNA purification	**100ml** **250ml**
	GTP, see Guanosine-5'-triphosphate disodium salt, J61414, p. 240 **Guaiacol**, see 2-Methoxyphenol, A16319, p. 285 **Guaiacol glyceryl ether**, see 3-(2-Methoxyphenoxy)-1,2-propanediol, A16827, p. 285 **Guaifenesin**, see 3-(2-Methoxyphenoxy)-1,2-propanediol, A16827, p. 285 **Guanazole**, see 3,5-Diamino-1,2,4-triazole, B22775, p. 183	
A13543	**Guanidine hydrochloride, 98% ■** [50-01-1], CH_5N_3·HCl, F.W. 95.53, m.p. 178-185°, d. 1.344, Merck **14**,4562, EINECS 200-002-3, RTECS MF4300000, BRN 3591990, MDL MFCD00013026, †  H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501a	**250g** **1kg** **5kg**
J60786	**Guanidine hydrochloride, 99+% ■** [50-01-1], CH_5N_3·HCl, F.W. 95.53, Powder, m.p. 185-188°, d. 1.344, Merck **14**,4562, EINECS 200-002-3, RTECS MF4300000, BRN 3591990, MDL MFCD00013026, † H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501a	**100g** **500g** **1kg**
J65661	**Guanidine hydrochloride, Molecular Biology Grade ■** [50-01-1], CH_5N_3·HCl, F.W. 95.53, Crystalline solid, m.p. 178-185°, d. 1.34, EINECS 200-002-3, RTECS MF4300000, BRN 3591990, MDL MFCD00013026, † H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501 Application(s): A protein denaturant	**100g** **500g**
J65485	**Guanidine hydrochloride, ultrapure, 99% ■** [50-01-1], CH_5N_3·HCl, F.W. 95.53, Powder, m.p. 185-188°, d. 1.344, Merck **14**,4562, EINECS 200-002-3, RTECS MF4300000, BRN 3591990, MDL MFCD00013026, † H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501	**500g** **1kg** **10g**
	Guanidine rhodanide, see Guanidine thiocyanate, B21250, p. 239	
B21250	**Guanidine thiocyanate, 99% ▲** *[Guanidine rhodanide]* [593-84-0], $C_2H_5N_3S$, F.W. 118.16, m.p. 118-122°, d. 1.29, EINECS 209-812-1, RTECS XL1225000, BRN 3563461, MDL MFCD00013027, †  H:H302-EUH032-H312-H332-H412, P:P261-P280-P302+P352-P304+P340-P322-P501a	**100g** **500g** **2.5kg**
J65104	**Guanidine thiocyanate, Molecular Biology Grade ▲** *[Guanidine rhodanide]* [593-84-0], CH_5N_3.CHNS, F.W. 118.16, Crystalline solid, m.p. 118-122°, d. 1.29, EINECS 209-812-1, RTECS XL1225000, BRN 3563461, MDL MFCD00013027, † H:H302-EUH032-H312-H332-H412, P:P261-P280-P302+P352-P304+P340-P322-P501a Application(s): A protein denaturant	**50g** **250g** **500g**

Stock #	Description	Size
A12024	**Guanine, 98%** *[2-Amino-6-hydroxypurine]* [73-40-5], $C_5H_5N_5O$, F.W. 151.13, m.p. >300°, Merck **14**,4564, EINECS 200-799-8, RTECS MF8260000, BRN 9680, MDL MFCD00071533, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**25g** **100g** **500g**
	Guanine-2'-deoxyriboside hydrate, see 2'-Deoxyguanosine hydrate, L14519, p. 178	
A11328	**Guanosine, 98+%** [118-00-3], $C_{10}H_{13}N_5O_5$, F.W. 283.24, m.p. ca 250° dec., $[\alpha]_D^{20}$ -72° (c=1.5 in 0.1N NaOH), Merck **14**,4566, EINECS 204-227-8, RTECS MF8750000, BRN 625911, MDL MFCD00010182, † 	**25g** **50g** **100g** **250g**
J61646	**Guanosine-5'-diphosphate disodium salt** *[GDP]* [7415-69-2], $C_{10}H_{13}N_5Na_2O_{11}P_2$, F.W. 487.17, Powder, EINECS 231-026-2, MDL MFCD00084665	**100mg** **500mg**
J61414	**Guanosine-5'-triphosphate disodium salt** *[GTP]* [56001-37-7], $C_{10}H_{14}N_5Na_2O_{14}P_3$, F.W. 567.15, Powder, EINECS 259-940-7, BRN 4113439, MDL MFCD00083629 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**250mg** **500mg** **1g**
J64285	**Guanylin, human** *[Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr- Gly-Cys (disulfide bridges: Cys4-Cys12, Cys7-Cys15)]* $C_{58}H_{87}N_{15}O_{21}S_4$, F.W. 1458.66, Solid	**1mg**
J65417	**Guanylin, rat, mouse** *[Pro-Asn-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr- Gly-Cys(Disulfide bridge: Cys4-Cys12, Cys7-Cys15)]* [144940-98-7], $C_{60}H_{90}N_{16}O_{22}S_4$, F.W. 1515.71, Solid	**1mg**
	Gum arabic, see Acacia, 36499, p. 69 **Gum karaya from sterculia tree**, see Karaya Gum, J61844, p. 262 **Gum tragacanth**, see Tragacanth powder, A18502, p. 372	
J61083	**Guvacine hydrochloride, 99+%** [498-96-4], $C_6H_9NO_2{\cdot}HCl$, F.W. 163.60, Powder, Merck **14**,4584, MDL MFCD00055191 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): GABA uptake inhibitor	**100mg**
J65634	**GW 9662** *[2-Chloro-5-nitro-N-phenylbenzamide]* [22978-25-2], $C_{13}H_{19}N_2O_3Cl$, F.W. 276.68, Powder, MDL MFCD01215270 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
	GW-786034, see Pazopanib, 99+%, J62470, p. 312	
J61697	**H-7 dihydrochloride** *[1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine dihydrochloride, Isoquinoline-5-sulfonic 2-methyl-1-piperazide dihydrochloride]* [108930-17-2], $C_{14}H_{17}N_3O_2S{\cdot}2HCl$, F.W. 364.29, Powder, m.p. 191-193°, BRN 5840763, MDL MFCD00036961 Application(s): Protein kinase inhibitor. Inhibits cyclic nucleotide dependent protein kinase (PKA) and protein kinase C	**10mg** **50mg**
J63638	**H-9 dihydrochloride** *[N-(2-Aminoethyl)-5-isoquinolinesulfonamide hydrochloride]* [84468-17-7], $C_{11}H_{13}N_3O_2S{\cdot}2HCl$, F.W. 324.22, Powder, MDL MFCD00069286 Application(s): Protein kinase inhibitor. Most effective for cAMP and cGMP dependent protein kinases	**10mg** **50mg**
	HA-1077, see Fasudil, 98+%, J63525, p. 219 **HA-1077 dihydrochloride**, see Fasudil dihydrochloride, 99+%, J60594, p. 219 **HA-1077 hydrochloride**, see Fasudil monohydrochloride, 99+%, J60751, p. 219 **HABA**, see 2-(p-Hydroxyphenylazo)benzoic acid, A10333, p. 250 **Haematin**, see Hematin, A18518, p. 241 **Haematoporphyrin dihydrochloride**, see Hematoporphyrin dihydrochloride, A18579, p. 241 **Haematoxylin**, see Hematoxylin hydrate, A12431, p. 242 **Haemin**, see Hemin, A11165, p. 242	
J63728	**Haloenol Lactone Suicide Substrate, 98+%** *[HELSS, Bromoenol lactone]* [88070-98-8], $C_{16}H_{13}BrO_2$, F.W. 317.18, Powder, m.p. 103-106°, MDL MFCD00270871 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Irreversibly inhibits calcium-independent phospholipase A-2	**5mg** **10mg** **25mg**

Stock #	Description	Size
J61688	**Haloperidol** [52-86-8], $C_{21}H_{23}ClFNO_2$, F.W. 375.86, Powder, Merck **14**,4598, UN2811, EINECS 200-155-6, RTECS EU1575000, MDL MFCD00051423 H:H301-H360-H315-H319-H317-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An antagonist for D2, D3, and D4 dopamine receptors that induces apoptosis of neurons in the striatum of rats	5g 25g
J60543	**Hamburger Pentapeptide** *[Asp-Ser-Asp-Pro-Arg, IgE Peptide III]* [62087-72-3], $C_{22}H_{38}N_8O_{11}$, F.W. 588.60, Lyophilized powder, Merck **14**,7128, MDL MFCD00081022 Application(s): Potent inhibitor of IgE formation	25mg
J61699	**Harmaline, 98+%** *[1-Methyl-7-methoxy-3,4-dihydro-β-carboline, Dihydroharmine]* [304-21-2], $C_{13}H_{14}N_2O$, F.W. 214.27, Crystals, m.p. 239-241°, Merck **14**,4613, EINECS 206-152-6, RTECS UU9800000, BRN 207310, MDL MFCD00004955 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): CNS stimulant; may act through NMDA receptors. Reversible inhibitor of MAO-A	1g 5g
L19068	**Harmine, 98+%** *[6-Methoxyharmane, 7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole]* [442-51-3], $C_{13}H_{12}N_2O$, F.W. 212.25, m.p. 262-266°, Merck **14**,4616, EINECS 207-131-4, RTECS UV0175000, BRN 178813, MDL MFCD00004958  H:H302-H332-H319, P:P280h-P305+P351+P338 Application(s): A monoamine oxidase inhibitor	250mg 1g
J61135	**Harmol** [487-03-6], $C_{12}H_{10}N_2O$, F.W. 198.22, Powder, m.p. 231°, EINECS 207-645-9, MDL MFCD00834164 Application(s): Induces apoptosis by Caspase-8 activation	1g 5g
J63827	**Harmol hydrochloride dihydrate, 98%** *[1-Methyl-9H-pyrido-[3,4-b]indole-7-ol]* [149022-16-2], $C_{12}H_{10}N_2O.HCl{\cdot}2H_2O$, F.W. 270.72 (234.69anhy), Powder, MDL MFCD00150058 Application(s): Induces apoptosis by Caspase-8 activation	1g 5g
	Harnal, see Tamsulosin hydrochloride, 98+%, J61999, p. 357 **HBTU**, see O-(1H-Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, B23597, p. 120	
J60507	**HDBA, 98+%** *[Lavendustin, 2-Hydroxy-5-(2,5-dihydroxybenzylamino)benzoic acid]* [125697-93-0], $C_{14}H_{13}NO_5$, F.W. 275.26, Powder, BRN 6657779, MDL MFCD00153955 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inhibits calcium/calmodulin-dependent protein kinase II	1mg 5mg 10mg
	Hebanil, see Chlorpromazine hydrochloride, 98+%, J63659, p. 160	
J65734	**Helodermin** $C_{176}H_{285}N_{47}O_{49}$, F.W. 3843.42, Solid	0.5mg 1mg
J65020	**Helospectin II** $C_{180}H_{288}N_{46}O_{57}$, F.W. 4008.48, Solid	1mg
	HELSS, see Haloenol Lactone Suicide Substrate, 98+%, J63728, p. 240	
A18518	**Hematin, 97%** *[Haematin]* [15489-90-4], $C_{34}H_{33}FeN_4O_5$, F.W. 633.51, Merck **14**,4635, EINECS 239-518-9, RTECS NO6725000, MDL MFCD00011615  Application(s): Stimulates synthesis of globulin	1g 5g 25g
A18579	**Hematoporphyrin dihydrochloride** *[Haematoporphyrin dihydrochloride]* [17696-69-4], $C_{34}H_{38}N_4O_6{\cdot}2HCl$, F.W. 671.62, Merck **14**,4636, EINECS 241-699-4, RTECS TS5505000, BRN 78957, MDL MFCD00013470, †  H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Endogenous porphyrin formed by the acid hydrolysis of hemoglobin	1g 5g 25g

Stock #	Description	Size
A12431	**Hematoxylin hydrate, 96% (dry wt.), water ca 6% ▲** *[C.I. 75290, Natural Black 1]* [517-28-2], $C_{16}H_{14}O_6 \cdot xH_2O$, F.W. 302.29(anhy), m.p. ca 200° dec., Merck **14**,4637, EINECS 208-237-3, RTECS MH7875000, BRN 91399, MDL MFCD00078111, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Biological stain. Acid-base indicator: pH 5.0 - 6.0.  Application(s): Extracted from the bark of the logwood tree	**5g** **25g** **100g**
	Hemimellitic acid dihydrate, see 1,2,3-Benzenetricarboxylic acid dihydrate, A17491, p. 119	
A11165	**Hemin (porcine), 98+%** *[Haemin, Ferriprotoporphyrin IX chloride]* [16009-13-5], $C_{34}H_{32}ClFeN_4O_4$, F.W. 651.95, m.p. >300°, Merck **14**,4644, EINECS 240-140-1, RTECS LJ8080000, BRN 5229914, MDL MFCD00010726, †  Application(s): Stimulates synthesis of globulin	**1g** **5g** **25g**
	Hemin chloride, see Hemin, A11165, p. 242	
J63838	**Hemoglobin, bovine** [9008-02-0], Powder, 64.5 kDa, MDL MFCD00131282, † Application(s): Iron-containing oxygen-transport metalloprotein in red blood cells	**5g** **25g** **100g**
J65288	**Hemokinin 1, human** *[HEK-1, human, Thr-Gly-Lys-Ala-Ser-Gln-Phe-Phe-Gly-Leu-Met-NH2]* [491851-53-7], $C_{54}H_{82}N_{14}O_{14}S$, F.W. 1183.38, Solid, MDL MFCD06656083	**5mg** **10mg**
A16198	**Heparin sodium salt, from porcine intestinal mucosa, IU>=100/mg** [9041-08-1], Merck **14**,4653, RTECS MI0850000, MDL MFCD00081689, † Application(s): Blood anti-coagulant	**250mg** **1g** **5g**
J60443	**Heparin Binding Peptide** [125720-21-0], $C_{47}H_{74}N_{16}O_{10}$, F.W. 1023.21, Solid, MDL MFCD00237001	**1mg**
A14777	**HEPES, 99%** *[4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid]* [7365-45-9], $C_8H_{18}N_2O_4S$, F.W. 238.31, m.p. ca 236° dec., Merck **14**,4654, EINECS 230-907-9, RTECS TL6809000, BRN 883043, MDL MFCD00006158, † Biological buffer, pKa = 7.55 at 20°: *Biochemistry*, **5**, 467 (1966).  Application(s): A zwitterionic buffer	**10g** **50g** **250g**
J61830	**HEPES hemisodium salt** *[4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid sodium salt]* [103404-87-1], $(C_8H_{17}N_2O_4S)_2Na$, F.W. 497.58, Crystalline powder, MDL MFCD00036463 Application(s): A zwitterionic buffer	**100g** **250g** **500g**
A16516	**HEPES sodium salt, 99% ■** *[4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid sodium salt]* [75277-39-3], $C_8H_{17}N_2NaO_4S$, F.W. 260.28, EINECS 278-169-7, MDL MFCD00036463, † 	**25g** **100g**
J60463	**HEPES, 0.5M buffer soln., pH 6.5** [7365-45-9], Liquid, †	**100ml** **250ml**
J60064	**HEPES, 0.5M buffer soln., pH 7.0** [7365-45-9], Liquid, †	**100ml** **250ml**
J61275	**HEPES, 0.5M buffer soln., pH 7.5** [7365-45-9], Liquid, †	**100ml** **250ml**
J61047	**HEPES, 0.5M buffer soln., pH 7.6** [7365-45-9], Liquid, †	**100ml** **250ml**
J63002	**HEPES, 0.5M buffer soln., pH 8.0** [7365-45-9], Liquid, †	**100ml** **250ml**
J63218	**HEPES, 0.5M buffer soln., pH 8.5** [7365-45-9], Liquid, †	**100ml** **250ml**
J63614	**HEPES, 0.5M buffer soln., pH 9.0** [7365-45-9], Liquid, †	**100ml** **250ml**
J61017	**HEPES, 1.0M buffer soln., pH 6.5** [7365-45-9], Liquid, †	**250ml** **500ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62688	**HEPES, 1.0M buffer soln., pH 7.0** [7365-45-9], Liquid, †	250ml 500ml
J60712	**HEPES, 1.0M buffer soln., pH 7.5** [7365-45-9], Liquid, †	250ml 500ml
J63578	**HEPES, 1.0M buffer soln., pH 8.0** [7365-45-9], Liquid, †	250ml 500ml
J61360	**HEPES, 1.0M buffer soln., pH 8.5** [7365-45-9], Liquid, †	250ml 500ml
J60440	**HEPES, 1.0M buffer soln., pH 9.0** [7365-45-9], Liquid, †	250ml 500ml
J61239	**HEPES-buffered saline, pH 6.5 (5X)** [7365-45-9], Liquid, Note: Contains 125mM HEPES and 750mM sodium chloride, pH 6.5, †	250ml 500ml
J62623	**HEPES-buffered saline, pH 7.0 (2X for transfection)** [7365-45-9], Liquid, Note: Contains 280mM sodium chloride, 10mM potassium chloride, 1.5mM sodium phosphate, 12mM dextrose and 50mM HEPES, pH 7.0, †	250ml 500ml
J60753	**HEPES-buffered saline, pH 7.0 (5X)** [7365-45-9], Liquid, Note: Contains 125mM HEPES and 750mM sodium chloride, at pH 7.0, †	250ml 500ml
J62915	**HEPES lysis buffer with NP-40** Liquid, Note: This buffer contains 50mM HEPES, 150mM NaCl, 1% NP-40 and 5mM EDTA at pH 7.4.	250ml 500ml
J63867	**HEPES lysis buffer with NP-40 (2X)** Liquid, Note: This buffer contains 100mM HEPES, 300mM NaCl, 2% NP-40 and 10mM EDTA at pH 7.4.	125ml 250ml
J63860	**HEPES lysis buffer with Triton® X-100** Liquid, Note: This buffer contains 25mM HEPES, 150mM NaCl, 1% Triton X-100 and 5mM EDTA at pH 7.4.	250ml 500ml
J62809	**HEPES lysis buffer with Triton® X-100 (2X)** Liquid, Note: This buffer contains 50mM HEPES, 300mM NaCl, 2% Triton X-100 and 10mM EDTA at pH 7.4.	125ml 250ml
J63297	**HEPES protein extraction buffer (5X)** Liquid, Note: This buffer contains 250mM HEPES and 10% calcium chloride at pH 7.4. Add protease inhibitors according to your protocol.	250ml 500ml
J63043	**HEPES-Triton® X-100 extraction buffer** [7365-45-9], Liquid, Note: Contains 50mM HEPES (pH 7.4) and 10% Triton X-100. Add protease inhibitors according to your protocol., † H:H318, P:P280-P305+P351+P338-P310	250ml 500ml
J63877	**HEPPSO, 0.2M buffer soln., pH 7.0** [68399-78-0], Liquid, †	100ml 250ml
J61640	**HEPPSO, 0.2M buffer soln., pH 7.5** [68399-78-0], Liquid, †	100ml 250ml
J62529	**HEPPSO, 0.2M buffer soln., pH 8.0** [68399-78-0], Liquid, †	100ml 250ml
J60760	**HEPPSO, 0.2M buffer soln., pH 8.5** [68399-78-0], Liquid, †	100ml 250ml
	1-Heptanesulfonic acid sodium salt, see Sodium 1-heptanesulfonate, A10917, p. 346	
J61806	**(R)-2-Heptanol** [6033-24-5], $C_7H_{16}O$, F.W. 116.20, Liquid, f.p. 64°(147°F), BRN 1719090, MDL MFCD00065956 H:H312-H319, P:P280-P305+P351+P338-P302+P352-P322-P312-P501 Application(s): For synthesis of optically active products	1g 5g
33795	**(S)-(+)-2-Heptanol, 98%** [6033-23-4], $C_7H_{16}O$, F.W. 116.20, Liquid, b.p. 160-162°, f.p. 59°(138°F), d. 0.815, n_D^{20} 1.4210, UN1987, MDL MFCD00065003 H:H226-H312-H319, P:P210-P241-P303+P361+P353-P305+P351+P338-P302+P352-P501a	250mg 1g 5g
	Hesperetin 7-rhamnoglucoside, see Hesperidin, 98+%, J62126, p. 244	

Stock #	Description	Size
J62126	**Hesperidin, 98+%** *[Hesperetin 7-rhamnoglucoside, Hesperitin-7-rutinoside]* [520-26-3], $C_{28}H_{34}O_{15}$, F.W. 610.56, Powder, m.p. 250-255° dec., Merck **14**,4671, EINECS 208-288-1, RTECS MK6650000, BRN 75140, MDL MFCD00075663, † Application(s): Acts as an antioxidant	**25g** **100g**
	Hesperetin, see 3',5,7-Trihydroxy-4'-methoxyflavanone, B20528, p. 377 **Hesperitin-7-rutinoside**, see Hesperidin, 98+%, J62126, p. 244 **Heterauxin**, see Indole-3-acetic acid, A10556, p. 256	
J60853	**1,2,3,4,5,6-Hexabromocyclohexane** *[NSC 7908, Benzene hexabromide]* [1837-91-8], $C_6H_6Br_6$, F.W. 557.50, Solid, MDL MFCD00059127, † Application(s): Potently and directly inhibits JAK2 tyrosine kinase autophosphorylation	**1g** **5g**
	Hexadecanoic acid, see Palmitic acid, B20322, p. 311	
A11180	**1-Hexadecanol, 98%** *[Cetyl alcohol, n-Hexadecyl alcohol]* [36653-82-4], $CH_3(CH_2)_{15}OH$, F.W. 242.45, m.p. 47-51°, b.p. 190°/15mm, f.p. 135°(275°F), d. 0.817, Merck **14**,2028, Solubility: Soluble in alcohol, chloroform, ether, EINECS 253-149-0, RTECS MM0225000, BRN 1748475, MDL MFCD00004760, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**500g** **2.5kg**
	n-Hexadecyl alcohol, see 1-Hexadecanol, A11180, p. 244	
A13499	**(1-Hexadecyl)pyridinium chloride monohydrate, 98%** *[Cetylpyridinium chloride monohydrate]* [6004-24-6], $C_{21}H_{38}ClN{\cdot}H_2O$, F.W. 358.02 (339.99anhy), m.p. 83-86°, Merck **14**,2032, Solubility: Soluble in water, alcohol, chloroform, UN2811, EINECS 204-593-9, RTECS UU5075000, BRN 3578606, MDL MFCD00149977, †  H:H301-H330-H400-H410-H315-H319-H335, P:P301+P310-P304+P340-P305+P351+P338-P320-P330-P405-P501a Catalyst, used in combination with tungstophosphoric acid for the chemoselective oxidation of anilines to nitroso- or nitrobenzenes by hydrogen peroxide: *J. Org. Chem.*, **58**, 3633 (1993).	**25g** **100g** **500g**
A15235	**(1-Hexadecyl)trimethylammonium bromide, 98%** ■ *[Cetrimonium bromide, Cetyltrimethylammonium bromide]* [57-09-0], $CH_3(CH_2)_{15}N(CH_3)_3Br$, F.W. 364.46, m.p. ca 245° dec., Merck **14**,2025, Fieser **15**,77, UN3077, EINECS 200-311-3, RTECS BQ7875000, BRN 3598189, MDL MFCD00011772, † H:H318-H400-H410-H302-H335-H315, P:P280-P273-P305+P351+P338-P337+P313-P391-P501a Surfactant-type catalyst with many applications: O-Alkylation of alcohols and phenols; see **2,6-Dimethylphenol**, **A11947**. Surfactant-assisted permanganate oxidations: *Can. J. Chem.*, **67**, 1381 (1989). Reduction of alkyl halides to alkanes using zinc powder in micelles: *Synth. Commun.*, **19**, 1649 (1989). Control of *ortho-para* ratio in the bromination of anilines: *Tetrahedron Lett.*, **30**, 6209 (1989). Also facilitates ligand-free palladium salt-catalyzed Heck and Suzuki cross-coupling reactions in water: *Tetrahedron Lett.*, **46**, 3357 (2005).	**100g** **500g** **5kg**
	Hexa-2,4-dienoic acid, see Sorbic acid, A16196, p. 349 **2,2',3,3,3',3'-Hexahydroxy-2,2'-biindan-1,1'-dione**, see Hydrindantin dihydrate, A12462, p. 247 **Hexahydroxycyclohexane**, see myo-Inositol, A13586, p. 257 **4,4',5,5',7,7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone**, see Hypericin, H26425, p. 253 **4,4',5,5',6,6'-Hexahydroxydiphenic acid 2,6,2',6'-dilactone hydrate**, see Ellagic acid hydrate, A15722, p. 205	
J60466	**Hexamethonium bromide, 98+%** *[Hexane-1,6-bis(trimethylammonium bromide), N,N,N,N',N',N'-Hexamethylhexamethylenediammonium dibromide]* [55-97-0], $(CH_3)_3N(Br)(CH_2)_6N(Br)(CH_3)_3$, F.W. 362.19, Powder, m.p. 282-285° dec., Merck **14**,4688, EINECS 200-249-7, RTECS BQ8575000, BRN 3715749, MDL MFCD00011787, † Application(s): Nicotinic acetyl choline receptor antagonist	**25g** **100g**
	N,N'-Hexamethylenebis(acetamide), see N,N'-Diacetyl-1,6-diaminohexane, B22771, p. 182	
36462	**Hexamethylenetetramine, ACS, 99+%** ■ *[Hexamine, Methenamine]* [100-97-0], $C_6H_{12}N_4$, F.W. 140.19, Solid, m.p. 280° subl., f.p. 250°(482°F), d. 1.33, Merck **14**,5966, Fieser **1**,427 **2**,208 **4**,243 **9**,234 **18**,178 **19**,164 **20**,185, UN1328, EINECS 202-905-8, RTECS MN4725000, BRN 2018, MDL MFCD00006895, † Maximum level of impurities: Loss on drying 2.0%, Residue after ignition 0.1%, Heavy Metals (as Pb) 0.001% H:H228-H317, P:P210-P241-P261-P302+P352-P321-P501a	**100g** **500g** **2kg**
	N,N,N,N',N',N'-Hexamethylhexamethylenediammonium dibromide, see Hexamethonium bromide, 98+%, J60466, p. 244 **Hexamethylpararosaniline chloride**, see Crystal Violet, 22866, p. 170 **2,6,10,15,19,23-Hexamethyl-2,6,10,14,18,22-tetracosahexaene**, see Squalene, B20944, p. 351	
H25929	**Hexanamide, 99%** *[Caproamide]* [628-02-4], $CH_3(CH_2)_4CONH_2$, F.W. 115.18, m.p. 100-102°, EINECS 211-024-8, RTECS MN7875000, MDL MFCD00008046, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g**
	Hexane-1,6-bis(trimethylammonium bromide), see Hexamethonium bromide, 98+%, J60466, p. 244 **Hexanedioic acid**, see Adipic acid, A13705, p. 79 **Hexanedioic acid dimethyl ester**, see Dimethyl adipate, B21174, p. 196 **Hexanedioyl dichloride**, see Adipoyl chloride, A13168, p. 80	

Stock #	Description	Size
L10401	**(S)-(+)-2-Hexanol, 98%** [52019-78-0], $C_6H_{14}O$, F.W. 102.18, b.p. 137-138°, f.p. 45°(113°F), d. 0.818, n_D^{20} 1.4140, $[\alpha]_D^{20}$ +10.5° (neat), UN2282, BRN 1718997, MDL MFCD00065955 H:H226-H302, P:P261-P280f	**250mg** **1g**
J60889	**Hexestrol, 98+%** *[4,4'-(1,2-Diethylethylene)diphenol, meso-3,4-Bis(4-hydroxyphenyl)hexane]* [84-16-2], $C_{18}H_{22}O_2$, F.W. 270.37, Powder, m.p. 186°, Merck **14**,4701, EINECS 201-518-1, RTECS SL0560850, BRN 3209460, MDL MFCD00068996 H:H350, P:P281-P201-P202-P308+P313-P405-P501 Application(s): Nonsteroidal synthetic estrogen	**1g** **10g**
J63795	**Hexokinase, yeast** ■ [9001-51-8], Lyophilized powder, EINECS 232-611-5, MDL MFCD00131321, Note: Minimum 140 units/mg protein. One unit converts 1 micromole of D-glucose to glucose-6-phosphate per min at 25 degrees C and pH 7.5 in the presence of ATP, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 Application(s): Catalyzes the phosphorylation of D-hexose sugars at the C6 position utilizing ATP as a phosphate source. Used to determine glucose, fructose, mannose and ATP	**1kilounit** **10kilounits**
	1-Hexyl-3,7-dimethylxanthine, see 1-n-Hexyltheobromine, L13597, p. 245	
L13597	**1-n-Hexyltheobromine, 98+%** *[1-Hexyl-3,7-dimethylxanthine, Pentifylline]* [1028-33-7], $C_{13}H_{20}N_4O_2$, F.W. 264.33, m.p. 80-81°, Merck **14**,7127, EINECS 213-842-0, RTECS UO8450000, BRN 270632, MDL MFCD00041424 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A vasodilator	**250mg** **1g**
	5-HIAA, see 5-Hydroxyindole-3-acetic acid, 98%, J61435, p. 249 **Highlink® GB**, see N,N'-(1,2-Dihydroxyethylene)bisacrylamide, L19211, p. 192	
A12690	**Hippuric acid, 98%** *[N-Benzoylglycine]* [495-69-2], $C_6H_5CONHCH_2CO_2H$, F.W. 179.18, m.p. 188-191°, d. 1.371, Merck **14**,4716, Fieser **1**,432, EINECS 207-806-3, RTECS MR8150000, BRN 1073987, MDL MFCD00002692, † Condensation with aldehydes gives azlactones, which are intermediates in a classical route to amino acids; see, e.g.: *Org. Synth. Coll.*, **2**, 489 (1943). An alternative approach involves alkylation of the trianion of hippuric acid, prepared by LDA/TMEDA in THF: *Tetrahedron Lett.*, 2205 (1976). For cyclization with acetic anhydride to 2-phenyl-5-oxazolone, see: *Org. Synth. Coll.*, **5**, 946 (1973).	**100g** **500g** **1kg**
	Hismanal, see Astemizole, 99+%, J60339, p. 111	
J61727	**Histamine** [51-45-6], $C_5H_9N_3$, F.W. 111.15, Powder, Merck **14**,4719, UN2811, EINECS 200-100-6, RTECS MS1050000, BRN 2012, MDL MFCD00005210, † H:H301-H334-H315-H319-H317-H335, P:P285-P301+P310-P305+P351+P338-P302+P352-P405-P501a Application(s): Endogenous H1 and H2 histamine receptor agonist; H1 activation mobilizes calcium; H2 activation stimulates adenylate cyclase activity in neurons; activates nitric oxide synthetase; potent vasodilator	**1g** **5g**
L09198	**Histamine dihydrochloride, 98+%** [56-92-8], $C_5H_9N_3 \cdot 2HCl$, F.W. 184.07, m.p. 245-249°, Merck **14**,4719, EINECS 200-298-4, RTECS MS1575000, BRN 3624116, MDL MFCD00012703, † H:H334-H335-H315-H319-H317, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g**
J61088	**Histamine diphosphate, 99+%** [51-74-1], $C_5H_9N_3 \cdot 2H_3PO_4$, F.W. 307.14, Powder, Merck **14**,4719, EINECS 200-118-4, RTECS NI5425000, † H:H302-H315-H318-H334-H317-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Endogenous H1 and H2 agonist	**5g** **25g**
J64792	**Histatin 5** *[Asp-Ser-His-Ala-Lys-Arg-His-His-Gly-Tyr-Lys-Arg-Lys-Phe-His-Glu-Lys-His-His-Ser-His-Arg-Gly-Tyr]* [104339-66-4], $C_{133}H_{195}N_{51}O_{33}$, F.W. 3036.29, Solid, MDL MFCD00210682	**0.5mg** **1mg**
B21027	**D-Histidine, 99%** *[(R)-2-Amino-3-(4-imidazolyl)propionic acid, H-D-His-OH]* [351-50-8], $C_6H_9N_3O_2$, F.W. 155.16, m.p. ca 285° dec., $[\alpha]_D^{20}$ +39° (c=5 in water), EINECS 206-513-8, BRN 84089, MDL MFCD00065963, †	**5g** **25g** **100g**
A10413	**L-Histidine, 98+%** *[(S)-2-Amino-3-(4-imidazolyl)propionic acid, H-His-OH]* [71-00-1], $C_6H_9N_3O_2$, F.W. 155.16, m.p. ca 281° dec., $[\alpha]_D^{20}$ -39° (c=5 in water), Merck **14**,4720, EINECS 200-745-3, RTECS MS3070000, BRN 4673585, MDL MFCD00064315, †	**25g** **100g** **500g**

Stock #	Description	Size
J63065	**L-Histidine, Cell Culture Reagent** *[L-2-Amino-3-(4-imidazolyl)propionic acid]* [71-00-1], $C_6H_9N_3O_2$, F.W. 155.16, Powder, m.p. ca 281° dec., Merck **14**,4720, EINECS 200-745-3, RTECS MS3070000, BRN 84088, MDL MFCD00064315, †	**10g** **100g** **500g** **1kg**
A16165	**DL-Histidine monohydrochloride monohydrate, 99%** *[H-DL-His-OH.HCl.H2O]* [123333-71-1], $C_6H_9N_3O_2 \cdot HCl \cdot H_2O$, F.W. 209.63 (191.62anhy), m.p. ca 250° dec., MDL MFCD00151028, † 	**5g** **25g** **100g**
A17627	**L-Histidine monohydrochloride monohydrate, 99%** *[H-His-OH.HCl.H2O]* [5934-29-2], $C_6H_9N_3O_2 \cdot HCl \cdot H_2O$, F.W. 209.63 (191.62anhy), m.p. ca 240° dec., $[\alpha]_D^{20}$ +9.3° (c=5 in 5N HCl), Merck **14**,4720, EINECS 211-438-9, RTECS MS3119000, BRN 4168261, MDL MFCD00151027, † 	**50g** **250g** **500g**
J61465	**L-Histidine monohydrochloride monohydrate, Cell Culture Reagent** *[L-2-Amino-3-(4-imidazolyl)propionic acid monohydrochloride monohydrate]* [5934-29-2], $C_6H_9N_3O_2 \cdot HCl \cdot H_2O$, F.W. 209.63 (191.62anhy), Powder, m.p. ca 240° dec., Merck **14**,4720, EINECS 211-438-9, RTECS MS3119000, BRN 4168261, MDL MFCD00151027	**10g** **100g** **500g** **1kg**
J65939	**Histone Acetyltransferase Inhibitor IV, CPTH2 ▲** *[HAT Inhibitor IV, Gcn5p Inhibitor]* [357649-93-5], $C_{14}H_{14}ClN_3S$, F.W. 291.80, Solid, MDL MFCD02307488	**5mg** **10mg**
J65479	**Histone Deacetylase Inhibitor II ▲** *[m-Carboxy cinnamic acid bis-hydroxamide, CBHA]* [174664-65-4], $C_{10}H_{10}N_2O_4$, F.W. 222.20, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg** **10mg**
J64940	**Histone Deacetylase Inhibitor III ▲** *[M 344, 4-Dimethylamino-N-(6-hydroxycarbamoylhexyl) benzamide]* [251456-60-7], $C_{16}H_{25}N_3O_3$, F.W. 307.39, Powder, MDL MFCD03453554 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg** **10mg**
	HL-725, see Trequinsin hydrochloride, 98+%, J63999, p. 374 **H M P resin**, see Wang resin, L17028, p. 393	
J64917	**HNHA ▲** *[Histone Deacetylase Inhibitor VI]* [926908-04-5], $C_{17}H_{21}NO_2S$, F.W. 303.42, Crystalline solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg**
	HNMPA, see (Hydroxy-2-naphthylmethyl)phosphonic acid, 98%, J63913, p. 250 **Hoechst 33342®**, see bis-Benzimide H-33342 trihydrochloride trihydrate, 98%, J62134, p. 126 **Homidium bromide**, see Ethidium bromide soln., 10mg/ml, J62282, p. 214	
H31749	**DL-β-Homoproline hydrochloride, 97%** [71985-79-0], $C_6H_{12}ClNO_2$, F.W. 165.62, m.p. 171-174° 	**250mg** **1g**
	Homoprotocatechuic acid, see 3,4-Dihydroxyphenylacetic acid, A15893, p. 193	
A12441	**Homovanillic acid, 98+%** *[4-Hydroxy-3-methoxyphenylacetic acid]* [306-08-1], $C_9H_{10}O_4$, F.W. 182.18, m.p. 140-145°, Merck **14**,4740, EINECS 206-176-7, BRN 2213447, MDL MFCD00004350, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reagent for the determination of enzymes: *Anal. Chem.*, **40**, 190 (1968), and amino acids: *Anal. Biochem.*, **26**, 1 (1968). Application(s): Fluorimetric reagent and major catecholamine metabolite	**1g** **5g** **25g**
J63434	**Honokiol, 98+%** *[5,3'-Diallyl-2,4'-dihydroxybiphenyl]* [35354-74-6], $C_{18}H_{18}O_2$, F.W. 266.34, Powder, m.p. 86°, Merck **14**,4742, UN3077, MDL MFCD00016674 H:H318-H411, P:P280-P273-P305+P351+P338-P310-P391-P501a Application(s): Induces apoptosis in human squamous lung cancer cells	**10mg** **25mg** **100mg**
J61851	**Horse serum** Liquid, Note: 10% Horse serum , 0.02% sodium azide in PBS	**100ml** **250ml**
	HOSu, see N-Hydroxysuccinimide, A10312, p. 251 **3-HPA·HCl**, see 1-(3-Methoxyphenyl)homopiperazine monohydrochloride, H51751, p. 285 **4-HPA·HCl**, see 1-(4-Methoxyphenyl)homopiperazine monohydrochloride, H51703, p. 285 **HRP**, see Peroxidase, horseradish, J60026, p. 314 **5-HT**, see Serotonin hydrochloride, B21263, p. 342 **HTF bovine native protein**, see Transferrin (HOLO), bovine plasma, 98+%, J61046, p. 373 **5-HTP**, see L-5-Hydroxytryptophan hydrate, A13954, p. 252 **Human C carcinoma**, see Calcitonin, human, 97+%, J63192, p. 142	

Stock #	Description	Size
J65512	**Human Epidermal Growth Factor Enzyme Immunoassay Kit** Note: One kit contains sufficient reagents and precoated 96-well strips to perform an ELISA assay for EGF Application(s): For detection of Epidermal Growth factor. Detection range is 0.5-100ng/ml	1kit
J60566	**Hyaluronic acid, bovine vitreous humor** [9004-61-9], $(C_{14}H_{21}NaNO_{11})_n$, Lyophilized powder, Merck **14**,4757, EINECS 232-678-0, †	10mg 50mg 100mg
	Application(s): A natural high-viscosity polymer of acetylglucosamine and glucuronic acid	
J64856	**Hybidoma Cell Growth Supplement**	2x25ml
J60455	**Hybridization solution in SSC** Liquid, Note: 6X Saline-sodium citrate (SSC) with 5% Blotto, pH 7.0 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For hybridization of probes to nucleic acids	100ml 250ml
J61559	**Hybridization solution in SSPE** Liquid, Note: Contains 6X saline-sodium phosphate-EDTA (SSPE) and 5% Blotto. Application(s): For hybridization of probes to nucleic acids	100ml 250ml
A12486	**Hydantoin, 99%** *[2,4-Imidazolidinedione]* [461-72-3], $C_3H_4N_2O_2$, F.W. 100.08, m.p. 221-223°, Merck **14**,4761, EINECS 207-313-3, RTECS MT8210000, BRN 110598, MDL MFCD00005259, † 	100g 500g 2.5kg
	Hydralazine hydrochloride, see 1-Hydrazinophthalazine hydrochloride, B22995, p. 247 **Hydramycin**, see Doxycycline hyclate, J60579, p. 202	
40120	**Hydrazine sulfate, ACS, 99.0% min** [10034-93-2], $H_2NNH_2{\cdot}H_2SO_4$, F.W. 130.12, Crystalline, m.p. ca 255° dec., d. 1.370, Merck **14**,4772, Fieser **1**,445, UN3288, EINECS 233-110-4, RTECS MV9625000, MDL MFCD00044873, Note: Special handling precautions required. View MSDS prior to purchase. MSDS are available online at www.alfa.com, † Maximum level of impurities: Insoluble matter 0.005%, Residue after ignition 0.05%, Cl 0.005%, Heavy Metals (as Pb) 0.002%, Fe 0.001% H:H301-H311-H331-H350-H400-H410-H317, P:P301+P310-P361-P302+P352-P321-P405-P501a Application(s): Reagent for determination of C-terminal amino acids	500g
B22995	**1-Hydrazinophthalazine hydrochloride, 98%** *[Hydralazine hydrochloride, 1(2H)-Phthalazinone hydrazone]* [304-20-1], $C_8H_8N_4{\cdot}HCl$, F.W. 196.64, m.p. ca 275° dec., Merck **14**,4763, UN2811, EINECS 206-151-0, RTECS TH9000000, BRN 3568329, MDL MFCD00135998, †  H:H301-H351-H361, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): A monoamine oxidase inhibitor	5g 25g
A12462	**Hydrindantin dihydrate, 98%** *[2,2',3,3,3',3'-Hexahydroxy-2,2'-biindan-1,1'-dione]* [5950-69-6], $C_{18}H_{10}O_6{\cdot}2H_2O$, F.W. 358.30 (322.27anhy), m.p. ca 250° dec., Merck **14**,4775, EINECS 227-713-1, RTECS DU2989000, BRN 1895666, MDL MFCD00149242, † Reagent for photometric determination of amino acids.  Application(s): Used in amino acid determinations as a ninhydrin synergist	25g 100g 500g
35640	**Hydrochloric acid, 1.0N Standardized Solution** [7647-01-0], HCl, F.W. 36.46, Liquid, EINECS 231-595-7, RTECS MW4025000, MDL MFCD00011324, †	1L 4L 20L
33257	**Hydrochloric acid, ACS, HCl 36.5-38.0%** *[Muriatic acid]* [7647-01-0], HCl, F.W. 36.46, Liquid, b.p. 81.5-110°, d. 1.19, Merck **14**,4780, Fieser **1**,308 **2**,215 **4**,250 **5**,322 **6**,283 **7**,172 **8**,246 **9**,239, Solubility: Soluble in water, alcohol, ether and benzene, UN1789, EINECS 231-595-7, RTECS MW4025000, MDL MFCD00011324, Note: Free from suspended matter or sediment, † Maximum level of impurities: Color (APHA) 10, Residue after ignition 5ppm, Br 0.005%, SO_4 1ppm, SO_3 1ppm, Extractable organic substances 5ppm, Free chlorine (Cl) 1ppm, NH_4 3ppm, As 0.01ppm, Heavy Metals (as Pb) 1ppm, Fe 0.2ppm H:H314-H335, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Acidizing petroleum wells, chemical intermediate, ore reduction, food processing, pickling and metal cleaning, general cleaning, and laboratory reagent	6lb 6x6lb
B22093	**Hydrochlorothiazide, 98%** *[6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide]* [58-93-5], $C_7H_8ClN_3O_4S_2$, F.W. 297.74, m.p. 266-272°, Merck **14**,4781, EINECS 200-403-3, RTECS DK9100000, BRN 625101, MDL MFCD00051765, †  H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A carbonic anhydrase inhibitor	5g 25g 100g

Stock #	Description	Size
A16292	**Hydrocortisone, 98%** [50-23-7], $C_{21}H_{30}O_5$, F.W. 362.47, m.p. 213-215°, Merck **14**,4787, EINECS 200-020-1, RTECS GM8925000, BRN 1354819, MDL MFCD00011654, † H:H361, P:P281-P201-P202-P308+P313-P405-P501a Application(s): A natural corticosteroid and anti-inflammatory compound 	1g 5g
A18089	**Hydrocortisone acetate, 97+% ▲** [50-03-3], $C_{23}H_{32}O_6$, F.W. 404.51, m.p. ca 220° dec., Merck **14**,4787, EINECS 200-004-4, RTECS GM8960000, BRN 2066841, MDL MFCD00037714 H:H361, P:P281-P201-P202-P308+P313-P405-P501a 	1g 5g
A11411	**Hydroquinone, 99%** *[1,4-Dihydroxybenzene, Quinol]* [123-31-9], $C_6H_6O_2$, F.W. 110.11, m.p. 170-172°, b.p. 285-287°, f.p. 165°(329°F), d. 1.320, Merck **14**,4808, Fieser **5**,341, UN3077, EINECS 204-617-8, RTECS MX3500000, BRN 605970, MDL MFCD00002339, † H:H318-H341-H351-H400-H302-H317, P:P280-P273-P305+P351+P338 Widely used as a radical trap to inhibit polymerization and peroxidation reactions. Forms inclusion compounds (clathrates) with three molecules of hydroquinone held together by H bonds to form a cage in which a single guest molecule can be accommodated. For a review, see: D. D. MacNicol in *Inclusion Compounds*, Vol. 2, J. L. Atwood *et al*, Eds., Academic Press, London (1984), p1. A stable 1:1 complex with hydrazine has been isolated and found to be a useful, safer replacement for anhydrous hydrazine, e.g. in the solid state reaction with esters to give hydrazides: *J. Chem. Soc., Chem. Commun.*, 1531 (1995). 	250g 1kg 5kg
	Hydroquinone-glucose, see Arbutin, L14945, p. 109 **(S)-(-)-Hydrosuccinic acid**, see L-(-)-Malic acid, 99%, J63221, p. 276 **4'-Hydroxyacetanilide**, see 4-Acetamidophenol, A11240, p. 70 **Hydroxyacetic acid**, see Glycolic acid, A12511, p. 237 **5-Hydroxyanthranilic acid**, see 2-Amino-5-hydroxybenzoic acid, L08256, p. 95 **2-Hydroxybenzaldehyde**, see Salicylaldehyde, A13833, p. 340 **2-Hydroxybenzoic acid**, see Salicylic acid, 30782, p. 340 **2-Hydroxybenzoic acid sodium salt**, see Sodium salicylate, A17056, p. 348 **4-Hydroxybenzoic acid ethyl ester**, see Ethyl 4-hydroxybenzoate, A13172, p. 216	
A14410	**2-Hydroxybenzyl alcohol, 99%** *[Salicyl alcohol, Saligenin]* [90-01-7], $C_7H_8O_2$, F.W. 124.14, m.p. 83-87°, Merck **14**,8325, EINECS 201-960-5, RTECS DO6430000, BRN 1907195, MDL MFCD00004617, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Acts as a local anesthetic 	50g 250g 1kg
L04651	**4-Hydroxybenzylidenemalononitrile, 98%** [3785-90-8], $C_{10}H_6N_2O$, F.W. 170.17, m.p. 187-190°, UN3439, EINECS 223-253-0, RTECS OO4200000, BRN 2209079, MDL MFCD00020189 H:H302-H312-H332-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibitor of transducin GTPase activity 	10g 50g
	2-Hydroxybiphenyl, see 2-Phenylphenol, A10592, p. 317 **(R)-(-)-3-Hydroxybutyric acid ethyl ester**, see Ethyl (R)-(-)-3-hydroxybutyrate, J63400, p. 216 **(S)-(-)-3-Hydroxybutyric acid ethyl ester**, see Ethyl (S)-(-)-3-hydroxybutyrate, J63184, p. 216 **2-Hydroxy-2,4,6-cycloheptatrien-1-one**, see Tropolone, A11299, p. 384 **14-Hydroxydaunomycin**, see Doxorubicin hydrochloride, J64000, p. 202	
J61434	**5-Hydroxydecanoic acid sodium salt, 98%** *[Sodium 5-hydroxydecanoate]* [624-00-0], $C_{10}H_{19}NaO_3$, F.W. 210.25, Powder, MDL MFCD00153808 Application(s): A potassium channel antagonist which blocks the postischemic effects of the potassium channel activator cromakalim	100mg 500mg
J64095	**4'-Hydroxydiclofenac** *[[2-(2,6-Dichloro-4-hydroxy-phenylamino)phenyl]acetic acid, 4'-OHD]* [64118-84-9], $C_{14}H_{11}Cl_2NO_3$, F.W. 312.15, Powder, UN2811, RTECS AG6542800, BRN 4198042, MDL MFCD01671980 H:H301-H315-H318-H335-H410, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501	5mg
	2-Hydroxy-5-(2,5-dihydroxybenzylamino)benzoic acid, see HDBA, 98+%, J60507, p. 241	
J61065	**(±)-7-Hydroxy-2-di-n-propylaminotetralin hydrobromide** *[7-Hydroxy-DPAT hydrobromide]* [74938-11-7], $C_{16}H_{25}NO{\cdot}HBr$, F.W. 329.29, Powder, m.p. 168-170°, MDL MFCD00153809 Application(s): Selective agonist for D3 dopamine	10mg 50mg
	7-Hydroxy-DPAT hydrobromide, see (+/-)-7-Hydroxy-2-di-n-propylaminotetralin hydrobromide, J61065, p. 248 **20-Hydroxyecdysone**, see Ecdysterone, J63091, p. 204 **2-Hydroxyethanesulfonic acid sodium salt**, see Isethionic acid sodium salt, A12054, p. 260 **2-Hydroxyethanethiol**, see 2-Mercaptoethanol, A15890, p. 281 **2-Hydroxyethylamine**, see Ethanolamine, A11697, p. 213 **2-Hydroxyethyl ether**, see Diethylene glycol, A14728, p. 189 **3-(2-Hydroxyethyl)indole**, see Tryptophol, L02555, p. 385	

Contact us for pricing on bulk sizes

Stock #	Description	Size
	4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid, see HEPES, A14777, p. 242 **4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid sodium salt**, see HEPES hemisodium salt, J61830, p. 242	
J62548	**(R)-2-(1-Hydroxyethyl)pyridine** [27911-63-3], C_7H_9NO, F.W. 123.16, Solid, MDL MFCD04972322 H:H302-H315-H318-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**1g**
J60980	**(S)-2-(1-Hydroxyethyl)pyridine** [59042-90-9], C_7H_9NO, F.W. 123.16, Solid, MDL MFCD06795465 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**1g**
	(2-Hydroxyethyl)trimethylammonium chloride, see Choline chloride, A15828, p. 161	
B25016	**6-Hydroxyflavone, 98%** [6665-83-4], $C_{15}H_{10}O_3$, F.W. 238.25, m.p. 234-236°, EINECS 229-704-8, BRN 15827, MDL MFCD00017329 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**1g** **5g** **25g**
J61354	**Hydroxyguanidine sulfate** [6345-29-5], $CH_5N_3O \cdot 0.5H_2SO_4$, F.W. 124.11, Crystals, m.p. 132-134° dec., EINECS 228-749-0, MDL MFCD00042033, † Application(s): Reacts with nitric oxide forming an adduct which is a potent and stable vasodilator	**50mg**
	5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one, see Kojic acid, A10760, p. 264	
J61435	**5-Hydroxyindole-3-acetic acid, 98% ▲** *[5-HIAA]* [54-16-0], $C_{10}H_9NO_3$, F.W. 191.19, Crystalline powder, m.p. 161-164° dec., EINECS 200-195-4, RTECS NL3650000, BRN 168797, MDL MFCD00005639 Application(s): Metabolite of melatonin	**500mg** **1g**
	N-[4-[1-Hydroxy-2-(isopropylamino)ethyl]phenyl]methanesulfonamide hydrochloride, see Sotalol hydrochloride, 98%, J63772, p. 350	
A15398	**Hydroxylamine hydrochloride, 99% ■** *[Hydroxylammonium chloride]* [5470-11-1], $NH_2OH \cdot HCl$, F.W. 69.49, m.p. 152° dec., d. 1.67[17], Merck **14**,4828, Fieser **1**,478 **2**,217 **7**,176 **9**,245 **11**,257 **15**,170 **18**,186 **21**,222, UN2923, EINECS 226-798-2, RTECS NC3675000, BRN 3539763, MDL MFCD00051089, † H:H351-H373-H290-H400-H302-H312-H317-H315-H319, P:P280h-P273-P406 For examples of preparation of oximes from carbonyl compounds, see: *Org. Synth. Coll.*, **2**, 70, 313 (1955); **7**, 149 (1990). Dehydration of aldoximes is a valuable route to nitriles. The preparation of an oxime, and dehydration with acetic anhydride, are exemplified for veratraldehyde: *Org. Synth. Coll.*, **2**, 622 (1943). For other methods of dehydrating oximes to nitriles, see **Benzaldoxime**, **A12053**. Procedures for the one-pot conversion of aldehydes to nitriles, without isolation of the intermediate oxime, include: refluxing the aldehyde with hydroxylamine hydrochloride in formic acid/ sodium acetate: *J. Chem. Soc.*, 1564 (1965); formic acid alone: *Synthesis*, 112 (1979); in pyridine and toluene, with azeotropic water removal: *Synthesis*, 190 (1982); in DMF (reflux; aromatics only): *Z. Chem.*, **15**, 302 (1975); heating in NMP at 110-115°, effective for aromatic and aliphatic substrates; under these conditions, DMF gave only 20-30% conversion: *Synthesis*, 586 (1999). A more recent ambient temperature one-pot procedure utilizes DBU in combination with ethyl dichlorophosphate: *Synlett*, 1317 (2007). For a one-pot synthesis of pyrazoles from aldehydes by cyclization of the intermediate oxime in acidic medium with potassium dihyrogen phosphate, see: *Tetrahedron Lett.*, **47**, 43 (2006). For a brief feature on uses of this reagent in Organic synthesis, see: *Synlett*, 1326 (2007). Application(s): A monoamine oxidase inhibitor	**100g** **250g** **500g** **1kg** **5kg**
36416	**Hydroxylamine hydrochloride, ACS, 96+% ■** *[Hydroxylammonium chloride]* [5470-11-1], $NH_2OH \cdot HCl$, F.W. 69.49, Solid, m.p. 152° dec., d. 1.67[17], Merck **14**,4828, Fieser **1**,478 **2**,217 **7**,176 **9**,245 **11**,257 **15**,170 **18**,186 **21**,222, Solubility: Soluble in water, alcohol, methanol, glycerol, UN2923, EINECS 226-798-2, RTECS NC3675000, BRN 3539763, MDL MFCD00051089, † Maximum level of impurities: Clarity of alcohol solution P.T., Residue after ignition 0.05%, Titratable free acid 0.25meq/g, NH_4 P.T., Sulfur compounds (as SO_4) 0.005%, Heavy Metals (as Pb) 5ppm, Fe 5ppm H:H351-H373-H290-H400-H302-H312-H317-H315-H319, P:P280h-P273-P406 Application(s): A monoamine oxidase inhibitor; inhibits platelet aggregation	**100g** **500g**
	Hydroxylammonium chloride, see Hydroxylamine hydrochloride, 36416, p. 249	
J60076	**Hydroxylapatite, fast flow** *[Calcium phosphate hydroxide, Durapatite]* [1306-06-5], $Ca_5(OH)(PO_4)_3$, F.W. 502.32, Powder, Merck **14**,3467, EINECS 215-145-7, RTECS MY8434000, MDL MFCD00010904, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Used for fractionation and purification of proteins, enzymes, plasmids and nucleic acids	**10g** **50g**

Stock #	Description	Size
J61818	**Hydroxylapatite, high resolution** *[Calcium phosphate hydroxide, Durapatite]* [1306-06-5], $Ca_5(OH)(PO_4)_3$, F.W. 502.32, Powder, Merck **14**,3467, EINECS 215-145-7, RTECS MY8434000, MDL MFCD00010904, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Used for fractionation and purification of proteins, enzymes, plasmids and nucleic acids	**10g** **25g**
	4-Hydroxy-2-mercapto-6-methylpyrimidine, see 6-Methyl-2-thiouracil, A17982, p. 290 **4-Hydroxy-2-mercaptopyrimidine**, see 2-Thiouracil, A18119, p. 368 **4-Hydroxy-3-methoxybenzaldehyde**, see Vanillin, A11169, p. 390 **4-Hydroxy-3-methoxybenzoic acid**, see Vanillic acid, A12074, p. 390	
A13890	**trans-4-Hydroxy-3-methoxycinnamic acid, 99%** *[Ferulic acid]* [537-98-4], $C_{10}H_{10}O_4$, F.W. 194.19, m.p. 170-175°, Merck **14**,4062, EINECS 208-679-7, RTECS UD3365500, BRN 1371483, MDL MFCD00004400, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A chemopreventive analogue of caffeic acid	**25g** **100g** **500g**
	4-Hydroxy-3-methoxyphenylacetic acid, see Homovanillic acid, A12441, p. 246 **6-[(E)-4-Hydroxy-3-methylbut-2-enylamino]purine**, see trans-Zeatin, 97%, J61972, p. 395 **6-[(E)-4-Hydroxy-3-methylbut-2-enylamino]-9▲-D-ribofuranosylpurine**, see trans-Zeatin-riboside, J63382, p. 396 **(S)-(2-Hydroxy-1-methylethyl)carbamic acid benzyl ester**, see N-Benzyloxycarbonyl-L-alaninol, H27066, p. 123 **(2R,3R,4R,5S)-2-(Hydroxymethyl)-3,4,5-piperidinetriol**, see (+)-1-Deoxynojirimycin , J62602, p. 179	
L18358	**(R)-(-)-5-(Hydroxymethyl)-2-pyrrolidinone, 99%** *[D-Pyroglutaminol, H-D-Pyr-ol]* [66673-40-3], $C_5H_9NO_2$, F.W. 115.13, m.p. 83-85°, b.p. 147-149°/0.06m, $[\alpha]_D^{20}$ -30° (c=2 in ethanol), BRN 5728422, MDL MFCD00077791 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g**
L18359	**(S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone, 98%** *[L-Pyroglutaminol, H-Pyr-ol]* [17342-08-4], $C_5H_9NO_2$, F.W. 115.13, m.p. 78-82°, b.p. 147-149°/0.06m, $[\alpha]_D^{20}$ +30° (c=2 in ethanol), BRN 4657914, MDL MFCD00077792 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g**
	(R)-(-)-2-(Hydroxymethyl)tetrahydrofuran, see (R)-(-)-Tetrahydrofurfuryl alcohol, L19044, p. 363 **(S)-(+)-2-(Hydroxymethyl)tetrahydrofuran**, see (S)-(+)-Tetrahydrofurfuryl alcohol, J62573, p. 363 **1-Hydroxynaphthalene**, see 1-Naphthol, A11862, p. 298 **2-Hydroxynaphthalene**, see 2-Naphthol, A14564, p. 298	
J63913	**(Hydroxy-2-naphthylmethyl)phosphonic acid, 98%** *[HNMPA]* [120943-99-9], $C_{11}H_{11}O_4P$, F.W. 238.18, Solid ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A selective insulin receptor tyrosine kinase inhibitor	**5mg** **25mg**
A15802	**6-Hydroxynicotinic acid, 98%** *[2-Hydroxypyridine-5-carboxylic acid, 6-Hydroxypyridine-3-carboxylic acid]* [5006-66-6], $C_6H_5NO_3$, F.W. 139.11, m.p. 314-316°, EINECS 225-682-9, BRN 472182, MDL MFCD00006277, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Metabolite of nicotinamide. Stimulates adrenocortical secretion	**5g** **25g** **100g**
A10562	**4-Hydroxy-3-nitrobenzoic acid, 98%** [616-82-0], $C_7H_5NO_5$, F.W. 183.12, m.p. 182-184°, EINECS 210-494-1, BRN 2213134, MDL MFCD00007119 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Standard in chymotrypsin assays	**25g** **100g**
	N-Hydroxy-N-nitrosobenzenamine ammonium salt, see Cupferron, 97+%, A16551, p. 170 **4-Hydroxyphenethylamine hydrochloride**, see Tyramine hydrochloride, A12220, p. 386 **7-Hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt**, see Resazurin sodium salt, B21187, p. 335 **2-Hydroxy-2-phenylacetophenone**, see Benzoin, A10188, p. 120 **3-(4-Hydroxyphenyl)-DL-alanine**, see DL-Tyrosine, A13740, p. 386 **3-(4-Hydroxyphenyl)-D-alanine**, see D-Tyrosine, A17709, p. 386 **3-(4-Hydroxyphenyl)-L-alanine**, see L-Tyrosine, A11141, p. 386	
A10333	**2-(p-Hydroxyphenylazo)benzoic acid, 98+%** *[HABA]* [1634-82-8], $C_{13}H_{10}N_2O_3$, F.W. 242.23, m.p. 205-207°, EINECS 216-655-2, BRN 1842696, MDL MFCD00002428, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Indicator used in determination of serum albumin	**10g** **50g** **250g**
	2-(4-Hydroxyphenyl)ethlamine, see Tyramine, 98+%, J60990, p. 386 **2-(4-Hydroxyphenyl)ethylamine hydrochloride**, see Tyramine hydrochloride, A12220, p. 386 **4-Hydroxyphenyl-β-D-glucopyranoside**, see Arbutin, L14945, p. 109	

Contact us for pricing on bulk sizes

Stock #	Description	Size
L07190	**D-(-)-4-Hydroxyphenylglycine, 98+%** *[(R)-(-)-α-Amino-(4-hydroxyphenyl)acetic acid, H-D-Phg(4-OH)-OH]* [22818-40-2], $C_8H_9NO_3$, F.W. 167.16, m.p. ca 240° dec., $[\alpha]_D^{20}$ -156° (c=1 in 1N HCl), EINECS 245-247-7, BRN 2210998, MDL MFCD00004262, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g**
	DL-3-Hydroxy-2-phenylpropionic acid, see DL-Tropic acid, B22040, p. 383 **2-Hydroxypropionic acid**, see DL-Lactic acid, L14259, p. 265 **(R)-2-Hydroxypropionic acid**, see D-Lactic acid, J61871, p. 265 **(S)-2-Hydroxypropionic acid**, see L-Lactic acid, L13242, p. 265 **6-Hydroxypurine**, see Hypoxanthine, A11481, p. 253	
A16974	**4-Hydroxy-1H-pyrazolo[3,4-d]pyrimidine, 98%** *[Allopurinol, 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one]* [315-30-0], $C_5H_4N_4O$, F.W. 136.11, m.p. >300°, UN2811, EINECS 206-250-9, MDL MFCD00599413, † H:H301-H317, P:P261-P301+P310-P302+P352-P321-P405-P501a Application(s): Xanthine oxidase inhibitor; decreases uric acid production	**5g** **25g**
	6-Hydroxy-1,3,8-pyrenetrisulfonic acid trisodium salt, see Pyranine, L11252, p. 332 **2-Hydroxypyridine-5-carboxylic acid**, see 6-Hydroxynicotinic acid, A15802, p. 250 **6-Hydroxypyridine-3-carboxylic acid**, see 6-Hydroxynicotinic acid, A15802, p. 250 **4-Hydroxypyridine-2,6-dicarboxylic acid hydrate**, see Chelidamic acid hydrate, L00782, p. 153 **4-Hydroxypyrimidine**, see 4(3H)-Pyrimidone, A10859, p. 332	
L19499	**(R)-(+)-3-Hydroxypyrrolidine, 99%, ee 99%** △ ■ *[(R)-(+)-3-Pyrrolidinol]* [2799-21-5], C_4H_9NO, F.W. 87.12, m.p. 15°, b.p. 108-110°/8mm, f.p. >110°(230°F), d. 1.048, n_D^{20} 1.4900, $[\alpha]_D^{20}$ +6.5° (c=3.5 in methanol), BRN 5376132, MDL MFCD00145220 H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 Product of Toray Industries, Inc.	**1g** **5g**
L19498	**(S)-(-)-3-Hydroxypyrrolidine, 99%, ee 99%** △ ■ *[(S)-(-)-3-Pyrrolidinol]* [100243-39-8], C_4H_9NO, F.W. 87.12, m.p. 15°, b.p. 108-110°/8mm, f.p. >110°(230°F), d. 1.048, n_D^{20} 1.4900, $[\alpha]_D^{20}$ -6.5° (c=3.5 in methanol), BRN 4652606, MDL MFCD00192426 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Product of Toray Industries, Inc.	**250mg** **1g** **5g**
	1-Hydroxy-2,5-pyrrolidinedione, see N-Hydroxysuccinimide, A10312, p. 251	
41272	**8-Hydroxyquinoline, ACS** *[8-Quinolinol, Oxine]* [148-24-3], C_9H_7NO, F.W. 145.16, Granular, m.p. 72-74°, b.p. 267°, Merck **14**,4843, Solubility: Almost insoluble in water and diethyl ether. Highly soluble in ethanol, acetone, chloroform, and benzene., EINECS 205-711-1, RTECS VC4200000, BRN 114512, MDL MFCD00006807, † Maximum level of impurities: Insoluble in alcohol 0.05%, Melting point 72.5-74.0°, Residue after ignition 0.05%, SO_4 0.02%, Suitability for magnesium determination P.T. H:H341-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): A bacteriostatic and fungistatic agent. Also a chelating agent for metals	**50g** **250g** **1kg**
A12602	**4-Hydroxyquinoline-2-carboxylic acid hydrate, 98%** *[Kynurenic acid]* [345909-35-5], $C_{10}H_7NO_3 \cdot xH_2O$, F.W. 189.17(anhy), m.p. ca 275° dec., Merck **14**,5327, EINECS 207-751-5, RTECS VB2080000, BRN 147451, MDL MFCD00006753 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Broad spectrum excitatory amino acid antagonist	**1g** **5g** **25g**
	3-Hydroxyquinuclidine, see 3-Quinuclidinol, B21503, p. 334	
J63588	**2-Hydroxysaclofen** *[3-Amino-2-(4-chlorophenyl)-2-hydroxypropanesulfonic acid]* [117354-64-0], $C_9H_{12}ClNO_4S$, F.W. 265.71, Solid, m.p. 268-271°, UN1759, RTECS DA0359200, MDL MFCD00069282 H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Selective antagonist at GABA-B receptors	**10mg** **50mg**
	3-β-Hydroxy-5-spirostene, see Diosgenin, J60976, p. 198 **N-Hydroxysuccimidobiotin**, see (+)-Biotin N-hydroxysuccinimide ester, 44771, p. 125 **(±)-Hydroxysuccinic acid**, see DL-Malic acid, A17874, p. 276 **(R)-(+)-Hydroxysuccinic acid**, see D-(+)-Malic acid, A11688, p. 276 **(S)-(-)-Hydroxysuccinic acid**, see L-(-)-Malic acid, 99%, J63221, p. 276	
A10312	**N-Hydroxysuccinimide, 98+%** ■ *[HOSu, 1-Hydroxy-2,5-pyrrolidinedione]* [6066-82-6], $C_4H_5NO_3$, F.W. 115.09, m.p. 94-99°, Fieser **1**,487 **9**,246, EINECS 228-001-3, BRN 113913, MDL MFCD00005516, † Reagent for the preparation of active N-hydroxysuccinimide esters for peptide coupling with minimum racemization: *J. Am. Chem. Soc.*, **86**, 1839 (1964), or as an additive in the DCC method (see **N,N'-Dicyclohexylcarbodiimide**, **A10973**, p. 187) to suppress racemization: *J. Am. Chem. Soc.*, **89**, 7151 (1967). For a study of the aminolysis of N-hydroxysuccinimide esters, see: *J. Org. Chem.*, **53**, 3583 (1988).	**25g** **100g** **500g**

Stock #	Description	Size
J60680	**Hydroxytacrine maleate salt** *[9-Amino-1,2,3,4-tetrahydro-1-acridinol (2Z)-2-butenedioate, Velnacrine maleate]* [118909-22-1], $C_{17}H_{18}N_2O_5$, F.W. 330.34, Solid, m.p. 171-173° Application(s): Cholinesterase inhibitor. Potential Alzheimer's disease therapeutic	**1g**
A12497	**4-Hydroxy-TEMPO, free radical, 98+%** *[4-Hydroxy-2,2,6,6-tetramethyl-1-piperidin-1-yloxy, free radical]* [2226-96-2], $C_9H_{18}NO_2$, F.W. 172.25, m.p. 69-72°, f.p. 146°(295°F), Fieser **9**,247, EINECS 218-760-9, RTECS TN8991000, BRN 1422990, MDL MFCD00006478, † H:H318-H302-H335-H315, P:P280-P305+P351+P338-P310-P405-P403+P233 Reviews: Synthesis and reactions of stable nitroxyl radicals: *Synthesis*, 190, 401 (1971); Advances in the chemistry of nitroxide spin labels: *Chem. Rev.*, **78**, 37 (1978); Recent advances in the chemistry of nitroxides and their applications in spin labelling: *J. Sci. Ind. Res.*, **54**, 623 (1995). For a brief feature on derived oxoammonium salts, see: *Synlett*, 1757 (2003). Compare also **4-Acetamido-TEMPO**, **B23456**, and **TEMPO**, **A1273**. Recommended as a stabilizer (antioxidant) for the protection of unsaturated fatty acids and their derivatives: *J. Am. Chem. Soc.*, **101**, 6748 (1979). Application(s): Superoxide scavenger with neuroprotective, anti-inflammatory and analgesic effects	**1g** **5g** **25g**
	4-Hydroxy-2,2,6,6-tetramethyl-1-piperidin-1-yloxy, free radical, see 4-Hydroxy-TEMPO, A12497, p. 252 **(R)-(-)-3-Hydroxy-4-(trimethylammonio)butyrate**, see L-Carnitine, A17618, p. 148 **5-Hydroxytryptamine hydrochloride**, see Serotonin hydrochloride, B21263, p. 342	
A12237	**DL-5-Hydroxytryptophan, 99%** *[DL-2-Amino-3-[3-(5-hydroxyindole)]propionic acid]* [56-69-9], $C_{11}H_{12}N_2O_3$, F.W. 220.23, m.p. ca 298° dec., Merck **14**,4847, EINECS 200-284-8, RTECS YN7100000, BRN 88199, MDL MFCD00005651, †	**1g** **5g**
A13954	**L-5-Hydroxytryptophan hydrate, 98%** *[L-2-Amino-3-[3-(5-hydroxyindole)]propionic acid, 5-HTP]* [4350-09-8], $C_{11}H_{12}N_2O_3 \cdot xH_2O$, F.W. 220.23(anhy), m.p. 258° dec., $[\alpha]_D^{20}$ -33° (c=1 in water), Merck **14**,4847, UN2811, EINECS 224-411-1, RTECS YN7110000, BRN 88200, MDL MFCD00064341, † H:H302, P:P264-P270-P301+P312-P330-P501a For routes to 2-bromo-5-hydroxytryptophan derivatives, see: *Synthesis*, 28 (1996).	**250mg** **1g**
	3-Hydroxytyramine hydrochloride, see Dopamine hydrochloride, A11136, p. 201 **3-Hydroxy-DL-tyrosine**, see 3,4-Dihydroxy-DL-phenylalanine, 41535, p. 193 **3-Hydroxy-L-tyrosine**, see L-3-(3,4-Dihydroxyphenyl)alanine, A11311, p. 193 **1-Hydroxyundecane**, see 1-Undecanol, A17817, p. 387	
A10831	**Hydroxyurea, 98%** [127-07-1], $CH_4N_2O_2$, F.W. 76.06, m.p. ca 140° dec., Merck **14**,4848, EINECS 204-821-7, RTECS YT4900000, BRN 1741548, MDL MFCD00007943 H:H340-H360, P:P281-P201-P202-P308+P313-P405-P501a Application(s): An inhibitor of DNA synthesis and an anticancer agent	**1g** **5g** **25g**
	9-Hydroxyxanthene, see Xanthydrol, A13476, p. 394 **17-Hydroxyyohimban-16-carboxylic acid methyl ester hydrochloride**, see Yohimbine hydrochloride, 98+%, J60185, p. 395 **17α-Hydroxy-20α-yohimban-16β-carboxylic acid methyl ester hydrochloride**, see Rauwolscine hydrochloride, 99%, J63198, p. 335	
J60681	**Hygromycin B** [31282-04-9], $C_{20}H_{37}N_3O_{13}$, F.W. 527.53, Lyophilized powder, Merck **14**,4852, UN3462, EINECS 250-545-5, RTECS WK2130000, MDL MFCD06795479 H:H300-H310-H330-H334-H318-H317, P:P301+P310-P304+P340-P305+P351+P338-P320-P330-P361-P405-P501a Application(s): An aminoglycoside antibiotic that kills bacteria by inhibiting protein synthesis	**100mg** **250mg** **1g**
J65234	**Hypercalcemia Malignancy Factor (1-34) amide, human** *[pTH-Related Protein (1-34) amide]* [112955-31-4], $C_{180}H_{288}N_{58}O_{47}$, F.W. 4016.56, Solid, MDL MFCD00166741	**0.5mg** **1mg**
J64361	**Hypercalcemia Malignancy Factor (7-34), amide, human** *[Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-NH2]* $C_{153}H_{247}N_{49}O_{37}$, F.W. 3364.89, Solid	**1mg**
J65499	**Hypercalcemia Malignancy Factor (1-34), human** [112540-82-6], $C_{180}H_{287}N_{57}O_{48}$, F.W. 4017.55, Solid	**1mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
H26425	**Hypericin, 98%** *[4,4',5,5',7,7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone, Hypericum red]* [548-04-9], $C_{30}H_{16}O_8$, F.W. 504.44, m.p. ca 320° dec., Merck **14**,4863, EINECS 208-941-0, BRN 1917913, MDL MFCD00016683 H:H302, P:P264-P270-P301+P312-P330-P501a Inhibitor of protein kinase C: *Biochem Biophys. Res. Commun.*, **165**, 1207 (1989); *Photochem. Photobiol.*, **82**, 720 (2006). Antiviral and antitumour photosensitizer: *Photochem. Photobiol.*, **54**, 95 (1991); *Curr. Drug Targets*, **3**, 55 (2002).  Application(s): Inhibitor of protein kinase C; induces photosynthesized apoptosis	**25mg** **100mg**
	Hypericum red, see Hypericin, H26425, p. 253 **Hypertensin I**, see Angiotensin I (human), J62102, p. 104	
A11481	**Hypoxanthine, 99%** *[6-Hydroxypurine]* [68-94-0], $C_5H_4N_4O$, F.W. 136.11, m.p. >300°, Merck **14**,4869, EINECS 200-697-3, RTECS UP0791000, BRN 5811, MDL MFCD00005725, † 	**5g** **25g** **100g**
	Hypoxanthine-9-β-D-ribofuranoside, see Inosine, A14459, p. 256	
J62443	**Ibandronate sodium, 98+%** [138844-81-2], $C_9H_{24}NNaO_8P_2$, F.W. 359.23, Crystalline powder, Merck **14**,4873, RTECS SZ8563300, MDL MFCD07197214 H:H400-H410, P:P273-P391-P501a Application(s): A third generation bisphosphonate used as bone resorptive inhibitor. Inhibits farnesyl diphosphate synthase	**100mg**
J60748	**Ibotenic acid hydrate, 98+%** *[α-Amino-3-hydroxy-5-isoxazoleacetic acid]* [2552-55-8], $C_5H_6N_2O_4 \cdot xH_2O$, F.W. 158.11(anhy), Powder, Merck **14**,4877, UN3462, RTECS NY2100000, MDL MFCD00069294 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Potent NMDA and glutamate receptor agonist	**1mg** **5mg** **25mg**
	Ibuprofen, see 4-Isobutyl-α-methylphenylacetic acid, B20989, p. 260	
H56358	**Ibutilide hemifumarate salt, 99%** *[(±)-N-[4-(4-[Ethyl(n-heptyl)amino]-1-hydroxybutyl)phenyl-]methanesulfonamide hemifumarate salt]* [122647-32-9], $C_{20}H_{36}N_2O_3S \cdot 0.5C_4H_4O_4$, F.W. 442.61, Merck **14**,4883, RTECS PB0475700, MDL MFCD01715410 	**25mg** **100mg**
	IDC, see 5-Iodo-2'-deoxycytidine, 99%, J61356, p. 258 **Idoxuridine**, see (+)-5-Iodo-2'-deoxyuridine, A11542, p. 258	
J63303	**IEF Anode buffer (50X)** Liquid, Note: Contains 350mM phosphoric acid at pH 2.4. H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For isoelectric focusing (IEF)	**500ml** **1L**
J61903	**IEF Cathode buffer (10X) with lysine** Liquid, Note: Contains 0.2M lysine (free base) pH 3-7 Application(s): For isoelectric focusing (IEF)	**250ml** **500ml**
J62204	**IEF Cathode buffer (10X) with lysine and arginine** Liquid, Note: Contains 0.2M arginine (free base) and 0.2mM lysine (free base) at pH 10.1 Application(s): For isoelectric focusing	**250ml** **500ml**
J62241	**IEF Sample buffer (2X) pH 3-10 with lysine and arginine** Liquid, Note: Contains 40mM arginine (free base), 40mM lysine (free base) and 30% glycerol. H:H319, P:P280-P264-P305+P351+P338-P337+P313	**25ml** **50ml**
J63633	**IEF Sample buffer (4X) pH 3-7 with lysine** Liquid, Note: Contains 80mM lysine (free base) and 60% glycerol. H:H319, P:P280-P264-P305+P351+P338-P337+P313	**25ml** **50ml**
J60932	**Ifenprodil hemitartrate, 99%** [23210-56-2], $C_{21}H_{27}NO_2 \cdot 0.5C_4H_6O_6$, F.W. 400.49, Powder, Merck **14**,4895, EINECS 245-491-4 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): NMDA receptor antagonist, acting at the polyamine site	**10mg** **50mg**
J61055	**IGEPAL® CA-630** *[Octylphenyl-polyethylene glycol]* [9036-19-5], $(C_2H_4O)nC_{14}H_{22}O$, Liquid, MDL MFCD00132505, Note: IGEPAL is a registered trademark of Rhodia Operations, † H:H318-H315, P:P280-P305+P351+P338-P302+P352-P321-P310-P362 Application(s): Detergent, equivalent to Nonidet P-40. For solubilizing membrane proteins	**100ml** **500ml**
	IgE Peptide III, see Hamburger Pentapeptide, J60543, p. 241	

Stock #	Description	Size
J65916	**IGF-1R Inhibitor, PPP ▲** *[Insulin-like Growth Factor-1 Receptor Inhibitor, Picropodophyllin]* [477-47-4], $C_{22}H_{22}O_8$, F.W. 414.40, Solid, Merck **14**,7546, UN3462, RTECS LV2510000, MDL MFCD01742647 H:H301-H312-H315-H319-H341-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501	**10mg**
J65132	**IKK-2 Inhibitor V ▲** *[N-(3,5-Bis-trifluoromethylphenyl)-5-chloro-2-hydroxybenzamide, IMD-0354]* [978-62-1], $C_{15}H_8ClF_6NO_2$, F.W. 383.67, Powder, MDL MFCD00218820 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg**
J65815	**IL-1R Antagonist** *[BB-loop Mimic, Hydrocinnamoyl-L-valyl pyrrolidine]* [566914-00-9], $C_{18}H_{26}N_2O_2$, F.W. 302.41, Oil	**25mg**
	H-Ile-OH, see L-Isoleucine, Cell Culture Reagent, J63045, p. 260	
J62346	**Imetit dihydrobromide, 98%** *[(S)-[2-(4-Imidazolyl)ethyl]isothiourea dihydrobromide]* [32385-58-3], $C_6H_{10}N_4S \cdot 2HBr$, F.W. 332.06, Powder, MDL MFCD00153816 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An extremely potent, high affinity agonist at H3 and H4 receptors	**25mg** **50mg** **100mg**
J61956	**Imidazole, 0.5M buffer soln., pH 6.0** [288-32-4], Liquid, † H:H318-H315, P:P280-P305+P351+P338-P302+P352-P321-P310-P362	**100ml** **250ml**
J62207	**Imidazole, 0.5M buffer soln., pH 6.5** [288-32-4], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J62593	**Imidazole, 0.5M buffer soln., pH 7.0** [288-32-4], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J63496	**Imidazole, 0.5M buffer soln., pH 7.5** [288-32-4], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
A10221	**Imidazole, 99%** *[Glyoxaline]* [288-32-4], $C_3H_4N_2$, F.W. 68.08, m.p. 88-92°, b.p. 256°, f.p. 145°(293°F), d. 1.03, Merck **14**,4912, Fieser **1**,492 **2**,220 **21**,224, UN2923, EINECS 206-019-2, RTECS NI3325000, BRN 103853, MDL MFCD00005183, † H:H301-H314, P:P260-P301+P310-P303+P361+P353-P305+P351+P338-P405-P501a Nucleophilic catalyst for many acylation and silylation reactions, compare **4-(Dimethylamino)pyridine**, **A13016**. For use in: silylation of 1,3-diketones, see **Hexamethyldisilazane**, **A15139**; introduction of the TBDMS and TBDPS groups; see: **tert-Butyldimethylchlorosilane**, **A13064**, and **tert-Butyldiphenylchlorosilane**, **A12721**, respectively. In combination with triphenylphosphine and iodine, vic-diols are converted to alkenes: *Synthesis*, 469 (1979), and alcohols to alkyl iodides: *Synth. Commun.*, **20**, 1473 (1990). With 2 moles of an aroyl halide gives, after hydrolysis, good yields of 2-aroylimidazoles: *Synthesis*, 675 (1978). Application(s): Excellent for buffer use in pH range 6.2 - 7.8. Also an histamine antagonist	**100g** **500g** **2.5kg**
B22473	**Imidazole-4-acetic acid monohydrochloride, 97%** [3251-69-2], $C_5H_6N_2O_2 \cdot HCl$, F.W. 162.58, m.p. 221-224°, EINECS 221-840-6, BRN 3701591, MDL MFCD00012698 Application(s): A GABAc antagonist	**1g** **5g**
J63887	**Imidazole-buffered saline (5X)** [288-32-4], Liquid, Note: Contains 50mM imidazole and 750mM sodium chloride at pH 7.0., † H:H301, P:P264-P270-P301+P310-P321-P405-P501a	**250ml** **500ml**
	2-Imidazolethiol, see 2-Mercaptoimidazole, L01346, p. 281 **2,4-Imidazolidinedione**, see Hydantoin, A12486, p. 247 **(S)-[2-(4-Imidazolyl)ethyl]isothiourea dihydrobromide**, see Imetit dihydrobromide, 98%, J62346, p. 254 **7H-Imidazo[4,5-d]pyrimidine**, see Purine, 98%, J60999, p. 331	
A11510	**Iminodiacetic acid, 98+%** [142-73-4], $HN(CH_2CO_2H)_2$, F.W. 133.10, m.p. ca 243° dec., Merck **14**,4917, EINECS 205-555-4, RTECS AI2975000, BRN 878499, MDL MFCD00004280, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibitor of bovine liver glutamate dehydrogenase	**100g** **500g** **2.5kg**
43809	**Iminodiacetic acid disodium salt hydrate, 97%** *[Sodium iminodiacetate dibasic hydrate]* [17593-73-6], $HN(CH_2CO_2Na)_2 \cdot xH_2O$, F.W. 177.07(anhy), Crystalline, Merck **14**,4917, MDL MFCD00150689, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
	2-Imino-1-methylimidazolidin-4-one, see Creatinine, B23097, p. 168	
J60131	**2-Iminothiolane hydrochloride** *[2-Thiolanimine hydrochloride, Traut's reagent]* [4781-83-3], $C_4H_7NS \cdot HCl$, F.W. 137.63, Powder, m.p. 190-195°, BRN 3620079, MDL MFCD00039013 Application(s): Protein modification and cross-linking reagent, cleavable by thiols	**250mg** **1g**
J63723	**Imipramine hydrochloride** [113-52-0], $C_{19}H_{24}N_2 \cdot HCl$, F.W. 316.87, Crystalline powder, m.p. 174-175°, Merck **14**,4920, EINECS 204-030-7, RTECS HO1925000, MDL MFCD00012669, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A serotonin uptake inhibitor	**5g** **25g** **100g**
J63990	**Imiquimod, 99%** [99011-02-6], $C_{14}H_{16}N_4$, F.W. 240.31, Solid, m.p. 292-294°, Merck **14**,4922, UN2811, MDL MFCD00866946 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A caspase 3 activator that acts as an immunomodulator and displays antiviral and antitumor activity	**100mg** **1g**
J64212	**Immethridine dihydrobromide** *[4-(1H-Imidazol-4-ylmethyl)pyridine dihydrobromide]* [87976-03-2], $C_9H_9N_3 \cdot 2HBr$, F.W. 321.01, Solid, MDL MFCD07370139 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
	IMP, see Inosine-5'-monophosphate disodium salt hydrate, J61959, p. 256	
J60062	**Inactivation Gate Peptide** *[Ac-Lys-Ile-Phe-Met-Lys-NH2]* [156162-44-6], $C_{34}H_{58}N_8O_6S$, F.W. 706.95, Lyophilized powder Application(s): Binds and inactivates open sodium channels	**25mg**
J63846	**Indapamide** [26807-65-8], $C_{16}H_{16}ClN_3O_3S$, F.W. 365.83, Powder, m.p. 160-162°, Merck **14**,4935, EINECS 248-012-7, MDL MFCD00079375 Application(s): Used as an antihypertensive. Diuretic	**1g** **5g**
J61485	**Indatraline hydrochloride, 99%** *[Lu 19-005]* [86939-10-8], $C_{16}H_{15}Cl_2N \cdot HCl$, F.W. 328.67, Solid, m.p. 186-188° Application(s): Potent inhibitor of dopamine, norepinephrine and serotonin uptake	**10mg** **50mg**
J61007	**India Ink** [8046-52-4], Liquid, Note: A ready to use solution of 0.2% India Ink in PBS with 0.05% Tween-20	**500ml** **1L**
A16052	**Indigo carmine** *[Indigo-5,5'-disulfonic acid disodium salt, C.I. 73051]* [860-22-0], $C_{16}H_8N_2Na_2O_8S_2$, F.W. 466.36, m.p. >300°, Merck **14**,4944, EINECS 212-728-8, RTECS DU3000000, BRN 4103904, MDL MFCD00005723, † H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Useful in the staining of Negri bodies	**25g** **100g**
	Indigo-5,5'-disulfonic acid disodium salt, see Indigo carmine, A16052, p. 255	
A14427	**Indole, 99% ▲** [120-72-9], C_8H_7N, F.W. 117.15, m.p. 50-54°, b.p. 253-254°, f.p. 121°(249°F), d. 1.220, Merck **14**,4963, UN2811, EINECS 204-420-7, RTECS NL2450000, BRN 107693, MDL MFCD00005607, † H:H311-H318-H400-H302, P:P280-P305+P351+P338-P361-P302+P352-P405-P501a Lithiation of N-protected indoles usually occurs at the 2-position, e.g. benzenesulfonation of the 1-lithio derivative, 2-lithiation with LDA and treatment with pyridine-3,4-dicarboxylic anhydride. This sequence has been reported in a synthetic route to ellipticene and olivacine: *J. Org. Chem.*, **57**, 5891 (1992). Regioselective synthesis of 3-substituted indoles has been described using a sequence of N-silylation, 3-bromination of the 1-TBDMS detivative with NBS, 3-lithiation, treatment with an electrophile to introduce the 3-substituent, and desilylation with TBAF. Good overall yields are obtained for a range of electrophiles: *J. Org. Chem.*, **59**, 10 (1994); *Org. Synth. Coll.*, **9**, 417 (1998). Treatment with EtMgI followed by $ZnCl_2$ leads to an N-zinc derivative. This undergoes acylation at the 3-position: *Tetrahedron*, **46**, 6061 (1990). Halogenation in the 2-position has been effected via the Li 1-carbamate and subsequent 2-lithiation: *J. Org. Chem.*, **57**, 2495 (1992):  Treatment of the carbamate with **Tri-n-butyltin chloride**, **A10746**, followed by Stille coupling enables synthesis of 2-aryl- and 2-vinylindoles: *J. Org. Chem.*, **60**, 6218 (1995).	**50g** **250g** **1kg**

Stock #	Description	Size
A10556	**Indole-3-acetic acid, 98+% ▲** *[Heterauxin, Indolyl-3-acetic acid]* [87-51-4], $C_{10}H_9NO_2$, F.W. 175.19, m.p. ca 167° dec., f.p. 171°(339°F), Merck **14**,4964, EINECS 201-748-2, RTECS NL3150000, BRN 143358, MDL MFCD00005636, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Plant growth hormone	**5g** **25g** **100g** **500g**
A15260	**Indole-3-butyric acid, 98%** *[4-(3-Indolyl)butyric acid]* [133-32-4], $C_{12}H_{13}NO_2$, F.W. 203.24, m.p. 121-125°, Merck **14**,4965, UN2811, EINECS 205-101-5, RTECS NL5250000, BRN 171120, MDL MFCD00005664, † H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g** **100g**
J65215	**Indolicidin** *[Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH2]* [140896-21-5], $C_{100}H_{132}N_{26}O_{13}$, F.W. 1906.28, Powder, Merck **14**,10224, RTECS NM1890250	**0.5mg** **1mg**
	2,3-Indolinedione, see Isatin, A12468, p. 260 **Indolyl acetate**, see 3-Indoxyl acetate, L04932, p. 256 **Indolyl-3-acetic acid**, see Indole-3-acetic acid, A10556, p. 256 **4-(3-Indolyl)butyric acid**, see Indole-3-butyric acid, A15260, p. 256 **2-(3-Indolyl)ethanol**, see Tryptophol, L02555, p. 385	
J63255	**Indomethacin, 99+% ▲** *[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid]* [53-86-1], $C_{19}H_{16}ClNO_4$, F.W. 357.80, Powder, m.p. 158-161°, Merck **14**,4968, UN2811, EINECS 200-186-5, RTECS NL3500000, BRN 497341, MDL MFCD00057095, † H:H300-H341, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Non-selective cyclooxygenase inhibitor	**1g** **5g** **25g**
L04932	**3-Indoxyl acetate, 97%** *[3-Acetoxyindole, Indolyl acetate]* [608-08-2], $C_{10}H_9NO_2$, F.W. 175.19, m.p. 128-130°, EINECS 210-154-2, RTECS AI3325000, BRN 143086, MDL MFCD00014561, † Substrate for enzyme assay: *Anal. Chem.*, **37**, 120 (1965). Application(s): Useful for detection of esterases	**1g** **5g**
J60552	**3-Indoxyl phosphate disodium salt** *[Disodium 3-indoxyl phosphate]* [3318-43-2], $C_8H_8NNa_2O_4P$, F.W. 257.09, Powder, EINECS 222-014-8, MDL MFCD00040646, † Application(s): A histochemical substrate for alkaline phosphatase	**250mg** **1g**
J60601	**Ingenol 3-angelate, 99%** [75567-37-2], $C_{25}H_{34}O_6$, F.W. 348.40, Powder, MDL MFCD07784504 Application(s): Protein kinase C activator	**1mg**
	Ingrain blue 1, see Alcian Blue 8GX, J63233, p. 134	
A14459	**Inosine, 98+%** *[Hypoxanthine-9-β-D-ribofuranoside]* [58-63-9], $C_{10}H_{12}N_4O_5$, F.W. 268.23, m.p. 212-215° dec., $[\alpha]_D^{20}$ -52° (c=1 in water), Merck **14**,4975, EINECS 200-390-4, RTECS NW7460000, BRN 624889, MDL MFCD00066770, † Application(s): Suppresses the increase of glucose and insulin in the blood	**5g** **25g** **100g**
J65397	**Inosine-5'-diphosphate disodium salt, 95%** *[IDP]* [54735-61-4], $C_{10}H_{12}N_4O_{11}P_2Na_2$, F.W. 472.15, Powder, EINECS 259-312-2, MDL MFCD00211028	**1g** **5g** **10g**
J61959	**Inosine-5'-monophosphate disodium salt hydrate** *[IMP]* [4691-65-0], $C_{10}H_{11}N_4Na_2O_8P \cdot xH_2O$, F.W. 392.17(anhy), Crystalline powder, EINECS 225-146-4, RTECS NM7519500, MDL MFCD00036201, †	**5g** **25g** **100g**
J65670	**Inosine-5'-triphosphate trisodium salt, 96%** [35908-31-7], $C_{10}H_{12}N_4Na_3O_{14}P_3$, F.W. 574.11, Powder, MDL MFCD00084678 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J60828	**myo-Inositol, 97+%** [87-89-8], $C_6H_{12}O_6$, F.W. 180.16, Crystalline powder, m.p. 222-227°, Merck **14**,4978, EINECS 201-781-2, RTECS NM7520800, BRN 1907329, MDL MFCD00077932, † Application(s): A lipotropic agent	**100g** **500g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A13586	**myo-Inositol, 98+%** *[Hexahydroxycyclohexane, Myoinositol]* [87-89-8], $C_6H_{12}O_6$, F.W. 180.16, m.p. 224-227°, d. 1.75, Merck **14**,4978, EINECS 201-781-2, RTECS NM7520800, BRN 1907329, MDL MFCD00077932, †  Application(s): A lipotropic agent	**100g** **500g** **2.5kg**
J62886	**D-myo-Inositol, Cell Culture Grade** [87-89-8], $C_6H_{12}O_6$, F.W. 180.16, Crystalline powder, m.p. 222-227°, Merck **14**,4978, EINECS 201-781-2, RTECS NM7520800, BRN 1907329, MDL MFCD00077932, † Application(s): A lipotropic agent	**50g** **100g** **250g**
J61170	**Insulin B (22-25)** *[H-Arg-Gly-Phe-Phe-OH]* [34367-73-2], $C_{26}H_{35}N_7O_5$, F.W. 525.61, Powder	**25mg** **100mg**
J61321	**Insulin, from porcine pancreas, 98+%** [12584-58-6], $C_{256}H_{381}N_{65}O_{76}S_6$, F.W. 5777.59, Lyophilized powder, Merck **14**,4980, EINECS 235-703-3, RTECS NM8895000, MDL MFCD00131380 Application(s): A hormone that is central to regulating energy and glucose metabolism in the body	**25mg** **250mg**
J64081	**Insulin-like Growth Factor-I, human, 97%** *[IGF-I, human, Somatomedin C]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for cell culture and radioimmunoassays. Supplied as an aseptically lyophilized powder.	**10micrograms**
J65170	**Insulin-like Growth Factor-II, human, 97%** *[IGF-II, human]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for cell culture and radioimmunoassays. Supplied as an aseptically lyophilized powder.	**10micrograms**
	INT, see 2-(p-Iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride hydrate, B22301, p. 258	
J65928	**β-Interleukin-I (163-171), human** *[Val-Gln-Gly-Glu-Glu-Ser-Asn-Asp-Lys]* [106021-96-9], $C_{39}H_{64}N_{12}O_{19}$, F.W. 1004.99, Solid	**1mg**
J65203	**β-Interleukin II (44-56)** *[Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu]* $C_{68}H_{113}N_{19}O_{19}$, F.W. 1500.74, Solid	**1mg**
J61698	**Intrinsic Factor** [9008-12-2], Lyophilized powder, MDL MFCD00131406 Application(s): A glycoprotein necessary for the absorption of vitamin B-12	**1kilounit**
A18425	**Inulin** [9005-80-5], Merck **14**,5004, EINECS 232-684-3, MDL MFCD00131407, Note: Yields D-fructose and D-glucose after acid hydrolysis., † Application(s): Mixture of fructose polymers that serves as carbohydrate storage in plants	**10g** **50g** **250g**
	Invertose, see Invert sugar, J60273, p. 257	
J60273	**Invert sugar** *[Invertose]* [8013-17-0], Thick syrup, Merck **14**,5006, EINECS 232-393-1, MDL MFCD00148911, Note: Mixture of about 50% glucose and 50% fructose obtained by hydrolysis of starch., † Application(s): Pure Syrup	**100g** **1kg**
J64994	**Involucrin, human, Enzyme Immunoassay Kit** Note: Contains sufficient material for 2500 tests or 25-96 well plates. Kit components include: anti-human Involucrin antibody (from rabbit), human Involucrin and goat anti-rabbit IgG-alkaline phosphatase conjugate. Application(s): For detection of involucrin. Detection range is 0.5-10ng/ml	**1kit**
A14715	**2-Iodoacetamide, 98%, stab. with ca 5-8% water** ▲ [144-48-9], ICH_2CONH_2, F.W. 184.96, m.p. 92-95°(dried), Fieser **1**,504, UN2811, EINECS 205-630-1, RTECS AC4200000, BRN 1739080, MDL MFCD00008028, † H:H301-H315-H319-H317-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Alkylating agent used in peptide mapping because it covalently binds with the thiols in cysteine to prevent disulfide bond formation	**5g** **25g** **100g**
	5-Iodoanthranilic acid, see 2-Amino-5-iodobenzoic acid, A19838, p. 96	
B24416	**4-Iodobenzenesulfonyl chloride, 97%** ▲◪ *[Pipsyl chloride]* [98-61-3], $C_6H_4ClIO_2S$, F.W. 302.52, m.p. 79-84°, Merck **14**,7486, UN3261, EINECS 202-686-9, BRN 2691661, MDL MFCD00007441, †  H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**5g** **25g** **100g**

Stock #	Description	Size
A10563	**2-Iodobenzoic acid, 98+% ▲** [88-67-5], $C_7H_5IO_2$, F.W. 248.02, m.p. 160-164°, d. 2.250, Merck **14**,5030, Fieser **1**,506, EINECS 201-850-7, RTECS DH2975000, BRN 1861406, MDL MFCD00002419, † ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Can be used to protect alcohols as their 2-iodobenzoates by DCC coupling. The group is removed by oxidation with chlorine under basic conditions: *Tetrahedron Lett.*, **28**, 5005 (1987). In the presence of **Tetrakis(triphenylphosphine)palladium(0)**, **10548**, and zinc chloride, undergoes cyclization with terminal acetylenes to give isocoumarins: *J. Org. Chem.*, **60**, 3711 (1995):  For related reactions, see **4,4-Dimethyl-2-pentyne**, **L10210**, **2-Iodoaniline**, **A13059**, and **2-Iodophenol**, **A13599**. Application(s): Reagent for detection of sulfhydryl groups in proteins	 **25g** **100g** **500g**
A10730	**4-Iodobenzoic acid, 97% ▲** [619-58-9], $C_7H_5IO_2$, F.W. 248.02, m.p. ca 265° dec., d. 2.18, EINECS 210-603-2, RTECS DH2976000, BRN 1860232, MDL MFCD00002533, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	 **10g** **50g** **250g**
J64698	**5-Iodocytidine, 99% ▲** *[1-β-D-Ribofuranosyl-5-iodocytosine]* [1147-23-5], $C_9H_{12}IN_3O_5$, F.W. 369.11, Powder	**1g**
J61356	**5-Iodo-2'-deoxycytidine, 99%** *[IDC]* [611-53-0], $C_9H_{12}IN_3O_4$, F.W. 353.11, Powder, m.p. 180-183°, EINECS 210-269-8, MDL MFCD00038063 ! H:H302, P:P264-P270-P301+P312-P330-P501a	**1g** **2g**
A11542	**(+)-5-Iodo-2'-deoxyuridine, 98% ▲** *[Idoxuridine]* [54-42-2], $C_9H_{11}IN_2O_5$, F.W. 354.10, m.p. ca 190° dec., Merck **14**,4891, EINECS 200-207-8, RTECS YU7700000, BRN 30397, MDL MFCD00134656, † H:H351-H361, P:P281-P201-P202-P308+P313-P405-P501a	 **1g** **5g**
J61498	**2-Iodomelatonin, 98+%** *[N-Acetyl-2-iodo-5-methoxytryptamine]* [93515-00-5], $C_{13}H_{15}IN_2O_2$, F.W. 358.18, Crystalline, RTECS AC4376000, MDL MFCD00055216 Application(s): Potent melatonin agonist	**10mg** **50mg**
	Iodonitrotetrazolium chloride, see Iodonitrotetrazolium violet, B22301, p. 258	
B22301	**Iodonitrotetrazolium violet, 95% ▲** *[INT, Iodonitrotetrazolium chloride]* [146-68-9], $C_{19}H_{13}ClIN_5O_2 \cdot xH_2O$, F.W. 505.70(anhy), m.p. ca 231° dec., EINECS 205-676-2, BRN 4093224, MDL MFCD00149999, † ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reagent for dehydrogenase determination: *Clin. Chem.*, **19**, 766 (1973); *J. Histochem. Cytochem.*, **28**, 408 (1980). Application(s): Used for dehydrogenase determination	 **1g** **5g** **25g**
	2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride hydrate, see Iodonitrotetrazolium violet, B22301, p. 258	
L15606	**2-Iodosobenzoic acid, 97% ▲** *[Iodosylbenzoic acid]* [304-91-6], $C_7H_5IO_3$, F.W. 264.02, m.p. ca 230° dec., Fieser **1**,509 **12**,259, EINECS 206-159-4, RTECS DH3056550, BRN 1939973, MDL MFCD00002401 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Probably exists as the cyclized form 1-Hydroxy-1,1-dihydro-1,2-benzodioxol-3(1H)-one; CAS registry no. [161-62-4]. Reagent for α-hydroxylation of ketones; the by-product benzoic acid is easily removed by base extraction: *Tetrahedron Lett.*, **25**, 691 (1984). For an example, see: *Org. Synth. Coll.*, **7**, 263 (1990). Catalyst for cleavage of toxic phosphates and reactive esters: *Tetrahedron Lett.*, **28**, 251 (1987); *J. Am. Chem. Soc.*, **108**, 788 (1986); **116**, 4471 (1994). For a review of polyvalent iodine compounds, see: *Chem. Rev.*, **96**, 1123 (1996). Application(s): Commonly used peptide reagent for cleavage at tryptophyl and tyrosyl residues	 **1g** **5g**
	Iodosylbenzoic acid, see 2-Iodosobenzoic acid, L15606, p. 258	
A18994	**5-Iodouracil, 97% ▲** [696-07-1], $C_4H_3IN_2O_2$, F.W. 237.99, m.p. 274-276°, EINECS 211-788-2, RTECS YR0525000, BRN 4891, MDL MFCD00006020, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a For a review of the use of uracils as starting materials in heterocyclic synthesis, see: *Adv. Het. Chem.*, **55**, 130 (1992).	 **10g** **50g** **250g**

Stock #	Description	Size
J62259	**5-Iodouridine, 96%** [1024-99-3], $C_9H_{11}IN_2O_6$, F.W. 370.10, Powder, EINECS 213-833-1, BRN 33665, MDL MFCD00006532	**1g** **5g**
J62448	**Ionomycin, 98%** [56092-81-0], $C_{41}H_{72}O_9$, F.W. 709.02, Solution in ethanol, RTECS NO0600000, BRN 3642126, MDL MFCD06798385 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Highly selective and potent calcium ionophore	**1mg** **5mg**
J60628	**Ionomycin calcium salt, 99% ▲** [56092-82-1], $C_{41}H_{70}CaO_9$, F.W. 747.08, Crystalline powder, RTECS NO0650000, BRN 1416163, MDL MFCD00151183 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Highly selective and potent calcium ionophore	**5mg**
J60453	**Ipratropium bromide, 99%** [22254-24-6], $C_{20}H_{30}BrNO_3$, F.W. 412.37, Powder, Merck **14**,5073, EINECS 244-873-8 H:H302-H332-H319, P:P261-P280-P305+P351+P338-P304+P340-P301+P312-P501 Application(s): Muscarinic acetylcholine receptor antagonist and a bronchodilator	**100mg**
	IPTG, see Isopropyl-β-D-thiogalactoside, B21149, p. 261	
J60743	**Irinotecan hydrochloride** [100286-90-6], $C_{33}H_{38}N_4O_6 \cdot HCl$, F.W. 623.14, Yellow powder, Merck **14**,5091, RTECS DW1061000, MDL MFCD01862255 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Topoisomerase I inhibitor	**50mg** **250mg**
J62370	**Irinotecan hydrochloride trihydrate** *[CPT11]* [100286-90-6], $C_{33}H_{38}N_4O_6 \cdot HCl \cdot 3H_2O$, F.W. 677.19 (623.15anhy), Crystalline powder, m.p. 256°, Merck **14**,5091, RTECS DW1060750, MDL MFCD01862255 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Topoisomerase I inhibitor	**100mg** **250mg**
	Iron alum, see Ammonium iron(III) sulfate dodecahydrate, 39391, p. 101 **Iron(II) ammonium sulfate**, see Ammonium iron(II) sulfate hexahydrate, 13448, p. 101	
12497	**Iron(III) chloride hexahydrate, ACS, 97.0-102.0% ■** *[Ferric chloride hexahydrate]* [10025-77-1], $FeCl_3 \cdot 6H_2O$, F.W. 270.30 (162.21anhy), Lump, m.p. 37°, b.p. 280-285°, d. 1.820, Merck **14**,4019, Fieser **1**,390 **3**,145 **6**,259 **10**,185 **11**,237 **12**,230 **13**,133 **20**,204 **21**,240, Solubility: Freely soluble in water, alcohol, ether, acetone., UN3260, EINECS 231-729-4, RTECS NO5425000, MDL MFCD00149712, Note: b.p. 280° $-H_2O$; 300° dec., † Maximum level of impurities: Insoluble matter 0.01%, NO_3 0.01%, Phosphorus compounds (as PO_4) 0.01%, SO_4 0.01%, Ca 0.01%, Cu 0.003%, Mg 0.005%, K 0.005%, Na 0.05%, Ferrous iron (Fe^{+2}) P.T. (limit about 0.002%), Zn 0.003% H:H314-H302, P:P280-P305+P351+P338-P309-P310	**25g** **250g** **1kg** **5kg**
A10276	**Iron(III) citrate hydrate, Fe(III) 16.5-20%; Fe(II) max 5% ▲** *[Citric acid iron(III) salt, Ferric citrate]* [334024-15-6], $C_6H_5FeO_7 \cdot xH_2O$, F.W. 244.94(anhy), EINECS 222-536-6, MDL MFCD00149617 	**50g** **250g** **1kg**
J62550	**Iron Dextran 10%** Powder H:H334-H317-H351, P:P285-P261-P302+P352-P321-P405-P501 Application(s): Prevents and treats neonatal anemia in pigs. The least toxic iron preparation available for parenteral administration	**1kg**
J62750	**Iron Dextran 20%** Powder H:H334-H317-H351, P:P285-P261-P302+P352-P321-P405-P501 Application(s): Prevents and treats neonatal anemia in pigs.	**1kg**
33315	**Iron(III) nitrate nonahydrate, ACS, 98.0-101.0%** [7782-61-8], $Fe(NO_3)_3 \cdot 9H_2O$, F.W. 403.99 (241.86anhy), Crystalline, m.p. 47°, b.p. 125° dec., d. 1.684, Merck **14**,4027, Solubility: Freely soluble in water, alcohol, acetone. Slightly soluble in cold and concentrated HNO_3, UN1466, EINECS 233-899-5, RTECS NO7175000, MDL MFCD00149708, † Maximum level of impurities: Insoluble matter 0.005%, Cl 5ppm, SO_4 0.01%, Ca 0.01%, Mg 0.005%, K 0.005%, Na 0.05% H:H272-H315-H319, P:P221-P210-P305+P351+P338-P302+P352-P321-P501a	**500g** **2kg** **5x2kg**

Stock #	Description	Size
A12468	**Isatin, 98%** *[2,3-Indolinedione]* [91-56-5], $C_8H_5NO_2$, F.W. 147.13, m.p. ca 194° dec., f.p. 220°(428°F), Merck **14**,5104, EINECS 202-077-8, RTECS NL7873000, BRN 383659, MDL MFCD00005718, † Isatins undergo a one-pot Wolff-Kishner like reduction with hydrazine hydrate, under surprisingly mild conditions, to give the corresponding oxindoles: *Synth. Commun.*, **24**, 2835 (1994). Reaction with acid anhydrides or condensation with **4-Methyl-2-pentanone**, **A11618**, results in the formation of quinoline-4-carboxylic acid derivatives; for examples, see: *J. Med. Chem.*, **35**, 4893 (1992); **36**, 617, 3286 (1993).:  Application(s): Chromatographic spray reagent for amino acid detection	**100g** **500g** **2.5kg**
A12054	**Isethionic acid sodium salt, 98%** *[Sodium isethionate, 2-Hydroxyethanesulfonic acid sodium salt]* [1562-00-1], $HO(CH_2)_2SO_3Na$, F.W. 148.11, m.p. 191-194°, EINECS 216-343-6, RTECS KI7700000, BRN 3633992, MDL MFCD00007534, † Application(s): A surfactant and skin and mucous membrane irritant	**1kg** **5kg**
36366	**D-(-)-Isoascorbic acid, 99%** *[D-(-)-Araboascorbic acid, Erythorbic acid]* [89-65-6], $C_6H_8O_6$, F.W. 176.12, Powder, m.p. 169-172° dec., Merck **14**,5126, EINECS 201-928-0, MDL MFCD00005378, †	**100g** **500g**
	Isobutanolamine, see 2-Amino-2-methyl-1-propanol, A17814, p. 97	
B20989	**4-Isobutyl-α-methylphenylacetic acid, 99%** *[Ibuprofen]* [15687-27-1], $C_{13}H_{18}O_2$, F.W. 206.29, m.p. 75-78°, b.p. 157°/4mm, Merck **14**,4881, UN3077, EINECS 239-784-6, RTECS MU6640000, MDL MFCD00010393, † H:H361-H302-H411, P:P281-P273-P301+P312-P308+P313-P405-P501a Application(s): NSAID that inhibits cyclooxygenase-1 and -2	**1g** **5g** **25g**
J65249	**N_2-Isobutyryl-2'-O-methylguanosine, 98%** $C_{15}H_{21}N_5O_6$, F.W. 367.36, Powder H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J65073	**Isocitrate Dehydrogenase** *[EC 1.1.1.42]* Lyophilized powder, Note: Component in the Cofactor Recycling Enzymes Kit, item J64535	**250mg** **500mg** **1g**
H54228	**Isocytosine, 99%** *[2-Amino-4-hydroxypyrimidine]* [108-53-2], $C_4H_5N_3O$, F.W. 111.10, EINECS 203-592-0, MDL MFCD00057557	**1g** **5g** **25g**
	4',7-Isoflavandiol, see (R,S)-Equol, J61383, p. 209	
J63243	**Isoguvacine hydrochloride, 99%** *[1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid hydrochloride]* [64603-90-3], $C_6H_9NO_2$·HCl, F.W. 163.60, Powder Application(s): Specific GABA agonist	**100mg**
A17521	**DL-Isoleucine, 99%** *[(+/-)-2-Amino-3-methylpentanoic acid, H-DL-Ile-OH]* [443-79-8], $C_6H_{13}NO_2$, F.W. 131.18, m.p. ca 280° dec., Merck **14**,5179, EINECS 207-139-8, BRN 1721796, MDL MFCD00004268, †	**25g** **100g**
H27488	**D-Isoleucine, 98%** *[(2R,3R)-2-Amino-3-methylpentanoic acid, H-D-Ile-OH]* [319-78-8], $C_6H_{13}NO_2$, F.W. 131.18, m.p. 265° subl., EINECS 206-269-2, RTECS NR4700000, MDL MFCD00064221	**250mg** **1g**
A13699	**L-Isoleucine, 99%** *[(2S,3S)-2-Amino-3-methylpentanoic acid, H-Ile-OH]* [73-32-5], $C_6H_{13}NO_2$, F.W. 131.18, m.p. ca 287° dec., $[\alpha]_D^{20}$ +40° (c=5 in 6N HCl), Merck **14**,5179, EINECS 200-798-2, RTECS NR4705000, BRN 1721792, MDL MFCD00064222, †	**10g** **50g** **100g** **250g**
J63045	**L-Isoleucine, Cell Culture Reagent** *[(2S,3S)-2-Amino-3-methylpentanoic acid, H-Ile-OH]* [73-32-5], $C_6H_{13}NO_2$, F.W. 131.18, Powder, m.p. ca 287° dec., Merck **14**,5179, EINECS 200-798-2, RTECS NR4705000, BRN 1721792, MDL MFCD00064222, †	**25g** **100g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64087	**L-Isoleucine 7-amido-4- methylcoumarin trifluoroacetate salt** *[H-Ile-AMC TFA]* [191723-68-9], $C_{16}H_{20}N_{203}.C_2HF_3O_2$, F.W. 402.36, Powder	**50mg**
	L-Isoleucyl-L-prolyl-L-isoleucine, see Diprotin A , J60369, p. 199	
J60884	**Isomaltose** *[6-O-α-D-Glucopyranosyl-D-glucose, α-1,6-Glucobiose]* [499-40-1], $C_{12}H_{22}O_{11}$, F.W. 342.30, Powder, EINECS 207-879-1, BRN 93355, MDL MFCD00065373	**1g**
	Isomaltulose, see Palatinose hydrate, 98+%, J60091, p. 311 **Isoniazid**, see Isonicotinic acid hydrazide, A10583, p. 261	
A18109	**Isonicotinic acid, 99%** *[Pyridine-4-carboxylic acid]* [55-22-1], $C_6H_5NO_2$, F.W. 123.11, m.p. ca 310° subl., b.p. 260°/15mm, Merck **14**,5187, EINECS 200-228-2, RTECS NS1103000, BRN 109599, MDL MFCD00006429, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2.5kg**
A10583	**Isonicotinic acid hydrazide, 98+%** *[Isoniazid, Pyridine-4-carboxylic hydrazide]* [54-85-3], $C_6H_7N_3O$, F.W. 137.14, m.p. 169-174°, Merck **14**,5186, EINECS 200-214-6, RTECS NS1751850, BRN 119374, MDL MFCD00006426, † ! H:H351-H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used for fluorescent HPLC detection of delta 4-3-ketosteroids	**50g** **100g** **500g** **1kg**
A11795	**Isonipecotic acid, 98%** *[H-DL-Inp-OH, Piperidine-4-carboxylic acid]* [498-94-2], $C_6H_{11}NO_2$, F.W. 129.16, m.p. >350°, Merck **14**,5189, EINECS 207-872-3, RTECS NS5150000, BRN 112553, MDL MFCD00006004, † Application(s): A GABA-A receptor partial agonist	**25g** **100g**
	(R)-(-)-Isopropanolamine, see (R)-(-)-1-Amino-2-propanol, L14101, p. 99 **(S)-(+)-Isopropanolamine**, see (S)-(+)-1-Amino-2-propanol, L14102, p. 99 **(+/-)1-(Isopropylamino)-3-[4-(β-methoxyethyl)phenoxy]-2-propanol (+)-tartrate salt**, see Metoprolol tartrate, 98+%, J61920, p. 291 **1-Isopropylamino-3-(1-naphthyloxy)-2-propanol hydrochloride**, see (±)-Propranolol hydrochloride, H26645, p. 329 **Isopropyl carbanilate**, see Isopropyl N-phenylcarbamate, B24998, p. 261 **(±)-1,2-O-Isopropylideneglycerol**, see Solketal, L02814, p. 349 **1-Isopropyl-4-methyl-1,3-cyclohexadiene**, see α-Terpinene, J62871, p. 360 **(±)-2-Isopropyl-5-methylcyclohexanol**, see DL-Menthol, A18098, p. 280 **(1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol**, see L-Menthol, A10474, p. 280 **(1S,2R,5S)-2-Isopropyl-5-methylcyclohexanol**, see D-Menthol, L06102, p. 280 **2-Isopropyl-5-methylphenol**, see Thymol, A14563, p. 369 **N-Isopropyl-DL-noradrenaline hydrochloride**, see DL-Isoproterenol hydrochloride, 99%, J61788, p. 261	
B24998	**Isopropyl N-phenylcarbamate, 96%** *[Isopropyl carbanilate]* [122-42-9], $C_{10}H_{13}NO_2$, F.W. 179.22, m.p. 86-89°, EINECS 204-542-0, RTECS FD9100000, MDL MFCD00026382, † ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Inhibitor of plant metabolism	**5g** **25g** **100g**
B21149	**Isopropyl-β-D-thiogalactoside, dioxane-free, 99%** *[IPTG]* [367-93-1], $C_9H_{18}O_5S$, F.W. 238.30, m.p. 109-115°, $[\alpha]_D^{20}$ -32° (c=1 in water), EINECS 206-703-0, BRN 4631, MDL MFCD00063273, † Application(s): β-galactosidase inducer	**1g** **5g**
J61788	**DL-Isoproterenol hydrochloride, 99%** *[(±)-Isoproterenol hydrochloride, N-Isopropyl-DL-noradrenaline hydrochloride]* [51-30-9], $C_{11}H_{17}NO_3{\cdot}HCl$, F.W. 247.72, Crystalline powder, m.p. 165-175° dec., EINECS 200-089-8, RTECS DO1925000, BRN 3917363, MDL MFCD00012603 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Standard selective β-adrenoceptor agonist	**25g**
	(+/-)-Isoproterenol hydrochloride, see DL-Isoproterenol hydrochloride, 99%, J61788, p. 261 **Isoquinoline-5-sulfonic 2-methyl-1-piperazide dihydrochloride**, see H-7 dihydrochloride, J61697, p. 240 **1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine dihydrochloride**, see H-7 dihydrochloride, J61697, p. 240	
J63674	**Isosorbide mononitrate, 98+%** [16051-77-7], $C_6H_9NO_6$, F.W. 191.14, Crystalline powder, m.p. 92°, Merck **14**,5225, UN3251, EINECS 240-197-2, RTECS LZ4386500, MDL MFCD00143462 ! H:H228-H302, P:P210-P241-P280-P240-P301+P312-P501a Application(s): A coronary vasodilator that does not require hepatic biotransformation	**5g** **10g** **25g**
	Isotretinoin, see 13-cis-Retinoic acid, J61666, p. 336	
J63920	**Isradipine, 98+%** *[PN 200-110]* [75695-93-1], $C_{19}H_{21}N_3O_5$, F.W. 371.39, Crystalline powder, Merck **14**,5240, MDL MFCD00153820 Application(s): L-type calcium channel blocker	**10mg** **50mg**

Stock #	Description	Size
A15566	**Itaconic acid, 99%** ■ *[Methylenebutanedioic acid, Methylenesuccinic acid]* [97-65-4], $C_5H_6O_4$, F.W. 130.10, m.p. 165-169°, b.p. 268°, d. 1.630, Merck **14**,5242, EINECS 202-599-6, BRN 1759501, MDL MFCD00004260, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **1kg** **5kg**
J62777	**Ivermectin** *[22,23-Dihydroavermectin B1, MK-933]* [70288-86-7], $C_{48}H_{74}O_{14}$, F.W. 875.11, Powder, Merck **14**,5248, UN2811, EINECS 274-536-0, RTECS IH7891500, MDL MFCD00869511 H:H300-H360-H319, P:P280-P301+P310-P305+P351+P338-P321-P405-P501a Application(s): Antiparasitic and macrolide antibiotic. Modulates glutamate-GABA-activated chloride channels. Also activates the glycine receptor chloride channel	**1g**
J65506	**JAK2 Inhibitor IV** ▲ *[4-(3-Amino-1H-indazol-4-yl)-N-(tert-butyl)benzenesulfonamide]* [1110502-30-1], $C_{17}H_{20}N_4O_2S$, F.W. 344.40, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
A17391	**Janus Green B** *[C.I. 11050]* [2869-83-2], $C_{30}H_{31}ClN_6$, F.W. 511.07, Merck **14**,5255, EINECS 220-695-6, RTECS SG1633000, MDL MFCD00011758, †	**5g** **25g**
J61077	**Jenner's Stain** *[Eosin-Methylene Blue]* [62851-42-7], Powder, MDL MFCD00081733 Application(s): For use in staining blood smears	**25g** **100g**
J65433	**JNJ 10191584 maleate** *[VUF 6002 maleate, 1-[(5-Chloro-1H-benzimidazol-2-yl)carbonyl]-4-methylpiperazine maleate]* [869497-75-6], $C_{13}H_{15}ClN_4O.C_4H_4O_4$, F.W. 394.81, Powder, MDL MFCD09878266 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
J62245	**Josamycin, 98+%** *[Leucomycin A3]* [16846-24-5], $C_{42}H_{69}NO_{15}$, F.W. 827.99, Powder, EINECS 240-871-6, RTECS OH4725810, MDL MFCD00211043 Application(s): Macrolide antibiotic	**100mg**
	K252a, see Protein Kinase Inhibitor, J61687, p. 331	
J63090	**K252c, 99%** *[Staurosporinone, 6,7,12,13-Tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one]* [85753-43-1], $C_{20}H_{13}N_3O$, F.W. 311.34, Crystalline solid Application(s): Inhibits protein kinase C	**1mg** **5mg**
J60373	**Kaempferol, 98+%** *[3,4',5,7-Tetrahydroxyflavone]* [520-18-3], $C_{15}H_{10}O_6$, F.W. 286.24, Powder, m.p. 276-278°, Merck **14**,5274, EINECS 208-287-6, RTECS LK9275200, BRN 304401, MDL MFCD00016938 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibits topoisomerase I catalyzed DNA religation. Induces apoptosis and is cytotoxic to human leukemic cell lines	**10mg** **50mg**
	Kallidin, see Lys-Bradykinin , J62067, p. 273 **Kallidin**, see Lys-Bradykinin acetate salt, J61171, p. 135	
J61272	**Kanamycin monosulfate** *[Kanamycin A]* [25389-94-0], $C_{18}H_{36}N_4O_{11}\cdot H_2SO_4$, F.W. 582.58, Powder, Merck **14**,5281, EINECS 246-933-9, RTECS NZ3225030, MDL MFCD00070253 H:H334-H360-H317, P:P285-P261-P302+P352-P321-P405-P501a Application(s): Antibiotic. Inhibits translocation during protein biosynthesis	**10g** **25g** **100g**
	Kanamycin A, see Kanamycin monosulfate, J61272, p. 262	
J60668	**Kanamycin monosulfate, Cell Culture Grade** *[Kanamycin A]* [25389-94-0], $C_{18}H_{36}N_4O_{11}\cdot H_2SO_4$, F.W. 582.58, Powder, Merck **14**,5281, EINECS 246-933-9, RTECS NZ3225030, MDL MFCD00070253 H:H334-H360-H317, P:P285-P261-P302+P352-P321-P405-P501a	**1g** **5g** **10g**
J61844	**Karaya Gum** *[Gum karaya from sterculia tree, Tragacanth Indian]* [9000-36-6], Powder, Merck **14**,5284, EINECS 232-539-4, MDL MFCD00131251, † Application(s): Used as a thickener and emulsifier	**500g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J60353	**Kassinin, 96%** *[H-Asp-Val-Pro-Lys-Ser-Asp-Gln-Phe-Val-Gly-Leu-Met-NH2]* [63968-82-1], $C_{59}H_{95}N_{15}O_{18}S$, F.W. 1334.56, Powder Application(s): Peptide of the tachykinin family	**1mg** **2mg** **5mg**
J65495	**Katacalcin** *[Asp-Met-Ser-Ser-Asp-Leu-Glu-Arg-Asp-His-Arg-Pro-His-Val-Ser-Met-Pro-Gln-Asn-Ala-Asn]* [85916-47-8], $C_{97}H_{154}N_{34}O_{36}S_2$, F.W. 2436.59, Solid	**0.5mg** **1mg**
J65791	**kb NB 142-70 ▲** *[9-Hydroxy-3,4-dihydrobenzo[4,5]thieno[2,3-f][1,4]thiazepin-5(2H)-one]* $C_{11}H_9NO_2S$, F.W. 251.32, Solid	**10mg**
J60591	**Kemptide** *[Phosphate acceptor peptide, Leu-Arg-Arg-Ala-Ser-Leu-Gly]* [65189-71-1], $C_{32}H_{61}N_{13}O_9$, F.W. 771.91, Powder, BRN 6263936, MDL MFCD00076710 Application(s): Synthetic peptide substrate for protein kinase A	**1mg** **5mg**
J61809	**Kentsin** *[Contraceptive Tetrapeptide, H-Thr-Pro-Arg-Lys-OH]* [56767-30-7], $C_{21}H_{40}N_8O_6$, F.W. 500.60, Lyophilized powder	**25mg** **100mg**
J62798	**Ketanserin tartrate, 98+%** *[R 41 468]* [83846-83-7], $C_{22}H_{22}FN_3O_3.C_4H_6O_6$, F.W. 545.52, Powder, Merck **14**,5296, UN2811, EINECS 281-062-8, RTECS VA1411195, MDL MFCD00084651 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Selective 5-HT2A serotonin receptor antagonist	**50mg** **250mg**
J60090	**Kethoxal** *[2-Keto-3-ethoxybutyraldehyde]* [27762-78-3], $C_6H_{12}O_4$, F.W. 148.16, Liquid, Merck **14**,5299 Application(s): Antivral agent that reacts with 30S ribosomal subunits	**5g** **10g**
J63367	**Ketoconazole, 98+%** [65277-42-1], $C_{26}H_{28}Cl_2N_4O_4$, F.W. 531.43, Powder, Merck **14**,5302, UN2811, EINECS 265-667-4, RTECS TK7912300, MDL MFCD00058579 H:H301-H360F-H373-H400-H410, P:P260-P281-P301+P310-P321-P405-P501a Application(s): Potent inhibitor of cytochrome P450c17	**5g** **25g**
	2-Keto-3-ethoxybutyraldehyde, see Kethoxal, J60090, p. 263	
A10256	**2-Ketoglutaric acid, 98%** *[2-Oxoglutaric acid]* [328-50-7], $C_5H_6O_5$, F.W. 146.10, m.p. 113-117°, Merck **14**,5303, Fieser **1**,531, EINECS 206-330-3, BRN 1705689, MDL MFCD00004165, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g** **500g**
J63154	**α-Ketoglutaric acid disodium salt dihydrate, 99% ■** [305-72-6], $C_5H_4Na_2O_5 \cdot 2H_2O$, F.W. 226.09 (190.06anhy), Powder, EINECS 206-167-8, RTECS SA0454700, MDL MFCD00150702	**1g** **25g** **100g** **250g**
J62702	**Ketoprofen** *[(2-[3-Benzoylphenyl]propionic acid)]* [22071-15-4], $C_{16}H_{14}O_3$, F.W. 254.29, Powder, m.p. 92-97°, Merck **14**,5305, UN2811, EINECS 244-759-8, RTECS UE7570000, MDL MFCD00055790, † H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A non-steroidal anti-inflammatory drug (NSAID); also inhibits cyclooxygenases-1 and -2	**5g** **25g**
	α-Ketopropionic acid sodium salt, see Sodium pyruvate, Cell Culture Grade, J61840, p. 348	
J63708	**Ketotifen fumarate, 99%** [34580-14-8], $C_{19}H_{19}NOS.C_4H_4O_4$, F.W. 425.50, Powder, Merck **14**,5307, EINECS 252-100-0, RTECS DE8260000, MDL MFCD00079394 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A H1-histamine receptor antagonist that inhibits the anaphylactic release of histamine	**250mg** **1g**
J61967	**Kinase buffer I (5X)** Liquid, Note: This buffer contains: 100mM Tris-HCl 100, 50mM magnesium chloride, 5mM dithiothreitol, and 5mM sodium orthovanadate, pH 7.4.	**100ml** **250ml**
J60269	**Kinase buffer II (5X)** Liquid, Note: This buffer contains: 100mM MOPS, 50mM magnesium acetate, 5mM DTT 5, 5mM EDTA, 25mM beta glycerophosphate, and 5mM sodium orthovanadate, pH 7.4.	**100ml** **250ml**

Stock #	Description	Size
J61566	**Kinase buffer III (5X)** Liquid, Note: This buffer contains: 100mM PIPES and 50mM manganese chloride at pH 8.0	**100ml** **250ml**
J63665	**Kinase buffer IV (5X)** Liquid, Note: This buffer contains: 200mM HEPES, 25 mM magnesium acetate, 10mM DTT, and 0.5mM EDTA, pH 8.0.	**100ml** **250ml**
J62045	**Kinase buffer V (5X)** Liquid, Note: This buffer contains: 100mM MOPS, 50mM magnesium chloride, and 50mM manganese chloride, pH 7.4.	**100ml** **250ml**
J63719	**Kinase Storage Buffer** Liquid, Note: This buffer contains: 10mM Tris, 50mM sodium chloride, 1mM magnesium chloride, and 50% glycerol, pH 7.5. H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100ml** **250ml**
J63865	**Kinetensin** *[Ile-Ala-Arg-Arg-His-Pro-Tyr-Phe-Leu, Neurotensin-related peptide]* [103131-69-7], $C_{56}H_{85}N_{17}O_{11}$, F.W. 1172.38, Powder Application(s): Increases vascular permeability	**1mg**
A13720	**Kinetin, 99%** *[N(6)-Furfuryladenine, 6-Furfurylaminopurine]* [525-79-1], $C_{10}H_9N_5O$, F.W. 215.22, m.p. ca 270° dec., Merck **14**,5311, EINECS 208-382-2, RTECS AU6270000, BRN 21703, MDL MFCD00075757, † Enhances the rate of cell-division in plants: *Plant Physiol.*, **54**, 644 (1974). Application(s): Plant growth accelerator	**1g** **5g** **25g**
J65487	**Kisspeptin-10** *[Metastin (45-54), amide, human, Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2]* $C_{63}H_{83}N_{17}O_{14}$, F.W. 1302.44, Powder, MDL MFCD03452696	**0.5mg** **1mg**
J64054	**Kisspeptin-13** *[Leu-Pro-Asn-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2]* [374675-18-0], $C_{78}H_{107}N_{21}O_{18}$, F.W. 1626.81, Solid	**0.5mg** **1mg**
A14769	**Kiton Red S** *[C.I. 45100, Sulforhodamine B]* [3520-42-1], $C_{27}H_{29}N_2NaO_7S_2$, F.W. 580.66, EINECS 222-529-8, RTECS BP6750000, BRN 3886008, MDL MFCD00010180, † Application(s): Fluorescent dye which uses laser-induced fluorescence for quantification of cellular proteins	**5g** **25g**
	Klorpromex, see Chlorpromazine hydrochloride, 98+%, J63659, p. 160	
J62444	**KN-62** [127191-97-3], $NH_2(CH_2)_{10}NH_2$, F.W. 721.84, Powder, m.p. 65-67°, MDL MFCD00083180 Application(s): Potently and specifically inhibits calcium/calmodulin kinase II	**1mg** **10mg**
A10760	**Kojic acid, 99%** *[5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one]* [501-30-4], $C_6H_6O_4$, F.W. 142.11, m.p. 152-155°, Merck **14**,5317, EINECS 207-922-4, RTECS UQ0875000, BRN 120895, MDL MFCD00006580 H:H351, P:P281-P201-P202-P308+P313-P405-P501a Application(s): A chelation agent that inhibits melanin production. Also a tyrosine kinase inhibitor	**5g** **25g** **100g**
	KT-611, see Naftopidil, 98+%, J60311, p. 297 **KT-611 hydrochloride**, see Naftopidil hydrochloride, 98+%, J63249, p. 297 **KT-5555**, see Lestaurtinib, 99+%, J60602, p. 268 **KWD-2183**, see Bambuterol hydrochloride, 98+%, J60424, p. 117 **KY 12420**, see Wortmannin, Penicillium funiculosum, 99+%, J63983, p. 393 **Kynurenic acid**, see 4-Hydroxyquinoline-2-carboxylic acid hydrate, A12602, p. 251	
J60199	**L-Kynurenine** *[β-Anthraniloyl-L-alanine, L-2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid]* [2922-83-0], $C_{10}H_{12}N_2O_3$, F.W. 208.21, Crystalline, RTECS CY9049700, MDL MFCD00069912 Application(s): Intermediate in the breakdown of tryptophan	**50mg**
J63771	**Kyotorphin** *[H-Tyr-Arg-OH]* [70904-56-2], $C_{15}H_{23}N_5O_4$, F.W. 337.38, Powder Application(s): Analgesic opioid peptide that modulates the Na+/Cl- dependent opioid peptide transporter	**5mg**
	H-D-Lac-OH, see D-Lactic acid, J61871, p. 265	
J63215	**Lactalbumin hydrolysate** *[Enzymatic Digest of Lactalbumin]* [68458-87-7], Powder, EINECS 270-615-9, MDL MFCD00147378, † Application(s): A solubilized enzymatic digest of lactalbumin	**500g** **1kg** **2.5kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63220	**Lactate dehydrogenase, rabbit muscle** *[E.C. 1.1.1.27, NAD oxidoreductase]* [9001-60-9], Suspension, Merck **14**,5334, EINECS 232-617-8, MDL MFCD00131466, Note: Minimum 400units/mg protein. One unit will reduce 1.0 micromole of pyruvate to L-lactate per min at pH 7.5 at 37 C, †	**50kilounits**
	Application(s): Catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+	
L14259	**DL-Lactic acid, 80-85% aq. soln.** *[2-Hydroxypropionic acid]* [50-21-5], $C_3H_6O_3$, F.W. 90.08, b.p. 122°/15mm, f.p. >110°(230°F), d. 1.209, n_D^{20} 1.4230, Merck **14**,5336, EINECS 200-018-0, RTECS OD2800000, BRN 1209341, MDL MFCD00004520, †  H:H318-H315, P:P280b-P305+P351+P338-P310	**250g** **1kg** **2.5kg**
36415	**Lactic acid, ACS, 85.0-90.0% aq. soln.** *[2-Hydroxypropionic acid]* [50-21-5], $C_3H_6O_3$, F.W. 90.08, Liquid, m.p. 18°, b.p. 122°/15mm, f.p. >110°(230°F), d. 1.209, n_D^{20} 1.4270, Merck **14**,5336, EINECS 200-018-0, RTECS OD2800000, BRN 1209341, MDL MFCD00004520, Note: Product is predominantly the L-isomer., † Maximum level of impurities: Residue after ignition 0.02%, Cl 0.001%, SO_4 0.002%, Heavy Metals (as Pb) 5ppm, Fe 5ppm, Substances darkened by sulfuric acid P.T.  H:H318-H315, P:P280b-P305+P351+P338-P310	**100g** **500g** **2kg**
J61871	**D-Lactic acid** *[(R)-2-Hydroxypropionic acid, H-D-Lac-OH]* [10326-41-7], $C_3H_6O_3$, F.W. 90.08, Powder, m.p. 52°, Merck **14**,5335, EINECS 233-713-2, BRN 1720254, MDL MFCD00068313, † H:H318-H315, P:P280-P305+P351+P338-P302+P352-P321-P310-P362	**250mg** **1g**
	Application(s): Useful chiral synthon, building block for depsipeptides	
L13242	**L-Lactic acid, anhydrous, 98%** ■ *[(S)-2-Hydroxypropionic acid]* [79-33-4], $C_3H_6O_3$, F.W. 90.08, m.p. 52-54°, b.p. 119°/12mm, f.p. >110°(230°F), d. 1.22, Merck **14**,5337, Fieser **15**,181, EINECS 201-196-2, RTECS OD3100000, BRN 1720251, MDL MFCD00064266, † H:H318-H315, P:P280b-P305+P351+P338-P337+P313	**5g** **25g** **100g**
	Application(s): Useful chiral synthon, building block for depsipeptides	
36218	**α-D-Lactose monohydrate, ACS** [64044-51-5], $C_{12}H_{22}O_{11}·H_2O$, F.W. 360.32 (342.30anhy), Crystalline, m.p. ca 218° dec., d. 1.525, Merck **14**,5343, EINECS 200-559-2, RTECS OD9625000, BRN 3768231, MDL MFCD00150747, † Maximum level of impurities: Insoluble matter 0.005%, Residue after ignition 0.03%, Dextrose P.T., Sucrose P.T., Heavy Metals (as Pb) 5ppm, Fe 5ppm, H_2O 4.0-6.0% 	**500g** **2kg**
J60160	**Lactulose, 99%** *[4-O-β-D-Galactopyranosyl-D-fructose]* [4618-18-2], $C_{12}H_{22}O_{11}$, F.W. 324.30, Powder, m.p. 169°, d. 1.32, Merck **14**,5346, EINECS 225-027-7, RTECS LS6965000, BRN 93773, MDL MFCD00151469, †	**25g** **50g** **100g**
	Application(s): A synthetic sugar	
J63615	**Laemmli SDS sample buffer, non-reducing (4X)** Liquid, Note: Contains 250mM Tris-HCl (pH 6.8), 8% SDS, 40% glycerol, and 0.02% bromophenol blue., † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**25ml** **50ml**
	Application(s): For protein sample preparation to be used in the Laemmli SDS-PAGE system	
J60660	**Laemmli SDS sample buffer, non-reducing (6X)** Liquid, Note: Contains 375mM Tris-HCl (pH 6.8), 9% SDS, 50% glycerol, and 0.03% bromophenol blue. H:H319, P:P280-P264-P305+P351+P338-P337+P313	**25ml** **50ml**
	Application(s): For protein sample preparation to be used in the Laemmli SDS-PAGE system	
J60015	**Laemmli SDS sample buffer, reducing (4X)** Liquid, Note: Contains 250mM Tris-HCl(pH 6.8), 8% SDS, 40% glycerol, 8% β-mercaptoethanol, and 0.02% bromophenol blue., † H:H318-H315-H412, P:P280-P305+P351+P338-P302+P352-P321-P310-P501a	**25ml** **50ml**
	Application(s): For protein sample preparation to be used in the Laemmli SDS-PAGE system	
J61337	**Laemmli SDS sample buffer, reducing (6X)** Liquid, Note: Contains 375mM Tris-HCl (pH 6.8), 9% SDS, 50% glycerol, 9% beta-mercaptoethanol, 0.03% bromophenol blue, † H:H318-H302-H315-H412, P:P280-P305+P351+P338-P302+P352-P321-P310-P501a	**25ml** **50ml**
	Application(s): For protein sample preparation to be used in the Laemmli SDS-PAGE system	
J61716	**Laemmli SDS sample buffer with pyronin Y, non-reducing (4X)** Liquid, Note: Contains 250mM Tris-HCl (pH 6.8), 8% SDS, 40% glycerol and 0.02% pyronin Y H:H319, P:P280-P264-P305+P351+P338-P337+P313	**25ml** **50ml**
	Application(s): For protein sample preparation to be used in the Laemmli SDS-PAGE system	

Stock #	Description	Size
J62115	**Laemmli SDS sample buffer with pyronin Y, reducing (4X)** Liquid, Note: Contains 250mM Tris-HCl (pH 6.8), 8% SDS, 40% glycerol, 8% β-mercaptoethanol, and 0.02% pyronin Y H:H312-H319, P:P280-P305+P351+P338-P302+P352-P322-P312-P501 Application(s): For protein sample preparation to be used in the Laemmli SDS-PAGE system	25ml 50ml
J64340	**Laminin (925-933)** *[Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg]* [110590-60-8], $C_{40}H_{62}N_{12}O_{14}S$, F.W. 967.05, Solid, MDL MFCD00076474	0.5mg 1mg
J64127	**Laminin (929-933)** *[Laminin Pentapeptide, Tyr-Ile-Gly-Ser-Arg]* [110590-64-2], $C_{26}H_{42}N_8O_8$, F.W. 594.66, Solid	1mg
J65640	**Laminin A Chain (2091-2108)** *[Cys-Ser-Arg-Ala-Arg-Lys-Gln-Ala-Ala-Ser-Ile-Lys-Val-Ala-Val-Ser-Ala-Asp-Arg]* $C_{82}H_{148}N_{31}O_{26}S$, F.W. 2016.30, Solid	0.5mg 1mg
J64356	**Laminin Pentapeptide amide** *[Tyr-Ile-Gly-Ser-Arg-NH2]* $C_{26}H_{43}N_9O_7$, F.W. 593.67, Solid	1mg
A16902	**Lanolin** *[Wool fat]* [8006-54-0], m.p. 38-44°, Merck **14**,5358, EINECS 232-348-6, RTECS OE3201000, MDL MFCD00081740, †	250g 1kg
J62008	**Lansoprazole, 98+%** *[AG-1749]* [103577-45-3], $C_{16}H_{14}F_3N_3O_2S$, F.W. 369.36, Crystalline powder, m.p. 173-175°, Merck **14**,5362, RTECS DD9487500, MDL MFCD00866873 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A proton pump inhibitor	500mg 1g 5g
J62299	**Lapatinib, 99+%** [231277-92-2], $C_{29}H_{26}ClFN_4O_4S$, F.W. 581.06, Powder, m.p. >240°, Merck **14**,5367, RTECS VA0952500 H:H361-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An EGFR and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor)	100mg 200mg 1g
J62401	**Lapatinib ditosylate, 99+%** [388082-78-8], $C_{29}H_{26}ClFN_4O_4S \cdot 2C_7H_8O_3S$, F.W. 925.46, Powder, m.p. 245-249°, Merck **14**,5367 Application(s): An EGFR and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor)	100mg 500mg 1g
	Larapam, see Piroxicam, J63239, p. 323	
J60040	**N-Lauroylsarcosine sodium salt, 95%** ■ *[N-Dodecanoyl-N-methylglycine sodium salt, Sarkosyl NL]* [137-16-6], $CH_3(CH_2)_{10}CON(CH_3)CH_2COONa$, F.W. 293.39, Powder, Merck **14**,4368, EINECS 205-281-5, BRN 5322974, MDL MFCD00042728, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Used in the cell lysis step of RNA purification. Anionic detergent	10g 50g
J64928	**N-Lauroylsarcosine sodium salt, ultrapure, 97%** ■ *[N-Dodecanoyl-N-methylglycine sodium salt, Sarkosyl NL]* [137-16-6], $C_{15}H_{29}NNaO_3$, F.W. 293.39, Powder, Merck **14**,4368, EINECS 205-281-5, BRN 5322974, MDL MFCD00042728, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	Call
	Lauryl gallate, see n-Dodecyl gallate, L06233, p. 201 **Lavendustin**, see HDBA, 98+%, J60507, p. 241	
J61525	**LB Agar plate, plain** Solid	20plates
J64986	**Lysozyme, human, Enzyme Immunoassay Kit** Note: One kit contains sufficient reagents and 1 precoated 96-well strip plate to perfom ELISA for human lysozyme Application(s): For detection of lysozyme. Detection range of 0.78-50ng/ml.	1kit
J63497	**LB Agar plate with 20µg/ml ampicillin** Solid	20plates
J61314	**LB Agar plate with 50µg/ml ampicillin** Solid	20plates
J63197	**LB Agar plate with 100µg/ml ampicillin** Solid	20plates

Stock #	Description	Size
J61842	**LB Agar plate with 50µg/ml ampicillin + tetracycline** Solid	20plates
J62796	**LB Agar plate with 100µg/ml ampicillin + tetracycline** Solid	20plates
J60487	**LB Agar plate with 25µg/ml kanamycin** Solid	20plates
J60540	**LB Agar plate with 50µg/ml kanamycin** Solid	20plates
J63541	**LB Agar plate with 10µg/ml streptomycin** Solid	20plates
J62665	**LB Agar plate with 50µg/ml streptomycin** Solid	20plates
J62894	**LB Agar plate with 10µg/ml tetracycline** Solid	20plates
J60347	**LB Agar plate with 50µg/ml tetracycline** Solid	20plates
J61405	**LB Agar plate with 20µg/ml carbenicillin** Solid	20plates
J62338	**LB Agar plate with 50µg/ml carbenicillin** Solid	20plates
J62923	**LB Agar plate with 25µg/ml chloramphenicol** Solid	20plates
J61140	**LB Agar plate with 50µg/ml chloramphenicol** Solid	20plates
J63820	**LB Agar plate with 50µg/ml gentamycin** Solid	20plates
J63211	**LB Agar plate with 25µg/ml NZY-kanamycin** Solid	20plates
J63296	**LB Agar plate with 50µg/ml NZY-kanamycin** Solid	20plates
J63732	**LB Agar plate with 25µg/ml spectinomycin** Solid	20plates
J60541	**LB Agar plate with 50µg/ml spectinomycin** Solid	20plates
H26760	**LB Broth (Lennox)** ◪ ■ *[Luria Bertani Broth (Lennox)]* MDL MFCD00147395	100g 500g
H26676	**LB Broth (Miller's modification)** ■ MDL MFCD00240868	100g 500g
J63905	**LB Medium, Miller** Liquid, Note: Ingredients (per liter amounts): 10g Bacto tryptone, 5g Bacto yeast extract, 10g NaCl	500ml 1L
J64111	**Lck Inhibitor II** ▲ *[3-(2-(1H-Benzo[d]imidazol-1-yl)-6-(2-morpholinoethoxy)-pyrimidin-4-ylamino)-4-methylphenol]* [918870-43-6], $C_{24}H_{26}N_6O_3$, F.W. 446.50, Solid	5mg
J61894	**LDS-sample buffer (4X), non-reducing** Liquid, Note: This buffer contains: 988mM Tris-HCl, 2.04mM EDTA, 8% LDS, 40% glycerol, 0.88% Coomassie blue and 0.7mM phenol red at pH 8.5., † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	25ml 50ml
J61942	**LDS-sample buffer (4X), reducing** Liquid, Note: This buffer contains 988mM Tris-HCl, 2.04mM EDTA, 8% LDS, 40% glycerol, 0.88% Coomassie blue, and 0.7mM phenol red, and 8% mercaptoethanol at pH 7.5. ! H:H312-H315-H319-H412, P:P280-P305+P351+P338-P302+P352-P321-P322-P501	25ml 50ml

Stock #	Description	Size
14243	**Lead(II) nitrate, ACS, 99.0% min** ■ [10099-74-8], $Pb(NO_3)_2$, F.W. 331.20, Crystalline, m.p. 470° dec., d. 4.530, Merck **14**,5414, Solubility: Freely soluble in water. Soluble in absolute alcohol, methanol. Insoluble in concentrated HNO_3, UN1469, EINECS 233-245-9, RTECS OG2100000, MDL MFCD00011153, Note: pH of 20% aqueous solution ≈ 3.0-4.0, † Maximum level of impurities: Insoluble matter 0.005%, Cl 0.001%, Ca 0.005%, Cu 0.002%, Fe 0.001%, K 0.005%, Na 0.02% H:H272-H360-H373-H400-H410-H302-H332, P:P221-P210-P260-P220-P405-P501a Application(s): As an oxidizer in dye industry, in manufacturing of mother-of-pearl, as mordant in printing textile, as sensitizer in photography	500g 2kg
J60576	**Lecithin, 60%, egg** *[L-α-Phosphatidylcholine]* [8002-43-5], Powder, Merck **14**,5428, EINECS 232-307-2, RTECS OG7565000, BRN 5209585, † Application(s): Naturally occuring lipid that protects cells from oxidation. Useful as an emulsifier	100g 250g 500g
J61675	**Lecithin, 90%, soybean** *[L-α-Phosphatidylcholine]* [8002-43-5], Solid, Merck **14**,5428, EINECS 232-307-2, RTECS OG7565000, BRN 5209585, † Application(s): Naturally occuring lipid that protects cells from oxidation. Useful as an emulsifier	50g 100g 250g
	Leelamine hydrochloride, see (+)-Dehydroabietylamine, J63123, p. 176	
J65917	**Leflunomide** *[5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide), Leflunomida]* [75706-12-6], $C_{12}H_9F_3N_2O_2$, F.W. 270.21, Crystalline solid, Merck **14**,5432, UN2811, RTECS NY2354200, MDL MFCD00867593 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	100mg 500mg
A11644	**Leishman Stain** [12627-53-1], EINECS 235-732-1, MDL MFCD00131498 Application(s): Used to stain blood smears to identify parasites, leukocytes and trypanosomas	25g 100g
J62344	**LENOX medium** Liquid, Note: Ingredients (per liter amounts): 10g Tryptone, 5g Yeast Extract, 5g sodium chloride, 15g agar	500ml 1L
J63784	**Leptomycin B, 99+%, 1mM soln. in ethanol** [87081-35-4], $C_{33}H_{48}O_6$, F.W. 540.73, Liquid, f.p. 11°(52°F), Merck **14**,5444, UN1993, MDL MFCD06795848, Note: Supplied as a 1mM solution in ethanol. H:H225, P:P210-P241-P280-P240-P303+P361+P353-P501a Application(s): Potent, specific inhibitor of nuclear export signal (NES)-dependent protein export from the nucleus	100micrograms
J60602	**Lestaurtinib, 99+%** *[KT-5555]* [111358-88-4], $C_{26}H_{21}N_3O_4$, F.W. 439.47, Powder, MDL MFCD12828858 Application(s): Potent inhibitor of several tyrosine kinases	1mg 5mg
	H-L-Leu-OH, see L-Leucine, Cell Culture Reagent, J62824, p. 268	
A10590	**DL-Leucine, 99%** *[(+/-)-2-Amino-4-methylpentanoic acid, H-DL-Leu-OH]* [328-39-2], $C_6H_{13}NO_2$, F.W. 131.18, m.p. ca 294° subl., d. 1.293, Merck **14**,5451, EINECS 206-328-2, BRN 636005, MDL MFCD00063087, †	50g 250g 1kg
A14842	**D-Leucine, 99%** *[(R)-2-Amino-4-methylpentanoic acid, H-D-Leu-OH]* [328-38-1], $C_6H_{13}NO_2$, F.W. 131.18, m.p. >300°, $[\alpha]_D^{20}$ -15° (c=5 in 5N HCl), EINECS 206-327-7, RTECS OH2840000, BRN 1721721, MDL MFCD00063088, †	5g 25g 100g
A12311	**L-Leucine, 99%** *[(S)-2-Amino-4-methylpentanoic acid, H-Leu-OH]* [61-90-5], $C_6H_{13}NO_2$, F.W. 131.18, m.p. >300°, d. 1.293, $[\alpha]_D^{20}$ +15.5° (c=2 in 5N HCl), Merck **14**,5451, EINECS 200-522-0, RTECS OH2850000, BRN 1721722, MDL MFCD00002617, †	100g 500g 2.5kg
J62824	**L-Leucine, Cell Culture Reagent** *[H-L-Leu-OH]* [61-90-5], $C_6H_{13}NO_2$, F.W. 131.17, Powder, EINECS 200-522-0, RTECS OH2850000, BRN 1721722, MDL MFCD00002617, †	100g 250g 500g
J64951	**L-Leucine 7-amido-4-methylcoumarin hydrate** *[H-Leu-AMC]* [66447-31-2], $C_{16}H_{20}N_2O_3.xH_2O$, F.W. 288.37 (anhy), Powder, EINECS 266-363-4	250mg
B23745	**L-Leucinol, 97%** △ *[(S)-2-Amino-4-methylpentanol, H-Leu-ol]* [7533-40-6], $C_6H_{15}NO$, F.W. 117.19, b.p. 198-200°, f.p. 90°(194°F), d. 0.917, n_D^{20} 1.4510, $[\alpha]_D^{20}$ +1.1° (neat), EINECS 231-400-5, BRN 1719240, MDL MFCD00063676 H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	5g 25g

Stock #	Description	Size
	Leucomycin A3, see Josamycin, 98+%, J62245, p. 262 **Leukaemomycin C**, see Daunorubicin hydrochloride, J60224, p. 175	
J61188	**Leupeptin hemisulfate** [103476-89-7], $C_{20}H_{38}N_6O_4 \cdot 0.5H_2SO_4$, F.W. 475.59, Powder, MDL MFCD00037012 Application(s): Reversible protease inhibitor which inhibits cathepsin B, calpain and trypsin	**25mg** **100mg**
J62147	**Leuprolide** *[Leuprorelin, [Des-Gly10, D-Leu6, Pro-NHEt9]LH-RH]* [53714-56-0], $C_{59}H_{84}N_{16}O_{12}$, F.W. 1209.41, Powder, Merck **14**,5457, Note: Supplied as an acetate salt. Sequence: pGlu-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NHEt Application(s): Highly active luteinizing hormone releasing hormone (LHRH) agonist	**1mg** **5mg**
J62967	**Leuprolide, human, synthetic** *[Leuprorelin, [Des-Gly10, D-Leu6, Pro-NHEt9]LH-RH]* [53714-56-0], $C_{59}H_{84}N_{16}O_{12}$, F.W. 1209.41, Powder, Merck **14**,5457	**5mg** **25mg**
	Leupropelin, see Leuprolide, J62147, p. 269	
J62880	**Levitide, 96%** *[pGlu-Gly-Met-Ile-Gly-Thr-Leu-Thr-Ser-Lys-Arg-Ile-Lys-Gln-NH2]* [114281-19-5], $C_{66}H_{119}N_{21}O_{19}S$, F.W. 1542.85, Powder, MDL MFCD00076644 Application(s): Neurohormone-like peptide found in the skin of Xenopus laevis	**1mg**
	Levodopa, see L-3-(3,4-Dihydroxyphenyl)alanine, A11311, p. 193 **D-Levulose**, see D-Fructose, A17718, p. 228 **LGD-1069**, see Bexarotene, 99+%, J63701, p. 124	
J64141	**LH-RH (4-10)** *[Luteinizing Hormone Releasing Hormone (4-10), Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2]* $C_{33}H_{53}N_{11}O_9$, F.W. 747.84, Solid H:H360, P:P281-P201-P202-P308+P313-P405-P501	**1mg**
J64883	**LH-RH free acid** *[Luteinizing Hormone Releasing Hormone, free acid, Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly]* $C_{55}H_{74}N_{16}O_{14}$, F.W. 1183.27, Solid	**5mg**
J65645	**LH-RH, human** *[Gonadoreline, Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2]* [71447-49-9], $C_{55}H_{75}N_{17}O_{13}$, F.W. 1182.29, Powder, RTECS OK6470000 H:H360, P:P281-P201-P202-P308+P313-P405-P501	**5mg**
J64173	**LH-RH, salmon** *[Luteinizing Hormone Releasing Hormone, salmon, Glp-His-Trp-Ser-Tyr-Gly-Trp-Leu-Pro-Gly-NH2]* [86073-88-3], $C_{60}H_{73}N_{15}O_{13}$, F.W. 1212.31, Powder, MDL MFCD00133497 H:H360, P:P281-P201-P202-P308+P313-P405-P501	**1mg**
	[Des-Gly10, D-Leu6, Pro-NHEt9]LH-RH, see Leuprolide, J62147, p. 269	
J65648	**[Gln$_8$] LH-RH, chicken** *[Glp-His-Trp-Ser-Tyr-Gly-Leu-Gln-Pro-Gly-NH2]* $C_{54}H_{71}N_{15}O_{14}$, F.W. 1154.23, Solid H:H360, P:P281-P201-P202-P308+P313-P405-P501	**1mg**
J65994	**[Hyp$_9$] LH-RH** *[[Hyp9] Luteinizing Hormone Releasing Hormone, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Hyp-Gly-NH2]* [67019-13-0], $C_{55}H_{75}N_{17}O_{14}$, F.W. 1198.29, Solid, MDL MFCD00214314 H:H360, P:P281-P201-P202-P308+P313-P405-P501	**5mg**
J65530	**[D-Trp$_6$] LH-RH amide** *[Triptorelin, Glp-His-Trp-Ser-Tyr-DTrp-Leu-Arg-Pro-Gly-NH2]* [57773-63-4], $C_{64}H_{82}N_{18}O_{13}$, F.W. 1311.45, Powder, Merck **14**,9748, RTECS OK6371950, MDL MFCD00167541 H:H360, P:P281-P201-P202-P308+P313-P405-P501	**5mg**
J64762	**[D-Trp$_6$] LH-RH ethylamide** *[Triptoreline ethyl amide, Glp-His-Trp-Ser-Tyr-DTrp-Leu-Arg-Pro-Gly-NHEt]* $C_{66}H_{86}N_{18}O_{13}$, F.W. 1339.5, Solid H:H360, P:P281-P201-P202-P308+P313-P405-P501	**5mg**
J63035	**Lidocaine hydrochloride monohydrate, 98%** [6108-05-0], $C_{14}H_{22}N_2O \cdot HCl \cdot H_2O$, F.W. 288.82 (270.80anhy), Crystalline powder, m.p. 75-79°, Merck **14**,5482, UN2811, RTECS AN7700000, MDL MFCD00150329, † H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Anesthetic. Blocks voltage-gated sodium channels	**5g** **25g** **100g**

Stock #	Description	Size
J60678	**Lidocaine N-ethyl bromide, 99+%** *[QX-314 bromide, N-(2,6-Dimethylphenylcarbamoylmethyl)triethylammonium bromide]* [21306-56-9], $C_{16}H_{27}BrN_2O$, F.W. 343.31, Crystalline solid, MDL MFCD00083182 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Blocker of voltage-activated sodium channels	50mg 100mg
B23330	**Light Green SF Yellowish** *[Acid Green 5, C.I. 42095]* [5141-20-8], $C_{37}H_{34}N_2Na_2O_9S_3$, F.W. 792.86, m.p. ca 288° dec., Merck **14**,5485, EINECS 225-906-5, RTECS BQ4900000, BRN 5717828, MDL MFCD00012121, † H:H351, P:P281-P201-P202-P308+P313-P405-P501a Biological stain. Application(s): Useful as a general plasma stain, as a histological stain, and a cytological counterstain 	10g 50g
J61251	**Lincomycin hydrochloride** [859-18-7], $C_{18}H_{34}N_2O_6S \cdot HCl$, F.W. 443.00, Crystalline powder, EINECS 212-726-7, RTECS RH6315000, BRN 4171650, MDL MFCD00058237 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Lincosamide anitbiotic active against gram-positive bacteria	1g 5g 25g
L07949	**Linoleic acid, 97%** △ *[9,12-Octadecadienoic acid]* [60-33-3], $CH_3(CH_2)_4CH{=}CHCH_2CH{=}CH(CH_2)_7CO_2H$, F.W. 280.45, m.p. -12°, b.p. 230°/16mm, f.p. >110°(230°F), d. 0.902, n_D^{20} 1.4699, Merck **14**,5505, EINECS 200-470-9, RTECS RF9990000, BRN 1727101, MDL MFCD00064241, † Application(s): Unsaturated omega-6 fatty acid	5g 25g 100g
J65453	**Linomide** *[1,2-Dihydro-4-hydroxy-N,N-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide]* [84088-42-6], $C_{18}H_{16}N_2O_3$, F.W. 308.33, Powder H:H302, P:P264-P270-P301+P312-P330-P501	10mg
	Liothyronine sodium salt, see 3,3',5'-Triiodo-L-thyronine sodium salt, J63312, p. 378	
J62903	**Lipase, from porcine pancreas** *[PPL, Triacylglycerol acylhydrolase]* [9001-62-1], Powder, Merck **14**,5511, EINECS 232-619-9, RTECS TO9776500, MDL MFCD00131509, Note: Minimum 24 USP units per mg. One unit liberates 1 micromole of fatty acid per min from olive oil at 37 degrees C and pH 9.0., † Application(s): Catalyzes hydrolysis of emulsified esters of glycerol and long chain fatty acids	500g
J64732	**Lipase Kit - 12 variants (L1 through L12)** *[EC 3.1.1.3]* Lyophilized powder, Note: Contains 100mg of each variant Application(s): Catalyzes enantioselective hydrolysis and interesterification of esters of primary and secondary alcohols. Catalyzes enantioselective synthesis and hydrolysis of amides	1each
J65152	**Lipase L1** *[EC 3.1.1.3]* Lyophilized powder	250mg 500mg 1g
J64108	**Lipase L2** *[EC 3.1.1.3]* Lyophilized powder	250mg 500mg 1g
J64010	**Lipase L3** *[EC 3.1.1.3]* Lyophilized powder	250mg 500mg 1g
J64017	**Lipase L4** *[EC 3.1.1.3]* Lyophilized powder	250mg 500mg 1g
J64113	**Lipase L5** *[EC 3.1.1.3]* Lyophilized powder	250mg 500mg 1g
J65835	**Lipase L6** *[EC 3.1.1.3]* Lyophilized powder	250mg 500mg 1g
J65293	**Lipase L7** *[EC 3.1.1.3]* Lyophilized powder	250mg 500mg 1g

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64563	**Lipase L8** *[EC 3.1.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J65421	**Lipase L9** *[EC 3.1.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J65151	**Lipase L10** *[EC 3.1.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J65838	**Lipase L11** *[EC 3.1.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
J65235	**Lipase L12** *[EC 3.1.1.3]* Lyophilized powder	**250mg** **500mg** **1g**
	α-Lipoic acid, see DL-Thioctic acid, L04711, p. 366	
J64606	**Lipoprotein(a), human plasma, 99%** *[Lp(a)]*	**100micrograms**
J65029	**Lipoprotein, low density, acetylated, human plasma, 99%** *[Ac-LDL, Acetylated LDL]*	**2mg**
J64426	**Lipoprotein, low density, carbamylated, human plasma, 99%** *[Carbamylated-LDL, Low density lipoprotein, carbamylated]*	**1each**
J65039	**Lipoprotein, low density, human plasma, 99%** *[LDL, human, Low density lipoprotein]*	**5mg**
J65591	**Lipoprotein, low density, oxidized, human plasma, 99%** *[Ox-LDL, Oxidized LDL]*	**2mg**
J65261	**Lipoprotein, low density, oxidized, human plasma, Hi-TBAR, 99%** *[Ox-LDL, Oxidized LDL]*	**2mg**
J64223	**Lipoprotein, low density, oxidized, human plasma, Low-TBAR, 99%** *[Ox-LDL, Oxidized LDL]*	**1each**
J64903	**Lipoprotein, high density, human plasma, 99%** *[HDL, human, High density lipoprotein]*	**10mg**
J65642	**Lipoprotein, very low density, human plasma, 99%** *[Very low density lipoprotein, VLDL]*	**1mg**
J65182	**Lipoprotein Deficient Serum, bovine** *[LPDS, Bovine Serum, lipoprotein deficient]* Note: Typical protein concentration is 90-120mg protein/ml	**1each**
J65516	**Lipoprotein Deficient Serum, human** *[h-LPDS, Human Serum, lipoprotein deficient]* Note: Typical protein concentration is approximately 50mg protein/ml	**1each**
	β-Lipotropin (61-76), see α-Endorphin, J63462, p. 206	
J60087	**LiSorb** Liquid, Note: Contains: 100mM Lithium acetate, 50mM Tris-HCl, 1mM EDTA and 1 mM Sorbitol, pH 8.0 Application(s): For transformation of competent cells	**250ml** **500ml**
	Lithiophor, see Lithium sulfate monohydrate, 36216, p. 272	
36225	**Lithium carbonate, ACS, 99.0% min** [554-13-2], Li_2CO_3, F.W. 73.90, Powder, m.p. 723°, b.p. 1310°, d. 2.11, Merck **14**,5527, EINECS 209-062-5, MDL MFCD00011084, † Maximum level of impurities: Insoluble in dilute hydrochloric acid 0.01%, Cl 0.005%, NO_3 5ppm, Sulfur compounds (as SO_4) 0.2%, NH_4 5ppm, Heavy Metals (as Pb) 0.002%, Fe 0.002%, Ca 0.01%, K 0.01%, Na 0.1% H:H318-H302-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**500g** **2kg**
J62644	**Lithium chloride, 200mM aq. soln.** [7447-41-8], LiCl, F.W. 42.39, Liquid, †	**100ml** **250ml**
J61895	**Lithium chloride, 1M aq. soln.** [7447-41-8], LiCl, F.W. 42.39, Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**50ml** **100ml**

Stock #	Description	Size
36217	**Lithium chloride, ACS, 99% min** ■ [7447-41-8], LiCl, F.W. 42.39, Granular, m.p. 605°, b.p. 1325-1360°, d. 2.068, Merck **14**,5528, Fieser **1**,609 **2**,246 **4**,298 **5**,677 **13**,332 **16**,194 **18**,211 **20**,215 **21**,248, Solubility: Very soluble in water, alcohol, ether, pyridine, and nitrobenzene, EINECS 231-212-3, RTECS OJ5950000, MDL MFCD00011078, † Maximum level of impurities: Insoluble matter 0.01%, Titratable base 0.008meq/g, Loss on drying at 105° 1.0%, NO_3 0.001%, SO_4 0.01%, Ba 0.003%, Heavy Metals (as Pb) 0.002%, Fe 0.001%, Ca 0.01%, K 0.01%, Na 0.20% H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): In air-conditioning, welding and soldering flux, dry batteries, heat-exchange media, salt baths, and desiccants	**500g** **2kg**
39328	**Lithium dodecylsulfate, 99+%** [2044-56-6], $CH_3(CH_2)_{11}OSO_3Li$, F.W. 272.33, Powder, EINECS 218-058-2, MDL MFCD00007467, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Detergent for solubilizing proteins for electrophoresis which exhibits greater solubility than SDS at lower temperatures	**10g** **50g**
J65509	**Lithium dodecylsulfate, ultrapure, 99%** [2044-56-6], $CH_3(CH_2)_{11}OSO_3Li$, F.W. 272.33, Powder, EINECS 218-058-2, MDL MFCD00007467, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10g** **50g**
	Lithium-Duriles, see Lithium sulfate monohydrate, 36216, p. 272	
A11818	**Lithium L-lactate, 97%** ■ *[L-Lactic acid lithium salt]* [27848-80-2], $CH_3CH(OH)CO_2Li$, F.W. 96.01, m.p. 253-255°, $[\alpha]_D^{20}$ -14° (c=1 in water), EINECS 248-692-5, RTECS OJ6311000, BRN 3568332, MDL MFCD00065399, † H:H303, P:P312 Application(s): Useful chiral synthon, building block for depsipeptides	**50g** **250g** **1kg**
36216	**Lithium sulfate monohydrate, ACS, 99.0% min** *[Lithiophor, Lithium-Duriles]* [10102-25-7], $Li_2SO_4 \cdot H_2O$, F.W. 127.96 (109.94anhy), Crystalline, m.p. 130° $-H_2O$, d. 2.06, Merck **14**,5541, Solubility: Soluble in water, EINECS 233-820-4, MDL MFCD00149766, † Maximum level of impurities: Loss on drying at 150° 13.0-15.0%, Insoluble matter 0.01%, Cl 0.002%, NO_3 0.001%, Heavy Metals (as Pb) 0.001%, Fe 0.001%, K 0.05%, Na 0.05% H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2kg**
J60177	**Litorin** *[pGlu-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH2, Pituitary adenylate cyclase activating fragment 21-38]* [55749-97-8], $C_{51}H_{68}N_{14}O_{11}S$, F.W. 1085.25, Lyophilized powder, MDL MFCD00167519 Application(s): Bombesin-like nonapeptide from the skin of poisonous frogs	**1mg**
J60485	**Liver Cell Growth Factor** *[Gly-His-Lys, Glycyl-Histidyl-Lysine]* [72957-37-0], $C_{14}H_{24}N_6O_4$, F.W. 340.38, Powder, EINECS 277-125-4, MDL MFCD00012699 Application(s): Growth modulating tripeptide	**5mg**
J64233	**Liver Cell Growth Factor acetate salt** *[GHK acetate salt, Gly-His-Lys-acetate salt]* [72957-37-0], $C_{14}H_{24}N_6O_4C_2H_4O_2$, F.W. 400.43, Powder, EINECS 277-125-4, MDL MFCD00012699	**250mg**
J64425	**Locostatin** *[UIC-1005, (4S)-3-[(E)-But-2-enoyl]-4-benzyl-2-oxazolidinone]* [133812-16-5], $C_{14}H_{15}NO_3$, F.W. 245.27, Powder, MDL MFCD00278769	**10mg** **50mg**
J63960	**Lofexidine hydrochloride, 98+%** [21498-08-8], $C_{11}H_{12}Cl_2N_2O \cdot HCl$, F.W. 295.60, Crystalline powder, m.p. 225-232°, Merck **14**,5558, UN2811 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): α-2 adrenergic agonist	**1g** **5g**
J60168	**Loperamide hydrochloride, 98+%** *[4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutyramide hydrochloride]* [34552-83-5], $C_{29}H_{33}ClN_2O_2 \cdot HCl$, F.W. 513.51, Powder, Merck **14**,5571, UN2811, EINECS 252-082-4, RTECS TM4960000, MDL MFCD00058581 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): At nanomolar concentrations, binds to mu-opioid receptors. L-type calcium channel blocker	**5g** **25g**
J60190	**Loratadine, 98+%** [79794-75-5], $C_{22}H_{23}N_2O_2Cl$, F.W. 382.88, Powder, m.p. 134°, Merck **14**,5578, RTECS TM6129200, MDL MFCD00672869 Application(s): A nonsedating-type histamine H1-receptor antagonist	**500mg** **1g** **5g**
J61713	**Lorglumide sodium salt, 98+%** [97964-56-2], $C_{22}H_{31}Cl_2N_2NaO_4$, F.W. 481.39, Powder, RTECS SA3680700, MDL MFCD00083183 Application(s): Potent and specific non-peptide cholecystokinin (CCK) receptor antagonist	**25mg** **100mg**

Stock #	Description	Size
H52792	**Lovastatin, 97%** *[Mevacor]* [75330-75-5], $C_{24}H_{36}O_5$, F.W. 404.56, m.p. 175°, RTECS EK7907000, MDL MFCD00072164 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	5g 25g
J65822	**Loxistatin** *[EST, E-64d]* [88321-09-9], $C_{17}H_{30}N_2O_5$, F.W. 342.43, Powder, RTECS RR0404300, MDL MFCD00132883 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1mg 5mg
	Ludiomil hydrochloride, see Maprotiline hydrochloride, 99%, J62321, p. 277	
J61462	**Luminol and oxidizing solutions (each bottle)** Liquid, Note: Mix equal amounts of luminol and oxidizing solution, then incubate the membrane for 1 min. Expose membrane to x-ray film for at least one minute. Adjust exposure as necessary. Application(s): For chemiluminecent detection of HRP-based Western blotting systems.	250ml 500ml
	Luteinizing Hormone Releasing Hormone, see LH-RH **Luteolin**, see 3',4',5,7-Tetrahydroxyflavone, L14186, p. 363 **Lutocyclin**, see Ethisterone, 98%, J63580, p. 214	
J61915	**Luzindole, 97%** *[N-[2-[2-(Phenylmethyl)-1H-indol-3-yl]ethyl]acetamide, N-Acetyl-2-benzyltryptamine]* [117946-91-5], $C_{19}H_{20}N_2O$, F.W. 292.37, Powder, m.p. 44-46°, MDL MFCD00672498 Application(s): A melatonin receptor antagonist	5mg 25mg
	LY-110,140 hydrochloride, see Fluoxetine hydrochloride, 99%, J61197, p. 224 **H-Lys-OH.HCl**, see L-Lysine monohydrochloride, Cell Culture Reagent, J62099, p. 273	
J62067	**Lys-Bradykinin** *[Kallidin, Lys-Arg-Pro-Pro-Gly- Phe-Ser-Pro-Phe-Arg]* [100900-38-7], $C_{56}H_{88}N_{17}O_{12}$, F.W. 1188.40, Powder Application(s): Endogenous bradykinin receptor agonist	5mg 25mg
J62225	**L-Lysine, 98%** *[(S)-2,6-Diaminocaproic acid]* [56-87-1], $C_6H_{14}N_2O_2$, F.W. 146.19, Powder, m.p. 215°, Merck **14**,5636, EINECS 200-294-2, RTECS OL5540000, BRN 1722531, MDL MFCD00064433, †	25g 100g 500g
A11066	**DL-Lysine monohydrochloride, 99%** *[(+/-)-2,6-Diaminohexanoic acid monohydrochloride]* [70-53-1], $C_6H_{14}N_2O_2 \cdot HCl$, F.W. 182.65, m.p. 267° dec., EINECS 200-739-0, BRN 4711993, MDL MFCD00064563, † 	25g 100g
L07710	**D-Lysine monohydrochloride, 98%** *[(R)-2,6-Diaminohexanoic acid monohydrochloride, H-D-Lys-OH.HCl]* [7274-88-6], $C_6H_{14}N_2O_2 \cdot HCl$, F.W. 182.65, m.p. ca 260° dec., $[\alpha]_D^{20}$ -20.5° (c=5 in 5N HCl), EINECS 230-691-6, RTECS OL5632500, BRN 4356907, MDL MFCD00012920, † 	1g 5g
A16249	**L-Lysine monohydrochloride, 99+%** *[(S)-2,6-Diaminohexanoic acid monohydrochloride, H-Lys-OH.HCl]* [657-27-2], $C_6H_{14}N_2O_2 \cdot HCl$, F.W. 182.65, m.p. ca 260° dec., $[\alpha]_D^{20}$ +20.5° (c=5 in 5N HCl), Merck **14**,5636, EINECS 211-519-9, RTECS OL5650000, BRN 3563889, MDL MFCD00064564, † 	50g 250g 1kg
J62099	**L-Lysine monohydrochloride, Cell Culture Reagent** [657-27-2], $C_6H_{14}N_2O_2 \cdot HCl$, F.W. 182.65, Powder, Merck **14**,5636, EINECS 211-519-9, RTECS OL5650000, BRN 3563889, MDL MFCD00064564, †	100g 500g 1kg
A18157	**L-Lysine methyl ester dihydrochloride, 99%** ■ *[(S)-2,6-Diaminohexanoic acid methyl ester dihydrochloride, H-Lys-OMe.2HCl]* [26348-70-9], $C_7H_{16}N_2O_2 \cdot 2HCl$, F.W. 233.14, m.p. ca 200° dec., EINECS 247-625-7, BRN 5302183, MDL MFCD00039067 	25g 100g 500g
J63892	**Lysis buffer, pH 8.0** Liquid, Note: This buffer contains: 50mM sodium phosphate, 300mM sodium chloride and 10mM imidazole at pH 8.0. Application(s): For isolation of His-tag proteins	500ml
J61792	**Lysis buffer, 0.5% Tween 20, pH 8.0** Liquid, Note: Contains 50mM sodium phosphate, 300mM sodium chloride, 10mM imidazole and 0.5% Tween-20. Application(s): For isolation of His-tag proteins	500ml

Stock #	Description	Size
J60701	**Lysozyme, chicken egg white** *[E.C. 3.2.1.17, Muramidase]* [12650-88-3], Powder, Merck **14**,5640, EINECS 235-747-3, RTECS OL5989000, MDL MFCD00131557, Note: Minimum 23,500 units/mg. One unit is the amount of enzyme causing a decrease in absorbance at 450nm of 0.001 per minute at 25 C and pH 6.2 with Micrococcous Lysodeikticus as a substrate in a 2.6 mL reaction mixture (1 cm light path) Application(s): Catalyzes the hydrolysis of peptidoglycans found in bacterial cell walls	**1g** **5g** **25g**
	Lyticase, see Yeast Lytic Enzyme, Arthrobacter luteus, J63195, p. 395	
J65036	**M50054** ▲ *[2,2'-Methylenebis(1,3-cyclohexanedione)]* [54135-60-3], $C_{13}H_{16}O_4$, F.W. 236.00, Solid, EINECS 258-989-1	**10mg**
J64242	**MAC 1753** *[5-(3,5-Dichlorophenoxy)-N-4-pyridinyl-2-furancarboxamide]* [685830-90-4], $C_{16}H_{10}Cl_2N_2O_3$, F.W. 349.17 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
J60917	**α-2-Macroglobulin, human plasma** Lyophilized powder, 725 kDa Application(s): A large plasma protein found in the blood capable of inactivating many proteases	**0.2mg** **1mg**
J63844	**Macrophage Inhibitory Peptide** *[H-Thr-Lys-Pro-OH, Tuftsin (1-3)]* [41961-56-2], $C_{15}H_{28}N_4O_5$, F.W. 344.41, Powder Application(s): A tripeptide of the second constant domain of human immunoglobulin G. Inhibitor of macrophage functions	**50mg** **250mg**
J60301	**Magainin I** *[H-Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Gly-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Lys-Ser-OH]* [108433-99-4], $C_{112}H_{177}N_{29}O_{28}S$, F.W. 2409.88, Powder, MDL MFCD00133521 Application(s): Peptide that demonstrates antibiotic activity	**0.5mg**
J61172	**Magainin II** *[Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Asn-Ser]* [108433-95-0], $C_{114}H_{180}N_{30}O_{29}S$, F.W. 2466.93, Powder, MDL MFCD00133522 Application(s): Peptide with potent antibiotic properties	**0.5mg** **1mg** **2.5mg**
	Magenta I, see Basic Fuchsin, A12952, p. 117	
J60041	**Magnesium acetate, 1M aq. soln.** [142-72-3], $Mg(CH_3COO)_2$, F.W. 142.39, Liquid, † H:H302, P:P264-P270-P301+P312-P330-P501a	**50ml** **100ml**
J62411	**Magnesium chloride, 1M aq. soln.** [7786-30-3], $MgCl_2$, F.W. 95.22, Liquid, † H:H303, P:P312	**50ml** **100ml**
J61014	**Magnesium chloride, 1M aq. soln., sterile** [7786-30-3], $MgCl_2$, F.W. 95.22, Liquid, † H:H303, P:P312	**125ml** **250ml**
36226	**Magnesium chloride hexahydrate, ACS, 99.0-102.0%** ■ [7791-18-6], $MgCl_2 \cdot 6H_2O$, F.W. 203.30 (95.22anhy), Crystalline, m.p. 117° dec., d. 1.570, Merck **14**,5662, Fieser **10**,251, EINECS 232-094-6, RTECS OM2975000, MDL MFCD00149781, † Maximum level of impurities: Insoluble matter 0.005%, NO_3 0.001%, PO_4 5ppm, SO_4 0.002%, NH_4 0.002%, Ba 0.005%, Ca 0.01%, Heavy Metals (as Pb) 5ppm, Fe 5ppm, Mn 5ppm, K 0.0005%, Na 0.005%, Sr 0.005%	**500g** **2kg**
J62575	**Magnesium chloride hexahydrate, Cell Culture Reagent** [7791-18-6], $MgCl_2 \cdot 6H_2O$, F.W. 203.30 (95.22anhy), Powder, Merck **14**,5662, EINECS 232-094-6, RTECS OM2975000, MDL MFCD00149781, †	**250g** **500g** **1kg**
40318	**Magnesium silicate monohydrate (Talc)** [14807-96-6], $3MgO \cdot 4SiO_2 \cdot H_2O$, F.W. 379.28 (361.27anhy), Powder, d. 2.7, Merck **14**,9037, Solubility: Insoluble in water, cold acids, alkalies, EINECS 238-877-9, RTECS WW2710000, MDL MFCD00792903, † H:H332, P:P261-P271-P304+P340-P312 Application(s): Lubricant, filler, electric and heat insulator, in clarifying liquids by filtration	**100g** **500g** **2.5kg**
J63953	**Magnesium sulfate, 1M aq. soln.** [7487-88-9], $MgSO_4$, F.W. 120.37, Liquid, †	**50ml** **100ml**
J61030	**Magnesium sulfate, 1M aq. soln., sterile** [7487-88-9], $MgSO_4$, F.W. 120.37, Liquid, †	**125ml** **250ml**

Stock #	Description	Size
11596	**Magnesium sulfate heptahydrate, ACS, 98.0-102.0%** *[Epsom salt]* [10034-99-8], $MgSO_4 \cdot 7H_2O$, F.W. 246.48 (120.37anhy), Crystalline, d. 1.68, Merck **14**,5691, Fieser **1**,634 **5**,421, Solubility: Soluble in water. Slightly soluble in alcohol, glycerol, EINECS 231-298-2, RTECS OM4508000, MDL MFCD00149785, Note: 150° $-6H_2O$, 200° $-7H_2O$, † Maximum level of impurities: Insoluble matter 0.005%, pH of a 5% solution 5.0-8.2 at 25°, Cl 5ppm, NO_3 0.002%, NH_4 0.002%, Ca 0.02%, Heavy Metals (as Pb) 5ppm, Fe 5ppm, Mn 5ppm, K 0.005%, Na 0.005%, Sr 0.005% Application(s): Fireproofing, textiles, catalyst carrier, ceramics	**100g** **500g** **2kg**
33337	**Magnesium sulfate, anhydrous, 99.5% min** ■ [7487-88-9], $MgSO_4$, F.W. 120.37, Powder, m.p. 1124° dec., d. 2.66, Merck **14**,5691, EINECS 231-298-2, MDL MFCD00011110, † Application(s): Suitable for sensitive molecular biology applications	**500g** **2kg** **10kg**
J61839	**Magnesium sulfate heptahydrate, Cell Culture Reagent** *[Epsom salt]* [10034-99-8], $MgSO_4 \cdot 7H_2O$, F.W. 246.48 (120.37anhy), Powder, d. 1.68, Merck **14**,5691, EINECS 231-298-2, RTECS OM4508000, MDL MFCD00149785	**500g** **1kg**
	Magon sulfate, see Xylidyl Blue I sodium salt, L10863, p. 394	
A16186	**Malachite Green oxalate** *[C.I. 42000]* [2437-29-8], $C_{52}H_{54}N_4O_{12}$, F.W. 927.02, m.p. 164° dec., Merck **14**,5699, UN2811, EINECS 219-441-7, RTECS BQ1190000, BRN 3644550, MDL MFCD00011766 ! H:H302-H312, P:P280-P302+P352-P322-P301+P312-P312-P501a Application(s): Biological stain, dye reagent, acid base indicator: pH 0.0 yellow, 2.0 green;11.6 green, 14 colorless 	**25g** **100g**
J62283	**Malantide** *[Arg-Thr-Lys-Arg-Ser-Gly-Ser-Val-Tyr-Glu-Pro-Leu-Lys-Ile]* [86555-35-3], $C_{72}H_{124}N_{22}O_{21}$, F.W. 1633.91, Powder Application(s): Substrate for cAMP-dependent protein kinase	**1mg** **2mg** **5mg**
J60582	**Maleate, 0.2M buffer soln., pH 5.0** [676-46-0], Liquid	**250ml** **500ml**
J62049	**Maleate, 0.2M buffer soln., pH 5.5** [676-46-0], Liquid	**250ml** **500ml**
J62035	**Maleate, 0.2M buffer soln., pH 6.0** [676-46-0], Liquid	**250ml** **500ml**
J61156	**Maleate, 0.2M buffer soln., pH 6.5** [676-46-0], Liquid	**250ml** **500ml**
J61297	**Maleate, 0.2M buffer soln., pH 7.0** [676-46-0], Liquid	**250ml** **500ml**
A14596	**Maleic acid, 98+%** *[cis-2-Butenedioic acid]* [110-16-7], $C_4H_4O_4$, F.W. 116.07, m.p. 132-136°, f.p. 127°(260°F), d. 1.59, Merck **14**,5703, EINECS 203-742-5, RTECS OM9625000, BRN 605762, MDL MFCD00063177, † ! H:H302-H315-H319-H317-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**250g** **1kg** **5kg**
A12178	**Maleic anhydride, 98+%** ◢ *[cis-Butenedioic anhydride, 2,5-Furandione]* [108-31-6], $C_4H_2O_3$, F.W. 98.06, m.p. 52-56°, b.p. 202°, f.p. 103°(217°F), Merck **14**,5704, Fieser **4**,316 **5**,422, UN2215, EINECS 203-571-6, RTECS ON3675000, BRN 106909, MDL MFCD00005518, † H:H334-H314-H302-H317, P:P260-P285-P303+P361+P353-P305+P351+P338-P405-P501a Reactive dienophile. For a review of its Diels-Alder reactions, see: *Org. React.*, **4**, 1 (1948). For examples, see: *Org. Synth. Coll.*, **3**, 807 (1955); **4**, 890 (1963). For reaction with Danishefsky's diene (**1-Methoxy-3-trimethylsiloxy-1,3-butadiene**, **L14672**), see: *Org. Synth. Coll.*, **7**, 312 (1990). Also undergoes photochemical and thermal (2+2)-cycloadditions with alkenes. For reaction with 1-alkynes, see: *Chem. Ber.*, **102**, 3974 (1969). For thermal (2+2)-cycloaddition with allene at high temperature, see: *Org. Synth. Coll.*, **5**, 459 (1973). For use in combination with **Urea hydrogen peroxide adduct**, **L13940**, to generate peroxymaleic acid in epoxidation and Baeyer-Villiger reactions, see: *Heterocycles*, **36**, 1075 (1993). Peroxymaleic acid can also be generated *in situ* from maleic anhydride and 30% H_2O_2 in NMP, and has been found to be a very effective oxidant for conversion of sulfides to sulfoxides. For a study of stoichiometric and catalytic oxidations with this system, see: *J. Org. Chem.*, **61**, 5693 (1996). 	**250g** **1kg** **5kg**
A13135	**Maleimide, 98+%** *[2,5-Dioxo-3-pyrroline, 1H-Pyrrole-2,5-dione]* [541-59-3], $C_4H_3NO_2$, F.W. 97.07, m.p. 90-94°, b.p. 97-103/5mm, d. 1.249, Solubility: Soluble in water, UN2923, EINECS 208-787-4, RTECS ON4800000, BRN 106910, MDL MFCD00005494, † H:H301-H314-H317, P:P260-P301+P310-P303+P361+P353-P305+P351+P338-P405-P501a 	**5g** **25g** **50g** **250g**

Stock #	Description	Size
	Stereoselective Diels-Alder reaction with an exocyclic diene has been used in the synthesis of a cyclohexannulated [5.3.1]propellane as a precursor of an ABC ring analogue of paclitaxel (Taxolγ): *J. Chem. Soc., Chem. Commun.*, 1395 (1995). Application(s): Reacts quantitatively with sulfhydryl groups	
	3-Maleimidobenzoic acid N-hydroxysuccinimide ester, see N-Succinimidyl 3-maleimidobenzoate, J61410, p. 354	
J61850	**N-(γ-Maleimidobutyryloxy)succinimide** *[GMBS]* [80307-12-6], $C_{12}H_{12}N_2O_6$, F.W. 280.23, Powder, m.p. 130-132°, BRN 6427689, MDL MFCD00036817 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A heterobifunctional cross-linking reagent with amine and sulfhydryl reactivity. Useful in enzyme immunoassays	**100mg**
A17874	**DL-Malic acid, 98%** *[(±)-Hydroxysuccinic acid]* [6915-15-7], $C_4H_6O_5$, F.W. 134.09, m.p. 130-133°, f.p. 203°(397°F), d. 1.609, Merck **14**,5707, Solubility: Soluble in acetone, dioxane, water, methanol and ethanol. Insoluble in benzene., EINECS 210-514-9, RTECS ON7175000, BRN 1723539, MDL MFCD00064212, † H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**500g** **2.5kg**
A11688	**D-(+)-Malic acid, 98+%** *[(R)-(+)-Hydroxysuccinic acid]* [636-61-3], $C_4H_6O_5$, F.W. 134.09, m.p. 100-104°, d. 1.60, $[\alpha]_D^{20}$ +27° (c=5.5 in pyridine), Merck **14**,5707, EINECS 211-262-2, RTECS ON7260000, BRN 1723540, MDL MFCD00004245 H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
J63221	**L-(-)-Malic acid, 99%** *[(S)-(-)-Hydroxysuccinic acid, (S)-(-)-Hydrosuccinic acid]* [97-67-6], $C_4H_6O_5$, F.W. 134.09, Crystalline powder, m.p. 100-106°, f.p. 220°(428°F), d. 1.6, Merck **14**,5707, EINECS 202-601-5, RTECS ON7175000, BRN 1723541, MDL MFCD00064213, † H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2.5kg**
J65970	**Malic decarboxylase variant A** Lyophilized powder, Note: Component in the Cofactor Recycling Enzymes Kit, item J64535	**250mg** **500mg** **1g**
J64878	**Malic decarboxylase variant B** Lyophilized powder, Note: Component in the Cofactor Recycling Enzymes Kit, item J64535	**250mg** **500mg** **1g**
A17939	**Malonamide, 98%** [108-13-4], $C_3H_6N_2O_2$, F.W. 102.09, m.p. 167-171°, EINECS 203-553-8, RTECS ON9125000, BRN 1751401, MDL MFCD00008034, † Reagent for fluorimetric determination of reducing carbohydrates: *Anal. Chim. Acta*, **108**, 421 (1979).	**100g** **500g** **2.5kg**
A11526	**Malonic acid, 99%** *[Propanedioic acid]* [141-82-2], $C_3H_4O_4$, F.W. 104.06, m.p. 132-136° dec., f.p. 157°(314°F), d. 1.62, Merck **14**,5710, EINECS 205-503-0, RTECS OO0175000, BRN 1751370, MDL MFCD00002707, † H:H318-H302-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Knoevenagel condensation with aldehydes yields substituted acrylic (e.g. cinnamic) acids; review: *Org. React.*, **15**, 204 (1967). For an example of the Doebner modification, using pyridine as solvent/base, see: *Org. Synth. Coll.*, **3**, 425 (1955); a catalytic amount of piperidine often gives superior results; see, e.g.: *Org. Synth. Coll.*, **4**, 327 (1963).	**100g** **500g** **2.5kg**
31715	**Malonic acid, Reagent Grade, 99.5+%** *[Propanedioic acid]* [141-82-2], $H_2C(CO_2H)_2$, F.W. 104.06, Crystalline, m.p. 132-136° dec., f.p. 157°(314°F), d. 1.62, Merck **14**,5710, Solubility: Soluble in water, alcohol. Moderately soluble in pyridine, ether, EINECS 205-503-0, RTECS OO8175000, BRN 1751370, MDL MFCD00002707, † H:H318-H302-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2.5kg**
44841	**Malonic acid disodium salt, 99%** *[Disodium malonate]* [141-95-7], $CH_2(COONa)_2$, F.W. 148.03, Powder, EINECS 205-514-0, RTECS OO1750000, MDL MFCD00002708, †	**25g** **100g**
	Malonoben, see Tyrphostin A9, 99%, J63058, p. 386	
A15046	**Malononitrile, 99%** *[Dicyanomethane, Propanedinitrile]* [109-77-3], $C_3H_2N_2$, F.W. 66.06, m.p. 30-34°, b.p. 220-222°, f.p. 112°(233°F), d. 1.049, n_D^{20} 1.4150, Merck **14**,5711, Fieser **4**,317 **18**,228, Solubility: Soluble in water, UN2647, EINECS 203-703-2, RTECS OO3150000, BRN 773697, MDL MFCD00001883, † H:H301-H311-H331-H400-H410, P:P301+P310-P361-P302+P352-P321-P405-P501a The Na derivative can be arylated by reaction with aryl halides with a Pd catalyst: *J. Chem. Soc., Chem. Commun.*, 932 (1984). In the presence of butadiene, an additional 4-carbon unit is introduced: *J. Chem. Soc., Perkin 1*, 647 (1990):	**100g** **500g** **2.5kg**

Contact us for pricing on bulk sizes



Ternary condensation with an aromatic aldehyde and a cycloalkanone in the presence of ammonium acetate can give a variety of products. With cyclohexanone, the 2-amino-4-aryl-5,6,7,8-tetrahydroquinoline-3-carbonitriles are the major products: *J. Chem. Res. (Synop.)*, 146 (1995).
Reviews of the chemistry of malononitrile: *Chem. Rev.*, **69**, 591 (1969); *Synthesis*, 165, 241 (1978); 925 (1981); *Synlett*, 2247 (2004).

Application(s): Crosslinking agent for modification of proteins via amidation

A16266 **D-(+)-Maltose monohydrate, 95%** — **100g 500g**
[4-O-α-Glucopyranosyl-D-glucose monohydrate]
[6363-53-7], $C_{12}H_{22}O_{11}\cdot H_2O$, F.W. 360.32 (342.30anhy), m.p. ca 120° dec., $[\alpha]_D^{20}$ +130° (c=2 in water, 24h), Merck **14**,5714, Solubility: Soluble in water. Slightly soluble in alcohol. Insoluble in ether, EINECS 200-716-5, RTECS OO5250000, BRN 5784659, MDL MFCD00149343, †



D-Mandelonitrile-β-D-glucosido-6-β-D-glucoside, see D-Amygdalin, 98+%, J61472, p. 103

J63150 **Manganese(II) chloride, 1M aq. soln.** — **50ml 100ml**
[7773-01-5], $MnCl_2$, F.W. 125.84, Liquid, †
H:H302, P:P264-P270-P301+P312-P330-P501a

36526 **Manganese(II) chloride tetrahydrate, ACS, 98.0-101.0%** ■ — **100g 500g 2kg**
[13446-34-9], $MnCl_2\cdot 4H_2O$, F.W. 197.90 (125.84anhy), Crystalline, m.p. 58°, d. 2.010, Merck **14**,5728, Solubility: Soluble in water, alcohol, EINECS 231-869-6, MDL MFCD00149792, †
Maximum level of impurities: Insoluble matter 0.005%, pH of a 5% solution 3.5-6.0 at 25°, SO_4 0.005%, Ca 0.005%, K 0.01%, Na 0.05%, Heavy Metals (as Pb) 5ppm, Fe 5ppm, Zn 0.005%
H:H302, P:P264-P270-P301+P312-P330-P501a

J63305 **Manidipine** — **100mg 1g**
[89226-50-6], $C_{35}H_{38}N_4O_6$, F.W. 610.71, Crystalline powder, Merck **14**,5743, UN2811
H:H302, P:P264-P270-P301+P312-P330-P501a

Application(s): A calcium channel blocker

J60496 **Manidipine dihydrochloride** — **25mg 100mg 250mg**
[89226-75-5], $C_{35}H_{38}N_4O_6\cdot 2HCl$, F.W. 683.63, Crystalline powder, Merck **14**,5743, UN2811
H:H301, P:P264-P270-P301+P310-P321-P405-P501a

Application(s): Calcium channel blocker

A14030 **D-Mannitol, 99%** — **250g 1kg 5kg**
[69-65-8], $C_6H_{14}O_6$, F.W. 182.17, m.p. 167-169°, b.p. 290-295°/3.5mm, d. 1.489, $[\alpha]_D^{20}$ +24° (in borax solution), Merck **14**,5745, EINECS 200-711-8, RTECS OP2060000, BRN 1721898, MDL MFCD00064287, †



33342 **D-Mannitol, ACS** — **500g 2.5kg**
[69-65-8], $HOCH_2(CHOH)_4CH_2OH$, F.W. 182.17, Crystalline, m.p. 165-167°, b.p. 290-295°/3.5mm, d. 1.489, Merck **14**,5745, Solubility: Soluble in water, alcohol, pyridine, aniline. Insoluble in ether, EINECS 200-711-8, RTECS OP2060000, BRN 1721898, MDL MFCD00064287, †
Maximum level of impurities: Insoluble matter 0.01%, Residue after ignition 0.01%, Titratable acid 0.0008meq/g, Reducing sugars P.T., Heavy Metals (as Pb) 5ppm, Specific rotation at 25° +23.3° to +24.3°

A10842 **D-(+)-Mannose, 99%** ■ — **25g 100g 500g**
[3458-28-4], $C_6H_{12}O_6$, F.W. 180.16, m.p. 127-133°, d. 1.54, $[\alpha]_D^{20}$ +13.8° (c=10 in water, 24h), Merck **14**,5747, Solubility: Soluble in water, EINECS 222-392-4, BRN 1564373, MDL MFCD00064122, †
Chiral building block. For use in a 15-step synthesis of the macrocycle (+)-aspicilin, in which 3 of the 4 asymmetric centers come from mannose, see: *Helv. Chim. Acta*, **72**, 1753 (1989).



A17722 **L-(-)-Mannose, 99%** — **250mg 1g**
[10030-80-5], $C_6H_{12}O_6$, F.W. 180.16, m.p. 129-131°, EINECS 233-080-2, BRN 1724628, MDL MFCD00136021, †



J62321 **Maprotiline hydrochloride, 99%** — **1g 5g**
[Ludiomil hydrochloride]
[10347-81-6], $C_{20}H_{23}N\cdot HCl$, F.W. 313.87, Crystalline powder, m.p. 230-232°, Merck **14**,5748, EINECS 233-758-8, RTECS KJ4555000, MDL MFCD00079464
H:H302, P:P264-P270-P301+P312-P330-P501

Application(s): Selective norepinephrine uptake inhibitor

Marcaine, see Bupivacaine hydrochloride, 98+%, J62835, p. 140

Stock #	Description	Size
J61103	**Margatoxin, 99+%** *[rMargatoxin, MgTx]* [145808-47-5], $C_{178}H_{286}N_{52}O_{50}S_7$, F.W. 4178.95, Powder, Merck **14**,5752 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501 Application(s): Peptide that blocks voltage-dependent Kv1.3 potassium channels	**0.1mg** **5x5micrograms** **5x10micrograms**
	rMargatoxin, see Margatoxin, 99+%, J61103, p. 278	
J62588	**Masitinib, 99+%** [790299-79-5], $C_{28}H_{30}N_6OS$, F.W. 498.64, Crystalline solid H:H361-H319-H317, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Protein tyrosine kinase inhibitor	**25mg** **50mg**
J63412	**Mast Cell Degranulating Peptide** *[H-Ile-Lys-Cys-Asn-Cys-Lys-Arg-His-Val-Ile-Lys-Pro-His-Ile- Cys-Arg-Lys-Ile-Cys-Gly-Lys-Asn-NH2(Cys3-Cys15, Cys5-Cys19), MCD Peptide]* [32908-73-9], $C_{110}H_{192}N_{40}O_{24}S_4$, F.W. 2587.22, Powder, RTECS OQ5980000, MDL MFCD00167557 Application(s): Degranulates mast cells, initiating histamine release	**0.5mg**
J63655	**Mast Cell Degranulating Peptide HR-1** *[Ile-Asn-Leu-Lys-Ala-Ile-Ala-Ala-Leu-Val-Lys-Lys-Val-Leu-NH2]* [80533-94-4], $C_{71}H_{133}N_{19}O_{15}$, F.W. 1492.96, Powder, MDL MFCD00133526 Application(s): Degranulates mast cells, initiating histamine release	**1mg** **5mg**
J60447	**Mast Cell Degranulating Peptide HR-2** *[Phe-Leu-Pro-Leu-Ile-Leu-Gly-Lys-Leu-Val-Lys-Gly-Leu-Leu-NH2]* [80388-04-1], $C_{77}H_{135}N_{17}O_{14}$, F.W. 1523.02, Powder Application(s): Degranulates mast cells, initiating histamine release	**1mg** **5mg**
J61662	**Mastoparan** *[Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2]* [72093-21-1], $C_{70}H_{131}N_{19}O_{15}$, F.W. 1478.93, Powder, BRN 5491949, MDL MFCD00076865 Application(s): A peptide toxin originally isolated from wasp venom; stimulates exocytosis	**1mg** **5mg**
J61173	**Mastoparan X** *[Ile-Asn-Trp-Lys-Gly-Ile-Ala-Ala-Met-Ala-Lys-Lys-Leu-Leu-NH2]* [72093-22-2], $C_{73}H_{126}N_{20}O_{15}S$, F.W. 1555.97, Powder Application(s): Has effects similar to mastoparan; binds with high affinity to calmodulin and inhibits sarcoplasmic reticulum calcium-ATPase	**1mg**
J65221	**Matrix Metalloproteinase Inhibitor I** *[MMP Inhibitor I, 4-Abz-Gly-Pro-D-Leu-D-Ala-NHOH]* $C_{23}H_{34}N_6O_6$, F.W. 490.55, Powder, MDL MFCD00237459	**5mg**
	Maxivent, see Doxofylline, J60575, p. 201 **MBHA.HCl resin**, see 4-Methylbenzhydrylamine resin bound, 44455, p. 286 **MCD Peptide**, see Mast Cell Degranulating Peptide , J63412, p. 278 **MDL**, see Calpain Inhibitor III, 95+%, J62919, p. 144 **MDL 16455 hydrochloride**, see Fexofenadine hydrochloride, J63262, p. 220 **MDL-72222**, see 3-Tropanyl-3,5-dichlorobenzoate, 99+%, J62583, p. 383	
J64692	**MDM2 Inhibitor ▲** *[trans-4-Iodo-4'-boranyl-chalcone, (E)-4-(3-(4-Iodophenyl)acryloyl)phenylboronic acid]* [562823-84-1], $C_{15}H_{12}BIO_3$, F.W. 377.97, Solid, MDL MFCD06798340	**10mg**
	MEAD acid, see cis-5,8,11-Eicosatrienoic acid, J63870, p. 204	
H26694	**Meat Peptone ◪■** *[Peptones, meat]* [73049-73-7], MDL MFCD00131829, †	**100g** **500g**
	Application(s): Peptone is used in nutrient media for growing bacteria and fungi	
J60257	**Mecamylamine hydrochloride** [826-39-1], $C_{11}H_{21}N{\cdot}HCl$, F.W. 203.75, Powder, Merck **14**,5774, UN2811, EINECS 212-555-8, RTECS RB6900000, MDL MFCD00151462 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Nicotinyl acetylcholine receptor antagonist	**5mg** **25mg** **100mg**
	Mechlorethamine hydrochloride, see Chloromethyl pivalate, A11967, p. 157	
J62464	**Meclizine dihydrochloride monohydrate** [31884-77-2], $C_{25}H_{27}ClN_2{\cdot}2HCl{\cdot}H_2O$, F.W. 481.89 (463.88anhy), Powder, m.p. 210-213°, Merck **14**,5777 H:H302-H361, P:P281-P264-P301+P312-P308+P313-P405-P501 Application(s): Antiemetic and H1-histamine receptor antagonist	**1g** **5g** **10g**
	Meclofenamate sodium, see Meclofenamic acid sodium salt, 99+%, J60484, p. 279	

Stock #	Description	Size
J60484	**Meclofenamic acid sodium salt, 99+%** *[Meclofenamate sodium, 2-[(2,6-Dichloro-3-methylphenyl)-amino]benzoic acid]* [6385-02-0], $C_{14}H_{10}Cl_2NNaO_2$, F.W. 318.13, Powder, EINECS 228-983-3, RTECS CB2975500, MDL MFCD00077376 Application(s): Inhibits 5-lipoxygenase and cyclooxygenase; NSAID	**1g** **5g** **25g**
	Mecobalamin, see Methylcobalamin hydrate, A11176, p. 286 **Mefanacid**, see Mefenamic acid, 98%, J62705, p. 279	
J62705	**Mefenamic acid, 98%** *[2-[(2,3-Dimethylphenyl)amino]benzoic acid, Mefanacid]* [61-68-7], $C_{15}H_{15}NO_2$, F.W. 214.29, Powder, Merck **14**,5798, EINECS 200-513-1, RTECS CB4550000, MDL MFCD00051721 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): An non-steroidal anti-inflammatory drug with antiproliferative activity against human colon cancer cells	**25g** **100g**
	MEGA-10, see N-Decanoyl-N-methylglucamine, J60173, p. 176 **MEGA-8**, see N-Octanoyl-N-methylglucamine, J63574, p. 306 **Meglumine**, see N-Methyl-D-glucamine, L14282, p. 288	
J64424	**[Met 210] Melanocyte Protein PMEL 17 (209-217), human, mouse** *[Ile-Met-Asp-Gln-Val-Pro-Phe-Ser-Val]* $C_{47}H_{74}N_{10}O_{14}S$, F.W. 1035.21, Solid, MDL MFCD03093433	**1mg**
J64310	**α-Melanocyte Stimulating Hormone amide** *[α-MSH amide]* [581-05-5], $C_{77}H_{109}N_{21}O_{19}S$, F.W. 1664.88, Solid	**1mg** **5mg**
J64142	**α-Melanocyte Stimulating Hormone free acid** *[α-MSH free acid]* [10466-28-1], $C_{77}H_{108}N_{20}O_{20}S$, F.W. 1665.86, Solid	**1mg**
J65192	**β-Melanocyte Stimulating Hormone, human** *[β-Melanotropin, human,* *Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp]* [17908-57-5], $C_{118}H_{174}N_{34}O_{35}S$, F.W. 2660.91, Solid, MDL MFCD00167548	**1mg**
J65088	**[D-Trp8] γ-Melanocyte Stimulating Hormone** *[Tyr-Val-Met-Gly-His-Phe-Arg-DTrp-Asp-Arg-Phe-Gly, D-Trp-γ-MSH]* $C_{74}H_{99}N_{21}O_{16}S$, F.W. 1570.77, Solid	**1mg**
J60045	**Melanocyte-Stimulating Hormone-Release Inhibiting Factor, synthetic** *[H-Pro-Leu-Gly-NH2, MIF-I]* [2002-44-0], $C_{13}H_{24}N_4O_3$, F.W. 284.36, Lyophilized powder, Merck **14**,5813, EINECS 217-902-7, MDL MFCD00037866 Application(s): Blocks the release of α-melanocyte stimulating hormone, increases brain dopamine levels and antagonizes physiological and behavioral opioid effects in vivo	**250mg** **1g**
J65115	**Melanotan II** *[(Acetyl-Nle4, Asp5, DPhe7, Lys10)-cyclo-α-MSH (4-10) amide, Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2]* [121062-08-6], $C_{50}H_{69}N_{15}O_9$, F.W. 1024.18, Solid, RTECS OL4225000, MDL MFCD06795842	**1mg**
J62452	**Melatonin, 99+%** *[Regulin, N-Acetyl-5-methoxytryptamine]* [73-31-4], $C_{13}H_{16}N_2O_2$, F.W. 232.28, Powder, m.p. 116-120°, Merck **14**,5816, EINECS 200-797-7, RTECS AC5955000, BRN 205542, MDL MFCD00005655 H:H361, P:P281-P201-P202-P308+P313-P405-P501a Application(s): A pineal gland hormone associated with sleep regulation. It induces apoptosis	**5g** **25g**
B22209	**D-(+)-Melezitose hydrate, 99%** ■ [207511-10-2], $C_{18}H_{32}O_{16}{\cdot}xH_2O$, F.W. 504.46 (anhy), m.p. ca 160° dec., $[\alpha]_D^{20}$ +88° (c=4 in water), Merck **14**,5819, EINECS 209-894-9, BRN 99539, MDL MFCD00149448, † 	**10g** **50g**
J60439	**α-D-(+)-Melibiose** *[6-O-α-D-Galactopyranosyl-D-glucose]* [585-99-9], $C_{12}H_{22}O_{11}$, F.W. 342.30, Crystalline powder, Merck **14**,5820, EINECS 209-568-6, MDL MFCD00198188, †	**5g** **25g**
	Melitose pentahydrate, see D-(+)-Raffinose pentahydrate, A18313, p. 335	

Stock #	Description	Size
J60635	**Meloxicam** *[MOBIC, Metacam]* [71125-38-7], $C_{14}H_{13}N_3O_4S_2$, F.W. 351.39, Powder, m.p. 255°, Merck **14**,5826, UN2811, RTECS DL0702000, MDL MFCD00868752 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A NSAID with high inhibitory action against cyclooxygenase (COX-2)	**5g** **25g**
J63830	**Memantine hydrochloride** [41100-52-1], $C_{12}H_{21}N{\cdot}HCl$, F.W. 215.76, Powder, Merck **14**,5829, EINECS 255-219-6, MDL MFCD00214336 Application(s): An NMDA receptor antagonist; stimulates dopamine release	**50mg**
	Menadione, see 2-Methyl-1,4-naphthoquinone, A13593, p. 289 **Menaphthone**, see 2-Methyl-1,4-naphthoquinone, A13593, p. 289 **p-Menth-1-en-8-ol**, see α-Terpineol, 16285, p. 360	
A18098	**DL-Menthol, 98+%** *[(±)-2-Isopropyl-5-methylcyclohexanol]* [89-78-1], $C_{10}H_{20}O$, F.W. 156.27, m.p. 33-36°, b.p. 212-216°, f.p. 93°(199°F), d. 0.890, n_D^{20} 1.4615, Merck **14**,5837, Fieser **12**,294 **13**,172, EINECS 201-939-0, RTECS OT0350000, BRN 3194263, MDL MFCD00001484, †  H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Has local anesthetic and counter-irritant effects; a weak kappa-opioid receptor agonist	**50g** **100g** **250g** **1kg**
L06102	**D-Menthol, 99%** *[(1S,2R,5S)-2-Isopropyl-5-methylcyclohexanol]* [15356-60-2], $C_{10}H_{20}O$, F.W. 156.27, m.p. 41-44°, b.p. 104-105°/10mm, f.p. 91°(195°F), d. 0.890, $[\alpha]_D^{20}$ +49° (c=10 in ethanol), Fieser **12**,294 **13**,172 **16**,203, EINECS 239-387-8, RTECS OT0350000, BRN 1902292, MDL MFCD00062983, †  H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g**
A10474	**L-Menthol, 99%** *[(1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol]* [2216-51-5], $C_{10}H_{20}O$, F.W. 156.27, m.p. 42-45°, b.p. 212-216°, f.p. 93°(199°F), d. 0.89, $[\alpha]_D^{20}$ -50° (c=10 in ethanol), Merck **14**,5837, Fieser **12**,294 **13**,172 **16**,203, EINECS 218-690-9, RTECS OT0700000, BRN 1902293, MDL MFCD00062979, †  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a The L-menthyl ester of succinic acid has been used in a chiral synthesis of (1S,2S)-cyclopropanedicarboxylic acid: *Org. Synth. Coll.*, **8**, 141 (1993):  One recrystallization gives the pure enantiomer.	**50g** **250g** **1kg**
	Mepyramine maleate, see Pyrilamine maleate, J63247, p. 332	
B20391	**Mercaptoacetic acid, 97+%** △ *[Thioglycolic acid]* [68-11-1], $HSCH_2CO_2H$, F.W. 92.11, m.p. -12°, b.p. 220°, f.p. 119°(246°F), d. 1.295, n_D^{20} 1.5045, Merck **14**,9336, Fieser **1**,1153 **7**,366, UN1940, EINECS 200-677-4, RTECS AI5950000, BRN 506166, MDL MFCD00004876, † H:H301-H311-H331-H314, P:P301+P310-P303+P361+P353-P305+P351+P338-P361-P405-P501a Application(s): Reagent that protects tryptophan in amino acid analysis	**100g** **500g** **2.5kg**
L14356	**Mercaptoacetic acid sodium salt, 97%** △ ■ *[Sodium mercaptoacetate, Sodium thioglycolate]* [367-51-1], $HSCH_2CO_2Na$, F.W. 114.10, m.p. ca 305°, Merck **14**,8692, UN3335, EINECS 206-696-4, RTECS AI7700000, BRN 4569109, MDL MFCD00043386, † H:H302-H317, P:P261-P280-P302+P352-P321-P301+P312-P501a Application(s): Reagent that protects tryptophan in amino acid analysis	**25g** **100g** **500g**
J60290	**Mercaptoacetic acid sodium salt, 98%** △ ■ *[Sodium mercaptoacetate, Sodium thioglycolate]* [367-51-1], $HSCH_2CO_2Na$, F.W. 114.10, Powder, m.p. ca 305°, Merck **14**,8692, UN3335, EINECS 206-696-4, RTECS AI7700000, BRN 4569109, MDL MFCD00043386, † H:H302-H317, P:P261-P280-P302+P352-P321-P301+P312-P501a Application(s): Reagent that protects tryptophan in amino acid analysis	**25g** **100g** **1kg**
	2-Mercaptobenzoic acid, see Thiosalicylic acid, A13401, p. 367	
A14086	**2-Mercaptobenzothiazole, 97%** △ *[Benzothiazole-2-thiol]* [149-30-4], $C_7H_5NS_2$, F.W. 167.25, m.p. 178-182°, f.p. 243°(469°F), d. 1.420, Merck **14**,5868, Solubility: Soluble in alkali and alkali carbonate solutions, UN3077, EINECS 205-736-8, RTECS DL6475000, BRN 119484, MDL MFCD00005781, †  H:H400-H410-H317, P:P261-P280-P302+P352-P321-P363-P501a Reagent for determination of Ag, Au, Bu, Cd, Hg, Ir, Pt, Tl.	**10g** **100g** **500g** **2.5kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63989	**2-Mercaptoethane sulfonic acid sodium salt, 96%** *[Coenzyme M sodium salt, MESNA]* [19767-45-4], $HSCH_2CH_2SO_3Na$, F.W. 164.18, Powder, Merck **14**,5909, EINECS 243-285-9, RTECS KI7968000, BRN 3657828, MDL MFCD00007535 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Water-soluble disulfide reducing agent. Cofactor in methyl transfer reactions	**10g** **25g**
A15890	**2-Mercaptoethanol, 98+%** △ ■ *[Thioethylene glycol, Thioglycol]* [60-24-2], $HSCH_2CH_2OH$, F.W. 78.13, m.p. -100°, b.p. 156-158°, f.p. 73°(163°F), d. 1.114, n_D^{20} 1.5 00, Merck **14**,5869, Fieser **1**,643, UN2966, EINECS 200-464-6, RTECS KL5600000, BRN 773648, MDL MFCD00004890, † H:H301-H311-H330-H318-H400-H410-H315-H317-H335, P:P301+P310-P304+P340-P305+P351+P338-P320-P330-P361-P405-P501a Protective agent for preventing oxidation of thiol groups in proteins: *Enzyme Assays*, R. Eisenthal and M. J. Danson, Eds., OUP, Oxford (1992), p 265. In the presence of BF_3 etherate, reacts with carbonyl compounds to give monothioacetals (1,3-oxathiolanes): *J. Org. Chem.*, **33**, 2133 (1968). Amberlyst 15 is also effective: *Synthesis*, 1826 (2001), as is $In(OTf)_3$: *Synlett*, 1535 (2002). 1,3-Oxathiolanes can be prepared from acid-sensitive aldehydes with $LiBH_4$ as catalyst in acetonitrile: *Synlett*, 238 (2001). Cleavage can be effected, e.g. with chloramine-T: *Tetrahedron Lett.*, 3445 (1971), isoamyl nitrite: *Tetrahedron. Lett.*, 3561 (1978), or periodic acid: *Tetrahedron Lett.*, **37**, 4331 (1996). Selective cleavage of oxathiolanes in the presence of dithiolanes has been achieved with triphenylcarbenium tetrafluoroborate: *J. Chem. Soc., Perkin 1*, 542 (1972), or 4-nitrobenzaldehyde catalyzed by TMS-OTf: *J. Chem. Soc. Chem. Commun.*, 1937 (1994). Compare **1,2-Ethanedithiol**, **L12865**. 2-Mercaptoethanol is a reagent for the specific cleavage of the N-dithiasuccinimide protecting group from amines. See **Chlorocarbonylsulfenyl chloride**, **L06432**. Application(s): Solubilizes proteins by reducing disulfide linkages	**250g** **1kg** **5kg**
A14377	**2-Mercaptoethylamine hydrochloride, 98+%** ■ *[Aminoethanethiol hydrochloride, Cysteamine hydrochloride]* [156-57-0], $HSCH_2CH_2NH_2{\cdot}HCl$, F.W. 113.61, m.p. 65-69°, Merck **14**,2779, Solubility: Soluble in water and alcohol, EINECS 205-858-1, RTECS KJ0200000, BRN 3590083, MDL MFCD00012904, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a For selective protection of nitrogen by silylation, see: *Synthesis*, 924 (1980). Application(s): An inhibitor of DMBA-induced mammary tumors	**25g** **100g** **500g**
L01346	**2-Mercaptoimidazole, 98+%** *[2-Imidazolethiol]* [872-35-5], $C_3H_4N_2S$, F.W. 100.14, m.p. 222-227°, EINECS 212-823-4, RTECS NI8515000, BRN 105775, MDL MFCD00005188, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
A13094	**2-Mercapto-1-methylimidazole, 98%** *[Methimazole, 1-Methylimidazole-2-thiol]* [60-56-0], $C_4H_6N_2S$, F.W. 114.17, m.p. 144-147°, b.p. 280° dec., Merck **14**,5971, Solubility: Freely soluble in water. Soluble in alcohol, chloroform. Sparingly soluble in ether, benzene., EINECS 200-482-4, RTECS NI8615000, BRN 108646, MDL MFCD00179321, † H:H361-H317, P:P261-P280-P302+P352-P321-P405-P501a Application(s): Possesses antioxidant properties	**25g** **100g**
	N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline, see Captopril, J63593, p. 146	
L10257	**2-Mercaptopropionic acid, 97%** *[Thiolactic acid]* [79-42-5], $C_3H_6O_2S$, F.W. 106.14, m.p. 10-14°, b.p. 217°, f.p. 107°(225°F), d. 1.196, n_D^{20} 1.4820, Merck **14**,9340, UN2936, EINECS 201-206-5, RTECS UF5250000, BRN 506218, MDL MFCD00004862, † H:H314-H302-H332, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**10g** **100g** **500g**
A12197	**6-Mercaptopurine monohydrate, 98%** *[6-Purinethiol monohydrate]* [6112-76-1], $C_5H_4N_4S{\cdot}H_2O$, F.W. 170.19 (152.17anhy), m.p. ca 315° dec., Merck **14**,5871, EINECS 200-037-4, RTECS UP0400000, BRN 4012091, MDL MFCD03854445 H:H341-H361-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a	**1g** **5g** **25g**
	2-Mercaptopyrimidine-4,6-dione, see 4,6-Dihydroxy-2-mercaptopyrimidine, A12681, p. 192	
B23301	**Mercaptosuccinic acid, 98%** *[Thiomalic acid]* [70-49-5], $C_4H_6O_4S$, F.W. 150.15, m.p. 150-154°, Merck **14**,9343, EINECS 200-736-4, RTECS WM8225000, BRN 1099858, MDL MFCD00004860, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g** **500g**
	3-Mercapto-DL-valine, see DL-Penicillamine, B24710, p. 313 **3-Mercapto-D-valine**, see D-(-)-Penicillamine, A11446, p. 313	

Stock #	Description	Size
J61250	**Mercurochrome** *[Mercury dibromofluorescein disodium salt]* [129-16-8], $C_{20}H_8Br_2HgNa_2O_6$, F.W. 750.65, Crystalline powder, Merck **14**,5867, UN2025, EINECS 204-933-6, RTECS LM5250000, MDL MFCD00013081 H:H300-H310-H330-H373-H400-H410, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Merbromin. An organomercuric compound that is a topical antiseptic	**25g** **100g**
	Mercury dibromofluorescein disodium salt, see Mercurochrome, J61250, p. 282	
L17027	**Merrifield Resin, 1% crosslinked, 200-400 mesh, 1.0-1.3mmol/g** *[Chloromethyl polystyrene, Chloromethylated styrene-divinylbenzene copolymer]* [55844-94-5], MDL MFCD00146406 Crosslinked with 1% divinylbenzene. Supporting resin for solid phase peptide synthesis.	**5g** **25g** **100g**
J63257	**MES, 0.2M buffer soln., pH 5.5** [145224-94-8], Liquid	**250ml** **500ml**
J60930	**MES, 0.2M buffer soln., pH 6.0** [145224-94-8], Liquid H:EUH210	**250ml** **500ml**
J62081	**MES, 0.5M buffer soln., pH 5.0** [145224-94-8], Liquid	**100ml** **250ml**
J62534	**MES, 0.5M buffer soln., pH 5.5** [145224-94-8], Liquid	**100ml** **250ml**
J62574	**MES, 0.5M buffer soln., pH 6.0** [145224-94-8], Liquid	**100ml** **250ml**
J63778	**MES, 0.5M buffer soln., pH 6.5** [145224-94-8], Liquid	**100ml** **250ml**
J63089	**MES, 0.5M buffer soln., pH 7.0** [145224-94-8], Liquid	**100ml** **250ml**
J63706	**MES, 0.5M buffer soln., pH 7.5** [145224-94-8], Liquid	**100ml** **250ml**
J61665	**MES, 0.5M buffer soln., pH 8.0** [145224-94-8], Liquid	**100ml** **250ml**
J63944	**MES, 0.5M buffer soln., pH 8.5** [145224-94-8], Liquid	**100ml** **250ml**
J60031	**MES, 0.5M buffer soln., pH 9.0** [145224-94-8], Liquid	**100ml** **250ml**
J61960	**MES, 1.0M buffer soln., pH 5.0** [145224-94-8], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**250ml** **500ml**
J63341	**MES, 1.0M buffer soln., pH 5.5** [145224-94-8], Liquid	**250ml** **500ml**
J60763	**MES, 1.0M buffer soln., pH 6.0** [145224-94-8], Liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J61587	**MES, 1.0M buffer soln., pH 6.5** [145224-94-8], Liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J62231	**MES, 1.0M buffer soln., pH 7.0** [145224-94-8], Liquid	**250ml** **500ml**
J62752	**MES, 1.0M buffer soln., pH 7.5** [145224-94-8], Liquid	**250ml** **500ml**
J61556	**MES, 1.0M buffer soln., pH 8.0** [145224-94-8], Liquid	**250ml** **500ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62720	**MES, 1.0M buffer soln., pH 8.5** [145224-94-8], Liquid	**250ml** **500ml**
J61656	**MES, 1.0M buffer soln., pH 9.0** [145224-94-8], Liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
A16104	**MES monohydrate, 98%** *[4-Morpholineethanesulfonic acid monohydrate, 2-(4-Morpholinyl)ethanesulfonic acid monohydrate]* [145224-94-8], $C_6H_{13}NO_4S{\cdot}H_2O$, F.W. 213.26 (195.24anhy), m.p. ca 308° dec., Merck **14**,5902, EINECS 224-632-3, RTECS QE3479500, BRN 141319, MDL MFCD00149409, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Biological buffer, pKa = 6.15 at 20°: *Biochemistry*, **5**, 467 (1966). Application(s): Good's buffer	**25g** **100g** **500g**
H56472	**MES hydrate, 99+%** *[2-(4-Morpholinyl)ethanesulfonic acid hydrate, 4-Morpholineethanesulfonic acid hydrate]* [4432-31-9], $C_6H_{13}NO_4S{\cdot}xH_2O$, F.W. 195.24(anhy), m.p. ca 308° dec., Merck **14**,5902, EINECS 224-632-3, RTECS QE3479500, BRN 141319, MDL MFCD00149409, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **500g**
J61979	**MES-buffered saline (5X), pH 6.5** [145224-94-8], Liquid, Note: Contains 125mM MES and 750mM NaCl 7 at pH 6.5 H:EUH210	**250ml** **500ml**
J61938	**MES-buffered saline (5X), pH 7.0** [145224-94-8], Liquid, Note: Contains 125mM MES and 750mM NaCl 7.0 at pH 7.0	**250ml** **500ml**
J63411	**MES lysis buffer with NP-40** Liquid, Note: This buffer contains: 25mM MES, 150mM NaCl, 1% NP-40, and 5mM EDTA, pH 7.0. H:H319, P:P280-P264-P305+P351+P338-P337+P313	**250ml** **500ml**
J60244	**MES lysis buffer with NP-40 (2X)** Liquid, Note: This buffer contains 50mM MES, 300mM sodium chloride, 1% NP-40, and 10mM EDTA at pH 7.0. H:H319, P:P280-P264-P305+P351+P338-P337+P313	**125ml** **250ml**
J62693	**MES lysis buffer with Triton® X-100** Liquid, Note: This buffer contains: 25mM MES, 150mM sodium chloride, 1% Triton X-100, and 5mM EDTA at pH 7.0.	**250ml** **500ml**
J63169	**MES lysis buffer with Triton® X-100 (2X)** Liquid, Note: This buffer contains: 50mM MES, 300mM NaCl, 2% Triton X-100 and 10mM EDTA at pH 7.0.	**125ml** **250ml**
	MESNA, see 2-Mercaptoethane sulfonic acid sodium salt, 96%, J63989, p. 281 **Mesoxalylurea monohydrate**, see Alloxan monohydrate, A15324, p. 89	
J62138	**MES-SDS running buffer (20X)** Liquid, Note: This buffer contains: 1M MES, 1M Tris base,2% SDS and 20mM EDTA at pH 7.3.	**500ml** **1L**
	H-L-Met-OH, see L-Methionine, Cell Culture Reagent, J61904, p. 284 **L-Met-AFC**, see L-Methionine-7-amido-4-trifluoromethylcoumarin, J65843, p. 284 **Metacam**, see Meloxicam, J60635, p. 280	
A17527	**Metanil Yellow** *[C.I. 13065]* [587-98-4], $C_{18}H_{14}N_3NaO_3S$, F.W. 375.38, Merck **14**,5928, EINECS 209-608-2, RTECS DB7329500, BRN 3831568, MDL MFCD00007486, † H:H318-H412, P:P280-P273-P305+P351+P338-P310-P501a Application(s): As indicator. Transition interval: pH: 1.2 (red) to 2.3 (yellow)	**50g** **250g**
	Metformin hydrochloride, see 1,1-Dimethylbiguanide hydrochloride, J63361, p. 196	
44571	**Methanol, Biograde, 99.8+%** [67-56-1], CH_3OH, F.W. 32.04, Liquid, m.p. -98°, b.p. 64.7°, f.p. 11°(52°F), d. 0.791, n_D^{20} 1.3290, Merck **14**,5957, UN1230, EINECS 200-659-6, RTECS PC1400000, BRN 1098229, MDL MFCD00004595, Note: Filtered through 0.2 µ filter, † H:H225-H301-H311-H331-H370, P:P210-P301+P310-P303+P361+P353-P361-P405-P501a Application(s): In nucleic acid and peptide synthesis	**4L** **4x4L**
	Methimazole, see 2-Mercapto-1-methylimidazole, A13094, p. 281	
A11457	**DL-Methionine, 99%** *[(+/-)-2-Amino-4-(methylthio)butyric acid, H-DL-Met-OH]* [59-51-8], $C_5H_{11}NO_2S$, F.W. 149.21, m.p. ca 272° dec., d. 1.34, Merck **14**,5975, EINECS 200-432-1, RTECS PD0456000, BRN 636185, MDL MFCD00063096, † Soft nucleophile, which acts as a methyl acceptor in the cleavage of methyl ethers of phenols by **Methanesulfonic acid**, **A13565**.	**250g** **1kg** **5kg**

Stock #	Description	Size
B21213	**D-Methionine, 99%** *[(R)-2-Amino-4-(methylthio)butyric acid, H-D-Met-OH]* [348-67-4], $C_5H_{11}NO_2S$, F.W. 149.21, m.p. ca 280° dec., $[\alpha]_D^{20}$ -23° (c=2 in 2N HCl), Merck **14**,5975, EINECS 206-483-6, RTECS PD0455000, BRN 1722293, MDL MFCD00002622, † 	**5g** **25g** **100g**
A10318	**L-Methionine, 98+%** *[(S)-2-Amino-4-(methylthio)butyric acid, H-Met-OH]* [63-68-3], $C_5H_{11}NO_2S$, F.W. 149.21, m.p. ca 280° dec., $[\alpha]_D^{20}$ +23° (c=2 in 2N HCl), Merck **14**,5975, EINECS 200-562-9, RTECS PD0457000, BRN 1722294, MDL MFCD00063097, † 	**100g** **500g** **2.5kg**
J61904	**L-Methionine, Cell Culture Reagent** *[H-L-Met-OH]* [63-68-3], $C_5H_{11}NO_2S$, F.W. 149.21, Powder, m.p. 284° dec., Merck **14**,5975, EINECS 200-562-9, BRN 1722294, MDL MFCD00063097, †	**50g** **100g** **500g**
J65843	**L-Methionine-7-amido-4-trifluoromethylcoumarin** *[L-Met-AFC, L-M-AFC]* $C_{15}H_{15}F_3N_2O_3S$, F.W. 360.35, Powder	**10mg** **25mg**
B25094	**DL-Methionine sulfone, 98%** *[H-DL-Met(O2)-OH]* [820-10-0], $C_5H_{11}NO_4S$, F.W. 181.21, EINECS 212-466-4, MDL MFCD00025079, † 	**1g** **5g** **25g**
A17027	**L-Methionine sulfone, 99+%** *[H-Met(O2)-OH]* [7314-32-1], $C_5H_{11}NO_4S$, F.W. 181.21, m.p. 254° dec., $[\alpha]_D^{20}$ +11.6° (c=0.69 in water), EINECS 230-774-7, BRN 1725510, MDL MFCD00066020 	**1g** **5g**
A18081	**DL-Methionine sulfoxide, 98+%** *[H-DL-Met(O)-OH]* [62697-73-8], $C_5H_{11}NO_3S$, F.W. 165.21, m.p. ca 230° dec., EINECS 263-700-7, MDL MFCD00002620, † 	**5g** **25g**
J62873	**L-Methionine sulfoxide** [3226-65-1], $C_5H_{11}NO_3S$, F.W. 165.21, Powder, EINECS 221-758-0, BRN 4129939, MDL MFCD00063093 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g** **25g**
J63075	**Methotrexate ▲■** [59-05-2], $C_{20}H_{24}N_8O_5$, F.W. 472.45, Powder, UN1544, EINECS 200-413-8, RTECS MA1225000, MDL MFCD00150847, † H:H301-H360-H315-H319, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Anti-inflammatory, cytotoxic drug that acts as a potent folic acid antagonist	**100mg** **1g**
J64730	**5-Methoxybenzoxazole-2-thiol ▲◪** *[2-Mercapto-5-methoxybenzo[d]oxazole, 5-Methoxy-2(3H)-benzoxazolethione]* [49559-83-3], $C_8H_7NO_2S$, F.W. 181.21, Powder, m.p. 218-223°, MDL MFCD03030041 H:H302-H315-H318-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **25g** **100g**
	1-(4-Methoxybenzoyl)-2-pyrrolidinone, see Aniracetam, J61661, p. 104 **(2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate**, see Anisomycin, 97+%, J62964, p. 104	
J63839	**Methoxychlor** [72-43-5], $C_{16}H_{15}Cl_3O_2$, F.W. 345.65, Crystalline powder, m.p. 87°, Merck **14**,5990, UN3077, EINECS 200-779-9, RTECS KJ3675000, BRN 2057367, MDL MFCD00000803 H:H351-H302-H312-H332, P:P261-P280-P281-P302+P352-P405-P501a Application(s): Molecule with estrogenic activity	**5g** **25g**
J62475	**7-Methoxycoumarin-4-acetic acid, 99%** *[7-Methoxy-2-oxo-2H-1-benzopyran-4-acetic acid]* [62935-72-2], $C_{12}H_{10}O_5$, F.W. 234.21, Crystalline solid, m.p. 193°, f.p. 87°(189°F), MDL MFCD00009774 Application(s): Precursor to coumarin-type fluorescent reagents	**100mg** **250mg** **1g**
	1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]pyrrole-2,5-dione, see U-73122, 99+%, J62898, p. 387 **1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]pyrrolidine-2,5-dione**, see U-73343, 98%, J62719, p. 387	
A17459	**2-Methoxyethanol, 99%** *[Ethylene glycol monomethyl ether, Methyl Cellosolve]* [109-86-4], $CH_3OCH_2CH_2OH$, F.W. 76.10, m.p. -85°, b.p. 124-125°, f.p. 46°(115°F), d. 0.965, n_D^{20} 1.4025, Merck **14**,6038, UN1188, EINECS 203-713-7, RTECS KL5775000, BRN 1731074, MDL MFCD00002867, † H:H360FD-H226-H302-H312-H332, P:P210-P241-P303+P361+P353-P302+P352-P405-P501a Application(s): Solvent for ninhydrin color reagent	**500ml** **2.5L** **10L**
	2-Methoxyethyl ether, see Diethylene glycol dimethyl ether, A13397, p. 189 **6-Methoxyharmane**, see Harmine, L19068, p. 241	

Contact us for pricing on bulk sizes

Stock #	Description	Size
	(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, see (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid, L09855, p. 285	
	7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole, see Harmine, L19068, p. 241	
	4-(6-Methoxy-2-naphthyl)-2-butanone, see Nabumetone, J63072, p. 296	
L09855	**(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid, 99%** *[(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, Naproxen]* [22204-53-1], $C_{14}H_{14}O_3$, F.W. 230.27, m.p. 154-156°, $[\alpha]_D^{20}$ +66° (c=1 in chloroform), Merck **14**,6417, UN2811, EINECS 244-838-7, RTECS UF5275000, BRN 3591067, MDL MFCD00010500 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g**
	7-Methoxy-2-oxo-2H-1-benzopyran-4-acetic acid, see 7-Methoxycoumarin-4-acetic acid, 99%, J62475, p. 284	
A16319	**2-Methoxyphenol, 98+%** ▲ △ *[Catechol monomethyl ether, Guaiacol]* [90-05-1], $C_7H_8O_2$, F.W. 124.14, m.p. 28-31°, b.p. 204-206°, f.p. 82°(179°F), d. 1.129, n_D^{20} 1.5430, Merck **14**,4553, EINECS 201-964-7, RTECS SL7525000, BRN 508112, MDL MFCD00002185, † H:H302-H315-H319, P:P305+P351+P338	**250g** **1kg** **5kg**
A16827	**3-(2-Methoxyphenoxy)-1,2-propanediol, 99+%** *[Guaiacol glyceryl ether, Guaifenesin]* [93-14-1], $C_{10}H_{14}O_4$, F.W. 198.22, m.p. 80-82°, b.p. 215°/19mm, Merck **14**,4555, EINECS 202-222-5, RTECS TY8400000, BRN 2049375, MDL MFCD00016873, † H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Centrally acting muscle relaxant with expectorant properties	**50g** **250g** **1kg**
H51751	**1-(3-Methoxyphenyl)homopiperazine monohydrochloride, 98%** *[3-HPA·HCl]* $C_{12}H_{18}N_2O$·HCl, F.W. 242.74, m.p. 169-173°, MDL MFCD16172199, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd. Application(s): Useful intermediate for synthesis	**500mg**
H51703	**1-(4-Methoxyphenyl)homopiperazine monohydrochloride, 98%** *[4-HPA·HCl]* [934992-02-6], $C_{12}H_{18}N_2O$·HCl, F.W. 242.74, m.p. 175-179°, MDL MFCD11501072, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd. H:H315-H319-H335, P:P280g-P305+P351+P338 Application(s): Useful intermediate for synthesis	**500mg**
	1-[2-(4-Methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]imidazole, see SKF-96365 hydrochloride, 99+%, J60937, p. 342	
	4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol hydrochloride, see Naftopidil hydrochloride, 98+%, J63249, p. 297	
	1-[4-(2-Methoxyphenyl)piperazinyl]-3-(1-naphthyloxy)propan-2-ol, see Naftopidil, 98+%, J60311, p. 297	
	6-(3-[4-(2-Methoxyphenyl)-1-piperaziny]propylamino)-1,3-dimethyluracil hydrochloride, see Urapidil hydrochloride, 98+%, J63219, p. 388	
J63467	**(R)-1-Methoxy-2-propanol** [4984-22-9], $C_4H_9O_2$, F.W. 89.11, Liquid, m.p. 119-121°, f.p. 33°(91°F), d. 0.921, n_D^{20} 1.403, UN3092, BRN 1718941, MDL MFCD01632587 H:H226-H336, P:P210-P241-P261-P303+P361+P353-P405-P501 Application(s): For synthesis of optically active products	**Call**
J62757	**(S)-1-Methoxy-2-propanol** [26550-55-0], $C_4H_9O_2$, F.W. 89.11, Liquid, m.p. 119-121°, f.p. 33°(91°F), d. 0.921, n_D^{20} 1.403, UN3092, BRN 1718940, MDL MFCD01632588 H:H226-H336, P:P210-P241-P261-P303+P361+P353-P405-P501 Application(s): For synthesis of optically active products	**Call**
	(E)-1-Methoxy-4-propenylbenzene, see trans-Anethole, A13482, p. 103	
A17108	**8-Methoxypsoralen, 99%** ▲ *[Xanthotoxin]* [298-81-7], $C_{12}H_8O_4$, F.W. 216.20, m.p. 146-150°, Merck **14**,5988, EINECS 206-066-9, RTECS LV1400000, BRN 196453, MDL MFCD00005009, † H:H340-H350-H318-H302, P:P280-P281-P305+P351+P338-P310-P405-P501a Application(s): A naturally occuring photoreactive substance	**1g** **5g** **25g**
J64435	**N-Methoxysuccinyl-Phe-Leu-Phe-7-amino-4-trifluoromethylcoumarin** *[MeOSuc-FLF-AFC]* $C_{39}H_{41}F_3N_4O_8$, F.W. 750.76, Solid, MDL MFCD03452969	**10mg**
	4'-Methoxy-3',5,7-trihydroxyflavanone, see 3',5,7-Trihydroxy-4'-methoxyflavanone, B20528, p. 377	
J64922	**2'-O-Methyladenosine, 99%** [2140-79-6], $C_{11}H_{15}N_5O_4$, F.W. 281.27, Powder, MDL MFCD00056002	**1g**
	2-Methylalanine, see 2-Aminoisobutyric acid, A13021, p. 96	

Stock #	Description	Size
A12291	**Methylamine hydrochloride, 99%** ■ [593-51-1], $CH_3NH_2 \cdot HCl$, F.W. 67.52, m.p. 230-234°, b.p. 225-230°/15mm, Merck **14**,6014, Solubility: Soluble in water, absolute alcohol, EINECS 209-795-0, RTECS PA0603000, BRN 3588822, MDL MFCD00012849, † ! H:H302-H319, P:P280f-P305+P351+P338	**100g** **500g** **2.5kg**
	Methylaminoacetic acid, see Sarcosine, A14594, p. 340 **Methylaminoacetic acid hydrochloride**, see Sarcosine hydrochloride, B25536, p. 340 **(R)-2-(Methylamino)succinic acid**, see N-Methyl-D-aspartic acid, 98+%, J61361, p. 286 **3-Methylanthranilic acid**, see 2-Amino-3-methylbenzoic acid, B24230, p. 96	
J62431	**N-Methyl-L-arginine** [2480-28-6], $C_7H_{16}N_4O_2$, F.W. 188.23, Powder	**10mg** **50mg**
J60890	**Nω-Methyl-L-arginine acetate, 99+%** *[L-NMMA]* [53308-83-1], $C_9H_{20}N_4O_4$, F.W. 248.28, Powder, Merck **14**,6022, BRN 6674255, MDL MFCD00069311 Application(s): Nitric oxide synthase inhibitor	**10mg** **50mg**
J61361	**N-Methyl-D-aspartic acid, 98+%** *[NMDA, (R)-2-(Methylamino)succinic acid]* [6384-92-5], $C_5H_9NO_4$, F.W. 147.13, Powder, m.p. 187-192°, Merck **14**,6662, RTECS CI9457000, BRN 1724431, MDL MFCD00004226	**50mg** **100mg** **500mg**
	4-Methylbenzenesulfonic acid monohydrate, see p-Toluenesulfonic acid monohydrate, 36506, p. 371	
44455	**4-Methylbenzhydrylamine hydrochloride resin bound** *[MBHA.HCl resin]* Powder, MDL MFCD00801150, Note: Poly(styrene-divinylbenzene). 1% cross-linked, 100-200 mesh base resin, loading 0.5-1.0mmol/g ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g**
	(R)-(+)-α-Methylbenzyl alcohol, see (R)-(+)-1-Phenylethanol, L19296, p. 316 **(S)-(-)-α-Methylbenzyl alcohol**, see (S)-(-)-1-Phenylethanol, B21188, p. 316	
J63786	**Methyl caffeate** *[Caffeic acid methyl ester]* [3843-74-1], $C_{10}H_{10}O_4$, F.W. 194.19, Powder, m.p. 158-161°, MDL MFCD00210468 Application(s): Inhibitor of protein tyrosine kinase	**250mg** **1g**
	Methyl caprylate, see Methyl octanoate, A10991, p. 289 **Methyl Cellosolve®**, see 2-Methoxyethanol, A17459, p. 284	
45490	**Methyl cellulose, viscosity 15 cPs** [9004-67-5], Powder, Merck **14**,6040, MDL MFCD00081763, †	**100g** **500g** **2.5kg**
43147	**Methyl cellulose, viscosity 400 cPs** [9004-67-5], Powder, Merck **14**,6040, MDL MFCD00081763, Note: Viscosity: 300-560 cPs for a 2% aqueous solution at 20°C, †	**100g** **500g** **2.5kg**
43146	**Methyl cellulose, viscosity 1600 cPs** [9004-67-5], Powder, Merck **14**,6040, MDL MFCD00081763, Note: Viscosity: 1125-2100 cPs for a 2% aqueous solution at 20°C, †	**100g** **500g** **2.5kg**
43483	**Methyl cellulose, viscosity 8000 cPs** [9004-67-5], Powder, Merck **14**,6040, MDL MFCD00081763, Note: Viscosity 7000-10,000 cPs for a 2% aqueous solution at 20°C, †	**100g** **500g**
36718	**Methyl cellulose, viscosity 4000 cPs** [9004-67-5], Powder, Merck **14**,6040, MDL MFCD00081763, Note: Viscosity 4000 cPs for a 2% aqueous solution at 20°C, †	**100g** **500g**
	3-O-Methyl-D-chiro-inositol, see D-Pinitol, H56648, p. 321	
A11176	**Methylcobalamin hydrate, 99%** *[Cobinamide, Mecobalamin]* [13422-55-4], $C_{63}H_{91}N_{13}O_{14}P \cdot xH_2O$, F.W. 1344.41(anhy), EINECS 236-535-3, RTECS GG3745000, MDL MFCD00149221	**100mg** **500mg**



Contact us for pricing on bulk sizes

Stock #	Description	Size
J65528	**2'-O-Methylcytidine, 99%** [2140-72-9], $C_{10}H_{15}N_3O_5$, F.W. 257.24, Powder, MDL MFCD00056067	1g
43492	**5-Methylcytosine, 97%** [554-01-8], $C_5H_7N_3O$, F.W. 125.13, Crystalline, Merck **14**,6050, EINECS 209-058-3, RTECS UW7362350, MDL MFCD00233537 	100mg 500mg
J64961	**N_6-Methyl-2'-deoxyadenosine, 99%** *[2'-Deoxy-N6-methyladenosine]* [2002-35-9], $C_{11}H_{15}N_5O_3$, F.W. 265.27, Powder, MDL MFCD00055999	1g
J65209	**5-Methyl-2'-deoxycytidine, 99%** *[2'-Deoxy-5-methylcytidine]* [838-07-3], $C_{10}H_{15}N_3O_4$, F.W. 241.24, Powder, EINECS 212-655-1, RTECS HA3860000, MDL MFCD00006549	1g
J60509	**N-Methyldeoxynojirimycin** [69567-10-8], $C_7H_{15}NO_4$, F.W. 177.20, Powder, m.p. 126-128°, BRN 1524564, MDL MFCD00133609 Application(s): α-1,6-glucosidase inhibitor	5mg 10mg
	N-Methyl-N-desacetylcolchicine, see Colcemid, 98+%, J63900, p. 167 **(5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cycl ohepten-5,10-imine maleate**, see Dizocilpine maleate, 99+%, J63917, p. 200 **5-Methyl-5,6-dihydrouracil**, see 5,6-Dihydro-5-methyluracil, L01996, p. 191 **Methyl 2,5-dihydroxycinnamate** , see Erbstatin analog, J61612, p. 209	
J60306	**N-Methyldopamine hydrochloride, 98+%** *[Epinine hydrochloride, Deoxyepinephrine hydrochloride]* [62-32-8], $C_9H_{13}NO_2 \cdot HCl$, F.W. 203.67, Powder, EINECS 200-528-3 Application(s): Dopamine agonist	1g 5g
	Methylene Azure, see Azure I, A17508, p. 116	
J63265	**N,N'-Methylenebisacrylamide, 2% soln.** *[Bis-acrylamide, BAC]* [110-26-9], $C_7H_{10}N_2O_2$, F.W. 154.17, Liquid, EINECS 203-750-9, MDL MFCD00008625, †	500ml 1L
43701	**N,N'-Methylenebisacrylamide, 99+%** *[Bis-acrylamide, BAC]* [110-26-9], $C_7H_{10}N_2O_2$, F.W. 154.17, Powder, m.p. >300°, d. 1.235, EINECS 203-750-9, RTECS AS3678000, BRN 1706297, MDL MFCD00008625, †  ! H:H302, P:P264-P270-P301+P312-P330-P501a Crosslinking agent for the synthesis of polyacrylamide gels.	25g 100g
	3,3'-Methylenebis(4-hydroxycoumarin), see Dicumarol, J63634, p. 187 **4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)**, see Pamoic acid, A15207, p. 311	
A18174	**Methylene Blue, high purity, biological stain** *[Basic Blue 9, C.I. 52015]* [122965-43-9], $C_{16}H_{18}ClN_3S \cdot xH_2O$, F.W. 319.86(anhy), m.p. ca 180° dec., Merck **14**,6060, EINECS 200-515-2, RTECS SO5600000, BRN 3599847, MDL MFCD00150006 ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Sensitive stain for RNA and ribonuclease	5g 25g 100g 500g
J60823	**Methylene Blue trihydrate** *[C.I. 52015, Basic Blue 9]* [7220-79-3], $C_{16}H_{18}ClN_3S \cdot 3H_2O$, F.W. 373.90 (319.86anhy), Green crystalline Powder, Merck **14**,6060, EINECS 200-515-2, RTECS SP5740000, BRN 3599847, MDL MFCD00150008, † ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Sensitive stain for RNA and ribonuclease	25g 100g 250g
	Methylenebutanedioic acid, see Itaconic acid, A15566, p. 262 **Methylene chloride**, see Dichloromethane, L13089, p. 186	
J61773	**(R)-2-(Methylenemethoxy)propane-1,2-diol** $C_5H_{12}O_3$, F.W. 120.15, Solid Application(s): For synthesis of optically active products	Call
J62190	**(S)-2-(Methylenemethoxy)propane-1,2-diol** $C_5H_{12}O_3$, F.W. 120.15, Solid Application(s): For synthesis of optically active products	Call
	Methylenesuccinic acid, see Itaconic acid, A15566, p. 262 **3-Methyl-2,5-furandione**, see Citraconic anhydride, L05238, p. 164	

Stock #	Description	Size
L14282	**N-Methyl-D-glucamine, 99%** △ ■ *[D-1-Deoxy-1-(methylamino)glucitol, Meglumine]* [6284-40-8], $C_7H_{17}NO_5$, F.W. 195.22, m.p. 128-131°, $[\alpha]_D^{20}$ -16.5° (c=2 in water), Merck **14**,6078, EINECS 228-506-9, BRN 385906, MDL MFCD00004707, †  ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g**
	γ-Methyl L-glutamate, see L-Glutamic acid 5-methyl ester, B24859, p. 235 **N-Methylglycine**, see Sarcosine, A14594, p. 340 **N-Methylglycine hydrochloride**, see Sarcosine hydrochloride, B25536, p. 340 **Methyl glycol**, see 2-Methoxyethanol, A17459, p. 284	
42747	**Methyl Green, 0.1% w/v aq. soln.** $C_{27}H_{35}BrClN_3$, F.W. 516.95, Liquid, MDL MFCD00036449, Note: Transition interval: pH 0.2 (yellow) to pH 1.8 (blue), †	**100ml**
J61509	**Methyl Green, zinc chloride** *[C.I. 42590]* [7114-03-6], $C_{27}H_{35}Cl_2N_3.ZnCl_2$, F.W. 653.24, Powder, m.p. >300°, EINECS 230-415-4, BRN 3914106, MDL MFCD00151094 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): DNA stain useful as tracking dye in acid buffers for electrophoresis. Binds selectively to AT-rich regions of native DNA.	**25g** **100g**
J60033	**Methylguanidine hydrochloride, 98%** *[TMG hydrochloride]* [22661-87-6], $C_2H_7N_3 \cdot HCl$, F.W. 109.56, Crystalline Powder, EINECS 245-147-3, RTECS MF3990000, MDL MFCD00012576 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5g** **25g**
J65770	**2'-O-Methylguanosine, 99%** [2140-71-8], $C_{11}H_{15}N_5O_5$, F.W. 297.27, Powder ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g**
J61636	**(R)-(-)-α-Methylhistamine dihydrochloride** [75614-89-0], $C_6H_{11}N_3 \cdot 2HCl$, F.W. 198.10, Powder, MDL MFCD00083176 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg**
J60865	**α-Methyl-DL-histidine dihydrochloride, 99%** *[H-α-Me-DL-His-OH.2HCl]* [32381-18-3], $C_7H_{11}N_3O_2 \cdot 2HCl$, F.W. 242.11, Powder, MDL MFCD00055953	**250mg** **500mg**
A12575	**1-Methylimidazole, 99%** ■ [616-47-7], $C_4H_6N_2$, F.W. 82.11, m.p. -6°, b.p. 195-197°, f.p. 92°(197°F), d. 1.031, n_D^{20} 1.4970, Fieser **5**,447 **18**,239, UN2922, EINECS 210-484-7, RTECS NI7000000, BRN 105197, MDL MFCD00005292, †  ! H:H314-H302-H312, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Useful base for peptide coupling, etc. See, e.g.: *J. Chem. Soc., Chem. Commun.*, 2223 (1995). Undergoes lithiation at the 2-position. Reaction of the Li derivative with ketones followed by dehydration with acetic anhydride is a good route to 2-alkylideneimidazoles: *Synthesis*, 78 (1990). Likewise, reaction with benzonitrile gives the 2-benzoyl derivative, the carbonyl group of which undergoes Wittig methylenation: *Synth. Commun.*, **20**, 321 (1990). Reacts with acid chlorides, including chloroformates, to give N-acylimidazolium salts, which are useful reagents for the acylation of, for example, amino acids: *Bull. Soc. Chim. Fr.*, 1021 (1973).	**100g** **500g** **2kg**
	1-Methylimidazole-2-thiol, see 2-Mercapto-1-methylimidazole, A13094, p. 281	
L03890	**3-Methylindole, 99%** ▲ *[Skatole]* [83-34-1], C_9H_9N, F.W. 131.18, m.p. 94-97°, b.p. 265-268°, f.p. 132°(269°F), Merck **14**,8560, EINECS 201-471-7, RTECS NM0350000, BRN 111296, MDL MFCD00005627, †  ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a N-Protection as the lithium carbamate permits lithiation at the 2-position: *Synth. Commun.*, **18**, 1151 (1988):  See also **Indole**, **A14427**, p. 255 for a similar procedure.	**5g** **25g** **50g**
J64748	**2'-O-Methylinosine, 99%** [3881-21-8], $C_{11}H_{14}N_4O_5$, F.W. 282.25, Powder	**1g**
J63667	**5-(N-Methyl-N-isobutyl)amiloride, 98+%** *[MIA]* [96861-65-3], $C_{11}H_{18}ClN_7O$, F.W. 299.76, Powder, MDL MFCD00078567 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inhibitor of Na+/H+ antiporter. Possible antitumor agent	**5mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
H27029	**1-Methylisoquinoline, 97%** [1721-93-3], $C_{10}H_9N$, F.W. 143.19, m.p. 10-12°, b.p. 126-128°/16mm, f.p. >110°(230°F), d. 1.078, n_D^{20} 1.6140, EINECS 217-017-6, MDL MFCD00006902 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	1g 5g
J64389	**7-Methyl lumazine** *[NSC 160394]* [13401-38-2], $C_7H_6N_4O_2$, F.W. 178.15, Powder	25mg
	Methylmaleic anhydride, see Citraconic anhydride, L05238, p. 164 **6-(Methylmercapto)purine**, see 6-(Methylthio)purine, L01836, p. 290 **1-Methyl-7-methoxy-3,4-dihydro-▲-carboline**, see Harmaline, 98+%, J61699, p. 241 **Methyl-(3-methylphenyl)carbamothioic acid O-2-naphthyl ester**, see Tolnaftate, J61834, p. 371	
A13593	**2-Methyl-1,4-naphthoquinone, 98% ▲** *[Menadione, Vitamin K3]* [58-27-5], $C_{11}H_8O_2$, F.W. 172.18, m.p. 104-107°, Merck **14**,5831, EINECS 200-372-6, RTECS QL9100000, BRN 1908453, MDL MFCD00001681, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	10g 50g 250g
	(S)-(+)-Methyl n-propyl carbinol, see (S)-(+)-2-Pentanol, L09314, p. 313 **Methyl 5-n-propylthio-2-benzimidazolecarbamate**, see Albendazole, H25925, p. 83	
A10991	**Methyl octanoate, 99%** *[Methyl caprylate, Octanoic acid methyl ester]* [111-11-5], $CH_3(CH_2)_6CO_2CH_3$, F.W. 158.24, m.p. -40°, b.p. 193-194°, f.p. 72°(161°F), d. 0.875, n_D^{20} 1.4170, EINECS 203-835-0, RTECS RH0778000, BRN 1752270, MDL MFCD00009551, †	50g 250g 1kg
38695	**Methyl Orange, 0.1% w/v aq. soln.** $C_{14}H_{14}N_3NaO_3S$, F.W. 327.34, Liquid, d. 0.987, EINECS 208-925-3, MDL MFCD00007502, Note: Transition interval: pH 3.2 (pink or red) to pH 4.4 (yellow), †	500ml
A17604	**Methyl Orange** *[Acid Orange 52, C.I. 13025]* [547-58-0], $C_{14}H_{14}N_3NaO_3S$, F.W. 327.34, m.p. >300°, Merck **14**,6105, UN3143, EINECS 208-925-3, RTECS DB6327000, BRN 4732884, MDL MFCD00007502, † H:H301, P:P264-P270-P301+P310-P321-P405-P501a Acid-base indicator: pH 3.2 - 4.4. 	25g 100g 500g
L18881	**(R)-(-)-4-Methyl-2-pentanol, 99%** [16404-54-9], $C_6H_{14}O$, F.W. 102.18, b.p. 130-131°, f.p. 41°(105°F), d. 0.802, n_D^{20} 1.4110, $[\alpha]_D^{20}$ -21° (neat), UN2053, BRN 1718992, MDL MFCD03093077 H:H226-H335, P:P262 Application(s): For synthesis of optically active products 	250mg 1g
L18882	**(S)-(+)-4-Methyl-2-pentanol, 99%** [14898-80-7], $C_6H_{14}O$, F.W. 102.18, b.p. 130-131°, f.p. 41°(105°F), d. 0.802, n_D^{20} 1.4110, $[\alpha]_D^{20}$ +21° (neat), UN2053, BRN 1718991, MDL MFCD03093078 H:H226-H335, P:P262 Application(s): For synthesis of optically active products 	250mg 1g
H51685	**1-(2-Methylphenyl)homopiperazine monohydrochloride, 98%** *[2-MPHP·HCl]* $C_{12}H_{18}N_2 \cdot HCl$, F.W. 226.75, m.p. 184-188°, MDL MFCD09953904, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd. Application(s): Useful intermediate for synthesis 	500mg
H51700	**1-(3-Methylphenyl)homopiperazine monohydrochloride, 98%** *[3-MPHP·HCl]* [934991-97-6], $C_{12}H_{18}N_2 \cdot HCl$, F.W. 226.75, m.p. 136-140°, MDL MFCD08436120, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd. Application(s): Useful intermediate for synthesis 	500mg
H51750	**1-(4-Methylphenyl)homopiperazine monohydrochloride, 98%** *[4-MPHP·HCl]* $C_{12}H_{18}N_2 \cdot HCl$, F.W. 226.75, m.p. 177-181°, MDL MFCD16172201, Note: Sold in collaboration with Tosoh Organic Chemical Co., Ltd. Application(s): Useful intermediate for synthesis 	500mg
	(R)-(-)-1-Methylpropylamine, see (R)-(-)-2-Aminobutane, L03889, p. 92 **(S)-(+)-1-Methylpropylamine**, see (S)-(+)-2-Aminobutene, L10069, p. 92 **1-Methyl-9H-pyrido-[3,4-b]indole-7-ol**, see Harmol hydrochloride dihydrate, 98%, J63827, p. 241 **Methyl 2-pyridyl ketone**, see 2-Acetylpyridine, A12688, p. 74 **Methyl 3-pyridyl ketone**, see 3-Acetylpyridine, A14246, p. 74 **N(1)-(4-Methyl-2-pyrimidyl)sulfanilamide**, see Sulfamerazine, L04194, p. 355	

Stock #	Description	Size
43894	**1-Methyl-2-pyrrolidinone, ACS grade, 99.0+%** [872-50-4], C_5H_9NO, F.W. 99.13, Liquid, m.p. -24°, b.p. 204°, f.p. 86°(187°F), d. 1.033, n_D^{20} 1.4705, Merck **14**,6117, Fieser **1**,696 **2**,281 **9**,316, EINECS 212-828-1, RTECS UY5790000, BRN 106420, MDL MFCD00003193, † Maximum level of impurities: Color (APHA) 50, H_2O 0.05%, Free amines (as CH_3NH_2) 0.01%, Cl 1ppm H:H360D-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	500ml 1L 4L 4x1L 4x4L
44063	**1-Methyl-2-pyrrolidinone, Biograde, 99.5%** ■ [872-50-4], C_5H_9NO, F.W. 99.13, Liquid, packaged under Argon, m.p. -24°, b.p. 204°, f.p. 86°(187°F), d. 1.033, n_D^{20} 1.4705, Merck **14**,6117, Fieser **1**,696 **2**,281 **9**,316, EINECS 212-828-1, RTECS UY5790000, BRN 106420, MDL MFCD00003193, Note: Amines (as dimethylamine) <10ppm. H_2O 200ppm, † H:H360D-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a **UV absorption - 1cm cell vs H_2O** λ(nm) 400 350 325 300 285 A 0.01 0.03 0.01 0.50 1.00 Application(s): Suitable for Biotech applications	1L 4L 4x4L
	2-Methylquinoline, see Quinaldine, A13412, p. 333	
38698	**Methyl Red, 0.1% w/v solution in ethanol** $(CH_3)_2NC_6H_4N{=}NC_6H_4CO_2H$, F.W. 269.30, Liquid, UN1170, MDL MFCD00002425, Note: Transition interval: pH 4.2 (pink) to pH 6.2 (yellow), † H:H224, P:P210-P241-P280-P240-P303+P361+P353-P501a	100ml 500ml
A16690	**Methyl Red** *[C.I. 13020]* [493-52-7], $C_{15}H_{15}N_3O_2$, F.W. 269.30, m.p. 179-182°, Merck **14**,6119, EINECS 207-776-1, RTECS DG8960000, BRN 750102, MDL MFCD00002425, † Acid-base indicator: pH 4.2 - 6.2.	100g 500g
36682	**Methyl Red, ACS** *[C.I. 13020]* [493-52-7], $C_{15}H_{15}N_3O_2$, F.W. 269.30, Crystalline, m.p. 179-182°, Merck **14**,6119, Solubility: Practically insoluble in water. Soluble in alcohol, acetic acid, EINECS 207-776-1, RTECS DG8960000, BRN 750102, MDL MFCD00002425, † Specifications: Melting point (range) 179-182°, Clarity of alcohol solution P.T., Visual transition interval from pH 4.2 (pink) to 6.2 (yellow) H:H351-EUH070, P:P281-P201-P202-P308+P313-P405-P501a Application(s): pH indicator in pH range 4.2 - 6.3	25g 100g
36668	**Methyl Red hydrochloride, ACS** *[2-[4-(Dimethylamino)phenyl]azobenzoic acid]* [63451-28-5], $C_{15}H_{15}N_3O_2 \cdot HCl$, F.W. 305.77, Crystalline, m.p. 175° dec., EINECS 264-190-9, MDL MFCD00012614 Specifications: Clarity of alcohol solution P.T., Visual transition interval from pH 4.2 (pink) to 6.2 (yellow) H:H351, P:P281-P201-P202-P308+P313-P405-P501a	25g 100g
36667	**Methyl Red sodium salt, ACS** *[2-[4-(Dimethylamino)phenyl]azobenzoic acid sodium salt]* [845-10-3], $C_{15}H_{14}N_3NaO_2$, F.W. 291.29, Crystalline, EINECS 212-682-9, BRN 4065488, MDL MFCD00002426, † Specifications: Clarity of alcohol solution P.T., Clarity of aqueous solution P.T., Visual transition interval from pH 4.2 (pink) to 6.2 (yellow) H:H302, P:P264-P270-P301+P312-P330-P501a	25g 100g
	5-Methylresorcinol, see 3,5-Dihydroxytoluene, L18567, p. 193 **Methylrosaniline chloride**, see Crystal Violet, B21932, p. 170 **Methyl sulfoxide**, see Dimethyl sulfoxide, 36480, p. 197 **3-Methyl-2-thionoimidazoline-1-carboxylic acid ethyl ester**, see Ethyl 3-methyl-2-thionoimidazoline-1-carboxylate, L08218, p. 217	
L01836	**6-(Methylthio)purine, 97%** *[6-(Methylmercapto)purine]* [50-66-8], $C_6H_6N_4S$, F.W. 166.20, m.p. 220-223°, EINECS 200-057-3, RTECS UO8976000, BRN 7695, MDL MFCD00005576	1g 5g
A17982	**6-Methyl-2-thiouracil, 98%** *[4-Hydroxy-2-mercapto-6-methylpyrimidine]* [56-04-2], $C_5H_6N_2OS$, F.W. 142.18, m.p. ca 329° dec., Merck **14**,6128, EINECS 200-252-3, RTECS YR0875000, BRN 115648, MDL MFCD00006040, † H:H351-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a	50g 250g 1kg
	6-Methyl-1,2,4-triazine-3,5(2H,4H)-dione, see 6-Azathymine, L06762, p. 114 **5-Methyluracil**, see Thymine, A15879, p. 369	

Stock #	Description	Size
B24191	**6-Methyluracil, 97%** *[2,4-Dihydroxy-6-methylpyrimidine]* [626-48-2], $C_5H_6N_2O_2$, F.W. 126.12, m.p. 317-320°, Merck **14**,6133, EINECS 210-949-4, RTECS YR0700000, BRN 115647, MDL MFCD00006028, † H:H361, P:P281-P201-P202-P308+P313-P405-P501a	100g 500g 2.5kg
J64897	**2'-O-Methyluridine, 99%** [2140-76-3], $C_{10}H_{14}N_2O_6$, F.W. 258.23, Powder	1g
	8-Methyl-N-vanillyl-trans-6-nonenamide, see Capsaicin, J62865, p. 146 **Methyl Violet 10B**, see Crystal Violet, B21932, p. 170	
J61545	**Metoclopramide hydrochloride monohydrate** [54143-57-6], $C_{14}H_{22}ClN_3O_2 \cdot HCl \cdot H_2O$, F.W. 354.28 (336.26anhy), Crystalline solid, Merck **14**,6143 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): 5-HT3 serotonin antagonist; D2 dopamine antagonist	10g 25g 100g
J61920	**Metoprolol tartrate, 98+%** *[(±)1-(Isopropylamino)-3-[4-(β-methoxyethyl)phenoxy]-2-propanol (+)-tartrate salt]* [56392-17-7], $(C_{15}H_{25}NO_3)_2.C_4H_6O_6$, F.W. 684.82, Powder, m.p. 120°, Merck **14**,6151, EINECS 260-148-9, RTECS UB7450100, MDL MFCD00056257 Application(s): A β-adrenergic blocker	5g 25g
	Mevacor, see Lovastatin, H52792, p. 273	
J61357	**Mevastatin, 98%** [73573-88-3], $C_{23}H_{34}O_5$, F.W. 390.52, Powder, Merck **14**,6164, BRN 1269441, MDL MFCD05662341 Application(s): Inhibitor of HMG-CoA reductase. Induces apoptosis	5mg 10mg 25mg
	Mexocine, see Demeclocycline hydrochloride, J63102, p. 176	
J62440	**Mezerein, Daphne mezereum** [34807-41-5], $C_{38}H_{38}O_{10}$, F.W. 654.71, 34807-41-5, RTECS HB5425500, BRN 1675867, MDL MFCD00135953 H:H315, P:P280-P264-P302+P352-P321-P362-P332+P313 Application(s): Protein kinase C (PKC) activator. Inflammatory tumor promoter	1mg
	o-3M3FBS, see 2,4,6-Trimethyl-N-[2-(trifluoromethyl)phenyl]benzenesulfonamide, J65391, p. 378 **m-3M3FBS**, see 2,4,6-Trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide, J65999, p. 378	
J63250	**MG 132** *[Z-Leu-Leu-Leu-aldehyde]* [133407-82-6], $C_{26}H_{41}N_3O_5$, F.W. 475.63, Crystalline solid, MDL MFCD00674886 Application(s): Inhibitor of calpain proteases	1mg 5mg 10mg
	MG-341, see Bortezomib, 99%, J60378, p. 134 **MIA**, see 5-(N-Methyl-N-isobutyl)amiloride, 98+%, J63667, p. 288	
J61570	**Mianserin hydrochloride** [21535-47-7], $C_{18}H_{20}N_2 \cdot HCl$, F.W. 300.83, Powder, Merck **14**,6172, EINECS 244-426-7, RTECS HP8780000, MDL MFCD00055072 H:H302, P:P264-P270-P301+P312-P330-P501	100mg
J60872	**Miconazole, 99% ▲** [22916-47-8], $C_{18}H_{14}Cl_4N_2O$, F.W. 416.13, Powder, m.p. 170°, Merck **14**,6178, EINECS 245-324-5, RTECS NI4770000 H:H302-H317, P:P261-P280-P302+P352-P321-P301+P312-P501a Application(s): Inhibits cytochrome P450-dependent 14-α-demethylase	1g 5g 25g
J60796	**(±)-Miconazole nitrate, 98+%** [22832-87-7], $C_{18}H_{14}Cl_4N_2O \cdot HNO_3$, F.W. 479.15, Powder, m.p. 170-185°, Merck **14**,6178, EINECS 245-256-6, RTECS NI4771000, MDL MFCD00058161 H:H302-H317, P:P261-P280-P302+P352-P321-P301+P312-P501 Application(s): Inhibits cytochrome P450-dependent 14α-demethylase	5g 25g
J62917	**Midostaurin** *[PKC412, 4'-N-Benzoylstaurosporine]* [120685-11-2], $C_{35}H_{30}N_4O_4$, F.W. 570.64, Powder, m.p. 235-260°, Merck **14**,6185, MDL MFCD12828879 Application(s): Inhibits a variety of serine/threonine and tyrosine kinases including PKC	1mg 5mg
J64947	**MIF Antagonist, ISO-1 ▲** *[(S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid, methyl ester, Macrophage Migration Inhibitory Factor Antagonist]* [478336-92-4], $C_{12}H_{13}NO_4$, F.W. 235.24, Solid	5mg 25mg
	MIF-I, see Melanocyte-Stimulating Hormone-Release Inhibiting Factor, synthetic, J60045, p. 279 **Milrila**, see Milrinone, 98+%, J62659, p. 292	

Stock #	Description	Size
J62659	**Milrinone, 98+%** *[Corotrope, Milrila]* [78415-72-2], $C_{12}H_9N_3O$, F.W. 211.22, Powder, m.p. 264°, Merck **14**,6197, UN2811, EINECS 278-903-6, RTECS DW1762000, MDL MFCD00133539  H:H300-H311-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Potent cAMP-specific phosphodiesterase inhibitor	**10mg** **50mg** **100mg**
J62592	**Mineral oil, high purity** [8042-47-5], Oily liquid, EINECS 232-455-8, RTECS PY8047000, MDL MFCD00131611, † Application(s): Suitable for PCR applications	**100ml** **500ml**
J61803	**Minoxidil** [38304-91-5], $C_9H_{15}N_5O$, F.W. 209.25, Crystalline powder, m.p. 248-265°, Merck **14**,6203, EINECS 253-874-2, RTECS UV8200000, MDL MFCD00063409 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Stimulates ATP-activated potassium channels	**1g** **5g** **25g**
J65156	**MIRA-1** *[1-[(1-Oxopropoxy)methyl]-1H-pyrrole 2,5-dione]* [72835-26-8], $C_6H_9NO_4$, F.W. 183.16, Powder	**10mg**
J63193	**Mitomycin C** [50-07-7], $C_{15}H_{18}N_4O_5$, F.W. 334.33, Powder, m.p. 360°, Merck **14**,6215, UN2811, EINECS 200-008-6, RTECS CN0700000, BRN 7231816, MDL MFCD00078109, † H:H300-H351, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Antineoplastic agent which inhibits DNA synthesis and induces apoptosis	**1mg** **5mg** **10mg**
	MK-0457, see Tozasertib, 99+%, J63232, p. 372 **MK-217**, see Alendronate sodium trihydrate, 97%, J61397, p. 88 **MK-231**, see Sulindac, J61772, p. 356 **(+)-MK 801 maleate**, see Dizocilpine maleate, 99+%, J63917, p. 200 **MK-933**, see Ivermectin, J62777, p. 262 **MLN518**, see Tandutinib, 99%, J62004, p. 358 **MMLV RT**, see Reverse Transcriptase, murine, Moloney Murine Leukemia Virus, J60167, p. 336	
J65638	**MMP Inhibitor II** *[N-Hydroxy-1,3-bis(4-methoxyphenylsulfonyl)-5,5-dimethylhexahydropyrimidine-2-carboxamide]* [203915-59-7], $C_{21}H_{27}N_3O_8S_2$, F.W. 513.58, Solid	**5mg** **10mg**
J65783	**MMP-3 Inhibitor ▲** *[N-Hydroxy-2(R)-[(4-methoxyphenyl)sulfonyl]-[benzylamino]-4-methylpentanamide]* $C_{20}H_{26}N_2O_5S$, F.W. 406.50, Solid	**5mg**
J64823	**MMP-3 Inhibitor III ▲** *[(S)-3-Phenyl-2-(3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)ureido)propanoic acid]* $C_{12}H_{12}N_4O_3S_2$, F.W. 324.40, Solid	**2mg**
J64368	**MMP-3 Inhibitor VIII ▲** *[(R)-2-(N-benzyl-4-methoxyphenylsulfonamido)-N-hydroxy-4-methylpentanamide]* [208663-26-7], $C_{20}H_{26}N_2O_5S$, F.W. 406.49, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
J64304	**MMP-9 Inhibitor I ▲** *[2-(N-Benzyl-4-methoxyphenylsulfonamido)-5-((diethylamino)methyl)-N-hydroxy-3-methylbenzamide]* [1177749-58-4], $C_{27}H_{33}N_3O_5S$, F.W. 511.63, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**5mg**
J65620	**MMP-2/MMP-3 Inhibitor** *[N-[(4,5-Dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]carbo nyl]-Lphenylalanine methyl ester]* $C_{13}H_{14}N_4O_3S_2$, F.W. 338.40, Solid	**5mg**
J64580	**MMP-9/MMP-13 Inhibitor I ▲** *[N-Hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(4-biphenylcarbonyl)piperazine-2-carboxamide]* [204140-01-2], $C_{25}H_{25}N_3O_6S$, F.W. 459.55, Solid  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1mg**
J60690	**MNE buffer, pH 6.5** Liquid, Note: 20mM MES, 150mM NaCl, 5mM EDTA, pH 6.5	**250ml** **500ml**
	MOBIC, see Meloxicam, J60635, p. 280	
J61416	**MOBS, 0.2M buffer soln., pH 7.0** *[4-(4-Morpholinyl)butanesulfonic acid]* [115724-21-5], Liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100ml** **250ml**

Stock #	Description	Size
J63519	**MOBS, 0.2M buffer soln., pH 7.5** *[4-(4-Morpholinyl)butanesulfonic acid]* [115724-21-5], Liquid ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100ml** **250ml**
J63594	**MOBS, 0.2M buffer soln., pH 8.0** *[4-(4-Morpholinyl)butanesulfonic acid]* [115724-21-5], Liquid ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100ml** **250ml**
J62203	**MOBS, 0.2M buffer soln., pH 8.5** *[4-(4-Morpholinyl)butanesulfonic acid]* [115724-21-5], Liquid ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100ml** **250ml**
L05383	**Molecular sieves, 3A, 0.4-0.8mm (0.02-0.03in) beads** ■ [308080-99-1], MDL MFCD00131613 Molecular sieve of 3 Angstrom pore size useful where dynamic mass transfer needs to be maximized at the expense of physical strength and pressure drop.	**250g** **1kg**
L05335	**Molecular sieves, 3A, 1-2mm (0.04-0.08in) beads** ■ [308080-99-1], MDL MFCD00131613 Molecular sieve of 3 Angstrom pore size of particular use in the drying of liquids, especially methanol and ethanol. A detailed comparison has been made of the drying of various alcohols, using 3A or 4A powder or beads. In general, the powder form is more effective for ethanol, 2-butanol, t-butanol and ethylene glycol, but beads are better for methanol. In all cases studied, 3A sieves were more effective than 4A: *J. Org. Chem.*, **48**, 2420 (1983). Superior drying agent for acetonitrile: *J. Org. Chem.*, **49**, 3852 (1984).	**250g** **1kg** **5kg**
87957	**Molecular sieves, 3A, 1-2mm (0.04-0.08in) dia. pellets** ■ [308080-99-1], Pellets, MDL MFCD00147627	**1kg** **5kg**
33530	**Molecular sieves, 3A, 3-4mm (0.12-0.16in) dia. pellets** ■ [308080-99-1], Pellets, MDL MFCD00147627	**1kg** **5kg**
L05359	**Molecular sieves, 3A, 3-5mm (0.12-0.20in) beads** ■ [308080-99-1], MDL MFCD00131613 Molecular sieve of 3 Angstrom pore size suitable for the drying of small molecular gas streams or where it is essential to exclude large molecules from the micropores to prevent undesirable reactions.	**250g** **1kg**
B21165	**Molecular sieves, 3A, powder** ■ [308080-99-1], MDL MFCD00147627 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **1kg** **5kg**
32256	**Molecular sieves, 4A with indicator, -8+12 (ca 2mm) beads** [70955-01-0], -8+12 Beads, MDL MFCD00147627	**250g** **1kg** **5kg**
L05512	**Molecular sieves, 4A, 0.4-0.8mm (0.02-0.03in) beads** ■ [70955-01-0], MDL MFCD00131613 Molecular sieve of 4 Angstrom pore size useful where dynamic mass transfer needs to be maximized at the expense of physical strength and pressure drop.	**250g** **1kg**
87956	**Molecular sieves, 4A, 1-2mm (0.04-0.08in) dia. pellets** ■ [70955-01-0], Pellets, MDL MFCD00131613	**1kg** **5kg**
88120	**Molecular sieves, 4A, 3-4mm (0.12-0.16in) dia. pellets** ■ [70955-01-0], Pellets, MDL MFCD00131613	**1kg** **5kg**
L05454	**Molecular sieves, 4A, 1-2mm (0.04-0.08in) beads** ■ [70955-01-0], MDL MFCD00131613 Molecular sieve of 4 Angstrom pore size useful in general liquid and gas drying applications.	**250g** **1kg** **5kg**
L05466	**Molecular sieves, 4A, 3-5mm (0.12-0.20in) beads** ■ [70955-01-0], MDL MFCD00131613 Molecular sieve of 4 Angstrom pore size useful in general gas drying applications.	**250g** **1kg** **5kg**
A11535	**Molecular sieves, 4A, powder** ■ [70955-01-0], MDL MFCD00131613 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Unformed molecular sieve of 4 Angstrom pore size useful in homogeneous drying applications.	**250g** **1kg** **5kg**
87955	**Molecular sieves, 5A, 1-2mm (0.04-0.08in) dia. pellets** ■ [69912-79-4], Pellets, MDL MFCD00147627	**1kg** **5kg**

Stock #	Description	Size
33551	**Molecular sieves, 5A, 3-4mm (0.12-0.16in) dia. pellets** ■ [69912-79-4], Pellets, MDL MFCD00147627	**1kg** **5kg**
L05722	**Molecular sieves, 5A, 3-5mm (0.12-0.20in) beads** ■ [69912-79-4], MDL MFCD00131613	**250g** **1kg**
B21109	**Molecular sieves, 13X, 1.6-2.5mm (0.063-0.098in) beads** ■ [63231-69-6], MDL MFCD00131613 Molecular sieve of 8.5 Angstrom pore size for removal of carbon dioxide, water and trace organic constituents in air pre-purification, LPG drying and sweetening, and various hydrocarbon separation processes.	**250g** **1kg** **5kg**
87954	**Molecular sieves, 13X, 1-2mm (0.04-0.08in) dia. pellets** ■ [63231-69-6], 1/16in Pellets, MDL MFCD00131613	**1kg** **5kg**
33550	**Molecular sieves, 13X, 3-4mm (0.12-0.16in) dia. pellets** ■ [63231-69-6], 1/8in Pellets, MDL MFCD00131613	**1kg** **5kg**
L06085	**Molecular sieves, 13X, 3-5mm (0.12-0.20in) beads** ■ [63231-69-6], MDL MFCD00131613	**250g** **1kg** **5kg**
A10378	**Molecular sieves, 13X, powder** ■ [63231-69-6], MDL MFCD00131613 Unformed molecular sieve of 8.5 Angstrom pore size useful in homogeneous separation processes.	**250g** **1kg** **5kg**
J62389	**Molluscan Cardioexcitatory Neuropeptide** *[Phe-Met-Arg-Phe-NH2, FMRF amide]* [64190-70-1], $C_{29}H_{42}N_8O_4S$, F.W. 598.76, Powder, MDL MFCD00076625 Application(s): A neuropeptide involved in neuronal nitric oxide production	**10mg**
J61669	**Monensin sodium salt, 90-95.5%** *[Coban® 3M, Rumensin]* [22373-78-0], $C_{36}H_{61}NaO_{11}$, F.W. 692.86, Powder, m.p. 267-269°, Merck **14**,6246, UN3462, EINECS 244-941-7, RTECS JH2830000, BRN 4122200, MDL MFCD00077826 H:H300, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Antibiotic that functions as an sodium ionophore. Induces apoptosis in HL-60 cells	**1g** **5g**
	Monochloroacetic acid, see Chloroacetic acid, A11482, p. 154 **Monoethylene glycol**, see Ethylene glycol, A11591, p. 216 **Monosodium glutamate**, see L-Glutamic acid monosodium salt, J63424, p. 234 **Monosodium orthophosphate**, see Sodium dihydrogen phosphate monohydrate, 11591, p. 345	
A12914	**MOPS, 99%** *[4-Morpholinepropanesulfonic acid, 3-(4-Morpholinyl)propanesulfonic acid]*  [1132-61-2], $C_7H_{15}NO_4S$, F.W. 209.27, m.p. 277-280° dec., f.p. 110°(230°F), Merck **14**,6265, EINECS 214-478-5, RTECS QE9104530, BRN 1106776, MDL MFCD00006183, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Biological buffer, pKa = 7.2 at 20°C: *Biochemistry*, **5**, 467 (1966). Utilized to promote a mimetic of the transketolase reaction: *Eur. J. Org. Chem.*, 1121 (2006). Application(s): Good's buffer	**25g** **100g** **500g**
J62477	**MOPS, 0.5M buffer soln., pH 5.5** [1132-61-2], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J62476	**MOPS, 0.5M buffer soln., pH 6.0** [1132-61-2], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J63369	**MOPS, 0.5M buffer soln., pH 6.5** [1132-61-2], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J60328	**MOPS, 0.5M buffer soln., pH 7.0** [1132-61-2], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J62839	**MOPS, 0.5M buffer soln., pH 7.5** [1132-61-2], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J61236	**MOPS, 0.5M buffer soln., pH 8.0** [1132-61-2], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62368	**MOPS, 0.5M buffer soln., pH 8.5** [1132-61-2], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J60922	**MOPS, 0.5M buffer soln., pH 9.0** [1132-61-2], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
J62261	**MOPS, 1.0M buffer soln., pH 5.5** [1132-61-2], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J62840	**MOPS, 1.0M buffer soln., pH 6.0** [1132-61-2], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J61797	**MOPS, 1.0M buffer soln., pH 6.5** [1132-61-2], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J61821	**MOPS, 1.0M buffer soln., pH 7.0** [1132-61-2], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J61843	**MOPS, 1.0M buffer soln., pH 7.5** [1132-61-2], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J61958	**MOPS, 1.0M buffer soln., pH 8.0** [1132-61-2], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J62682	**MOPS, 1.0M buffer soln., pH 8.5** [1132-61-2], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J60097	**MOPS, 1.0M buffer soln., pH 9.0** [1132-61-2], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J63986	**MOPS-buffered saline (5X), pH 7.0** [1132-61-2], Liquid, Note: 125mM MOPS and 750mM NaCl, pH 7.0., †	**250ml** **500ml**
J60490	**MOPS-buffered saline (5X), pH 7.2** [1132-61-2], Liquid, Note: 125mM MOPS and 750mM NaCl, pH 7.2, †	**250ml** **500ml**
J61616	**MOPS-buffered saline (5X), pH 7.5** [1132-61-2], Liquid, Note: 125mM MOPS and 750mM NaCl 750 mM, pH 7.5, †	**250ml** **500ml**
J60184	**MOPS-EDTA-sodium acetate buffer (MESA)** Liquid, Note: This buffer contains: 0.4M MOPS, 0.1M sodium acetate and 10mM EDTA at pH 7.0., †	**500ml** **1L**
J60993	**MOPSO, 0.2M buffer soln., pH 6.0** [79803-73-9], Liquid	**100ml** **250ml**
J61833	**MOPSO, 0.2M buffer soln., pH 6.5** [79803-73-9], Liquid	**100ml** **250ml**
J61469	**MOPSO, 0.2M buffer soln., pH 7.0** [79803-73-9], Liquid	**100ml** **250ml**
J60464	**MOPSO, 0.2M buffer soln., pH 7.5** [79803-73-9], Liquid	**100ml** **250ml**
J62847	**MOPS-SDS running buffer (20X)** Liquid, Note: This buffer contains: 1M MOPS, 1M Tris base, 2% SDS and 20mM EDTA at pH 7.7.	**500ml** **1L**
	Mordant Black 3, see Eriochrome® Blue Black B ®Ciba Specialty Chemicals Corp., J63396, p. 210	

Stock #	Description	Size
J61987	**Morphiceptin acetate** *[β-Casomorphin (1-4) amide (bovine)]* [87777-29-5], $C_{28}H_{35}N_5O_5$, F.W. 521.61, Powder Application(s): Agonist for μ-opioid receptors	**25mg** **100mg**
	4-Morpholineethanesulfonic acid monohydrate, see MES monohydrate, A16104, p. 283 **4-Morpholinepropanesulfonic acid**, see MOPS, A12914, p. 294 **2-(4-Morpholinyl)ethanesulfonic acid monohydrate**, see MES monohydrate, A16104, p. 283 **3-(4-Morpholinyl)propanesulfonic acid**, see MOPS, A12914, p. 294 **2-MPHP·HCl**, see 1-(2-Methylphenyl)homopiperazine monohydrochloride, H51685, p. 289 **3-MPHP·HCl**, see 1-(3-Methylphenyl)homopiperazine monohydrochloride, H51700, p. 289 **4-MPHP·HCl**, see 1-(4-Methylphenyl)homopiperazine monohydrochloride, H51750, p. 289 **MRITC**, see 5(6)-Tetramethylrhodamine isothiocyanate, J62258, p. 365 **MTT**, see Thiazolyl Blue tetrazolium bromide, L11939, p. 366	
J63859	**Mucin, bovine submaxillary gland** [84195-52-8], Powder, 400-4000 kDa, EINECS 282-357-4, MDL MFCD00131629 Application(s): Neuraminidase substrate	**100mg** **500mg**
J65685	**Mu-Phe-HomoPhe-fluoromethyl ketone** *[Mu-Phe-HomoPhe-FMK, N-Morpholineurea-phenylalanyl-homophenylalanylfluoromethyl ketone]* $C_{25}H_{30}FN_3O_4$, F.W. 455.52, Powder, MDL MFCD03452972	**5mg** **10mg**
	Muramidase, see Lysozyme, chicken egg white, J60701, p. 274 **Muramyl dipeptide**, see Adjuvant Peptide, J62385, p. 80	
A17540	**Murexide** *[Ammonium purpurate]* [3051-09-0], $C_8H_8N_6O_6$, F.W. 284.19, m.p. >300°, Merck **14**,6306, EINECS 221-266-6, BRN 3582175, MDL MFCD00012777, † Indicator for complexometric titration. Application(s): Indicator for calcium determinations	**10g** **50g** **250g**
	Muriatic acid, see Hydrochloric acid, 33257, p. 247	
J61720	**Muscimol, 99+%** [2763-96-4], $C_4H_6N_2O_2$, F.W. 114.10, Powder, Merck **14**,6312, UN1544, EINECS 220-430-4, RTECS NY3325000, BRN 1618960, MDL MFCD00057894, † H:H300, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Selective GABAa agonist	**5mg** **10mg** **50mg**
	Musculamine, see Spermine, L19562, p. 351	
J61905	**Mycophenolic acid, 99+%** [24280-93-1], $C_{17}H_{20}O_6$, F.W. 320.34, Powder, m.p. 139-141°, Merck **14**,6327, EINECS 246-119-3, RTECS MP8050000, BRN 1295848, MDL MFCD00036814 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Immunosupressant agent. Blocks inosine monophosphate dehydrogenase in the guanosine monophosphate pathway	**1g** **5g** **10g**
	Mycosporan, see Bifonazole, 99%, J63253, p. 125 **Myoinositol**, see myo-Inositol, A13586, p. 257	
J60450	**Myricetin, 98%** *[Cannabiscetin, Delphidenolon 1575]* [529-44-2], $C_{15}H_{10}O_8$, F.W. 318.24, Crystalline solid, m.p. >300°, Merck **14**,6332, EINECS 208-463-2, BRN 332331, MDL MFCD00006827 Application(s): Common flavanol in plants that inhibits phenolsulfotransferase. Strongly inhibits yeast α-glucosidase	**10mg** **25mg** **50mg**
	Myristic acid, see Tetradecanoic acid, A12067, p. 362 **Myristyltrimethylammonium bromide**, see (1-Tetradecyl)trimethylammonium bromide, L10294, p. 362 **Myristyltrimethylammonium chloride hydrate**, see Benzyldimethyl-n-tetradecylammonium chloride hydrate, 98%, J63465, p. 122	
J63072	**Nabumetone** *[4-(6-Methoxy-2-naphthyl)-2-butanone]* [42924-53-8], $C_{15}H_{16}O_2$, F.W. 228.29, Crystalline powder, m.p. 76-78°, Merck **14**,6343, RTECS EL9085000, MDL MFCD00079518 Application(s): Anti-inflammatory, anti-bacterial. A non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase	**5g** **25g**
	β-NAD, see β-Nicotinamide adenine dinucleotide, 98+%, J62337, p. 301 **β-NADH disodium salt trihydrate**, see β-Nicotinamide adenine dinucleotide reduced disodium salt trihydrate, 98%, J61461, p. 302 **β-NADH disodium salt**, see β-Nicotinamide adenine dinucleotide reduced disodium salt, 98%, J61638, p. 302 **NAD oxidoreductase**, see Lactate dehydrogenase, rabbit muscle, J63220, p. 265 **β-NADP monosodium salt**, see β-Nicotinamide adenine dinucleotide phosphate sodium salt, 44126, p. 301 **β-NADP disodium salt**, see β-Nicotinamide adenine dinucleotide phosphate disodium salt, 98+%, J62556, p. 301 **β-NADPH tetrasodium salt**, see β-Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt, 98+%, J62089, p. 302 **β-NADPH tetrasodium salt tetrahydrate**, see β-Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt tetrahydrate, 98+%, J60387, p. 301	

Stock #	Description	Size
J60311	**Naftopidil, 98+%** *[KT-611, 1-[4-(2-Methoxyphenyl)piperazinyl]-3-(1-naphthyloxy)propan-2-ol]* [57149-07-2], $C_{24}H_{28}N_2O_3$, F.W. 392.49, Powder, m.p. 127°, Merck **14**,6356, RTECS TL9336500, MDL MFCD00242741 Application(s): α1-adrenoceptor antagonist; antihypertensive	**5g**
J63249	**Naftopidil hydrochloride, 98+%** *[KT-611 hydrochloride, 4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol hydrochloride]* $C_{24}H_{28}N_2O_3 \cdot HCl$, F.W. 428.96, Powder, m.p. 116-118°, RTECS TL9336500 Application(s): An α1-adrenoceptor antagonist and antihypertensive	**10mg** **50mg**
B25096	**Nalidixic acid, 99%** *[1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid,* *1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid]* [389-08-2], $C_{13}H_{12}N_2O_3$, F.W. 232.24, m.p. 228-230°, Merck **14**,6359, EINECS 206-864-7, RTECS QN2885000, BRN 750515, MDL MFCD00006884 H:H302, P:P264-P270-P301+P312-P330-P501a	**5g** **25g** **100g**
J63550	**Nalidixic acid sodium salt** [3374-05-8], $C_{12}H_{11}N_2NaO_3$, F.W. 254.22, Powder, m.p. >280°, EINECS 222-159-7, RTECS QN2885000, BRN 3580062, MDL MFCD00064376 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): Inhibitor of bacterial DNA gyrase. An antibacterial agent	**5g** **25g** **100g**
J60013	**Naloxone hydrochloride, 98%** [357-08-4], $C_{19}H_{21}NO_4 \cdot HCl$, F.W. 363.84, Crystalline powder, m.p. 200-205°, Merck **14**,6362, EINECS 206-611-0, RTECS QD2275000, MDL MFCD00069322 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A specific opiate antagonist. Blocks the action of sigma-agonists at opioid sites	**100mg** **500mg** **1g**
J60590	**Naltrexone hydrochloride ▲** [16676-29-2], $C_{19}H_{21}NO_4 \cdot HCl$, F.W. 377.86, Powder, Merck **14**,6363, EINECS 240-723-0, RTECS QD2160000, BRN 3580333, MDL MFCD00069324 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A congener of naloxone and also an opioid antagonist	**250mg** **1g**
	NANA, see N-(-)-Acetylneuraminic acid, L13950, p. 74 **Naphazoline nitrate**, see 2-(1-Naphthylmethyl)-2-imidazoline nitrate, L12617, p. 298 **Naphthalene Black 10B**, see Amido Black 10B, A11374, p. 91 **Naphthalene-1-carboxylic acid**, see 1-Naphthoic acid, A10273, p. 297 **Naphthalene-2-carboxylic acid**, see 2-Naphthoic acid, L05102, p. 297 **2,3-Naphthalenediamine**, see 2,3-Diaminonaphthalene, A12993, p. 183 **1,3-Naphthalenediol**, see 1,3-Dihydroxynaphthalene, A17739, p. 192 **1-Naphthalenol**, see 1-Naphthol, A11862, p. 298	
A18542	**α-Naphthoflavone, 97%** *[7,8-Benzoflavone]* [604-59-1], $C_{19}H_{12}O_2$, F.W. 272.31, m.p. 156-159°, EINECS 210-071-1, RTECS QL6250000, BRN 210862, MDL MFCD00004985, † Application(s): An aryl hydrocarbon receptor antagonist	**5g** **25g**
A18543	**β-Naphthoflavone, 98+%** *[5,6-Benzoflavone]* [6051-87-2], $C_{19}H_{12}O_2$, F.W. 272.31, m.p. 162-166°, EINECS 227-958-4, RTECS QL6200000, BRN 18991, MDL MFCD00004986 Application(s): Inhibitor of aryl hydrocarbon hydroxylase	**1g** **5g**
A10273	**1-Naphthoic acid, 98%** *[Naphthalene-1-carboxylic acid]* [86-55-5], $C_{11}H_8O_2$, F.W. 172.18, m.p. 160-162°, b.p. >300°, f.p. 195°(383°F), d. 1.398, Merck **14**,6381, EINECS 201-681-9, RTECS QL0960000, BRN 1908896, MDL MFCD00004007, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a The unprotected acid undergoes lithiation, e.g. with s-BuLi, by stereospecific 1,4-addition, providing a facile route to 1,1,2-trisubstituted 1,2-dihydronaphthalenes: *J. Org. Chem.*, **61**, 5206 (1996).	**25g** **100g**
L05102	**2-Naphthoic acid, 98+%** *[Naphthalene-2-carboxylic acid]* [93-09-4], $C_{11}H_8O_2$, F.W. 172.18, m.p. 182-186°, f.p. 205°(401°F), d. 1.08, Merck **14**,6382, EINECS 202-217-8, RTECS QL1050000, BRN 972039, MDL MFCD00004101, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a The unprotected acid undergoes lithiation, e.g. with s-BuLi, by stereospecific 1,4-addition, providing a facile route to 1,2,2-trisubstituted 1,2-dihydronaphthalenes: *J. Org. Chem.*, **61**, 5206 (1996).	**5g** **25g**
	α-Naphthol, see 1-Naphthol, A11862, p. 298 **β-Naphthol**, see 2-Naphthol, A14564, p. 298	

Stock #	Description	Size
A11862	**1-Naphthol, 99% ▲ △** *[α-Naphthol, 1-Hydroxynaphthalene]* [90-15-3], $C_{10}H_8O$, F.W. 144.17, m.p. 95-97°, b.p. 278-280°, f.p. 125°(257°F), d. 1.28, Merck **14**,6383, Solubility: Soluble in alcohol, benzene, chloroform, ether, UN2811, EINECS 201-969-4, RTECS QL2800000, BRN 1817321, MDL MFCD00003930, † H:H318-H302-H312-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2.5kg**
A14564	**2-Naphthol, 98+% ▲** *[β-Naphthol, 2-Hydroxynaphthalene]* [135-19-3], $C_{10}H_8O$, F.W. 144.17, m.p. 120-124°, b.p. 285-286°, f.p. 153°(307°F), d. 1.280, Merck **14**,6384, UN3077, EINECS 205-182-7, RTECS QL2975000, BRN 742134, MDL MFCD00004067, † H:H400-H302-H332, P:P261-P273-P304+P340-P301+P312-P312-P501a Application(s): Fluorescence indicator	**250g** **1kg** **5kg**
	Naphthol Blue Black, see Amido Black 10B, A11374, p. 91	
A18268	**Naphthol Green B** *[Acid Green 1, C.I. 10020]* [19381-50-1], $C_{30}H_{15}FeN_3Na_3O_{15}S_3$, F.W. 878.47, EINECS 243-010-2, RTECS LJ8930000, MDL MFCD00003886, †	**25g** **100g**
	2-Naphthol hydrogen sulfate potassium salt, see 2-Naphthyl sulfate potassium salt, 44061, p. 298	
B20872	**Naphthol Yellow S** *[C.I. 10316, 5,7-Dinitro-8-hydroxy-2-naphthalenesulfonic acid disodium salt]* [846-70-8], $C_{10}H_4N_2Na_2O_8S$, F.W. 358.20, m.p. >300°, Merck **14**,6393, EINECS 212-690-2, RTECS QK1813000, BRN 2708476, MDL MFCD00003958, Note: C.I. 10316, †	**50g** **250g** **1kg**
	Naphthoresorcinol, see 1,3-Dihydroxynaphthalene, A17739, p. 192 **1-Naphthylamine-6-sulfonic acid**, see 5-Aminonaphthalene-2-sulfonic acid, L03099, p. 97	
J63214	**N-(1-Naphthyl)ethylenediamine dihydrochloride, ACS ▲■** [1465-25-4], $C_{12}H_{14}N_2 \cdot 2HCl$, F.W. 259.18, Powder, m.p. ca 195°, Merck **14**,6409, EINECS 215-981-2, RTECS KV5330000, BRN 3707471, MDL MFCD00012556, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used for colorimetric determination of sulfonamide in blood	**5g** **25g** **100g**
L12617	**2-(1-Naphthylmethyl)-2-imidazoline nitrate, 99% ■** *[Naphazoline nitrate]* [5144-52-5], $C_{14}H_{14}N_2 \cdot HNO_3$, F.W. 273.29, m.p. 168-170°, EINECS 225-915-4, RTECS NJ4376000, BRN 3779329, MDL MFCD00014316 H:H302, P:P264-P270-P301+P312-P330-P501a	**25g** **100g**
B22866	**1-Naphthyl phosphate disodium salt hydrate, 99%** *[Disodium 1-naphthyl phosphate hydrate]* [207569-06-0], $C_{10}H_7Na_2O_4P \cdot xH_2O$, F.W. 268.12(anhy), m.p. >300°, EINECS 218-564-3, BRN 4895811, MDL MFCD00150614 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Substrate for phosphatases: *Methods of Enzymatic Analysis*, 3rd ed., H. U. Bergmeyer, Ed., Verlag Chemie, Weinheim (1984), vol. 4, p102.	**1g** **5g** **25g**
J63004	**1-Naphthyl phosphate monosodium salt monohydrate, 97+%** [81012-89-7], $C_{10}H_8NaO_4P \cdot H_2O$, F.W. 264.15 (246.13anhy), Powder, BRN 1877764, MDL MFCD00150615 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Substrate for determination of phosphatases	**5g** **25g**
J62097	**1-(1-Naphthyl)piperazine hydrochloride** [104113-71-5], $C_{14}H_{16}N_2 \cdot HCl$, F.W. 248.75, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): 5-HT1 serotonin receptor agonist. 5-HT2 serotonin receptor antagonist	**1g** **5g**
44061	**2-Naphthyl sulfate potassium salt, 98%** *[2-Naphthol hydrogen sulfate potassium salt, Potassium 2-naphthyl sulfate]* [1733-89-7], $C_{10}H_7KO_4S$, F.W. 262.33, Powder, m.p. >300°, EINECS 217-072-6, MDL MFCD00004059, †	**250mg** **1g**
	Naproxen, see (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid, L09855, p. 285	
J63103	**Naproxen sodium, 98%** [26159-34-2], $C_{14}H_{13}NaO_3$, F.W. 252.24, Powder, m.p. 259-262°, Merck **14**,6417, EINECS 247-486-2, RTECS QJ1047000, MDL MFCD00058507 Application(s): A cyclooxygenase inhibitor	**5g** **25g** **100g**
	Naringenin, see 4',5,7-Trihydroxyflavanone, L09834, p. 377 **Naringenin-7-rhamnoglucoside**, see Naringin, J63166, p. 299	

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63166	**Naringin** *[Naringenin-7-rhamnoglucoside]* [14259-46-2], $C_{27}H_{32}O_{14}$, F.W. 580.53, Powder, EINECS 238-138-0, RTECS QN6340000, BRN 102012, MDL MFCD00148888 Application(s): A citrus bioflavanoid that inhibits cytochrome P-450 monooxygenase activity	**25g** **100g**
L10163	**Naringin hydrate, 98%** [10236-47-2], $C_{27}H_{32}O_{14}{\cdot}xH_2O$, F.W. 580.55(anhy), m.p. ca 166° dec., $[\alpha]_D^{20}$ -90° (c=1 in ethanol), Merck **14**,6424, EINECS 233-566-4, RTECS QN6340000, BRN 102012, MDL MFCD00149445, † Bitter principle of grapefruit. Application(s): A citrus bioflavanoid that inhibits cytochrome P450 monooxygenase activity 	**10g** **50g**
	Natural Black 1, see Hematoxylin hydrate, A12431, p. 242 **Natural Yellow 18**, see Berberine chloride, J62311, p. 123 **NBD chloride**, see 4-Chloro-7-nitrobenzofurazan, A14165, p. 157 **NBD-F**, see 4-Fluoro-7-nitrobenzofurozan, J61336, p. 224 **NBS**, see N-Bromosuccinimide, A15922, p. 138 **NCS**, see N-Chlorosuccinimide, A10310, p. 159 **NCS 382 sodium salt**, see 6,7,8,9-Tetrahydro-5H-benzocycloheptene-5-ol-4-ylidene acetic acid, J63941, p. 362 **NECA**, see 5'-N-Ethylcarboxamidoadenosine, J60405, p. 215	
J64372	**Necrosis Inhibitor, IM-54** *[1-Methyl-3-(1-methyl-1H-indol-3-yl)-4-(pentylamino)-1H-pyrrole-2,5-dione]* [861891-50-1], $C_{19}H_{23}N_3O_2$, F.W. 325.40, Powder	**5mg**
J65341	**Necrostatin-1 ▲** *[Nec-1, Necroptotic Inhibitor]* [4311-88-0], $C_{13}H_{13}N_3OS$, F.W. 259.33, Powder, MDL MFCD00056916	**20mg**
J64646	**Necrostatin-1, Inactive Control ▲** *[Nec-1i, 5-(Indol-3-ylmethyl)-2-thiohydantoin]* [64419-92-7], $C_{12}H_{11}N_3OS$, F.W. 245.30, Powder	**5mg**
J62793	**Nefazodone hydrochloride, 98+%** *[BMY-13754]* [82752-99-6], $C_{25}H_{32}ClN_5O_2{\cdot}HCl$, F.W. 506.47, Powder, m.p. 186-187°, Merck **14**,6438, MDL MFCD00935760 Application(s): An antidepressant acts by modifying serotonin transmission. Mixed 5-HT2A serotonin receptor antagonist/serotonin uptake inhibitor	**1g** **5g**
	NEM, see N-Ethylmaleimide, L00355, p. 217 **Neocuproine**, see 2,9-Dimethyl-1,10-phenanthroline hemihydrate, A11398, p. 197	
J65680	**α-Neo-Endorphin (1-7)** *[Tyr-Gly-Gly-Phe-Leu-Arg-Lys]* $C_{40}H_{61}N_{11}O_9$, F.W. 839.98, Solid	**10mg** **25mg**
J65819	**[Met5, Lys6] α-Neo-Endorphin (1-6)** *[Tyr-Gly-Gly-Phe-Met-Lys]* $C_{33}H_{47}N_7O_8S$, F.W. 701.83, Solid	**10mg** **25mg**
J64851	**[Met5, Lys6,7] α-Neo-Endorphin (1-7)** *[Tyr-Gly-Gly-Phe-Met-Lys-Lys]* $C_{39}H_{59}N_9O_9S$, F.W. 830, Solid	**10mg** **25mg**
J62922	**Neohesperidin dihydrochalcone hydrate, 98+%** [20702-77-6], $C_{28}H_{36}O_{15}{\cdot}xH_2O$, F.W. 612.58(anhy), Crystalline powder, Merck **14**,6452, EINECS 243-978-6, RTECS LZ5785000, MDL MFCD03840557 Application(s): Artificial sweetener derived from citrus	**5g** **25g**
J61499	**Neomycin sulfate hydrate** [1405-10-3], $C_{23}H_{46}N_6O_{13}{\cdot}3H_2SO_4{\cdot}xH_2O$, F.W. 908.87(anhy), Powder, Merck **14**,6454, EINECS 215-773-1, † H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501 Application(s): An antibiotic. Acts as an inhibitor of protein biosynthesis	**25g** **100g**
	Neonicotine, see (±)-Anabasine, L12089, p. 103	
J62300	**Neostigmine bromide** [114-80-7], $C_{12}H_{19}BrN_2O_2$, F.W. 303.20, Powder, m.p. 175-177°, Merck **14**,6464, UN2811, EINECS 204-054-8, RTECS BR3150000, MDL MFCD00011795 H:H300-H310-H330-H334-H315-H319-H317-H335, P:P301+P310-P304+P340-P305+P351+P338-P320-P330-P361-P405-P501a Application(s): A reversible acetylcholinesterase inhibitor	**250mg** **1g**
	NEPIS, see 2-Ethyl-5-phenylisoxazolium-3'-sulfonate, J61826, p. 217 **Neriine**, see Conessine, 97%, J62617, p. 167	

Stock #	Description	Size
J64864	**Nerve Growth Factor 2.5S, mouse submaxillary gland, 95%** *[NGF-2.5S]* Note: Receptor Grade. Suitable for cell culture. Supplied as an aseptically lyophilized powder.	**10micrograms** **5x10micrograms**
J60711	**Neuraminidase, Clostridium perfringens, 50% w/w sucrose** *[Acyl-neuraminyl hydrolase, EC 3.2.1.18]* [9001-67-6], Lyophilized powder, EINECS 232-624-6, RTECS QQ3450000, MDL MFCD00131711, Note: Minimum 10 units per mg protein. One unit releases one micromole of sialic acid per minute at 37°C and pH 5.0, from bovine submaxillary mucin, † Application(s): A hydrolytic enzyme that removes sialic acid from mucoproteins	**5units** **10units**
J63259	**Neuraminidase, Clostridium perfringens** *[Acyl-neuraminyl hydrolase, EC 3.2.1.18]* [9001-67-6], Lyophilized powder, EINECS 232-624-6, RTECS QQ3450000, MDL MFCD00131711, Note: Minimum 0.5 units per mg dry weight. One unit releases one micromole of sialic acid per minute at 37°C and pH 5.0, from bovine submaxillary mucin, † Application(s): A hydrolytic enzyme that removes sialic acid from mucoproteins	**10mg**
	Neuridine, see Spermine, L19562, p. 351	
J63747	**Neuromedin N** *[Lys-Ile-Pro-Tyr-Ile-Leu]* [92169-45-4], $C_{38}H_{63}N_7O_8$, F.W. 745.96, Lyophilized powder Application(s): Neurotensin-like peptide which can induce hypotension	**10mg**
J63359	**Neurotensin** *[Glp-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu]* [55508-42-4], $C_{78}H_{121}N_{21}O_2$, F.W. 1672.92, Lyophilized powder Application(s): A neuromodulator of dopamine transmission and of anterior pituitary hormone secretion that exhibtis a wide spectrum of pharmacological effects	**1mg** **5mg**
J62461	**Neurotensin (1-6)** *[Glp-Leu-Tyr-Glu-Asn-Lys]* [87620-09-5], $C_{35}H_{52}N_8O_{12}$, F.W. 776.80, Lyophilized powder Application(s): Fragment of neurotensin	**1mg**
J62253	**Neurotensin (1-8)** *[Glp-Leu-Tyr-Glu-Asn-Lys-Pro-Arg]* [80887-44-1], $C_{46}H_{71}N_{13}O_{14}$, F.W. 1030.15, Lyophilized powder Application(s): Neurotensin fragment	**5mg** **25mg**
J63799	**Neurotensin (1-11)** *[Pyr-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-OH]* [74032-89-6], $C_{66}H_{99}N_{19}O_{18}$, F.W. 1446.63, Lyophilized powder Application(s): Fragment of neurotensin	**1mg** **5mg**
J61112	**Neurotensin (8-13)** *[Arg-Arg-Pro-Tyr-Ile-Leu]* [60482-95-3], $C_{38}H_{64}N_{12}O_8$, F.W. 817.00, Lyophilized powder Application(s): Shortest analog of neurotensin with full binding and pharmacological activities	**5mg**
	Neurotensin-related peptide, see Kinetensin, J63865, p. 264	
J60275	**Neutralization solution** Liquid, Note: This solution contains: 1.5M NaCl and 1M Tris, pH range 7.0-7.2.	**250ml** **500ml**
J61379	**Neutral Red, 1% aq. solution, Ready-to-use** *[Basic Red 5, C.I. 50040]* [553-24-2], $C_{15}H_{17}ClN_4$, F.W. 288.78, Liquid, Merck **14**,6488, EINECS 209-035-8, MDL MFCD00012651, † Application(s): Nuclear counterstain useful in pH range 6.8 - 8.0	**500ml** **1L**
J63054	**Neutral Red** *[Basic Red 5, C.I. 50040]* [553-24-2], $C_{15}H_{17}ClN_4$, F.W. 288.78, Powder, m.p. 290° dec., Merck **14**,6488, EINECS 209-035-8, RTECS SG1400000, BRN 3918740, MDL MFCD00012651, † Application(s): Nuclear counterstain useful in pH range 6.8 - 8.0	**1g** **5g** **25g**
J62643	**Neutral Red, ACS** *[Basic Red 5, C.I. 50040]* [553-24-2], $C_{15}H_{17}ClN_4$, F.W. 288.78, Powder, m.p. 290° dec., Merck **14**,6488, EINECS 209-035-8, RTECS SG1400000, BRN 3918740, MDL MFCD00012651, † Application(s): Nuclear counterstain useful in pH range 6.8 - 8.0	**50g** **250g**
	Neutrophil elastase substrate, fluorogenic, see Elastase Substrate V, J60093, p. 205	
J65706	**NF-kB Activation Inhibitor IV ▲** *[(E)-2-Fluoro-4'-methoxystilbene]* $C_{15}H_{13}FO$, F.W. 228.26, Solid ! H:H302, P:P264-P270-P301+P312-P330-P501	**10mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64555	**NF-kB Activation Inhibitor VI, BOT-64 ▲** *[(Z)-6,6-Dimethyl-2-(phenylimino)-6,7-dihydrobenzo[d][1,3]oxathiol-4(5H)-one]* [113760-29-5], $C_{15}H_{15}NO_2S$, F.W. 273.40, Solid	**5mg** **25mg**
	Niacin, see Nicotinic acid, A12683, p. 302 **Niacinamide**, see Nicotinamide, A15970, p. 301	
J61269	**Nicardipine hydrochloride, 98+%** [54527-84-3], $C_{26}H_{29}N_3O_6 \cdot HCl$, F.W. 515.99, Powder, Merck **14**,6495, UN2811, EINECS 259-198-4, RTECS US7972100, MDL MFCD00057327 H:H301-H311-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): L-type calcium channel blocker	**1g** **5g**
J63295	**Nicergoline** *[5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester]* [27848-84-6], $C_{24}H_{26}BrN_3O_3$, F.W. 484.39, Powder, Merck **14**,6496, EINECS 248-694-6, RTECS KE6341000, MDL MFCD00869626 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Cerebral and peripheral vasodilator	**100mg** **1g**
J61204	**Nickel(II) chloride, 0.5M aq. soln.** [7791-20-0], $NiCl_2$, F.W. 129.6, Liquid, †  H:H312-H332-H341-H350-H360-H372-H411, P:P260-P261-P280-P302+P352-P405-P501	**50ml** **100ml**
J61993	**Nickel(II) sulfate, 0.5M aq. soln.** [10101-97-0], $NiSO_4$, F.W. 262.86, Liquid, †  H:H334-H350i-H360D-H372-H341-H315-H317-H411, P:P260-P285-P302+P352-P321-P405-P501a	**50ml** **100ml**
12514	**Nickel(II) sulfate hexahydrate, 98%** [10101-97-0], $NiSO_4 \cdot 6H_2O$, F.W. 262.86 (154.77anhy), Crystalline, d. 2.070, Merck **14**,6517, Solubility: Soluble in water. Slightly soluble in alcohol, methanol, UN3288, EINECS 232-104-9, RTECS QR9600000, MDL MFCD00149813, Note: m.p. 100° -$5H_2O$, 280° -$6H_2O$, †  H:H334-H350i-H360D-H372-H341-H400-H410-H302-H332-H315-H317, P:P273-P201-P309+P311-P501a Application(s): In nickel plating, as mordant in dyeing and in printing textiles	**500g** **2kg**
36336	**Nickel(II) sulfate hexahydrate, ACS, 98.0% min** [10101-97-0], $NiSO_4 \cdot 6H_2O$, F.W. 262.86 (154.77anhy), Powder, d. 2.070, Merck **14**,6517, UN3288, EINECS 232-104-9, RTECS QR9600000, MDL MFCD00149813, Note: m.p. 100° -$5H_2O$, 280° -$6H_2O$, † Maximum level of impurities: Insoluble matter 0.005%, Cl 0.001%, Nitrogen compounds (as N) 0.002%, Co 0.002%, Mg 0.005%, Mn 0.002%, K 0.01%, Na 0.05%, Cu 0.005%, Fe 0.001%, Ca 0.005%  H:H334-H350i-H360D-H372-H341-H400-H410-H302-H332-H315-H317, P:P273-P201-P309+P311-P501a	**100g** **500g** **2.5kg**
J60879	**Nicorandil, 98+%** *[2-(3-Pyridylcarbonylamino)ethyl nitrate]* [65141-46-0], $C_8H_9N_3O_4$, F.W. 211.17, Powder, m.p. 92-93°, Merck **14**,6521, EINECS 265-514-1, RTECS US4667600, MDL MFCD00186520 H:H302-H318, P:P280-P264-P305+P351+P338-P310-P301+P312-P501 Application(s): A vasodilator that activates ATP-sensitive potassium channels	**250mg** **1g**
A15970	**Nicotinamide, 99%** *[Niacinamide, Pyridine-3-carboxamide]* [98-92-0], $C_6H_6N_2O$, F.W. 122.13, m.p. 128-132°, f.p. 182°(360°F), d. 1.40, Merck **14**,6523, EINECS 202-713-4, RTECS QS3675000, BRN 383619, MDL MFCD00006395, †  H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): The amide of nicotinic acid (vitamin B-3)	**100g** **250g** **1kg**
J62337	**β-Nicotinamide adenine dinucleotide, 98+%** *[β-NAD]* [53-84-9], $C_{21}H_{27}N_7O_{14}P_2$, F.W. 663.43, Powder, Merck **14**,6344, EINECS 200-184-4, RTECS UU3450000, BRN 3584133, MDL MFCD00036253, †	**1g** **5g** **25g**
44126	**β-Nicotinamide adenine dinucleotide phosphate monosodium salt** *[β-NADP monosodium salt, Triphosphopyridine nucleotide monosodium salt]* [1184-16-3], $C_{21}H_{27}N_7NaO_{17}P_3$, F.W. 765.40, Powder, EINECS 214-664-6, BRN 4779954, MDL MFCD00036973 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250mg** **1g**
J62556	**β-Nicotinamide adenine dinucleotide phosphate disodium salt, 97%** *[β-NADP disodium salt]* [24292-60-2], $C_{21}H_{26}N_7Na_2O_{17}P_3$, F.W. 787.37, Powder, EINECS 246-129-8, MDL MFCD00065390	**250mg** **1g**
J60387	**β-Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt hydrate, 98+%** *[β-NADPH tetrasodium salt tetrahydrate]* $C_{21}H_{26}N_7Na_4O_{17}P_3 \cdot xH_2O$, F.W. 905.42 (833.35anhy), Powder	**100mg** **500mg**

Stock #	Description	Size
J62089	**β-Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt, 95% ▲** *[β-NADPH tetrasodium salt]* [2646-71-1], $C_{21}H_{26}N_7Na_4O_{17}P_3.3H_2O$, F.W. 833.35, Powder, EINECS 220-163-3, MDL MFCD00036263	100mg 500mg
J61461	**β-Nicotinamide adenine dinucleotide reduced disodium salt trihydrate, 98%** *[β-NADH disodium salt trihydrate]* $C_{21}H_{27}N_7Na_2O_{14}P_2·3H_2O$, F.W. 763.46 (709.41anhy), Powder	1g 5g
J61638	**β-Nicotinamide adenine dinucleotide reduced disodium salt, 98%** *[β-NADH disodium salt]* [606-68-8], $C_{21}H_{27}N_7Na_2O_{14}P_2$, F.W. 709.41, Powder, EINECS 210-123-3, BRN 5230241, MDL MFCD00036200, †	1g 5g
A12398	**(S)-(-)-Nicotine, 99% ▲△■** [54-11-5], $C_{10}H_{14}N_2$, F.W. 162.24, m.p. -79°, b.p. 245-248°, f.p. 101°(213°F), d. 1.017, n_D^{20} 1.5265, $[\alpha]_D^{20}$ -168° (neat), Merck **14**,6524, UN1654, EINECS 200-193-3, RTECS QS5250000, BRN 82109, MDL MFCD00006369, † H:H301-H310-H411, P:P301+P310-P361-P302+P350-P321-P405-P501a	25g 100g
A12683	**Nicotinic acid, 99%** *[Niacin, Pyridine-3-carboxylic acid]* [59-67-6], $C_6H_5NO_2$, F.W. 123.11, m.p. 236-239°, f.p. 293°(559°F), d. 1.4, Merck **14**,6525, EINECS 200-441-0, RTECS QT0525000, BRN 109591, MDL MFCD00006391, † H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): Vitamin of the B complex with hypolipidemic properties occurring in various animal and plant tissues. Required by the body for the formation of coenzymes NAD and NADP	250g 1kg 5kg
J64759	**Nicotinic acid adenine dinucleotide phosphate tetrasodium salt** *[NAADP, NAADP tetrasodium salt]* [5502-96-5], $C_{21}H_{23}N_8Na_4O_{18}P_3$, F.W. 832.32, Solid, MDL MFCD00274064 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	10mg
	Nicotinoyl-Gly-OH, see Nicotinuric acid, 98+%, J62215, p. 302	
J62215	**Nicotinuric acid, 98+%** *[Nicotinylglycine, Nicotinoyl-Gly-OH]* [583-08-4], $C_8H_8N_2O_3$, F.W. 180.16, Crystalline powder, EINECS 209-497-0, MDL MFCD00023578 Application(s): The major detoxification product of nicotinic acid. A nicotinic acid antagonist	5g 25g
	Nicotinylglycine, see Nicotinuric acid, 98+%, J62215, p. 302	
J62811	**Nifedipine, 98%** [21829-25-4], $C_{17}H_{18}N_2O_6$, F.W. 346.33, Powder, m.p. 171-175°, Merck **14**,6528, EINECS 244-598-3, RTECS US7975000, MDL MFCD00057326 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): L-type calcium channel blocker; induces apoptosis in human glioblastoma cells	5g 25g 100g
J60489	**Niflumic acid, 99+% ▲** *[2-[3-(Trifluoromethyl)anilino]nicotinic acid, 2-(α,α,α-Trifluoro-m-toluidino)nicotinic acid]* [4394-00-7], $C_{13}H_9F_3N_2O_2$, F.W. 282.22, Crystalline powder, m.p. 203-204°, Merck **14**,6531, UN2811, EINECS 224-516-2, RTECS QT2999100, MDL MFCD00010569 H:H301-H312-H332-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Selective cyclooxygenase-2 (COX-2) inhibitor. A NSAID found to be a potent anion channel blocker	5g 10g 50g
J61349	**Nigericin sodium salt, 98+%** *[Antibiotic K178 sodium salt]* [28380-24-7], $C_{40}H_{67}NaO_{11}$, F.W. 746.94, Powder, Merck **14**,6541, UN3462, RTECS QT6840000, BRN 3892398, MDL MFCD00036825 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A potassium ionophore	10mg 50mg
J61186	**Nigrosin, alcohol soluble** *[Solvent Black 5, C.I. 50415]* [11099-03-9], Powder, RTECS GE5800000, MDL MFCD00149005, †	25g 100g 1kg
A18147	**Nigrosin water soluble** *[Acid Black 2, C.I. 50420]* [8005-03-6], RTECS GC4762250, MDL MFCD00044681, † Application(s): Fairly common biological stain for tissues and cells	25g 100g
A17174	**Nile Blue A** *[C.I. 51180, Basic Blue 12]* [3625-57-8], $C_{40}H_{40}N_6O_6S$, F.W. 732.84, m.p. >300° dec., EINECS 222-832-5, RTECS DJ1931000, MDL MFCD00064529	5g 25g

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62578	**Nilotinib, 99+%** *[AMN107]* [641571-10-0], $C_{28}H_{22}F_3N_7O$, F.W. 529.52, Powder, m.p. 230-242°, RTECS CV5581770 H:H360, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Tyrosine kinase inhibitor specifically targeting Bcr-Abl	**100mg** **500mg**
J63699	**Nimesulide** *[N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide]* [51803-78-2], $C_{13}H_{12}N_2O_5S$, F.W. 308.31, Needle-like crystals, m.p. 145-147°, Merck **14**,6548, UN2811, EINECS 257-431-4, RTECS PB0970000, MDL MFCD00079470 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Highly selective cyclooxygenase-2 inhibitor which induces apoptosis	**5g** **25g**
J61287	**Nimodipine, 98+%** [66085-59-4], $C_{21}H_{26}N_2O_7$, F.W. 418.44, Powder, Merck **14**,6551, EINECS 266-127-0, RTECS US7975500, MDL MFCD00153848 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501a Application(s): Potent L-type calcium channel antagonist	**500mg** **1g** **5g**
43846	**Ninhydrin, ACS reagent ▲** *[2,2-Dihydroxy-1,3-indanedione]* [485-47-2], $C_9H_6O_4$, F.W. 178.14, Crystalline, m.p. 251° dec., Merck **14**,6554, Fieser **1**,732 **4**,356, Solubility: Soluble in water and alcohol, EINECS 207-618-1, RTECS NK5425000, BRN 1910963, MDL MFCD00003791, † Maximum level of impurities: Appearance White to brownish-white crystals, Identification and melting point P.T., Solubility P.T., Sensitivity to amino acids P.T.  H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Reagent for determination of amino acids and amine containing compounds, as an intermediate.	**25g** **100g** **500g**
B24723	**Nipecotic acid, 98%** *[H-DL-Nip-OH, (+/-)-Piperidine-3-carboxylic acid]* [498-95-3], $C_6H_{11}NO_2$, F.W. 129.16, m.p. ca 261° dec., Merck **14**,6561, Solubility: Soluble in water, EINECS 207-873-9, RTECS TM6125380, BRN 81096, MDL MFCD00005992  H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): GABA reuptake inhibitor	**1g** **5g** **25g**
	Nitogenin, see Diosgenin, J60976, p. 198	
J60281	**Nitrazine Yellow** *[C.I. 14890, Delta Yellow]* [5423-07-4], $C_{16}H_8N_4Na_2O_{11}S_2$, F.W. 542.36, Powder, MDL MFCD00003938, † Application(s): pH indicator	**1g** **5g** **25g**
J60841	**Nitrendipine** [39562-70-4], $C_{18}H_{20}N_2O_6$, F.W. 360.36, Powder, EINECS 254-513-1, RTECS US5653000, MDL MFCD00082255 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501 Application(s): L-type calcium channel blocker	**100mg** **1g**
35624	**Nitric acid, 1.0N Standardized Solution** [7697-37-2], HNO_3, F.W. 63.01, Liquid, UN3624, EINECS 231-714-2, MDL MFCD00011349, † H:H330-H314, P:P280-P303+P361+P353-P305+P351+P338-P310	**500ml** **1L**
36515	**Nitrilotriacetic acid, ACS, 98.0% min** *[Tris(carboxymethyl)amine, N,N-Bis(carboxymethyl)glycine]* [139-13-9], $N(CH_2CO_2H)_3$, F.W. 191.14, Powder, m.p. 246° dec., Merck **14**,6579, EINECS 205-355-7, RTECS AJ0175000, BRN 1710776, MDL MFCD00004287, Note: Clarity of solution passes test, † H:H351-H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Chelating and sequestering agent. Used in the manufacture of synthetic detergents	**100g** **500g**
	2,2',2''-Nitrilotriethanol, see Triethanolamine, L04486, p. 376 **2,2',2''-Nitrilotriethanol hydrochloride**, see Triethanolamine hydrochloride, A15678, p. 376	
J60230	**Nitro Blue Tetrazolium chloride, 99%** *[Nitro BT, Nitrotetrazolium Blue chloride]* [298-83-9], $C_{40}H_{30}Cl_2N_{10}O_6$, F.W. 817.65, Crystalline powder, m.p. ca 190° dec., EINECS 206-067-4, RTECS XF8045000, BRN 4115923, MDL MFCD00012159, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Intense blue dye used in histochemistry determinations	**1g** **5g**
	Nitro BT, see Nitro Blue Tetrazolium chloride, 99%, J60230, p. 303	
J62541	**Nitrocellulose stripping buffer (10X)** Liquid, Note: This buffer contains 0.5X SSC and 100 mM EDTA at pH 8.0. To strip the membrane perform 2 to 3 changes (15 seconds each) of boiling hot stripping buffer., †	**250ml** **500ml**

Stock #	Description	Size
A18593	**5-Nitro-2-furaldehyde semicarbazone, 98+% ▲** *[Furacin, Nitrofurazone]* [59-87-0], $C_6H_6N_4O_4$, F.W. 198.14, m.p. ca 240° dec., Merck **14**,6600, EINECS 200-443-1, RTECS LT7700000, BRN 86403, MDL MFCD00003225, † H:H341-H351-H361-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): Bactericidal compound used as an antibiotic	**25g** **100g** **250g**
B24079	**Nitrofurantoin, 98% ▲■** *[N-(5-Nitro-2-furfurylidene)-1-aminohydantoin]* [67-20-9], $C_8H_6N_4O_5$, F.W. 238.16, m.p. ca 265° dec., EINECS 200-646-5, MDL MFCD00003224, † H:H334-H341-H351-H361-H302-H317, P:P285-P261-P302+P352-P321-P405-P501a Application(s): An antibiotic used to treat urinary tract infections	**25g** **100g** **500g**
	Nitrofurazone, see 5-Nitro-2-furfurylidene semicarbazone, A18593, p. 304 **5-Nitrofurfural semicarbazone**, see 5-Nitro-2-furfurylidene semicarbazone, A18593, p. 304 **N-(5-Nitro-2-furfurylidene)-1-aminohydantoin**, see Nitrofurantoin, B24079, p. 304 **3-(5-Nitrofurfurylideneamino)-2-oxazolidinone**, see Furazolidone, B20834, p. 229	
L07970	**7-Nitro-1H-indazole, 98%** [2942-42-9], $C_7H_5N_3O_2$, F.W. 163.14, m.p. 184-189°, EINECS 220-934-4, RTECS NK7962200, BRN 6809, MDL MFCD00022789 H:H341-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Nitrix oxide synthase inhibitor	**1g** **5g** **25g**
	N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide, see Nimesulide, J63699, p. 303	
J61401	**4-Nitrophenyl phosphate disodium salt hexahydrate, 5mg tablets** *[pNPP disodium salt, Disodium 4-nitrophenyl phosphate]* [4264-83-9], $C_6H_4NNa_2O_6P{\cdot}6H_2O$, F.W. 371.15 (263.05anhy), Tablets, EINECS 224-246-5, BRN 5324661, MDL MFCD00066288, † Application(s): Substrate for alkaline and acid phosphatase determinations	**100pcs** **1000pcs**
A12310	**4-Nitrophenyl phosphate disodium salt hexahydrate, 98%** [4264-83-9], $C_6H_4NNa_2O_6P{\cdot}6H_2O$, F.W. 371.15 (253.06anhy), m.p. >300°, EINECS 224-246-5, BRN 5324661, MDL MFCD00007319, † Chromogenic substrate for phosphatases: *Methods of Enzymatic Analysis*, 3rd ed., H. U. Bergmeyer, Ed., Verlag Chemie, Weinheim (1984), vol. 4, p76. Application(s): Substrate for alkaline and acid phosphatase determinations	**5g** **25g** **100g**
	N-Nitroso-N-phenylhydroxylamine ammonium salt, see Cupferron, 97+%, A16551, p. 170 **Nitrotetrazolium Blue chloride**, see Nitro Blue Tetrazolium chloride, 99%, J60230, p. 303 **L-NMMA**, see Nω-Methyl-L-arginine acetate, 99+%, J60890, p. 286 **Nonanoic acid cholesteryl ester**, see Cholesteryl nonanoate, L02857, p. 161	
A19166	**(+)-Nootkatone, crystalline, 98+%** [4674-50-4], $C_{15}H_{22}O$, F.W. 218.34, m.p. 34-36°, b.p. 125°/0.5mm, f.p. 99°(210°F), d. 0.997, $[\alpha]_D^{20}$ +185° (c=1 in chloroform), EINECS 225-124-4, BRN 4676969, MDL MFCD00036591, †	**1g** **5g** **25g**
L08087	**L-Noradrenaline, 98% ▲△** *[L-Arterenol, L-Norepinephrine]* [51-41-2], $C_8H_{11}NO_3$, F.W. 169.18, m.p. ca 220° dec., $[\alpha]_D^{20}$ -45° (c=5 in 0.5 N HCl), Merck **14**,6695, UN2811, EINECS 200-096-6, RTECS DN5950000, BRN 4231961, MDL MFCD00025592 H:H300, P:P264-P270-P301+P310-P321-P405-P501a	**1g**
L03149	**Nordihydroguaiaretic acid, 97%** *[1,4-Bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane]* [500-38-9], $C_{18}H_{22}O_4$, F.W. 302.37, m.p. 184-188°, Merck **14**,6693, EINECS 207-903-0, RTECS UX1750000, BRN 2056825, MDL MFCD00002206 H:H302-H315-H319-H335, P:P280h-P305+P351+P338 Naturally-occurring antioxidant. Application(s): Naturally occuring antioxidant and inhibitor of lipoxygenase	**1g** **5g**
	L-Norepinephrine, see L-Noradrenaline, L08087, p. 304	
J62652	**Norfloxacin** *[Baccidal, Sebercim]* [70458-96-7], $C_{16}H_{18}FN_3O_3$, F.W. 319.33, Powder, m.p. 220-221°, Merck **14**,6700, EINECS 274-614-4, RTECS VB5005000, MDL MFCD00079532 Application(s): A synthetic fluoroquinolone antibiotic	**1g** **5g** **25g**
L08257	**D-(-)-Norleucine, 99%** *[(R)-(-)-2-Aminohexanoic acid, H-D-Nle-OH]* [327-56-0], $C_6H_{13}NO_2$, F.W. 131.18, m.p. >300°, $[\alpha]_D^{20}$ -23° (c=5 in 5N HCl), Merck **14**,6706, EINECS 206-320-9, BRN 1721749, MDL MFCD00008099	**1g** **5g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
L03913	**L-(+)-Norleucine, 99%** *[(S)-(+)-2-Aminohexanoic acid, H-Nle-OH]* [327-57-1], $C_6H_{13}NO_2$, F.W. 131.18, m.p. >300°, $[\alpha]_D^{20}$ +23° (c=5 in 5N HCl), Merck **14**,6706, EINECS 206-321-4, RTECS RC6308000, BRN 1721750, MDL MFCD00064423, † Internal standard for amino acid analysis: *Anal. Biochem.*, **150**, 174 (1985). 	**1g** **5g** **25g**
L10809	**DL-Nornicotine, 98% ■** *[DL-2-(3-Pyridyl)pyrrolidine]* [5746-86-1], $C_9H_{12}N_2$, F.W. 148.21, b.p. 107-108°/2mm, f.p. 101°(213°F), d. 1.074, n_D^{20} 1.5490, Merck **14**,6712, UN2810, RTECS QS6350000, BRN 81968, MDL MFCD00016913 ! H:H302-H312-H332-H315-H319, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a Application(s): Nicotinic acetylcholine receptor agonist. Tobacco alkaloid 	**10mg** **50mg**
A15900	**DL-Norvaline, 98%** *[(+/-)-2-Aminopentanoic acid, DL-2-Aminovaleric acid]* [760-78-1], $C_5H_{11}NO_2$, F.W. 117.15, m.p. >300°, Merck **14**,6716, EINECS 212-082-7, BRN 1721163, MDL MFCD00064420, † 	**100g** **500g**
B23444	**D-Norvaline, 99%** *[(R)-2-Aminopentanoic acid, D-2-Aminovaleric acid]* [2013-12-9], $C_5H_{11}NO_2$, F.W. 117.15, m.p. >300°, $[\alpha]_D^{20}$ -25° (c=10 in 20% HCl), Merck **14**,6716, EINECS 217-936-2, BRN 1721161, MDL MFCD00008097 	**1g** **5g** **25g**
L08658	**L-Norvaline, 99%** *[(S)-2-Aminopentanoic acid, L-2-Aminovaleric acid]* [6600-40-4], $C_5H_{11}NO_2$, F.W. 117.15, m.p. >300°, $[\alpha]_D^{20}$ +25° (c=10 in 20% HCl), Merck **14**,6716, EINECS 229-543-3, BRN 1721162, MDL MFCD00064421 	**1g** **5g**
J60928	**Novobiocin sodium salt** [1476-53-5], $C_{31}H_{36}N_2NaO_{11}$, F.W. 634.61, Powder, m.p. 215°, Merck **14**,6722, EINECS 216-023-6, RTECS RD5425000, BRN 3892910 ! H:H319-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a Application(s): Topoisomerase II inhibitor	**1g** **5g** **10g**
J60766	**NP-40 lysis buffer** Liquid, Note: This buffer contains: 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1%NP-40 and 5mM EDTA., †	**250ml** **500ml**
J62805	**NP-40 lysis buffer (2X)** Liquid, Note: This buffer contains: 100mM Tris-HCl (pH 7.4), 300mM NaCl, 2% NP-40, and 10mM EDTA.	**125ml** **250ml**
J61428	**NP-40 lysis buffer, high salt** Liquid, Note: This buffer contains: 50mM Tris-HCl (pH 7.4), 500mM NaCl, 1% NP-40 and 5mM EDTA.	**250ml** **500ml**
J60902	**NP-40 lysis buffer, low salt** Liquid, Note: This buffer contains: 50mM Tris-HCl (pH 7.4), 1% NP-40, and 5mM EDTA.	**250ml** **500ml**
J60143	**NP-40 lysis buffer with glycerol (2X)** Liquid, Note: This buffer contains: 100mM Tris-HCl (pH 8.0), 300mM sodium chloride, 2% NP-40, 10mM EDTA, and 10% glycerol.	**125ml** **250ml**
J60838	**NP-40 permeating solution in PBS (10X)** Liquid, Note: 1 % (v/v) NP-40 in 10X PBS., † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	**250ml** **500ml**
J62410	**NP-40 permeating solution in TBS (10X)** Liquid, Note: 1 % (v/v) NP-40 in 10X TBS.	**250ml** **500ml**
	NSC 7908, see 1,2,3,4,5,6-Hexabromocyclohexane, J60853, p. 244	
J64979	**NSC 23766 ▲■** *[Rac1 Inhibitor]* [733767-34-5], $C_{24}H_{35}N_{7}{}_{3}HCl$, F.W. 530.96, Powder	**10mg**
	NSC-85998, see Streptozotocin, 98%, J61601, p. 352 **NSC 122023**, see Valinomycin, 90+%, J62312, p. 390 **NSC 101806**, see 8-Cyclopentyl-1,3-dimethylxanthine, J61565, p. 172 **NSC 122750**, see Geldanamycin, 99+%, J63397, p. 231 **NSC 339554**, see Bryostatin 2, J61551, p. 139 **NTA**, see Nitrilotriacetic acid, 36515, p. 303	
J62974	**Nylon membrane stripping buffer (10X)** Liquid, Note: This buffer contains 10mM Tris-HCl (pH 8.0) and 10mM EDTA. To strip the membrane incubate for 2 hours in the stripping buffer at 75C.	**250ml** **500ml**
J62486	**Nystatin** [1400-61-9], $C_{47}H_{75}NO_{17}$, F.W. 926.09, Fine powder, m.p. 160°, Merck **14**,6736, EINECS 215-749-0, RTECS RF5950000 Application(s): Increases the permeability of the cell membrane of sensitive fungi by binding to sterols	**5g** **10g**

Stock #	Description	Size
J60555	**NZCYM medium** Liquid, Note: Ingredients (per liter amounts): 10g NZ amine, 5g NaCl, 5g Bacto yeast extract,1g Casamino acids and 2g magnesium sulfate heptahydrate Application(s): NZCYM Medium is used for cultivating recombinant strains of Escherichia coli	**500ml** **1L**
J61680	**NZM medium** Liquid, Note: Ingredients (per liter amounts): 10g NZ amine, 5g NaCl, and 2g magnesium sulfate heptahydrate Application(s): For the cultivation of recombinant strains of Escherichia coli. NZM medium is a modification of NZCYM medium	**500ml** **1L**
J60918	**NZYM medium** Liquid, Note: Ingredients (per liter amounts: 10g NZ amine, 5g NaCl, 5g Bacto yeast extract, 2g magnesium sulfate heptahydrate Application(s): NZYM Medium is used for cultivating recombinant strains of Escherichia coli	**500ml** **1L**
	3,4,5,6,3',5',3'',5''-Octabromophenolsulfonphthalein, see Tetrabromophenol Blue, B20123, p. 361 **Octadecanoic acid cholesteryl ester**, see Cholesteryl stearate, A14771, p. 161 **cis-9-Octadecenoic acid**, see Oleic acid, 31997, p. 307 **trans-9-Octadecenoic acid**, see Elaidic acid, A14832, p. 205 **Octadehydroarachidonic acid**, see 5,8,11,14-Eicosatetraynoic acid, J61624, p. 204 **1-Octanesulfonic acid sodium salt**, see Sodium 1-octanesulfonate, A14292, p. 347 **Octanoic acid methyl ester**, see Methyl caprylate, A10991, p. 289	
L11502	**(R)-(-)-2-Octanol, 99%** [5978-70-1], $C_8H_{18}O$, F.W. 130.23, b.p. 179-180°, f.p. 76°(169°F), d. 0.819, n_D^{20} 1.4260, $[\alpha]_D^{20}$ -10° (c=1 in ethanol), Merck **14**,6752, EINECS 227-777-0, BRN 1719324, MDL MFCD00064284, † ! H:H319, P:P261-P305+P351+P338	**1g** **5g**
L12425	**(S)-(+)-2-Octanol, 99%** [6169-06-8], $C_8H_{18}O$, F.W. 130.23, b.p. 179-180°, f.p. 76°(169°F), d. 0.819, n_D^{20} 1.4260, $[\alpha]_D^{20}$ +10° (c=1 in ethanol), Merck **14**,6752, EINECS 228-213-6, BRN 1719323, MDL MFCD00064283, † ! H:H319, P:P261-P305+P351+P338	**1g** **5g**
J63574	**N-Octanoyl-N-methylglucamine** *[MEGA-8, N-(D-Glucityl)-N-methyloctanamide]* [85316-98-9], $C_{15}H_{31}NO_6$, F.W. 321.41, Powder, m.p. 88-89°, BRN 5816747, MDL MFCD00134152 Application(s): Non-ionic detergent for solubilizing membrane proteins	**1g** **5g**
J60071	**(S)-1-Octen-3-ol** [24587-53-9], $C_8H_{16}O$, F.W. 128.21, Liquid, MDL MFCD04972323 ! H:H302-H332-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**Call**
J61281	**(±)-Octopamine hydrochloride, 99%** *[α-(Aminomethyl)-4-hydroxybenzyl alcohol hydrochloride]* [770-05-8], $C_8H_{11}NO_2 \cdot xHCl$, F.W. 189.64, Powder, m.p. 170° dec., Merck **14**,6759, EINECS 212-216-4, BRN 3915414, MDL MFCD00012881 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): α-adrenoceptor agonist; invertebrate neurotransmitter and neuromodulator	**1g** **5g** **10g**
	Octoxynol-9, see Triton® X-100, A16046, p. 383	
L13259	**n-Octyl-β-D-glucopyranoside** *[n-Octyl-β-D-glucoside, OGD]* [29836-26-8], $C_{14}H_{28}O_6$, F.W. 292.37, m.p. 103-104°, $[\alpha]_D^{20}$ -31° (c=2 in methanol), EINECS 249-887-8, BRN 84118, MDL MFCD00063288 Nonionic dialyzable detergent. Application(s): Non-ionic detergent for membrane proteins	**250mg** **1g**
	n-Octyl-β-D-glucoside, see n-Octyl-β-D-glucopyranoside, L13259, p. 306 **Octylphenyl-polyethylene glycol**, see Igepal CA-630® Rhodia, J61055, p. 253 **n-Octyltetraoxyethylene**, see Tetraethylene glycol monooctyl ether, J62496, p. 362	
J61028	**n-Octyl-β-D-thioglucopyranoside, 98+%** *[Octyl thioglucoside]* [85618-21-9], $C_{14}H_{28}O_5S$, F.W. 308.44, Crystalline powder, m.p. 128°, BRN 4182783, MDL MFCD00012189 Application(s): Non-ionic detergent used for the solubilization of membrane proteins	**2.5g** **5g** **10g**
	Octyl thioglucoside, see n-Octyl-β-D-thioglucopyranoside, 98+%, J61028, p. 306 **ODQ**, see 1H-[1,2,4]Oxadiazolo[4,3-a]-quinoxalin-1-one, 99+%, J62250, p. 310 **Oflocet**, see Ofloxacin, J62080, p. 306	
J62080	**Ofloxacin** *[Oflocet, Ofloxacine]* [82419-36-1], $C_{18}H_{20}FN_3O_4$, F.W. 361.37, Crystalline powder, m.p. 270-275°, Merck **14**,6771, RTECS UU8815500, MDL MFCD00226105 Application(s): Fluorinated nalidixic acid analog with broad-spectrum antibacterial activity	**1g** **5g**
	Ofloxacine, see Ofloxacin, J62080, p. 306	

Contact us for pricing on bulk sizes

Stock #	Description	Size
	OGD, see n-Octyl-β-D-glucopyranoside, L13259, p. 306	
A12989	**Oil Red O** *[C.I. 26125, Solvent Red 27]* [1320-06-5], $C_{26}H_{24}N_4O$, F.W. 408.51, m.p. ca 166° dec., EINECS 215-295-3, BRN 3491382, MDL MFCD00003898, †  Application(s): Suitable as a lipid and lipoprotein stain on cellulose acetate	**25g** **100g**
J60155	**Okadaic acid, 98%** [78111-17-8], $C_{44}H_{68}O_{13}$, F.W. 805.02, Powder, Merck **14**,6819, UN3462, RTECS AA8227800, MDL MFCD00083455 H:H301-H311-H330-H315, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Potent inhibitor of serine/threonine-specific protein phosphatases 1 and 2A (PP1 and PP2A). Does not inhibit tyrosine or alkaline phosphatases	**300micrograms**
J61791	**Okadaic acid potassium salt, 98%** [155751-72-7], $C_{44}H_{67}KO_{13}$, F.W. 843.11, Powder, UN3462, MDL MFCD00214356 H:H301-H311-H330-H315, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Potent inhibitor of serine/threonine-specific protein phosphatases 1 and 2A (PP1 and PP2A). Does not inhibit tyrosine or alkaline phosphatases	**300micrograms**
J62463	**Okadaic acid sodium salt, 98%** [209266-80-8], $C_{44}H_{67}NaO_{13}$, F.W. 827.00, Powder, UN3462, MDL MFCD00210208 H:H301-H311-H330-H315, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Potent inhibitor of serine/threonine-specific protein phosphatases 1 and 2A (PP1 and PP2A). Does not inhibit tyrosine or alkaline phosphatases	**300micrograms**
A16663	**Oleic acid, tech. 90%** △ *[cis-9-Octadecenoic acid]* [112-80-1], $C_{18}H_{34}O_2$, F.W. 282.47, m.p. 13-14°, b.p. 286°/100mm, d. 0.887, n_D^{20} 1.4610, Merck **14**,6828, EINECS 204-007-1, RTECS RG2275000, BRN 1726542, MDL MFCD00064242, †  H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**1L** **5L**
31997	**Oleic acid, 99%** △ *[cis-9-Octadecenoic acid]* [112-80-1], $C_{18}H_{34}O_2$, F.W. 282.47, Liquid, m.p. 13-14°, b.p. 286°/100mm, d. 0.887, n_D^{20} 1.4610, Merck **14**,6828, EINECS 204-007-1, RTECS RG2275000, BRN 1726542, MDL MFCD00064242, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**5g** **25g** **100g**
	trans-Oleic acid, see Elaidic acid, A14832, p. 205 **Oleic acid cholesteryl ester**, see Cholesteryl oleate, A11378, p. 161 **Oleum tiglii**, see Croton oil, J62367, p. 169	
J61898	**Oligomycin** [1404-19-9], $C_{45}H_{74}O_{11}$, F.W. 791.07, Powder, Merck **14**,6833, EINECS 215-767-9, BRN 7615308 H:H300-H330-H373, P:P301+P310-P304+P340-P320-P330-P405-P501a Application(s): Inhibits respiration in mitochondria. Also inhibits ATP synthase	**10mg**
J60211	**Oligomycin A, 99+%** [579-13-5], $C_{45}H_{74}O_{11}$, F.W. 791.07, Powder, Merck **14**,6833, EINECS 209-437-3, RTECS RK3328000, BRN 5702132, MDL MFCD00065705 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Inhibits growth of molds	**10mg** **25mg**
J60388	**Olomoucine, 98%** [101622-51-9], $C_{15}H_{18}N_6O$, F.W. 298.35, Crystalline powder, m.p. 120-130°, MDL MFCD00189360 Application(s): Selective inhibitor of cdc2, cdk and other cyclin-related kinases	**5mg** **25mg**
J62860	**Omeprazole, 98%** [73590-58-6], $C_{17}H_{19}N_3O_3S$, F.W. 345.42, Powder, m.p. 158-159°, Merck **14**,6845, RTECS DD9087000, MDL MFCD00083192 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A proton pump inhibitor	**1g** **5g** **25g**
J65767	**Omi/HtrA2 Protease Inhibitor** ▲ *[High Temperature Requirement A2 Inhibitor I, 5-((5-(2-Nitrophenyl)furan-2-yl)methyl-ene)-1,3-diphenyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione]* $C_{27}H_{17}N_3O_5S$, F.W. 495.50, Solid	**10mg**
J64018	**Oncrasin 1** ▲ *[1-[(4-Chlorophenyl)methyl]-1H-indole-3-carboxaldehyde]* [75629-57-1], $C_{16}H_{12}ClNO$, F.W. 269.73, Powder, MDL MFCD01051808	**10mg**
	OPC-13013, see Cilostazol, 98%, J62301, p. 163	

Stock #	Description	Size
J62709	**Opiorphin** *[H-Gln-Arg-Phe-Ser-Arg-OH]* [864084-88-8], $C_{29}H_{48}N_{12}O_8$, F.W. 692.78, Powder Application(s): Modulator of mood-related states and pain sensation	5mg 25mg
J62743	**Orange G, Electrophoresis Grade** *[C.I. 16230, Acid Orange 10]* [1936-15-8], $C_{16}H_{10}N_2Na_2O_7S$, F.W. 452.38, Powder, EINECS 217-705-6, RTECS QJ6500000, BRN 4120705, MDL MFCD00012457, †	25g 100g 1kg
	Application(s): Collagen stain for connective tissue	
J60562	**Orange G loading dye (6X), glycerol based** Liquid, Note: Contains: 0.25% Orange-G and 30% glycerol in autoclaved DI water, † ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	25ml 50ml
J62098	**Orange G/blue dye (6X)** Liquid, Note: Contains: 0.25% Orange-G, 0.25% bromophenol blue, 0.25% xylene cyanol FF, 30mM EDTA in autoclaved DI water	10ml 25ml
J61877	**Orange G/blue loading dye (6X)** Liquid, Note: Contains: 0.25% Orange-G, 0.25% bromophenol blue, 0.25% xylene cyanol FF, 15% Ficoll, 30mM EDTA in autoclaved DI water	10ml 25ml
B20294	**Orcein, for analysis** [1400-62-0], Merck **14**,6863, EINECS 215-750-6, MDL MFCD00062310, † Application(s): Red in acidic pH and blue in alkaline pH	1g 5g
	Orcinol, see 3,5-Dihydroxytoluene, L18567, p. 193	
J65378	**Orexin A, human** $C_{152}H_{243}N_{47}O_{44}S_4$, F.W. 3561.09, Solid	0.5mg
J65811	**Orexin B, canine** *[Arg-Pro-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2]* $C_{125}H_{213}N_{44}O_{34}S$, F.W. 2908.36, Solid	0.5mg 1mg
J65110	**Orexin B, human** ▲ *[Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2]* $C_{123}H_{212}N_{44}O_{35}S$, F.W. 2899.33, Lyophilized powder	0.5mg 1mg
J65275	**Orexin B, mouse, rat** *[Arg-Pro-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Asn-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2]* [202801-92-1], $C_{126}H_{214}N_{45}O_{34}S$, F.W. 2935.38, Solid	0.5mg 1mg
J64476	**[Ala$_{11}$, D-Leu$_{15}$] Orexin B, human** *[Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Ala-Gln-Arg-Leu-DLeu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2]* [532932-99-3], $C_{120}H_{206}N_{44}O_{35}S$, F.W. 2857.25, Solid	1mg
J62999	**Orlistat, 98%** *[(-)-Tetrahydrolipstatin, Ro-18-0647]* [96829-58-2], $C_{29}H_{53}NO_5$, F.W. 495.73, Solid, m.p. <50°, Merck **14**,6869, RTECS OH3167600, MDL MFCD05662360 Application(s): Novel inhibitor of fatty acid sythase. Halts tumor cell proliferation and induces tumor cell apoptosis	50mg 100mg 250mg
	H-Orn-OH.HCl, see L-Ornithine hydrochloride, Cell Culture Reagent, J60241, p. 309	
J63100	**Ornidazole, 99%** *[1-(3-Chloro-2-hydroxypropyl)-2-methyl-5-nitroimidazole]* [16773-42-5], $C_7H_{10}ClN_3O_3$, F.W. 219.63, Powder, m.p. 84-86°, Merck **14**,6872, EINECS 240-826-0, RTECS NI5460000, MDL MFCD00057960 ! H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Interferes with electron transport in metabolic pathways	5g 25g
A18173	**DL-Ornithine monohydrochloride, 99%** *[(+/-)-2,5-Diaminopentanoic acid hydrochloride, H-DL-Orn-OH.HCl]* [1069-31-4], $C_5H_{12}N_2O_2{\cdot}HCl$, F.W. 168.62, m.p. ca 225° dec., EINECS 213-956-0, BRN 4153338, MDL MFCD00065398, †	5g 25g 50g
L00793	**D-Ornithine hydrochloride, 98+%** *[(R)-(-)-2,5-Diaminopentanoic acid hydrochloride, H-D-Orn-OH.HCl]* [16682-12-5], $C_5H_{12}N_2O_2{\cdot}HCl$, F.W. 168.62, m.p. 237° dec., $[\alpha]_D^{20}$ -23° (c=5 in 5N HCl), EINECS 240-729-3, BRN 4153339, MDL MFCD00012917	1g 5g

Contact us for pricing on bulk sizes

Stock #	Description	Size
A12111	**L-Ornithine hydrochloride, 99%** *[(S)-(+)-2,5-Diaminopentanoic acid hydrochloride, H-Orn-OH.HCl]* [3184-13-2], $C_5H_{12}N_2O_2 \cdot HCl$, F.W. 168.62, m.p. ca 238° dec., $[\alpha]_D^{20}$ +23° (c=5 in 5N HCl), Merck **14**,6874, EINECS 221-678-6, RTECS RM2985000, BRN 3625847, MDL MFCD00064562, † 	**25g** **100g** **500g**
J60241	**L-Ornithine hydrochloride, Cell Culture Reagent** *[(S)-(+)-2,5-Diaminopentanoic acid hydrochloride, H-Orn-OH.HCl]* [3184-13-2], $C_5H_{12}N_2O_2 \cdot HCl$, F.W. 168.62, White crystalline powder, m.p. ca 238° dec., Merck **14**,6874, EINECS 221-678-6, RTECS RM2985000, BRN 3625847, MDL MFCD00064562, †	**50g** **100g** **250g**
A18594	**Orotic acid hydrate, 98%** *[1,2,3,6-Tetrahydro-2,6-dioxopyrimidine-4-carboxylic acid hydrate, Uracil-4-carboxylic acid hydrate]* [50887-69-9], $C_5H_4N_2O_4 \cdot xH_2O$, F.W. 156.10(anhy), m.p. >300°, Merck **14**,6876, EINECS 200-619-8, BRN 383901, MDL MFCD00006027, †  ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g**
B25349	**Orotic acid, anhydrous, 97%** *[1,2,3,6-Tetrahydro-2,6-dioxopyrimidine-4-carboxylic acid, Uracil-4-carboxylic acid]* [65-86-1], $C_5H_4N_2O_4$, F.W. 156.10, m.p. 344-347°, EINECS 200-619-8, RTECS RM3180000, MDL MFCD00006027, †  ! H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501a	**100g** **500g**
	Orthoboric acid, see Boric acid, 33253, p. 134	
A18067	**Orthophosphoric acid, 85% aq. soln.** *[Phosphoric acid (ortho)]* [7664-38-2], H_3PO_4, F.W. 98.00, m.p. 19-21°, d. 1.700, n_D^{20} 1.4310, Merck **14**,7344, Fieser **1**,860 **4**,387 **7**,255 **10**,317 **15**,266, UN1805, EINECS 231-633-2, RTECS TB6300000, MDL MFCD00011340, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**500ml** **2.5L** **10L**
33266	**Orthophosphoric acid, 85% w/w aq. soln., ACS** *[Phosphoric acid (ortho)]* [7664-38-2], H_3PO_4, F.W. 98.00, Liquid, m.p. 19-21°, d. 1.70, Merck **14**,7344, Fieser **1**,860 **4**,387 **7**,255 **10**,317 **15**,266, UN1805, EINECS 231-633-2, RTECS TB6300000, MDL MFCD00011340, † Maximum level of impurities: Color (APHA) 10, Insoluble matter 0.001%, Cl 3ppm, NO_3 5ppm, SO_4 0.003%, Volatile acids (as CH_3COOH) 0.001%, Sb 0.002%, Ca 0.002%, Mg 0.002%, As 1ppm, Heavy Metals (as Pb) 0.001%, Fe 0.003%, Mn 0.5ppm, K 0.005%, Na 0.025%, Red H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**100g** **1kg** **4x1kg**
J65012	**Osteocalcin (1-49), human** $C_{269}H_{379}N_{68}O_{81}S_2$, F.W. 5925.41, Solid	**1mg**
J65386	**Osteocalcin (7-19), human** *[Gly-Ala-Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-Glu-Pro-Arg]* [120944-72-1], $C_{65}H_{98}N_{16}O_{19}$, F.W. 1407.57, Solid, MDL MFCD00133727	**1mg** **5mg**
J65959	**Osteocalcin (45-49), human** *[Phe-Tyr-Gly-Pro-Val]* [85679-70-5], $C_{30}H_{39}N_5O_7$, F.W. 581.66, Solid, MDL MFCD00076322	**10mg** **25mg**
J64816	**Osteocalcin, human, intact, Enzyme Immunoassay Kit** Note: One kit contains all the necessary reagents and a 96-well strip plate to perform an ELISA for intact human osteocalcin. Application(s): For detection of osteocalcin. Detection range is 1.0-50ng/ml	**1kit**
J64764	**Osteocalcin, human, mid-tact, Enzyme Immunoassay Kit** Note: One kit contains all the necessary reagents and a 96-well strip plate to perform an ELISA for mid-tact human osteocalcin. Application(s): For detection of osteocalcin. Detection range is 1.0-50ng/ml	**1kit**
J65214	**Osteocalcin, rat, Enzyme Immunoassay Kit** Note: One kit contains all the necessary reagents and a 96-well strip plate to perform an ELISA for rat osteocalcin. Application(s): For detection of rat osteocalcin. Detection range is 0.3-20ng/ml	**1kit**
J64231	**Osteocalcin, rat, 99.9%**	**10micrograms**
J64239	**Osteocalcin, mouse, Enzyme Immunoassay Kit** Note: One kit contains all the necessary reagents and a 96-well strip plate to perform an ELISA for mouse osteocalcin. Application(s): For detection of mouse osteocalcin. Detection range is 1.0-50ng/ml	**1kit**
	Otercil potassium, see Oxonic acid potassium salt, J60400, p. 310	

Stock #	Description	Size
J60724	**Ouabain octahydrate, 98% ▲** *[γ-Strophanthin]* [11018-89-6], $C_{29}H_{44}O_{12}\cdot 8H_2O$, F.W. 728.78 (584.66anhy), Powder, UN1544, RTECS RN3675000, BRN 101712, MDL MFCD00149240 H:H301-H330-H373, P:P301+P310-P304+P340-P320-P330-P405-P501a Application(s): Inhibitor of sodium-potassium-dependent ATPase	**1g** **5g**
	7-Oxabicyclo [2.2.1] heptane-2,3-dicarboxylic acid, see Endothall, J60948, p. 206	
J62250	**1H-[1,2,4]Oxadiazolo[4,3-a]-quinoxalin-1-one, 99+%** *[ODQ]* [41443-28-1], $C_9H_5N_3O_2$, F.W. 187.15, Powder, m.p. 160-170°, MDL MFCD00792620 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Selective inhibitor of nitric oxide-sensitive guanylyl cyclase	**10mg** **50mg**
33262	**Oxalic acid dihydrate, ACS, 99.5-102.5%** [6153-56-6], $HO_2CCO_2H\cdot 2H_2O$, F.W. 126.07 (90.04anhy), Crystalline, m.p. 101-105°, d. 1.65, Merck **14**,6911, Fieser **1**,764, Solubility: Very soluble in water. Moderately soluble in ethanol. Sparingly soluble in ether, UN3261, EINECS 205-634-3, RTECS KI1600000, BRN 3679436, MDL MFCD00149102, † Maximum level of impurities: Insoluble matter 0.005%, Residue after ignition 0.01%, Cl 0.002%, SO_4 0.005%, Ca 0.001%, Nitrogen compounds (as N) 0.001%, Heavy Metals (as Pb) 5ppm, Fe 2ppm, Substances darkened by hot sulfuric acid P.T. H:H302-H312, P:P280-P302+P352-P322-P301+P312-P312-P501a Application(s): As an analytical reagent, in dye and paint industries, in polymers, in metal treatment, in cleaning and textile finishing, and as a reagent for dehydration and condensation	**50g** **250g** **1kg** **5kg**
A12739	**Oxalacetic acid, 97%** *[2-Oxobutanedioic acid, 2-Oxosuccinic acid]* [328-42-7], $C_4H_4O_5$, F.W. 132.07, m.p. 161° dec., f.p. 88°(190°F), Merck **14**,6909, UN3261, EINECS 206-329-8, BRN 1705475, MDL MFCD00002592, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Substrate for citrate synthase.	**5g** **25g** **100g**
15789	**Oxalacetic acid, 98+%** [328-42-7], $C_4H_4O_5$, F.W. 132.07, Powder, m.p. 161° dec., f.p. 88°(190°F), Merck **14**,6909, UN3261, EINECS 206-329-8, BRN 1705475, MDL MFCD00002592, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**2g** **10g**
44410	**Oxalic acid, anhydrous, 98%** [144-62-7], HO_2CCO_2H, F.W. 90.04, Crystalline, m.p. ca 185° dec., d. 1.9^{17}, Merck **14**,6911, UN3261, EINECS 205-634-3, RTECS RO2450000, BRN 385686, MDL MFCD00002573, † H:H302-H312, P:P280-P302+P352-P322-P301+P312-P312-P501a	**50g** **250g**
	Oxalic acid sodium salt, see Sodium oxalate, A11648, p. 347 **Oxine**, see 8-Hydroxyquinoline, 41272, p. 251 **2-Oxo-2H-1-benzopyran-3-carboxylic acid**, see Coumarin-3-carboxylic acid, L07133, p. 168 **2-Oxobutanedioic acid**, see Oxalacetic acid, A12739, p. 310	
H27294	**4-Oxocyclohexanecarboxylic acid, 98%** *[Cyclohexanone-4-carboxylic acid]* [874-61-3], $C_7H_{10}O_3$, F.W. 142.16, MDL MFCD00102035 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250mg** **1g**
	2-Oxoglutaric acid, see 2-Ketoglutaric acid, A10256, p. 263	
J60400	**Oxonic acid potassium salt** *[Allantoxanic acid potassium salt, Otercil potassium]* [2207-75-2], $C_4H_2KN_3O_4$, F.W. 195.18, Powder, m.p. 300°, EINECS 218-627-5, RTECS RR4580000, MDL MFCD00010565 Application(s): Inhibitor of uricase	**5g** **25g** **100g**
	2-Oxopropionic acid, see Pyruvic acid, A13875, p. 333 **2-Oxosuccinic acid**, see Oxalacetic acid, A12739, p. 310 **L-(-)-2-Oxothiazolidine-4-carboxylic acid**, see (R)-(-)-2-Oxothiazolidine-4-carboxylic acid, J62254, p. 310	
J62254	**(R)-(-)-2-Oxothiazolidine-4-carboxylic acid** *[L-(-)-Thiazolidin-2-one-4-carboxylic acid, L-(-)-2-Oxothiazolidine-4-carboxylic acid]* [19771-63-2], $C_4H_5NO_3S$, F.W. 147.15, Powder, m.p. 174° dec., Merck **14**,6950, RTECS XJ5426650, BRN 4179169, MDL MFCD00066092 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Reagent for hepatic glutathione studies.	**1g** **5g**
	2,2'-Oxydiethanol, see Diethylene glycol, A14728, p. 189 **Oxypurinol**, see 4,6-Dihydroxypyrazolo[3,4-d]pyrimidine, L07160, p. 193	
J62427	**Oxytetracycline, 98+%** [79-57-2], $C_{22}H_{24}N_2O_9$, F.W. 460.43, Powder, m.p. 184-185°, Merck **14**,6976, EINECS 201-212-8, RTECS QI7875000, MDL MFCD00003700, † H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Impairs mitochondrial protein synthesis	**10g** **50g** **100g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62489	**Oxytetracycline hydrochloride** ▲ △ [2058-46-0], $C_{22}H_{24}N_2O_9 \cdot HCl$, F.W. 496.90, Crystalline powder, m.p. 180°, Merck **14**,6976, EINECS 218-161-2, RTECS QI8225000, BRN 3853107, MDL MFCD00135815, † Application(s): Impairs mitochondrial protein synthesis	25g 100g
J63421	**Oxytocin, 96%** *[Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2]* [50-56-6], $C_{43}H_{66}N_{12}O_{12}S_2$, F.W. 1007.19, Lyophilized powder, Merck **14**,6979, UN2811, EINECS 200-048-4, RTECS RS7534000 H:H300-H361, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Peptide hormone that acts predominantly as a neurotransmitter; stimulates uterine contraction and lactation	5mg 25mg
J65848	**p21-Activated Kinase Inhibitor III, IPA-3** ▲ *[PAK Inhibitor III, 1,1'-Disulfanediylbis(naphthalen-2-ol)]* [42521-82-4], $C_{20}H_{14}O_2S_2$, F.W. 350.50, Solid, UN3077, MDL MFCD00388917 H:H318-H410, P:P280-P273-P305+P351+P338-P310-P391-P501	5mg 10mg
	PABA, see 4-Aminobenzoic acid sodium salt, 99%, J63428, p. 92	
J62734	**Paclitaxel, 99.5+%** [33069-62-4], $C_{47}H_{51}NO_{14}$, F.W. 853.91, Crystalline solid, m.p. 213° dec., Merck **14**,6982, RTECS DA8340700, BRN 1420457, MDL MFCD00869953, Note: Isolated from Taxus brevifolia H:H334-H341-H361-H318-H302-H312-H332-H335-H315-H317, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Promotes assembly and inhibits disassembly of microtubules (anti-cancer agent)	100mg 500mg 1g
J60091	**Palatinose hydrate, 98+%** *[6-O-α-D -Glucopyranosyl-D-fructose, Isomaltulose]* [13718-94-0], $C_{12}H_{22}O_{11} \cdot xH_2O$, F.W. 342.30, Powder, m.p. 122-124°, Merck **14**,5182, EINECS 237-282-1, RTECS LS7175420, BRN 1757215, MDL MFCD00076094	25g 100g
B20322	**Palmitic acid, 95%** *[Hexadecanoic acid]* [57-10-3], $CH_3(CH_2)_{14}COOH$, F.W. 256.43, m.p. 60-62°, b.p. 215°/15mm, f.p. 206°(402°F), d. 0.853, n_D^{20} 1.4273, Merck **14**,6996, EINECS 200-312-9, RTECS RT4550000, BRN 607489, MDL MFCD00002747, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A saturated fatty acid	500g 2.5kg 10kg
A15207	**Pamoic acid, 99%** *[Embonic acid, 4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)]* [130-85-8], $C_{23}H_{16}O_6$, F.W. 388.38, m.p. >300°, Merck **14**,7005, Solubility: Soluble in nitrobenzene, pyridine, EINECS 204-998-0, RTECS QL2180000, BRN 901319, MDL MFCD00004079, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used in preparation of repository derivatives of medicinal agents 	50g 250g
J62162	**Pancreatin, porcine pancreas** *[Pancreatin from porcine pancreas]* [8049-47-6], Lyophilized powder, Merck **14**,7006, EINECS 232-468-9, RTECS RT9033000, MDL MFCD00131789, Note: Pancreatin will convert not less than 25 times its weight of potato starch into soluble carbohydrates in 5 minutes in water at 40 °C, will digest not less than 25 times its weight of casein in 60 minutes at pH7.5 at 40 °C and will release not less than 2 , † H:H334-H335-H315-H319, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Hydrolyzes starch into dextrins and sugar	250g 1kg
	Pancreatopeptidase E, see Elastase, porcine pancreas, J61874, p. 205 **Pancreatopeptidase E**, see Elastase, porcine pancreas aqueous suspension, J61753, p. 205	
A18499	**D-Panthenol, 98+%** ■ *[Dexpanthenol, Provitamin B]* [81-13-0], $C_9H_{19}NO_4$, F.W. 205.26, b.p. 118-120°/0.02m, f.p. 159°(318°F), d. 1.162, n_D^{20} 1.4990, $[\alpha]_D^{20}$ -30° (c=5 in water), Merck **14**,2947, EINECS 201-327-3, RTECS ES4316000, BRN 1724947, MDL MFCD00065006, † 	100g 500g
A16609	**D-Pantothenic acid calcium salt hydrate, 98%** ■ *[Calcium D-pantothenate hydrate]* [331748-07-3], $C_{18}H_{32}CaN_2O_{10} \cdot xH_2O$, F.W. 476.54(anhy), m.p. ca 138° dec., $[\alpha]_D^{20}$ +27° (c=5 in water), Merck **14**,7015, EINECS 205-278-9, RTECS RU4375000, BRN 3769272, MDL MFCD00002766, †  Application(s): Vitamin B-5	100g 500g
	D-Pantothenol, see D-Panthenol, A18499, p. 311	
J61875	**Papain, Carica Papaya Latex** *[EC 3.4.22.2]* [9001-73-4], Lyophilized powder, 23 kDa, Merck **14**,7016, EINECS 232-627-2, RTECS RU4950000, MDL MFCD00131791, Note: Activates to at least 15 units per mg protein. One unit hydrolyzes one micromole of benzoyl-L-arginine ethyl ester per minute at 25°C and pH 6.2 after activation in a solution containing 1.1 mM EDTA, 0.067 mM mercaptoethanol and 5.5 mM cysteine-HCl for 30, † H:H315-H319-H334-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A cysteine protease; breaks down intercellular matrix of cartilage	25mg 100mg 1g

Stock #	Description	Size
L04152	**Papaverine, 97% ▲** [58-74-2], $C_{20}H_{21}NO_4$, F.W. 339.38, m.p. 146-147°, Merck **14**,7019, EINECS 200-397-2, RTECS NW8450000, BRN 312930, MDL MFCD00024138 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A phosphodiesterase inhibitor	**5g** **25g**
B25412	**Papaverine hydrochloride, 99% ▲** *[1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride]* [61-25-6], $C_{20}H_{21}NO_4 \cdot HCl$, F.W. 375.85, m.p. ca 220° dec., Merck **14**,7019, EINECS 200-502-1, RTECS NW8575000, MDL MFCD00012745, † H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A phosphodiesterase inhibitor	**5g** **25g**
	Paracetamol, see 4-Acetamidophenol, A11240, p. 70	
J61899	**Paraformaldehyde, 4% in PBS** Liquid H:H318-H351-H317-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J62478	**Paraformaldehyde, 4% in PBS + Mg + EGTA** Liquid, Note: 4% Paraformaldehyde in PBS with 2mM magnesium chloride and 5mM EGTA H:H318-H351-H317-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): For histology.	**250ml** **500ml**
J61984	**Paraformaldehyde fixative solution** Liquid, Note: Contains 3.7 % (w/v) paraformaldehyde and 3 % (w/v) sucrose in PBS, pH 7.4., † H:H351-H317, P:P261-P280-P302+P352-P321-P405-P501a	**250ml** **500ml**
J61274	**Paromomycin sulfate** [1263-89-4], $C_{23}H_{45}N_5O_{14} \cdot H_2SO_4$, F.W. 713.71, White to off-white powder, Merck **14**,7041, EINECS 215-031-7, RTECS WK2320000, BRN 5715182, MDL MFCD00079278 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibits initiation and elongation during protein synthesis	**1g** **5g** **25g**
J64413	**PARP Inhibitor VIII, PJ34 ▲■** *[2-Dimethylamino-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide dihydrochloride]* [344458-15-7], $C_{17}H_{17}N_3O \cdot 2HCl$, F.W. 352.26, Solid	**5mg** **25mg**
J61341	**Paxilline, 97+%** [57186-25-1], $C_{27}H_{33}NO_4$, F.W. 435.56, Powder, UN2811, RTECS DJ2830000, MDL MFCD00083464 H:H301-H311-H330-H318-H315-H335, P:P301+P310-P304+P340-P305+P351+P338-P320-P330-P361-P405-P501a Application(s): Potent blocker of high-conductance calcium-activated potassium (BKCa) channels	**5mg** **25mg**
J62470	**Pazopanib, 99+%** *[GW-786034]* [444731-52-6], $C_{21}H_{23}N_7O_2S$, F.W. 437.52, Powder, m.p. 309-311°, RTECS DB2356200 Application(s): Second generation multi-targeted tyrosine kinase receptor inhibitor	**25mg** **50mg** **100mg**
	PCMX, see 4-Chloro-3,5-dimethylphenol, B21964, p. 155	
J60502	**PCO-400** *[Potassium Channel Opener]* [121055-10-5], $C_{17}H_{17}NO_4$, F.W. 299.33, Solid Application(s): A potassium channel activator	**20mg** **100mg**
J65158	**PD 151746 ▲** *[3-(5-Fluoro-3-indolyl)-2-mercapto-(Z)-2-propenoic acid]* [179461-52-0], $C_{11}H_8FNO_2$, F.W. 237.30, Solid	**5mg**
	PD-183805, see Canertinib dihydrochloride salt, 99+%, J63750, p. 145	
J61021	**Pectin Citrus** *[Poly-D-galacturonic acid methyl ester]* [9000-69-5], Powder, Merck **14**,7063, EINECS 232-553-0, RTECS RX4280000, MDL MFCD00081838, †	**100g** **500g**
J63408	**Pectinase, Aspergillus niger** *[EC 4.2.2.10]* [9032-75-1], Powder, EINECS 232-885-6, Note: Minimum 20 units per mg dry weight. One unit releases 1 micromole of D-galacturonic acid from polygalacturonic acid per minute at 37°C and pH 5.0, †	**250mg** **1g**
	Pelargonic acid cholesteryl ester, see Cholesteryl nonanoate, L02857, p. 161 **Penetrex® The Clorox Company**, see Enoxacin, J61912, p. 207	

Contact us for pricing on bulk sizes

Stock #	Description	Size
B24710	**DL-Penicillamine, 97+%** *[3,3-Dimethyl-DL-cysteine, 3-Mercapto-DL-valine]* [52-66-4], $C_5H_{11}NO_2S$, F.W. 149.21, m.p. ca 212° dec., Merck **14**,7088, EINECS 200-147-2, RTECS YV9445000, BRN 2039817, MDL MFCD00004856  H:H302-H315-H319-H335, P:P280h-P305+P351+P338 Metal chelating agent. Application(s): Heavy metal chelating agent	1g 5g 25g
A11446	**D-(-)-Penicillamine, 99%** *[3,3-Dimethyl-D-cysteine, 3-Mercapto-D-valine]* [52-67-5], $C_5H_{11}NO_2S$, F.W. 149.21, m.p. 202-204° dec., $[\alpha]_D^{20}$ -63° (c=1 in 1N NaOH), Merck **14**,7088, EINECS 200-148-8, RTECS YV9425000, BRN 1722375, MDL MFCD00064302  H:H315-H319-H335, P:P280g-P305+P351+P338 Application(s): Exogenous nitric oxide synthase (NOS) modulator. Physiological chelating agent for heavy metals	5g 25g 100g
J63901	**Penicillin G potassium salt** *[Benzylpenicillin potassium salt, Potassium benzylpenicillinate]* [113-98-4], $C_{16}H_{17}KN_2O_4S$, F.W. 372.48, Powder, Merck **14**,7094, EINECS 204-038-0, RTECS XH9700000, BRN 3832841, MDL MFCD00036193, † H:H334-H302-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): Inhibits bacterial cell wall synthesis	25g 100g
J63032	**Penicillin G sodium salt** *[Benzylpenicillin sodium salt]* [69-57-8], $C_{16}H_{17}N_2NaO_4S$, F.W. 356.37, Powder, Merck **14**,7094, EINECS 200-710-2, RTECS XH9800000, BRN 3834217, MDL MFCD00069666 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): Inhibits bacterial cell wall synthesis	5g 25g 100g
J62442	**Penicillin V potassium salt** *[Phenoxymethylpenicillinic acid potassium salt]* [132-98-9], $C_{16}H_{17}KN_2O_5S$, F.W. 388.48, Powder, m.p. 197-202°, Merck **14**,7100, EINECS 205-086-5, RTECS XH9275000, BRN 3899451, MDL MFCD00051771, † H:H302-H334-H317, P:P285-P261-P280-P302+P352-P501 Application(s): Inhibits bacterial cell wall synthesis	10g 25g 100g
J61700	**(R)-3,3,4,4,4-Pentafluorobutanol** $C_4H_4F_5O$, F.W. 164.07, Liquid H:H226-H315-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-501 Application(s): For synthesis of optically active products	Call
J60988	**(S)-3,3,4,4,4-Pentafluorobutanol** $C_4H_4F_5O$, F.W. 164.07, Liquid H:H226-H315-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-501 Application(s): For synthesis of optically active products	Call
	(-)-cis-3,3',4',5,7-Pentahydroxyflavane, see (-)-Epicatechin , J61218, p. 208 **3,3',4',5,7-Pentahydroxyflavone dihydrate**, see Quercetin dihydrate, A15807, p. 333 **1,5-Pentanediamine**, see 1,5-Diaminopentane, B23039, p. 183	
J63298	**(R)-(-)-2-Pentanol, 97%** [31087-44-2], $C_5H_{12}O$, F.W. 88.15, Liquid, b.p. 119-120°, f.p. 34°(93°F), d. 0.81, n_D^{20} 1.406, UN1105, BRN 4652311, MDL MFCD00065953 H:H226-H332-H335-EUH066, P:P210-P241-P261-P303+P361+P353-P405-P501 Application(s): For synthesis of optically active products	250mg 1g
L09314	**(S)-(+)-2-Pentanol, 97%** *[(S)-(+)-Methyl n-propyl carbinol]* [26184-62-3], $C_5H_{12}O$, F.W. 88.15, b.p. 118-119°, f.p. 33°(91°F), d. 0.810, n_D^{20} 1.4060, $[\alpha]_D^{20}$ +13.7° (neat), UN1105, RTECS SA4900000, BRN 1718820, MDL MFCD00065952  H:H226-H332-H335-EUH066, P:P210-P241-P261-P303+P361+P353-P405-P501a	250mg 1g
	Pentanophenone, see Valerophenone, A10525, p. 390 **Pentetic acid**, see Diethylenetriaminepentaacetic acid, A10926, p. 189 **Pentifylline**, see 1-n-Hexyltheobromine, L13597, p. 245	
J61679	**Pepsin, porcine stomach** *[EC 3.4.23.1, Pepsin A]* [9001-75-6], Powder, Merck **14**,7146, EINECS 232-629-3, RTECS SC6132000, Note: Minimum 2,500 units/mg. One unit increases absorbance at 280nm by 0.001 per minute at 37°C and pH 2.0, measured as TCA soluble products from denatured hemoglobin, † H:H334-H335-H315-H319, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a	1g 5g 10g
	Pepsin A, see Pepsin, porcine stomach, J61679, p. 313	

Stock #	Description	Size
J60237	**Pepstatin A, 98%** [26305-03-3], $C_{34}H_{63}N_5O_9$, F.W. 685.90, Powder, m.p. 233° dec., Merck **14**,7147, EINECS 247-600-0, RTECS SC6155000, BRN 2201362, MDL MFCD00060740 Application(s): Protease inhibitor that acts on pepsin, renin and cathepsin D	**5mg** **25mg**
	PEP-tri, see Phosphoenolpyruvic acid tricyclohexylammonium salt, 99+%, J61943, p. 321 **PEP-triNa**, see Phosphoenolpyruvic acid trisodium salt heptahydrate, 98%, J63013, p. 321 **Permeability Glycoprotein Inhibitor**, see Dextran sulfate sodium salt, MW ca 8,000, J65630, p. 314	
J60026	**Peroxidase, horseradish** *[EC 1.11.1.7, HRP]* [9003-99-0], Lyophilized powder, EINECS 232-668-6, Note: Minimum 85 units/mg dry weight. One unit decomposes 1 micromole of hydrogen peroxide per minute at 25°C and pH 7.0 using aminoantipyrine and phenol, †	**100mg** **1g**
J65630	**P-Glycoprotein Inhibitor** *[trans-4-Chloro-N-(3-[3-(4-hydroxy-3-methoxyphenyl)acryloyl]phenyl)benzamide, Permeability Glycoprotein Inhibitor]* $C_{23}H_{18}ClNO_4$, F.W. 407.85, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Transports a variety of substrates across cellular membranes	**10mg**
	Pharmasin, see Tylosin tartrate, 98+%, J62633, p. 386 **(R)-(+)-sec-Phenethyl alcohol**, see (R)-(+)-1-Phenylethanol, L19296, p. 316 **(S)-(-)-sec-Phenethyl alcohol**, see (S)-(-)-1-Phenylethanol, B21188, p. 316	
33213	**Phenol, ACS, 99+%, stab.** △ [108-95-2], C_6H_5OH, F.W. 94.11, Crystalline, m.p. 40-43°, b.p. 181°, f.p. 79°(175°F), d. 1.071, Merck **14**,7241, Fieser **1**,828, UN1671, EINECS 203-632-7, RTECS SJ3325000, BRN 969616, MDL MFCD00002143, † Maximum level of impurities: Clarity of solution P.T., Evaporation residue 0.05%, H_2O 0.5%, Freezing point ≥ 40.5° H:H301-H311-H331-H314-H341-H373, P:P301+P310-P303+P361+P353-P305+P351+P338-P361-P405-P501a	**100g** **500g** **2kg**
J64011	**Phenol, ultrapure, 99%** △ [108-95-2], C_6H_5OH, F.W. 94.11, Crystalline, m.p. 40-43°, b.p. 181°, f.p. 79°(175°F), d. 1.071, Merck **14**,7241, UN1671, EINECS 203-632-7, RTECS SJ3325000, BRN 969616, MDL MFCD00002143, †	**100g** **500g**
44526	**Phenol, 99.5%, unstab.** ■ [108-95-2], C_6H_5OH, F.W. 94.11, Solid melt, m.p. 40-43°, b.p. 181°, f.p. 79°(175°F), d. 1.071, Merck **14**,7241, Fieser **1**,828, UN1671, EINECS 203-632-7, RTECS SJ3325000, BRN 969616, MDL MFCD00002143, Note: Doubly distilled., † H:H301-H311-H331-H314-H341-H373, P:P301+P310-P303+P361+P353-P305+P351+P338-P361-P405-P501a Application(s): Molecular biology	**100g**
J62336	**Phenol:Chloroform:Isoamyl alcohol 25:24:1, Ready-to-use saturated aq. soln., pH 5.2, with alkaline buffer** [136112-00-0], Liquid, UN2922, MDL MFCD00133763 H:H331-H314-H341-H351-H373-H302-H312, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Useful for purifying RNA	**100ml** **500ml**
J60331	**Phenol:Chloroform:Isoamyl alcohol 25:24:1, Ready-to-use saturated aq. soln., pH 6.7, with alkaline buffer** [136112-00-0], Liquid, UN2922, MDL MFCD00133763 H:H331-H314-H341-H351-H373-H302-H312, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Useful for purifying RNA	**100ml** **400ml**
J63452	**Phenol:Chloroform 1:1, Ready-to-use soln., pH 6.7, with alkaline buffer** Liquid, UN2922 H:H331-H314-H341-H351-H373-H302-H312, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Useful for purifying RNA	**100ml** **1L**
A17135	**Phenolphthalein, 98%** [77-09-8], $C_{20}H_{14}O_4$, F.W. 318.33, m.p. 258-262°, d. 1.299, Merck **14**,7243, EINECS 201-004-7, RTECS SM8380000, BRN 284423, MDL MFCD00005913, † H:H350-H341-H361f, P:P281-P201-P202-P308+P313-P405-P501a Acid-base indicator: pH 8.0 - 10.0.	**50g** **250g** **1kg**
38705	**Phenolphthalein, ACS** [77-09-8], $C_{20}H_{14}O_4$, F.W. 318.33, Powder, m.p. 258-262°, d. 1.299, Merck **14**,7243, Solubility: Soluble in alcohol. Slightly soluble in ether, EINECS 201-004-7, RTECS SM8380000, BRN 284423, MDL MFCD00005913, † Specifications: Clarity of alcohol solution P.T., Visual transition interval from pH 8.0 (colorless) to 10.0 (red)  H:H350-H341-H361f, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Indicator	**100g** **500g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
38703	**Phenolphthalein, 0.5% w/v in alcohol** [77-09-8], $C_{20}H_{14}O_4$, F.W. 318.33, Liquid, f.p. 24°(76°F), d. 0.918, UN1987, EINECS 201-004-7, MDL MFCD00005913, Note: Transition interval: pH 8.0 (colorless) to pH 10.0 (red), † H:H225-H350-H371-H302-H312-H332, P:P210-P241-P260-P303+P361+P353-P405-P501a	**500ml** **1L**
38704	**Phenolphthalein, 1% w/v in alcohol** [77-09-8], $C_{20}H_{14}O_4$, F.W. 318.33, Liquid, UN1986, EINECS 201-004-7, MDL MFCD00005913, Note: Transition interval: pH 8.0 (colorless) to pH 10.0 (red), † H:H225-H350-H370-H341, P:P210-P241-P260-P303+P361+P353-P405-P501a	**500ml**
J61785	**Phenolphthalein, 2% soln. in 95% ethanol** [77-09-8], $C_{20}H_{14}O_4$, F.W. 318.33, Liquid, Merck **14**,7243, UN1987, EINECS 201-004-7, MDL MFCD00005913, † H:H225-H350-H341-H371, P:P210-P241-P260-P303+P361+P353-P405-P501a Application(s): pH indicator	**100ml** **1L**
16294	**Phenol Red, ACS** *[Phenolsulfonphthalein, Phenylsulfonephthalein]* [143-74-8], $C_{19}H_{14}O_5S$, F.W. 354.38, Crystalline, m.p. >300°, Merck **14**,7247, Solubility: Practically insoluble in chloroform, ether. Soluble in aqueous alkali hydroxides or carbonates with red color (removed by boiling with zinc dust). Solubility in water: approximately 1g/1300ml. Solubility in alcohol: approximately 1g/350ml, EINECS 205-609-7, RTECS SJ7490000, BRN 326470, MDL MFCD00003552, † Specifications: Clarity of solution P.T., Visual transition interval from pH 6.8 (yellow) to 8.2 (red) H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): pH indicator	**5g** **25g** **100g**
38702	**Phenol Red sodium salt, 0.02% w/v aq. soln.** $C_{19}H_{13}NaO_5S$, F.W. 376.37, Liquid, d. 0.972, EINECS 252-057-8, MDL MFCD00066901, Note: Transition interval: pH 6.8 (yellow) to pH 8.2 (red), †	**100ml** **500ml** **6x100ml**
15987	**Phenol Red sodium salt, ACS** [34487-61-1], $C_{19}H_{13}NaO_5S$, F.W. 376.37, Crystalline, m.p. 285° dec., Merck **14**,7247, EINECS 252-057-8, BRN 6260026, MDL MFCD00066901, † Specifications: Clarity of solution P.T., Visual transition interval from pH 6.8 (yellow) to 8.2 (red) H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): pH indicator	**5g** **25g**
	Phenolsulfonphthalein, see Phenol Red, 16294, p. 315	
A12517	**Phenothiazine, 98+% ▲** [92-84-2], $C_{12}H_9NS$, F.W. 199.28, m.p. 182-186°, b.p. 235°/21mm, Merck **14**,7252, EINECS 202-196-5, RTECS SN5075000, BRN 143237, MDL MFCD00005015, † H:H319-H317-H412, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a Lithiation in THF gives orange crystals of (phenothiazin-10-yl)lithium.3THF. Carboxylation and the orientation of a second lithiation have been studied: *Angew. Chem. Int. Ed.*, **34**, 921 (1995). Application(s): Acts on type I calcium/calmodulin dependent phosphodiesterase	**250g** **500g** **5kg**
	Phenoxyacetic acid ethyl ester, see Ethyl phenoxyacetate, A14156, p. 217	
J61900	**Phenoxybenzamine hydrochloride** [63-92-3], $C_{18}H_{22}ClNO \cdot HCl$, F.W. 340.29, Powder, Merck **14**,7256, EINECS 200-569-7, RTECS DP3750000, MDL MFCD00055152 H:H302-H351, P:P281-P264-P301+P312-P308+P313-P405-P501 Application(s): Selective α adrenergic blocking agent. Irreversible calmodulin inhibitor	**250mg** **1g**
	Phenoxymethylpenicillinic acid potassium salt, see Penicillin V potassium salt, J62442, p. 313 **2-Phenylacetohydrazide**, see N-Acetyl-N'-phenylhydrazine, A14446, p. 74	
A10132	**DL-Phenylalanine, 99%** *[(+/-)-2-Amino-3-phenylpropionic acid, H-DL-Phe-OH]* [150-30-1], $C_9H_{11}NO_2$, F.W. 165.19, m.p. ca 266° dec., Merck **14**,7271, EINECS 205-756-7, BRN 1910407, MDL MFCD00064225, †	**25g** **100g** **500g**
A10572	**D-Phenylalanine, 99%** *[(R)-2-Amino-3-phenylpropionic acid, H-D-Phe-OH]* [673-06-3], $C_9H_{11}NO_2$, F.W. 165.19, m.p. ca 275° dec., $[\alpha]_D^{20}$ +34° (c=2 in water), Merck **14**,7271, EINECS 211-603-5, RTECS AY7533000, BRN 2804068, MDL MFCD00004270, †	**5g** **25g** **100g**
A13238	**L-Phenylalanine, 99%** *[(S)-2-Amino-3-phenylpropionic acid, H-Phe-OH]* [63-91-2], $C_9H_{11}NO_2$, F.W. 165.19, m.p. 227° dec., $[\alpha]_D^{20}$ -34° (c=2 in water), Merck **14**,7271, EINECS 200-568-1, RTECS AY7535000, BRN 1910408, MDL MFCD00064227, † Other amino acids have been resolved by crystallization of their complexes with L-phenylalanine, and decomplexation with activated carbon: *Chem. Lett.*, 113 (1984). Formation of the N,N-dibenzyl benzyl ester by reaction with benzyl bromide and base, followed by LAH reduction and Swern oxidation, lead to the N,N-dibenzyl (S)-α-amino aldehyde, a useful chiral intermediate: *Org. Synth.*, **76**, 110 (1998).	**25g** **50g** **100g** **500g** **1kg**

Stock #	Description	Size
J63925	**L-Phenylalanine, Cell Culture Reagent** [63-91-2], $C_9H_{11}NO_2$, F.W. 165.19, Powder, Merck **14**,7271, EINECS 200-568-1, RTECS AY7535000, BRN 1910408, MDL MFCD00064227, †	**100g** **250g** **500g**
J64524	**Phenylalanine Dehydrogenase** *[EC 1.4.1.20]* Lyophilized powder, Note: Component in the Cofactor Recycling Enzymes Kit, item J64535	**250mg** **500mg** **1g**
L09697	**D-Phenylalaninol, 98%** △ *[(R)-(+)-2-Amino-3-phenyl-1-propanol, H-D-Phe-ol]* [5267-64-1], $C_9H_{13}NO$, F.W. 151.21, m.p. 89-94°, $[\alpha]_D^{20}$ +23° (c=5 in ethanol), UN3259, EINECS 226-086-1, BRN 4665408, MDL MFCD00064298 H:H314, P:P280-P303+P361+P353-P305+P351+P338-P310 Has been used as a chiral auxiliary for asymmetric Michael reactions: *J. Org. Chem.*, **50**, 3863 (1985).	**250mg** **1g**
A11586	**L-Phenylalaninol, 98%** △ *[(S)-(-)-2-Amino-3-phenyl-1-propanol, H-Phe-ol]* [3182-95-4], $C_9H_{13}NO$, F.W. 151.21, m.p. 89-94°, $[\alpha]_D^{20}$ -23° (c=5 in ethanol), UN3259, EINECS 221-674-4, RTECS UA6900000, BRN 2208238, MDL MFCD00004732 H:H314, P:P280-P303+P361+P353-P305+P351+P338-P310	**1g** **5g** **25g**
J60043	**L-Phenylalanyl-L-phenylalanine** *[H-Phe-Phe-OH, Di-L-Phenylalanine]* [2577-40-4], $C_{18}H_{20}N_2O_3$, F.W. 312.37, Powder, EINECS 219-930-5, MDL MFCD00063154 Application(s): Plays a role in nanotube formation	**1g** **5g**
J60063	**L-Phenylalanyl-L-proline** *[H-Phe-Pro-OH]* [7669-65-0], $C_{14}H_{18}N_2O_3$, F.W. 262.31, Powder, MDL MFCD00020833 Application(s): Substrate for skin fibroblast prolidase	**1g** **5g**
	Phenylbenzene, see Biphenyl, A10265, p. 125 **4-Phenylbenzoyl chloride**, see 4-Biphenylcarbonyl chloride, A13956, p. 125 **1-Phenyl-1,3-butanedione**, see Benzoylacetone, A14537, p. 121	
L03449	**Phenylbutazone, 98%** *[4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione]* [50-33-9], $C_{19}H_{20}N_2O_2$, F.W. 308.38, m.p. 105-108°, Merck **14**,7277, UN2811, EINECS 200-029-0, RTECS UQ8225000, BRN 290080, MDL MFCD00005500, † H:H301-H351-H361d-H319, P:P280h-P305+P351+P338-P309-P310 Application(s): A non-steroidal anti-inflammatory drug	**25g** **100g**
	Phenyl dichlorophosphate, see Phenyl phosphorodichloridate, A10479, p. 317	
J60354	**o-Phenylenediamine dihydrochloride, 98+%** *[1,2-Diaminobenzene dihydrochloride]* [615-28-1], $C_6H_8N_2 \cdot 2HCl$, F.W. 181.07, Powder, UN2811, EINECS 210-418-7, RTECS ST0175000, BRN 3912045, MDL MFCD00012966, † H:H301-H341-H351-H400-H410-H312-H332-H319-H317, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A peroxidase substrate for ELISA procedures	**25g** **100g** **500g**
L19296	**(R)-(+)-1-Phenylethanol, ChiPros® 99%, ee 97+%** *[(R)-(+)-α-Methylbenzyl alcohol, (R)-(+)-sec-Phenethyl alcohol]* [1517-69-7], $C_8H_{10}O$, F.W. 122.17, m.p. 9-11°, b.p. 88-89°/10mm, f.p. 85°(185°F), d. 1.012, n_D^{20} 1.5280, $[\alpha]_D^{20}$ +45° (c=5 in methanol), UN2937, BRN 2039798, MDL MFCD00064263 H:H318-H302-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): For synthesis of optically active products	**5g** **25g**
B21188	**(S)-(-)-1-Phenylethanol, 99%** *[(S)-(-)-α-Methylbenzyl alcohol, (S)-(-)-sec-Phenethyl alcohol]* [1445-91-6], $C_8H_{10}O$, F.W. 122.17, m.p. 9-11°, b.p. 97-99°/20mm, f.p. 85°(185°F), n_D^{20} 1.5280, UN2937, BRN 2039797, MDL MFCD00064264 H:H318-H302-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): For synthesis of optically active products	**1g** **5g**
	Phenylethyl caffeate, see Phenylethyl 3,4-dihydroxycinnamate, 99+%, J61386, p. 316	
J61386	**Phenylethyl 3,4-dihydroxycinnamate, 99+%** *[3,4-Dihydroxycinnamic acid phenylethyl ester, Phenylethyl caffeate]* [104594-70-9], $C_{17}H_{16}O_4$, F.W. 284.31, Powder, RTECS UD3334375, MDL MFCD00866470 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inhibitor of protein tyrosine kinase, and is cytotoxic to cancer cell lines	**250mg** **1g**
J64722	**Phenylethyl 3-methylcaffeate** *[(E)-Phenethyl 3-(4-hydroxy-3-methoxyphenyl)acrylate, CCRIS 7791]* [71835-85-3], $C_{18}H_{18}O_4$, F.W. 298.33, Solid, m.p. 80-81°	**50mg** **100mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A14182	**N-Phenylglycine, 97%** [103-01-5], $(C_6H_5)NHCH_2CO_2H$, F.W. 151.17, m.p. 117-119°, Merck **14**,7292, EINECS 203-070-2, BRN 509838, MDL MFCD00014009, †	**10g** **50g**
	Application(s): Pharmaceutical intermediate	
A15669	**D-(-)-2-Phenylglycine, 99%** *[D-(-)-α-Aminophenylacetic acid, H-D-Phg-OH]* [875-74-1], $C_8H_9NO_2$, F.W. 151.17, m.p. 277° dec., $[\alpha]_D^{20}$ -154° (c=1 in 1N HCl), Merck **14**,7291, EINECS 212-876-3, BRN 2208676, MDL MFCD00008061, † 	**25g** **100g** **500g**
A19360	**L-(+)-2-Phenylglycine, 98+%** *[(S)-(+)-α-Aminophenylacetic acid, H-Phg-OH]* [2935-35-5], $C_8H_9NO_2$, F.W. 151.17, m.p. 288° dec., $[\alpha]_D^{20}$ +156° (c=1 in 1N HCl), Merck **14**,7291, Fieser **17**,278, EINECS 220-909-8, BRN 2208675, MDL MFCD00064403, † 	**25g** **100g** **500g**
A19030	**(R)-(-)-2-Phenylglycinol, 98%** △ *[(R)-(-)-2-Amino-2-phenylethanol, H-D-Phg-ol]* [56613-80-0], $C_8H_{11}NO$, F.W. 137.18, m.p. 76-78°, $[\alpha]_D^{20}$ -30° (c=0.75 in 1N HCl), Fieser **15**,256 **17**,279, EINECS 260-287-5, BRN 2935848, MDL MFCD00008062 	**1g** **5g** **25g**
	H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Condensation with glutaraldehyde gives a useful intermediate in asymmetric synthesis of alkaloids: *Org. Synth. Coll.*, **9**, 176 (1998):  Starting material for the enantioselective synthesis of 2,6-disubstituted piperazines: *Synthesis*, 833 (1996), and for chiral α-amino phosphonates: *Org. Synth.*, **75**, 19 (1997).	
L13265	**(S)-(+)-2-Phenylglycinol, 98+%** △ *[(S)-(+)-2-Amino-2-phenylethanol, H-Phg-ol]* [20989-17-7], $C_8H_{11}NO$, F.W. 137.18, m.p. 76-78°, $[\alpha]_D^{20}$ +30° (c=0.75 in 1N HCl), Fieser **15**,256, BRN 3196190, MDL MFCD00064404 	**1g** **5g** **25g**
	H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reagent for the resolution of acids via the easily hydrolyzed amides: *J. Org. Chem* ., **51**, 4836 (1986).	
	Phenylmethanephosphonic acid, see Benzylphosphonic acid, A13850, p. 123 **Phenylmethanesulfonyl fluoride**, see α-Toluenesulfonyl fluoride, B22146, p. 371 **N-[2-[2-(Phenylmethyl)-1H-indol-3-yl]ethyl]acetamide**, see Luzindole, 97%, J61915, p. 273 **Phenylmethylsulfonyl fluoride**, see α-Toluenesulfonyl fluoride, B22146, p. 371	
A10592	**2-Phenylphenol, 99%** *[Biphenyl-2-ol, 2-Hydroxybiphenyl]* [90-43-7], $C_{12}H_{10}O$, F.W. 170.21, m.p. 54-58°, b.p. 152-154°/15mm, f.p. 124°(255°F), d. 1.293, Merck **14**,7304, UN3077, EINECS 201-993-5, RTECS DV5775000, BRN 606907, MDL MFCD00002208, † 	**250g** **500g** **2.5kg** **10kg**
	H:H400-H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	
44711	**Phenyl phosphate disodium salt hydrate, 98%** ■ [3279-54-7], $C_6H_5OPO(ONa)_2 \cdot xH_2O$, F.W. 218.06(anhy), Crystalline, Merck **14**,3357, EINECS 221-917-4, BRN 4167154, MDL MFCD00002133, †	**25g** **100g**
	Application(s): Used in phosphatase determinations	
A10479	**Phenyl phosphorodichloridate, 97%** ◢ *[Phenyl dichlorophosphate]* [770-12-7], $C_6H_5Cl_2O_2P$, F.W. 210.98, m.p. -1°, b.p. 241-243°, f.p. 112°(233°F), d. 1.415, n_D^{20} 1.5230, Fieser **1**,84712,384 **13**,240 **15**,255, UN2922, EINECS 212-220-6, RTECS TD4393000, BRN 511863, MDL MFCD00002067, † 	**25g** **100g** **500g**
	H:H310-H314-H302, P:P260-P303+P361+P353-P305+P351+P338-P361-P405-P501a Reagent for the preparation of phosphate diesters. The phenyl group is removable by hydrogenolysis: *J. Am. Chem. Soc.*, **75**, 4510 (1953). Coupling reagent, e.g. in pyridine for the preparation of derivatives of sulfinic acids with alcohols, amines, thiols etc.: *Synthesis*, 937 (1980). Similarly, carboxylic acids in pyridine can be coupled with thiols to give thiocarboxylic acid S-esters: *Can. J. Chem.*, **58**, 2645 (1980), and with sodium azide in the presence of a phase-transfer catalyst to give acyl azides: *Synth. Commun.*, **13**, 289 (1983). Reacts with the Li enolates of β-diketones, in the presence of LiCl, to give β-chloro-α,β-enones: *Can. J. Chem.*, **64**, 520 (1986). In combination with NaI, cleaves dialkyl ethers to iodides in high yield: *Synth. Commun.*, **18**, 119 (1988), and 1,3-dithianes and other dithioacetals to carbonyl groups: *Tetrahedron Lett.*, **29**, 5471 (1988). In combination with **Dimethyl sulfoxide**, **A13280**, effects selective oxidation of alcohols to aldehydes or ketones with less α-chlorination than the more usual Swern (**Oxalyl chloride**, **A18012**) system: *J. Org. Chem.*, **52**, 5621 (1987). Similarly, benzylamines have been converted to benzaldehydes: *Synth. Commun.*, **19**, 3407 (1989). For a brief feature on uses of the reagent in synthesis, see: *Synlett*, 1651 (2004).	
	Application(s): Reagent for preparation of phosphate diesters	

Stock #	Description	Size
L05681	**(R)-(+)-1-Phenyl-1-propanol, 99%** *[(R)-(+)-α-Ethylbenzyl alcohol]* [1565-74-8], $C_9H_{12}O$, F.W. 136.19, b.p. 217-219°, f.p. 95°(203°F), d. 0.993, n_D^{20} 1.5200, $[\alpha]_D^{20}$ +47° (c=2.2 in hexane), RTECS DO5470000, BRN 2041555, MDL MFCD00064279 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): For synthesis of optically active products	**100mg** **500mg**
L06608	**(S)-(-)-1-Phenyl-1-propanol, 99%** *[(S)-(-)-α-Ethylbenzyl alcohol]* [613-87-6], $C_9H_{12}O$, F.W. 136.19, b.p. 217-219°, f.p. 95°(203°F), d. 0.993, n_D^{20} 1.5200, $[\alpha]_D^{20}$ -47° (c=2.2 in hexane), RTECS DO5470000, BRN 2041556, MDL MFCD00066207 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): For synthesis of optically active products	**100mg** **500mg**
L13999	**(R)-(+)-2-Phenyl-1-propanol, 98+%** [19141-40-3], $C_9H_{12}O$, F.W. 136.19, b.p. 220°, f.p. 108°(226°F), d. 0.975, n_D^{20} 1.5260, $[\alpha]_D^{20}$ +18° (neat), MDL MFCD00145206 H:H302, P:P280f Application(s): For synthesis of optically active products	**250mg**
L13988	**(S)-(-)-2-Phenyl-1-propanol, 98+%** [37778-99-7], $C_9H_{12}O$, F.W. 136.19, b.p. 220°, f.p. 108°(226°F), d. 0.975, n_D^{20} 1.5260, $[\alpha]_D^{20}$ -18° (neat), MDL MFCD00145249 H:H302, P:P280f Application(s): For synthesis of optically active products	**250mg** **1g**
J61693	**(R)-2-Phenylpropionamide** [14182-57-1], $C_9H_{11}NO$, F.W. 149.19, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**Call**
J60150	**(S)-2-Phenylpropionamide** [13490-74-9], $C_9H_{11}NO$, F.W. 149.19, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): For synthesis of optically active products	**Call**
L16319	**(R)-(+)-1-Phenylpropylamine, ChiPros® 99+%, ee 98%** △ *[(R)-(+)-1-Amino-1-phenylpropane, (R)-(+)-α-Ethylbenzylamine]* [3082-64-2], $C_9H_{13}N$, F.W. 135.21, m.p. -69°, b.p. 205°, f.p. 77°(170°F), d. 0.930, n_D^{20} 1.5200, $[\alpha]_D^{20}$ +20° (neat), UN2735, BRN 3029904, MDL MFCD00083057 H:H314-H302-H411, P:P280-P273-P305+P351+P338-P309-P310 Application(s): For synthesis of optically active products	**1g** **5g** **25g**
L16320	**(S)-(-)-1-Phenylpropylamine, ChiPros® 99+%, ee 99%** △ *[(S)-(-)-1-Amino-1-phenylpropane, (S)-(-)-α-Ethylbenzylamine]* [3789-59-1], $C_9H_{13}N$, F.W. 135.21, m.p. -69°, b.p. 205°, f.p. 77°(170°F), d. 0.930, n_D^{20} 1.5200, $[\alpha]_D^{20}$ -20° (neat), UN2735, BRN 2412016, MDL MFCD00082356 H:H314-H302-H411, P:P280-P273-P305+P351+P338-P309-P310 Application(s): For synthesis of optically active products	**1g** **5g** **25g**
	Phenylsulfonephthalein, see Phenol Red, 16294, p. 315	
L10991	**Phloretin, 98%** *[2',4',6'-Trihydroxy-3-(4-hydroxyphenyl)propiophenone]* [60-82-2], $C_{15}H_{14}O_5$, F.W. 274.28, m.p. ca 263° dec., Merck **14**,7326, EINECS 200-488-7, BRN 1887240, MDL MFCD00002288 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Topical antioxidant	**25mg** **100mg**
B25502	**Phloroglucinol, anhydrous, 98%** ▲■ *[1,3,5-Trihydroxybenzene, 1,3,5-Benzenetriol, anhydrous]* [108-73-6], $C_6H_6O_3$, F.W. 126.11, m.p. 215-220°, Merck **14**,7328, EINECS 203-611-2, RTECS SY1050000, BRN 1341907, MDL MFCD00002286, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reacts with mono- or dimethylamine in DMF-water, with displacement of one of the OH groups, to give 5-aminoresorcinols: *Helv. Chim. Acta*, **56**, 510 (1973). The electron-rich nucleus undergoes acylation with nitriles under mild Lewis acid catalysis, to give ketones (Houben-Hoesch reaction). Selective monobromination cannot be achieved conventionally. For bromination-debromination protocols for the preparation of the mono- and di-brominated derivatives, see: *Can. J. Chem.*, **67**, 335 (1989). Application(s): Reagent for pentoses, pentosans and aldehydes. Used as a bone decalcifier in microscopy specimens	**50g** **250g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63916	**Phorbol 12-myristate 13-acetate, 99+% ▲** *[PMA, TPA]* [16561-29-8], $C_{36}H_{56}O_8$, F.W. 616.83, Film or powder, Merck **14**,7332, RTECS QH4377000, BRN 2407201, MDL MFCD00036736 ! H:H315, P:P280-P264-P302+P352-P321-P362-P332+P313 Application(s): Activates protein kinase C and promotes skin tumors in mice.	**1mg** **5mg** **10mg** **25mg**
J61099	**4α-Phorbol 12-myristate 13-acetate, 99% ▲** *[4α-PMA]* [63597-44-4], $C_{36}H_{56}O_8$, F.W. 616.83, Powder or film, Merck **14**,7332, MDL MFCD00153860 Application(s): Negative control for phorbol ester activation of protein kinase C	**1mg** **5mg**
J62267	**Phosphatase buffer 1 (5X)** Liquid, Note: This buffer contains: 100mM Tris (pH 7.5) and 100mM magnesium chloride.	**100ml** **250ml**
J65354	**Phosphatase Inhibitor Cocktail A** Liquid, Note: Contains 2.5mM (-)-p-Bromotetramisole oxalate, 500uM cantharidin and 500nM microcystin-LR Application(s): For use with tissue and cell extracts, including extracts containing detergents	**1unit**
J64651	**Phosphatase Inhibitor Cocktail B ■** Lyophilized solid, UN2811, Note: Reconstitute in 1ml water to make a solution with 200mM imidazole, 100mM sodium fluoride, 115mM sodium molybdate, 100mM sodium orthovanadate and 400mM sodium tartrate ! ! H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501 Application(s): For the inhibition of protein tyrosine phosphatases, acid- and alkaline-phosphatases	**1unit**
J64216	**Phosphatase Inhibitor Cocktail III ■** Lyophilized solid, Note: One unit contains 250mM sodium fluoride, 5mM sodium orthovanadate, 50mM sodium pyrophosphate and 50mM β-glycerophosphate when reconstituted in 1ml of water ! H:H302+EUH032-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1unit**
J64084	**Phosphatase Inhibitor Cocktail IV** Liquid, Note: 1ml in DMSO. Contains 2.5mM (-)-p-bromotetramisole oxalate, 500uM cantharidin and 1uM calyculin A, Discodermia calyx Application(s): For inhibition of both serine/threonine and alkaline phosphatases	**1ml**
J63907	**Phosphatase Inhibitor Cocktail I** Liquid, Note: This cocktail will inhibit acid-, alkaline-, and tyrosine phosphatases and is suitable for cell and tissue lysis. Contains imidazole, sodium fluoride, sodium molybdate, sodium orthovanadate, sodium pyrophosphate, and tartrate. 100X concentrate. Store at -, † ! H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**5ml**
J61022	**Phosphatase Inhibitor Cocktail II** Liquid, Note: This cocktail will inhibit broad spectrum of serine/theorine and tyrosine phosphatases and is suitable for cell and tissue lysis. Contains: sodium fluoride, sodium orthovanadate, sodium pyrophosphate, b-glycerophosphate. 100X concentrate. Store at -20 C., † ! H:H302, P:P264-P270-P301+P312-P330-P501a	**5ml**
	Phosphate acceptor peptide, see Kemptide, J60591, p. 263	
J60467	**Phosphate, 0.2M buffer soln., pH 4.4** [7558-80-7], Liquid, †	**500ml** **1L**
J60325	**Phosphate, 0.2M buffer soln., pH 6.8** [7558-80-7], Liquid, †	**500ml** **1L**
J60669	**Phosphate, 0.2M buffer soln., pH 7.0** [7558-80-7], Liquid, †	**500ml** **1L**
J62899	**Phosphate, 0.2M buffer soln., pH 7.2** [7558-80-7], Liquid, †	**500ml** **1L**
J60380	**Phosphate, 0.2M buffer soln., pH 7.4** [7558-80-7], Liquid, †	**500ml** **1L**
J61324	**Phosphate, 0.2M buffer soln., pH 7.5** [7558-80-7], Liquid, †	**500ml** **1L**
J61870	**Phosphate, 0.2M buffer soln., pH 7.6** [7558-80-7], Liquid, †	**500ml** **1L**
J60480	**Phosphate, 0.2M buffer soln., pH 8.0** [7558-80-7], Liquid, †	**500ml** **1L**
J61925	**Phosphate, 0.2M buffer soln., pH 8.5** [7558-80-7], Liquid, †	**500ml** **1L**

Stock #	Description	Size
J63581	**Phosphate, 0.2M buffer soln., pH 9.0** [7558-80-7], Liquid, †	500ml 1L
J60819	**Phosphate, 0.2M buffer soln., pH 9.5** [7558-80-7], Liquid, †	500ml 1L
J60845	**Phosphate, 0.5M buffer soln., pH 6.5** [7558-80-7], Liquid, †	250ml 500ml
J62749	**Phosphate, 0.5M buffer soln., pH 7.0** [7558-80-7], Liquid, †	250ml 500ml
J63974	**Phosphate, 0.5M buffer soln., pH 7.2** [7558-80-7], Liquid, †	250ml 500ml
J60785	**Phosphate, 0.5M buffer soln., pH 7.4** [7558-80-7], Liquid, †	250ml 500ml
J63349	**Phosphate, 0.5M buffer soln., pH 7.5** [7558-80-7], Liquid, †	250ml 500ml
J60197	**Phosphate, 0.5M buffer soln., pH 7.6** [7558-80-7], Liquid, †	250ml 500ml
J61722	**Phosphate, 0.5M buffer soln., pH 8.0** [7558-80-7], Liquid, †	250ml 500ml
J61086	**Phosphate, 0.5M buffer soln., pH 8.5** [7558-80-7], Liquid, †	250ml 500ml
J62345	**Phosphate, 0.5M buffer soln., pH 9.0** [7558-80-7], Liquid, † H:EUH210	250ml 500ml
J62025	**Phosphate, 0.5M buffer soln., pH 9.5** [7558-80-7], Liquid, †	250ml 500ml
J62694	**Phosphate buffered RIPA** Liquid, Note: This product contains: 10mM sodium phosphate (pH 7.2), 150mM sodium chloride, 1% Triton X-100 , 0.5% sodium deoxycholate and 0.1% SDS.	250ml 500ml
J60780	**Phosphate buffered RIPA (2X)** Liquid, Note: Contains: 20mM sodium phosphate, 300mM NaCl, 2% Triton X-100,1% sodium deoxycholate, and 0.2% SDS, pH 7.2., †	125ml 250ml
J62939	**Phosphate buffered RIPA with glycerol (2X)** Liquid, Note: Contains: 20mM sodium phosphate, 300mM NaCl, 2% Triton X-100,1% sodium deoxycholate, and 0.2% SDS, with 10% glycerol, pH 7.2.	125ml 250ml
J62036	**Phosphate-buffered saline (PBS, 10X), pH 7.4** Liquid, Note: Contains 100mM phosphate buffer, 27mM potassium chloride, and 1.37M sodium chloride at pH 7.4, †	1L 2L 4L
J60801	**Phosphate-buffered saline (PBS, 10X), pH 7.4, for Western blot** Liquid, Note: Contains: 100mM phosphate and 1.5M NaCl at pH 7.4 Application(s): For western blot washing.	1L 2L 4L
J62692	**Phosphate-buffered saline (PBS, 10X), pH 7.6** Liquid, Note: Contains 100mM phosphate, 27mM KCl and 1.37M NaCl, pH 7.6.	1L 2L 4L
J62851	**Phosphate-buffered saline (PBS, 10X), RNAse free** Liquid, †	250ml 500ml
J61917	**Phosphate-buffered saline (DPBS, 10X), Dulbecco's formula** Liquid	500ml 1L 2L
J61196	**Phosphate-buffered saline (PBS, 1X), sterile** Liquid, Note: 137mM sodium chloride 2.7mM potassium chloride, 10mM Na2HPO4, and 1mM KH2PO4, pH 7.4, †	500ml
J60893	**Phosphate-buffered saline (PBS, 5X), with EDTA** Liquid, Note: 5X PBS with 50mM EDTA, pH 7.4	1L 2L

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63521	**Phosphate-buffered saline (PBS, 10X), with Triton® X-100** Liquid, Note: 10X formulation with 1% Triton X-100.	250ml 500ml
J60465	**Phosphate-buffered saline (PBS, 10X), no potassium** Liquid, Note: Contains 80mM phosphate, 1.37 M NaCl, at pH range 7.4. H:EUH210	500ml 1L
J62982	**Phosphate-Citrate Buffer (5X)** Liquid, Note: Contains 1M sodium phosphate and 0.5M sodium citrate.	100ml 250ml
	L-a-Phosphatidylcholine , see Lecithin, 60%, egg, J60576, p. 268	
J64598	**Phosphodiesterase Inhibitor (IBMX)**	100mg
J64453	**Phosphodiesterase 4 Inhibitor ▲** *[Ethyl 3,5-dimethyl-1-(3-nitrophenyl)-1H-pyrazole-4-carboxylate]* [346440-86-6], $C_{14}H_{15}N_3O_4$, F.W. 289.29, Solid	5mg 25mg
	Phosphoenolpyruvate kinase, see Pyruvate Kinase, rabbit muscle, J61373, p. 333	
J61943	**Phosphoenolpyruvic acid tricyclohexylammonium salt, 99+%** *[2-(Phosphonooxy)-2-propenoic acid tri(cyclohexylammonium) salt, PEP-tri]* [35556-70-8], $C_3H_5O_6P \cdot 3C_6H_{13}N$, F.W. 465.58, Powder, EINECS 252-618-7, BRN 3752336, MDL MFCD00004258, † Application(s): Metabolic intermediate in many kinase reactions	1g 5g 25g
J63013	**Phosphoenolpyruvic acid trisodium salt heptahydrate, 98%** *[2-(Phosphonooxy)-2-propenoic acid trisodium salt, PEP-triNa]* [5541-93-5], $C_3H_2Na_3O_6P \cdot 7H_2O$, F.W. 360.09, Powder, EINECS 226-906-8, MDL MFCD00150737, † Application(s): When coupled with pyruvate kinase it completes an ATP-regenerating system	1g 5g
	Phosphoenol transphosphorylase, see Pyruvate Kinase, rabbit muscle, J61373, p. 333 **2-(Phosphonooxy)-2-propenoic acid tri(cyclohexylammonium) salt**, see Phosphoenolpyruvic acid tricyclohexylammonium salt, 99+%, J61943, p. 321 **2-(Phosphonooxy)-2-propenoic acid trisodium salt**, see Phosphoenolpyruvic acid tricyclohexylammonium salt, 99+%, J63013, p. 321	
J63456	**Phosphoramidon disodium salt, 97+%** [119942-99-3], $C_{23}H_{32}N_3Na_2O_{10}P$, F.W. 587.47, Solid, BRN 8105669, MDL MFCD00077870 Application(s): Inhibitor of thermolysin and collagenase	5mg
	Phosphoric acid (ortho), see Orthophosphoric acid, 33266, p. 309 **1(2H)-Phthalazinone hydrazone**, see 1-Hydrazinophthalazine hydrochloride, B22995, p. 247 **Phthalein complexone**, see o-Cresolphthalein complexone, L03859, p. 169 **Phthalic acid di-n-butyl ester**, see Di-n-butyl phthalate, A13257, p. 185 **Phylloquinone**, see Vitamin K_1, L10575, p. 393	
J62647	**Physalaemin** *[Glp-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH2]* [2507-24-6], $C_{58}H_{84}N_{14}O_{16}S$, F.W. 1265.45, Powder, Merck **14**,7381, MDL MFCD00076375 Application(s): A vasodilator and hypotensive agent	1mg 5mg
	Physostigmine, see Eserine, J61477, p. 210 **Phytagel**, see Gellan Gum, J63423, p. 231	
J64277	**Pifithrin-α, p-Nitro hydrobromide ▲■** *[1-(4-Nitrophenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzpthiazolyl)ethanone hydrobromide]* [389850-21-9], $C_{15}H_{16}BrN_3O_3S \cdot HBr$, F.W. 398.30, Solid	5mg
B21410	**(+)-Pilocarpine hydrochloride, 99% ▲■** [54-71-7], $C_{11}H_{16}N_2O_2 \cdot HCl$, F.W. 244.72, m.p. 202-205°, Merck **14**,7424, UN1544, EINECS 200-212-5, RTECS TK1450000, MDL MFCD00012722, † H:H300-H330, P:P301+P310-P304+P340-P320-P330-P405-P501a 	1g 5g 25g
H56648	**D-Pinitol, 95%** *[3-O-Methyl-D-chiro-inositol]* [10284-63-6], $C_7H_{14}O_6$, F.W. 194.18, m.p. 178-185°, Merck **14**,10361, MDL MFCD00216659 	250mg 1g 5g
	Piperazine-1,4-bis(ethanesulfonic acid), see PIPES, A16090, p. 322 **Piperazine-1,4-bis(ethanesulfonic acid) monosodium salt**, see PIPES monosodium salt, B21835, p. 322 **2,5-Piperazinedione**, see Glycine anhydride, A18822, p. 237 **2-(1-Piperazinyl)quinoline maleate salt**, see Quipazine dimaleate, 99+%, J61933, p. 334	
A12442	**Piperidine, 99% △** [110-89-4], $C_5H_{11}N$, F.W. 85.15, m.p. -11°, b.p. 105-106°, f.p. 3°(37°F), d. 0.862, n_D^{20} 1.4520, Merck **14**,7468, Fieser **1**,886 **2**,332 **4**,393 **6**,472 **7**,293 **19**,272, UN2401, EINECS 203-813-0, RTECS TM3500000, BRN 102438, MDL MFCD00005979, †  H:H225-H311-H331-H314, P:P210-P303+P361+P353-P305+P351+P338-P361-P405-P501a Base catalyst in the Doebner modification of the Knoevenagel condensation; see **Malonic acid**, **A11526**, p. 276. Widely used for cleavage of Fmoc protecting groups: *J. Org. Chem.*, **52**, 1197 (1987); *Tetrahedron Lett.*, **34**, 6135 (1993). For preparation of the piperidine enamine of cyclooctanecarboxaldehyde, and its subsequent use in the synthesis of spirohexadienones, see: *Org. Synth. Coll.*, **7**, 473 (1990).	100ml 500ml 2.5L

Stock #	Description	Size
	(±)-Piperidine-3-carboxylic acid, see Nipecotic acid, B24723, p. 303 **Piperidine-4-carboxylic acid**, see Isonipecotic acid, A11795, p. 261 **N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate salt**, see Flecainide acetate, 98%, J63527, p. 221	
A16090	**PIPES, 98%** *[Piperazine-1,4-bis(ethanesulfonic acid)]* [5625-37-6], $C_8H_{18}N_2O_6S_2$, F.W. 302.37, m.p. >300°, Merck **14**,7479, EINECS 227-057-6, BRN 817713, MDL MFCD00006159, † Biological buffer, pKa = 6.8 at 20°: *Biochemistry*, **5**, 467 (1966). 	**25g** **100g** **500g**
B21835	**PIPES monosodium salt hydrate, 99%** *[Piperazine-1,4-bis(ethanesulfonic acid) monosodium salt]* [10010-67-0], $C_8H_{17}N_2NaO_6S_2 \cdot xH_2O$, F.W. 324.34(anhy), m.p. >300°, Merck **14**,7479, EINECS 233-005-3, MDL MFCD00065472, † 	**25g** **100g**
J60891	**PIPES, 0.5M buffer soln., pH 5.5** [5625-37-6], Liquid, †	**100ml** **250ml**
J62224	**PIPES, 0.5M buffer soln., pH 6.0** [5625-37-6], Liquid, †	**100ml** **250ml**
J61224	**PIPES, 0.5M buffer soln., pH 6.5** [5625-37-6], Liquid, †	**100ml** **250ml**
J61786	**PIPES, 0.5M buffer soln., pH 6.8** [5625-37-6], Liquid, †	**100ml** **250ml**
J63234	**PIPES, 0.5M buffer soln., pH 7.0** [5625-37-6], Liquid, †	**100ml** **250ml**
J63617	**PIPES, 0.5M buffer soln., pH 7.5** [5625-37-6], Liquid, †	**100ml** **250ml**
J61406	**PIPES, 0.5M buffer soln., pH 8.0** [5625-37-6], Liquid, †	**100ml** **250ml**
J60611	**PIPES, 1.0M buffer soln., pH 6.0** [5625-37-6], Liquid, †	**250ml** **500ml**
J60659	**PIPES, 1.0M buffer soln., pH 6.5** [5625-37-6], Liquid, †	**250ml** **500ml**
J60300	**PIPES, 1.0M buffer soln., pH 6.8** [5625-37-6], Liquid, †	**250ml** **500ml**
J62195	**PIPES, 1.0M buffer soln., pH 7.0** [5625-37-6], Liquid, †	**250ml** **500ml**
J62494	**PIPES, 1.0M buffer soln., pH 7.5** [5625-37-6], Liquid, †	**250ml** **500ml**
J60618	**PIPES, 1.0M buffer soln., pH 8.0** [5625-37-6], Liquid, †	**250ml** **500ml**
J63152	**PIPES-buffered saline (5X), pH 6.5** [5625-37-6], Liquid, Note: Contains 50mM PIPES and 750mM NaCl, pH 6.5., †	**250ml** **500ml**
J60947	**PIPES-buffered saline (5X), pH 6.8** [5625-37-6], Liquid, Note: Contains 50mM PIPES, 750mM NaCl at pH 6.8., †	**250ml** **500ml**
J63543	**PIPES-buffered saline (5X), pH 7.0** [5625-37-6], Liquid, Note: Contains 50mM PIPES, 750mM NaCl at pH 7.0., †	**250ml** **500ml**
J62278	**PIPES lysis buffer with NP-40** Liquid, Note: Contains 25mM PIPES (pH 7.0), 150mM sodium chloride, 1% NP-40 and 5mM EDTA.	**250ml** **500ml**
J60568	**PIPES lysis buffer with NP-40 (2X)** Liquid, Note: Contains 50mM PIPES (pH 7.0), 300mM NaCl, 2% NP-40 and 10mM EDTA.	**125ml** **250ml**
J62360	**PIPES lysis buffer with Triton® X-100** Liquid, Note: Contains 25mM PIPES (pH 7.0), 150mM NaCl, 1% Triton X-100 and 5mM EDTA.	**250ml** **500ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62068	**PIPES lysis buffer with Triton® X-100 (2X)** Liquid, Note: Contains 50mM PIPES (pH 7.0), 300mM NaCl, 2% Triton X-100 and 10mM EDTA.	**125ml** **250ml**
	Pipsyl chloride, see 4-Iodobenzenesulfonyl chloride, B24416, p. 257	
J62252	**Pirenzepine dihydrochloride, 99%** ■ [29868-97-1], $C_{19}H_{21}N_5O_2 \cdot 2HCl$, F.W. 424.32, Powder, m.p. 192-198°, Merck **14**,7491, EINECS 249-907-5, RTECS UU7883000, MDL MFCD00055214 Application(s): A M1 muscarinic receptor antagonist	**100mg** **1g** **5g**
J63239	**Piroxicam** *[Piroxicamum, Larapam]* [36322-90-4], $C_{15}H_{13}N_3O_4S$, F.W. 331.35, Powder, Merck **14**,7506, UN2811, EINECS 252-974-3, RTECS DL0705000, MDL MFCD00057317 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): A non-steroidal anti-inflammatory drug (NSAID) that is a highly selective inhibitor of cyclooxygenase-1 (COX-1)	**1g** **5g** **10g**
	Piroxicamum, see Piroxicam, J63239, p. 323 **Pituitary adenylate cyclase activating fragment 21-38**, see Litorin, J60177, p. 272 **Pivaloyloxymethyl chloride**, see Chloromethyl pivalate, A11967, p. 157	
J61263	**Plasmid DNA isolation solution I** Liquid, Note: Contains 50mM glucose, 25mM Tris-HCl (pH 8.0) and EDTA	**250ml** **500ml**
J63486	**Plasmid DNA isolation solution II** Liquid, Note: Contains 0.2M sodium hydroxide and 1% SDS. H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**250ml** **500ml**
J60196	**Plasmid DNA isolation solution III** Liquid, Note: Contains 5M Potassium Acetate and 11.5ml glacial acetic acid in 28.5ml of water. The resulting solution is 3M with respect to potassium and 5M with respect to acetate.	**250ml** **500ml**
J64463	**Platelet-Derived Growth Factor-AA, human, Receptor Grade, 97%** *[PdGF-AA]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for use in cell culture. Supplied as an aseptically lyophilized powder	**5micrograms**
J64812	**Platelet-Derived Growth Factor-BB, human, Receptor Grade, 97%** *[PdGF-BB]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for cell culture. Supplied as a a lyophilzed powder in silanized vial.	**1microgram**
J64483	**Platelet-Poor Plasma Derived Serum, bovine** *[Bovine serum, from platelet poor plasma]*	**10ml** **100ml**
	Plendil, see Felodipine, J61195, p. 219 **PN 200-110**, see Isradipine, 98+%, J63920, p. 261 **pNPP disodium salt**, see 4-Nitrophenyl phosphate disodium salt hexahydrate, 5mg tablets, J61401, p. 304	
J61495	**Polyethylene glycol (PEG), 50% soln.** [25322-68-3], $H(OCH_2CH_2)_nOH$, Liquid, Note: Contains 50% PEG 3350 in 1M Lithium Acetate solution, pH 4.9., † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**100ml** **250ml**
B21918	**Polyethylene glycol 200** ■ *[PEG 200]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. -55 to -40°, f.p. 171°(339°F), d. 1.127, n_D^{20} 1.4590, Merck **14**,7568, Fieser **12**,399, EINECS 203-473-3, RTECS TQ3600000, MDL MFCD01779596, † A mixture of PEG200 with dichloromethane has been recommended as a solvent system for the Sandmeyer conversion of aromatic amines to halides, giving particularly good results for aryl chlorides: *J. Chem. Soc., Chem. Commun.*, 1523 (1984). For use of polyethylene glycols as phase-transfer catalysts, see **Polyethylene glycol 400**, **B21992**, p. 323.	**250g** **500g** **1kg**
B21992	**Polyethylene glycol 400** ■ *[PEG 400]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 4-8°, n_D^{20} 1.4660, Merck **14**,7568, MDL MFCD01779601, † Polyethylene glycols can act as effective solvents and low-cost phase-transfer catalysts by complexing with cations Examples of reactions promoted by these species: Nucleophilic displacements of benzyl halides: *Synthesis*, 184 (1977). Permanganate oxidations: *J. Org. Chem.*, **43**, 1532 (1978); *Tetrahedron Lett.*, 3543 (1979). Dichromate oxidations; similar results to carcinogenic HMPA, and to crown ethers. Good solvent for borohydride reductions: *Tetrahedron Lett.*, 4581 (1979). Stereoselective reduction of alkynes to *cis*-alkenes using $NaBH_4$ and a catalytic amount of $PdCl_2$ in dichloromethane-PEG: *J. Chem. Soc., Chem. Commun.*, 515 (1982). Wacker oxidation of olefins to methyl ketones: *Tetrahedron Lett.*, **26**, 2263 (1985). Conversion of acids to peracids; see **Potassium peroxydisulfate**, **A15310**. Recyclable medium for rapid Baylis-Hillman reactions (see **Ammonium bismuth citrate**, **A17003**): *Tetrahedron Lett.*, **45**, 5865 (2004).	**250g** **1kg**

Stock #	Description	Size
B21798	**Polyethylene glycol 600** *[PEG 600]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 17-23°, f.p. 252°(485°F), d. 1.120, n_D^{20} 1.4680, Merck **14**,7568, Fieser **12**,399, EINECS 500-038-2, RTECS TQ3800000, MDL MFCD00081839, † Catalyzes the reaction of potassium aryloxides with dichloromethane at room temperature to give good yields of diaryloxymethanes: *J. Chem. Res. (Synop.)*, 503 (1995).	**250g** **1kg**
B22134	**Polyethylene glycol 1,000** *[PEG 1000]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 35-40°, f.p. 260°(500°F), d. 1.101, Merck **14**,7568, Fieser **12**,399, RTECS TQ4025000, MDL MFCD01779605, †	**250g** **1kg**
A16241	**Polyethylene glycol 1,500** *[PEG 1500]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 44-48°, Merck **14**,7568, EINECS 500-038-2, RTECS TQ4030000, MDL MFCD01779609, Note: M.W. range 1,300-1,600, †	**250g** **1kg**
B22181	**Polyethylene glycol 2,000** *[PEG 2000]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 53-55°, Merck **14**,7568, RTECS TQ4041000, MDL MFCD01779611, †	**250g** **1kg**
A16151	**Polyethylene glycol 4,000** *[PEG 4000]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 58-62°, Merck **14**,7568, RTECS TQ4050000, MDL MFCD01779612, Note: M.W range 3,000-3,700, †	**250g** **1kg** **5kg**
A17541	**Polyethylene glycol 6,000** *[PEG 6000]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 60-63°, Merck **14**,7568, EINECS 203-473-3, RTECS TQ4100000, MDL MFCD01779614, †	**250g** **1kg** **5kg**
43443	**Polyethylene glycol 8,000** *[PEG 8000]* [25322-68-3], $H(OCH_2CH_2)_nOH$, Powder, m.p. 60-63°, Merck **14**,7568, MDL MFCD01779615, Note: M.W. range 7000 - 9000, †	**100g** **500g** **2kg** **10kg**
B21955	**Polyethylene glycol 10,000** *[PEG 10000]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 58-63°, f.p. 265°(509°F), d. 1.2, Merck **14**,7568, EINECS 203-473-3, RTECS TQ4110000, MDL MFCD00081839, †	**250g** **1kg**
42635	**Polyethylene glycol 12,000** *[PEG 12000, Carbowax®]* [25322-68-3], $H(OCH_2CH_2)_nOH$, Powder, m.p. 64-65°, f.p. ≥240°(464°F), Merck **14**,7568, MDL MFCD00081839, Note: M.W. range 11,000 - 13,000, †	**250g** **1kg**
A17925	**Polyethylene glycol 20,000** *[PEG 20000]* [25322-68-3], $H(OCH_2CH_2)_nOH$, m.p. 63-66°, f.p. 260°(500°F), d. 1.20, Merck **14**,7568, EINECS 203-473-3, MDL MFCD00081839, Note: M.W. ≈20,000, †	**250g** **1kg**
J62213	**Polyethylene glycol-lithium acetate soln.** *[PEG-LiOAc soltuion, PEG-lithium acetate solution]* Liquid, Note: Contains 40% PEG 3350 in solution with 100mM lithium acetate, 10mM Tris-HCl, and 1mM EDTA, pH8.0. Application(s): Common solution for protein and DNA isolation from yeast	**250ml** **500ml**
	Polyethylene glycol tert-octylphenyl ether, see Triton® X-100, A16046, p. 383	
J61270	**Polyethyleneimine, M.W. 60,000, 50% w/w aq. soln.** [9002-98-6], -HN-$[CH_2CH_2NH-]_n$, Liquid, d. 1.07, MDL MFCD00084427, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A protein precipitant used to purify proteins	**100g** **250g**
40529	**Polyethyleneimine, branched, M.W. 70,000, 30% w/v aq. soln.** [9002-98-6], $(-NHCH_2CH_2-)_x(-N(CH_2CH_2NH_2)CH_2CH_2-)y$, Liquid, MDL MFCD00803910, † ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A protein precipitant used to purify proteins	**25g** **100g** **500g**
	Poly-D-galacturonic acid methyl ester, see Pectin Citrus, J61021, p. 312	
J65578	**Poly-D-lysine hydrobromide**	**5mg**
	Polymannuronic acid, see Alginic acid, A17582, p. 89 **Polymannuronic acid sodium salt**, see Alginic acid sodium salt, A18565, p. 89	

Stock #	Description	Size
J63074	**Polymixin B sulfate** *[Aerosporin]* [1405-20-5], $C_{55}H_{96}N_{16}O_{13}·2H_2SO_4$, F.W. 1385.63, Powder, Merck **14**,7573, EINECS 215-774-7, RTECS TR150000, MDL MFCD00131991 ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Antibiotic for gram-negative bacteria	**1g** **5g**
J61763	**Polymixin B sulfate, Cell Culture Reagent** [1405-20-5], $C_{55}H_{96}N_{16}O_{13}·2H_2SO_4$, F.W. 1385.63, Powder, Merck **14**,7573, EINECS 215-774-7, RTECS TR150000, MDL MFCD00131991 ! H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Antibiotic for gram-negative bacteria	**1g** **5g**
	Polymyxin E, see Colistin sulfate, J60915, p. 167 **Polyoxyethylene sorbitan monolaurate**, see Polysorbate 20, L15029, p. 325 **Polyoxyethylene sorbitan monooleate**, see Polysorbate 80, L13315, p. 325	
L15029	**Polysorbate 20** *[Polyoxyethylene sorbitan monolaurate]* [9005-64-5], $C_{58}H_{114}O_{26}$, b.p. >100°, f.p. >110°(230°F), d. 1.105, n_D^{20} 1.4700, RTECS TR7400000, MDL MFCD00165986, † Application(s): Used for solubilizing membrane proteins during isolation and purification	**100ml** **500ml**
L13315	**Polysorbate 80** *[Polyoxyethylene sorbitan monooleate]* [9005-65-6], b.p. >100°, f.p. >149°(300°F), d. 1.064, n_D^{20} 1.4720, Merck **14**,7582, RTECS WG2932500, MDL MFCD00082107, † Application(s): Used for solubilizing membrane proteins during isolation and purification	**100ml** **500ml** **2.5L**
	Polystyrene PHB, see Wang resin, L17028, p. 393 **Polysucrose 400**, see Ficoll® 400, B22095, p. 221	
41238	**Polyvinyl alcohol, 86-89% hydrolyzed, low molecular weight** [9002-89-5], $[-CH_2CH(OH)-]_n$, MDL MFCD00081922, Note: Average MW: 10,000 to 26,000, †	**25g** **100g** **500g**
41626	**Polyvinylpyrrolidone, M.W. 8,000** *[PVP]* [9003-39-8], $(C_6H_9NO)_n$, Powder, m.p. 130°, Merck **14**,7697, MDL MFCD00149016, †  Application(s): A cryoprotectant, also useful in plant cell culture research	**100g** **500g**
J60382	**Polyvinylpyrrolidone, M.W. 10,000** *[PVP K15, Povidone]* [9003-39-8], $(C_6H_9NO)_n$, Powder, Merck **14**,7697, RTECS TR8370000, MDL MFCD00149016, † Application(s): A cryoprotectant, also useful in plant cell culture research	**25g** **100g** **500g**
J62417	**Polyvinylpyrrolidone, M.W. 40,000** *[PVP, Povidone]* [9003-39-8], $(C_6H_9NO)_n$, Powder, Merck **14**,7697, RTECS TR8370000, MDL MFCD00149016, † Application(s): A cryoprotectant, also useful in plant cell culture research	**100g** **500g** **1kg**
A14315	**Polyvinylpyrrolidone, average M.W. 58,000** *[PVP K-30]* [9003-39-8], $(C_6H_9NO)_n$, Merck **14**,7697, MDL MFCD00149016, † Application(s): A cryoprotectant, also useful in plant cell culture research	**100g** **500g** **2.5kg**
J61381	**Polyvinylpyrrolidone, M.W. 360,000** *[PVP K90, Povidone]* [9003-39-8], $(C_6H_9NO)_n$, Powder, Merck **14**,7697, RTECS TR8370000, MDL MFCD00149016, † Application(s): A cryoprotectant, also useful in plant cell culture research	**250g** **500g** **1kg**
43728	**Polyvinylpyrrolidone, M.W. 1,300,000** ■ [9003-39-8], $(C_6H_9NO)_n$, Powder, Merck **14**,7697, MDL MFCD00149016, †	**50g** **250g** **1kg**
	POM-Cl, see Chloromethyl pivalate, A11967, p. 157	
J63139	**Ponceau S, 0.2% v/v soln. in 5% acetic acid** *[C.I. 27195, Acid Red 112]* [6226-79-5], $C_{22}H_{12}N_4Na_4O_{13}S_4$, F.W. 760.56, Liquid, MDL MFCD00003892 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**500ml** **1L**
J60744	**Ponceau S, Electrophoresis Grade** *[C.I. 27195]* [6226-79-5], $C_{22}H_{12}N_4Na_4O_{13}S_4$, F.W. 760.58, Powder, EINECS 228-319-2, RTECS QJ6600000, MDL MFCD00003892, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Protein stain for electrophoresis	**10g** **50g** **250g**
	Pontamine Sky Blue 6BX, see Chicago Sky Blue 6B, A14242, p. 153	

Stock #	Description	Size
J63333	**POPSO, 0.2M buffer soln., pH 7.0** [108321-07-9], Liquid	**100ml** **250ml**
J60869	**POPSO, 0.2M buffer soln., pH 7.5** [108321-07-9], Liquid	**100ml** **250ml**
J60085	**POPSO, 0.2M buffer soln., pH 8.0** [108321-07-9], Liquid	**100ml** **250ml**
J60623	**POPSO, 0.2M buffer soln., pH 8.5** [108321-07-9], Liquid	**100ml** **250ml**
J62817	**Potassium acetate, 1M aq. soln., pH 7.5** [127-08-2], CH_3CO_2K, F.W. 98.15, Liquid, †	**100ml** **250ml**
J60832	**Potassium acetate, 1M aq. soln., pH 7.5, RNAse free** [127-08-2], CH_3CO_2K, F.W. 98.15, Liquid, †	**125ml** **250ml**
J63372	**Potassium acetate, 8M aq. soln.** [127-08-2], CH_3CO_2K, F.W. 98.15, Liquid, † H:H303, P:P312	**100ml** **250ml**
J62856	**Potassium acetate, 8M aq. soln., RNAse free** [127-08-2], CH_3CO_2K, F.W. 98.15, Liquid, † H:H303, P:P312	**125ml** **250ml**
	Potassium benzylpenicillinate, see Penicillin G potassium salt, J63901, p. 313 **Potassium Channel Opener**, see PCO-400, J60502, p. 312	
J63739	**Potassium chloride, 1M aq. soln.** [7447-40-7], KCl, F.W. 74.55, Liquid, †	**100ml** **250ml**
J60105	**Potassium chloride, 1M aq. soln., autoclaved** [7447-40-7], KCl, F.W. 74.55, Liquid, † H:H303, P:P312	**100ml** **250ml**
J62422	**Potassium chloride, 1M aq. soln., RNAse free** [7447-40-7], KCl, F.W. 74.55, Liquid, † H:H303, P:P312	**125ml** **250ml**
11595	**Potassium chloride, ACS, 99.0-100.5%** ■ [7447-40-7], KCl, F.W. 74.55, Crystalline, m.p. 773°, b.p. 1500° subl., d. 1.984, n_D^{20} 1.490, Merck **14**,7621, Fieser **6**,480, Solubility: Freely soluble in water. Soluble in glycerol, alcohol, EINECS 231-211-8, RTECS TS8050000, MDL MFCD00011360, † Maximum level of impurities: Insoluble matter 0.005%, pH of a 5% solution 5.4-8.6 at 25°, I 0.002%, Br 0.01%, NO_3 0.003%, PO_4 5ppm, SO_4 0.001%, Ba P.T. (limit about 0.001%), Ca 0.002%, Mg 0.001%, Heavy Metals (as Pb) 5ppm, Fe 3ppm, Na 0.005% H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): In buffer solution, electrode cells, photography, lab reagent, fertilizer, spectroscopy	**1kg** **5kg**
J65093	**Potassium dihydrogen arsenate, 98%** *[Potassium arsenate, monobasic, Arsenic acid potassium salt]* [7784-41-0], KH_2AsO_4, F.W. 180.03, Powder, m.p. 277-283°, Merck **14**,7607, UN1677, EINECS 232-065-8, RTECS CG1100000, MDL MFCD00036296, † H:H301-H330-H350-H410, P:P301+P310-P304+P340-P320-P330-P405-P501	**25g** **100g** **500g**
11594	**Potassium dihydrogen phosphate, ACS, 99.0% min** ■ *[Potassium orthophosphate, Potassium phosphate, monobasic]* [7778-77-0], KH_2PO_4, F.W. 136.09, Crystalline, m.p. 253°, d. 2.338, Merck **14**,7659, Solubility: Slightly soluble in water. Insoluble in alcohol, EINECS 231-913-4, RTECS TC6615500, MDL MFCD00011401, Note: Loses H_2O at 400°, forming metaphosphate, † Maximum level of impurities: Insoluble matter 0.01%, Loss on drying at 105° 0.2%, pH of a 5% solution 4.1-4.5 at 25°, Cl 0.001%, SO_4 0.003%, Heavy Metals (as Pb) 0.001%, Fe 0.002%, Na 0.005% H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 Application(s): In buffers for pH determination.	**250g** **500g** **1kg**
11593	**Potassium hydrogen phosphate, ACS, 98.0% min** ■ *[Potassium phosphate, dibasic, Dipotassium phosphate]* [7758-11-4], K_2HPO_4, F.W. 174.18, Powder, Merck **14**,7658, Solubility: Soluble in water. Slightly soluble in alcohol, EINECS 231-834-5, RTECS TC5580000, MDL MFCD00011383, † Maximum level of impurities: Insoluble matter 0.01%, Loss on drying at 105° 1.0%, pH of a 5% solution 8.5-9.6 at 25°, Cl 0.003%, Nitrogen compounds (as N) 0.001%, SO_4 0.005%, Heavy Metals (as Pb) 5ppm, Fe 0.001%, Na 0.05% H:H319, P:P280-P264-P305+P351+P338-P337+P313	**250g** **1kg** **5kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A12428	**Potassium hydrogen sulfate, 97%** ■ *[Potassium bisulfate]* [7646-93-7], $KHSO_4$, F.W. 136.17, m.p. 195-197° dec., d. 2.240, Merck **14**,7613, Fieser **1**,909, UN2509, EINECS 231-594-1, RTECS TS7200000, MDL MFCD00011404, † H:H314-H335, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**100g** **500g** **2.5kg** **10kg**
13451	**Potassium hydroxide, ACS, 85% min, K_2CO_3 2.0% max** △ ■ [1310-58-3], KOH, F.W. 56.11, Pellets, m.p. 360°, b.p. 1320-1324°, d. 2.044, Merck **14**,7640, Fieser **1**,935 **4**,409 **5**,557 **6**,486 **7**,303 **8**,415 **9**,387 **11439**, **21**,360, Solubility: Soluble in water, alcohol, and glycerol. Slightly soluble in ether, UN1813, EINECS 215-181-3, RTECS TT2100000, MDL MFCD00003553, Note: Usually contains 10-15% water, † Maximum level of impurities: Cl 0.01%, Nitrogen compounds (as N) 0.001%, PO_4 5ppm, SO_4 0.003%, Heavy Metals (as Ag) 0.001%, Fe 0.001%, Ni 0.001%, Ca 0.005%, Mg 0.002%, Na 0.05% H:H314-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): In soap manufacture, in bleaching, as an electrolyte, as an absorbent, in dyestuffs, in liquid fertilizer, in electroplating, as a reagent	**50g** **500g** **2kg** **10kg**
	Potassium 2-naphthyl sulfate, see 2-Naphthyl sulfate potassium salt, 44061, p. 298 **Potassium orthophosphate**, see Potassium dihydrogen phosphate, 11594, p. 326	
13145	**Potassium peroxydisulfate, ACS, 99.0% min** *[Potassium persulfate]* [7727-21-1], $K_2S_2O_8$, F.W. 270.33, Crystalline, m.p. 100° dec., d. 2.477, Merck **14**,7656, Fieser **1**,952 **3**,238 **5**,563 **7**,274 **8**,417 **10**,331 **11**,441 **15**,274 **20**,316, UN1492, EINECS 231-781-8, RTECS SE0400000, MDL MFCD00011386, † Maximum level of impurities: Insoluble matter 0.005%, Chlorine compounds (as Cl) 0.001%, Heavy Metals (as Pb) 0.001%, Fe 5ppm, Mn 2ppm H:H334-H272-H302-H335-H315-H319-H317, P:P221-P210-P285-P305+P351+P338-P405-P501a Application(s): A polymerization accelerant for PAGE gels	**250g** **1kg**
	Potassium persulfate, see Potassium peroxydisulfate, 13145, p. 327	
J61261	**Potassium phosphate, 0.2M buffer soln., pH 7.0** [7778-77-0], Liquid, †	**500ml** **1L**
J60664	**Potassium phosphate, 0.2M buffer soln., pH 7.2** [7778-77-0], Liquid, †	**500ml** **1L**
J62397	**Potassium phosphate, 0.2M buffer soln., pH 7.4** [7778-77-0], Liquid, †	**500ml** **1L**
J62239	**Potassium phosphate, 0.2M buffer soln., pH 7.5** [7778-77-0], Liquid, †	**500ml** **1L**
J63128	**Potassium phosphate, 0.2M buffer soln., pH 7.6** [7778-77-0], Liquid, †	**500ml** **1L**
J60851	**Potassium phosphate, 0.2M buffer soln., pH 8.0** [7778-77-0], Liquid, †	**500ml** **1L**
J60584	**Potassium phosphate, 0.5M buffer soln., pH 7.0** [7778-77-0], Liquid, †	**250ml** **500ml**
J60326	**Potassium phosphate, 0.5M buffer soln., pH 7.2** [7778-77-0], Liquid, †	**250ml** **500ml**
J61413	**Potassium phosphate, 0.5M buffer soln., pH 7.4** [7778-77-0], Liquid, †	**250ml** **500ml**
J61553	**Potassium phosphate, 0.5M buffer soln., pH 7.5** [7778-77-0], Liquid, †	**250ml** **500ml**
J63189	**Potassium phosphate, 0.5M buffer soln., pH 7.6** [7778-77-0], Liquid, †	**250ml** **500ml**
	Potassium phosphate, dibasic, see Potassium hydrogen phosphate, 11593, p. 326 **Potassium phosphate, monobasic**, see Potassium dihydrogen phosphate, 11594, p. 326	
33241	**Potassium sodium L-tartrate tetrahydrate, ACS, 99.0-102.0%** *[Rochelle Salt, Sodium potassium tartrate]* [6381-59-5], $C_4H_4KNaO_6 \cdot 4H_2O$, F.W. 282.23 (210.29anhy), Crystalline, m.p. 70-80°, d. 1.77, Merck **14**,7670, EINECS 206-156-8, BRN 6113568, MDL MFCD00150989, Note: Loses water of crystallization at 140° unstable above 225°, † Maximum level of impurities: Insoluble matter 0.005%, Chloride (as Cl) 0.0015, PO_4 0.002%, SO_4 0.005%, NH_4 0.002%, Ca 0.005%, Heavy Metals (as Pb) 5ppm, Fe 0.001%, pH of a 5% solution 6.0-8.5 at 25°	**100g** **500g** **2.5kg**

Stock #	Description	Size
14311	**Potassium sulfate, ACS, 99.0% min** [7778-80-5], K_2SO_4, F.W. 174.27, Crystalline, m.p. 1069°, b.p. 1689°, d. 2.662, Merck **14**,7674, Solubility: Soluble in water. Insoluble in alcohol, EINECS 231-915-5, RTECS TT5900000, MDL MFCD00011388, † Maximum level of impurities: Insoluble matter 0.01%, pH of a 5% solution 5.5-8.5 at 25°, Cl 0.001%, Nitrogen compounds (as N) 5ppm, Ca 0.01%, Mg 0.005%, Heavy Metals (as Pb) 5ppm, Fe 5ppm, Na 0.02%	500g 2kg
	Potassium sulfocyanate, see Potassium thiocyanate, 14318, p. 328	
14318	**Potassium thiocyanate, ACS, 98.5% min** ▲◪ *[Potassium sulfocyanate]* [333-20-0], KSCN, F.W. 97.18, Crystalline, m.p. 172-175°, b.p. 500° dec., d. 1.89, Merck **14**,7691, Fieser **1**,954, Solubility: Soluble in water, acetone, and alcohol. When dissolved in its own weight of water, the temperature drops ≈30°, EINECS 206-370-1, RTECS XL1925000, BRN 3594799, MDL MFCD00011413, † Maximum level of impurities: Insoluble in water 0.005%, pH of a 5% solution 5.3-8.7 at 25°, Cl 0.005%, SO_4 0.005%, NH_4 0.003%, Heavy Metals (as Pb) 5ppm, Fe 2ppm, Na 0.005%, Iodine-consuming substances P.T. H:H302-EUH032-H312-H332-H412, P:P261-P280-P302+P352-P304+P340-P322-P501a	100g 500g
	Povidone, see Polyvinylpyrrolidone, M.W. 360,000, J61381, p. 325 **Povidone**, see Polyvinylpyrrolidone, M.W. 40,000, J62417, p. 325 **Povidone**, see Polyvinylpyrrolidone, M.W. 10,000, J60382, p. 325 **PPL**, see Lipase, from porcine pancreas, J62903, p. 270	
J64165	**PPM1D Phosphatase Inhibitor** ▲ *[2,5-Bis-(2-Thienylidene)cyclopentanone, CCT007093]* [176957-55-4], $C_{15}H_{12}OS_2$, F.W. 272.40, Solid, MDL MFCD00121546 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	10mg 50mg
J61712	**Prazosin hydrochloride** [19237-84-4], $C_{19}H_{21}N_5O_4$·HCl, F.W. 419.86, Powder, m.p. 285°, Merck **14**,7717, EINECS 242-903-4, RTECS VA1350000, BRN 4303561, MDL MFCD00058177 H:H302-H315-H319-H361-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An α adrenoceptor antagonist	250mg 1g
J63618	**Prehybridization solutions in SSC** Liquid, Note: Contains 6X SSC, 5X Denhardt's solution, 0.5% SDS, and 100ug/ml of denatured DNA from salmon testes. Application(s): For the hybridization of probes to nucleic acids in Nothern and Southern blotting	50ml 100ml
J61729	**Prehybridization solutions in SSPE** Liquid, Note: Contains 6X SSPE, 5X Denhardt's solution, 0.5% SDS, and 100ug/ml of denatured DNA from salmon testes Application(s): For the hybridization of probes to nucleic acids in Nothern and Southern Blotting	50ml 100ml
	(Ile3)-Pressinoic acid, see Tocinoic acid, 96%, J62846, p. 370	
J60648	**Prilocaine hydrochloride, 98%** [1786-81-8], $C_{13}H_{20}N_2O$·HCl, F.W. 256.77, Powder, m.p. 167-168°, Merck **14**,7743, EINECS 217-244-0, RTECS UG5775000, MDL MFCD00079279 Application(s): A local anesthetic	1g 5g 10g
J64071	**Prima-1** ▲ *[2,2-Bis(hydroxymethyl)quinuclidin-3-one]* [5608-24-2], $C_9H_{15}NO_3$, F.W. 185.20, Solid, MDL MFCD04974196 H:H302-H317, P:P261-P280-P302+P352-P321-P301+P312-P501	10mg 50mg
J63833	**Proadifen hydrochloride** *[SKF-525A hydrochloride, N,N-Diethylaminoethyl 2,2-diphenylvalerate]* [62-68-0], $C_{23}H_{31}NO_2$·HCl, F.W. 389.97, Powder, m.p. 122-123°, RTECS YV7175000, MDL MFCD00055151 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Inhibits cytochrome P-450, blocks glibenclamide-sensitive potassium channels. Also inhibits neuronal nitric oxide synthase	500mg 1g 2g
B20010	**Probenecid, 98%** *[4-(Di-n-propylaminosulfonyl)benzoic acid, 4-(Di-n-propylsulfamoyl)benzoic acid]* [57-66-9], $C_{13}H_{19}NO_4S$, F.W. 285.36, m.p. 198-199°, Merck **14**,7754, EINECS 200-344-3, RTECS DG9400000, MDL MFCD00038402, †  H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	2.5g 10g
	Procaine hydrochloride, see 2-Diethylaminoethyl 4-aminobenzoate hydrochloride, A17485, p. 188	
J64824	**Procaspase-3 Activator** ▲ *[PAC-1, (4-Benzylpiperazino)acetic acid-(3-allyl-2-hydroxybenzylidene)hydrazide]* [315183-21-2], $C_{23}H_{28}N_4O_2$, F.W. 392.49, Powder, UN3077, MDL MFCD03302441 H:H302-H315-H319-H335-H410, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	25mg 50mg
J60532	**Proctolin** *[Arg-Tyr-Leu-Pro-Thr]* [57966-42-4], $C_{30}H_{48}N_8O_8$, F.W. 648.76, Powder Application(s): An insect neuropeptide	1mg

Stock #	Description	Size
L11109	**(R)-(-)-Prolinol, 98+%** △ ■ *[H-D-Pro-ol, (R)-(-)-2-Pyrrolidinemethanol]* [68832-13-3], $C_5H_{11}NO$, F.W. 101.15, b.p. 74-76°/2mm, f.p. 86°(186°F), d. 1.025, n_D^{20} 1.4849, $[\alpha]_D^{20}$ -31° (c=1 in toluene), BRN 1523669, MDL MFCD00064321 H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	1g 5g 25g
L09779	**(S)-(+)-Prolinol, 98%** △ ■ *[H-Pro-ol, (S)-(+)-2-Pyrrolidinemethanol]* [23356-96-9], $C_5H_{11}NO$, F.W. 101.15, m.p. 42-44°, b.p. 74-76°/2mm, f.p. 86°(186°F), d. 1.025, n_D^{20} 1.4853, $[\alpha]_D^{20}$ +31° (c=1 in toluene), Fieser **10**,332 **13**,261, EINECS 245-605-2, BRN 79843, MDL MFCD00005255 H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	1g 5g 25g
J64533	**Prolyl Endopeptidase Inhibitor** ▲ *[Z-PP-CHO]* [86925-97-5], $C_{18}H_{22}N_2O_4$, F.W. 330.40, Oil	5mg
	Propanedinitrile, see Malononitrile, A15046, p. 276 **Propanedioic acid**, see Malonic acid, A11526, p. 276	
30948	**1,2-Propanediol, ACS, 99.5%** ■ *[(±)-Propylene glycol, 1,2-Dihydroxypropane]* [57-55-6], $C_3H_8O_2$, F.W. 76.10, Liquid, m.p. -60°, b.p. 186-188°, f.p. 107°(225°F), d. 1.036, n_D^{20} 1.4320, Merck **14**,7855, Solubility: Miscible with water, acetone, chloroform. Soluble in ether, EINECS 200-338-0, RTECS TY2000000, BRN 1340498, MDL MFCD00064272, † Maximum level of impurities: Color (APHA) 10, Residue after ignition 0.005%, Titratable acid 0.0005meq/g, Cl 1ppm, H_2O 0.2% Application(s): As a substitute for ethylene glycol and glycerol. Good solvent for resins. Dissolves many essential oils, but immiscible with fixed oils.	500ml 1L 4L 4x1L
A11923	**1,3-Propanesultone, 99%** ◪ *[3-Hydroxy-1-propanesulfonic acid γ-sultone]* [1120-71-4], $C_3H_6O_3S$, F.W. 122.14, m.p. 30-33°, b.p. 179-181°/30mm, f.p. >110°(230°F), d. 1.392, UN2811, EINECS 214-317-9, RTECS RP5425000, BRN 109782, MDL MFCD00005355, Note: Special handling precautions required. View MSDS prior to purchase. MSDS are available online at www.alfa.com, † H:H350-H302-H312, P:P280-P281-P302+P352-P322-P405-P501a For a review of the chemistry of sultones, see: *Tetrahedron*, **43**, 1027 (1987).	10g 50g 250g
	1,2,3-Propanetriol, see Glycerol, Cell Culture Grade, J62399, p. 235 **(1Z)-Propene-1,2,3-tricarboxylic acid**, see cis-Aconitic acid, A16010, p. 76 **1,2,3-Propenetricarboxylic acid**, see trans-Aconitic acid, B20087, p. 76 **trans-4-Propenylanisole**, see trans-Anethole, A13482, p. 103	
L04210	**Propionic acid, 99%** [79-09-4], $CH_3CH_2CO_2H$, F.W. 74.08, m.p. -21°, b.p. 140-141°, f.p. 51°(123°F), d. 0.992, n_D^{20} 1.3870, Merck **14**,7825, Fieser **12**,415, UN3463, EINECS 201-176-3, RTECS UE5950000, BRN 506071, MDL MFCD00002756, † H:H314-H226, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	100g 1kg 2.5kg
	Propofol, see 2,6-Diisopropylphenol, L06841, p. 193	
H26645	**(±)-Propranolol hydrochloride, 99%** *[1-Isopropylamino-3-(1-naphthyloxy)-2-propanol hydrochloride]* [318-98-9], $C_{16}H_{21}NO_2$·HCl, F.W. 295.80, m.p. 163-165°, Merck **14**,7840, EINECS 206-268-7, MDL MFCD00012558 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A β-adrenergic blocker	5g 25g
	(±)-Propylene glycol, see 1,2-Propanediol, 30948, p. 329	
J60971	**Prostratin, 99+%** [60857-08-1], $C_{22}H_{30}O_6$, F.W. 390.47, Powder, m.p. 216-219°, MDL MFCD00674138 Application(s): 12-Deoxyphorbol 13-acetate; activator of protein kinase C. A weak mouse ear irritant, but lethal at 1ug per mouse	1mg 5mg
J62926	**Protamine sulfate** ■ [9009-65-8], Powder, RTECS UK9450000, † Application(s): Reverses the anticoagulant effects of heparin	1g 5g 10g
J64401	**Protease Inhibitor Cocktail I** ■ Lyophilized solid, Note: Forms 100x solution when reconstituted in 1ml water. A 1x solution contains 500uM AEBSF.HCl, 150nM aprotinin, 1uM E-64, 0.5mM EDTA disodium salt, and 1uM leupeptin hemisulfate	1unit
J65358	**Protease Inhibitor Cocktail I, Animal Free** ■ Solid, Note: A 1x stock solution contains 500uM AEBSF.HCl, 150nM aprotinin, 1uM E-64, 0.5mM EDTA and 1uM leupeptin hemisulfate. Reconstitute each vial with 1ml water to obtain a 100X stock solution	1unit

Stock #	Description	Size
J64963	**Protease Inhibitor Cocktail II** ■ Lyophilized solid, Note: Reconstitute each vial with 1ml DMSO and 4ml H20 to obtain a 5ml stock solution containing 20 mM AEBSF.HCl, 1.7mM bestatin, 200uM E-64, 85mM EDTA, and 2mM pepstatin A Application(s): Inhibits aspartic, cysteine, serine, and metalloproteases, as well as aminopeptidases. Recommended for use with bacterial cell extracts	**1unit**
J64283	**Protease Inhibitor Cocktail III** Liquid, Note: 1ml in DMSO. One unit contains 100mM AEBSF.HCl, 80µM aprotinin, 5mM bestatin, 1.5mM E-64, 2mM leupeptin hemisulfate, and 1mM pepstatin A Application(s): For use with mammalian cell and tissue extracts	**1unit**
J64156	**Protease Inhibitor Cocktail III, Animal-Free** Liquid, Note: Each vial contains 100mM AEBSF.HCl, 80uM recombinant aprotinin, 5mM bestatin, 1.5mM E-64, 2mM leupeptin hemisulfate and 1mM pepstatin A Application(s): For use with mammalian cell and tissue extracts	**1ml**
J64112	**Protease Inhibitor Cocktail III, Animal-Free, DMSO-Free** ■ Lyophilized solid, Note: Will make a 1ml solution of 100mM AEBSF.HCl, 80uM recombinant aprotinin, 5mM bestatin, 1.5mM E-64, 2mM leupeptin hemisulfate and 1mM pepstatin A when reconstituted in water	**1unit**
J65789	**Protease Inhibitor Cocktail IV** Liquid, Note: One unit contains 100mM AEBSF.HCl, 1.5mM E-64, 2mM pepstatin A and 500mM 1,10-phenanthroline. 1ml in DMSO Application(s): For use with fungal and yeast extracts	**1unit**
J65412	**Protease Inhibitor Cocktail V, EDTA-Free** ■ Lyophilized solid, Note: A 1x stock solution contains 500uM AEBSF.HCl, 150nM aprotinin, 1uM E-64 and 1uM leupeptin hemisulfate	**1unit**
J64920	**Protease Inhibitor Cocktail V, EDTA-Free, Animal-Free** ■ Lyophilized solid, Note: Makes 100x stock solution with 1ml of water. A 1X stock solution contains 500 uM AEBSF.HCl, 150nM aprotinin, 1uM E-64 and 1uM leupeptin hemisulfate Application(s): For the inhibition of serine- and cysteine-proteases, but not metalloproteases. For applications that require animal-free reagents	**1unit**
J65974	**Protease Inhibitor Cocktail VI, General Use** ■ Lyophilized solid, Note: Reconstitute with 100ml water. The reconstituted cocktail solution contains 2mM AEBSF.HCl, 1mM EDTA disodium salt, 130 uM bestatin, 1uM E-64, 1uM leupeptin hemisulfate and 0.3uM aprotinin	**1unit**
J64576	**Protease Inhibitor Cocktail VI, Plant Cells** Liquid, UN2922, Note: 1ml solution in DMSO containing 200mM AEBSF.HCl, 10mM bestatin, 3mM E-64, 2mM leupeptin hemisulfate, 500mM o-phenanthroline and 2mM pepstatin A H:H301-H314-H410, P:P260-P301+P310-P303+P631+P353-P305+P351+P338-P405-P501	**1ml**
J64016	**Protease Inhibitor Cocktail VII, for His Tag Sequences** Liquid, Note: 1ml in DMSO. Contains 100mM AEBSF.HCl, 5 mM bestatin, 1.5mM E-64, 2mM pepstatin A and 200µM phosphoramidon disodium salt.	**1unit**
J65553	**Protease Inhibitor Cocktail VII, for His Tag Sequences, DMSO-Free** ■ Lyophilized solid, Note: When reconstituted to 1ml, 1 unit makes a solution containing 100 mM AEBSF.HCl, 5mM bestatin, 1.5mM E-64, 2mM pepstatin A and 200uM phosphoramidon disodium salt	**1unit**
J65384	**Protease Inhibitor Cocktail VIII** Liquid, Note: A 1ml DMSO solution containing 1.56mM ALLN, 500uM antipain and 1.5mM E-64 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Has selective specificity for the inhibition of cysteine proteases, including calpains, cathepsins and papain	**1ml**
J61852	**Protease Inhibitor Cocktail, for general use** Liquid, Note: Contains AEBSF, Aprotinin, E-64, Bestatin, Leupeptin, and EDTA. 1 ml of 100X concentrate store at -20C	**1ml**
J61473	**Protease Inhibitor Cocktail, for mammalian cells** Liquid, Note: Contains AEBSF, Aprotinin, E-64, Bestatin and Leupeptin. 1 ml of 100X concentrate store at -20C	**1ml**
J64973	**Proteasome Inhibitor II** *[Z-LLF-CHO, Z-Leu-Leu-Phe-CHO]* $C_{29}H_{39}N_3O_5$, F.W. 509.64, Powder, MDL MFCD01862616	**1mg** **5mg**
J64492	**Proteasome Substrate** ▲ *[Z-LLL-AMC, Z-Leu-Leu-Leu-AMC]* $C_{36}H_{48}N_4O_7$, F.W. 648.79, Lyophilized powder, MDL MFCD01074988	**1mg** **5mg**
J63404	**Protein A, Staph. aureus** *[SpA]* Lyophilized powder, 47 kDa, MDL MFCD00081934 Application(s): Used to detect immunoglobins in immunochemical assays	**25mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J63377	**Protein coupling kit** Liquid, Note: This kit contains 1L of: Gel swelling solution (1 mM HCl), Gel Coupling Solution (10mM sodium borate or citrate, 500mM sodium chloride, pH 9.3), Gel washing solution (100mM sodium acetate, 500mM sodium chloride, pH 4.0). Application(s): For protein coupling in affinity chromatography applications	**1kit**
J61622	**Protein Kinase C Substrate** *[Val-Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu]* $C_{51}H_{100}N_{22}O_{11}$, F.W. 1197.50, Lyophilized powder	**1mg** **5mg**
J61687	**Protein Kinase Inhibitor** *[K252a]* [97161-97-2], $C_{27}H_{21}N_3O_5$, F.W. 467.47, Powder, RTECS NZ0550000, MDL MFCD00133989 Application(s): Inhibitor of protein kinase A	**1mg** **5mg**
J62051	**Proteinase K, Tritirachium album limber** [39450-01-6], Lyophilized powder, 28.9 kDa, EINECS 254-457-8, MDL MFCD00132129, Note: Minimum 20 units per mg dry weight. One unit releases one micromole of Folin positive amino acids, measured as tyrosine, at 37°C and pH 7.5, using urea denatured hemoglobin as the substrate H:H315-H319-H334-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A stable and highly reactive serine protease; used for protein and nucleic acid isolation	**25mg** **100mg**
J63710	**Proteinase K, Ready-to-use soln.** [39450-01-6], Liquid, 28.9 kDa, EINECS 254-457-8, Note: Minimum 400 units per ml. One unit releases one micromole of Folin positive amino acids, measured as tyrosine, at 37°C and pH 7.5, using urea denatured hemoglobin as the substrate. H:H315-H319-H334-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A stable and highly reactive serine protease; used for protein and nucleic acid isolation	**5ml** **25ml**
	Provitamin B, see D-Panthenol, A18499, p. 311 **Provitamin D2**, see Ergosterol hydrate, B23840, p. 209	
J60042	**Psoralen, 97%** *[7H-Furo[3,2-g]benzopyran-7-one, Furo[3,2-g]coumarin]* [66-97-7], $C_{11}H_6O_3$, F.W. 186.16, Solid, m.p. 163-164°, Merck **14**,7928, EINECS 200-639-7, RTECS LV0944000, BRN 152784, MDL MFCD00010520 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Intercalates into DNA; photochemical reagent for the investigation of nucleic acid structure	**100mg** **500mg**
	PteGlu, see Folic acid, Cell Culture Reagent, J62937, p. 227 **Pteroyl-L-glutamic acid**, see Folic acid, crystalline, J60833, p. 227 **Pteroyl-L-glutamic acid**, see Folic acid, Cell Culture Reagent, J62937, p. 227	
J64512	**PTP1B Inhibitor ▲** *[3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide]* [765317-72-4], $C_{26}H_{19}Br_2N_3O_7S_3$, F.W. 741.45, Solid	**5mg**
J60999	**Purine, 98%** *[7H-Imidazo[4,5-d]pyrimidine]* [120-73-0], $C_5H_4N_4$, F.W. 120.11, Crystals, m.p. 215-217°, Merck **14**,7942, EINECS 204-421-2, RTECS UO7450000, BRN 3200, MDL MFCD00079221	**1g** **5g**
	6-Purinethiol monohydrate, see 6-Mercaptopurine monohydrate, A12197, p. 281	
J60175	**Puromycin, 98+%** [53-79-2], $C_{22}H_{29}N_7O_5$, F.W. 471.51, Powder, Merck **14**,7943, UN2811, RTECS AU7350000, BRN 3853613, MDL MFCD00012691 H:H300, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Causes premature chain termination in protein synthesis	**10mg** **25mg** **100mg**
J61278	**Puromycin dihydrochloride, 99+%** [58-58-2], $C_{22}H_{29}N_7O_5 \cdot 2HCl$, F.W. 544.44, Powder, m.p. 168-170°, Merck **14**,7943, EINECS 200-387-8, RTECS AU355000, BRN 3853613, MDL MFCD00012691 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Causes premature chain termination in protein synthesis	**25mg** **100mg** **500mg**
	Putrescine, see 1,4-Diaminobutane, B21316, p. 182 **Putrescine dihydrochloride**, see 1,4-Diaminobutane dihydrochloride, A18312, p. 182 **PVP**, see Polyvinylpyrrolidone, M.W. 40,000, J62417, p. 325 **PVP K15**, see Polyvinylpyrrolidone, M.W. 10,000, J60382, p. 325 **PVP K-30**, see Polyvinylpyrrolidone, average M.W. 58,000, A14315, p. 325 **PVP K90**, see Polyvinylpyrrolidone, M.W. 360,000, J61381, p. 325	

Stock #	Description	Size
L11252	**Pyranine** *[C.I. 59040, 6-Hydroxy-1,3,8-pyrenetrisulfonic acid trisodium salt]* [6358-69-6], $C_{16}H_7Na_3O_{10}S_3$, F.W. 524.39, EINECS 228-783-6, RTECS UR2700000, BRN 4107272, MDL MFCD00037575, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**5g** **25g**
	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, see 4,6-Dihydroxy-1H-pyrazolo[3,4-d]pyrimidine, L07160, p. 193 **4-Pyridinamine**, see 4-Aminopyridine, 99+%, J61470, p. 99 **Pyridine-3-carboxamide**, see Nicotinamide, A15970, p. 301 **Pyridine-3-carboxylic acid**, see Nicotinic acid, A12683, p. 302 **Pyridine-4-carboxylic acid**, see Isonicotinic acid, A18109, p. 261 **Pyridine-4-carboxylic hydrazide**, see Isonicotinic acid hydrazide, A10583, p. 261	
A11414	**Pyridine-2,3-dicarboxylic acid, 99%** *[Quinolinic acid]* [89-00-9], $C_7H_5NO_4$, F.W. 167.12, m.p. ca 188° dec., Merck **14**,8073, EINECS 201-874-8, RTECS US7967250, BRN 137110, MDL MFCD00006295, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Endogenous NMDA agonist 	**25g** **100g**
A14580	**Pyridine-3,4-dicarboxylic acid, 98%** *[Cinchomeronic acid]* [490-11-9], $C_7H_5NO_4$, F.W. 167.12, m.p. ca 255° dec., Merck **14**,2283, EINECS 207-705-4, BRN 137242, MDL MFCD00006392 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**10g** **50g**
	Pyridine-3-thiocarboxamide, see Thionicotinamide, A11144, p. 367	
A12323	**Pyridoxal-5-phosphate monohydrate, 98% ▲** [41468-25-1], $C_8H_{10}NO_6P{\cdot}H_2O$, F.W. 265.17 (247.15anhy), m.p. 140-143°, Merck **14**,7979, MDL MFCD00149414, † Application(s): Active form of Vitamin B-6 	**1g** **5g** **25g**
J62679	**Pyridoxamine dihydrochloride, Cell Culture Reagent** *[4-(Aminomethyl)-5-hydroxy-6-methyl-3-pyridinemethanol dihydrochloride]* [524-36-7], $C_8H_{12}N_2O_2{\cdot}2HCl$, F.W. 241.12, Solid, m.p. 220-224°, Merck **14**,7980, EINECS 208-357-6, RTECS UV1230000, BRN 3632748, MDL MFCD00012808 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A vitamin in the Vitamin B-6 family	**2.5g** **5g** **10g**
	2-(3-Pyridylcarbonylamino)ethyl nitrate, see Nicorandil, 98+%, J60879, p. 301 **2-(3-Pyridyl)piperidine**, see (±)-Anabasine, L12089, p. 103 **DL-2-(3-Pyridyl)pyrrolidine**, see DL-Nornicotine, L10809, p. 305	
J63247	**Pyrilamine maleate** *[Mepyramine maleate]* [59-33-6], $C_{17}H_{23}N_3O{\cdot}C_4H_4O_4$, F.W. 401.46, Powder, Merck **14**,7984, EINECS 200-422-7, RTECS UT1225000, MDL MFCD00069333, † ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Selective inverse agonist for the H- histamine receptor	**25g** **100g**
	2-Pyrimidinamine, see 2-Aminopyrimidine, B24594, p. 99 **4,6-Pyrimidinediol**, see 4,6-Dihydroxypyrimidine, A15688, p. 193 **2,4,5,6(1H,3H)-Pyrimidinetetrone**, see Alloxan monohydrate, A15324, p. 89 **4-Pyrimidinol**, see 4(3H)-Pyrimidone, A10859, p. 332	
A10859	**4(3H)-Pyrimidone, 98+%** *[4-Hydroxypyrimidine, 4-Pyrimidinol]* [51953-17-4], $C_4H_4N_2O$, F.W. 96.09, m.p. 164-167°, EINECS 257-545-4, RTECS UW7350000, BRN 106975, MDL MFCD00167178, † 	**1g** **5g**
	4-Pyrimidone, see 4(3H)-Pyrimidone, A10859, p. 332 **Pyrocatechol**, see Catechol, A10164, p. 150 **DL-Pyroglutamic acid**, see (±)-2-Pyrrolidinone-5-carboxylic acid, L09424, p. 333 **D-Pyroglutaminol**, see (R)-(-)-5-(Hydroxymethyl)-2-pyrrolidinone, L18358, p. 250 **L-Pyroglutaminol**, see (S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone, L18359, p. 250 **Pyronin G**, see Pyronin Y, J61068, p. 332	
J61068	**Pyronin Y** *[C.I. 45005, Pyronin G]* [92-32-0], $C_{17}H_{19}ClNO$, F.W. 302.80, Crystalline powder, m.p. 250-260°, Merck **14**,8007, EINECS 202-147-8, RTECS BQ1450000, BRN 3795789, MDL MFCD00011725, † Application(s): Marker dye for RNA useful in acid buffer systems	**1g** **5g** **10g**
J60505	**Pyronin Y, 0.2% w/v aq. soln.** *[C.I. 45005, Pyronin G]* [92-32-0], $C_{17}H_{19}ClNO$, F.W. 302.80, Liquid, Merck **14**,8007, BRN 3795789, MDL MFCD00011725, †	**10ml** **25ml**
	1H-Pyrrole-2,5-dione, see Maleimide, A13135, p. 275	

Contact us for pricing on bulk sizes

Stock #	Description	Size
	(+/-)-Pyrrolidine-2-acetic acid hydrochloride, see DL-▲-Homoproline hydrochloride, H31749, p. 246	
B23731	**1-Pyrrolidinecarbodithioic acid ammonium salt, 98%** ■ *[Ammonium pyrrolidinedithiocarbamate, APDC]* [5108-96-3], $C_5H_{12}N_2S_2$, F.W. 164.29, m.p. 150-155°, EINECS 225-834-4, BRN 3730472, MDL MFCD00012720, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Chelating ligand useful for the extraction of many metals from aqueous solution.	**25g** **100g**
	2,5-Pyrrolidinedione, see Succinimide, A13503, p. 354 **(R)-(-)-2-Pyrrolidinemethanol**, see (R)-(-)-Prolinol, L11109, p. 329 **(S)-(+)-2-Pyrrolidinemethanol**, see (S)-(+)-Prolinol, L09779, p. 329 **(R)-(+)-3-Pyrrolidinol**, see (R)-(+)-3-Hydroxypyrrolidine, L19499, p. 251 **(S)-(-)-3-Pyrrolidinol**, see (S)-(-)-3-Hydroxypyrrolidine, L19498, p. 251	
L09424	**(±)-2-Pyrrolidinone-5-carboxylic acid, 99%** *[DL-Pyroglutamic acid, H-DL-Pyr-OH]* [149-87-1], $C_5H_7NO_3$, F.W. 129.12, m.p. 183-185°, EINECS 205-748-3, BRN 82131, MDL MFCD00064322 H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g**
	DL-2-Pyrrolidone-5-carboxylic acid, see (±)-2-Pyrrolidinone-5-carboxylic acid, L09424, p. 333 **1H-Pyrrolo[2,3-b]pyridine**, see 7-Azaindole, L07983, p. 114	
J61373	**Pyruvate Kinase, rabbit muscle** *[Phosphoenolpyruvate kinase, Phosphoenol transphosphorylase]* [9001-59-6], Lyophilized powder, EINECS 232-616-2, MDL MFCD00081946, Note: Minimum 375 units per mg solid; 500 units per mg protein. One unit liberates 1 micromole pyruvate per minute from PEP in the presence of ADP at 30 C and pH 7.6., †	**50kilounits**
A13875	**Pyruvic acid, 98%** *[2-Oxopropionic acid]* [127-17-3], $C_3H_4O_3$, F.W. 88.06, m.p. 11-12°, b.p. 164-166°, f.p. 83°(181°F), d. 1.267, n_D^{20} 1.4295, Merck **14**,8021, Fieser **1**,974, UN3265, EINECS 204-824-3, RTECS UZ0829800, BRN 506211, MDL MFCD00002585, † H:H314, P:P280-P305+P351+P338-P309-P310	**100g** **500g** **2.5kg**
	Pyruvic acid sodium salt, see Sodium pyruvate, Cell Culture Grade, J61840, p. 348	
A15807	**Quercetin dihydrate, 97%** *[3,3',4',5,7-Pentahydroxyflavone dihydrate, Quercetin hydrate]* [6151-25-3], $C_{15}H_{10}O_7 \cdot 2H_2O$, F.W. 338.28 (302.25anhy), m.p. 310-315°, Merck **14**,8034, UN2811, EINECS 204-187-1, RTECS LK8950000, BRN 317313, MDL MFCD00149487, † H:H301-H341, P:P281-P301+P310-P321-P308+P313-P405-P501a Application(s): Inhibitor of protein tyrosine kinase	**25g** **100g** **500g**
	Quercetin hydrate, see Quercetin dihydrate, A15807, p. 333	
J61919	**Quin 2** [73630-23-6], $C_{26}H_{23}K_4N_3O_{10}$, F.W. 693.87, Powder, Merck **14**,8042, BRN 5374262, MDL MFCD00065487 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A highly specific fluorescent calcium indicator	**100mg**
A13412	**Quinaldine, 97+%** ▲△ *[2-Methylquinoline]* [91-63-4], $C_{10}H_9N$, F.W. 143.19, m.p. -2°, b.p. 247-248°, f.p. 79°(174°F), d. 1.058, n_D^{20} 1.6120, Merck **14**,8047, EINECS 202-085-1, RTECS UZ9625000, BRN 110309, MDL MFCD00006756, † H:H302-H312-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used in preparation of oil-soluble dyes	**25g** **100g** **500g**
J61913	**Quinapril hydrochloride, 98%** [82586-55-8], $C_{25}H_{30}N_2O_5 \cdot HCl$, F.W. 474.99, Solid, m.p. 120-130°, Merck **14**,8051, RTECS NW7176000, MDL MFCD00889215 Application(s): Angiotensin-converting enzyme inhibitor	**100mg** **1g** **5g**
B24094	**Quinazoline, 98%** [253-82-7], $C_8H_6N_2$, F.W. 130.15, m.p. 45-48°, b.p. 243°, f.p. 106°(224°F), Merck **14**,8053, EINECS 205-965-3, MDL MFCD00006712 Application(s): Anti-malarial agent	**1g** **5g**
A12559	**(+)-Quinidine** ▲ [56-54-2], $C_{20}H_{24}N_2O_2$, F.W. 324.42, m.p. 171-173°, $[\alpha]_D^{20}$ +260° (c=1 in ethanol), Merck **14**,8060, Fieser **15**,277, EINECS 200-279-0, RTECS VA4725000, BRN 91866, MDL MFCD00135581, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Antiarrhythmic agent that blocks the inward sodium channel	**1g** **5g** **25g**

Stock #	Description	Size
J60426	**Quinidine sulfate dihydrate, 98+%** [6591-63-5], $C_{40}H_{48}N_4O_4.H_2O_4S.2H_2O$, F.W. 782.94, Powder, m.p. 212-214°, Merck **14**,8060, RTECS VA5605000, MDL MFCD00149346 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A sodium channel blocker, and to a lesser extent also blocks potassium channels	**5g** **25g**
A10459	**Quinine, anhydrous, 99% (total base), may cont. up to 5% dihydroquinine ▲** [130-95-0], $C_{20}H_{24}N_2O_2$, F.W. 324.42, m.p. ca 177° dec., $[\alpha]_D^{20}$ -166° (c=1 in ethanol), Merck **14**,8061, Fieser **6**,501 **7**,311 **8**,430 **9**,403 **10**,338 **11**,456 **15**,277, EINECS 205-003-2, RTECS VA6020000, BRN 91867, MDL MFCD00198096, † H:H334-H302-H335-H315-H319-H317, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Resolving agent for chiral acids. For a review of resolutions, see: *Topics Stereochem.*, **6**, 107 (1977). Application(s): A potassium channel blocker	**10g** **50g** **250g**
A17036	**Quinine hemisulfate monohydrate, 99% ▲** *[Quinine sulfate dihydrate]* [6119-70-6], $C_{20}H_{24}N_2O_2 \cdot 0.5H_2SO_4 \cdot H_2O$, F.W. 391.47 (373.46anhy), m.p. 217-218° dec., $[\alpha]_D^{20}$ -230° (c=2 in 0.1M HCl), Merck **14**,8061, EINECS 212-359-2, RTECS VA8440000, BRN 6113937, MDL MFCD00150792, † H:H334-H302-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): A potassium channel blocker	**10g** **50g** **250g**
	Quinine sulfate dihydrate, see Quinine hemisulfate monohydrate, A17036, p. 334 **Quinizarin**, see 1,4-Dihydroxyanthraquinone, A11010, p. 191 **Quinol**, see Hydroquinone, A11411, p. 248 **Quinolinic acid**, see Pyridine-2,3-dicarboxylic acid, A11414, p. 332 **8-Quinolinol**, see 8-Hydroxyquinoline, 41272, p. 251	
J65627	**N-(2-Quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)methyl ketone hydrate ▲■** *[Q-VD-OPH hydrate, Q-Val-Asp-CH2-OPh]* [1135695-98-5], $C_{26}H_{25}F_2N_3O_6 \cdot xH_2O$, F.W. 513.49 (anhy), Powder, MDL MFCD20527311	**5mg**
A14055	**Quinoxaline, 98+%** [91-19-0], $C_8H_6N_2$, F.W. 130.15, m.p. 27-32°, b.p. 220-223°, f.p. 98°(208°F), d. 1.124, Merck **14**,8078, EINECS 202-047-4, RTECS VD1225000, BRN 109351, MDL MFCD00006719, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Used as dyes, pharmaceuticals and antibiotics intermediate	**100g** **500g** **2.5kg**
B21503	**3-Quinuclidinol, 98+% △** *[1-Azabicyclo[2.2.2]octan-3-ol, 3-Hydroxyquinuclidine]* [1619-34-7], $C_7H_{13}NO$, F.W. 127.19, m.p. 217-224°, Merck **14**,8082, Fieser **6**,501, UN3263, EINECS 216-578-4, RTECS VD6191700, BRN 104327, MDL MFCD00151326, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Reagent for selective cleavage of β-keto esters to ketones in high yield: *Synth. Commun.*, **5**, 341 (1975). Geminal diesters are converted to monoesters in high yield under similar conditions: *J. Org. Chem.*, **41**, 208 (1976). Superior catalyst for the Baylis-Hillman reaction: the addition of acrylic esters to aldehydes, often very slow (4-7 days) with the usual catalyst **1,4-Diazabicyclo[2.2.2]octane**, **A14003**, is much faster (<1 day) in the presence of quinuclidinol: *Synth. Commun.*, **18**, 495 (1988); *Tetrahedron Lett.*, **32**, 5611 (1991). For more recent discussion and methodology, see: *J. Org. Chem.*, **67**, 510 (2002); **68**, 692 (2003). For reviews of the Baylis-Hillman reaction, see: *Tetrahedron*, **44**, 4653 (1988); **52**, 8001 (1996). The rate of addition of enones to aldehydes is similarly enhanced: *Synth. Commun.*, **18**, 495 (1988); **19**, 959 (1989).	**5g** **25g** **100g**
A13320	**3-Quinuclidinone hydrochloride, 98+% ■** *[1-Azabicyclo[2.2.2]octan-3-one hydrochloride]* [1193-65-3], $C_7H_{11}NO \cdot HCl$, F.W. 161.63, m.p. ca 300° dec., EINECS 214-776-5, BRN 3695039, MDL MFCD00137391, †	**5g** **25g** **100g**
J61933	**Quipazine dimaleate, 99+%** *[2-(1-Piperazinyl)quinoline maleate salt]* [5786-68-5], $C_{13}H_{15}N_3 \cdot 2C_4H_4O_4$, F.W. 445.43, Solid, m.p. 151-154°, UN2811, EINECS 227-314-2, RTECS VC2515000, MDL MFCD00133796 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Selective 5-HT-3 receptor agonist	**100mg**
J61591	**(+)-Quisqualic acid, 99+%** *[β-(3,5-Dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine, 3-(3,5-Dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine]* [52809-07-1], $C_5H_7N_3O_5$, F.W. 189.13, Powder, m.p. 185-187°, Merck **14**,8085, BRN 1078734, MDL MFCD00069337 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501 Application(s): Group I mGlu receptor agonist. AMPA agonist	**5mg** **10mg** **50mg**
	QX-314 bromide, see Lidocaine N-ethyl bromide, 99+%, J60678, p. 270 **R 41 468**, see Ketanserin tartrate, 98+%, J62798, p. 263	
J65639	**R5C3** *[5-Methyl-N-(2-phenoxybenzoyl)-1-[(phenylmethoxy)carbonyl]-D/L-tryptophan]* [753504-14-2], $C_{33}H_{28}N_2O_6$, F.W. 548.58, Powder, MDL MFCD08705330	**10mg**

Stock #	Description	Size
J65195	**Rabbit Serum**	**5ml**
A18313	**D-(+)-Raffinose pentahydrate, 99%** ■ *[Melitose pentahydrate]* [17629-30-0], $C_{18}H_{32}O_{16}·5H_2O$, F.W. 594.52 (504.45anhy), m.p. 78-82°, $[\alpha]_D^{20}$ +105° (c=10 in water), Merck **14**,8096, EINECS 208-146-9, RTECS LZ5851200, BRN 4285763, MDL MFCD00071590, Note: $[\alpha]_D^{20}$=+105.2°(C=4), † 	**10g** **50g**
	RAMP, see (R)-(+)-1-Amino-2-(methoxymethyl)pyrrolidine, J60524, p. 96	
J61334	**Ranatensin, 96%** *[Glp-Val-Pro-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH2]* [29451-71-6], $C_{61}H_{84}N_{16}O_{13}S$, F.W. 1281.48, Powder, MDL MFCD00167518 Application(s): Demonstrates various blood pressure effects	**2mg**
B22260	**Ranitidine hydrochloride, 99%** [66357-59-3], $C_{13}H_{22}N_4O_3S·HCl$, F.W. 350.86, m.p. ca 134° dec., Merck **14**,8110, EINECS 266-333-0, MDL MFCD00069339  H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): An H-2 histamine receptor antagonist	**5g** **25g**
J62473	**Rapamycin, 99+%** *[Sirolimus, AY-22989]* [53123-88-9], $C_{51}H_{79}NO_{13}$, F.W. 914.17, Powder, Merck **14**,8114, RTECS VE6250000, MDL MFCD00867594, Note: Store at -20 Application(s): Blocks cytokine-mediated signal transduction pathways	**50mg** **100mg** **200mg**
J61347	**Rapid stain G-250** Liquid	**500ml** **1L**
J61969	**Rapid stain R-250** Liquid	**500ml** **1L**
J63198	**Rauwolscine hydrochloride, 99%** ▲ *[α-Yohimbine hydrochloride, 17α-Hydroxy-20α-yohimban-16β-carboxylic acid methyl ester hydrochloride]* [6211-32-1], $C_{21}H_{26}N_2O_3·HCl$, F.W. 390.91, Powder, UN1544, EINECS 228-279-6, RTECS ZG1035000, MDL MFCD06668052 H:H301-H311-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Standard α-2 adrenergic antagonist	**100mg**
J62990	**RBC lysis buffer for human** Liquid, Note: Contains 150mM ammonium chloride, 10mM potassium bicarbonate , 0.1mM EDTA at pH 7.2-7.4., † Application(s): For lysis of human red blood cells.	**250ml** **500ml**
J62150	**RBC lysis buffer for mouse** Liquid, Note: Contains 10mM Tris-HCl, 150mM ammonium chloride at pH 7.2-7.4., † Application(s): For lysis of mouse red blood cells	**250ml** **500ml**
	RC-160, see Vapreotide, J61096, p. 391 **Regulin**, see Melatonin, 99+%, J62452, p. 279 **Reinecke salt**, see Ammonium diamminetetrathiocyanatochromate(III) monohydrate, 87777, p. 101	
B21187	**Resazurin sodium salt** *[7-Hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt]* [62758-13-8], $C_{12}H_6NNaO_4$, F.W. 251.18, Merck **14**,8141, EINECS 263-718-5, RTECS SP7700000, BRN 3794971, MDL MFCD00005036, †  H:H315-H319-H335, P:P280g-P305+P351+P338 Application(s): As indicator pH 3.8 (orange) to 6.5 (dark violet)	**1g** **5g**
L03506	**Reserpine, 99%** [50-55-5], $C_{33}H_{40}N_2O_9$, F.W. 608.69, m.p. ca 265°, $[\alpha]_D^{20}$ -122° (c=1 in chloroform), Merck **14**,8145, EINECS 200-047-9, RTECS ZG0350000, BRN 102014, MDL MFCD00005091, †  H:H360-H351-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): Inhibits vesicular uptake of catecholamines and serotonin	**1g** **5g**

Stock #	Description	Size
J62458	**Resiniferatoxin, 99+%** [57444-62-9], $C_{37}H_{40}O_9$, F.W. 628.71, Solid, UN2811, RTECS CY1633700, BRN 5371150, MDL MFCD00135927 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Diterpene ester related to phorbol but apparently not tumorigenic; activates protein kinase C	**1mg** **5mg** **10mg**
A13080	**Resorcinol, 99% ▲ △** *[1,3-Dihydroxybenzene, 1,3-Benzenediol]* [108-46-3], $C_6H_6O_2$, F.W. 110.11, m.p. 109-112°, b.p. 280-281°, f.p. 171°(339°F), d. 1.272, Merck **14**,8155, UN2876, EINECS 203-585-2, RTECS VG9625000, BRN 906905, MDL MFCD00002269, † H:H400-H302-H315-H319, P:P280h-P273-P305+P351+P338-P308+P313-P410-P501a	**50g** **250g** **1kg** **5kg**
36248	**Resorcinol, ACS, 99.0-100.5% ▲ △** *[1,3-Dihydroxybenzene, 1,3-Benzenediol]* [108-46-3], $C_6H_6O_2$, F.W. 110.11, Crystalline, m.p. 109-112°, b.p. 280-281°, f.p. 171°(339°F), d. 1.272, Merck **14**,8155, Solubility: Soluble in water, alcohol, ether, and glycerol, UN2876, EINECS 203-585-2, RTECS VG9625000, BRN 906905, MDL MFCD00002269, † Maximum level of impurities: Melting point 110-112°, Insoluble matter 0.005%, Residue after ignition 0.01%, Titratable acid 0.004meq/g H:H400-H302-H315-H319, P:P280h-P273-P305+P351+P338-P308+P313-P410-P501a	**25g** **100g** **500g**
	Resorufin ethyl ether, see 7-Ethoxyresorufin, J62987, p. 214	
J60790	**Resveratrol, 98%** [501-36-0], $C_{14}H_{12}O_3$, F.W. 228.24, Powder, Merck **14**,8158, RTECS CZ8987000, MDL MFCD00133799 H:H315-H318-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A phytoestrogen with antitumor, antioxidant, antiplatelet, anti-inflammatory effects. Inhibits cytochrome P450 1A1 (IC_{50} = 23 d_4^{15}M) and displays mixed agonist/antagonist actions at ER-α and ER-β estrogen receptors	**500mg**
J62219	**9-cis-Retinoic acid** [5300-03-8], $C_{20}H_{28}O_2$, F.W. 300.44, Powder, Merck **14**,249, RTECS VH6450000, MDL MFCD00270072 H:H315-H319-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A high affinity ligand for the retinoid X receptor	**5mg**
J61666	**13-cis-Retinoic acid** *[Isotretinoin]* [4759-48-2], $C_{20}H_{28}O_2$, F.W. 300.44, Powder, m.p. 172-175°, Merck **14**,5228, EINECS 225-296-0, RTECS VH6440000, MDL MFCD00079542, † H:H315-H319-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A vitamin A analog that inhibits cell proliferation and induces cell differentiation	**500mg**
44540	**Retinoic acid, 98% ▲** *[Vitamin A acid]* [302-79-4], $C_{20}H_{28}O_2$, F.W. 300.44, Crystalline, m.p. 180-182°, Merck **14**,8165, EINECS 206-129-0, RTECS VH6475000, BRN 2057223, MDL MFCD00001551, † H:H361-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a	**100mg** **500mg** **2g**
J62079	**Retinol, 98%, synthetic ▲◪** *[Vitamin A alcohol]* [68-26-8], $C_{20}H_{30}O$, F.W. 286.46, Crystalline solid, Merck **14**,10013, EINECS 200-683-7, RTECS VH6750000, BRN 403040, MDL MFCD00001552, † H:H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P501a	**1g** **5g**
	Retinol acetate, see Vitamin A acetate in gelatin, A16237, p. 392 **Retinol palmitate**, see Retinol palmitate, 98+%, J63022, p. 392 **Retinyl acetate**, see Vitamin A acetate in gelatin, A16237, p. 392 **Retinyl palmitate**, see Vitamin A Palmitate, 98+%, J63022, p. 392	
J65829	**Reverse Transcriptase, Avian Myeloblastosis Virus in phosphate buffer** *[EC 2.7.7.49]* Liquid Application(s): Synthesizes DNA complements to RNA transcripts	**1kilounit**
J60167	**Reverse Transcriptase, murine, Moloney Murine Leukemia Virus** *[MMLV RT]* [9068-38-6], Liquid, EINECS 232-964-5, MDL MFCD00283754, Note: One unit is the amount of enzyme required to catalyze the transfer of 1 nmol of deoxynucleotide into acid-precipitable material in 10 minutes at 37°C. 200,000 units/ml in 20 mM Tris-HCl (pH 7.5), 200 mM NaCl, 1 mM DTT, 0.01% NP-40, 0.1 mM EDTA, 50% glycer Application(s): Synthesizes a complementary DNA strand using single-stranded RNA or DNA in the presence of a primer	**10kilounits**
A16166	**L-(+)-Rhamnose monohydrate, 99%** *[6-Deoxy-L-mannose monohydrate]* [10030-85-0], $C_6H_{12}O_5 \cdot H_2O$, F.W. 182.19 (164.17anhy), m.p. 89-94°, d. 1.47, $[\alpha]_D^{20}$ +8° (c=10 in water, 20h), Merck **14**,8172, EINECS 222-793-4, BRN 5988592, MDL MFCD00149363, †	**5g** **25g** **100g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62315	**Rhodamine 6G** *[Basic Red 1, C.I. 45160]* [989-38-8], $C_{28}H_{31}ClN_2O_3$, F.W. 479.02, Powder, EINECS 213-584-9, RTECS DH0175000, BRN 3900071, MDL MFCD00012665, † H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Suitable for fluorescent labelling	25g 100g
A13572	**Rhodamine B** *[Basic Violet 10, C.I. 45170]* [81-88-9], $C_{28}H_{31}ClN_2O_3$, F.W. 479.02, m.p. ca 210° dec., d. 1.31, Merck **14**,8183, EINECS 201-383-9, RTECS BP3675000, BRN 4119648, MDL MFCD00011931, † H:H318-H351-H302, P:P280-P281-P305+P351+P338-P310-P405-P501a Biological stain. Reagent for determination of Cd and Zn: *Anal. Chem.*, **176**, 285 (1960); also for various other metals. Application(s): Suitable for fluorescent labelling	50g 250g 1kg
A13622	**Rhodanile Blue** [14969-56-3], $C_{48}H_{48}ClN_5O_3$, F.W. 778.40, EINECS 239-040-0, MDL MFCD00011937 H:H351-H319, P:P280-P281-P305+P351+P338-P308+P313-P405-P501a Application(s): Complex of Rhodamine B and Nile Blue.	1g 5g 25g
	Rhodeose, see D-(+)-Fucose, A18234, p. 228 **Ribitol**, see Adonitol, L03253, p. 80	
A11764	**Riboflavin, 98% ▲** *[Vitamin B2]* [83-88-5], $C_{17}H_{20}N_4O_6$, F.W. 376.37, m.p. >300°, Merck **14**,8200, EINECS 201-507-1, MDL MFCD00005022, † Application(s): Photoinitiator of polymerization for PAGE gels	25g 100g
	Riboflavin 5'-adenosine diphosphate disodium salt, see Flavin adenine dinucleotide disodium salt hydrate, A14495, p. 221	
A14545	**Riboflavin-5'-phosphate sodium salt dihydrate** *[FMN-Na]* [6184-17-4], $C_{17}H_{20}N_4NaO_9P \cdot 2H_2O$, F.W. 514.36 (478.34anhy), m.p. >300°, Merck **14**,8201, EINECS 204-988-6, BRN 4106529, MDL MFCD00150993, † Application(s): Photoinitiator of polymerization for PAGE gels	10g 50g
	2-β-D-Ribofuranosyl-1,2,4-triazine-3,5(2H,4H)-dione, see 6-Azauridine, J61309, p. 114	
J62952	**Ribonuclease, bovine pancreas** Lyophilized powder, Note: 0.22 micron filtered; sterile. Minimum 2,500 units per mg. One unit causes an increase in absorbance of 1.0 at 260nm at 37 C and pH 5.0 when yeast ribosomal RNA is hydrolyzed to acid soluble oliognucleotides.	100mg
J62232	**Ribonuclease A, bovine pancreas, Molecular Biology Grade** ◢ *[EC 3.1.27.5, Rnase A]* [9001-99-4], Lyophilized powder, Merck **14**,8202, EINECS 232-646-6, RTECS RF0760000, MDL MFCD00132181, Note: Minimum 2500 units/mg dry wt. Chromatographically purified. One unit causes an increase in absorbance of 1.0 at 260nm at 37°C and pH 5.0 when yeast ribosomal RNA is hydrolyzed to acid soluble oliognucleotides., †	200mg 1g
J61996	**Ribonuclease A, bovine pancreas, purified** ◢ *[EC 3.1.27.5, Rnase A]* [9001-99-4], Lyophilized powder, Merck **14**,8202, EINECS 232-646-6, RTECS RF0760000, MDL MFCD00132181, Note: Chromatographically purified. Unsuitable for heat treatment. Minimum 3000 units/mg dry wt. One unit causes an increase in absorbance of 1.0 at 260nm at 37°C and pH 5.0 when yeast ribosomal RNA is hydrolyzed to acid soluble oliognucleotides., †	25mg 100mg
J62334	**Ribonuclease B, bovine pancreas** ◢ *[EC 3.1.4.22, RNase B]* [9001-99-4], Lyophilized powder, Merck **14**,8202, EINECS 232-646-6, RTECS RF0760000, MDL MFCD00132181, Note: Minimum 1000 units/mg dry wt. One unit causes an increase in absorbance of 1.0 at 260nm at 37°C and pH 5.0 when yeast ribosomal RNA is hydrolyzed to acid soluble oliognucleotides, †	100mg
J61644	**Ribonuclease T1, Aspergillus oryzae in 2.8M ammonium sulfate** [9026-12-4], Liquid, MDL MFCD00132191, Note: One unit causes an increase in absorbance of 1.0 at 260nm at 37°C, pH 7.5 in 15 minutes. Minimum 300,000 units/mg protein.	100kilounits 500kilounits
J61215	**Ribonucleic acid from Baker's yeast** [63231-63-0], Powder, MDL MFCD00132195, Note: Primarily ribosomal RNA. Suitable substrate for ribonuclease assays, †	100mg 1g

Stock #	Description	Size
A17894	**D-(-)-Ribose, 98%** ■ [50-69-1], $C_5H_{10}O_5$, F.W. 150.13, m.p. 82-86°, $[\alpha]_D^{20}$ -20° (c=10 in water, 28h), Merck **14**,8204, EINECS 200-059-4, RTECS VJ2275000, BRN 1723081, MDL MFCD00135453, † For an evaluation of the potential of D-ribose as an enantiopure building block for construction of the C-ring of taxol, see: *J. Org. Chem.*, **60**, 7849 (1995). 	**10g** **50g** **250g**
B21117	**L-(+)-Ribose, 99%** ■ [24259-59-4], $C_5H_{10}O_5$, F.W. 150.13, m.p. 85-88°, EINECS 246-110-4, MDL MFCD00167010 	**250mg** **1g** **5g**
J60836	**Rifampin, Molecular Biology Grade** *[Rifampicin]* [13292-46-1], $C_{43}H_{58}N_4O_{12}$, F.W. 822.94, Powder, m.p. 183-188°, Merck **14**,8216, EINECS 236-312-0, RTECS VJ7000000, BRN 5723476, MDL MFCD00151389 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Antibiotic effective against mycobacteria. Can also inhibit DNA polymerase	**1g** **5g** **25g**
J63095	**Rifamycin SV sodium, 98+%** [14897-39-3], $C_{37}H_{46}NNaO_{12}$, F.W. 719.45, Powder, Merck **14**,8218, EINECS 238-965-7 Application(s): Antibiotic effective against mycobacteria. Can also inhibit DNA polymerase	**1g** **5g**
J63099	**Rigin, 96%** *[Gly-Gln-Pro-Arg]* [77727-17-4], $C_{18}H_{32}N_8O_6$, F.W. 456.51, Powder Application(s): Phagocytosis-stimulating tetrapeptide	**5mg**
J63306	**RIPA buffer** Liquid, Note: 50mM Tris-HCl (pH 7.4), 150mM NaCl 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**250ml** **500ml**
J63324	**RIPA buffer (2X)** Liquid, Note: Contains: 100mM Tris-HCl (pH 7.4) 300 mM NaCl, 2% NP-40, 1% sodium deoxycholate and 0.2 %SDS., † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**125ml** **250ml**
J62524	**RIPA buffer (5X)** Liquid, Note: 250mM Tris-HCl (pH 7.4), 750mM NaCl, 5% NP-40, 2.5% sodium deoxycholate,0.5% SDS., † H:H318, P:P280-P305+P351+P338-P310	**50ml** **100ml**
J61529	**RIPA buffer with EDTA** Liquid, Note: 50mM Tris-HCl (pH 7.4), 150mM NaCl 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS with 5mM EDTA.	**250ml** **500ml**
J60645	**RIPA buffer with EDTA + EGTA** Liquid, Note: 50mM Tris-HCl (pH 7.4), 150mM NaCl 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS with 5mM EDTA and 1mM EGTA.	**250ml** **500ml**
J61951	**RIPA buffer with EGTA** Liquid, Note: 50mM Tris-HCl (pH 7.4), 150mM NaCl 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS with 1mM EGTA.	**250ml** **500ml**
J61734	**RIPA with glycerol (2X)** Liquid	**125ml** **250ml**
J62725	**RIPA buffer with Triton® X-100 (1X)** Liquid, Note: 50mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS.	**250ml** **500ml**
J60488	**RIPA buffer with Triton® X-100 (2X)** Liquid, Note: 100mM Tris-HCl (pH 7.4), 300 mM NaCl, 2% Triton X-100, 1.0% sodium deoxycholate, 0.2% SDS.	**125ml** **250ml**
J62885	**RIPA buffer with Triton® X-100 (5X)** Liquid, Note: 250mM Tris-HCl (pH 7.4), 750 mM NaCl, 5% Triton X-100, 2.5% sodium deoxycholate, 0.5% SDS.	**50ml** **100ml**
J60423	**RIPA buffer with Triton® X-100 + 10% glycerol (2X)** Liquid, Note: 100mM Tris-HCl (pH 7.4) 300mM NaCl, 2% Triton X-100,1% sodium deoxycholate, 0.2% SDS, 10% glycerol.	**125ml** **250ml**
J62189	**RIPA buffer-2** Liquid, Note: 50mM Tris-HCl (pH 8.0), 150mM NaCl, 1% NP-40 0.5% sodium deoxycholate, 0.1% SDS.	**250ml** **500ml**
J60629	**RIPA buffer-2 (2X)** Liquid, Note: 100mM Tris-HCl (pH 8.0), 300mM NaCl, 2% NP-40,1.0% sodium deoxycholate, 0.2% SDS.	**125ml** **250ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J65379	**RITA, p53 inhibitor III ▲** *[5,5'-(2,5-Furandiyl)bis-2-thiophenemethanol, NSC 652287]* [213261-59-7], $C_{14}H_{12}O_3S_2$, F.W. 292.40, Crystalline solid	**1mg** **10mg**
J62832	**RNA sample loading buffer** Liquid, Note: 62.5% Formadide, 1.14M Formaldehyde, 50ug/mL ethidium bromide in 1.25X MOPS buffer, H:H317-H351-H360, P:P261-P280-P302+P352-P321-P405-P501	**1ml** **2ml**
J62468	**RNA sample loading buffer (6X)** Liquid, Note: Contains 50% glycerol, 1mM EDTA, 0.25% bromophenol blue and 0.25% xylene cyanol FF	**1ml** **2ml**
J61937	**RNA sample loading buffer, no ethidium bromide** Liquid, Note: 62.5% formamide, 1.14M formaldehyde in MOPS buffer. 1.25X concentrate. H:H317-H351-H360, P:P261-P280-P302+P352-P321-P405-P501 Application(s): Formulated for electrophoresis of RNA on formaldehyde-agarose gels with or without ethidium bromide	**1ml** **2ml**
	Rnase A, see Ribonuclease A, bovine pancreas, Molecular Biology Grade, J62232, p. 337 **Rnase A**, see Ribonuclease A, bovine pancreas, purified, J61996, p. 337 **RNase B**, see Ribonuclease B, bovine pancreas, J62334, p. 337	
J61574	**RNase Removal Reagent** Liquid, d. 1.00, Note: Supplied in a spray bottle Application(s): Destroys RNases and DNases on contact	**475ml**
	Ro 1-7683, see Tropicamide, 99+%, J61132, p. 383 **Ro-18-0647**, see Orlistat, 98%, J62999, p. 308 **Ro 15-1788**, see Flumazenil, 98%, J62537, p. 222 **Romemsin**, see Monensin sodium salt, 90-95.5%, J61669, p. 294 **Roquessine**, see Conessine, 97%, J62617, p. 167 **Rosaniline hydrochloride**, see Basic Fuchsin, A12952, p. 117 **Rotundine**, see L-Tetrahydropalmatine, J63911, p. 363 **RP-87086**, see Glucose-6-phosphate dehydrogenase, yeast, J61181, p. 234 **Saccharin**, see o-Benzoic sulfimide, B23938, p. 119 **Saccharin sodium hydrate**, see o-Benzoic sulfimide sodium salt hydrate, A15530, p. 119 **D-(+)-Saccharose**, see Sucrose, 36508, p. 354	
J63345	**Saclofen, 99+%** *[β-(Aminomethyl)-4-chlorobenzeneethanesulfonic acid]* [125464-42-8], $C_9H_{12}ClNO_3S$, F.W. 249.71, Solid, MDL MFCD00216817 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Selective antagonist at GABA-B receptors. An analog of baclofen	**10mg** **50mg**
J63982	**Safflower oil, Carthamus tinctorius** *[Carthamus tinctorius oil]* [8001-23-8], Oil, f.p. >113°(235°F), d. 0.921, n_D^{20} 1.476, EINECS 232-276-5, RTECS VN2230000, MDL MFCD00132216, †	**500ml** **1L**
B21674	**Safranine O** *[C.I. 50240, 3,7-Diamino-2,8-dimethyl-5-phenylphenazinium chloride]* [477-73-6], $C_{20}H_{19}ClN_4$, F.W. 350.85, EINECS 207-518-8, RTECS SG1623000, BRN 3924099, MDL MFCD00011759, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Biological stain. Application(s): Redox and adsorption indicator. Biological stain used in histology, cytology, bacteriology	**10g** **50g**
J65248	**SAG ▲** *[3-Chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[[3-(4-pyridinyl)phenyl]methyl]-benzo[b]thiophene-2-carboxamide]* [912545-86-9], $C_{28}H_{28}ClN_3OS$, F.W. 490.06, Oil	**1mg**
J63741	**Salbutamol, 99%** *[Albuterol]* [18559-94-9], $C_{13}H_{21}NO_3$, F.W. 239.31, Powder, m.p. 157-158°, Merck **14**,216, EINECS 242-424-0, RTECS ZE4400000, BRN 6405698, MDL MFCD00148978 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A β-adrenergic agonist	**1g** **5g** **25g**
A18544	**Salbutamol sulfate, 99% ▲** *[Albuterol sulfate, α-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol sulfate]* [51022-70-9], $C_{26}H_{42}N_2O_6 \cdot H_2SO_4$, F.W. 576.70, EINECS 256-916-8, RTECS CZ6430100, MDL MFCD00055200 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): A β-adrenergic agonist	**1g** **5g** **25g**

Stock #	Description	Size
A16524	**D-(-)-Salicin, 99%** [138-52-3], $C_{13}H_{18}O_7$, F.W. 286.28, m.p. 200-203°, $[\alpha]_D^{20}$ -62.5° (c=3 in water), Merck **14**,8324, EINECS 205-331-6, RTECS LZ5901700, BRN 89593, MDL MFCD00006590, † Substrate for β -glucosidase.  Application(s): An analgesic and antipyretic. Substrate for β-glucosidase	**5g** **25g** **100g**
	Salicyl alcohol, see 2-Hydroxybenzyl alcohol, A14410, p. 248	
A13833	**Salicylaldehyde, 99%** ▲ △ *[2-Hydroxybenzaldehyde]* [90-02-8], $C_7H_6O_2$, F.W. 122.12, m.p. -7°, b.p. 197°, f.p. 76°(168°F), d. 1.168, n_D^{20} 1.5730, Merck **14**,8326, EINECS 201-961-0, RTECS VN5250000, BRN 471388, MDL MFCD00003317, †  ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a A convenient method for the racemization of amino acids consists in heating in acetic acid with 0.05 equivalents of an aldehyde, such as salicylaldehyde: *J. Org. Chem.*, **48**, 843 (1983). For a review of the use of circular dichroism studies of salicylidene derivatives of chiral amines, to establish their absolute configurations using the "salicylidene chirality rule", see: *Chem. Rev.*, **83**, 359 (1983). Application(s): Precursor to a variey of chelating agents	**100g** **500g** **2.5kg**
A12253	**Salicylic acid, 99%** ▲ *[2-Hydroxybenzoic acid]* [69-72-7], $C_7H_6O_3$, F.W. 138.12, m.p. 158-160°, b.p. 211°/20mm, f.p. 157°(315°F), d. 1.443, Merck **14**,8332, EINECS 200-712-3, RTECS VO0525000, BRN 774890, MDL MFCD00002439, †  ! H:H318-H302-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **500g** **2.5kg**
30782	**Salicylic acid, ACS, 99+%** *[2-Hydroxybenzoic acid]* [69-72-7], $C_7H_6O_3$, F.W. 138.12, Powder, m.p. 158-160°, b.p. 211°/20mm, f.p. 157°(315°F), d. 1.443, Merck **14**,8332, Solubility: Soluble in alcohol, acetone, ether. Slightly soluble in cold water. More soluble in boiling water. Water solubility increased by Na_3PO_4, alkali acetates or alkali citrates, EINECS 200-712-3, RTECS VO0525000, BRN 774890, MDL MFCD00002439, † Maximum level of impurities: Melting point 158.0-161.0°, Residue after ignition 0.01%, Cl 0.001%, SO_4 0.003%, Heavy Metals (as Pb) 5ppm, Fe 2ppm, Substances darkened by sulfuric acid P.T. ! H:H318-H302-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2.5kg**
	Salicylic acid sodium salt, see Sodium salicylate, A17056, p. 348 **Saligenin**, see 2-Hydroxybenzyl alcohol, A14410, p. 248	
J64192	**Salubrinal** ▲ *[eIF-2α Inhibitor, SAL]* [405060-95-9], $C_{21}H_{17}Cl_3N_4OS$, F.W. 479.81, Powder	**5mg** **10mg**
	SAMP, see (S)-(-)-1-Amino-2-(methoxymethyl)pyrrolidine, J61723, p. 96	
J65294	**SANT-1** ▲◪ *[(4-Benzyl-piperazin-1-yl)-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethylene)-amine]* [304909-07-7], $C_{23}H_{27}N_5$, F.W. 373.49, Solid, MDL MFCD01827306	**10mg** **50mg**
A18820	**Saponin** [8047-15-2], m.p. 158° dec., Merck **14**,8365, EINECS 232-462-6, RTECS VQ1400000, MDL MFCD00081981, † ! H:H319-H335, P:P261-P280-P305+P351+P338-P304+P340-P405-P501a Application(s): A glycoside used to permeabilize cellular membranes	**25g** **100g**
J63209	**Saponin permeating solution, 0.5% w/v soln. in PBS (5X)** Liquid H:EUH210 Application(s): Cell permeabilizing agent	**125ml** **250ml**
	H-Sar-OH, see Sarcosine, A14594, p. 340	
A14594	**Sarcosine, 98%** ■ *[Methylaminoacetic acid, N-Methylglycine]* [107-97-1], $CH_3NHCH_2CO_2H$, F.W. 89.09, m.p. ca 208° dec., Merck **14**,8373, EINECS 203-538-6, RTECS VQ2897000, BRN 1699442, MDL MFCD00004279, † Application(s): A type 1 glycine transporter inhibitor	**100g** **500g** **2.5kg**
B25536	**Sarcosine hydrochloride, 99%** *[Methylaminoacetic acid hydrochloride, N-Methylglycine hydrochloride]* [637-96-7], $CH_3NHCH_2CO_2H{\cdot}HCl$, F.W. 125.56, m.p. ca 173° dec., Merck **14**,8373, EINECS 211-310-2, MDL MFCD00012609, † Application(s): A type 1 glycine transporter inhibitor	**25g** **100g**
	Sarkosyl NL, see N-Lauroylsarcosine sodium salt, J60040, p. 266	
J60950	**SB 202190, 99+%** *[4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole]* [152121-30-7], $C_{20}H_{14}FN_3O$, F.W. 331.35, Powder, m.p. 240-243°, MDL MFCD00941964 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inhibits p38 kinase activity in vivo through competition with ATP	**25mg** **50mg** **100mg**

Stock #	Description	Size
J61482	**SB 203580, 99%** *[4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)imidazole]* [152121-47-6], $C_{21}H_{16}FN_3OS$, F.W. 377.44, Powder, m.p. 235-247°, MDL MFCD00922198 H:H302-H318, P:P280-P264-P305+P351+P338-P310-P301+P312-P501 Application(s): Highly specific new inhibitor of p38 kinase and MAP Kinase homologues	25mg 50mg 100mg
J65387	**SB 225002** ◢ *[1-(2-Bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea]* [182498-32-4], $C_{13}H_{10}BrN_3O_4$, F.W. 352.10, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	5mg 10mg
	Scarlet Red, see Sudan IV, A12181, p. 355 **Schardinger α-dextrin**, see α-Cyclodextrin, J60687, p. 171 **Schardinger β-dextrin**, see β-Cyclodextrin hydrate, A14529, p. 171 **Schardinger γ-dextrin**, see γ-Cyclodextrin hydrate, L11271, p. 171	
J62171	**Schiff's Reagent** Liquid, † Application(s): Used for detection of glycoproteins in polyacrylamide gels	500ml
	Sebercim, see Norfloxacin, J62652, p. 304	
J64068	**γ-Secretase Inhibitor I** ■ *[Z-Leu-Leu-Nle-CHO (Nle = Norleucine)]* [133407-83-7], $C_{28}H_{41}N_3O_5$, F.W. 475.62, Solid	5mg
J64828	**γ-Secretase Inhibitor II** *[MW167]* $C_{20}H_{30}N_2O_4$, F.W. 362.47, Solid	1mg 5mg
	Secreted Frizzled Related Protein-1 Inhibitor, see sFRP-1 Inhibitor, J65910, p. 342 **Selegiline**, see (R)-(-)-Deprenyl hydrochloride, J61286, p. 180	
J63664	**Semi dry blot transfer buffer (10X)** Liquid, Note: 480mM Tris base, 390mM glycine, 0.375% SDS. Add methanol according to your protocol.	1L 2L
J60181	**Separating or resolving buffer (4X)** Liquid, Note: 1.5M Tris-HCl and 0.4% SDS, pH 8.8. H:H319, P:P280-P264-P305+P351+P338-P337+P313	500ml 1L
	H-L-Ser-OH, see L-Serine, Cell Culture Reagent, J62187, p. 341	
A15184	**DL-Serine, 99%** *[(+/-)-2-Amino-3-hydroxypropionic acid, H-DL-Ser-OH]* [302-84-1], $C_3H_7NO_3$, F.W. 105.09, m.p. ca 240° dec., Merck **14**,8460, EINECS 206-130-6, BRN 1721402, MDL MFCD00064223, †	100g 500g
A11353	**D-Serine, 99%** *[(R)-2-Amino-3-hydroxypropionic acid, H-D-Ser-OH]* [312-84-5], $C_3H_7NO_3$, F.W. 105.09, m.p. 218-220° dec., $[\alpha]_D^{20}$ -13° (c=5 in 5N HCl), Merck **14**,8460, Fieser **14**,282, EINECS 206-229-4, RTECS VT8200000, BRN 1721403, MDL MFCD00004269, †	5g 25g 100g
A11179	**L-Serine, 99%** *[(S)-2-Amino-3-hydroxypropionic acid, H-Ser-OH]* [56-45-1], $C_3H_7NO_3$, F.W. 105.09, m.p. 214-224° dec., $[\alpha]_D^{20}$ +14.5° (c=9 in 1N HCl), Merck **14**,8460, Fieser **12**,430 **14**,282, EINECS 200-274-3, RTECS VT8100000, BRN 1721404, MDL MFCD00064224, † Has been used in a synthesis of D-amino acids. The configuration is inverted by conversion of the carboxyl group to the new alkyl chain by reaction with an organolithium reagent to give the ketone, which is deoxygenated by Raney nickel desulfurization of the thioketal, the hydroxymethyl group becoming the new carboxyl group by oxidation with oxygen over a Pt catalyst: *J. Am. Chem. Soc.*, **106**, 1095 (1984):  	25g 100g 500g
J62187	**L-Serine, Cell Culture Reagent** *[H-L-Ser-OH]* [56-45-1], $C_3H_7NO_3$, F.W. 105.09, Powder, m.p. 222°, Merck **14**,8460, EINECS 200-274-3, RTECS VT8100000, BRN 1721404, MDL MFCD00064224, †	10g 100g 500g 1kg
J64695	**Serine Protease Inhibitor Cocktail I** ■ Lyophilized solid, Note: Makes a 100X stock solution in 1ml of water. A 1x solution contains 500uM AEBSF.HCl, 420nM aprotinin, 20uM elastatinal and 1uM GGACK	1unit
	Sermorelin, see Growth Hormone Releasing Factor (GRF) (1-29) amide, human, J61111, p. 238 **H-DL-Ser-OH**, see DL-Serine, A15184, p. 341 **H-D-Ser-OH**, see D-Serine, A11353, p. 341 **H-Ser-OH**, see L-Serine, A11179, p. 341	

Stock #	Description	Size
B21263	**Serotonin hydrochloride, 99% ▲■** *[3-(2-Aminoethyl)-5-hydroxyindole hydrochloride, 5-HT]* [153-98-0], $C_{10}H_{12}N_2O{\cdot}HCl$, F.W. 212.68, m.p. 167-172°, Merck **14**,8463, UN2811, EINECS 244-464-4, RTECS NM2571000, BRN 3570963, MDL MFCD00012686 H:H301, P:P264-P270-P301+P310-P321-P405-P501a	 **1g** **5g** **10g**
J65910	**sFRP-1 Inhibitor ▲** *[Secreted Frizzled Related Protein-1 Inhibitor]* [915754-88-0], $C_{19}H_{26}N_2O_4S_2$, F.W. 410.60, Oil	**5mg** **25mg**
L04848	**(-)-Shikimic acid, 98% ■** *[3,4,5-Trihydroxy-1-cyclohexene-1-carboxylic acid]* [138-59-0], $C_7H_{10}O_5$, F.W. 174.16, m.p. 184-188°, $[\alpha]_D^{20}$ -175° (c=2 in water), Merck **14**,8480, EINECS 205-334-2, RTECS GW4600000, BRN 4782717, MDL MFCD00066278 Key intermediate in the biosynthesis of aromatic amino acids. Monograph: E. Haslam, *Shikimic Acid*, Wiley, Chichester (1993). Reviews: *Chem. Rev.*, **65**, 435 (1965); *Tetrahedron*, **34**, 3353 (1978); *Biosynthesis*, **6**, 40 (1980); *Natural Prod. Rep.*, **10**, 233 (1993); *Synthesis*, 179 (1993). Application(s): Inhibits rapamycin biosynthesis	 **250mg** **1g**
	O-Sialic acid, see N-(-)-Acetylneuraminic acid, L13950, p. 74 **Siderophilin, iron-saturated**, see Transferrin (HOLO), bovine plasma, 98+%, J61046, p. 373	
11660	**Silver acetate, anhydrous, 99% ▲** [563-63-3], $AgOOCCH_3$, F.W. 166.92, Crystalline, m.p. dec., d. 3.26, Merck **14**,8505, Solubility: Soluble in dilute HNO_3. Water solubility increases with temperature, UN3077, EINECS 209-254-9, RTECS AJ4100000, MDL MFCD00012446, † H:H400-H410-H315, P:P280-P273-P302+P352-P321-P362-P501a	**25g** **100g**
20835	**Silver lactate ▲** [128-00-7], $CH_3CH(OH)CO_2Ag$, F.W. 196.94, Powder, m.p. 120-122°, Merck **14**,8517, UN3077, RTECS UA2465550, MDL MFCD00043279 H:H400-H315-H319-H335, P:P280g-P273-P305+P351+P338	**10g** **50g**
	Sirius Red, see Direct Red 80, B21693, p. 199 **Sirolimus**, see Rapamycin, 99+%, J62473, p. 335	
J64486	**Sirtinol** *[(E)-2-((2-Hydroxynaphthalen-1-yl)methyleneamino)-N-(1-phenylethyl)benzamide]* [410536-97-9], $C_{26}H_{22}N_2O_2$, F.W. 394.46, Crystals H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
J64980	**SJA 6017 ▲** *[N-(4-Fluorophenylsulfonyl)-L-valyl-L-leucinal]* [190274-53-4], $C_{17}H_{25}FN_2O_4S$, F.W. 372.50, Lyophilized solid	**1mg** **5mg**
	Skatole, see 3-Methylindole, L03890, p. 288 **SKF-525A hydrochloride**, see Proadifen hydrochloride, J63833, p. 328 **SKF-92334**, see Cimetidine, 98+% , J62825, p. 163	
J60937	**SKF-96365 hydrochloride, 99+%** *[1-[2-(4-Methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]imidazole]* [130495-35-1], $C_{22}H_{26}N_2O_3{\cdot}HCl$, F.W. 402.92, Powder, RTECS NI6823500, MDL MFCD00236407 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Inhibits receptor-mediated calcium influx	**10mg** **50mg**
J61367	**SM buffer, pH 7.5** Liquid, Note: 50mM Tris-HCl, 8mM magnesium sulfate, 100mM sodium chloride, and 0.01% gelatin, pH7.5 Application(s): Phage diluent and storage buffer. Used for routine manipulation of phage suspensions.	**100ml** **250ml**
J64726	**Smoothened Agonist dihydrochloride dihydrate ▲■** *[SAG1.3 HCl]* [364590-63-6], $C_{28}H_{28}ClN_3OS.2HCl.2H_2O$, F.W. 599.00, Solid	**1mg** **5mg**
J62210	**SOB medium** Liquid, Note: Contains 0.5% Yeast Extract, 2% Tryptone, 10mM NaCl, 2.5mM KCl, 10mM magnesium chloride and 10mM magnesium sulfate Application(s): For cultivating recombinant strains of Escherichia coli	**100ml** **250ml**
J60255	**SOC medium** Liquid, Note: Contains 0.5% Yeast Extract, 2% Tryptone, 10mM NaCl, 2.5mM KCl, 10mM magnesium chloride,10mM magnesium sulfate and 20mM glucose Application(s): for cultivating recombinant strains of Escherichia coli	**100ml** **250ml**
	SOD, see Superoxide Dismutase, bovine erythrocytes, J63003, p. 356	
J63669	**Sodium acetate, 1M aq. soln., pH 4.5, RNAse free** [127-09-3], $NaOOCCH_3$, F.W. 82.03, Liquid, †	**125ml** **250ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J61288	**Sodium acetate, 3M aq. soln., pH 4.5, autoclaved** [127-09-3], $NaOOCCH_3$, F.W. 82.03, Liquid, †	**125ml** **250ml**
J63560	**Sodium acetate, 3M aq. soln., pH 5.2, autoclaved** [127-09-3], $NaOOCCH_3$, F.W. 82.03, Liquid, †	**125ml** **250ml**
J61928	**Sodium acetate, 3M aq. soln., pH 5.2, RNAse free** [127-09-3], $NaOOCCH_3$, F.W. 82.03, Liquid, †	**125ml** **250ml**
J60899	**Sodium acetate, 3M aq. soln., pH 7.0, autoclaved** [127-09-3], $NaOOCCH_3$, F.W. 82.03, Liquid, †	**125ml** **250ml**
J61934	**Sodium acetate, 3M aq. soln., pH 7.0, RNAse free** [127-09-3], $NaOOCCH_3$, F.W. 82.03, Liquid, †	**125ml** **250ml**
A16230	**Sodium acetate trihydrate, 99%** *[Acetic acid sodium salt trihydrate]* [6131-90-4], $NaOOCCH_3 \cdot 3H_2O$, F.W. 136.08 (82.03anhy), m.p. 62-64°, d. 1.45, Merck **14**,8571, Fieser **1**,1024 **5**,59, EINECS 204-823-8, RTECS AJ4580000, BRN 3732037, MDL MFCD00071557, Note: $-3H_2O$ @ 120°, †	**500g** **2.5kg** **10kg**
11553	**Sodium acetate trihydrate, ACS, 99.0%-100.5%** *[Acetic acid sodium salt trihydrate]* [6131-90-4], $NaOOCCH_3 \cdot 3H_2O$, F.W. 136.08 (82.03anhy), Crystalline, m.p. 62-64°, d. 1.45, Merck **14**,8571, Fieser **1**,1024 **5**,59, Solubility: Freely soluble in alcohol, EINECS 204-823-8, RTECS AJ4580000, BRN 3732037, MDL MFCD00071557, Note: 120° $-3H_2O$, † Maximum level of impurities: Insoluble matter 0.005%, pH of a 5% solution 7.5-9.2 at 25°, Cl 0.001%, PO_4 5ppm, SO_4 0.002%, Ca 0.005%, Mg 0.002%, Heavy Metals (as Pb) 5ppm, Fe 5ppm, Substances reducing permanganate P.T., K 0.005% Application(s): In photography, analytical laboratory as buffer, pharmaceutical	**500g** **2kg**
11554	**Sodium acetate, anhydrous, ACS, 99.0% min** ■ *[Acetic acid sodium salt]* [127-09-3], $NaOOCCH_3$, F.W. 82.03, Crystalline, m.p. 324°, d. 1.528, Merck **14**,8571, Fieser **1**,1024 **5**,59, EINECS 204-823-8, RTECS AJ4300010, BRN 3595639, MDL MFCD00012459, † Maximum level of impurities: Insoluble matter 0.01%, Loss on drying at 120° 1.0%, pH of a 5% solution 7.5-9.2 at 25°, Cl 0.002%, PO_4 0.001%, SO_4 0.003%, Ca 0.005%, Mg 0.002%, Heavy Metals (as Pb) 0.001%, Fe 0.001% H:H303, P:P312	**250g** **1kg** **5kg**
	Sodium alginate, see Alginic acid sodium salt, high viscosity, J61887, p. 89 **Sodium 4-aminobenzoate**, see 4-Aminobenzoic acid sodium salt, 99%, J63428, p. 92	
J64449	**Sodium 4-aminosalicylate dihydrate, 98%** ▲ △ *[4-Amino-2-hydroxybenzoic acid sodium salt, 4-Aminosalicylic acid sodium salt dihydrate]* [6018-19-5], $C_7H_6NNaO_3 \cdot 2H_2O$, F.W. 211.14 (175.12ahy), Powder, m.p. 250°, EINECS 205-091-2, RTECS VO1700000, MDL MFCD00151044, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25g** **100g** **500g**
	Sodium L-aspartate monohydrate, see L-Aspartic acid monosodium salt monohydrate, B22321, p. 111	
14314	**Sodium azide, 99%** △ [26628-22-8], NaN_3, F.W. 65.01, Powder or Granular, m.p. ca 275° dec, d. 1.846, Merck **14**,8581, Solubility: Soluble in water and liquid ammonia. Slightly soluble in alcohol, UN1687, EINECS 247-852-1, RTECS VY8050000, MDL MFCD00003536, † H:H300-EUH032-H400-H410, P:P273-P264-P301+P310-P321-P405-P501a The reaction of alkyl halides with the highly-nucleophilic azide anion gives alkyl azides which, because of their facile reduction by hydrogenation, $SnCl_2$, P(III) reagents, etc., provide an excellent, mild route to primary amines. For a review of the preparation and synthetic uses of azides, see: *Chem. Rev.*, **88**, 297 (1988). The preparation of alkyl azides is ideally suited to phase-transfer methods: *Synthesis*, 823 (1979); *Tetrahedron Lett.*, 3107 (1978); **30**, 1245 (1989). The use of ultrasound has also been found to be effective: *Acta Chem. Scand. B*, **38**, 895 (1984). For a one-pot conversion of alkyl bromides to amines using the Staudinger reaction, see **Triethyl phosphite**, **L00339**; see also **Triphenylphosphine**, **L02502**. For reviews, see: *Tetrahedron*, **37**, 437 (1981); **48**, 1353 (1992). Reaction with acyl halides or mixed anhydrides gives acyl azides. These undergo the Curtius rearrangement to isocyanates, which can be isolated, or hydrolyzed *in situ* to the primary amine. For examples, see: *Org. Synth. Coll.*, **6**, 95, 910 (1988). Reagent for selective cleavage of methyldiphenylsilyl ethers; see **Chloro(methyl)diphenylsilane**, **L04162**. For a brief feature on uses of this reagent in Organic synthesis, see: *Synlett*, 505 (2007). Application(s): In airbag inflation, as a preservative in diagnostic medicinals	**10g** **100g** **500g**
	Sodium bentonite, see Bentonite, A15795, p. 118	
A15946	**Sodium benzoate, 99%** *[Benzoic acid sodium salt]* [532-32-1], $C_7H_5NaO_2$, F.W. 144.11, m.p. >300°, Merck **14**,8582, Fieser **1**,1044 **2**,377, Solubility: Soluble in water, alcohol, EINECS 208-534-8, RTECS DH6650000, BRN 3572467, MDL MFCD00012463, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	 **250g** **500g** **2.5kg** **10kg**
	Sodium o-benzosulfimide hydrate, see o-Benzoic sulfimide sodium salt hydrate, A15530, p. 119 **Sodium bicarbonate**, see Sodium hydrogen carbonate, 14707, p. 346	
J62495	**Sodium bicarbonate, 1M buffer soln., pH 8.0** [144-55-8], Liquid, †	**500ml** **1L**

Stock #	Description	Size
J60408	**Sodium bicarbonate, 1M buffer soln., pH 8.5** [144-55-8], Liquid, †	**250ml** **500ml** **1L**
J60066	**Sodium bicarbonate, 1M buffer soln., pH 9.0** [144-55-8], Liquid, †	**250ml** **500ml** **1L**
J62808	**Sodium bicarbonate, 1M buffer soln., pH 9.4** [144-55-8], Liquid, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**250ml** **500ml**
J63025	**Sodium bicarbonate, 1M buffer soln., pH 10.0** [144-55-8], Liquid, † H:H319, P:P280-P264-P305+P351+P338-P337+P313	**250ml** **500ml**
J60068	**Sodium borate, 0.5M buffer soln., pH 8.0** [1330-43-4], Liquid, † H:H360FD, P:P281-P201-P202-P308+P313-P405-P501a	**250ml** **500ml**
J62902	**Sodium borate, 0.5M buffer soln., pH 8.5** [1330-43-4], Liquid, † H:H360, P:P281-P201-P202-P308+P313-P405-P501	**250ml** **500ml**
J63637	**Sodium borate, 0.5M buffer soln., pH 9.0** [1330-43-4], Liquid, † H:H360FD, P:P281-P201-P202-P308+P313-P405-P501a	**250ml** **500ml**
	Sodium borate (tetra) decahydrate, see Sodium tetraborate decahydrate, 40114, p. 349	
A11079	**Sodium butyrate, 98+%** ■ *[Butyric acid sodium salt]* [156-54-7], $CH_3(CH_2)_2CO_2Na$, F.W. 110.09, m.p. >300°, EINECS 205-857-6, RTECS ET6400000, BRN 3629439, MDL MFCD00002816, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Decreases calcium release from intracellular stores. Inhibits histone deacetylase	**5g** **100g** **500g**
J60367	**Sodium cacodylate, 0.1M buffer soln., pH 6.5** [6131-99-3], Liquid	**100ml** **250ml**
J62202	**Sodium cacodylate, 0.1M buffer soln., pH 6.8** [6131-99-3], Liquid	**100ml** **250ml**
J60344	**Sodium cacodylate, 0.1M buffer soln., pH 7.0** [6131-99-3], Liquid, † H:H412, P:P273-P501a	**125ml** **250ml**
	Sodium cacodylate trihydrate, see Cacodylic acid sodium salt trihydrate, A18139, p. 141	
11552	**Sodium carbonate, anhydrous, ACS, 99.5% min** ■ [497-19-8], Na_2CO_3, F.W. 105.99, Granular, d. 2.53, n_D^{20} 1.535, Merck **14**,8596, Fieser **7**,332, Solubility: Soluble in water. Insoluble in alcohol, EINECS 207-838-8, RTECS VZ4050000, BRN 4154566, MDL MFCD00003494, Note: m.p. 851° (begins to lose CO_2 at 400°), † Maximum level of impurities: Insoluble matter 0.01%, Loss on heating at 285° 1.0%, Cl 0.001%, PO_4 0.001%, SiO_2 0.005%, Sulfur compounds (as SO_4) 0.003%, Ca 0.03%, Mg 0.005%, Heavy Metals (as Pb) 5ppm, Fe 5ppm, K 0.005% H:H319, P:P280-P264-P305+P351+P338-P337+P313	**50g** **500g** **2kg**
33377	**Sodium carbonate, ACS primary standard, 99.95-100.05% (dried basis)** ■ [497-19-8], Na_2CO_3, F.W. 105.99, Granular, d. 2.53, n_D^{20} 1.535, Merck **14**,8596, Fieser **7**,332, EINECS 207-838-8, RTECS VZ4050000, BRN 4154566, MDL MFCD00003494, Note: m.p. 851° (begins to lose CO_2 at 400°). For use as an alkalimetric standard, material should be heated at 285° for 2 hrs., † Maximum level of impurities: Insoluble matter 0.01%, Loss on drying at 285° 1.0%, Cl 0.001%, Nitrogen compounds (as N) 0.001%, PO_4 0.001%, SiO_2 0.005%, Sulfur compounds (as SO_4) 0.003%, Ammonium hyrdoxide precipitate 0.01%, Ca 0.02%, Mg 0.004%, Heavy Meta H:H319, P:P280-P264-P305+P351+P338-P337+P313	**100g** **500g**
J61807	**Sodium chloride, 5M aq. soln., pH 8.0, autoclaved** [7647-14-5], NaCl, F.W. 58.44, Liquid, † H:H303, P:P312	**250ml** **500ml**
J61890	**Sodium chloride, 5M aq. soln., autoclaved** [7647-14-5], NaCl, F.W. 58.44, Liquid, †	**250ml** **500ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J60434	**Sodium chloride, 5M aq. soln., RNAse free** [7647-14-5], NaCl, F.W. 58.44, Liquid, † H:H303, P:P312	**125ml** **250ml**
12314	**Sodium chloride, ACS, 99.0% min** ■ [7647-14-5], NaCl, F.W. 58.44, Crystalline, m.p. 801°, b.p. 1413°, d. 2.165, n_D^{20} 1.5442, Merck **14**,8599, Fieser **6**,285, Solubility: Soluble in water, glycerol. Very slightly soluble in alcohol, EINECS 231-598-3, RTECS VZ4725000, MDL MFCD00003477, † Maximum level of impurities: Insoluble matter 0.005%, pH of a 5% solution 5.0-9.0 at 25°, I 0.002%, Br 0.01%, Chlorate and nitrate (as NO_3) 0.003%, PO_4 5ppm, SO_4 0.004%, Ba P.T., Ca 0.002%, Mg 0.001%, Heavy Metals (as Pb) 5ppm, Fe 2ppm, K 0.005% H:H303, P:P312	**500g** **2kg** **10kg**
A17074	**Sodium cholate hydrate, 99%** *[Cholic acid sodium salt hydrate]* [206986-87-0], $C_{24}H_{39}NaO_5 \cdot xH_2O$, F.W. 430.56(anhy), RTECS FZ9600000, BRN 3582354, MDL MFCD00064138, † H:H303, P:P312 Application(s): Biochemical solubilizing agent	**10g** **50g**
J62918	**Sodium citrate, 0.5M buffer soln., pH 5.0** Liquid	**250ml** **500ml**
J63199	**Sodium citrate, 0.5M buffer soln., pH 5.5** Liquid	**250ml** **500ml**
J61815	**Sodium citrate, 0.5M buffer soln., pH 6.0** Liquid ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	**250ml** **500ml**
J63888	**Sodium citrate, 0.5M buffer soln., pH 6.5** Liquid	**250ml** **500ml**
	Sodium creatine phosphate dibasic tetrahydrate, see Creatine phosphate disodium salt tetrahydrate, A15362, p. 168	
A14638	**Sodium 1-decanesulfonate, 99% (dry wt.), water <1.5%** *[1-Decanesulfonic acid sodium salt]* [13419-61-9], $CH_3(CH_2)_9SO_3Na$, F.W. 244.33, m.p. >300°, EINECS 236-525-9, BRN 3918920, MDL MFCD00007526 Application(s): Ion-associating reagent for HPLC, useful for analysis of peptides and proteins.	**5g** **25g** **100g**
B21060	**Sodium dehydroacetate, 97%** *[3-Acetyl-4-hydroxy-6-methyl-2-pyrone sodium salt, Dehydroacetic acid sodium salt]* [4418-26-2], $C_8H_7NaO_4$, F.W. 190.13, m.p. ca 295° dec., EINECS 224-580-1, RTECS UP8225000, MDL MFCD00040583, † ! H:H302, P:P264-P270-P301+P312-P330-P501a	**100g** **500g** **2.5kg**
B20759	**Sodium deoxycholate monohydrate, 98%** *[Deoxycholic acid sodium salt monohydrate]* [145224-92-6], $C_{24}H_{39}NaO_4 \cdot H_2O$, F.W. 432.58 (414.58anhy), m.p. >300°, $[\alpha]_D^{20}$ +44° (c=2 in water), Merck **14**,2899, EINECS 206-132-7, RTECS FZ2250000, BRN 3643164, MDL MFCD00150750, † ! H:H302-H335, P:P261-P304+P340-P301+P312-P312-P405-P501a	**25g** **100g** **500g**
	Sodium dextran sulfate, see Dextran sulfate sodium salt **Sodium 2-(2,6-dichloroanilino)phenylacetate**, see Diclofenac sodium salt, J62609, p. 186 **Sodium 2,5-dichloroindophenoxide hydrate**, see 2,6-Dichloroindophenol sodium salt hydrate, A10107, p. 185	
A15898	**Sodium diethyldithiocarbamate trihydrate, 98%** ■ *[Diethyldithiocarbamic acid sodium salt trihydrate, Dithiocarb sodium]* [20624-25-3], $C_5H_{10}NNaS_2 \cdot 3H_2O$, F.W. 225.31 (171.28anhy), m.p. 94-102°, Merck **14**,3378, EINECS 205-710-6, RTECS EZ6550000, BRN 3920507, MDL MFCD00150617, † ! H:H302, P:P264-P270-P301+P312-P330-P501a Reagent for extraction of heavy metals: *Anal. Chem.*, **54**, 2536 (1982).	**100g** **500g**
11591	**Sodium dihydrogen phosphate monohydrate, ACS, 98.0-102.0%** ■ *[Monosodium orthophosphate, Sodium phosphate, monobasic]* [10049-21-5], $NaH_2PO_4 \cdot H_2O$, F.W. 137.99 (119.98anhy), Crystalline, m.p. 100° $-H_2O$, Merck **14**,8660, Fieser **1**,395, EINECS 231-449-2, RTECS WA1900000, MDL MFCD00149208, † Maximum level of impurities: Insoluble matter 0.01%, pH of a 5% solution 4.1-4.5 at 25%, Cl 5ppm, SO_4 0.003%, Ca 0.005%, K 0.01%, As 0.5ppm, Heavy Metals (as Pb) 0.001%, Fe 0.001% ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **1kg** **5kg**
J63394	**Sodium n-dodecyl sulfate (SDS), 20% aq. soln.** [151-21-3], $CH_3(CH_2)_{11}OSO_3Na$, F.W. 288.38, Liquid, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**

Stock #	Description	Size
A11183	**Sodium n-dodecyl sulfate, 99% (dry wt.), water <1.5%** *[n-Dodecyl sulfate sodium salt, Sodium lauryl sulfate]* [151-21-3], $CH_3(CH_2)_{11}OSO_3Na$, F.W. 288.38, m.p. ca 206°, Merck **14**,8636, Fieser **13**,281, EINECS 205-788-1, RTECS WT1050000, BRN 3599286, MDL MFCD00036175, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a The reaction rate and endo:exo ratio in the Diels-Alder cycloadditions of acrylic acid derivatives to cyclopentadiene is increased in the presence of this surfactant: *Tetrahedron Lett.*, **27**, 1285 (1986). Application(s): Denatures and solubilizes proteins for electrophoresis	**25g** **100g** **500g**
J64241	**Sodium n-dodecyl sulfate, ultrapure, 99%** *[n-Dodecyl sulfate sodium salt, Sodium lauryl sulfate]* [151-21-3], $CH_3(CH_2)_{11}OSO_3Na$, F.W. 288.38, Powder, m.p. ca 206°, Merck **14**,8636, EINECS 205-788-1, RTECS WT1050000, BRN 3599286, MDL MFCD00036175, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25g** **100g** **500g**
J60251	**Sodium fluoride, 200mM aq. soln.** [7681-49-4], NaF, F.W. 41.99, Liquid, † H:H303, P:P312	**100ml** **250ml**
A11276	**Sodium fumarate, 98%** ■ *[Fumaric acid disodium salt]* [17013-01-3], $C_4H_2Na_2O_4$, F.W. 160.04, EINECS 241-087-7, RTECS LT1830000, MDL MFCD00064567 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **2.5kg**
	Sodium furegrelate, see Furegrelate sodium salt, 99+%, J61378, p. 229	
A10464	**Sodium D-gluconate, 97%** *[D-Gluconic acid sodium salt]* [527-07-1], $C_6H_{11}NaO_7$, F.W. 218.14, m.p. ca 206° dec., $[\alpha]_D^{20}$ +12° (c=20 in water), Merck **14**,4456, EINECS 208-407-7, RTECS LZ5235000, BRN 3919651, MDL MFCD00064210, †	**2.5kg** **10kg**
A10917	**Sodium 1-heptanesulfonate, 99% (dry wt.), water <2%** *[1-Heptanesulfonic acid sodium salt]* [22767-50-6], $CH_3(CH_2)_6SO_3Na$, F.W. 202.24, m.p. >300°, EINECS 245-210-5, BRN 3731762, MDL MFCD00007543, † Application(s): HPLC reagent used for ion-association in analyses of peptides and proteins	**5g** **25g** **100g**
14707	**Sodium hydrogen carbonate, ACS, 99.7-100.3%** *[Sodium bicarbonate]* [144-55-8], $NaHCO_3$, F.W. 84.01, Granular, d. 2.159, n_D^{20} 1.500, Merck **14**,8583, Fieser **3**,260 **5**,595, Solubility: Soluble in water. Insoluble in alcohol, EINECS 205-633-8, RTECS VZ0950000, BRN 4153970, MDL MFCD00003528, Note: m.p. ≈50°, begins to lose CO_2. ≈100°, converts to Na_2CO_3. Aqueous solutions begin to decompose into CO_2 and Na_2CO_3 at ≈20°. Completely decomposed upon boiling, † Maximum level of impurities: Insoluble matter 0.015%, Cl 0.003%, PO_4 0.001%, SO_4 0.003%, NH_4 5ppm, Ca 0.02%, Mg 0.005%, Heavy Metals (as Pb) 5ppm, Fe 0.001%, K 0.005% H:H303, P:P312 Application(s): As a source of CO_2, in making sodium salts, baking powder, cleaning compounds	**500g** **2kg** **10kg**
11592	**Sodium hydrogen phosphate heptahydrate, ACS, 98.0-102.0%** *[Disodium phosphate, Sodium phosphate, dibasic]* [7782-85-6], $Na_2HPO_4·7H_2O$, F.W. 268.07 (141.98anhy), Crystalline, m.p. 48.1°-$5H_2O$, d. 1.7, Merck **14**,8659, EINECS 231-448-7, RTECS WC4600000, MDL MFCD00149180, † Maximum level of impurities: pH of a 5% solution 8.7-9.3 at 25°, Insoluble matter 0.005%, Cl 0.001%, SO_4 0.005%, Heavy Metals (as Pb) 0.001%, Fe 0.001% H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**500g** **2kg**
13437	**Sodium hydrogen phosphate, anhydrous, ACS, 99.0% min** ■ *[Disodium phosphate, Sodium phosphate, dibasic]* [7558-79-4], Na_2HPO_4, F.W. 141.98, Granular, Merck **14**,8659, EINECS 231-448-7, RTECS WC4500000, MDL MFCD00003496, Note: Suitable for buffer solutions, † Maximum level of impurities: Insoluble matter 0.01%, Loss on drying at 105° 0.2%, pH of a 5% solution 8.7-9.3 at 25°, Cl 0.002%, SO_4 0.005%, Heavy Metals (as Pb) 0.001%, Fe 0.002% H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **1kg** **5kg**
J63736	**Sodium hydroxide, 10N aq. soln.** [1310-73-2], NaOH, F.W. 40.00, Liquid, UN1824, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a	**100ml** **250ml**
13455	**Sodium hydroxide (low chloride), ACS, 97.0% min** △ ■ [1310-73-2], NaOH, F.W. 40.00, Pellets, m.p. 318°, b.p. 1390°, d. 2.13, Merck **14**,8627, Fieser **5**,616 **7**,336 **8**,460 **18**,334, Solubility: Soluble in water, alcohol and glycerol, UN1823, EINECS 215-185-5, RTECS WB4900000, MDL MFCD00003548, † Maximum level of impurities: Cl 0.005%, N 0.001%, PO_4 0.001%, SO_4 0.003%, Heavy Metals (as Ag) 0.002%, Fe 0.001%, Hg 0.1ppm, Ca 0.005%, Mg 0.002%, Ni 0.001%, K 0.02%, Na_2CO_3 1.0% H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): In chemical manufacture, rayon and cellophane, as a neutralizing agent in petroleum refining, in pulp, paper detergents and textiles, and as a lab reagent. NaOH solutions precipitate most metals as hydroxides from aqueous solutions of the metal salts	**2.5g** **100g** **500g** **2kg** **10kg** **2x12.5kg**

Stock #	Description	Size
J60415	**Sodium hydroxide and β-mercaptoethanol buffer** Liquid, UN2922, Note: Solution contains: 1.85M sodium hydroxide and 7.5% β-mercaptoethanol. H:H318-H315-H412, P:P280-P305+P351+P338-P302+P352-P321-P310-P501a Application(s): Common solution for protein and DNA isolation from yeast.	**250ml** **500ml**
	Sodium 2-hydroxybenzoate, see Sodium salicylate, A17056, p. 348 **Sodium 5-hydroxydecanoate**, see 5-Hydroxydecanoic acid sodium salt, 98%, J61434, p. 248 **Sodium iminodiacetate dibasic hydrate**, see Iminodiacetic acid disodium salt hydrate, 43809, p. 254 **Sodium isethionate**, see Isethionic acid sodium salt, A12054, p. 260	
41529	**Sodium DL-lactate, 60% w/w aq. soln.** *[DL-Lactic acid sodium salt]* [72-17-3], $CH_3CH(OH)CO_2Na$, F.W. 112.06, Liquid, d. 1.326, Merck **14**,8635, EINECS 200-772-0, RTECS OD5680000, BRN 4332999, MDL MFCD00065400, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Useful chiral synthon; building block for depsipeptides	**250ml** **1L**
	Sodium lauryl sulfate, see Sodium n-dodecyl sulfate, A11183, p. 346 **Sodium mercaptoacetate**, see Mercaptoacetic acid sodium salt, 98%, J60290, p. 280 **Sodium nitroferricyanide(III)**, see Sodium pentacyanonitrosylferrate(III) dihydrate, 87683, p. 347 **Sodium nitroprusside**, see Sodium pentacyanonitrosylferrate(III) dihydrate, 87683, p. 347	
A14292	**Sodium 1-octanesulfonate, 99%** *[1-Octanesulfonic acid sodium salt]* [5324-84-5], $CH_3(CH_2)_7SO_3Na$, F.W. 216.28, m.p. >300°, EINECS 226-195-4, BRN 3574241, MDL MFCD00007544, † Application(s): Reagent for HPLC analysis of peptides and proteins	**5g** **25g** **100g**
81104	**Sodium orthovanadate, 99.9% (metals basis)** *[Sodium vanadate (ortho), Sodium vanadium oxide]* [13721-39-6], Na_3VO_4, F.W. 183.94, Granular, m.p. 850-866°, EINECS 237-287-9, RTECS YW1120000, MDL MFCD00003511, † H:H302-H332-H315-H319-H335, P:P280h-P305+P351+P338 Application(s): Inhibitor of protein tyrosine phosphatase and alkaline phosphate	**25g** **100g** **500g**
J60191	**Sodium orthovanadate, 100mM aq. soln.** [13721-39-6], Na_3VO_4, F.W. 183.94, Liquid, † H:EUH210	**50ml** **100ml**
A11648	**Sodium oxalate, 99%** ■ *[Oxalic acid sodium salt]* [62-76-0], $Na_2C_2O_4$, F.W. 134.00, m.p. ca 250-270° dec., d. 2.340, Merck **14**,8650, EINECS 200-550-3, RTECS KI1750000, BRN 3631622, MDL MFCD00012465, † H:H302-H312, P:P280-P302+P352-P322-P301+P312-P312-P501a	**100g** **500g** **2.5kg**
87683	**Sodium pentacyanonitrosylferrate(III) dihydrate, ACS, 99.0-102.0%** *[Sodium nitroprusside, Sodium nitroferricyanide(III)]* [13755-38-9], $Na_2[Fe(CN)_5NO]\cdot 2H_2O$, F.W. 297.95 (261.92anhy), Crystalline, d. 1.72, Merck **14**,8649, Fieser **18**,337, UN1588, EINECS 238-373-9, RTECS LJ8925000, MDL MFCD00149192, † Maximum level of impurities: Insoluble matter 0.01%, Cl 0.02%, SO_4 P.T. (limit about 0.01%) H:H301-H312-H332, P:P261-P301+P310-P302+P352-P321-P405-P501a Application(s): For chromatographic detection of peptides	**50g** **250g**
A15713	**Sodium phosphate dodecahydrate, 97%** *[Sodium phosphate, tribasic dodecahydrate, Trisodium phosphate dodecahydrate]* [10101-89-0], $Na_3PO_4\cdot 12H_2O$, F.W. 380.12 (163.94anhy), m.p. ca 75° dec., d. 1.62, Merck **14**,8662, UN3262, EINECS 231-509-8, RTECS TC9575000, MDL MFCD00149198, † H:H314, P:P280-P305+P351+P338-P309-P310	**500g** **2.5kg** **10kg**
13438	**Sodium phosphate, tribasic, anhydrous, tech.** ■ *[Trisodium phosphate]* [7601-54-9], Na_3PO_4, F.W. 163.94, -100 Mesh Powder, Merck **14**,8662, UN3262, EINECS 231-509-8, RTECS TC9490000, MDL MFCD00003510, † H:H314, P:P280-P305+P351+P338-P309-P310	**1kg** **5kg**
J63482	**Sodium phosphate, 0.2M buffer soln., pH 7.0** Liquid, †	**500ml** **1L**
J63816	**Sodium phosphate, 0.2M buffer soln., pH 7.2** Liquid, †	**500ml** **1L**
J62152	**Sodium phosphate, 0.2M buffer soln., pH 7.4** Liquid, †	**500ml** **1L**

Stock #	Description	Size
J62041	**Sodium phosphate, 0.2M buffer soln., pH 7.5** Liquid, †	500ml 1L
J62815	**Sodium phosphate, 0.2M buffer soln., pH 7.6** Liquid, †	500ml 1L
J62733	**Sodium phosphate, 0.2M buffer soln., pH 8.0** Liquid, †	500ml 1L
J61372	**Sodium phosphate, 0.2M buffer soln., pH 8.5** Liquid, †	500ml 1L
J60565	**Sodium phosphate, 0.2M buffer soln., pH 9.0** Liquid, †	500ml 1L
J63159	**Sodium phosphate, 0.2M buffer soln., pH 9.5** Liquid, †	500ml 1L
J63791	**Sodium phosphate, 0.5M buffer soln., pH 7.0** Liquid, †	250ml 500ml
J61561	**Sodium phosphate, 0.5M buffer soln., pH 7.5** Liquid, †	250ml 500ml
J60158	**Sodium phosphate, 0.5M buffer soln., pH 7.6** Liquid, †	250ml 500ml
J60825	**Sodium phosphate, 0.5M buffer soln., pH 8.0** Liquid, †	250ml 500ml
J61151	**Sodium phosphate, 0.5M buffer soln., pH 8.5** Liquid, †	250ml 500ml
J60651	**Sodium phosphate, 0.5M buffer soln., pH 9.0** Liquid, †	250ml 500ml
J61456	**Sodium phosphate, 0.5M buffer soln., pH 9.5** Liquid, †	250ml 500ml
	Sodium phosphate, dibasic, see Sodium hydrogen phosphate heptahydrate, 11592, p. 346 **Sodium phosphate, monobasic**, see Sodium dihydrogen phosphate monohydrate, 11591, p. 345 **Sodium potassium tartrate**, see Potassium sodium L-tartrate tetrahydrate, 33241, p. 327	
A17440	**Sodium propionate, 99%** ■ *[Propionic acid sodium salt]* [137-40-6], $CH_3CH_2CO_2Na$, F.W. 96.06, m.p. 285-291°, Merck **14**,8669, EINECS 205-290-4, RTECS UF7525000, MDL MFCD00002759, † ! H:H312, P:P280-P302+P352-P322-P312-P363-P501a	500g 2.5kg
J62052	**Sodium pyrophosphate, 200mM buffer soln.** [7758-16-9], Liquid, †	100ml 250ml
A11148	**Sodium pyruvate, 99%** *[Pyruvic acid sodium salt]* [113-24-6], $C_3H_3NaO_3$, F.W. 110.04, m.p. >300°, EINECS 204-024-4, BRN 3568341, MDL MFCD00002586, † 	50g 250g 500g
J61840	**Sodium pyruvate, Cell Culture Grade** *[Pyruvic acid sodium salt, α-Ketopropionic acid sodium salt]* [113-24-6], $CH_3COCOONa$, F.W. 110.04, Powder, EINECS 204-024-4, BRN 3568341, MDL MFCD00002586, †	50g 100g 500g
	Sodium saccharin, see o-Benzoic sulfimide sodium salt hydrate, A15530, p. 119	
A17056	**Sodium salicylate, 99%** ▲ *[Salicylic acid sodium salt, Sodium 2-hydroxybenzoate]* [54-21-7], $C_7H_5NaO_3$, F.W. 160.11, m.p. >300°, Merck **14**,8332, EINECS 200-198-0, RTECS VO5075000, BRN 3732792, MDL MFCD00002440, †  ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	250g 1kg
12585	**Sodium selenite, anhydrous, 99% min, typically 99.75% min (metals basis)** ■ *[Selenious acid disodium salt]* [10102-18-8], Na_2SeO_3, F.W. 172.94, Powder, m.p. >350°, Merck **14**,8673, Solubility: Freely soluble in water. Insoluble in alcohol, UN2630, EINECS 233-267-9, RTECS VS7350000, MDL MFCD00003489, † H:H300-EUH031-H331-H317-H411, P:P261-P301+P310-P302+P352-P321-P405-P501a Application(s): In glass manufacturing	100g 500g

Contact us for pricing on bulk sizes

Stock #	Description	Size
11560	**Sodium sulfate, ACS, 99.0% min** ■ [7757-82-6], Na_2SO_4, F.W. 142.04, Granular, m.p. 884°, d. 2.680, n_D^{20} 1.484, Merck **14**,8680, Fieser **1**,1103, Solubility: Soluble in water. Insoluble in alcohol, EINECS 231-820-9, RTECS WE1650000, MDL MFCD00003504, † Maximum level of impurities: Insoluble matter 0.01%, Loss on ignition 0.5%, Cl 0.001%, N 5ppm, PO_4 0.001%, Heavy Metals (as Pb) 5ppm, Fe 0.001%, Ca 0.01%, Mg 0.005%, K 0.01%, pH of a 5% solution 5.2-9.2 at 25° Application(s): In drying organic liquids, in Kjeldahl nitrogen determination, in manufacturing of glass	**500g** **2kg** **10kg**
A18346	**Sodium taurocholate hydrate, 97%** *[Taurocholic acid sodium salt]* [145-42-6], $C_{26}H_{44}NNaO_7S{\cdot}xH_2O$, F.W. 537.73(anhy), $[\alpha]_D^{20}$ +23.0° (c=3 in water), Merck **14**,9075, EINECS 205-653-7, MDL MFCD00150819, † 	**1g** **5g** **25g**
40114	**Sodium tetraborate decahydrate, ACS, 99.5-105.0%** *[Borax, Sodium borate (tetra) decahydrate]* [1303-96-4], $Na_2B_4O_7{\cdot}10H_2O$, F.W. 381.37 (201.22anhy), Powder, m.p. 75°, d. 1.73, Merck **14**,8590, Solubility: Soluble in water, glycerol. Insoluble in alcohol, EINECS 215-540-4, RTECS VZ2275000, MDL MFCD00149193, Note: 100° $-5H_2O$, 150° $-9H_2O$, 320° $-10H_2O$, † Maximum level of impurities: Insoluble matter 0.005%, Cl 0.001%, PO_4 0.001%, SO_4 0.005%, Ca 0.005%, Heavy Metals (as Pb) 0.001%, Fe 5ppm, pH of a 0.01M solution 9.15-9.20 at 25° H:H360FD, P:P201-P308+P313	**500g**
	Sodium thioglycolate, see Mercaptoacetic acid sodium salt, 98%, J60290, p. 280	
A17629	**Sodium thiosulfate, anhydrous, 99%** ■ [7772-98-7], $Na_2S_2O_3$, F.W. 158.11, d. 1.667, Merck **14**,8694, EINECS 231-867-5, RTECS XN6476000, MDL MFCD00003499, †	**500g** **2.5kg**
36489	**Sodium tungsten oxide dihydrate, ACS, 99.0-101.0%** [10213-10-2], $Na_2WO_4{\cdot}2H_2O$, F.W. 329.86 (293.83anhy), Powder, m.p. 100° $-2H_2O$, d. 3.250, Merck **14**,8698, Fieser **13**,145 **15**,295, EINECS 236-743-4, RTECS YO7900000, MDL MFCD00149190, † Maximum level of impurities: Insoluble matter 0.01%, Titratable free base 0.02meq/g, Cl 0.005%, Mo 0.001%, SO_4 0.01%, Heavy metals and iron (as Pb) 0.001% H:H302-H319, P:P280-P264-P305+P351+P338-P301+P312-P337+P313-P501a	**100g** **500g**
	Sodium vanadate (ortho), see Sodium orthovanadate, 81104, p. 347 **Sodium vanadium oxide**, see Sodium orthovanadate, 81104, p. 347	
L02814	**Solketal, 97%** *[(+/-)-2,2-Dimethyl-1,3-dioxolane-4-methanol, (+/-)-2,3-O-Isopropylideneglycerol]* [100-79-8], $C_6H_{12}O_3$, F.W. 132.16, m.p. -27°, b.p. 188-190°, f.p. 80°(176°F), d. 1.064, n_D^{20} 1.4340, Merck **14**,5213, EINECS 202-888-7, RTECS JI0400000, BRN 104465, MDL MFCD00063238, † H:H227  Application(s): Useful for synthesis of mono-, di- and triglycerides	**100g** **500g** **2.5kg**
	Solvent Black 3, see Sudan Black B, J62268, p. 355 **Solvent Black 5**, see Nigrosin, alcohol soluble, J61186, p. 302	
A15395	**Solvent Blue 38** *[C.I. 74180, Direct Blue 86]* [1328-51-4], m.p. ca 235° dec., EINECS 215-523-1, MDL MFCD00071424	**25g** **100g**
	Solvent Orange 7, see Sudan II, A17613, p. 355 **Solvent Red 24**, see Sudan IV, A12181, p. 355 **Solvent Red 27**, see Oil Red O, A12989, p. 307 **Solvent Red 140** , see Erythrosin B, spirit soluble , J62619, p. 210 **Solvent Yellow 3**, see Fast Garnet GBC base, J60574, p. 218 **Solvent Yellow 94**, see Fluorescein, L13251, p. 222	
J62984	**Sorafenib, 99+%** *[BAY 43-9006]* [284461-73-0], $C_{21}H_{16}ClF_3N_4O_3$, F.W. 464.83, Crystalline powder, Merck **14**,8720 Application(s): An inhibitor of Raf kinase, PDGF, VEGF receptor 2&3 kinases	**1g** **2g** **5g**
A16196	**Sorbic acid, 99%** *[Hexa-2,4-dienoic acid]* [110-44-1], $CH_3CH{=}CHCH{=}CHCO_2H$, F.W. 112.13, m.p. 132-135°, b.p. 228° dec., f.p. 127°(260°F), d. 1.205, Merck **14**,8721, Fieser **15**,296, EINECS 203-768-7, RTECS WG2100000, BRN 1741831, MDL MFCD00002703, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **500g** **1kg** **5kg**
	Sorbitan monooctadecanoate, see Sorbitan monostearate, L11435, p. 350	
J62576	**Sorbitan monooleate** *[Span® 80]* [1338-43-8], $C_{24}H_{44}O_6$, F.W. 428.61, Viscous liquid, f.p. 113°(235°F), Merck **14**,8724, EINECS 215-665-4, RTECS WG2932400, MDL MFCD00080948, † Application(s): An emulsifier	**1L**

Stock #	Description	Size
L11435	**Sorbitan monostearate** *[Sorbitan monooctadecanoate, Span® 60]* [1338-41-6], $C_{24}H_{46}O_6$, F.W. 430.63, m.p. 53-57°, f.p. >149°(300°F), d. 1.00, Merck **14**,8724, EINECS 215-664-9, RTECS WG2933500, MDL MFCD00005366, † Span® is a registered trademark of ICI Group. Nonionic surfactant.  Application(s): Emulsifier used in cosmetics, pharmaceuticals and food preparation	250g 1kg
J62648	**Sorbitan sesquioleate** *[Arlacel® 83, Span® 83]* [8007-43-0], $C_{42}H_{76}O_7$, F.W. 693.06, Viscous liquid, f.p. 113°(235°F), d. 0.989, n_D^{20} 1.478, EINECS 232-360-1, RTECS WG2934330, MDL MFCD00151568, † Application(s): An emulsifier	500ml 1L
36404	**D-Sorbitol, 98%** ■ *[D-Glucitol]* [50-70-4], $C_6H_{14}O_6$, F.W. 182.17, Powder, m.p. 98-100°, Merck **14**,8725, Solubility: Soluble in water, methanol, acetone, DMF, EINECS 200-061-5, RTECS LZ4290000, BRN 1721899, MDL MFCD00004708, † 	500g 2kg
B21208	**D-Sorbose, 98%** [3615-56-3], $C_6H_{12}O_6$, F.W. 180.16, m.p. 163-165°, EINECS 222-796-0, MDL MFCD00151095 	100mg 500mg
J63772	**Sotalol hydrochloride, 98%** *[N-[4-[1-Hydroxy-2-(isopropylamino)ethyl]phenyl]methanesulfonamide hydrochloride]* [959-24-0], $C_{12}H_{20}N_2O_3S{\cdot}HCl$, F.W. 308.82, Powder, Merck **14**,8728, EINECS 213-496-0, RTECS PB0826000, MDL MFCD00242937 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Potent β adrenergic antagonist	100mg 1g 5g
J61399	**Soybean oil** *[Glycine Soja]* [8001-22-7], Oil, f.p. >113°(235°F), d. 0.92, n_D^{20} 1.4743, EINECS 232-274-4, RTECS WG4862000, MDL MFCD00132356, † Application(s): For use with SP6 RNA Polymerase product no. J65792	500ml 1L
J65573	**SP6 RNA Polymerase in potassium phosphate buffer** *[RNA Polymerase from Salmonella enterica serotype typhimurium, SP6-infected]* [9014-24-8], Liquid, MDL MFCD00132197, † Application(s): Transcribes RNA from DNA sequences	1kilounit 5kilounits
J65792	**SP6 RNA Polymerase in Tris buffer** *[RNA Polymerase from Salmonella enterica serotype typhimurium, SP6-infected]* [9014-24-8], Liquid, MDL MFCD00132197, † Application(s): Transcribes RNA from DNA sequences	2kilounits 10kilounits
J64124	**SP6 RNA Polymerase 10X Reaction Buffer** Liquid Application(s): For use with SP6 RNA Polymerase product no. J65573	6ml
J65092	**SP6 RNA Polymerase 5X Transcription Optimized Buffer** Liquid Application(s): For use with SP6 RNA Polymerase product no. J65573	200microliters
	SpA, see Protein A, Staph. aureus, J63404, p. 330 **Span® 60**, see Sorbitan monostearate, L11435, p. 350 **Span® 80**, see Sorbitan monooleate, J62576, p. 349 **Span® 83**, see Sorbitan sesquioleate, J62648, p. 350	
J61820	**Spectinomycin dihydrochloride pentahydrate, Cell Culture Grade** *[Spectinomycin dihydrochloride]* [22189-32-8], $C_{14}H_{24}N_2O_7{\cdot}2HCl.5H_2Oa$, F.W. 495.35 (405.28anhy), Powder, EINECS 244-554-3, RTECS WG7400000, MDL MFCD00150886, Note: Greater than 600 micrograms per milligram Application(s): An aminocyclitol antibiotic that binds to the 30S ribosomal subunit of bacteria and interrupts protein synthesis	5g 25g
	Spectinomycin dihydrochloride , see Spectinomycin dihydrochloride pentahydrate, Cell Culture Grade, J61820, p. 350	
A19096	**Spermidine, 99%** △ *[N-(3-Aminopropyl)-1,4-diaminobutane, 1,8-Diamino-4-azaoctane]* [124-20-9], $H_2N(CH_2)_3NH(CH_2)_4NH_2$, F.W. 145.25, m.p. 22-25°, b.p. 128-130°/14mm, f.p. >110°(230°F), d. 0.925, n_D^{20} 1.4790, Merck **14**,8742, UN2735, EINECS 204-689-0, RTECS EJ7000000, BRN 1698591, MDL MFCD00008229, † H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Binds to the polyamine modulatory site of NMDA	1g 5g 25g 100g

Contact us for pricing on bulk sizes

Stock #	Description	Size
J61595	**Spermidine trihydrochloride, 99+%** *[N-(3-Aminopropyl)-1,4-butanediamine trihydrochloride]* [334-50-9], $NH_2(CH_2)_3NH(CH_2)_4NH_2 \cdot 3HCl$, F.W. 254.63, Powder, m.p. 250° dec., Merck **14**,8742, EINECS 206-379-0, RTECS EJ7023000, BRN 3552356, MDL MFCD00012918, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Binds and precipitates DNA; may be used for purification of DNA binding proteins	**100mg**
L19562	**Spermine, 97%** △ ■ *[Neuridine, Musculamine]* [71-44-3], $C_{10}H_{26}N_4$, F.W. 202.35, m.p. 28-30°, b.p. 150°/5mm, f.p. >110°(230°F), Merck **14**,8743, UN3259, EINECS 200-754-2, RTECS EJ7175000, BRN 1751791, MDL MFCD00008215, †  H:H314, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Binds to the polyamine modulatory site of NMDA	**1g** **5g**
J63060	**Spermine tetrahydrochloride, 99%** *[N,N'-Bis(3-aminopropyl)-1,4-butanediamine tetrahydrochloride]* [306-67-2], $C_{10}H_{26}N_4 \cdot 4HCl$, F.W. 348.19, Powder, EINECS 206-189-8, RTECS EJ7230000, BRN 3911771, MDL MFCD00012914, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Binds to the polyamine modulatory site of NMDA	**1g** **5g** **25g**
	DL-Sphinganine, see DL-erythro-Dihydrosphingosine, J62103, p. 191 **4-Sphingenine**, see D-erythro-Sphingosine, 99+%, J63584, p. 351	
J63584	**D-erythro-Sphingosine, 99+%** *[4-Sphingenine, trans-D-erythro-2-Amino-4-octadecene-1,3-diol]* [123-78-4], $C_{18}H_{37}NO_2$, F.W. 299.50, Powder, Merck **14**,8747, EINECS 204-651-3, BRN 1727294, MDL MFCD00036751 Application(s): Inhibits protein kinase C and calmodulin-dependent enzymes. Induces apoptosis. A constituent of cell membranes	**5mg** **25mg**
H52427	**D-erythro-Sphingosine hydrochloride, 97%** *[trans-D-erythro-2-Amino-4-octadecene-1,3-diol hydrochloride]* [2673-72-5], $C_{18}H_{37}NO_2 \cdot HCl$, F.W. 335.96  Application(s): Inhibitor of protein kinase C and calmodulin-dependent enzymes, but may stimulate mast cells by activation of protein kinase C	**100mg** **500mg**
J60119	**Spironolactone** [52-01-7], $C_{24}H_{32}O_4S$, F.W. 416.58, Powder, m.p. 207-208°, Merck **14**,8760, EINECS 200-133-6, RTECS TU4725000, MDL MFCD00082250, † H:H360, P:P281-P201-P202-P308+P313-P405-P501 Application(s): Antihypertensive potassium sparing diuretic; aldosterone receptor antagonist	**1g** **5g** **10g**
B20944	**Squalene, 98%** ▲ △ *[2,6,10,15,19,23-Hexamethyl-2,6,10,14,18,22-tetracosahexaene]* [111-02-4], $C_{30}H_{50}$, F.W. 410.73, m.p. -75°, b.p. 285°/25mm, f.p. 218°(424°F), d. 0.855, n_D^{20} 1.4955, Merck **14**,8768, EINECS 203-826-1, MDL MFCD00008912, †  Application(s): Biosynthetic precursor to all steroids	**100g** **500g**
J60839	**SSC buffer (20X)** Liquid, Note: 0.3M sodium citrate, 3.0M sodium chloride, pH 7.0.	**1L** **2L** **4L**
J60561	**SSC (20X), RNAse free** Liquid, Note: 0.3M sodium citrate, 3.0M sodium chloride, pH 7.0.	**250ml** **500ml**
J61214	**SSPE (20X)** Liquid, Note: 0.2M sodium phosphate, 3.0M sodium chloride, 20mM EDTA, pH approx. 7.4	**1L** **2L** **4L**
J60783	**SSPE (20X), RNAse free** Liquid, Note: 0.2M sodium phosphate, 3.0M sodium chloride, 20mM EDTA.	**250ml** **500ml**
J63450	**Stacking buffer (4X)** Liquid, Note: Contains 0.5M Tris-HCl, 0.4% SDS, pH 6.8.	**500ml** **1L**
J62630	**Stains-All, 95%** ▲ [7423-31-6], $C_{30}H_{27}BrN_2S_2$, F.W. 559.58, Powder, EINECS 231-047-7, BRN 3865213, MDL MFCD00078788, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Cationic carbocyanine dye used in electrophoresis to stain proteins and nucleic acids	**1g** **5g**

Stock #	Description	Size
H32127	**Stains-All, 96%** *[1-Ethyl-2-[(E)-3-(1-ethylnaphtho[1,2-d]thiazolin-2-ylidene)-2-methylpropenyl-]naphtho[1,2-d]thiazolium bromide, 3,3'-Diethyl-9-methyl-4,5,4',5'-dibenzothiacarbocyanine]* [7423-31-6], $C_{30}H_{27}BrN_2S_2$, F.W. 559.58, EINECS 231-047-7, BRN 3865213, MDL MFCD00078788, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a  Application(s): General protein and nucleic acid stain, which stains different colors on bands of RNA (bluish purple), DNA (blue) and proteins (red)	1g 5g
36703	**Starch, soluble, ACS (for iodometry)** *[Amylodextrin]* [9005-84-9], Powder, m.p. 256-258° dec., Merck **14**,8799, Solubility: Soluble in hot water, EINECS 232-686-4, MDL MFCD00082026, † Maximum level of impurities: Solubility P.T., pH of a 2% solution 5.0-7.0 at 25°, Residue after ignition 0.4%, Sensitivity P.T.	50g 250g 1kg
J65749	**STAT5 Inhibitor ▲** *[(E)-N'-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide]* $C_{16}H_{11}N_3O_3$, F.W. 293.30, Solid	10mg
J62837	**Staurosporine, 99+%** *[Antibiotic AM-2282]* [62996-74-1], $C_{28}H_{26}N_4O_3$, F.W. 466.54, Powder, m.p. 240-243°, Merck **14**,8802, RTECS KD5084000, BRN 1060573, MDL MFCD00077402 H:H350, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Broad spectrum protein kinase inhibitor	1mg 5mg 10mg
	Staurosporinone, see K252c, 99%, J63090, p. 262	
J60265	**STE buffer soln.** Liquid, Note: Contains 100mM NaCl, 10mM Tris-HCl, 1mM EDTA, pH 8.0.	1L 2L
A12244	**Stearic acid, 98%** *[Octadecanoic acid]* [57-11-4], $CH_3(CH_2)_{16}CO_2H$, F.W. 284.48, m.p. 69-72°, b.p. 232°/15mm, f.p. 196°(384°F), d. 0.941, Merck **14**,8804, EINECS 200-313-4, RTECS WI2800000, BRN 608585, MDL MFCD00002752, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A saturated fatty acid	5g 25g 100g
	Stearic acid cholesteryl ester, see Cholesteryl stearate, A14771, p. 161	
J65114	**Stem-Cell Factor/c-Kit Inhibitor ▲** *[SCF/c-Kit Signaling Inhibitor, ISCK03]* [945526-43-2], $C_{19}H_{21}N_3O_2S$, F.W. 355.50, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	10mg 50mg
J60563	**STET** Liquid, Note: 100mM NaCl, 10mM Tris-HCl (pH 8.0), 1mM EDTA, 5% Triton X-100.	500ml 1L
A11924	**cis-Stilbene, 97% ▲** *[cis-1,2-Diphenylethylene]* [645-49-8], $C_{14}H_{12}$, F.W. 180.25, m.p. 1-2°, b.p. 307°, f.p. >110°(230°F), d. 1.04, n_D^{20} 1.6220, Merck **14**,8817, EINECS 211-445-7, RTECS DA0513600, BRN 1616739, MDL MFCD00004788 H:H319, P:P305+P351+P338 	1g 5g 25g
	D-Streptamine, see Apramycin, 98+%, J63874, p. 108	
J62428	**Streptavidin, Streptomyces avidinii, 96%** [9013-20-1], Lyophilized powder, 13.5 kDa, MDL MFCD00082035 Application(s): A protein with high affinity for biotin	2mg 10mg
J61299	**Streptomycin sulfate, Cell Culture Reagent** [3810-74-0], $C_{21}H_{39}N_7O_{12} \cdot 1.5H_2SO_4$, F.W. 728.69, Powder, Merck **14**,8826, EINECS 223-286-0, RTECS WK4990000, BRN 3894995, MDL MFCD00037023, † H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Inhibits initiation and causes misreading of rRNA in protein synthesis	50g 100g
J61601	**Streptozotocin, 97+% ■** *[NSC-85998, U-9889]* [18883-66-4], $C_8H_{15}N_3O_7$, F.W. 265.22, Powder, m.p. 121°, Merck **14**,8832, EINECS 242-646-8, RTECS LZ5775000, BRN 2060675, MDL MFCD00006607 H:H351, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Antibiotic and antitumor agent. Potent methylating agent for DNA	500mg 1g
J60925	**Stripping buffer (4X)** Liquid, Note: 150mM Tris-HCl, 8% SDS, pH 6.8. Add mercaptoethnol according to your protocol. H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	250ml 500ml

Stock #	Description	Size
J62023	**Stripping buffer-2 (4X)** Liquid, Note: 0.2M Glycine, pH 2.5.	250ml 500ml
J60810	**Stripping buffer-3 (4X)** Liquid, Note: 0.4M Glycine, 0.2% SDS, 2% Tween-20, pH 2.5.	250ml 500ml
	γ-**Strophanthin**, see Oubain octahydrate, 98%, J60724, p. 310	
J61534	**SU buffer, SDS + Urea** Liquid, Note: 5% SDS, 8M Urea, 50mM Tris-HCl and 0.05% bromophenol blue, pH 6.8 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	50ml 100ml
J63489	**Substance P** *[Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2]* [33507-63-0], $C_{63}H_{98}N_{18}O_{13}S$, F.W. 1347.64, Powder, EINECS 251-545-8, MDL MFCD00076780 Application(s): A neurokinin NK-1 receptor agonist	1mg 5mg 25mg
J61828	**Substance P free acid** *[H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-OH]* [71977-09-8], $C_{63}H_{97}N_{17}O_{14}S$, F.W. 1348.63, Powder Application(s): A neurokinin NK-1 receptor agonist	5mg
J62756	**Substance P (1-4)** *[Arg-Pro-Lys-Pro]* [57468-16-3], $C_{22}H_{40}N_8O_5$, F.W. 496.61, Powder Application(s): Active fragment of Substance P	5mg
J60018	**Substance P (1-7), 96%** *[Arg-Pro-Lys-Pro-Gln-Gln-Phe]* [68060-49-1], $C_{41}H_{65}N_{13}O_{10}$, F.W. 900.05, Powder, MDL MFCD00076789 Application(s): Active fragment of Substance P	2mg 5mg
J61891	**Substance P (4-11)** *[Octa-Substance P, Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2]* [53749-60-3], $C_{46}H_{67}N_{11}O_{10}S$, F.W. 966.17, Powder Application(s): Active fragment of Substance P	5mg 25mg
J63228	**Substance P (6-11)** *[Hexa-Substance P, Gln-Phe-Phe-Gly-Leu-Met-NH2]* [51165-09-4], $C_{41}H_{60}N_{10}O_9S$, F.W. 869.05, Powder Application(s): Active fragment of Substance P	5mg 25mg
J63619	**Succinate, 0.2M buffer soln., pH 4.0** [110-15-6], Liquid, † H:H303, P:P312	250ml 500ml
J63881	**Succinate, 0.2M buffer soln., pH 4.5** [110-15-6], Liquid, † H:H303, P:P312	250ml 500ml
J63863	**Succinate, 0.2M buffer soln., pH 5.0** [110-15-6], Liquid, † H:H303, P:P312	250ml 500ml
J61100	**Succinate, 0.2M buffer soln., pH 5.5** [110-15-6], Liquid, † H:H303, P:P312	250ml 500ml
J61853	**Succinate, 0.2M buffer soln., pH 6.0** [110-15-6], Liquid, † H:H303, P:P312	250ml 500ml
J62078	**Succinate, 0.2M buffer soln., pH 6.5** [110-15-6], Liquid, † H:H303, P:P312	250ml 500ml
33272	**Succinic acid, ACS, 99.0% min** *[Butanedioic acid]* [110-15-6], $HO_2CCH_2CH_2CO_2H$, F.W. 118.09, Crystalline, m.p. 186-188°, b.p. 235°, f.p. 206°(402°F), d. 1.56, Merck **14**,8869, Solubility: Soluble in water (increasing with temperature). Soluble in alcohol, methanol, EINECS 203-740-4, RTECS WM4900000, BRN 1754069, MDL MFCD00002789, † Maximum level of impurities: Insoluble matter 0.01%, Residue after ignition 0.02%, Cl 0.001%, PO_4 0.001%, SO_4 0.003%, Nitrogen compounds (as N) 0.001%, Heavy Metals (as Pb) 5ppm, Fe 5ppm, Melting point 185.0°-191.0° ! H:H318-H335-H315, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	500g 2kg

Stock #	Description	Size
A12245	**Succinic anhydride, 99%** ◪ *[Butanedioic anhydride, Dihydro-2,5-furandione]* [108-30-5], $C_4H_4O_3$, F.W. 100.07, m.p. 118-121°, b.p. 261°, f.p. 157°(314°F), d. 1.572, Merck **14**,8870, Fieser **4**,468, Solubility: Soluble in chloroform, EINECS 203-570-0, RTECS WN0875000, BRN 108441, MDL MFCD00005525, † H:H302-H319-H335, P:P261-P280-P305+P351+P338-P304+P340-P405-P501a Friedel-Crafts reaction with arenes gives 3-aroylpropionic acids: *Org. Synth. Coll.*, **2**, 81 (1943). For a review of the Friedel-Crafts reactions of the anhydrides of dibasic acids, see: *Org. React.*, **5**, 229 (1949). For reaction with phosphoranes, in a route to 2,2-disubstituted cyclopentane-1,3-diones, see **(1-Ethoxycarbonylethylidene)triphenylphosphorane**, **A15619**. A method for protecting both H atoms of a primary amine consists of formation of the succinimide, followed by enolsilylation with **Triisopropylsilyl trifluoromethanesulfonate**, **B21127**, to form the 2,5-bis(triisopropylsiloxy)pyrroles. Deprotection can be effected by desilylation with dilute HCl, followed by hydrazinolysis: *Tetrahedron Lett.*, **38**, 2617 (1997).	**250g** **500g** **1kg** **5kg**
A13503	**Succinimide, 98+%** *[Butanimide, 2,5-Pyrrolidinedione]* [123-56-8], $C_4H_5NO_2$, F.W. 99.09, m.p. 121-126°, b.p. 287-288°, f.p. 201°(393°F), d. 1.410, Merck **14**,8871, EINECS 204-635-6, RTECS WN2200000, BRN 108440, MDL MFCD00005495, † With the cycloalkenylation agent **(1-Ethoxycarbonylcyclopropyl)triphenylphosphonium tetrafluoroborate**, **A18305**, gives a bridgehead lactam (pyrrolizinone) which is an intermediate in a diastereoselective synthesis of (±)-isoretronecanol: *Liebigs Ann. Chem.*, 521 (1983):  	**250g** **1kg** **5kg**
J64834	**N-Succinimidyl 15-azido-4,7,10,13-tetraoxapentadecanoate** *[Azido-PEG4-NHS ester]* $C_{15}H_{24}N_4O_8$, F.W. 308.37, Liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg** **1g**
J61410	**N-Succinimidyl 3-maleimidobenzoate, 98+%** ▲◪ *[3-Maleimidobenzoic acid N-hydroxysuccinimide ester]* [58626-38-3], $C_{15}H_{10}N_2O_6$, F.W. 314.26, Powder, m.p. 175-177°, EINECS 261-368-8, BRN 1505254, MDL MFCD00005514 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A heterobifunctional coupling reagent useful for forming enzyme immunoconjugates	**250mg** **1g** **5g**
J64496	**N-Succinimidyl 3-(propargyloxy)propionate** *[Acetylene-PEG-NHS ester]* $C_{10}H_{11}NO_5$, F.W. 225.20, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg**
J64902	**N-Succinimidyl 4,7,10,13-tetraoxahexadec-15-ynoate** *[Acetylene-PEG4-NHS ester]* $C_{16}H_{23}NO_8$, F.W. 357.36, Viscous liquid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25mg** **100mg**
J65375	**N-Succinyl-Gly-Gly-Phe-p-nitroanilide** ▲ *[Suc-Gly-Gly-Phe-pNA, Chymotrypsin Substrate I, Colorimetric]* [68982-90-1], $C_{23}H_{25}N_5)_8$, F.W. 499.47, Solid, EINECS 273-486-7, MDL MFCD00038721	**5mg** **50mg**
A15583	**Sucrose, 99%** *[D-(+)-Saccharose]* [57-50-1], $C_{12}H_{22}O_{11}$, F.W. 342.30, m.p. 186-190°, d. 1.580, $[\alpha]_D^{20}$ +66.5° (c=10 in water), Merck **14**,8881, EINECS 200-334-9, RTECS WN6500000, BRN 90825, MDL MFCD00006626, † Application(s): Used for protein purification in sucrose density gradient studies	**500g** **2.5kg** **10kg**
36508	**Sucrose, ACS** *[D-(+)-Saccharose]* [57-50-1], $C_{12}H_{22}O_{11}$, F.W. 342.30, Crystalline, m.p. 185-187°, d. 1.58, Merck **14**,8881, Solubility: Soluble in water. Slightly soluble in alcohol, methanol, EINECS 200-334-9, RTECS WN6500000, BRN 90825, MDL MFCD00006626, † Maximum level of impurities: Specific rotation $[\alpha]_D^{25}$ +66.3° to +66.8°, Insoluble matter 0.005%, Loss on drying at 105° 0.03%, Residue after ignition 0.01%, Titratable acid 0.0008meq/g, Cl 0.005%, Sulfate and sulfite (as SO_4) 0.005%, Heavy Metals (as Pb) 5ppm, 	**250g** **1kg**
J65148	**Sucrose, Molecular Biology Grade** *[D-(+)-Saccharose]* [57-50-1], $C_{12}H_{22}O_{11}$, F.W. 342.30, Crystalline solid, m.p. 185-187°, d. 1.58, EINECS 200-334-9, RTECS WN6500000, BRN 90825, MDL MFCD00006626, † Application(s): For protein purification by sucrose density gradients	**100g** **500g** **1kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64270	**Sucrose, ultrapure, 99%** *[D-(+)-Saccharose]* [57-50-1], $C_{12}H_{22}O_{11}$, F.W. 342.30, Crystalline, m.p. 185-187°, d. 1.58, Merck **14**,8881, EINECS 200-334-9, RTECS WN6500000, BRN 90825, MDL MFCD00006626, †	**100g** **500g** **1kg**
J63662	**Sucrose, 1.2M aq. soln.** [57-50-1], $C_{12}H_{22}O_{11}$, F.W. 342.30, Liquid, †	**500ml** **1L**
J60720	**Sucrose, 80%, in MNE buffer, MES + NaCl + EDTA** Liquid	**250ml** **500ml**
J63979	**Sucrose gelatin veronal buffer (SGVB), pH 7.2** Liquid, Note: Contains 5mM barbital, 30mM NaCl, 227mM sucrose, 0.1% gelatin, 0.5mM magnesium chloride, 0.15mM calcium chloride, pH 7.2.	**250ml** **500ml**
J62587	**Sucrose gelatin veronal buffer with EDTA (SGVBE), pH 7.2** Liquid, Note: Contains 5mM barbital, 30mM NaCl, 227mM sucrose, 0.1% gelatin, 10mM EDTA, pH 7.2.	**250ml** **500ml**
A17613	**Sudan II** *[C.I. 12140, Solvent Orange 7]* [3118-97-6], $C_{18}H_{16}N_2O$, F.W. 276.34, m.p. 156-160°, EINECS 221-490-4, MDL MFCD00003896, † H:H351-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**25g** **100g**
A18318	**Sudan III** *[C.I. 26100, Solvent Red 23]* [85-86-9], $C_{22}H_{16}N_4O$, F.W. 352.40, m.p. ca 200° dec., Merck **14**,8884, EINECS 201-638-4, RTECS QK4250000, BRN 931185, MDL MFCD00003905, † H:H341-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**25g** **100g** **500g**
A12181	**Sudan IV** *[C.I. 26105, Scarlet Red]* [85-83-6], $C_{24}H_{20}N_4O$, F.W. 380.45, m.p. ca 185° dec., Merck **14**,8393, EINECS 201-635-8, MDL MFCD00003893, † H:H341-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a  Application(s): Useful as a stain for fat in animal tissue	**25g** **100g**
J62268	**Sudan Black B** *[C.I. 26150, Solvent Black 3]* [4197-25-5], $C_{29}H_{24}N_6$, F.W. 456.55, Powder, m.p. 118-126°, Merck **14**,8885, EINECS 224-087-1, RTECS SD4431500, BRN 723248, MDL MFCD00006919, † Application(s): Histochemical stain for chromosomes	**10g** **25g** **100g**
A19836	**Sulfacetamide, 98%** *[N-(4-Aminobenzenesulfonyl)acetamide, N-Sulfanilylacetamide]* [144-80-9], $C_8H_{10}N_2O_3S$, F.W. 214.24, m.p. 182-184°, Merck **14**,8899, EINECS 205-640-6, RTECS AC8450000, BRN 981718, MDL MFCD00066501, † H:H341, P:P281-P201-P202-P308+P313-P405-P501a  Application(s): Sulfonamide antibiotic with antibacterial activity, especially against acne	**50g** **250g**
	Sulfadimidine, see Sulfamethazine, A19276, p. 355	
L04194	**Sulfamerazine, 98+%** *[N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide, 2-Sulfanilamido-4-methylpyrimidine]* [127-79-7], $C_{11}H_{12}N_4O_2S$, F.W. 264.30, m.p. 234-238°, Merck **14**,8913, EINECS 204-866-2, RTECS WP0750000, BRN 249133, MDL MFCD00023212, † 	**25g** **100g**
A19276	**Sulfamethazine, 99%** *[N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide, Sulfadimidine]* [57-68-1], $C_{12}H_{14}N_4O_2S$, F.W. 278.34, m.p. 198-201°, EINECS 200-346-4, MDL MFCD00006066, †  Application(s): Sulfonamide antibacterial	**25g** **100g**
	Sulfamic acid, see Amidosulfonic acid, 33233, p. 91	
A13001	**Sulfanilamide, 98%** *[4-Aminobenzenesulfonamide]* [63-74-1], $C_6H_8N_2O_2S$, F.W. 172.21, m.p. 163-168°, d. 1.08, Merck **14**,8925, EINECS 200-563-4, RTECS WO8400000, BRN 511852, MDL MFCD00007939, †  H:H302, P:P264-P270-P301+P312-P330-P501a Intermediate for preparation of 2,6-disubstituted anilines, by electrophilic substitution followed by removal of the sulfonamide blocking group by desulfonation with sulfuric acid. See, e.g.: *Org. Synth. Coll.*, **3**, 262 (1955). Application(s): Sulfonamide antibacterial	**100g** **500g** **2.5kg**
	2-Sulfanilamido-4-methylpyrimidine, see Sulfamerazine, L04194, p. 355	

Stock #	Description	Size
41540	**Sulfanilic acid, ACS, 98.0-102.0%** [121-57-3], $C_6H_7NO_3S$, F.W. 173.19, Powder, m.p. ca 365°, Merck **14**,8926, EINECS 204-482-5, RTECS WP3895500, BRN 908765, MDL MFCD00007886, † Maximum level of impurities: Residue after ignition 0.01%, Insoluble in sodium carbonate 0.02%, Cl 0.002%, NO_4 0.5ppm, SO_4 0.01% H:H315-H319-H317, P:P261-P280-P305+P351+P338-P302+P352-P321-P501a Application(s): Reagent for chromatographic detection of histidine	50g 250g
	N-Sulfanilylacetamide, see Sulfacetamide, A19836, p. 355	
A10727	**Sulfathiazole, 99%** *[N(1)-(2-Thiazolyl)sulfanilamide]* [72-14-0], $C_9H_9N_3O_2S_2$, F.W. 255.32, m.p. 200-203°, Merck **14**,8943, EINECS 200-771-5, MDL MFCD00005319, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	100g 500g
A10486	**Sulfonazo III tetrasodium salt** [68504-35-8], $C_{22}H_{12}N_4Na_4O_{14}S_4$, F.W. 776.57, m.p. ≈300°, EINECS 270-924-9, MDL MFCD00003942 Indicator for determination of sulfates and sulfur: *Anal. Chem.*, **37**, 1159 (1965). Spectrophotometric reagent for alkaline earth metals. Application(s): Spectrophotometric reagent for alkaline earth metals and indicator for sulfate titrations	5g 25g
J60581	**Sulforhodamine 101 acid chloride** *[Texas Red®, Sulforhodamine 101 sulfonyl chloride]* [82354-19-6], $C_{31}H_{29}ClN_2O_6S_2$, F.W. 625.15, Powder, BRN 8667894, MDL MFCD00012406 H:H302-H351-H373, P:P260-P281-P301+P312-P308+P313-P405-P501 Application(s): Fluorescent labeling compound	10mg
	Sulforhodamine 101 sulfonyl chloride, see Sulforhodamine 101 acid chloride, J60581, p. 356 **Sulforhodamine B**, see Kiton Red S, A14769, p. 264	
43144	**5-Sulfosalicylic acid dihydrate, ACS, 99+%** *[2-Hydroxy-5-sulfobenzoic acid dihydrate]* [5965-83-3], $C_7H_6O_6S \cdot 2H_2O$, F.W. 254.22 (218.19anhy), Powder, m.p. 103-112°, Merck **14**,8964, Fieser **1**,1118, UN2585, EINECS 202-555-6, RTECS VO6500000, BRN 650741, MDL MFCD00007508, † Maximum level of impurities: Insoluble matter 0.02%, Residue after ignition 0.1%, Cl 0.001%, HOC_6H_4COOH 0.04%, SO_4 0.02%, Pb 0.002%, Fe 0.001% H:H314-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Reagent for precipitation of proteins	25g 100g 500g
J61772	**Sulindac** *[cis-5-Fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]indene-3-acetic acid, MK-231]* [38194-50-2], $C_{20}H_{17}FO_3S$, F.W. 356.41, Powder, m.p. 182-185°, Merck **14**,8982, UN2811, EINECS 253-819-2, RTECS NK8226000, MDL MFCD00599589 H:H301-H334-H361-H317, P:P285-P301+P310-P302+P352-P321-P405-P501a Application(s): A non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 and induces apoptosis in HT-29 cells	5g 25g
J62104	**Sulindac sulfide** [32004-67-4], $C_{20}H_{17}FO_2S$, F.W. 340.41, Powder, m.p. 189-191°, EINECS 250-892-2, MDL MFCD00869764 H:H302-H334-H317-H361, P:P285-P261-P302+P352-P321-P405-P501 Application(s): Active metabolite of sulindac; inhibits cyclooxygenase-1	100mg
	Sunsorb® 770, see 2-Deoxy-D-ribose, A11990, p. 180	
J63003	**Superoxide Dismutase, bovine erythrocytes** *[EC 1.15.1.1, SOD]* [9054-89-1], Lyophilized powder, Merck **14**,9002, EINECS 232-943-0, MDL MFCD00132404, Note: Minimum 1,400 units/mg dry wt. One unit inhibits by 50% the maximum reduction of nitro blue tetrazolium under the specified conditions Application(s): Catalyzes the dismutation of superoxide radicals to hydrogen peroxide and molecular oxygen	2mg 10mg
J64422	**Suptopin-2** *[(E)-4-Hydroxy-3-(3-(4-hydroxy-3,5-dimethoxyphenyl)acryloyl)-6-methyl-2H-pyran-2-one]* [331852-66-5], $C_{17}H_{16}O_7$, F.W. 332.30, Powder, MDL MFCD00810236	10mg
J61707	**Suramin hexasodium salt, 98+%** [129-46-4], $C_{51}H_{34}N_6Na_6O_{23}S_6$, F.W. 1429.16, Powder, Merck **14**,9006, EINECS 204-949-3, RTECS QM7000000, BRN 3694087, MDL MFCD00210217 Application(s): An antitumor and antiparasitic compound. Inhibits reverse transcriptase	250mg 500mg 1g
J64281	**Syk Inhibitor ▲** *[Spleen Tyrosine Kinase Inhibitor]* [622387-85-3], $C_{18}H_{15}N_3O_3S$, F.W. 353.40, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1mg 5mg

Stock #	Description	Size
J62843	**Syntide 2, 96%** *[Pro-Leu-Ala-Arg-Thr-Leu-Ser-Val-Ala-Gly-Leu-Pro-Gly-Lys-Lys]* [108334-68-5], $C_{68}H_{122}N_{20}O_{18}$, F.W. 1507.84, Lyophilized powder Application(s): Selective substrate for calmodulin-dependent protein kinase II	**1mg** **5mg**
J65312	**T4 DNA Ligase, in 20mM Tris HCl and 50mM KCl** *[EC 6.5.1.1]* [9015-85-4], F.W. 62kDa, Liquid, EINECS 232-770-0, MDL MFCD00163508, † Application(s): Seals nicks in double stranded DNA and RNA and also in DNA/RNA hybrids. For ligation of blunt ended or cohesive DNA fragments	**1kilounit** **5kilounits**
J65133	**T4 DNA Ligase, 99+%, in 10mM Tris HCl and 50mM NaCl** *[EC 6.5.1.1]* [9015-85-4], F.W. 55.3kDa, Liquid, EINECS 232-770-0, MDL MFCD00163508, † Application(s): Forms an energy dependent phosphodiester linkage between the termini of adjacent polynucleotides of duplex DNA. For ligation of cloning vector and restriction insert fragments	**150kilounits**
J65896	**T7 RNA Polymerase, in 20mM potassium phosphate and 10mM DTT** *[EC 2.7.7.6]* [9014-24-8], Liquid, EINECS 232-756-4, † Application(s): For synthesis of RNA transcripts, biologically active mRNA and antisense RNA	**1kilounit** **5kilounits**
J60070	**Tacrine hydrochloride hydrate, 98+%** *[9-Amino-1,2,3,4-tetrahydroacridine hydrochloride, THA hydrochloride]* [1684-40-8], $C_{13}H_{14}N_2 \cdot HCl \cdot xH_2O$, F.W. 234.73(anhy), Powder, m.p. 283-284°, Merck **14**,9024, UN2811, EINECS 216-867-5, RTECS AR9532500, MDL MFCD00150067 H:H302-H332-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A potent centrally acting anticholinesterase	**500mg** **1g** **5g**
J63571	**Tacrolimus, 99+%** *[FK-506, Fugimycin]* [104987-11-3], $C_{44}H_{69}NO_{12}$, F.W. 804.02, Powder, m.p. 120-125°, Merck **14**,9025, UN2811, RTECS KD4200000, MDL MFCD11045918 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Interacts with the immunophilins cyclophilin and FKBP-12	**50mg** **100mg** **500mg**
J63677	**TAE (10X), TRIS + acetate + EDTA** Liquid, Note: 0.4M Tris base, 0.4M acetate, 10mM EDTA, pH 8.0., †	**1L** **2L** **4L**
J63931	**TAE (50X), TRIS + acetate + EDTA** Liquid, Note: 2M Tris base, 1M acetate, 50mM EDTA, pH 8.0., † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1L** **2L** **4L**
B21192	**D-Tagatose, 99%** [87-81-0], $C_6H_{12}O_6$, F.W. 180.16, m.p. 129-135°, $[\alpha]_D^{20}$ -4.7° (c=1 in water), Merck **14**,9030, EINECS 201-772-3, BRN 1724555, MDL MFCD00134449 	**250mg** **1g** **5g**
J64028	**Tamibarotene** *[AM 80]* [94497-51-5], $C_{22}H_{25}NO_3$, F.W. 351.44, Solid, Merck **14**,9047, RTECS DH6940000, MDL MFCD00866188	**10mg** **50mg**
J64893	**Tamm Horsfall Glycoprotein, human, 99%** *[Uromodulin]*	**100micrograms**
J63509	**Tamoxifen, 98+%** *[cis-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene]* [10540-29-1], $C_{26}H_{29}NO$, F.W. 371.52, Powder, Merck **14**,9048, EINECS 234-118-0, RTECS KR5919600, MDL MFCD00010454 H:H350-H360+H362, P:P263-P260-P281-P308+P313-P405-P501 Application(s): Inhibitor of protein kinase C and induces apoptosis in cancer cells	**500mg** **1g** **5g**
J60955	**Tamoxifen citrate ▲■** *[cis-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene citrate]* [54965-24-1], $C_{26}H_{29}NO.C_6H_8O_7$, F.W. 563.65, White to off-white powder, Merck **14**,9048, EINECS 259-415-2, RTECS KH2387000, MDL MFCD00058321 H:H350-H360+H362-H302, P:P263-P260-P281-P301+P312-P405-P501a Application(s): Inhibitor of protein kinase C and induces apoptosis in cancer cells	**1g** **5g**
J61999	**Tamsulosin hydrochloride, 98+%** *[Harnal]* [106463-17-6], $C_{20}H_{28}N_2O_5S \cdot HCl$, F.W. 444.97, Powder, m.p. 228-230°, Merck **14**,9049, RTECS DB2430000, MDL MFCD00922997 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): An α-1 adrenoceptor antagonist	**10mg** **25mg** **100mg**

Stock #	Description	Size
J62004	**Tandutinib, 99%** *[MLN518, CT53518]* [387867-13-2], $C_{31}H_{42}N_6O_4$, F.W. 562.71, Powder, m.p. 177-178° Application(s): Tyrosine kinase receptor inhibitor with antineoplastic activity	**25mg** **50mg** **100mg**
A17022	**Tannic acid** ▲ △ [1401-55-4], $C_{76}H_{52}O_{46}$, F.W. 1701.23, m.p. ca 218° dec., Merck **14**,9052, EINECS 215-753-2, RTECS WW5075000, BRN 8186396, MDL MFCD00066397, † H:H303, P:P312 Application(s): Used for enzyme immobilization and protein adsorption	**250g** **1kg**
J64330	**TAPI-2** ▲ ■ *[TNF-β Protease Inhibitor-2]* [187034-31-7], $C_{19}H_{37}N_5O_5$, F.W. 415.53, Solid	**1mg**
A17754	**TAPS, 99%** *[3-[Tris(hydroxymethyl)methyl]amino-1-propanesulfonic acid]* [29915-38-6], $(HOCH_2)_3CNH(CH_2)_3SO_3H$, F.W. 243.28, m.p. 239-241° dec., EINECS 249-954-1, MDL MFCD00007538, † Application(s): A zwitterionic Good's Buffer	**25g** **100g**
J60322	**TAPS, 0.2M buffer soln., pH 8.0** [91000-53-2], Liquid	**100ml** **250ml**
J63268	**TAPS, 0.2M buffer soln., pH 8.5** [91000-53-2], Liquid	**100ml** **250ml**
J61189	**TAPS sodium salt, 98%** [91000-53-2], $(HOCH_2)_3CNH(CH_2)_3SO_3Na$, F.W. 265.26, Powder, MDL MFCD00069903 Application(s): Zwitterionic buffer	**25g** **100g**
J64594	**Taq DNA Polymerase** *[EC 2.7.7.7]* [9012-90-2], Liquid, EINECS 232-741-2, † Application(s): Catalyzes polymeration of deoxyribonucleotides into DNA strands. Suitable for PCR and automated sequencing reactions	**400units**
J64587	**Taq DNA Polymerase Standard 10X Reaction Buffer** Liquid Application(s): For use with Taq DNA Polymerase product no. J64594	**6ml**
	Targretin, see Bexarotene, 99+%, J63701, p. 124	
A10683	**DL-Tartaric acid, 99%** [133-37-9], $C_4H_6O_6$, F.W. 150.09, m.p. 210-212° dec., Merck **14**,9069, EINECS 205-105-7, BRN 1725148, MDL MFCD00071626, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **500g** **1kg**
A11264	**D-(-)-Tartaric acid, 99%** [147-71-7], $C_4H_6O_6$, F.W. 150.09, m.p. 166-170°, f.p. 210°(410°F), $[\alpha]_D^{20}$ -13° (c=10 in water), Merck **14**,9068, Fieser **16**,312 **17**,321, EINECS 205-695-6, BRN 1725145, MDL MFCD00004238, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Useful as a resolving agent	**25g** **100g** **500g**
36405	**L-(+)-Tartaric acid, ACS** *[2,3-Dihydroxybutanedioic acid]* [87-69-4], $C_4H_6O_6$, F.W. 150.09, Granular, m.p. 168-170°, d. 1.760, Merck **14**,9070, Solubility: Soluble in water, methanol, ethanol, glycerol, EINECS 201-766-0, RTECS WW7875000, BRN 1725147, MDL MFCD00064207, † Maximum level of impurities: Insoluble matter 0.005%, Residue after ignition 0.02%, Cl 0.001%, C_2O_4 P.T. (limit about 0.1%), PO_4 0.001%, Sulfur compounds (as S) 0.002%, Heavy Metals (as Pb) 5ppm, Fe 5ppm H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Useful as a resolving agent	**100g** **500g** **2kg**
	L-(+)-Tartaric acid diammonium salt, see Ammonium L-(+)-tartrate, 17658, p. 102	
A17682	**Tartrazine** *[Acid Yellow 23, C.I. 19140]* [1934-21-0], $C_{16}H_{19}N_4Na_3O_9S_2$, F.W. 534.37, Merck **14**,9072, EINECS 217-699-5, MDL MFCD00148908, † H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a	**25g** **100g** **500g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A12403	**Taurine, 99%** *[2-Aminoethanesulfonic acid]* [107-35-7], $H_2NCH_2CH_2SO_3H$, F.W. 125.15, m.p. >300°, Merck **14**,9074, EINECS 203-483-8, RTECS WX0175000, BRN 1751215, MDL MFCD00008197, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a For a monograph, see: *Taurine*, R. Huxtable, A. Barbeau, Eds., Raven Press, N.Y., (1975).	**100g** **500g** **2.5kg**
J62308	**Taurine, Cell Culture Grade** [107-35-7], $NH_2CH_2CH_2SO_3H$, F.W. 125.15, Powder, m.p. >300° dec., Merck **14**,9074, EINECS 203-483-8, RTECS WX0175000, BRN 1751215, MDL MFCD00008197, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g** **1kg**
	Taurocholic acid sodium salt, see Sodium taurocholate hydrate, A18346, p. 349	
J62568	**TB Solution-I** Liquid, Note: 250mM potassium chloride, 15mM calcium chloride, 10mM PIPES, 55mM manganese chloride, pH 6.5. Application(s): For transformation of competent cells.	**125ml** **250ml**
J60028	**TB Solution-II** Liquid, Note: 250mM potassium chloride, 15mM calcium chloride, 10mM HEPES, 55mM manganese chloride, pH 6.5. Application(s): For transformation of competent cells.	**125ml** **250ml**
J63410	**TB Solution-III** Liquid, Note: 30mM potassium acetate, 150mM calcium chloride, 50mM manganese chloride, 10 mM rubidium chloride, 15% glycerol. Application(s): For transformation of competent cells.	**125ml** **250ml**
J63318	**TB Solution-IV** Liquid, Note: Contains 10mM MOPS, 10mM rubidium chloride and 15% glycerol Application(s): For transformation of competent cells	**125ml** **250ml**
	TBAC, see Tetra-n-butylammonium chloride (up to ca 15% bromide), A15186, p. 361	
J63487	**TBE (5X), TRIS + borate + EDTA** Liquid, Note: 0.45M Tris base, 0.45M boric acid, 10mM EDTA. H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**2L** **4L**
J62449	**TBE (10X), TRIS + borate + EDTA** Liquid, Note: 0.9M Tris base, 0.9M boric acid, 20mM EDTA H:H315-H319-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1L** **2L** **4L**
J60357	**TBE sample buffer (6X)** Liquid, Note: 270mM Tris base, 270mM boric acid, 6mM EDTA, 36% glycerol, 0.03% bromophenol blue, 0.03% xylene cyanol. H:H315-H319-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**25ml** **50ml**
J62788	**TBE running buffer (10X)** Liquid, Note: 0.89M Tris base, 0.89 boric acid, 20mM EDTA, pH 8.3. H:H315-H319-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1L** **2L** **4L**
J60186	**TBE urea sample buffer (2X)** Liquid, Note: Contains 90mM Tris base, 90mM boric acid, 2mM EDTA, 12% Ficol, 7M urea, 0.03% bromophenol blue, 0.03% xylene cyanol. H:H315-H319-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10ml** **25ml**
	TBTU, see O-(1H-Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, L13470, p. 120 **TCA**, see Trichloroacetic acid, 10% w/v aq. soln., J62355, p. 374 **TCA**, see Trichloroacetic acid, 5% w/v aq. soln., J62366, p. 374 **TCT**, see Cyanuric chloride, L03442, p. 170	
J60738	**TE buffer, (20X), pH 7.4, autoclaved** Liquid, Note: 200mM Tris-HCl, 20mM EDTA.	**250ml** **500ml**
J61110	**TE buffer, (20X), pH 7.6, autoclaved** Liquid	**250ml** **500ml**
J62388	**TE buffer, (20X), pH 8.0, autoclaved** Liquid	**250ml** **500ml**
J60234	**TE buffer, pH 7.4, RNAse free** Liquid, Note: 200mM Tris-HCl with 20mM EDTA	**125ml** **250ml**
J62285	**TE buffer, pH 7.6, RNAse free** Liquid, Note: 200mM Tris-HCl with 20mM EDTA .	**125ml** **250ml**

Stock #	Description	Size
J62745	**TE buffer, pH 8.1, RNAse free** Liquid, Note: 200mM Tris-HCl with 20mM EDTA	**125ml** **250ml**
J61546	**TEA, 0.2M buffer soln., pH 7.0** [102-71-6], Liquid, †	**250ml** **500ml**
J61319	**TEA, 0.2M buffer soln., pH 7.5** [102-71-6], Liquid, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250ml** **500ml**
J63793	**TEA, 0.2M buffer soln., pH 8.0** [102-71-6], Liquid, † H:EUH210	**250ml** **500ml**
J61668	**TEA, 0.2M buffer soln., pH 8.5** [102-71-6], Liquid, †	**250ml** **500ml**
	TEAC, see Tetraethylammonium chloride, J62507, p. 362 **TEA chloride**, see Tetraethylammonium chloride, J62507, p. 362	
J61441	**Telmisartan, 99%** *[BIBR 277, 4'-[(1,4'-Dimethyl-2'-n-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]biphenyl-2-carboxylic acid]* [144701-48-4], $C_{33}H_{30}N_4O_2$, F.W. 514.62, Powder, m.p. 261-263°, Merck **14**,9129, RTECS DV2037500, MDL MFCD00918125 Application(s): An angiotensin II receptor antagonist	**250mg** **1g**
	TEMED, see N,N,N',N'-Tetramethylethylenediamine, Electrophoresis Grade, J63734, p. 365	
J63654	**Temsirolimus, 99+%** [162635-04-3], $C_{56}H_{87}NO_{16}$, F.W. 1030.29, Powder, Merck **14**,9142 H:H302-H373, P:P260-P264-P270-P301+P312-P314-P501 Application(s): A Rapamycin derivative with anti-cancer activity that inhibits mTOR	**25mg** **50mg** **100mg**
J62055	**Terazosin hydrochloride, 99+%** [63074-08-8], $C_{19}H_{25}N_5O_4 \cdot HCl$, F.W. 423.90, Powder, RTECS TK8044925, MDL MFCD00467965 Application(s): α-1 adrenoceptor antagonist	**50mg**
J61936	**Terfenadine** [50679-08-8], $C_{32}H_{41}NO_2$, F.W. 471.67, Powder, m.p. 145-152°, Merck **14**,9163, EINECS 256-710-8, RTECS TM4969000, MDL MFCD00079622 Application(s): An antihistamine	**100mg**
	Terfenidine carboxylate hydrochloride, see Fexofenadine hydrochloride, J63262, p. 220	
J62871	**α-Terpinene** *[α-Terpinene, 1-Isopropyl-4-methyl-1,3-cyclohexadiene]* [99-86-5], $C_{10}H_{16}$, F.W. 136.23, Liquid, b.p. 173-175°, f.p. 50°(122°F), d. 0.837, n_D^{20} 1.4780, Merck **14**,9170, UN2319, EINECS 202-795-1, RTECS OS8060000, BRN 1853379, MDL MFCD00001534, † H:H226-H302-H315-H319-H335-H411, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	**100ml** **500ml**
16285	**α-Terpineol, 96%** *[α,α,4-Trimethyl-3-cyclohexene-1-methanol, p-Menth-1-en-8-ol]* [98-55-5], $C_{10}H_{18}O$, F.W. 154.24, Liquid, m.p. 31-32°, b.p. 210-219°, f.p. 90°(194°F), d. 0.930, n_D^{20} 1.4830, Merck **14**,9171, EINECS 202-680-6, RTECS WZ6700000, MDL MFCD00001557, † H:H315, P:P280-P264-P302+P352-P321-P362-P332+P313 Application(s): A naturally-occuring monoterpene alcohol 	**25g** **100g** **500g**
H26824	**Terrific Broth** ◪■ MDL MFCD00243264	**100g** **500g**
J63379	**TES, 0.2M buffer soln., pH 7.0** [70331-82-7], Liquid, †	**100ml** **250ml**
J61350	**TES, 0.2M buffer soln., pH 7.5** [70331-82-7], Liquid, †	**100ml** **250ml**
J61889	**TES, 0.2M buffer soln., pH 8.0** [70331-82-7], Liquid, †	**100ml** **250ml**
B21819	**TES, 99%** *[2-([Tris(hydroxymethyl)methyl]amino)ethane-1-sulfonic acid]* [7365-44-8], $(HOCH_2)_3CNHCH_2CH_2SO_3H$, F.W. 229.25, m.p. ca 225° dec., Merck **14**,9176, EINECS 230-906-3, BRN 1957061, MDL MFCD00007532, † Biological buffer useful in pH range 7.0 - 8.0: *Biochemistry*, **5**, 467 (1966). Application(s): A zwitterionic Good's Buffer	**10g** **50g** **250g**

Stock #	Description	Size
J62706	**TES sodium salt** *[2-([Tris(hydroxymethyl)methyl]amino)ethane-1-sulfonic acid sodium salt]* [70331-82-7], $C_6H_{14}NNaO_6S$, F.W. 251.23, Powder, Merck **14**,9176, BRN 1957061, MDL MFCD00065482, † Application(s): A zwitterionic Good's Buffer	**25g** **250g** **1kg**
	2',4',5',7'-Tetrabromofluorescein disodium salt, see Eosin Yellowish, B24535, p. 208	
B20123	**Tetrabromophenol Blue** *[3,4,5,6,3',5',3'',5''-Octabromophenolsulfonphthalein]* [4430-25-5], $C_{19}H_8Br_8O_5S$, F.W. 985.55, m.p. 203-205° dec., EINECS 224-622-9, BRN 378438, MDL MFCD00005876, † Acid-base indicator: pH 3.0 - 4.6. Application(s): Phase transfer catalyst	**1g** **5g** **25g**
A10249	**Tetra-n-butylammonium bromide, 98+%** ■ *[TBAB, Aliquat® 100]* [1643-19-2], $[CH_3(CH_2)_3]_4NBr$, F.W. 322.38, m.p. 101-105°, d. 1.15, Fieser **4**,477 **5**,644 **7**,353 **18**,286 **20**,356 **21**,407, EINECS 216-699-2, BRN 3570983, MDL MFCD00011633, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Phase-transfer catalyst of wide application. Some illustrative examples are given below. K salts of ω-bromocarboxylic acids can be cyclized to lactones under effectively "high-dilution" conditions by extracting into toluene in the presence of a small amount of catalyst. The 16-membered ring lactone was formed in 92% yield: *J. Org. Chem.*, **48**, 1533 (1983). Primary alkyl chlorides can be converted to alcohols in excellent yield by phase-transfer reaction with sodium formate and hydrolysis of the resulting formate esters: *Synthesis*, 763 (1986). β-Lactones are formed by the cyclization of β-bromoacids under phase-transfer conditions: *Chem. Pharm. Bull.*, **29**, 1063 (1981). An improved procedure for the Curtius rearrangement involves reaction of acid chlorides with azide ion under phase-transfer conditions: *Synthesis*, 38 (1983). Aromatic carboxamides undergo N-alkylation with alkyl halides using KOH under solvent-free conditions: *Synth. Commun.*, **22**, 1661 (1992). Has been used as an "ionic liquid" in the regioselective O-alkylation of ambident nucleophiles: *Tetrahedron Lett.*, **33**, 4435 (1992). A method is described whereby the "solvent" can be recovered quantitatively. A semi-molten mixture with KF or CsF has been found to be an effective system for fluorodehalogenation of, e.g., benzyl bromide: *J. Fluorine Chem.*, **73**, 185 (1995). Effective catalyst for amination reactions of alkyl or activated aryl halides, by increasing the solubility of ammonia in organic media: *J. Chem. Soc., Chem. Commun.*, 267 (1987). Application(s): Phase transfer catalyst	**100g** **500g** **2.5kg**
A15186	**Tetra-n-butylammonium chloride (up to ca 15% bromide), 95% ex total halide** ■ *[TBAC]* [1112-67-0], $[CH_3(CH_2)_3]_4NCl$, F.W. 277.92, m.p. ca 70°, Fieser **20**,356, EINECS 214-195-7, BRN 3571227, MDL MFCD00011635, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Phase-transfer catalyst used in the N-alkylation of ureas: *Monatsh.*, **123**, 599 (1994). For improved phase-transfer alkylation of ethyl acetoacetate and diethyl malonate using toluene-water, see: *Org. Prep. Proced. Int.*, **26**, 469 (1994). Application(s): Phase transfer catalyst	**5g** **25g** **100g**
A14047	**Tetra-n-butylammonium hydrogen sulfate, 97%** ■ [32503-27-8], $[CH_3(CH_2)_3]_4NHSO_4$, F.W. 339.54, m.p. 168-172°, Fieser **6**,565 **7**,354 **18**,286, EINECS 251-068-5, MDL MFCD00011637, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Widely used phase-transfer catalyst. Some illustrative applications are given below: Benzanilides have been N-alkylated in the presence of NaOH and K_2CO_3: *Synth. Commun.*, **18**, 2011 (1988). It was the most effective catalyst studied for the cyclization of β-amino acids to β-lactams by methanesulfonyl chloride and $KHCO_3$: *Chem. Lett.*, 443 (1981). In the dehydrohalogenation of aryl 2-haloethyl ethers to give vinyl ethers, this catalyst was found much more effective than the corresponding halides or benzyltriethylammonium salts: *Synthesis*, 688 (1979). For use in the permanganate oxidation of benzylic positions, see **Potassium permanganate**, **A12170**. The oxidation of primary alcohols to aldehydes by potassium chromate under phase-transfer conditions is better for higher homologues, where solubility in the aqueous phase is limited: *Synthesis*, 134 (1979). For phase-transfer catalyzed dichromate oxidation of secondary alcohols to ketones, see: *Tetrahedron Lett.*, 1601 (1978). For phase-transfer catalyzed conversion of nitriles to amides by alkaline H_2O_2, see: *Synthesis*, 243 (1980). Application(s): Phase transfer catalyst	**50g** **250g** **1kg**
J63272	**Tetracaine hydrochloride** *[2-(Dimethylamino)ethyl 4-(n-butylamino)benzoate hydrochloride]* [136-47-0], $C_{15}H_{24}N_2O_2 \cdot HCl$, F.W. 300.82, Powder, Merck **14**,9188, UN2811, EINECS 205-248-5, RTECS DG4900000, MDL MFCD00038912 H:H301-H334-H319-H317, P:P285-P301+P310-P305+P351+P338-P302+P352-P405-P501a Application(s): A potent topical local anesthetic	**25g** **100g**
J61714	**Tetracycline** [60-54-8], $C_{22}H_{24}N_2O_8$, F.W. 444.43, Crystalline powder, m.p. 172-174°, Merck **14**,9196, EINECS 200-481-9, RTECS QI8750000, BRN 2230417, MDL MFCD00151232 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): Can induce apoptosis in osteoclasts	**5g** **25g** **100g**

Stock #	Description	Size
B21408	**Tetracycline hydrochloride, 98%** ▲ △ [64-75-5], $C_{22}H_{24}N_2O_8 \cdot HCl$, F.W. 480.91, m.p. 220-223°, Merck **14**,9196, EINECS 200-593-8, MDL MFCD00078142, † H:H361, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Can induce apoptosis in osteoclasts 	**25g** **100g**
A12067	**Tetradecanoic acid, 98%** *[Myristic acid]* [544-63-8], $CH_3(CH_2)_{12}CO_2H$, F.W. 228.38, m.p. 53-56°, b.p. 326°, f.p. 175°(347°F), d. 0.862, Merck **14**,6333, EINECS 208-875-2, RTECS QH4375000, BRN 508624, MDL MFCD00002744, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **500g** **2.5kg**
	n-Tetradecylbenzyldimethylammonium chloride hydrate, see Benzyldimethyl-n-tetradecylammonium chloride hydrate, 98%, J63465, p. 122	
L10294	**(1-Tetradecyl)trimethylammonium bromide, 98%** *[Myristyltrimethylammonium bromide, Trimethyl-n-tetradecylammonium bromide]* [1119-97-7], $CH_3(CH_2)_{13}N(CH_3)_3Br$, F.W. 336.40, m.p. 245-250°, Merck **14**,6336, UN1759, EINECS 214-291-9, RTECS BS5776000, BRN 3633227, MDL MFCD00011770, † H:H314-H411, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Phase transfer catalyst	**25g** **100g** **500g**
A13835	**Tetraethylammonium bromide, 98%** ■ [71-91-0], $(CH_3CH_2)_4NBr$, F.W. 210.16, m.p. ca 285° dec., d. 1.397, Merck **14**,9199, Fieser **6**,568 **10**,305, EINECS 200-769-4, RTECS BS5950000, BRN 3563430, MDL MFCD00011825, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Phase-transfer catalyst. For use in combination with anhydrous HBr as a reagent for selective monohydrobromination of an alkyne, see: *Org. Synth.*, **76**, 263 (1998). Application(s): Phase transfer catalyst	**250g** **1kg** **5kg**
J62507	**Tetraethylammonium chloride** ■ *[TEA chloride, TEAC]* [56-34-8], $(CH_3CH_2)_4NCl$, F.W. 165.71, Powder, Merck **14**,9200, EINECS 200-267-5, RTECS BS6125000, BRN 3563247, MDL MFCD00011828, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Phase transfer catalyst	**25g** **100g**
30818	**Tetraethylammonium chloride monohydrate, 98+%** [68696-18-4], $(C_2H_5)_4NCl \cdot H_2O$, F.W. 183.72 (165.71anhy), Crystalline, m.p. ca 110°, d. 1.0801, Merck **14**,9200, Fieser **1**,1137, EINECS 200-267-5, RTECS BS6125000, BRN 3563247, MDL MFCD00149992, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Phase transfer catalyst	**50g** **250g**
B23880	**Tetraethylene glycol, 99%** *[Tetraglycol]* [112-60-7], $O(CH_2CH_2OCH_2CH_2OH)_2$, F.W. 194.23, m.p. -4°, b.p. 313-314°, f.p. 193°(379°F), d. 1.125, n_D^{20} 1.4590, EINECS 203-989-9, RTECS XC2100000, BRN 1634320, MDL MFCD00002879, † Application(s): Used as a solvent to dissolve water-insoluble compounds	**500ml** **2.5L**
J62496	**Tetraethylene glycol monooctyl ether** *[n-Octyltetraoxyethylene]* [19327-39-0], $CH_3(CH_2)_7(OCH_2CH_2)_4OH$, F.W. 306.44, Solid, BRN 1781226, MDL MFCD00043033, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Reagent for solubilizing membrane proteins	**1g** **5g**
	Tetraethylrhodamine, see Rhodamine B, A13572, p. 337	
B20721	**Tetraethylthiuram disulfide, 97%** *[Disulfiram]* [97-77-8], $C_{10}H_{20}N_2S_4$, F.W. 296.54, m.p. 69-72°, b.p. 117°/17mm, d. 1.300, Merck **14**,3364, Fieser **6**,569, UN3077, EINECS 202-607-8, RTECS JO1225000, BRN 1712560, MDL MFCD00009048, † H:H373-H400-H410-H302-H317, P:P260-P261-P280-P302+P352-P321-P501a Application(s): Dopamine β-hydroxylase inhibitor 	**100g** **250g** **1kg** **5kg**
	Tetraglycol, see Tetraethylene glycol, B23880, p. 362	
J63941	**6,7,8,9-Tetrahydro-5H-benzocycloheptene-5-ol-4-ylidene acetic acid** *[NCS 382 sodium salt]* [131733-92-1], $C_{13}H_{13}NaO_3$, F.W. 240.23, Powder, m.p. 141-143°, RTECS MA0600800, MDL MFCD11046018 Application(s): γ-Hydroxybutyrate (GHB) receptor antagonist	**100mg**
	1,2,3,6-Tetrahydro-2,6-dioxopyrimidine-4-carboxylic acid, see Orotic acid, B25349, p. 309 **1,2,3,6-Tetrahydro-2,6-dioxopyrimidine-4-carboxylic acid hydrate**, see Orotic acid hydrate, A18594, p. 309	

Contact us for pricing on bulk sizes

Stock #	Description	Size
44505	**Tetrahydrofuran, Biograde, 99.8%, unstab.** [109-99-9], C_4H_8O, F.W. 72.11, Liquid, m.p. -108°, b.p. 66°, f.p. -17°(1°F), d. 0.889, n_D^{20} 1.4070, Merck **14**,9211, Fieser **1**,1140 **2**,398 **3**,278 **5**,649 **6**,570, UN2056, EINECS 203-726-8, RTECS LU5950000, BRN 102391, MDL MFCD00005356, Note: Water <100ppm, † Maximum level of impurities: Color (APHA) 10, Peroxide (as H_2O_2) 0.015%, Residue after evaporation 5 ppm H_2O 0.01% H:H225-EUH019-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a **UV absorption - 1cm cell vs H_2O** λ(nm) 300 250 225 212 A 0.01 0.17 0.50 1.00 Application(s): Nucleic acid and peptide synthesis	1L 4L 4x1L
32468	**Tetrahydrofuran, Spectrophotometric Grade, 99.7+%, unstab.** [109-99-9], C_4H_8O, F.W. 72.11, Liquid, distilled in glass, m.p. -108°, b.p. 66°, f.p. -17°(1°F), d. 0.889, n_D^{20} 1.4070, Merck **14**,9211, Fieser **1**,1140 **2**,398 **3**,278 **5**,649 **6**,570, UN2056, EINECS 203-726-8, RTECS LU5950000, BRN 102391, MDL MFCD00005356, Note: Filtered through 0.2µ filters. Suitable for spectophotometry, † Maximum level of impurities: Evaporation residue 5ppm, H_2O 0.03%, Acidity (CH_3COOH) 0.005%, Peroxides (as H_2O_2) 0.03% H:H225-EUH019-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a **UV absorption - 1cm cell vs H_2O** λ(nm) 300 250 225 212 A 0.01 0.18 0.50 1.00	100ml 1L 4L 4x1L
J62007	**(R)-Tetrahydrofuran-2-carboxamide** [539820-25-2], $C_5H_9NO_2$, F.W. 115.13, Solid Application(s): For synthesis of optically active products	Call
J60420	**(S)-Tetrahydrofuran-2-carboxamide** [498573-81-2], $C_5H_9NO_2$, F.W. 115.13, Solid, MDL MFCD04039924 Application(s): For synthesis of optically active products	Call
L19044	**(R)-(-)-Tetrahydrofurfuryl alcohol, 98+%** *[(R)-(-)-2-(Hydroxymethyl)tetrahydrofuran]* [22415-59-4], $C_5H_{10}O_2$, F.W. 102.13, b.p. 173-175°, f.p. 75°(167°F), d. 1.053, n_D^{20} 1.4520, $[\alpha]_D^{20}$ -2.3° (neat), BRN 79846, MDL MFCD03093085 H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): For synthesis of optically active products	250mg 1g
J62573	**(S)-(+)-Tetrahydrofurfuryl alcohol** *[(S)-(+)-2-(Hydroxymethyl)tetrahydrofuran]* [72074-94-3], $C_5H_{10}O_2$, F.W. 102.13, Liquid H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): For synthesis of optically active products	Call
	(-)-Tetrahydrolipstatin, see Orlistat, 98%, J62999, p. 308	
J63911	**L-Tetrahydropalmatine** *[Gindarine, Rotundine]* [10097-84-4], $C_{21}H_{25}NO_4$, F.W. 355.43, Powder, m.p. 147°, Merck **14**,9215 Application(s): Voltage dependent L-type calcium channel inhibitor	1g 25g
J63328	**Tetrahydropalmatine, 98%** *[THP]* [2934-97-6], $C_{21}H_{25}NO_4$, F.W. 355.43, Powder, m.p. 155°, MDL MFCD00214191 H:H302, P:P264-P270-P301+P312-P330-P501	1g 5g
	1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid hydrochloride, see Isoguvacine hydrochloride, 99%, J63243, p. 260 **Tetrahydrothiazole**, see Thiazolidine, H26427, p. 366 **1,3,4,5-Tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate)**, see Chlorogenic acid, J60457, p. 157	
L14186	**3',4',5,7-Tetrahydroxyflavone, 97%** *[Luteolin]* [491-70-3], $C_{15}H_{10}O_6$, F.W. 286.24, m.p. >300°, Merck **14**,5614, EINECS 207-741-0, RTECS LK9275210, BRN 292084, MDL MFCD00017309 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Anti-oxidant and radical scavenger in biological systems: *Methods Enzymol.*, **234**, 420 (1994). Application(s): An apoptosis inducer	100mg 500mg
	3,4',5,7-Tetrahydroxyflavone, see Kaempferol, 98+%, J60373, p. 262 **(1S,6S,7R,8R,8aR)-1,6,7,8-Tetrahydroxyoctahydroindolizidine**, see Castanospermine, 99%, J61071, p. 150	

Stock #	Description	Size
J64414	**2-(4,5,6,7-Tetraiodo-1,3-dioxoisoindolin-2-yl)acetic acid** *[CAY10578]* [19231-60-8], $C_{10}H_3I_4NO_4$, F.W. 708.75, Powder	**10mg**
	Tetraiodofluorescein sodium salt, see Erythrosin B, A14180, p. 210 **3,3',5,5'-Tetraiodo-L-thyronine**, see L-Thyroxine, 98%, J62606, p. 370	
J64206	**N,N,N',N'-Tetrakis-(2-pyridylmethyl)ethylenediamine** *[TPEN, TPEDA]* [16858-02-9], $C_{26}H_{28}N_6$, F.W. 424.54, Powder, m.p. 110-112°, BRN 4211982, MDL MFCD00036918 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100mg** **300mg**
A13288	**Tetramethylammonium chloride, 97%, may cont. ca 3% silica as anticaking agent** ■ [75-57-0], $(CH_3)_4NCl$, F.W. 109.60, m.p. >300°, d. 1.17, UN2811, EINECS 200-880-8, RTECS BS7700000, BRN 2496575, MDL MFCD00011628, † H:H301-H311-H315-H319-H335, P:P280h-P305+P351+P338-P309-P310 Thermally-stable phase-transfer catalyst which has been used in nucleophilic displacement reactions of aryl nitro groups with KF in tetramethylene sulfone: *J. Org. Chem.*, **56**, 6406 (1991). A detailed study of the halex Cl^-/F^- exchange reaction of activated aryl chlorides, for example the conversion of 1,2-dichloro-4-nitrobenzene to 2-chloro-1-fluoro-4-nitrobenzene in DMSO at 120°C showed tetramethylammonium chloride to be superior to other common phase-transfer catalysts. It was necessary to pre-dry the catalyst to <0.2% water to avoid competition from hydrolytic displacement: *Chem. Commun.*, 297 (1996). Compare also **Tetraphenylphosphonium bromide**, **A15860**, and **Tetraphenylphosphonium chloride**, **A10575**.	**250g** **1kg** **5kg**

Application(s): Phase transfer catalyst

J61325	**3,3',5,5'-Tetramethylbenzidine soln., Ready-to-Use, high sensitivity** *[TMB soluble reagent, high sensitivity]* [54827-17-7], $C_{16}H_{20}N_2$, F.W. 240.35, Liquid, EINECS 259-364-6, BRN 2808541, MDL MFCD00007748, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Excellent colorimetric substrate for detection of horseradish peroxidase labelled probes and is used with peroxidase and peroxidase coupled systems, particularly in ELISA techniques, blue result	**125ml** **500ml** **1L**
J60461	**3,3',5,5'-Tetramethylbenzidine soln., Ready-to-Use, precipitating, standard sensitivity** *[TMB reagent, standard sensitivity]* [54827-17-7], $C_{16}H_{20}N_2$, F.W. 240.35, Liquid, EINECS 259-364-6, BRN 2808541, MDL MFCD00007748, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Excellent colorimetric substrate for detection of horseradish peroxidase labelled probes and is used with peroxidase and peroxidase coupled systems, particularly in ELISA techniques, blue result	**125ml** **500ml** **1L**
J60808	**3,3',5,5'-Tetramethylbenzidine aq. soln.** *[TMB soluble reagent, aq. soln.]* [54827-17-7], $C_{16}H_{20}N_2$, F.W. 240.35, Liquid, EINECS 259-364-6, BRN 2808541, MDL MFCD00007748, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Excellent colorimetric substrate for detection of horseradish peroxidase labelled probes and is used with peroxidase and peroxidase coupled systems, particularly in ELISA techniques, blue result	**125ml** **500ml** **1L**
A13868	**3,3',5,5'-Tetramethylbenzidine, 98%** ▲ *[4,4'-Diamino-3,3',5,5'-tetramethylbiphenyl]* [54827-17-7], $C_{16}H_{20}N_2$, F.W. 240.35, m.p. 168-171°, EINECS 259-364-6, RTECS DV2300000, BRN 2808541, MDL MFCD00007748, †  H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Excellent colorimetric substrate for detection of horseradish peroxidase labelled probes; particularly useful in ELISA techniques, blue result can be read spectrophotometrically at 370 or 650 nm	**1g** **5g** **25g**
J60332	**3,3',5,5'-Tetramethylbenzidine dihydrochloride hydrate, 99+%** ▲◢ *[TMB dihydrochloride hydrate]* [207738-08-7], $C_{16}H_{20}N_2 \cdot 2HCl \cdot xH_2O$, F.W. 313.27(anhy), Powder, MDL MFCD00150104 H:H341-H302-H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Excellent colorimetric substrate for detection of horseradish peroxidase labelled probes and is used with peroxidase and peroxidase coupled systems, particularly in ELISA techniques, blue result	**1g** **2.5g** **5g**
A12536	**N,N,N',N'-Tetramethylethylenediamine, 99%** △ ■ *[1,2-Bis(dimethylamino)ethane, TMEDA]* [110-18-9], $(CH_3)_2NCH_2CH_2N(CH_3)_2$, F.W. 116.21, m.p. -55°, b.p. 120-122°, f.p. 18°(62°F), d. 0.775, n_D^{20} 1.4180, Fieser **2**,403 **3**,284 **4**,485 **5**,652 **6**,576 **7**,358 **12**,477 **13**,57, UN2372, EINECS 203-744-6, RTECS KV7175000, BRN 1732991, MDL MFCD00008335, † H:H225-H314-H302-H332, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Widely used complexing agent in lithiation reactions, often giving enhanced reactivity in otherwise difficult metallations: *J. Am. Chem. Soc.*, **92**, 4664 (1970). Subsequent work by Collum and others indicated that the situation may be much less straightforward than was previously thought, but the effect of TMEDA is likely to be most pronounced in the absence of strong donor solvents such as THF. For a discussion of the factors involved, see: *Acc. Chem. Res.*, **25**, 448 (1992). Under some conditions also, TMEDA itself may undergo lithiation: *Organometallics*, **13**, 5173 (1994). Used in combination with alkyllithiums in the *ortho*-metallation of aromatics; see, e.g.: *Org. Synth. Coll.*, **6**, 478 (1988); *Org. Synth. Coll.*, **9**, 559 (1998). For discussion of the dramatic acceleration of the rate of *ortho*-lithiation of anisole in the presence of TMEDA, effective also in sub-stoichiometric amounts, see: *Tetrahedron Lett.*, **35**, 385 (1994). See also *Tetrahedron Lett.*, **35**, 401 (1994), *J. Org. Chem.*, **62**, 3024 (1997) for further discussion of the role of TMEDA in *ortho*-metallation.	**100ml** **500ml** **2.5L**

The oxidative coupling of terminal acetylenes to diynes, by O_2 in the presence of CuCl, is improved by addition of TMEDA as a complexing agent: *J. Org. Chem.*, **27**, 3320 (1962). For example and discussion, see: *Org. Synth. Coll.*, **8**, 63 (1993):

In catalytic amounts, produces up to a 20-fold increase in reaction rate in aqueous Michael additions catalyzed by ytterbium triflate: *J. Org. Chem.*, **71**, 352 (2006).

J63734 **N,N,N',N'-Tetramethylethylenediamine, Electrophoresis Grade** ■ — **25ml 100ml**
[TEMED]
[110-18-9], $(CH_3)_2NCH_2CH_2N(CH_3)_2$, F.W. 116.21, Liquid, m.p. -55°, b.p. 120-122°, f.p. 18°(154°F), d. 0.775, n_D^{20} 1.4180, Merck **14**,9134, UN2372, EINECS 203-744-6, RTECS KV7175000, BRN 1732991, MDL MFCD00008335, †
H:H225-H314-H302-H332, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a

J62258 **5(6)-Tetramethylrhodamine isothiocyanate** — **10mg**
[TRITC, MRITC]
[95197-95-8], $C_{25}H_{21}N_3O_3S$, F.W. 443.52, Powder
H:H315-H319-H334-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501

Application(s): Reagent for fluorescent labelling of proteins

J61080 **Tetranitro blue tetrazolium chloride, 97%** — **100mg 1g**
[TNBT]
[1184-43-6], $C_{40}H_{28}Cl_2N_{12}O_{10}\cdot 2C_2H_6O$, F.W. 999.78, Powder, EINECS 214-665-1, BRN 3897475, MDL MFCD00036338, †
H:H350, P:P281-P201-P202-P308+P313-P405-P501

Application(s): Redox indicator for enzymes

J61034 **1H-Tetrazole, 0.45M in acetonitrile** — **200ml 450ml**
[288-94-8], CH_2N_4, F.W. 70.05, Liquid, d. 0.798, Merck **14**,2786, UN1648, EINECS 206-023-4, RTECS UW7370000, BRN 105799, MDL MFCD00005247
H:H225-H302-H312-H332-H319, P:P210-P241-P303+P361+P353-P305+P351+P338-P302+P352-P501a

Application(s): Coupling reagent for preparation of polynucleotides

Tetrazolium Blue chloride, see Blue Tetrazolium chloride, A12502, p. 129
Texas Red®, see Sulforhodamine 101 acid chloride, J60581, p. 356
THA hydrochloride, see Tacrine hydrochloride hydrate, 98+%, J60070, p. 357

J60271 **Thalidomide** — **100mg**
[50-35-1], $C_{13}H_{10}N_2O_4$, F.W. 258.23, Powder, Merck **14**,9255, UN2811, EINECS 200-031-1, RTECS TI4375000
H:H301-H340-H360-H312, P:P280-P301+P310-P302+P352-P321-P405-P501a

Application(s): Teratogenic compound found to inhibit HIV-1 replication and FGF-induced angiogenesis

J62266 **(±)-Thalidomide, 99+%** — **100mg**
[50-35-1], $C_{13}H_{10}N_2O_4$, F.W. 258.23, Powder, Merck **14**,9255, UN2811, EINECS 200-031-1, RTECS TI4375000, MDL MFCD00153873
H:H301-H340-H360-H312, P:P280-P301+P310-P302+P352-P321-P405-P501a

Application(s): Teratogenic compound found to inhibit HIV-1 replication and FGF-induced angiogenesis

J62866 **Thapsigargin, 95%** ▲ — **1mg 5mg 10mg**
[67526-95-8], $C_{34}H_{50}O_{12}$, F.W. 650.75, Solid film, Merck **14**,9272, RTECS RH0325700, MDL MFCD00083511
H:H334-H335-H315-H319, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a

Application(s): Cell permeable sesquiterpene lactone tumor promoter. Inhibits endoplasmic reticulum calcium-ATPase

J63668 **Thaumatin, Thaumatococcus daniellii** — **25mg 100mg 250mg**
[53850-34-3], Powder, Merck **14**,9273, EINECS 258-822-2

Application(s): A mixture of the intensely sweet proteins thaumatin I and thaumatin II

2-Thenoic acid, see Thiophene-2-carboxylic acid, A12514, p. 367

A11861 **Theobromine, 99%** — **50g 100g 250g**
[3,7-Dimethylxanthine]
[83-67-0], $C_7H_8N_4O_2$, F.W. 180.17, m.p. 345-350°, d. 1.50, Merck **14**,9282, EINECS 201-494-2, RTECS XH2275000, BRN 16464, MDL MFCD00022830, †

H:H302, P:P264-P270-P301+P312-P330-P501a

Application(s): Phosphosdiesterase inhibitor

A15997 **Theophylline monohydrate, 99%** — **50g 250g 1kg**
[1,3-Dimethylxanthine monohydrate]
[5967-84-0], $C_7H_8N_4O_2\cdot H_2O$, F.W. 198.18 (180.16anhy), m.p. 270-274°, Merck **14**,9285, UN2811, EINECS 200-385-7, RTECS XH3850000, BRN 13463, MDL MFCD00151659, †

H:H301, P:P264-P270-P301+P310-P321-P405-P501a

Application(s): Dimethylxanthine. A methylxanthine drug used in therapy for respiratory diseases such as COPD and asthma

Stock #	Description	Size
J60203	**Theophylline** *[1,3-Dimethylxanthine, 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione]* [58-55-9], $C_7H_8N_4O_2$, F.W. 180.16, Powder, m.p. 270-274°, Merck **14**,9285, UN2811, EINECS 200-385-7, RTECS XH3850000, BRN 13463, MDL MFCD00079619, † H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Phosphodiesterase inhibitor; diuretic; cardiac stimulant; muscle relaxant; asthma medication. A methylxanthine drug used in therapy for respiratory diseases such as COPD and asthma	**1lb** **5lb**
	Theophylline hemi(ethylenediamine) complex, see Aminophylline, anhydrous, 98%, J60705, p. 98 **Thespesin**, see Gossypol, 98+%, J63767, p. 238	
J60009	**Thiabendazole, 98+%** *[2-(4-Thiazolyl)benzimidazole]* [148-79-8], $C_{10}H_7N_3S$, F.W. 201.25, Powder, m.p. 304-305°, Merck **14**,9289, UN3077, EINECS 205-725-8, RTECS DE0700000, BRN 611403, MDL MFCD00005587, † H:H400-H410, P:P273-P391-P501a	**10g** **100g** **500g**
	Thiactin, see Thiostrepton, Streptomyces laurentii, 98%, J62332, p. 368	
A19560	**Thiamine hydrochloride, 99% (dry wt.), may cont. up to 5% water ▲■** *[Vitamin B1 hydrochloride, Aneurine hydrochloride]* [67-03-8], $C_{12}H_{17}ClN_4OS{\cdot}HCl$, F.W. 337.28, m.p. ca 250° dec., Merck **14**,9295, EINECS 200-641-8, RTECS XI7350000, BRN 3851771, MDL MFCD00012780, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **250g** **1kg**
J60014	**Thiamine nitrate** *[Vitamin B_1 nitrate]* [532-43-4], $C_{12}H_{17}N_5O_4S$, F.W. 327.36, Powder, m.p. 190°, Merck **14**,9295, EINECS 208-537-4, RTECS XI7400000, MDL MFCD00036330, †	**10g** **25g**
J61483	**Thiamine pyrophosphate chloride, 98%** *[Aneurinepyrophosphoric acid, Cocarboxylase]* [154-87-0], $C_{12}H_{19}ClN_4O_7P_2S$, F.W. 460.77, Powder, Merck **14**,9296, EINECS 205-836-1, RTECS XI7552000, BRN 3875902, MDL MFCD00038740, † Application(s): Cocarboxylase, a form of Vitamin B-1	**5g** **25g**
J63575	**Thiamphenicol** [15318-45-3], $C_{12}H_{15}Cl_2NO_5S$, F.W. 356.22, Powder, Merck **14**,9301, EINECS 239-355-3, RTECS AB6680000, BRN 2819542, MDL MFCD00467983 Application(s): The methyl-sulfonyl analogue of chloramphenicol	**1g** **5g** **25g**
H26427	**Thiazolidine, 97%** *[Tetrahydrothiazole]* [504-78-9], C_3H_7NS, F.W. 89.16, b.p. 165°, f.p. 56°(133°F), d. 1.131, n_D^{20} 1.5545, UN1993, EINECS 208-002-5, RTECS XJ5123700, MDL MFCD00005211 H:H226-H315-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a	**1g** **5g**
	L-(-)-Thiazolidin-2-one-4-carboxylic acid, see L-(-)-2-Oxothiazolidine-4-carboxylic acid, J62254, p. 310 **2-(4-Thiazolyl)benzimidazole**, see Thiabendazole, 98+%, J60009, p. 366	
L11939	**Thiazolyl Blue tetrazolium bromide, 98% ▲** *[3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, MTT]* [298-93-1], $C_{18}H_{16}BrN_5S$, F.W. 414.33, m.p. ca 195° dec., EINECS 206-069-5, RTECS XF8060000, BRN 3825277, MDL MFCD00011964, † Application(s): Used in measurement of cell proliferation. Produces a yellowish solution that is converted to dark blue, water-insoluble MTT formazan by mitochondrial dehydrogenases of living cells	**1g** **5g**
	N(1)-(2-Thiazolyl)sulfanilamide, see Sulfathiazole, A10727, p. 356	
J61799	**Thimerosal** *[2-(Ethylmercuriomercapto)benzoic acid sodium salt]* [54-64-8], $C_9H_9HgNaO_2S$, F.W. 404.81, Powder, m.p. 234-237°, f.p. 250°(482°F), Merck **14**,9317, UN2025, EINECS 200-210-4, RTECS OV8400000, BRN 8169555, MDL MFCD00013062, † H:H301-H310-H330-H373-H400-H410, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): A bacteriostatic and fungistatic mercurial agent	**10g** **25g**
	2-Thiobarbituric acid, see 4,6-Dihydroxy-2-mercaptopyrimidine, A12681, p. 192 **Thiocarbamide**, see Thiourea, A12828, p. 368 **Thioconazole**, see Tioconazole, 98+%, J60459, p. 370	
L04711	**DL-Thioctic acid, 98%** *[1,2-Dithiolane-3-valeric acid, DL-6,8-Dithiooctanoic acid]* [1077-28-7], $C_8H_{14}O_2S_2$, F.W. 206.33, m.p. 59-63°, b.p. 160-165°, Merck **14**,9326, EINECS 214-071-2, RTECS JP1192000, BRN 81853, MDL MFCD00005474 H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): α Lipoic acid. A hydrogen transferrin cofactor	**5g** **25g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A17002	**2,2'-Thiodiethanol, 99%** *[Bis(2-hydroxyethyl) sulfide, Thiodiglycol]* [111-48-8], $S(CH_2CH_2OH)_2$, F.W. 122.19, m.p. -16°, b.p. 164-166°/20mm, f.p. 160°(320°F), d. 1.221, n_D^{20} 1.5210, Merck **14**,9330, EINECS 203-874-3, RTECS XR1700000, BRN 1236325, MDL MFCD00002910, † H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): Useful antioxidant in amino acid determinations	**100g** **500g** **2.5kg**
	Thiodiglycol, see 2,2'-Thiodiethanol, A17002, p. 367 **Thioethanolamine hydrochloride**, see 2-Mercaptoethylamine hydrochloride, A14377, p. 281 **Thioethylene glycol**, see 2-Mercaptoethanol, A15890, p. 281	
J61043	**Thioflavine T, tech. 75%** *[Basic Yellow 1, C.I. 49005]* [2390-54-7], $C_{17}H_{19}ClN_2S$, F.W. 318.86, Powder, EINECS 219-228-9, BRN 3922452, MDL MFCD00011944, † Application(s): A dye used to visualize β-amyloid plaques, like those associated with Alzheimer's Disease	**5g** **25g**
J63621	**5-Thio-D-glucose, 97+%** [20408-97-3], $C_6H_{12}O_5S$, F.W. 196.22, Powder, m.p. 135-138°, Merck **14**,9334, EINECS 243-798-8, RTECS LZ7500000, BRN 1865193, MDL MFCD00006663	**5mg** **10mg** **25mg**
	Thioglycol, see 2-Mercaptoethanol, A15890, p. 281 **Thioglycolic acid**, see Mercaptoacetic acid, B20391, p. 280 **Thioglycolic acid sodium salt**, see Mercaptoacetic acid sodium salt, L14356, p. 280	
B21280	**6-Thioguanine, 98%** *[2-Amino-6-mercaptopurine, 2-Amino-6-purinethiol]* [154-42-7], $C_5H_5N_5S$, F.W. 167.19, m.p. >360°, Merck **14**,9337, UN2811, EINECS 205-827-2, RTECS UP0740000, BRN 157765, MDL MFCD00233553 H:H301-H341, P:P281-P301+P310-P321-P308+P313-P405-P501a	**1g** **5g**
B24934	**2-Thiohydantoin, 99%** [503-87-7], $C_3H_4N_2OS$, F.W. 116.14, m.p. 229-231° dec., EINECS 207-977-4, RTECS MU4200000, MDL MFCD00005277, † H:H302, P:P264-P270-P301+P312-P330-P501a	**5g** **25g** **100g**
	Thiolactic acid, see 2-Mercaptopropionic acid, L10257, p. 281 **2-Thiolanimine hydrochloride**, see 2-Iminothiolane hydrochloride, J60131, p. 255 **Thiomalic acid**, see Mercaptosuccinic acid, B23301, p. 281	
A11144	**Thionicotinamide, 98%** *[Pyridine-3-thiocarboxamide]* [4621-66-3], $C_6H_6N_2S$, F.W. 138.19, m.p. ca 190° dec., f.p. 160°(320°F), EINECS 225-036-6, RTECS QS4488000, BRN 109593, MDL MFCD00006399, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**25g** **100g**
A12514	**Thiophene-2-carboxylic acid, 99%** *[2-Thenoic acid]* [527-72-0], $C_5H_4O_2S$, F.W. 128.15, m.p. 126-130°, b.p. 259-261°, d. 1.42, Merck **14**,9354, EINECS 208-423-4, RTECS XM8330200, BRN 110150, MDL MFCD00005437, † H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A hypoglycemic, anti-lipolytic agent	**25g** **100g** **500g**
J60895	**Thioridazine hydrochloride ▲■** [130-61-0], $C_{21}H_{26}N_2S_2 \cdot HCl$, F.W. 407.03, Powder, m.p. 161-163°, Merck **14**,9359, UN3077, EINECS 204-992-8, RTECS SP2275000, MDL MFCD00012655 H:H301-H400-H410-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An anti-psychotic that blocks neurotransmission at dopaminergic synapses	**5g**
J62557	**DL-Thiorphan** [76721-89-6], $C_{12}H_{15}NOS$, F.W. 253.32, Powder, m.p. 124-126°, BRN 4872101, MDL MFCD00058435 Application(s): Potent and specific inhibitor of enkephalinase with antinociceptive activity. Substrate for peptidylglycine α-amidating monooxygenase.	**25mg**
A13401	**Thiosalicylic acid, 98% ▲△** *[2-Mercaptobenzoic acid]* [147-93-3], $C_7H_6O_2S$, F.W. 154.19, m.p. 165-168°, d. 1.49, Merck **14**,9360, EINECS 205-704-3, RTECS DH3325000, BRN 508507, MDL MFCD00004836, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g** **1kg**
A14630	**Thiosemicarbazide, 99%** [79-19-6], CH_5N_3S, F.W. 91.14, m.p. ca 180° dec., Merck **14**,9361, Fieser **1**,1164, UN2811, EINECS 201-184-7, RTECS VT4200000, BRN 506320, MDL MFCD00007620, † H:H300, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Used in TLC to stain α-keto acids	**100g** **500g** **2.5kg**

Stock #	Description	Size
J62332	**Thiostrepton, Streptomyces laurentii, 90+%** *[Bryamycin, Thiactin]* [1393-48-2], $C_{72}H_{85}O_{18}N_{19}S_5$, F.W. 1664.89, Powder, Merck **14**,9364, EINECS 215-734-9, RTECS XN6300100, MDL MFCD00135828 Application(s): Natural cyclic oligopeptide antibiotic	**1g** **5g**
A18119	**2-Thiouracil, 98%** *[4-Hydroxy-2-mercaptopyrimidine]* [141-90-2], $C_4H_4N_2OS$, F.W. 128.15, m.p. >300°, Merck **14**,9366, EINECS 205-508-8, RTECS YR1575000, BRN 112227, MDL MFCD00006039, † H:H351, P:P281-P201-P202-P308+P313-P405-P501a	**25g** **100g** **500g**
A12828	**Thiourea, 99%** *[Thiocarbamide]* [62-56-6], CH_4N_2S, F.W. 76.12, m.p. 172-178°, d. 1.405, Merck **14**,9367, Fieser **1**,1164 **2**,412 **3**,290 **6**,586 **11**,519 **15**,308 **19**,336 **20**,371 **21**,421, UN3077, EINECS 200-543-5, RTECS YU2800000, BRN 605327, MDL MFCD00008067, † H:H351-H361d-H302-H411, P:P280h-P273 Reagent for the conversion of alkyl halides to thiols by base hydrolysis of the isothiouronium salts; see also **N-Acetylthiourea**, **B21198**. Cleavage of isothiouronium salts with base and alkylation of the resulting thiolate has been used as a convenient synthesis of unsymmetrical sulfides: *Synth. Commun.*, **14**, 209 (1984). Epoxides are converted to episulfides: *J. Org. Chem.*, **26**, 3467 (1961). The 2,3-epoxy alcohols resulting from the Sharpless enantioselective epoxidation can be converted to the corresponding episulfides with retention at both centers, using $Ti(O\text{-}i\text{-}Pr)_4$ as mediator: *J. Org. Chem.*, **53**, 4114 (1988). Widely used in heterocyclic syntheses, e.g. of thiazoles and pyrimidines. Has been used in a convenient synthesis of isothiocyanates from oximes via the nitrile oxide: *Tetrahedron Lett.*, **34**, 8283 (1993); see also **Benzaldoxime**, **A12053**:  Application(s): Reagent for organic synthesis	**100g** **500g** **2.5kg** **10kg**
36609	**Thiourea, ACS, 99% min.** *[Thiocarbamide]* [62-56-6], H_2NCSNH_2, F.W. 76.12, Crystalline, m.p. 175-178°, d. 1.405, Merck **14**,9367, Fieser **1**,1164 **2**,412 **3**,290 **6**,586 **11**,519 **15**,308 **19**,336 **20**,371 **21**,421, UN3077, EINECS 200-543-5, RTECS YU2800000, BRN 605327, MDL MFCD00008067, † Maximum level of impurities: Solubility in water P.T., Residue after ignition 0.1%, Loss on drying 0.5%, Melting point 174-177° H:H351-H361d-H302-H411, P:P281-P273-P301+P312-P308+P313-P405-P501a Application(s): Reagent for organic synthesis	**50g** **250g** **1kg**
J60679	**4-Thiouridine, 98+%** [13957-31-8], $C_9H_{12}N_2O_5S$, F.W. 260.27, Crystalline, EINECS 237-735-3, MDL MFCD00006538	**5mg** **25mg** **100mg**
	Thiouridine, see 4-Thiouridine, 98+%, J60679, p. 368 **THP**, see Tetrahydropalmatine, 98%, J63328, p. 363	
A10606	**DL-Threonine, 99%** *[(+/-)-2-Amino-3-hydroxybutyric acid, H-DL-Thr-OH]* [80-68-2], $C_4H_9NO_3$, F.W. 119.12, m.p. ca 244° dec., Merck **14**,9380, EINECS 201-300-6, BRN 1721647, MDL MFCD00063722, †	**25g** **100g** **500g**
B21177	**D-Threonine, 99%** *[(2R,3S)-2-Amino-3-hydroxybutyric acid, H-D-Thr-OH]* [632-20-2], $C_4H_9NO_3$, F.W. 119.12, m.p. ca 274° dec., $[\alpha]_D^{20}$ +29° (c=5 in water), EINECS 211-171-8, RTECS XO8580000, BRN 1721643, MDL MFCD00064269 For conversion to enantiomerically pure 1,3-butanediol, see: *Synth. Commun* ., **21**, 2295 (1991).	**5g** **25g** **100g**
A16851	**L-Threonine, 98+%** *[(2S,3R)-2-Amino-3-hydroxybutyric acid, H-Thr-OH]* [72-19-5], $C_4H_9NO_3$, F.W. 119.12, m.p. 255° dec., $[\alpha]_D^{20}$ -28° (c=5 in water), Merck **14**,9380, EINECS 200-774-1, RTECS XO8590000, BRN 1721646, MDL MFCD00064270, †	**25g** **100g** **500g**
J63709	**L-Threonine, Cell Culture Reagent** *[(2S,3R)-2-Amino-3-hydroxybutyric acid]* [72-19-5], $C_4H_9NO_3$, F.W. 119.12, Powder, m.p. 256° dec., Merck **14**,9380, EINECS 200-774-1, RTECS XO8590000, BRN 1721646, MDL MFCD00064270, †	**250g** **1kg**
J63383	**Thrombin, bovine plasma** *[Factor IIa, EC 3.4.21.5]* [9002-04-4], Powder, Merck **14**,9383, EINECS 232-648-7, RTECS XO8950000, MDL MFCD00166053	**100kilounits** **500kilounits**
J63240	**Thrombin buffer, pH 8.0** Liquid, Note: 50mM Tris-HCl (pH 8.0), 150mM NaCl, 2mM calcium chloride.	**250ml** **500ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
A11493	**Thymidine, 99%** [50-89-5], $C_{10}H_{14}N_2O_5$, F.W. 242.23, m.p. 186-190°, $[\alpha]_D^{20}$ +19° (c=1 in water), Merck **14**,9397, EINECS 200-070-4, RTECS XP2071000, BRN 89285, MDL MFCD00006537, † 	**5g** **25g** **100g**
J60747	**Thymidine-5'-monophosphate disodium salt** *[TMP]* [33430-62-5], $C_{10}H_{13}N_2Na_2O_8P$, F.W. 366.18, Powder, EINECS 251-518-0, BRN 4086927, MDL MFCD09039259	**100mg** **250mg** **1g** **5g**
A15879	**Thymine, 97%** *[2,4-Dihydroxy-5-methylpyrimidine, 5-Methyluracil]* [65-71-4], $C_5H_6N_2O_2$, F.W. 126.12, m.p. 316-317°, Merck **14**,9398, EINECS 200-616-1, RTECS XP2100000, BRN 607626, MDL MFCD00006026, † 	**25g** **100g** **500g**
A14563	**Thymol, 98+%** *[2-Isopropyl-5-methylphenol]* [89-83-8], $C_{10}H_{14}O$, F.W. 150.22, m.p. 49-52°, b.p. 231-233°, f.p. 102°(215°F), d. 0.970, Merck **14**,9399, UN2430, EINECS 201-944-8, RTECS XP2275000, BRN 1907135, MDL MFCD00002309, †  H:H314-H302-H411, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Has strong antiseptic properties	**100g** **250g** **500g**
B21370	**Thymol Blue** [76-61-9], $C_{27}H_{30}O_5S$, F.W. 466.60, m.p. 223° dec., Merck **14**,9400, EINECS 200-973-3, RTECS XP2575000, MDL MFCD00005869, † 	**10g** **50g**
16272	**Thymol Blue, ACS** *[Thymolsulfonphthalein]* [76-61-9], $C_{27}H_{30}O_5S$, F.W. 466.60, Crystalline, m.p. 223° dec., Merck **14**,9400, Solubility: Insoluble in water. Soluble in alcohol, dilute alkali solutions, EINECS 200-973-3, RTECS XP2575000, MDL MFCD00005869, † Specifications: Clarity of solution P.T., Visual transition interval (acid range) pH 1.2 (red) to 2.8 (yellow), Visual transition range (alkaline range) pH 8.0 (yellow) to 9.2 (blue)  Application(s): pH indicator: 1.2 (red) to 2.8 (yellow) to 9.6 (blue)	**2g** **10g** **50g**
38692	**Thymol Blue sodium salt, 0.04% w/v aq. soln.** [62625-21-2], $C_{27}H_{29}NaO_5S$, F.W. 488.58, Liquid, d. 0.979, EINECS 200-973-3, MDL MFCD00151093, Note: Transition interval: pH 1.2 (red) to pH 2.8 (yellow); pH 8.0 (yellow) to pH 9.2 (blue), †	**100ml** **500ml** **6x100ml**
42785	**Thymol Blue sodium salt, ACS** [62625-21-2], $C_{27}H_{29}NaO_5S$, F.W. 488.58, Crystalline, m.p. ca 284° dec., Solubility: Soluble in water, EINECS 263-650-6, BRN 3861515, MDL MFCD00151093, Note: Thymolsulfonphthalein, † Specifications: Clarity of solution P.T., Visual transition interval (acid range) pH 1.2 (red) to pH 2.8 (yellow), Visual transition interval (alkaline range) pH 8.0 (yellow) to pH 9.2 (blue) Application(s): Water soluble pH indicator	**2g** **10g**
38706	**Thymolphthalein, 0.05% w/v solution in ethanol** [125-20-2], $C_{28}H_{30}O_4$, F.W. 430.55, Liquid, f.p. 11°(52°F), d. 0.920, Merck **14**,9401, UN1170, BRN 359413, MDL MFCD00005909, Note: Transition interval: pH 8.8 (colorless) to pH 10.5 (blue), †  H:H225-H371, P:P210-P241-P260-P303+P361+P353-P405-P501a	**100ml** **500ml**
16245	**Thymolphthalein, ACS** [125-20-2], $C_{28}H_{30}O_4$, F.W. 430.55, Crystalline, m.p. 251-253°, Merck **14**,9401, Solubility: Insoluble in water. Soluble in alcohol, acetone, dilute alkalies (blue color), H_2SO_4 (red color), EINECS 204-729-7, BRN 359413, MDL MFCD00005909, † Maximum level of impurities: Clarity of solution P.T., Visual transition interval from pH 8.8 (colorless) to 10.5 (blue) Application(s): pH indicator; colorless below pH 9.3, blue above pH 10.5	**5g** **25g**
	Thymolsulfonphthalein, see Thymol Blue, 16272, p. 369	
J61431	**Thymopentin, 99+%** *[Arg-Lys-Asp-Val-Tyr, TP-5]* [69558-55-0], $C_{30}H_{49}N_9O_9$, F.W. 679.77, Powder, Merck **14**,9403, MDL MFCD00214200 Application(s): Reduces endocrine responses	**25mg** **100mg**

Stock #	Description	Size
J62120	**Thyrotropin-Releasing Hormone** *[TRH, Pyr-His-Pro-NH2]* [24305-27-9], $C_{16}H_{22}N_6O_4$, F.W. 362.38, Powder, Merck **14**,9588, EINECS 246-143-4, RTECS TW3580000, BRN 770238, MDL MFCD00038640 Application(s): Two-chain glycoprotein hormone. Activates adenylate cyclase in the thyroid gland, stimulating iodine uptake, thyroxine synthesis and release	**50mg**
J62606	**L-Thyroxine, 98%** *[3,3',5,5'-Tetraiodo-L-thyronine]* [51-48-9], $C_{15}H_{11}I_4NO_4$, F.W. 776.87, Crystalline powder, m.p. 223° dec., Merck **14**,9415, EINECS 200-101-1, RTECS YP2833500, BRN 2228515, MDL MFCD00002595, †	**1g** **5g**
J63971	**Ticlopidine hydrochloride** *[5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride]* [53885-35-1], $C_{14}H_{14}ClNS{\cdot}HCl$, F.W. 300.25, Powder, Merck **14**,9429, EINECS 258-837-4, RTECS XJ9089100, MDL MFCD00079606 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Platelet aggregation inhibitor capable of inducing apoptosis in various cancer cell lines	**5g** **25g**
J60459	**Tioconazole, 98+%** *[Thioconazole]* [65899-73-2], $C_{16}H_{13}Cl_3N_2OS$, F.W. 387.71, Powder, Merck **14**,9452, EINECS 265-973-8, RTECS NI4480000, MDL MFCD00057276 H:H302-H413, P:P273-P264-P270-P301+P312-P330-P501a Application(s): Potent inhibitor of cytochrome-P450	**1g** **5g** **25g**
	TIS, see Triisopropylsilane, L09585, p. 378 **TLCK**, see Nα-(p-Toluenesulfonyl)-L-Lysine chloromethyl ketone hydrochloride, J60120, p. 371 **TLCK**, see Nα-(p-Toluenesulfonyl)-DL-Lysine chloromethyl ketone hydrochloride, 98%, J63959, p. 371	
J63355	**TM media, TRIS + $MgSO_4.7H_2O$** Liquid, Note: 5.5mM Tris-HCl, 8mM magnesium sulfate, pH 7. 5.	**100ml** **250ml**
	TMB-8 hydrochloride, see 8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride, 97%, J62528, p. 188 **TMB dihydrochloride hydrate**, see 3,3',5,5'-Tetramethylbenzidine dihydrochloride hydrate, 99+%, J60332, p. 364 **TMB soluble reagent, aq. soln.**, see 3,3',5,5'-Tetramethylbenzidine aq. soln., J60808, p. 364 **TMB soluble reagent, high sensitivity**, see 3,3',5,5'-Tetramethylbenzidine soln., Ready-to-Use, high sensitivity, J61325, p. 364 **TMB reagent, standard sensitivity**, see 3,3',5,5'-Tetramethylbenzidine soln., Ready-to-Use, precipitating, standard sensitivity, J60461, p. 364 **TMEDA**, see N,N,N',N'-Tetramethylethylenediamine, A12536, p. 364 **TMG hydrochloride**, see Methylguanidine hydrochloride, 98%, J60033, p. 288 **TMP**, see Thymidine-5'-monophosphate disodium salt, J60747, p. 369 **TMP**, see 4,5',8-Trimethylpsoralen, 99%, J63226, p. 378	
J63985	**TN buffer soln.** *[TRIS NaCl buffer soln]* Liquid, Note: 10mM Tris-HCl, 150mM sodium chloride, pH 8.0.	**500ml** **1L**
	TNBT, see Tetranitro Blue Tetrazolium chloride, 97%, J61080, p. 365 **TNBT**, see Tetranitro Blue tetrazolium chloride, J61080, p. 365	
J60622	**TNT buffer soln.** *[TRIS NaCl Tween 20 buffer soln.]* Liquid, Note: 10mM Tris-HCl, 150mM NaCl, 0.05% Tween-20, pH 8.0.	**1L** **2L**
J62995	**Tobramycin sulfate** [79645-27-5], $(C_{18}H_{37}N_5O_9)_2{\cdot}5H_2SO_4$, F.W. 1425.41, Powder, Merck **14**,9490, RTECS WK2110000, MDL MFCD00133864 H:H302-H312-332-H360, P:P261-P280-P281-P302+P352-P405-P501 Application(s): A water-soluble aminoglycoside antibiotic	**100mg** **1g**
J62846	**Tocinoic acid, 96%** *[(Ile3)-Pressinoic acid, H-Cys-Tyr-Ile-Gln-Asn-Cys-OH]* [34330-23-9], $C_{30}H_{44}N_8O_{10}S_2$, F.W. 740.86, Powder, MDL MFCD00076737 Application(s): A ring-structured analog of oxytocin that decreases locomotor activity	**25mg**
A17039	**DL-α-Tocopherol, 97+% ▲ △** *[Vitamin E]* [10191-41-0], $C_{29}H_{50}O_2$, F.W. 430.72, m.p. 2-4°, b.p. 200-220°/0.1mm, f.p. 240°(464°F), d. 0.950, n_D^{20} 1.5050, Merck **14**,10021, EINECS 233-466-0, RTECS GA8746000, BRN 94012, MDL MFCD00072051, †  **DL-α-Tocopheryl acetate**, see Vitamin E acetate, A14505, p. 393 **Toddaline**, see Chelerythrine chloride, 99+%, J62906, p. 153 **Tolazoline hydrochloride**, see 2-Benzyl-2-imidazoline hydrochloride, B21764, p. 122	**50g** **250g** **1kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
B21698	**Tolbutamide, 98%** *[1-n-Butyl-3-(p-tolylsulfonyl)urea]* [64-77-7], $C_{12}H_{18}N_2O_3S$, F.W. 270.35, m.p. 128-130°, Merck **14**,9507, EINECS 200-594-3, RTECS YS4550000, BRN 1984428, MDL MFCD00027169, †  H:H302-H317, P:P261-P280-P302+P352-P321-P301+P312-P501a Application(s): A first-generation potassium channel blocker	**10g** **50g** **250g**
J61256	**Tolfenamic acid, 99+%** *[2 (3-Chloro-2-methylanilino)benzoic acid, Clotam]* [13710-19-5], $C_{14}H_{12}ClNO_2$, F.W. 261.70, Crystalline powder, Merck **14**,9513, UN2811, EINECS 237-264-3, RTECS CB2687500, MDL MFCD00133865 H:H301, P:P264-P270-P301+P310-P321-P405-P501a Application(s): NSAID that activates calcium-activated potassium channels	**5g** **10g** **25g**
J62663	**Tolmetin sodium salt dihydrate, 98+%** [64490-92-2], $C_{15}H_{14}NNaO_3 \cdot 2H_2O$, F.W. 315.30 (279.27anhy), Powder, Merck **14**,9518, RTECS UX9280000, MDL MFCD00150761 H:H302-H315, P:P280-P302+P352-P321-P362-P301+P312-P501 Application(s): An NSAID compound	**1g** **5g** **25g**
J61834	**Tolnaftate** *[Methyl-(3-methylphenyl)carbamothioic acid O-2-naphthyl ester, Carbamothioic acid]* [2398-96-1], $C_{19}H_{17}NOS$, F.W. 307.41, Powder, m.p. 110-113°, Merck **14**,9519, EINECS 219-266-6, MDL MFCD00056611, † Application(s): Antifungal agent	**1g** **5g** **25g**
	α-Toluenephosphonic acid, see Benzylphosphonic acid, A13850, p. 123	
36506	**p-Toluenesulfonic acid monohydrate, 97%** *[4-Methylbenzenesulfonic acid monohydrate]* [6192-52-5], $CH_3C_6H_4SO_3H \cdot H_2O$, F.W. 190.22 (172.20anhy), Solid, m.p. 103-106°, b.p. 140°/20mm, f.p. 150°(302°F), d. 1.24, Merck **14**,9533, Fieser **1**,1172 **4**,508 **5**,673 **6**,597 **7**,374 **8**,488 **9**,471 **11**,535 **12**,507, UN2585, EINECS 203-180-0, RTECS XT6300000, BRN 3568023, MDL MFCD00142137, † H:H315-H319-H335, P:P280-P305+P351+P338-P309-P310	**25g** **100g** **500g**
B22146	**α-Toluenesulfonyl fluoride, 99%** ◢ *[Phenylmethanesulfonyl fluoride, Phenylmethylsulfonyl fluoride]* [329-98-6], $C_7H_7FO_2S$, F.W. 174.19, m.p. 92-94°, UN2923, EINECS 206-350-2, RTECS XT8040000, BRN 2088311, MDL MFCD00007424, †  H:H301-H314, P:P260-P301+P310-P303+P361+P353-P305+P351+P338-P405-P501a Application(s): A powerful protease inhibitor	**1g** **5g** **25g**
J63959	**N-α-(p-Toluenesulfonyl)-DL-lysine chloromethyl ketone hydrochloride, 98%** *[TLCK, Nα-p-Tosyl-DL-lysine chloromethyl ketone hydrochloride]* [4238-41-9], $C_{14}H_{21}ClN_2O_3S \cdot HCl$, F.W. 369.31, Powder, EINECS 224-199-0, RTECS XT5160000 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inhibitor of papain and trypsin	**50mg** **100mg** **250mg**
J60120	**N-α-(p-Toluenesulfonyl)-L-lysine chloromethyl ketone hydrochloride** *[TLCK, Nα-p-Tosyl-L-lysine chloromethyl ketone hydrochloride]* [4272-74-6], $C_{14}H_{21}ClN_2O_3S \cdot HCl$, F.W. 369.31, Powder, EINECS 224-266-4, RTECS XT5160000, BRN 7106867, MDL MFCD00065395 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inhibitor of papain and trypsin	**500mg** **1g**
J60639	**N-(p-Toluenesulfonyl)-L-phenylalanine chloromethyl ketone** *[TPCK, N-p-Tosyl-L-phenylalanine chloromethyl ketone]* [402-71-1], $C_{17}H_{18}ClNO_3S$, F.W. 351.85, Powder, EINECS 206-954-6, RTECS XT5613500, BRN 2895215, MDL MFCD00000935, † H:H315-H318-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Enzyme inhibitor that inactivates chymotrypsin but not trypsin	**1g** **5g**
J63803	**Toremifene, 98+%** *[Toremifene base, 2-(4-[(1Z)-4-Chloro-1,2-diphenyl-1-butenyl]phenoxy)-N,N-dimethylethanamine]* [89778-26-7], $C_{26}H_{28}ClNO$, F.W. 405.96, Powder, m.p. 108-110°, Merck **14**,9550, UN3077 H:H318-H400-H410-H302, P:P280-P273-P305+P351+P338-P310-P301+P312-P501a Application(s): A chlorinated tamoxifen analogue, that induces apoptosis in some cells	**500mg** **1g** **5g**
	Nα-p-Tosyl-L-lysine chloromethyl ketone hydrochloride, see Nα-(p-Toluenesulfonyl)-L-lysine chloromethyl ketone hydrochloride, J60120, p. 371 **N-p-Tosyl-L-phenylalanine chloromethyl ketone**, see N-(p-Toluenesulfonyl)-L-phenylalanine chloromethyl ketone, J60639, p. 371	

Stock #	Description	Size
J63232	**Tozasertib, 99+%** *[VX-680, MK-0457]* [639089-54-6], $C_{23}H_{28}N_8OS$, F.W. 464.59, Powder, m.p. 245-260° H:H360, P:P281-P201-P202-P308+P313-P405-P501 Application(s): Important inhibitor of all aurora kinases. Induces apoptosis and blocks tumor growth in varieties of leukemia, colon and pancreatic tumors	**10mg** **25mg** **50mg**
	TP-5, see Thymopentin, 99+%, J61431, p. 369 **TPCK**, see N-(p-Toluenesulfonyl)-L-phenylalanine chloromethyl ketone, J60639, p. 371	
J60233	**TPE (10X), TRIS + phosphate + EDTA** Liquid, Note: 0.9M Tris base, 0.9M phosphate, 200mM EDTA. H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**1L** **2L** **4L**
J65162	**T4 Polynucleotide Kinase** *[EC 2.7.1.78, Polynucleotide Kinase from T4-infected Escherichia coli]* [37211-65-7], Liquid, EINECS 253-400-4, † Application(s): Transfers the γ-phosphate of ATP to the 5' hydroxyl terminus of single- and double-stranded nucleic acids and 3'-nucleoside monophosphates. Used in the 5' phosphorylation of oligonucleotides	**500units**
A18502	**Tragacanth powder** *[Gum tragacanth]* [9000-65-1], Merck **14**,4581, EINECS 232-552-5, RTECS XW7750000, MDL MFCD00131255, †	**100g** **500g**
	Tragacanth Indian, see Karaya Gum, J61844, p. 262	
J60019	**TRAM 34** *[1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole]* [289905-88-0], $C_{22}H_{17}ClN_2$, F.W. 344.84, Powder, m.p. 145-147°, MDL MFCD09842562 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): TRAM-34 is a potent inhibitor of the intermediate-conductance calcium-activated potassium channel	**25mg**
J64941	**Transaminase Kit - 12 variants (TA1 through TA12)** Lyophilized powder, Note: Contains 100mg of each variant Application(s): Enzymes catalyze the synthesis of chiral amines from prochiral ketones by asymmetric amino transfer	**1each**
J64306	**Transaminase Kit - 20 variants (TA1 through TA20)** Lyophilized powder, Note: Contains 100mg of each variant Application(s): Catalyze synthesis of chiral amines from prochiral ketones by asymmetric amino transfer	**1each**
J64836	**Transaminase TA1** Lyophilized powder	**250mg** **500mg** **1g**
J65711	**Transaminase TA2** Lyophilized powder	**250mg** **500mg** **1g**
J64914	**Transaminase TA3** Lyophilized powder	**250mg** **500mg** **1g**
J64900	**Transaminase TA4** Lyophilized powder	**250mg** **500mg** **1g**
J64513	**Transaminase TA5** Lyophilized powder	**250mg** **500mg** **1g**
J64473	**Transaminase TA6** Lyophilized powder	**250mg** **500mg** **1g**
J64783	**Transaminase TA7** Lyophilized powder	**250mg** **500mg** **1g**
J64699	**Transaminase TA8** Lyophilized powder	**250mg** **500mg** **1g**
J64060	**Transaminase TA9** Lyophilized powder	**250mg** **500mg** **1g**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64092	**Transaminase TA10** Lyophilized powder	**250mg** **500mg** **1g**
J65720	**Transaminase TA11** Lyophilized powder	**250mg** **500mg** **1g**
J64376	**Transaminase TA12** Lyophilized powder	**250mg** **500mg** **1g**
J65452	**Transaminase TA13** Lyophilized powder	**250mg** **500mg** **1g**
J64756	**Transaminase TA14** Lyophilized powder	**250mg** **500mg** **1g**
J65834	**Transaminase TA15** Lyophilized powder	**250mg** **500mg** **1g**
J64791	**Transaminase TA16** Lyophilized powder	**250mg** **500mg** **1g**
J64260	**Transaminase TA17** Lyophilized powder	**250mg** **500mg** **1g**
J65905	**Transaminase TA18** Lyophilized powder	**250mg** **500mg** **1g**
J64421	**Transaminase TA19** Lyophilized powder	**250mg** **500mg** **1g**
J65112	**Transaminase TA20** Lyophilized powder	**250mg** **500mg** **1g**
J63037	**Transfer or electro blotting buffer (10X), pH 8.5** Liquid, Note: 0.25M Tris base, 1.92M glycine, pH 8.5. Add methanol according to your protocol.	**1L** **2L** **4L**
J61626	**Transferrin (Apo), bovine plasma, 98+%** *[Apo Transferrin]* [11096-37-0], Lyophilized powder, Merck **14**,9571, EINECS 234-318-8, MDL MFCD00130536, † Application(s): Blood plasma protein for iron delivery. Apo-transferrin is iron-free	**50mg** **500mg** **1g**
J61046	**Transferrin (Holo), bovine plasma, 98+%** *[Siderophilin, iron-saturated, HTF bovine native protein]* [11096-37-0], Lyophilized powder, Merck **14**,9571, EINECS 234-318-8, MDL MFCD00131337, † Application(s): Blood plasma protein for iron delivery. HOLO-transferrin has iron bound at the N-terminus	**50mg** **500mg** **1g**
J63244	**Transformation buffer-1, pH 7.5** Liquid, Note: Contains 30mM potassium-acetate, 150mM calcium chloride, 10mM PIPES, 100mM potassium chloride, 50mM manganese chloride and 15% glycerol, pH 7.5	**125ml** **250ml**
J63293	**Transformation buffer-2, pH 7.5** Liquid, Note: Contains 10mM MOPS, 75mM calcium chloride, 10mM potassium chloride, and 15% glycerol, pH 7.5	**125ml** **250ml**
J64478	**Transforming Growth Factor-a, human, 98%** *[TGF-alpha]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for radioimmunoassays. Supplied as a lyophilized powder	**2micrograms**
J65773	**Transforming Growth Factor-β 1, human platelets, 97%** *[TGF-beta1]* Note: Receptor Grade. Suitable for use in cell culture. Supplied as a lyophilized powder with BSA.	**0.5micrograms**

Stock #	Description	Size
J65044	**Transforming Growth Factor-β 1, human platelets, carrier free, 97%** *[TGF-beta1]* Note: Receptor Grade. Suitable for use in cell culture. Supplied as 5ug in TFA and acetonitrile.	5micrograms
J65173	**Transforming Growth Factor-β 1, human platelets, lyophilized with BSA, 97%** *[TGF-beta1]* Note: Receptor Grade. Suitable for use in cell culture. Supplied as a lyophilized powder with BSA.	5micrograms
	Traut's reagent, see 2-Iminothiolane hydrochloride, J60131, p. 255	
J63070	**Trazodone hydrochloride** [25332-39-2], $C_{19}H_{22}ClN_5O \cdot HCl$, F.W. 408.33, Powder, m.p. 222-227°, Merck **14**,9579, EINECS 246-855-5, RTECS XZ5660000, MDL MFCD00079603 H:H302-H351, P:P281-P264-P301+P312-P308+P313-P405-P501 Application(s): A serotonin uptake inhibitor	1g 5g 25g
A19434	**D-(+)-Trehalose dihydrate, 99%** ■ *[α-D-Glucopyranosyl-α-D-glucopyranoside]* [6138-23-4], $C_{12}H_{22}O_{11} \cdot 2H_2O$, F.W. 378.33 (342.29anhy), m.p. 97-99°, $[\alpha]_D^{20}$ +179° (c=2 in water), Merck **14**,9580, EINECS 202-739-6, BRN 5322018, MDL MFCD00071594, † 	5g 25g 100g
J63999	**Trequinsin hydrochloride, 98+%** *[HL-725]* [78416-81-6], $C_{24}H_{27}N_3O_3 \cdot HCl$, F.W. 441.95, Powder, RTECS UW7727000, MDL MFCD01076563 Application(s): Anti-hypertensive agent, inhibitor of cGMP-inhibited phosphodiesterase	10mg
	TRH, see Thyrotropin-Releasing Hormone, J62120, p. 370 **Triacetin**, see Glycerol triacetate, A17132, p. 236 **Triacylglycerol acylhydrolase**, see Lipase, from porcine pancreas, J62903, p. 270	
J63548	**Triamcinolone acetonide, 98+%** *[9α-Fluoro-16α-hydroxyprednisolone-16α,17α-acetonide]* [76-25-5], $C_{24}H_{31}FO_6$, F.W. 434.50, Powder, m.p. 274-278°, Merck **14**,9596, EINECS 200-948-7, RTECS TU3920000, MDL MFCD00056834, † H:H360-H302, P:P281-P264-P301+P312-P308+P313-P405-P501a Application(s): A glucocorticoid, antiasthmatic (inhalant); antiallergic (nasal)	1g
B20044	**2,4,7-Triamino-6-phenylpteridine, 98%** *[Triamterene]* [396-01-0], $C_{12}H_{11}N_7$, F.W. 253.27, m.p. >300°, Merck **14**,9599, EINECS 206-904-3, RTECS UO3470000, BRN 266723, MDL MFCD00006708  H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Weak diuretic with potassium sparing properties that blocks sodium reuptake in the kidneys	5g 25g 100g
	Triamterene, see 2,4,7-Triamino-6-phenylpteridine, B20044, p. 374 **1,2,4-Triazine-3,5(2H,4H)-dione**, see 6-Azauracil, A14389, p. 114	
A11597	**1,2,4-Triazole, 99%** [288-88-0], $C_2H_3N_3$, F.W. 69.07, m.p. 118-122°, b.p. 260°, f.p. 158°(316°F), Merck **14**,9605, Fieser **1**,1188 **2**,423, EINECS 206-022-9, RTECS XZ3806000, BRN 104767, MDL MFCD00005228, †  H:H361d-H302-H319, P:P280-P281-P305+P351+P338-P301+P312-P405-P501a Bifunctional acylation catalyst, often superior to **Imidazole**, **A10221**, p. 254, for esterification, amidation, etc. Has found limited use as a catalyst for low-racemization peptide bond formation: *Proc. Chem. Soc.*, 266 (1963); *Rec. Trav. Chim.*, **84**, 213 (1965); *Liebigs Ann. Chem.*, **691**, 212 (1966). In a comparative study of 1- vs 4-alkylation using different bases it was found that the best yields of the 1-substituted regioisomers were obtained with DBU: *Tetrahedron Lett.*, **41**, 1297 (2000). Application(s): Useful as an antifungal compound	25g 100g 500g
	1H-1,2,4-Triazole-3,5-diamine, see 3,5-Diamino-1,2,4-triazole, B22775, p. 183 **Tributyrin**, see Glycerol tributyrate, A11830, p. 236	
J62366	**Trichloroacetic acid, 5% w/v aq. soln.** *[TCA]* [76-03-9], Cl_3CCO_2H, F.W. 163.39, Liquid, Merck **14**,9627, UN2564, EINECS 200-927-2, BRN 970119, MDL MFCD00004177, † H:H314-H335+H336-H411, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Protein precipitation reagent	500ml 1L
J62355	**Trichloroacetic acid, 10% w/v aq. soln.** *[TCA]* [76-03-9], Cl_3CCO_2H, F.W. 163.39, Liquid, Merck **14**,9627, UN2564, EINECS 200-927-2, RTECS AJ7875000, BRN 970119, MDL MFCD00004177, † H:H314-H335+H336-H411, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Protein precipitation reagent	500ml

Contact us for pricing on bulk sizes

Stock #	Description	Size
A11156	**Trichloroacetic acid, 99%** ■ *[TCA]* [76-03-9], Cl_3CCO_2H, F.W. 163.39, m.p. 54-58°, b.p. 196°, d. 1.629, Merck **14**,9627, Fieser **1**,1194 **2**,425 **4**,520, UN1839, EINECS 200-927-2, RTECS AJ7875000, BRN 970119, MDL MFCD00004177, † H:H314-H400-H410, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Trihaloacetic acids react with aldehydes in DMSO at room temperature to give trihalomethyl carbinols: *J. Chem. Soc., Perkin 2*, 1247 (1984):  The acid and its Na salt (1:1) in DMF are also effective: *Tetrahedron Lett.*, **33**, 3435 (1992). Use of HMPA or DMI extends the scope to less reactive aldehydes: *Synthesis*, 327 (1990). Application(s): Protein precipitation reagent	**250g** **500g** **1kg** **5kg**
22156	**Trichloroacetic acid, ACS, 99%** ■ *[TCA]* [76-03-9], CCl_3CO_2H, F.W. 163.39, Crystalline, m.p. 54-58°, b.p. 196°, d. 1.629, Merck **14**,9627, Fieser **1**,1194 **2**,425 **4**,520, UN1839, EINECS 200-927-2, RTECS AJ7875000, BRN 970119, MDL MFCD00004177, † Maximum level of impurities: Clarity of solution P.T. Insoluble matter 0.01%, Residue after ignition 0.03%, Cl 0.002%, NO_3 0.002%, PO_4 5ppm, SO_4 0.02%, Heavy Metals (as Pb) 0.002%, Fe 0.001%, Substances darkened by sulfuric acid P.T. H:H314-H400-H410, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Protein precipitation reagent	**50g** **250g** **1kg**
	1,2-O-(2,2,2-Trichloroethylidene)-α-D-glucofuranose, see α-Chloralose, A11492, p. 153 **Trichloromethane**, see Chloroform, 32614, p. 156 **2,4,6-Trichloro-1,3,5-triazine**, see Cyanuric chloride, L03442, p. 170	
A14695	**Tricine, 98+%** *[N-(Trishydroxymethylmethyl)glycine]* [5704-04-1], $(HOCH_2)_3CNHCH_2CO_2H$, F.W. 179.17, m.p. ca 183° dec., Merck **14**,9651, EINECS 227-193-6, BRN 1937804, MDL MFCD00004277, Note: pH range: 7.8-8.8, † Biological buffer, pKa = 8.15 at 20°: *Biochemistry*, **5**, 467 (1966). Application(s): Good's buffers	**25g** **100g** **500g**
J60107	**Tricine, 0.5M buffer soln., pH 6.5** [5704-04-1], Liquid	**100ml** **250ml**
J62234	**Tricine, 0.5M buffer soln., pH 7.0** [5704-04-1], Liquid	**100ml** **250ml**
J62672	**Tricine, 0.5M buffer soln., pH 7.5** [5704-04-1], Liquid	**100ml** **250ml**
J62983	**Tricine, 0.5M buffer soln., pH 8.0** [5704-04-1], Liquid	**100ml** **250ml**
J63108	**Tricine, 0.5M buffer soln., pH 8.5** [5704-04-1], Liquid	**100ml** **250ml**
J63880	**Tricine, 0.5M buffer soln., pH 9.0** [5704-04-1], Liquid	**100ml** **250ml**
J60811	**Tricine-buffered saline (5X), pH 7.0** [5704-04-1], Liquid, Note: 50mM tricine and 750mM NaCl, pH 7.0	**250ml** **500ml**
J63294	**Tricine-buffered saline (5X), pH 7.5** [5704-04-1], Liquid, Note: 50mM Tricine and 750mM NaCl, pH 7.5	**250ml** **500ml**
J60745	**Tricine-buffered saline (5X), pH 8.0** [5704-04-1], Liquid, Note: 50mM Tricine and 750mM NaCl, pH 8.0	**250ml** **500ml**
J64437	**Tricine, Electrophoresis Grade, 99%** *[N-(Trishydroxymethylmethyl)glycine]* [5704-04-1], $(HOCH_2)_3CNHCH_2CO_2H$, F.W. 179.17, Powder, m.p. ca 183° dec., Merck **14**,9651, EINECS 227-193-6, BRN 1937804, MDL MFCD00004277, †	**Call**
J62677	**Tricine-SDS Sample Buffer (2X), non-reducing** Liquid, Note: Contains: 900mM Tris-HCl (pH 8.45), 8% SDS, 20% glycerol, 0.01% Coomassie blue, 0.01% Phenol Red	**25ml** **50ml**
J61042	**Tricine-SDS Sample Buffer (2X), reducing** Liquid, Note: Contains 900mM Tris-HCl (pH 8.45), 8% SDS , 20% glycerol, 0.01% Coomassie blue, 0.01% Phenol Red, 4% mercaptoethnol.	**25ml** **50ml**
	Tricosaethylene glycol mono-n-dodecyl ether, see Brij® L23, A15809, p. 135	

Stock #	Description	Size
J63015	**Tricyclodecan-9-yl xanthogenate potassium salt, 98+%** *[D609 potassium salt, O-Tricyclo[5.2.1.0^{2,6}]dec-9-yl dithiocarbonate potassium salt]* [83373-60-8], $C_{11}H_{15}KOS_2$, F.W. 266.46, Powder, EINECS 280-379-9, MDL MFCD00171401 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Inhibitor of phosphatidylcholine-specific phospholipase C	**5mg** **25mg**
	O-Tricyclo[5.2.1.0^2^,^6]dec-9-yl dithiocarbonate potassium salt, see Tricyclodecan-9-yl xanthogenate potassium salt, 98+%, J63015, p. 376 **1,2,3-Tridodecanoylglycerol**, see Trilaurin, J62962, p. 378	
L04486	**Triethanolamine, 98+%** △ ■ *[2,2',2''-Nitrilotriethanol, Tris(2-hydroxyethyl)amine]* [102-71-6], $(HOCH_2CH_2)_3N$, F.W. 149.19, m.p. 19-21°, b.p. 206-207°/15mm, f.p. 185°(365°F), d. 1.124, n_D^{20} 1.4850, Merck **14**,9665, Fieser **1**,1196, EINECS 203-049-8, RTECS KL9275000, BRN 1699263, MDL MFCD00002855, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 Reacts with N-alkylanilines in dioxane (autoclave) in the presence of **Dichlorotris(triphenylphosphine)ruthenium(II)**, **L00373**, to give 1-alkyl indoles in good yield: *Synth. Commun.*, **26**, 1349 (1996). Application(s): Protein purification reagent	**100g** **500g** **2.5kg**
A15678	**Triethanolamine hydrochloride, 99+%** ■ *[2,2',2''-Nitrilotriethanol hydrochloride, Tris(2-hydroxyethyl)amine hydrochloride]* [637-39-8], $(HOCH_2CH_2)_3N{\cdot}HCl$, F.W. 185.65, m.p. 177-179°, Merck **14**,9665, EINECS 211-284-2, RTECS KL9346500, BRN 3909940, MDL MFCD00012596, † Application(s): Protein purification reagent	**250g** **1kg** **5kg**
A17318	**Triethylamine hydrochloride, 98%** ■ *[Triethylammonium chloride]* [554-68-7], $(CH_3CH_2)_3N{\cdot}HCl$, F.W. 137.65, m.p. ca 260° dec., d. 1.07, EINECS 209-067-2, RTECS YE2111500, BRN 3906409, MDL MFCD00012500, † H:H302-H315-H319-H335, P:P280h-P305+P351+P338 Application(s): Protein purification reagent	**250g** **1kg**
	Triethylammonium chloride, see Triethylamine hydrochloride, A17318, p. 376	
L04128	**Triethylene glycol dimethyl ether, 99%** ■ *[Triglyme]* [112-49-2], $CH_3O(CH_2CH_2O)_3CH_3$, F.W. 178.23, m.p. -45°, b.p. 215-216°, f.p. 113°(235°F), d. 0.986, n_D^{20} 1.4230, Merck **14**,9692, EINECS 203-977-3, RTECS XF0665000, BRN 1700630, MDL MFCD00008504, † H:H360Df-EUH019, P:P281-P201-P202-P308+P313-P405-P501a Useful aprotic solvent with chelating properties. Has been used as solvent in a simplified Wittig synthesis, with anhydrous K_2CO_3 as base and the phosphonium salt, such as **Methyltriphenylphosphonium bromide**, **A15878**, acting as both reactant and phase-transfer catalyst: *Synth. Commun.*, **22**, 513 (1992).	**100g** **500g** **2.5kg**
A16128	**Triethylenetetramine, tech. 60%, balance branched and cyclic triethylenetetramines** ■ [112-24-3], $H_2NCH_2CH_2(NHCH_2CH_2)_2NH_2$, F.W. 146.24, m.p. ca -35°, b.p. ca 267°, f.p. 122°(252°F), d. 0.982, n_D^{20} 1.4980, Merck **14**,9663, UN2259, EINECS 203-950-6, RTECS YE6650000, BRN 605448, MDL MFCD00008169, † H:H314-H312-H317-H412, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Catalyzes the hydrolysis of N-terminal peptide bonds	**500ml** **2.5L**
J63112	**Triflumuron, 98+%** *[Trifluron, 2-Chloro-N-[[4-(trifluoromethoxy)phenyl]amino)carbonyl]benzamide]* [64628-44-0], $C_{15}H_{10}ClF_3N_2O_3$, F.W. 358.70, Solid, m.p. 198°, Merck **14**,9678, EINECS 264-980-3, RTECS CV2474000, BRN 2776684, MDL MFCD00072496 Application(s): Inhibits uridine incorporation into RNA	**10g** **25g** **100g**
A14365	**Trifluoroacetic acid, biochemical grade, 99.5+%** ■ [76-05-1], CF_3CO_2H, F.W. 114.02, m.p. -15°, b.p. 72-73°, d. 1.480, n_D^{20} 1.2840, Merck **14**,9681, Fieser **1**,1219 **6**,613 **11**,557, **15**,338 **17**,369 **18**,375 **20**,395 **21**,446, UN2699, EINECS 200-929-3, RTECS AJ9625000, BRN 742035, MDL MFCD00004169, † H:H314-H332-H412, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Used to cleave peptide blocking groups	**50g** **250g** **1kg**
A10788	**2,2,2-Trifluoroethanol, 99+%** *[Trifluoroethyl alcohol]* [75-89-8], CF_3CH_2OH, F.W. 100.04, m.p. -44°, b.p. 74-75°, f.p. 29°(84°F), d. 1.391, n_D^{20} 1.2900, UN2929, EINECS 200-913-6, RTECS KM5250000, BRN 1733203, MDL MFCD00004672, † H:H301-H311-H331-H318-H226-H361f-H315-H335, P:P260-P280-P305+P351+P338-P304+P340-P310 Useful ionizing solvent, see: *Tetrahedron Lett.*, 2335 (1974), and references therein. Good solvent for oligopeptides with potential as a cosolvent along with proton acceptors such as DMF for peptide coupling reactions: *Tetrahedron Lett.*, **33**, 7007 (1992). Compare **1,1,1,3,3,3-Hexafluoro-2-propanol**, **A12747**. Effective solvent for uncatalyzed epoxidations of alkenes with hydrogen peroxide (caution! 60%): *Synlett*, 248 (2001). For a review of fluorinated alcohols as solvents for selective and clean reactions, see: *Synlett*, 18 (2004). Trifluoroethyl esters have also found use as active esters in peptide coupling; see, for example: *J. Chem. Soc., Perkin 1*, 2867 (1996). Reacts with triphenylphosphine dibromide to give the bis(trifluoroethoxy)phosphorane, which converts alcohols to trifluoroethyl ethers, carboxylic acids to trifluoroethyl esters and aldehydes to bis(trifluoroethyl) acetals: *J. Org. Chem.*, **45**, 5052 (1980).	**50g** **100g** **500g** **1kg**

The stereodirecting effect of the MEM group (see **2-Methoxyethoxymethyl chloride**, **L01050**) has been exploited by Percy *et al* in the formation of a new fluorine-containing acyl anion equivalent: *Tetrahedron*, **51**, 9201 (1995):



Claisen or Wittig rearrangements of the derived difluoroallyl alcohols can be used in routes to molecules containing a CF_2 group: *Tetrahedron*, **51**, 11327 (1995); *J. Org. Chem.*, **61**, 166 (1996), or to monofluorinated vinylic compounds: *Tetrahedron Lett.*, **37**, 5183 (1996).

Trifluoroethyl alcohol, see 2,2,2-Trifluoroethanol, A10788, p. 376
2-[3-(Trifluoromethyl)anilino]nicotinic acid, see Niflumic acid, 99+%, J60489, p. 302
N-(3-Trifluoromethylphenyl)anthranilic acid, see Flufenamic acid, B23583, p. 222

L10465 **1-(2-Trifluoromethylphenyl)imidazole, 98+% ▲** — **1g**
[TRIM]
[25371-96-4], $C_{10}H_7F_3N_2$, F.W. 212.18, m.p. 50-53°, b.p. 75°/0.025mm, BRN 3955637, MDL MFCD00041206



H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a

Application(s): Potent nitric oxide synthase inhibitor

2-(α,α,α-Trifluoro-m-toluidino)nicotinic acid, see Niflumic acid, 99+%, J60489, p. 302
Trifluron, see Triflumuron, 98+%, J63112, p. 376
Triglycine, see Glycylglycylglycine, A13778, p. 237
Triglyme, see Triethylene glycol dimethyl ether, L04128, p. 376

B20303 **1,8,9-Trihydroxyanthracene, 97%** — **1g 5g 25g**
[Dithranol]
[1143-38-0], $C_{14}H_{10}O_3$, F.W. 226.23, m.p. 177-181°, Merck **14**,684, EINECS 214-538-0, RTECS CB1225000, BRN 2054360, MDL MFCD00001250



H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a

Application(s): Inhibits leukotriene biosynthesis

1,3,5-Trihydroxybenzene, see Phloroglucinol, B25502, p. 318

B24887 **3,4,5-Trihydroxybenzoic acid, anhydrous, 99% ▲■** — **250g 1kg 5kg**
[Gallic acid]
[149-91-7], $C_7H_6O_5$, F.W. 170.12, m.p. ca 251° dec., d. 1.694, Merck **14**,4345, EINECS 205-749-9, RTECS LW7525000, BRN 2050274, MDL MFCD00002510, †



H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a

Application(s): Organic acid used as a standard for determining phenols in the Folin-Ciocalteau assay

2-(3,4,5-Trihydroxybenzylidene)malononitrile, see Tyrphostin A25, 99+%, J62936, p. 386
3,4,5-Trihydroxy-1-cyclohexene-1-carboxylic acid, see (-)-Shikimic acid, L04848, p. 342

L09834 **4',5,7-Trihydroxyflavanone, 97%** — **2g 10g**
[Naringenin]
[67604-48-2], $C_{15}H_{12}O_5$, F.W. 272.26, m.p. 248-251°, Merck **14**,6424, EINECS 266-769-1, RTECS DJ2981530, MDL MFCD00006844



H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a

L15041 **4',5,7-Trihydroxyflavone, 97%** — **25mg 100mg**
[Apigenin]
[520-36-5], $C_{15}H_{10}O_5$, F.W. 270.24, m.p. ca 315° dec., Merck **14**,730, EINECS 208-292-3, RTECS LK9276000, BRN 262620, MDL MFCD00006831



H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a

Application(s): Nonmutagenic flavonoid shown to inhibit cell proliferation, angiogenesis, and protein kinase. Also induces apoptosis in breast cancer cells

2',4',6'-Trihydroxy-3-(4-hydroxyphenyl)propiophenone, see Phloretin, L10991, p. 318

L14171 **4',5,7-Trihydroxyisoflavone, 97%** — **100mg 500mg**
[Genistein]
[446-72-0], $C_{15}H_{10}O_5$, F.W. 270.24, m.p. ca 300°, Merck **14**,4391, EINECS 207-174-9, RTECS NR2392000, BRN 263823, MDL MFCD00016952, †
Tyrosine kinase inhibitor: *J. Biol. Chem.*, **262**, 5592 (1987).



J63241 **4',5,7-Trihydroxyisoflavone, 99+%** — **100mg 1g 10g**
[Genistein]
[446-72-0], $C_{15}H_{10}O_5$, F.W. 270.24, Powder, m.p. ca 300°, Merck **14**,4391, EINECS 207-174-9, RTECS NR2392000, BRN 263823, MDL MFCD00016952, †

Application(s): Inhibitor of tyrosine protein kinase

B20528 **3',5,7-Trihydroxy-4'-methoxyflavanone, 97%** — **1g 5g 25g**
[Hesperetin, 4'-Methoxy-3',5,7-trihydroxyflavanone]
[520-33-2], $C_{16}H_{14}O_6$, F.W. 302.30, m.p. 227-232°, Merck **14**,4670, EINECS 208-290-2, BRN 309850, MDL MFCD00075646



H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a

Stock #	Description	Size
	3',5,7-Trihydroxy-4'-methoxyflavone 7-rutinoside, see Diosmin, J62073, p. 198 **(2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol**, see (-)-Gallocatechin, J60731, p. 230 **(2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate)**, see (-)-Gallocatechin gallate, J62740, p. 230	
J63312	**3,3',5'-Triiodo-L-thyronine sodium salt** *[Liothyronine sodium salt]* [55-06-1], $C_{15}H_{11}I_3NNaO_4$, F.W. 672.96, Powder, m.p. 205°, Merck **14**,5510, EINECS 200-223-5, RTECS YP2836500, BRN 8179867, MDL MFCD00002594 H:H302-H312-H332, P:P261-P280-P302+P352-P304+P340-P322-P501a	**500mg** **1g**
L09585	**Triisopropylsilane, 98%** *[TIS]* [6485-79-6], $[(CH_3)_2CH]_3SiH$, F.W. 158.36, b.p. 166°, f.p. 35°(95°F), d. 0.773, n_D^{20} 1.4340, UN1993, BRN 1733718, MDL MFCD00009657 H:H226-H315-H319-H335, P:P210-P241-P303+P361+P353-P305+P351+P338-P405-P501a Selective silylation of primary OH groups in the presence of secondary has been carried out with this reagent in combination with CsF and imidazole: *J. Organomet. Chem.*, **282**, 155 (1985). Triethylsilane and triisopropylsilane have been studied as cation scavengers in the deprotection of peptides with TFA, and were found to give good results, with triisopropylsilane being particularly effective in trapping trityl cations in the TFA deprotection of cysteine containing peptides. The use of triisopropylsilane minimizes the risk of reduction of the indole nucleus in tryptophan-containing peptides: *Tetrahedron Lett.*, **30**, 2739 (1989).	**5g** **25g** **100g**
	3,7,12-Triketocholanic acid, see Dehydrocholic acid, A19666, p. 176	
J62962	**Trilaurin** *[Glyceryl tridodecanoate, 1,2,3-Tridodecanoylglycerol]* [538-24-9], $[CH_3(CH_2)_{10}COOCH_2]_2CHOCO(CH_2)_{10}CH_3$, F.W. 639.01, Powder, m.p. 47°, EINECS 208-687-0, BRN 1730452, MDL MFCD00026559, †	**25g**
	TRIM, see 1-(2-Trifluoromethylphenyl)imidazole, L10465, p. 377	
J63053	**Trimethoprim** *[2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine]* [738-70-5], $C_{14}H_{18}N_4O_3$, F.W. 290.32, Powder, m.p. 199-203°, Merck **14**,9709, EINECS 212-006-2, RTECS UV8225000, BRN 625127, MDL MFCD00036761 Application(s): An antibacterial and inhibitor of formylation. Dihydrofolate reductase inhibitor with selectivity for the prokaryote enzyme	**1g** **5g** **25g**
J65567	**cis-3,4',5-Trimethoxy-3'-aminostilbene** *[(Z)-5-(3,5-Dimethoxystyryl)-2-methoxyaniline]* [586410-12-0], $C_{17}H_{19}NO_3$, F.W. 285.34, Oil H:H302, P:P264-P270-P301+P312-P330-P501	**10mg**
	3,4,5-Trimethoxybenzoic acid 8-(diethylamino)octyl ester hydrochloride, see 8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride, 97%, J62528, p. 188 **α,α,4-Trimethyl-3-cyclohexene-1-methanol**, see α-Terpineol, 16285, p. 360 **3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol**, see Farnesol, A19316, p. 218 **Trimethylenediamine**, see 1,3-Diaminopropane, A11932, p. 183 **1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane**, see 1,8-Cineole, A12269, p. 163	
J63226	**4,5',8-Trimethylpsoralen, 99%** *[Trioxsalen, TMP]* [3902-71-4], $C_{14}H_{12}O_3$, F.W. 228.25, Powder, m.p. 229-231°, Merck **14**,9735, UN1759, EINECS 223-459-0, RTECS LV1576000, BRN 221723, MDL MFCD00005010, † H:H314-H351, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Photochemical crosslinker of DNA. Useful for treatment of psoriasis	**1g** **5g**
	2,4,6-Trimethylpyridine, see 2,4,6-Collidine, A11058, p. 167 **Trimethyl-n-tetradecylammonium bromide**, see (1-Tetradecyl)trimethylammonium bromide, L10294, p. 362	
J65391	**2,4,6-Trimethyl-N-[2-(trifluoromethyl)phenyl]benzenesulfonamide** *[o-3M3FBS]* [313981-55-4], $C_{16}H_{16}F_3NO_2S$, F.W. 343.36, Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
J65999	**2,4,6-Trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide** *[m-3M3FBS]* [200933-14-8], $C_{16}H_{16}F_3NO_2S$, F.W. 343.36, Powder, MDL MFCD00095824 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
	1,3,7-Trimethylxanthine, see Caffeine, A10431, p. 142	
J62819	**Trimyristin, 95%** *[Glyceryl trimethyristate, 1,2,3-Tritetradecanoylglycerol]* [555-45-3], $[CH_3(CH_2)_{12}COOCH_2]_2CHOCO(CH_2)_{12}CH_3$, F.W. 723.16, Powder, m.p. 56-57°, Merck **14**,9724, EINECS 209-099-7, BRN 1718242, MDL MFCD00036229, †	**25g**
	1,2,3-Tri(cis-9-octadecenoyl)glycerol, see Triolein, J62419, p. 379	

Stock #	Description	Size
J62419	**Triolein** *[1,2,3-Tri(cis-9-octadecenoyl)glycerol, Glycerol trioleate]* [122-32-7], $(C_{17}H_{33}COOCH_2)_2CHOCOC_{17}H_{33}$, F.W. 885.45, Liquid, b.p. 235-240°/18mm, f.p. 330°(626°F), d. 0.91, n_D^{20} 1.468, Merck **14**,9732, EINECS 204-534-7, RTECS RG1936500, BRN 1718692, MDL MFCD00137563, †	**25g** **100g**
	3,7,12-Trioxo-5β-cholan-24-oic acid, see Dehydrocholic acid, A19666, p. 176 **Trioxsalen**, see 4,5',8-Trimethylpsoralen, 99%, J63226, p. 378 **Tripalmitin**, see Glycerol tripalmitate, A10922, p. 236	
J64760	**Tripeptidylpeptidase Inhibitor ▲** *[H-AAF-CMK, TPPII Inhibitor]* [184901-82-4], $C_{16}H_{22}ClN_3O_3$, F.W. 453.90, Solid	**5mg** **10mg**
	N-(Triphenylmethyl)glycine, see N-Tritylglycine, L09095, p. 383	
A10870	**2,3,5-Triphenyl-2H-tetrazolium chloride, 98% ▲■** *[TTC]* [298-96-4], $C_{19}H_{15}ClN_4$, F.W. 334.81, m.p. ca 250° dec., Merck **14**,9744, EINECS 206-071-6, RTECS XF8100000, BRN 3923356, MDL MFCD00011963, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reagent for detection of reducing sugars. Oxidizing agent, reduced to the colored formazan, capable of introducing a -hydroxyl substituent into steroidal enones: *J. Chem. Soc., Perkin 1*, 2687 (1988). Application(s): Useful indicator for reducing substances	**10g** **50g** **250g**
	Triphosphopyridine nucleotide monosodium salt, see β-Nicotinamide adenine dinucleotide phosphate monosodium salt, 44126, p. 301 **2,4,6-Tri(2-pyridyl)-s-triazine**, see 2,4,6-Tri(2-pyridyl)-1,3,5-triazine, A17201, p. 379	
A17201	**2,4,6-Tri(2-pyridyl)-1,3,5-triazine, 98%** *[2,4,6-Tri(2-pyridyl)-s-triazine]* [3682-35-7], $C_{18}H_{12}N_6$, F.W. 312.34, m.p. 248-252°, Merck **14**,9750, EINECS 222-965-9, RTECS XZ2050000, BRN 282581, MDL MFCD00006045, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Reagent for determination of Fe: *Anal. Chem.*, **31**, 1862 (1959). Application(s): Reagent for the colorimetric determination of iron	**5g** **25g** **100g**
	TRIS, see Tris(hydroxymethyl)aminomethane, Electrophoresis Grade, 99.5%, J61016, p. 382	
J61787	**TRIS, 0.5M buffer soln., pH 6.5** [77-86-1], Liquid, †	**500ml** **1L**
J63735	**TRIS, 0.5M buffer soln., pH 6.8** [77-86-1], Liquid, †	**500ml** **1L**
J61213	**TRIS, 0.5M buffer soln., pH 7.0** [77-86-1], Liquid, †	**500ml** **1L**
J61009	**TRIS, 0.5M buffer soln., pH 7.2** [77-86-1], Liquid, †	**500ml** **1L**
J62778	**TRIS, 0.5M buffer soln., pH 7.4** [77-86-1], Liquid, †	**500ml** **1L**
J61141	**TRIS, 0.5M buffer soln., pH 7.5** [77-86-1], Liquid, †	**500ml** **1L**
J62736	**TRIS, 0.5M buffer soln., pH 7.6** [77-86-1], Liquid, †	**500ml** **1L**
J61944	**TRIS, 0.5M buffer soln., pH 7.8** [77-86-1], Liquid, †	**500ml** **1L**
J62552	**TRIS, 0.5M buffer soln., pH 8.0** [77-86-1], Liquid, †	**500ml** **1L**
J62944	**TRIS, 0.5M buffer soln., pH 8.2** [77-86-1], Liquid, †	**500ml** **1L**
J61537	**TRIS, 0.5M buffer soln., pH 8.4** [77-86-1], Liquid, †	**500ml** **1L**
J62131	**TRIS, 0.5M buffer soln., pH 8.5** [77-86-1], Liquid, †	**500ml** **1L**
J62287	**TRIS, 0.5M buffer soln., pH 8.6** [77-86-1], Liquid, †	**500ml** **1L**

Stock #	Description	Size
J61144	**TRIS, 0.5M buffer soln., pH 8.8** [77-86-1], Liquid, †	**500ml** **1L**
J62551	**TRIS, 0.5M buffer soln., pH 9.0** [77-86-1], Liquid, †	**500ml** **1L**
J63134	**TRIS, 0.5M buffer soln., pH 9.5** [77-86-1], Liquid, †	**500ml** **1L**
J60381	**TRIS, 1.0M buffer soln., pH 6.5** [77-86-1], Liquid, †	**1L**
J62264	**TRIS, 1.0M buffer soln., pH 6.5, 0.2 micron filtered** [77-86-1], Liquid, †	**500ml**
J63831	**TRIS, 1.0M buffer soln., pH 6.8** [77-86-1], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**1L**
J62657	**TRIS, 1.0M buffer soln., pH 7.0** [77-86-1], Liquid, †	**1L**
J60822	**TRIS, 1.0M buffer soln., pH 7.0, 0.2 micron filtered** [77-86-1], Liquid, †	**500ml**
J62186	**TRIS, 1.0M buffer soln., pH 7.2** [77-86-1], Liquid, †	**1L**
J60202	**TRIS, 1.0M buffer soln., pH 7.4** [77-86-1], Liquid, †	**1L**
J60636	**TRIS, 1.0M buffer soln., pH 7.5** [77-86-1], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**1L**
J62993	**TRIS, 1.0M buffer soln., pH 7.5, 0.2 micron filtered** [77-86-1], Liquid, †	**500ml**
J61036	**TRIS, 1.0M buffer soln., pH 7.6** [77-86-1], Liquid, †	**1L**
J61579	**TRIS, 1.0M buffer soln., pH 7.8** [77-86-1], Liquid, †	**1L**
J62726	**TRIS, 1.0M buffer soln., pH 8.0** [77-86-1], Liquid, †	**1L**
J61429	**TRIS, 1.0M buffer soln., pH 8.0, 0.2 micron filtered** [77-86-1], Liquid, †	**500ml**
J61798	**TRIS, 1.0M buffer soln., pH 8.2** [77-86-1], Liquid, †	**1L**
J62577	**TRIS, 1.0M buffer soln., pH 8.4** [77-86-1], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**1L**
J61038	**TRIS, 1.0M buffer soln., pH 8.5, 0.2 micron filtered** [77-86-1], Liquid, †	**500ml**
J61066	**TRIS, 1.0M buffer soln., pH 8.6** [77-86-1], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**1L**
J60452	**TRIS, 1.0M buffer soln., pH 8.8** [77-86-1], Liquid, †	**1L**
J62085	**TRIS, 1.0M buffer soln., pH 9.0** [77-86-1], Liquid, †	**1L**
J60707	**TRIS, 1.0M buffer soln., pH 9.0, 0.2 micron filtered** [77-86-1], Liquid, † H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**500ml**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J62084	**TRIS, 1.0M buffer soln., pH 9.5** [77-86-1], Liquid, † ! H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	1L
	TRIS hydrochloride, see Tris(hydroxymethyl)aminomethane hydrochloride, A11379, p. 382	
J62560	**TRIS-acetate-SDS running buffer (10X), pH 8.3** Liquid, Note: 500mM Tris base, 500mM Tricine, 3.5mM SDS, pH 8.3. Application(s): Running buffer for TRIS-acetate gels	500ml 1L
J62664	**TRIS-buffered saline (TBS, 10X, high salt) pH 7.4** [77-86-1], Liquid, Note: Contains 250mM Tris, 5M NaCl, pH 7.4., †	500ml 1L 2L
J60102	**TRIS-buffered saline (TBS, 10X, low salt) pH 8.0** [77-86-1], Liquid, Note: 250mM Tris, 0.5M NaCl, pH8.0., †	1L 2L 4L
J62938	**TRIS-buffered saline (TBS, 10X) pH 7.4, for Western blot** [77-86-1], Liquid, Note: 250mM Tris, 1.5M NaCl, pH 7.4., † Application(s): For Western blot washing.	1L 2L 4L
J60764	**TRIS-buffered saline (TBS, 10X) pH 7.4** Liquid, Note: 250mM Tris, 27mM potassium chloride, 1.37M sodium chloride, pH 7.4., †	1L 2L 4L
J60877	**TRIS-buffered saline (TBS, 20X) pH 7.4** [77-86-1], Liquid, Note: Contains: 0.5M Tris, 54mM KCl, and 2.74M NaCl, pH 7.4, †	1L 2L
J62662	**TRIS-buffered saline (TBS, 10X) pH 7.6** [77-86-1], Liquid, Note: 250mM Tris, 27mM potassium chloride, 1.37M sodium chloride, pH 7.6., †	2L 4L
J62780	**TRIS-buffered saline (TBS, 10X) pH 8.0** [77-86-1], Liquid, Note: 250mM Tris, 27mM KCl, 1.37M NaCl, pH 8.0., †	1L 2L 4L
J63692	**TRIS-buffered saline (TBS, 5X), with EDTA** Liquid, Note: 125mM Tris, 14mM KCl, 0.68M NaCl, pH 7.4, with 50mM EDTA	1L 2L
J62533	**TRIS-buffered saline (TBS, 10X), with 1% Triton® X-100** Liquid, Note: 250mM Tris, 27mM KCl, 1.37M NaCl, pH 7.4 with 1% Triton X-100	500ml 1L
J60448	**TRIS-buffered saline (TBS, 10X), with 0.5% Tween 20** Liquid, Note: 250mM Tris, 27mM KCl, 1.37M NaCl, pH 7.4 with 0.5% Tween 20	500ml 1L 2L
J63682	**TRIS-buffered saline (TBS, 20X), with 0.5% Tween 20** Liquid	1L 2L
J62955	**TRIS-buffered saline (TBS, 10X), with 1% Tween 20** Liquid, Note: 250mM Tris, 27mM KCl, 1.37M NaCl, pH 7.4, with 1% Tween 20	500ml 1L 2L
J60497	**TRIS-buffered saline (TBS, 20X), with 1% Tween 20** Liquid, Note: 500mM Tris-HCl, 54mM KCl, 2.74M NaCl, pH 7.4 with 1% Tween-20	1L 2L
J61339	**TRIS-CAPS buffer (10X)** Liquid, Note: Contains: 0.6M Tris, and 0.4M CAPS. pH 9.6 Anode, pH 9.5 Cathode., † Application(s): For blot transfer	500ml 1L
	Tris(carboxymethyl)amine, see Nitrilotriacetic acid, 36515, p. 303	
J62914	**TRIS-glycine-native running buffer (10X), pH 8.5** Liquid, Note: 0.25M Tris base,1.92M glycine, pH 8.5. ! H:H319, P:P280-P264-P305+P351+P338-P337+P313	1L 2L 4L
J61006	**TRIS-glycine-SDS running buffer (10X), pH 8.3** Liquid, Note: 0.25M Tris base, 1.92M glycine, 1% SDS, pH 8.3., †	1L 2L 4L
J61864	**TRIS-glycine native sample buffer (4X), pH 8.6** Liquid, Note: 400mM Tris HCl (pH 8.6), 40% glycerol, 0.02% bromophenol blue. ! H:H319, P:P280-P264-P305+P351+P338-P337+P313 Application(s): For preparation of protein samples for native gel electrophoresis	25ml 50ml

Stock #	Description	Size
J62737	**TRIS-HEPES-native running buffer (10X), pH 8.0** Liquid, Note: 1M Tris base, 1M HEPES, pH 8.0.	**500ml** **1L** **2L**
J61789	**TRIS-HEPES-SDS running buffer (10X), pH 8.0** Liquid, Note: 1M Tris base, 1M HEPES, 30mM SDS, pH 8.0., † ! H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313	**500ml** **1L** **2L**
	Tris(2-hydroxyethyl)amine, see Triethanolamine, L04486, p. 376 **Tris(2-hydroxyethyl)amine hydrochloride**, see Triethanolamine hydrochloride, A15678, p. 376	
31801	**Tris(hydroxymethyl)aminomethane, ACS, 99.8-100.1% (Assay, dried basis)** ■ *[2-Amino-2-hydroxymethyl-1,3-propanediol, TRIS]* [77-86-1], $(HOCH_2)_3CNH_2$, F.W. 121.14, Crystalline, m.p. 171-172°, b.p. 219-220°/10mm, d. 1.353, Merck **14**,9772, EINECS 201-064-4, RTECS TY2900000, BRN 741883, MDL MFCD00004679, † Maximum level of impurities: Absorbance P.T., H_2O 2.0%, Insoluble matter 0.005%, Heavy Metals (as Pb) 5ppm, Fe 5ppm ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **250g** **1kg**
J61016	**Tris(hydroxymethyl)aminomethane, Electrophoresis Grade, 99.5%** *[TRIS]* [77-86-1], $C_4H_{11}NO_3$, F.W. 121.14, Crystalline powder, Merck **14**,9772, EINECS 201-064-4, RTECS TY2900000, BRN 741883, MDL MFCD00004679, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100g** **500g**
J62569	**Tris(hydroxymethyl)aminomethane, Electrophoresis Grade, 99.9%** *[TRIS]* [77-86-1], $C_4H_{11}NO_3$, F.W. 121.14, Crystalline powder, Merck **14**,9772, EINECS 201-064-4, RTECS TY2900000, BRN 741883, MDL MFCD00004679, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100g** **500g** **5kg**
J61062	**Tris(hydroxymethyl)aminomethane, Molecular Biology Grade, 99.9%** *[TRIS]* [77-86-1], $C_4H_{11}NO_3$, F.W. 121.14, Crystalline powder, Merck **14**,9772, EINECS 201-064-4, RTECS TY2900000, BRN 741883, MDL MFCD00004679, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100g** **500g**
J65594	**Tris(hydroxymethyl)aminomethane, ultrapure, 99.9%** ■ *[TRIS]* [77-86-1], $C_4H_{11}NO_3$, F.W. 121.14, Crystalline powder, m.p. 167-172°, b.p. 219-220°, d. 1.35, Merck **14**,9772, EINECS 201-064-4, RTECS TY2900000, BRN 741883, MDL MFCD00004679, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1kg** **5kg**
J63636	**Tris(hydroxymethyl)aminomethane hydrochloride, 1M stock soln, pH 8.0** *[TRIS-HCl]* [1185-53-1], Liquid	**1L**
J62848	**Tris(hydroxymethyl)aminomethane hydrochloride, 1M soln., pH 7,4, RNase free** *[TRIS-HCl]* [1185-53-1], Liquid, Note: 1M TRIS-HCl, †	**250ml**
J60080	**Tris(hydroxymethyl)aminomethane hydrochloride, 1M soln., pH 8.0, RNase free** *[Tris-HCl]* [1185-53-1], Liquid, Note: 1M TRIS-HCl, †	**250ml**
A11379	**Tris(hydroxymethyl)aminomethane hydrochloride, 99+%** ■ *[2-Amino-2-hydroxymethyl-1,3-propanediol hydrochloride, TRIS hydrochloride]* [1185-53-1], $(HOCH_2)_3CNH_2 \cdot HCl$, F.W. 157.60, m.p. ca 152° dec., EINECS 214-684-5, BRN 3675235, MDL MFCD00012590, † Biological buffer.	**50g** **250g** **1kg**
	Tris(hydroxymethyl)methylamine hydrochloride, see Tris(hydroxymethyl)aminomethane hydrochloride, A11379, p. 382 **N-[Tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid**, see TES, B21819, p. 360 **N-[Tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid sodium salt**, see TES sodium salt, J62706, p. 361 **3-[Tris(hydroxymethyl)methyl]amino-1-propanesulfonic acid**, see TAPS, A17754, p. 358 **N-(Trishydroxymethylmethyl)glycine**, see Tricine, A14695, p. 375	
36439	**Trisodium citrate dihydrate, ACS, 99.0% min** [6132-04-3], $Na_3C_6H_5O_7 \cdot 2H_2O$, F.W. 294.10 (258.07anhy), Crystalline, m.p. 150° -2H_2O, Merck **14**,8602, Solubility: Soluble in water. Insoluble in alcohol, EINECS 200-675-3, BRN 6104939, MDL MFCD00150031, † Maximum level of impurities: pH of a 5% solution 7.0-9.0 at 25°, Insoluble matter 0.005%, Cl 0.003%, SO_4 0.005%, NH_3 0.003%, Ca 0.005%, Heavy Metals (as Pb) 5ppm, Fe 5ppm Application(s): Sequestering agent, buffer, photography	**500g** **2kg**
	Trisodium phosphate, see Sodium phosphate, tribasic, 13438, p. 347 **Trisodium phosphate dodecahydrate**, see Sodium phosphate dodecahydrate, A15713, p. 347	

Stock #	Description	Size
J63948	**TRIS-Tricine-SDS kit (10X)** Liquid, Note: Contains one each of Tris anode buffer and Tris-Tricine-SDS cathode buffer for PAGE.	**500ml** **1L**
J63375	**TRIS-Tricine-SDS running buffer (10X), anode buffer, pH 8.9** Liquid, Note: 2M Tris-HCl, pH 8.9. H:H302-H319, P:P280-P264-P305+P351+P338-P301+P312-P337+P313-P501 Application(s): For TRIS-Tricine gel electrophoresis	**500ml** **1L**
J60992	**TRIS-Tricine-SDS running buffer (10X), cathode buffer, pH 8.3** Liquid, Note: 1M Tris base, 1M Tricine, 1% SDS, pH 8.3. Application(s): For TRIS-Tricine SDS gel electrophoresis	**500ml** **1L**
	TRITC, see 5(6)-Tetramethylrhodamine isothiocyanate, J62258, p. 365 **1,2,3-Tritetradecanoylglycerol**, see Trimyristin, 95%, J62819, p. 378 **Triton® B**, see Benzyltrimethylammonium hydroxide, A14927, p. 123	
A16046	**Triton® X-100** *[Octoxynol-9, Polyethylene glycol tert-octylphenyl ether]* [9002-93-1], F.W. ca. 625, m.p. ca 5°, b.p. >250°, f.p. 180°(356°F), d. 1.061, n_D^{20} 1.4900, Merck **14**,6761, RTECS MD0907600, MDL MFCD00132505, †  H:H302-H319-H412, P:P280d-P305+P351+P338-P337+P313 Nonionic detergent and emulsifier. Application(s): Detergent, equivalent to Nonidet P-40	**100ml** **500ml** **2.5L**
J62289	**Triton® X-100 lysis buffer, pH 7.4** Liquid, Note: Contains 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1% Triton X-100, and 5mM EDTA., †	**250ml** **500ml**
J63653	**Triton® X-100 lysis buffer (2X), pH 7.4** Liquid, Note: 100mM Tris-HCl (pH 7.4), 300mM NaCl, 2% Triton X-100, 10mM EDTA.	**125ml** **250ml**
J62526	**Triton® X-100 lysis buffer-2, pH 8.0** Liquid, Note: 50mM Tris-HCl (pH 8.0), 150mM NaCl, 1% Triton X-100, 5mM EDTA., †	**250ml** **500ml**
J63866	**Triton® X-100 lysis buffer with glycerol (2X), pH 7.4** Liquid, Note: Contains 100mM Tris-HCl (pH 7.4), 300mM NaCl, 2% Triton X-100, 10mM EDTA, and 10% glycerol.	**125ml** **250ml**
	Nε-Trityl-Nβ-Fmoc-L-homoglutamine, see L-3-(Fmoc-amino)-N-trityladipic acid 6-amide, H52195, p. 225	
L09095	**N-Tritylglycine, 97%** *[N-(Triphenylmethyl)glycine, Trt-Gly-OH]* [5893-05-0], $(C_6H_5)_3CNHCH_2CO_2H$, F.W. 317.39, m.p. 170-174° dec., BRN 1998718, MDL MFCD00004276	**5g** **25g** **100g**
J64810	**TrkA Inhibitor ▲** *[(Z)-4-(((2-Oxoindolin-3-ylidene)methyl)amino)benzenesulfonamide]* [388626-12-8], $C_{15}H_{13}N_3O_3S$, F.W. 315.40, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1mg** **5mg**
	Tromethamine hydrochloride, see Tris(hydroxymethyl)aminomethane hydrochloride, A11379, p. 382	
J62583	**3-Tropanyl-3,5-dichlorobenzoate, 99+%** *[MDL-72222, Bemesetron]* [40796-97-2], $C_{15}H_{17}Cl_2NO_2$, F.W. 314.21, Powder, RTECS DG7580000 Application(s): 5-HT3 serotonin antagonist	**50mg**
J62807	**3-Tropanylindole-3-carboxylate hydrochloride** *[Tropisetron hydrochloride]* [105826-92-4], $C_{17}H_{20}N_2O_2$·HCl, F.W. 320.82, Powder, Merck **14**,9783, MDL MFCD00210221 Application(s): A selective 5-HT3 serotonin receptor antagonist	**100mg** **1g**
B22040	**DL-Tropic acid, 99%** *[DL-3-Hydroxy-2-phenylpropionic acid]* [552-63-6], $C_9H_{10}O_3$, F.W. 166.18, m.p. 117-119°, Merck **14**,9779, EINECS 208-465-3, BRN 2209199, MDL MFCD00004255, † 	**10g** **50g**
J61132	**Tropicamide, 99+%** *[N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide, Ro 1-7683]* [1508-75-4], $C_{17}H_{20}N_2O_2$, F.W. 284.35, Powder, m.p. 98°, Merck **14**,9780, EINECS 216-140-2, RTECS CY1487860, MDL MFCD00058580 H:H302-H312-H332-H315-H319-H334-H317-H335, P:P285-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): A muscarinic antagonist	**1g**
J64677	**Tropine DL-tropate, 99% ▲** *[DL-Hyoscyamine, Atropine]* [51-55-8], $C_{17}H_{23}NO_3$, F.W. 289.37, Powder, Merck **14**,875, UN1544, EINECS 200-104-8, RTECS CK0700000, BRN 91260, MDL MFCD00022622, † H:H300-H330, P:P301+P310-P304+P340-P320-P330-P405-P501 Application(s): Reduces brain levels of acetylcholine	**1g** **5g** **25g**

Stock #	Description	Size
	Tropisetron hydrochloride, see 3-Tropanylindole-3-carboxylate hydrochloride, J62807, p. 383	
A11299	**Tropolone, 98%** ■ *[2-Hydroxy-2,4,6-cycloheptatrien-1-one]* [533-75-5], $C_7H_6O_2$, F.W. 122.12, m.p. 50-55°, b.p. 115°/12mm, f.p. >110°(230°F), EINECS 208-577-2, RTECS GU4075000, BRN 1904978, MDL MFCD00004158 Reagent for Rh: *Mikrochim. Acta,* 459 (1972). Non-benzenoid aromatic system, analogous to phenol. For a review of 7-membered conjugated cyclic systems, see: *Chem. Rev.*, **73**, 293 (1973). For a study of the role of chelation and resonance in the intrinsic acidity and basicity of tropolone, see: *J. Org. Chem.*, **62**, 3200 (1997).  Application(s): A non-benzenoid aromatic compound	**1g** **5g** **25g**
A18600	**Trypan Blue, dye content >60%** *[C.I. 23850, Direct Blue 14]* [72-57-1], $C_{34}H_{24}N_6Na_4O_{14}S_4$, F.W. 960.82, m.p. >300°, Merck **14**,9792, EINECS 200-786-7, RTECS QJ6475000, MDL MFCD00003969, †  H:H350-H361, P:P281-P201-P202-P308+P313-P405-P501a Application(s): Used in dye exclusion studies in cell culture	**25g** **100g** **500g**
J63688	**Trypsin, bovine pancreas** *[EC 3.4.21.4, Peptidyl peptide hydrolase]* [9002-07-7], Powder, Merck **14**,9795, EINECS 232-650-8, RTECS YN5075000, MDL MFCD00082094, Note: Minimum 2500 USP units/mg. One unit causes a decrease in absorbance at 253nm of 0.003 per minute at 25 C., † H:H334-H335-H315-H319, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A pancreatic serine protease	**1g** **10g**
J63993	**Trypsin 1:250, porcine pancreas** *[EC 3.4.21.4]* [9002-07-7], Powder, Merck **14**,9795, EINECS 232-650-8, RTECS YN5075000, Note: Low endotoxin. Minimum 225 units/mg. One unit causes a decrease in absorbance at 253 nm of 0.003 per minute at 25C., † H:H334-H335-H315-H319, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A pancreatic serine protease	**10g** **50g**
J60402	**Trypsin, porcine pancreas** *[EC 3.4.21.4, Trypsin IV porcine]* [9002-07-7], Lyophilized Powder, 23.8 kDa, Merck **14**,9795, EINECS 232-650-8, RTECS YN5075000, MDL MFCD00082094, Note: Minimum 250 units/mg. One unit causes a decrease in absorbance at 253nm of 0.003 per minute at 25C., † H:H334-H335-H315-H319, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A pancreatic serine protease	**10g** **50g**
J63927	**Trypsin inhibitor, chicken egg whites** *[Trypsin inhibitor, ovomucoid]* [9035-81-8], Powder, EINECS 232-906-9, MDL MFCD00082102 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501 Application(s): Inhibits the pancreatic enzyme trypsin	**500mg** **1g** **2g**
J60982	**Trypsin inhibitor, soybeans** [9035-81-8], Powder, EINECS 232-906-9, MDL MFCD00082103 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501a Application(s): Inhibits the pancreatic enzyme trypsin	**100mg** **1g**
L05936	**DL-Tryptophan, 99%** *[(+/-)-2-Amino-3-(3-indolyl)propionic acid, H-DL-Trp-OH]* [54-12-6], $C_{11}H_{12}N_2O_2$, F.W. 204.23, m.p. ca 280° dec., EINECS 200-194-9, RTECS YN6129200, BRN 86196, MDL MFCD00064339, † 	**5g** **25g** **100g**
A18426	**D-Tryptophan, 99%** *[(R)-2-Amino-3-(3-indolyl)propionic acid, H-D-Trp-OH]* [153-94-6], $C_{11}H_{12}N_2O_2$, F.W. 204.23, m.p. 273° dec., $[\alpha]_D^{20}$ +31.5° (c=1 in water), EINECS 205-819-9, RTECS YN6129000, BRN 86198, MDL MFCD00005647, † 	**5g** **25g** **100g**
A10230	**L-Tryptophan, 99%** *[(S)-2-Amino-3-(3-indolyl)propionic acid, H-Trp-OH]* [73-22-3], $C_{11}H_{12}N_2O_2$, F.W. 204.23, m.p. 280° 285°, $[\alpha]_D^{20}$ -31.5° (c=1 in water), Merck **14**,9797, EINECS 200-795-6, RTECS YN6130000, BRN 86197, MDL MFCD00064340, † 	**25g** **100g** **500g**
J62508	**L-Tryptophan, Cell Culture Reagent** [73-22-3], $C_{11}H_{12}N_2O_2$, F.W. 204.23, Powder, m.p. 280-285°, Merck **14**,9797, EINECS 200-795-6, RTECS YN6130000, BRN 86197, MDL MFCD00064340, †	**10g** **100g** **1kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
L02555	**Tryptophol, 97%** *[3-(2-Hydroxyethyl)indole, 2-(3-Indolyl)ethanol]* [526-55-6], $C_{10}H_{11}NO$, F.W. 161.20, m.p. 56-59°, b.p. 174°/2mm, f.p. 255°(491°F), Merck **14**,9798, EINECS 208-393-2, RTECS KL3685000, BRN 125553, MDL MFCD00005659, † 	**1g** **5g**
J62318	**TSS (Transformation & Storage Soln.), pH 6.5** Liquid, Note: Contains 85% LB medium, 10% (w/v) PEG MW 8000, 5% (v/v) DMSO, 50mM magnesium chloride , pH 6.5, sterile filtered. Application(s): Enables preparation of competent E. coli in a single step and allows transformation of cells without heat-shock	**125ml** **250ml**
	TTC, see 2,3,5-Triphenyl-2H-tetrazolium chloride, A10870, p. 379	
J60222	**D-Tubocurarine chloride** △ [57-94-3], $C_{37}H_{41}ClN_2O_6 \cdot HCl$, F.W. 681.65, Powder, Merck **14**,9807, UN1544, EINECS 200-356-9 H:H300, P:P264-P270-P301+P310-P321-P405-P501a Application(s): Competitive, non-selective nicotinic acetylcholine receptor antagonist	**10mg** **50mg**
J63904	**Tuftsin, 96%** *[Thr-Lys-Pro-Arg]* [72103-53-8], $C_{21}H_{40}N_8O_6$, F.W. 500.60, Powder Application(s): An immunomodulating peptide	**5mg**
	Tuftsin (1-3), see Macrophage Inhibitory Peptide, J63844, p. 274	
J63975	**Tulobuterol** [41570-61-0], $C_{12}H_{18}ClNO$, F.W. 227.73, White to off-white crystalline powder, m.p. 159-163°, Merck **14**,9811, RTECS DA4734170 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): β-2-adrenergic receptor agonist	**1g** **5g**
J61448	**Tulobuterol hydrochloride, 98%** ■ [56776-01-3], $C_{12}H_{18}ClNO \cdot HCl$, F.W. 264.19, Powder, m.p. 159-163°, Merck **14**,9811, RTECS DN8785000, MDL MFCD00214398 H:H302, P:P264-P270-P301+P312-P330-P501a Application(s): β-2-adrenergic receptor agonist	**1g** **5g**
J62217	**Tunicamycin, 95%** ▲◪ [11089-65-9], $C_{39}H_{64}N_4O_{16}$, F.W. 844.95, Powder, Merck **14**,9819, UN3462, RTECS YO7980200, BRN 6888090, MDL MFCD00065709 H:H300-H330-H373, P:P301+P310-P304+P340-P320-P330-P405-P501a Application(s): A mixture of homologous nucleoside antibiotics	**10mg**
B21224	**D-Turanose, 98%** *[3-O-α-D-glucopyranosyl-D-fructose]* [547-25-1], $C_{12}H_{22}O_{11}$, F.W. 342.30, m.p. ca 170° dec., Merck **14**,9821, EINECS 208-918-5, BRN 93771, MDL MFCD00006606, † Application(s): Sucrose analog not metabolized by higher plants. Carbon source for fungi and bacteria 	**1g** **5g**
	Tween®, see Polysorbate, L15029, p. 325	
J61544	**Tween 20 blocking buffer, 1% in PBS (10X)** Liquid	**500ml** **1L** **2L**
J60304	**Tween 20 blocking buffer, 0.5% in PBS (10X)** Liquid	**500ml** **1L** **2L**
J63314	**Tween 20 washing buffer, 1% in PBS (10X)** Liquid	**500ml** **1L** **2L**
J63596	**Tween 20 washing buffer, 0.5% in PBS (10X)** Liquid	**500ml** **1L** **2L**
J61419	**Tween 20 washing buffer, 1% in PBS (20X)** Liquid	**1L** **2L**
J62844	**Tween 20 washing buffer, 0.5% in PBS (20X)** Liquid	**1L** **2L**

Stock #	Description	Size
J62633	**Tylosin tartrate, 98+%** *[Pharmasin, (R-(R'R'))-2,3-dihydroxybutanedionate Tylosin (salt)]* [1405-54-5], $C_{46}H_{77}NO_{17}.C_4H_6O_6$, F.W. 1066.20, Powder, EINECS 215-781-5 H:H334-H317, P:P285-P261-P280-P302+P352-P321-P501 Application(s): Macrolide antibiotic	**1g** **5g** **10g**
	H-L-Tyr-OH, see L-Tyrosine, Cell Culture Reagent, J63511, p. 386	
J60990	**Tyramine, 98+%** *[2-(4-Hydroxyphenyl)ethlamine, 4-(2-Aminoethyl)phenol]* [51-67-2], $C_8H_{11}NO$, F.W. 137.18, Powder, m.p. 160-162°, b.p. 175-181°, Merck **14**,9835, EINECS 200-115-8, RTECS SJ5950000, BRN 1099914, MDL MFCD00008193 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Reagent for fluorescence enzyme immunoassay	**1g** **5g** **25g**
A12220	**Tyramine hydrochloride, 98%** *[4-Hydroxyphenethylamine hydrochloride, 2-(4-Hydroxyphenyl)ethylamine hydrochloride]* [60-19-5], $C_8H_{11}NO{\cdot}HCl$, F.W. 173.65, m.p. 271-274°, Merck **14**,9835, EINECS 200-462-5, RTECS SJ6050000, BRN 3627058, MDL MFCD00012901, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Reagent for fluorescence enzyme immunoassay	**5g** **25g** **100g**
A13740	**DL-Tyrosine, 98%** *[3-(4-Hydroxyphenyl)-DL-alanine, H-DL-Tyr-OH]* [556-03-6], $C_9H_{11}NO_3$, F.W. 181.19, m.p. ca 325° dec., Merck **14**,9839, EINECS 209-113-1, BRN 515881, MDL MFCD00063074, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**10g** **50g** **250g**
A17709	**D-Tyrosine, 99%** *[3-(4-Hydroxyphenyl)-D-alanine, H-D-Tyr-OH]* [556-02-5], $C_9H_{11}NO_3$, F.W. 181.19, m.p. 310-314°, $[\alpha]_D^{20}$ +11° (c=4 in 1N HCl), Merck **14**,9839, EINECS 209-112-6, BRN 2212157, MDL MFCD00063073, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
A11141	**L-Tyrosine, 99%** *[3-(4-Hydroxyphenyl)-L-alanine, H-Tyr-OH]* [60-18-4], $C_9H_{11}NO_3$, F.W. 181.19, m.p. >300°, d. 1.46, $[\alpha]_D^{20}$ -11° (c=4 in 1N HCl), Merck **14**,9839, EINECS 200-460-4, RTECS YP2275600, BRN 392441, MDL MFCD00002606, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**50g** **100g** **250g** **1kg**
J63511	**L-Tyrosine, Cell Culture Reagent** *[H-L-Tyr-OH]* [60-18-4], $C_9H_{11}NO_3$, F.W. 181.19, Powder, m.p. >300°, Merck **14**,9839, EINECS 200-460-4, RTECS YP2275600, BRN 392441, MDL MFCD00002606, †	**10g** **100g** **500g** **1kg**
J61770	**L-Tyrosine disodium salt dihydrate, 99%** [122666-87-9], $C_9H_9NNa_2O_3{\cdot}2H_2O$, F.W. 265.47 (225.15anhy), Powder H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**100g** **500g** **1kg**
J63058	**Tyrphostin A9, 99%** *[Tyrphostin AG-17, Malonoben]* [10537-47-0], $C_{18}H_{22}N_2O$, F.W. 282.39, Powder, UN2811, RTECS OO3737000, MDL MFCD00209853 H:H301-H311-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Selective inhibitor of PDGF receptor tyrosine kinase	**50mg** **100mg**
J60308	**Tyrphostin A23, 99%** *[Tyrphostin AG-18, 2-(3,4-Dihydroxybenzylidene)malononitrile]* [118409-57-7], $C_{10}H_6N_2O_2$, F.W. 186.17, Powder, MDL MFCD00133899 Application(s): Potent inhibitor of EGF receptor kinase activity	**5mg** **10mg** **25mg**
J62936	**Tyrphostin A25, 99+%** *[Tyrphostin AG-82, 2-(3,4,5-Trihydroxybenzylidene)malononitrile]* [118409-58-8], $C_{10}H_6N_2O_3$, F.W. 202.14, Crystalline powder, m.p. 245° Application(s): Potent inhibitor of EGF receptor kinase activity	**5mg** **10mg** **25mg**
J60482	**Tyrphostin A46, 99%** *[Tyrphostin AG-99, (E)-2-Cyano-3-(3,4-dihydroxyphenyl)-2-propenamide]* [122520-85-8], $C_{10}H_8N_2O_3$, F.W. 204.19, Powder Application(s): Inhibitor of EGF receptor kinase activity	**5mg** **10mg** **25mg**
	Tyrphostin AG-17, see Tyrphostin A9, 99%, J63058, p. 386 **Tyrphostin AG-18**, see Tyrphostin A23, 99%, J60308, p. 386 **Tyrphostin AG-82**, see Tyrphostin A25, 99+%, J62936, p. 386 **Tyrphostin AG-99**, see Tyrphostin A46, 99%, J60482, p. 386 **Tyrphostin AG-370**, see Tyrphostin B7, 95%, cis + trans, J63126, p. 387	

Contact us for pricing on bulk sizes

Stock #	Description	Size
	Tyrphostin AG-490, see Tyrphostin B42, 99+%, J61715, p. 387	
J65263	**Tyrphostin AG 537** ▲ *[Bis-Tyrphostin]* $C_{23}H_{20}N_4O_6$, F.W. 448.43, Powder	**10mg** **100mg**
	Tyrphostin AG-555, see Tyrphostin B46, 99+%, J61704, p. 387 **Tyrphostin AG 879**, see AG-879, 99%, J62625, p. 81	
J63126	**Tyrphostin B7, 95%, cis + trans** *[Tyrphostin AG-370, 2-Amino-4-(5-indolyl)-1,1,3-tricyanobuta-1,3-diene]* [134036-53-6], $C_{15}H_9N_5$, F.W. 259.27, Powder, MDL MFCD00236449 Application(s): A protein kinase inhibitor	**1mg** **5mg** **10mg**
J61715	**Tyrphostin B42, 99+%** *[Tyrphostin AG-490, N-Benzyl-2-(3,4-dihydroxybenzylidene)cyanoacetamide]* [134036-52-5], $C_{17}H_{14}N_2O_3$, F.W. 294.31, Powder, MDL MFCD00236452 Application(s): A protein kinase inhibitor	**25mg** **100mg**
J61704	**Tyrphostin B46, 98+%** *[Tyrphostin AG-555, (E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)-2-propenamide]* [133550-34-2], $C_{19}H_{18}N_2O_3$, F.W. 322.36, Powder, MDL MFCD00209865 Application(s): Inhibitor of EGF receptor kinase activity	**10mg** **50mg**
J65227	**Tyrphostin C15** ▲ *[AG 825, Tyrphostin AG-825]* [149092-50-2], $C_{19}H_{15}N_3O_3S_2$, F.W. 397.47, Powder, MDL MFCD01074971	**10mg**
J61246	**U0126, 99+%** *[1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene]* [109511-58-2], $C_{18}H_{16}N_6S_2$, F.W. 380.49, Powder Application(s): Selective inhibitor of mitogen-activated protein kinases MEK-1 and MEK-2	**25mg** **100mg** **300mg**
	U-9889, see Streptozotocin, 98%, J61601, p. 352 **U-22324**, see Alamethicin, J63829, p. 82 **U-29135**, see Geldanamycin, 99+%, J63397, p. 231 **U-63557A**, see Furegrelate sodium salt, 99+%, J61378, p. 229	
J62898	**U-73122, 99+%** *[1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]pyrrole-2,5-dione]* [112648-68-7], $C_{29}H_{40}N_2O_3$, F.W. 464.65, Crystalline solid ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inhibitor of phospholipase C activation and inhibits the down regulation of muscarinic receptors	**1mg** **5mg** **10mg**
J62719	**U-73343, 98%** *[1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]pyrrolidine-2,5-dione]* [142878-12-4], $C_{29}H_{42}N_2O_3$, F.W. 466.66, Powder, m.p. 136-138°, MDL MFCD00211221 ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Inactive analog of U-73122	**5mg** **25mg**
	Ubenimex, see Bestatin, J61106, p. 124	
J65388	**Ubiquitin E1 Inhibitor, PYR-41** ▲ *[Ubiquitin-Activating Enzyme E1 Inhibitor, PYR-41]* [418805-02-4], $C_{17}H_{13}N_3O_7 \cdot 3H_2O$, F.W. 425.40, Solid ! H:H302-H317, P:P261-P280-P302+P352-P321-P301+P312-P501	**25mg** **100mg**
	UCN-1028c, see Calphostin C, 99+%, J60647, p. 144 **UDP sodium salt**, see Uridine-5'-diphosphate sodium salt, 98+%, J60141, p. 389 **UK-48340**, see Amlodipine, 98+%, J62242, p. 100	
A16101	**Undecanal, 97%** △ *[n-Undecyl aldehyde, Undecylic aldehyde]* [112-44-7], $CH_3(CH_2)_9CHO$, F.W. 170.30, m.p. -2°, b.p. 110-112°/12mm, f.p. 95°(203°F), d. 0.827, n_D^{20} 1.4340, EINECS 203-972-6, RTECS YQ1500000, BRN 1753213, MDL MFCD00007016, † H:H227, P:P210-P280-P370+P378a-P403+P235-P501a	**25g** **100g**
A11244	**Undecanoic acid, 98%** [112-37-8], $CH_3(CH_2)_9CO_2H$, F.W. 186.30, m.p. 26-29°, b.p. 283-285°, f.p. >110°(230°F), EINECS 203-964-2, RTECS YQ2275000, BRN 1759287, MDL MFCD00002730, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): An unsaturated fatty acid	**50g** **250g** **1kg**
A17817	**1-Undecanol, 98%** *[n-Undecyl alcohol, 1-Hydroxyundecane]* [112-42-5], $CH_3(CH_2)_{10}OH$, F.W. 172.31, m.p. 13-15°, b.p. 243°, f.p. 113°(235°F), d. 0.831, n_D^{20} 1.4400, UN3082, EINECS 203-970-5, RTECS YQ3155000, BRN 1698334, MDL MFCD00004751, † ! H:H315-H319-H411, P:P280g-P273-P305+P351+P338	**100g** **500g**

Stock #	Description	Size
A19122	**10-Undecenoic acid, 99%** *[Undecylenic acid]* [112-38-9], $C_{11}H_{20}O_2$, F.W. 184.28, m.p. 22-25°, b.p. 126-128°/1mm, f.p. 160°(320°F), d. 0.910, n_D^{20} 1.4493, Merck **14**,9848, EINECS 203-965-8, RTECS YQ2975000, BRN 1762631, MDL MFCD00004442, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**250g** **1kg**
	n-Undecyl alcohol, see 1-Undecanol, A17817, p. 387 **n-Undecyl aldehyde**, see Undecanal, A16101, p. 387 **Undecylenic acid**, see 10-Undecenoic acid, A19122, p. 388 **Undecylic aldehyde**, see Undecanal, A16101, p. 387	
J64874	**uPA Inhibitor II, UK122 ▲** $C_{17}H_{13}N_3O_2.CF_3CO_2H$, F.W. 405.30, Solid	**5mg** **25mg**
A15570	**Uracil, 99+%** *[2,4-Dihydroxypyrimidine]* [66-22-8], $C_4H_4N_2O_2$, F.W. 112.09, m.p. ca 330°, Merck **14**,9850, EINECS 200-621-9, RTECS YQ8650000, BRN 606623, MDL MFCD00006016, † For a review of the use of uracils as starting materials in heterocyclic synthesis, see: *Adv. Het. Chem.*, **55**, 130 (1992).	**50g** **250g** **1kg**
	Uracil-4-carboxylic acid hydrate, see Orotic acid hydrate, A18594, p. 309 **Uracil deoxyriboside**, see 2'-Deoxyuridine, A16026, p. 180	
J63219	**Urapidil hydrochloride, 98+%** *[6-(3-[4-(2-Methoxypenyl)-1-piperaziny]propylamino)-1,3-dimethyluracil hydrochloride]* [64887-14-5], $C_{20}H_{29}N_5O_3 \cdot HCl$, F.W. 423.93, Powder, RTECS YQ9862000, MDL MFCD00078601 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): α-1-Adrenoceptor antagonist and 5-HT1A receptor agonist	**500mg** **1g** **5g**
A12360	**Urea, 98+%** *[Carbamide]* [57-13-6], NH_2CONH_2, F.W. 60.06, m.p. 130-135°, d. 1.335, Merck **14**,9867, Fieser **1**,1262 **2**,455, EINECS 200-315-5, RTECS YR6250000, BRN 635724, MDL MFCD00008022, † Widely used in diazotization reactions for the destruction of excess HNO_2. For the one-pot conversion of carboxylic acids to nitriles, by heating with urea in the presence of 1.5-2.0 moles of sulfamic acid, see: *Chimia*, **25**, 94 (1971). For a procedure for conversion of carboxylic acids to primary amides by heating with urea, see: *Org. Synth. Coll.*, **3**, 768 (1955); **4**, 513 (1963). Reacts with alcohols on prolonged heating to give alkyl carbamates; see, e.g.: *Org. Synth. Coll.*, **1**, 140 (1941). Application(s): Used as a protein denaturant	**500g** **2.5kg** **10kg**
36428	**Urea, ACS, 99.0-100.5%** *[Carbamide]* [57-13-6], NH_2CONH_2, F.W. 60.06, Crystalline, m.p. 132-135°, d. 1.335, Merck **14**,9867, Fieser **1**,1262 **2**,455, Solubility: Soluble in water, alcohol, methanol, glycerol, benzene, and conc. HCl. Practically insoluble in chloroform, ether, EINECS 200-315-5, RTECS YR6250000, BRN 635724, MDL MFCD00008022, † Maximum level of impurities: Insoluble matter 0.01%, Residue after ignition 0.01%, Cl 5ppm, SO_4 0.001%, Heavy Metals (as Pb) 0.001%, Fe 0.001%, Melting point 132-135° Application(s): Used as a protein denaturant	**100g** **500g** **2kg**
J64769	**Urea, Molecular Biology Grade** *[Carbamide]* [57-13-6], NH_2CONH_2, F.W. 60.06, Powder, m.p. 132-134°, d. 1.34, EINECS 200-315-5, RTECS YR6250000, BRN 635724, MDL MFCD00008022, † Application(s): A protein denaturant	**500g** **1kg** **2.5kg**
J65769	**Urea, ultrapure, 99%** *[Carbamide]* [57-13-6], NH_2CONH_2, F.W. 60.06, Crystalline, m.p. 132-135°, d. 1.335, Merck **14**,9867, EINECS 200-315-5, RTECS YR6250000, BRN 635724, MDL MFCD00008022, †	**100g** **500g** **2.5kg**
J60844	**Urea, 8M buffer soln., pH 7.5** Liquid	**250ml** **500ml**
	Urea amidohydrolase, see Urease, Jack Beans, J61455, p. 388	
J61455	**Urease, Jack Beans** *[EC 3.5.1.5, Urea amidohydrolase]* [9002-13-5], Lyophilized powder, 480 kDa, Merck **14**,9870, EINECS 232-656-0, RTECS YU1700000, MDL MFCD00070858, Note: Min 45 units/mg dry wt. One unit oxidizes one micromole of NADH per minute at 25 C and pH 7.6. The hydrolysis of urea is measured by coupling ammonia production to a glutamate dehydrogenase reaction., † H:H334-H335-H315-H319, P:P285-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Catalyzes hydrolysis of urea	**250mg** **1g** **10g**
	5-Ureidohydantoin, see Allantoin, A15571, p. 89	

Stock #	Description	Size
A13346	**Uric acid, 99%** [69-93-2], $C_5H_4N_4O_3$, F.W. 168.11, m.p. >300°, d. 1.89, Merck **14**,9875, EINECS 200-720-7, RTECS YU7050080, BRN 156158, MDL MFCD00005712, † 	**25g** **100g** **500g**
J60875	**Uricase, Candida utilis** *[EC 1.7.3.3]* [9002-12-4], Lyophilized powder, Merck **14**,9876, EINECS 232-655-5, MDL MFCD00082126, Note: Minimum 2 units per mg dry weight. One unit oxidizes one micromole of uric acid per minute Application(s): Oxidizes uric acid	**100units**
A15227	**Uridine, 99%** [58-96-8], $C_9H_{12}N_2O_6$, F.W. 244.20, m.p. 166-169°, $[\alpha]_D^{20}$ +9.5° (c=2 in water), Merck **14**,9877, EINECS 200-407-5, RTECS YR1450000, BRN 754904, MDL MFCD00006526, † 	**5g** **25g** **100g**
J64329	**Uridine-5'-diphosphate disodium salt, 98%** ◢ [27821-45-0], $C_9H_{12}N_2Na_2O_{12}P_2$, F.W. 448.13, Powder, EINECS 248-678-9, BRN 8817400, MDL MFCD00149253 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**1g** **5g**
J60141	**Uridine-5'-diphosphate sodium salt, 98+%** *[UDP sodium salt]* [21931-53-3], $C_9H_{12}N_2Na_2O_{12}P_2$, F.W. 448.12, Powder H:H302-H371, P:P260-P264-P309+P311-P301+P312-P405-P501	**100mg** **500mg**
A18601	**Uridine-5'-monophosphate disodium salt, 99%** *[5'-Uridylic acid disodium salt]* [3387-36-8], $C_9H_{11}N_2Na_2O_9P$, F.W. 368.15, m.p. ca 209° dec., EINECS 222-211-9, RTECS YU7975000, BRN 3582885, MDL MFCD00006525 	**5g** **25g** **100g**
J63427	**Uridine-5'-triphosphate trisodium salt, 98+%** *[UTP-Na3]* [19817-92-6], $C_9H_{12}N_2Na_3O_{15}P_3$, F.W. 550.09, Powder, EINECS 243-347-5, BRN 3585234, MDL MFCD00044310 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**100mg** **250mg**
	5'-Uridylic acid disodium salt, see Uridine-5'-monophosphate disodium salt, A18601, p. 389	
J64679	**cis-Urocanic acid** ▲ *[cis-3-(1H-Imidazol-4-yl)-2-propenoic acid, cis-UCA]* [7699-35-6], $C_6H_6N_2O_2$, F.W. 138.12, Solid, MDL MFCD11045310	**10mg** **100mg**
J65601	**Uroguanylin, human** *[Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr- Gly-Cys-Leu (disulfide bridges: Cys4-Cys12, Cys7-Cys15)]* $C_{64}H_{102}N_{18}O_{26}S_4$, F.W. 1667.86, Solid	**1mg**
J60553	**Urokinase, human urine** *[EC 3.4.21.73]* [9039-53-6], Lyophilized powder, 54 kDa, Merck **14**,9887, EINECS 232-917-9, RTECS OB8900000, MDL MFCD00132566, Note: 83,700IU/mg. 1nM UK will cause a change in absorbance of 0.001 at 405nm in 1 minute at R/T in 100 ul 0.05M Tris-HCl, 0.1M NaCl, pH 7.4, using S2444 (0.6mM) as the substrate, † Application(s): A serine protease; biological plasminogen activator	**100micrograms** **1mg** **5mg**
B20490	**Ursodeoxycholic acid, 99%** [128-13-2], $C_{24}H_{40}O_4$, F.W. 392.56, m.p. 201-204°, Merck **14**,9889, EINECS 204-879-3, RTECS FZ2000000, MDL MFCD00003680 H:H303, P:P312 Application(s): A secondary bile acid 	**1g** **5g** **25g**
H56612	**(+)-Usnic acid, 98%** *[2,6-Diacetyl-7,9-dihydroxy-8,9b-dimethyldibenzofuran-1,3(2H,9bH)-dione]* [7562-61-0], $C_{18}H_{16}O_7$, F.W. 344.32, m.p. 201-203°, EINECS 231-456-0, RTECS HP5295050, BRN 96698, MDL MFCD00016878 	**5g** **25g**
	UTP-Na3 , see Uridine-5'-triphosphate trisodium salt, 98+%, J63427, p. 389	

Stock #	Description	Size
	H-L-Val-OH, see L-Valine, Cell Culture Reagent, J62943, p. 390	
A10525	**Valerophenone, 99%** *[n-Butyl phenyl ketone, Pentanophenone]* [1009-14-9], $C_{11}H_{14}O$, F.W. 162.23, m.p. -9°, b.p. 244-245°, f.p. 102°(215°F), d. 0.978, n_D^{20} 1.5143, EINECS 213-767-3, BRN 1907717, MDL MFCD00009480, † 	**25g** **100g** **500g**
J62622	**Valethamate bromide, 99%** *[Epidosin, N,N-Diethyl-N-methyl-2-([3-methyl-1-oxo-2-phenylpentyl]oxy)ethanammonium bromide]* [90-22-2], $C_{19}H_{32}BrNO_2$, F.W. 386.37, Powder, m.p. 120-127°, Merck **14**,9906, EINECS 201-977-8, RTECS BP7600000, MDL MFCD00031617 ! H:H302-H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a	**5g** **25g**
A16756	**DL-Valine, 99%** *[DL-2-Aminoisovaleric acid, (+/-)-2-Amino-3-methylbutyric acid]* [516-06-3], $C_5H_{11}NO_2$, F.W. 117.15, m.p. ca 296° subl., Merck **14**,9909, EINECS 208-220-0, BRN 506689, MDL MFCD00004267, † 	**100g** **500g** **2.5kg**
A18894	**D-Valine, 98+%** *[D-2-Aminoisovaleric acid, (R)-(-)-2-Amino-3-methylbutyric acid]* [640-68-6], $C_5H_{11}NO_2$, F.W. 117.15, m.p. 295° dec., $[\alpha]_D^{20}$ -27° (c=5 in 5N HCl), EINECS 211-368-9, RTECS YV9360000, BRN 1721135, MDL MFCD00064219, † 	**5g** **25g** **100g**
A12720	**L-Valine, 99%** *[L-2-Aminoisovaleric acid, (S)-(+)-2-Amino-3-methylbutyric acid]* [72-18-4], $C_5H_{11}NO_2$, F.W. 117.15, m.p. ca 315°, d. 1.23, $[\alpha]_D^{20}$ +27° (c=5 in 5N HCl), Merck **14**,9909, EINECS 200-773-6, RTECS YV9361000, BRN 1721136, MDL MFCD00064220, † 	**25g** **100g** **500g**
J62943	**L-Valine, Cell Culture Reagent** *[H-L-Val-OH]* [72-18-4], $C_5H_{11}NO_2$, F.W. 117.15, Powder, Merck **14**,9909, EINECS 200-773-6, RTECS YV9361000, BRN 1721136, MDL MFCD00064220, †	**1g** **5g** **25g** **100g** **1kg**
L14166	**D-(-)-Valinol, 98%** △ *[(R)-(-)-2-Amino-3-methyl-1-butanol, H-D-Val-ol]* [4276-09-9], $C_5H_{13}NO$, F.W. 103.17, m.p. 30-34°, b.p. 189-190°, f.p. 78°(172°F), d. 0.931, n_D^{20} 1.4550, $[\alpha]_D^{20}$ -11° (c=10 in water), BRN 1719138, MDL MFCD00064297 ! H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 	**1g** **5g**
L11300	**L-(+)-Valinol, 97%** △ *[(S)-(+)-2-Amino-3-methyl-1-butanol, H-Val-ol]* [2026-48-4], $C_5H_{13}NO$, F.W. 103.17, m.p. 30-35°, b.p. 80-81°/8mm, f.p. 78°(172°F), d. 0.926, n_D^{20} 1.4548, $[\alpha]_D^{20}$ +17° (c=10 in ethanol), Fieser **12**,563 **13**,341 **16**,380, EINECS 217-975-5, BRN 1719137, MDL MFCD00064296 ! H:H315-H319, P:P280-P305+P351+P338-P302+P352-P321-P362-P332+P313 Chiral auxiliary and building block. See also **(4S)-(-)-Isopropyl-2-oxazolidinone**, **A14029**, for derived reagents. 	**1g** **5g** **25g**
J62312	**Valinomycin, 90+%** *[NSC 122023]* [2001-95-8], $C_{54}H_{90}N_6O_{18}$, F.W. 1111.34, Crystalline powder, Merck **14**,9910, UN2811, EINECS 217-896-6, RTECS YV9468000, BRN 78657, MDL MFCD00005114, † Application(s): Potassium-selective ionophoric cyclodepsipeptide; inhibitor of mitochondrial action	**100mg**
J65255	**D-Val-Leu-Lys-7-amino-4-methylcoumarin** *[D-VLK-AMC]* $C_{27}H_{41}N_5O_5$, F.W. 515.64, Solid, MDL MFCD00038828	**10mg**
J62790	**Vancomycin hydrochloride, Molecular Biology Grade** ■ [1404-93-9], $C_{66}H_{75}Cl_2N_9O_{24}$·HCl, F.W. 1485.73, Powder, Merck **14**,9929, RTECS YW4380000, BRN 3704657 ! H:H317, P:P261-P280-P302+P352-P321-P363-P501a Application(s): Inhibits bacterial mucopeptide synthesis	**1g** **5g**
A12074	**Vanillic acid, 98%** *[4-Hydroxy-3-methoxybenzoic acid]* [121-34-6], $C_8H_8O_4$, F.W. 168.15, m.p. 210-218°, Merck **14**,9931, EINECS 204-466-8, RTECS YW5300000, BRN 2208364, MDL MFCD00002551, † ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 	**25g** **100g** **500g**
A11169	**Vanillin, 99%** ▲ △ *[4-Hydroxy-3-methoxybenzaldehyde]* [121-33-5], $C_8H_8O_3$, F.W. 152.15, m.p. 81-83°, b.p. 170°/15mm, f.p. 153°(307°F), d. 1.06, Merck **14**,9932, EINECS 204-465-2, RTECS YW5775000, BRN 472792, MDL MFCD00006942, † ! H:H302-H332, P:P261-P264-P304+P340-P301+P312-P312-P501a 	**100g** **500g** **2.5kg**

Stock #	Description	Size
J61096	**Vapreotide** *[RC-160, DPhe-Cys-Tyr-DTrp-Lys-Val-Cys-Trp-NH2]* [103222-11-3], $C_{57}H_{70}N_{12}O_9S_2$, F.W. 1131.38, Lyophilized powder, Merck **14**,9934 Application(s): Analog of somatostatin shown to inhibit tumor growth	**1mg** **5mg**
J63082	**Vargatef, 99+%** *[BIBF 1120, Intedanib]* [928326-83-4], $C_{31}H_{33}N_5O_4$, F.W. 539.63, Crystalline solid or powder Application(s): Indolinone derivative that inhibits VEGFR, PDGFR and FGFR	**5mg** **10mg** **25mg**
J64375	**Vascular Endothelial Cell Growth Factor, 98%** *[VEGF]* Note: Recombinantly expressed in E. Coli. Receptor Grade. Suitable for use in cell culture. Supplied as an aseptically lyophilized powder.	**10micrograms**
J63980	**Vasoactive Intestinal Peptide, human, porcine, rat** *[VIP,* *His-Ser-Asp-Ala-Leu-Phe-Thr-Asp-Thr-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Met-Lys-Lys-Tyr-Leu-Asn-Ser-Val-Leu-Asn-NH2]* [40077-57-4], $C_{147}H_{238}N_{44}O_{42}S$, F.W. 3325.84, Powder, MDL MFCD00167535 Application(s): Demonstrates vasoconstrictor activity	**0.5mg** **1mg**
J61248	**Vasopressin, 98+%** *[Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2, AVP peptide]* [11000-17-2], $C_{46}H_{65}N_{15}O_{12}S_2$, F.W. 1084.24, Lyophilized powder, EINECS 234-236-2 Application(s): Has antidiuretic activity and plays a role in water balance in animals	**5mg** **25mg** **100mg**
	Velnacrine maleate, see Hydroxytacrine maleate salt, J60680, p. 252	
J61535	**(±)-Verapamil hydrochloride, 99+%** *[Arpamyl]* [152-11-4], $C_{27}H_{38}N_2O_4 \cdot HCl$, F.W. 491.07, Powder, m.p. 138-141°, Merck **14**,9950, UN2811, EINECS 205-800-5, RTECS YV8320000, BRN 3647093, MDL MFCD00055208 H:H301-H311-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): A calcium channel blocker with a chemopreventive character	**1g**
J62324	**Veratridine, 97+%** *[3-Veratroylveracevine]* [71-62-5], $C_{36}H_{51}NO_{11}$, F.W. 673.80, Powder, Merck **14**,9954, UN1544, EINECS 200-758-4, RTECS YX5600000, BRN 78875, MDL MFCD00082515 H:H300-H310-H330-H315-H319-H335, P:P301+P310-P304+P340-P305+P351+P338-P320-P330-P361-P405-P501a Application(s): Activates sodium ion channels	**10mg** **50mg**
A11985	**Veratrole, 99%** *[Catechol dimethyl ether, 1,2-Dimethoxybenzene]* [91-16-7], $C_8H_{10}O_2$, F.W. 138.17, m.p. 21-23°, b.p. 206-207°, f.p. 87°(188°F), d. 1.084, n_D^{20} 1.5330, Merck **14**,9956, EINECS 202-045-3, RTECS CZ6475000, BRN 1364621, MDL MFCD00008357, † H:H302, P:P264-P270-P301+P312-P330-P501a In contrast to **1,3-Dimethoxybenzene**, **A13380**, direct dilithiation with n-BuLi + TMEDA is feasible, giving, after reaction with TMS chloride, the 3,6-disilyl derivative as the major product in 50-60% yield: *J. Org. Chem.*, **49**, 4657 (1984).	 **250g** **1kg** **5kg**
	3-Veratroylveracevine, see Veratridine, 97+%, J62324, p. 391	
J61371	**Veronal-buffered saline (VBS), 5mM buffer soln., pH 7.0** Liquid, Note: 5mM barbital, 145mM NaCl, pH 7.0.	**250ml** **500ml**
J61611	**Veronal-buffered saline (VBS), 10mM buffer soln., pH 7.0** Liquid, Note: 10mM barbital, 145mM NaCl, pH 7.0.	**250ml** **500ml**
J63779	**Veronal-buffered saline (VBS), 10mM buffer soln., pH 7.4** Liquid, Note: 10mM barbital, 145mM NaCl	**250ml** **500ml**
J60003	**Veronal-buffered saline with MG + CA (VBS++), 5mM buffer soln., pH 7.2** Liquid, Note: 5mM barbital, 145mM sodium chloride, 0.5mM magnesium chloride 15mM calcium chloride, pH 7.2.	**250ml** **500ml**
J63853	**Veronal-buffered saline with MG + CA (VBS++), 10mM buffer soln., pH 7.2** Liquid, Note: 10mM barbital, 145mM sodium chloride, 0.5mM magnesium chloride 15mM calcium chloride, pH 7.2.	**250ml** **500ml**
J62759	**Veronal-buffered saline with EDTA (VBSE), 5mM buffer soln., pH 7.2** Liquid, Note: 5mM barbital. 145mM NaCl 10mM EDTA, pH 7.2.	**250ml** **500ml**
J63338	**Veronal-buffered saline with EDTA (VBSE), 10mM buffer soln., pH 7.2** Liquid, Note: 10mM barbital, 145mM NaCl, 10mM EDTA, pH 7.2.	**250ml** **500ml**

Stock #	Description	Size
J60535	**Veronal-buffered saline with MG + EGTA (VBSMG), 5mM buffer soln., pH 7.2** Liquid, Note: 5mM barbital, 145mM sodium chloride, 0.5mM magnesium chloride, 5mM EGTA, pH 7.2.	**250ml** **500ml**
J63417	**Veronal-buffered saline with MG + EGTA (VBSMG), 10mM buffer soln., pH 7.2** Liquid, Note: 10mM barbital, 145mM sodium chloride, 0.5mM magnesium chloride, 5mM EGTA, pH 7.2.	**250ml** **500ml**
J63598	**Vinblastine sulfate, 98%** *[Vincaleukblastine sulfate]* [143-67-9], $C_{46}H_{60}N_4O_{13}S$, F.W. 909.06, Powder, m.p. 267°, Merck **14**,9982, EINECS 205-606-0, RTECS YY8400000, BRN 3659812, MDL MFCD00082457 H:H302-H315-H318-H360-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501 Application(s): Anticancer agent; microtubule disrupter; Induces apoptosis	**10mg** **50mg**
	Vincaleukblastine sulfate, see Vinblastine sulfate, 98%, J63598, p. 392	
J60545	**Vincamine, 98%** [1617-90-9], $C_{21}H_{26}N_2O_3$, F.W. 354.45, Powder, m.p. 232°, Merck **14**,9983, EINECS 216-576-3, RTECS YY8575000, MDL MFCD00078054 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): A vasodilator	**1g** **5g**
J60907	**Vincristine sulfate, 98+%** [2068-78-2], $C_{46}H_{58}N_4O_{14}S$, F.W. 923.04, Powder, m.p. >300°, b.p. 273-281°, Merck **14**,9986, UN2811, EINECS 218-190-0, RTECS OH6340000, BRN 3924631, MDL MFCD00084729 H:H360-H341, P:P281-P201-P202-P308+P313-P405-P501a Application(s): An anti-tumor alkaloid used in cancer research	**5mg** **25mg**
J61000	**Vinpocetine, 98%** *[Eburnamenine-14-carboxylic acid ethyl ester]* [42971-09-5], $C_{22}H_{26}N_2O_2$, F.W. 350.46, Powder, m.p. 147-149°, Merck **14**,9991, EINECS 256-028-0, RTECS JW4792000, MDL MFCD00211233 H:H302, P:P264-P270-P301+P312-P330-P501 Application(s): Specific calcium-calmodulin-dependent phosphodiesterase inhibitor	**20mg** **100mg**
	5-Vinyloxazolidone-2-thione, see DL-Goitrin, L02639, p. 238 **VIP**, see Vasoactive Intestinal Peptide, human, porcine, rat, J63980, p. 391	
A16237	**Vitamin A acetate in gelatin, powder, 500,000 I.U./g** *[Retinol acetate, Retinyl acetate]* [127-47-9], Merck **14**,10013, EINECS 204-844-2, RTECS VH6825000, BRN 1915439, MDL MFCD00019413, † H:H361, P:P281-P201-P202-P308+P313-P405-P501a 	**25g** **100g** **500g**
	Vitamin A acid, see Retinoic acid, 44540, p. 336 **Vitamin A alcohol**, see Retinol, 98%, synthetic, J62079, p. 336	
J63022	**Vitamin A palmitate, 98+%** *[Retinyl palmitate, Retinol palmitate]* [79-81-2], $C_{36}H_{60}O_2$, F.W. 524.87, Solid, m.p. 28-29°, Merck **14**,10013, EINECS 201-228-5, RTECS VH6860000, BRN 1917366, MDL MFCD00019414, † H:H361, P:P281-P201-P202-P308+P313-P405-P501a	**25g** **100g**
	Vitamin B1 hydrochloride, see Thiamine hydrochloride, A19560, p. 366 **Vitamin B, Nitrate**, see Thiamine nitrate, J60014, p. 366 **Vitamin B2**, see Riboflavin, A11764, p. 337	
A14894	**Vitamin B12, 98+% (dry wt basis)** ■ *[Cyanocobalamine]* [68-19-9], $C_{63}H_{88}CoN_{14}O_{14}P$, F.W. 1355.38, Merck **14**,10014, EINECS 200-680-0, RTECS GG3750000, BRN 4122889, MDL MFCD00151092, † For monographs, see: B_{12} (2 vols), D. Dolphon, Ed., Wiley-Interscience, N.Y. (1982); *B_{12} and B_{12}-Proteins*, B. Kraeutler, T Golding, Eds., Wiley-VCH, Weinheim (1998). For a review, see: *Vitamins*, W. Friedrich, Ed., de Gruyter, Berlin (1988), pp 837-928. For review of biosynthesis, see: *Angew. Chem. Int. Ed.*, **32**, 1223 (1993).	**1g** **5g** **25g**
	Vitamin BT, see L-Carnitine, A17618, p. 148 **Vitamin C**, see L-(+)-Ascorbic acid, 36237, p. 110 **Vitamin C sodium salt**, see L-Ascorbic acid sodium salt, A17759, p. 110 **Vitamin D2**, see Calciferol, J61610, p. 142	
B22524	**Vitamin D3, 99%** ▲ △ *[Cholecalciferol]* [67-97-0], $C_{27}H_{44}O$, F.W. 384.65, m.p. 83-87°, Merck **14**,10019, UN2811, EINECS 200-673-2, RTECS VS2900000, BRN 2339331, MDL MFCD00078131, † H:H301-H311-H330-H372, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a 	**1g** **5g**
	Vitamin E, see DL-α-Tocopherol, A17039, p. 370	

Stock #	Description	Size
A14505	**Vitamin E acetate, 97%** ▲ △ *[DL-α-Tocopheryl acetate]* [7695-91-2], $C_{31}H_{52}O_3$, F.W. 472.76, m.p. -28°, b.p. >300°, f.p. 210°(410°F), d. 0.960, n_D^{20} 1.4960, Merck **14**,9495, EINECS 231-710-0, RTECS GA8747000, BRN 97512, MDL MFCD00072042, † 	**25g** **100g** **500g**
	Vitamin H, see D-(+)-Biotin, A14207, p. 125	
L10575	**Vitamin K_1** ▲ *[Phylloquinone]* [84-80-0], $C_{31}H_{46}O_2$, m.p. ca -20°, b.p. ca 140°/0.001m, f.p. >110°(230°F), d. 0.984, n_D^{20} 1.5260, Merck **14**,7380, EINECS 201-564-2, RTECS QJ5800000, BRN 2568816, MDL MFCD00214063, † 	**1g** **5g**
	Vitamin K_3, see 2-Methyl-1,4-naphthoquinone, A13593, p. 289 **VUF 9153**, see Clobenpropit dihydrobromide, 99+%, J60807, p. 165 **W-7 hydrochloride**, see N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride, J63012, p. 95	
L17028	**Wang resin, 1% cross-linked, 0.8-1.1mmol/g, 200-400 mesh** *[4-Benzyloxybenzyl alcohol, polymer supported, Polystyrene PHB]* MDL MFCD00131778, Note: Polystyrene-1% divinylbenzene resin, 200-400 mesh Supporting resin for solid phase synthesis. 	**5g** **25g**
J61918	**Wash buffer, pH 8.0** Liquid, Note: 50mM sodium dihydrogen phosphate, 300 mM sodium chloride, 20mM imidazole, pH 8.0. Application(s): For His-tag protein purification	**500ml**
J60428	**Wash buffer, 1.0% Triton® X-100, pH 8.0** Liquid, Note: 50mM Tris-HCl, 500mM NaCl, 1% Triton X-100 Application(s): For GST-fusion protein purification	**250ml** **500ml**
J60165	**Wash buffer, 0.5% Tween 20, pH 8.0** Liquid, Note: 50mM sodium dihydrogen phosphate, 300 mM sodium chloride, and 20mM imidazole with 0.5% Tween-20, pH 8.0. Application(s): For His-tag protein purification	**500ml**
J62087	**Water, DEPC-Treated** [7732-18-5], H_2O, F.W. 18.02, Liquid, b.p. 100°, d. 1.000, Merck **14**,10039, EINECS 231-791-2, RTECS ZC0110000, BRN 2050024, MDL MFCD00011332	**250ml** **1L**
J65589	**Water, Endotoxin-free** [7732-18-5], H_2O, F.W. 18.02, Liquid, b.p. 100°, d. 1.00, n_D^{20} 1.34, Merck **14**,10039, EINECS 231-791-2, RTECS ZC0110000, BRN 2050024, MDL MFCD00011332, †	**500ml** **1L**
J60610	**Water, RNase, DNase-free** [7732-18-5], H_2O, F.W. 18.02, Liquid, b.p. 100°, d. 1.000, Merck **14**,10039, EINECS 231-791-2, RTECS ZC0110000, BRN 2050024, MDL MFCD00011332, †	**3.8L**
J63969	**Wheat Germ Oil** [8006-95-9], Oil Application(s): A natural source of vitamin E	**5kg** **10kg** **15kg**
	Woodward's Reagent K, see 2-Ethyl-5-phenylisoxazolium-3'-sulfonate, J61826, p. 217 **Wool fat**, see Lanolin, A16902, p. 266	
J63983	**Wortmannin, Penicillium funiculosum, 99+%** ▲ *[KY 12420]* [19545-26-7], $C_{23}H_{24}O_8$, F.W. 428.44, Powder, Merck **14**,10053, UN3462, RTECS CB9641000, BRN 67676, MDL MFCD00133927 H:H300-H310-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Inhibitor of phosphatidylinositol 3-kinase	**10mg** **25mg** **50mg**
A17903	**Wright's Stain** [68988-92-1], EINECS 273-541-5, MDL MFCD00082143, † Biological stain. Application(s): Useful stain for blood and for bone marrow films	**25g** **100g**
	WSC, see 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, A10807, p. 196 **9-Xanthenol**, see 9-Hydroxyxanthene, A13476, p. 394 **Xanthen-9-one**, see Xanthone, A14812, p. 394	
A11077	**Xanthine, 99%** *[2,6-Dihydroxypurine]* [69-89-6], $C_5H_4N_4O_2$, F.W. 152.11, m.p. >300°, Merck **14**,10059, EINECS 200-718-6, RTECS ZD7700000, BRN 8733, MDL MFCD00078453, † 	**25g** **100g**

Stock #	Description	Size
A14812	**Xanthone, 99%** *[Xanthen-9-one]* [90-47-1], $C_{13}H_8O_2$, F.W. 196.21, m.p. 174-178°, b.p. 350-351°, Merck **14**,10062, EINECS 201-997-7, RTECS ZD5711000, BRN 140443, MDL MFCD00005060, † 	**25g** **100g** **500g**
	Xanthotoxin, see 8-Methoxypsoralen, A17108, p. 285	
A13476	**Xanthydrol, 98+% ▲** *[9-Hydroxyxanthene, 9-Xanthenol]* [90-46-0], $C_{13}H_{10}O_2$, F.W. 198.22, m.p. 122-126°, EINECS 201-996-1, RTECS ZD5710000, BRN 10395, MDL MFCD00005057, † Used in the protection of thiols as their S-xanthenyl (Xan) thioethers, by reaction in the presence of TFA. The Xan group can also be cleaved using TFA in dichloromethane in the presence of triethylsilane as a cation scavenger, or with iodine in acetic acid: *J. Org. Chem.*, **62**, 3841 (1997).  Application(s): Useful in tests for urea	**5g** **25g** **100g**
J61481	**Xenopsin** *[Glp-Gly-Lys-Arg-Pro-Trp-Ile-Leu]* [51827-01-1], $C_{47}H_{73}N_{13}O_{10}$, F.W. 980.18, Powder Application(s): Multifunctional neuropeptide isolated from frog skin	**1mg** **5mg**
	X-α-Gal, see 5-Bromo-4-chloro-3-indolyl-a-D-galactoside, J60151, p. 136	
J61726	**XTT sodium salt** *[2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt]* [111072-31-2], $C_{22}H_{16}N_7NaO_{13}S_2$, F.W. 673.52, Powder, MDL MFCD00083517 Application(s): Tetrazolium derivative useful in cancer research	**250mg**
J61430	**Xylazine** *[2-(2,6-Dimethylphenylamino)-5,6-dihydro-4H-thiazine hydrochloride]* [7361-61-7], $C_{12}H_{16}N_2S$, F.W. 220.33, Powder, Merck **14**,10080, UN2811, EINECS 230-902-1, RTECS XJ0776300, MDL MFCD00057908 H:H301-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a	**1g** **5g** **25g**
J62394	**Xylazine hydrochloride** [23076-35-9], $C_{12}H_{16}N_2S{\cdot}HCl$, F.W. 256.79, Powder, Merck **14**,10080, UN2811, EINECS 245-417-0, RTECS XJ0776350, BRN 6448471, MDL MFCD00058196 H:H301-H350-H315-H319-H335, P:P301+P310-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Agonist at the α-2 adrenergic receptor	**5g** **25g**
B21530	**Xylenecyanol FF, dye content 70%** *[Acid blue 147, C.I. 42135]* [2650-17-1], $C_{25}H_{27}N_2NaO_6S_2$, F.W. 538.61, m.p. ca 295° dec., EINECS 220-167-5, MDL MFCD00019481, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): A tracking dye for DNA sequencing 	**10g** **50g**
A17457	**Xylenol Blue** *[p-Xylenolsulfonephthalein]* [125-31-5], $C_{23}H_{22}O_5S$, F.W. 410.49, m.p. ca 212° dec., Merck **14**,10083, EINECS 204-736-5, BRN 363132, MDL MFCD00005870, † H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Acid-base indicator: pH 1.2 - 2.8; 8.0 - 9.6. Application(s): pH Indicator: pH 1.2 (red) -pH 2.8 (yellow); pH 8.0 (yellow)-pH 9.6 (blue) 	**1g** **5g**
	p-Xylenolsulfonephthalein, see Xylenol Blue, A17457, p. 394	
L10863	**Xylidyl Blue I sodium salt** *[Magon sulfate]* [14936-97-1], $C_{25}H_{20}N_3NaO_6S$, F.W. 513.51, EINECS 239-012-8, MDL MFCD00003890 Complexometric reagent for Mg. Application(s): Used in the colorimetric dermination of Mg 	**1g** **5g**
A16944	**Xylitol, 99% ■** [87-99-0], $C_5H_{12}O_5$, F.W. 152.15, m.p. 92-96°, d. 1.515, Merck **14**,10085, EINECS 201-788-0, RTECS ZF0800000, BRN 1720523, MDL MFCD00064292, † 	**100g** **500g**
A10643	**D-(+)-Xylose, 98+% ■** [58-86-6], $C_5H_{10}O_5$, F.W. 150.13, m.p. 147-151°, f.p. > 100°(212°F), d. 1.525, $[\alpha]_D^{20}$ +20° (c=10 in water, 10h), Merck **14**,10087, EINECS 200-400-7, RTECS ZF2285000, BRN 1562108, MDL MFCD00151475, † For conversion to the useful chiral synthon (2S,4S)-2,4,5-trihydroxypentanoic acid 4,5-acetonide methyl ester, see: *Org. Synth. Coll.*, **9**, 717 (1998). 	**100g** **500g** **2.5kg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
B21622	**L-(-)-Xylose, 99%** ■ [609-06-3], $C_5H_{10}O_5$, F.W. 150.13, m.p. 147-151°, d. 1.525, $[\alpha]_D^{20}$ -20° (c=10 in water, 10h), EINECS 210-174-1, BRN 1723080, MDL MFCD00151096, † 	**5g** **25g** **100g**
	Y-acetate, see 3-Indoxyl acetate, L04932, p. 256	
J60287	**Yeast extract** [8013-01-2], Powder, EINECS 232-387-9, RTECS ZF6610000, MDL MFCD00132599 Application(s): Microbial media	**1kg** **5kg**
J61459	**Yeast lysis solution for DNA isolation** Liquid, Note: 0,5M lithium chloride, 50mM Tris-HC, 1% Triton X-100 6.25mM EDTA, pH 8.0	**250ml** **500ml**
J63195	**Yeast Lytic Enzyme, Arthrobacter luteus** *[Lyticase, Zymolyase 20T]* [37340-57-1], Lyophilized powder, MDL MFCD00131560, Note: 20 units/mg. One unit decreases abosrbance at 800nm by 30% after 2 hour assay at 25 C using brewer's yeast as a substrate. H:H334, P:P285-P261-P342+P311-P304+P341-P501a Application(s): Hydrolyzes linear glucose polymers with β-1,3-linkages	**250mg** **500mg** **1g**
H26271	**Yeast Nitrogen Base** MDL MFCD00217952	**100g** **500g**
J60185	**Yohimbine hydrochloride, 98+%** ▲ *[17-Hydroxyyohimban-16-carboxylic acid methyl ester hydrochloride]* [65-19-0], $C_{21}H_{26}N_2O_3$·HCl, F.W. 390.91, Powder, m.p. 288-290°, Merck **14**,10102, UN1544, EINECS 200-600-4, RTECS ZG1015000, MDL MFCD00012674, † H:H300-H311-H330, P:P301+P310-P304+P340-P320-P330-P361-P405-P501a Application(s): Standard α-2-adrenergic antagonist	**1g** **5g**
	α-Yohimbine hydrochloride, see Rauwolscine hydrochloride, 99%, J63198, p. 335	
J61512	**YPAD Agar plates** Liquid, Note: Agar plates prepared with 10g Bacto Yeast extract, 20g Peptone, 20g dextrose, 40mg adenine sulfate and 20g agar in 1L of water.	**20plates**
H26407	**YP Base Medium** ◪■ MDL MFCD01636187, Note: Ingredients (per liter amounts): 20g tryptone and 10g yeast extract. Final pH of 7.0 at 25C Application(s): For maintaining and developing yeast in molecular microbiology procedures	**100g** **500g**
J63227	**2X YT Microbial medium** Liquid, Note: Ingredients (per liter amounts): 16g tryptone (pancreatic digest of casein), 10g yeast extract, 5g NaCl Application(s): Growth medium for culturing Escherichia coli, particularly laboratory or recombinant strains.	**500ml** **1L**
J64905	**Z-Ala-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone** *[Z-AEVD-FMK, Z-A-E(OMe)-V-Asp(OMe)-FMK]* $C_{28}H_{39}N_4O_{10}F$, F.W. 610.63, Powder, MDL MFCD03453601	**1mg**
	Zalcitabine, see 2',3'-Dideoxycytidine, L10619, p. 187	
J63326	**Zaprinast, 98+%** *[1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo(4,5-d)pyrimidin-7-one]* [37762-06-4], $C_{13}H_{13}N_5O_2$, F.W. 271.28, Powder, EINECS 253-655-1, RTECS XZ6157358, MDL MFCD00214073 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a Application(s): Phosphodiesterase inhibitor	**10mg** **50mg** **100mg**
J64569	**Z-Asp-Glu-Val-Asp-7-amido-4-trifluoromethylcoumarin** *[Z-DEVD-AFC, Z-Asp-Glu-Val-Asp-AFC]* $C_{36}H_{38}F_3N_5O_{14}$, F.W. 821.71, Powder	**5mg**
J65206	**Z-Asp(O-Me)-Glu(O-Me)-Val-Asp(O-Me)-fluoromethyl ketone** *[Z-DEVD-FMK]* $C_{30}H_{41}N_4O_{12}F$, F.W. 668.66, Powder	**5mg**
J65068	**Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethyl ketone** *[Z-Asp(OMe)-Gln-Met-Asp(OMe)-FMK, Z-D(OMe)QMD(OMe)-FMK]* $C_{29}H_{40}FN_5O_{11}S$, F.W. 685.72, Powder, MDL MFCD03452876	**1mg** **5mg**
J61972	**trans-Zeatin, 97%** *[6-[(E)-4-Hydroxy-3-methylbut-2-enylamino]purine]* [1637-39-4], $C_{10}H_{13}N_5O$, F.W. 219.25, Powder, m.p. 208-210°, Merck **14**,10117, RTECS EM9506000, BRN 616241, MDL MFCD00213654 Application(s): Plant growth hormone that stimulates cell division	**50mg** **100mg** **250mg**

Stock #	Description	Size
J63382	**trans-Zeatin-riboside** *[6-[(E)-4-Hydroxy-3-methylbut-2-enylamino]-9β-D-ribofuranosylpurine]* [6025-53-2], $C_{15}H_{21}N_5O_5$, F.W. 351.36, Powder, BRN 5460894, MDL MFCD00036809 Application(s): Main effects in tissue culture systems include control of shoot growth and formation, cell division and inhibition of leaf senescence	**25mg** **50mg** **100mg**
J65890	**Z-Glu-Asp-Val-Glu-p-nitroanilide** ◢ *[Z-DEVD-pNA, Z-DEVD-pNA colorimetric substrate]* $C_{32}H_{38}N_6O_{14}$, F.W. 730.67, Powder	**5mg**
J64796	**Z-Gly-Gly-Leu-7-amido-4-methylcoumarin** ▲ *[Z-Gly-Gly-Leu-AMC, Z-GGL-AMC]* $C_{28}H_{32}N_4O_7$, F.W. 536.57, Powder	**5mg** **50mg**
J65721	**Z-Gly-Leu-Phe-chloromethyl ketone** *[Z-GLF-CMK, Z-Gly-Leu-Phe-CMK]* $C_{26}H_{32}ClN_3O_5$, F.W. 502.00, Solid, MDL MFCD03452908	**10mg** **25mg**
J65505	**Z-Ile-Glu(O-ME)-Thr-Asp(O-Me) fluoromethyl ketone** ◢ *[Z-IETD-FMK, Caspase-8 inhibitor]* $C_{30}H_{43}FN_4O_{11}$, F.W. 654.68, Powder, MDL MFCD01861686	**5mg**
A12909	**Zinc acetate dihydrate, 97+%** *[Acetic acid zinc salt]* [5970-45-6], $Zn(OOCCH_3)_2{\cdot}2H_2O$, F.W. 219.48 (183.45anhy), m.p. 237°, d. 1.735, Merck **14**,10128, UN3077, EINECS 209-170-2, RTECS ZG8750000, BRN 3732513, MDL MFCD00066961, † H:H400-H410-H319, P:P280-P273-P264-P305+P351+P338-P337+P313-P501a	**100g** **500g** **2.5kg**
J62160	**Zinc chloride, 25mM aq. soln.** [7646-85-7], $ZnCl_2$, F.W. 136.28, Liquid, †	**50ml** **100ml**
12307	**Zinc chloride, ACS, 97%** ■ [7646-85-7], $ZnCl_2$, F.W. 136.28, Lump, m.p. 290°, b.p. 732°, d. 2.91, Merck **14**,10132, Fieser **1**,1289 **13**,349 **15**,368 **16**,391 **18**,410 **19**,409 **20**,439 **21**,493, Solubility: Freely soluble in water, dilute HCl, alcohol, glycerol, acetone, ether. Zinc oxychloride forms with much water, UN2331, EINECS 231-592-0, RTECS ZH1400000, MDL MFCD00011295, † Maximum level of impurities: Oxychloride P.T., Insoluble matter 0.005%, Ca 0.06%, Mg 0.01%, NO_3 0.003%, SO_4 0.01%, NH_4 0.005%, Fe 0.001%, Pb 0.005%, K 0.02%, Na 0.05% H:H314-H400-H410-H302, P:P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501a Application(s): Catalyst, dehydrating and condensing agent, soldering flux, metal etchant	**250g** **1kg** **5kg**
B23022	**Zinc gluconate hydrate, 97%** *[Gluconic acid zinc salt]* [4468-02-4], $C_{12}H_{22}O_{14}Zn{\cdot}xH_2O$, F.W. 455.69(anhy), Merck **14**,4456, EINECS 224-736-9, RTECS ZH3750000, MDL MFCD00868110, † H:H302, P:P264-P270-P301+P312-P330-P501a	**100g** **500g**
J60963	**Zinc sulfate, 100mM aq. soln.** [7733-02-0], $ZnSO_4$, F.W. 161.43, Liquid, † H:H319-H412, P:P280-P273-P264-P305+P351+P338-P337+P313-P501a	**50ml** **100ml**
33399	**Zinc sulfate heptahydrate, ACS, 99.0-103.0%** [7446-20-0], $ZnSO_4{\cdot}7H_2O$, F.W. 287.54 (161.43anhy), Lump, m.p. 100°, d. 1.97, Merck **14**,10159, Solubility: Soluble in water, glycerol, UN3077, EINECS 231-793-3, RTECS ZH5300000, MDL MFCD00149894, Note: 280° $-7H_2O$, † Maximum level of impurities: Insoluble matter 0.01%, pH of a 5% solution 4.4-6.0 at 25°, Cl 5ppm, NO_3 0.002%, NH_4 0.001%, Fe 0.001%, Pb 0.003%, Mn 3ppm, Ca 0.005%, Mg 0.005%, K 0.01%, Na 0.05% H:H318-H400-H410-H302, P:P280-P273-P305+P351+P338-P310-P301+P312-P501a	**100g** **500g** **2.5kg**
J64557	**ZJ-43** *[(S)-2-(3-((S)-1-carboxy-3-methylbutyl)ureido)pentanedioic acid]* [723331-20-2], $C_{12}H_{20}N_2O_7$, F.W. 304.30, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	**10mg** **50mg**
J64966	**Z-Leu-Glu(O-Me)-His-Asp(O-Me) fluoromethyl ketone trifluoroacetate salt hydrate** *[Z-LEHD-FMK]* $C_{32}H_{43}FN_6O^{1}0.xC_2HF_3O_2.yH_2O\ ^{1}H_{42}O_3Pd_2.CHGaC_{32}H_{43}FN$, F.W. 690.71 (free base), Powder, MDL MFCD01862609	**1mg** **10mg**
J64613	**Z-Leu-Leu-Glu-7-amido-4-methylcoumarin** ▲ *[BML-ZW9345, Z-LLE-AMC]* $C_{35}H_{44}N_4O_9$, F.W. 664.75, Lyophilized powder, MDL MFCD01074989	**5mg** **50mg**

Contact us for pricing on bulk sizes

Stock #	Description	Size
J64731	**Z-Leu-Val-Gly-diazomethyl ketone** *[C-3455]* [119670-30-3], $C_{22}H_{31}N_5O_5$, F.W. 445.52, Powder	25mg 100mg
J65730	**ZM 336372 ▲** *[N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide]* [208260-29-1], $C_{23}H_{23}N_3O_3$, F.W. 389.45, Solid ! H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501	1mg 5mg
J60616	**Zolmitriptan** *[(S)-4-(3-[2-(Dimethylamino)ethyl]-5-indolylmethyl)oxazolidin-2-one]* [139264-17-8], $C_{16}H_{21}N_3O_2$, F.W. 287.36, Crystalline powder, m.p. 136-141°, Merck **14**,10189, MDL MFCD00871503 Application(s): A serotonin 5HT1D-receptor agonist	100mg 1g
J65795	**Z-Phe-Ala fluoromethyl ketone** *[Z-FA-FMK, Z-Phe-Ala-FMK]* [105637-38-5], $C_{21}H_{23}N_2O_4F$, F.W. 386.42, Powder, MDL MFCD00883668	5mg 50mg
J64479	**Z-Phe-Arg-7-amido-4-trifluoromethylcoumarin** *[Z-Phe-Arg-AFC, Z-FR-AFC]* $C_{33}H_{33}F_3N_6O_6$, F.W. 666.64, Lyophilized powder	10mg
J65856	**Z-Phe-Phe-fluoromethyl ketone** *[Z-Phe-Phe-FMK, Z-FF-FMK]* $C_{27}H_{27}FN_2O_4$, F.W. 462.51, Powder, MDL MFCD03453604	1mg 5mg
J65523	**Z-Tyr-Val-Ala-Asp(OMe)-fluoromethyl ketone** *[Z-YVAD-FMK, Z-YVAD(OMe)-FMK]* $C_{31}H_{39}FN_4O_9$, F.W. 630.66, Powder	1mg 5mg
J65345	**Z-Val-Ala-Asp(OMe)-fluoromethyl ketone** *[Z-VAD(Ome)-FMK, Methyl 5-fluoro-3-[2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl-amino]-4-oxopentanoate]* [187389-52-2], $C_{22}H_{30}FN_3O_7$, F.W. 467.49, Powder	5mg 50mg
J65419	**Z-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone** *[Z-VDVAD-FMK, Z-VD(OMe)VAD(OMe)-FMK]* $C_{32}H_{46}FN_5O_{11}$, F.W. 695.73, Powder, MDL MFCD03452881	5mg 50mg
J65892	**Z-Val-Glu(OMe)-Ile-Asp(OMe)-fluoromethyl ketone** *[Z-VEID-FMK, Z-VE(OMe)ID(OMe)-FMK]* $C_{31}H_{45}FN_4O_{10}$, F.W. 652.71, Powder, MDL MFCD03452882	1mg 5mg
J65339	**Z-Val-Lys(biotin)-Asp(OMe)-fluoromethyl ketone** *[Z-Val-Lys(biotin)-Asp(OMe)-FMK, Z-VL(biotin)D(OMe)-FMK]* $C_{35}H_{51}FN_6O_9S$, F.W. 750.87, Solid	1mg 5mg
J64544	**Z-Val-Val-Nle-diazomethyl ketone** *[C-3890, Z-Val-Val-Nle-DMK]* [155026-49-6], $C_{25}H_{37}N_5O_5$, F.W. 487.60, Powder	50mg 250mg
J61375	**Zymogram developing buffer (10X), pH 7.45** Liquid, Note: 0.5M Tris-HCl, (pH 7.45), 2.0M sodium chloride, 50mM calcium chloride, 0.2% Brij 35.	500ml 1L
J63137	**Zymogram renaturation buffer (10X)** Liquid, Note: 27% (w/v) Triton X-100 in DI water. ! H:H302-H318-H412, P:P280-P273-P305+P351+P338-P310-P301+P312-P501	500ml 1L
J62774	**Zymogram sample buffer, pH 6.6** Liquid, Note: 63mM Tris HCl (pH 6.8), 2% SDS, 10% glycerol, 2% β-mercaptoethanol, 0.005% Bromophenol blue. H:H412, P:P273-P501	25ml 50ml
	Zymolyase 20T, see Yeast Lytic Enzyme, Arthrobacter luteus, J63195, p. 395	
J62876	**Zymosan, Saccharomyces cerevisiae** [58856-93-2], Powder, Merck **14**,10200, RTECS ZI2750000, MDL MFCD00082157 Application(s): An insoluble preparation of yeast cell, has been shown to activate macrophages via toll-like receptor 2	50mg 1g

Trademarks

Bitrex® is a trademark of Macfarlan Smith, a Johnson Matthey Company.

The following trademarks are acknowledged and are accurate to the best of our knowledge at the time of printing.

Aliquat®	General Mills, Inc.
Amberlite®	Rohm & Haas Company
Amberlyst®	Rohm & Haas Company
Arlacel 83®	Croda International PLC
Brij®	Uniqema Americas LLC
Carbowax®	Dow Chemical Co.
Celite®	Celite Corp.
ChiPros®	BASF
Coban®	3M Company
DNAzol®	Molecular Research Center, Inc.
Eriochrome®	Huntsman International LLC Corp.
Ficoll®	GE Healthcare Bio-Sciences
Hoechst 33342®	Invitrogen Corporation
IGEPAL®	Rhodia Operations
Penetrex®	The Clorox Company
Span™	Croda International PLC
Texas Red®	Molecular Probes, Inc.
Triton®	Dow Chemical Co.

Precautionary & Hazard Statements

GHS Hazard Symbols - Pictograms



GHS Precautionary and Hazard Statements

Hazardous products listed in this catalogue are marked with P and H numbers as assigned to the Precautionary and Hazard statements under UN legislation.

Precautionary Statements

General precautionary statements

P101 If medical advice is needed, have product container or label at hand
P102 Keep out of reach of children
P103 Read label before use

Prevention precautionary statements

P201 Obtain special instructions before use
P202 Do not handle until all safety precautions have been read and understood
P210 Keep away from heat/sparks/open flames/hot surfaces – No smoking
P211 Do not spray on an open flame or other ignition source
P220 Keep/Store away from clothing/…/combustible materials
P221 Take any precaution to avoid mixing with combustibles
P222 Do not allow contact with air
P223 Keep away from any possible contact with water, because of violent reaction and possible flash fire
P230 Keep wetted with …
P231 Handle under inert gas
P232 Protect from moisture
P233 Keep container tightly closed
P234 Keep only in original container
P235 Keep cool
P240 Ground/bond container and receiving equipment
P241 Use explosion-proof electrical/ventilating/light/…/equipment
P242 Use only non-sparking tools
P243 Take precautionary measures against static discharge
P244 Keep reduction valves free from grease and oil
P250 Do not subject to grinding/shock/…/friction
P251 Pressurized container – Do not pierce or burn, even after use
P260 Do not breathe dust/fume/gas/mist/vapours/spray
P261 Avoid breathing dust/fume/gas/mist/vapours/spray
P262 Do not get in eyes, on skin, or on clothing
P263 Avoid contact during pregnancy/while nursing
P264 Wash … thoroughly after handling
P270 Do not eat, drink or smoke when using this product
P271 Use only outdoors or in a well-ventilated area
P272 Contaminated work clothing should not be allowed out of the workplace
P273 Avoid release to the environment
P280 Wear protective gloves/protective clothing/eye protection/face protection
P281 Use personal protective equipment as required
P282 Wear cold insulating gloves/face shield/eye protection
P283 Wear fire/flame resistant/retardant clothing

P284 Wear respiratory protection
P285 In case of inadequate ventilation wear respiratory protection
P231+232 Handle under inert gas. Protect from moisture
P235+410 Keep cool. Protect from sunlight

Response precautionary statements

P301 IF SWALLOWED:
P302 IF ON SKIN:
P303 IF ON SKIN (or hair):
P304 IF INHALED:
P305 IF IN EYES:
P306 IF ON CLOTHING:
P307 IF exposed:
P308 IF exposed or concerned:
P309 IF exposed or you feel unwell:
P310 Immediately call a POISON CENTER or doctor/physician
P311 Call a POISON CENTER or doctor/physician
P312 Call a POISON CENTER or doctor/physician if you feel unwell
P313 Get medical advice/attention
P314 Get Medical advice/attention if you feel unwell
P315 Get immediate medical advice/attention
P320 Specific treatment is urgent (see … on this label)
P321 Specific treatment (see … on this label)
P322 Specific measures (see … on this label)
P330 Rinse mouth
P331 Do NOT induce vomiting
P332 If skin irritation occurs:
P333 If skin irritation or a rash occurs:
P334 Immerse in cool water/wrap in wet bandages
P335 Brush off loose particles from skin
P336 Thaw frosted parts with lukewarm water. Do not rub affected area
P337 If eye irritation persists:
P338 Remove contact lenses if present and easy to do. Continue rinsing
P340 Remove victim to fresh air and keep at rest in a position comfortable for breathing
P341 If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing
P342 If experiencing respiratory symptoms:
P350 Gently wash with plenty of soap and water
P351 Rinse continuously with water for several minutes
P352 Wash with plenty of soap and water
P353 Rinse skin with water/shower
P360 Rinse immediately contaminated clothing and skin with plenty of water before removing clothes
P361 Remove/Take off immediately all contaminated clothing
P362 Take off contaminated clothing and wash before reuse
P363 Wash contaminated clothing before reuse
P370 In case of fire:
P371 In case of major fire and large quantities:
P372 Explosion risk in case of fire
P373 DO NOT fight fire when fire reaches explosives
P374 Fight fire with normal precautions from a reasonable distance
P375 Fight fire remotely due to the risk of explosion
P376 Stop leak if safe to do so
P377 Leaking gas fire – do not extinguish, unless leak can be stopped safely
P378 Use … for extinction
P380 Evacuate area
P381 Eliminate all ignition sources if safe to do so
P390 Absorb spillage to prevent material damage
P391 Collect spillage
P301+310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P301+312 IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell
P301+330+331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting
P302+334 IF ON SKIN: Immerse in cool water/wrap in wet bandages
P302+350 IF ON SKIN: Gently wash with plenty of soap and water
P302+352 IF ON SKIN: Wash with plenty of soap and water
P303+361+353 IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with water/shower
P304+312 IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell
P304+340 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P304+341 IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing
P305+351+338 IF IN EYES: Rinse continuously with water for several minutes. Remove contact lenses if present and easy to do – continue rinsing
P306+360 IF ON CLOTHING: Rinse immediately contaminated clothing and skin with plenty of water before removing clothes
P307+311 IF exposed: Call a POISON CENTER or doctor/physician
P308+313 IF exposed or concerned: Get medical advice/attention
P309+311 IF exposed or you feel unwell: Call a POISON CENTER or doctor/physician
P332+313 If skin irritation occurs: Get medical advice/attention
P333+313 If skin irritation or a rash occurs: Get medical advice/attention
P335+334 Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages
P337+313 If eye irritation persists: Get medical advice/attention
P342+311 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician
P370+376 In case of fire: Stop leak if safe to do so
P370+378 In case of fire: Use … for extinction
P370+380 In case of fire: Evacuate area
P370+380+375 In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion
P371+380+375 In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion

Storage precautionary statements

P401 Store …
P402 Store in a dry place
P403 Store in a well ventilated place
P404 Store in a closed container
P405 Store locked up
P406 Store in a corrosive resistant/… container with a resistant inner liner
P407 Maintain air gap between stacks/pallets
P410 Protect from sunlight

P411 Store at temperatures not exceeding … °C/… °F
P412 Do not expose to temperatures exceeding 50 °C/122 °F
P413 Store bulk masses greater than ... kg/ ... lbs at temperatures not exceeding … °C/… °F
P420 Store away from other materials
P422 Store contents under …
P402+404 Store in a dry place. Store in a closed container
P403+233 Store in a well ventilated place. Keep container tightly closed
P403+235 Store in a well ventilated place. Keep cool
P410+403 Protect from sunlight. Store in a well ventilated place
P410+412 Protect from sunlight. Do not expose to temperatures exceeding 50 °C/122 °F
P411+235 Store at temperatures not exceeding… °C/… °F. Keep cool

Disposal precautionary statements

P501 Dispose of contents/container to …

Hazard Statements

Physical hazards

H200 Unstable explosive
H201 Explosive; mass explosion hazard
H202 Explosive; severe projection hazard
H203 Explosive; fire, blast or projection hazard
H204 Fire or projection hazard
H205 May mass explode in fire
H220 Extremely flammable gas
H221 Flammable gas
H222 Extremely flammable material
H223 Flammable material
H224 Extremely flammable liquid and vapour
H225 Highly flammable liquid and vapour
H226 Flammable liquid and vapour
H227 Combustible liquid
H228 Flammable solid
H240 Heating may cause an explosion
H241 Heating may cause a fire or explosion
H242 Heating may cause a fire
H250 Catches fire spontaneously if exposed to air
H251 Self-heating; may catch fire
H252 Self-heating in large quantities; may catch fire
H260 In contact with water releases flammable gases which may ignite spontaneously
H261 In contact with water releases flammable gas
H270 May cause or intensify fire; oxidizer
H271 May cause fire or explosion; strong oxidizer
H272 May intensify fire; oxidizer
H280 Contains gas under pressure; may explode if heated
H281 Contains refrigerated gas; may cause cryogenic burns or injury
H290 May be corrosive to metals

Health hazards

H300 Fatal if swallowed
H301 Toxic if swallowed
H302 Harmful if swallowed
H303 May be harmful if swallowed
H304 May be fatal if swallowed and enters airways
H305 May be harmful if swallowed and enters air ways
H310 Fatal in contact with skin
H311 Toxic in contact with skin
H312 Harmful in contact with skin
H313 May be harmful in contact with skin
H314 Causes severe skin burns and eye damage
H315 Causes skin irritation
H316 Causes mild skin irritation
H317 May cause an allergic skin reaction
H318 Causes serious eye damage
H319 Causes serious eye irritation
H320 Causes eye irritation
H330 Fatal if inhaled
H331 Toxic if inhaled
H332 Harmful if inhaled
H333 May be harmful if inhaled
H334 May cause allergy or asthma symptoms of breathing difficulties if inhaled
H335 May cause respiratory irritation
H336 May cause drowsiness or dizziness
H340 May cause genetic defects
H341 Suspected of causing genetic defects
H350 May cause cancer
H351 Suspected of causing cancer
H360 May damage fertility or the unborn child
H361 Suspected of damaging fertility or the unborn child
H362 May cause harm to breast-fed children
H370 Causes damage to organs
H371 May cause damage to organs
H372 Causes damage to organs through prolonged or repeated exposure
H373 May cause damage to organs through prolonged or repeated exposure

Environmental hazards

H400 Very toxic to aquatic life
H401 Toxic to aquatic life
H402 Harmful to aquatic life
H410 Very toxic to aquatic life with long lasting effects
H411 Toxic to aquatic life with long lasting effects
H412 Harmful to aquatic life with long lasting effects
H413 May cause long lasting harmful effects to aquatic life

EUH Statements

All H statements listed before are internationally valid. The following EUH statements are only valid in all countries within the EU.

EUH001 Explosive when dry.
EUH006 Explosive with or without contact with air.
EUH014 Reacts violently with water.
EUH018 In use may form flammable/explosive vapour/air mixture.
EUH019 May form explosive peroxides.
EUH044 Risk of explosion if heated under confinement.
EUH029 Contact with water liberates toxic gas.
EUH031 Contact with acids liberates toxic gas.
EUH032 Contact with acids liberates very toxic gas.
EUH066 Repeated exposure may cause skin dryness/cracking.
EUH070 Toxic by eye contact.
EUH071 Corrosive to the respiratory tract.
EUH059 Hazardous to the ozone layer.
EUH201 Contains lead. Should not be used on surfaces liable to being chewed or sucked.
EUH201A Warning! Contains lead.
EUH202 Cryanoacrylate. Danger. Bonds skin and eyes in seconds. Keep out of the reach of children.
EUH203 Contains chromium (VI). May produce an allergic reation.
EUH204 Contains isocyanates. May produce an allergic reaction.
EUH205 Contains epoxy constituents.
EUH206 Warning! Do not use together with other products. May release dangerous gases (chlorine).
EUH207 Warning! Contains cadmium. Dangerous fumes are formed during use. See information supplied by the manufaturer. Comply with the safety instructions.
EUH208 Contains <name of sensitising substance>. May produce an allergic reaction.
EUH209 Can become highly flammable in use.
EUH209A Can become flammable in use.
EUH210 Safety data sheet available on request.
EUH401 To avoid risks to human health and the environment, comply with the instructions for use.

Alfa Aesar

Periodic Table of Elements

Visit Our Website at **www.alfa.com**

1 IA																	18 VIIIA
1.00794 1 **H** $1s^1$ bp: -252.87°C d: 0.089 g/l Hydrogen	2 IIA											13 IIIA	14 IVA	15 VA	16 VIA	17 VIIA	4.002602 2 **He** $1s^2$ bp: -268.9°C d: 0.179 g/l Helium
6.941 3 **Li** [He] $2s^1$ mp: 180.5°C d: 0.53 g/cc Lithium	9.012182 4 **Be** [He] $2s^2$ mp: 1287°C d: 1.848 g/cc Beryllium											10.811 5 **B** [He] $2s^2$ $2p^1$ mp: 2076°C d: 2.46 g/cc Boron	12.0107 6 **C** [He] $2s^2$ $2p^2$ mp: 3527°C d: 2.26 g/cc Carbon	14.0067 7 **N** [He] $2s^2$ $2p^3$ bp: -195.8°C d: 1.25 g/l Nitrogen	15.9994 8 **O** [He] $2s^2$ $2p^4$ bp: -182.9°C d: 1.43 g/l Oxygen	18.9984032 9 **F** [He] $2s^2$ $2p^5$ bp: -188.1°C d: 1.696 g/l Fluorine	20.1797 10 **Ne** [He] $2s^2$ $2p^6$ bp: -246.1°C d: 0.8999 g/l Neon
22.989769 11 **Na** [Ne] $3s^1$ mp: 97.72°C d: 0.968 g/cc Sodium	24.3050 12 **Mg** [Ne] $3s^2$ mp: 650°C d: 1.738 g/cc Magnesium											26.981539 13 **Al** [Ne] $3s^2$ $3p^1$ mp: 660.3°C d: 2.70 g/cc Aluminum	28.0855 14 **Si** [Ne] $3s^2$ $3p^2$ mp: 1414°C d: 2.33 g/cc Silicon	30.973762 15 **P** [Ne] $3s^2$ $3p^3$ mp: 44.2°C d: 1.82 g/cc Phosphorus	32.065 16 **S** [Ne] $3s^2$ $3p^4$ mp: 115.21°C d: 1.96 g/cc Sulfur	35.453 17 **Cl** [Ne] $3s^2$ $3p^5$ bp: -34.0°C d: 3.21 g/l Chlorine	39.948 18 **Ar** [Ne] $3s^2$ $3p^6$ bp: -185.8°C d: 1.784 g/l Argon
39.0983 19 **K** [Ar] $4s^1$ mp: 63.4°C d: 0.856 g/cc Potassium	40.078 20 **Ca** [Ar] $4s^2$ mp: 842°C d: 1.55 g/cc Calcium	3 IIIB	4 IVB	5 VB	6 VIB	7 VIIB	8 VIII	9 VIII	10 VIII	11 IB	12 IIB	69.723 31 **Ga** [Ar] $3d^{10}$ $4s^2$ $4p^1$ mp: 29.8°C d: 5.90 g/cc Gallium	72.64 32 **Ge** [Ar] $3d^{10}$ $4s^2$ $4p^2$ mp: 938.3°C d: 5.32 g/cc Germanium	74.92160 33 **As** [Ar] $3d^{10}$ $4s^2$ $4p^3$ 817°C sublt. d: 5.73 g/cc Arsenic	78.96 34 **Se** [Ar] $3d^{10}$ $4s^2$ $4p^4$ mp: 221°C d: 4.82 g/cc Selenium	79.904 35 **Br** [Ar] $3d^{10}$ $4s^2$ $4p^5$ bp: 59.47°C d: 3.12 g/cc Bromine	83.798 36 **Kr** [Ar] $3d^{10}$ $4s^2$ $4p^6$ bp: -157.36°C 3.73 g/l Krypton
85.4678 37 **Rb** [Kr] $5s^1$ mp: 39.3°C d: 1.532 g/cc Rubidium	87.62 38 **Sr** [Kr] $5s^2$ mp: 777°C d: 2.64 g/cc Strontium	44.955912 21 **Sc** [Ar] $3d^1$ $4s^2$ mp: 1541°C d: 2.985 g/cc Scandium	47.867 22 **Ti** [Ar] $3d^2$ $4s^2$ mp: 1668°C d: 4.507 g/cc Titanium	50.9415 23 **V** [Ar] $3d^3$ $4s^2$ mp: 1910°C d: 6.11 g/cc Vanadium	51.9961 24 **Cr** [Ar] $3d^5$ $4s^1$ mp: 1907°C d: 7.14 g/cc Chromium	54.938045 25 **Mn** [Ar] $3d^5$ $4s^2$ mp: 1246°C d: 7.47 g/cc Manganese	55.845 26 **Fe** [Ar] $3d^6$ $4s^2$ mp: 1538°C d: 7.87 g/cc Iron	58.933195 27 **Co** [Ar] $3d^7$ $4s^2$ mp: 1495°C d: 8.90 g/cc Cobalt	58.6934 28 **Ni** [Ar] $3d^8$ $4s^2$ mp: 1435°C d: 8.908 g/cc Nickel	63.546 29 **Cu** [Ar] $3d^{10}$ $4s^1$ mp: 1084°C d: 8.92 g/cc Copper	65.38 30 **Zn** [Ar] $3d^{10}$ $4s^2$ mp: 419.5°C d: 7.14 g/cc Zinc						
88.90585 39 **Y** [Kr] $4d^1$ $5s^2$ mp: 1526°C d: 4.47 g/cc Yttrium	91.224 40 **Zr** [Kr] $4d^2$ $5s^2$ mp: 1855°C d: 6.51 g/cc Zirconium	92.90638 41 **Nb** [Kr] $4d^4$ $5s^1$ mp: 2477°C d: 8.57 g/cc Niobium	95.96 42 **Mo** [Kr] $4d^5$ $5s^1$ mp: 2623°C d: 10.28 g/cc Molybdenum	98 43 **Tc** [Kr] $4d^5$ $5s^2$ mp: 2157°C d: 11.50 g/cc Technetium	101.07 44 **Ru** [Kr] $4d^7$ $5s^1$ mp: 2334°C d: 12.37 g/cc Ruthenium	102.90550 45 **Rh** [Kr] $4d^8$ $5s^1$ mp: 1964°C d: 12.45 g/cc Rhodium	106.42 46 **Pd** [Kr] $4d^{10}$ mp: 1554.9°C d: 12.02 g/cc Palladium	107.8682 47 **Ag** [Kr] $4d^{10}$ $5s^1$ mp: 961.8°C d: 10.49 g/cc Silver	112.411 48 **Cd** [Kr] $4d^{10}$ $5s^2$ mp: 321.1°C d: 8.65 g/cc Cadmium	114.818 49 **In** [Kr] $4d^{10}$ $5s^2$ $5p^1$ mp: 156.6°C d: 7.31 g/cc Indium	118.710 50 **Sn** [Kr] $4d^{10}$ $5s^2$ $5p^2$ mp: 231.9°C d: 7.31 g/cc Tin	121.760 51 **Sb** [Kr] $4d^{10}$ $5s^2$ $5p^3$ mp: 630.6°C d: 6.69 g/cc Antimony	127.60 52 **Te** [Kr] $4d^{10}$ $5s^2$ $5p^4$ mp: 449.5°C d: 6.24 g/cc Tellurium	126.90447 53 **I** [Kr] $4d^{10}$ $5s^2$ $5p^5$ mp: 113.7°C d: 4.94 g/cc Iodine	131.293 54 **Xe** [Kr] $4d^{10}$ $5s^2$ $5p^6$ mp: -108°C d: 5.89 g/l Xenon
132.905452 55 **Cs** [Xe] $6s^1$ mp: 28.4°C d: 1.88 g/cc Cesium	137.327 56 **Ba** [Xe] $6s^2$ mp: 727°C d: 3.51 g/cc Barium	57-71 **La-Lu**	178.49 72 **Hf** [Xe] $4f^{14}$ $5d^2$ $6s^2$ mp: 2223°C d: 13.31 g/cc Hafnium	180.94788 73 **Ta** [Xe] $4f^{14}$ $5d^3$ $6s^2$ mp: 3017°C d: 16.65 g/cc Tantalum	183.84 74 **W** [Xe] $4f^{14}$ $5d^4$ $6s^2$ mp: 3422°C d: 19.25 g/cc Tungsten	186.207 75 **Re** [Xe] $4f^{14}$ $5d^5$ $6s^2$ mp: 3186°C d: 21.02 g/cc Rhenium	190.23 76 **Os** [Xe] $4f^{14}$ $5d^6$ $6s^2$ mp: 3033°C d: 22.61 g/cc Osmium	192.217 77 **Ir** [Xe] $4f^{14}$ $5d^7$ $6s^2$ mp: 2446°C d: Iridium	195.084 78 **Pt** [Xe] $4f^{14}$ $5d^9$ $6s$ mp: 1768.4°C d: 21.09 g/cc Platinum	196.966569 79 **Au** [Xe] $4f^{14}$ $5d^{10}$ $6s^1$ mp: 1064.2°C d: 19.30 g/cc Gold	200.59 80 **Hg** [Xe] $4f^{14}$ $5d^{10}$ $6s^2$ bp: 356.73°C d: 13.534 g/cc Mercury	204.3833 81 **Tl** [Xe] $4f^{14}$ $5d^{10}$ $6s^2$ $6p^1$ mp: 304°C d: 11.85 g/cc Thallium	207.2 82 **Pb** [Xe] $4f^{14}$ $5d^{10}$ $6s^2$ $6p^2$ mp: 327.5°C d: 11.34 g/cc Lead	208.98040 83 **Bi** [Xe] $4f^{14}$ $5d^{10}$ $6s^2$ $6p^3$ mp: 271.3°C d: 9.78 g/cc Bismuth	[209] 84 **Po** [Xe] $4f^{14}$ $5d^{10}$ $6s^2$ $6p^4$ mp: 254°C d: 9.20 g/cc Polonium	[210] 85 **At** [Xe] $4f^{14}$ $5d^{10}$ $6s^2$ $6p^5$ mp: 302°C d: no new Astatine	[222] 86 **Rn** [Xe] $4f^{14}$ $5d^{10}$ $6s^2$ $6p^6$ bp: -61.7°C d: 9.73 g/cc Radon
[223] 87 **Fr** [Rn] $7s^1$ mp: 27°C d: 2.29 g/cc Francium	[226] 88 **Ra** [Rn] $7s^2$ mp: 700°C d: 5.00 g/cc Radium	89-103 **Ac-Lr**	[261] 104 **Rf** [Rn] $5f^{14}$ $6d^2$ $7s^2$ mp: none d: none Rutherfordium	[262] 105 **Db** [Rn] $5f^{14}$ $6d^3$ $7s^2$ mp: none d: none Dubnium	[266] 106 **Sg** [Rn] $5f^{14}$ $6d^4$ $7s^2$ mp: none d: none Seaborgium	[264] 107 **Bh** [Rn] $5f^{14}$ $6d^5$ $7s^2$ mp: none d: none Bohrium	[277] 108 **Hs** [Rn] $5f^{14}$ $6d^6$ $7s^2$ mp: none d: none Hassium	[268] 109 **Mt** [Rn] $5f^{14}$ $6d^7$ $7s^2$ mp: none d: none Meitnerium	[271] 110 **Ds** [Rn] $5f^{14}$ $6d^9$ $7s^1$ mp: none d: none Darmstadtium	[272] 111 **Rg** [Rn] $5f^{14}$ $6d^{10}$ $7s^1$ mp: none d: none Roentgenium	[285] 112 **Cn** [Rn] $5f^{14}$ $6d^{10}$ $7s^2$ mp: none d: none Copernicium	[284] 113 **Uut** [Rn] $5f^{14}$ $6d^{10}$ $7s^2$ $7p^1$ mp: none d: none Ununtrium	[289] 114 **Uuq** [Rn] $5f^{14}$ $6d^{10}$ $7s^2$ $7p^2$ mp: none d: none Ununquadium	[288] 115 **Uup** [Rn] $5f^{14}$ $6d^{10}$ $7s^2$ $7p^3$ mp: none d: none Ununpentium	[293] 116 **Uuh** [Rn] $5f^{14}$ $6d^{10}$ $7s^2$ $7p^4$ mp: none d: none Ununhexium	ISO 9001:2008 ISO 14001:2004 BS OHSAS 18001:2007 Certified

138.90547 57 **La** [Xe] $5d^1$ $6s^2$ mp: 920°C d: 6.15 g/cc Lanthanum	140.116 58 **Ce** [Xe] $4f^1$ $5d^1$ $6s^2$ mp: 795°C d: 6.69 g/cc Cerium	140.90765 59 **Pr** [Xe] $4f^3$ $6s^2$ mp: 935°C d: 6.64 g/cc Praseodymium	144.242 60 **Nd** [Xe] $4f^4$ $6s^2$ mp: 1024°C d: 6.8 g/cc Neodymium	[145] 61 **Pm** [Xe] $4f^5$ $6s^2$ mp: 1100°C d: 7.26 g/cc Promethium	150.36 62 **Sm** [Xe] $4f^6$ $6s^2$ mp: 1072°C d: 7.35 g/cc Samarium	151.964 63 **Eu** [Xe] $4f^7$ $6s^2$ mp: 826°C d: 5.24 g/cc Europium	157.25 64 **Gd** [Xe] $4f^7$ $5d^1$ $6s^2$ mp: 1312°C d: 7.90 g/cc Gadolinium	158.92535 65 **Tb** [Xe] $4f^9$ $6s^2$ mp: 1356°C d: 8.22 g/cc Terbium	162.500 66 **Dy** [Xe] $4f^{10}$ $6s^2$ mp: 1407°C d: 8.55 g/cc Dysprosium	164.93032 67 **Ho** [Xe] $4f^{11}$ $6s^2$ mp: 1461°C d: 8.78 g/cc Holmium	167.259 68 **Er** [Xe] $4f^{12}$ $6s^2$ mp: 1529°C d: 9.07 g/cc Erbium	168.93421 69 **Tm** [Xe] $4f^{13}$ $6s^2$ mp: 1545°C d: 9.32 g/cc Thulium	173.054 70 **Yb** [Xe] $4f^{14}$ $6s^2$ mp: 824°C d: 6.57 g/cc Ytterbium	174.9668 71 **Lu** [Xe] $4f^{14}$ $5d$ $6s^2$ mp: 1652°C 9.84 g/cc Lutetium
[227] 89 **Ac** [Rn] $6d^1$ $7s^2$ mp: 1050°C d: 10.07 g/cc Actinium	232.03806 90 **Th** [Rn] $6d^2$ $7s^2$ mp: 1842°C d: 11.72 g/cc Thorium	231.03588 91 **Pa** [Rn] $5f^2$ $6d^1$ $7s^2$ mp: 1568°C d: 15.37 g/cc Protactinium	238.02891 92 **U** [Rn] $5f^3$ $6d^1$ $7s^2$ mp: 1132.3°C d: 19.05 g/cc Uranium	[237] 93 **Np** [Rn] $5f^4$ $6d^1$ $7s^2$ mp: 637°C d: 20.45 g/cc Neptunium	[244] 94 **Pu** [Rn] $5f^6$ $7s^2$ mp: 639.4°C d: 19.81 g/cc Plutonium	[243] 95 **Am** [Rn] $5f^7$ $7s^2$ mp: 1176°C d: 13.67 g/cc Americium	[247] 96 **Cm** [Rn] $5f^7$ $6d^1$ $7s^2$ mp: 1340°C d: 13.51 g/cc Curium	[247] 97 **Bk** [Rn] $5f^9$ $7s^2$ mp: 986°C d: 14.78 g/cc Berkelium	[251] 98 **Cf** [Rn] $5f^{10}$ $7s^2$ mp: 900°C d: 15.10 g/cc Californium	[252] 99 **Es** [Rn] $5f^{11}$ $7s^2$ mp: 860°C d: 8.84 g/cc Einsteinium	[257] 100 **Fm** [Rn] $5f^{12}$ $7s^2$ mp: 1527°C d: none Fermium	[258] 101 **Md** [Rn] $5f^{13}$ $7s^2$ mp: 827°C d: none Mendelevium	[259] 102 **No** [Rn] $5f^{14}$ $7s^2$ mp: 827°C d: none Nobelium	[262] 103 **Lr** [Rn] $5f^{14}$ $6d$ $7s^2$ mp: 1627°C d: none Lawrencium

Key

1.00794 1 **H** $1s^1$ bp: -259.3°C d: 0.088 g/l Hydrogen

- Element
- Density
- Boiling or Melting Point in °C
- Electron Configuration
- Symbol
- Atomic Weight
- Atomic Number

Access the Latest Information
www.alfa.com

Looking for new products?

Want to check product availability?

Need more information?

Visit www.alfa.com

Our website provides easy access to the following:

- Material Safety Data Sheets (MSDS)
- Certificates of Analysis
- Up-to-date product availability
- Current pricing and ability to request pricing quotations
- Structure/substructure search

Other enhancements to the site include:

- Improved search function
- Easy online shopping
- Order tracking and history
- Complete technical information and literature references

Alfa Aesar

Alfa Aesar